PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	FREEDMAN, BD; FLEISCHMANN, BK; PUNT, JA; GAULTON, G; HASHIMOTO, Y; KOTLIKOFF, MI				FREEDMAN, BD; FLEISCHMANN, BK; PUNT, JA; GAULTON, G; HASHIMOTO, Y; KOTLIKOFF, MI			IDENTIFICATION OF KV1.1 EXPRESSION BY MURINE CD4(-)CD8(-) THYMOCYTES - A ROLE FOR VOLTAGE-DEPENDENT K+ CHANNELS IN MURINE THYMOCYTE DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; CELL-VOLUME REGULATION; POTASSIUM CHANNELS; T-CELLS; CALCIUM INFLUX; CHARYBDOTOXIN; RECEPTOR; INTERLEUKIN-2; CA-2+; OSCILLATIONS	The patch-clamp recording technique and RNA-polymerase chain reaction were used to identify the voltage-dependent K+ channels expressed by murine fetal and adult CD4(-)CD8(-) thymocytes. Two distinct currents, encoded by the genes Kv1.1 and Kv1.3 were identified based upon their biophysical and pharmacologic characteristics and confirmed with RNA-polymerase chain reaction. Peptide blockers of Kv1.1 and Kv1.3 gene products were also applied to a murine fetal thymic organ culture system to investigate the developmental role of these K+ channels. Dendrotoxin (DTX) and charybdotoxin (CTX), antagonists of Kv1.1 and Kv1.3 channels, respectively, decreased thymocyte yields in organ culture without affecting thymocyte viability. DTX-treated thymi contained 56 +/- 8% (n = 8 experiments), and CTX-treated thymi contained 74 +/- 4% (n = 7 experiments) as many thymocytes as untreated lobes. DTX and CTX also altered the developmental progression of thymocytes in fetal organ culture. These data provide the first evidence of Kv1.1 expression in a lymphoid cell and indicate that thymocyte voltage-dependent K+ channels are critical to thymocyte preclonal expansion and/or maturation.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; SYNTEX INST IMMUNOL,NIIHARI,IBARAKI 30041,JAPAN	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	FREEDMAN, BD (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [R01 AI060921] Funding Source: Medline; NIAMS NIH HHS [AR-39910] Funding Source: Medline; NICHD NIH HHS [HD-01056] Funding Source: Medline; PHS HHS [A132748] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039910] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEUTSCH C, 1994, P NATL ACAD SCI USA, V90, P10036; DEUTSCH CJ, 1979, J CELL PHYSIOL, V99, P79, DOI 10.1002/jcp.1040990110; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; FREEDMAN BD, 1992, J IMMUNOL, V149, P3784; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GELFAND EW, 1987, J IMMUNOL, V138, P527; GELFAND EW, 1984, J CELL PHYSIOL, V121, P533, DOI 10.1002/jcp.1041210312; GRAY LS, 1987, CELL, V50, P119, DOI 10.1016/0092-8674(87)90668-4; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; GRINSTEIN S, 1989, AM J PHYSIOL, V257, pC197, DOI 10.1152/ajpcell.1989.257.2.C197; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; GRISSMER S, 1995, MOL PHARMACOL, V45, P1227; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HESS SD, 1993, J IMMUNOL, V150, P2620; JENKINSON EJ, 1981, J EXP MED, V153, P280, DOI 10.1084/jem.153.2.280; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MCKINNON D, 1986, J EXP MED, V164, P1846, DOI 10.1084/jem.164.6.1846; MILLS GB, 1985, J IMMUNOL, V134, P1640; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; OLESON DR, 1993, J MEMBRANE BIOL, V132, P229; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TAKAHAMA Y, 1994, J EXP MED, V179, P1495, DOI 10.1084/jem.179.5.1495; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	36	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22406	22411		10.1074/jbc.270.38.22406	http://dx.doi.org/10.1074/jbc.270.38.22406			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673227	hybrid			2022-12-27	WOS:A1995RW31400054
J	GRUPE, A; ALLEMAN, J; GOLDFINE, ID; SADICK, M; STEWART, TA				GRUPE, A; ALLEMAN, J; GOLDFINE, ID; SADICK, M; STEWART, TA			INHIBITION OF INSULIN-RECEPTOR PHOSPHORYLATION BY PC-1 IS NOT MEDIATED BY THE HYDROLYSIS OF ADENOSINE-TRIPHOSPHATE OR THE GENERATION OF ADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIFFERENTIATION ANTIGEN PC-1; CELL MEMBRANE GLYCOPROTEIN; RAT ADIPOCYTES; PHOSPHODIESTERASE; IDENTIFICATION; MONOPHOSPHATE; THREONINE; MUSCLE; ACID	Individuals with insulin resistance show increased levels of PC-1 expression in skeletal muscle and fibroblasts, and in transfected cell lines that overexpress PC-I there is a reduction in the insulin-stimulated insulin receptor tyrosine phosphorylation, As PC-1 is a type II transmembrane protein with extracellular phosphodiesterase and pyrophosphatase activity, increased expression of PC-1 at the cell surface will decrease extracellular adenosine triphosphate levels and increase extracellular adenosine levels, Consequently it is possible that PC-1-mediated insulin resistance could be caused either by a decrease in adenosine triphosphate or an indirect increase in adenosine levels, We have tested this hypothesis and find that the PC-1-mediated inhibition of insulin-stimulated insulin receptor autophosphorylation is not altered by agents that alter the level or action of adenosine. Further, a mutated PC-1 with a single amino acid change that abolishes the phosphodiesterase and pyrophosphatase activities is still able to inhibit insulin-stimulated insulin receptor phosphorylation, The results of these experiments indicate that the phosphodiesterase activity of PC-1 is not involved in the inhibition of insulin receptor autophosphorylation.	UNIV CALIF SAN FRANCISCO,MT ZION MED CTR,DIV DIABET & ENDOCRINE RES,SAN FRANCISCO,CA 94115	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	GRUPE, A (corresponding author), GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080, USA.							BELLI SI, 1994, BIOCHEM J, V304, P75, DOI 10.1042/bj3040075; BELLI SI, 1994, EUR J BIOCHEM, V226, P433, DOI 10.1111/j.1432-1033.1994.tb20068.x; BELLI SI, 1995, IN PRESS EUR J BIOCH; BUDOHOSKI L, 1984, FEBS LETT, V167, P1, DOI 10.1016/0014-5793(84)80820-0; CHALLISS RAJ, 1992, EUR J PHARM-MOLEC PH, V226, P121, DOI 10.1016/0922-4106(92)90172-R; CIARALDI TP, 1988, MOL CELL ENDOCRINOL, V60, P31, DOI 10.1016/0303-7207(88)90117-7; COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360; CULP JS, 1985, J BIOL CHEM, V260, P8320; FAIN JN, 1975, J BIOL CHEM, V250, P1027; HARAHAP AR, 1988, J IMMUNOL, V141, P2317; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAW WR, 1988, AM J PHYSIOL, V254, pH970, DOI 10.1152/ajpheart.1988.254.5.H970; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MORGAN DO, 1986, BIOCHEMISTRY-US, V25, P1364, DOI 10.1021/bi00354a026; MUELLER CE, 1993, PHARM ACTA HELV, V68, P77; ODA Y, 1991, J BIOL CHEM, V266, P16791; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; ROTH RA, 1992, J CELL BIOCHEM, V48, P12, DOI 10.1002/jcb.240480104; TAYLOR SI, 1991, ANNU REV MED, V42, P373, DOI 10.1146/annurev.me.42.020191.002105; TAYLOR WM, 1979, BIOCHEM J, V178, P381, DOI 10.1042/bj1780381; TERKELTAUB R, 1994, ARTHRITIS RHEUM, V37, P934, DOI 10.1002/art.1780370624; URIARTE M, 1993, BIOCHEM J, V293, P93, DOI 10.1042/bj2930093; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882; VERGAUWEN L, 1994, J CLIN INVEST, V93, P974, DOI 10.1172/JCI117104	28	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22085	22088		10.1074/jbc.270.38.22085	http://dx.doi.org/10.1074/jbc.270.38.22085			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673181	hybrid			2022-12-27	WOS:A1995RW31400003
J	HUANG, T; SCHIRCH, V				HUANG, T; SCHIRCH, V			MECHANISM FOR THE COUPLING OF ATP HYDROLYSIS TO THE CONVERSION OF 5-FORMYLTETRAHYDROFOLATE TO 5,10-METHENYLTETRAHYDROFOLATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHENYLTETRAHYDROFOLATE SYNTHETASE; PURIFICATION; POLYGLUTAMATES; INTERMEDIATE; PHOSPHATE; ENZYME; LIVER; ACID	5,10-Methenyltetrahydrofolate synthetase catalyzes the irreversible conversion of 5-formyl-tetrahydropteroylpolyglutamates (5-CHO-H(4)PteGlu(n)) to 5,10-methenyltetrahydropteroylpolyglutamates (5, 10-CH+-H(4)PteGlu(n)). The equilibrium of the nonenzymatic reaction, which equilibrates slowly in the absence of enzyme, greatly favors 5-CHO-H(4)PteGlu(n). The enzyme couples the reaction to the hydrolysis of ATP shifting the equilibrium to favor 5,10-CH+-H(4)PteGlu(n). Substrate-dependent non equilibrium isotope exchange of [H-3]ADP into ATP was observed, suggesting the formation of a phosphorylated intermediate of 5-CHO-H(4)PteGlu(n) during the enzyme catalyzed reaction, The competitive inhibitor 5-formyltetrahydrohomofolate also supported the ADP to ATP exchange, suggesting that this molecule could also form a phosphorylated intermediate, The initial rates of the ADP-ATP exchange with saturating ADP were about 70 s(-1) for both compounds, while the k(cat) values for product formation were 5 s(-1) for 5 CHO-H(4)PteGlu(n) and 0.005 s(-1) for 5-formyltetrahydrohomofolate. Starting with 5-[O-18]CHO-H(4)PteGlu(n), it was shown by P-31 NMR that the formyl oxygen of the substrate was transferred to the product phosphate during the reaction. This further supports the existence of a phosphorylated intermediate, The formyl group of 5-CHO-H(4)PteGlu(n) is known to be an equilibrium mixture of two rotamers. Stopped-Bow analysis of the enzymatic reaction showed that only one of the rotamers serves as a substrate for the enzyme.	VIRGINIA COMMONWEALTH UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENKOVIC SJ, 1972, J AM CHEM SOC, V94, P7542, DOI 10.1021/ja00776a043; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; DOMANICO P, 1981, J MED CHEM, V24, P1086; FEENEY J, 1980, J CHEM SOC PERK T 2, P176, DOI 10.1039/p29800000176; FEENEY J, 1981, BIOCHEMISTRY-US, V20, P1837, DOI 10.1021/bi00510a019; GREENBERG DM, 1965, BIOCHEMISTRY-US, V4, P1872, DOI 10.1021/bi00885a026; GRIMSHAW CE, 1984, J BIOL CHEM, V259, P2728; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; KAY LD, 1960, J BIOL CHEM, V235, P195; KOUNGA K, 1995, FEBS LETT, V364, P215, DOI 10.1016/0014-5793(95)00396-Q; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MACHOVER D, 1982, CANCER TREAT REP, V66, P1803; MARAS B, 1994, J BIOL CHEM, V269, P18429; MAY M, 1951, J AM CHEM SOC, V73, P3067, DOI 10.1021/ja01151a028; MEJILLANO MR, 1989, BIOCHEMISTRY-US, V28, P5136, DOI 10.1021/bi00438a034; PETERS JM, 1958, J AM CHEM SOC, V80, P2719, DOI 10.1021/ja01544a034; POE M, 1980, BIOCHEMISTRY-US, V19, P4576, DOI 10.1021/bi00561a006; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4356, DOI 10.1021/bi00363a027; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SEDDON AP, 1986, J BIOL CHEM, V261, P1538; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1991, J BIOL CHEM, V266, P1543; STOVER P, 1993, ADV EXP MED BIOL, V338, P723; TEMPLE C, 1984, CHEM BIOCH FOLATES, V1, P80	28	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22296	22300		10.1074/jbc.270.38.22296	http://dx.doi.org/10.1074/jbc.270.38.22296			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673211	hybrid			2022-12-27	WOS:A1995RW31400038
J	KITAGAWA, H; TANAKA, Y; TSUCHIDA, K; GOTO, F; OGAWA, T; LIDHOLT, K; LINDAHL, U; SUGAHARA, K				KITAGAWA, H; TANAKA, Y; TSUCHIDA, K; GOTO, F; OGAWA, T; LIDHOLT, K; LINDAHL, U; SUGAHARA, K			N-ACETYLGALACTOSAMINE (GALNAC) TRANSFER TO THE COMMON CARBOHYDRATE-PROTEIN LINKAGE REGION OF SULFATED GLYCOSAMINOGLYCANS - IDENTIFICATION OF UDP-GALNAC-CHONDRO-OLIGOSACCHARIDE ALPHA-N-ACETYLGALACTOSAMINYLTRANSFERASE IN FETAL BOVINE SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM MOUSE-TUMOR; CHONDROITIN-6-SULFATE PROTEOGLYCANS; SULFOTRANSFERASE ACTIVITIES; SHARK CARTILAGE; HEPARAN-SULFATE; ANIMAL SERA; PURIFICATION; BIOSYNTHESIS; 4-SULFATE	During the course of a study to elucidate the role of modification of the common polysaccharide-protein linkage structure, GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser, in biosynthetic sorting mechanisms of the different sulfated glycosaminoglycan chains, a novel N-acetylgalactosamine (GalNAc) transferase was discovered in fetal bovine serum, The enzyme catalyzed the transfer of [H-3]GaINAc from UDP-[H-3]GaINAc to linkage tetrasaccharide and hexasaccharide serines synthesized chemically and to various regular oligosaccharides containing terminal D-glucuronic acid (GlcA), which were prepared from chondroitin and chondroitin sulfate using testicular hyaluronidase digestion, The labeled products obtained with the linkage tetra- and hexasaccharide serines and with the tetrasaccharide (GlcA beta 1-3GalNAc)(2) were resistant to digestion with chondroitinase AC-II and beta-N-acetylhexosaminidase but sensitive to alpha-N-acetylgalactosaminidase digestion, indicating that the enzyme is an alpha-N-acetylgalactosaminyltransferase. This finding is in contrast to that of Rohrmann ef al, (Rohrmann, K., Niemann, R,, and Buddecke, E, (1985) Ear, J, Biochem., 148, 463-469), who reported that a corresponding product was susceptible to digestion with beta-N-acetylhexosaminidase. The presence of a sulfate group at C4 of the penultimate GalNAc or Gal units markedly inhibited the transfer of GalNAc to the terminal GlcA, while a sulfate group at C6 of the GalNAc had Little effect on the transfer, Moreover, a slight but significant transfer of [(3)]GalNAc was observed to an oligosaccharide containing terminal 2-O-sulfated GlcA as acceptor, whereas no incorporation was detected into oligosaccharides containing terminal unsaturated or 3-O-sulfated GlcA units, These results suggest that this novel serum enzyme is a UDP-GalNAc:chondro-oligosaccharide alpha 1-3- or 1-4-N-acetylgalactosaminyltransferase. The possibility of involvement of this enzyme in glycosaminoglycan biosynthesis is discussed.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,GRAD SCH AGR & LIFE SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,CTR BIOMED,S-75123 UPPSALA,SWEDEN	Kobe Pharmaceutical University; RIKEN; University of Tokyo; Uppsala University			Ogawa, Tomoya/C-3655-2009; Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; ETCHISON JR, 1995, J BIOL CHEM, V270, P756, DOI 10.1074/jbc.270.2.756; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GOTO F, 1992, TETRAHEDRON LETT, V33, P6841, DOI 10.1016/S0040-4039(00)61790-2; GOTO F, 1992, TETRAHEDRON LETT, V33, P5099, DOI 10.1016/S0040-4039(00)61200-5; GOTO F, 1993, PURE APPL CHEM, V65, P793, DOI 10.1351/pac199365040793; INOUE H, 1986, J BIOL CHEM, V261, P4460; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; LIND T, 1993, J BIOL CHEM, V268, P20705; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1989, J BIOCHEM-TOKYO, V106, P910, DOI 10.1093/oxfordjournals.jbchem.a122951; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGIURA M, 1982, J BIOL CHEM, V257, P9501; TANIGUCHI N, 1982, J BIOL CHEM, V257, P631	26	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22190	22195		10.1074/jbc.270.38.22190	http://dx.doi.org/10.1074/jbc.270.38.22190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673197	hybrid			2022-12-27	WOS:A1995RW31400022
J	BJORKOY, G; OVERVATN, A; DIAZMECO, MT; MOSCAT, J; JOHANSEN, T				BJORKOY, G; OVERVATN, A; DIAZMECO, MT; MOSCAT, J; JOHANSEN, T			EVIDENCE FOR A BIFURCATION OF THE MITOGENIC SIGNALING PATHWAY ACTIVATED BY RAS AND PHOSPHATIDYLCHOLINE-HYDROLYZING PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; XENOPUS-LAEVIS OOCYTES; NF-KAPPA-B; RAF-1 KINASE; ONCOGENIC P21(RAS); ALPHA-THROMBIN; ZETA-ISOFORM; IN-VITRO; CELLS	NIH 3T3 cells stably transfected with the gene encoding phosphatidylcholine-hydrolyzing phospholipase C (PC-PLC) from Bacillus cereus display a chronic elevation of intracellular diacylglycerol levels and a transformed phenotype, We have used such PC-PLC-transformed cells to evaluate the roles of the cytoplasmic serine/threonine kinases Raf-1, zeta protein kinase C (zeta PKC) and protein kinase A (PKA) in oncogenesis and mitogenic signal transduction elicited by phosphatidylcholine hydrolysis, We demonstrate here that stable expression of dominant negative mutants of both zeta PKC and Raf-1 lead to reversion of PC-PLC-transformed cells, Interestingly, expression of kinase defective zeta PKC also reverted NIH 3T3 cells transformed by the v-Ha-ras oncogene, Activation of PKA in response to elevation of cAMP levels also lead to reversion of PC-PLC-induced transformation, implicating PKA as a negative regulator acting downstream of PC-PLC, On the other hand, inhibition or depletion of phorbol ester responsive PKCs attenuated but did not block the ability of PC-PLC-transformed cells to induce DNA synthesis in the absence of growth factors, These results clearly implicate both Raf-1 and zeta PKC as necessary downstream components for transduction of the mitogenic/oncogenic signal generated by PLC-mediated hydrolysis of phosphatidylcholine and suggest, together with other recent evidence, a bifurcation in the signaling pathway downstream of PC-PLC.	UNIV TROMSO,INST MED BIOL,DEPT BIOCHEM,N-9037 TROMSO,NORWAY; UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN	UiT The Arctic University of Tromso; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Moscat, Jorge/A-7011-2009; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Bjorkoy, Geir/0000-0003-0031-8361; Diaz-Meco, Maria/0000-0003-0147-0998				BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1995, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; JOHANSEN T, 1994, MOL CELL BIOL, V14, P646, DOI 10.1128/MCB.14.1.646; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1994, J BIOL CHEM, V269, P17495; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QUERESCHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SANZ L, 1994, J BIOL CHEM, V269, P10044; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOZERI O, 1992, ONCOGENE, V7, P2259; STEPHENS EV, 1993, ONCOGENE, V8, P19; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	61	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21299	21306						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673165				2022-12-27	WOS:A1995RU05400066
J	GELFAND, CA; WANG, Q; RANDALL, S; JENTOFT, JE				GELFAND, CA; WANG, Q; RANDALL, S; JENTOFT, JE			INTERACTIONS OF AVIAN-MYELOBLASTOSIS VIRUS NUCLEOCAPSID PROTEIN WITH NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; REPRESSOR-OPERATOR INTERACTION; PRIMER TRANSFER-RNA; GENE 32 PROTEIN; VIRAL-RNA; ESCHERICHIA-COLI; LEUKEMIA-VIRUS; BINDING; DNA; RETROVIRUSES	The retroviral nucleocapsid protein (NC) associates, histone-like, with genomic RNA within the viral capsid. NC, an essential component of replication competent retroviruses, is also associated with events leading both to virus assembly and to reverse transcription. The nucleic acid binding properties of NC are key to understanding these properties, yet only a minimal biochemical description of NC-nucleic acid interactions is available. We have used the anisotropy of the intrinsic fluorescence of NC from avian myeloblastosis virus to quantify its binding to a variety of nucleic acids. Using salt back-titrations, the intrinsic equilibrium association constant per nucleic acid site, K(obs), was determined for NC binding to single- and double-stranded RNAs and DNAs. In 0.125 M NaCl, 40 mm HEPES at pH 7.0 and 27-degrees-C, the log K(obs) ranged from 3.3 to 4.0 (average 3.7) for these nucleic acids. From the salt dependence of K(obs), it was estimated that, on balance, 1 ion was displaced upon formation of each complex; it is likely that cation displacement from nucleic acid is offset by anion binding by protein during complex formation. The logarithm of the mean intrinsic affinity in the absence of polyelectrolyte effects, log K(T), was 3.1, corresponding to a DELTAG of -4.2 kcal/mol. K(obs), K(T), and the number of displaced ions were independent of pH between pH 5.6 and 8.9, indicating that NC residues that titrate in this pH range are not contributing to binding. K(obs) and K(T) increase with temperature, in the range 15 to 47-degrees-C. From van't Hoff analysis, entropy was found to be the driving force for formation of the NC-poly(rA) complex, even in the absence of the polyelectrolyte effect. The general nature of NC interactions with nucleic acids is shown by the similarity of the K(obs) values for RNAs and DNAs in both single-stranded and double-stranded structures. This ability of NC to interact with all types of nucleic acids may provide it with the necessary versatility to function like a histone in facilitating the packaging of viral RNA and yet function early in infection, where it has been ascribed a role in facilitating reverse transcription.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University					NIAMS NIH HHS [AR 20168] Funding Source: Medline; NIGMS NIH HHS [GM 36948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036948] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P454; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; DAVIS J, 1976, J VIROL, V18, P709, DOI 10.1128/JVI.18.2.709-718.1976; DAVIS NL, 1972, J VIROL, V10, P1010, DOI 10.1128/JVI.10.5.1010-1020.1972; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P477; FLEISSNER E, 1971, J VIROL, V8, P778, DOI 10.1128/JVI.8.5.778-785.1971; FU XD, 1985, J BIOL CHEM, V260, P9941; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; JOHNSON SP, 1983, J VIROL, V45, P876, DOI 10.1128/JVI.45.2.876-881.1983; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATZ RA, 1989, BIOESSAYS, V11, P176, DOI 10.1002/bies.950110605; KATZ RA, 1986, GENE, V50, P361, DOI 10.1016/0378-1119(86)90340-9; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; LEIS J, 1983, J VIROL, V48, P361, DOI 10.1128/JVI.48.2.361-369.1983; LEIS J, 1988, J VIROL, V62, P1808, DOI 10.1128/JVI.62.5.1808-1809.1988; LEIS JP, 1978, VIROLOGY, V84, P87, DOI 10.1016/0042-6822(78)90220-9; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PAL BK, 1977, VIROLOGY, V83, P423, DOI 10.1016/0042-6822(77)90188-X; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SECNIK J, 1992, BIOCHEMISTRY-US, V31, P2982, DOI 10.1021/bi00126a020; SECNIK J, 1990, BIOCHEMISTRY-US, V29, P7991, DOI 10.1021/bi00486a030; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; STEEG CM, 1990, J VIROL, V64, P847, DOI 10.1128/JVI.64.2.847-855.1990; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; TAKAHASHI M, 1990, BIOCHEMISTRY-US, V29, P3431, DOI 10.1021/bi00466a002	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18450	18456						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689554				2022-12-27	WOS:A1993LV65900014
J	SZUMILO, T; DRAKE, RR; YORK, JL; ELBEIN, AD				SZUMILO, T; DRAKE, RR; YORK, JL; ELBEIN, AD			GDP-MANNOSE PYROPHOSPHORYLASE - PURIFICATION TO HOMOGENEITY, PROPERTIES, AND UTILIZATION TO PREPARE PHOTOAFFINITY ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS	Pig liver GDP-mannose pyrophosphorylase was purified 5,000-fold to apparent homogeneity using standard techniques. The native enzyme showed a single band on gels of about 450 kDa and two subunits of 43 and 37 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The 37-kDa (beta-) subunit had only methionine at its amino terminus and a surprisingly hydrophobic sequence: Met-Lys-Ala-Leu-Ile-Leu-Val Gly-Gly-Tyr-Gly-Thr-Arg-Leu-Arg-Pro-Leu-Thr Leu-Ser-Ile-Pro-Lys. The 43-kDa (alpha-) subunit was blocked at the amino terminus, but a 29-kDa CNBr fragment had the following sequence: Leu-Asp-Ala-His-Arg-His-Arg-Pro-His-Pro-Phe-Leu-Leu-. Substrate specificity studies done in the direction of formation of nucleoside triphosphate and sugar-1-P indicated that the enzyme was most effective with GDP-glucose as substrate (100%) followed by IDP-mannose (72%) and then GDP-mannose (61%). That GDP-mannose and GDP-glucose activities were indeed catalyzed by the same enzyme was indicated by the following. (i) Various studies indicated that the enzyme was homogeneous. (ii) A staining procedure for production of GTP stained the same single band on native gels when either GDP-mannose or GDP-glucose was the substrate. (iii). GDP-mannose inhibited the utilization of GDP-glucose by the enzyme, and vice versa. When 8-azido-[P-32]GTP was incubated with native enzyme and exposed to UV light, both the 43-kDa and the 37-kDa subunits became labeled, although the 37-kDa subunit reacted more strongly. On the other hand, 8-azido-GDP-[P-32]mannose only photolabeled the 43-kDa band. Most importantly, the purified enzyme can be utilized to produce 8-azido-[P-32]GDP mannose or 8-azido-[P-32]GDP glucose.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,1301 W MARKHAM,MS 516,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; ELBEIN AD, 1979, ANNU REV PLANT PHYS, V30, P239, DOI 10.1146/annurev.pp.30.060179.001323; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GINSBURG V, 1964, ADV ENZYMOL REL S BI, V26, P35; GROVES WE, 1968, ANAL BIOCHEM, V22, P195, DOI 10.1016/0003-2697(68)90307-2; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUNCHPETERSEN A, 1956, ACTA CHEM SCAND, V10, P928, DOI 10.3891/acta.chem.scand.10-0928; PASTUSZAK I, 1990, Glycobiology, V1, P71, DOI 10.1093/glycob/1.1.71; PREISS J, 1964, J BIOL CHEM, V239, P3119; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; SMOOT JW, 1985, EUR J BIOCHEM, V148, P83, DOI 10.1111/j.1432-1033.1985.tb08810.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERACHTERT H, 1966, J BIOL CHEM, V241, P2007	17	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17943	17950						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688733				2022-12-27	WOS:A1993LT74300048
J	ZALATAN, F; GALLOWAYSALVO, J; PLATT, T				ZALATAN, F; GALLOWAYSALVO, J; PLATT, T			DELETION ANALYSIS OF THE ESCHERICHIA-COLI RHO-DEPENDENT TRANSCRIPTION TERMINATOR TRP-T'	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRO MESSENGER-RNA; ATPASE ACTIVITY; GENE-EXPRESSION; 3' END; REQUIREMENT; LAMBDA-TR1; SEQUENCE; UPSTREAM; DOMAINS; PROTEIN	We have analyzed with deletion mutations the Escherichia coli rho-dependent transcription terminator trp t'. This site, 211 nucleotides in length, contains multiple sequence elements that are recognized by rho. Among these multiple elements are two that together appear to be important for full transcription termination efficiency in vitro and are similar to the rutA and rutB sequence elements in the lambdatR1 rho-dependent terminator previously described by Chen and Richardson (1987). The results suggest for the first time that common functionally important elements are shared among rho-dependent terminators. Other regions of trp t' also appear to contribute to its functional efficiency, consistent with the idea that rho-dependent terminators contain dispersed and redundant recognition segments.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNION COLL,DEPT BIOL,SCHENECTADY,NY 12308	University of Rochester; University of Rochester; Union College					NIGMS NIH HHS [GM22830] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIFANO P, 1991, CELL, V64, P553; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; GALLOWAY J, 1987, THESIS YALE U; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLOWAY JL, 1986, REGULATION GENE EXPR, P155; HART CM, 1991, J BIOL CHEM, V266, P24140; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; LAU LF, 1985, J BIOL CHEM, V260, P574; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERYGOLDHAMME.C, 1974, P NATL ACAD SCI USA, V71, P1162; MCKENNY K, 1982, GENE AMPLIFICATION A, V2, P383; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1992, NUCLEIC ACIDS RES, V20, P6107, DOI 10.1093/nar/20.22.6107; NEHRKE KW, 1993, IN PRESS GENE EXPRES; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; RICHARDSON LV, 1992, NUCLEIC ACIDS RES, V20, P5383, DOI 10.1093/nar/20.20.5383; SCHNEIDER D, 1993, FASEB J, V7, P201, DOI 10.1096/fasebj.7.1.7678562; SEIFRIED SE, 1992, P NATL ACAD SCI USA, V89, P10454, DOI 10.1073/pnas.89.21.10454; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; WU AM, 1980, CELL, V19, P829, DOI 10.1016/0092-8674(80)90073-2; ZALATAN F, 1992, J BIOL CHEM, V267, P19082	32	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17051	17056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688721				2022-12-27	WOS:A1993LQ98800028
J	HANADA, K; IZAWA, K; NISHIJIMA, M; AKAMATSU, Y				HANADA, K; IZAWA, K; NISHIJIMA, M; AKAMATSU, Y			SPHINGOLIPID DEFICIENCY INDUCES HYPERSENSITIVITY OF CD14, A GLYCOSYL PHOSPHATIDYLINOSITOL-ANCHORED PROTEIN, TO PHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS BINDING; BIOSYNTHESIS; MEMBRANE; SPHINGOMYELIN; METABOLISM; RECEPTOR; MUTANT; CELLS	Strain SPB-1 is a temperature-sensitive Chinese hamster ovary cell mutant defective in sphingoid base biosynthesis. To examine the effects of sphingolipid deficiency on a glycosyl phosphatidylinositol-anchored protein, we constructed transfectants expressing mouse CD14 from the SPB-1 and the wild type cells. When the cells were precultured in a sphingolipid-deficient medium at 39-degrees-C, CD14 expressed in the SPB-1 cells was hypersensitive to phosphatidylinositol-specific phospholipase C (PI-PLC), compared with that in the wild type cells. Moreover, after exposure of the cells to fumonisin B1, an inhibitor of ceramide synthase, CD14, even in the wild type cells, became hypersensitive to PI-PLC. The PI-PLC hypersensitivity in the SPB-1 cells was almost completely suppressed when the cells were cultured in the presence of exogenous sphingosine or sphingomyelin. On the other hand, the hypersensitivity induced by fumonisin B1 was suppressed by exogenous sphingomyelin but not by sphingosine. The suppression by exogenous glucosylceramide was partial under both conditions. Likewise, CD14 molecules in membranes prepared from the sphingolipid-deficient cells were more sensitive to PI-PLC than those from the control cells. These results indicated that a deficiency in cellular complex sphingolipids caused the PI-PLC hypersensitivity of CD14, suggesting the interaction of CD14 with sphingolipids in membranes.	NATL INST HLTH,DEPT BIOCHEM & CELL BIOL,SHINJUKU KU,TOKYO 162,JAPAN					Hanada, Kentaro/0000-0003-1383-2781				BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1990, J BIOL CHEM, V265, P22137; HARAKUGE S, 1990, J BIOL CHEM, V265, P6606; HAZIOT A, 1988, J IMMUNOL, V141, P547; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUURA K, 1989, NUCLEIC ACIDS RES, V17, P2132, DOI 10.1093/nar/17.5.2132; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MILLERPODRAZA H, 1982, BIOCHEMISTRY-US, V21, P3260, DOI 10.1021/bi00257a002; NASU N, 1991, INT IMMUNOL, V3, P205, DOI 10.1093/intimm/3.2.205; NORRED WP, 1992, MYCOPATHOLOGIA, V117, P73, DOI 10.1007/BF00497281; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHUTT C, 1988, IMMUNOL LETT, V19, P321, DOI 10.1016/0165-2478(88)90162-9; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG E, 1991, J BIOL CHEM, V266, P14486; White D.A., 1973, FORM FUNCTION PHOSPH; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	30	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13820	13823						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686144				2022-12-27	WOS:A1993LJ82500011
J	NAJBAUER, J; JOHNSON, BA; YOUNG, AL; ASWAD, DW				NAJBAUER, J; JOHNSON, BA; YOUNG, AL; ASWAD, DW			PEPTIDES WITH SEQUENCES SIMILAR TO GLYCINE, ARGININE-RICH MOTIFS IN PROTEINS INTERACTING WITH RNA ARE EFFICIENTLY RECOGNIZED BY METHYLTRANSFERASE(S) MODIFYING ARGININE IN NUMEROUS PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; MAJOR NUCLEOLAR PROTEINS; BINDING PROTEINS; CDNA CLONING; PHOSPHOPROTEIN C23; POLYACRYLAMIDE GELS; COMPLEX PROTEIN-A1; PC12 CELLS; LOCALIZATION; GENE	Several proteins that interact with RNA, e.g. the heterogenous ribonucleoprotein particle A and B proteins, fibrillarin and nucleolin, contain the modified amino acid N(G),N(G)-dimethylarginine. Here, we report that two synthetic peptides, Ac-GGRGGFGGRGGFGGRGGFG-NH2 (R3) and GGFGGRGGFG-NH2 (R1), which are based on methylated sequences in fibrillarin and nucleolin, inhibit the methylation of a large majority of the methyl-accepting proteins observed in extracts of adenosine dialdehyde-treated PC12 cells. Concomitantly, the peptides themselves become methylated, suggesting that they compete for the same enzyme that carries out the bulk of N-methylation in PC12 cells. R3 potently inhibits formation of N(G),N(G)-dimethylarginine in PC12 substrates, with a lesser effect on N(G)-monomethylarginine and N(G),N'(G)-dimethylarginine. Bovine brain contains an activity that methylates PC12 methyl acceptors. After partial purification, the bovine methyltransferase efficiently modifies R3 and R1, yielding half-maximal rates of methylation at approximately 0.2 and approximately 2 muM peptide, respectively. A search of the GenPept database for the FGGRGGF motif revealed 13 candidate methyl acceptors containing arginine and at most two similar substitutions or one mismatch. Of these, 10 are known or presumed to interact with RNA. These findings are consistent with the hypothesis that a majority of proteins containing N(G),N(G)-dimethylarginine interact with RNA.	UNIV CALIF IRVINE,SCH BIOL SCI,ROOM 2205,BIOSCI 2,IRVINE,CA 92717	University of California System; University of California Irvine				Johnson, Brett/0000-0002-9260-245X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-17269] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; BOURBON HM, 1990, GENE, V88, P187, DOI 10.1016/0378-1119(90)90031-L; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; BUGLER B, 1987, J BIOL CHEM, V262, P10922; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GHISOLFI L, 1990, MOL BIOL REP, V14, P113, DOI 10.1007/BF00360437; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; HASSETT C, 1990, NUCLEIC ACIDS RES, V18, P1429, DOI 10.1093/nar/18.6.1429; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; JOHNSON BA, 1993, IN PRESS J BIOL CHEM, V268; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; KARN J, 1977, J BIOL CHEM, V252, P7307; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KAY BK, 1990, P NATL ACAD SCI USA, V87, P1367, DOI 10.1073/pnas.87.4.1367; KONDO K, 1992, J BIOL CHEM, V267, P16252; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LISCHWE MA, 1982, J BIOL CHEM, V257, P4600; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LISCHWE MA, 1981, EXP CELL RES, V136, P101, DOI 10.1016/0014-4827(81)90041-0; LISCHWE MA, 1990, PROTEIN METHYLATION, P97; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MORISHIMA N, 1987, BIOCHEMISTRY-US, V26, P8279, DOI 10.1021/bi00399a039; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NAJBAUER J, 1992, ARCH BIOCHEM BIOPHYS, V293, P85, DOI 10.1016/0003-9861(92)90369-8; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; NAJBAUER J, 1990, J BIOL CHEM, V265, P12717; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; OCHS RL, 1984, EXP CELL RES, V152, P260, DOI 10.1016/0014-4827(84)90251-9; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAIK MK, 1991, INT J BIOCHEM, V23, P939, DOI 10.1016/0020-711X(91)90083-Y; PAIK WK, 1990, PROTEIN METHYLATION, P23; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAJPUROHIT R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P183, DOI 10.1016/0167-4838(92)90322-5; REPORTER M, 1971, BIOCHEM BIOPH RES CO, V43, P644, DOI 10.1016/0006-291X(71)90663-2; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; ROMKES M, 1991, BIOCHEMISTRY-US, V30, P3247, DOI 10.1021/bi00227a012; SAPP M, 1986, NUCLEIC ACIDS RES, V14, P6803, DOI 10.1093/nar/14.17.6803; SCHENKEL J, 1988, EUR J BIOCHEM, V171, P565, DOI 10.1111/j.1432-1033.1988.tb13825.x; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SHOWALTER AM, 1991, PLANT MOL BIOL, V16, P547, DOI 10.1007/BF00023421; SOMMERVILLE J, 1986, TRENDS BIOCHEM SCI, V11, P438, DOI 10.1016/0968-0004(86)90242-2; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; STOCK A, 1987, FEBS LETT, V220, P8, DOI 10.1016/0014-5793(87)80866-9; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x	86	204	210	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10501	10509						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683681				2022-12-27	WOS:A1993LB80000076
J	WOLFF, DJ; DATTO, GA; SAMATOVICZ, RA; TEMPSICK, RA				WOLFF, DJ; DATTO, GA; SAMATOVICZ, RA; TEMPSICK, RA			CALMODULIN-DEPENDENT NITRIC-OXIDE SYNTHASE - MECHANISM OF INHIBITION BY IMIDAZOLE AND PHENYLIMIDAZOLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; FLAVOPROTEIN; REDUCTASE; FMN; CYTOCHROME-P-450BM-3; CEREBELLUM; INVITRO; FAD	Calmodulin-dependent nitric-oxide synthase from bovine brain and GH3 Pituitary cells is inhibited by imidazole, 1-phenylimidazole, 2-phenylimidazole, and 4-phenylimidazole, with half-maximal inhibition occurring at 200, 25, 160, and 600 muM concentrations of inhibitor, respectively. Imidazole inhibits the maximal velocity of citrulline formation by the enzyme, but does not alter the concentration of arginine, calmodulin, or (6R)-5,6,7,8,-tetrahydro-L-biopterin required for expression of half-maximal activity. Imidazole, 1-phenylimidazole, 2-phenylimidazole, and 4-phenylimidazole had no effect on calmodulin-dependent reduction of cytochrome c by the enzyme at concentrations up to 50-fold higher than those that inhibited citrulline formation. Imidazole inhibited calmodulin-dependent NADPH consumption by the enzyme with dissolved oxygen as the sole electron acceptor, with half-maximal inhibition occurring at a concentration of 225 muM. These observations are consistent with the proposal that imidazole and phenylimidazoles inhibit citrulline formation and oxygen reduction by acting as a sixth coordination ligand of the heme iron. This interaction prevents the formation of the activated reduced species of oxygen necessary for the formation of citrulline.			WOLFF, DJ (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011252] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11252] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; DUS K, 1976, BIOCHEM BIOPH RES CO, V69, P437, DOI 10.1016/0006-291X(76)90541-6; DUS K, 1977, MICROSOMES DRUG OXID, P95; EAST SJ, 1990, EUR J PHARMACOL, V184, P311, DOI 10.1016/0014-2999(90)90623-E; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MILES EW, 1975, METHOD ENZYMOL, V41, P431; MONCADA S, 1991, PHARMACOL REV, V43, P109; NARHI LO, 1987, J BIOL CHEM, V262, P6683; OSTER T, 1991, J BIOL CHEM, V266, P22718; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; ROGERSON TD, 1977, BIOCHEM PHARMACOL, V26, P1039, DOI 10.1016/0006-2952(77)90241-6; SCHENKMAN JB, 1981, PHARMACOL THERAPEUT, V12, P43, DOI 10.1016/0163-7258(81)90075-9; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1991, J BIOL CHEM, V266, P3369; SWANSON RA, 1979, J BIOL CHEM, V254, P7238; VERMILION JL, 1981, J BIOL CHEM, V256, P266; WHITAKER MJ, 1983, PROC R SOC SER B-BIO, V218, P397, DOI 10.1098/rspb.1983.0047; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1979, ADV CYCLIC NUCLEOTID, V11, P28; WOLFF DJ, 1992, BIOCHEM J, V284, P201	32	99	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9425	9429						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683651				2022-12-27	WOS:A1993LA68900044
J	MOY, P; LOBB, R; TIZARD, R; OLSON, D; HESSION, C				MOY, P; LOBB, R; TIZARD, R; OLSON, D; HESSION, C			CLONING OF AN INFLAMMATION-SPECIFIC PHOSPHATIDYL INOSITOL-LINKED FORM OF MURINE VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL; LEUKOCYTE ADHESION; INTEGRIN VLA-4; ENDOTHELIAL-CELLS; PROTEINS; VCAM-1; LYMPHOCYTES; EXPRESSION; BIOSYNTHESIS; PRECURSORS	Vascular cell adhesion molecule-1 (VCAM1) is a member of the immunoglobulin (Ig) superfamily which interacts with the integrin very late antigen-4 (VLA4). The VCAM1/VLA4 interaction mediates both adhesion and signal transduction and is thought to play an important role in inflammatory and immune responses in vivo. VCAM1 cDNAs cloned from mouse, rat, rabbit, and human libraries contain six, seven, or eight extracellular Ig-like domains generated by alternate splicing, but to date shorter forms have not been found. We have cloned a novel cDNA encoding only the three N-terminal domains of murine VCAM1 followed by a unique C-terminal tail generated by alternate splicing of a previously undescribed exon. This truncated form of murine VCAM1 (3D-VCAM1) is expressed in COS cells as a functional adhesion molecule which is lost from the cell surface following treatment with phosphatidylinositol-specific phospholipase C. 3D-VCAM1 is found only in endotoxin-treated but not control murine and rat tissues. Thus in rodents alternate splicing of the VCAM1 gene generates a unique truncated inflammation-specific phosphatidylinositol-linked form of VCAM1.	BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142	Biogen								BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BURKLY LC, 1991, EUR J IMMUNOL, V21, P2871, DOI 10.1002/eji.1830211132; CARLOS TM, 1990, BLOOD, V76, P965; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHISHOLM PL, 1993, IN PRESS EUR J IMMUN; CYBULSKY MI, 1991, P NATL ACAD SCI USA, V88, P7859, DOI 10.1073/pnas.88.17.7859; CYBULSKY MI, 1991, AM J PATHOL, V138, P815; DAMLE NK, 1991, P NATL ACAD SCI USA, V88, P6403, DOI 10.1073/pnas.88.15.6403; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GRABER N, 1990, J IMMUNOL, V145, P819; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HESSION C, 1991, J BIOL CHEM, V266, P6682; HESSION C, 1992, BIOCHEM BIOPH RES CO, V183, P163, DOI 10.1016/0006-291X(92)91623-X; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JOSEPH J, 1992, FASEB J, V6, P1200; LOBB RR, 1991, J IMMUNOL, V147, P124; LOBB RR, 1991, CELLULAR MOL MECHANI, V2, P151; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MARLOR CW, 1992, AM J PATHOL, V140, P1055; MCEVOY LM, 1992, FASEB J, V6, P5506; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; OBRIEN K, 1993, IN PRESS CIRCULATION; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PEPINSKY B, 1992, J BIOL CHEM, V267, P17820; POLTE T, 1991, DNA CELL BIOL, V10, P349, DOI 10.1089/dna.1991.10.349; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WEG VB, 1993, IN PRESS J EXP MED; WINN R, 1992, FASEB J, V6, P4359; WUTHRICH RP, 1992, KIDNEY INT, V42, P903, DOI 10.1038/ki.1992.367; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	51	48	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8835	8841						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682556				2022-12-27	WOS:A1993KX81100068
J	THEVENIN, C; LUCAS, BP; KOZLOW, EJ; KEHRL, JH				THEVENIN, C; LUCAS, BP; KOZLOW, EJ; KEHRL, JH			CELL TYPE-SPECIFIC AND STAGE-SPECIFIC EXPRESSION OF THE CD20/B1 ANTIGEN CORRELATES WITH THE ACTIVITY OF A DIVERGED OCTAMER DNA MOTIF PRESENT IN ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PROMOTER; TRANSCRIPTION FACTOR; STIMULATES TRANSCRIPTION; IMMUNOGLOBULIN GENES; BINDING PROTEINS; LYMPHOCYTES-B; HELA-CELLS; ACTIVATION; DOMAINS; REQUIREMENT	The CD20(B1) gene encodes a B cell-specific protein involved in the regulation of human B cell proliferation and differentiation. Studies with 5' deletion CD20 promoter-CAT constructs have previously revealed two regions of the promoter between bases -186 and -280 and between bases -280 and -454 which contained positive regulatory elements. In this study we identified a sequence element present in the most proximal region located between bases -214 and -201, TTCTTCTAATTAA, which is important in the high constitutive expression of CD20 in mature B cells and the induction of CD20 in pre-B cells. This sequence element was referred to as the BAT box and its deletion significantly reduced the activity of a CD20 promoter-CAT construct in B cells. Mobility shift assays with various mutant probes and B cell nuclear extracts demonstrated that the core sequence TAAT was essential for binding to this site. Cross competition experiments with an octamer sequence from the Ig heavy chain promoter, the BAT box, and a TA-rich sequence present in the CD21 promoter revealed that all three sequences bound the same nuclear proteins suggesting that the BAT box binding proteins were Oct-1 and Oct-2. Southwestern blotting and UV cross-linking studies confirmed that the BAT box binding proteins were Oct-1 and Oct-2. The affinity of the BAT box binding proteins for the BAT box was approximately 25-fold less than for the octamer sequence and the BAT box binding proteins dissociated from the BAT box 10-fold more rapidly than from the octamer sequence. Despite this lower affinity, a trimer of the BAT box sequence was as efficiently transactivated by an Oct-2 expression vector as was a trimer of the octamer sequence in HeLa cells. The BAT box and Oct-2 were also implicated in the induction of CD20 in the pre-B cell line, PB-697, via phorbol esters. The induction of CD20 mRNA was temporally associated with induction of Oct-2 mRNA and a BAT box-deleted CD20-CAT construct, in contrast to the wild type, was poorly induced by phorbol esters. Together these results suggest that the BAT box binding proteins are important in the B cell specific expression of CD20 and perhaps CD21.	NIAID, IMMUNOREGULAT LAB, BLDG 10, RM 11B-13, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel FM, 1991, CURRENT PROTOCOLS MO; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK EA, 1989, ADV CANCER RES, V52, P81; COOPER MD, 1987, NEW ENGL J MED, V317, P1452, DOI 10.1056/NEJM198712033172306; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LOKEN MR, 1987, BLOOD, V70, P1316; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; NADLER LM, 1982, J CLIN INVEST, V70, P433, DOI 10.1172/JCI110633; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; RAYHEL EJ, 1991, J IMMUNOL, V146, P2021; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SHERMAN PA, 1989, P NATL ACAD SCI USA, V86, P6739, DOI 10.1073/pnas.86.17.6739; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STASHENKO P, 1981, P NATL ACAD SCI-BIOL, V78, P3848, DOI 10.1073/pnas.78.6.3848; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STIMAC E, 1988, MOL CELL BIOL, V8, P3734, DOI 10.1128/MCB.8.9.3734; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YOZA BK, 1990, MOL CELL BIOL, V10, P2145, DOI 10.1128/MCB.10.5.2145	32	55	57	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5949	5956						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680653				2022-12-27	WOS:A1993KR82200088
J	COLE, F; FASY, TM; RAO, SS; DEPERALTA, MA; KOHTZ, DS				COLE, F; FASY, TM; RAO, SS; DEPERALTA, MA; KOHTZ, DS			GROWTH-FACTORS THAT REPRESS MYOBLAST DIFFERENTIATION SUSTAIN PHOSPHORYLATION OF A SPECIFIC SITE ON HISTONE-H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; DNA-BINDING; RNA GENES; TRANSCRIPTIONAL ACTIVATION; MYOGENIC DIFFERENTIATION; CHROMATIN; PROTEINS; INVITRO; SEQUENCE; STATES	A monoclonal antibody (12D11) is presented that binds an epitope on histone H1 only when it is phosphorylated. Skeletal myoblasts, which are cultured in high mitogen medium to induce proliferation and inhibit differentiation, contain histone HI reactive with monoclonal antibody 12D11, whereas differentiated myocytes and adult skeletal muscle do not. Phosphorylation of H1 at the 12D11 epitope, as assessed by antibody binding, is also induced and maintained in myoblasts cultured in low mitogen medium supplemented with transforming growth factor beta, which blocks differentiation but allows the cells to withdraw from the cell cycle (Olson, E., Sternberg, E., Hu, J., Spizz, G., and Wilcox, C. (1986) J. Cell Biol. 103, 1799-1805; Massague, J., Cheipetz, S., Endo, T., and Nadal-Ginard, B. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8206-8210). These observations suggest that phosphorylation of histone H1 at the 12D11 epitope is associated with the negative regulation of myoblast differentiation by growth factors.	CUNY MT SINAI SCH MED,DEPT PATHOL,1 GUSTAVE LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Cole, Francesca/0000-0001-6391-2363	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040659, R01HL043583] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43583, HL40659] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AJIRO K, 1990, J BIOL CHEM, V265, P6494; AJIRO K, 1981, BIOCHEMISTRY-US, V20, P1445, DOI 10.1021/bi00509a007; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FASY TM, 1979, BIOCHIM BIOPHYS ACTA, V564, P322, DOI 10.1016/0005-2787(79)90229-6; Feghali Rebecca, 1992, Gene Expression, V2, P49; FELSENFELD G, 1992, NATURE, V355, P218; GOSPODAROWICZ D, 1976, J CELL BIOL, V70, P395, DOI 10.1083/jcb.70.2.395; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HASHIMOTO S, 1984, P NATL ACAD SCI-BIOL, V81, P6637, DOI 10.1073/pnas.81.21.6637; JERZMANOWSKI A, 1990, J BIOL CHEM, V265, P10726; KOHTZ DS, 1987, J CELL BIOL, V104, P897, DOI 10.1083/jcb.104.4.897; KONIGSBERG IR, 1963, SCIENCE, V140, P1273, DOI 10.1126/science.140.3573.1273; KONIGSBERG IR, 1978, DEV BIOL, V63, P11, DOI 10.1016/0012-1606(78)90109-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1969, P NATL ACAD SCI USA, V64, P1276, DOI 10.1073/pnas.64.4.1276; LANGAN TA, 1968, SCIENCE, V162, P579, DOI 10.1126/science.162.3853.579; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, GENE DEV, V6, P76; LIN RL, 1991, GENE DEV, V5, P1601, DOI 10.1101/gad.5.9.1601; LINKHART TA, 1980, J SUPRAMOL STRUCT, V14, P384; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONESTIER M, 1989, MOL IMMUNOL, V26, P749, DOI 10.1016/0161-5890(89)90035-7; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROTH SY, 1988, J CELL BIOL, V107, P2473, DOI 10.1083/jcb.107.6.2473; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SLATER CR, 1976, DEV BIOL, V50, P264, DOI 10.1016/0012-1606(76)90151-2; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	51	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1580	1585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678408				2022-12-27	WOS:A1993KH62000015
J	DEBOER, HC; DEGROOT, PG; BOUMA, BN; PREISSNER, KT				DEBOER, HC; DEGROOT, PG; BOUMA, BN; PREISSNER, KT			TERNARY VITRONECTIN-THROMBIN-ANTITHROMBIN-III COMPLEXES IN HUMAN PLASMA - DETECTION AND MODE OF ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; PLASMINOGEN-ACTIVATOR INHIBITOR-1; BINDING DOMAIN; COAGULATION; COMPLEMENT; IDENTIFICATION; PURIFICATION; HEPARIN; MATRIX; SERUM	Radiolabeled antithrombin III (ATIII) was incubated at 37-degrees-C with purified vitronectin (VN) or fibrinogen-deficient plasma before thrombin was added to initiate complex formation. Incorporation of radiolabeled ATIII was detected using polyacrylamide gel electrophoresis (PAGE) and autoradiography. The PAGE conditions appeared to be crucial for the detection of VN.TAT complexes. In the absence of SDS, ternary complexes formed instantaneously, whereas in the presence of SDS, only 50% of the TAT was associated with VN after a 60-min incubation. Formation of ternary complexes could be confirmed by gel filtration of the plasma to which thrombin was added. Furthermore, TAT in patient plasmas (disseminated intravascular coagulation and sepsis) was found to bind to heparin-Sepharose, indicating that this endogenously formed TAT was also associated with VN. The amino-terminal region of VN and the thrombin moiety of the TAT complex were found to be responsible for their interaction, which was stabilized by disulfide bridges. These results indicate that in normal plasma all TAT is complexed with VN. This association alters the conformational state of plasma VN, which appears to be responsible for the clearance of thrombin complexes from the circulation.	MAX PLANCK INST PHYSIOL & CLIN RES,KERCKHOFF KLIN,HAEMOSTASIS RES UNIT,W-6350 BAD NAUHEIM,GERMANY	Kerckhoff Clinic; Max Planck Society	DEBOER, HC (corresponding author), UNIV HOSP UTRECHT,DEPT HAEMATOL G03647,BOX 85500,3508 GA UTRECHT,NETHERLANDS.							BHAKDI S, 1988, CLIN EXP IMMUNOL, V74, P459; BJORK I, 1992, J BIOL CHEM, V267, P1976; CONLAN MG, 1988, BLOOD, V72, P185; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DESWART CAM, 1984, THROMB HAEMOSTASIS, V52, P66; ELGUE G, 1990, THROMB HAEMOSTASIS, V63, P435; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; ILL CR, 1985, J BIOL CHEM, V260, P5610; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIMURO J, 1989, J BIOL CHEM, V264, P936; PODACK E R, 1979, Thrombosis and Haemostasis, V42, P170; PODACK ER, 1977, J IMMUNOL, V119, P2024; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PREISSNER KT, 1990, BIOCHEM BIOPH RES CO, V168, P966, DOI 10.1016/0006-291X(90)91123-A; PREISSNER KT, 1988, BLOOD, V71, P1581; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903	27	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1279	1283						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678252				2022-12-27	WOS:A1993KG07700077
J	MUSTONEN, P; KINNUNEN, PKJ				MUSTONEN, P; KINNUNEN, PKJ			ON THE REVERSAL BY DEOXYRIBONUCLEIC-ACID OF THE BINDING OF ADRIMYCIN TO CARDIOLIPIN-CONTAINING LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE LIPID-PEROXIDATION; RESONANCE ENERGY-TRANSFER; MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; DNAA PROTEIN; TUMOR-CELLS; RAT-LIVER; PHOSPHATIDYLCHOLINE BILAYERS; MITOCHONDRIAL-MEMBRANES; ADRIAMYCIN RESISTANCE	The binding of the cytotoxin adriamycin (doxorubicin) to phospholipids, DNA, and RNA was investigated using (i) fluorescence quenching by this drug of liposomes containing pyrene-labeled phospholipids and (ii) monomolecular cardiolipin films on an air/water interface. In accordance with previous studies, our fluorescence experiments revealed that the acidic phospholipids, phosphatidylglycerol, phosphatidylmethanol, and phosphatidic acid all have high and comparable affinities to adriamycin mainly due to electrostatic interactions whereas binding to phosphatidylcholine was much weaker. Highest affinity, however, was possessed by cardiolipin. Addition of 4 mM CaCl2 reduced the binding of adriamycin to the above lipids. Moreover, in the presence of calcium the affinity of the drug to the different lipids was similar. Ca2+ concentrations > 100 muM began to reverse the binding of adriamycin to cardiolipin-containing liposomes whereas lower concentrations had only an insignificant effect. The association of adriamycin with DNA, RNA, and cardiolipin was then compared by observing the reversal of the cytotoxin-cardiolipin association by nucleic acids. The affinity of adriamycin was found to decrease in the sequence DNA > cardiolipin > RNA with relative affinities of 7.8, 2.3, and 1, respectively. Penetration of the drug into cardiolipin monolayers spread on an air/water interface resulted in an increase in surface pressure pi whereas only a very weak increase was observed using dimyristoylphosphatidylcholine films. Removal of adriamycin from lipid monolayers was achieved by adding DNA into the aqueous subphase. Similar to the fluorescence quenching studies increase in pi after the inclusion of adriamycin into the aqueous subphase was significantly reduced in the presence of Ca2+ concentrations > 100 muM, whereas lower concentrations had only an insignificant effect. Residual drug-phospholipid interactions in the lipid monolayer observed in the presence of Ca2+ were also reversed by DNA.	UNIV HELSINKI, DEPT MED CHEM, SILTAVUORENPENGER 10A, SF-00170 HELSINKI 17, FINLAND	University of Helsinki								BARABAS K, 1992, J BIOL CHEM, V267, P9437; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BERMAN HM, 1981, ANNU REV BIOPHYS BIO, V10, P87, DOI 10.1146/annurev.bb.10.060181.000511; BURKE TG, 1985, BIOCHEMISTRY-US, V24, P1768, DOI 10.1021/bi00328a030; CANAVES JM, 1991, BIOCHEM J, V279, P413, DOI 10.1042/bj2790413; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3927, DOI 10.1021/bi00260a004; CONSTANTINIDES PP, 1990, BIOPHYS CHEM, V35, P259, DOI 10.1016/0301-4622(90)80013-W; CONSTANTINIDES PP, 1986, J BIOL CHEM, V261, P196; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3; DIETEL M, 1990, CANCER RES, V50, P6100; DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210; DRAKE JM, 1991, SCIENCE, V251, P1574, DOI 10.1126/science.2011737; DUPOUCEZANNE L, 1989, EUR J BIOCHEM, V181, P695, DOI 10.1111/j.1432-1033.1989.tb14779.x; EILERS M, 1989, J BIOL CHEM, V264, P2945; ESCRIBA PV, 1990, BIOCHEMISTRY-US, V29, P7275, DOI 10.1021/bi00483a017; FAN D, 1990, CANCER RES, V50, P3619; FERRERMONTIEL AV, 1988, BIOCHIM BIOPHYS ACTA, V937, P379, DOI 10.1016/0005-2736(88)90260-X; FIALLO MML, 1986, BIOCHIM BIOPHYS ACTA, V854, P143; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; FREZARD F, 1991, BIOCHEMISTRY-US, V30, P5038, DOI 10.1021/bi00234a028; FULLFORD AJC, 1980, BIOCHIM BIOPHYS ACTA, V598, P237; Gianni L, 1983, REV BIOCHEM TOXICOL, V5, P1; GOORMAGHTIGH E, 1987, BIOCHEMISTRY-US, V26, P1789, DOI 10.1021/bi00380a043; GOORMAGHTIGH E, 1982, BIOCHEM BIOPH RES CO, V104, P314, DOI 10.1016/0006-291X(82)91976-3; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GRIFFIN EA, 1986, BIOCHEMISTRY-US, V25, P7875, DOI 10.1021/bi00372a013; HENRY N, 1985, BIOCHEMISTRY-US, V24, P7085, DOI 10.1021/bi00346a010; HIRAI H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P191, DOI 10.1016/0167-4781(91)90054-P; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; HUART P, 1984, BIOCHIM BIOPHYS ACTA, V799, P199, DOI 10.1016/0304-4165(84)90296-4; HUBNER W, 1991, BIOCHIM BIOPHYS ACTA, V1066, P166, DOI 10.1016/0005-2736(91)90183-9; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; KONTTILA R, 1988, BIOCHEMISTRY-US, V27, P7443, DOI 10.1021/bi00419a040; LEMMETYINEN H, 1989, J PHYS CHEM-US, V93, P7170, DOI 10.1021/j100357a029; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V857, P123, DOI 10.1016/0005-2736(86)90105-7; MIMNAUGH EG, 1985, BIOCHEM PHARMACOL, V34, P847, DOI 10.1016/0006-2952(85)90766-X; MIMNAUGH EG, 1985, CANCER RES, V45, P3296; MIMNAUGH EG, 1981, TOXICOL APPL PHARM, V61, P313, DOI 10.1016/0041-008X(81)90352-5; MIZUSHIMA T, 1992, BIOCHEM J, V285, P503, DOI 10.1042/bj2850503; MONTAUDON D, 1986, CANCER RES, V46, P5602; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; MUSTONEN P, 1991, J BIOL CHEM, V266, P6302; NEIDLE S, 1977, CANCER TREAT REP, V61, P928; NICOLAY K, 1987, BIOCHIM BIOPHYS ACTA, V892, P320, DOI 10.1016/0005-2728(87)90236-2; NICOLAY K, 1984, BIOCHIM BIOPHYS ACTA, V778, P359, DOI 10.1016/0005-2736(84)90380-8; NICOLAY K, 1985, BIOCHIM BIOPHYS ACTA, V819, P55, DOI 10.1016/0005-2736(85)90195-6; POHLE W, 1990, BIOPHYS CHEM, V35, P213, DOI 10.1016/0301-4622(90)80010-5; POSADA J, 1989, CANCER RES, V49, P6634; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; SIEGFRIED JM, 1983, CANCER BIOCHEM BIOPH, V6, P137; SINHA BK, 1984, CANCER RES, V44, P2892; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; THUREN T, 1990, CHEM PHYS LIPIDS, V53, P129, DOI 10.1016/0009-3084(90)90039-T; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; TSURUO T, 1983, CANCER RES, V43, P2905; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUSA K, 1989, CANCER RES, V49, P5002; ZWELLING LA, 1982, CANCER RES, V42, P2687; [No title captured]	69	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1074	1080						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678246				2022-12-27	WOS:A1993KG07700049
J	TAKAHA, T; YANASE, M; OKADA, S; SMITH, SM				TAKAHA, T; YANASE, M; OKADA, S; SMITH, SM			DISPROPORTIONATING ENZYME (4-ALPHA-GLUCANOTRANSFERASE - EC 2.4.1.25) OF POTATO - PURIFICATION, MOLECULAR-CLONING, AND POTENTIAL ROLE IN STARCH METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBCELLULAR-LOCALIZATION; ARABIDOPSIS LEAF; TRANSIT PEPTIDE; EXPRESSION; PLANTS; PROTEIN; GENE; BIOSYNTHESIS; CHLOROPLAST	Disproportionating enzyme (D-enzyme, 4-alpha-glucanotransferase; EC 2.4.1.25) has been purified to homogeneity from potato tubers and its activity characterized. The enzyme catalyzes the transfer of maltooligosaccharides from one 1,4-alpha-D-glucan molecule to another, or to glucose. Maltooligosaccharides are effective donor molecules, but short chain amylose and amylopectin may also function as donors. Enzyme activity is not affected by inorganic phosphate, 3-phosphoglycerate, or hexose phosphates. A cDNA clone encoding the enzyme was isolated using oligonucleotide probes derived from partial peptide sequences of the purified enzyme. The identity of the cDNA clone was confirmed by expression in Escherichia coli resulting in D-enzyme activity. The amino acid sequence deduced from the cDNA shows significant homology with a 4-alpha-glucanotransferase from Streptococcus. The deduced sequence indicates the presence of an amino-terminal plastid transit peptide of 52 amino acid residues and a mature polypeptide of 524 residues. D-enzyme mRNA is present in leaves, stems, roots, and stolons but is most abundant in developing and mature tubers. The amount of mRNA in leaves increases in response to light and to sucrose added to the medium. These results are discussed in terms of the function of D-enzyme in potato starch metabolism.	UNIV EDINBURGH, INST CELL & MOLEC BIOL, KINGS BLDG, MAYFIELD RD, EDINBURGH EH9 3JH, MIDLOTHIAN, SCOTLAND; EZAKI GLICO CO LTD, BIOCHEM RES LABS, OSAKA 555, JAPAN	University of Edinburgh; Ezaki Glico Co., Ltd.			Smith, Steven/HDM-9496-2022; Smith, Steven M/G-7183-2015	Smith, Steven M/0000-0001-5661-9994				AKAZAWA T, 1985, ANNU REV PLANT PHYS, V36, P441; BARHAM D, 1972, ANALYST, V97, P142, DOI 10.1039/an9729700142; BECK E, 1989, ANNU REV PLANT PHYS, V40, P95, DOI 10.1146/annurev.pp.40.060189.000523; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAY I, 1992, PLANT J, V2, P193; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JOHNSON R, 1990, PLANT MOL BIOL, V14, P527, DOI 10.1007/BF00027498; KAKEFUDA G, 1986, PLANTA, V168, P175, DOI 10.1007/BF00402961; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIM SR, 1991, PLANT MOL BIOL, V17, P973, DOI 10.1007/BF00037137; KLOSGEN RB, 1991, MOL GEN GENET, V225, P297, DOI 10.1007/BF00269862; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; Kruger JN, 1990, PLANT PHYSL BIOCH MO, P59; LACKS SA, 1982, CELL, V31, P327, DOI 10.1016/0092-8674(82)90126-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee E. Y. C., 1971, ENZYMES, V5, P191; LIN TP, 1988, PLANT PHYSIOL, V86, P251, DOI 10.1104/pp.86.1.251; LIN TP, 1988, PLANT PHYSIOL, V86, P260, DOI 10.1104/pp.86.1.260; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; Maniatis T., 1982, MOL CLONING; MORI H, 1991, J BIOL CHEM, V266, P18446; MULLERROBER BT, 1990, MOL GEN GENET, V224, P136, DOI 10.1007/BF00259460; OKITA TW, 1979, PLANT PHYSIOL, V64, P187, DOI 10.1104/pp.64.2.187; PEAT S, 1956, J CHEM SOC, P44, DOI 10.1039/jr9560000044; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; STEUP M, 1976, BIOCHEM BIOPH RES CO, V72, P1554, DOI 10.1016/S0006-291X(76)80191-X; VISSER RGF, 1989, PLANT SCI, V64, P185, DOI 10.1016/0168-9452(89)90023-X; VISSER RGF, 1991, PLANT MOL BIOL, V17, P691, DOI 10.1007/BF00037054; YOSHIO N, 1986, J JPN SOC STARCH SCI, V33, P244; [No title captured]	40	100	108	2	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1391	1396						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678257				2022-12-27	WOS:A1993KG07700094
J	BERSE, B; BLUSZTAJN, JK				BERSE, B; BLUSZTAJN, JK			COORDINATED UP-REGULATION OF CHOLINE-ACETYLTRANSFERASE AND VESICULAR ACETYLCHOLINE TRANSPORTER GENE-EXPRESSION BY THE RETINOIC ACID RECEPTOR-ALPHA, CAMP, AND LEUKEMIA INHIBITORY FACTOR CILIARY NEUROTROPHIC FACTOR SIGNALING PATHWAYS IN A MURINE SEPTAL CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NEURONAL DIFFERENTIATION FACTOR; CYCLIC-AMP; TRANSCRIPTION; PROTEIN; NUCLEUS; MEMORY	The proteins responsible for acetylcholine (ACh) synthesis (choline acetyltransferase, ChAT) and storage (vesicular ACh transporter, VAChT) are encoded by two closely linked genes in vertebrates, with the VAChT coding sequence contained within the first intron of the ChAT gene, This unusual genomic organization suggests that the transcription of these two genes is coordinately regulated, Using Northern analysis we studied the modulation of ChAT and VAChT expression in a murine septal cell line (SN56) by three groups of agents: retinoids, trophic factors belonging to the leukemia inhibitory factor/ciliary neurotrophic factor (LIF/CNTF) family, and cAMP, All-trans-retinoic acid increased both ChAT and VAChT mRNA levels in SN56 cells up to 3.5-fold, and elevated intracellular ACh levels by 2.5-fold, This effect was mimicked by a retinoic acid receptor alpha (RAR alpha) agonist (Ro 40-6055) and prevented by a specific antagonist (Ro 41-5253), indicating that it was mediated by RAR alpha, ChAT- and VAChT-specific transcripts were also induced (up to 3-fold) by treatment with CNTF or LIF (20 ng/ml, 48 h), as well as by dibutyryl cAMP (1 mM), All these agents increased the ACh level in the cells (up to 2.5-fold). Dibutyryl cAMP had a greater effect on the level of VAChT mRNA (4-fold induction) than on the level of ChAT mRNA (2-fold induction), suggesting a quantitatively differential transcriptional regulation of the two genes by the cAMP pathway. The effects of the three groups of agents studied on ChAT and VAChT mRNA levels were additive, pointing to several independent mechanisms by which the cholinergic properties of septal neurons can be modulated.	BOSTON UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02118 USA	Boston University; Boston University				Berse, Brygida/0000-0002-0735-2792; /0000-0001-8438-3122	NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [AG09525] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; BLUSZTAJN JK, 1992, J NEUROSCI, V12, P793; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CASPER D, 1989, BRAIN RES, V478, P74, DOI 10.1016/0006-8993(89)91478-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1995, ONCOGENE, V10, P985; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FUKADA K, 1985, P NATL ACAD SCI USA, V82, P8795, DOI 10.1073/pnas.82.24.8795; HAMMOND DN, 1986, SCIENCE, V234, P1237, DOI 10.1126/science.3775382; HEFTI F, 1985, NEUROSCIENCE, V14, P55, DOI 10.1016/0306-4522(85)90163-0; HERSH LB, 1992, NEUROCHEM RES, V17, P1063, DOI 10.1007/BF00967282; INOUE H, 1995, J NEUROCHEM, V64, P985; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; LEE HJ, 1990, DEV BRAIN RES, V52, P219, DOI 10.1016/0165-3806(90)90238-T; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LI YP, 1993, NEUROCHEM RES, V18, P271, DOI 10.1007/BF00969082; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; MATSUOKA I, 1989, BRAIN RES, V502, P53, DOI 10.1016/0006-8993(89)90460-5; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MISAWA H, 1993, J NEUROCHEM, V60, P1383, DOI 10.1111/j.1471-4159.1993.tb03299.x; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PARK EA, 1993, J BIOL CHEM, V268, P613; PEDERSEN WA, 1995, J NEUROCHEM, V65, P50; POTTER PE, 1983, J NEUROCHEM, V41, P188, DOI 10.1111/j.1471-4159.1983.tb13668.x; RAO MS, 1993, NEURON, V11, P1175, DOI 10.1016/0896-6273(93)90229-K; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SYMES AJ, 1995, J BIOL CHEM, V270, P8068, DOI 10.1074/jbc.270.14.8068; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; WU DH, 1994, J NEUROCHEM, V62, P1653; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	45	153	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22101	22104		10.1074/jbc.270.38.22101	http://dx.doi.org/10.1074/jbc.270.38.22101			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673184	hybrid			2022-12-27	WOS:A1995RW31400007
J	ELHAYEK, R; ANTONIU, B; WANG, JP; HAMILTON, SL; IKEMOTO, N				ELHAYEK, R; ANTONIU, B; WANG, JP; HAMILTON, SL; IKEMOTO, N			IDENTIFICATION OF CALCIUM RELEASE-TRIGGERING AND BLOCKING REGIONS OF THE II-III-LOOP OF THE SKELETAL-MUSCLE DIHYDROPYRIDINE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SARCOPLASMIC-RETICULUM; CHARGE MOVEMENT; CHANNEL	In an attempt to identify and characterize functional domains of the rabbit skeletal muscle dihydropyridine receptor alpha(1), subunit II-III loop, we synthetized several peptides corresponding to different regions of the loop: peptides A, B, C, C1, C2, D (cf. Pig, 1). Peptide A (Thr(671)- Leu(690)) activated [H-3]ryanodine binding to, and induced Ca2+ release from, rabbit skeletal muscle triads, but none of the other peptides had such effects. Peptide A-induced Ca2+ release and activation of ryanodine binding were partially suppressed by an equimolar concentration of peptide C (Glu(724)-Pro(760)) but were not affected by the other peptides. These results suggest that the short stretch in the II-III loop, Thr(671)-Leu(690), is responsible for triggering SR Ca2+ release, while the other region, Glu(724)-Pro(760), functions as a blocker of the release trigger. A hypothesis is proposed to account for how these subdomains interact with the sarcoplasmic reticulum Ca2+ release channel protein during excitation-contraction coupling.	BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Boston Biomedical Research Institute; Baylor College of Medicine; Harvard University; Harvard Medical School				Hamilton, Susan/0000-0003-0241-9369	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37044] Funding Source: Medline; NIAMS NIH HHS [AR 16922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHANDLER WK, 1976, J PHYSIOL-LONDON, V254, P285, DOI 10.1113/jphysiol.1976.sp011233; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; ELHAYEK R, 1993, BIOPHYS J, V65, P779, DOI 10.1016/S0006-3495(93)81101-9; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GARCIA J, 1994, J GEN PHYSIOL, V103, P125, DOI 10.1085/jgp.103.1.125; IKEMOTO N, 1984, J BIOL CHEM, V259, P3151; IKEMOTO N, 1988, METHOD ENZYMOL, V157, P469; Lu Xiangyang, 1995, Biophysical Journal, V68, pA372; LU XY, 1994, J BIOL CHEM, V269, P6511; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nakai J., 1995, Biophysical Journal, V68, pA14; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROHRKASTEN A, 1988, J BIOL CHEM, V263, P15325; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0	22	121	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22116	22118		10.1074/jbc.270.38.22116	http://dx.doi.org/10.1074/jbc.270.38.22116			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673188	hybrid			2022-12-27	WOS:A1995RW31400011
J	LI, XY; LI, J; HARRINGTON, J; LIEBER, MR; BURGERS, PMJ				LI, XY; LI, J; HARRINGTON, J; LIEBER, MR; BURGERS, PMJ			LAGGING-STRAND DNA-SYNTHESIS AT THE EUKARYOTIC REPLICATION FORK INVOLVES BINDING AND STIMULATION OF FEN-1 BY PROLIFERATING CELL NUCLEAR ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN PROTEIN INTERACTIONS; SACCHAROMYCES-CEREVISIAE; FACTOR-C; POLYMERASE-III; PURIFICATION; SYSTEM	The 5' --> 3'-exonuclease domain of Escherichia coli DNA polymerase I is required for the completion of lagging strand DNA synthesis, and yet this domain is not present in any of the eukaryotic DNA polymerases, Recently, the gene encoding the functional and evolutionary equivalent of this 5' --> 3'-exonuclease domain has been identified, It is called FEN-1 in mouse and human cells and RTH1 in Saccharomyces cerevisiae, This 42-kDa enzyme is required for Okazaki fragment processing. Here we report that FEN-1 physically interacts with proliferating cell nuclear antigen (PCNA), the processivity factor for DNA polymerases delta and epsilon. Through protein-protein interactions, PCNA focuses FEN-1 on branched DNA substrates (flap structures) and on nicked DNA substrates, thereby stimulating its activity 10-50-fold but only if PCNA can functionally assemble as a toroidal trimer around the DNA, This interaction is important in the physical orchestration of lagging strand synthesis and may have implications for how PCNA stimulates other members of the FEN-1 nuclease family in a broad range of DNA metabolic transactions.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Burgers, Peter M/AAW-6621-2021	Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345	NATIONAL CANCER INSTITUTE [R01CA051105, R37CA051105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NCI NIH HHS [CA51105] Funding Source: Medline; NIGMS NIH HHS [GM32431, GM43236, R01 GM032431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BAUER GA, 1988, J BIOL CHEM, V263, P917; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; YODER BL, 1991, J BIOL CHEM, V266, P22689	28	251	261	8	75	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22109	22112		10.1074/jbc.270.38.22109	http://dx.doi.org/10.1074/jbc.270.38.22109			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673186	hybrid			2022-12-27	WOS:A1995RW31400009
J	PRIGENT, SA; PILLAY, TS; RAVICHANDRAN, KS; GULLICK, WJ				PRIGENT, SA; PILLAY, TS; RAVICHANDRAN, KS; GULLICK, WJ			BINDING OF SHC TO THE NPXY MOTIF IS MEDIATED BY ITS N-TERMINAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TYROSINE PHOSPHORYLATION; PROTEIN; RECEPTOR; KINASE; SITES	She is an SH2-containing adapter protein that binds to and is phosphorylated by a large number of growth factor receptors, Phosphorylated She is able to interact with the GrbB-Sos complex which is responsible for mediating nucleotide exchange on Ras. We have shown previously that binding of She to the epidermal growth factor (EGF)-like receptor, c-ErbB-3, is through an NPXY motif (Prigent, S, A., and Gullick, W, J, (1994) EMBO J. 13, 2831-2841) shared by middle T antigen, TrkA, and EGF receptor, It has recently been reported that a region distinct from the SH2 domain is able to bind to tyrosine-phosphorylated proteins. In this paper we have used fusion proteins of various She domains to show that it is the N-terminal domain of She that is primarily responsible for binding EGF receptor and c-ErbB-3. Furthermore, by competition studies with synthetic phosphopeptides we have shown that this N-terminal domain binds to the previously identified NPXY motif.	UNIV CALIF SAN DIEGO,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,ONCOL UNIT,LONDON W12 0HS,ENGLAND	University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Cancer Research UK; Imperial College London	PRIGENT, SA (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093, USA.		Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X; pillay, tahir/0000-0002-9982-9710				BALDARI CT, 1995, ONCOGENE, V10, P1141; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PILLAY TS, 1992, FEBS LETT, V308, P38, DOI 10.1016/0014-5793(92)81045-N; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SMIT L, 1994, J BIOL CHEM, V269, P20209; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHU XY, 1994, J BIOL CHEM, V269, P5518	40	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22097	22100		10.1074/jbc.270.38.22097	http://dx.doi.org/10.1074/jbc.270.38.22097			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673183	hybrid			2022-12-27	WOS:A1995RW31400006
J	TIPPNER, D; WAGNER, R				TIPPNER, D; WAGNER, R			FLUORESCENCE ANALYSIS OF THE ESCHERICHIA-COLI TRANSCRIPTION REGULATOR-H-NS REVEALS 2 DISTINGUISHABLE COMPLEXES DEPENDENT ON BINDING TO SPECIFIC OR NONSPECIFIC DNA SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RIBOSOMAL-RNA; CURVED DNA; PROTEIN H1; ELECTROPHORESIS; INVITRO; PHASE	Here we report a structural investigation of the transcription factor H-NS and its DNA interaction. H-NS has a general effect on transcription by compacting DNA; but for a number of specific genes, it is known to act directly as repressor or activator. The homodimeric protein binds to the major groove of DNA in a sequence-nonspecific manner, recognizing a curved conformation of the target DNA. H-NS consists of 136 amino acids with a single tryptophanyl residue at position 108. To overcome the apparent lack of any other structural details, we took advantage of the intrinsic fluorescence of Trp-108. Static and dynamic quenching constants obtained with the neutral quencher molecule acrylamide are consistent with a hydrophilic environment and high degree of solvent exposure for Trp-108. In addition, quenching studies in the presence of the anionic quencher iodide indicate a positively charged microenvironment for the same amino acid residue. Specific and nonspecific H-NS DNA complexes were studied by gel retardation and fluorescence analysis. While specific H-NS DNA complex formation is accompanied by a clear enhancement of the tryptophanyl fluorescence intensity, interaction in the presence of the nonspecific competitor DNA poly(dI-dC) decreases the fluorescence quantum yield.	UNIV DUSSELDORF,INST BIOL PHYS,D-40225 DUSSELDORF,GERMANY	Heinrich Heine University Dusseldorf								BARCELO F, 1991, BIOCHEMISTRY-US, V30, P4863, DOI 10.1021/bi00234a005; BERTIN P, 1990, BIOCHIMIE, V72, P889, DOI 10.1016/0300-9084(90)90008-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MP, 1994, J BIOL CHEM, V269, P12600; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; FRIEDRICH K, 1988, FEBS LETT, V229, P197, DOI 10.1016/0014-5793(88)80826-3; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; ITO K, 1994, J BACTERIOL, V176, P7383, DOI 10.1128/JB.176.23.7383-7386.1994; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Maniatis T., 1982, MOL CLONING; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MELLIES J, 1994, J BACTERIOL, V176, P3638, DOI 10.1128/JB.176.12.3638-3645.1994; OWENHUGHES TA, 1992, CELL, V71, P255, DOI 10.1016/0092-8674(92)90354-F; PON CL, 1988, MOL GEN GENET, V212, P199, DOI 10.1007/BF00334684; PORTER ME, 1994, J BACTERIOL, V176, P4187, DOI 10.1128/JB.176.13.4187-4191.1994; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; SHINDO H, 1995, FEBS LETT, V360, P125, DOI 10.1016/0014-5793(95)00079-O; SOMERO GN, 1986, AM J PHYSIOL, V251, P197; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; SPASSKY A, 1977, EUR J BIOCHEM, V81, P79, DOI 10.1111/j.1432-1033.1977.tb11929.x; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WAGNER R, 1994, ARCH MICROBIOL, V161, P100, DOI 10.1007/s002030050028; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; YAMADA H, 1991, MOL GEN GENET, V230, P332, DOI 10.1007/BF00290685; ZACHARIAS M, 1992, BIOCHEMISTRY-US, V31, P2621, DOI 10.1021/bi00124a024; ZACHARIAS M, 1991, BIOCHIMIE, V73, P699, DOI 10.1016/0300-9084(91)90050-B; ZUBER F, 1994, MOL MICROBIOL, V12, P231, DOI 10.1111/j.1365-2958.1994.tb01012.x	32	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22243	22247		10.1074/jbc.270.38.22243	http://dx.doi.org/10.1074/jbc.270.38.22243			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673203	hybrid			2022-12-27	WOS:A1995RW31400029
J	ICHIJO, H; HELLMAN, U; WERNSTEDT, C; GONEZ, LJ; CLAESSONWELSH, L; HELDIN, CH; MIYAZONO, K				ICHIJO, H; HELLMAN, U; WERNSTEDT, C; GONEZ, LJ; CLAESSONWELSH, L; HELDIN, CH; MIYAZONO, K			MOLECULAR-CLONING AND CHARACTERIZATION OF FICOLIN, A MULTIMERIC PROTEIN WITH FIBRINOGEN-LIKE AND COLLAGEN-LIKE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; BOVINE CONGLUTININ; BINDING-PROTEINS; HUMAN-COMPLEMENT; TYROSINE KINASE; RECEPTOR; SEQUENCES; ACTIVATION; NUCLEOTIDE; LECTIN	We have previously identified and purified transforming growth factor-beta1 (TGF-beta1)-binding proteins from porcine uterus membranes (Ichijo, H., Ronnstrand, L., Miyagawa, K., Ohashi, H., Heldin, C.-H., and Miyazono, K. (1991) J. Biol. Chem. 266, 2245922464). One of these TGF-beta1-binding proteins, with a molecular weight of 40,000, was purified to homogeneity and subjected to amino acid sequence analysis. The amino acid sequences obtained were used to isolate two closely related cDNA clones from a porcine uterus cDNA library. The deduced amino acid sequences revealed that both cDNAs encoded proteins that were mainly composed of fibrinogen-like and collagen-like domains. Therefore, they were denoted ficolin-alpha and ficolin-beta. Expression of ficolin-alpha and -beta cDNA in mammalian cells revealed that ficolin forms dimers, trimers, and several higher order of oligomers, whose molecular weights fit well with those of the purified TGF-beta1-binding proteins from porcine uterus. Moreover, immunoblotting analysis using a peptide antiserum against ficolin indicated that the TGF-beta1-binding proteins identified in porcine uterus are ficolin-alpha, -beta, and their oligomers or closely related molecules. However, recombinant ficolin-alpha and -beta did not bind TGF-beta1, despite the similarities in molecular weights and immunoreactivity with the material from the natural source. It is possible that a specific posttranslational modification of ficolin or interaction with another component is needed for TGF-beta1 binding. Analysis by Northern blotting revealed that the expression of ficolin-alpha mRNA is relatively restricted and most abundant in placenta and lung. On the other hand, ficolin-beta was mainly expressed in skeletal muscle. The in vivo functions of ficolin will be discussed.			ICHIJO, H (corresponding author), LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN.			Ichijo, Hidenori/0000-0002-5005-6438; Ronnstrand, Lars/0000-0003-1275-5809				BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER NR, 1978, J IMMUNOL, V120, P1862; DAVIS AE, 1984, BIOCHEMISTRY-US, V23, P2139, DOI 10.1021/bi00305a006; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ERDEI A, 1988, MOL IMMUNOL, V25, P1067, DOI 10.1016/0161-5890(88)90139-3; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FLOROS J, 1986, J BIOL CHEM, V261, P9029; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOYAMA T, 1987, P NATL ACAD SCI USA, V84, P1609, DOI 10.1073/pnas.84.6.1609; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LEE YM, 1991, J BIOL CHEM, V266, P2715; LINSCOTT WD, 1978, J IMMUNOL, V121, P658; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; REID KBM, 1983, BIOCHEM SOC T, V11, P1; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; UHLENBRUCK G, 1979, Z IMMUNITATSFORSCH, V155, P262; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; XUN X, 1990, P NATL ACAD SCI USA, V87, P2097, DOI 10.1073/pnas.87.6.2097; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	131	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14505	14513						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686157				2022-12-27	WOS:A1993LJ82500102
J	KANAI, F; NISHIOKA, Y; HAYASHI, H; KAMOHARA, S; TODAKA, M; EBINA, Y				KANAI, F; NISHIOKA, Y; HAYASHI, H; KAMOHARA, S; TODAKA, M; EBINA, Y			DIRECT DEMONSTRATION OF INSULIN-INDUCED GLUT4 TRANSLOCATION TO THE SURFACE OF INTACT-CELLS BY INSERTION OF A C-MYC EPITOPE INTO AN EXOFACIAL GLUT4 DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; RAT ADIPOSE CELL; PLASMA-MEMBRANE; STIMULATED TRANSLOCATION; ALPHA-TOXIN; RECEPTOR; EXPRESSION; PROTEIN; CDNA; SYSTEMS	Stimulation of glucose transport is the main physiological effect of insulin in target tissues. This effect is linked to translocation of the GLUT4 glucose transporter from an intracellular pool to the cell surface. To elucidate the molecular mechanisms involved in this effect, we developed a simple direct sensitive method to detect GLUT4 immunologically on the cell surface. cDNA containing GLUT4 inserted by a c-myc epitope in the first ectodomain (GLUT4myc) was constructed without disrupting the functions of GLUT4 and was expressed in 3T3-L1 and Chinese hamster ovary fibroblast cells. In response to insulin, the GLUT4myc expressed in 3T3-L1 adipocytes was translocated to the cell surface from the intracellular pool, as shown by assays of exofacial antibody binding against the myc epitope and of the uptake of 2-deoxyglucose. Insulin, guanosine 5'-O-(3-thiotriphosphate), guanylyl imidodiphosphate, NaF, and phorbol 12-myristate 13-acetate also induced the translocation of GLUT4myc in Chinese hamster ovary cells coexpressing the human insulin receptor.	UNIV TOKUSHIMA, INST ENZYME RES, DEPT ENZYME GENET, 3-18-15 KURAMOTO CHO, TOKUSHIMA 770, JAPAN	Tokushima University				Kamohara, Seika/0000-0002-2482-6611; Hayashi, Hideki/0000-0003-4585-6542				AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOULD GW, 1989, J BIOL CHEM, V264, P2180; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KARNIELI E, 1981, J BIOL CHEM, V256, P4772; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SALTIS J, 1991, J BIOL CHEM, V266, P261; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VOGT B, 1991, BIOCHEM J, V275, P597, DOI 10.1042/bj2750597	28	140	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14523	14526						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686158				2022-12-27	WOS:A1993LJ82500104
J	NAG, B; DESHPANDE, SV; SHARMA, SD; CLARK, BR				NAG, B; DESHPANDE, SV; SHARMA, SD; CLARK, BR			CLONED T-CELLS INTERNALIZE PEPTIDE FROM BOUND COMPLEXES OF PEPTIDE AND PURIFIED CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IA MOLECULES; RECEPTOR; STIMULATION; INHIBITION; BINDING; MHC; RECOGNITION; AFFINITY	Antigen presentation to helper T cells involves the formation of a trimolecular complex consisting of a class II major histocompatibility complex (MHC) antigen combined with an antigenic peptide on the surface of an antigen-presenting cell and a T cell receptor (TCR) on the T cell. The fate of the MHC class II, peptide, or TCR moieties of the ternary complex following antigen presentation is unknown. Using radio-labeled complexes of affinity-purified murine MHC class II molecules and peptides corresponding to T cell epitopes of myelin basic protein (MBP), this report presents evidence that the binding of preformed relevant MHC class II-peptide complexes to cloned T cells in vitro results in internalization of the peptide moiety. Neither the restricting MHC class II molecule nor the TCR moiety of the trimolecular complex was internalized by T cells. The specificity of peptide internalization was demonstrated using complexes of syngeneic MHC class II with an irrelevant MBP peptide analog and by cloned T cells restricted for a different epitope of the same MBP antigen. Furthermore, the peptide translocation mediated by MHC class II and TCR was demonstrated by antibody-blocking experiments using anti-class II and anti-TCR monoclonal antibodies. The peptide internalization by T cells was markedly reduced when binding was performed at 4-degrees-C as compared with 37-degrees-C. In addition, a significant inhibition of peptide translocation was observed in the presence of a metabolic inhibitor (sodium azide) but not in the presence of cytochalasin B. These results together demonstrate that the in vitro interaction of soluble MHC II-peptide complexes with cloned T cells is an active process associated with uptake of the antigenic peptide.			NAG, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSS S, 1987, IMMUNOL REV, V98, P115; BUUS S, 1986, P NATL ACAD SCI USA, V83, P3968, DOI 10.1073/pnas.83.11.3968; CARTER SB, 1967, NATURE, V213, P261, DOI 10.1038/213261a0; DAVIS CB, 1989, J IMMUNOL, V143, P2083; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JENKINS MK, 1990, J IMMUNOL, V144, P16; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUMAR V, 1989, ANNU REV IMMUNOL, V7, P657, DOI 10.1146/annurev.iy.07.040189.003301; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; NAG B, 1993, P NATL ACAD SCI USA, V90, P1604, DOI 10.1073/pnas.90.4.1604; NAG B, 1991, J IMMUNOL METHODS, V142, P105, DOI 10.1016/0022-1759(91)90297-S; NAG B, 1992, J IMMUNOL, V148, P369; NAG B, 1992, J BIOL CHEM, V267, P22624; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PELCHENMATTHEWS A, 1989, EMBO J, V8, P3641, DOI 10.1002/j.1460-2075.1989.tb08538.x; QUILL H, 1987, J IMMUNOL, V138, P3704; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SU XM, 1992, CELL IMMUNOL, V141, P485, DOI 10.1016/0008-8749(92)90165-L; YOSHINAGA M, 1972, P NATL ACAD SCI USA, V69, P3251, DOI 10.1073/pnas.69.11.3251	29	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14360	14366						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686154				2022-12-27	WOS:A1993LJ82500083
J	ROEBROEK, AJM; VANDEVELDE, HJK; VANBOKHOVEN, A; BROERS, JLV; RAMAEKERS, FCS; VANDEVEN, WJM				ROEBROEK, AJM; VANDEVELDE, HJK; VANBOKHOVEN, A; BROERS, JLV; RAMAEKERS, FCS; VANDEVEN, WJM			CLONING AND EXPRESSION OF ALTERNATIVE TRANSCRIPTS OF A NOVEL NEUROENDOCRINE-SPECIFIC GENE AND IDENTIFICATION OF ITS 135-KDA TRANSLATIONAL PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LUNG-CANCER; GROWTH-PROPERTIES; LINES; PROTEINS; ESTABLISHMENT; SEQUENCES	Monoclonal antibodies RNL-2 and RNL-3 were previously shown to react with four 35-45-kDa proteins, expressed only in small cell lung carcinoma NCI-H82 cells, but to stain a subset of neuroendocrine tissues and neoplasms (Broers, J. L. V., Mijnheere, E. P., Klein Rot, M., Schaart, G., Sijlmans, A., Boerman, 0. C., and Ramaekers, F. C. S. (1991) Cancer 67, 619-633). We used RNL-2 and RNL-3 to isolate cDNA sequences that code for proteins containing the two corresponding epitopes and utilized such cDNAs to develop second generation antibodies. Using these antibodies, we identified a novel 135-kDa protein. The corresponding cDNAs were found to belong to a previously unknown gene with a neuroendocrine-specific expression pattern, tentatively designated NSP gene. NSP transcription appeared to result in mRNAs of 3.4 and 1.8 kilobases (kb). In the NCI-H82 cells only, an apparently aberrant transcript of 2.3 kb was found. cDNAs containing coding sequences of the 3.4-, 2.3-, and 1.8-kb transcripts were isolated, and nucleotide sequence analysis revealed extensive sequence overlap and open reading frames for proteins of 776, 356, and 208 amino acids, respectively. The three deduced proteins all have a common carboxyl-terminal part with two large hydrophobic regions. Transfection of the complete coding sequences of the 3.4-kb transcript resulted in the production of a protein with an apparent molecular mass of 135 kDa. This protein is predicted to be highly negatively charged (calculated pI of 4.35), to be rich in proline and serine, and to contain multiple potential phosphorylation sites.	UNIV LIMBURG, DEPT MOLEC CELL BIOL & GENET, 6229 ER MAASTRICHT, NETHERLANDS	Hasselt University	ROEBROEK, AJM (corresponding author), CATHOLIC UNIV LEUVEN, CTR HUMAN GENET, MOLEC ONCOL LAB, HEREST 49, B-3000 LOUVAIN, BELGIUM.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; [Anonymous], 1982, Am J Clin Pathol, V77, P123; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEPLER G, 1987, J CANCER RES CLIN, V113, P31, DOI 10.1007/BF00389964; BEVERLY PCL, 1990, BR J CANCER S14, V63, P1; BROERS JLV, 1991, CANCER-AM CANCER SOC, V67, P619, DOI 10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y; CARNEY DN, 1985, CANCER RES, V45, P2913; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELEIJ L, 1985, CANCER RES, V45, P6024; GAZDAR AF, 1985, CANCER RES, V45, P2924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MINNA JD, 1985, CANCER PRINCIPLES PR, P505; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1989, CANCER RES, V49, P4154; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; Sambrook J, 1989, MOL CLONING LABORATO; TEMPLETON D, 1984, MOL CELL BIOL, V4, P817, DOI 10.1128/MCB.4.5.817; VANDEVEN WJM, 1978, J VIROL, V27, P595, DOI 10.1128/JVI.27.3.595-603.1978; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; WARREN WH, 1989, J THORAC CARDIOV SUR, V98, P321; WIEDENMANN B, 1989, VIRCHOWS ARCH B, V58, P95, DOI 10.1007/BF02890062; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	26	82	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13439	13447						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685762				2022-12-27	WOS:A1993LH55300061
J	SECKL, M; ROZENGURT, E				SECKL, M; ROZENGURT, E			TYRPHOSTIN INHIBITS BOMBESIN STIMULATION OF TYROSINE PHOSPHORYLATION, C-FOS EXPRESSION, AND DNA-SYNTHESIS IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AFFINITY CROSS-LINKING; GROWTH-FACTOR; RAPIDLY STIMULATE; PHOSPHOLIPASE-C; PHORBOL ESTERS; EARLY EVENTS; SIGNAL TRANSDUCTION; BETA-1 ISOZYME; GQ CLASS	Treatment of quiescent Swiss 3T3 cells with 20 muM {[(3,4,5-trihydroxyphenyl)methylene]propanedinitrile} (tyrphostin) caused a 76% r eduction in the tyrosine phosphorylation of the M(r) 110,000-130,000 band induced by bombesin. This was accompanied by a 48% reduction in the tyrosine phosphorylation of the cytosolic tyrosine kinase p125 focal adhesion kinase. Preincubation with 20 muM tyrphostin did not inhibit either protein kinase A activation by forskolin or protein kinase C (PKC) activation by phorbol 12,13-dibutyrate in intact Swiss 3T3 cells. Similarly, 20 muM tyrphostin neither interfered with binding of bombesin to its receptor nor prevented bombesin-stimulated Ca2+ mobilization or PKC activation. Thus tyrphostin selectively inhibits tyrosine phosphorylation induced by bombesin in intact Swiss 3T3 cells. Consequently, we examined the contribution of this tyrosine phosphorylation pathway to the subsequent induction of c-fos and stimulation of mitogenesis by bombesin. Tyrphostin prevented both c-fos mRNA expression and DNA synthesis induced by bombesin. The incorporation of [H-3] thymidine was inhibited by tyrphostin in a dose-dependent manner (IC50 = 20 muM), and this effect was not reversed even at high concentrations of bombesin. These results provide evidence that tyrosine phosphorylation is a mitogenic signal for bombesin.	IMPERIAL CANC RES FUND, POB 123, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ANAFI M, 1992, J BIOL CHEM, V267, P4518; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BILDER GE, 1991, AM J PHYSIOL, V260, pC721, DOI 10.1152/ajpcell.1991.260.4.C721; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MEHMET H, 1990, EXP CELL RES, V190, P265, DOI 10.1016/0014-4827(90)90195-G; MEHMET H, 1989, ONCOGENE RES, V4, P215; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETHI T, 1992, CANCER RES, V52, pS2737; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STADDON JM, 1991, J BIOL CHEM, V266, P4840; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	54	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9548	9554						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683655				2022-12-27	WOS:A1993LA68900062
J	MARTINIS, SA; SCHIMMEL, P				MARTINIS, SA; SCHIMMEL, P			MICROHELIX AMINOACYLATION BY A CLASS-I TRANSFER-RNA SYNTHETASE - NONCONSERVED BASE-PAIRS REQUIRED FOR SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SUPPRESSOR TRANSFER-RNAS; ESCHERICHIA-COLI; ENZYMATIC AMINOACYLATION; CHEMICAL SYNTHESIS; ACCEPTOR STEM; ANTICODON; RECOGNITION; IDENTITY; SEQUENCE; NUCLEOTIDES	Nucleotides in tRNAs that are conserved among isoacceptors are typically considered as candidates for tRNA synthetase recognition, with less importance attached to non-conserved nucleotides. Although the anticodon is an important contributor to the identity of methionine tRNAs, the class I methionine tRNA synthetase aminoacylates microhelices with high specificity. The microhelix substrates are comprised of as few as the 1st 4 base pairs of the acceptor stems of the elongator and initiator methionine tRNAs. For these two tRNAs, only the central 2:71 and 3:70 base pairs are common to the 1st 4 acceptor stem base pairs. We show here that, although the flanking 4:69 base pair is not conserved, a particular substitution at this position substantially reduces the gel electrophoresis-detected aminoacylation of an acceptor stem substrate that has the conserved 2:71 and 3:70 base pairs. Although the two methionine tRNAs have either U:A or G:C at position 4:69, substitution with C:G reduces charging of 9- or 4-base pair substrates that recreate part or all of the acceptor stem of a methionine tRNA. This effect is sufficient for methionine tRNA synthetase to discriminate between the closely related methionine and isoleucine tRNA acceptor stems. The ability to distinguish G:C and U:A from C:G is contrary to a simple scheme for recognition of atoms in the RNA minor groove.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Martinis, Susan/0000-0001-5730-8346	NIGMS NIH HHS [GM 15539] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015539, R01GM015539] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRANCKLYN C, 1992, EUR J BIOCHEM, V206, P315, DOI 10.1111/j.1432-1033.1992.tb16929.x; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; HARADA F, 1974, BIOCHEMISTRY-US, V13, P300, DOI 10.1021/bi00699a011; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NORMANLY J, 1989, ANNU REV BIOCHEM, V58, P1029, DOI 10.1146/annurev.bi.58.070189.005121; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMPSON JR, 1989, SCIENCE, V243, P1363; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; Schimmel P, 1991, CURR OPIN STRUC BIOL, V1, P811, DOI 10.1016/0959-440X(91)90183-T; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHI JP, 1992, BIOCHEMISTRY-US, V31, P4931, DOI 10.1021/bi00136a002; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	47	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6069	6072						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681057				2022-12-27	WOS:A1993KT36800002
J	TRIAS, JQ; BENZ, R				TRIAS, JQ; BENZ, R			CHARACTERIZATION OF THE CHANNEL FORMED BY THE MYCOBACTERIAL PORIN IN LIPID BILAYER-MEMBRANES - DEMONSTRATION OF VOLTAGE GATING AND OF NEGATIVE POINT CHARGES AT THE CHANNEL MOUTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA OUTER-MEMBRANE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; HYDROPHILIC SOLUTES; BACTERIAL PORINS; INTACT-CELLS; BINDING-SITE; PERMEABILITY; PROTEIN; IDENTIFICATION	We studied the channel formed by the mycobacterial porin from the cell wall of Mycobacterium chelonae (Trias, J., Jarlier, V., and Benz, R. (1992) Science 258, 1479-1481) by reconstituting the mycobacterial porin and cell wall extracts in lipid bilayer membranes. The channel exhibited two different states in lipid bilayer membranes at 10 mV of applied voltage. One was characterized by a steplike appearance while the other showed a fast, voltage-dependent, flickering behavior between a closed and an open state. The channel was voltage-gated, and starting at 40 mV of applied voltage the mycobacterial porin channel switched to a closed configuration in an asymmetric fashion. The channel was cation-selective and had 2.5-point negative charges at both sides of the channel. Identical channels were observed when membranes were reconstituted with cell wall extracts, suggesting that there is only one porin species in the mycobacterial cell wall.	UNIV PARIS 06,BACTERIOL VIROL LAB,F-75634 PARIS 13,FRANCE; UNIV WURZBURG,BIOZENTRUM,LEHRSTUHL BIOTECHNOL,W-8700 WURZBURG,GERMANY	UDICE-French Research Universities; Sorbonne Universite; University of Wurzburg				Benz, Roland/0000-0002-9510-9265				BENZ R, 1987, J GEN PHYSIOL, V89, P275, DOI 10.1085/jgp.89.2.275; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BENZ R, 1988, EUR J BIOCHEM, V176, P1, DOI 10.1111/j.1432-1033.1988.tb14245.x; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; BENZ R, 1987, J MEMBRANE BIOL, V100, P12; BRUNEN M, 1991, J BACTERIOL, V173, P4182, DOI 10.1128/jb.173.13.4182-4187.1991; DRAPER P, 1982, BIOL MYCOBACTERIA, P9; HELLIO R, 1988, CURR MICROBIOL, V17, P235, DOI 10.1007/BF01589458; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; MAIER C, 1988, J BIOL CHEM, V263, P2493; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; NELSON AP, 1975, J THEOR BIOL, V55, P13, DOI 10.1016/S0022-5193(75)80106-8; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; NIKAIDO H, 1986, METHOD ENZYMOL, V125, P265; RASTOGI N, 1986, CURR MICROBIOL, V13, P237, DOI 10.1007/BF01568645; RATLEDGE CR, 1982, BIOL MYCOBACTERIA, P53; SCHMID A, 1991, J BACTERIOL, V173, P4909, DOI 10.1128/jb.173.16.4909-4913.1991; SEN K, 1988, J BIOL CHEM, V263, P1182; STOCK JB, 1977, J BIOL CHEM, V252, P7850; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS J, 1990, J BIOL CHEM, V265, P15680; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202	27	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6234	6240						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681063				2022-12-27	WOS:A1993KT36800027
J	VONZASTROW, M; LINK, R; DAUNT, D; BARSH, G; KOBILKA, B				VONZASTROW, M; LINK, R; DAUNT, D; BARSH, G; KOBILKA, B			SUBTYPE-SPECIFIC DIFFERENCES IN THE INTRACELLULAR SORTING OF G-PROTEIN-COUPLED RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							VESICLES	We have examined the subcellular distribution of three subtypes of adrenergic receptor by immunocytochemical localization of wild-type and epitope-tagged proteins expressed in Cos-7 and K293 cells. Two subtypes (beta2 and Malpha2-10H) are localized in the plasma membrane at steady state in untreated cells, while another subtype (Malpha2-4H) is found both in the plasma membrane and in a population of intracellular vesicles. Within 15 min following the addition of adrenergic agonists, beta2 and Malpha2-10H receptors are differentially sorted; beta2 receptors are selectively internalized to intracellular vesicles, which are distinct from those containing Malpha2-4H receptors, while Malpha2-10H receptors remain in the plasma membrane. Subtype-specific sorting suggests a new class of functional properties that may differentiate the signaling and regulation of homologous G protein-coupled receptors.	STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,DIV CARDIOVASC MED,STANFORD,CA 94305; STANFORD UNIV,DEPT PEDIAT,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BYLUND DB, 1988, TRENDS PHARMACOL SCI, V9, P356, DOI 10.1016/0165-6147(88)90254-4; HARAGUCHI K, 1990, P NATL ACAD SCI USA, V87, P1208, DOI 10.1073/pnas.87.3.1208; INSEL PA, 1988, ALPHA 2 ADRENERGIC R, P281; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LINK R, 1992, MOL PHARMACOL, V42, P16; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PERKINS JP, 1991, BETA ADRENERGIC RECE, P73; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; SURYANARAYANA S, 1992, METHODS, V3, P193; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530	15	97	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					763	766						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678260				2022-12-27	WOS:A1993KG07700003
J	GERRITS, PM; OLSON, AL; PESSIN, JE				GERRITS, PM; OLSON, AL; PESSIN, JE			REGULATION OF THE GLUT4/MUSCLE-FAT GLUCOSE TRANSPORTER MESSENGER-RNA IN ADIPOSE-TISSUE OF INSULIN-DEFICIENT DIABETIC RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; DIFFERENTIAL REGULATION; PLASMA-MEMBRANE; EXPRESSION; CELLS; GLUT4; GENE; IDENTIFICATION; TRANSLOCATION; SUPPRESSION	Previous studies have documented that streptozotocin-induced insulin deficiency results in a marked decrease in adipose tissue GLUT4 glucose transporter mRNA levels (Sivitz, W. I., DeSautel, S. L., Kayano, T., Bell, G. I., and Pessin, J. E. (1989) Nature 340, 72-74). In this study, nuclear run-on analysis performed on diabetic and insulin-treated diabetic rats demonstrated that the decrease in GLUT4 mRNA occurs via a diabetes-induced decrease in GLUT4 transcription rate. The decrease in GLUT4 mRNA levels could be prevented by treatment of the diabetic animals with the adenosine receptor agonist phenylisopropyladenosine (PIA). Under these conditions, PIA completely blocked the elevation of intracellular cAMP levels associated with insulin deficiency. Surprisingly, isolation of primary rat adipocytes from control animals resulted in a rapid decrease (approximately 20-fold) in GLUT4 mRNA levels by 24 h with a concomitant increase (approximately 70-fold) in GLUT1 mRNA levels. This rapid loss of GLUT4 expression did not correlate with changes in adipocyte cAMP levels and was not prevented by treatment of the cells with either insulin and/or PIA. These data demonstrate that the decrease in GLUT4 transcription induced by insulin deficiency in vivo predominantly results from an increase in intracellular cAMP levels. In contrast, although GLUT4 transcription also decreases in adipocytes when removed from their normal physiological environment, this occurs independent of changes in cAMP levels.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042452, P30DK025295, K04DK001822] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42452, DK25295, DK01822] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HOFFMAN BB, 1986, J PHARMACOL EXP THER, V239, P715; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KAHN BB, 1991, J CLIN INVEST, V87, P2197, DOI 10.1172/JCI115254; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; RHOADS DB, 1988, P NATL ACAD SCI USA, V85, P9042, DOI 10.1073/pnas.85.23.9042; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RODBELL M, 1964, J BIOL CHEM, V239, P375; SELAWRY H, 1973, BIOCHEM BIOPH RES CO, V51, P198, DOI 10.1016/0006-291X(73)90528-7; SIVITZ WI, 1990, MOL ENDOCRINOL, V4, P583, DOI 10.1210/mend-4-4-583; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	28	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					640	644						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678005				2022-12-27	WOS:A1993KE60300096
J	PIERONI, JP; HARRY, A; CHEN, JQ; JACOBOWITZ, O; MAGNUSSON, RP; IYENGAR, R				PIERONI, JP; HARRY, A; CHEN, JQ; JACOBOWITZ, O; MAGNUSSON, RP; IYENGAR, R			DISTINCT CHARACTERISTICS OF THE BASAL ACTIVITIES OF ADENYLYL CYCLASE-2 AND CYCLASE-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHORBOL ESTER TREATMENT; BETA-GAMMA-SUBUNITS; HETEROLOGOUS DESENSITIZATION; INHIBITION; IDENTIFICATION; STIMULATION; DIVERSITY; CLONING; ENZYME	Regulation of basal activities of adenylyl cyclase (AC) 2 and 6, expressed in Sf9 cells by infection with recombinant baculovirus, was studied. An antipeptide antibody that recognizes AC2 and AC6 with equal sensitivity was used to establish that equivalent levels were expressed. Basal activities of AC2 and AC6 were compared at varying concentrations of Mg2+ or Mn2+ ions; AC2 had 15- and 10-fold greater activity than AC6, respectively. At 20 mM Mg2+, the K-m values for ATP were 88 and 39 mu M for AC2 and AC6, respectively, whereas their V-max values were 281 and 11 pmol/mg protein . min. With 100 mu M forskolin and either Mg2+ or Mn2+, the difference in activities between AC2 and AC6 was reduced to approximately 2-fold. Forskolin stimulated AC6 greater than 40-fold at 0.5-2 mM Mg2+, whereas AC2 was stimulated 4-6-fold. At 20 mM Mg2+, AC2 was stimulated 2-fold by forskolin, whereas AC6 was stimulated 18-fold. With Mg2+ alone, activities of AC2 and AC6 were not saturable up to 20 mM and yielded curvilinear Hofstee transformations. With forskolin, activities of both AC2 and AC6 were saturable by 10 mM Mg2+ and yielded linear Hofstee transformations. These data indicate that there are substantial differences in the basal enzymatic activities of adenylyl cyclase isoforms, due to differential regulation by Mg2+ ions rather than intrinsic catalytic capabilities. Thus the presence and relative abundance of adenylyl cyclase subtypes could greatly affect the resting cellular cAMP levels with consequent effects on important biological functions, such as differentiation and proliferation.			PIERONI, JP (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029, USA.		jacobowitz, ofer/U-2592-2017	jacobowitz, ofer/0000-0003-2290-0520	NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, T32DK007645] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761, DK-07645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BLAIR SS, 1995, NATURE, V373, P656, DOI 10.1038/373656a0; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COLLIER HOJ, 1980, NATURE, V283, P625, DOI 10.1038/283625a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RALL TW, 1982, HDB EXPT PHARM, V58, P3; RICH KA, 1984, J BIOL CHEM, V259, P7893; ROSS EM, 1978, J BIOL CHEM, V253, P6401; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SOMKUTI SG, 1982, J BIOL CHEM, V257, P6387; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	32	77	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21368	21373		10.1074/jbc.270.36.21368	http://dx.doi.org/10.1074/jbc.270.36.21368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673172	hybrid			2022-12-27	WOS:A1995RU05400076
J	ROSENWALD, IB; KASPAR, R; ROUSSEAU, D; GEHRKE, L; LEBOULCH, P; CHEN, JJ; SCHMIDT, EV; SONENBERG, N; LONDON, IM				ROSENWALD, IB; KASPAR, R; ROUSSEAU, D; GEHRKE, L; LEBOULCH, P; CHEN, JJ; SCHMIDT, EV; SONENBERG, N; LONDON, IM			EUKARYOTIC TRANSLATION INITIATION-FACTOR 4E REGULATES EXPRESSION OF CYCLIN D1 AT TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; RNA 5' CAP; MESSENGER-RNA; CELL-CYCLE; GENE-EXPRESSION; MALIGNANT TRANSFORMATION; RODENT FIBROBLASTS; LYMPHOCYTES-T; GROWTH; PHOSPHORYLATION	Regulation of the cell cycle is orchestrated by cyclins and cyclin-dependent kinases. We have demonstrated previously that overexpression of eukaryotic translation initiation factor 4E (eIF-4E) in NIH 3T3 cells growing in 10% fetal calf serum leads to highly elevated levels of cyclin D1 protein without significant increase in cyclin D1 mRNA levels, suggesting that a post-transcriptional mechanism is involved. (Rosenwald, I. B., Lazaris-Karatzas, A., Sonenberg, N., and Schmidt, E. V. (1993) Mol. Cell. Biol. 13, 7358-7363). In the present reseach, we did not find any significant effect of eIF-4E on polysomal distribution of cyclin D1 mRNA. However, the total amount of cyclin D1 mRNA associated with polysomes was significantly increased by eIF-4E overexpression. Further, we determined that the levels of both cyclin D1 protein and mRNA are increased in serum-deprived cells overexpressing eIF-4E. Nuclear run-on experiments demonstrated that the rate of the cyclin D1 transcription is not down-regulated in serum-deprived cells overexpressing eIF-4E. Thus, elevated levels of eIF-4E may lead to increased transcription of the cyclin D1 gene, and this effect becomes visible when serum deprivation down-regulates the rate of cyclin D1 mRNA synthesis in control cells. However, artificial overexpression of cyclin D1 mRNA in serum-deprived cells in the absence of eIF-4E overexpression did not cause the elevation of cyclin D1 protein, and this overexpressed cyclin D1 mRNA accumulated in the nucleus, suggesting that one post-transcriptional role of eIF-4E is to transport cyclin D1 mRNA from the nucleus to cytoplasmic polysomes.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02129	Harvard University; Brigham & Women's Hospital; Harvard Medical School; McGill University; Harvard University; Harvard Medical School; Massachusetts General Hospital	ROSENWALD, IB (corresponding author), HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [R01-CA63117-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK016272, DK-16272] Funding Source: Medline; NIGMS NIH HHS [R01 GM042504, GM-42504] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016272, R56DK016272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042504] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARVE SS, 1994, J IMMUNOL, V152, P1171; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EPIFANOVA OI, 1977, INT REV CYTOL      S, V5, P303; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; HERBER B, 1994, ONCOGENE, V9, P1295; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; JIANG W, 1993, ONCOGENE, V8, P3447; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P6912; LOVEC H, 1994, ONCOGENE, V9, P323; MAO XH, 1992, J BIOL CHEM, V267, P20444; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RONNING OW, 1981, J CELL PHYSIOL, V109, P411, DOI 10.1002/jcp.1041090306; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WHITHER DA, 1991, MOL CELL BIOL, V11, P4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	40	228	231	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21176	21180		10.1074/jbc.270.36.21176	http://dx.doi.org/10.1074/jbc.270.36.21176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673150	hybrid			2022-12-27	WOS:A1995RU05400049
J	THOMAS, DC; VEAUTE, X; FUCHS, RPP; KUNKEL, TA				THOMAS, DC; VEAUTE, X; FUCHS, RPP; KUNKEL, TA			FREQUENCY AND FIDELITY OF TRANSLESION SYNTHESIS OF SITE-SPECIFIC N-2-ACETYLAMINOFLUORENE ADDUCTS DURING DNA-REPLICATION IN A HUMAN CELL EXTRACT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; UV-IRRADIATED DNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REPETITIVE SEQUENCES; ANGSTROM RESOLUTION; MUTAGENESIS; POLYMERASE; MUTATIONS; INVITRO	We have previously analyzed the effects of site-specific N-2-acetylaminofluorene (AAF) adducts on the efficiency and frameshift fidelity of SV40-based DNA replication in a human cell extract (Thomas, D. C., Veaute, X,, Kunkel, T. A., and Fuchs, R. P. P. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 7752-7756). Here we use two sets of substrates to examine the probability of replication termination and error-free and error-prone bypass of AAF adducts. The substrates contained site-specific adducts at one of three guanines in a NarI sequence (5'-GGCGCC-3') placed within the lacZ alpha reporter gene and located on the template for either leading or lagging strand replication. The presence of the adduct at any position strongly reduces the efficiency of a single round of replication in a HeLa cell extract, Product analysis reveals preferential replication of the undamaged strand and termination of replication of the damaged strand occurring one nucleotide before incorporation opposite either a leading or lagging strand adduct, Products resistant to restriction endonuclease cleavage at the adducted site were generated in amounts consistent with 16-48% lesion bypass during replication, Most of this bypass was error-free, However, two-nucleotide deletion errors were detected in the replication products of DNA containing an AAF adduct in either the leading or lagging strand, but only when present at the third guanine position. Collectively, the data suggest that the replication apparatus in a HeLa cell extract generates a template-primer slippage error at an AAF adduct once for every 30-100 bypass events.	NIEHS,MOLEC GENET LAB,RES TRIANGLE PK,NC 27709; ECOLE SUPER BIOTECHNOL STRASBOURG,CNRS,UPR CANCEROGENESE & MUTAGENESE & STRUCT,F-67400 ILLKIRCH GRAFFENS,FRANCE	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Centre National de la Recherche Scientifique (CNRS)			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788				BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BELGUISEVALLADI.P, 1994, J MOL BIOL, V236, P151; BOYER JC, 1993, CANCER RES, V53, P3270; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; HAUSER J, 1988, MOL CELL BIOL, V8, P3267, DOI 10.1128/MCB.8.8.3267; IZUTA S, 1995, J BIOL CHEM, V270, P2595, DOI 10.1074/jbc.270.6.2595; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOFFELSCHWARTZ N, 1987, J MOL BIOL, V193, P651, DOI 10.1016/0022-2836(87)90348-2; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORNBERG A, 1992, DNA PEPLICATION; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; MILHE C, 1994, NUCLEIC ACIDS RES, V22, P4646, DOI 10.1093/nar/22.22.4646; MINNICK DT, 1994, NUCLEIC ACIDS RES, V22, P5658, DOI 10.1093/nar/22.25.5658; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RABKIN SD, 1984, J MOL BIOL, V178, P569, DOI 10.1016/0022-2836(84)90239-0; ROBERTS JD, 1993, BIOCHEMISTRY-US, V32, P4083, DOI 10.1021/bi00066a033; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; ROBERTS JD, 1995, IN PRESS DNA REPLICA; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; THOMAS DC, 1993, P NATL ACAD SCI USA, V90, P7744, DOI 10.1073/pnas.90.16.7744; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; THOMAS DC, 1993, BIOCHEMISTRY-US, V32, P11476, DOI 10.1021/bi00094a002; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022	36	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21226	21233		10.1074/jbc.270.36.21226	http://dx.doi.org/10.1074/jbc.270.36.21226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673156	hybrid			2022-12-27	WOS:A1995RU05400056
J	LIVINGSTON, BD; PAULSON, JC				LIVINGSTON, BD; PAULSON, JC			POLYMERASE CHAIN-REACTION CLONING OF A DEVELOPMENTALLY-REGULATED MEMBER OF THE SIALYLTRANSFERASE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAL-BETA-1->3(4)GLCNAC ALPHA-2->3 SIALYLTRANSFERASE; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; MOLECULAR-CLONING; CELL-ADHESION; RAT-LIVER; ENZYMATIC CHARACTERIZATION; DETERMINES EXPRESSION; CDNA; PURIFICATION; HOMOGENEITY	We have cloned a new member of the sialyltransferase gene family from newborn rat brain cDNA using the polymerase chain reaction and degenerate primers based on sequences found in a continuous region of homology present in three previously cloned sialyltransferases. The predicted amino acid sequence of the new gene contains 24 of the 31 amino acids that are invariantly conserved in the previously cloned sialyltransferases and encodes a type II transmembrane protein characteristic of glycosyltransferases. In contrast to previously cloned sialyltransferase genes, the expression of the new gene is highly restricted, being abundantly expressed in newborn brain but not in adult brain or any other adult or newborn tissues.	CYTEL CORP,3525 JOHN HOPKINS COURT,SAN DIEGO,CA 92121				Paulson, James/AAG-3565-2019					CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P136; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; INNIS MA, 1990, PCR PROTOCOLS; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P125; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MELKERSONWATSON LJ, 1991, J BIOL CHEM, V266, P4448; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADLER JE, 1979, J BIOL CHEM, V254, P5934; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	30	188	196	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11504	11507						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685014				2022-12-27	WOS:A1993LF28400009
J	PANETTI, TS; MCKEOWNLONGO, PJ				PANETTI, TS; MCKEOWNLONGO, PJ			RECEPTOR-MEDIATED ENDOCYTOSIS OF VITRONECTIN IS REGULATED BY ITS CONFORMATIONAL STATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; ARG-GLY-ASP; THROMBIN-ANTITHROMBIN-III; HUMAN S-PROTEIN; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; HUMAN-PLASMA; VONWILLEBRAND-FACTOR; ADHESIVE PROTEINS; SPREADING FACTOR	Vitronectin is a structurally labile molecule with a native, non-heparin binding form and a conformationally altered, heparin binding form. To understand the physiological significance of the two conformers of vitronectin, we examined the metabolism of both conformers by cultured human skin fibroblasts. Both native and altered vitronectin bound to confluent fibroblast monolayers. Both conformers of vitronectin competed equally well for the binding of altered vitronectin to the cell layer, suggesting that both conformers bound to the same site in the cell layer. In contrast, I-125-altered vitronectin, but not I-125-native vitronectin, was degraded to trichloroacetic acid-soluble radioactivity by the fibroblast monolayer. Degradation of vitronectin was saturable, sensitive to chloroquine, and occurred intracellularly, suggesting that vitronectin was degraded through a lysosomal pathway. Heparin and thrombospondin inhibited the degradation of altered vitronectin. The degradation of native vitronectin was induced by addition of gamma-thrombin which exposes vitronectin's cryptic heparin-binding domain. These studies suggest that the heparin-binding domain in vitronectin is required for the clearance of vitronectin from the matrix. In addition, these data demonstrate that the conformation of vitronectin regulates its half-life in the matrix. These studies provide the first evidence for a distinct function for the conformers of vitronectin.	ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,ALBANY,NY 12208	Albany Medical College					NATIONAL CANCER INSTITUTE [R01CA037785] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37785] Funding Source: Medline; NHLBI NIH HHS [HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BARNES DW, 1985, J CELL PHYSIOL, V125, P207, DOI 10.1002/jcp.1041250206; BLYSTONE SD, 1991, BLOOD, V78, P2900; BODARY SC, 1990, J BIOL CHEM, V265, P5938; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; GEBB C, 1986, J BIOL CHEM, V261, P6698; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; ILL CR, 1985, J BIOL CHEM, V260, P5610; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MOSHER DF, 1980, J BIOL CHEM, V255, P1181; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; PODACK ER, 1978, J IMMUNOL, V120, P1841; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; TOMASINI BR, 1986, BLOOD, V68, P737; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1990, PROG HEMOSTASIS THRO, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7671; UNDERWOOD PA, 1989, J CELL SCI, V93, P641; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	45	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11988	11993						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685028				2022-12-27	WOS:A1993LF28400080
J	ZHANG, YL; CRAMER, WA				ZHANG, YL; CRAMER, WA			INTRAMEMBRANE HELIX-HELIX INTERACTIONS AS THE BASIS OF INHIBITION OF THE COLICIN-E1 ION CHANNEL BY ITS IMMUNITY PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL PEPTIDE; COLE1 GENE-PRODUCTS; ESCHERICHIA-COLI; CONFERRING IMMUNITY; MEMBRANE TOPOGRAPHY; DNA; LOCALIZATION; TOLA; E1; DEPOLARIZATION	It had previously been hypothesized that the ability of a small number of immunity protein molecules in the cytoplasmic membrane to confer protection against the lethal effects of a channel-forming colicin involves a complex stabilized by electrostatic or polar interactions between immunity protein, the colicin channel, and specific sites on the cytoplasmic membrane surface defined by the presence of the tol gene translocation proteins. The hypothesis was tested (a) by constructing a hybrid colicin molecule, IaE1, containing the E1 channel domain, and the translocation and receptor domains of la, and (b) by altering charged residues in all peripheral regions of the immunity protein to neutral residues. It was concluded that the specificity of immunity protein requires neither specific translocation proteins, nor a specific arrangement of charged residues in the immunity protein. (c) In addition, by making 65 site-directed mutations, ''immunity by-pass'' mutants were found at five different loci, Ala474, Ser477, His440, Phe443, and Gly444, on two proposed membrane-spanning helices of the open colicin channel, one hydrophobic (A471-A488) and one amphiphilic (V441-W460). The mutants in the hydrophobic helix showed a larger bypass effect. The ''bypass'' phenotype could be assayed by (i) cytotoxicity and (ii) K+ efflux in imm+ cells caused by a bypass mutant but not wild-type colicin. It is concluded that the immunity protein exerts its specific effect through rapid lateral diffusion in the cytoplasmic membrane and helix-helix recognition and interaction with at least one hydrophobic and one amphiphilic trans-membrane helix of the colicin channel. Interaction with the amphiphilic helix implies that the immunity protein can react with the channel in the open state.	PURDUE UNIV,LILLY HALL LIFE SCI,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIGMS NIH HHS [GM-18457] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018457] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZARAL M, 1968, J MOL BIOL, V36, P185, DOI 10.1016/0022-2836(68)90374-4; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BISHOP LJ, 1985, J BACTERIOL, V164, P237, DOI 10.1128/JB.164.1.237-244.1985; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; BULLOCK JO, 1983, J BIOL CHEM, V258, P9908; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRAMER WA, 1992, FASEB J, V6, P3397, DOI 10.1096/fasebj.6.15.1464373; CRAMER WA, 1991, ENERGY TRANSDUCTION, P205; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; GELI V, 1989, MOL MICROBIOL, V3, P679, DOI 10.1111/j.1365-2958.1989.tb00216.x; GELI V, 1989, FEMS MICROBIOL LETT, V60, P239; GELI V, 1986, MOL GEN GENET, V202, P455, DOI 10.1007/BF00333276; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; GELI V, 1992, J BACTERIOL, V174, P6432, DOI 10.1128/JB.174.20.6432-6437.1992; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V202, P1299, DOI 10.1111/j.1432-1033.1991.tb16503.x; GOULD JM, 1977, J BIOL CHEM, V252, P5491; Jakes KS., 1982, MOL ACTION TOXINS VI, P131; KOPECKY AL, 1975, P NATL ACAD SCI USA, V72, P4631, DOI 10.1073/pnas.72.11.4631; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; MANKOVICH JA, 1986, J BACTERIOL, V168, P228, DOI 10.1128/jb.168.1.228-236.1986; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; Neidhardt F.C., 1987, CELLULAR MOL BIOL, VI; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PHILLIPS SK, 1973, BIOCHEMISTRY-US, V12, P1170, DOI 10.1021/bi00730a024; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; RATH P, 1991, BIOPHYS J, V59, P516, DOI 10.1016/S0006-3495(91)82268-8; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SCHALLER K, 1976, P NATL ACAD SCI USA, V73, P3989, DOI 10.1073/pnas.73.11.3989; SHIRABE K, 1993, IN PRESS PLASMID; SIDIKARO J, 1974, J BIOL CHEM, V249, P445; Song H. Y., 1991, THESIS; SONG HY, 1991, J BACTERIOL, V173, P2935, DOI 10.1128/JB.173.9.2935-2943.1991; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SZCZEPANIAK A, 1991, EMBO J, V10, P2757, DOI 10.1002/j.1460-2075.1991.tb07824.x; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WENDT L, 1970, J BACTERIOL, V104, P1236, DOI 10.1128/JB.104.3.1236-1241.1970; YAMADA M, 1982, P NATL ACAD SCI-BIOL, V79, P2827, DOI 10.1073/pnas.79.9.2827; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	43	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10176	10184						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683669				2022-12-27	WOS:A1993LB80000037
J	POTTS, M; SUN, H; MOCKAITIS, K; KENNELLY, PJ; REED, D; TONKS, NK				POTTS, M; SUN, H; MOCKAITIS, K; KENNELLY, PJ; REED, D; TONKS, NK			A PROTEIN-TYROSINE SERINE PHOSPHATASE ENCODED BY THE GENOME OF THE CYANOBACTERIUM NOSTOC-COMMUNE UTEX-584	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID SEQUENCE; ESCHERICHIA-COLI; VIRULENCE DETERMINANT; HUMAN-PLACENTA; RECEPTOR; FAMILY; YERSINIA; GENE	Protein-tyrosine phosphorylation has long been regarded as an exclusively eukaryotic phenomenon. Although some non-eukaryotes, mainly viruses, possess genes encoding protein-tyrosine kinases or protein-tyrosine phosphatases, these were probably appropriated from the eukaryotic hosts that constitute the sites of action of these enzymes. Herein we identify a gene, iphP, from the chromosome of the cyanobacterium Nostoc commune UTEX 584 that contains the His-Cys-Xaa-Ala-Gly-Xaa-Xaa-Arg sequence characteristic of known protein-tyrosine phosphatases. The expressed gene product, IphP, displayed protein-tyrosine phosphatase activity toward phosphotyrosine residues on reduced, carboxyamidomethylated, and maleylated lysozyme with optimum activity at pH 5.0. In addition, IphP dephosphorylated the phosphoseryl groups on casein that had been phosphorylated by the cAMP-dependent protein kinase. Cell lysates of N. commune probed with antibodies to phosphotyrosine indicated the presence of a tyrosine-phosphorylated protein of M(r) almost-equal-to 85 kDa. This tyrosine-phosphorylated protein was detected in cells grown in the presence of combined nitrogen but not in nitrogen-deficient media that induces the formation of differentiated N2-fixing cells (heterocysts). Together, these data suggest a role for protein-tyrosine phosphorylation in regulating cellular functions in this cyanobacterium. IphP is the first protein-tyrosine phosphatase to be discovered that is encoded by the chromosomal DNA of any prokaryote. Given the free-living nature of N. commune and the phylogenetic antiquity of the cyanobacteria, these findings suggest for the first time the existence of a protein-tyrosine phosphatase of genuine, unambiguous prokaryotic ancestry, thus raising fundamental questions as to the origin and role of tyrosine phosphorylation.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory	POTTS, M (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM & NUTR,BLACKSBURG,VA 24061, USA.				NCI NIH HHS [CA 53840] Funding Source: Medline; NIGMS NIH HHS [GM 45368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053840, R37CA053840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045368] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1978, P NATL ACAD SCI USA, V75, P3732, DOI 10.1073/pnas.75.8.3732; ATKINSON M, 1992, J BACTERIOL, V174, P4356, DOI 10.1128/JB.174.13.4356-4360.1992; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; COULTON JW, 1986, J BACTERIOL, V165, P181, DOI 10.1128/jb.165.1.181-192.1986; CUNNINGHAM PR, 1990, BIOTECHNIQUES, V9, P713; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; KOSTER W, 1986, MOL GEN GENET, V204, P435, DOI 10.1007/BF00331021; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2441; POTTS M, 1992, SCIENCE, V256, P1690, DOI 10.1126/science.256.5064.1690; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schopf JW, 1982, BIOL CYANOBACTERIA, P543; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITTON BA, 1990, PHYCOLOGIA, V29, P139, DOI 10.2216/i0031-8884-29-2-139.1; XIE WQ, 1989, GENE ANAL TECH, V6, P17, DOI 10.1016/0735-0651(89)90008-3; XIE WQ, 1989, J BACTERIOL, V171, P708, DOI 10.1128/jb.171.2.708-713.1989	26	68	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7632	7635						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681825				2022-12-27	WOS:A1993KW97900009
J	MORGAN, WT; MUSTER, P; TATUM, F; KAO, SM; ALAM, J; SMITH, A				MORGAN, WT; MUSTER, P; TATUM, F; KAO, SM; ALAM, J; SMITH, A			IDENTIFICATION OF THE HISTIDINE-RESIDUES OF HEMOPEXIN THAT COORDINATE WITH HEME-IRON AND OF A RECEPTOR-BINDING REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; RABBIT HEMOPEXIN; GENE-EXPRESSION; MEDIATED TRANSPORT; SEQUENCE; RAT; PROTEINS; SERUM; DETERMINANTS; COMPLEXES	Rabbit hemopexin cDNA was cloned from a rabbit liver lambdagt11 cDNA expression library using a mixture of five monoclonal antibodies raised against rabbit hemopexin, and the entire rabbit hemopexin sequence was determined. The heme-binding domain I of rabbit hemopexin (Smith, A., and Morgan, W. T. (1984) J. Biol. Chem. 259, 12049-12053) contains only 4 histidine residues which are conserved in rabbit, human, rat, and mouse hemopexin. The 2 axial heme-iron coordinating histidine residues, identified by Edman microsequencing and amino acid analyses of chemically modified domain I and isolated fragments of domain I, are the conserved histidine residues at positions 56 and 127 of the mature rabbit protein. The epitope recognized by JEN-14 (a monoclonal antibody which specifically reacts with domain I and blocks the hemopexin-receptor interaction (Morgan, W. T., Muster, P., Tatum, F. M., McConnell, J., Conway, T. P., Hensley, P., and Smith, A. (1988) J. Biol. Chem. 263, 8220-8225) was shown to lie between residues 122 and 142 by Western blotting of protease-digested domain I and transposon-insertion mutants of domain I expressed in a plasmid vector system. The location of this epitope near the heme-binding histidine residue 127 is compatible with a transport mechanism in which the release of heme from hemopexin is accompanied by a concomitant transfer of heme to the hemopexin receptor or the membrane heme-binding protein (Smith, A., and Morgan, W. T. (1985) J. Biol. Chem. 260, 8325-8329).			MORGAN, WT (corresponding author), UNIV MISSOURI, SCH BIOL SCI, DIV MOLEC BIOL & BIOCHEM, 5100 ROCKHILL RD, KANSAS CITY, MO 64110 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NIDDK NIH HHS [DK-27237] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027237] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1989, J BIOL CHEM, V264, P17637; ALAM J, 1992, J BIOL CHEM, V267, P16379; ALTRUDA F, 1985, NUCLEIC ACIDS RES, V13, P3841, DOI 10.1093/nar/13.11.3841; BEARDEN AJ, 1974, BIOCHEM BIOPH RES CO, V61, P265, DOI 10.1016/0006-291X(74)90562-2; BERG DE, 1983, BIO-TECHNOL, V1, P417, DOI 10.1038/nbt0783-417; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BROWN SB, 1969, BIOCHEM J, V115, P279, DOI 10.1042/bj1150279; CONWAY TP, 1975, J BIOL CHEM, V250, P3067; DAVIES DM, 1979, BIOCHEM BIOPH RES CO, V91, P1504, DOI 10.1016/0006-291X(79)91235-X; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HANSON MS, 1992, P NATL ACAD SCI USA, V89, P1973, DOI 10.1073/pnas.89.5.1973; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Miles E W, 1977, Methods Enzymol, V47, P431; MILLAND J, 1990, AM J PHYSIOL, V259, pG340, DOI 10.1152/ajpgi.1990.259.3.G340; MORGAN WT, 1988, J BIOL CHEM, V263, P8226; MORGAN WT, 1976, BIOCHIM BIOPHYS ACTA, V434, P311, DOI 10.1016/0005-2795(76)90223-3; MORGAN WT, 1988, J BIOL CHEM, V263, P8220; MORGAN WT, 1984, J BIOL CHEM, V259, P2001; MORGAN WT, 1976, ARCH BIOCHEM BIOPHYS, V176, P431, DOI 10.1016/0003-9861(76)90185-5; MORGAN WT, 1974, ENZYME, V17, P108, DOI 10.1159/000459315; MORGAN WT, 1972, J BIOL CHEM, V247, P7181; MORGAN WT, 1978, J BIOL CHEM, V253, P2940; MORGAN WT, 1976, ANN CLIN RES, V8, P223; MORRIS JP, 1981, BIOCHEMISTRY-US, V20, P4811, DOI 10.1021/bi00520a001; MULLEREBERHARD U, 1970, J LAB CLIN MED, V76, P426; MUSTER P, 1991, J PROTEIN CHEM, V10, P123, DOI 10.1007/BF01024662; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SEERY VL, 1972, ARCH BIOCHEM BIOPHYS, V150, P269, DOI 10.1016/0003-9861(72)90035-5; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; SMITH A, 1985, J BIOL CHEM, V260, P8325; SMITH A, 1985, BIOCHEM J, V231, P663, DOI 10.1042/bj2310663; SMITH A, 1988, J BIOL CHEM, V263, P5224; SMITH A, 1990, EUR J CELL BIOL, V53, P234; SMITH A, 1978, BIOCHEM BIOPH RES CO, V84, P151, DOI 10.1016/0006-291X(78)90276-0; SMITH A, 1981, J BIOL CHEM, V256, P902; SMITH A, 1984, J BIOL CHEM, V259, P2049; Smith A., 1990, BIOSYNTHESIS HEME CH, P435; STRUHL K, 1985, Biotechniques, V3, P452; SUTTNAR J, 1986, INT J BIOCHEM, V18, P283, DOI 10.1016/0020-711X(86)90120-5; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P2021, DOI 10.1073/pnas.81.7.2021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	49	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6256	6262						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681064				2022-12-27	WOS:A1993KT36800030
J	MARTIN, JL; WILSON, JE; FURFINE, ES; HOPKINS, SE; FURMAN, PA				MARTIN, JL; WILSON, JE; FURFINE, ES; HOPKINS, SE; FURMAN, PA			BIOCHEMICAL-ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS-1 REVERSE-TRANSCRIPTASE CONTAINING A MUTATION AT POSITION LYSINE-263	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING DOMAIN; RNASE-H ACTIVITY; DNA-POLYMERASE; PYRIDOXAL 5'-PHOSPHATE; MUTAGENESIS; SITE; RETROVIRUS; IDENTIFICATION; INHIBITION	Site-directed mutagenesis has been used to assess the importance of lysine 263 in substrate binding of human immunodeficiency virus-1 (HIV-1) reverse transcriptase. Previous studies have indicated that lysine 263 functions in the binding of 2'-deoxynucleoside 5'-triphosphate (dNTP) substrates (Basu, A., Tirumalai, R. S., and Modak, M. J. (1989) J. Biol. Chem. 264, 8746-8752). We studied this interaction directly by using site-specific mutagenesis to change lysine 263 to a serine. Highly purified mutant enzyme K263S bound natural dNTP substrates and primed polynucleic acid substrates with equal affinity when compared to the wild type reverse transcriptase. No difference was observed in the binding of 3'-azido-2',3'-dideoxythymidine 5'-triphosphate to the mutant reverse transcriptase on the basis of K(m) and K(i) determinations. The serine substitution had no effect on RNase H activity. These results indicate that lysine 263 is not essential in the binding of substrates to HIV-1 reverse transcriptase.	BURROUGHS WELLCOME CO,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709	Burroughs Wellcome Fund	MARTIN, JL (corresponding author), BURROUGHS WELLCOME CO,DIV VIROL,3030 CORNWALLIS RD,RES TRIANGLE PK,NC 27709, USA.							BASU A, 1988, J BIOL CHEM, V263, P1648; BASU A, 1990, J BIOL CHEM, V265, P17162; BASU A, 1989, J BIOL CHEM, V264, P8746; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FURFINE ES, 1991, J BIOL CHEM, V266, P406; FURMAN PA, 1991, P NATL ACAD SCI USA, V88, P6013, DOI 10.1073/pnas.88.14.6013; FURMAN PA, 1979, J VIROL, V32, P72, DOI 10.1128/JVI.32.1.72-77.1979; HAZRA AK, 1984, BIOCHEMISTRY-US, V23, P2073, DOI 10.1021/bi00304a030; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15667; Maniatis T., 1982, MOL CLONING; MEYERS G, 1989, HUMAN RETROVIRUSES A; OLSEN DB, 1990, P NATL ACAD SCI USA, V87, P1451, DOI 10.1073/pnas.87.4.1451; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RESTLE T, 1990, J BIOL CHEM, V265, P8986; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504	28	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2565	2570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679098				2022-12-27	WOS:A1993KK81500047
J	SAGGIORO, D; SORIO, C; CALDERAZZO, F; CALLEGARO, L; PANOZZO, M; BERTON, G; CHIECOBIANCHI, L				SAGGIORO, D; SORIO, C; CALDERAZZO, F; CALLEGARO, L; PANOZZO, M; BERTON, G; CHIECOBIANCHI, L			MECHANISM OF ACTION OF THE MONOSIALOGANGLIOSIDE G(M1) AS A MODULATOR OF CD4 EXPRESSION - EVIDENCE THAT G(M1)-CD4 INTERACTION TRIGGERS DISSOCIATION OF P56LCK FROM CD4, AND CD4 INTERNALIZATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN LYMPHOCYTES-T; CYTOPLASMIC DOMAIN; HIV INFECTION; SELECTIVE MODULATION; GANGLIOSIDES; INHIBITION; MOLECULES; CELLS; PHOSPHORYLATION	Analyzing the mechanisms underlying the capability of the monosialoganglioside G(M1) to induce CD4 modulation we observed that G(M1) has a dual effect on the CD4 molecule. G(M1) treatment of the lymphoma cell line MOLT-3 and CD4-transfected HeLa cells for times shorter than 30 min prevented binding of monoclonal antibodies (mAbs) recognizing epitopes located within the first NH2-terminal domains of CD4, but not of the OKT4 mAb, which binds to the region of CD4 proximal to the transmembrane domain. However, no binding of the OKT4 mAb was observed after a few hours of treatment with G(M1) in both MOLT-3 cells and HeLa cells transfected with an intact CD4 molecule, but not in HeLa cells transfected with a CD4 molecule lacking the bulk of the cytoplasmic domain, suggesting that modulation of CD4 by G(M1) depends on the integrity of the cytoplasmic domain. G(M1) treatment blocked binding of several mAbs which recognize epitopes located within the first two NH2-terminal domains of CD4 and did not induce CD4 down-modulation if MOLT-3 cells were preincubated with the OKT4A or the OKT4 mAbs. Immunoprecipitation studies with [S-35]methionine-labeled MOLT-3 cells showed that G(M1)-induced CD4 down-modulation was accompanied by CD4 degradation, and this was preceded by dissociation of p56lck from CD4. G(M1)-induced CD4 down-modulation, dissociation of p56lck from CD4, and CD4 degradation were unaffected by staurosporine, which, on the contrary, blocked these events in response to phorbol 12-myristate 13-acetate. These observations demonstrate that the first action of G(M1) is to mask epitopes located within the first two NH2-terminal domains; then, G(M1) triggers protein kinase C-independent signals which cause p56lck dissociation from CD4 and the delivery of the molecule to an intracellular compartment where it is eventually degraded.	UNIV VERONA, INST GEN PATHOL, I-37100 VERONA, ITALY; FIDIA RES LABS, PADUA, ITALY	University of Verona	SAGGIORO, D (corresponding author), UNIV PADUA, INTERUNIV CTR CANC RES, IST SCI TUMORI GENOVA, INST ONCOL, BIOTECHNOL SECT, I-35128 PADUA, ITALY.		Sorio, Claudio/F-2764-2018; Saggioro, Daniela/W-1443-2018	Sorio, Claudio/0000-0003-2739-4014; Saggioro, Daniela/0000-0002-7136-2821				ACRES RB, 1986, J BIOL CHEM, V261, P6210; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BLUE ML, 1987, J IMMUNOL, V139, P3949; BLUE ML, 1989, J IMMUNOL, V142, P374; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; CHIECOBIANCHI L, 1989, AIDS, V3, P501, DOI 10.1097/00002030-198908000-00003; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; DALGLEISH AG, 1986, IMMUNOL TODAY, V7, P142, DOI 10.1016/0167-5699(86)90080-0; DEROSSI A, 1991, VIROLOGY, V184, P187; GRASSI F, 1990, EUR J IMMUNOL, V20, P145, DOI 10.1002/eji.1830200121; HANDA A, 1991, BIOCHEM BIOPH RES CO, V175, P1, DOI 10.1016/S0006-291X(05)81191-X; HOXIE JA, 1988, J IMMUNOL, V140, P786; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JASIN M, 1991, J VIROL, V65, P440, DOI 10.1128/JVI.65.1.440-444.1991; KAWAGUCHI T, 1989, BIOCHEM BIOPH RES CO, V158, P1050, DOI 10.1016/0006-291X(89)92828-3; KIEBEREMMONS T, 1989, BIOCHIM BIOPHYS ACTA, V989, P281; LAMARRE D, 1989, EMBO J, V8, P3271, DOI 10.1002/j.1460-2075.1989.tb08487.x; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MERKENSCHLAGER M, 1990, J IMMUNOL, V145, P2389; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; MORRISON WJ, 1991, IMMUNOPHARMACOLOGY, V22, P77, DOI 10.1016/0162-3109(91)90032-T; NAKAKUMA H, 1989, JPN J CANCER RES, V80, P702, DOI 10.1111/j.1349-7006.1989.tb01700.x; OFFNER H, 1987, J IMMUNOL, V139, P3295; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PELCHENMATTHEWS A, 1991, J EXP MED, V173, P575, DOI 10.1084/jem.173.3.575; POLI G, 1991, J CELL SCI, V100, P833; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; TRAVERS P, 1992, Current Biology, V2, P38, DOI 10.1016/0960-9822(92)90430-I; WEYAND CM, 1987, J IMMUNOL, V138, P1351	34	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1368	1375						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678256				2022-12-27	WOS:A1993KG07700091
J	QUIRK, PG; HICKS, DB; KRULWICH, TA				QUIRK, PG; HICKS, DB; KRULWICH, TA			CLONING OF THE CTA OPERON FROM ALKALIPHILIC BACILLUS-FIRMUS OF4 AND CHARACTERIZATION OF THE PH-REGULATED CYTOCHROME CAA3 OXIDASE IT ENCODES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACTERIUM PS3; C-OXIDASE; ESCHERICHIA-COLI; ALKALOPHILIC BACILLUS; PARACOCCUS-DENITRIFICANS; NUCLEOTIDE-SEQUENCE; TERMINAL OXIDASES; MOLECULAR-CLONING; SUBUNIT-III; HEME-A	We have cloned and sequenced the DNA of alkaliphilic Bacillus firmus OF4 encompassing the cta operon that encodes a pH-regulated cytochrome caa3 oxidase. The gene organization is identical with that of the homologous Bacillus subtilis caa3 oxidase locus (van der Oost, J., von Wachenfeld, C., Hederstedt, L. & Saraste, M. (1991) Mol. Microbiol. 5, 2063-2072). The deduced amino acid sequences of the four putative structural subunits (CtaC-F) indicate substantial similarity to caa3-type oxidases from other Bacillus species and to other members of the family of mitochondrial-type aa3 oxidases. A marked paucity of basic residues was noted in the cytochrome c-containing domain of CtaC, which faces the highly alkaline external milieu. We have also purified the enzyme as a three-subunit complex, with possible trace amounts of a fourth subunit. N-terminal sequence analysis of the two largest subunits confirmed them to be encoded by the cloned cta genes. An additional, minor caa3 component with distinctive chromatographic properties was noted during purification. Analysis of mRNA with a ctaD probe revealed an abundant 4-kilobase message of the right size to encode CtaC-F. The cellular content of this message varied with growth pH. Cells grown at pH 10.5 contained 2 to 2.5 times more message than those grown at pH 7.5, in good correspondence with the relative amounts of caa3 oxidase found in the cells. The ctaB gene, immediately upstream from the ctaC-F genes, was found to be transcribed onto a low abundance 5-kilobase message, which is likely also to encode CtaC-F. Levels of this message were not affected by growth pH.	CUNY MT SINAI SCH MED,DEPT BIOCHEM,BOX 1020,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ANSORGE W, 1982, ELECTROPHORESIS 82, P235; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIJ W, 1983, EUR J BIOCHEM, V131, P97; DURHAM DR, 1987, J BACTERIOL, V169, P2762, DOI 10.1128/jb.169.6.2762-2768.1987; GARCIAHORSMAN JA, 1991, EUR J BIOCHEM, V199, P761, DOI 10.1111/j.1432-1033.1991.tb16181.x; GUFFANTI AA, 1991, J GEN MICROBIOL, V137, P2375, DOI 10.1099/00221287-137-10-2375; GUFFANTI AA, 1983, J GEN MICROBIOL, V129, P3239; GUFFANTI AA, 1992, J BIOL CHEM, V267, P9580; GUIKEMA JA, 1981, BIOCHIM BIOPHYS ACTA, V637, P189, DOI 10.1016/0005-2728(81)90157-2; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HALTIA T, 1989, EMBO J, V8, P3571, DOI 10.1002/j.1460-2075.1989.tb08529.x; HICKS DB, 1991, J BACTERIOL, V173, P5010, DOI 10.1128/jb.173.16.5010-5016.1991; HICKS DB, 1990, J BIOL CHEM, V265, P20547; ISHIZUKA M, 1990, J BIOCHEM-TOKYO, V108, P866, DOI 10.1093/oxfordjournals.jbchem.a123294; IVEY DM, 1991, MOL GEN GENET, V229, P292, DOI 10.1007/BF00272169; IVEY DM, 1991, J BIOL CHEM, V266, P23483; IVEY DM, 1992, RES MICROBIOL, V143, P467, DOI 10.1016/0923-2508(92)90092-3; JAMES WS, 1989, FEMS MICROBIOL LETT, V58, P277; KELNER A, 1964, J BACTERIOL, V87, P1295, DOI 10.1128/JB.87.6.1295-1303.1964; KITADA M, 1984, J BACTERIOL, V158, P963, DOI 10.1128/JB.158.3.963-966.1984; KRULWICH TA, 1989, ANNU REV MICROBIOL, V43, P435; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGYAR A, 1990, BIOCHEM BIOPH RES CO, V173, P872, DOI 10.1016/S0006-291X(05)80867-8; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MUELLER JP, 1989, J BACTERIOL, V171, P4967, DOI 10.1128/jb.171.9.4967-4978.1989; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; QUIRK PG, 1991, BIOCHIM BIOPHYS ACTA, V1058, P131, DOI 10.1016/S0005-2728(05)80229-4; QURESHI MH, 1990, J BIOCHEM-TOKYO, V107, P480, DOI 10.1093/oxfordjournals.jbchem.a123071; RAITIO M, 1990, FEBS LETT, V261, P431, DOI 10.1016/0014-5793(90)80609-M; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR GB, 1984, J BIOL CHEM, V259, P6033; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1990, FEBS LETT, V262, P249, DOI 10.1016/0014-5793(90)80202-T; SVENSSON B, 1992, EBECII42 SHORT REP, V7; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; TOCHIKUBO K, 1971, J BACTERIOL, V108, P652, DOI 10.1128/JB.108.2.652-661.1971; VANDEROOST J, 1991, J BIOENERG BIOMEMBR, V23, P257, DOI 10.1007/BF00762221; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; VELLANOWETH RL, 1992, MOL MICROBIOL, V6, P1105, DOI 10.1111/j.1365-2958.1992.tb01548.x; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WILSON CM, 1983, METHOD ENZYMOL, V91, P236; YASBIN RE, 1985, MOL BIOL BACILLI, V2, P33; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	53	77	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					678	685						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678007				2022-12-27	WOS:A1993KE60300102
J	MIURA, M; SURMACZ, E; BURGAUD, JL; BASERGA, R				MIURA, M; SURMACZ, E; BURGAUD, JL; BASERGA, R			DIFFERENT EFFECTS ON MITOGENESIS AND TRANSFORMATION OF A MUTATION AT TYROSINE-1251 OF THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; RAT GLIOBLASTOMA; IGF-1 RECEPTOR; CELLS; OVEREXPRESSION; PROTEIN; TRANSCRIPTION; FIBROBLASTS; EXPRESSION; CANCER	The wild type insulin-like growth factor I (IGF-I) receptor has both mitogenic and transforming activities. We have examined the effect of point mutations at tyrosine residues 1250 and 1251 on these two properties of the receptor, For this purpose, we stably transfected plasmids expressing mutant and wild type receptors into R(-) cells, which are 3T3-like cells, derived from mouse embryos with a targeted disruption of the IGF-I receptor genes, and therefore devoid of endogenous IGF-I receptors. A tyrosine to phenylalanine mutation of either the 1250 or 1251 residue, or both, has no effect on the ability of the receptor to transmit a mitogenic signal. However, the tyrosine 1251 mutant receptor and the double mutant have lost the ability to transform R(-) cells (colony formation in soft agar), even when the receptors are expressed at very high levels, while the Y1250F mutant is fully transforming. These experiments show that the 1251 tyrosine residue is required for the transforming activity of the IGF-I receptor.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA 53484] Funding Source: Medline; NIGMS NIH HHS [GM 133694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; GIORGINO F, 1991, MOL ENDOCRINOL, V5, P452, DOI 10.1210/mend-5-3-452; HARRINGTON EA, 1994, EMBO J, V14, P3286; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LONG L, 1995, CANCER RES, V55, P1006; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1994, CANCER RES, V54, P2472; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RANDAZZO PA, 1990, EXP CELL RES, V190, P25, DOI 10.1016/0014-4827(90)90139-2; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROSE DW, 1994, P NATL ACAD SCI USA, V81, P797; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TARTARE S, 1994, J BIOL CHEM, V269, P11449; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VALENTINIS B, 1994, ONCOGENE, V9, P825; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; ZONG CS, 1994, P NATL ACAD SCI USA, V61, P10982	52	109	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22639	22644		10.1074/jbc.270.38.22639	http://dx.doi.org/10.1074/jbc.270.38.22639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673254	hybrid			2022-12-27	WOS:A1995RW31400088
J	TORIGOE, H; NAKAYAMA, T; IMAZATO, M; SHIMADA, I; ARATA, Y; SARAI, A				TORIGOE, H; NAKAYAMA, T; IMAZATO, M; SHIMADA, I; ARATA, Y; SARAI, A			THE AFFINITY MATURATION OF ANTI-4-HYDROXY-3-NITROPHENYLACETYL MOUSE MONOCLONAL-ANTIBODY - A CALORIMETRIC STUDY OF THE ANTIGEN-ANTIBODY INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; IMMUNE-RESPONSE; SOMATIC MUTATION; VARIABLE REGION; LIGAND-BINDING; HEAT-CAPACITY; C57BL/6 MICE; SURFACE-AREA; THERMODYNAMICS; NP	To understand the mechanism of affinity maturation, we examined the antigen-antibody interactions between 4-hydroxy-3-nitrophenylacetyl (NP) caproic acid and the Fab fragments of three anti-NP antibodies, N1G9, 3B44, and 3B62, by isothermal titration calorimetry. The analyses have revealed that all of these interactions are mainly driven by negative changes in enthalpy. The enthalpy changes decreased linearly with temperature in the range of 25-45 degrees C, producing negative changes in heat capacity. On the basis of the dependence of binding constants on the sodium chloride concentration, we have shown that, during the affinity maturation of the anti-NP antibody, the electrostatic effect does not significantly contribute to the increase in the binding affinity. We have found that, as the logarithm of the binding constants increases during the affinity maturation of the anti-NP antibody, the magnitudes of the corresponding enthalpy, heat capacity, and unitary entropy changes increase almost Linearly. On the basis of this correlation, we have concluded that, during the affinity maturation of the anti-NP antibody, a better surface complementarity is attained in the specific complex in order to obtain a higher binding affinity.	UNIV TOKYO,FAC PHARMACEUT SCI,TOKYO 113,JAPAN	University of Tokyo	TORIGOE, H (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENE BANK,TSUKUBA,IBARAKI 305,JAPAN.							ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; AZUMA T, 1987, MOL IMMUNOL, V24, P287; BAINS G, 1992, BIOCHEMISTRY-US, V31, P12624, DOI 10.1021/bi00165a012; BARISAS BG, 1971, BIOCHEMISTRY-US, V10, P2816; BAUGH RJ, 1972, J BIOL CHEM, V247, P7498; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; CONNELLY PR, 1993, BIOCHEMISTRY-US, V32, P5583, DOI 10.1021/bi00072a013; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; FUKADA H, 1985, BIOCHEMISTRY-US, V24, P5109, DOI 10.1021/bi00340a023; GURNEY RW, 1953, IONIC PROCESSES SOLU, P89; HALSEY JF, 1975, BIOCHEMISTRY-US, V14, P800, DOI 10.1021/bi00675a024; HALSEY JF, 1975, BIOCHEMISTRY-US, V14, P5221, DOI 10.1021/bi00694a032; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HIBBITS KA, 1994, BIOCHEMISTRY-US, V33, P3584, DOI 10.1021/bi00178a015; ITO W, 1993, J BIOL CHEM, V268, P16639; JACK RS, 1977, EUR J IMMUNOL, V8, P559; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JOHNSTON MF, 1974, BIOCHEMISTRY-US, V13, P390, DOI 10.1021/bi00699a026; KATO K, 1991, BIOCHEMISTRY-US, V30, P270, DOI 10.1021/bi00215a037; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; Langerman N, 1979, Methods Enzymol, V61, P261; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MAKELA O, 1977, IMMUNOL REV, V34, P119, DOI 10.1111/j.1600-065X.1977.tb00370.x; MILOS M, 1988, J BIOL CHEM, V263, P9218; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; NAKAYAMA T, 1993, BIOCHEMISTRY-US, V32, P13961, DOI 10.1021/bi00213a028; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TAKAHASHI K, 1985, BIOCHEMISTRY-US, V24, P297, DOI 10.1021/bi00323a009; TANFORD C, 1980, HYDROPHOBIC EFFECT; TELLO D, 1993, BIOCHEM SOC T, V21, P943, DOI 10.1042/bst0210943; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WYSOCKI L, 1986, P NATL ACAD SCI USA, V83, P1847, DOI 10.1073/pnas.83.6.1847; YSERN X, 1994, J MOL BIOL, V238, P496	55	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22218	22222		10.1074/jbc.270.38.22218	http://dx.doi.org/10.1074/jbc.270.38.22218			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673199	hybrid			2022-12-27	WOS:A1995RW31400025
J	FERNANDEZCANON, JM; PENALVA, MA				FERNANDEZCANON, JM; PENALVA, MA			MOLECULAR CHARACTERIZATION OF A GENE ENCODING A HOMOGENTISATE DIOXYGENASE FROM ASPERGILLUS-NIDULANS AND IDENTIFICATION OF ITS HUMAN AND PLANT HOMOLOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								We report here the first characterization of a gene encoding a homogentisate dioxygenase, the Aspergillus nidulans hmgA gene. The HmgA protein catalyzes an essential step in phenylalanine catabolism, and disruption of the gene results in accumulation of homogentisate in broths containing phenylalanine. hmgA putatively encodes a 448-residue polypeptide (M(r) = 50,168) containing 21 histidine and 23 tyrosine residues. This polypeptide has been expressed in Escherichia coli as a fusion to glutathione S-transferase, and the affinity-purified protein has homogentisate dioxygenase activity. A. nidulans, an ascomycete amenable to classical and reverse genetic analysis, is a good metabolic model to study inborn errors in human Phe catabolism. One such disease, alkaptonuria, was the first human inborn error recognized (Garrod, A. E. (1902) Lancet 2, 1616-1620) and results from loss of homogentisate dioxygenase. Here we take advantage of the high degree of conservation between the amino acid sequences of the fungal. and higher eukaryote enzymes of this pathway to identify expressed sequence tags encoding human and plant homologues of HmgA. This is a significant advance in characterizing the genetic defect(s) of alkaptonuria and illustrates the usefulness of our fungal model.	CSIC,CTR INVEST BIOL,DEPT MOLEC MICROBIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Fernandez-canon, Jose/ADI-4196-2022; Fernández-Cañón, José Manuel/AAO-6088-2020; Fernández-Cañón, José Manuel/AAO-5607-2020; Penalva, Miguel A/G-2295-2015	Fernández-Cañón, José Manuel/0000-0002-8092-2181; Penalva, Miguel A/0000-0002-3102-2806				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; EDWARDS SW, 1955, METHOD ENZYMOL, V2, P292; ESPESO EA, 1992, MOL MICROBIOL, V6, P1457, DOI 10.1111/j.1365-2958.1992.tb00866.x; FERNANDEZCANON JM, 1995, IN PRESS P NATL ACAD; Garrod AE, 1902, LANCET, V2, P1616; JANOCHA S, 1994, GENOMICS, V19, P5, DOI 10.1006/geno.1994.1003; LADU BN, 1958, J BIOL CHEM, V230, P251; MCKUSICK VA, 1994, GENOMICS, V19, P3; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; POLLAK MR, 1993, NAT GENET, V5, P201, DOI 10.1038/ng1093-201; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT TD, 1987, METHOD ENZYMOL, V152, P423; SCHMIDT SR, 1995, EUR J BIOCHEM, V228, P425, DOI 10.1111/j.1432-1033.1995.00425.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; ZIMMERMANN CR, 1980, CELL, V21, P709, DOI 10.1016/0092-8674(80)90434-1	18	99	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21199	21205		10.1074/jbc.270.36.21199	http://dx.doi.org/10.1074/jbc.270.36.21199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673153	hybrid, Green Published			2022-12-27	WOS:A1995RU05400053
J	RUSS, G; ESQUIVEL, F; YEWDELL, JW; CRESSWELL, P; SPIES, T; BENNICK, JR				RUSS, G; ESQUIVEL, F; YEWDELL, JW; CRESSWELL, P; SPIES, T; BENNICK, JR			ASSEMBLY, INTRACELLULAR-LOCALIZATION, AND NUCLEOTIDE-BINDING PROPERTIES OF THE HUMAN PEPTIDE TRANSPORTERS TAP1 AND TAP2 EXPRESSED BY RECOMBINANT VACCINIA VIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; MEMBRANE-PROTEINS; ABC TRANSPORTER; LYMPHOCYTES-T; MHC; REGION; TRANSLOCATION	The transporter associated with antigen processing (TAP) transports short peptides from the cytosol to the endoplasmic reticulum, where peptides assemble with class I molecules of the major histocompatibility complex, TAP is comprised of two subunits, termed TAP1 and TAP2, We produced recombinant vaccinia viruses that direct synthesis of the TAP subunits, either individually or together, Virus-encoded TAP is rapidly and efficiently assembled (t(1/2) of 5 min or less) by cells and does not spontaneously assemble in detergent extracts, By confocal immunofluorescence microscopy, TAP1 when expressed alone or with TAP2 is largely, if not exclusively, localized to the endoplasmic reticulum, Metabolic labeling with [2-H-3]mannose demonstrates that TAP1 (but not TAP2) possesses Asn-Linked oligosaccharides, but the lack of binding of [S-35]methionine-labeled TAP to concanavalin A-agarose suggests that the glycosylated form represents a minor population of TAP1, The two subunits of the assembled complex present in detergent extracts photolabeled equally with 8-azido-[alpha-P-32]ATP. Photolabeling of the two subunits was inhibited in parallel by various di- and trinucleotides, suggesting that their nucleotide binding sites function in a highly similar manner, Incubation of detergent extracts at 37 degrees C results in the rapid loss of TAP1 immunoreactivity, indicating either an unusual sensitivity to proteases or an irreversible conformation alteration.	YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; DANA FARBER CANC INST,BOSTON,MA 02115	Howard Hughes Medical Institute; Yale University; Harvard University; Dana-Farber Cancer Institute	RUSS, G (corresponding author), NIAID,VIRAL DIS LAB,BLDG 4,ROOM 205,BETHESDA,MD 20892, USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Esquivel, Fernando/0000-0002-2962-0428				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYLE DB, 1986, J GEN VIROL, V67, P1591, DOI 10.1099/0022-1317-67-8-1591; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CORNWELL MM, 1987, FASEB J, P51; COUPAR BEH, 1988, GENE, V68, P1, DOI 10.1016/0378-1119(88)90593-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GERHARD W, 1981, NATURE, V290, P713, DOI 10.1038/290713a0; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; KAGEYAMA S, 1995, J IMMUNOL, V154, P567; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPHAM CK, 1993, J EXP MED, V177, P1633, DOI 10.1084/jem.177.6.1633; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MOMBURG F, 1994, NATURE, V367, P648, DOI 10.1038/367648a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MULLER KM, 1994, J BIOL CHEM, V269, P14032; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NEISIG A, 1995, J IMMUNOL, V154, P1273; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; RUSS G, 1991, CELL REGUL, V2, P549, DOI 10.1091/mbc.2.7.549; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SCHUMACHER TNM, 1994, P NATL ACAD SCI USA, V91, P13004, DOI 10.1073/pnas.91.26.13004; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WANG K, 1994, FEBS LETT, V350, P337, DOI 10.1016/0014-5793(94)00806-X; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL J, 1994, J IMMUNOL, V152, P1163; YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	56	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21312	21318		10.1074/jbc.270.36.21312	http://dx.doi.org/10.1074/jbc.270.36.21312			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673167	hybrid			2022-12-27	WOS:A1995RU05400068
J	OKADA, M; HOWELL, BW; BROOME, MA; COOPER, JA				OKADA, M; HOWELL, BW; BROOME, MA; COOPER, JA			DELETION OF THE SH3 DOMAIN OF SRC INTERFERES WITH REGULATION BY THE PHOSPHORYLATED CARBOXYL-TERMINAL TYROSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; STABLE ASSOCIATION; BINDING SITE; PROTEIN; KINASE; P60C-SRC; PP60C-SRC; MUTATIONS; AUTOPHOSPHORYLATION; PHOSPHOTYROSINE	A current model for the regulation of the Src protein-tyrosine kinase proposes that the COOH-terminal phosphotyrosine, Tyr-527, binds to the Src homology 2 (SH2) region in an intramolecular interaction that represses the kinase domain. This model is consistent with the activation of Src by mutations in the SH2 domain or COOH terminus. Mutations in the SH3 domain also activate Src, although this region is not thought to bind phosphotyrosine. Seidel-Dugan et al. (Seidel-Dugan, C., Meyer, B. E., Thomas, S. M., and Brugge, J. S. (1992) Mol. Cell. Biol. 12, 1835-1845) have shown that Src mutants with deletions in the SH2 or SH3 domain transform chicken embryo fibroblasts and have increased kinase activity. These mutant proteins are underphosphorylated at Tyr-527, a change that could in itself activate the mutants. Therefore, it is not possible to distinguish whether the SH2 and SH3 domains are needed for phosphorylation of Tyr-527 or for Src to adopt or maintain the repressed state. We have artificially increased the level of Tyr-527 phosphorylation of SH2 and SH3 deletion mutants by coexpressing them with the Tyr-527 kinase, Csk, in yeast cells. We find that both the SH2 and SH3 domains are needed for inhibition of Src by Csk. The SH2 domain is needed for efficient phosphorylation by Csk, both in yeast cells and in vitro. The SH3 domain is needed for Src to be inhibited when Tyr-527 is phosphorylated by Csk. This suggests that the SH3 domain cooperates with the SH2 domain and phosphorylated Tyr-527 to inhibit the kinase domain. Dephosphorylation of SH3 domain mutants at Tyr-527 in fibroblasts could be a consequence of a failure of the proposed SH2/phosphotyrosine interaction.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; SALK INST BIOL STUDIES, SAN DIEGO, CA 92138 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Fred Hutchinson Cancer Center; Salk Institute; University of California System; University of California San Diego				Howell, Brian/0000-0002-0204-0773	NCI NIH HHS [CA-41072, CA-39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; DHANG S, 1991, CELL PHYSIOL BIOCHEM, V1, P24; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACAULEY A, 1990, New Biologist, V2, P828; MACAULEY A, 1993, ONCOGENE, V8, P117; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARTANEN J, 1991, ONCOGENE, V6, P2013; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	43	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18070	18075						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688738				2022-12-27	WOS:A1993LT74300064
J	BACOLLA, A; SHIH, CK; ROSE, JM; PIRAS, G; WARREN, TC; GRYGON, CA; INGRAHAM, RH; COUSINS, RC; GREENWOOD, DJ; RICHMAN, D; CHENG, YC; GRIFFIN, JA				BACOLLA, A; SHIH, CK; ROSE, JM; PIRAS, G; WARREN, TC; GRYGON, CA; INGRAHAM, RH; COUSINS, RC; GREENWOOD, DJ; RICHMAN, D; CHENG, YC; GRIFFIN, JA			AMINO-ACID SUBSTITUTIONS IN HIV-1 REVERSE-TRANSCRIPTASE WITH CORRESPONDING RESIDUES FROM HIV-2 - EFFECT ON KINETIC CONSTANTS AND INHIBITION BY NONNUCLEOSIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONNUCLEOSIDE INHIBITORS; BINDING-SITE; TYPE-1; MUTAGENESIS; RESISTANCE; BI-RG-587; SELECTION	Nevirapine is a highly potent and specific inhibitor of human immunodeficiency virus type 1 (HIV-1) polymerase, but is inactive against HIV-2 and other polymerases. Previous studies demonstrated that residues 176-190 of HIV-1 reverse transcriptase (RT) can confer nevirapine sensitivity to HIV-2 RT. To better characterize the role of this sequence in HIV-1 RT, we have progressively substituted residues 176-190 of HIV-2 RT for those of HIV-1 RT and monitored the impact on the kinetic properties; inhibitory activity of nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[2,3-b:2',3'-e][1,4]diazepin-6-one), E-BPU (5-ethyl-1-benzyloxymethyl-6-(phenylthio)-uracil), and TIBO-R82150 ((+)-S-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-thione); and inhibitor-induced fluorescence changes of the mutant enzymes. The study revealed that in addition to Tyr-181 and Tyr- 188, a new amino acid residue (Gly-190) plays an important role in determining susceptibility to nevirapine and E-BPU, but not to TIBO-R82150. These data argue that these non-nucleoside inhibitors fit differently, even though they share a common binding pocket. Nevirapine was seen to exert inhibitory activity by altering the interaction of the enzyme with the template-primer. Kinetic parameters were modulated by the template (DNA versus RNA) as well as by some of the mutations.	BOEHRINGER INGELHEIM PHARMACEUT INC, DEPT MOLEC BIOL, R&D, 900 RIDGEBURY RD, POB 368, RIDGEFIELD, CT 06877 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL & MED, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, DEPT PATHOL MED, SAN DIEGO, CA 92093 USA	Boehringer Ingelheim; Yale University; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423; Piras, Giovanna/0000-0003-4550-6606	NATIONAL CANCER INSTITUTE [R35CA044358] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44358] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1986, PICO TAG AMINO ACID; BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; CHENG YC, 1987, J BIOL CHEM, V262, P2187; COHEN KA, 1991, J BIOL CHEM, V266, P14670; CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045; HIZI A, 1991, J BIOL CHEM, V266, P6230; KLUNDER JM, 1992, J MED CHEM, V35, P1887, DOI 10.1021/jm00088a027; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Le Pecq J B, 1971, Methods Biochem Anal, V20, P41, DOI 10.1002/9780470110393.ch2; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MITSUYA H, 1992, J ENZYM INHIB, V6, P1, DOI 10.3109/14756369209041352; MULLER B, 1989, J BIOL CHEM, V264, P13975; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; Sambrook J, 1989, MOL CLONING LABORATO; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; TONG L, 1993, BIOORG MED CHEM LETT, V3, P721, DOI 10.1016/S0960-894X(01)81262-2; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WARREN TC, 1992, PROTEIN EXPRES PURIF, V3, P479, DOI 10.1016/1046-5928(92)90065-5; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	28	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16571	16577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688367				2022-12-27	WOS:A1993LQ33600071
J	BENARTZI, H; ZEELON, E; AMIT, B; WORTZEL, A; GORECKI, M; PANET, A				BENARTZI, H; ZEELON, E; AMIT, B; WORTZEL, A; GORECKI, M; PANET, A			RNASE H ACTIVITY OF REVERSE TRANSCRIPTASES ON SUBSTRATES DERIVED FROM THE 5' END OF RETROVIRAL GENOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT DNA POLYMERASE; PLUS-STRAND DNA; RIBONUCLEASE-H; SARCOMA VIRUS; HTLV-III; HIV-1; ENDONUCLEASE; HYDROLYSIS; VIRIONS	RNA/DNA substrates derived from the 5' ends of human immunodeficiency virus (HIV) and Moloney murine leukemia virus (MMuLV) genomes were used to study the specificity of the RNase H activities of HIV, AMV (avian myeloblastosis virus), and MMuLV reverse transcriptases. These substrates were selected because they represent the site for the first template switch during proviral DNA synthesis. Variability of cleavage was observed depending on the origin of the enzyme as well as the sequence of the RNA/DNA substrate. The minimal size of hybrid recognized by the RNase H activity of reverse transcriptase was also affected by the same parameters, namely, the enzyme and the substrate origin. Moreover, the size of the residual 5'-undigested RNA after completion of the RNase H reaction depended on the position of the DNA annealed to the genomic RNA. When the hybrid was located at the 5' R region of the viral genome, stable hybrids with RNAs of 13-18 nucleotides remained following digestion by HIV reverse transcriptase, and 21-24 nucleotides following digestion by AMV reverse transcriptase and MMuLV reverse transcriptase. On the other hand, with all three enzymes, smaller sized hybrids remained when the DNA was hybridized to internal U5 or R sequences. The reason for this variance in size appears to be the inability of RNase H to efficiently digest at the 5' end of hybrid structures. Surprisingly, hybridization to the RNA template, of a DNA oligomer that extended 15 nucleotides beyond the 5' end of the RNA R region sequences, resulted in further digestion of the RNA. This unexpected mode of action of RNase H at the 5' end of the genomic RNA should be taken in consideration in studies of the first template switch.			BENARTZI, H (corresponding author), BIOTECHNOL GEN LTD,KIRYAT WEIZMANN,IL-76326 REHOVOT,ISRAEL.				NIAID NIH HHS [R1AI33353A] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033353] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; FISCHER M, 1992, PROTEIN EXPRES PURIF, V3, P301, DOI 10.1016/1046-5928(92)90005-H; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; LUO GX, 1990, J VIROL, V64, P592, DOI 10.1128/JVI.64.2.592-597.1990; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; MOLLING K, 1971, NATURE, V234, P241; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEISS R, 1985, RNA TUMOUR VIRUSES, P369	25	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16465	16471						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688365				2022-12-27	WOS:A1993LQ33600057
J	CHOI, SY; COOPER, AD				CHOI, SY; COOPER, AD			A COMPARISON OF THE ROLES OF THE LOW-DENSITY-LIPOPROTEIN (LDL) RECEPTOR AND THE LDL RECEPTOR-RELATED PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR IN CHYLOMICRON REMNANT REMOVAL IN THE MOUSE IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; RAT-LIVER; CHOLESTEROL-SYNTHESIS; HIGH-AFFINITY; WHHL RABBITS; PROTEIN; BINDING; CLEARANCE; RECOGNITION; MECHANISM	Two cell surface molecules, the low density lipoprotein (LDL) receptor and the LDL receptor-related protein (LRP)/alpha2-macroglobulin receptor, have been found to have a role in the removal of apoE-rich lipoproteins. To further study this process and to assess the relative contributions of these proteins to the removal of chylomicron remnants, we used an anti-LDL receptor antibody, activated alpha2-macroglobulin and the 39-kDa receptor-associated protein (RAP) as inhibitors of chylomicron remnant removal in intact mice. The advantage of this study is that we were able to use the same litters of animals and batches of lipoprotein for the experiment. In cultured Chinese hamster ovary cells, the anti-LDL receptor antibody inhibited remnant uptake and degradation about 80% as well as did unlabeled remnants. It did not affect activated alpha2-macroglobulin uptake or degradation. Activated alpha2-macroglobulin did not inhibit remnant uptake in normal cells but is reported to block uptake in cells that lack LDL receptors. Chylomicron remnants blocked activated alpha2-macroglobulin uptake as effectively as unlabeled activated alpha2-MaCroglobulin. This confirmed that the two ligands are cross-competitors but suggests that the LDL receptor is the primary mediator of remnant uptake in cultured cells that express the LDL receptor. In vivo, pretreatment with the anti-LDL receptor antibody decreased remnant uptake 5 min after injection by one-third. The antibody did not affect the removal of activated alpha2-macroglobulin. Activated alpha2-macroglobulin had a small, but reproducible effect on remnant removal, decreasing it by about 7% at 5 min. Injection of chylomicron remnants affected activated alpha2-macroglobulin removal slightly. A similar pattern, but somewhat greater effect was seen on the hepatic uptake of the ligands. Anti-LDL receptor antibody reduced chylomicron remnant uptake by about half, and activated alpha2-macroglobulin reduced it by about 15%. Studies with RAP provided results generally similar to those with activated alpha2-macroglobulin, although RAP appears to bind to a site not recognized by either remnants or activated alpha2-macroglobulin in addition to sharing a site with these ligands. Together, these results add support for the hypothesis that, although both receptors can play a role in chylomicron remnant removal, in the normal mouse in vivo the LDL receptor plays a substantially greater role, making the role of the LRP difficult to appreciate. The same is true in cells that express LDL receptors. However, the persistent, fairly rapid clearance of these particles in the presence of both competitors suggests that there is either a site on the LRP that is not blocked by activated alpha2-macroglobulin or RAP or there is another, perhaps non-endocytic mechanism for their removal from plasma as well.	PALO ALTO MED FDN,RES INST,860 BRYANT ST,PALO ALTO,CA 94301; STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Palo Alto Medical Foundation Research Institute; Stanford University					NIDDK NIH HHS [DK38318] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038318] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BARNARD GF, 1984, J CLIN INVEST, V74, P173, DOI 10.1172/JCI111399; BEAUMONT JL, 1990, ATHEROSCLEROSIS, V85, P103, DOI 10.1016/0021-9150(90)90102-O; BEISIEGEL U, 1988, ARTERIOSCLEROSIS, V8, P288, DOI 10.1161/01.ATV.8.3.288; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BOWLER A, 1991, BIOCHEM J, V276, P381, DOI 10.1042/bj2760381; CAHILL PD, 1988, J VASC SURG, V7, P108, DOI 10.1067/mva.1988.avs0070108; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; COOPER AD, 1977, BIOCHIM BIOPHYS ACTA, V488, P464, DOI 10.1016/0005-2760(77)90204-1; COOPER AD, 1987, J LIPID RES, V28, P59; COOPER AD, 1974, GASTROENTEROLOGY, V66, P586; ELLSWORTH JL, 1987, J BIOL CHEM, V262, P2316; ELLSWORTH JL, 1990, J LIPID RES, V31, P1399; FLOREN CH, 1981, J BIOL CHEM, V256, P425; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; HAVEL RJ, 1992, SEMIN LIVER DIS, V12, P356, DOI 10.1055/s-2008-1040405; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; JI ZS, 1992, ARTERIOSCLEROSIS, V8, pI550; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1977, J BIOL CHEM, V252, P3980; MAY K, 1990, J LIPID RES, V31, P1683; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; REDGRAVE TG, 1977, ATHEROSCLEROSIS, V28, P69, DOI 10.1016/0021-9150(77)90200-3; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; RUDLING M, 1992, J LIPID RES, V33, P493; SPADY DK, 1985, J CLIN INVEST, V76, P1113, DOI 10.1172/JCI112066; STIFANI S, 1991, J BIOL CHEM, V266, P19079; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VANZUIDEN PEA, 1983, J LIPID RES, V24, P418; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	49	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15804	15811						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687998				2022-12-27	WOS:A1993LN30500071
J	NORGARD, KE; MOORE, KL; DIAZ, S; STULTS, NL; USHIYAMA, S; MCEVER, RP; CUMMINGS, RD; VARKI, A				NORGARD, KE; MOORE, KL; DIAZ, S; STULTS, NL; USHIYAMA, S; MCEVER, RP; CUMMINGS, RD; VARKI, A			CHARACTERIZATION OF A SPECIFIC LIGAND FOR P-SELECTIN ON MYELOID CELLS - A MINOR GLYCOPROTEIN WITH SIALYLATED O-LINKED OLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECTIN AFFINITY-CHROMATOGRAPHY; ADHESION MOLECULE-1 ELAM-1; ACID-DEPENDENT EPITOPE; SIALIC-ACID; CARBOHYDRATE LIGAND; MONOCLONAL-ANTIBODY; LYSOSOMAL-ENZYME; STRUCTURAL DETERMINANTS; LIQUID-CHROMATOGRAPHY; IGA1 IMMUNOGLOBULIN	Lectin-carbohydrate recognition between the selectins and their ligands are among the earliest events in leukocyte recirculation, leukocyte recruitment into inflamed areas, and abnormal egress of leukocytes in diseases. Previously, we have described a dimeric sialoglycoprotein from myeloid cells with subunits of molecular mass = 120 kDa, which is selectively recognized by P-selectin (Moore, K. L., Stults, N. L., Diaz, S., Smith, D. F., Cummings, R. D., Varki, A., and McEver, R. P. (1992) J. Cell Biol. 188, 445-456). Here, we demonstrate that this P-selectin ligand carries alpha2-3-linked sialic acids and the sialyl-Lewis(x) (SLe(x)) tetrasaccharide motif. This glycoprotein contains < 1 % of the total membrane-bound sialic acids and a very small fraction of the total SLe(x) on neutrophil membranes. In spite of a relative resistance to sialidase digestion, the predominant form of sialic acid on the ligand is N-acetylneuraminic acid. Selective periodate oxidation of the side chain of sialic acids does not affect P-selectin binding and allows the introduction of tritium label into the truncated sialic acids. Beta-elimination with alkaline borohydride releases labeled O-linked oligosaccharides both from the labeled neutrophil ligand and from the ligand purified from HL-60 cells metabolically labeled with [H-3]glucosamine. The ligand from both neutrophils and HL-60 cells is also susceptible to cleavage by the enzyme O-sialoglycoprotease from Pasteurella hemolytica. Analysis of the specificity of this enzyme suggests that the P-selectin ligand carries large numbers of closely spaced sialylated O-linked oligosaccharides. O-Sialoglycoprotease abolishes both direct binding of P-selectin to HL-60 cells and the adhesion of HL-60 cells to immobilized P-selectin, without significantly decreasing overall cell surface SLe(x) expression. This indicates that the 120-kDa ligand may be the major determinant of P-selectin: myeloid cell interaction in vivo. Finally, based on the current and previous data, we hypothesize that the high affinity recognition site(s) of this P-selectin ligand may be derived from a ''clustered saccharide patch'' of sialylated fucosylated O-linked oligosaccharide sequences.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, 0063, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOLEC MED, LA JOLLA, CA 92093 USA; UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; OKLAHOMA MED RES FDN, CARDIOL BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA HLTH SCI CTR, WK WARREN MED RES INST, DEPT MED, OKLAHOMA CITY, OK 73190 USA; UNIV OKLAHOMA HLTH SCI CTR, WK WARREN MED RES INST, DEPT BIOCHEM, OKLAHOMA CITY, OK 73190 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University System of Georgia; University of Georgia; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL CANCER INSTITUTE [R01CA038701, R01CA037626] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R37HL034363] Funding Source: NIH RePORTER; NCI NIH HHS [CA37626, CA38701] Funding Source: Medline; NHLBI NIH HHS [HL 34363] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ALEXANDER LJ, 1988, EUR J BIOCHEM, V178, P395, DOI 10.1111/j.1432-1033.1988.tb14463.x; ALSINET E, 1990, EUR J IMMUNOL, V20, P2801, DOI 10.1002/eji.1830201240; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARA J, 1992, J IMMUNOL METHODS, V149, P105, DOI 10.1016/S0022-1759(12)80054-8; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BAZIL V, 1989, IMMUNOGENETICS, V29, P202, DOI 10.1007/BF00373646; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CARVER JP, 1989, CIBA F SYMP, V145, P6; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; DEVINE PL, 1991, BIOL CHEM H-S, V372, P935, DOI 10.1515/bchm3.1991.372.2.935; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DO SI, 1992, GLYCOBIOLOGY, V2, P345, DOI 10.1093/glycob/2.4.345; DRZENIEK R, 1973, HISTOCHEM J, V5, P271, DOI 10.1007/BF01004994; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; Fukuda M., 1992, CELL SURFACE CARBOHY, P127; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; FURTHMAYR H, 1977, J SUPRAMOL STR CELL, V7, P121, DOI 10.1002/jss.400070111; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAMBURGER SA, 1990, BLOOD, V75, P550; HANDA K, 1991, BIOCHEM BIOPH RES CO, V181, P1223, DOI 10.1016/0006-291X(91)92069-V; HANISCH FG, 1992, CANCER RES, V52, P3138; HANISCH FG, 1988, CARBOHYD RES, V178, P29, DOI 10.1016/0008-6215(88)80100-9; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; HORTIN GL, 1990, ANAL BIOCHEM, V191, P262, DOI 10.1016/0003-2697(90)90217-W; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KITAGAWA H, 1988, J BIOCHEM-TOKYO, V104, P817, DOI 10.1093/oxfordjournals.jbchem.a122555; LAI R, 1991, LAB INVEST, V64, P844; LARKIN M, 1991, CLIN EXP IMMUNOL, V85, P536; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MARSH JCW, 1992, LEUKEMIA, V6, P926; MARTI T, 1988, EUR J BIOCHEM, V173, P57, DOI 10.1111/j.1432-1033.1988.tb13966.x; MATROSOVICH MN, 1991, VIROLOGY, V182, P879, DOI 10.1016/0042-6822(91)90634-N; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCLEAN RL, 1971, J BIOL CHEM, V246, P803; MEHMET H, 1990, CLIN EXP IMMUNOL, V81, P489; MOORE KL, 1992, BIOCHEM BIOPH RES CO, V186, P173, DOI 10.1016/S0006-291X(05)80790-9; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POPPEMA S, 1991, J IMMUNOL, V147, P218; POWELLLD, 1993, J BIOL CHEM, V268, P7019; PUTNAM FW, 1979, J BIOL CHEM, V254, P2865; REMOLDODONNELL E, 1990, J IMMUNOL, V145, P3372; REUTER G, 1989, GLYCOCONJUGATE J, V6, P35, DOI 10.1007/BF01047888; RICE KG, 1991, BIOCHEMISTRY-US, V30, P6646, DOI 10.1021/bi00241a003; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SGROI D, 1993, J BIOL CHEM, V268, P7011; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; STAHLI C, 1988, CANCER RES, V48, P6799; STOLL M, 1989, LEUKOCYTE TYPING 4, P604; STOOLMAN LM, 1992, CELL SURFACE CARBOHY, P71; SUTHERLAND DR, 1992, EXP HEMATOL, V20, P590; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; VARKI A, 1991, FASEB J, V5, P226, DOI 10.1096/fasebj.5.2.2004668; VARKI A, 1983, J BIOL CHEM, V258, P2465; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	113	248	256	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12764	12774						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685350				2022-12-27	WOS:A1993LG65800080
J	ZHOU, SB; TANNERY, NH; YANG, J; PUSZKIN, S; LAFER, EM				ZHOU, SB; TANNERY, NH; YANG, J; PUSZKIN, S; LAFER, EM			THE SYNAPSE-SPECIFIC PHOSPHOPROTEIN-F1-20 IS IDENTICAL TO THE CLATHRIN ASSEMBLY PROTEIN AP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; COATED VESICLE PROTEINS; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; MOLECULAR CHARACTERIZATION; NERVE-ENDINGS; LIGHT-CHAINS; BOVINE BRAIN; BINDING; SEQUENCE	F1-20 and AP-3 are independently described, synapse-associated, developmentally regulated phosphoproteins with similar apparent molecular masses on SDS-polyacrylamide gel electrophoresis (PAGE). F1-20 was cloned and characterized because of its synapse specificity. AP-3 was purified and studied biochemically because of its function as a clathrin assembly protein. Here we present evidence that establishes the identity of F1-20 and AP-3. Monoclonal antibodies against F1-20 and AP-3 both specifically recognize a single protein from mouse brain with an apparent molecular mass of 190 kDa on SDS-PAGE. These monoclonal antibodies also specifically recognize the cloned F1-20 protein expressed in Escherichia coli. The anti-F1-20 monoclonal antibody (mAb) stains a bovine protein with an apparent molecular mass on SDS-PAGE of 190 kDa that copurifies with brain clathrin-coated vesicles (CCVs) and that can be extracted from the brain CCVs under conditions that extract AP-3. The anti-F1-20 and anti-AP-3 mAbs specifically recognize the same spot on a two-dimensional gel run on a bovine brain clathrin-coated vesicle extract. AP-3 purified from bovine brain CCVs is recognized by both the anti-F1-20 and anti-AP-3 mAbs. Purified preparations of bovine AP-3 and bacterially, expressed mouse F1-20 give identical patterns of protease digestion with bromelain and subtilisin. Sequence analyses reveal that F1-20 has an essentially neutral 30-kDa NH2-terminal domain with an amino acid composition typical of a globular structure and an acidic COOH-terminal domain rich in proline, serine, threonine, and alanine. This is consistent with proteolysis experiments that suggested that AP-3 could be divided into a 30-kDa globular uncharged clathrin-binding domain and an acidic, anomalously migrating domain.	UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA; CUNY MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Tannery, Nancy Hrinya/B-5688-2009	Tannery, Nancy Hrinya/0000-0003-3478-3720; Lafer, Eileen/0000-0002-0493-6522	NCRR NIH HHS [U41 RR04154] Funding Source: Medline; NINDS NIH HHS [NS29051, R01 NS029051] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [U41RR004154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029051, R56NS029051] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; CHIN SSM, 1990, J NEUROSCI, V10, P3714; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; JULIEN JP, 1982, J BIOL CHEM, V257, P467; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; KOHTZ DS, 1989, J NEUROCHEM, V52, P285, DOI 10.1111/j.1471-4159.1989.tb10929.x; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LINDNER R, 1992, J BIOL CHEM, V267, P16567; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRY DG, 1991, J HISTOCHEM CYTOCHEM, V39, P1461, DOI 10.1177/39.11.1918924; PERRY DG, 1992, J NEUROSCI RES, V33, P408, DOI 10.1002/jnr.490330307; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEE YP, 1990, PROTEIN STRUCTURE PR, P1; SOUSA R, 1990, NEUROSCIENCE, V34, P403, DOI 10.1016/0306-4522(90)90149-X; SOUSA R, 1992, J NEUROSCI, V12, P2130; SU B, 1991, J NEUROSCI RES, V29, P461, DOI 10.1002/jnr.490290406; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1989, ANAL BIOCHEM, V179, P352, DOI 10.1016/0003-2697(89)90143-7; VIGERS GP, 1989, EMBO J, V5, P2079; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHOU SB, 1992, J NEUROSCI, V12, P2144	46	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12655	12662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685348				2022-12-27	WOS:A1993LG65800064
J	SCHODERBEK, WE; ROBERSON, MS; MAURER, RA				SCHODERBEK, WE; ROBERSON, MS; MAURER, RA			2 DIFFERENT DNA ELEMENTS MEDIATE GONADOTROPIN-RELEASING-HORMONE EFFECTS ON EXPRESSION OF THE GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; HYPOTHALAMIC-PITUITARY DISCONNECTION; BETA-LUTEINIZING HORMONE; PROTEIN KINASE-C; OVARIECTOMIZED EWES; PROLACTIN GENE; GROWTH-HORMONE; RAT; TRANSCRIPTION; STIMULATION	Transient transfection studies using gonadotrope-derived, alphaT3-1 cells were used to determine the DNA sequences of the mouse glycoprotein hormone alpha-subunit gene that mediate the transcriptional response to gonadotropin releasing hormone (GnRH). The roles of phorbol esters and cyclic AMP in mediating the GnRH response were also investigated. The initial studies demonstrated that a construct containing approximately 500 base pairs of alpha-subunit flanking sequence was sufficient to mediate responses to a GnRH agonist (GnRHa), phorbol myristate acetate (PMA) and a cAMP analog. Responses to combinations of cAMP and GnRHa or cAMP and PMA were approximately additive, whereas the response to the combination of GnRHa and PMA was similar to that seen with either of the agents alone. Cotransfection studies with an expression vector for the heat-stable inhibitor of the cAMP-dependent protein kinase demonstrated that GnRHa and PMA responses are not dependent on the cAMP-dependent kinase. Deletion analysis indicated that sequences between -507 and -205 were involved in mediating responses to GnRHa and PMA. To determine if this region alone could support responses to these agents, the -507 to -205 region was linked to a minimal promoter and tested in transient transfections. The results demonstrated that this region supports responses to GnRHa, PMA, and cAMP. Clustered point mutations of this region were used to further characterize sequences involved in the GnRH response. Mutations in two regions, one at positions -406 to -399 and one at positions -337 to -330, resulted in decreased responses to GnRH and PMA. There is no obvious sequence similarity between the two regions that are required for the GnRH response. An enhancer test demonstrated that multimers of the -416 to -385 region were able to function as a GnRH-responsive element when linked to a minimal promoter, although a single copy of this region was not sufficient to permit a response to GnRH. In contrast, multimers of the -344 to -300 region did not permit a response to GnRH, but enhanced basal transcription. These findings are consistent with the identification of a two-component GnRH response unit, which probably involves the functional cooperation of two different transcription factors. The observation that GnRH responsiveness appears to co-localize with PMA responsiveness suggests that GnRH effects on the alpha-subunit transcription are likely mediated by the protein kinase C pathway.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NICHD NIH HHS [HD07555] Funding Source: Medline; NIDDK NIH HHS [DK36407, DK25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007555] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036407, P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS WV, 1988, J BIOL CHEM, V263, P13755; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIN JM, 1989, MOL ENDOCRINOL, V3, P1643, DOI 10.1210/mend-3-10-1643; CLARKE IJ, 1982, ENDOCRINOLOGY, V111, P1737, DOI 10.1210/endo-111-5-1737; DALKIN AC, 1989, ENDOCRINOLOGY, V125, P917, DOI 10.1210/endo-125-2-917; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DAY RN, 1989, J BIOL CHEM, V264, P431; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DING Y, 1991, MOL ENDOCRINOL, V5, P1239, DOI 10.1210/mend-5-9-1239; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GORDON DF, 1988, DNA-J MOLEC CELL BIO, V7, P679, DOI 10.1089/dna.1988.7.679; HAMERNIK DL, 1986, ENDOCRINOLOGY, V119, P2704, DOI 10.1210/endo-119-6-2704; HAMERNIK DL, 1988, ENDOCRINOLOGY, V122, P959, DOI 10.1210/endo-122-3-959; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KATO Y, 1991, J MOL ENDOCRINOL, V7, P27, DOI 10.1677/jme.0.0070027; KIM KE, 1990, MOL CELL ENDOCRINOL, V74, P101, DOI 10.1016/0303-7207(90)90112-L; LALLOZ MRA, 1988, ENDOCRINOLOGY, V122, P1681, DOI 10.1210/endo-122-4-1681; LEAL JA, 1988, J CLIN ENDOCR METAB, V67, P1325, DOI 10.1210/jcem-67-6-1325; LEUNG K, 1987, MOL ENDOCRINOL, V1, P724, DOI 10.1210/mend-1-10-724; LEVINE JE, 1982, ENDOCRINOLOGY, V111, P1439, DOI 10.1210/endo-111-5-1439; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCARDLE CA, 1987, J BIOL CHEM, V262, P5028; PAPAVASILIOU SS, 1986, P NATL ACAD SCI USA, V83, P4026, DOI 10.1073/pnas.83.11.4026; PEERS B, 1991, J BIOL CHEM, V266, P18127; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SALTON SRJ, 1988, MOL ENDOCRINOL, V2, P1033, DOI 10.1210/mend-2-11-1033; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P1444, DOI 10.1210/mend-4-10-1444; STANLEY HF, 1988, MOL ENDOCRINOL, V2, P1302, DOI 10.1210/mend-2-12-1302; WIERMAN ME, 1989, ENDOCRINOLOGY, V124, P272, DOI 10.1210/endo-124-1-272; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YEO T, 1981, J ENDOCRINOL, V91, P33, DOI 10.1677/joe.0.0910033	36	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3903	3910						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680035				2022-12-27	WOS:A1993KN53300020
J	ZHANG, JZ; MCCRACKEN, A; WYATT, GR				ZHANG, JZ; MCCRACKEN, A; WYATT, GR			PROPERTIES AND SEQUENCE OF A FEMALE-SPECIFIC, JUVENILE HORMONE-INDUCED PROTEIN FROM LOCUST HEMOLYMPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITELLOGENIN MESSENGER-RNA; FAT-BODY; NUCLEOTIDE-SEQUENCES; APOLIPOPHORIN-III; MIGRATORY LOCUST; PURIFICATION; CLONING; GENES	In the fat body of Locusta migratoria, an RNA transcript of about 800 nucleotides has been detected that is specific to the adult female and dependent on induction by juvenile hormone (JH) or an analog. The corresponding cDNA has been cloned (lambda21) and a 718-base pair sequence determined. It encodes a 196-amino acid polypeptide, including a signal peptide. An NH2-terminal sequence has 24 out of 28 amino acids identical with those of a previously described 19K locust hemolymph protein, but the remainder of the sequence shows no similarity. From adult female hemolymph, a 21-kDa protein, designated 21K protein, has been purified, with an NH2-terminal sequence exactly matching that deduced from clone lambda21. This 21K protein is found only in the adult female, is dependent on induction by JH, and is assumed to represent the product of the lambda21 gene. It shows no immunochemical cross-reaction with locust 19K protein, apolipophorin III, nor with vitellogenin (Vg). Its isoelectric point is pH 5.4; it contains some carbohydrate. 21K protein is synthesized in adult female fat body, accumulates in hemolymph, and is taken up into the developing oocytes in parallel with Vg. In locusts deprived of JH with precocene, production of 21K protein and of lambda21-hybridizing transcripts is induced by the JH analog, methoprene, in parallel with Vg and its mRNA. Because of its sex-, stage-, and JH-dependent regulation, coordinate with Vg, the 21K protein will be valuable for analysis of gene expression.	QUEENS UNIV, DEPT BIOL, KINGSTON K7L 3N6, ONTARIO, CANADA	Queens University - Canada								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BENSON S A, 1984, Biotechniques, V2, P126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN TT, 1978, J BIOL CHEM, V253, P5325; CHINO H, 1986, J LIPID RES, V27, P377; CHINZEI Y, 1982, CAN J BIOCHEM CELL B, V60, P243, DOI 10.1139/o82-029; CHINZEI Y, 1985, J INSECT PHYSIOL, V31, P441, DOI 10.1016/0022-1910(85)90090-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DHADIALLA TS, 1987, DEV BIOL, V123, P108, DOI 10.1016/0012-1606(87)90432-5; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ENGELMANN F, 1983, ENDOCRINOLOGY INSECT, P259; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMES BD, 1981, GEL ELECTROPHORESIS, P23; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JOHNSTONDOW L, 1987, BIOTECHNIQUES, V5, P754; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; KANOST MR, 1988, J BIOL CHEM, V263, P10568; KANOST MR, 1988, ARCH INSECT BIOCHEM, V8, P203, DOI 10.1002/arch.940080402; KAWOOYA JK, 1983, BIOCHEM BIOPH RES CO, V117, P643, DOI 10.1016/0006-291X(83)91249-4; Koeppe J.K., 1985, P165; LOCKE J, 1987, DNA-J MOLEC CELL BIO, V6, P331, DOI 10.1089/dna.1987.6.331; LOCKE L, 1985, THESIS QUEENS U KING; Maniatis T., 1982, MOL CLONING; Telfer W. H., 1981, REGULATION INSECT DE, P637; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE BN, 1977, ANAL BIOCH INSECTS, P85; WYATT GR, 1988, CAN J ZOOL, V66, P2600, DOI 10.1139/z88-384; WYATT GR, 1992, ARCH INSECT BIOCHEM, V20, P167, DOI 10.1002/arch.940200302; WYATT GR, 1990, MOL INSECT SCI, P163; WYATT GR, 1984, ADV INVERTEBRATE REP, P73; WYATT GR, 1992, RECENT PROGR JUVENIL, P285; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG JZ, 1990, MOL INSECT SCI, P385; ZHANG YJ, 1992, INSECT BIOCHEM MOLEC, V22, P293, DOI 10.1016/0965-1748(92)90067-O	37	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3282	3288						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679110				2022-12-27	WOS:A1993KM16100043
J	BRUEL, C; DIRAGO, JP; SLONIMSKI, PP; LEMESLEMEUNIER, D				BRUEL, C; DIRAGO, JP; SLONIMSKI, PP; LEMESLEMEUNIER, D			ROLE OF THE EVOLUTIONARILY CONSERVED CYTOCHROME-B TRYPTOPHAN-142 IN THE UBIQUINOL OXIDATION CATALYZED BY THE BC(1)-COMPLEX IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; DIURON-RESISTANT MUTATIONS; RHODOBACTER-SPHAEROIDES; C REDUCTASE; BC1 COMPLEX; ELECTRON-TRANSFER; MOLECULAR-BASIS; SEQUENCE-ANALYSIS; DEFICIENT MUTANT; WILD-TYPE	Trp-142 is a highly conserved residue of the cytochrome b subunit in the bc(1) complexes. To study the importance of this residue in the quinol oxidation catalyzed by the bc(1) complex, we characterized four yeast mutants with arginine, lysine, threonine, and serine at position 142. The mutant W142R was isolated previously as a respiration-deficient mutant unable to grow on nonfermentable carbon sources (Lemesle-Meunier, D., Brivet-Chevillotte, P., di Rage, J.-P, Slonimski, P. P., Bruel, C., Tron, T., and Forget, N. (1993) J. Biol. Chem. 268, 15626-15632). The mutants W142K, W142T, and W142S were obtained here as respiration-sufficient revertants from mutant W142R. Mutant W142R exhibited a decreased complex II turnover both in the presence and absence of antimycin A; this suggests that the structural effect of W142R in the bc(1) complex probably interferes with the correct assembly of the succinate-ubiquinone reductase complex. The mutations resulted in a parallel decrease in turnover number and apparent K-m, with the result that there was no significant change in the second-order rate constant for ubiquinol oxidation. Mutants W142K and W142T exhibited some resistance toward myxothiazol, whereas mutant W142R showed increased sensitivity. The cytochrome cc(1) reduction kinetics were found to be severely affected in mutants W142R, W142K, and W142T. The respiratory activities and the amounts of reduced cytochrome b measured during steady state suggest that the W142S mutation also modified the quinol-cytochrome c(1) electron transfer pathway. The cytochrome b reduction kinetics through center P were affected when Trp-142 was replaced with arginine or lysine, but not when it was replaced with threonine or serine. Of the four amino acids tested at position 142, only arginine resulted in a decrease in cytochrome b reduction through center N. These findings are discussed in terms of the structure and function of the quinol oxidation site and seem to indicate that Trp-142 is not critical to the kinetic interaction of ubiquinol with the reductase, but plays an important role in the electron transfer reactions that intervene between ubiquinol oxidation and cytochrome c(1) reduction.	LAB BIOENERGET & INGN PROT,CNRS,F-13402 MARSEILLE 20,FRANCE; UNIV PARIS 06,CTR GENET MOLEC,CNRS,PROPRE LAB,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay								ATTAASAFOADJEI E, 1991, P NATL ACAD SCI USA, V88, P492, DOI 10.1073/pnas.88.2.492; BENNOUN P, 1992, MOL GEN GENET, V234, P147, DOI 10.1007/BF00272356; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BRASSEUR G, 1994, FEBS LETT, V354, P23, DOI 10.1016/0014-5793(94)01077-3; BRASSEUR R, 1988, J BIOL CHEM, V263, P12571; BRIVETCHEVILLOT.P, 1989, FEBS LETT, V255, P5, DOI 10.1016/0014-5793(89)81050-6; BRUEL C, 1993, BIOCHEM SOC T, V22, pS61; CHEVILLOTTEBRIV.P, 1983, EUR J BIOCHEM, V129, P653; CHEVILLOTTEBRIV.P, 1980, EUR J BIOCHEM, V111, P161; CHEVILLOTTEBRIV.P, 1987, BIOCHIMIE, V69, P25; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; COPPEE JY, 1994, J BIOL CHEM, V269, P4221; CROFTS A, 1992, BIOCHIM BIOPHYS ACTA, V1101, P162, DOI 10.1016/S0005-2728(05)80009-X; CROFTS A, 1987, CYTOCHROME SYSTEMS M, P617; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; CROFTS AR, 1985, ENZYMES BIOL MEMBR, P347; DALDAL F, 1989, EMBO J, V8, P3951, DOI 10.1002/j.1460-2075.1989.tb08578.x; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DEGLIESPOSTI M, 1991, ARCH BIOCHEM BIOPHYS, V289, P303; DEISENHOFER J, 1989, EMBO J, V8, P2149, DOI 10.1002/j.1460-2075.1989.tb08338.x; DIRAGO JP, 1990, FEBS LETT, V263, P93, DOI 10.1016/0014-5793(90)80713-S; DIRAGO JP, 1989, J BIOL CHEM, V264, P14543; DIRAGO JP, 1988, J BIOL CHEM, V263, P12564; DIRAGO JP, 1993, FEBS LETT, V328, P153, DOI 10.1016/0014-5793(93)80984-3; DIRAGO JP, 1990, J BIOL CHEM, V265, P15750; DIRAGO JP, 1986, FEBS LETT, V208, P208, DOI 10.1016/0014-5793(86)81019-5; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; FAYE G, 1973, BIOCHIMIE, V55, P779, DOI 10.1016/S0300-9084(73)80030-6; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GIESSLER A, 1994, EUR J BIOCHEM, V222, P147, DOI 10.1111/j.1432-1033.1994.tb18852.x; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7; HOWELL N, 1990, BIOCHEMISTRY-US, V29, P8970, DOI 10.1021/bi00490a013; HOWELL N, 1987, J BIOL CHEM, V262, P2411; KOMIYA H, 1988, P NATL ACAD SCI USA, V85, P9012, DOI 10.1073/pnas.85.23.9012; KOTYLAK Z, 1976, GENETIC FUNCTION MIT, P143; KOVAC L, 1967, SCIENCE, V158, P1564, DOI 10.1126/science.158.3808.1564; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LEMESLEMEUNIER D, 1993, J BIOL CHEM, V268, P15626; LINK TA, 1993, J BIOENERG BIOMEMBR, V25, P221, DOI 10.1007/BF00762584; MEUNIER B, 1989, EUR J BIOCHEM, V184, P651, DOI 10.1111/j.1432-1033.1989.tb15062.x; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; SPECK SH, 1984, J BIOL CHEM, V259, P1064; TIAN GL, 1991, J MOL BIOL, V218, P744; TRON T, 1990, CURR GENET, V18, P413, DOI 10.1007/BF00309910; TRON T, 1991, EUR J BIOCHEM, V199, P753, DOI 10.1111/j.1432-1033.1991.tb16180.x; TRON T, 1991, FEBS LETT, V278, P26, DOI 10.1016/0014-5793(91)80075-E; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; WEBER S, 1988, FEBS LETT, V237, P31, DOI 10.1016/0014-5793(88)80165-0; YUN CH, 1991, BIOCHEMISTRY-US, V30, P6747, DOI 10.1021/bi00241a017; YUN CH, 1991, J BIOL CHEM, V266, P10967; YUN CH, 1992, J BIOL CHEM, V267, P5901	59	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22321	22328		10.1074/jbc.270.38.22321	http://dx.doi.org/10.1074/jbc.270.38.22321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673215	hybrid			2022-12-27	WOS:A1995RW31400042
J	CHOI, MY; MILLER, A; CHO, NY; ROTHMANDENES, LB				CHOI, MY; MILLER, A; CHO, NY; ROTHMANDENES, LB			IDENTIFICATION, CLONING, AND CHARACTERIZATION OF THE BACTERIOPHAGE-N4 GENE ENCODING THE SINGLE-STRANDED DNA BINDING-PROTEIN - A PROTEIN REQUIRED FOR PHAGE REPLICATION, RECOMBINATION, AND LATE TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PURIFICATION	The coliphage N4-coded single-stranded DNA-binding protein (N4SSB) is essential for phage replication and for expression of the phage late genes, which are transcribed by the Escherichia coli sigma(70) RNA polymerase. As a first step in investigating the role of N4SSB in replication and transcriptional activation, we have identified and sequenced the N4SSB gene. The gene encodes a 265-amino acid protein with no apparent sequence homology to other single-stranded DNA-binding proteins. Ne present data indicating that N4SSB is also essential for phage recombination. Mutational analysis of the carboxyl terminus of the protein indicates that this region is required for protein-protein interactions with the N4 replication, N4 recombination, and E. coli transcriptional machineries, while the rest of the protein contains the determinants for single-stranded DNA binding.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,COMM DEV BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago					NIAID NIH HHS [AI 12575] Funding Source: Medline; NIGMS NIH HHS [GM 35170] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035170] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; BOLLE A, 1969, J MOL BIOL, V31, P325; BROSIUS J, 1987, METHOD ENZYMOL, V153, P54; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P130; CHO NY, 1995, J MOL BIOL, V246, P461, DOI 10.1006/jmbi.1994.0098; GLASSBERG J, 1979, J BACTERIOL, V140, P14, DOI 10.1128/JB.140.1.14-19.1979; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GUINTA D, 1986, VIROLOGY, V150, P33, DOI 10.1016/0042-6822(86)90263-1; KIM YT, 1992, J BIOL CHEM, V267, P15022; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LINDBERG GK, 1988, J BIOL CHEM, V263, P11319; LINDBERG GK, 1988, DNA REPLICATION MUTA, P130; LOPILATO J, 1986, MOL GEN GENET, V205, P285, DOI 10.1007/BF00430440; MALONE C, 1988, VIROLOGY, V162, P328, DOI 10.1016/0042-6822(88)90472-2; MARKIEWICZ P, 1992, GENE DEV, V6, P2010, DOI 10.1101/gad.6.10.2010; PRASAD BVV, 1987, J MOL BIOL, V193, P579; RIST JK, 1986, J BIOL CHEM, V261, P506; ROTHMANDENES LB, 1995, SEMIN VIROL, V6, P15, DOI 10.1016/S1044-5773(05)80005-8; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; VANDERLAAN K, 1977, VIROLOGY, V76, P596, DOI 10.1016/0042-6822(77)90241-0; WILLIAMS KR, 1990, BIOL NONSPECIFIC DNA, P197; ZIVIN R, 1980, VIROLOGY, V104, P205, DOI 10.1016/0042-6822(80)90378-5	24	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22541	22547		10.1074/jbc.270.38.22541	http://dx.doi.org/10.1074/jbc.270.38.22541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673246	hybrid			2022-12-27	WOS:A1995RW31400075
J	KEATING, DH; CAREY, MR; CRONAN, JE				KEATING, DH; CAREY, MR; CRONAN, JE			THE UNMODIFIED (APO) FORM OF ESCHERICHIA-COLI ACYL CARRIER PROTEIN IS A POTENT INHIBITOR OF CELL-GROWTH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; BACTERIOPHAGE-T7 DNA-POLYMERASE; PURIFICATION; DEFICIENT; PROMOTER; GENETICS; SPINACH; MUTANT	Acyl carrier protein (ACP) is the carrier of fatty acids during their synthesis and utilization. ACPs (or ACP-like protein domains) have been found throughout biology and share significant amino acid sequence similarities. All ACPs undergo a post-translational modification in which 4'-phosphopantetheine is transferred from CoA to a specific serine of apo-ACP, This modification is essential for activity because fatty acids are bound in thioester linkage to the sulfhydryl of the prosthetic group. Overproduction of Escherichia coli ACP from multicopy plasmids strongly inhibits growth off. coli. We report that upon overexpression of ACP in E. coli post-translational modification is inefficient and the apo protein accumulates and blocks cell growth by inhibition of lipid metabolism. Moreover, a mutant form of ACP that is unable to undergo post-translational modification is a potent inhibitor of growth. Finally, we observed that an increase in the efficiency of modification of overexpressed ACP results in decreased toxicity. The accumulated apo-ACP acts as a potent in vitro inhibitor of the sn-glycerol 3-phosphate acyltransferase resulting in an inability to transfer the completed fatty acid to sn-glycerol 3-phosphate. The degree of inhibition depended upon the species of donor acyl chain, Utilization of cis-vaccenoyl-ACP by the sn-glycerol-3-phosphate acyltransferase was inhibited to a much greater extent by apo-ACP than was utilization of palmitoyl-ACP. l-Acyl glycerol-3-phosphate acyltransferase was also inhibited in vitro by apo-ACP, although not at physiologically relevant concentrations, These in vitro data are supported by in vivo labeling data, which showed a large decrease in cis-vaccenate incorporation into phospholipid during overproduction of ACP, but no decrease in the rate of synthesis of long chain acyl-ACPs. These data indicate that acylation of sn-glycerol S-phosphate is the major site of inhibition by apo-ACP.	UNIV ILLINOIS, DEPT MICROBIOL, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15650] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; COLEMAN J, 1990, J BIOL CHEM, V265, P17215; CRONAN JE, 1978, ANNU REV BIOCHEM, V47, P163, DOI 10.1146/annurev.bi.47.070178.001115; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; Davis R., 1980, ADV BACTERIAL GENETI; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; ELOVSON J, 1975, ARCH BIOCHEM BIOPHYS, V168, P490, DOI 10.1016/0003-9861(75)90279-9; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; GOELZ SE, 1981, BIOCHEMISTRY-US, V21, P189; GRANA D, 1988, GENETICS, V120, P319; GUERRA DJ, 1988, J BIOL CHEM, V263, P4386; HEATON MP, 1994, J BACTERIOL, V176, P681, DOI 10.1128/jb.176.3.681-690.1994; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MORRIS LJ, 1967, J CHROMATOGR, V31, P69, DOI 10.1016/S0021-9673(01)86026-X; NACHIAPPAN V, 1994, ANAL BIOCHEM, V222, P283, DOI 10.1006/abio.1994.1487; POLACCO ML, 1981, J BIOL CHEM, V256, P5750; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; RAWLINGS M, 1993, THESIS U ILLINOIS UR; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1980, ANAL BIOCHEM, V102, P362, DOI 10.1016/0003-2697(80)90168-2; ROCK CO, 1981, J BIOL CHEM, V256, P736; Sambrook J, 1989, MOL CLONING LABORATO; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THERISOD H, 1987, P NATL ACAD SCI USA, V84, P8235, DOI 10.1073/pnas.84.23.8235; Vagelos P. R., 1973, ENZYMES, V8, P155; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317	41	83	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22229	22235		10.1074/jbc.270.38.22229	http://dx.doi.org/10.1074/jbc.270.38.22229			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673201	hybrid			2022-12-27	WOS:A1995RW31400027
J	MAROM, M; HAKLAI, R; BENBARUCH, G; MARCIANO, D; EGOZI, Y; KLOOG, Y				MAROM, M; HAKLAI, R; BENBARUCH, G; MARCIANO, D; EGOZI, Y; KLOOG, Y			SELECTIVE-INHIBITION OF RAS-DEPENDENT CELL-GROWTH BY FARNESYLTHIOSALICYLIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASE; POSTTRANSLATIONAL MODIFICATION; FARNESYL CYSTEINE; GAMMA-SUBUNIT; SIGNAL TRANSDUCTION; GTP-BINDING; METHYLATION; BRAIN; IDENTIFICATION; PRENYLATION	S-trans,trans-FarnesylthiosalicyIic acid (FTS) is a novel farnesylated rigid carboxylic acid derivative, In cell-free systems, it acts as a potent competitive inhibitor (K-i = 2.6 mu M) of the enzyme prenylated protein methyltransferase (PPMTase), which methylates the carboxyl-terminal S-prenylcysteine in a large number of prenylated proteins including has, In such systems, FTS inhibits Ras methylation but not Ras farnesylation. Inhibition of the PPMTase by FTS in homogenates or membranes of a variety of tissues and cell lines is inferred from a block in the methylation of exogenously added substrates such as N-acetyl-S-trans,trans-farnesyl-L-cysteine and of endogenous substrates including small GTP-binding proteins, FTS can also inhibit methylation of these proteins in intact cells (e.g. in Rat-1 fibroblasts, Ras transformed Rat-1, and B16 melanoma cells), Unlike in cell-free systems, however, relatively high concentrations of FTS (50-100 mu M) are required for partial blocking (10-40%) of protein methylation in the intact cells, Thus, FTS is a weak inhibitor of methylation in intact cells, Because methylation is the last step in the processing of Ras and related proteins, FTS is not likely to affect steps that precede it, e.g. protein prenylation. This may explain why the growth and gross morphology of a variety of cultured cell types (including Chinese hamster ovary, NIH3T3, Rat1, B16 melanoma, and PC12) is not affected by up to 25 mu M FTS and is consistent with the observed lack of FTS-induced cytotoxicity. Nevertheless, FTS reduces the levels of Ras in cell membranes and can inhibit Ras-dependent cell growth in vitro, independently of methylation, It inhibits the growth of human Ha-ras-transformed cells (EJ cells) and reverses their transformed morphology in a dose-dependent manner (0.1-10 mu M). The drug does not interfere with the growth of cells transformed by v-Raf or T-antigen but inhibits the growth of ErbB2-transformed cells and blocks the mitogenic effects of epidermal and basic fibroblast growth factors, thus implying its selectivity toward Ras growth signaling, possibly via modulation of Ras-Raf communication, Taken together, the results raise the possibility that FTS may specifically interfere with the interaction of Ras with a farnesylcysteine recognition domain in the cell membrane, This drug, and perhaps other farnesylated rigid carboxylic acid analogs, may be used for in vitro characterization of the PPMTase and for the identification of a putative Ras farnesylcysteine recognition domain in cell membranes.	GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, TEL HASHOMER, ISRAEL; CHAIM SHEBA MED CTR, DEPT OBSTET & GYNECOL, IL-52621 TEL HASHOMER, ISRAEL; TEL AVIV UNIV, SACKLER SCH MED, IL-69978 TEL AVIV, ISRAEL; ISRAEL INST BIOL RES, IL-70450 NESS ZIONA, ISRAEL	Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ASHBY MN, 1993, YEAST, V9, P907, DOI 10.1002/yea.320090810; AUDUS KL, 1987, ANN NY ACAD SCI, V507, P9, DOI 10.1111/j.1749-6632.1987.tb45787.x; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; BENBARUCH G, 1993, BIOCHEM BIOPH RES CO, V195, P282, DOI 10.1006/bbrc.1993.2042; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; ENOMOTO T, 1990, CANCER RES, V50, P6139; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAKLAI R, 1990, BIOCHEM PHARMACOL, V40, P1365, DOI 10.1016/0006-2952(90)90405-A; HAKLAI R, 1993, NEUROPEPTIDES, V24, P11, DOI 10.1016/0143-4179(93)90036-A; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MA YT, 1994, BIOCHEMISTRY-US, V33, P5414, DOI 10.1021/bi00184a009; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAN EW, 1991, J BIOL CHEM, V266, P10719; VOLKER C, 1991, J BIOL CHEM, V266, P21515; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	47	174	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22263	22270		10.1074/jbc.270.38.22263	http://dx.doi.org/10.1074/jbc.270.38.22263			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673206	hybrid			2022-12-27	WOS:A1995RW31400033
J	ONORATO, JJ; GILLIS, ME; LIU, Y; BENOVIC, JL; RUOHO, AE				ONORATO, JJ; GILLIS, ME; LIU, Y; BENOVIC, JL; RUOHO, AE			THE BETA-ADRENERGIC-RECEPTOR KINASE (GRK2) IS REGULATED BY PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN KINASE; G-PROTEINS; BETA-2-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; PHOSPHORYLATION; DESENSITIZATION; AGONIST; TRANSLOCATION; ACTIVATION; MECHANISM	The beta-adrenergic receptor kinase (beta ARK) is a member of growing family of G protein coupled receptor kinases (GRKs). beta ARK and other members of the GRK family play a role in the mechanism of agonist-specific desensitization by virtue of their ability to phosphorylate G protein-coupled receptors in an agonist-dependent manner. beta ARK activation is known to occur following the interaction of the kinase with the agonist-occupied form of the receptor substrate and heterotrimeric G protein beta gamma subunits. Recently, lipid regulation of GRK2, GRK3, and GRK5 have also been described. Using a mixed micelle assay, GRK2 (beta ARK1) was found to require phospholipid in order to phosphorylate the beta(2)-adrenergic receptor. As determined with a nonreceptor peptide substrate of beta ARK, catalytic activity of the kinase increased in the presence of phospholipid without a change in the K-m for the peptide. Data obtained with the heterobifunctional cross-linking agent N-3-[I-125] iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)-cysteine ([I-125]ACTP) suggests that the activation by phospholipid was associated with a conformational change in the kinase. [I-125]ACTP incorporation increased 2-fold in the presence of crude phosphatidylcholine, and this increase in [I-125]ACTP labeling is completely blocked by the addition of MgATP. Furthermore, proteolytic mapping was consistent with the modification of a distinct site when GRK2 was labeled in the presence of phospholipid. While an acidic phospholipid specificity was demonstrated using the mixed micelle phosphorylation assay, a notable exception was observed with PIP2. In the presence of PIP2, kinase activity as well as [(125)]ACTP labeling was inhibited. These data demonstrate the direct regulation of GRK2 activity by phospholipids and supports the hypothesis that this effect is the result of a conformational change within the kinase.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19107; UNIV WISCONSIN,DEPT PHARMACOL,MADISON,WI 53706	Jefferson University; University of Wisconsin System; University of Wisconsin Madison	ONORATO, JJ (corresponding author), UNIV WISCONSIN,DEPT MED,4285 MSC,1300 UNIV AVE,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047120, R01GM033138, R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47120, GM33138, GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOVIC JL, 1990, SOC GEN PHY, V45, P87; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; GOMEZ J, 1992, MOL BIOL RECEPTORS T, P1; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	40	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21346	21353		10.1074/jbc.270.36.21346	http://dx.doi.org/10.1074/jbc.270.36.21346			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673171	hybrid			2022-12-27	WOS:A1995RU05400073
J	BURNS, LA; KARNITZ, LM; SUTOR, SL; ABRAHAM, RT				BURNS, LA; KARNITZ, LM; SUTOR, SL; ABRAHAM, RT			INTERLEUKIN-2-INDUCED TYROSINE PHOSPHORYLATION OF P52(SHC) IN T-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; CELL LINE; ACTIVATION; RECEPTOR; SHC; ASSOCIATION; P56LCK; DOMAIN	Stimulation of activated T cells with interleukin-2 (IL-2) results in the tyrosine phosphorylation of several intracellular proteins. The present studies demonstrate that IL-2 stimulation induces phosphorylation of the src homology 2 domain-containing protein, p52shc, on both tyrosine and serine residues. The level of p52shc phosphorylation was maximal within 5 min after growth factor addition and declined gradually thereafter. In addition, anti-Shc immunoprecipitates from IL-2-stimulated T cells contained a co-precipitating protein tyrosine kinase (PTK) activity that phosphorylated p52shc on tyrosine residues in immune complex kinase assays. These results demonstrate that p52shc is an early substrate for IL-2 receptor-coupled PTK activity(s) and suggest that this protein may be involved in the transduction of PTK-dependent regulatory signals in IL-2-stimulated T cells.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,RM 342B,GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047286] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09127] Funding Source: Medline; NIGMS NIH HHS [GM47286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SATOH T, 1992, J BIOL CHEM, V267, P2537; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227	23	92	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17659	17661						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688728				2022-12-27	WOS:A1993LT74300003
J	MOLMENTI, EP; ZIAMBARAS, T; PERLMUTTER, DH				MOLMENTI, EP; ZIAMBARAS, T; PERLMUTTER, DH			EVIDENCE FOR AN ACUTE-PHASE RESPONSE IN HUMAN INTESTINAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTOR; SERUM AMYLOID-A; HUMAN INTERLEUKIN-6; GENE-EXPRESSION; MESSENGER-RNA; FACTOR-B; PROTEIN; FIBROBLASTS; ALPHA-1-ANTITRYPSIN; COMBINATIONS	During the host response to inflammation/tissue in jury there are many changes in intermediary metabolism including a dramatic change in the concentration of many 'acute phase'' plasma proteins. Although many of these acute phase proteins are predominantly derived from the liver and the response can be elicited from liver cells incubated in tissue culture with cytokines such as interleukin-6 (IL-6), interleukin-I (IL-1), tumor necrosis factor-alpha, interferon-gamma, leukemia inhibitory factor, interleukin-11 (IL-11), and oncostatin M, there is now evidence that the response can also be elicited in extrahepatic tissues and cell types. In this study, we show that many of the acute phase plasma proteins are expressed in human intestinal epithelial cell lines Caco2 and T84 and that their expression is induced or regulated by cytokines IL-6, IL-1, interferon, and tumor necrosis factor in a manner characteristic of the acute phase response. In fact, effects of IL-1 and IL-6 which are additive, synergistic, and antagonistic in liver cell lines are also observed in these intestinal epithelial cell lines. Responses to IL-6 and IL-1 are seen at all stages of differentiation of Caco2 cells from crypt-like enterocytes to villus-like enterocytes. Caco2 cells express binding sites for IL-6 at both poles, for IL-I at the basolateral pole and, to a lesser extent, at the apical pole. T84 cells have IL-1 and IL-6 receptor binding sites only at the basolateral pole. IL-6 and IL-1 also regulate the expression of enterocyte-specific integral membrane proteins as exemplified by down-regulation of sucrase-isomaltase gene expression in response to IL-6. These data raise the possibility that enterocytes are involved in a local response to injury/inflammation at the epithelial surface and establish a model system for examining coordination of the acute phase response in a bipolar cell.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [DK45085] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045085] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENSTEDT O, 1990, NEW ENGL J MED, V322, P1345, DOI 10.1056/NEJM199005103221903; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; CROSS HS, 1991, AM J PHYSIOL, V261, pC1173; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; FALUS A, 1987, J IMMUNOL, V138, P856; GANAPATHI MK, 1991, J IMMUNOL, V147, P1261; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GITLIN JD, 1987, LYMPHOKINES, V14, P123; HAFEEZ W, 1992, J CLIN INVEST, V89, P1214, DOI 10.1172/JCI115705; HUBI M, 1990, CELL, V63, P1149; KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605; KULICS J, 1990, J CLIN INVEST, V85, P943, DOI 10.1172/JCI114523; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MAY LT, 1988, J BIOL CHEM, V263, P7760; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MIURA N, 1987, J BIOL CHEM, V262, P7298; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PERLMUTTER DH, 1984, J BIOL CHEM, V259, P380; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P9485; PERLMUTTER DH, 1986, J CLIN INVEST, V78, P1349, DOI 10.1172/JCI112721; PERLMUTTER DH, 1989, J CLIN INVEST, V84, P138, DOI 10.1172/JCI114133; PERLMUTTER DH, 1986, SCIENCE, V232, P850, DOI 10.1126/science.3010455; PERLMUTTER DH, 1989, ANN NY ACAD SCI, V557, P337; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RAMADORI G, 1985, J IMMUNOL, V135, P3645; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; VALENTINE JF, 1992, GASTROENTEROLOGY, V103, P905, DOI 10.1016/0016-5085(92)90024-S; WU GD, 1992, J BIOL CHEM, V267, P7863; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YU S, 1984, J BIOL CHEM, V259, P574	40	213	219	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14116	14124						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686149				2022-12-27	WOS:A1993LJ82500051
J	SALLES, JP; GAYRALTAMINH, M; FAUVEL, J; DELOBBE, I; MIGNONCONTE, M; CONTE, JJ; CHAP, H				SALLES, JP; GAYRALTAMINH, M; FAUVEL, J; DELOBBE, I; MIGNONCONTE, M; CONTE, JJ; CHAP, H			SUSTAINED EFFECT OF ANGIOTENSIN-II ON TYROSINE PHOSPHORYLATION OF ANNEXIN-I IN GLOMERULAR MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PHOSPHOLIPID BINDING-PROTEINS; SWISS 3T3 CELLS; GROWTH-FACTOR; LIPOCORTIN-I; CALPACTIN-I; BILAYER-MEMBRANES; RECEPTOR KINASE; A-431 CELLS; CALCIUM	By means of selective extraction in a Ca2+-chelating medium and immunoblotting, four annexins (I, II, V, and VI) were identified in both isolated rat renal glomeruli and rat glomerular mesangial cells. Upon P-32 labeling of these cells in culture, annexin I was immunoprecipitated using a specific polyclonal antibody and was found to incorporate radioactivity in a constitutive manner. However, as with epidermal growth factor (200 ng/ml), addition of angiotensin II (10(-7) M), arginine-vasopressin (10(-7) M), or endothelin I (10(-7) M) resulted in a 2-3-fold stimulation of annexin I phosphorylation. The basal phosphorylation as well as the stimulating effect of angiotensin II were also detected by immunoblotting annexin extracts using an anti-phosphotyrosine antibody. In addition, among various phosphotyrosyl proteins isolated from EGTA extracts by adsorption onto an anti-phosphotyrosine antibody, annexin I was specifically recognized by Western blotting using a monoclonal anti-annexin I antibody, and displayed the same increase upon cell stimulation with angiotensin II. Moreover, thin layer chromatographic analysis of phosphoamino acids present in immunoprecipitated [P-32]annexin I showed an exclusive labeling of phosphotyrosine residue(s). Finally, the effect of angiotensin II was detectable after 10 min, maximal at 6 h, and present until 12 h of incubation. Using 12-h stimulation, tyrosine phosphorylation of annexin I displayed a maximum at 10(-7) to 10(-6) M angiotensin II. These data report for the first time the stimulation of annexin I tyrosine phosphorylation by biologically active peptides acting via receptors belonging to the superfamily of seven hydrophobic domain, G-protein-linked receptors, which lack an intrinsic protein tyrosine kinase. This suggests a possible role of annexin I in the mitogenic effect of angiotensin II, arginine-vasopressin, and endothelin I, which was previously observed on rat glomerular mesangial cells as well as on other cells.	HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; HOP PURPAN,NEPHROL LAB,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse			SALLES, Jean Pierre/K-2998-2014					AARSMAN AJ, 1987, FEBS LETT, V219, P176, DOI 10.1016/0014-5793(87)81212-7; BIENKOWSKI MJ, 1989, J BIOL CHEM, V264, P6536; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; BURGOYNE RD, 1988, NATURE, V331, P20, DOI 10.1038/331020a0; BURNS AL, 1989, P NATL ACAD SCI USA, V86, P3398; CHAP H, 1988, BIOCHEM BIOPH RES CO, V150, P972, DOI 10.1016/0006-291X(88)90724-3; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; CIRINO G, 1987, NATURE, V328, P270, DOI 10.1038/328270a0; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; DAVIDSON FF, 1987, J BIOL CHEM, V262, P1698; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FAUVEL J, 1987, FEBS LETT, V216, P45, DOI 10.1016/0014-5793(87)80754-8; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FORCE T, 1991, J BIOL CHEM, V266, P6650; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; GASSAMADIAGNE A, 1990, J BIOL CHEM, V265, P4309; GEISOW MJ, 1987, BIOSCIENCE REP, V7, P289, DOI 10.1007/BF01121450; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HULLIN F, 1989, J BIOL CHEM, V264, P3506; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; JOHNSTON PA, 1990, J BIOL CHEM, V265, P11382; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KUMBLE KD, 1991, J CELL SCI, V99, P751; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIN HC, 1992, CELL, V70, P283, DOI 10.1016/0092-8674(92)90102-I; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; NORTHUP JK, 1988, J CLIN INVEST, V82, P1347, DOI 10.1172/JCI113737; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; RAY PE, 1991, KIDNEY INT, V40, P764, DOI 10.1038/ki.1991.273; RAYNAL P, 1992, BIOCHEM BIOPH RES CO, V186, P432, DOI 10.1016/S0006-291X(05)80826-5; ROJAS E, 1990, J BIOL CHEM, V265, P21207; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SCHLAEPFER DD, 1988, BIOCHEMISTRY-US, V27, P4253, DOI 10.1021/bi00412a008; SCHLAEPFER DD, 1992, J BIOL CHEM, V267, P9529; STRIKER GE, 1985, LAB INVEST, V53, P122; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; TOKUMITSU H, 1992, J BIOL CHEM, V267, P8919; TOWLE CA, 1992, J BIOL CHEM, V267, P5416; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; WEBER K, 1987, EMBO J, V6, P1599, DOI 10.1002/j.1460-2075.1987.tb02406.x; WOLTHUIS A, 1992, KIDNEY INT, V41, P124, DOI 10.1038/ki.1992.16; WU YN, 1991, FEBS LETT, V282, P197, DOI 10.1016/0014-5793(91)80476-J; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	61	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12805	12811						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685351				2022-12-27	WOS:A1993LG65800085
J	CIFUENTES, ME; HONKANEN, L; REBECCHI, MJ				CIFUENTES, ME; HONKANEN, L; REBECCHI, MJ			PROTEOLYTIC FRAGMENTS OF PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C-DELTA-1 - CATALYTIC AND MEMBRANE-BINDING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; KINETIC-ANALYSIS; MIXED MICELLES; POLYACRYLAMIDE GELS; BOVINE BRAIN; C-GAMMA; PURIFICATION; PROTEINS; SEQUENCE; FORMS	Active proteolytic fragments of phosphoinositide-specific phospholipase C-delta1 (PLC-delta1) were generated by trypsin digestion of the native protein. Brief proteolysis produced a 77-kDa fragment that contained the highly conserved X and Y regions but lacked the amino-terminal domain (amino acids 1-60). Prolonged digestion of PLC-delta1 produced two fragments, one of 45 kDa that contained the entire X region and another of 32 kDa that consisted of the entire Y region and COOH-terminal domain. The 45- and 32-kDa fragments were isolated as an active heterodimeric complex. The 77-kDa fragment and the complex catalyzed calcium-dependent hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in detergent/phospholipid mixed micelles. When compared with the native enzyme, both the 77-kDa fragment and the complex exhibited a reduced capacity to processively hydrolyze PIP2; increasing the mole fraction of PIP2 in the mixed micelle surface greatly increased the rate of PIP2 hydrolysis catalyzed by the native enzyme but not the fragments. Both fragments also exhibited a reduced affinity for substrate; the native enzyme bound to bilayer vesicles consisting of phosphatidylcholine and PIP2 with high affinity (K(a) is similar to 10(6) M-1), whereas the fragments bound weakly (K(a) < 10(4) M-1). These results demonstrate that the X, Y, and COOH-terminal regions form a calcium-dependent catalytic core that is resistant to proteolysis. The amino-terminal domain appears to be essential for high affinity binding to PIP2 but not catalysis. These observations are consistent with the idea that the amino-terminal domain forms part of a PIP2 binding site, which anchors PLC-delta1 to the membrane surface during processive hydrolysis of its substrate.	SUNY, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College				Cifuentes-Pagano, Eugenia/0000-0002-2482-080X	NIGMS NIH HHS [GM-43422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043422, R01GM043422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; COCKCROFT S, 1992, BIOCHEM J, V288, P1; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUKUI T, 1988, J BIOL CHEM, V263, P17730; GENTRY LE, 1983, J BIOL CHEM, V258, P1219; HARDEN TK, 1991, BIOCHEM SOC T, V19, P342, DOI 10.1042/bst0190342; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HOMMA Y, 1988, J BIOL CHEM, V263, P6592; Hurn B A, 1980, Methods Enzymol, V70, P104; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; KATAN M, 1988, COLD SPRING HARB SYM, V53, P921, DOI 10.1101/SQB.1988.053.01.106; KIM JW, 1990, J BIOL CHEM, V265, P3940; KRIZ R, 1990, CIBA F SYMP, V150, P112; Low M. G, 1990, METHODS INOSITIDE RE, P145; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONALD LJ, 1989, BIOCHEMISTRY-US, V28, P9926, DOI 10.1021/bi00452a008; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P3925, DOI 10.1021/bi00411a006; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI MJ, 1987, J BIOL CHEM, V262, P12526; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; Segel I.H., 1975, ENZYME KINETICS; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WILSON DB, 1984, J BIOL CHEM, V259, P1718	43	159	161	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11586	11593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685017				2022-12-27	WOS:A1993LF28400023
J	CHANG, XB; TABCHARANI, JA; HOU, YX; JENSEN, TJ; KARTNER, N; ALON, N; HANRAHAN, JW; RIORDAN, JR				CHANG, XB; TABCHARANI, JA; HOU, YX; JENSEN, TJ; KARTNER, N; ALON, N; HANRAHAN, JW; RIORDAN, JR			PROTEIN KINASE-A (PKA) STILL ACTIVATES CFTR CHLORIDE CHANNEL AFTER MUTAGENESIS OF ALL 10 PKA CONSENSUS PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS GENE; R-DOMAIN; CONDUCTANCE; IDENTIFICATION; EXPRESSION; CAMP	The cystic fibrosis transmembrane conductance regulator (CFTR) plays a central role in transepithelial ion transport by acting as a tightly regulated apical chloride channel. Regulation is achieved by the concerted action of ATP at conserved nucleotide binding folds and serine phosphorylation at multiple sites by protein kinases A (PKA) and C (PKC). A previous investigation concluded that activation by PKA is critically dependent on phosphorylation at four of the nine predicted PKA sites in the R domain (S660A, S737A, S795A, S813A), because a ''Quad'' mutant lacking these sites could not be activated. We show in the present work that not only can this mutant be phosphorylated and activated, but a mutant in which all 10 predicted PKA sites have been altered still retains significant PKA-activated function. Potentiation of the PKA response by PKC is also preserved in this mutant. Thus CFTR may be regulated by cryptic PKA sites which also mediate interactions between different kinases. Such hierarchical phosphorylation of CFTR by obvious and cryptic PKA sites could provide a metered response to secretagogues.	HOSP SICK CHILDREN,RES INST,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Toronto; University of Toronto			Hanrahan, John/AGG-1926-2022; Alon, Noga/GOV-5970-2022	Hanrahan, John/0000-0001-9080-2039; Alon, Noga/0000-0003-1332-4883				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; REED J, 1984, BIOCHEMISTRY-US, V23, P1357, DOI 10.1021/bi00302a004; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K	23	268	271	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11304	11311						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684377				2022-12-27	WOS:A1993LD46600086
J	ITOH, N; NAGATA, S				ITOH, N; NAGATA, S			A NOVEL PROTEIN DOMAIN REQUIRED FOR APOPTOSIS - MUTATIONAL ANALYSIS OF HUMAN FAS ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; LYMPHOCYTES-T; EXPRESSION; FAMILY; DEATH; CELLS	The Fas antigen is a cell surface protein that can mediate apoptosis and that belongs to the tumor necrosis factor receptor family. Murine fibroblast L929 cells or T-cell lymphoma WR19L cells expressing the human Fas antigen were killed within 4-6 h by anti-human Fas antibody in a concentration-dependent manner. Human Fas antigen cDNAs with various mutations in the cytoplasmic region were constructed and expressed in L929 cells. A deletion of 15 amino acids from the C terminus of the Fas antigen enhanced the Fas antibody-induced killing activity, whereas a further deletion abolished its activity. This suggests the presence of an inhibitory as well as a signal-transducing domain in the cytoplasmic region of the Fas antigen. A 68-amino acid portion of the signal-transducing domain significantly conserved in the Fas antigen as well as in the type I tumor necrosis factor receptor was considered to be the novel protein domain required for apoptotic signal transduction.			ITOH, N (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				CAMERINI D, 1991, J IMMUNOL, V147, P3165; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; OEHM A, 1992, J BIOL CHEM, V267, P10709; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; ULLICH A, 1990, CELL, V61, P203; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	31	784	851	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10932	10937						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684370				2022-12-27	WOS:A1993LD46600036
J	BRUGNARA, C; DEFRANCESCHI, L; ALPER, SL				BRUGNARA, C; DEFRANCESCHI, L; ALPER, SL			CA2+-ACTIVATED K+ TRANSPORT IN ERYTHROCYTES - COMPARISON OF BINDING AND TRANSPORT INHIBITION BY SCORPION TOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNEL; SICKLE-CELL-ANEMIA; HUMAN RED-CELLS; HIGH-AFFINITY; HUMAN-LYMPHOCYTES; CHARYBDOTOXIN; CONDUCTANCE; MEMBRANES; ASSOCIATION; CATION	We have investigated the interactions of synthetic charybdotoxin (ChTX), synthetic iberiotoxin (IbTX), and recombinant mutant ChTX peptides with the Ca2+-activated K+ channel (Gardos pathway) in human and rabbit erythrocytes. We measured the binding of I-125-ChTX to erythrocytes, the displacement of bound I-125-ChTX by unlabeled toxin and analogs, and then compared these data with isotopic and electrical indices of channel activity measured under the same conditions. We found that a major portion of I-125-ChTX bound to red cells was displaceable by excess unlabeled ChTX. This specific I-125-ChTX binding to human red cells was markedly increased in low ionic strength conditions as compared with that measured at physiological ionic strength and at alkaline pH as compared with normal pH. At pH 8 and low ionic strength, specific binding could be described most simply as a single class of sites of K(d) = 94 +/- 49 pM and B(max) = 120 +/- 36 sites/cell (n = 3). Ca2+-activated Rb-86 influx measured under identical conditions revealed an ID50 for ChTX of 21 +/- 15 pM (n = 6) at low ionic strength and 4 +/- 2.4 nM (n = 4) at physiological ionic strength. Similar studies in rabbit erythrocytes at low ionic strength revealed a K(d) for I-125-ChTX = 37 +/- 17 pM, with 126 +/- 24 binding sites/cell and an ID50 for inhibition of Rb-86 influx by ChTX = 25 pM. Whereas IbTX neither inhibited Ca2+-activated Rb-86 influx nor displaced I-125-ChTX in human red cells, it partially displaced I-125-ChTX and partially inhibited Rb-86 influx in rabbit red cells. Studies with recombinant mutant ChTX peptides showed that the mutant toxin K27Q was inactive as a transport inhibitor and displayed a large reduction in ability to displace I-125-ChTX. The mutation K31Q resulted in abolition of ionic strength dependence of the inhibitory effect on the Ca2+-activated K+ permeability. In view of the similarity between the I-125-ChTX binding constant and the transport inhibition constant of ChTX, we examined the potency of I-125-ChTX as a transport inhibitor. I-125-ChTX inhibited Ca2+-activated K+ transport with ID50 values of 3.3 +/- 1 nM (n = 7) at low ionic strength and 4.1 +/- 3 nM (n = 6) at physiologic ionic strength. Thus, at physiologic ionic strength I-125-ChTX and ChTX are indistinguishable as inhibitors of erythroid Ca2+-activated K+ transport. However, iodination of Y36 is associated with abolition of the 200-fold increase in inhibitory potency shown by ChTX at low ionic strength.	BETH ISRAEL HOSP,MOLEC MED UNIT,330 BROOKLINE AVE,BOSTON,MA 02215; BETH ISRAEL HOSP,RENAL UNIT,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039249] Funding Source: NIH RePORTER; NHLBI NIH HHS [P60-HL15157] Funding Source: Medline; NIDDK NIH HHS [DK39249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALVAREZ J, 1987, BIOCHIM BIOPHYS ACTA, V903, P543, DOI 10.1016/0005-2736(87)90062-9; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BONTEMS F, 1992, BIOCHEMISTRY-US, V31, P7756, DOI 10.1021/bi00149a003; BOOKCHIN RM, 1991, J CLIN INVEST, V87, P113, DOI 10.1172/JCI114959; BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486; BRUGNARA C, 1989, AM J PHYSIOL, V256, pC994, DOI 10.1152/ajpcell.1989.256.5.C994; BRUGNARA C, 1992, BLOOD, V80, P344; CANESSA M, 1986, FEBS LETT, V200, P197, DOI 10.1016/0014-5793(86)80538-5; CASTLE NA, 1989, TRENDS NEUROSCI, V12, P59, DOI 10.1016/0166-2236(89)90137-9; CHRISTOPHERSEN P, 1991, J MEMBRANE BIOL, V119, P75, DOI 10.1007/BF01868542; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARDOS G, 1956, Acta Physiol Acad Sci Hung, V10, P185; GIANGIACOMO K M, 1991, Biophysical Journal, V59, p214A; GOLDSTEIN S A N, 1992, Biophysical Journal, V61, pA151; GRINSTEIN S, 1990, J GEN PHYSIOL, V95, P97, DOI 10.1085/jgp.95.1.97; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; HALPERIN JA, 1989, AM J PHYSIOL, V257, pC986, DOI 10.1152/ajpcell.1989.257.5.C986; Hamill O.P., 1983, SINGLE CHANNEL RECOR, P451; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEW VL, 1982, NATURE, V296, P742, DOI 10.1038/296742a0; LIN MC, 1976, BIOCHEMISTRY-US, V15, P4537, DOI 10.1021/bi00665a031; LIN MC, 1975, BIOCHEMISTRY-US, V14, P1559, DOI 10.1021/bi00679a002; LU L, 1990, J BIOL CHEM, V265, P16190; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MACEY RI, 1978, BIOCHIM BIOPHYS ACTA, V512, P284, DOI 10.1016/0005-2736(78)90253-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MILLER C, 1990, BIOCHEMISTRY-US, V29, P5320, DOI 10.1021/bi00474a016; OHNISHI ST, 1989, BIOCHIM BIOPHYS ACTA, V1010, P199; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; SUGG EE, 1990, J BIOL CHEM, V265, P18745; VAZQUEZ J, 1989, J BIOL CHEM, V264, P20902; VESTERGAARDBOGIND B, 1987, J MEMBRANE BIOL, V95, P121, DOI 10.1007/BF01869157; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WOLFF D, 1988, J MEMBRANE BIOL, V106, P243, DOI 10.1007/BF01872162	46	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8760	8768						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682555				2022-12-27	WOS:A1993KX81100058
J	CAMPAGNONI, AT; PRIBYL, TM; CAMPAGNONI, CW; KAMPF, K; AMURUMARJEE, S; LANDRY, CF; HANDLEY, VW; NEWMAN, SL; GARBAY, B; KITAMURA, K				CAMPAGNONI, AT; PRIBYL, TM; CAMPAGNONI, CW; KAMPF, K; AMURUMARJEE, S; LANDRY, CF; HANDLEY, VW; NEWMAN, SL; GARBAY, B; KITAMURA, K			STRUCTURE AND DEVELOPMENTAL REGULATION OF GOLLI-MBP, A 105-KILOBASE GENE THAT ENCOMPASSES THE MYELIN BASIC-PROTEIN GENE AND IS EXPRESSED IN CELLS IN THE OLIGODENROCYTE LINEAGE IN THE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; TRANSGENIC SHIVERER MICE; CENTRAL-NERVOUS-SYSTEM; MOUSE-BRAIN; INSITU HYBRIDIZATION; MESSENGER-RNAS; IDENTIFICATION; TRANSCRIPTION; CULTURES; PROMOTER	We have identified a novel transcription unit of 105 kilobases (called the Golli-mbp gene) that encompasses the mouse myelin basic protein (MBP) gene. Three unique exons within this gene are alternatively spliced into MBP exons and introns to produce a family of MBP gene-related mRNAs that are under individual developmental regulation. These mRNAs are temporally expressed within cells of the oligodendrocyte lineage at progressive stages of differentiation. Thus, the MBP gene is a part of a more complex gene structure, the products of which may play a role in oligodendrocyte differentiation prior to myelination. One Golli-mbp mRNA that encodes a protein antigenically related to MBP is also expressed in the spleen and other non-neural tissues.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT BIOCHEM & MOLEC BIOPHYS, RICHMOND, VA 23298 USA; CNRS, INST BIOCHEM CELLULAIRE & NEUROCHEM, F-33077 BORDEAUX, FRANCE; SAITAMA MED SCH, DEPT PHYSIOL, MOROYAMA, SAITAMA 35004, JAPAN	Virginia Commonwealth University; Centre National de la Recherche Scientifique (CNRS); Saitama Medical University	CAMPAGNONI, AT (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, MENTAL RETARDAT RES CTR, LOS ANGELES, CA 90024 USA.			GARBAY, Bertrand/0000-0001-5756-2627	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023322, R01NS023022] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25831] Funding Source: Medline; NINDS NIH HHS [NS23022, NS23322] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMURUMARJEE SG, 1990, DEV NEUROSCI-BASEL, V12, P263, DOI 10.1159/000111855; AMURUMARJEE SG, 1990, DEV NEUROSCI-BASEL, V12, P251, DOI 10.1159/000111854; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; ARUGA J, 1991, J NEUROCHEM, V56, P1222, DOI 10.1111/j.1471-4159.1991.tb11414.x; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BANSAL G, 1987, J NEUROIMMUNOL, V15, P279, DOI 10.1016/0165-5728(87)90122-6; BARBARESE E, 1981, P NATL ACAD SCI-BIOL, V78, P1953, DOI 10.1073/pnas.78.3.1953; BARBARESE E, 1983, J NEUROCHEM, V40, P1680, DOI 10.1111/j.1471-4159.1983.tb08142.x; Bell R B, 1991, Semin Immunol, V3, P237; CAMERON RS, 1991, GLIA, V4, P124, DOI 10.1002/glia.440040204; CAMPAGNONI AT, 1974, J NEUROCHEM, V23, P887, DOI 10.1111/j.1471-4159.1974.tb04422.x; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CAMPAGNONI AT, 1988, J NEUROCHEM, V51, P1, DOI 10.1111/j.1471-4159.1988.tb04827.x; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DIVINEBEACH K, 1990, J BIOL CHEM, V265, P13830; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HRUBY S, 1987, MOL IMMUNOL, V24, P1359, DOI 10.1016/0161-5890(87)90132-5; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KIMURA M, 1989, P NATL ACAD SCI USA, V86, P5661, DOI 10.1073/pnas.86.14.5661; KITAMURA K, 1990, J NEUROCHEM, V54, P2032, DOI 10.1111/j.1471-4159.1990.tb04908.x; KNAPP PE, 1991, J NEUROSCI RES, V30, P336, DOI 10.1002/jnr.490300209; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDRY CF, 1989, MOL BRAIN RES, V6, P251, DOI 10.1016/0169-328X(89)90071-5; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MISKIMINS R, 1992, DEV BRAIN RES, V65, P217, DOI 10.1016/0165-3806(92)90182-V; MIURA M, 1989, GENE, V75, P31; MOLINEAUX SM, 1986, P NATL ACAD SCI USA, V83, P7542, DOI 10.1073/pnas.83.19.7542; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; READHEAD C, 1990, ANN NY ACAD SCI, V605, P280; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; SUZUMURA A, 1984, BRAIN RES, V324, P379, DOI 10.1016/0006-8993(84)90054-4; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; VERDI JM, 1990, J BIOL CHEM, V265, P20314; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	41	212	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4930	4938						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680345				2022-12-27	WOS:A1993KP88400057
J	SHIMAMOTO, T; HSU, MY; INOUYE, S; INOUYE, M				SHIMAMOTO, T; HSU, MY; INOUYE, S; INOUYE, M			REVERSE TRANSCRIPTASES FROM BACTERIAL RETRONS REQUIRE SPECIFIC SECONDARY STRUCTURES AT THE 5'-END OF THE TEMPLATE FOR THE CDNA PRIMING REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; BRANCHED RNA; MYXOCOCCUS-XANTHUS; PHYLOGENETIC DISTRIBUTION; STIGMATELLA-AURANTIACA; 5' END; MSDNA; BIOSYNTHESIS; MUTAGENESIS	Multicopy single-stranded DNA (msDNA) is a peculiar molecule consisting of a single-stranded DNA that is branched out from an internal G residue of an RNA molecule (msdRNA) via a 2',5'-phosphodiester linkage. The genetic unit required for msDNA synthesis is designated ''retron'' and consists of msr (a gene for msdRNA), msd (a gene for msDNA), and a gene for reverse transcriptase (RT) in a single operon. To date, four different msDNAs have been isolated from Escherichia coli. They do not share any primary sequences in either RNA or DNA. To elucidate the specificity of bacterial RT for msDNA synthesis, the msr-msd region from retron-Ec67 was introduced into E. coli cells producing RT-Ec73, or the msr-msd region from retron-Ec73 into E. coli cells producing RT-Ec67. In both cases, msDNA was not synthesized. However, when the msdRNA coding regions (msr) for retron-Ec67 and -Ec73 were mutually exchanged and the chimeric genes were introduced into E. coli cells producing either RT-Ec67 or RT-Ec73, it was thus found that msDNA was produced only when msr and RT were from the same retron. Requirement of the msr region for msDNA synthesis by RT was further investigated by mutations in the msr region for retron-Ec67. These analyses revealed that there is a strict requirement for specific primary sequences as well as the secondary structure in msdRNA. This finding is discussed in relationship to the mechanism of the priming reaction of cDNA synthesis by eukaryotic retroviral RTs using tRNAs.			SHIMAMOTO, T (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.		Inouye, Sharon/R-7216-2019; Shimamoto, Tadashi/A-7109-2018	Shimamoto, Tadashi/0000-0002-5538-0595	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHUNDALE A, 1988, J BIOL CHEM, V263, P9055; DHUNDALE A, 1987, CELL, V51, P1105, DOI 10.1016/0092-8674(87)90596-4; DHUNDALE AR, 1985, J BACTERIOL, V164, P914, DOI 10.1128/JB.164.2.914-917.1985; FURUICHI T, 1987, CELL, V48, P55, DOI 10.1016/0092-8674(87)90355-2; FURUICHI T, 1987, CELL, V48, P47, DOI 10.1016/0092-8674(87)90354-0; HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; HERZER PJ, 1990, J BACTERIOL, V172, P6175, DOI 10.1128/jb.172.11.6175-6181.1990; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU MY, 1989, J BIOL CHEM, V264, P6214; HSU MY, 1992, J BIOL CHEM, V267, P13823; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; INOUYE M, 1992, J BACTERIOL, V174, P2419, DOI 10.1128/jb.174.8.2419-2424.1992; INOUYE M, 1992, REVERSE TRANSCRIPTAS; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LAMPSON BC, 1990, J BIOL CHEM, V265, P8490; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; OHSHIMA A, 1992, P NATL ACAD SCI USA, V89, P1016, DOI 10.1073/pnas.89.3.1016; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; VARMUS H, 1985, RNA TUMOR VIRUSES, V2, P369; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; YEE T, 1984, CELL, V38, P203, DOI 10.1016/0092-8674(84)90541-5	31	39	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2684	2692						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679101				2022-12-27	WOS:A1993KK81500064
J	GEORGES, E; TSURUO, T; LING, V				GEORGES, E; TSURUO, T; LING, V			TOPOLOGY OF P-GLYCOPROTEIN AS DETERMINED BY EPITOPE MAPPING OF MRK-16 MONOCLONAL-ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; BACTERIAL TRANSPORT PROTEINS; PEPTIDE-SYNTHESIS; 3-DIMENSIONAL STRUCTURE; CHINESE-HAMSTER; CDNA SEQUENCE; CELL-LINES; EXPRESSION; MEMBRANE; HOMOLOGY	There is growing evidence for the direct role of P-glycoprotein mediating multidrug resistance in tumor cells. P-glycoprotein is thought to function as an energy-dependent drug efflux pump. The monoclonal antibody MRK-16 binds to an external domain of P-glycoprotein and partially inhibits drug efflux in multidrug-resistant cells. As an approach toward elucidating the mechanism by which MRK-16 affects drug transport, we undertook the definition of the precise binding site of this antibody. In this study we have mapped the epitope of MRK-16 monoclonal antibody to a resolution of a single amino acid using a series of overlapping synthetic peptides. We demonstrate that MRK-16 recognizes only the class I isoform (MDR1) of human P-glycoprotein and that its epitope encompasses at least two (first and fourth) of the six predicted extracellular peptide loops. These results suggest that the epitope of MRK-16 is discontinuous and that the sequences involved which are separated by about 625 amino acids in the linear sequence must be spatially situated in close proximity in the native protein. Based on these results, we present a model for transmembrane alpha-helical packing of P-glycoprotein in the lipid bilayer. This may have implications for understanding the function of P-glycoprotein in drug transport.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Tokyo					NCI NIH HHS [CA37130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037130] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BECK WT, 1981, P AM ASSOC CANC RES, V22, P204; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HAMADA H, 1987, ANAL BIOCHEM, V160, P483, DOI 10.1016/0003-2697(87)90080-7; HAMADA H, 1986, P NATL ACAD SCI USA, V83, P7785, DOI 10.1073/pnas.83.20.7785; HAMADA H, 1988, J BIOL CHEM, V263, P1454; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; MITCHELL AR, 1978, J ORG CHEM, V43, P2845, DOI 10.1021/jo00408a022; MUKHOPADHYAY T, 1988, J NATL CANCER I, V80, P269, DOI 10.1093/jnci/80.4.269; NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; SANCHEZ JA, 1986, J GEN PHYSIOL, V87, P985, DOI 10.1085/jgp.87.6.985; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Stewart JM, 1984, SOLID PHASE PEPTIDE; SUGAWARA I, 1988, CANCER RES, V48, P1926; SUGAWARA I, 1989, JPN J CANCER RES, V80, P1199, DOI 10.1111/j.1349-7006.1989.tb01655.x; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; 1969, BIOCHEM J, V113, P1	37	132	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1792	1798						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678410				2022-12-27	WOS:A1993KH62000046
J	HUFF, CA; YUSPA, SH; ROSENTHAL, D				HUFF, CA; YUSPA, SH; ROSENTHAL, D			IDENTIFICATION OF CONTROL ELEMENTS 3' TO THE HUMAN KERATIN-1 GENE THAT REGULATE CELL TYPE AND DIFFERENTIATION-SPECIFIC EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EPIDERMAL-CELLS; BETA-GLOBIN GENE; TISSUE-SPECIFIC EXPRESSION; HUMAN TYPE-I; TERMINAL DIFFERENTIATION; TRANSCRIPTIONAL ENHANCER; CYTOKERATIN GENES; SILENCER ELEMENTS; TRANSGENIC MICE; C-FOS	To define DNA regulatory elements that mediate the response of the keratin 1 (K1) gene to Ca2+-induced differentiation, regions spanning the 5'- and 3'-flanking sequences, coding regions, and introns from the human K1 gene were cloned into vectors containing the chloramphenicol acetyltransferase (CAT) reporter gene and transfected into cultured mouse keratinocytes. A 4.3-kilobase (kb) region located 3' to the K1 gene stimulated CAT activity in response to increasing Ca2+ concentrations from 0.05 mM (basal cells) to 1.2 mm (differentiated cells). The 4.3-kb fragment was also active in human epidermal cells but inactive in NIH 3T3 cells and primary mouse fibroblasts. Deletion analysis localized the activity to the terminal 1682 base pairs (bp) of the flanking sequence which retained Ca2+ sensitivity in epidermal cells but was not active in mesenchymal cells. Removal of a 207-base pair element created an enhancer which was active in both epidermal and mesenchumal cells but was still Ca2+-inducible. Further deletions identified two elements which functioned synergistically to give maximal Ca2+-sensitive activity. Stably transfected epidermal cell lines expressed CAT under the direction of these elements when grafted onto nude mice to reconstitute an intact epidermis. Previously reported keratin regulatory motifs were not contained in the 1682-bp fragment, but an AP-1 site was identified in one of the synergistic subunits.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Rosenthal, Dean/0000-0002-7624-0209				ATWEH GF, 1988, MOL CELL BIOL, V8, P5047, DOI 10.1128/MCB.8.11.5047; AYER S, 1990, MOL CELL BIOL, V10, P3512, DOI 10.1128/MCB.10.7.3512; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERG PE, 1989, NUCLEIC ACIDS RES, V17, P8833, DOI 10.1093/nar/17.21.8833; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BOWDEN PE, 1984, EUR J BIOCHEM, V142, P29, DOI 10.1111/j.1432-1033.1984.tb08246.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHIN MT, 1989, J VIROL, V63, P2967, DOI 10.1128/JVI.63.7.2967-2976.1989; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHOI Y, 1990, CELL REGUL, V1, P791, DOI 10.1091/mbc.1.11.791; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1979, CELL, V17, P573, DOI 10.1016/0092-8674(79)90265-4; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HARPER JR, 1988, J INVEST DERMATOL, V91, P150, DOI 10.1111/1523-1747.ep12464396; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, J CELL PHYSIOL, V116, P265, DOI 10.1002/jcp.1041160303; HIROCHIKA H, 1988, GENE DEV, V2, P54, DOI 10.1101/gad.2.1.54; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JACKSON AE, 1988, MOL ENDOCRINOL, V2, P1139, DOI 10.1210/mend-2-11-1139; JIANG CK, 1991, J INVEST DERMATOL, V96, P162, DOI 10.1111/1523-1747.ep12460939; JIANG CK, 1990, NUCLEIC ACIDS RES, V18, P247, DOI 10.1093/nar/18.2.247; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; JONAS EA, 1989, DEVELOPMENT, V106, P399; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KOLLIAS G, 1987, NUCLEIC ACIDS RES, V15, P5739, DOI 10.1093/nar/15.14.5739; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; Maniatis T., 1982, MOL CLONING; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MCNAB AR, 1990, P NATL ACAD SCI USA, V87, P6848, DOI 10.1073/pnas.87.17.6848; MERCOLA M, 1983, SCIENCE, V221, P663, DOI 10.1126/science.6306772; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PATARCA R, 1989, GENE, V85, P461, DOI 10.1016/0378-1119(89)90440-X; POIRIER MC, 1979, CANCER RES, V39, P1377; POPESCU NC, 1989, HUM GENET, V82, P109, DOI 10.1007/BF00284039; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROMANO V, 1988, CYTOGENET CELL GENET, V48, P148, DOI 10.1159/000132612; ROOP DR, 1988, CANCER RES, V48, P3245; ROOP DR, 1989, PHARM RETINOIDS SKIN, P1; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; TAKEMOTO Y, 1991, NUCLEIC ACIDS RES, V19, P2761, DOI 10.1093/nar/19.10.2761; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YAMAGUCHI M, 1989, J CELL PHYSIOL, V141, P431, DOI 10.1002/jcp.1041410225; YAMAGUCHI M, 1989, J BIOL CHEM, V264, P16887; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490; YUSPA SH, 1980, TRANSPLANT P, V12, P114; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	73	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					377	384						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677999				2022-12-27	WOS:A1993KE60300058
J	JOHNSON, TM; ROSENBERG, MP; MEISLER, MH				JOHNSON, TM; ROSENBERG, MP; MEISLER, MH			AN INSULIN-RESPONSIVE ELEMENT IN THE PANCREATIC ENHANCER OF THE AMYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; NUCLEAR-PROTEIN; DIABETIC MICE; RAT PANCREAS; ACINAR-CELLS; DNA; BINDING; TRANSCRIPTION	We have identified a distinct insulin-responsive element (IRE) located within the pancreatic enhancer of the mouse amylase gene Amy-2.2. A 30-base pair (bp) fragment was previously shown to be sufficient to transfer insulin response to a heterologous promoter. The 30-bp fragment overlaps the tissue-specific pancreatic enhancer that binds the putative transcriptional activator PTF1. To determine whether enhancer and IRE activities could be separated, we introduced three 10-base pair substitutions into the 30-bp region. The mutated regulatory regions were cloned upstream of a heterologous promoter and transferred to transgenic mice. Mutants 1 and 2 retained PTF1 binding activity and insulin response. Mutant 3 retained PTF1 binding, but was defective in insulin response. The results indicate that the IRE is functionally distinct from the PTF1-binding site, although the two overlap physically. In contrast to the wild-type gene, mutant 3 is characterized by constitutive expression in diabetic animals, suggesting that a binding site for a repressor has been destroyed. A nuclear protein with affinity for the IRE was detected in normal and diabetic pancreas. This protein does not bind mutant 3, suggesting that it may be involved in negative regulation of amylase in diabetic pancreas.	UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; GLAXO RES INC,RES TRIANGLE PK,NC 27709	University of Michigan System; University of Michigan; GlaxoSmithKline					NIDDK NIH HHS [DK 36089] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036089] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENABDEL.A, 1965, BIOCHEM BIOPH RES CO, V18, P71, DOI 10.1016/0006-291X(65)90884-3; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLOOR JH, 1981, J BIOL CHEM, V256, P373; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DRANGINIS A, 1984, J BIOL CHEM, V259, P2216; GIORGI D, 1984, EMBO J, V3, P1521, DOI 10.1002/j.1460-2075.1984.tb02005.x; GUMUCIO DL, 1985, J BIOL CHEM, V260, P3483; HJORTH JP, 1979, BIOCHEM GENET, V17, P665, DOI 10.1007/BF00502125; HOWARD G, 1989, NUCLEIC ACIDS RES, V17, P8185, DOI 10.1093/nar/17.20.8185; JOHNSON TM, 1990, DIABETES, V39, P757, DOI 10.2337/diabetes.39.6.757; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KORC M, 1981, SCIENCE, V213, P351, DOI 10.1126/science.6166044; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MEISTER A, 1989, J BIOL CHEM, V264, P20744; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; OSBORN L, 1988, J BIOL CHEM, V263, P16519; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PALLA JC, 1968, BIOCHIM BIOPHYS ACTA, V158, P25, DOI 10.1016/0304-4165(68)90068-8; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SCHMID RM, 1992, AM J PHYSIOL, V262, pG971, DOI 10.1152/ajpgi.1992.262.6.G971; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOLING HD, 1972, EUR J CLIN INVEST, V2, P199, DOI 10.1111/j.1365-2362.1972.tb00645.x; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; SWIFT GH, 1984, CELL, V38, P639, DOI 10.1016/0092-8674(84)90258-7; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679	36	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					464	468						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678001				2022-12-27	WOS:A1993KE60300071
J	CHAN, SDH; ANTONIUCCI, DM; FOK, KS; ALAJOKI, ML; HARKINS, RN; THOMPSON, SA; WADA, HG				CHAN, SDH; ANTONIUCCI, DM; FOK, KS; ALAJOKI, ML; HARKINS, RN; THOMPSON, SA; WADA, HG			HEREGULIN ACTIVATION OF EXTRACELLULAR ACIDIFICATION IN MAMMARY-CARCINOMA CELLS IS ASSOCIATED WITH EXPRESSION OF HER2 AND HER3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; LIGAND; PROTEIN; ONCOGENE; PRODUCT; GENE; HER4/P180(ERBB4); DIFFERENTIATION	HER2, the erbB-2/neu proto-oncogene product, is a 185-kDa transmembrane glycoprotein related to the epidermal growth factor receptor. Overexpression of HERB was reported in several human adenocarcinomas, including mammary and ovarian carcinomas. A family of glycoproteins, the heregulin/neu differentiation factors, was characterized and implicated as the Ligands for HERS. Recently, it has been shown that HERB alone is not sufficient to reconstitute high affinity heregulin receptors and that HER3 or HER4 may be the required components of the heregulin receptors on mammary carcinoma cells (Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A, Fitzpatrick, V. D., Nuijens, A., Fendly, B. M., Cerione, R. A., Vandlen, R. L., and Carraway, K. L., III (1994) J. Biol. Chem. 269, 14661-14665; Plowman, G. D., Green, J. M., Culouscou, J. -M., Carlton, G. W., Rothwell, V. M., and Buckley, W. (1993) Nature 366, 473-475). Using the Cytosensor(R) to measure the extracellular acidification rate, we have examined the effects of recombinant human heregulin-alpha on three mammary carcinoma cell lines expressing HER2 (MDA-MB-453, SK-BR-3, and MCF-7), an ovarian carcinoma cell line expressing HERB (SH-OV-3), and CHO-K1 and 293-EBNA cells stably transfected with HERB. By reverse transcription polymerase chain reaction and Western blotting, we found that the breast cells also express HER3 and that the ovarian line co-expresses the HER4 message. A dramatic increase in the acidification rate was observed for the mammary carcinoma cells co-expressing high levels of HERS and HER3. In contrast, the ovarian cells expressing high levels of HERB and low levels of HER4 or CHO-K1 and 293-EBNA cells expressing HERB alone were not responsive to heregulin. When these same transfected cells were exposed to monoclonal anti-HER2 antibody followed by anti-IgG to cause aggregation of the HERB molecules, an increase in the acidification rate was observed, indicating coupling of transfected HERB to the signal transduction pathway. Transfection of HER2 into MCF-7 cells, on the other hand, gave 4-fold enhanced acidification responses. These data, together with the previously reported high affinity heregulin binding and activation of tyrosine phosphorylation in HERB and HER3 co-transfected cells support the role of HERB and HER3 as components of the heregulin receptor in breast cells.	MOLEC DEVICES CORP,SUNNYVALE,CA 94089; BERLEX BIOSCI,RICHMOND,CA 94804									AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHEN SDH, 1994, FASEB J, V8, P668; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCONNELL HM, 1993, SCIENCE, V257, P1906; NAG B, 1992, J IMMUNOL, V148, P2040; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	32	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22608	22613		10.1074/jbc.270.38.22608	http://dx.doi.org/10.1074/jbc.270.38.22608			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673253	hybrid			2022-12-27	WOS:A1995RW31400084
J	DOBROWSKY, RT; JENKINS, GM; HANNUN, YA				DOBROWSKY, RT; JENKINS, GM; HANNUN, YA			NEUROTROPHINS INDUCE SPHINGOMYELIN HYDROLYSIS - MODULATION BY COEXPRESSION OF P75(NTR) WITH TRK RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; TUMOR-NECROSIS-FACTOR; BINDING; PROTOONCOGENE; CELLS; DIFFERENTIATION; INTERNALIZATION; IDENTIFICATION	We examined neurotrophin-induced sphingomyelin hydrolysis in cells expressing solely the law affinity neurotrophin receptor, p75(NTR), and in PC12 cells that coexpress p75(NTR) and Trk receptors, Nerve growth factor (NGF), brain-derived neurotrophic factor, neurotrophin-3 (NT-3), and NT-5 stimulated sphingomyelin hydrolysis with similar kinetics in p75(NTR)-NIH-3T3 cells, Although brain-derived neurotrophic factor (10 ng/ml) was slightly more potent than NGF at inducing sphingomyelin hydrolysis, NT-3 and NT-5 induced significant hydrolysis (30-35%) at 0.1 to 1 ng/ml in p75(NTR)-NIH-3T3 cells, NT-3 did not induce sphingomyelin hydrolysis in Trk C-NIH-3T3 cells nor in cells expressing a mutated p75(NTR) containing a 57-amino acid cytoplasmic deletion, thus demonstrating the role of p75(NTR) in this signal transduction pathway, In p75(NTR)-NIH-3T3 cells, neurotrophin-induced sphingomyelin hydrolysis 1) localized to an internal pool of sphingomyelin, 2) was not a consequence of receptor internalization, and 3) showed no specificity with respect to the molecular species of sphingomyelin hydrolyzed, In contrast to cells expressing solely p75(NTR), NGF (100 ng/ml) did not induce sphingomyelin hydrolysis in PC12 cells, Interestingly, NT-3 (10 ng/ml) induced the same extent of sphingomyelin hydrolysis in PC12 cells as was apparent in p75(NTR)-NIH-3T3 cells. However, in the presence of NGF, NT-3 was unable to induce sphingomyelin hydrolysis, raising the possibility that Trk was modulating p75(NTR)-dependent sphingomyelin hydrolysis, Inhibition of Trk tyrosine kinase activity with 200 nM K252a enabled both NGF and NT-3 in the presence of NGF to induce sphingomyelin hydrolysis, These data support that p75(NTR) serves as a common signaling receptor for neurotrophins through induction of sphingomyelin hydrolysis and that crosstalk pathways exist between Trk and p75(NTR)-dependent signaling pathways.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BARDE YA, 1983, EMBO J, V1, P549; BARKER PA, 1994, J BIOL CHEM, V269, P30645; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BERG MM, 1992, J BIOL CHEM, V267, P13; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; FEINSTEIN DL, 1990, FEBS LETT, V272, P7, DOI 10.1016/0014-5793(90)80437-N; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HANNUM YA, 1994, BIOCH BIOPYYS ACTA, V1221, P54; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JUNGALWALA FB, 1979, J LIPID RES, V20, P579; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LOEB DM, 1994, J BIOL CHEM, V269, P8901; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; RYDEN M, 1995, EMBO J, V14, P1979, DOI 10.1002/j.1460-2075.1995.tb07190.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SZEBERENYI J, 1994, BBA-MOL CELL RES, V1222, P187, DOI 10.1016/0167-4889(94)90168-6; TAMURA HO, 1994, TOXICON, V32, P629, DOI 10.1016/0041-0101(94)90211-9; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VERDI JM, 1994, NEURON, V13, P733	63	216	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22135	22142		10.1074/jbc.270.38.22135	http://dx.doi.org/10.1074/jbc.270.38.22135			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673191	hybrid			2022-12-27	WOS:A1995RW31400015
J	SAKURAI, T; HELL, JW; WOPPMANN, A; MILJANICH, GP; CATTERALL, WA				SAKURAI, T; HELL, JW; WOPPMANN, A; MILJANICH, GP; CATTERALL, WA			IMMUNOCHEMICAL IDENTIFICATION AND DIFFERENTIAL PHOSPHORYLATION OF ALTERNATIVELY SPLICED FORMS OF THE ALPHA(1A) SUBUNIT OF BRAIN CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CENTRAL-NERVOUS-SYSTEM; NEURONAL CLASS-C; OMEGA-AGA-IVA; 2 SIZE FORMS; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; CA2+ CHANNELS; BETA-SUBUNIT; ALPHA-1 SUBUNIT	Biochemical properties of the alpha(1) subunits of class A brain calcium channels (alpha(1A)) were examined in adult rat brain membrane fractions using a site-directed antipeptide antibody (anti-CNA3) specific for alpha(1A). Anti-CNA3 specifically immunoprecipitated high affinity receptor sites for omega-conotoxin MVIIC (K-d similar to 100 pM), but not receptor sites for the dihydropyridine isradipine or for omega-conotoxin GVIA. In immunoblotting and immunoprecipitation experiments, anti-CNA3 recognized at least two distinct immunoreactive alpha(1A) polypeptides, a major form with an apparent molecular mass of 190 kDa and a minor, full-length form with an apparent molecular mass of 220 kDa. The 220- and 190-kDa alpha(1A) polypeptides were also specifically recognized by both anti-BI-Nt and anti-HI-1-Ct antibodies, which are directed against the NH2- and COOH-terminal ends of alpha(1A) predicted from cDNA sequence, respectively. These data indicate that the predicted NH2 and COOH termini are present in both size forms and therefore that these isoforms of alpha(1A) are created by alternative RNA splicing rather than post-translational proteolytic processing of the NH2 or COOH termini. The 220-kDa form was phosphorylated preferentially by cAMP-dependent protein kinase, whereas protein kinase C and cGMP-dependent protein kinase preferentially phosphorylated the 190-kDa form. Our results identify at least two distinct alpha(1A) subunits with different molecular mass, demonstrate that they may result from alternative mRNA splicing, and suggest that they may be differentially regulated by protein phosphorylation.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; NEUREX CORP,MENLO PK,CA 94025	University of Washington; University of Washington Seattle			Hell, Johannes W./P-5085-2019		NINDS NIH HHS [NS22625] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022625] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BOWERSOX SS, 1995, IN PRESS J PHARM EXP; BROWN AM, 1994, J PHYSIOL-LONDON, V475, P197, DOI 10.1113/jphysiol.1994.sp020061; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CATTERALL WA, 1994, CELLULAR MOL MECHANI, P275; COPPOLA T, 1994, FEBS LETT, V338, P1, DOI 10.1016/0014-5793(94)80105-3; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; FOURNIER F, 1993, FEBS LETT, V317, P118, DOI 10.1016/0014-5793(93)81504-S; FOURNIER F, 1993, PFLUG ARCH EUR J PHY, V423, P173, DOI 10.1007/BF00374391; FUJITA Y, 1993, NEURON, V10, P585, DOI 10.1016/0896-6273(93)90162-K; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; HELL JW, 1994, J BIOL CHEM, V269, P7390; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HELL JW, 1993, J BIOL CHEM, V268, P19451; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1993, NEURON, V10, P889, DOI 10.1016/0896-6273(93)90204-5; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOGUL DJ, 1993, NEURON, V10, P327, DOI 10.1016/0896-6273(93)90322-I; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OUSLEY AH, 1994, P NATL ACAD SCI USA, V91, P12263, DOI 10.1073/pnas.91.25.12263; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; RANDALL A, 1995, J NEUROSCI, V15, P2995; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; REGAN LJ, 1991, J NEUROSCI, V11, P2259; REGEHR WG, 1994, NEURON, V12, P605, DOI 10.1016/0896-6273(94)90216-X; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SOONG TW, 1994, 24TH SOC NEUR, V20; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEA A, 1994, SOC NEUR ABSTR, V20; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; Swartz K. J., 1993, Society for Neuroscience Abstracts, V19, P1478; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WESTENBROEK RE, 1995, IN PRESS J NEUROSCI; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; WOPPMANN A, 1994, MOL CELL NEUROSCI, V5, P350, DOI 10.1006/mcne.1994.1042; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	83	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21234	21242		10.1074/jbc.270.36.21234	http://dx.doi.org/10.1074/jbc.270.36.21234			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673157	hybrid			2022-12-27	WOS:A1995RU05400057
J	SOHN, RH; CHEN, J; KOBLAN, KS; BRAY, PF; GOLDSCHMIDTCLERMONT, PJ				SOHN, RH; CHEN, J; KOBLAN, KS; BRAY, PF; GOLDSCHMIDTCLERMONT, PJ			LOCALIZATION OF A BINDING-SITE FOR PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE ON HUMAN PROFILIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND ADENOSINE 5'-TRIPHOSPHATE; ACANTHAMOEBA PROFILIN; PHOSPHOLIPASE-C; PHOSPHOINOSITIDE-BINDING; ACTIN POLYMERIZATION; HUMAN PLATELET; PROFILACTIN; EXCHANGE; SEQUENCE; CELLS	Profilin is a small 12-15-kDa actin-binding protein, which in eukaryotic organisms is ubiquitous and necessary for normal cell growth and function. Although profilin's interactions with its three known ligands (actin monomers, phosphatidylinositol 4,5-bisphosphate (PIP2), and poly-L-proline (PLP)) have been well characterized in vitro, its precise role in cells remains largely unknown. By binding to clusters of PIP2, profilin is able to inhibit the hydrolysis of PIP2 by phospholipase C gamma 1 (PLC gamma 1). This ability is the result of profilin's affinity for PIP2, but the specific residues of profilin's amino acid sequence involved in the binding of PIP2 are not known. Using site-directed mutagenesis, we sought to localize regions of profilin important for this interaction by generating the following mutants of human profilin (named according to the wild-type amino acid altered, its position, and the amino acid substituted in its place): Y6F, D8A, L10R, K25Q, K53I, R74L, R88L, R88L/K90E, H119D, G121D, and K125Q. With the exception of L10R, all of the mutants were successfully expressed in Escherichia coli and purified by affinity chromatography on PLP-Sepharose. Only Y6F and K25Q demonstrated moderately less stringent binding to PLP, indicating that most of the mutations did not induce marked alterations of profilin's structure. When tested for their relative abilities to inhibit the hydrolysis of PIP2 by PLC gamma 1, most of the mutants were indistinguishable from wild-type profilin. Exceptions included D8A, which demonstrated increased inhibition of PLC gamma 1, and R88L, which demonstrated decreased inhibition of PLC gamma 1. To assess the importance of the region surrounding residue 88 of human profilin, three synthetic decapeptides selected to correspond to non-overlapping stretches of the human profilin sequence were tested for their abilities to inhibit PLC gamma 1. We found that only the decapeptide that matched the peptide stretch centered around residue 88 was able to inhibit PLC gamma 1 activity substantially and was able to do so at nearly wild-type profilin levels. Taken together with the finding that mutating residue 88 resulted in decreased inhibition of PLC gamma 1 activity, these data provide strong evidence that this region of human profilin represents an important binding site for PIP2.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DIV HEMATOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANAT & CELL BIOL, BALTIMORE, MD 21287 USA; MERCK RES LABS, DEPT CANC RES, W POINT, PA 19486 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Merck & Company								ARCHER SJ, 1994, FEBS LETT, V337, P145, DOI 10.1016/0014-5793(94)80262-9; BALASUBRAMANIAN MK, 1994, J CELL BIOL, V125, P1289, DOI 10.1083/jcb.125.6.1289; BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P6010, DOI 10.1021/bi00440a043; BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FEDOROV AA, 1994, P NATL ACAD SCI USA, V91, P8636, DOI 10.1073/pnas.91.18.8636; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; GIULIANO KA, 1994, J CELL BIOL, V124, P971, DOI 10.1083/jcb.124.6.971; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KOBLAN KS, 1995, BIOCHEM J, V305, P745, DOI 10.1042/bj3050745; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MACHESKY LM, 1990, CELL REGUL, V1, P937, DOI 10.1091/mbc.1.12.937; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MALM B, 1983, J MUSCLE RES CELL M, V4, P569, DOI 10.1007/BF00712116; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; POLLARD TD, 1991, CELL MOTIL CYTOSKEL, V20, P169, DOI 10.1002/cm.970200209; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SOHN RH, 1994, BIOESSAYS, V16, P465, DOI 10.1002/bies.950160705; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TOBACMAN LS, 1982, J BIOL CHEM, V257, P4166; TSENG PCH, 1984, J CELL BIOL, V98, P214, DOI 10.1083/jcb.98.1.214; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; VINSON VK, 1993, J CELL BIOL, V122, P1277, DOI 10.1083/jcb.122.6.1277; WAECHTER F, 1975, EUR J BIOCHEM, V57, P453, DOI 10.1111/j.1432-1033.1975.tb02320.x; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1992, J BIOL CHEM, V267, P14616	48	99	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21114	21120		10.1074/jbc.270.36.21114	http://dx.doi.org/10.1074/jbc.270.36.21114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673143	hybrid			2022-12-27	WOS:A1995RU05400041
J	MARSDEN, PA; HENG, HHQ; SCHERER, SW; STEWART, RJ; HALL, AV; SHI, XM; TSUI, LC; SCHAPPERT, KT				MARSDEN, PA; HENG, HHQ; SCHERER, SW; STEWART, RJ; HALL, AV; SHI, XM; TSUI, LC; SCHAPPERT, KT			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE HUMAN CONSTITUTIVE ENDOTHELIAL NITRIC-OXIDE SYNTHASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; MOLECULAR-CLONING; BINDING PROTEIN; RECEPTOR GENE; HUMAN DNA; CYTOCHROME-P-450 REDUCTASE; TRANSCRIPTIONAL REGULATION; PREPROENDOTHELIN-1 GENE; SYNERGISTIC ACTIVATION; NUCLEOTIDE-SEQUENCE	Endothelial nitric oxide (NO) synthase is a unique NO synthase isoform that is expressed constitutively by vascular endothelium both in vivo and in vitro and is believed essential to local vascular homeostasis. This calcium/calmodulin-dependent isoform is distinct from neuronal NO synthase. Genomic clones encoding the human endothelial NO synthase were isolated and the structural organization of the gene was determined. The gene contains 26 exons spanning almost-equal-to 21 kilobases of genomic DNA, encodes a messenger RNA of 4052 nucleotides, and is present as a single copy in the haploid human genome. Characterization of 5'-flanking genomic regions indicates that the endothelial NO synthase promoter is ''TATA-less'' and exhibits proximal promoter elements consistent with a constitutively expressed gene that is found in endothelial cells, namely Sp1 and GATA motifs. The 5'-flanking region contains putative AP-1, AP-2, NF-1, heavy metal, acute-phase response shear stress, and sterol-regulatory cis-elements. The human endothelial NO synthase gene was assigned to the 7q35 --> 7q36 region of chromosome 7 by Southern blot hybridization of human-rodent somatic cell hybrid lines and fluorescence in situ hybridization, whereas human neuronal NO synthase localized to the 12q24.2 region of chromosome 12.	UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	MARSDEN, PA (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,DIV RENAL,TORONTO M5S 1A8,ONTARIO,CANADA.		Scherer, Stephen W./B-3785-2013; Tsui, Lap-chee/A-1081-2010; Marsden, Philip A/B-1441-2012	Scherer, Stephen W./0000-0002-8326-1999; 				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARAKI E, 1991, J BIOL CHEM, V266, P3944; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; ECONOMOU EP, 1990, P NATL ACAD SCI USA, V87, P2951, DOI 10.1073/pnas.87.8.2951; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE A, 1989, J BIOL CHEM, V264, P14954; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JONES KA, 1985, CELL, V42, P5559; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO J, 1992, GENOMICS, V14, P802, DOI 10.1016/S0888-7543(05)80192-2; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE ME, 1991, J BIOL CHEM, V266, P16188; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PENNY LA, 1991, GENOMICS, V11, P974, DOI 10.1016/0888-7543(91)90022-7; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHERER SW, 1991, CYTOGENET CELL GENET, V56, P176, DOI 10.1159/000133081; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHARP S, 1981, P NATL ACAD SCI-BIOL, V78, P6657, DOI 10.1073/pnas.78.11.6657; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEPHARD EA, 1989, ANN HUM GENET, V53, P291, DOI 10.1111/j.1469-1809.1989.tb01798.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH MW, 1988, J MOL EVOL, V27, P45, DOI 10.1007/BF02099729; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TSAI S, 1989, NATURE, V339, P448; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UPHOLT WB, 1986, P NATL ACAD SCI USA, V83, P2325, DOI 10.1073/pnas.83.8.2325; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZULIANI G, 1990, AM J HUM GENET, V46, P963	88	761	804	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17478	17488						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688726				2022-12-27	WOS:A1993LQ98800087
J	CROVELLO, CS; FURIE, BC; FURIE, B				CROVELLO, CS; FURIE, BC; FURIE, B			RAPID PHOSPHORYLATION AND SELECTIVE DEPHOSPHORYLATION OF P-SELECTIN ACCOMPANIES PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GRANULE MEMBRANE-PROTEIN; LYMPHOCYTE HOMING RECEPTOR; WEIBEL-PALADE BODIES; CELL-CYCLE; ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIIA; PLASMA-MEMBRANE; ADHESION; THROMBIN; GMP-140	P-selectin, a receptor for neutrophils and monocytes, is an adhesion molecule on the surface of activated platelets that resides in the alpha granule membrane of unstimulated platelets. To determine whether phosphorylation of P-selectin might accompany platelet activation, P-selectin in resting and thrombin-stimulated platelets labeled with o-[P-32]phosphate was immunoprecipitated with the monoclonal antibody AC1.2 directed against P-selectin. SDS-gel electrophoresis of the immunoprecipitates indicated about 10-20-fold higher levels of P-32 incorporated into P-selectin from thrombin-activated platelets than in resting platelets, although both sets of platelets contained equivalent amounts of P-selectin. The lower limits of the molar ratio of phosphate to P-selectin in activated platelets is about 0.52 +/- 0.08. Other platelet agonists, including the thrombin receptor peptide (SFLLR), epinephrine, ADP, and collagen, similarly stimulated phosphorylation of P-selectin. The kinetics of P-selectin phosphorylation following thrombin stimulation was rapid, with maximum phosphorylation observed at 15-30 s. Phosphoamino acid analysis of the phosphorylated P-selectin revealed the rapid synthesis of phosphoserine, phosphothreonine, and phosphotyrosine, but 80-90% of the phosphotyrosine and phosphothreonine disappeared within 5 min of platelet activation while the maximal level of phosphoserine remained stable. The rapid phosphorylation and selective dephosphorylation of specific amino acids in P-selectin following platelet activation may be important for P-selectin function and signal transduction within platelets.	TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts University; Tufts University	CROVELLO, CS (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.				NHLBI NIH HHS [HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; Brass L F, 1991, Prog Hemost Thromb, V10, P127; BRYCKAERT MC, 1989, J BIOL CHEM, V264, P4336; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CARTY DJ, 1986, BLOOD, V67, P1738; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DIDIER M, 1992, MOL BIOL CELL, V3, P309; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KROLL MH, 1989, BLOOD, V74, P1181; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PARISE LV, 1990, BLOOD, V75, P2363; SCOTT PC, 1991, IMMUNOGENETICS, V34, P69; SHAI SY, 1990, BIOCHEM BIOPH RES CO, V167, P1128, DOI 10.1016/0006-291X(90)90640-9; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILSON DB, 1985, J BIOL CHEM, V260, P1046	41	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14590	14593						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686899				2022-12-27	WOS:A1993LL75900011
J	DEPINTO, V; ALJAMAL, JA; PALMIERI, F				DEPINTO, V; ALJAMAL, JA; PALMIERI, F			LOCATION OF THE DICYCLOHEXYLCARBODIIMIDE-REACTIVE GLUTAMATE RESIDUE IN THE BOVINE HEART MITOCHONDRIAL PORIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOKINASE-BINDING PROTEIN; RAT-LIVER MITOCHONDRIA; OUTER-MEMBRANE; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; ENZYMES; CHANNEL; ATPASE; VDAC; PURIFICATION	The mitochondrial porin or VDAC (Voltage-Dependent Anion Channel), the pore-forming structure responsible for the high permeability of the outer mitochondrial membrane, was found to be one of only three mitochondrial proteins bound by [C-14]dicyclohexylcarbodiimide (DCCD) at low dosages (1.5 nmol/mg of Mitochondrial porin) (De Pinto, V., Tommasino, M., Benz, R., and Palmieri, F. (1985) Biochim. Biophys. Acta 813, 230-242). Treatment of intact mitochondria with DCCD results in the inhibition of their ability to binding hexokinase (Nakashima, R. A., Mangan, P. S., Colombini, M., and Pedersen, P. L. (1986) Biochemistry 25, 1015-1021). In the present study, mitochondrial porin was purified from [C-14]DCCD-labeled mitochondria. The purified labeled porin was treated with the cleavage reagent CNBr and with the endoproteases trypsin and V8 from Staphylococcus aureus and blotted to polyvinylidene difluoride membrane. The transferred peptides were detected with Coomassie Blue dye, excised, and sequenced. The sequences of several labeled and unlabeled peptides were obtained and then overlapped. The region containing the [C-14] DCCD radioactivity was limited to 50 amino acid residues and completely sequenced. Covalently incorporated [C-14]DCCD was exclusively released at the position corresponding to glutamate 72. The DCCD-reactive residue is located in the 4th of 16 predicted transmembrane amphipathic beta-strands. When the sequence surrounding the DCCD site was compared to those surrounding the DCCD-reactive residue of other membrane proteins, no homology was apparent.			DEPINTO, V (corresponding author), UNIV BARI,DEPT PHARMACO BIOL,BIOCHEM & MOLEC BIOL LAB,I-70125 BARI,ITALY.		De Pinto, Vito/AAC-2634-2019	De Pinto, Vito/0000-0001-5513-2906				ARORA KK, 1988, J BIOL CHEM, V263, P17422; AZZI A, 1984, BIOCHIM BIOPHYS ACTA, V768, P209, DOI 10.1016/0304-4173(84)90017-X; BEECHEY RB, 1967, BIOCHEMISTRY-US, V6, P3867, DOI 10.1021/bi00864a033; Bessman S P, 1980, Curr Top Cell Regul, V16, P55; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYYDYSON E, 1992, NATO ARW MOL BIOL MI; DEPINTO V, 1991, EUR J BIOCHEM, V202, P903; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; DEPINTO V, 1985, BIOCHIM BIOPHYS ACTA, V813, P230; FELGNER PL, 1977, ARCH BIOCHEM BIOPHYS, V182, P282, DOI 10.1016/0003-9861(77)90309-5; FELGNER PL, 1979, J BIOL CHEM, V254, P4946; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HALTIA T, 1991, EMBO J, V10, P2015, DOI 10.1002/j.1460-2075.1991.tb07731.x; HOUSTEK J, 1981, BIOCHIM BIOPHYS ACTA, V634, P331, DOI 10.1016/0005-2728(81)90151-1; KANAZAWA H, 1982, BIOCHEM BIOPH RES CO, V105, P1257, DOI 10.1016/0006-291X(82)90922-6; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KROGER A, 1966, BIOCHEM Z, V344, P317; KUSOV YY, 1978, ANAL BIOCHEM, V88, P256, DOI 10.1016/0003-2697(78)90417-7; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; RENTHAL R, 1985, BIOCHEMISTRY-US, V24, P4275, DOI 10.1021/bi00337a004; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHILTZ E, 1991, EUR J BIOCHEM, V199, P587, DOI 10.1111/j.1432-1033.1991.tb16158.x; SEBALD W, 1979, FUNCTION MOL ASPECTS, P63; SOLIOZ M, 1984, TRENDS BIOCHEM SCI, V9, P309, DOI 10.1016/0968-0004(84)90298-6; THOMAS L, 1991, J STRUCT BIOL, V106, P161, DOI 10.1016/1047-8477(91)90085-B; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	34	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12977	12982						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685355				2022-12-27	WOS:A1993LG65800108
J	GODSON, C; BELL, KS; INSEL, PA				GODSON, C; BELL, KS; INSEL, PA			INHIBITION OF EXPRESSION OF PROTEIN KINASE-C-ALPHA BY ANTISENSE CDNA INHIBITS PHORBOL ESTER-MEDIATED ARACHIDONATE RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; CANINE KIDNEY-CELLS; RAT FIBROBLASTS; DOWN-REGULATION; ACTIVATION; ISOZYMES; RECEPTOR; CLONING; CA-2+; FORMS	A major unresolved issue in the area of signal transduction relates to the role of particular isoforms of protein kinase C (PKC) in mediating cellular responses subsequent to activation of that enzyme. We have addressed this issue by the use of antisense technology. We have stably transfected Madin-Darby canine kidney cells with antisense PKCalpha, PKCbeta, or both PKCalpha and -beta cDNAs. The transfected cDNA was integrated and expressed. We have isolated cells in which expression of PKCalpha is inhibited. In cells transfected with antisense PKCalpha or both PKCalpha and -beta, phorbol ester-stimulated release of arachidonate and its metabolites was inhibited, whereas in cells transfected with antisense PKCbeta cDNA alone, phorbol ester-stimulated arachidonate release was not significantly different from control cells. We thus demonstrate the use of a novel technique to inhibit PKC isoform expression. We show that inhibition of expression of PKCalpha causes a loss in phospholipase A2-mediated arachidonate release. Antisense-inhibited expression of PKC isoforms may provide a useful approach to define additional functions of particular PKC isoforms.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				Godson, Catherine/0000-0003-0655-1041	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35018] Funding Source: Medline; NIGMS NIH HHS [GM 31987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOVENTRE JV, 1990, J BIOL CHEM, V266, P4934; BRICKGHANNAM C, 1991, J BIOL CHEM, V266, P24169; BURCH RM, 1986, P NATL ACAD SCI USA, V83, P7201, DOI 10.1073/pnas.83.19.7201; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; GODSON C, 1990, J BIOL CHEM, V265, P8369; GODSON C, 1991, FASEB J, V5, pA834; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; ISAKOV N, 1990, J BIOL CHEM, V265, P2091; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; MASLIAH E, 1990, J NEUROSCI, V10, P2113; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; TOQUI L, 1986, NATURE, V321, P177; WEISS BA, 1991, J BIOL CHEM, V266, P2126; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	36	66	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11946	11950						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685027				2022-12-27	WOS:A1993LF28400073
J	MASUDA, S; NAGAO, M; TAKAHATA, K; KONISHI, Y; GALLYAS, F; TABIRA, T; SASAKI, R				MASUDA, S; NAGAO, M; TAKAHATA, K; KONISHI, Y; GALLYAS, F; TABIRA, T; SASAKI, R			FUNCTIONAL ERYTHROPOIETIN RECEPTOR OF THE CELLS WITH NEURAL CHARACTERISTICS - COMPARISON WITH RECEPTOR PROPERTIES OF ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; RECOMBINANT HUMAN ERYTHROPOIETIN; NERVE GROWTH-FACTOR; BETA-CHAIN; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; GENE-EXPRESSION; ALPHA-CHAIN; GM-CSF; INVITRO	Radioiodinated erythropoietin (Epo) was bound specifically to the cells of two non-erythroid clonal lines, PC12 and SN6, which expressed neuronal characteristics. The binding was time-, cell number-, and dose-dependent and was reversible. Although the cloned Epo receptor from PC12 cells (derived from rat adrenal medulla) was identical to that from rat erythroid cells, significant differences in the ligand binding properties between two cell lineages were found; 1) PC12 cells had a single class of binding sites with very low affinity (K(d) = 16 nM), whereas erythroid cells had two classes of binding sites with different affinities (K(d) = 95 pM for high affinity sites and 1.9 nM for low affinity sites), and 2) cross-linking experiments revealed one cross-linked product of 105 kDa for PC12 cells and two products of 140 and 120 kDa for erythroid cells. Taken together with additional results, the presence of a putative accessory protein(s) that may alter the ligand binding affinity through interaction with Epo receptor is discussed. The binding of Epo to PC12 cells caused a rapid increase in the cytosolic concentration of free calcium. The presence of EGTA had no effect on the Epo binding but completely inhibited the calcium increase, indicating that Epo stimulated the calcium influx from outside of the cells. The addition of Epo to the culture media of PC12 cells elevated the intracellular concentrations of monoamines.	KYOTO UNIV, FAC AGR, DEPT FOOD SCI & TECHNOL, KYOTO 606, JAPAN; NATL INST NEUROSCI, NATL CTR NEUROL & PSYCHIAT, DIV DEMYELINATING DIS & AGING, TOKYO 187, JAPAN; OKAYAMA UNIV, FAC AGR, DEPT BIORESOURCES CHEM, OKAYAMA 700, JAPAN	Kyoto University; National Center for Neurology & Psychiatry - Japan; Okayama University			Gallyas, Ferenc/C-2272-2012	Gallyas, Ferenc/0000-0002-1906-4333				ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ATKINS HL, 1991, BLOOD, V77, P2577; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALKER D, 1989, J NEUROCHEM, V52, P38; CAROTHERS AM, 1989, BIOTECHNIQUES, V7, P494; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V186, P1236, DOI 10.1016/S0006-291X(05)81538-4; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V184, P485, DOI 10.1016/0006-291X(92)91220-K; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; GOTO M, 1989, BLOOD, V74, P1415; GOTO M, 1988, BIO-TECHNOL, V6, P67, DOI 10.1038/nbt0188-67; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMMOND DN, 1986, SCIENCE, V234, P1237, DOI 10.1126/science.3775382; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; IKURA K, 1984, AGR BIOL CHEM TOKYO, V48, P1835, DOI 10.1080/00021369.1984.10866399; IMAGAWA S, 1989, BLOOD, V73, P1452; ISHIBASHI T, 1987, J CLIN INVEST, V79, P286, DOI 10.1172/JCI112796; JONES SS, 1990, BLOOD, V76, P31; KIMATA H, 1991, CLIN EXP IMMUNOL, V85, P151; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KONISHI Y, 1993, IN PRESS BRAIN RES; KRANTZ SB, 1991, BLOOD, V77, P419; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; MASUDA S, 1992, FEBS LETT, V298, P169, DOI 10.1016/0014-5793(92)80048-L; MAYEUX P, 1987, J BIOL CHEM, V262, P13985; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; NAGAO M, 1993, IN PRESS BLOOD; OGAWA M, 1984, NATURE, V307, P66, DOI 10.1038/307066a0; OKANO M, 1992, J NUTR, V122, P1376, DOI 10.1093/jn/122.7.1376; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI R, 1987, EUR J BIOCHEM, V168, P43, DOI 10.1111/j.1432-1033.1987.tb13384.x; SAWYER ST, 1989, BLOOD, V74, P103; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; TABOR S, 1989, J BIOL CHEM, V264, P6447; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TSUDA E, 1990, EUR J BIOCHEM, V188, P405, DOI 10.1111/j.1432-1033.1990.tb15417.x; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1990, BLOOD, V76, P24; WOGNUM AW, 1990, BLOOD, V76, P697; YAMAGUCHI K, 1991, J BIOL CHEM, V266, P20434; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	60	371	393	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11208	11216						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684373				2022-12-27	WOS:A1993LD46600073
J	KING, MP; ATTARDI, G				KING, MP; ATTARDI, G			POSTTRANSCRIPTIONAL REGULATION OF THE STEADY-STATE LEVELS OF MITOCHONDRIAL TRANSFER-RNAS IN HELA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON-CHOICE PATTERNS; ESCHERICHIA-COLI; RIBOSOMAL-RNA; HEAVY-STRAND; SACCHAROMYCES-CEREVISIAE; RESPECTIVE CODONS; RIBONUCLEIC-ACID; PROTEIN GENES; DNA; YEAST	In human mitochondrial DNA (mtDNA), the tRNA genes are located in three different transcription units that are transcribed at three different rates. To analyze the regulation of tRNA formation by the three transcription units, we have examined the steady-state levels and metabolic properties of the tRNAs of HeLa cell mitochondria. DNA excess hybridization experiments utilizing separated strands of mtDNA and purified tRNA samples from exponential cells long term labeled with [P-32]orthophosphate have revealed a steady-state level of 6 x 10(5) tRNA molecules/cell, with three-fourths being encoded in the H-strand and one-fourth in the L-strand. Hybridization of the tRNAs with a panel of M13 clones of human mtDNA containing, in most cases, single tRNA genes and a quantitation of two-dimensional electrophoretic fractionations of the tRNAs have shown that the steady-state levels of tRNA(Phe) and tRNA(Val) are two to three times higher than the average level of the other H-strand-encoded tRNAs and three to four times higher than the average level of the L-strand-encoded tRNAs. Similar experiments carried out with tRNAs isolated from cells labeled with very short pulses of [5-H-3]uridine have indicated that the rates of formation of the individual tRNA species are proportional to their steady-state amounts. Therefore, the approximately 25-fold higher rate of transcription of the tRNA(Phe) and tRNA(Val) genes relative to the other H-strand tRNA genes and the 10-16-fold higher rate of transcription of the L-strand tRNA genes relative to the H-strand tRNA genes are not reflected in the steady-state levels or the rates of formation of the corresponding tRNAs. A comparison of the steady-state levels of the individual tRNAs with the corresponding codon usage for protein synthesis, as determined from the DNA sequence and the rates of synthesis of the various polypeptides, has not revealed any significant correlation between the two parameters.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM11726, GM07616] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007616] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONI Y, 1971, P NATL ACAD SCI USA, V68, P1757, DOI 10.1073/pnas.68.8.1757; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATKINS JF, 1979, CELL, V18, P1119, DOI 10.1016/0092-8674(79)90225-3; ATTARDI B, 1971, J MOL BIOL, V55, P231, DOI 10.1016/0022-2836(71)90194-X; ATTARDI B, 1969, J MOL BIOL, V44, P47, DOI 10.1016/0022-2836(69)90404-5; ATTARDI G, 1983, METHOD ENZYMOL, V97, P435; ATTARDI G, 1990, BIOCHEM SOC T, V18, P509, DOI 10.1042/bst0180509; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; BOGENHAGEN DF, 1984, CELL, V36, P1105, DOI 10.1016/0092-8674(84)90061-8; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHIA LLSY, 1976, BIOCHIM BIOPHYS ACTA, V425, P49, DOI 10.1016/0005-2787(76)90215-X; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHOMYN A, 1987, CYTOCHROME SYSTEMS M, P145; CHOMYN A, 1992, BECHANISMS BIOENERGE, P483; CREWS S, 1980, CELL, V19, P775, DOI 10.1016/S0092-8674(80)80053-5; DARNELL JE, 1968, BACTERIOL REV, V32, P262, DOI 10.1128/MMBR.32.3.262-290.1968; DEBRUIJN MHL, 1980, NUCLEIC ACIDS RES, V8, P5213, DOI 10.1093/nar/8.22.5213; DENNIS PP, 1974, J BACTERIOL, V119, P270, DOI 10.1128/JB.119.1.270-281.1974; DUBIN DT, 1974, BIOCHIM BIOPHYS ACTA, V340, P269, DOI 10.1016/0005-2787(74)90272-X; DUBIN DT, 1982, J MOL BIOL, V157, P1, DOI 10.1016/0022-2836(82)90510-1; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GILLESPIE D, 1973, BIOCHEM GENET, V10, P175, DOI 10.1007/BF00485764; GOUY M, 1980, FEBS LETT, V115, P151, DOI 10.1016/0014-5793(80)81155-0; IKEMURA T, 1982, COLD SPRING HARB SYM, V47, P1087, DOI 10.1101/SQB.1983.047.01.123; IKEMURA T, 1982, J MOL BIOL, V158, P573, DOI 10.1016/0022-2836(82)90250-9; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; IKEMURA T, 1973, J BIOL CHEM, V248, P5033; JEANTEUR P, 1968, MOL CELL BIOL, V33, P757; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KNIGHT E, 1969, BIOCHEMISTRY-US, V8, P5089, DOI 10.1021/bi00840a062; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; LABBE D, 1990, J BIOL CHEM, V265, P2988; LIN JP, 1986, GENE, V49, P383, DOI 10.1016/0378-1119(86)90375-6; LYNCH DC, 1976, J MOL BIOL, V102, P125, DOI 10.1016/0022-2836(76)90077-2; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195; MORAES CT, 1991, CURRENT NEUROLOGY, V11, P83; MUELLER DM, 1986, J BIOL CHEM, V261, P1816; MURPHY WI, 1977, BIOCHEM BIOPH RES CO, V74, P291, DOI 10.1016/0006-291X(77)91407-3; NEIDHARDT FC, 1977, J BACTERIOL, V129, P378, DOI 10.1128/JB.129.1.378-387.1977; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; PURE GA, 1985, J MOL BIOL, V183, P31, DOI 10.1016/0022-2836(85)90278-5; Roe B. A., 1981, RECOMBINANT DNA, P167; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; SPANJAARD RA, 1990, NUCLEIC ACIDS RES, V18, P5031, DOI 10.1093/nar/18.17.5031; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; ULRICH AK, 1991, BIOCHIM BIOPHYS ACTA, V1089, P362, DOI 10.1016/0167-4781(91)90177-N; WALACE DC, 1992, ANN REV BIOCH, V61, P1175; WEISS WA, 1986, J MOL BIOL, V192, P725, DOI 10.1016/0022-2836(86)90024-0; YAMAO F, 1991, NUCLEIC ACIDS RES, V19, P6119, DOI 10.1093/nar/19.22.6119; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOZA BK, 1984, J BIOL CHEM, V259, P3909; ZYLBER E, 1969, J MOL BIOL, V46, P201, DOI 10.1016/0022-2836(69)90067-9	60	97	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10228	10237						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683672				2022-12-27	WOS:A1993LB80000043
J	SCHWALB, DM; HAN, HM; MARINO, M; WARREN, R; PORTER, A; GOH, C; FAIR, WR; DONNER, DB				SCHWALB, DM; HAN, HM; MARINO, M; WARREN, R; PORTER, A; GOH, C; FAIR, WR; DONNER, DB			IDENTIFICATION OF A NEW RECEPTOR SUBTYPE FOR TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-ENDOTHELIAL CELLS; PHASE-I TRIAL; FACTOR-BETA; MOLECULAR-CLONING; FACTOR TNF; LYMPHOTOXIN; EXPRESSION; PURIFICATION; MALIGNANCY; PROTEINS	Two distinct receptors, which bind both tumor necrosis factor-alpha and tumor necrosis factor-beta (TNF-alpha and TNF-beta), have been previously identified and cloned from transformed cells. The present study identifies a novel receptor subtype in normal human liver which binds TNF-alpha but not TNF-beta. TNF-alpha but not TNF-beta competes for I-125-TNF-alpha binding and incorporation into affinity-labeled complexes in human liver plasma membranes (HLPM). Antisera to the cloned receptors competed for I-125-TNF-alpha binding to plasma membranes isolated from various transformed cell lines but not to HLPM. However, mRNAs corresponding in size to both known TNF receptors were detected in liver RNA, making it likely that post-transcriptional modifications account for the TNF-alpha specificity of HLPM. These observations suggest that the effects of TNF-alpha and TNF-beta on some normal tissues may be more distinct than previously realized.	MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,SLOAN KETTERING DIV,NEW YORK,NY 10021; MEM HOSP CANC & ALLIED DIS,UROL SERV,NEW YORK,NY 10021; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore					NATIONAL CANCER INSTITUTE [R01CA044747] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44747] Funding Source: Medline; NIADDK NIH HHS [AM07313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS JS, 1990, J IMMUNOL, V144, P2582; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUDY VC, 1987, J IMMUNOL, V138, P4298; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; GAMM H, 1991, EUR J CANCER, V27, P856, DOI 10.1016/0277-5379(91)90134-Y; HAN HM, 1990, J BIOL CHEM, V265, P18590; HAYAKAWA M, 1991, ARCH BIOCHEM BIOPHYS, V286, P323, DOI 10.1016/0003-9861(91)90047-M; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MEAGER A, 1989, J IMMUNOL METHODS, V116, P1, DOI 10.1016/0022-1759(89)90306-2; MIKI T, 1992, P NATL ACAD SCI USA, V89, P2246; OSTER W, 1987, BLOOD, V70, P1700; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PORTER A G, 1990, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V64, P193, DOI 10.1016/0378-1097(90)90609-T; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEOW HF, 1989, BIO-TECHNOL, V7, P363, DOI 10.1038/nbt0489-363; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STARNES HF, 1987, J CLIN INVEST, V80, P1384, DOI 10.1172/JCI113216; STAUBER GB, 1988, J BIOL CHEM, V263, P19098; STAUBER GB, 1989, J BIOL CHEM, V264, P3573; VILCEK J, 1991, J BIOL CHEM, V266, P7313	22	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9949	9954						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683686				2022-12-27	WOS:A1993LB80000004
J	BRATTON, DL				BRATTON, DL			RELEASE OF PLATELET ACTIVATION FACTOR FROM ACTIVATED NEUTROPHILS - TRANSGLUTAMINASE-DEPENDENT ENHANCEMENT OF TRANSBILAYER MOVEMENT ACROSS THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE-MEMBRANE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CA2+-ENRICHED HUMAN-ERYTHROCYTES; PROTEIN-CATALYZED TRANSFER; PHOSPHOLIPID ASYMMETRY; CROSS-LINKING; PROCOAGULANT ACTIVITY; RABBIT PLATELETS; LIPID ASYMMETRY; FACTOR PAF	Extracellular release of platelet activating factor (PAF) following synthesis in inflammatory cells is variable and modulated by a number of as yet undefined cellular mechanisms. Using human neutrophils loaded with the tritiated, nonmetabolizable PAF analog, 1-O-alkyl-2-N-methylcarbamyl-sn-glycero-3-phosphocholine (C-PAF), extracellular release was studied by techniques involving an albumin extraction method. Further modeling of plasma membrane events in the neutrophil was accomplished using movement across the membrane of erythrocyte ghosts. The data demonstrate that C-PAF release is dependent on cellular activation and is accompanied by alterations in the physical properties of the plasma membrane as measured by enhancement of merocyanine 540 (MC540) staining, as well as by bulk, nonspecific transbilayer movement of endogenous phospholipids as detected by the procoagulant activity of externalized phosphatidylserine (a phospholipid class usually sequestered in the plasma membrane inner leaflet). The finding that competitive inhibitors of transglutaminase significantly inhibited C-PAF release, enhancement of MC540 staining, and externalization of phosphatidylserine, strongly suggest a role for this enzyme in the enhancement of phospholipid transbilayer movement. Furthermore, the data suggest that recycling of C-PAF in the plasma membrane is likewise transglutaminase dependent and limits the net extracellular release of C-PAF which, like liberation of endogenously produced PAF, is dependent on extracellular ''acceptors'' and shown to be albumin concentration- and cell density-dependent.			BRATTON, DL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLAS SK, 1985, BIOCHIM BIOPHYS ACTA, V812, P234, DOI 10.1016/0005-2736(85)90543-7; BANKS JB, 1988, BIOCHIM BIOPHYS ACTA, V961, P48, DOI 10.1016/0005-2760(88)90129-4; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BETZ SJ, 1980, J IMMUNOL, V125, P2749; BETZ SJ, 1980, J IMMUNOL, V125, P2756; BEVERS EM, 1989, BIOCHEMISTRY-US, V28, P2382, DOI 10.1021/bi00432a007; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRATTON DL, 1988, BIOCHIM BIOPHYS ACTA, V941, P76, DOI 10.1016/0005-2736(88)90216-7; BRATTON DL, 1992, J IMMUNOL, V148, P514; BRATTON DL, 1992, IN PRESS HDB IMMUNOP; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; CHAM BE, 1976, J LIPID RES, V17, P176; CHIU D, 1981, BLOOD, V58, P398; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; CLUZEL M, 1989, J IMMUNOL, V143, P3659; CLUZEL M, 1991, BIOCHEM J, V278, P453, DOI 10.1042/bj2780453; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DEVAUX PF, 1988, FEBS LETT, V234, P8, DOI 10.1016/0014-5793(88)81291-2; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; FESUS L, 1984, MOL IMMUNOL, V21, P1161, DOI 10.1016/0161-5890(84)90005-1; FRANCK PFH, 1985, J CLIN INVEST, V75, P183, DOI 10.1172/JCI111672; GERRITSEN WJ, 1980, BIOCHIM BIOPHYS ACTA, V600, P607, DOI 10.1016/0005-2736(80)90464-2; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUNZLER V, 1982, FEBS LETT, V150, P390, DOI 10.1016/0014-5793(82)80774-6; HAEST CWM, 1976, BIOCHIM BIOPHYS ACTA, V436, P353, DOI 10.1016/0005-2736(76)90199-1; HASLETT C, 1985, AM J PATHOL, V119, P101; HENRIKSSON P, 1985, J CLIN INVEST, V76, P528, DOI 10.1172/JCI112002; HENSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127, DOI 10.1016/0005-2736(90)90445-T; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HOMAN R, 1988, BIOCHIM BIOPHYS ACTA, V938, P155, DOI 10.1016/0005-2736(88)90155-1; HOMMA H, 1987, J BIOL CHEM, V262, P10582; KARNOVSKY M, 1961, J BIOL CHEM, V236, P1895; KRAMP W, 1984, CHEM PHYS LIPIDS, V35, P49, DOI 10.1016/0009-3084(84)90032-X; LEYRAVAUD S, 1989, BIOCHIM BIOPHYS ACTA, V1005, P192, DOI 10.1016/0005-2760(89)90187-2; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; LORAND L, 1987, BIOCHEMISTRY-US, V26, P308, DOI 10.1021/bi00375a043; LORAND L, 1983, J BIOL CHEM, V258, P5300; LUDWIG CJ, 1986, ADV INFLAMMAT RES, V11, P111; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; LUMB RH, 1983, BIOCHIM BIOPHYS ACTA, V750, P217, DOI 10.1016/0005-2760(83)90021-8; LYNCH JM, 1986, J IMMUNOL, V137, P2653; Matsumoto M, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P705; MCEVOY L, 1988, J LEUKOCYTE BIOL, V44, P337, DOI 10.1002/jlb.44.5.337; MIDDELKOOP E, 1989, BIOCHIM BIOPHYS ACTA, V981, P151, DOI 10.1016/0005-2736(89)90093-X; MIDDELKOOP E, 1988, BIOCHIM BIOPHYS ACTA, V937, P281, DOI 10.1016/0005-2736(88)90250-7; MOHANDAS N, 1982, J BIOL CHEM, V257, P6537; MURTAUGH MP, 1984, J EXP MED, V159, P114, DOI 10.1084/jem.159.1.114; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; OFLAHERTY JT, 1987, BIOCHEM BIOPH RES CO, V147, P18, DOI 10.1016/S0006-291X(87)80081-5; OWEN RA, 1988, BIOCHIM BIOPHYS ACTA, V968, P220, DOI 10.1016/0167-4889(88)90011-0; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PIACENTINI M, 1986, BIOCHEM J, V234, P435, DOI 10.1042/bj2340435; PUSZKIN EG, 1985, J BIOL CHEM, V260, P6012; RICHES DWH, 1990, J IMMUNOL, V145, P3062; SCHLEGEL RA, 1987, J CELL PHYSIOL, V132, P381, DOI 10.1002/jcp.1041320229; SCHNEIDER E, 1986, BIOCHIM BIOPHYS ACTA, V855, P325, DOI 10.1016/0005-2736(86)90078-7; SCHROFF G, 1981, EUR J IMMUNOL, V11, P637, DOI 10.1002/eji.1830110809; STEWART AG, 1991, IMMUNOLOGY, V72, P206; SUNE A, 1987, BIOCHEMISTRY-US, V26, P2972, DOI 10.1021/bi00385a003; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TOKUMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1044, P91, DOI 10.1016/0005-2760(90)90223-K; TOKUMURA A, 1987, THROMB RES, V47, P51; VALLARI DS, 1990, ARCH BIOCHEM BIOPHYS, V276, P538, DOI 10.1016/0003-9861(90)90756-O; VALONE FH, 1988, J IMMUNOL, V141, P3945; VERHALLEN PFJ, 1988, BIOCHIM BIOPHYS ACTA, V942, P150, DOI 10.1016/0005-2736(88)90284-2; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2	75	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3364	3373						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679111				2022-12-27	WOS:A1993KM16100055
J	MUGA, A; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F; SUREWICZ, WK				MUGA, A; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F; SUREWICZ, WK			PH-DEPENDENT STABILITY AND MEMBRANE INTERACTION OF THE PORE-FORMING DOMAIN OF COLICIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; MITOCHONDRIAL PRECURSOR PROTEIN; C-TERMINAL DOMAIN; PHOSPHOLIPID-VESICLES; PSEUDOMONAS EXOTOXIN; INSERTION; TOXIN; TRANSLOCATION; BINDING; DENATURATION	Thermal stability of the pore-forming domain of colicin A was studied by high sensitivity differential scanning calorimetry and circular dichroism spectroscopy. In the pH range between 8 and 5, the thermal denaturation of the protein in solution occurs at 66-69-degrees-C and is characterized by the calorimetric enthalpy of approximately 90 kcal/M. At pH below 5, there is a rapid pH-dependent destabilization of the pore-forming domain resulting in the lowering of the midpoint denaturation temperature and a decrease in the calorimetric enthalpy of denaturation. Circular dichroism spectra in the near and far ultraviolet show that the thermotropic transition is associated with collapse of the native tertiary structure of the pore-forming domain, although a large proportion of the helical secondary structure remains preserved. The present data indicate some similarity also between acid-induced and temperature-induced denaturation of the pore-forming domain of colicin A. Association of the pore-forming domain with phospholipid vesicles of dioleoylphosphatidylglycerol results in total disappearance of the calorimetric transition, even at pH values as high as 7. Since lipid binding also induces collapse of the near ultraviolet circular dichroism spectrum, these data indicate that interaction with the membrane facilitates a conformational change within the pore-forming domain to a looser (denaturated-like) state. These findings are discussed in relation to the recent model (van der Goot, F. G., Gonzalez-Manas, J. M., Lakey, J. H., Pattus, F. (1991) Nature 354, 408-410) which postulates that a flexible ''molten globule'' state is an intermediate on the pathway to membrane insertion of colicin A.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	National Research Council Canada; European Molecular Biology Laboratory (EMBL)			Muga, Arturo/N-1174-2014	Muga, Arturo/0000-0003-0345-6882; Lakey, Jeremy/0000-0003-4646-9085				CAVARD D, 1979, EUR J BIOCHEM, V96, P519, DOI 10.1111/j.1432-1033.1979.tb13065.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ENDO T, 1989, FEBS LETT, V249, P173, DOI 10.1016/0014-5793(89)80618-0; ENDO T, 1989, J BIOL CHEM, V264, P2951; FARAHBAKHSH ZT, 1989, BIOCHEMISTRY-US, V28, P580, DOI 10.1021/bi00428a025; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LOHNER K, 1991, BIOCHEMISTRY-US, V30, P6620, DOI 10.1021/bi00240a035; MARTINEZ MC, 1983, EMBO J, V2, P1501, DOI 10.1002/j.1460-2075.1983.tb01614.x; MASSOTTE D, 1989, BIOCHEMISTRY-US, V28, P7713, DOI 10.1021/bi00445a029; MENESTRINA G, 1989, BIOPHYS J, V55, P393, DOI 10.1016/S0006-3495(89)82833-4; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; PAIN R, 1991, NATURE, V354, P353, DOI 10.1038/354353a0; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PATTUS F, 1990, EXPERIENTIA, V46, P180; PATTUS F, 1983, BIOCHEMISTRY-US, V22, P5698, DOI 10.1021/bi00294a003; RAMSAY G, 1989, BIOCHEMISTRY-US, V28, P529, DOI 10.1021/bi00428a018; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; TUCKER AD, 1986, J MOL BIOL, V190, P133, DOI 10.1016/0022-2836(86)90084-7; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	28	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1553	1557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678407				2022-12-27	WOS:A1993KH62000011
J	ZHU, GC; DECKER, SJ; MAYER, BJ; SALTIEL, AR				ZHU, GC; DECKER, SJ; MAYER, BJ; SALTIEL, AR			DIRECT ANALYSIS OF THE BINDING OF THE ABL SRC HOMOLOGY-2 DOMAIN TO THE ACTIVATED EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC SIGNALING PROTEINS; TYROSINE KINASES; PHOSPHOLIPASE-C; PHILADELPHIA-CHROMOSOME; STRUCTURAL SIMILARITY; ONCOGENIC ACTIVATION; SEQUENCE SIMILARITY; NUCLEOTIDE-SEQUENCE; REGULATORY DOMAIN; SH2 DOMAINS	Src homology regions 2 (SH2) and 3 (SH3) are noncatalytic domains that are conserved among several proteins implicated in the regulation of cell proliferation. Using bacterially expressed fusion proteins containing the SH2 domain of the abl tyrosine kinase, we have quantitated the binding of these domains to the activated epidermal growth factor (EGF) receptor (EGFR). A S-35-labeled abl SH2 fusion protein binds to the human EGFR immunoprecipitated from EGF-treated NIH3T3 cells that overexpress the receptor. This binding is totally dependent on the pretreatment of cells with EGF. The interaction is rapid, reaching 50% of maximum within 1 min, and attaining apparent equilibrium by 10 min. Dissociation of the complex is biphasic with a rapidly dissociating component (t1/2 of less than 1 min), as well as a slowly dissociable component. The S-35-labeled abl SH2 fusion protein specifically binds to the EGFR in a saturable manner and is differentially inhibited by unlabeled fusion proteins containing SH2 domains from phospholipase C, the p85 subunit of phosphatidylinositol-3 kinase, and the GTPase activation protein of ras. To identify residues critical for abl SH2-EGFR binding, six point mutants were constructed in the highly conserved FLVRES motif. Three mutants (V170L, E172Q, and E174Q) display binding affinities similar to that of wild type. However, three other mutants (R171K, S173C, and S175C) have greatly reduced affinity. Interestingly, the binding affinity to the EGFR determined by the in vitro assay directly correlates with the transforming ability of the corresponding v-abl constructs in vivo (Mayer, B. J., Jackson, P. K., Etten, R. A. V., and Baltimore, D. (1992) Mol. Cell. Biol. 12, 609-618). These data indicate that the Arg-171, Ser-173, and Ser-175 are critical for both transformation and abl SH2 domain binding to phosphotyrosine-containing proteins.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; WARNER LAMBER CO, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Pfizer; Rockefeller University; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA08875, CA37754] Funding Source: Medline; NIDDK NIH HHS [DK33804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008875, R01CA037754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033804, R23DK033804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GUAN K, 1991, J BIOL CHEM, V266, P12964; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOHNSON KA, 1990, J VIROL, V64, P3337, DOI 10.1128/JVI.64.7.3337-3349.1990; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATUDA M, 1990, SCIENCE, V248, P1537; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHU GC, 1991, BIOCHEM BIOPH RES CO, V177, P771, DOI 10.1016/0006-291X(91)91855-7; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	45	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1775	1779						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678409				2022-12-27	WOS:A1993KH62000043
J	MITCHELL, MT; BENFIELD, PA				MITCHELL, MT; BENFIELD, PA			TATA BOX-MEDIATED INVITRO TRANSCRIPTION BY RNA POLYMERASE-III - EVIDENCE FOR TATA-BINDING PROTEIN IN A POLYMERASE-III TYPE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U6 SNRNA GENES; PROMOTER ELEMENTS; REGULATORY ELEMENTS; UPSTREAM PROMOTER; YEAST; REGION; IDENTIFICATION; INITIATION; EXPRESSION; ACTIVATION	We have shown previously that under specific conditions, a TATA box will mediate efficient in vitro transcription by RNA polymerase (pol) III in the absence of a PSE or other promoter elements. The reaction requires a HeLa cell phosphocellulose protein fraction, fraction B, which must be preincubated with the template DNA. Fraction B does not contain any detectable pol II type transcription factor IID (TFIID) activity. In this report, the relationship between fraction B and TFIID was further examined. Purified human TATA-binding protein (TBP) can substitute for fraction B to mediate TATA-dependent pol III transcription. Both TBP and fraction B prefer a reverse TATA box for pol III transcription, yet TBP bound to a reverse TATA box functions poorly for pol II transcription. Like TFIID, fraction B forms a template-committed complex with TATA-containing promoters. TBP, however, will not template commit for pol III transcription unless premixed with phosphocellulose fraction C. TBP-mediated pol III transcription is also more sensitive to the detergent Sarkosyl (N-lauroylsarcosine, Sigma) than is the fraction B reaction unless it is premixed with fraction C. Together, the data suggest that TBP can complex with a component of fraction C, and this complex is then functionally equivalent to fraction B. We propose that fraction B contains TBP in a complex with some other component(s) of the pol III transcription machinery and that this B complex TBP may be specific for pol III transcription.	DUPONT MERCK PHARMACEUT CO,POB 80328,WILMINGTON,DE 19880	DuPont								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FOWLKES DM, 1980, CELL, V22, P405, DOI 10.1016/0092-8674(80)90351-7; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LEE BJ, 1989, J BIOL CHEM, V264, P9696; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OHSHIMA Y, 1981, NUCLEIC ACIDS RES, V9, P5145, DOI 10.1093/nar/9.19.5145; PARRY HD, 1990, EMBO J, V9, P1097, DOI 10.1002/j.1460-2075.1990.tb08215.x; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TYLER BM, 1987, J MOL BIOL, V196, P801, DOI 10.1016/0022-2836(87)90406-2; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WASYLYK B, 1980, P NATL ACAD SCI-BIOL, V77, P7024, DOI 10.1073/pnas.77.12.7024; WEINMANN R, 1974, P NATL ACAD SCI USA, V71, P3426, DOI 10.1073/pnas.71.9.3426; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WINGENDER E, 1986, J BIOL CHEM, V261, P1409; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	58	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1141	1150						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678250				2022-12-27	WOS:A1993KG07700058
J	PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P				PRESTON, GM; JUNG, JS; GUGGINO, WB; AGRE, P			THE MERCURY-SENSITIVE RESIDUE AT CYSTEINE-189 IN THE CHIP28 WATER CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEIN; XENOPUS-OOCYTES; TRANSPORT; PURIFICATION; FAMILY	Water channels provide the plasma membranes of red cells and renal proximal tubules with high permeability to water, thereby permitting water to move in the direction of an osmotic gradient. Molecular identification of CHIP28 protein as the membrane water channel was first accomplished by measurement of osmotic swelling of Xenopus oocytes injected with CHIP28 RNA (Preston, G. M., Carroll, T. P., Guggino, W. B., and Agre, P. (1992) Science 256, 385-387). Since water channels are pharmacologically inhibited by submillimolar concentrations of Hg2+, site-directed mutagenesis was undertaken to demonstrate which of the 4 cysteines (87, 102, 152, or 189) is the Hg2+-sensitive residue in the CHIP28 molecule. Each cysteine was individually replaced by serine, and oocytes expressing each of the four mutants exhibited osmotic water permeability (P(f)) equivalent to wild-type CHIP28. After incubation in HgCl2, all were significantly inhibited, except C189S which was not inhibited even at 3 mM HgCl2. CHIP28 exists as a multisubunit complex in the native membrane; however, although oocytes injected with mixed CHIP28 and C189S RNAs exhibited P(f) corresponding to the sum of their individual activities, exposure to Hg2+ only reduced the P(f) to the level of the C189S mutant. Of the six substitutions at residue 189, only the serine and alanine mutants exhibited increased P(f) and had glycosylation patterns resembling wild-type CHIP28 on immunoblots. These studies demonstrated: (i) CHIP28 water channel activity is retained despite substitution of individual cysteines with serine; (ii) cysteine 189 is the Hg2+-sensitive residue; (iii) the subunits of the CHIP28 complex are individually active water pores; (iv) residue 189 is critical to proper processing of the CHIP28 protein.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, HUNTERIAN 103, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL ANAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL033991, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, IN PRESS A BENZON S, V34; DAVIS JQ, 1984, J BIOL CHEM, V259, P1874; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Finkelstein A., 1987, WATER MOVEMENT LIPID; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU L, 1990, BIOPHYS J, V57, P1117, DOI 10.1016/S0006-3495(90)82632-1; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SMITH BL, 1991, J BIOL CHEM, V266, P6407; SOLOMON AK, 1983, ANN NY ACAD SCI, V414, P97, DOI 10.1111/j.1749-6632.1983.tb31678.x; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1990, J BIOL CHEM, V265, P15375	23	431	453	4	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					17	20						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677994				2022-12-27	WOS:A1993KE60300005
J	NOTHIAS, JY; MAJUMDER, S; KANEKO, KJ; DEPAMPHILIS, ML				NOTHIAS, JY; MAJUMDER, S; KANEKO, KJ; DEPAMPHILIS, ML			REGULATION OF GENE-EXPRESSION AT THE BEGINNING OF MAMMALIAN DEVELOPMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FACTOR-I TEF-1; MOUSE EMBRYOS; DNA-REPLICATION; PREIMPLANTATION EMBRYOS; OOCYTE MATURATION; MICROINJECTED DNA; PROMOTER ACTIVITY; ONE-CELL; TRANSCRIPTION; ENHANCER				NOTHIAS, JY (corresponding author), ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110, USA.			Kaneko, Kotaro/0000-0002-3195-5294				ALMOUZNI G, 1995, EMBO J, V14, P1752, DOI 10.1002/j.1460-2075.1995.tb07164.x; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; BOLTON VN, 1984, J EMBRYOL EXP MORPH, V79, P139; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; CHALIFOUR LE, 1987, GENE DEV, V1, P1096, DOI 10.1101/gad.1.10.1096; CHEN HY, 1986, MOL DEV BIOL, P149; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CHRISTIANS E, 1995, DEVELOPMENT, V121, P113; CHRISTIANS E, 1994, DEV BIOL, V164, P160, DOI 10.1006/dbio.1994.1188; CLARKE HJ, 1992, DEVELOPMENT, V115, P791; CLEGG KB, 1983, DEV BIOL, V95, P331, DOI 10.1016/0012-1606(83)90034-9; DELOUIS C, 1992, EXP CELL RES, V201, P284, DOI 10.1016/0014-4827(92)90275-D; DEPAMPHILIS ML, 1988, CANCER CELL, V6, P165; DOOLEY TP, 1989, DEVELOPMENT, V107, P945; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; HENERY C, 1994, DEV BIOL, V169, P448; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOWLETT SK, 1986, ROUX ARCH DEV BIOL, V195, P499, DOI 10.1007/BF00375890; LATHAM KE, 1992, DEV BIOL, V149, P457, DOI 10.1016/0012-1606(92)90300-6; LATHAM KE, 1991, DEVELOPMENT, V112, P921; LATHAM KE, 1994, DEV BIOL, V163, P341, DOI 10.1006/dbio.1994.1153; LIRA SA, 1990, P NATL ACAD SCI USA, V87, P7215, DOI 10.1073/pnas.87.18.7215; MAJUMDER S, 1993, EMBO J, V12, P1131, DOI 10.1002/j.1460-2075.1993.tb05754.x; MAJUMDER S, 1994, J CELL BIOCHEM, V55, P59, DOI 10.1002/jcb.240550107; MAJUMDER S, 1994, MOL CELL BIOL, V14, P4258, DOI 10.1128/MCB.14.6.4258; MANEJWALA FM, 1991, DEV BIOL, V144, P301, DOI 10.1016/0012-1606(91)90423-Z; MARTINEZSALAS E, 1989, GENE DEV, V3, P1493, DOI 10.1101/gad.3.10.1493; MARTINEZSALAS E, 1988, GENE DEV, V2, P1115, DOI 10.1101/gad.2.9.1115; MATSUMOTO K, 1994, MOL REPROD DEV, V39, P136, DOI 10.1002/mrd.1080390203; MCGRATH J, 1984, SCIENCE, V226, P1317, DOI 10.1126/science.6542249; MELIN F, 1993, EMBO J, V12, P4657, DOI 10.1002/j.1460-2075.1993.tb06154.x; MILLAR SE, 1991, MOL CELL BIOL, V11, P6197, DOI 10.1128/MCB.11.12.6197; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PAYNTON BV, 1988, DEV BIOL, V129, P304, DOI 10.1016/0012-1606(88)90377-6; PIKO L, 1982, DEV BIOL, V89, P363; PRIOLEAU MN, 1994, CELL, V77, P439, DOI 10.1016/0092-8674(94)90158-9; RAM PT, 1993, DEV BIOL, V156, P552, DOI 10.1006/dbio.1993.1101; SCHULTZ GA, 1992, MUTAT RES, V296, P17, DOI 10.1016/0165-1110(92)90029-9; SCHULTZ RM, 1993, BIOESSAYS, V15, P531, DOI 10.1002/bies.950150806; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSUNODA Y, 1987, J EXP ZOOL, V242, P147, DOI 10.1002/jez.1402420205; TURNER BM, 1991, J CELL SCI, V99, P13; URA K, 1994, J BIOL CHEM, V269, P27171; VERNET M, 1992, MECH DEVELOP, V36, P129, DOI 10.1016/0925-4773(92)90064-Q; WASSARMAN PM, 1993, MUTAT RES, V296, P3; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WIEKOWSKI M, 1991, DEV BIOL, V147, P403, DOI 10.1016/0012-1606(91)90298-H; WIEKOWSKI M, 1993, DEV BIOL, V159, P366, DOI 10.1006/dbio.1993.1248; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORRAD DM, 1994, DEVELOPMENT, V120, P2347; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YASUDA GK, 1992, TRENDS GENET, V8, P124	56	233	249	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22077	22080		10.1074/jbc.270.38.22077	http://dx.doi.org/10.1074/jbc.270.38.22077			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673179	hybrid			2022-12-27	WOS:A1995RW31400001
J	MENG, QH; CALABRESI, L; FRUCHART, JC; MARCEL, YL				MENG, QH; CALABRESI, L; FRUCHART, JC; MARCEL, YL			APOLIPOPROTEIN-A-I DOMAINS INVOLVED IN THE ACTIVATION OF LECITHIN - CHOLESTEROL ACYLTRANSFERASE - IMPORTANCE OF THE CENTRAL DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; GRADIENT GEL-ELECTROPHORESIS; MICELLAR COMPLEXES; PHOSPHATIDYLCHOLINE; EPITOPES	The reaction of highly purified lecithin:cholesterol acyltransferase (LCAT) with defined reconstituted discoidal apoA-I-containing lipoproteins (LpA-I) with 2, 3, or 4 apoA-I molecules/particle (Lp2, 3, or 4A-I) has been studied in the presence of a number of specific anti apoA-I antibodies. Among nine anti-apoA-I monoclonal antibodies (mAbs) reacting with epitopes distributed over 80% of the sequence, three significantly inhibit the LCAT reaction with all particles. The position of their epitopes located in the middle to COOH-terminal region between residues 96-121 (3G10), 135-148 (A03), and 149-186 (A44) is compatible with an inhibition by steric hindrance over a central domain. Antibody 4H1 binding to the NH2 terminus (residues 2-8) profoundly increases (5-fold) the LCAT reaction with Lp2A-I (7.8 nm), but not with other particles. Other mAbs, A11 and 5F6, binding to epitopes (residues 99-139 and 118-141) enhance LCAT reactivity with the small Lp2A-I (7.8 nm) and Lp3A-I (10.8 nm) but not with their larger counterparts. Most mAbs have similar effects on LCAT reaction with native high density lipoprotein3 as with LpA-I. The inhibitory or enhancing effects of these mAbs are also observed with Fab fragments and not related to their binding affinity for apoA-I containing reconstituted lipoprotein particles. The intercalation of epitopes for mAbs that inhibit or enhance LCAT reaction with small LpA-I is compatible not with steric hindrance but with conformational modifications of apoA-I and indirectly of the lipids in small particles. We propose that enhancing mAbs act by stabilization of an apoA-I conformation which is not favored in small LpA-I, i.e. by increasing binding of amphipathic helices to lipids or by interfering with the mobility of a hinged domain. The epitopes for the inhibitory mAbs can be shown to overlap on several LpA-I models, indicating that steric hindrance over a single site is a possible mechanism of inhibition.	UNIV OTTAWA,OTTAWA HEART INST,LIPOPROT & ATHEROSCLEROSIS GRP,1053 CARLING AVE,OTTAWA K1Y 4E9,ONTARIO,CANADA; INST PASTEUR,SERV ETUD & RECH LIPIDES & ATHEROSCLEROSE,F-59019 LILLE,FRANCE	University of Ottawa; University of Ottawa Heart Institute; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Calabresi, Laura/0000-0001-5042-9532				BANKA CL, 1991, J BIOL CHEM, V266, P23886; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CALABRESI L, 1993, IN PRESS BIOCHEMISTR; CHEN CH, 1982, J LIPID RES, V23, P680; CHEUNG MC, 1987, J LIPID RES, V28, P913; COLLET X, 1991, J BIOL CHEM, V266, P9145; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; GLOMSET JA, 1972, BLOOD LIPIDS LIPOPRO, P745; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MILNE R, 1987, MOL IMMUNOL, V24, P127, DOI 10.1016/0161-5890(87)90084-8; MILTHORP P, 1986, HUMAN APOLIPOPROTEIN, P103; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; NICHOLS AV, 1987, J LIPID RES, V28, P719; NISHIDA HI, 1986, J BIOL CHEM, V261, P2028; PETIT E, 1987, BIOCHIM BIOPHYS ACTA, V919, P287, DOI 10.1016/0005-2760(87)90268-2; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; WALD JH, 1990, J BIOL CHEM, V265, P20037; WILLIAMS PT, 1990, J LIPID RES, V31, P1131	28	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16966	16973						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688720				2022-12-27	WOS:A1993LQ98800016
J	JIANG, GJ; MCKENZIE, TL; CONRAD, DG; SHECHTER, I				JIANG, GJ; MCKENZIE, TL; CONRAD, DG; SHECHTER, I			TRANSCRIPTIONAL REGULATION BY LOVASTATIN AND 25-HYDROXYCHOLESTEROL IN HEPG2 CELLS AND MOLECULAR-CLONING AND EXPRESSION OF THE CDNA FOR THE HUMAN HEPATIC SQUALENE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; DENSITY-LIPOPROTEIN RECEPTOR; MESSENGER-RNA; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; COORDINATE REGULATION; SYNTHETASE; PROTEIN; GENE; SOLUBILIZATION; PURIFICATION	Primers, bared on the cDNA nucleotide sequences for rat hepatic squalene synthase (EC 2.5.1.21) (McKenzie, T. L., Jiang, G., Straubhaar, J. R., Conrad, D., and Shechter, I. (1992) J. Biol. Chem. 267, 21368-21374), were synthesized and used for the amplification and sequencing of a 1672-base pair (bp) cDNA for the human hepatic squalene synthase (HSS) from human hepatic RNA. An open reading frame of 1251 bp encoding 417 amino acids (M(r) = 48,200) was detected for HSS. We have constructed a pHSS1286 expression vector by molecular cloning of a 1286-bp cDNA, that includes sequences of the entire coding region for HSS, into pBluescript. Expression in Escherichia coli of a functional, full-length HSS was confirmed by immunoblot analysis and enzymatic activity. Northern blot analyses of poly(A+) RNA obtained from the human hepatoma cell line HepG2 show three distinct size classes of mRNA for HSS. 1.4-, 1.6- and 2.1-kilobase mRNA were observed. The relative abundance is in the order 1.6 > 1.4 > 2.1 and did not change when the cells were grown in the presence of 25-hydroxycholesterol or lovastatin. The ratio between the level of HSS mRNA in cells grown in the absence and presence of 5 mug/ml 25-hydroxycholesterol varies between 8- and 16-fold. This lowering of the mRNA level was observed when the cells were grown in 10% of either full serum or lipid-depleted serum. A 2.7- and 4.0-fold increase of HSS mRNA was observed when HepG2 cells were grown in the presence of 5 mug/ml lovastatin in lipid-depleted or full serum, respectively. These studies show that HSS exhibit a relatively high level of transcriptional regulation in response to 25-hydroxycholesterol regardless of the presence of cholesterol in the growth media.	ELEANOR ROOSEVELT INST,1899 GAYLORD ST,DENVER,CO 80206									AGNEW WS, 1978, J BIOL CHEM, V253, P4574; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAM BE, 1976, J LIPID RES, V17, P176; CHIN DL, 1983, P NATL ACAD SCI USA, V79, P7704; COHEN LH, 1988, BIOCHEM J, V255, P61, DOI 10.1042/bj2550061; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOLOS TG, 1988, BIOCHEMISTRY-US, V27, P3503, DOI 10.1021/bi00409a056; HANDLER B, 1991, ABSTR PAP AM CHEM S, V201, P1; HARDIE DG, 1992, BIOESSAYS, V14, P699, DOI 10.1002/bies.950141011; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUSWIKRABIEGA G, 1987, J BIOL CHEM, V262, P1505; LISCUM L, 1983, J BIOL CHEM, V258, P8450; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; LUSKEY KL, 1987, MOL CELL BIOL, V7, P1881, DOI 10.1128/MCB.7.5.1881; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; NESS GC, 1991, J BIOL CHEM, V266, P14854; POULTER CD, 1981, BIOSYNTHESIS ISOPREN, P413; RAMHARACK R, 1990, DNA CELL BIOL, V9, P677, DOI 10.1089/dna.1990.9.677; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RILLING HC, 1969, J AM CHEM SOC, V19, P1041; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; RUDLING M, 1992, J LIPID RES, V33, P493; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASIAK K, 1988, ARCH BIOCHEM BIOPHYS, V260, P622, DOI 10.1016/0003-9861(88)90490-0; SHECHTER I, 1971, J BIOL CHEM, V246, P7690; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SPADY DK, 1992, J BIOL CHEM, V267, P5584; STAMELLOS KD, 1993, J BIOL CHEM, V268, P12825; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367	39	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12818	12824						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685352				2022-12-27	WOS:A1993LG65800087
J	ENDEMANN, G; STANTON, LW; MADDEN, KS; BRYANT, CM; WHITE, RT; PROTTER, AA				ENDEMANN, G; STANTON, LW; MADDEN, KS; BRYANT, CM; WHITE, RT; PROTTER, AA			CD36 IS A RECEPTOR FOR OXIDIZED LOW-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; ENHANCED MACROPHAGE DEGRADATION; MONOCLONAL-ANTIBODY; SCAVENGER RECEPTOR; HUMAN-MONOCYTES; INFECTED ERYTHROCYTES; PLATELET ACTIVATION; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS	The oxidation of low density lipoprotein (LDL) in the arterial wall is thought to contribute to human atherosclerotic lesion formation, in part by the high affinity uptake of oxidized LDL (OxLDL) by macrophages, resulting in foam cell formation. We have utilized cloning by expression to identify CD36 as a macrophage receptor for OxLDL. Transfection of a CD36 clone into 293 cells results in the specific and high affinity binding of OxLDL, followed by its internalization and degradation. An anti-CD36 antibody blocks 50% of the binding of OxLDL to platelets and to human macrophage-like THP cells. Furthermore, like mouse macrophages, 293 cells expressing CD36 recognize LDL which has been oxidized only 4 h, whereas more extensive oxidation of the LDL is required for recognition by the other known OxLDL receptors, the acetylated LDL (AcLDL) receptor and FcgammaRII-B2. CD36 may play a role in scavenging LDL modified by oxidation and may mediate effects of OxLDL on monocytes and platelets in atherosclerotic lesions.			ENDEMANN, G (corresponding author), SCIOS NOVA INC,2450 BAYSHORE PKWY,MT VIEW,CA 94043, USA.				NHLBI NIH HHS [1R43 HL47220-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL047220] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN ML, 1990, BLOOD, V76, P2501; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; ARDLIE NG, 1989, ATHEROSCLEROSIS, V76, P117, DOI 10.1016/0021-9150(89)90094-4; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; FONG LG, 1987, J LIPID RES, V28, P1466; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORSEWOOD P, 1991, BLOOD, V78, P1019; KAMPS JAAM, 1992, ARTERIOSCLER THROMB, V12, P1079, DOI 10.1161/01.ATV.12.9.1079; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P178, DOI 10.1161/01.ATV.10.2.178; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BLOOD, V78, P2809; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VALONE FH, 1979, IMMUNOLOGY, V37, P841; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; YAMAMOTO N, 1990, THROMB HAEMOSTASIS, V63, P97; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	45	1065	1096	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11811	11816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685021				2022-12-27	WOS:A1993LF28400054
J	KENNARD, O; SALISBURY, SA				KENNARD, O; SALISBURY, SA			OLIGONUCLEOTIDE X-RAY STRUCTURES IN THE STUDY OF CONFORMATION AND INTERACTIONS OF NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TRANSCRIPTION FACTOR-IIIA; CRYSTAL-STRUCTURE; BASE-PAIRS; BINDING-SITE; B-DNA; DRUG; FRAGMENT; MISMATCH; LATTICE; TRACT				KENNARD, O (corresponding author), CAMBRIDGE CRYSTALLOG DATA CTR, 12 UNION RD, CAMBRIDGE CB2 1EZ, ENGLAND.							BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CARRONDO MAAFDT, 1989, BIOCHEMISTRY-US, V28, P7849, DOI 10.1021/bi00445a047; CHATTOPADHYAYA R, 1988, NATURE, V334, P175, DOI 10.1038/334175a0; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DOUCET J, 1989, NATURE, V337, P190, DOI 10.1038/337190a0; EGLI M, 1992, P NATL ACAD SCI USA, V89, P534, DOI 10.1073/pnas.89.2.534; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KAMITORI S, 1992, J MOL BIOL, V225, P445, DOI 10.1016/0022-2836(92)90931-9; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KENNARD O, 1991, ANGEW CHEM INT EDIT, V30, P1254, DOI 10.1002/anie.199112541; KENNARD O, 1987, NUCL ACIDS MOL BIOL, P25; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; MCCALL M, 1986, NATURE, V322, P661, DOI 10.1038/322661a0; NEIDLE S, 1987, BIOCHEM J, V243, P1; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PRIVE GG, 1987, SCIENCE, V238, P498, DOI 10.1126/science.3310237; QUIGLEY GJ, 1986, SCIENCE, V232, P1255, DOI 10.1126/science.3704650; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SHAKKED Z, 1981, PROC R SOC SER B-BIO, V213, P479, DOI 10.1098/rspb.1981.0076; TENG M, 1988, NUCLEIC ACIDS RES, V16, P2671, DOI 10.1093/nar/16.6.2671; TIMSIT Y, 1989, NATURE, V341, P459, DOI 10.1038/341459a0; VISWAMITRA MA, 1978, NATURE, V273, P687, DOI 10.1038/273687a0; WANG AHJ, 1990, JERUS SYM Q, V23, P1; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0	34	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10701	10704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684365				2022-12-27	WOS:A1993LD46600001
J	LUTZ, MP; SUTOR, SL; ABRAHAM, RT; MILLER, LJ				LUTZ, MP; SUTOR, SL; ABRAHAM, RT; MILLER, LJ			A ROLE FOR CHOLECYSTOKININ-STIMULATED PROTEIN-TYROSINE PHOSPHORYLATION IN REGULATED SECRETION BY THE PANCREATIC ACINAR CELL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; KINASE-C; ENZYME-SECRETION; AMYLASE SECRETION; GROWTH-FACTOR; INTACT-CELLS; RECEPTOR; STAUROSPORINE; BOMBESIN; CALCIUM	Cholecystokinin (CCK) is a gastrointestinal hormone that acts through a G protein-coupled receptor to stimulate pancreatic enzyme secretion. In this work, we demonstrate that CCK stimulation of dispersed pancreatic acini results in increased tyrosine phosphorylation of several cellular proteins. This is mediated via a calcium-dependent pathway, also activated by a phenethyl ester analogue of CCK and calcium ionophores, and by a protein kinase C-dependent cascade, also activated by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. All demonstrable stimulated tyrosine phosphorylation events were inhibited by genistein, with different subsets of proteins affected by staurosporine and H-7. The importance of tyrosine phosphorylation events in agonist-stimulated amylase secretion was studied using genistein and staurosporine as protein kinase inhibitors. Genistein inhibited the secretory response to CCK, its phenethyl ester analogue, and calcium ionophores, all known to stimulate secretion in a calcium-dependent fashion. In contrast, genistein had no effect on the secretory response to 12-O-tetradecanoylphorbol-13-acetate, suggesting that the protein kinase C-dependent tyrosine phosphorylation events were not involved in the secretory mechanism. Furthermore, CCK-induced secretion was not affected by relatively specific protein kinase C inhibition by H-7, but was decreased by staurosporine, an inhibitor of both protein kinase C and tyrosine kinase activities in these cells. These results provide evidence that acinar cell tyrosine phosphorylation is stimulated by agonists acting via calcium-dependent and protein kinase C-dependent pathways, with only the calcium-dependent tyrosine phosphorylation cascade involved in triggering hormone-induced amylase release.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,GUGGENHEIM 17,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic				Lutz, Manfred/0000-0003-1989-4553	PHS HHS [D32878] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; CESKA M, 1969, CLIN CHIM ACTA, V26, P437, DOI 10.1016/0009-8981(69)90071-0; EDERVEEN AGH, 1990, EUR J BIOCHEM, V193, P291, DOI 10.1111/j.1432-1033.1990.tb19335.x; FREEDMAN SD, 1982, J CELL BIOL, V95, P903, DOI 10.1083/jcb.95.3.903; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JENA BP, 1991, J BIOL CHEM, V266, P17744; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KUSUI T, 1991, BIOCHIM BIOPHYS ACTA, V1094, P231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LOGSDON CD, 1986, AM J PHYSIOL, V251, pG487, DOI 10.1152/ajpgi.1986.251.4.G487; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; PANDOL SJ, 1986, J BIOL CHEM, V261, P4438; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SCHULTZ GS, 1980, EXP CELL RES, V130, P49, DOI 10.1016/0014-4827(80)90041-5; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; VERME TB, 1989, AM J PHYSIOL, V257, pG548, DOI 10.1152/ajpgi.1989.257.4.G548; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WILLIAMS JA, 1980, AM J PHYSIOL, V238, pG269, DOI 10.1152/ajpgi.1980.238.4.G269; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126	29	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11119	11124						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684371				2022-12-27	WOS:A1993LD46600061
J	ISLAM, TC; BUGGE, TH; BOHM, S				ISLAM, TC; BUGGE, TH; BOHM, S			THE LONG TERMINAL REPEAT OF VL30 RETROTRANSPOSONS CONTAINS SEQUENCES THAT DETERMINE RETINOIC ACID-INDUCED TRANSCRIPTION IN CULTURED KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; RESPONSIVE ELEMENT; GENE-EXPRESSION; THYROID-HORMONE; RECEPTOR-GAMMA; DIFFERENTIATION; IDENTIFICATION; PROMOTERS; SKIN	The characterization of retinoic acid (RA)-regulated gene transcription in keratinocytes has important implications as to the function of retinoids in epidermal homeostasis and to the central role retinoids play in the pharmaco-therapy of a variety of skin disorders. We show that cultured mouse keratinocytes (Balb/MK) responded to RA with induced expression of VL30 retrotransposons. The induction was rapid, was present at nanomolar concentrations of RA, was independent of new protein synthesis, and occurred both in proliferating and differentiated keratinocytes. The long terminal repeat of a VL30 retrotransposon, expressed in mouse epidermis in vivo, was found to contain two RA-responsive elements (RREs) that independently conferred RA responsiveness on a heterologous promoter in both cultured Balb/MK cells and normal human keratinocytes. Functional characterization and in vitro binding analysis showed that the sequence requirement for binding of retinoid X receptor alpha (RXRalpha) and retinoic acid receptor (RAR, either alpha beta, or gamma) heterodimers, correlated with the sequence requirement for RA-induced transcription in keratinocytes. The VL30 RREs differed functionally from the RA response element present in the RAR-beta2 promoter, in that the VL30 RREs were non-responsive in fibroblasts cultured from human skin. The non-responsiveness correlated with a reduced complex formation between a VL30 RRE and endogenously expressed nuclear factors present in skin fibroblasts. The data suggest that a direct repeat of two half-sites, spaced by two base pairs, with the consensus sequence T(A/G)AACTTTT(T/C)ACC(T/C), bound RAR-RXR heterodimers and mediated, at constitutive receptor levels, a primary RA response on gene transcription specifically in keratinocytes.	KAROLINSKA INST, NOVUM, CTR BIOTECHNOL, BLICKAGANGEN 6, S-14157 HUDDINGE, SWEDEN; EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY	Karolinska Institutet; European Molecular Biology Laboratory (EMBL)								ASTROM A, 1990, BIOCHEM BIOPH RES CO, V173, P339, DOI 10.1016/S0006-291X(05)81062-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BOHM S, 1990, CANCER RES, V50, P1626; BOHM S, 1991, J BIOL CHEM, V266, P24834; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHYTIL F, 1984, PHARMACOL REV, V36, P93; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; ELDER JT, 1992, J INVEST DERMATOL, V98, P673, DOI 10.1111/1523-1747.ep12499896; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KANNAN P, 1991, J VIROL, V65, P6343, DOI 10.1128/JVI.65.11.6343-6348.1991; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KESHET E, 1991, ADV CANCER RES, V56, P215; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; REISS M, 1988, IN VITRO CELL DEV B, V24, P537, DOI 10.1007/BF02629088; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; Sambrook J, 1989, MOL CLONING LABORATO; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STRUHL K, 1990, CURRENT PROTOCOLS S, V11; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	49	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3251	3259						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679109				2022-12-27	WOS:A1993KM16100038
J	SACHAIS, BS; SNIDER, RM; LOWE, JA; KRAUSE, JE				SACHAIS, BS; SNIDER, RM; LOWE, JA; KRAUSE, JE			MOLECULAR-BASIS FOR THE SPECIES SELECTIVITY OF THE SUBSTANCE-P ANTAGONIST-CP-96,345	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ADRENERGIC-RECEPTOR; CDNA; BINDING; GONADOTROPIN; ORGANIZATION; TACHYKININS; ANTAGONISTS; AFFINITY; PROTEINS	The non-peptide substance P (SP) antagonist 96,345 has a 90-fold selectivity for the human neurokinin-1 (NK-1) or SP receptor over the rat NK-1 receptor, while the agonist SP shows no such selectivity. The cloned NK-1 receptors from these two species have primary protein structures that differ in only 22 of 407 residues. Wild type, chimeric, and point-mutated NK-1 receptors have been created and functionally expressed to understand the structural basis of this species selectivity. Residue 290 in the seventh putative membrane-spanning region is responsible for 20-fold of the affinity difference seen for CP-96,345 between the rat and human NK-1 receptors. Residues in the second extracellular loop and in membrane-spanning region six contribute the additional 3-5-fold of the species difference. The direct or indirect action of these residues with this nonpeptidic antagonist is discussed. This study serves to emphasize the need for species-appropriate in vitro models for the screening of antagonists in the search for therapeutics, and provides useful information to model nonpeptidic antagonist interactions with peptide hormone receptors.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID,BOX 8108,ST LOUIS,MO 63110; PFIZER INC,DIV CENT RES,DEPT EXPLORATORY MED CHEM,GROTON,CT 06340; PFIZER INC,DEPT NEUROSCI,GROTON,CT 06340	Washington University (WUSTL); Pfizer; Pfizer			Sachais, Bruce/D-1236-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021937, R55NS021937] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07805] Funding Source: Medline; NINDS NIH HHS [NS21937] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GITTER BD, 1991, EUR J PHARMACOL, V197, P237, DOI 10.1016/0014-2999(91)90532-U; GUAN XM, 1992, MOL PHARMACOL, V41, P695; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HERSHEY AD, 1991, THESIS WASHINGTON U; HOPKINS B, 1991, BIOCHEM BIOPH RES CO, V180, P1110, DOI 10.1016/S0006-291X(05)81181-7; LEE CM, 1983, MOL PHARMACOL, V23, P563; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P51; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; MACDONALD MR, 1989, J BIOL CHEM, V264, P15578; MACDONALD SG, 1989, J NEUROCHEM, V53, P264, DOI 10.1111/j.1471-4159.1989.tb07323.x; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; PARKER I, 1986, PROC R SOC SER B-BIO, V229, P151, DOI 10.1098/rspb.1986.0079; PAYAN DG, 1989, ANNU REV MED, V40, P341; PERNOW B, 1983, PHARMACOL REV, V35, P85; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; TOTA MR, 1990, J BIOL CHEM, V265, P16891; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	27	134	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2319	2323						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679096				2022-12-27	WOS:A1993KK81500013
J	NALEFSKI, EA; SHAW, KTY; RAO, A				NALEFSKI, EA; SHAW, KTY; RAO, A			AN ION-PAIR IN CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX HETERODIMERS CRITICAL FOR SURFACE EXPRESSION AND PEPTIDE PRESENTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; ANTIGEN-BINDING SITE; MOUSE MHC ANTIGENS; A-BETA-CHAIN; INVARIANT-CHAIN; MONOCLONAL-ANTIBODIES; VIRAL PEPTIDES; INTRACELLULAR-TRANSPORT; 3-DIMENSIONAL STRUCTURE; ALPHA-CHAIN	In this report we demonstrate that the ion pair Arg-80 alpha and Asp-57 beta, located in the peptide-binding site of nearly all class II major histocompatibility complex (MHC) proteins, is important for surface expression and function of the murine class II heterodimer I-A(d). Charge reversal at either of these two residues by site-directed mutagenesis generated mutant class Il molecules that failed to appear at the cell surface. This defect in surface expression was partially reversed when the invariant chain was present or when the mutants were paired with the corresponding charge-reversed variant of the opposite chain. Surprisingly, surface expression was restored when cells expressing the single-site mutants were cultured at reduced temperature, In addition, the substitution of Asp-57 beta with residues found in alleles of class II molecules associated with diabetes resulted in heterodimers that were inefficiently expressed at the cell surface and presented foreign peptide poorly. Together, these results demonstrate that the formation of a salt-bridge between Arg-80 alpha and Asp-57 beta is required for efficient surface expression of class II MHC molecules, therefore representing an important step in the assembly and transport of functional class II heterodimers to the cell surface.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIAID NIH HHS [AI22900] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022900] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUERSTEDDE JM, 1988, J EXP MED, V167, P473, DOI 10.1084/jem.167.2.473; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GLUTZMAN Y, 1981, CELL, V23, P175; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; GUILLET JG, 1986, NATURE, V324, P260, DOI 10.1038/324260a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KASIBHATLA S, 1993, J IMMUNOL, V151, P3140; KOCH N, 1982, EUR J IMMUNOL, V12, P909, DOI 10.1002/eji.1830121103; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LECHLER RI, 1990, J IMMUNOL, V144, P329; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NALEFSKI EA, 1990, J BIOL CHEM, V265, P8842; NALEFSKI EA, 1992, J EXP MED, V175, P1553, DOI 10.1084/jem.175.6.1553; NALEFSKI EA, 1993, J IMMUNOL, V150, P3806; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; OZATO K, 1981, J IMMUNOL, V126, P317; OZATO K, 1980, J IMMUNOL, V124, P533; OZATO K, 1980, J IMMUNOL, V125, P2473; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; REICH EP, 1994, J IMMUNOL, V152, P2279; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; Sambrook J, 1989, MOL CLONING LABORATO; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VANBLEEK GM, 1990, NATURE, V348, P213; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	69	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22351	22360		10.1074/jbc.270.38.22351	http://dx.doi.org/10.1074/jbc.270.38.22351			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673219	hybrid			2022-12-27	WOS:A1995RW31400046
J	BEHRENDS, S; HARTENECK, C; SCHULTZ, G; KOESLING, D				BEHRENDS, S; HARTENECK, C; SCHULTZ, G; KOESLING, D			A VARIANT OF THE ALPHA(2) SUBUNIT OF SOLUBLE GUANYLYL CYCLASE CONTAINS AN INSERT HOMOLOGOUS TO A REGION WITHIN ADENYLYL CYCLASES AND FUNCTIONS AS A DOMINANT-NEGATIVE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MOLECULAR-CLONING; ACTIVITY REQUIRES; ENZYME SUBUNITS; RAT-KIDNEY; KINASE-C; EXPRESSION; RECEPTOR; LUNG; ACTIVATION	A variant of the alpha(2) subunit of soluble guanylyl cyclase (alpha(2i)) containing 31 additional amino acids was identified in a number of cell lines and tissues. The in-frame sequence of the insert was within the proposed catalytic domain of guanylyl cyclases and was homologous to a region within the putative catalytic domain of adenylyl cyclases. Messenger RNA for the new variant was detected in some but not all cell lines and tissues expressing the alpha(2) subunit, The novel form, as well as the alpha(2) subunit lacking the insert, were coexpressed with the beta(1) subunit in Sf9 and COS-7 cells; alpha(2)/beta(1), coexpression yielded a NO-sensitive recombinant protein, whereas the coexpressed alpha(2i)/beta(1) subunits exhibited no guanylyl or adenylyl cyclase activities. Because both subunits (alpha(2i)/ beta(1)) copurified, the novel variant retains its ability to heterodimerize. In coexpression experiments, the alpha(2i) subunit competed with the alpha(2) subunit for dimerization with the beta(1) subunit, thereby reducing alpha(2)/beta(1)-catalyzed guanylyl cyclase activity. These data show that the novel variant functions as a dominant negative protein and that post-transcriptional mRNA processing represents a potential mechanism for regulation of NO-sensitive guanylyl cyclase acitivity.	FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin			Behrends, Sönke/A-2551-2010	Behrends, Sönke/0000-0002-9068-0729				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; DAYHOFF MOO, 1987, ATLAS PROTEIN SEQ S3, V5, P1; DUDA T, 1990, MOL CELL BIOCHEM, V93, P179; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; GARBERS DL, 1992, CELL, V71, P1; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HARTENECK C, 1991, FEBS LETT, V292, P217, DOI 10.1016/0014-5793(91)80871-Y; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KOESLING D, 1990, FEBS LETT, V266, P128, DOI 10.1016/0014-5793(90)81523-Q; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MEI L, 1994, J BIOL CHEM, V269, P12254; MITTAL CK, 1977, J BIOL CHEM, V252, P3136; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P369; SCHULTZ G, 1984, METHOD ENZYMAT AN, V4, P379; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; UJIIE K, 1994, J PHARMACOL EXP THER, V270, P761; UJIIE K, 1993, J CLIN INVEST, V91, P730, DOI 10.1172/JCI116255; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193; ZWILLER J, 1985, J BIOL CHEM, V260, P1350	39	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21109	21113		10.1074/jbc.270.36.21109	http://dx.doi.org/10.1074/jbc.270.36.21109			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673142	hybrid			2022-12-27	WOS:A1995RU05400040
J	HALLE, JP; STELZER, G; GOPPELT, A; MEISTERERNST, M				HALLE, JP; STELZER, G; GOPPELT, A; MEISTERERNST, M			ACTIVATION OF TRANSCRIPTION BY RECOMBINANT UPSTREAM STIMULATORY FACTOR-1 IS MEDIATED BY A NOVEL POSITIVE COFACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; HELIX-LOOP-HELIX; MAJOR LATE PROMOTER; TATA-BINDING PROTEIN; DNA TOPOISOMERASE-I; FACTOR USF; GENE-TRANSCRIPTION; MULTIPLE FORMS; COMPLEXES; IDENTIFICATION	The transcription factor USF1 belongs to the family of basic helix-loop helix proteins that are involved in the regulation of various important cellular processes. Here we characterized the factors involved in the activation of transcription by upstream stimulatory factor 1 (USF1) in a reconstituted class II gene transcription system. Activation of transcription by both wild type USF1 and a GAL-USF (amino acids 1-94 of the yeast activator protein GAL4 fused to amino acids 17-196 of USF) fusion protein required the presence of at least one positive cofactor. A novel positive cofactor (PC5) that functions specifically through the activation domain of USF1 was partially purified and biochemicaly distinguished from previously described positive cofactors. The mechanism by which PC5 mediates activation of transcription through USF1 was investigated in order-of-addition experiments. PC5 had to be present during binding of transcription factor (TF) IID to the TATA box to observe transcriptional activation, However, this event alone did not result in transcriptional activation, which also required the presence of the activator and of PC5 after binding of TFIID. Hence, PC5 may enter transcription during binding of TFIID to function in concert with the activator during subsequent steps in transcription.	UNIV MUNICH,GENZENTRUM,MOLEK BIOL LAB,D-81375 MUNICH,GERMANY	University of Munich				Halle, Joern-Peter/0000-0002-1178-5275				BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KRETZSCHMAR M, 1994, MOL CELL BIOL, V6, P3927; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SIROTO M, 1994, NUCLEIC ACIDS RES, V22, P427; STELZER G, 1994, MOL CELL BIOL, V7, P4712; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	48	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21307	21311		10.1074/jbc.270.36.21307	http://dx.doi.org/10.1074/jbc.270.36.21307			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673166	hybrid			2022-12-27	WOS:A1995RU05400067
J	NICOLAES, GAF; TANS, G; THOMASSEN, MCLGD; HEMKER, HC; PABINGER, I; VARADI, K; SCHWARZ, HP; ROSING, J				NICOLAES, GAF; TANS, G; THOMASSEN, MCLGD; HEMKER, HC; PABINGER, I; VARADI, K; SCHWARZ, HP; ROSING, J			PEPTIDE-BOND CLEAVAGES AND LOSS OF FUNCTIONAL-ACTIVITY DURING INACTIVATION OF FACTOR VA AND FACTOR VA(R506Q) BY ACTIVATED PROTEIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-CATALYZED ACTIVATION; POOR ANTICOAGULANT RESPONSE; COAGULATION FACTOR-V; BOVINE FACTOR-X; PROTHROMBIN ACTIVATION; BLOOD-COAGULATION; S DEFICIENCY; PHOSPHOLIPIDS; PLASMA; THROMBOPHILIA	Factor V was purified from the plasma of an activated protein C (APC)-resistant patient who is homozygous for the mutation Arg(506) --> Gln (factor V-R506Q). Factor V-R506Q was converted by thrombin into factor Va which was further purified yielding a factor Va preparation that had the same cofactor activity in prothrombin activation as normal factor Va. Inactivation of low concentrations of normal factor Va (<5 nM) by 0.15 nM APC in the presence of phospholipid vesicles proceeded via a biphasic reaction that consisted of a rapid phase (k = 4.3 x 10(7) M(-1)s(-1)), yielding a reaction intermediate with reduced cofactor activity that was fully inactivated during the subsequent slow phase (k = 2.3 x 10(6) M(-1)s(-1)). Inactivation of factor Va(R506Q) proceeded via a monophasic reaction (k = 1.7 x 10(6) M(-1)s(-1)). Immunoblot analysis showed that APC-catalyzed inactivation of factor Va occurred via peptide bond cleavages in the heavy chain. The rapid phase of inactivation of normal factor Va was associated with cleavage at Arg(506) and full inactivation of factor Va required subsequent cleavage at Arg(306). The slow monophasic inactivation of factor Va(R506Q) correlated with cleavage at Arg(306). Cleavage at Arg(506) in normal factor Va resulted in accumulation of a reaction intermediate that exhibited 40% cofactor activity in prothrombin activation mixtures that contained a high factor Xa concentration (5 nM). Compared with native factor Va, the reaction intermediate retained virtually no cofactor activity at low factor Xa concentrations (0.3 nM). This demonstrates that factor Va that is cleaved at Arg(506) is impaired in its ability to interact with factor Xa. Michaelis-Menten kinetic analysis showed that cleavage at Arg(506) in membrane-bound factor Va was characterized by a low K-m for factor Va (20 nM) and k(cat) = 0.96 s(-1). For cleavage at Arg(306) in factor Va(R506Q) the kinetic parameters were K-m = 196 nM and k(cat) = 0.37 s(-1). This means that differences between APC-catalyzed inactivation of factors Va and Va(R506Q) become much less pronounced at high factor Va concentrations. When factor Va(R506Q) was inactivated by APC in the absence of phospholipids, cleavage at Arg(679) of the heavy chain also contributed to factor Va inactivation. Comparison of rate constants for APC-catalyzed cleavage at Arg(306), Arg(506) and Arg(679) in the absence and presence of phospholipids indicated that phospholipids accelerated these cleavages to a different extent. This indicates that the binding of factor Va to phospholipids changes the accessibility of the cleavage sites and/or the sequence of peptide bond cleavage by APC.	UNIV LIMBURG,CARDIOVASC RES INST MAASTRICHT,DEPT BIOCHEM,6200 MD MAASTRICHT,NETHERLANDS; UNIV HOSP VIENNA,DEPT HEMATOL & BLOOD COAGULAT,VIENNA,AUSTRIA; IMMUNO AG WIEN,VIENNA,AUSTRIA	Hasselt University; Maastricht University; University Hospital Vienna			Nicolaes, Gerry A.F./A-8421-2016	Nicolaes, Gerry A.F./0000-0002-2482-0412; Thomassen, Stella/0000-0002-9686-6364; Hemker, Coen/0000-0003-1669-2358				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BEAUCHAMP NJ, 1994, BRIT J HAEMATOL, V88, P219, DOI 10.1111/j.1365-2141.1994.tb05005.x; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FERSHT A, 1985, ENZYME STRUCTURE MEC, P128; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1989, BLOOD, V73, P639; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1990, BLOOD, V76, P1; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSING J, 1993, J BIOL CHEM, V268, P21130; ROSING J, 1980, J BIOL CHEM, V255, P274; SALA N, 1984, BLOOD, V63, P671; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SCHWARZ HP, 1984, BLOOD, V64, P1297; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1973, J BIOL CHEM, V248, P2418; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; SUZUKI K, 1993, J BIOL CHEM, V258, P1914; TANS G, 1991, BLOOD, V77, P2641; TANS G, 1991, J BIOL CHEM, V266, P21864; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8	41	232	238	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21158	21166		10.1074/jbc.270.36.21158	http://dx.doi.org/10.1074/jbc.270.36.21158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673148	hybrid			2022-12-27	WOS:A1995RU05400047
J	CONESA, C; SWANSON, RN; SCHULTZ, P; OUDET, P; SENTENAC, A				CONESA, C; SWANSON, RN; SCHULTZ, P; OUDET, P; SENTENAC, A			ON THE SUBUNIT COMPOSITION, STOICHIOMETRY, AND PHOSPHORYLATION OF THE YEAST TRANSCRIPTION FACTOR-TFIIIC/TAU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; FACTOR-TAU; GENE; PURIFICATION; POLYPEPTIDE; TFIIIB; MUTAGENESIS	Saccharomyces cerevisiae transcription factor IIIC/tau is a multisubunit DNA-binding protein that plays key roles in tRNA and 5 S rRNA gene activation. Subunit composition, stoichiometry, and in vivo phosphorylation of TFIIIC/tau factor were investigated using factor prepared from strains carrying modified forms of TFC1, the gene encoding the 95-kDa TFIIIC/tau subunit (tau95). Using an epitope-tagged TFC1 as well as a TFC1-lacZ fusion, TFIIIC was shown to contain a single 95-kDa subunit, which was localized by electron microscopy into tauA, the A block-binding domain of TFIIIC/tau. Three S-35-labeled polypeptides (at 138, 131, and 91 kDa) coimmunoprecipitated with a tau95-beta-galactosidase fusion protein. The coprecipitation of the 91-kDa polypeptide makes it a likely subunit of the factor. Immunoprecipitation from P-32-labeled extracts revealed that three of the subunits (138, 131, and 95 kDa), but not the 91-kDa component, are phosphorylated in vivo.	CTR ETUD SACLAY, SERV BIOCHIM & GENET MOLEC, F-91191 GIF SUR YVETTE, FRANCE; LAB GENET MOLEC EUCARYOTES, F-67085 STRASBOURG, FRANCE					schultz, patrick/0000-0002-7310-6186				BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; CHIANNILKULCHAI N, 1992, J BIOL CHEM, V267, P23099; CLARK ME, 1990, MOL CELL BIOL, V10, P5106, DOI 10.1128/MCB.10.10.5106; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FRADKIN LG, 1989, MOL CELL BIOL, V9, P4941, DOI 10.1128/MCB.9.11.4941; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEFEBVRE O, 1992, P NATL ACAD SCI USA, V89, P10512, DOI 10.1073/pnas.89.21.10512; MARCK C, 1993, IN PRESS P NATL ACAD; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; Miller J.H., 1972, EXPT MOL GENETICS; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; PARSONS MC, 1992, J BIOL CHEM, V267, P2894; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SHERMAN F, 1986, LABORATORY COURSE MA; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726	41	33	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18047	18052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688737				2022-12-27	WOS:A1993LT74300061
J	WILLIAMS, R; SANGHERA, J; WU, F; CARBONAROHALL, D; CAMPBELL, DL; WARBURTON, D; PELECH, S; HALL, F				WILLIAMS, R; SANGHERA, J; WU, F; CARBONAROHALL, D; CAMPBELL, DL; WARBURTON, D; PELECH, S; HALL, F			IDENTIFICATION OF A HUMAN EPIDERMAL GROWTH-FACTOR RECEPTOR-ASSOCIATED PROTEIN-KINASE AS A NEW MEMBER OF THE MITOGEN-ACTIVATED PROTEIN-KINASE EXTRACELLULAR SIGNAL-REGULATED PROTEIN-KINASE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA STAR OOCYTES; SERINE THREONINE PHOSPHORYLATION; MAP KINASES; TYROSYL PHOSPHORYLATION; MATURATION; RAF-1; PURIFICATION; SUBSTRATE; RESIDUES; TISSUES	A putative mitogen-activated protein kinase (MAPK) has recently been identified, which potentially phosphorylates the human epidermal growth factor (EGF) receptor at a physiological site (Thr-669) and is distinguished from other MAPKs/extracellular signal-regulated protein kinases (ERKs) on the basis of chromatographic, immunological, and kinetic data. Here we report that this newly discovered MAPK is physically associated with the EGF receptor in A431 cells and with the related receptor/tyrosine kinase HER2 (encoded by c-neu) in enzyme preparations obtained from Wilm's tumors. This human EGF receptor-associated kinase is characterized as a 40-kDa Thr-669 kinase that exists in a high molecular mass complex with the respective growth factor receptor. EGF treatment of A431 cells stimulates the tyrosine phosphorylation of p40 and increases Thr-669 kinase activity in p40-containing fractions. The 40-kDa kinase is recognized by affinity-purified polyclonal antibodies directed against the sea star p44mpk and a Pan-ERK antibody directed against the conserved subdomain VIII of MAPKs/ERKs, but is not recognized by antibodies selective for the rat p44erk1 and/or the p42mapk/erk2 isoforms, thus identifying the EGF receptor-associated kinase as a novel MAPK that may regulate receptor function in vivo.	UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV ORTHOPAED SURG,ORTHOPAED SURG RES LAB,LOS ANGELES,CA 90054; UNIV SO CALIF,CHILDRENS HOSP LOS ANGELES,SCH MED,DIV NEONATOL & PEDIAT PULMONOL,LOS ANGELES,CA 90054; UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90054; KINETEK BIOTECHNOL CORP,BIOMED RES LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of British Columbia								ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HALL F L, 1989, Journal of Cell Biology, V109, p217A; HALL FL, 1991, J BIOL CHEM, V266, P17430; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kulp K S, 1990, Proc West Pharmacol Soc, V33, P219; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1992, J BIOL CHEM, V267, P1088; MIKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRESS MF, 1990, ONCOGENE, V5, P953; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SANGHERA JS, 1991, BIOCHIM BIOPHYS ACTA, V1095, P153, DOI 10.1016/0167-4889(91)90078-C; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILLIAMS RT, 1992, ONCOGENE, V7, P423	40	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18213	18217						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688742				2022-12-27	WOS:A1993LT74300084
J	THIMMIG, RL; MCHENRY, CS				THIMMIG, RL; MCHENRY, CS			HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE - EXPRESSION IN ESCHERICHIA-COLI, PURIFICATION, AND CHARACTERIZATION OF A FUNCTIONALLY AND STRUCTURALLY ASYMMETRIC DIMERIC POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; PHOSPHOROTHIOATE-MODIFIED DNA; SACCHAROMYCES-CEREVISIAE; TRANSFER-RNALYS; RIBONUCLEASE-H; III HOLOENZYME; AIDS VIRUS; METHIONINE AMINOPEPTIDASE; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE	Human immunodeficiency virus (HIV) reverse transcriptase isolated from viral particles contains two subunits, p51 and p66. We have produced both subunits in separate Escherichia coli strains using expression vectors. Stop codons were placed immediately after the codon for the carboxyl-terminal residue of the mature processed p51 and p66 subunits found in viral particles. Insertion of a methionine in front of the HIV protease cleavage site in the recombinant protein enabled synthesis of both subunits with the natural amino-terminal proline, since E. coli methionine aminopeptidase cleaves a Met-Pro amino-terminal linkage. That this occurred to an extent greater than 95% was confirmed by sequencing the purified subunits. Examination of the activities of the individual p51 and p66 subunits on a variety of templates and under solution conditions optimized for each subunit revealed a significant catalytic activity for the natural p51 subunit. This result contrasts to results reported earlier for many recombinant forms without the natural amino and/or carboxyl termini. As expected from earlier work, the optimal homopolymeric template for the p66 subunit was poly(rA). For the p51 subunit, poly(dC) was found to be the optimal template; its activity is 2- to 4-fold greater than p66 on poly(dC). The p51 subunit is 13- to 50-fold less active on poly(rC). These findings are discussed in the context of our earlier hypothesis (McHenry, C. S. (1989) in Molecular Biology of Chromosome Function (Adolph, K., ed) Chap. 5, Springer-Verlag, New York) that the HIV reverse transcriptase might be functionally asymmetric with distinct plus- and minus-strand polymerases.			THIMMIG, RL (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80262 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026600] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26600] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARR PJ, 1987, BIO-TECHNOL, V5, P486, DOI 10.1038/nbt0587-486; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; BUISER RG, 1991, J BIOL CHEM, V266, P13103; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHANDRA A, 1986, FEBS LETT, V200, P327, DOI 10.1016/0014-5793(86)81162-0; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; DEVLIN PE, 1988, GENE, V65, P13, DOI 10.1016/0378-1119(88)90412-X; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOLD L, 1990, METHOD ENZYMOL, V185, P89; GRAVES MC, 1988, P NATL ACAD SCI USA, V85, P2449, DOI 10.1073/pnas.85.8.2449; GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; Kornberg A., 1974, DNA REPLICATION; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LEGRICE SFJ, 1987, GENE, V55, P95, DOI 10.1016/0378-1119(87)90252-6; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCHENRY CS, 1988, CANCER CELL, V6, P35; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; MCHENRY CS, 1986, MECHANISMS DNA REPLI, P47; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RHIM H, 1991, J VIROL, V65, P4555, DOI 10.1128/JVI.65.9.4555-4564.1991; ROWLEY GL, 1990, BIOCHEM BIOPH RES CO, V167, P673, DOI 10.1016/0006-291X(90)92078-E; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINHA NK, 1980, J BIOL CHEM, V255, P4290; STARNES M, 1988, J BIOL CHEM, V263, P1; STORMO GD, 1986, MAXIMIZING GENE EXPR, P195; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1986, J VIROL, V59, P743, DOI 10.1128/JVI.59.3.743-745.1986; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEISS R, 1984, RNA TUMOR VIRUSES MO; WEISS R, 1985, RNA TUMOR VIRUSES, V2; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074	80	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16528	16536						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688366				2022-12-27	WOS:A1993LQ33600065
J	DEBIEC, H; RONCO, PM				DEBIEC, H; RONCO, PM			IDENTIFICATION AND EPITOPE ANALYSIS OF THE RENAL NA+/P(I) COTRANSPORT PROTEIN USING MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; DEPENDENT PHOSPHATE-TRANSPORT; OPOSSUM KIDNEY-CELLS; PARATHYROID-HORMONE; CONFORMATIONAL-CHANGES; FUNCTIONAL ASYMMETRY; RAT; VESICLES; CORTEX; SYSTEM	Seven monoclonal antibodies (mAbs) were raised against a rabbit renal brush-border glycoprotein (molecular mass, 63-66 kDa), presumably involved in Na+/P(i) cotransport, which we had previously purified and reconstituted in active form in proteoliposomes (Debiec, H., Lorenc, R., and Ronco, P. M. (1992) Biochem. J. 286, 97-102). Antibody specificity for the 63-66-kDa protein was analyzed by enzyme-linked immunosorbent assay and confirmed by Western blotting and immunoaffinity chromatography of solubilized brush-border membranes (BBM), which both yielded a single 63-66-kDa band. Enzyme-linked immunosorbent assay and immunoblotting of renal cortical cell subfractions localized the immunoreactive protein to the brush-border membrane. This location was confirmed by indirect immunofluorescence of kidney cortex sections. Binding of two of the seven mAbs (63A20 and 206A126) to native BBM only occurred when the related epitope was exposed in the presence or absence of Na+, respectively; the other mAbs did not react with native BBM probably because of intramembranous orientation of the epitopes. mAb 63A20 inhibited dose-dependently Na+/P(i) cotransport when preincubation of BBM was carried out in the presence of Na+ but did not affect Na+/D-glucose cotransport. Proteoliposomes formed from BBM proteins depleted of the 63-66-kDa protein by affinity chromatography with mAb 63A20 showed an 85% reduction in Na+/P(i) cotransport, whereas Na+/D-glucose cotransport was not modified. These results thus establish that the 63-66-kDa BBM protein is the essential component of the Na+/P(i) cotransport system. The present study also provides the first immunologic tools available for immunohistochemical localization of the Na+/P(i) cotransporter. Finally, the identification of a functional epitope by mAb 63A20 opens up new ways to explore the molecular aspects of P(i) uptake.			DEBIEC, H (corresponding author), HOP TENON, INSERM, U64, 4 RUE CHINE, F-75970 PARIS 20, FRANCE.		Ronco, Pierre/AAC-8390-2022; Debiec, Hanna/AAL-8144-2021	Debiec, Hanna/0000-0002-8946-8245				ALMAHROUQ HA, 1991, J BIOL CHEM, V266, P1422; AMIEL C, 1970, PFLUG ARCH EUR J PHY, V317, P93, DOI 10.1007/BF00592495; AMSTUTZ M, 1985, AM J PHYSIOL, V248, pF705, DOI 10.1152/ajprenal.1985.248.5.F705; BAGINSKY ML, 1969, J BIOL CHEM, V244, P5313; BELIVEAU R, 1987, J BIOL CHEM, V262, P16885; BELIVEAU R, 1990, BIOCHEM J, V268, P195, DOI 10.1042/bj2680195; BELIVEAU R, 1988, AM J PHYSIOL, V23, pF329; BERNER W, 1976, BIOCHEM J, V160, P467, DOI 10.1042/bj1600467; BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BOUMENDILPODEVIN EF, 1983, BIOCHIM BIOPHYS ACTA, V735, P86, DOI 10.1016/0005-2736(83)90263-8; BRUNETTE MG, 1985, PEDIATR RES, V19, P1179, DOI 10.1203/00006450-198511000-00013; CAVERZASIO J, 1986, J BIOL CHEM, V261, P3233; CAVERZASIO J, 1988, CALCIFIED TISSUE INT, V43, P83, DOI 10.1007/BF02555151; CROSS HS, 1990, MINER ELECTROL METAB, V16, P115; DEBIEC H, 1992, BIOCHEM J, V286, P97, DOI 10.1042/bj2860097; DEBIEC H, 1991, Journal of the American Society of Nephrology, V2, P759; DEBIEC H, 1988, BIOCHEM J, V255, P185, DOI 10.1042/bj2550185; DEBOLAND AR, 1983, BIOCHIM BIOPHYS ACTA, V733, P264, DOI 10.1016/0005-2736(83)90531-X; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DESCHATRETTE J, 1980, CELL, V19, P1043, DOI 10.1016/0092-8674(80)90095-1; FORSTNER GG, 1968, BIOCHEM J, V106, P381, DOI 10.1042/bj1060381; GORG A., 1985, SCI TOOLS, V32, P5; HAMMERMAN MR, 1983, KIDNEY INT, V23, P100; HRUSKA K, 1984, ADV EXP MED BIOL, V178, P3; JACK MG, 1989, J BIOL CHEM, V264, P3904; KAPLAN RS, 1989, METHOD ENZYMOL, V172, P393; KEMPSON SA, 1986, BIOCHEM PHARMACOL, V35, P721, DOI 10.1016/0006-2952(86)90237-6; KOEPSELL H, 1988, J BIOL CHEM, V263, P18419; KOHLER G, 1975, NATURE, V256, P498; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JT, 1984, BIOCHIM BIOPHYS ACTA, V774, P254, DOI 10.1016/0005-2736(84)90299-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORMICK JI, 1988, P NATL ACAD SCI USA, V85, P7877, DOI 10.1073/pnas.85.21.7877; MIZGALA CL, 1985, PHYSIOL REV, V65, P431, DOI 10.1152/physrev.1985.65.2.431; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PEERCE BE, 1989, AM J PHYSIOL, V256, pG645, DOI 10.1152/ajpgi.1989.256.4.G645; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; PIMPLIKAR SW, 1988, J BIOL CHEM, V263, P4485; QUAMME GA, 1990, AM J PHYSIOL, pF356; QUIGLEY JP, 1969, BIOCHIM BIOPHYS ACTA, V173, P456, DOI 10.1016/0005-2736(69)90010-8; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P624, DOI 10.1007/BF00370606; RESHKIN SJ, 1990, PFLUG ARCH EUR J PHY, V416, P554, DOI 10.1007/BF00382689; RONCO P, 1986, AM J PHYSIOL, V250, pC506, DOI 10.1152/ajpcell.1986.250.3.C506; SCHALI C, 1986, BIOCHEM J, V235, P189, DOI 10.1042/bj2350189; SCHWAB SJ, 1984, AM J PHYSIOL, V246, pF663, DOI 10.1152/ajprenal.1984.246.5.F663; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; WALKER JJ, 1987, AM J PHYSIOL, V252, pF226, DOI 10.1152/ajprenal.1987.252.2.F226; WELLS RG, 1990, J AM SOC NEPHROL, V1, P746; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; WU JSR, 1987, BIOCHEMISTRY-US, V26, P5783, DOI 10.1021/bi00392a030; WUARIN F, 1989, BIOCHIM BIOPHYS ACTA, V981, P185, DOI 10.1016/0005-2736(89)90027-8	53	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13356	13363						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685760				2022-12-27	WOS:A1993LH55300051
J	TSE, CM; LEVINE, SA; YUN, CHC; MONTROSE, MH; LITTLE, PJ; POUYSSEGUR, J; DONOWITZ, M				TSE, CM; LEVINE, SA; YUN, CHC; MONTROSE, MH; LITTLE, PJ; POUYSSEGUR, J; DONOWITZ, M			CLONING AND EXPRESSION OF A RABBIT CDNA-ENCODING A SERUM-ACTIVATED ETHYLISOPROPYLAMILORIDE-RESISTANT EPITHELIAL NA+/H+ EXCHANGER ISOFORM (NHE-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; H+ EXCHANGER; GROWTH; CELLS; PH; GLYCOPROTEIN; ANTIPORTER; TRANSPORT; KINETICS	A unique Na+/H+ exchanger isoform, NHE-2, was cloned and characterized. NHE-2 is a protein of 809 amino acids with a calculated size of 90,787. It exhibits overall amino acid identity of 50, 44, and 60% with other cloned mammalian Na+/H+ exchangers NHE-1, NHE-3, and NHE-4, respectively. Northern blot analysis of poly(A+) RNA isolated from rabbit ileum, kidney cortex, and kidney medulla using NHE-2 cDNA as a probe revealed messages of 5.2, 4.2, and 3.2 kilobases with relative abundance (in descending order) kidney medulla > kidney cortex > ileum. More detailed tissue distribution of message was performed by ribonuclease protection assay. NHE-2 was predominantly expressed in kidney, intestine, and adrenal gland with a small amount in skeletal muscle and trachea. Stable expression of NHE-2 in PS120 fibroblasts confirmed that NHE-2 is a functional Na+/H+ exchanger which is defined by amiloride-sensitive Na+-dependent alkalinization of acid-loaded cells. NHE-2 has the same K(i) for amiloride inhibition as NHE-1 (1 muM) but is 25-fold more resistant to ethylisopropylamiloride inhibition than is NHE-1 (500 versus 20 nM). Like NHE-1, NHE-2 can be activated by serum. Expression of NHE-2 in a polarized human intestinal epithelial cell line, Caco-2 cells, results in functional expression of NHE-2 in the apical membrane. Thus, we conclude that NHE-2 is a candidate to be an apical membrane Na+/H+ exchanger in intestinal and renal epithelial cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205; CNRS,CTR BIOCHIM,F-06034 NICE,FRANCE	Johns Hopkins University; Centre National de la Recherche Scientifique (CNRS)	TSE, CM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,DIV GASTROENTEROL,918 ROSS RES BLDG,720 RUTLAND AVE,BALTIMORE,MD 21205, USA.		Little, Peter J./F-9865-2015	Little, Peter J./0000-0002-0335-3835	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043778, R01DK042457, R01DK026523] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK26523, R29DK43778, R01DK42457] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BRANT SR, 1993, IN PRESS GENOMICS, V15; CLARK JD, 1991, AM J PHYSIOL, V261, pC945, DOI 10.1152/ajpcell.1991.261.6.C945; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGGERTY C, 1988, P NATL ACAD SCI USA, V88, P6797; HILDEBRANDT F, 1991, BIOCHIM BIOPHYS ACTA, V1129, P105, DOI 10.1016/0167-4781(91)90221-7; KNICKELBEIN R, 1983, AM J PHYSIOL, V245, pG504, DOI 10.1152/ajpgi.1983.245.4.G504; KNICKELBEIN RG, 1990, AM J PHYSIOL, V259, pG802, DOI 10.1152/ajpgi.1990.259.5.G802; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; Maniatis T, 1989, DECONTAMINATION DILU; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RALEYSUSMAN KM, 1991, J BIOL CHEM, V266, P2739; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WATSON AJM, 1991, AM J PHYSIOL, V261, pG229, DOI 10.1152/ajpgi.1991.261.2.G229; WEISER MM, 1973, J BIOL CHEM, V248, P2536	24	240	246	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11917	11924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685025				2022-12-27	WOS:A1993LF28400069
J	KIRCHHAUSEN, T; TOYODA, T				KIRCHHAUSEN, T; TOYODA, T			IMMUNOELECTRON MICROSCOPIC EVIDENCE FOR THE EXTENDED CONFORMATION OF LIGHT-CHAINS IN CLATHRIN TRIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEX AP-2; HEAVY-CHAIN; ELECTRON-MICROSCOPY; UNCOATING ATPASE; BINDING; DOMAINS; INTERMEDIATE; SEQUENCES; COATS	Clathrin is a major component of the basket-like network of hexagons and pentagons that forms the ''coat'' on the cytoplasmic face of the plasma membrane and the trans Golgi network during the invagination of coated pits. Soluble clathrin is a three-legged structure (triskelion) comprising three identical heavy chains and three different light chains located toward the center of the triskelion on the proximal segment of the leg. All mammalian light chains contain a central domain of 10 heptad repeats, which is necessary for the interaction with heavy chain. Because the repeats are characteristic of alpha helical coiled coils, we proposed that the central domain had an extended conformation (Kirchhausen, T., Scarmato, P., and Harrison, S. C. et al. (1987) Science 236, 320-324). However, an alternative model has recently been proposed (Nathke, I. S., Heuser, J., Lupas, A., Stock, J., Turck, C. W., and Brodsky, F. M. (1992) Cell 68, 899-910). Here, we use single-molecule electron microscopy of clathrin decorated with monoclonal antibodies directed against different epitopes on light chains to show that the light chain central domain has an extended conformation and reaches along most of the proximal segment of the heavy chain leg.	HARVARD UNIV, SCH MED, DEPT ANAT & CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	KIRCHHAUSEN, T (corresponding author), HARVARD UNIV, SCH MED, CTR BLOOD RES, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.							BRODSKY FM, 1987, NATURE, V326, P203, DOI 10.1038/326203a0; FLAHERTY CD, 1990, CELL, V62, P875; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1986, J ULTRA MOL STRUCT R, V94, P199, DOI 10.1016/0889-1605(86)90067-4; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; LISANTI MP, 1982, BIOCHEM J, V201, P297, DOI 10.1042/bj2010297; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MUNRO S, 1984, EMBO J, V3, P3087, DOI 10.1002/j.1460-2075.1984.tb02263.x; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SCHMID SL, 1984, NATURE, V311, P228, DOI 10.1038/311228a0; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; UNGEWICKELL E, 1981, COLD SPRING HARB SYM, V46, P723, DOI 10.1101/SQB.1982.046.01.069; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x	26	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10268	10273						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683673				2022-12-27	WOS:A1993LB80000048
J	KLARMANN, GJ; SCHAUBER, CA; PRESTON, BD				KLARMANN, GJ; SCHAUBER, CA; PRESTON, BD			TEMPLATE-DIRECTED PAUSING OF DNA-SYNTHESIS BY HIV-1 REVERSE-TRANSCRIPTASE DURING POLYMERIZATION OF HIV-1 SEQUENCES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRAL RECOMBINATION; PLUS-STRAND; PROCESSIVITY; REPLICATION; MECHANISM; KINETICS	Replication of human immunodericiency virus type 1 (HIV-1) requires reverse transcriptase (RT) to synthesize double-stranded proviral DNA (9.7 kilobases) through a complex mechanism utilizing both RNA and DNA templates. We have examined DNA synthesis by HIV-1 RT on RNA and DNA templates derived from the HIV-1 genome using a primer extension assay in vitro. Analysis of polymerization products on sequencing gels revealed strong pauses in synthesis, on both RNA and DNA templates, in homopolymeric nucleotide runs, and at regions of predicted secondary structure. Polymerization pauses occurred in runs of template rGs (greater-than-or-equal-to 4 bases) and rCs (greater-than-or-equal-to 3 bases) during minus-strand synthesis on RNA templates, and in most runs (greater-than-or-equal-to 4 bases) of template dTs and dAs during plus-strand synthesis on DNA templates. Pausing also occurred on both templates within the first few nucleotides of the predicted hairpin structures of the Rev response element. The locations of pauses were dependent on template sequence and were unaffected by primer positioning, RT concentration, and ionic strength. Recombinant and virion-derived HIV-1 RTs showed similar pausing patterns. DNA products that accumulated at HIV-1 RT pause sites on RNA templates were extended by continued incubation with excess RT from Moloney murine leukemia virus, showing that the RNA templates were not broken or otherwise unable to support polymerization. Polymerizations conducted in the presence of a poly(rA).oligo(dT) trap showed that pausing results from two mechanisms: 1) RT remaining bound to the primer-template and polymerizing at a greatly reduced rate, or 2) RT dissociating from the primer-template. These results demonstrate that specific HIV-1 RNA and DNA template sequences are capable of interrupting processive DNA synthesis by HIV-1 RT in vitro. Pausing may serve specific functions in HIV-1 replication and mutagenesis. Moreover, these data suggest that one or more accessory factors are required to complete proviral DNA synthesis in vivo and that efficient HIV-1 DNA synthesis may require multiple origins.	RUTGERS UNIV,COLL PHARM,CANC RES LAB,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick					NATIONAL CANCER INSTITUTE [R29CA048174, S15CA051339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005022] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA48174, S15 CA51339] Funding Source: Medline; NIEHS NIH HHS [P30 ES05022] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOONE LR, 1981, J VIROL, V37, P109, DOI 10.1128/JVI.37.1.109-116.1981; BORROTOESODA K, 1991, J VIROL, V65, P1952, DOI 10.1128/JVI.65.4.1952-1959.1991; BUISER RG, 1991, J BIOL CHEM, V266, P13103; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; Coffin J. M., 1990, VIROLOGY, P1437; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DECLERCQ E, 1991, J ACQ IMMUN DEF SYND, V4, P207; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON C, 1984, RNA TUMOR VIRUSES MO, P513; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HIZI A, 1991, J BIOL CHEM, V266, P6230; HOUTS GE, 1979, J VIROL, V29, P517, DOI 10.1128/JVI.29.2.517-522.1979; HSU TW, 1982, J VIROL, V44, P47, DOI 10.1128/JVI.44.1.47-53.1982; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUBER HE, 1989, J BIOL CHEM, V264, P4669; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; LE SY, 1988, NUCLEIC ACIDS RES, V16, P5153, DOI 10.1093/nar/16.11.5153; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MCHENRY CS, 1989, MOL BIOL CHROMOSOME, P97; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SAENGER W, 1984, PRINCIPLES NUCLEIC A; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; YU H, 1992, J BIOL CHEM, V267, P10888; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	48	181	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9793	9802						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683663				2022-12-27	WOS:A1993LA68900093
J	SIMONSON, MS; HERMAN, WH				SIMONSON, MS; HERMAN, WH			PROTEIN-KINASE-C AND PROTEIN-TYROSINE KINASE-ACTIVITY CONTRIBUTE TO MITOGENIC SIGNALING BY ENDOTHELIN-1 - CROSS-TALK BETWEEN G-PROTEIN-COUPLED RECEPTORS AND PP60C-SRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; VASCULAR SMOOTH-MUSCLE; CHROMOSOMAL ASSIGNMENT; DNA-SYNTHESIS; VASOCONSTRICTOR PEPTIDE; DEPENDENT MECHANISM; PHOSPHOLIPASE-C; CDNA CLONING; RAT-KIDNEY; EXPRESSION	Endothelin (ET) peptides are potent growth factors that bind to G protein-coupled receptors. Although short-term signals activated by ET receptors have been extensively characterized, relatively little is known about mitogenic signal transduction. We investigated the ET receptor subtype involved in mitogenic signaling in glomerular mesangial cells and the role of protein kinase C (PKC) and protein tyrosine kinase (PTK) activity. Pertussis toxin attenuates increases in [Ca2+]i by ET-1 but not [H-3]thymidine uptake. An ET(A)-selective receptor antagonist, BQ 123, blocks increments in [Ca2+]i by ET-1 and inhibits [H-3]thymidine uptake. A nonselective ET(A)-ET(B) receptor antagonist (PD 142893) blocked [H-3]thymidine uptake, but ET(B) receptor-selective agonists (S6c and [Ala1,Ala3,Ala11,Ala15]ET-1(6-21)) were unable to increase [Ca2+]i or [H-3]thymidine uptake. Collectively, these data suggest that mitogenic signaling occurs through an ET(A) receptor subtype in mesangial cells. Experiments with both PKC inhibition and depletion demonstrate that PKC was necessary but not sufficient for mitogenic signaling. ET-1 increased tyrosine phosphorylation of cellular proteins in quiescent mesangial cells that was blocked by preincubation with herbimycin A. Two chemically and mechanistically dissimilar PTK inhibitors (herbimycin A and genistein) blocked [H-3]thymidine uptake by ET-1. In addition, herbimycin A attenuated c-fos induction, AP-1 DNA binding, and transcription directed by an AP-1 cis-element in response to ET-1. Taken together, these data suggest that mitogenic signaling by ET-1 also involves a PTK-based mechanism. We further demonstrated that ET-1 stimulated autophosphorylation of pp60c-src and pp60c-arc-catalyzed phosphorylation of a peptide substrate specific for PTK activity. That the dose-response relationship for ET-1-induced pp60c-src activation and [H-3]thymidine uptake were similar suggests that these events might be functionally linked. Thus, cross-talk between G protein-coupled receptors and nonreceptor PTK such as pp60c-src might be involved in transcriptional regulation and mitogenic signaling by ET-1.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, DIV NEPHROL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046939] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46939-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BALDI E, 1991, J PHARMACOL EXP THER, V256, P581; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BLOCH KD, 1991, GENOMICS, V10, P236, DOI 10.1016/0888-7543(91)90505-9; BLOCH KD, 1989, J BIOL CHEM, V264, P18156; BOBIK A, 1990, AM J PHYSIOL, V258, pC408, DOI 10.1152/ajpcell.1990.258.3.C408; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CODY WL, 1992, J MED CHEM, V35, P3301, DOI 10.1021/jm00095a029; Dubin D, 1989, J VASC MED BIOL, V1, P150; EGUCHI S, 1992, FEBS LETT, V302, P243, DOI 10.1016/0014-5793(92)80451-L; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; JAFFER FE, 1990, KIDNEY INT, V38, P1193, DOI 10.1038/ki.1990.333; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KUSUHARA M, 1992, CANCER RES, V52, P3011; LANDAN G, 1991, TOXICON, V29, P237, DOI 10.1016/0041-0101(91)90108-4; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; MACRAE AD, 1992, TRENDS ENDOCRIN MET, V3, P153, DOI 10.1016/1043-2760(92)90164-V; MARSDEN PA, 1991, AM J PHYSIOL, V261, pF117, DOI 10.1152/ajprenal.1991.261.1.F117; MARTIN ER, 1990, J BIOL CHEM, V265, P14044; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; OHLSTEIN EH, 1992, EUR J PHARM-MOLEC PH, V225, P347, DOI 10.1016/0922-4106(92)90109-9; PAI JK, 1991, CELL REGUL, V2, P897, DOI 10.1091/mbc.2.11.897; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RUBANYI GM, 1992, ENDOTHELIN; SAEKI T, 1991, BIOCHEM BIOPH RES CO, V179, P286, DOI 10.1016/0006-291X(91)91367-L; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SIMONSON MS, 1991, EXP CELL RES, V192, P148, DOI 10.1016/0014-4827(91)90169-U; TAKEDA M, 1992, KIDNEY INT, V41, P1713, DOI 10.1038/ki.1992.245; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; THOMAS CP, 1991, AM J PHYSIOL, V260, pF347, DOI 10.1152/ajprenal.1991.260.3.F347; TORTI M, 1992, BIOCHEM BIOPH RES CO, V186, P440, DOI 10.1016/S0006-291X(05)80827-7; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; WILKES BM, 1991, AM J PHYSIOL, V260, pF913, DOI 10.1152/ajprenal.1991.260.6.F913; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHANG W, 1991, NEUROSCI LETT, V123, P164, DOI 10.1016/0304-3940(91)90921-F	66	229	232	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9347	9357						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683650				2022-12-27	WOS:A1993LA68900033
J	RODRIGUEZPARIS, JM; NOLTA, KV; STECK, TL				RODRIGUEZPARIS, JM; NOLTA, KV; STECK, TL			CHARACTERIZATION OF LYSOSOMES ISOLATED FROM DICTYOSTELIUM-DISCOIDEUM BY MAGNETIC FRACTIONATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ENDOCYTIC PATHWAY; PLASMA-MEMBRANE; ENDOSOMES; SEPARATION; VACUOLES; CELLS; IRON; PHOSPHATIDYLGLYCEROL; QUANTITATION	Superparamagnetic particles were prepared with iron oxide cores of congruent-to 8 nm diameter and dextran coats. After feeding the probe to the amoeba, Dictyostelium discoideum, for 15 min and chasing for 15 min, a lysosome fraction was isolated magnetically. Isolates contained 76% of ingested iron, 82% of ingested fluorescent dextran, 1.3% of cell protein, 4% of the lipid, 28% of acid phosphatase, and 5% of the vacuolar H+-ATPase. Enrichment in endocytic markers was congruent-to 60-fold; markers for other organelles were <0.5%. The lysosomes were homogeneous, round (0.4-1.1 mum in diameter), and frequently adherent to one another through zones of intimate apposition. Cells were also fed the iron probe continuously for 3 h to fill their entire endocytic pathway; in this case, isolates contained 3.3% of cell protein, 11% of lipid, and 49% of cell acid phosphatase. Bis(monoacylglycerol)phosphate (BMP), a lipid characteristic of lysosomes in animal cells, comprised congruent-to 6% of biosynthetically labelled cell lipids and up to half of the lipid in the endocytic pathway. Essentially all of the cellular BMP was recovered in isolates prepared after 3 h of feeding. The specificity and abundance of BMP in the endocytic organelles of this early diverged protist suggests that this phospholipid serves a universal and essential function in endocytosis.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM 07183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; BANERJEE P, 1990, BIOCHIM BIOPHYS ACTA, V1044, P305, DOI 10.1016/0005-2760(90)90074-8; BAUER A, 1990, BIOL CELL, V70, P61, DOI 10.1016/0248-4900(90)90361-6; BEAUFAY H, 1969, LYSOSOM BIOL PATHOL, P515; BEAUMELLE BD, 1990, J CELL BIOL, V111, P1811, DOI 10.1083/jcb.111.5.1811; BECICH MJ, 1991, EUR J CELL BIOL, V55, P71; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DECHASTELLIER C, 1983, EUR J CELL BIOL, V30, P233; FERBER E, 1970, EUR J BIOCHEM, V14, P253, DOI 10.1111/j.1432-1033.1970.tb00284.x; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FUCHS R, 1989, J BIOL CHEM, V264, P2212; HEFTMANN E, 1960, ARCH BIOCHEM BIOPHYS, V91, P266, DOI 10.1016/0003-9861(60)90500-2; Holtzman E, 1989, LYSOSOMES; HOSTETLER KY, 1992, METHOD ENZYMOL, V209, P104; HUTERER SJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P68, DOI 10.1016/0005-2760(89)90308-1; Kates M, 1972, TECHNIQUES LIPIDOLOG, P351; KHALAFALLA SE, 1980, IEEE T MAGN, V16, P178, DOI 10.1109/TMAG.1980.1060578; KLEIN G, 1986, BIOCHEM BIOPH RES CO, V138, P1146, DOI 10.1016/S0006-291X(86)80402-8; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOHDEN U, 1989, ANAL BIOCHEM, V182, P77, DOI 10.1016/0003-2697(89)90721-5; LONG BH, 1974, J BIOL CHEM, V249, P521; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATSUZAWA Y, 1980, J LIPID RES, V21, P202; MATSUZAWA Y, 1978, J BIOL CHEM, V353, P6650; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; OHKUMA S, 1987, LYSOSOMES THEIR ROLE, P115; OWEN CS, 1987, CELL SEPARATION METH, V4, P259; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1993, J BIOL CHEM, V268, P6742; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; POORTHUIS BJHM, 1976, J BIOL CHEM, V251, P4596; RENKONEN O, 1965, J AM OIL CHEM SOC, V42, P298, DOI 10.1007/BF02540133; SAKO Y, 1990, J BIOCHEM-TOKYO, V107, P846, DOI 10.1093/oxfordjournals.jbchem.a123136; SATO SB, 1986, J BIOCHEM-TOKYO, V100, P1481, DOI 10.1093/oxfordjournals.jbchem.a121855; SKIPSKI VP, 1974, METHOD ENZYMOL, V34, P396; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1983; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; THILO L, 1983, METHOD ENZYMOL, V98, P415; THILO L, 1980, P NATL ACAD SCI-BIOL, V77, P1015, DOI 10.1073/pnas.77.2.1015; THOMPSON GA, 1969, J PROTOZOOL, V16, P397, DOI 10.1111/j.1550-7408.1969.tb02287.x; THORNBURG T, 1991, J BIOL CHEM, V266, P6834; WAITE M, 1990, J BIOL CHEM, V265, P21720; WETZEL MG, 1969, J CELL BIOL, V43, P90, DOI 10.1083/jcb.43.1.90; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114; Whitesides G.M., 1983, TRENDS BIOTECHNOL, V1, P144, DOI [DOI 10.1016/0167-7799(83)90005-7, 10.1016/0167-7799(83)90005-7]; WOODING A, 1988, IEEE T MAGN, V24, P1650, DOI 10.1109/20.11559; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	50	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9110	9116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682559				2022-12-27	WOS:A1993KX81100103
J	SALI, A; MATSUMOTO, R; MCNEIL, HP; KARPLUS, M; STEVENS, RL				SALI, A; MATSUMOTO, R; MCNEIL, HP; KARPLUS, M; STEVENS, RL			3-DIMENSIONAL MODELS OF 4 MOUSE MAST-CELL CHYMASES - IDENTIFICATION OF PROTEOGLYCAN BINDING REGIONS AND PROTEASE-SPECIFIC ANTIGENIC EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSTATIC INTERACTIONS CONTRIBUTE; CHONDROITIN SULFATE PROTEOGLYCAN; SECRETORY GRANULE PROTEOGLYCANS; MOLECULAR-CLONING; SERINE PROTEASE; BONE-MARROW; HEPARIN PROTEOGLYCANS; PROTEOLYTIC-ENZYMES; HOMOLOGOUS PROTEINS; NEUTRAL PROTEASES	Mouse mast cell protease (mMCP) 1, mMCP-2, MMCP-4, and mMCP-5 are serine proteases which are predicted to have chymotryptic specificity (chymases). They are bound to negatively charged heparin or chondroitin sulfate proteoglycans and are stored in secretory granules. Three-dimensional (3D) models of these four proteases were constructed with a comparative molecular modeling technique based on satisfaction of spatial constraints. The models were used to predict immunogenic epitopes and surface regions that are likely to interact with proteoglycans. Nine potential antigenic segments in the four chymases were identified on the basis of solvent accessibility, protrusion, flexibility, and sequence variability. These segments are suitable epitopes for preparation of protease-specific antipeptide immunoglobulin. Two regions with net charges ranging from +6 to +10 at neutral pH were found on the surfaces of mMCP-4 and mMCP-5. The two regions are located far from the substrate binding cleft at diametrically opposite ends of the folded proteases. A strong positive electrostatic potential surrounds the two regions. Thus, they are good candidates for binding sites that interact with heparin proteoglycan in the granules of serosal mast cells. In contrast, mMCP-1 and mMCP-2, which are present in granules of mucosal mast cells that contain chondroitin sulfate, lack one of these regions and have a lower charge density in the other. The differences between the 3D models provide a structural basis for the selective localization of specific chymases within mouse mast cells that contain different proteoglycans.	HARVARD UNIV,DEPT CHEM,12 OXFORD ST,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital				McNeil, Hugh Patrick/0000-0003-4336-2960	NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-31599, AI-23483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, R01AI023483, U19AI031599] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; BODE W, 1992, PROTEIN SCI, V1, P426; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BRAUN W, 1985, J MOL BIOL, V186, P611, DOI 10.1016/0022-2836(85)90134-2; BRIGGAMAN RA, 1984, J EXP MED, V160, P1027, DOI 10.1084/jem.160.4.1027; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BURKS C, 1985, COMPUT APPL BIOSCI, V1, P225; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CHAKRABARTI B, 1980, CRC CR REV BIOCH MOL, V8, P225, DOI 10.3109/10409238009102572; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DAOPIN S, 1991, J MOL BIOL, V221, P873, DOI 10.1016/0022-2836(91)80181-S; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DELAPAZ P, 1986, EMBO J, V5, P415, DOI 10.1002/j.1460-2075.1986.tb04227.x; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FORSBERG LS, 1988, BIOCHIM BIOPHYS ACTA, V416, P416; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; FROMMEL C, 1988, J THEOR BIOL, V132, P171, DOI 10.1016/S0022-5193(88)80155-3; FUJINAGA M, 1987, J MOL BIOL, V195, P373, DOI 10.1016/0022-2836(87)90658-9; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1992, J BIOL CHEM, V267, P8473; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P4918, DOI 10.1073/pnas.89.11.4918; GREER J, 1990, PROTEINS, V7, P317, DOI 10.1002/prot.340070404; GRUBER BL, 1988, J IMMUNOL, V140, P3936; GUO NH, 1992, J BIOL CHEM, V267, P19349; GURISH MF, 1992, FASEB J, V6, pA1723; HEUCK CC, 1985, J BIOL CHEM, V260, P4598; HORN D, 1980, POLYM AMINES AMMONIU, P333; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUBBARD TJP, 1987, PROTEIN ENG, V1, P159, DOI 10.1093/protein/1.3.159; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOKKONEN JO, 1989, J BIOL CHEM, V264, P10749; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; MAIER M, 1983, J IMMUNOL, V130, P2352; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; MCLACHLAN AD, 1979, J MOL BIOL, V128, P49, DOI 10.1016/0022-2836(79)90308-5; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MIZUTANI H, 1991, J EXP MED, V174, P821, DOI 10.1084/jem.174.4.821; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; NOVOTNY J, 1987, IMMUNOL TODAY, V8, P26, DOI 10.1016/0167-5699(87)90828-0; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RAZIN E, 1982, J BIOL CHEM, V257, P7229; READ RJ, 1988, J MOL BIOL, V200, P523, DOI 10.1016/0022-2836(88)90541-4; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; REYNOLDS RA, 1985, ACTA CRYSTALLOGR B, V41, P139, DOI 10.1107/S010876818500177X; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SALEMME FR, 1976, J MOL BIOL, V102, P562; SALI A, 1990, TRENDS BIOCHEM SCI, V15, P235, DOI 10.1016/0968-0004(90)90036-B; SALI A, 1990, J MOL BIOL, V212, P403, DOI 10.1016/0022-2836(90)90134-8; SALI A, 1991, THESIS U LONDON LOND; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; Seppa H, 1979, Acta Histochem, V64, P64; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STEVENS FL, 1992, ARTHRITIS RHEUM, V35, P325; STEVENS RL, 1986, J IMMUNOL, V137, P291; SUMMERS NL, 1989, J MOL BIOL, V210, P785, DOI 10.1016/0022-2836(89)90109-5; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; Swindells MB, 1991, CURR OPIN STRUC BIOL, V1, P219, DOI 10.1016/0959-440X(91)90064-Z; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; THORNTON JM, 1986, EMBO J, V5, P409, DOI 10.1002/j.1460-2075.1986.tb04226.x; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6; URATA H, 1990, J BIOL CHEM, V265, P22348; VARTIO T, 1981, J BIOL CHEM, V256, P471; WALTER J, 1982, ACTA CRYSTALLOGR B, V38, P1462, DOI 10.1107/S0567740882006153; WENDOLOSKI JJ, 1989, PROTEINS, V5, P313, DOI 10.1002/prot.340050407; WESTHOF E, 1984, NATURE, V311, P123, DOI 10.1038/311123a0; WHINNA HC, 1991, J BIOL CHEM, V266, P8129; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144; YURT RW, 1977, J BIOL CHEM, V252, P518; ZHU ZY, 1992, PROTEIN ENG, V5, P43, DOI 10.1093/protein/5.1.43	97	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9023	9034						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682557				2022-12-27	WOS:A1993KX81100092
J	SIMONET, WS; BUCAY, N; LAUER, SJ; TAYLOR, JM				SIMONET, WS; BUCAY, N; LAUER, SJ; TAYLOR, JM			A FAR-DOWNSTREAM HEPATOCYTE-SPECIFIC CONTROL REGION DIRECTS EXPRESSION OF THE LINKED HUMAN APOLIPOPROTEIN-E AND C-I GENES IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; E MESSENGER-RNA; PERIPHERAL-TISSUES; NONHUMAN-PRIMATES; NEGATIVE ELEMENTS; ENHANCER ELEMENTS; GLOBIN GENE; HIGH-LEVEL; LIVER; LIPOPROTEINS	The human apolipoprotein (apo) E and apoC-I genes are located 5 kilobases apart in the same transcriptional orientation on chromosome 19, and they are expressed at high levels in the liver with lower levels of expression in selected other tissues. Analysis of a series of overlapping human apoE and apoC-I genomic fragments in transgenic mice revealed that the expression of these transgenes in the liver requires a common cis-acting regulatory domain. This hepatic control region (HCR) was localized to a 764-base pair region that is located about 18 kilobases downstream of the apoE promoter and about 9 kilobases downstream of the apoC-I promoter. All the transgenic animals that had been prepared with a construct that contained this region had relatively high levels of transgene expression in the liver, whereas constructs that lacked this region showed no expression in the liver. In situ hybridization studies showed that the HCR directed apoE and apoC-I transgene expression in hepatocytes. When the HCR from the apoE/C-I gene locus was ligated proximal to a human apoA-IV gene fragment, which is not normally expressed in the liver, the resulting apoA-IV/HCR fusion construct was expressed at high levels in the liver, indicating that the HCR could direct high level liver expression of a heterologous promoter/gene construct. Expression of the apoE transgene in the liver and kidney, and perhaps other tissues, required the presence of a nonspecific proximal enhancer element in the apolipoprotein E gene promoter, located between 161 and 141 bp relative to the transcription initiation site. However, the proximal apoE gene promoter, including this enhancer element, contained no sequences capable of directing hepatocyte expression in the absence of the HCR. Thus, the far-downstream HCR appears to contain all of the sequences necessary for determining high level liver-specific gene expression.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,POB 419100,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes					NHLBI NIH HHS [HL37063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; GILMAN M, 1990, CURRENT PROTOCOLS MO, V1; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HANSCOMBE O, 1989, GENE DEV, V3, P1572, DOI 10.1101/gad.3.10.1572; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LAUER SJ, 1991, ARTERIOSCLEROSIS, V11, pA1390; LIN CT, 1986, J CLIN INVEST, V78, P947, DOI 10.1172/JCI112685; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Maniatis T., 1982, MOL CLONING; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RALL SC, 1982, J BIOL CHEM, V257, P4171; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMITH JD, 1988, J BIOL CHEM, V263, P8300; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WILLIAMS DL, 1985, J BIOL CHEM, V260, P2444; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059	37	201	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8221	8229						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681840				2022-12-27	WOS:A1993KW97900092
J	SATOH, MS; POIRIER, GG; LINDAHL, T				SATOH, MS; POIRIER, GG; LINDAHL, T			NAD+-DEPENDENT REPAIR OF DAMAGED DNA BY HUMAN CELL-EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; ESCHERICHIA-COLI; STRAND BREAKS; ADP-RIBOSYLATION; HUMAN-FIBROBLASTS; AP ENDONUCLEASES; EXCISION REPAIR; BINDING DOMAIN; CDNA SEQUENCE; ENZYME	Rejoining of DNA single-strand breaks generated by treatment of plasmids with gamma-rays, neocarzinostatin, or bleomycin was catalyzed inefficiently by human cell extracts. The reaction was strongly promoted by the addition of NAD+, which was employed for rapid and transient synthesis of poly(ADP-ribose). The DNA rejoining reaction was accompanied by DNA repair replication, apparently due to replacement of damaged residues at termini. Selective depletion of poly(ADP-ribose) polymerase from cell extracts improved the repair of DNA exposed to a variety of DNA-damaging agents by removing the NAD+ dependence of the repair reaction. NAD+-promoted DNA repair by soluble cell extracts also occurred with alkylated DNA as substrate and was suppressed by 3-aminobenzamide. A similar stimulatory effect by NAD+ was observed for repair of ultraviolet-irradiated DNA, and this could be ascribed to the presence of pyrimidine hydrates as minor radiation-induced DNA lesions. No effect was observed on the sealing of gamma-irradiated DNA by supplementation of cell extracts with purified mammalian DNA ligase I or DNA ligase II. The results indicate that poly(ADP-ribose) polymerase interferes with base excision-repair processes because bound enzyme molecules block DNA strand interruptions. Release of bound poly(ADP-ribose) polymerase following automodification, or physical removal of the protein from reaction mixtures, facilitates DNA repair.	LAVAL UNIV,MED CTR,DEPT MOLEC ENDOCRINOL,ST FOY G1V 4G2,PQ,CANADA	Laval University	SATOH, MS (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Poirier, Guy/0000-0002-4869-1424				ALTHAUS FR, 1987, ADP RIBOSYLATION PRO, P1; AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BAILLY V, 1989, NUCLEIC ACIDS RES, V17, P3617, DOI 10.1093/nar/17.9.3617; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; CHATTERJEE S, 1989, EXP CELL RES, V184, P1, DOI 10.1016/0014-4827(89)90358-3; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DING RC, 1992, J BIOL CHEM, V267, P12804; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FERRO AM, 1982, J BIOL CHEM, V257, P7808; HECHT SM, 1986, FASEB J, V45, P2784; HENNER WD, 1983, J BIOL CHEM, V258, P5198; HERZOG H, 1989, P NATL ACAD SCI USA, V86, P3514, DOI 10.1073/pnas.86.10.3514; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUET J, 1985, CANCER RES, V45, P987; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JAMES MR, 1982, BIOCHEMISTRY-US, V21, P4007, DOI 10.1021/bi00260a016; JONSSON GG, 1988, CANCER RES, V48, P4233; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAMESHITA I, 1984, J BIOL CHEM, V259, P4770; KAPPEN LS, 1982, P NATL ACAD SCI-BIOL, V79, P744, DOI 10.1073/pnas.79.3.744; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LJUNGQUIST S, 1977, NUCLEIC ACIDS RES, V4, P2871, DOI 10.1093/nar/4.8.2871; LUDWIG A, 1988, J BIOL CHEM, V263, P6993; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; PARK IS, 1989, BIOCHEM BIOPH RES CO, V164, P1226, DOI 10.1016/0006-291X(89)91800-7; REALINI CA, 1992, J BIOL CHEM, V267, P18858; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SHALL S, 1984, ADV RADIAT BIOL, V11, P1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Sugimura T, 1980, Adv Enzyme Regul, V18, P195, DOI 10.1016/0065-2571(80)90016-3; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; UCHIDA K, 1987, BIOCHEM BIOPH RES CO, V148, P617, DOI 10.1016/0006-291X(87)90921-1; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WARNER HR, 1980, P NATL ACAD SCI-BIOL, V77, P4602, DOI 10.1073/pnas.77.8.4602; WINTERS TA, 1992, NUCLEIC ACIDS RES, V20, P2573, DOI 10.1093/nar/20.10.2573; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YOSHIHARA K, 1992, EXP CELL RES, V200, P126, DOI 10.1016/S0014-4827(05)80080-1; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x; ZAHRADKA P, 1982, EUR J BIOCHEM, V127, P579	54	185	191	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5480	5487						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680646				2022-12-27	WOS:A1993KR82200023
J	MCCAFFREY, PG; PERRINO, BA; SODERLING, TR; RAO, A				MCCAFFREY, PG; PERRINO, BA; SODERLING, TR; RAO, A			NF-ATP, A LYMPHOCYTE-T DNA-BINDING PROTEIN THAT IS A TARGET FOR CALCINEURIN AND IMMUNOSUPPRESSIVE DRUGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; CYCLOSPORINE-A; KAPPA-B; ACTIVATION; IDENTIFICATION; REQUIREMENTS; SPECIFICITY; RECEPTOR; CELLS	The nuclear factor of activated T cells (NF-AT) is essential for transcription of the interleukin-2 gene upon T cell activation. Here we use a technique involving elution and renaturation of proteins from SDS-acrylamide gels to identify a DNA-binding component of NF-AT (NF-AT(p)) that is present in hypotonic extracts of T cells prior to activation and appears in nuclear extracts when T cells are activated. NF-AT(p) is present in resting T cells predominantly in a form migrating with an apparent molecular weight of 110,000-140,000, while NF-AT(p) from nuclear extracts of activated T cells migrates with a lower apparent molecular weight (90,000-125,000). This difference is likely to reflect dephosphorylation of NF-AT(p) since treatment of NF-AT(p) with calf intestinal phosphatase or the calcium- and calmodulin-dependent phosphatase calcineurin in vitro results in a similar decrease in its apparent molecular weight. We show that NF-AT(p) is dephosphorylated in cell lysates by a calcium-dependent process that is blocked by inclusion of EGTA or a specific peptide inhibitor of calcineurin in the cell lysis buffer. Moreover, dephosphorylation of NF-AT(p) in cell extracts is inhibited by prior treatment of T cells with the immunosuppressive drugs cyclosporin A or FK506, which inhibit the phosphatase activity of calcineurin when complexed with their specific binding proteins, cyclophilin and FK506-binding protein. This work identifies NF-AT(p) as a DNA-binding phosphoprotein and a target for the drug/immunophilin/calcineurin complexes thought to mediate the inhibition of interleukin-2 gene induction by cyclosporin A and FK506.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Harvard University; Harvard Medical School; Oregon Health & Science University	MCCAFFREY, PG (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR VIROL, BOSTON, MA 02115 USA.				NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM41292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAMIESON C, 1991, J IMMUNOL, V147, P416; KING MM, 1987, J BIOL CHEM, V262, P10658; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788	21	283	293	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3747	3752						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679116				2022-12-27	WOS:A1993KM16100109
J	BARTOLOME, S; BERMUDEZ, A; DABAN, JR				BARTOLOME, S; BERMUDEZ, A; DABAN, JR			ELECTROPHORESIS OF CHROMATIN ON NONDENATURING AGAROSE GELS CONTAINING MG2+ - SELF-ASSEMBLY OF SMALL CHROMATIN FRAGMENTS AND FOLDING OF THE 30-NM FIBER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; X-RAY-SCATTERING; NUCLEOSOME CORE PARTICLE; LINKER LENGTH; COOPERATIVE BINDING; GLOBULAR DOMAIN; UNIT LENGTH; HISTONE H5; DNA; FIBERS	We show that nondenaturing agarose gels can be used for the study of the structure and dynamic properties of native (uncross-Linked) chromatin. In gels containing 1.7 mM Mg2+, chicken erythrocyte chromatin fragments having from about 6 to 50 nucleosomes produce well defined bands. These bands have an electrophoretic mobility that decreases only slightly with molecular weight. This surprising behavior is not observed in low ionic strength gels. Fragments with less than 6 nucleosomes and low content of histones H1-H5 give rise to broad bands in gels with Mg2+. In contrast, fragments containing only 3-4 nucleosomes but with the normal H1-H5 content are able to form associated structures with a mobility similar to that observed for high molecular weight chromatin. Electron microscopy results indicate that the associated fragments and the fragments of higher molecular weight show similar electrophoretic properties because they become very compact in the presence of Mg2+ and form cylindrical structures with a diameter of similar to 33 nn. Our results suggest that the interactions involved in the self-assembly of small fragments are the same that direct the folding of larger fragments; in both cases, the resulting compact chromatin structure is formed hom a basic element containing 5-7 nucleosomes.	UNIV AUTONOMA BARCELONA, FAC CIENCIES, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona			Daban, Joan-Ramon/G-8518-2017	Daban, Joan-Ramon/0000-0001-9946-6764				ARAGAY AM, 1991, BIOCHEMISTRY-US, V30, P5022, DOI 10.1021/bi00234a026; ARAGAY AM, 1988, J MOL BIOL, V204, P141, DOI 10.1016/0022-2836(88)90605-5; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ATHEY BD, 1990, J CELL BIOL, V111, P795, DOI 10.1083/jcb.111.3.795; BARTOLOME S, 1994, J CELL SCI, V107, P2983; BAVYKIN S, 1993, P NATL ACAD SCI USA, V90, P3918, DOI 10.1073/pnas.90.9.3918; BORDAS J, 1986, EUR BIOPHYS J BIOPHY, V13, P175, DOI 10.1007/BF00542561; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRADBURY EM, 1986, SUPRAMOLECULAR STRUC, P35; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; DABAN JR, 1991, ANAL BIOCHEM, V199, P169, DOI 10.1016/0003-2697(91)90085-8; DIMITROV SI, 1990, J BIOMOL STRUCT DYN, V8, P23, DOI 10.1080/07391102.1990.10507787; GALLEGO F, 1995, BIOCHEMISTRY-US, V34, P6711, DOI 10.1021/bi00020a016; GERCHMAN SE, 1987, P NATL ACAD SCI USA, V84, P7802, DOI 10.1073/pnas.84.22.7802; GRAU LP, 1982, CHROMOSOMA, V87, P437; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; GREULICH KO, 1987, J MOL BIOL, V193, P709, DOI 10.1016/0022-2836(87)90353-6; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; JIN YJ, 1986, J BIOL CHEM, V261, P5805; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; KRAJEWSKI WA, 1993, BIOCHEM BIOPH RES CO, V193, P113, DOI 10.1006/bbrc.1993.1597; LANGMORE JP, 1983, J CELL BIOL, V96, P1120, DOI 10.1083/jcb.96.4.1120; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LIBERTINI LJ, 1988, BIOPOLYMERS, V27, P1459, DOI 10.1002/bip.360270911; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MITRA S, 1984, NATURE, V308, P247, DOI 10.1038/308247a0; MUYLDERMANS S, 1985, EUR J BIOCHEM, V150, P441, DOI 10.1111/j.1432-1033.1985.tb09040.x; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RENZ M, 1977, P NATL ACAD SCI USA, V74, P1879, DOI 10.1073/pnas.74.5.1879; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; SACCONE GTP, 1983, FEBS LETT, V157, P111, DOI 10.1016/0014-5793(83)81126-0; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; STAYNOV DZ, 1983, INT J BIOL MACROMOL, V5, P3, DOI 10.1016/0141-8130(83)90071-5; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; SUBIRANA JA, 1985, CHROMOSOMA, V91, P377, DOI 10.1007/BF00291012; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1985, EUR J BIOCHEM, V147, P143, DOI 10.1111/j.1432-1033.1985.tb08730.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WATANABE F, 1986, NUCLEIC ACIDS RES, V14, P3573, DOI 10.1093/nar/14.8.3573; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WILLIAMS SP, 1991, BIOPHYS J, V59, P606, DOI 10.1016/S0006-3495(91)82276-7; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; ZENTGRAF H, 1984, J CELL BIOL, V99, P272, DOI 10.1083/jcb.99.1.272; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	56	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22514	22521		10.1074/jbc.270.38.22514	http://dx.doi.org/10.1074/jbc.270.38.22514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673242	hybrid			2022-12-27	WOS:A1995RW31400071
J	KNAUS, HG; EBERHART, A; KOCH, ROA; MUNUJOS, P; SCHMALHOFER, WA; WARMKE, JW; KACZOROWSKI, GJ; GARCIA, ML				KNAUS, HG; EBERHART, A; KOCH, ROA; MUNUJOS, P; SCHMALHOFER, WA; WARMKE, JW; KACZOROWSKI, GJ; GARCIA, ML			CHARACTERIZATION OF TISSUE-EXPRESSED ALPHA-SUBUNITS OF THE HIGH-CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CHARYBDOTOXIN; PURIFICATION; INHIBITOR; POTENT	Purified high conductance calcium-activated potassium (maxi-K) channels from tracheal smooth muscle have been shown to consist of a 60-70-kDa alpha subunit, encoded by the slo gene, and a 31-kDa beta subunit. Although the size of the beta subunit is that expected for the product of the gene encoding this protein, the size of the alpha subunit is smaller than that predicted from the slo coding region, To determine the basis for this discrepancy, sequence-directed antibodies have been raised against slo. These antibodies specifically precipitate the in vitro translation product of mslo, which yields an alpha subunit of the expected molecular mass (135 kDa), Immunostaining experiments employing smooth muscle sarcolemma, skeletal muscle T-tubules, as well as membranes derived from GH(3) cells reveal the presence of an Lu subunit with an apparent molecular mass of 125 kDa, The difference in size of the alpha subunit as expressed in these membranes and the purified preparations is due to a highly reproducible proteolytic decay that occurs mostly at an advanced stage of the maxi-g channel purification, In the purified maxi-K channel preparations investigated, the full-length alpha subunit, an intermediate size product of 90 kDa, and the 65-kDa polypeptide, as well as other smaller fragments can be detected using appropriate antibodies, Proteolysis occurs exclusively at two distinct positions within the long C-terminal tail of slo, In addition, evidence for the tissue expression of distinct splice variants in membrane-bound as well as purified maxi-It channels is presented.	MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MEMBRANE BIOCHEM & BIOPHYS, RAHWAY, NJ 07065 USA; MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT MOLEC BIOL & GENET, RAHWAY, NJ 07065 USA	Merck & Company; Merck & Company	KNAUS, HG (corresponding author), UNIV INNSBRUCK, INST BIOCHEM PHARMACOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA.							ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KNAUS HG, 1995, BIOPHYS J, V68, P267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MOSS GWJ, 1995, BIOPHYS J, V68, P29; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5	20	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22434	22439		10.1074/jbc.270.38.22434	http://dx.doi.org/10.1074/jbc.270.38.22434			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673230	hybrid			2022-12-27	WOS:A1995RW31400059
J	APONE, S; HAUSCHKA, SD				APONE, S; HAUSCHKA, SD			MUSCLE GENE E-BOX CONTROL ELEMENTS - EVIDENCE FOR QUANTITATIVELY DIFFERENT TRANSCRIPTIONAL ACTIVITIES AND THE BINDING OF DISTINCT REGULATORY FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; CREATINE-KINASE GENE; MYOGENIC DETERMINATION FACTORS; DNA-BINDING; ENHANCER; PROTEIN; MYOD; ACTIVATION; SKELETAL; SITE	The muscle creatine kinase gene enhancer contains two regulatory elements (MCK-R and MCK-L) with the consensus E-box sequence (CAnnTG). A myocyte specific protein complex, MEF1, binds the MCK-R site. MEF1 contains several basic H-L-H myogenic determination factors (MDFs), each dimerized with ubiquitous members of the bH-L-H family (e.g. E12/E47). We now demonstrate that the ubiquitous bH-L-H factor E2-2 is a major component of the endogenous MCK-R site specific complex. Previous studies described the MCK-L site as a similar but low affinity MDF/bH-L-H heterodimer binding site. However, we find that the MCK-L site exhibits prefer ential binding of an unknown ubiquitous factor which contains neither E12/E47 nor E2-2, and that it exhibits differential transcriptional activity with muscle and non-muscle cells. The differential behavior of the MCK-L and MCK-R sites may be a general trait of E-box elements since one among several E-boxes in the MLC 1/3 enhancer also binds preferentially to the MCK-L factor. From our studies we now propose separate consensus sequences for MCK-R and MCK-L E-box types: AACAc/gc/gTGCa/t and GGa/cCANGTGGc/gNa/g. Our results suggest that while many muscle gene E-boxes are capa ble of binding the previously characterized spectrum of MDF/bH-L-H heterodimers in vitro, MCK-L type E-boxes probably bind qualitatively different factors in vivo.			APONE, S (corresponding author), UNIV WASHINGTON,DEPT BIOCHEM,SJ-70,SEATTLE,WA 98195, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM018860] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039070] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39070, HL03174] Funding Source: Medline; NIADDK NIH HHS [AM18860] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1992, J BIOL CHEM, V267, P17498; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAUSCHKA SD, 1994, MYOLOGY, P3; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P678, DOI 10.1093/nar/18.3.678; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIN H, 1992, J BIOL CHEM, V267, P4773; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YI TM, 1991, NUCLEIC ACIDS RES, V19, P3027, DOI 10.1093/nar/19.11.3027; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	43	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21420	21427		10.1074/jbc.270.36.21420	http://dx.doi.org/10.1074/jbc.270.36.21420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673178	hybrid			2022-12-27	WOS:A1995RU05400083
J	POLLARD, S; THOMPSON, CL; STEPHENSON, FA				POLLARD, S; THOMPSON, CL; STEPHENSON, FA			QUANTITATIVE CHARACTERIZATION OF ALPHA-6 AND ALPHA-1-ALPHA-6 SUBUNIT-CONTAINING NATIVE GAMMA-AMINOBUTYRIC ACID(A) RECEPTORS OF ADULT-RAT CEREBELLUM DEMONSTRATES 2 ALPHA-SUBUNITS PER RECEPTOR OLIGOMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; BENZODIAZEPINE RECEPTOR; BINDING; BRAIN; SUBPOPULATIONS; POPULATIONS; ANTIBODIES	gamma-Aminobutyric acid(A) (GABA(A)) receptors were purified from adult rat cerebella by anti-alpha 6(1-16 Cys) antibody affinity chromatography, Immunoblots of the alpha 6 subunit-containing receptors showed the copurification of the alpha 1, beta 2/3, gamma 2, delta but not alpha 2 and alpha 3 GABA(A) receptor polypeptides. Further fractionation of this receptor subpopulation by anti-GABA(A) receptor subunit alpha 6(1-16 Cys) and anti-alpha 1(413-429) antibody affinity columns in series substantiated the coassociation of the alpha 1 and alpha 6 polypeptides, The percentage of coexistence of the two subunits was determined by quantitative immunoblotting, which found that 41 +/- 12% of alpha 6 subunit immunoreactivity is associated with the alpha 1 subunit, The ratios of the alpha 1:alpha 6 subunits in the double purified receptor preparations was found to be 1:1, thus determining directly for the first time subunit ratios within native GABA(A) receptors. The benzodiazepine pharmacology of the alpha 1 alpha 6 subunit-containing receptors was shown to be predominantly benzodiazepine insensitive by quantitative immunoprecipitation assays. These results are the first direct quantitative studies of subunit ratios within a population of native GABA(A) receptors.	UNIV LONDON,SCH PHARM,DEPT PHARMACEUT CHEM,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy								BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENKE D, 1991, J BIOL CHEM, V266, P4478; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; KERN W, 1994, J NEUROCHEM, V62, P764; KHAN ZU, 1994, J NEUROCHEM, V63, P371; KORPI ER, 1993, MOL PHARMACOL, V44, P87; LUDDENS H, 1991, TRENDS PHARMACOL SCI, V12, P49, DOI 10.1016/0165-6147(91)90495-E; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MATHEWS GC, 1994, NEURON, V13, P149, DOI 10.1016/0896-6273(94)90465-0; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MERTENS S, 1993, J BIOL CHEM, V268, P5965; NAYEEM N, 1994, J NEUROCHEM, V62, P815; NUSSER Z, 1995, BRAN RES ASS ABSTR, V12, P114; POLLARD S, 1993, J BIOL CHEM, V268, P3753; POLLARD S, 1991, FEBS LETT, V295, P81, DOI 10.1016/0014-5793(91)81390-T; QUIRK K, 1994, J BIOL CHEM, V269, P16020; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; STEPHENSON FA, 1991, MOL NEUROBIOL, P183; THOMPSON CL, 1992, NEUROSCI LETT, V144, P53, DOI 10.1016/0304-3940(92)90714-I; UUSIOUKARI M, 1992, J NEUROCHEM, V59, P568, DOI 10.1111/j.1471-4159.1992.tb09407.x; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	26	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21285	21290		10.1074/jbc.270.36.21285	http://dx.doi.org/10.1074/jbc.270.36.21285			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673164	hybrid			2022-12-27	WOS:A1995RU05400064
J	SMITH, DF; BAGGENSTOSS, BA; MARION, TN; RIMERMAN, RA				SMITH, DF; BAGGENSTOSS, BA; MARION, TN; RIMERMAN, RA			2 FKBP-RELATED PROTEINS ARE ASSOCIATED WITH PROGESTERONE-RECEPTOR COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; 59-KILODALTON PROTEIN; FK506-BINDING PROTEIN; POLYCLONAL ANTIBODY; HSP56; CELL; ELECTROPHORESIS; RECONSTITUTION; IMMUNOPHILINS	Unactivated steroid receptors are in heterooligomeric complexes that perhaps stabilize a partially folded receptor polypeptide prior to hormone-dependent activation. Hsp90 is a common receptor component and hsp70 is a component of progesterone receptors; both appear to be important as general mediators of protein folding and assembly events. In addition to hsp90, mammalian steroid receptor complexes contain a 52-59-kDa protein that is an FK506-binding immunophilin and has peptidyl-prolyl isomerase activity. Other receptor-associated proteins have been identified but not well-characterized. In the present study, we obtained partial amino acid sequences for two avian progesterone receptor components, p50 and p54. From sequence comparisons with known proteins, they appear to be distinct members of the FKBP family of immunophilins. Six p50 peptide sequences have 80% identity with regions of rabbit FKBP52; seven p54 peptide sequences have 60% identity with rabbit FKBP52. Interaction of p54 with receptor is distinct from p50 in that its binding in vitro is highly sensitive to progesterone or N-ethylmaleimide. An anti-p54 monoclonal antibody was developed that detects a 55-kDa protein in rabbit and human tissues; in a cell-free reconstitution system, the rabbit antigen binds to chicken progesterone receptor along with rFKBP52. While p50 appears to be the chicken homolog of FKBP52, p54 is perhaps a novel member of the FKBP family that, in addition to FKBP52, interacts with progesterone receptor.	UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198; UNIV TENNESSEE CTR HLTH SCI,MED CTR,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Tennessee System; University of Tennessee Health Science Center					NIDDK NIH HHS [DK-44923] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044923] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DUMONT FJ, 1990, J IMMUNOL, V144, P251; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FERNANDEZPATRON C, 1992, BIOTECHNIQUES, V12, P564; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTHCISON KA, 1993, BIOCHEMISTRY-US, V32, P3953; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; NAKAO K, 1985, CAN J BIOCHEM CELL B, V63, P33, DOI 10.1139/o85-005; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAETTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974; PRATT WB, 1992, TRENDS ENDOCRIN MET, V3, P326, DOI 10.1016/1043-2760(92)90111-D; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; TAI PKK, 1985, CAN J BIOCHEM CELL B, V63, P41, DOI 10.1139/o85-006; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TRANDINH CC, 1992, FASEB J, V6, P3410, DOI 10.1096/fasebj.6.15.1464374; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Welch WJ, 1991, CURR OPIN CELL BIOL, V3, P1033, DOI 10.1016/0955-0674(91)90125-I; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; YEM AW, 1992, J BIOL CHEM, V267, P2868	38	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18365	18371						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688746				2022-12-27	WOS:A1993LT74300105
J	LANDRY, D; SULLIVAN, S; NICOLAIDES, M; REDHEAD, C; EDELMAN, A; FIELD, M; ALAWQATI, Q; EDWARDS, J				LANDRY, D; SULLIVAN, S; NICOLAIDES, M; REDHEAD, C; EDELMAN, A; FIELD, M; ALAWQATI, Q; EDWARDS, J			MOLECULAR-CLONING AND CHARACTERIZATION OF P64, A CHLORIDE CHANNEL PROTEIN FROM KIDNEY MICROSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS GENE; EXPRESSION; CONDUCTANCE; ACIDIFICATION; VESICLES; CELLS; IDENTIFICATION; RECONSTITUTION; PURIFICATION; EPITHELIA	Chloride channels were previously purified from bovine kidney cortex membranes using a drug affinity column. Reconstitution of the purified proteins into artificial liposomes and planar bilayers yielded chloride channels. A 64-kDa protein, p64, identified as a component of this chloride channel was used to generate antibodies which depleted solubilized kidney membranes of all chloride channel activity. This antibody has now been used to identify a clone, H2B, from a kidney cDNA library. Antibodies, affinity-purified against the fusion protein of H2B also depleted solubilized kidney cortex from all chloride channel activity. The predicted amino acid sequence of p64 shows that it contains two and possibly four putative transmembrane domains and potential phosphorylation sites by protein kinase A, protein kinase C, and casein kinase II. There was no significant homology to other protein (or DNA) sequences in the data base. The protein is expressed in all cells tested. Expression of its mRNA in Xenopus laevis oocytes led to the insertion of a protein with the appropriate molecular mass in microsomes but not in the plasma membrane. It is likely that p64 represents the chloride channel of intracellular organelles.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University			Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040	NIDDK NIH HHS [DK41146, DK39532, DK01336] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041146, K12DK001336, R01DK039532] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1988, J CELL BIOL, V107, P2137, DOI 10.1083/jcb.107.6.2137; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; BRETAG AH, 1987, PHYSIOL REV, V65, P310; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS R, 1982, NUCLEIC ACIDS RES, V10, P6353, DOI 10.1093/nar/10.20.6353; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FRIZZELL RA, 1986, FASEB J, V45, P2727; GARTY H, 1983, J BIOL CHEM, V258, P3094; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GREGER R, 1988, ANNU REV PHYSIOL, V50, P111; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MULBERG AE, 1991, J BIOL CHEM, V266, P20590; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; RAN S, 1991, J BIOL CHEM, V266, P4782; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REENSTRA WW, 1992, BIOCHEMISTRY-US, V31, P175, DOI 10.1021/bi00116a026; RIORDAN JR, 1989, SCIENCE, V245, P1066; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; Sambrook J, 1989, MOL CLONING LABORATO; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STONE DK, 1983, J BIOL CHEM, V258, P4059; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TOYOSHIMA Y, 1975, BIOCHEMISTRY-US, V14, P1525, DOI 10.1021/bi00678a028; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	43	123	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14948	14955						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686908				2022-12-27	WOS:A1993LL75900063
J	REDDY, GL; IWAMOTO, T; TOMICH, JM; MONTAL, M				REDDY, GL; IWAMOTO, T; TOMICH, JM; MONTAL, M			SYNTHETIC PEPTIDES AND 4-HELIX BUNDLE PROTEINS AS MODEL SYSTEMS FOR THE PORE-FORMING STRUCTURE OF CHANNEL PROTEINS .2. TRANSMEMBRANE SEGMENT M2 OF THE BRAIN GLYCINE RECEPTOR IS A PLAUSIBLE CANDIDATE FOR THE PORE-LINING STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; IONIC CHANNELS; CHOLINERGIC RECEPTOR; H-3 CHLORPROMAZINE; CHLORIDE CHANNEL; XENOPUS OOCYTES; ALPHA-HELICES; BINDING-SITE; SPINAL-CORD	A synthetic 23-mer peptide (M2GlyR) with the amino acid sequence of the putative transmembrane segment M2 of the strychnine-binding alpha subunit of the inhibitory glycine receptor forms anion-selective channels in phospholipid bilayers. The most frequent events show single-channel conductances, gamma, of 25 pS and 49 pS in symmetric 0.5 M KCl with channel open lifetimes, tau(o), in the millisecond time range. These properties match those of authentic glycine receptors studied in inside-out patches of cultured rat spinal cord neurons, namely gamma = 27 pS and gamma = 45 pS, and tau(o) in the millisecond time range. The channel activity of M2GlyR is sequence-specific: 1) a synthetic peptide with the sequence of putative transmembrane segment M1 (M1GlyR), not considered to contribute to the channel lining, does not form channels; 2) an analog of M2GlyR with site-specific substitutions displays distinct channel properties: 2 arginine residues at the N and C termini of M2, postulated to contribute to the anion selectivity of the channel, are substituted by glutamic acids, and the analog peptide ([Glu3,22]M2GlyR) forms cation-selective channels. Further, a four-helix bundle protein (T4M2GlyR) formed by tethering four identical M2GlyR modules to a carrier template forms homogeneous anion-selective channels with gamma = 25 pS in 0.5 M KCl. These channels are blocked by picrotoxin and by the anion channel blockers 9-anthracene carboxylic acid and niflumic acid, but not by an analog of the local anesthetic lidocaine (QX-222), a cation channel blocker. Observed single-channel properties suggest that a pentameric assembly of alpha and beta subunits with a central pore lined by M2 segments would account for conductance properties of the authentic glycine receptor and the 2 arginines at either end of M2 could confer anion specificity to the receptor channel.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, CHILDRENS HOSP, LOS ANGELES, CA 90027 USA	University of California System; University of California San Diego; University of Southern California; University of Southern California; Children's Hospital Los Angeles; University of Southern California				TOMICH, JOHN M./0000-0001-7848-8307	NIGMS NIH HHS [GM-43617, GM-42340] Funding Source: Medline; NIMH NIH HHS [MH-44638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043617, R29GM043617, R01GM042340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKAIKE N, 1985, EXPERIENTIA, V41, P70; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; EISENMAN G, 1990, PROG CELL R, V1, P195; GARCIACALVO M, 1989, BIOCHEMISTRY-US, V28, P6405, DOI 10.1021/bi00441a037; GESELL J, 1992, 6TH S PROT SOC, V52; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; GROVE A, 1992, METHOD ENZYMOL, V207, P510; GROVE A, 1991, P NATL ACAD SCI USA, V88, P6418, DOI 10.1073/pnas.88.15.6418; GROVE A, 1991, BIOTECHNOLOGY CELL R, V4, P89; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; KRNJEVIC K, 1974, PHYSIOL REV, V54, P418, DOI 10.1152/physrev.1974.54.2.418; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABARCA P, 1985, BIOPHYS J, V47, P469, DOI 10.1016/S0006-3495(85)83939-4; LANGOSCH D, 1991, BIOCHIM BIOPHYS ACTA, V1063, P36, DOI 10.1016/0005-2736(91)90350-H; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; MONTAL M, 1986, ION CHANNEL RECONSTI, P157; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; NUMA S, 1989, HARVEY LECT, V83, P121; OBLATTMONTAL M, 1993, J BIOL CHEM, V268, P14601; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OIKI S, 1990, PROTEINS, V8, P226, DOI 10.1002/prot.340080305; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RUIZGOMEZ A, 1990, BIOCHEMISTRY-US, V29, P7033, DOI 10.1021/bi00482a012; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; TWYMAN RE, 1991, J PHYSIOL-LONDON, V435, P303, DOI 10.1113/jphysiol.1991.sp018512; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE MM, 1990, MOL PHARMACOL, V37, P720	39	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14608	14615						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686901				2022-12-27	WOS:A1993LL75900015
J	ODA, A; DRUKER, BJ; ARIYOSHI, H; SMITH, M; SALZMAN, EW				ODA, A; DRUKER, BJ; ARIYOSHI, H; SMITH, M; SALZMAN, EW			PP60SRC IS AN ENDOGENOUS SUBSTRATE FOR CALPAIN IN HUMAN BLOOD-PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; CA-2+-DEPENDENT PROTEASE; STIMULATED PLATELETS; INHIBITOR CALPEPTIN; PLASMA-MEMBRANE; ACTIVATION; THROMBIN; AGGREGATION; PHOSPHORYLATION; PP60C-SRC	Calpain is distributed ubiquitously in virtually every tissue (Croall, D. E., and DeMartino, G. N. (1991) Physiol. Rev. 71, 813-846), but its physiological role remains to be determined. The identification of its natural endogenous substrates would be of great interest. Since pp60src, a major tyrosine kinase in platelets, is known to be easily cleaved during purification from cells (Feder, D., and Bishop, J. M. (1990) J. Biol. Chem. 265, 8205-8211), we examined the possibility that it is an endogenous substrate of calpain. In the whole cell lysate from resting platelets, which was analyzed by Western blotting with monoclonal antibody 327, we found pp60src almost exclusively in a 60-kDa form, with a trace of 52-kDa form. Addition of A23187 (a calcium ionophore) or dibucaine, which are known to be activators of platelet calpain (Croall and DeMartino, 1991; Fox, J. E., Reynolds, C., Morrow, J. S., and Phillips, D. R. (1987) Blood 76, 2510-2519; Fox, J. E., Austin, C. D., Boyles, J. K., and Steffen, P. K. (1990b) J. Cell Biol. 111, 483-493), caused dose- and time-dependent cleavage of actin-binding protein and p235 protein (talin). At the same time, loss of the 60-kDa species of pp60src and generation of the 52-kDa (occasionally seen as doublets) and 47-kDa species were detected by the Western blotting. In platelets aggregated by 1 unit/ml thrombin, apparently identical cleavage products were found. The cleavage of pp60src was inhibited by calpeptin (20 muM), an inhibitor of calpain (Tsujinaka, T., Kajiwara, Y., Kambayashi, J., Sakon, M., Higuchi, N., Tanaka, T., and Mori, T. (1988) Biochem. Biophys. Res. Commun. 153,1201-1208; Tsujinaka, T., Ariyoshi, H., Uemura, Y., Sakon, M., Kambayashi, J., and Mori, T. (1990) Life Sci. 46, 1059-1066; Fox, J. E., Clifford, C. C., and Austin, C. D. (1990) Blood 76, 2510-2519; Fox, J. E., Austin, C. D., Boyles, J. K., and Steffen, P. K. (1990) J. Cell. Biol. 111, 483-493; Fox, J. E., Austin, C. D., Clifford, C. C., and Steffen, P. K. (1991) J. Biol. Chem. 266, 13289-13295). Addition of EGTA (3 mM) to the extracellular media completely inhibited the cleavage of actin-binding protein, talin, and pp60src in response to A23187 (1 muM). Intact pp60src was distributed in both cytosolic and particulate (membrane) fractions. Cleaved species were found exclusively in the cytosolic fraction. pp60src-associated enolase kinase activity was reduced. Thus, pp60src is an endogenous substrate for calpain, the cleavage of which may have regulatory effects on the kinase.	BETH ISRAEL HOSP,DEPT SURG,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR MOLEC BIOL,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Druker, Brian/0000-0001-8331-8206	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033014] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DHAR A, 1991, J BIOL CHEM, V266, P18797; ELCE JS, 1989, BIOCHEM J, V261, P1039, DOI 10.1042/bj2611039; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FOX JEB, 1990, BLOOD, V76, P2510; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NACHMIAS VT, 1979, BLOOD, V53, P63; ODA A, 1992, AM J PHYSIOL, V262, pC701, DOI 10.1152/ajpcell.1992.262.3.C701; ODA A, 1992, J BIOL CHEM, V267, P20075; OKITA JR, 1989, BLOOD, V74, P715; PEERSCHKE EIB, 1986, BLOOD, V68, P463; RESH MD, 1990, ONCOGENE, V5, P1437; TSUJINAKA T, 1990, LIFE SCI, V46, P1059, DOI 10.1016/0024-3205(90)90414-M; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WENCELDRAKE JD, 1991, ARTERIOSCLER THROMB, V11, P882, DOI 10.1161/01.ATV.11.4.882; WHEELERJONES CPD, 1989, BIOCHEM J, V263, P969, DOI 10.1042/bj2630969; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005	33	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12603	12608						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685344				2022-12-27	WOS:A1993LG65800057
J	PARK, HY; RUSSAKOVSKY, V; OHNO, S; GILCHREST, BA				PARK, HY; RUSSAKOVSKY, V; OHNO, S; GILCHREST, BA			THE BETA ISOFORM OF PROTEIN-KINASE-C STIMULATES HUMAN MELANOGENESIS BY ACTIVATING TYROSINASE IN PIGMENT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN MELANOCYTES; PHORBOL-ESTER; RAT FIBROBLASTS; MELANOMA-CELLS; 3T3-L1 CELLS; CYCLIC-AMP; PHOSPHORYLATION; DIACYLGLYCEROL; EXPRESSION	We have investigated the role of protein kinase C (PKC) in human melanogenesis. The level of PKC activity paralleled the total melanin content in cultured newborn melanocytes. Activation of PKC by treatment with 5 x 10(-7) M phorbol dibutyrate acutely caused a doubling in the activity of tyrosinase, the rate-limiting enzyme in melanogenesis, known to correlate directly with melanin synthesis in these cells. When PKC was depleted to 5-10% of initial levels, there was a 40-50% parallel reduction in tyrosinase activity; and regeneration of PKC activity was associated with the recovery of tyrosinase activity. By Northern blot analysis, the alpha and beta but not the gamma isoforms were detectable in melanocytes. By Western blot analysis, the racially determined pigment level in cultured melanocytes correlated with PKC-beta protein expression. In a pigmented human melanoma line (P-MM4, 20-30 ng melanin/mug protein) and its nonpigmented subclone (NP-MM4, undetectable melanin), PKC-alpha mRNA was expressed in both, whereas PKC-beta mRNA was detectable only in P-MM4 cells. Tyrosinase protein level was comparable in both cell lines. When NP-MM4 cell lysate was incubated with melanocyte lysate known to contain PKC-beta, tyrosinase activity per mug of melanocyte protein in the combined lysate increased, consistent with activation of the previously inactive tyrosinase of NP-MM4 origin. Moreover, NP-MM4 cells transiently transfected with PKC-beta cDNA increased tyrosinase activity from undetectable to detectable levels. These combined data show that PKC-beta regulates human melanogenesis by activating tyrosinase.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOLEC BIOL,KANAZAWA KU,YOKOHAMA 236,JAPAN	Yokohama City University	PARK, HY (corresponding author), BOSTON UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02118, USA.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024538] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24538] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS G, 1991, CANCER RES, V51, P3281; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; GILCHREST BA, 1984, J INVEST DERMATOL, V83, P370, DOI 10.1111/1523-1747.ep12264638; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JENG AY, 1987, BIOCHEM BIOPH RES CO, V145, P782, DOI 10.1016/0006-291X(87)91033-3; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCAFFREY PG, 1984, J BIOL CHEM, V259, P2502; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORELLI JG, 1992, J INVEST DERMATOL, V98, P55, DOI 10.1111/1523-1747.ep12494602; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P2597; NILES RM, 1989, CANCER RES, V49, P4483; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PARK HY, 1990, CANCER RES, V50, P7145; PARK HY, 1992, J INVEST DERMATOL, V98, P562; PARK HY, 1992, IN PRESS CLIN RES; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; POMERANT.SH, 1966, J BIOL CHEM, V241, P161; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UEDA H, 1991, FEBS LETT, V292, P57, DOI 10.1016/0014-5793(91)80833-O; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; WOOTEN MW, 1992, FEBS LETT, V298, P74, DOI 10.1016/0014-5793(92)80025-C; YAMANISHI DT, 1991, CARCINOGENESIS, V12, P105, DOI 10.1093/carcin/12.1.105; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	50	133	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11742	11749						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685020				2022-12-27	WOS:A1993LF28400044
J	GREGSON, JM; CRAIN, PF; EDMONDS, CG; GUPTA, R; HASHIZUME, T; PHILLIPSON, DW; MCCLOSKEY, JA				GREGSON, JM; CRAIN, PF; EDMONDS, CG; GUPTA, R; HASHIZUME, T; PHILLIPSON, DW; MCCLOSKEY, JA			STRUCTURE OF THE ARCHAEAL TRANSFER-RNA NUCLEOSIDE-G-ASTERISK-15 (2-AMINO-4,7-DIHYDRO-4-OXO-7-BETA-D-RIBOFURANOSYL-1H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBOXIMIDAMIDE (ARCHAEOSINE))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; ARCHAEBACTERIAL TRANSFER-RNA; TRANSFER RIBONUCLEIC-ACID; COLI TRANSFER-RNA; LIQUID-CHROMATOGRAPHY; HALOBACTERIUM-VOLCANII; MODIFIED NUCLEOSIDE; GAS-PHASE; SEQUENCES; IONS	A number of post-transcriptional modifications in tRNA are phylogenetically characteristic of the bacterial, eukaryal, or archaeal domains, both with respect to sequence location and molecular structure at the nucleoside level. One of the most distinct such modifications is nucleoside G*, located in archaeal tRNA at position 15, which in bacterial and eukaryal tRNAs is a conserved site involved in maintenance of the dihydrouridine loop-T-loop tertiary interactions. G* occurs widely in nearly every branch of the archaeal phylogenetic domain, in contrast to its absence in all reported bacterial and eukaryal tRNA sequences. The structure of G*- 15 is 2-amino-4,7-dihydro-4-oxo-7-beta-D-ribofuranosyl-1H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide (7-formamidino-7-deazaguanosine), which is a non-purine, non-pyrimidine ribonucleoside; its structure thus reflects extensive modification beyond the guanine-15 specified by corresponding gene sequences. The structure was established by mass spectrometry, and in particular from collision-induced dissociation mass spectra of derivatives formed by microscale permethylation, and is confirmed by chemical synthesis.	UNIV UTAH,DEPT MED CHEM,311A SKAGGS HALL,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; SO ILLINOIS UNIV,DEPT MED BIOCHEM,CARBONDALE,IL 62901	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Southern Illinois University System; Southern Illinois University					NIGMS NIH HHS [GM29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORK GR, 1984, PROCESSING RNA, P291; BROCK TD, 1972, ARCH MIKROBIOL, V84, P554; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CHENG CS, 1981, THESIS U UTAH; CRAIN PF, 1990, MASS SPECTROM REV, V9, P505, DOI 10.1002/mas.1280090504; CRAIN PF, 1990, METHOD ENZYMOL, V193, P782, DOI 10.1016/0076-6879(90)93450-Y; CRAIN PF, 1990, BIOLOGICAL MASS SPECTROMETRY /, P509; CRAIN PF, 1980, ADV MASS SPECTROM, V8, P1135; CROW FW, 1984, ANAL BIOCHEM, V139, P243, DOI 10.1016/0003-2697(84)90412-3; DOCKBREGEON AC, 1989, J MOL BIOL, V206, P707, DOI 10.1016/0022-2836(89)90578-0; EDMONDS CG, 1988, ANAL CHEM, V60, P2314, DOI 10.1021/ac00171a034; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; EDMONDS CG, 1985, NUCLEIC ACIDS RES, V13, P8197, DOI 10.1093/nar/13.22.8197; EDMONDS CG, 1988, 36TH P ANN C MASS SP, P1256; GUPTA R, 1984, J BIOL CHEM, V259, P9461; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; GUPTA R, 1980, CURR MICROBIOL, V4, P245, DOI 10.1007/BF02605865; GUPTA R, 1985, BACTERIA, V8, P311; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HINSHAW BC, 1975, J CHEM SOC PERK T 1, P1248, DOI 10.1039/p19750001248; HINSHAW BC, 1970, J ORG CHEM, V35, P236, DOI 10.1021/jo00826a049; HOLMES JL, 1985, ORG MASS SPECTROM, V20, P169, DOI 10.1002/oms.1210200302; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KAWAI G, 1992, NUCLEOS NUCLEOT, V11, P759, DOI 10.1080/07328319208021740; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KILPATRICK MW, 1982, ZBL BAKT MIK HYG I C, V3, P79, DOI 10.1016/S0721-9571(82)80056-2; LEVSEN K, 1976, ANGEW CHEM INT EDIT, V15, P509, DOI 10.1002/anie.197605091; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P825, DOI 10.1016/0076-6879(90)93453-R; MCCLOSKEY JA, 1990, METHOD ENZYMOL, V193, P771, DOI 10.1016/0076-6879(90)93449-U; MCCLOSKEY JA, 1986, SYST APPL MICROBIOL, V7, P246; NELSON CC, 1992, J AM CHEM SOC, V114, P3661, DOI 10.1021/ja00036a014; NOGUCHI S, 1978, NUCLEIC ACIDS RES, V5, P4215, DOI 10.1093/nar/5.11.4215; OKADA N, 1978, NUCLEIC ACIDS RES, V5, P2289, DOI 10.1093/nar/5.7.2289; PANG H, 1982, J BIOL CHEM, V257, P3589; PHILLIPSON DW, 1987, J BIOL CHEM, V262, P3462; POMERANTZ SC, 1990, METHOD ENZYMOL, V193, P796, DOI 10.1016/0076-6879(90)93452-Q; REDDY DM, 1992, NUCLEIC ACIDS RES, V20, P5607, DOI 10.1093/nar/20.21.5607; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; Schram K. H., 1979, GLC HPLC DETERMINA 3, P1149; SCHRAM KH, 1975, J CHEM SOC PERK T 1, P1253, DOI 10.1039/p19750001253; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; STETTER KO, 1993, EARLY LIFE EARTH; STETTER KO, 1986, THERMOPHILES GENERAL, P39; von Ehrenstein G, 1967, METHOD ENZYMOL, V12, P588; VONMINDE.DL, 1973, J AM CHEM SOC, V95, P7480, DOI 10.1021/ja00803a044; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	49	90	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10076	10086						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683667				2022-12-27	WOS:A1993LB80000023
J	STINDL, A; KELLER, U				STINDL, A; KELLER, U			THE INITIATION OF PEPTIDE FORMATION IN THE BIOSYNTHESIS OF ACTINOMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE; ACID ACTIVATING ENZYME; STREPTOMYCES-CHRYSOMALLUS; PROTEINS; GENE; PURIFICATION; EXPRESSION; BINDING; PATHWAY; LIGASE	Actinomycin Synthetase II (ACMS II), which activates threonine and valine by a thioltemplate mechanism during the synthesis of the actinomycin half-molecule 4-methyl-3-hydroxyanthranilic acid (4-MHA) pentapeptide lactone, was purified to near homogeneity from Streptomyces chrysomallus. It is a single polypeptide chain of M(r) 280,000 and contains 4'-phosphopantetheine as a covalently bound prosthetic group. ACMS II charges itself with threonine but not with the 4-MHA analogue p-toluic acid via a specific sulfhydryl group at the expense of ATP. Charging of ACMS II with p-toluic acid in thioester linkage took place, however, only when actinomycin synthetase I (ACMS I), a 4-MHA-AMP ligase, was present. In the additional presence Of L-threonine, enzyme-bound P-toluyl-L-threonine was formed on ACMS II. The latter compound was also formed when chemically synthesized p-toluic acid adenylate was added instead of ACMS I and p-toluic acid. This indicates that p-toluic acid adenylate is a free intermediate in the reaction and that charging of the enzyme and acylation of threonine are both catalyzed by ACMS II rather than by ACMS I. Chemically synthesized thioesters of p-toluic acid and coenzyme A, pantetheine, or beta-alanyl-cysteamine reacted with ACMS II, threonine, and ATP with formation of enzyme-bound p-toluyl-threonine. In contrast, p-toluyl-cysteamine thioester was inactive, which indicates structural constraints in the reactivity of free thioesters of p-toluic acid with ACMS II. Such constraints obviously require structural similarity of the artificial substrate to a p-toluic acid thioester formed on the enzyme's surface in the course of the reaction. Since free coenzyme A was not involved in the charging of p-toluic acid or in p-toluyl-threonine formation, the sulfhydryl group of the 4'-phosphopantetheine cofactor is most likely the primary acceptor of p-toluic acid (or 4-MHA) in the initiation of peptide lactone formation.	TECH UNIV BERLIN,INST BIOCHEM & MOLEC BIOL,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY	Technical University of Berlin								BARDEN RE, 1983, METHOD ENZYMOL, V91, P633; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1988, BIOL ACTINOMYCETES 8, P395; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; GILHUUSMOE CC, 1970, FEBS LETT, V7, P287, DOI 10.1016/0014-5793(70)80183-1; GLUND K, 1990, BIOCHEMISTRY-US, V29, P3522, DOI 10.1021/bi00466a015; HAESE A, 1988, J BACTERIOL, V170, P1360, DOI 10.1128/jb.170.3.1360-1368.1988; HAESE A, 1993, IN PRESS MOL MICROBI; JAEGER E, 1974, METHODEN ORGANIC CHE, V2, P721; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; KELLER U, 1985, J GEN MICROBIOL, V131, P1181; KELLER U, 1992, J BIOL CHEM, V267, P11745; KELLER U, 1993, GENETICS BIOCH ANTIB, P71; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; LYNEN F, 1961, FED PROC, V20, P941; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MAJERUS PW, 1969, METHOD ENZYMOL, V14, P43; MARAHIEL MA, 1992, FEBS LETT, V307, P40, DOI 10.1016/0014-5793(92)80898-Q; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; PUGH EL, 1965, J BIOL CHEM, V240, P4727; RUSNAK F, 1989, BIOCHEMISTRY-US, V28, P6827, DOI 10.1021/bi00443a008; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCHLUMBOHM W, 1990, J BIOL CHEM, V265, P2156; STAAB JF, 1989, FEMS MICROBIOL LETT, V59, P15; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P931, DOI 10.1016/S0076-6879(57)03481-3; STAHL E, 1967, DUNNSCHICHT CHROMATO, P843; STOOPS JK, 1990, J BIOL CHEM, V265, P16971; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; Vagelos P. R., 1973, ENZYMES, V8, P155; VATER J, 1976, BIOCHIM BIOPHYS ACTA, V429, P1062, DOI 10.1016/0005-2744(76)90351-X; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008	37	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10612	10620						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683683				2022-12-27	WOS:A1993LB80000091
J	TAIEB, J; VITTEMONY, I; AUFFREDOU, MT; DORSEUIL, O; GACON, G; BERTOGLIO, J; VAZQUEZ, A				TAIEB, J; VITTEMONY, I; AUFFREDOU, MT; DORSEUIL, O; GACON, G; BERTOGLIO, J; VAZQUEZ, A			REGULATION OF P56LCK KINASE EXPRESSION AND CONTROL OF DNA-SYNTHESIS IN ACTIVATED HUMAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN-TYROSINE KINASES; CELL ANTIGEN RECEPTOR; PROLIFERATION; ASSOCIATION; PHOSPHORYLATION; MODULATION; FAMILY; CD4	In this study, we analyzed the expression and regulation of src kinase p56lck expression during human B lymphocyte activation. We show that upon mitogenic stimulation with anti-IgM antibodies and interleukin-2, specific mRNA for p56lck becomes detectable in B cells after 24 h of activation and is followed by an increase in p56lck protein expression on days 2 and 3. This up-regulation is specific for p56lck since expression of other src kinases such as fyn, lyn, or yes was not modified. Furthermore, immune complex kinase assays show that p56lck protein expressed on day 2 is associated with kinase activity. Experiments using lck-specific antisense oligonucleotides show that the G0-G1 transition does not require p56lck, whereas DNA synthesis is dependent upon its expression. Thus, our data demonstrate that p56lck expression is up-regulated during human B cell stimulation and this kinase plays an important role during the control of late steps of B lymphocyte activation such as S phase entry.	INSERM,U131,32 RUE CARNETS,F-92140 CLAMART,FRANCE; IGR,INSERM,U333,F-94805 VILLEJUIF,FRANCE; ICGM,INSERM,U257,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; COOPER JA, 1984, J BIOL CHEM, V259, P7835; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LEPRINCE C, 1992, EUR J IMMUNOL, V22, P2093, DOI 10.1002/eji.1830220820; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; VAZQUEZ A, 1989, J IMMUNOL, V142, P94; VAZQUEZ A, 1991, J IMMUNOL, V146, P4222; VAZQUEZ A, 1991, EUR J IMMUNOL, V21, P2311, DOI 10.1002/eji.1830211004; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	20	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9169	9171						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683644				2022-12-27	WOS:A1993LA68900004
J	LEE, YM; BEINBORN, M; MCBRIDE, EW; LU, M; KOLAKOWSKI, LF; KOPIN, AS				LEE, YM; BEINBORN, M; MCBRIDE, EW; LU, M; KOLAKOWSKI, LF; KOPIN, AS			THE HUMAN BRAIN CHOLECYSTOKININ-B GASTRIN RECEPTOR - CLONING AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; ANTAGONIST; CELLS; CCK; L-365,260; POTENT; ANALGESIA; PEPTIDES; PANCREAS; ANXIETY	The predominant brain cholecystokinin receptor (CCK-B/gastrin) has been implicated in mediating many of the central effects of cholecystokinin, including anxiety, panic attacks, satiety, and analgesia, suggesting it is an important pharmacologic target. We now report the cloning and characterization of the cDNA encoding the human brain CCK-B/gastrin receptor. The cDNA was isolated from a human brain library by low stringency screening using the canine ''gastrin'' receptor cDNA as a hybridization probe. Nucleotide sequence analysis revealed an open reading frame encoding a 447-amino-acid protein with seven putative hydrophobic transmembrane domains and significant homology with other known members of the gastrin/cholecystokinin receptor family. Agonist and antagonist affinities of the recombinant human brain receptor expressed in COS-7 cells are consistent with a classical ''CCK-B'' receptor as defined by the literature. In COS-7 cells expressing the cloned receptor, CCK-8-stimulated phosphatidylinositol hydrolysis and intracellular Ca2+ mobilization suggesting second messenger signaling through phospholipase C. CCK-B/gastrin receptor transcripts were identified in human brain, stomach, and pancreas using high stringency Northern blot analysis. Southern blot hybridization analysis of human genomic DNA indicates that a single gene encodes both the brain and the stomach CCK-B/gastrin receptors. Our data suggest that the CCK-B and gastrin receptors are identical and that the long standing distinction between them may no longer apply.	TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,GRASP DIGEST DIS CTR,BOSTON,MA 02111; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77035; MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114; MED SCH HANNOVER,DEPT GEN PHARMACOL,W-3000 HANNOVER 61,GERMANY	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Baylor College of Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Hannover Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001934, P30DK034928, R01DK046767] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK34928, DK01934, DK46767] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOURISH CT, 1989, SCIENCE, V245, P1509, DOI 10.1126/science.2781294; DOURISH CT, 1990, EUR J PHARMACOL, V176, P35, DOI 10.1016/0014-2999(90)90129-T; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOURMY D, 1987, EUR J BIOCHEM, V165, P683, DOI 10.1111/j.1432-1033.1987.tb11495.x; HAYS SE, 1980, NEUROPEPTIDES, V1, P53, DOI 10.1016/0143-4179(80)90009-8; HILL DR, 1990, J NEUROSCI, V10, P1070; HILL DR, 1990, BRAIN RES, V526, P276, DOI 10.1016/0006-8993(90)91232-6; HUGHES J, 1990, P NATL ACAD SCI USA, V87, P6728, DOI 10.1073/pnas.87.17.6728; INNIS RB, 1980, P NATL ACAD SCI-BIOL, V77, P6917, DOI 10.1073/pnas.77.11.6917; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; JENSEN RT, 1990, GASTROINTEST ENDOSC, P95; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RAVARD S, 1990, TRENDS PHARMACOL SCI, V11, P271, DOI 10.1016/0165-6147(90)90004-R; REHFELD JF, 1978, J BIOL CHEM, V253, P4022; SAITO A, 1980, SCIENCE, V208, P1155, DOI 10.1126/science.6246582; SINGH L, 1991, P NATL ACAD SCI USA, V88, P1130, DOI 10.1073/pnas.88.4.1130; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; SWAROOP A, 1988, NUCLEIC ACIDS RES, V16, P8739, DOI 10.1093/nar/16.17.8739; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WATSON S, 1992, TRENDS PHARM SCI S, V11, P11; WIERTELAK EP, 1992, SCIENCE, V256, P830, DOI 10.1126/science.1589765; WOODRUFF GN, 1991, NEUROPEPTIDES S, V19, P57	38	249	264	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8164	8169						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681836				2022-12-27	WOS:A1993KW97900083
J	SHAPIRO, SD; KOBAYASHI, DK; PENTLAND, AP; WELGUS, HG				SHAPIRO, SD; KOBAYASHI, DK; PENTLAND, AP; WELGUS, HG			INDUCTION OF MACROPHAGE METALLOPROTEINASES BY EXTRACELLULAR-MATRIX EVIDENCE FOR ENZYME-SPECIFIC AND SUBSTRATE-SPECIFIC RESPONSES INVOLVING PROSTAGLANDIN-DEPENDENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST COLLAGENASE; STROMELYSIN GENE-EXPRESSION; HUMAN ALVEOLAR MACROPHAGES; HUMAN SYNOVIAL-CELLS; STIMULATES COLLAGENASE; INHIBITOR; LIPOPOLYSACCHARIDE; DEXAMETHASONE; BIOSYNTHESIS; MODULATION	Many cellular properties are influenced by the surrounding environment of extracellular matrix. To better define the interaction between mononuclear phagocytes and the extracellular matrix components they contact, we studied the effect of various matrices on the biosynthesis and secretion of metalloenzymes and the tissue inhibitor of metalloproteinases in human alveolar macrophages. We found that native and denatured collagen types I and III markedly augmented production of interstitial collagenase (>25-fold) and increased tissue inhibitor of metalloproteinases to a lesser degree (2.5-fold). In contrast, the biosynthesis of another major secreted macrophage metalloproteinase, 92-kDa gelatinase, was unaffected by contact with extracellular matrices. Furthermore, other matrix components (i.e. type IV collagen, laminin, fibronectin, elastin) failed to induce collagenase production. Maximal stimulation of macrophage collagenase production was achieved with 1-5 mug/ml (3-15 x 10(-9) M) denatured collagen in contact with cells for 2 h. Increased biosynthesis of collagenase was detected within 24 h of cell contact with native or denatured collagen and was accompanied by marked induction of collagenase mRNA levels. Our studies of signal transduction mechanisms demonstrated that indomethacin decreased gelatin-induced collagenase production by 90%, with enzyme levels completely restored by the addition of exogenous prostaglandin E2. Prostaglandin E2 Was only effective when added within the first 2 h after indomethacin treatment. These results indicate that extracellular matrix can directly influence its remodeling and repair via regulation of the production of metalloenzymes by resident inflammatory cells. Furthermore, matrix-metalloproteinase inductive interactions are both enzyme- and matrix-specific, and are mediated, at least in part, by a prostaglandin-dependent mechanism.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DIV DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	SHAPIRO, SD (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,216 S KINGSHIGHWAY,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035805, P01AR032087] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAMS NIH HHS [AR-35805, AR-32087] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BISWAS C, 1979, CELL, V18, P1035, DOI 10.1016/0092-8674(79)90216-2; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TW, 1982, COLLAGEN REL RES, V3, P205; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; CURY JD, 1988, J IMMUNOL, V141, P4306; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1979, J CLIN INVEST, V64, P1386, DOI 10.1172/JCI109596; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GROSS J, 1958, J EXP MED, V108, P215, DOI 10.1084/jem.108.2.215; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; KING J, 1971, J MOL BIOL, V62, P464; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; PIEZ KA, 1963, BIOCHEMISTRY-US, V2, P58, DOI 10.1021/bi00901a012; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SHAPIRO SD, 1990, J CLIN INVEST, V86, P1204, DOI 10.1172/JCI114826; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; TRELSTAD RL, 1976, ANAL BIOCHEM, V71, P114, DOI 10.1016/0003-2697(76)90016-6; WAHL LM, 1984, ARCH BIOCHEM BIOPHYS, V230, P661, DOI 10.1016/0003-9861(84)90447-8; WELGUS HG, 1990, J BIOL CHEM, V265, P13521; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877	31	124	124	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8170	8175						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681837				2022-12-27	WOS:A1993KW97900084
J	FINGAR, DC; HAUSDORFF, SF; BLENIS, J; BIRNBAUM, MJ				FINGAR, DC; HAUSDORFF, SF; BLENIS, J; BIRNBAUM, MJ			DISSOCIATION OF PP70 RIBOSOMAL-PROTEIN S6 KINASE FROM INSULIN-STIMULATED GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKADAIC ACID; MOLECULAR MECHANISM; SKELETAL-MUSCLE; PHORBOL ESTER; PHOSPHORYLATION; CELLS; IDENTIFICATION; ACTIVATION; METABOLISM; EXPRESSION	The metabolic and mitogenic actions of insulin have been proposed to be mediated by cellular serine/threonine kinases such as the ribosomal protein S6 kinases pp70-S6 (pp70-S6 kinase) and pp90rsk and the erk-encoded mitogen-activated protein kinases (pp42mapk and pp44mapk). Rapamycin completely blocked activation of pp70-S6 kinase by insulin in 3T3-L1 adipocytes, but did not inhibit insulin-stimulated glucose transport, translocation of GLUT4 to the cell surface, or activation of pp90rsk or pp44mapk by insulin. Concordant with the inhibition of kinase activity, rapamycin prevented the insulin-induced decrease in mobility of pp70-S6 kinase visualized by SDS-polyacrylamide gel electrophoresis, reflecting a reduction in the hormone-stimulated phosphorylation of the enzyme. The structurally related macrolide, FK506, had no effect on pp70-S6 kinase or hexose uptake. These data demonstrate that rapamycin blocks insulin activation of pp70-S6 kinase in 3T3-L1 adipocytes and that pp70-S6 kinase is not required in the signaling pathway leading to insulin-stimulated glucose transport.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,25 SHATTUCK ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [F32 DK08714, R01 DK39519] Funding Source: Medline; NIGMS NIH HHS [GM07226] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008714, R01DK039519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007226] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CZECH MP, 1992, TRENDS BIOCHEM SCI, V17, P197, DOI 10.1016/0968-0004(92)90266-C; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TANTI JF, 1991, J BIOL CHEM, V266, P2099	30	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					3005	3008						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679106				2022-12-27	WOS:A1993KK81500109
J	PURI, PL; AVANTAGGIATI, ML; BURGIO, VL; CHIRILLO, P; COLLEPARDO, D; NATOLI, G; BALSANO, C; LEVRERO, M				PURI, PL; AVANTAGGIATI, ML; BURGIO, VL; CHIRILLO, P; COLLEPARDO, D; NATOLI, G; BALSANO, C; LEVRERO, M			REACTIVE OXYGEN INTERMEDIATES MEDIATE ANGIOTENSIN-II-INDUCED C-JUN-CENTER-DOT-C-FOS HETERODIMER DNA-BINDING ACTIVITY AND PROLIFERATIVE HYPERTROPHIC RESPONSES IN MYOGENIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CARDIAC-HYPERTROPHY; MOLECULAR CHARACTERIZATION; PROTEIN-SYNTHESIS; ARACHIDONIC-ACID; TYROSINE KINASE; ACTIVATION; PHOSPHORYLATION; MYOCYTES; INCREASE	Angiotensin II (Ang-II) receptor engagement activates many immediate early response genes in both vascular smooth muscle cells and cardiomyocytes whether a hyperplastic or hypertrophic response is taking place, Although the signaling pathways stimulated by Ang-II in different cell lines have been widely characterized, the correlation between the generation of different second messengers and specific physiological responses remains relatively unexplored, In this study, we report how in both C2C12 quiescent myoblasts and differentiated myotubes Ang II significantly stimulates AP1-driven transcription and c-Jun . c-Fos heterodimer DNA binding activity. Using a set of different protein kinase inhibitors, we could demonstrate that Ang-II-induced increase in API binding is not mediated by the cAMP-dependent pathway and that both protein kinase C and tyrosine kinases are involved. The observation that in quiescent myoblasts Ang-II increase of AP1 binding and induction of DNA synthesis and, in differentiated myotubes, Ang-II stimulation of protein synthesis are abolished by the cysteine-derivative and glutathione precursor N-acetyl-L-cysteine strongly suggests a role for reactive oxygen intermediates in the intracellular transduction of Ang-II signals for immediate early gene induction, cell proliferation, and hypertrophic responses.	UNIV ROMA LA SAPIENZA,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY; UNIV CAGLIARI,IST MED INTERNA,I-09124 CAGLIARI,ITALY	Sapienza University Rome; University of L'Aquila; University of Cagliari	PURI, PL (corresponding author), UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST CLIN MED 1,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Balsano, Clara/AAK-9870-2020; Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Levrero, Massimo/0000-0002-4978-0875; Puri, Pier Lorenzo/0000-0003-4964-0095				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1272, P129; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BAKER KM, 1989, J PHARMACOL EXP THER, V251, P578; BAKER KM, 1990, AM J PHYSIOL, V259, pH324, DOI 10.1152/ajpheart.1990.259.2.H324; BAKER KM, 1990, AM J PHYSIOL, V259, pH610, DOI 10.1152/ajpheart.1990.259.2.H610; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUY GR, 1993, J BIOL CHEM, V268, P2141; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HASSID A, 1986, J PHARMACOL EXP THER, V239, P334; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; KHAIRALLAH PA, 1983, PERSPECTIVE CARDIOVA, V8, P337; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; KOJIMA I, 1985, ENDOCRINOLOGY, V117, P1057, DOI 10.1210/endo-117-3-1057; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LASSEGUE B, 1991, BIOCHEM J, V276, P19, DOI 10.1042/bj2760019; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LINZ W, 1989, CLIN EXP HYPERTENS A, V11, P1325, DOI 10.3109/10641968909038172; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; NATOLI G, 1994, MOL CELL BIOL, V14, P898; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO GN, 1993, ONCOGENE, V8, P2759; RIVERA V M, 1990, New Biologist, V2, P751; ROZENGURT E, 1990, EUR J CLIN INVEST, V21, P123; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; STOUFFER GA, 1992, CIRC RES, V70, P820, DOI 10.1161/01.RES.70.4.820; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; Yaffe D, 1977, NATURE, V270, P725, DOI DOI 10.1038/270725A0	49	108	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22129	22134		10.1074/jbc.270.38.22129	http://dx.doi.org/10.1074/jbc.270.38.22129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673190	hybrid			2022-12-27	WOS:A1995RW31400014
J	WREGGETT, KA; WELLS, JW				WREGGETT, KA; WELLS, JW			COOPERATIVITY MANIFEST IN THE BINDING-PROPERTIES OF PURIFIED CARDIAC MUSCARINIC RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TERNARY COMPLEX MODEL; PROTEIN-LINKED RECEPTORS; ADENYLATE-CYCLASE SYSTEM; PIG CEREBRAL-CORTEX; ACETYLCHOLINE-RECEPTOR; ANTAGONIST BINDING; RAT-BRAIN; D2-DOPAMINE RECEPTOR; H-3 HISTAMINE	Muscarinic receptors were solubilized from porcine atria in digitonin-cholate and were purified by chromatography on DEAE-Sepharose and 3-(2'-aminobenzhydryloxy)tropane-Sepharose. The product identified on Western blots migrated with an apparent molecular mass of 60-75 kDa, with additional bands indicative of homotrimers (190 kDa) and homotetramers (240 kDa). Receptor eluted from the affinity column was accompanied by a mixture of guanyl nucleotide-binding proteins (G-proteins) identified on Western blots as G(i1/2), G(o), G(q/11), and G(s) (preparation M2G); the G-proteins were largely removed by further processing on hydroxyapatite (preparation M2). Solubilized purified receptors bound muscarinic ligands in an apparently cooperative manner. In studies at equilibrium, the antagonists [H-3]AF-DX 384, N-[H-3]methylscopolamine (NMS), and [H-3]quinuclidinylbenzilate (QNB) revealed Hill coefficients between about 0.8 and 1.2. Also, the apparent capacity for [H-3]QNB exceeded that for [H-3]AF-DX 384 and [H-3]NMS by about 1.5-fold in M2 and by S-fold in M2G. Binding to M2G at high concentrations of [H-3]QNB was fully inhibited by unlabeled NMS, which therefore affected sites not labeled at similar concentrations of [H-3]NMS. Oxotremorine-M displayed a biphasic inhibitory effect on the binding of [H-3]AF-DX 384 in M2 and M2G, suggesting that multiple states of affinity are intrinsic to the receptor; 5'-guanylylimidodiphosphate was without appreciable effect in M2 but resulted in a bell-shaped binding profile for the agonist in M2G. All of the data can be described in terms of cooperative interactions within a receptor that is at least tetravalent and presumably an oligomer. In the context of the model, copurifying G-proteins and guanyl nucleotides serve to regulate the degree of cooperativity between successive equivalents of muscarinic ligands.	UNIV TORONTO,FAC PHARM,TORONTO,ON M5S 2S2,CANADA	University of Toronto								AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOYER JL, 1986, BIOCHEM BIOPH RES CO, V134, P172, DOI 10.1016/0006-291X(86)90543-7; CASTOLDI AF, 1991, RES COMMUN CHEM PATH, V74, P371; CHIDIAC P, 1992, BIOCHEMISTRY-US, V31, P10908, DOI 10.1021/bi00159a035; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COULTER S, 1992, P NATL ACAD SCI USA, V89, P5842, DOI 10.1073/pnas.89.13.5842; DADI HK, 1984, EUR J BIOCHEM, V144, P617, DOI 10.1111/j.1432-1033.1984.tb08510.x; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; EHLERT FJ, 1990, MOL PHARMACOL, V38, P148; EHLERT FJ, 1985, MOL PHARMACOL, V28, P410; ENTZEROTH M, 1991, J RECEPTOR RES, V11, P141, DOI 10.3109/10799899109066395; FLORIO VA, 1985, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRAESER D, 1993, MOL PHARMACOL, V43, P434; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; IKEGAYA T, 1990, J MOL CELL CARDIOL, V22, P343, DOI 10.1016/0022-2828(90)91467-L; JAHANGEER S, 1993, P NATL ACAD SCI USA, V90, P8782, DOI 10.1073/pnas.90.19.8782; KAUFMANN SH, 1987, ANAL BIOCHEM, V161, P89, DOI 10.1016/0003-2697(87)90656-7; KENT RS, 1980, MOL PHARMACOL, V17, P14; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1985, J PHARMACOL EXP THER, V233, P707; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; LEUNG E, 1990, MOL PHARMACOL, V38, P72; LIMBIRD LE, 1975, BIOCHEM BIOPH RES CO, V64, P1160, DOI 10.1016/0006-291X(75)90815-3; LIMBIRD LE, 1980, P NATL ACAD SCI-BIOL, V77, P775, DOI 10.1073/pnas.77.2.775; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Marquardt D. W., 1963, J SOC IND APPL MATH, V2, P431; MATESIC DF, 1991, FEBS LETT, V284, P184, DOI 10.1016/0014-5793(91)80680-2; MATESIC DF, 1991, MOL PHARMACOL, V40, P347; MATESIC DF, 1988, J BIOL CHEM, V264, P21638; MATTERA R, 1985, J BIOL CHEM, V260, P7410; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1988, BIOCHEMISTRY-US, V27, P2374, DOI 10.1021/bi00407a019; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PARKER EM, 1991, J BIOL CHEM, V266, P519; PETERSON GL, 1984, PREP BIOCHEM, V14, P33, DOI 10.1080/10826068408070612; PETERSON GL, 1984, P NATL ACAD SCI-BIOL, V81, P4993, DOI 10.1073/pnas.81.15.4993; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; POYNER DR, 1989, MOL PHARMACOL, V36, P420; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEEMAN P, 1992, EUR J PHARM-MOLEC PH, V227, P139, DOI 10.1016/0922-4106(92)90121-B; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; SINKINS WG, 1993, MOL PHARMACOL, V43, P583; SINKINS WG, 1993, MOL PHARMACOL, V43, P569; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; WELLS JW, 1990, EUR J PHARMACOL, V183, P1731, DOI 10.1016/0014-2999(90)92036-I; WONG HMS, 1986, BIOCHEMISTRY-US, V25, P6995, DOI 10.1021/bi00370a037; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; WREGGETT KA, 1987, BIOCHEM BIOPH RES CO, V147, P1070, DOI 10.1016/S0006-291X(87)80179-1; Wyman J, 1990, BINDING LINKAGE FUNC	70	156	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22488	22499		10.1074/jbc.270.38.22488	http://dx.doi.org/10.1074/jbc.270.38.22488			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673239	hybrid			2022-12-27	WOS:A1995RW31400068
J	YELISEEV, AA; KAPLAN, S				YELISEEV, AA; KAPLAN, S			A SENSORY TRANSDUCER HOMOLOGOUS TO THE MAMMALIAN PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR REGULATES PHOTOSYNTHETIC MEMBRANE COMPLEX-FORMATION IN RHODOBACTER-SPHAEROIDES-2.4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS GENE-CLUSTER; RHODOPSEUDOMONAS-SPHAEROIDES; ESCHERICHIA-COLI; PROTEIN; CAPSULATUS; SEQUENCE; CONSTRUCTION; LOCALIZATION; EXPRESSION; CLONING	The Rhodobacter sphaeroides 2.4.1 tryptophan rich Sensory protein gene, tspO (formerly crtK, ORF160) encodes a 17-kDa protein which has an unusually high content of aromatic amino acids in general and of L-tryptophan in particular. The TspO protein was localized to the outer membrane of aerobically grown R. sphaeroides 2.4.1 by use of a polyclonal antibody against the purified protein. This protein is present in severalfold higher levels in photosynthetic as opposed to aerobic grown cells. Although tspO lies within the crt gene cluster, null mutations have an intact carotenoid biosynthetic pathway. In the TSPO1 mutant there was an increased production of carotenoids and bacteriochlorophyll relative to the wild type, particularly when cells were grown aerobically or semiaerobically. When present in trans the tspO gene restored ''normal'' pigment production to TSPO1. The effect of the tspO gene on pigment production was shown to take place at the level of gene expression. Because the tspO gene product of R. sphaeroides 2.4.1 shows significant sequence homology and similarity to the peripheral-type benzodoazepine receptor from mammalian sources, TspO-specific anti bodies when probed against liver and kidney mitochondrial protein showed strong cross-reactivity. The role of TspO in R. sphaeroides 2.4.1 and its relation to photosynthesis gene expression are discussed.	UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & MOLEC GENET,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston			Yeliseev, Alexei A/B-3143-2009		NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTKIEWICZMICHA.L, 1988, J BIOL CHEM, V263, P17317; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER ME, 1991, CELL, V65, P721, DOI 10.1016/0092-8674(91)90379-D; BOLLIVAR DW, 1992, BIOCHEM J, V282, P471, DOI 10.1042/bj2820471; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DEAL CD, 1983, J BIOL CHEM, V258, P6524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONOHUE TJ, 1986, J BACTERIOL, V168, P962, DOI 10.1128/jb.168.2.962-972.1986; DRYDEN SC, 1993, J BACTERIOL, V175, P6392, DOI 10.1128/jb.175.20.6392-6402.1993; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; EVANS MB, 1988, BIOCHIM BIOPHYS ACTA, V935, P292, DOI 10.1016/0005-2728(88)90224-1; GIULIANO G, 1988, MOL GEN GENET, V213, P78, DOI 10.1007/BF00333401; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; HARLOW E, 1988, ANTIBODIES LABORATOR; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KILEY PJ, 1988, MICROBIOL REV, V52, P50, DOI 10.1128/MMBR.52.1.50-69.1988; LACKS S, 1977, J MOL BIOL, V114, P153, DOI 10.1016/0022-2836(77)90289-3; LANG HP, 1995, J BACTERIOL, V177, P2064, DOI 10.1128/jb.177.8.2064-2073.1995; LEE JK, 1992, J BACTERIOL, V174, P1158, DOI 10.1128/jb.174.4.1158-1171.1992; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARTIN JP, 1987, J BACTERIOL, V169, P2516, DOI 10.1128/jb.169.6.2516-2522.1987; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCENERY MW, 1992, P NATL ACAD SCI USA, P3170; MEINHARDT SW, 1985, ARCH BIOCHEM BIOPHYS, V236, P130, DOI 10.1016/0003-9861(85)90612-5; MOORE MD, 1989, J BACTERIOL, V171, P4385, DOI 10.1128/JB.171.8.4385-4394.1989; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Sambrook J, 1989, MOL CLONING LABORATO; Simon R., 1983, BIOTECHNOLOGY, V1, P37; TAI SP, 1985, J BACTERIOL, V164, P181, DOI 10.1128/JB.164.1.181-186.1985; VARGA AR, 1989, J BACTERIOL, V171, P5830, DOI 10.1128/jb.171.11.5830-5839.1989; WEISS RL, 1976, J BACTERIOL, V128, P668, DOI 10.1128/JB.128.2.668-670.1976; ZEILSTRARYALLS JH, 1995, J BACTERIOL, V177, P2760, DOI 10.1128/jb.177.10.2760-2768.1995	35	101	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21167	21175		10.1074/jbc.270.36.21167	http://dx.doi.org/10.1074/jbc.270.36.21167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673149	hybrid			2022-12-27	WOS:A1995RU05400048
J	ZENG, FY; KAPHALIA, BS; ANSARI, GAS; WEIGEL, PH				ZENG, FY; KAPHALIA, BS; ANSARI, GAS; WEIGEL, PH			FATTY ACYLATION OF THE RAT ASIALOGLYCOPROTEIN RECEPTOR - THE 3 SUBUNITS FROM ACTIVE RECEPTORS CONTAIN COVALENTLY BOUND PALMITATE AND STEARATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; MEDIATED ENDOCYTOSIS; GALACTOSYL RECEPTORS; ISOLATED HEPATOCYTES; PALMITOYLATION; LIVER; CELLS; INACTIVATION; PROTEINS; DEGRADATION	Rat hepatic asialoglycoprotein receptors (ASGP-Rs) are hetero-oligomers composed of three homologous glycoprotein subunits, designated rat hepatic lectins (RHL) 1, 2, and 3. ASGP-Rs mediate the endocytosis and degradation of circulating glycoconjugates containing terminal N-acetylgalactosamine or galactose, including desialylated plasma glycoproteins. We have shown in permeable rat hepatocytes that the ligand binding activity of one subpopulation of receptors (designated State 2 ASGP-Rs) can be decreased or increased, respectively, by ATP and palmitoyl-CoA (Weigel, P. H., and Oka, J. A. (1993) J. Biol. Chem. 268, 27186-27190). We proposed that a reversible and cyclic acylation/deacylation process may regulate ASGP-R activity during endocytosis, receptor-ligand dissociation, and receptor recycling. In the accompanying paper (Zeng, F-Y., and Weigel, P. H. (1995) J. Biol. Chem. 270, 21388-21395), we show that the ligand binding activity of affinity-purified State 2 ASGP-Rs is decreased by treatment with hydroxylamine under mild conditions consistent with these ASGP-Rs being fatty acylated in vivo. In this study, we used a chemical method to determine the presence of covalently-bound fatty acids in individual ASGP-R subunits. The affinity-purified ASGP-R preparations were separated by SDS-polyacrylamide gel electrophoresis under nonreducing conditions, and the gel slices containing individual RHL subunits were treated with alkali to release covalently bound fatty acids, which were subsequently analyzed by gas chromatography and confirmed by gas chromatography-mass spectrometry. Both stearic and palmitic acids were detected in all three receptor subunits. Pretreatment of ASGP-Rs with hydroxylamine before SDS-polyacrylamide gel electrophoresis reduced the content of both fatty acids by 66-80%, indicating that most of these fatty acids are attached to cysteine residues via thioester linkages. Furthermore, when freshly isolated hepatocytes were cultured in the presence of [H-3]palmitate, all three RHL subunits in affinity-purified ASGP-Rs were metabolically labeled. We conclude that RHL1, RHL2, and RHL3 are modified by fatty acylation in intact cells.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190; UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77555	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 04815] Funding Source: Medline; NIGMS NIH HHS [GM 49695] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; DRICKAMER K, 1987, KIDNEY INT, V32, P167; GRASSIE MA, 1993, BIOCH SOC T S, V21, P499; HAYNES PA, 1995, J BIOL CHEM, V269, P33146; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KAPHALIA BS, 1995, IN PRESS FUNDAM APPL; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MEDH JD, 1991, J BIOL CHEM, V266, P8771; MURPHY RC, 1993, HDB LIPID RES, P290; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OMARY MB, 1981, J BIOL CHEM, V256, P4715; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P687; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TAKAHASHI T, 1985, BIOCHEM BIOPH RES CO, V126, P1054, DOI 10.1016/0006-291X(85)90292-X; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388	37	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21382	21387		10.1074/jbc.270.36.21382	http://dx.doi.org/10.1074/jbc.270.36.21382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673174	hybrid			2022-12-27	WOS:A1995RU05400078
J	ZENG, FY; WEIGEL, PH				ZENG, FY; WEIGEL, PH			HYDROXYLAMINE TREATMENT DIFFERENTIALLY INACTIVATES PURIFIED RAT HEPATIC ASIALOGLYCOPROTEIN RECEPTORS AND DISTINGUISHES 2 RECEPTOR POPULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSYL RECEPTORS; COVALENT MODIFICATION; MEDIATED ENDOCYTOSIS; TRANSFERRIN RECEPTOR; ISOLATED HEPATOCYTES; EUKARYOTIC PROTEINS; ATP DEPLETION; PALMITIC ACID; LIVER; SUBPOPULATION	We previously showed that two subpopulations of asialoglycoprotein receptors (ASGP-Rs), designated State 1 and State 2 ASGP-Rs, are present in intact cells and that State 2 ASGP-Rs can be inactivated in permeable rat hepatocytes in a temperature- and ATP-dependent manner. These inactivated ASGP-Rs can be quantitatively reactivated by the addition of palmitoyl-CoA (Weigel, P. H., and Oka, J. A. (1993) J. Biol. Chem. 268, 27186-27190). Here we show that similar to 50% of purified rat ASGP-Rs are inactivated by treatment with hydroxylamine under mild conditions. The activity of affinity purified ASGP-Rs was assessed by measuring the specific binding of I-125-asialo-orosomucoid (ASOR) in a dot-blot assay after immobilization onto nitrocellulose. Treatment of ASGP-Rs in solution with 0.0125-1.0 M NH2OH, pH 7.4, at 4 degrees C for 4 h resulted in a progressive loss of ASOR binding activity, ASGP-R inactivation with NH2OH occurred more readily at basic pH or at room temperature, Similar treatment with Tris had no effect on ASGP-R activity. The kinetics of ASGP-R activity loss and the dose-response for this inactivation were both biphasic, indicating the presence of two equal populations of ASGP-Rs with different sensitivities to NH2OH. The more sensitive population of ASGP-Rs (similar to 50%) was inactivated by treatment with 0.2 M NH2OH (4 degrees C, 4 h) or with 1.0 M NH2OH (4 degrees C, 1 h) without detectable peptide cleavage as assessed by SDS-polyacrylamide gel electrophoresis, State 1 ASGP-Rs, purified from chloroquine- or monensin-treated hepatocytes, showed significantly less sensitivity to NH2OH treatment (both in kinetics and dose dependence). Furthermore, under mild conditions NH2OH caused dissociation and inactivation of similar to 50% of the total ASGP-Rs (State 1 and State 2) that were prebound to ASOR-Sepharose, whereas the same treatment caused dissociation of only <20% of State 1 ASGP-Rs from such preformed complexes, As shown in the accompanying paper (Zeng, F. Y., Kaphalia, B. S., Ansari, G. A. S., and Weigel, P. H. (1995) J. Biol. Chem. 270, 21382-21387) all three RHL subunits of active ASGP-Rs, in fact, contain covalently attached palmitate and stearate. In cultured cells, [H-3]palmitic acid is metabolically incorporated into all three subunits. These radio-labeled fatty acids are completely released from purified ASGP-Rs by mild NH2OH treatment. We conclude that the NH2OH-sensitive subpopulation of ASGP-Rs corresponds to the previously described State 2 ASGP-Rs and that these receptors require fatty acylation for their ligand binding activity.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM M, 1988, ARCH BIOCHEM BIOPHYS, V264, P553, DOI 10.1016/0003-9861(88)90321-9; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Bornstein P, 1977, Methods Enzymol, V47, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; DRICKAMER K, 1987, KIDNEY INT, V32, pS167; FIETE D, 1983, J BIOL CHEM, V25, P817; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; KOCH N, 1986, J BIOL CHEM, V261, P3434; KWONG MY, 1994, PROTEIN SCI, V3, P147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MEDH JD, 1991, J BIOL CHEM, V266, P8771; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; OKA JA, 1991, ARCH BIOCHEM BIOPHYS, V289, P362, DOI 10.1016/0003-9861(91)90424-H; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OMARY MB, 1981, J BIOL CHEM, V256, P4715; RAY DA, 1985, ANAL BIOCHEM, V145, P37, DOI 10.1016/0003-2697(85)90323-9; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHMIDT MFG, 1985, J GEN VIROL, V66, P2635, DOI 10.1099/0022-1317-66-12-2635; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STEER CJ, 1981, J BIOL CHEM, V256, P5851; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TILDON JT, 1972, J BIOL CHEM, V247, P1265; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TRAXLER KW, 1994, BIOCHEMISTRY-US, V33, P1718, DOI 10.1021/bi00173a014; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382; ZENG FY, 1994, FASEB J, V8, pA1406	53	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21388	21395		10.1074/jbc.270.36.21388	http://dx.doi.org/10.1074/jbc.270.36.21388			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673175	hybrid			2022-12-27	WOS:A1995RU05400079
J	LI, WX; HOWARD, RJ; LEUNG, LLK				LI, WX; HOWARD, RJ; LEUNG, LLK			IDENTIFICATION OF SVTCG IN THROMBOSPONDIN AS THE CONFORMATION-DEPENDENT, HIGH-AFFINITY BINDING-SITE FOR ITS RECEPTOR, CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLATELET THROMBOSPONDIN; HUMAN MALARIA PARASITE; GLYCOPROTEIN-IV CD36; CELL-ADHESION; MONOCLONAL-ANTIBODIES; PROTEIN-G; AGGREGATION; FIBRINOGEN; MOLECULES; PROPERDIN	Thrombospondin (TSP) binds to its cellular receptor, CD36 (glycoprotein IV or IIIb), and participates in many adhesive cell interactions. We have shown that the CD36-TSP interaction occurs in a stepwise, conformation-dependent process. CD36 sequence 139-155 binds TSP and induces a second CD36-binding site, which binds CD36 sequence 93-110 with high affinity. To characterize this high affinity CD36-binding site on TSP, an anti-TSP monoclonal antibody (mAb), 7A-1e, was identified that showed augmentation of TSP binding in the presence of CD36 peptide P139-155. Purified mAb 7A-1e IgG specifically blocked both P139-155-augmented CD36 binding and P139-155-dependent CD36 peptide P93-110 binding to TSP, indicating that the binding sites on TSP for mAb 7A-1e and P93-110 are closely related. mAb 7A-1e IgG inhibited collagen-induced platelet aggregation in platelet-rich plasma. SVTCG is a cell adhesive motif in TSP. Both mAb 7A-1e and P93-110 specifically bound to a TSP peptide containing SVTCG, and the binding of mAb 7A-1e or P93-110 to TSP was inhibited by soluble SVTCG peptide. The SVTCG cell adhesive domain in TSP is the conformation-dependent, high affinity binding site for CD36 sequence 93-110.	STANFORD UNIV,MED CTR,SCH MED,DIV HEMATOL,STANFORD,CA 94305; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Stanford University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042943] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL42943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; CLEZARDIN P, 1986, EUR J BIOCHEM, V154, P95, DOI 10.1111/j.1432-1033.1986.tb09363.x; COLIGAN JE, 1984, J BIOL CHEM, V259, P3944; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; FREDRIKSON G, 1987, J IMMUNOL METHODS, V97, P65, DOI 10.1016/0022-1759(87)90106-2; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; IAN RH, 1992, LANCET, V399, P1453; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; LOFTUS JC, 1987, P NATL ACAD SCI USA, V84, P7114, DOI 10.1073/pnas.84.20.7114; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TUSZYNSKI GP, 1993, J CELL BIOL, V120, P513, DOI 10.1083/jcb.120.2.513; ZAMARRON C, 1991, J BIOL CHEM, V266, P16193	32	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16179	16184						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688364				2022-12-27	WOS:A1993LQ33600017
J	BREUER, W; GLICKSTEIN, H; KARTNER, N; RIORDAN, JR; AUSIELLO, DA; CABANTCHIK, IZ				BREUER, W; GLICKSTEIN, H; KARTNER, N; RIORDAN, JR; AUSIELLO, DA; CABANTCHIK, IZ			PROTEIN-KINASE-C MEDIATES DOWN-REGULATION OF CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR LEVELS IN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; R-DOMAIN; GENE; TRANSPORT; PHOSPHORYLATION; EXPRESSION	Expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in epithelial cells is known to be down-regulated by the action of phorbol myristate acetate (PMA). We show here that in addition to suppressing the rate of transcription of the CFTR gene, PMA treatment stimulates degradation of the CFTR protein. HT-29 colon epithelial cells and the CFTR-transfected pancreatic cells PLJ-4.7 lost 55-80% of their CFTR protein after 3-6 h of treatment with 100 nm PMA, as analyzed by quantitative Western blotting. In contrast to PMA, actinomycin D and cycloheximide reduced the CFTR protein content by 19 and 9% in HT-29 cells and by 22 and 40% in PLJ-4.7 cells, respectively, while inhibiting total cellular RNA and protein synthesis by over 80%. The PMA-induced loss of CFTR was partially reversed by the protein kinase C inhibitor GF109203X. The PMA-induced degradation of CFTR may represent a regulatory pathway for terminating CFTR-mediated chloride and mucin secretion.	HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,RENAL SECT,CHARLESTON,MA 02113	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Massachusetts General Hospital	BREUER, W (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040158] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BLACKSHEAR PJ, 1988, AM J MED SCI, V296, P231, DOI 10.1016/S0002-9629(15)40866-3; BREUER W, 1992, J BIOL CHEM, V267, P10465; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHOU JL, 1991, J BIOL CHEM, V266, P24471; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P71; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; KUNZELMANN K, 1993, UNPUB PFLUGERS ARCH; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; MCCOOL DJ, 1990, BIOCHEM J, V267, P491, DOI 10.1042/bj2670491; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1059; SARKADI B, 1992, J BIOL CHEM, V267, P2087; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	35	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13935	13939						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686146				2022-12-27	WOS:A1993LJ82500027
J	VELCICH, A; AUGENLICHT, LH				VELCICH, A; AUGENLICHT, LH			REGULATED EXPRESSION OF AN INTESTINAL MUCIN GENE IN HT29 COLONIC-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SODIUM-BUTYRATE; MOLECULAR-CLONING; ADENOCARCINOMA CELLS; CANCER-CELLS; ENTEROCYTIC DIFFERENTIATION; ALKALINE-PHOSPHATASE; COLORECTAL-CARCINOMA; OKADAIC ACID; CALPHOSTIN-C	We have investigated the regulation of the intestinal mucin gene MUC2 in HT29 cells. Surprisingly, sodium butyrate, an effective inducer of aspects of colonic cell differentiation in HT29 cells, fails to induce MUC2 during short-term exposure, despite the fact that it has been used to select stably differentiated clones of HT29 that resemble goblet cells and produce mucin. However, 12-O-tetradecanoylphorbol-13-acetate and forskolin, which trigger the protein kinase C- and A-dependent signal transduction pathways, respectively, are potent inducers of MUC2 gene expression. 12-O-Tetradecanoylphorbol-13-acetate and forskolin operate through distinct mechanisms, with the former requiring de novo protein synthesis and the latter not. Experiments using specific protein kinase inhibitors suggest that both inducers operate by triggering their respective signal transduction pathways. Nuclear run-off analyses suggest that post-transcriptional (rather than transcriptional) mechanisms are important in the accumulation of MUC2 mRNA. Finally, we show that in several cell lines from human mucinous tumors, characterized by elevated levels of mucin production, MUC2 expression is very high and constitutive compared to forskolin-treated HT29 cells. Thus, the different regulation of MUC2 in HT29 cells and in mucinous tumor cell lines may reflect molecular pathways that characterize colon carcinomas of different histology and pathology.			VELCICH, A (corresponding author), ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R29CA055913, R01CA056081, K04CA001330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55913, CA-56081, P30-CA-1330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; AUGENLICHT LH, 1989, CELL MOL BIOL COLON, P166; AUGERON C, 1984, CANCER RES, V44, P3961; AUGERON C, 1986, ION GRADIENT COUPLED, P363; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CHANG WWL, 1971, AM J ANAT, V131, P73, DOI 10.1002/aja.1001310105; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1992, ONCOGENE, V7, P2281; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1987, J BIOL CHEM, V262, P1092; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUM JR, 1992, J BIOL CHEM, V267, P21375; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; HEERDT BG, 1991, J BIOL CHEM, V266, P19120; HEERDT BG, 1991, ONCOGENE, V6, P125; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JARRY A, 1992, DIGEST DIS SCI, V37, P1170, DOI 10.1007/BF01296556; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAN MS, 1990, J BIOL CHEM, V265, P15294; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NISHIZUKA Y, 1984, RECENT PROG HORM RES, V40, P301; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTE AP, 1989, CELL, V58, P641, DOI 10.1016/0092-8674(89)90099-8; PARK JG, 1987, CANCER RES, V47, P6710; PINTO M, 1982, BIOL CELL, V44, P193; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; POTTEN CS, 1979, BIOCHIM BIOPHYS ACTA, V560, P281, DOI 10.1016/0304-419X(79)90022-2; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SILVER G, 1990, MOL CELL BIOL, V10, P6765, DOI 10.1128/MCB.10.12.6765; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; TIBBETTS LM, 1988, CANCER RES, V48, P3751; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TSAO D, 1982, CANCER RES, V42, P1052; VANCONG N, 1990, HUM GENET, V86, P167; VELCICH A, 1989, ONCOGENE RES, V5, P31; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU G, 1992, BIOCHEM BIOPH RES CO, V183, P821, DOI 10.1016/0006-291X(92)90557-2; XU GQ, 1992, J BIOL CHEM, V267, P5401; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	70	62	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13956	13961						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686147				2022-12-27	WOS:A1993LJ82500030
J	UEDA, E; SEVLEVER, D; PRINCE, GM; ROSENBERRY, TL; HIROSE, S; MEDOF, ME				UEDA, E; SEVLEVER, D; PRINCE, GM; ROSENBERRY, TL; HIROSE, S; MEDOF, ME			A CANDIDATE MAMMALIAN GLYCOINOSITOL PHOSPHOLIPID PRECURSOR CONTAINING 3 PHOSPHOETHANOLAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; GLYCOLIPID MEMBRANE ANCHOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; TRYPANOSOMA-BRUCEI; STRUCTURAL CHARACTERIZATION; BIOSYNTHESIS; MUTANTS	The glycoinositol phospholipid (GPI) anchors of mammalian proteins contain linear ethanolamine (EthN)-P-6ManManManGlcN glycan sequences that bear additional EthN-P substituents and in some cases include a fourth Man and a GalNAc or sialic acid-Gal-GalNAc. Precursors of these anchoring structures are preassembled in the endoplasmic reticulum by sequential glycosylation of inositol phospholipid. In previous studies (Hirose, S., Prince, G. M, Sevlever, D., Ravi, L., Rosenberry, T. L., Ueda, E., and Medof, M. E. (1992) J. Biol. Chem. 267, 16968-16974), a series of putative intermediates of this assembly process were isolated from human HeLa cells and murine lymphomas, and several of the more polar products were found to contain a second EthN-P attached to the Man residue (Man 1) proximal to GlcN. In this study, the most polar HeLa cell GPI species was purified by normal phase Iatrobead high performance liquid chromatography, and its glycan was characterized. Dionex anion exchange chromatographic analyses of fragments produced by nitrous acid deamination, hydrofluoric acid dephosphorylation, and trifluoroacetic acid hydrolysis in conjunction with biosynthetic labeling studies indicated a structure containing a third EthN-P substituent linked to the 6-position of Man 2. The polar GPI product exhibited a ManManManGlcN core lacking additional Man or GalNAc. The implications of the identification of this triply phosphoethanolamine-substituted species to mammalian GPI anchor biosynthesis are discussed.	CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106; FUKUOKA UNIV,SCH MED,FUKUOKA 81401,JAPAN; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Fukuoka University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23598] Funding Source: Medline; NIDDK NIH HHS [P01DK38181] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANGS JD, 1988, J BIOL CHEM, V263, P17697; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEEG MA, 1992, J BIOL CHEM, V267, P18573; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025, DOI 10.1073/pnas.89.13.6025; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MAYOR S, 1992, J BIOL CHEM, V267, P754; MAYOR S, 1991, J CELL BIOL, V114, P61, DOI 10.1083/jcb.114.1.61; MENON AK, 1990, J BIOL CHEM, V265, P9033; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHUBERT J, 1993, J BIOL CHEM, V268, P6281; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; URAKAZE M, 1992, J BIOL CHEM, V267, P6459	22	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9998	10002						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683688				2022-12-27	WOS:A1993LB80000012
J	KAUFMANN, J; HAASEMANN, M; MODROW, S; MULLERESTERL, W				KAUFMANN, J; HAASEMANN, M; MODROW, S; MULLERESTERL, W			STRUCTURAL DISSECTION OF THE MULTIDOMAIN KININOGENS - FINE MAPPING OF THE TARGET EPITOPES OF ANTIBODIES INTERFERING WITH THEIR FUNCTIONAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-MOLECULAR-WEIGHT; PREKALLIKREIN BINDING DOMAIN; MONOCLONAL-ANTIBODIES; CYSTEINE PROTEINASES; LIGHT CHAIN; ANTIIDIOTYPIC ANTIBODIES; PLASMA PREKALLIKREIN; HEAVY-CHAIN; EGG-WHITE; SITE	Kininogens, the large precursor molecules of the vasoactive kinin peptides, are prototypic multidomain proteins serving numerous functions. To investigate their structure-function relationships, we have raised a panel of monoclonal antibodies against human H-kininogen and L-kininogen and fragments thereof and characterized them with respect to their target epitopes. Of 35 antibodies, 12 were directed to the aminoterminal domains (D1 to D3) of cystatin-like structure, 3 recognized domain D4 bearing the kinin segment, 17 bound to the carboxyl-terminal domains of H-kininogen (D5H and D6H), and 3 bound to the carboxyl-terminal domain D5L of L-kininogen. At least 14 distinct epitopes spread over the kininogen molecules were identified: 9 epitopes located on L-kininogen and 13 epitopes harbored by H-kininogen. Of these, 8 are shared by the two types of kininogens. Fine mapping of the epitopes by proteolytic fragments, recombinant proteins, and anti-idiotypic antibodies demonstrated that most but not all of the antibodies recognize linear epitopes. Synthesis of 28 peptides covering more than one-third of the entire kininogen sequences allowed us to narrow down seven major epitopes to 7-31 residues. Functional analyses identified 14 antibodies interfering with specific biological roles of the kininogens, i.e. cysteine proteinase inhibition, platelet attachment, cofactor binding, contact activation, and kinin delivery. Cross-reactivity studies indicated that three of the epitopes are present throughout the mammalian kininogens and further identified a unique epitope characteristic for the H/L-type of kininogens not present in their T-type. The panel of mapped antibodies provides powerful tools for the characterization of relevant interaction sites exposed by the pleiotropic kininogens and for the development of molecular surrogates mimicking these functional loci.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, W-6500 MAINZ 1, GERMANY; UNIV MUNICH, MAX VONPETTENKOFER INST, W-8000 MUNICH 2, GERMANY	Johannes Gutenberg University of Mainz; University of Munich								ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; ATASSI MZ, 1984, EUR J BIOCHEM, V145, P1, DOI 10.1111/j.1432-1033.1984.tb08516.x; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BEREK C, 1985, NATURE, V316, P412, DOI 10.1038/316412a0; BERRETTINI M, 1986, BLOOD, V68, P455; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; CADENA RAD, 1991, TRENDS PHARMACOL SCI, V12, P272, DOI 10.1016/0165-6147(91)90569-E; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; COLMAN RW, 1992, THROMB HAEMOSTASIS, V68, P99; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; ENJYOJI K, 1988, J BIOL CHEM, V263, P973; ERLANGER BF, 1991, BIOCHEM SOC T, V19, P138, DOI 10.1042/bst0190138; FIGUEROA CD, 1992, BLOOD, V79, P754; FONG D, 1991, HUM GENET, V87, P189, DOI 10.1007/BF00204179; GARCIA KC, 1992, SCIENCE, V257, P528, DOI 10.1126/science.1636087; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOODFRIEND TL, 1964, SCIENCE, V144, P1344, DOI 10.1126/science.144.3624.1344; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HAYASHI I, 1985, J BIOL CHEM, V260, P6115; HIGASHIYAMA S, 1987, BIOCHEMISTRY-US, V26, P7450, DOI 10.1021/bi00397a038; HOCK J, 1990, J BIOL CHEM, V265, P12005; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P7021, DOI 10.1021/bi00396a025; JIANG YP, 1992, J BIOL CHEM, V267, P3712; JIANG YP, 1992, THROMB HAEMOSTASIS, V68, P143; KATO H, 1981, METHOD ENZYMOL, V80, P172; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; LOTTSPEICH F, 1985, EUR J BIOCHEM, V152, P307, DOI 10.1111/j.1432-1033.1985.tb09199.x; MODROW S, 1986, P NATL ACAD SCI USA, V83, P5703, DOI 10.1073/pnas.83.15.5703; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OHKUBO I, 1984, BIOCHEMISTRY-US, V23, P5691, DOI 10.1021/bi00319a005; OKAMOTO H, 1983, BIOCHEM BIOPH RES CO, V112, P701, DOI 10.1016/0006-291X(83)91519-X; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; REDDIGARI SR, 1989, BLOOD, V74, P695; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCARSDALE JN, 1990, J PROTEIN CHEM, V9, P647, DOI 10.1007/BF01025019; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCOTT CF, 1985, J BIOL CHEM, V260, P856; STROSBERG AD, 1985, CURR TOP MICROBIOL, V119, P91; SUGO T, 1980, BIOCHEMISTRY-US, V19, P3215, DOI 10.1021/bi00555a018; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; VOGEL R, 1988, J BIOL CHEM, V263, P12661; VOGEL R, 1990, J BIOL CHEM, V265, P12494; WALLMARK A, 1984, P NATL ACAD SCI-BIOL, V81, P5690, DOI 10.1073/pnas.81.18.5690; YOU JL, 1991, J PROTEIN CHEM, V10, P301, DOI 10.1007/BF01025629	59	52	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					9079	9091						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682558				2022-12-27	WOS:A1993KX81100099
J	KICKHOEFER, VA; SEARLES, RP; KEDERSHA, NL; GARBER, ME; JOHNSON, DL; ROME, LH				KICKHOEFER, VA; SEARLES, RP; KEDERSHA, NL; GARBER, ME; JOHNSON, DL; ROME, LH			VAULT RIBONUCLEOPROTEIN-PARTICLES FROM RAT AND BULLFROG CONTAIN A RELATED SMALL RNA THAT IS TRANSCRIBED BY RNA POLYMERASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-ASSOCIATED RNAI; ADENOVIRUS VAI-RNA; INITIATION-FACTOR; SILK-GLAND; TAR RNA; GENES; DROSOPHILA; SEQUENCES; EXTRACT; DNA	Vaults are large cytoplasmic ribonucleoprotein particles with a sedimentation value of about 150 S. These particles contain a unique small RNA (vault RNA (vRNA)). We have determined the sequence of the RNA associated with vaults purified from both rat and bullfrog. The rat vRNA is 141 bases in length, whereas the bullfrog vRNA is present as two highly related species of 89 and 94 bases. Despite the differences in length the predicted secondary structures of the three vRNAs are clearly related. All of the vRNAs contain sequences related to the internal promoter elements necessary for transcription by RNA polymerase III. The gene for the rat vRNA was isolated and sequenced from a rat genomic library, and its transcription by RNA polymerase III was verified using an in vitro transcription assay. The rat vRNA gene was efficiently transcribed in vitro, producing a single transcript of about 140 bases. Unlike most RNA polymerase III genes, the rat vRNA is present as a single copy gene and has a distinct tissue-specific expression pattern.	UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, 33-257 CHS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, MENTAL RETARDAT RES CTR, LOS ANGELES, CA 90024 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH PHARM, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Southern California; University of Southern California			Rome, Leonard H/E-8786-2016	Rome, Leonard H/0000-0002-1236-2063	NIGMS NIH HHS [GM45299, GM40623, GM38097] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040623, R01GM045299, R01GM038097] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1980, P NATL ACAD SCI-BIOL, V77, P2424, DOI 10.1073/pnas.77.5.2424; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CHUGANI D C, 1991, Journal of Cell Biology, V115, p458A; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; England T E, 1980, Methods Enzymol, V65, P65; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GUILFOYLE R, 1981, P NATL ACAD SCI-BIOL, V78, P3378, DOI 10.1073/pnas.78.6.3378; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; JOHNSON DL, 1991, J BIOL CHEM, V266, P16037; JOHNSONBURKE DL, 1983, J BIOL CHEM, V258, P15224; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MEZA L, 1977, FEBS LETT, V77, P255, DOI 10.1016/0014-5793(77)80246-9; MONSTEIN HJ, 1981, NUCLEIC ACIDS RES, V9, P4239, DOI 10.1093/nar/9.17.4239; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER RJ, 1985, P NATL ACAD SCI USA, V82, P4321, DOI 10.1073/pnas.82.13.4321; SCHNEIDER RJ, 1986, CURRENT COMMUNICATIO; SIEKIERKA J, 1986, CURRENT COMMUNICATIO; SPRAGUE KU, 1977, CELL, V11, P561, DOI 10.1016/0092-8674(77)90074-5; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	38	96	109	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7868	7873						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681830				2022-12-27	WOS:A1993KW97900045
J	TAMURA, M; ARAKAKI, N; TSUBOUCHI, H; TAKADA, H; DAIKUHARA, Y				TAMURA, M; ARAKAKI, N; TSUBOUCHI, H; TAKADA, H; DAIKUHARA, Y			ENHANCEMENT OF HUMAN HEPATOCYTE GROWTH-FACTOR PRODUCTION BY INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA AND TUMOR-NECROSIS-FACTOR-ALPHA BY FIBROBLASTS IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULMINANT HEPATIC-FAILURE; NF-KAPPA-B; SCATTER FACTOR; MESSENGER-RNA; BIOLOGICAL-ACTIVITIES; TRANSCRIPTION FACTOR; PARTIAL-HEPATECTOMY; LIVER-REGENERATION; MOLECULAR-CLONING; CYTOTOXIC FACTOR	Human hepatocyte growth factor (hHGF) was first purified from plasma of patients with fulminant hepatic failure (Gohda, E., Tsubouchi, H., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., Miyazaki, H., Hashimoto, S., and Daikuhara, Y. (1988) J. Clin. Invest. 81, 414-419) and is now identified to be the same protein as the scatter factor (Weidner, K. M., Arakaki, N., Hartmann, G., Vandekerckhove, J., Weingart, S., Rieder, H., Fonatsch, C., Tsubouchi, H., Hishida, T., Daikuhara, Y., and Birchmeier, W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 7001-7005) and tumor cytotoxic factor (Shima, N., Nakao, M., Ogaki, F., Tsuda, E., Murakami, A., and Higashio, K. (1991) Biochem. Biophys. Res. Commun. 180, 1151-1158), and it is known to be produced by fibroblasts in culture. Here we report that inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor (TNF) stimulate production of hHGF from human embryonic lung fibroblasts, MRC-5, and human gingival fibroblasts, GF-5. Recombinant human IL-1alpha (rhIL-1alpha) and recombinant human TNF-alpha (rhTNF-alpha) increased hHGF levels in culture supernatants of MRC-5 and GF-5 cells dose-dependently as determined by an enzyme-linked immunosorbent assay for hHGF. The half-maximal stimulatory concentrations of rhIL-1alpha and rhTNF-alpha were about 1 ng/ml and 10 units/ml, respectively. rhIL-1beta showed almost the same effect as IL-1alpha on stimulation of production of immunoreactive hHGF from the two cell lines. However, rhIL-6 failed to show the stimulatory effect on hHGF production by the cells in the range of 2-200 units/ml. Human interferon-beta and -gamma also did not show the stimulatory activity. Stimulation of hHGF production was observed 6-12 h after addition of rhIL-1alpha or rhTNF-alpha and lasted at least 48 h, and the observed stimulation of hHGF production by cytokines was suppressed by addition of corresponding antiserum. hHGF mRNA levels of MRC-5 cells increased by addition of rhIL-1alpha and rhTNF-alpha in a dose-dependent manner as determined by Northern blot analysis using cDNA for hHGF as a probe. In addition, results from nuclear run-off transcription experiments showed that the two cytokines regulated increasing hHGF gene expression at transcriptional levels rather than a change in mRNA stability. These observations indicate that the inflammatory cytokines modulate the production and secretion of hHGF by fibroblasts and may play an important role for tissue repair and regeneration.	KAGOSHIMA UNIV, SCH DENT, DEPT BIOCHEM, 35-1 SAKURAGAOKA 8, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, SCH DENT, DEPT MICROBIOL, KAGOSHIMA 890, JAPAN; KAGOSHIMA UNIV, FAC MED, DEPT INTERNAL MED 2, KAGOSHIMA 890, JAPAN	Kagoshima University; Kagoshima University; Kagoshima University			Tamura, Masato/B-7304-2009	Tamura, Masato/0000-0003-3700-5203				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ASAMI O, 1991, J BIOCHEM-TOKYO, V109, P8; BHARGAVA MM, 1991, EXP SUPPL, V59, P63; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; DINARELLO CA, 1991, CYTOKINE HDB, P47; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUYAMA R, 1991, GENOMICS, V11, P410, DOI 10.1016/0888-7543(91)90149-9; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOHDA E, 1990, BIOCHIM BIOPHYS ACTA, V1053, P21, DOI 10.1016/0167-4889(90)90020-E; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GOHDA E, 1992, J PHARMACOBIO-DYNAM, V15, P131, DOI 10.1248/bpb1978.15.131; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1989, CURRENT PROGR MOL BI; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JAATTELA M, 1991, LAB INVEST, V64, P724; JOPLIN R, 1992, J CLIN INVEST, V90, P1284, DOI 10.1172/JCI115992; KAMALATI T, 1992, J CELL SCI, V101, P323; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; LE JM, 1987, LAB INVEST, V56, P234; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MANOGUE KR, 1991, CYTOKINE HDB, P241; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MIYAZAKI M, 1992, CELL BIOL INT REP, V16, P145, DOI 10.1016/S0309-1651(06)80108-6; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NAKAYAMA H, 1985, BIOMED RES-TOKYO, V6, P231; NISHINO T, 1991, BIOCHEM BIOPH RES CO, V181, P323, DOI 10.1016/S0006-291X(05)81421-4; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J, 1989, MOL CLONING LABORATO; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; STOKER M, 1985, J CELL SCI, V77, P209; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; TAKADA H, 1991, INFECT IMMUN, V59, P295, DOI 10.1128/IAI.59.1.295-301.1991; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUBOUCHI H, 1989, HEPATOLOGY, V9, P875, DOI 10.1002/hep.1840090615; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOLF HK, 1991, AM J PATHOL, V138, P1035; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314	59	213	217	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8140	8145						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681834				2022-12-27	WOS:A1993KW97900079
J	CATAPANO, CV; PERRINO, FW; FERNANDES, DJ				CATAPANO, CV; PERRINO, FW; FERNANDES, DJ			PRIMER RNA CHAIN TERMINATION INDUCED BY 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-TRIPHOSPHATE - A MECHANISM OF DNA-SYNTHESIS INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA; RIBONUCLEOTIDE REDUCTASE; HUMAN-LYMPHOCYTES; PRIMASE ACTIVITY; CALF THYMUS; TRIPHOSPHATE; FIDELITY; INVITRO; CELLS	The studies described herein were aimed at defining the mechanism by which 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate (FaraATP), the active intracellular metabolite of fludarabine phosphate, inhibits the synthesis of primer RNA and RNA-primed DNA by the polymerase alpha-primase complex. Incubation of the purified DNA polymerase alpha-primase complex with a poly(dT) template, 500 muM ATP, and increasing concentrations of FaraATP from 2.5 to 50 muM resulted in the progressive accumulation of smaller oligoribonucleotides (2-6 nucleotides) at the expense of the full-length products of DNA primase (7-10 nucleotides). Comparison of the k(cat)/K(M) values for incorporation of FaraATP and ATP into oligoribonucleotides revealed that DNA primase incorporated FaraATP 30-fold more efficiently than ATP. FaraAMP was present exclusively at the 3'-termini of the growing primer RNA chains, which prevented further elongation of the primers by DNA primase (primer RNA chain termination). At all FaraATP concentrations tested, inhibition of RNA-primed DNA synthesis was accompanied by primer chain termination. In contrast, DNA polymerase alpha added FaraATP onto full-length primer RNAs about 8-fold less efficiently than dATP, and the incorporation of FaraAMP at the 3'-termini of the primers did not prevent further elongation of these primers by DNA polymerase alpha. These results indicate that primer RNA chain termination is the major effect responsible for the inhibition of RNA-primed DNA synthesis by fludarabine phosphate.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center				Catapano, Carlo V./0000-0002-7079-557X				BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CATAPANO CV, 1991, CANCER RES, V51, P1829; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; Fersht A., 1985, ENZYME STRUCTURE MEC; FURTH JJ, 1968, CANCER RES, V28, P2061; HUANG P, 1990, J BIOL CHEM, V265, P16617; KUCHTA RD, 1992, BIOCHEMISTRY-US, V31, P4720, DOI 10.1021/bi00134a027; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; KUCHTA RD, 1991, BIOCHEMISTRY-US, V30, P797, DOI 10.1021/bi00217a033; PARKER WB, 1987, MOL PHARMACOL, V31, P146; PARKER WB, 1991, CANCER RES, V51, P2386; PERRELLA FW, 1988, ANAL BIOCHEM, V135, P841; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Sambrook J, 1989, MOL CLONING LABORATO; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSENG BY, 1977, CELL, V12, P483, DOI 10.1016/0092-8674(77)90124-6; TSENG BY, 1982, J BIOL CHEM, V257, P7280; TSENG WC, 1982, MOL PHARMACOL, V21, P474; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; YANG SW, 1992, J BIOL CHEM, V267, P2345; YOSHIDA S, 1977, BIOCHIM BIOPHYS ACTA, V477, P144, DOI 10.1016/0005-2787(77)90230-1; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054	24	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7179	7185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	7681821				2022-12-27	WOS:A1993KV14100056
J	MATSUDA, M; NAGATA, S; TANAKA, S; NAGASHIMA, K; KURATA, T				MATSUDA, M; NAGATA, S; TANAKA, S; NAGASHIMA, K; KURATA, T			STRUCTURAL REQUIREMENT OF CRK SH2 REGION FOR BINDING TO PHOSPHOTYROSINE-CONTAINING PROTEINS - EVIDENCE FROM REACTIVITY TO MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL-3 KINASE; CATALYTIC DOMAINS; ONCOGENE PRODUCT; SARCOMA-VIRUS; SRC; SEQUENCE	The SH2 region of signal-transducing proteins mediates binding to phosphotyrosine-containing proteins. We analyzed the structure-function relationship of the SH2 region of the human CRK protein by using a series of monoclonal antibodies (mAbs). Seventeen mAbs against the CRK SH2 region were classified into 5 groups according to the reactivity with mutant CRK proteins expressed in COS7 cells and in Escherichia coli and by epitope scanning with synthetic nonapeptides. Two groups of mAbs (groups A and B) were reactive only with intact SH2. Mutation(s) in either the amino-terminal B box or the carboxyl-terminal C box, which are the two subdomains of SH2, abolished the reactivity of the CRK mutants to the mAbs of groups A and B. Group A mAbs competed the binding of the CRK SH2 region to the phosphotyrosine-containing proteins. Moreover, the spectrum of the CRK mutants which were recognized by group A mAbs coincided with that of the CRK mutants which could bind phosphotyrosine-containing proteins, suggesting that group A mAbs were directed against the site of binding to phosphotyrosine-containing proteins. Group C mAbs, directed against the region between the B and C boxes, were reactive with both wild-type and mutant CRK proteins and did not affect the capacity of SH2 to bind phosphotyrosine-containing proteins. Contrary to group A and B mAbs, mAbs belonging to groups D and E, which were mapped onto the C box, did not bind well to the native CRK proteins, but bound to CRK mutants with mutation(s) in either the B or the C box. These results suggest that the B and C boxes, which are separated by a hinge region, coordinately form the functional SH2 domain that binds to the phosphotyrosine-containing proteins and to the group A mAbs.	RES DEV CORP JAPAN,CELL & INFORMAT,SHIMOGYO KU,KYOTO 600,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT PATHOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Japan Science & Technology Agency (JST); Hokkaido University	MATSUDA, M (corresponding author), NATL INST HLTH,DEPT PATHOL,1-23-1 TOYAMA,SHINJUKU KU,TOKYO 162,JAPAN.		Tanaka, Shinya/D-3586-2011	Matsuda, Michiyuki/0000-0002-5876-9969; Nagata, Satoshi/0000-0001-9156-5215				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LABORATOR; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2354; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAGATA S, 1991, HYBRIDOMA, V10, P369, DOI 10.1089/hyb.1991.10.369; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1988, ONCOGENE, V3, P491; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4441	4446						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680038				2022-12-27	WOS:A1993KN53300090
J	BERGER, HA; TRAVIS, SM; WELSH, MJ				BERGER, HA; TRAVIS, SM; WELSH, MJ			REGULATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CL- CHANNEL BY SPECIFIC PROTEIN-KINASES AND PROTEIN PHOSPHATASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL CHLORIDE CHANNELS; CANINE TRACHEAL EPITHELIUM; COLONIC CELL-LINE; AIRWAY EPITHELIA; ELECTROLYTE TRANSPORT; NUCLEOTIDE-SEQUENCE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; XENOPUS OOCYTES; PHORBOL ESTER	Cystic fibrosis transmembrane conductance regulator (CFTR) is a regulated Cl- channel; in secretory epithelia, it is located in the apical membrane where it regulates transepithelial Cl- secretion. Previous studies have shown that cAMP-dependent protein kinase (PKA) can phosphorylate and activate CFTR Cl- channels. We asked whether other kinases would phosphorylate CFTR in vitro and activate CFTR Cl- channels in excised, inside-out patches of membrane from NIH 3T3 fibroblasts stably expressing recombinant CFTR. We found that both Ca2+-independent and Ca2+-dependent isoforms of protein kinase C (PKC) activated the CFTR Cl- channel. Consistent with this finding, PKC also phosphorylated CFTR in vitro. In contrast, the multifunctional Ca2+/calmodulin-dependent protein kinase failed to either activate or to phosphorylate CFTR Cl- channels, suggesting that this enzyme has no direct effect on CFTR. We found that cGMP-dependent protein kinase (cGK) (purified from bovine lung) phosphorylated CFTR in vitro. However, cGMP failed to increase the apical membrane Cl- permeability in human airway epithelia, and addition of cGMP, ATP, and cGK failed to activate CFTR Cl- channels. These results suggest that if cGK phosphorylates CFTR in vivo, it does so at sites not involved in CFTR Cl- channel activation. Because cAMP-dependent activation of CFTR Cl- channels and Cl- secretion in intact cells is reversible, we asked whether specific phosphatases can dephosphorylate and inactivate CFTR Cl- channels. Addition of protein phosphatase 2A (PP2A) decreased PKA-activated current by 67% within 10 min. The phosphatase inhibitor calyculin-A blocked the effect of PP2A. In contrast, neither protein phosphatases 1, 2B, nor two preparations of alkaline phosphatase inactivated PKA-phosphorylated CFTR Cl- channels. The effects of protein phosphatases on CFTR function were paralleled by their ability to dephosphorylate CFTR in vitro. Our data indicate that CFTR Cl- channels can be phosphorylated and activated by PKA as well as by Ca2+-dependent and Ca2+-independent isoforms of PKC and can be dephosphorylated and thus inactivated by PP2A.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, 500 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa				Welsh, Michael/0000-0002-1646-6206; Berger, Herbert/0000-0003-4383-2643	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385] Funding Source: Medline; PHS HHS [H1 07638] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MP, 1990, AM J PHYSIOL, V258, pL294, DOI 10.1152/ajplung.1990.258.6.L294; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; DEJONGE HR, 1976, NATURE, V262, P590, DOI 10.1038/262590a0; DEJONGE HR, 1981, ADV CYCLIC NUCLEOTID; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DEVOR DC, 1990, AM J PHYSIOL, V258, pC318, DOI 10.1152/ajpcell.1990.258.2.C318; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FINN AL, 1992, AM J PHYSIOL, V263, pC172, DOI 10.1152/ajpcell.1992.263.1.C172; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUARINO A, 1987, AM J PHYSIOL, V253, pG775, DOI 10.1152/ajpgi.1987.253.6.G775; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; HEMMINGS BA, 1988, NUCLEIC ACIDS RES, V16, P11366, DOI 10.1093/nar/16.23.11366; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSLEY PR, 1990, BIOCHEMISTRY-US, V29, P3578, DOI 10.1021/bi00466a022; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; LA BQ, 1991, AM J PHYSIOL, V260, pC1217; LIN MQ, 1992, AM J PHYSIOL, V262, pC1304, DOI 10.1152/ajpcell.1992.262.5.C1304; MCCANN JD, 1990, AM J PHYSIOL, V258, pL343, DOI 10.1152/ajplung.1990.258.6.L343; MCCANN JD, 1989, AM J PHYSIOL, V257, pL116, DOI 10.1152/ajplung.1989.257.2.L116; MCROBERTS JA, 1985, J BIOL CHEM, V260, P4163; MORRIS AP, 1990, CELL REGUL, V1, P951, DOI 10.1091/mbc.1.12.951; NAYUDU RV, 1989, FEBS LETT, V255, P163, DOI 10.1016/0014-5793(89)81082-8; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; REINHART PH, 1991, J NEUROSCI, V11, P1627; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SMITH JJ, 1990, AM J PHYSIOL, V258, pL369, DOI 10.1152/ajplung.1990.258.6.L369; SMITH PL, 1982, J MEMBRANE BIOL, V70, P217, DOI 10.1007/BF01870564; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; UBERALL F, 1991, CANCER RES, V51, P5821; VAANDRAGER AB, 1991, AM J PHYSIOL, V261, pG958, DOI 10.1152/ajpgi.1991.261.6.G958; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1987, AM J PHYSIOL, V253, pC828, DOI 10.1152/ajpcell.1987.253.6.C828; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WIDDICOMBE JH, 1986, AM J PHYSIOL, V251, pR818, DOI 10.1152/ajpregu.1986.251.4.R818; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713	68	232	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2037	2047						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678414				2022-12-27	WOS:A1993KH62000082
J	KITZMAN, HH; MCMAHON, RJ; WILLIAMS, MG; FROST, SC				KITZMAN, HH; MCMAHON, RJ; WILLIAMS, MG; FROST, SC			EFFECT OF GLUCOSE DEPRIVATION ON GLUT-1 EXPRESSION IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-INDUCED TRANSLOCATION; CHICKEN-EMBRYO FIBROBLASTS; SENSITIVE HEXOSE UPTAKE; BRAIN GLIAL-CELLS; TRANSPORT ACTIVITY; PLASMA-MEMBRANE; MESSENGER-RNA; DIFFERENTIAL REGULATION; PROTEIN-SYNTHESIS; DEPENDENT REGULATION	Elevated glucose transport rates during glucose deprivation are phenomena that have been observed in several different types of cells in culture. We show here that glucose transport rates in 3T3-L1 adipocytes increased by 10-fold within 18 h in response to glucose deprivation, confirming earlier work by Van Putten and Krans (Van Putten, J. P. M., and Krans, H. M. J. (1985) J. Biol. Chem. 260, 7996-8001). Mannose and 3-O-methylglucose (a nonmetabolizable glucose analog), but not fructose or galactose, blocked the increase in transport activity. Although the increase in transport was dependent on new protein synthesis, only a small and transient increase in GLUT 1 mRNA (less than 2-fold) was observed. In addition, the level of the normal isoform of GLUT 1 (46 kDa) did not increase. A lower molecular mass isoform (37 kDa) was observed but not until 15 h after glucose removal, the appearance of which was clearly not correlated with the increase in activity. Further, the extracellular glucose concentration required to elicit accumulation of this form (p37) was 2 orders of magnitude less than that required for transport stimulation (5 muM versus 500 muM glucose; p37 accumulation and transport activation, respectively). Interestingly, p37 was seen in the presence of galactose, but not fructose, despite elevated transport activity with either sugar. The p37 isoform was slightly larger than N-glycosidase F-treated GLUT 1 (36 kDa), implying that this form is still glycosylated, albeit incompletely. It is not known if p37 is functional, but the time- and sugar-dependent appearance of the lower isoform suggests that p37 is not responsible for starvation-induced transport but potentially represents an underglycosylated precursor of the normal, 46-kDa isoform of GLUT 1.	UNIV FLORIDA,DEPT BIOCHEM & MOLEC BIOL,BOX 100245 JHMHC,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NIDDK NIH HHS [DK45035, DK39135] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039135, R01DK045035] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1989, J BIOL CHEM, V264, P3416; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DULBECCO R, 1959, VIROLOGY, V8, P396, DOI 10.1016/0042-6822(59)90043-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUNG KP, 1986, BIOCHEM BIOPH RES CO, V134, P1231, DOI 10.1016/0006-291X(86)90382-7; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GIBBS EM, 1988, BIOCHEMISTRY-US, V27, P6681, DOI 10.1021/bi00418a006; GODWIN AK, 1991, MOL CARCINOGEN, V4, P275, DOI 10.1002/mc.2940040406; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; HARRISON SA, 1991, P NATL ACAD SCI USA, V88, P7839, DOI 10.1073/pnas.88.17.7839; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KITAGAWA T, 1991, J BIOL CHEM, V266, P18066; KLETZIEN RF, 1975, J BIOL CHEM, V250, P593; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SG, 1978, P NATL ACAD SCI USA, V75, P5427, DOI 10.1073/pnas.75.11.5427; LEE SG, 1977, P NATL ACAD SCI USA, V74, P163, DOI 10.1073/pnas.74.1.163; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARSHALL S, 1991, FASEB J, V5, P3031, DOI 10.1096/fasebj.5.15.1743436; ORTIZ PA, 1992, BIOCHEMISTRY-US, V31, P5386, DOI 10.1021/bi00138a021; PESSIN JE, 1982, P NATL ACAD SCI-BIOL, V79, P2286, DOI 10.1073/pnas.79.7.2286; PETTENGELL K, 1989, BIOCHEM BIOPH RES CO, V161, P633, DOI 10.1016/0006-291X(89)92646-6; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; RIZZOLO LJ, 1976, BIOCHEMISTRY-US, V15, P3433, DOI 10.1021/bi00661a006; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAI PKK, 1990, J BIOL CHEM, V265, P21828; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; VANPUTTEN JPM, 1985, J BIOL CHEM, V260, P7996; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WONG WT, 1991, BIOCHEM J, V275, P313, DOI 10.1042/bj2750313; YAMADA K, 1983, J BIOL CHEM, V258, P9786; ZORZANO A, 1989, J BIOL CHEM, V264, P12358; ZUBAY G, 1988, BIOCHEMISTRY-US, P648	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1320	1325						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678253				2022-12-27	WOS:A1993KG07700083
J	SANTOCANALE, C; FOIANI, M; LUCCHINI, G; PLEVANI, P				SANTOCANALE, C; FOIANI, M; LUCCHINI, G; PLEVANI, P			THE ISOLATED 48,000-DALTON SUBUNIT OF YEAST DNA PRIMASE IS SUFFICIENT FOR RNA PRIMER SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE PROTEIN COMPLEX; SINGLE ESSENTIAL GENE; SACCHAROMYCES-CEREVISIAE; BACTERIOPHAGE-T4 GENE-41; REPLICATION FORK; ALPHA; PURIFICATION; POLYPEPTIDE; HELICASE; CLONING	The monoclonal antibody (mAb) 21A6, which specifically inhibits yeast DNA primase activity, has been used to verify whether only one of the two polypeptides of heterodimeric DNA primase (48 and 58 kDa) was responsible for DNA primase function in vitro. Immunoaffinity chromatography of a crude extract from cells of Saccharomyces cerevisiae on a mAb 21A6 protein A-Sepharose 6B column allowed the purification of the p48 primase polypeptide in an isolated form. This polypeptide was not derived through the dissociation of the four-subunit DNA polymerase alpha-primase complex, which can be purified from the same extract by affinity chromatography with a mAb recognizing the DNA polymerase alpha polypeptide. Therefore, free p48 was already present in the yeast extract and, possibly, within the cell. Isolated p48, devoid of any detectable p58 subunit, was sufficient for RNA primer synthesis, although free primase appeared to extend RNA primer-monomers to primer-multimers less efficiently. Primase activity associated with free p48 was highly unstable, indicating that although p48 bears the catalytic site, its association with the other polypeptides of the polymerase-primase complex plays an important role in stabilizing enzyme activity.	DIPARTIMENTO GENET & BIOL MICRORGANISMI,VIA CELORIA 26,I-20133 MILAN,ITALY; UNIV SASSARI,IST GENET,I-07100 SASSARI,ITALY	University of Sassari			Foiani, Marco/M-8234-2014	Foiani, Marco/0000-0003-4795-834X; Santocanale, Corrado/0000-0003-1337-5656; PLEVANI, PAOLO/0000-0003-1869-2626				BINTON DM, 1987, J BIOL CHEM, V262, P10873; BISWAS EE, 1987, BIOCHEMISTRY-US, V26, P5377, DOI 10.1021/bi00391a024; BROOKE RG, 1991, J BIOL CHEM, V266, P10093; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; BROOKS M, 1989, J BIOL CHEM, V264, P3602; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FOIANI M, 1989, J BIOL CHEM, V264, P2189; FRANCESCONI S, 1991, P NATL ACAD SCI USA, V88, P3877, DOI 10.1073/pnas.88.9.3877; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P453; Kornberg A., 1991, DNA REPLICATION; KUCHTA RD, 1990, J BIOL CHEM, V265, P16158; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LUCCHINI G, 1987, EMBO J, V6, P737, DOI 10.1002/j.1460-2075.1987.tb04815.x; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PAUSCH MH, 1988, CANCER CELL, V6, P359; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PLEVANI P, 1984, J BIOL CHEM, V259, P7532; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; SINGH H, 1986, J BIOL CHEM, V261, P8564; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	28	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1343	1348						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678254				2022-12-27	WOS:A1993KG07700087
J	CLEMENTI, E; SCIORATI, C; RICCIO, M; MILOSO, M; MELDOLESI, J; NISTICO, G				CLEMENTI, E; SCIORATI, C; RICCIO, M; MILOSO, M; MELDOLESI, J; NISTICO, G			NITRIC-OXIDE ACTION ON GROWTH FACTOR-ELICITED SIGNALS - PHOSPHOINOSITIDE HYDROLYSIS AND [CA2+](I) RESPONSES ARE NEGATIVELY MODULATED VIA A CGMP-DEPENDENT PROTEIN-KINASE-I PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CELLULAR PROLIFERATION; INVERSE CORRELATION; DNA-SYNTHESIS; CELLS; ACTIVATION; HYPERPOLARIZATION; STIMULATION; INHIBITION; PLATELETS	The role of nitric oxide (NO) in the phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis and intracellular Ca2+ release responses induced by epidermal, platelet derived, and fibroblast growth factors was investigated in three cell Lines, a clone of NIH-3T3 fibroblasts overexpressing epidermal growth factor receptors and the tumoral epithelial cells A431 and KB. In all three cell types, pretreatment with NO donors decreased growth factor-induced PIP2 and Ca2+ responses, whereas pretreatment with NO synthase inhibitors increased them. The Ca2+-dependent PIP, hydroysis induced by micromolar concentrations-of the Ca2+ ionophore, ionomycin, was also modulated negatively and positively by NO donors and synthase inhibitors, respectively. In contrast, the Ca2+ content of the intracellular stores was unaffected by the various pretreatments employed. NO donors and synthase inhibitors induced an increase and decrease, respectively, of the intracellular cGMP formation in all three cell lines investigated, All of the effects of the NO donors were mimicked by 8-bromo-cGMP administration and abolished by pretreatment with the specific blocker of the cGMP-dependent protein kinase I, KT5823, which by itself mimicked the effects of the synthase inhibitors. Together with previous observations on G protein-coupled receptors, the present results demonstrate that PIP, hydrolysis and Ca2+ release occur under the feedback control of NO, independently of the phospholipase C (beta, gamma, or delta type) involved and of the mechanism of activation. Such a control, which appears to be effected by the cGMP-dependent protein kinase I acting at the level of the phospholipases C themselves, might ultimately contribute to the inhibitory role of NO on growth previously observed with various cell types.	IST SCI SAN RAFFAELE, DIBIT, MOLEC ONCOL UNIT, I-20132 MILAN, ITALY; UNIV MILAN, MILAN, ITALY; UNIV ROMA TOR VERGATA, MONDINO NEUROBIOL CTR, DEPT BIOL, ROME, ITALY; UNIV REGGIO CALABRIA, FAC PHARM, DEPT PHARMACOL, I-88021 CATANZARO, ITALY; CNR, CTR CYTOPHARMACOL, DEPT PHARMACOL, I-20133 MILAN, ITALY; CNR, B CECCARELLI CTR, I-20133 MILAN, ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; University of Rome Tor Vergata; Universita Mediterranea di Reggio Calabria; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	CLEMENTI, E (corresponding author), IST SCI SAN RAFFAELE, DIBIT, RECEPTOR BIOCHEM UNIT, VIA OLGETTINA 58, I-20132 MILAN, ITALY.		Miloso, Mariarosaria/AAC-7373-2021; sciorati, clara/K-4823-2016	sciorati, clara/0000-0003-2030-9366				BANNO Y, 1994, J BIOL CHEM, V269, P15846; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; CLEMENTI E, 1995, EUR J PHARM-MOLEC PH, V289, P113, DOI 10.1016/0922-4106(95)90176-0; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GADBOIS DM, 1992, P NATL ACAD SCI USA, V89, P8626, DOI 10.1073/pnas.89.18.8626; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JHON DY, 1993, J BIOL CHEM, V268, P6654; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LEE KH, 1994, J BIOL CHEM, V269, P14371; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; MIYAZAKI M, 1992, EXP CELL RES, V200, P404, DOI 10.1016/0014-4827(92)90188-E; MUNOZFERNANDEZ MA, 1994, J NEUROCHEM, V62, P1330; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; PANDIELLA A, 1989, J BIOL CHEM, V264, P12914; PANDIELLA A, 1989, BIOCHEM BIOPH RES CO, V163, P1325, DOI 10.1016/0006-291X(89)91123-6; PERANOVICH TMS, 1995, BIOCHEM J, V305, P613, DOI 10.1042/bj3050613; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUNJABI CJ, 1992, J IMMUNOL, V149, P2179; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAHL MI, 1992, J BIOL CHEM, V267, P10447; XU X, 1994, J BIOL CHEM, V269, P12645	36	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22277	22282		10.1074/jbc.270.38.22277	http://dx.doi.org/10.1074/jbc.270.38.22277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673208	hybrid			2022-12-27	WOS:A1995RW31400035
J	DANG, Q; WALKER, D; TAYLOR, S; ALLAN, C; CHIN, P; FAN, JL; TAYLOR, J				DANG, Q; WALKER, D; TAYLOR, S; ALLAN, C; CHIN, P; FAN, JL; TAYLOR, J			STRUCTURE OF THE HEPATIC CONTROL REGION OF THE HUMAN APOLIPOPROTEIN-E/C-I GENE LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC ENHANCER; ALPHA-FETOPROTEIN GENE; TRANSGENIC MICE; ALZHEIMERS-DISEASE; BINDING PROTEIN; NUCLEAR FACTOR; ALU FAMILY; PROMOTER; TRANSCRIPTION; DNA	The specificity of expression in the liver of the human apolipoprotein (ape) E/C-I gene locus is determined by a hepatic control region (HCR) that is located 15 kilobases downstream of the apoE gene, DNase I footprint studies of this sequence using nuclear extracts identified a region of the HCR that is enriched in nuclear protein-binding sites. Nuclease analysis of chromatin revealed liver-specific DNase I-hypersensitive sites that were associated with this region, and additional liver-specific nuclease-sensitive sites associated with the apoE gene were identified, The HCR domain has a limited binding affinity for the nuclear scaffold, The specific domain required for liver expression was tested by ligating subfragments of the HCR to the apoE gene and examining their activity in transgenic mice, A segment of 319 nucleotides that contained several potential regulatory sequences was required for full activity of liver-specific transcription with shorter segments yielding much lower levels of expression in the liver. All constructs that contained a fully active HCR were expressed in approximately a copy-dependent manner, suggesting that transgene expression was independent of integration position. Taken together, the properties of the HCR are consistent with its function as a locus control region for the liver-specific expression of the apoE gene.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37063, HL 07731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BOISSIER F, 1991, J BIOL CHEM, V266, P9822; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHOW BKC, 1991, J BIOL CHEM, V266, P18927; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DAS HK, 1985, J BIOL CHEM, V260, P6240; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAYASHI Y, 1992, J BIOL CHEM, V267, P14580; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Maniatis T., 1982, MOL CLONING; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; METZGER S, 1990, J BIOL CHEM, V265, P9978; NICOLIS S, 1989, NUCLEIC ACIDS RES, V17, P5509, DOI 10.1093/nar/17.14.5509; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TRUJILLO MA, 1991, P NATL ACAD SCI USA, V88, P3797, DOI 10.1073/pnas.88.9.3797; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	51	63	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22577	22585		10.1074/jbc.270.38.22577	http://dx.doi.org/10.1074/jbc.270.38.22577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673250	hybrid			2022-12-27	WOS:A1995RW31400080
J	MARCINKEVICIENE, JA; MAGLIOZZO, RS; BLANCHARD, JS				MARCINKEVICIENE, JA; MAGLIOZZO, RS; BLANCHARD, JS			PURIFICATION AND CHARACTERIZATION OF THE MYCOBACTERIUM-SMEGMATIS CATALASE-PEROXIDASE INVOLVED IN ISONIAZID ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; TUBERCULOSIS; GENE; KATG; HEME; RESONANCE; ENZYME; SPECTROSCOPY	The unique antitubercular activity of isoniazid requires that the drug be oxidized by the katG-encoded mycobacterial catalase-peroxidase to an activated drug form. In order to quantitatively assess the catalytic capabilities of the enzyme, the native catalase-peroxidase from Mycobacterium smegmatis was purified over 200-fold to homogeneity. The enzyme was shown to exhibit both catalase and peroxidase activities, and in the presence of either hydrogen peroxide or t-butyl peroxide, was found 60 catalyze the oxidation of the reduced pyridine nucleotides, NADH and NADPH, as well as artificial peroxidase substrates, at rates between 2.7 and 20 s(-1). The homogeneous enzyme exhibited a visible absorbance spectrum typical of ferric heme-containing catalase-peroxidases, with a Soret maximum at 406 nm. Low temperature (10 K) electron paramagnetic resonance spectra in the presence of ethylene glycol revealed a high spin Fe(III) signal with g values of 5.9 and 5.6. The enzyme was very slowly (t(1/2) = similar to 20 min) reduced by dithionite, and the reduced form showed typical spectral changes when either KCN or CO were subsequently added, The M. smegmatis catalase-peroxidase was found to contain 2 heme molecules per tetramer, which were identified as iron protoporphyrin IX by the pyridine hemochromogen assay. The peroxidatic activity was inhibited by KCN, NaN3, isoniazid (isonicotinic acid hydrazide), and its isomer, nicotinic acid hydrazide, but not by 3-amino-1,2,4-triazole. The role of mycobacterial catalase-peroxidases in the oxidative activation of the antitubercular prodrug isoniazid is discussed.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCRR NIH HHS [RR02583] Funding Source: Medline; NIGMS NIH HHS [GM40168, GM33449] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040168, R01GM033449, R01GM040168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARTHOLOMEW WR, 1968, AM REV RESPIR DIS, V97, P710; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; BROWNPETERSON NJ, 1993, J BACTERIOL, V175, P4197, DOI 10.1128/JB.175.13.4197-4202.1993; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; Cleland W W, 1979, Methods Enzymol, V63, P103; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DIAZ GA, 1974, AM REV RESPIR DIS, V110, P312, DOI 10.1164/arrd.1974.110.3.312; Falk J. E., 1964, PORPHYRINS METALLOPO, P804; GRUFT H, 1971, J CHROMATOGR, V56, P168, DOI 10.1016/S0021-9673(00)97797-5; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; JACKETT PS, 1978, J GEN MICROBIOL, V104, P37, DOI 10.1099/00221287-104-1-37; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KALYANARAMAN B, 1985, J BIOL CHEM, V260, P4003; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LEBEDEVA O V, 1977, Biokhimiya, V42, P1372; LEVY E, 1992, ARCH BIOCHEM BIOPHYS, V296, P321, DOI 10.1016/0003-9861(92)90579-L; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; MORISHIMA I, 1977, BIOCHEMISTRY-US, V16, P5109, DOI 10.1021/bi00642a025; MORRIS SL, 1992, J GEN MICROBIOL, V138, P2363, DOI 10.1099/00221287-138-11-2363; MORSE PD, 1987, BIOPHYS J, V51, pA440; PEISACH J, 1971, J BIOL CHEM, V246, P3342; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; SCHEJTER A, 1976, ARCH BIOCHEM BIOPHYS, V174, P36, DOI 10.1016/0003-9861(76)90321-0; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SIEVERS G, 1983, BIOCHIM BIOPHYS ACTA, V742, P659, DOI 10.1016/0167-4838(83)90285-6; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; WALLACE RJ, 1988, J INFECT DIS, V158, P52, DOI 10.1093/infdis/158.1.52; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; WITTENBERG BA, 1968, J BIOL CHEM, V243, P1863; YONETANI T, 1987, J BIOL CHEM, V262, P9547; YOUN HD, 1995, J BIOL CHEM, V270, P13740, DOI 10.1074/jbc.270.23.13740; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	49	107	110	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22290	22295		10.1074/jbc.270.38.22290	http://dx.doi.org/10.1074/jbc.270.38.22290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673210	hybrid			2022-12-27	WOS:A1995RW31400037
J	PEHRSON, JR				PEHRSON, JR			PROBING THE CONFORMATION OF NUCLEOSOME LINKER DNA IN-SITU WITH PYRIMIDINE DIMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; CHROMATIN FIBERS; LENGTH; MODEL; LIGHT; SUPERSTRUCTURE; PHOTOPRODUCTS; TRANSCRIPTION; ORGANIZATION; EXONUCLEASE	The distribution of pyrimidine dimers formed in nucleosomal DNA by irradiation of intact nuclei isolated from rat liver has been examined. Whereas pyrimidine dimer formation in the core region of the nucleosome occurred with peaks at approximately 10-nucleotide intervals as previously reported, the distribution of pyrimidine dimers through the linker region was nearly uniform. This distinction between core and linker DNA was found to be independent of linker length over a range of 38-60 nucleotides. Because there is now ample evidence that DNA curvature is the source of the peaks of pyrimidine dimer formation in the core region, the uniform distribution of pyrimidine dimers observed in the linker region indicates that linker DNA is relatively straight. This suggests that higher order chromatin structure in situ is based on a zigzag chain of nucleosomes.			PEHRSON, JR (corresponding author), UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024019] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927] Funding Source: Medline; NIGMS NIH HHS [GM-24019, GM-49351] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BORDAS J, 1986, EUR BIOPHYS J BIOPHY, V13, P175, DOI 10.1007/BF00542561; BROWN DW, 1993, BIOCHEMISTRY-US, V32, P10527, DOI 10.1021/bi00091a001; BURGOYNE LA, 1985, CYTOBIOS, V43, P141; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CARTWRIGHT IL, 1989, METHOD ENZYMOL, V170, P359; CECH T, 1977, CELL, V11, P631, DOI 10.1016/0092-8674(77)90080-0; COHEN LH, 1975, SCIENCE, V190, P994, DOI 10.1126/science.1237932; COLE RD, 1984, ANAL BIOCHEM, V136, P24, DOI 10.1016/0003-2697(84)90303-8; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1990, PHOTOCHEM PHOTOBIOL, V51, P411, DOI 10.1111/j.1751-1097.1990.tb01732.x; GRAZIANO V, 1994, NATURE, V368, P351, DOI 10.1038/368351a0; HOROWITZ RA, 1994, J CELL BIOL, V125, P1, DOI 10.1083/jcb.125.1.1; JAHN CL, 1979, BIOCHEMISTRY-US, V18, P1442, DOI 10.1021/bi00575a009; MARION C, 1981, EUR J BIOCHEM, V120, P169, DOI 10.1111/j.1432-1033.1981.tb05685.x; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MEISTRICH ML, 1972, J MOL BIOL, V66, P83, DOI 10.1016/S0022-2836(72)80007-X; METZGER G, 1977, BIOCHEM BIOPH RES CO, V75, P703, DOI 10.1016/0006-291X(77)91529-7; OSIPOVA TN, 1980, EUR J BIOCHEM, V113, P183; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PEHRSON JR, 1992, NUCLEIC ACIDS RES, V20, P1321, DOI 10.1093/nar/20.6.1321; RATTNER JB, 1979, J CELL BIOL, V81, P453, DOI 10.1083/jcb.81.2.453; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROSE SM, 1984, J BIOL CHEM, V259, P8534; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; SEN D, 1986, BIOCHEMISTRY-US, V25, P3441, DOI 10.1021/bi00359a052; SMITH MF, 1990, J CELL BIOL, V110, P245, DOI 10.1083/jcb.110.2.245; SNAPKA RM, 1981, BIOCHEMISTRY-US, V20, P68, DOI 10.1021/bi00504a012; STAYNOV DZ, 1983, INT J BIOL MACROMOL, V5, P3, DOI 10.1016/0141-8130(83)90071-5; STRAUSS F, 1982, NUCLEIC ACIDS RES, V10, P2275, DOI 10.1093/nar/10.7.2275; SUBIRANA JA, 1985, CHROMOSOMA, V91, P377, DOI 10.1007/BF00291012; SUQUET C, 1993, J BIOL CHEM, V268, P23755; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1977, CELL, V10, P633, DOI 10.1016/0092-8674(77)90096-4; VANHOLDE KE, 1988, CHROMATIN, P291; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CL, 1993, P NATL ACAD SCI USA, V90, P9021, DOI 10.1073/pnas.90.19.9021; WOODCOCK CL, 1994, J CELL BIOL, V125, P11, DOI 10.1083/jcb.125.1.11; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; ZLATANOVA J, 1994, P NATL ACAD SCI USA, V91, P5277, DOI 10.1073/pnas.91.12.5277	47	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22440	22444						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673231				2022-12-27	WOS:A1995RW31400060
J	TEIXEIRA, SMR; KIRCHHOFF, LV; DONELSON, JE				TEIXEIRA, SMR; KIRCHHOFF, LV; DONELSON, JE			POSTTRANSCRIPTIONAL ELEMENTS REGULATING EXPRESSION OF MESSENGER-RNAS FROM THE AMASTIN TUZIN GENE-CLUSTER OF TRYPANOSOMA-CRUZI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; PROTEIN PARP GENES; MESSENGER-RNA; SURFACE GLYCOPROTEIN; BRUCEI; LEISHMANIA; PROMOTER; SEQUENCES; CELLS; SITE	The genome of Trypanosoma cruzi contains tandemly arrayed copies of the gene encoding amastin, an abundant protein on the surface of the amastigote stage of the parasite. The transcription rate of the amastin genes is the same in the different developmental stages, but the steady state level of the 1.4-kilobase amastin mRNA is 50-85 times higher in amastigotes than in epimastigotes or trypomastigotes (1). Here we show that the amastin genes alternate with genes encoding another protein, called tuzin, whose 1.7-kilobase mRNA is much less abundant in amastigotes. The 3'-untranslated region (UTR) of tuzin mRNA is only a few nucleotides in length or even nonexistent, in contrast with the 630-nucleotide 3'-UTR of amastin mRNA. No promoter elements were found upstream or within the amastin/tuzin gene cluster. However, in amastigotes, the protein synthesis inhibitor cycloheximide caused a 3-fold decrease in amastin mRNA and a 7-fold increase in tuzin mRNA. Furthermore, when the amastin 3'-UTR plus its downstream intergenic region were fused behind the luciferase coding region in a chimeric plasmid for transient transfections, luciferase activity increased 7-fold in amastigotes and decreased 5-fold in epimastigotes. Thus, developmental expression of these alternating genes is regulated by different mechanisms.	UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; DEPT VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA; HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Howard Hughes Medical Institute			Donelson, John E/F-5795-2010; TEIXEIRA, SANTUZA MR/I-8137-2013		NHLBI NIH HHS [HL 07121-20] Funding Source: Medline; NIAID NIH HHS [AI24711] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024711] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CHUNG SH, 1990, NUCLEIC ACIDS RES, V18, P4561, DOI 10.1093/nar/18.15.4561; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; DEARRUDA MV, 1990, MOL BIOCHEM PARASIT, V40, P35, DOI 10.1016/0166-6851(90)90077-Y; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIETRICH P, 1993, GENE, V125, P103, DOI 10.1016/0378-1119(93)90753-P; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; DORN PL, 1991, MOL BIOCHEM PARASIT, V44, P133, DOI 10.1016/0166-6851(91)90229-Y; ERONDU NE, 1991, MOL BIOCHEM PARASIT, V49, P303, DOI 10.1016/0166-6851(91)90074-G; Fourney R.M., 1988, FOCUS, V10, P5; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GONZALEZ A, 1985, NUCLEIC ACIDS RES, V13, P5789, DOI 10.1093/nar/13.16.5789; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HOFT DF, 1989, INFECT IMMUN, V57, P1959, DOI 10.1128/IAI.57.7.1959-1967.1989; HOFT DF, 1995, J PARASITOL, V81, P549, DOI 10.2307/3283851; HUANG J, 1991, EMBO J, V10, P3877, DOI 10.1002/j.1460-2075.1991.tb04957.x; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAPOTAS N, 1993, NUCLEIC ACIDS RES, V21, P4067, DOI 10.1093/nar/21.17.4067; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KIRCHHOFF LV, 1984, J IMMUNOL, V133, P2731; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LU HY, 1991, MOL BIOCHEM PARASIT, V44, P109, DOI 10.1016/0166-6851(91)90226-V; MATTHEWS KR, 1994, GENE DEV, V8, P491, DOI 10.1101/gad.8.4.491; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; OTSU K, 1993, MOL BIOCHEM PARASIT, V57, P317, DOI 10.1016/0166-6851(93)90207-E; PEREIRA IS, 1982, ACTA TROP, V39, P275; PIZZI T, 1957, THESIS U CHILE SANTI; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; TEIXEIRA SMR, 1994, J BIOL CHEM, V269, P20509; TYLERCROSS RE, 1995, MOL BIOCHEM PARASIT, V72, P23, DOI 10.1016/0166-6851(95)00061-5; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VAZQUEZ D, 1979, RIBOSOMES STRUCTURE, P847; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WILLIAMS RD, 1976, IN VITRO CELL DEV B, V12, P623; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON ME, 1993, J BIOL CHEM, V268, P15731; WONG S, 1993, MOL CELL BIOL, V13, P207, DOI 10.1128/MCB.13.1.207; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	54	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22586	22594		10.1074/jbc.270.38.22586	http://dx.doi.org/10.1074/jbc.270.38.22586			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673251	hybrid			2022-12-27	WOS:A1995RW31400081
J	ISHIGURO, H; KIM, KT; JOH, TH; KIM, KS				ISHIGURO, H; KIM, KT; JOH, TH; KIM, KS			NEURON-SPECIFIC EXPRESSION OF THE HUMAN DOPAMINE-BETA-HYDROXYLASE GENE REQUIRES BOTH THE CAMP-RESPONSE ELEMENT AND A SILENCER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; TISSUE-SPECIFIC EXPRESSION; CELL-SPECIFIC EXPRESSION; SODIUM-CHANNEL GENE; NERVE GROWTH-FACTOR; MESSENGER-RNA TYPES; CYCLIC-AMP; TYROSINE-HYDROXYLASE; REGULATORY ELEMENTS; RAT-BRAIN	Dopamine beta-hydroxylase (DBH), the enzyme catalyzing the conversion of dopamine to norepinephrine, is specifically expressed in adrenergic and noradrenergic neurons in the central nervous system. DNase I hypersensitive sites were found in the 5'-flanking region of the DBH gene in noradrenergic human neuroblastoma SK-N-BE(2)C cells, but not in DBH-nonexpressing HeLa cells. We report here that the 4.3-kilobase upstream sequence of the human DBH gene confers cell type-specific expression as assessed by transient expression assay. Furthermore, deletional and mutational analyses revealed two genetic regulatory elements required for the regulation of cell type specificity. First, deletion of the cAMP-response element (CRE) abolished >95% of the transcriptional activity by the DBH upstream promoter, thus implicating the CRE as an essential positive genetic element. Second, deletion of a region between -490 and -263 base pairs resulted in 10-fold increase of reporter gene activity only in HeLa cells, indicating that this region contains a cell-specific silencer. A 13-base pair fragment residing within that region shows 77% sequence identity with the neuron-specific silencer motif recently identified in two neuronal genes, i.e. SCG10 and type II sodium channel genes. We propose that the interplay between the CRE and this neuron-specific silencer region plays an important role in the tissue-specific expression of the DBH gene in noradrenergic cells.	CORNELL UNIV,COLL MED,BURKE MED RES INST,MOLEC NEUROBIOL LAB,785 MAMARONEK AVE,WHITE PLAINS,NY 10605	Cornell University				KIM, KYONG-TAI/0000-0001-7292-2627	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH024285, R01MH048866, R37MH024285, R29MH048866] Funding Source: NIH RePORTER; NIMH NIH HHS [MH24285, MH48866] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACHESON AL, 1984, J NEUROSCI, V4, P1771; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ANDRISANI OM, 1989, P NATL ACAD SCI USA, V86, P2181, DOI 10.1073/pnas.86.7.2181; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BADOYANNIS HC, 1991, MOL BRAIN RES, V11, P79, DOI 10.1016/0169-328X(91)90024-R; BIGUET NF, 1986, EMBO J, V5, P287, DOI 10.1002/j.1460-2075.1986.tb04211.x; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CICCARONE V, 1989, CANCER RES, V49, P219; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GOODALL M, 1957, J BIOL CHEM, V226, P213; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIM KS, 1993, J BIOL CHEM, V268, P15689; KIM KT, 1993, J NEUROCHEM, V60, P946, DOI 10.1111/j.1471-4159.1993.tb03241.x; KOBAYASHI K, 1988, J BIOCHEM, V103, P907, DOI 10.1093/oxfordjournals.jbchem.a122386; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LAMOUROUX A, 1993, J NEUROCHEM, V60, P364, DOI 10.1111/j.1471-4159.1993.tb05861.x; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; OTTEN U, 1976, MOL PHARMACOL, V12, P353; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; SABBAN EL, 1983, J BIOL CHEM, V258, P7819; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLNICK SB, 1986, SCIENCE, V234, P998, DOI 10.1126/science.3095924; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X	43	128	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17987	17994						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688735				2022-12-27	WOS:A1993LT74300054
J	SUWANICKUL, A; MORRIS, SL; POWELL, DR				SUWANICKUL, A; MORRIS, SL; POWELL, DR			IDENTIFICATION OF AN INSULIN-RESPONSIVE ELEMENT IN THE PROMOTER OF THE HUMAN GENE FOR INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; HUMAN AMNIOTIC-FLUID; HEPATOMA-CELLS; IGF-I; MULTIHORMONAL REGULATION; PHENOTYPIC SELECTION; MAMMALIAN-CELLS; DOMINANT ROLE; TRANSCRIPTION; FOS	Insulin inhibits the hepatic transcription of insulin-like growth factor binding protein-1 (IGFBP-1). In the present studies, human HEP G2 hepatoma cells were transiently transfected with human IGFBP-1 gene promoter constructs in order to identify cis elements and trans-acting factors that confer the insulin effect. Transfections of IGFBP-1 promoter deletion constructs localized an insulin responsive element (IRE) between approximately 140- and approximately 103-base pair (bp) 5' to the mRNA capsite. This region contains a 25-bp sequence which is 100% conserved in the rat IGFBP-1 promoter and which has two AT-rich, 8-bp elements exhibiting dyad symmetry. Site-directed mutagenesis of both elements in the same 1205-bp IGFBP-1 promoter construct abolished the inhibitory effect of insulin on promoter activity. Also, the native but not the mutant IGFBP-1 IRE conferred the inhibitory effect of insulin to the heterologous thymidine kinase promoter. Gel mobility shift assays identified a DNA binding activity which specifically binds the native IGFBP-1 IRE and which is not altered by prior insulin treatment. The IGFBP-1 IRE sequence is similar to those of functionally mapped IREs from other gene promoters, suggesting that this common IRE and the protein(s) which it binds confer the insulin effect to a number of insulin-sensitive genes.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; ALEXANDERBRIDGES M, 1992, MOL CELL BIOCHEM, V109, P99; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BRISMAR K, 1993, GROWTH REGULAT, V3, P98; BRISMAR K, 1988, J ENDOCRINOL INVEST, V11, P599, DOI 10.1007/BF03350189; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; CHEN L, 1989, P NATL ACAD SCI USA, V86, P1367, DOI 10.1073/pnas.86.4.1367; CONOVER CA, 1990, J CLIN ENDOCR METAB, V70, P1062, DOI 10.1210/jcem-70-4-1062; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, DIABETES, V39, P1251, DOI 10.2337/diabetes.39.10.1251; CONOVER CA, 1993, IN PRESS ACTA ENDOCR; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P908, DOI 10.1210/jcem-59-5-908; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Montminy M R, 1990, Recent Prog Horm Res, V46, P219; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; POWELL DR, 1989, INT CONGR SER, V881, P3; POWELL DR, 1991, J BIOL CHEM, V266, P18868; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; UNTERMAN TG, 1992, BIOCHEM BIOPH RES CO, V185, P993, DOI 10.1016/0006-291X(92)91725-6; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; YEOH SI, 1988, ACTA ENDOCRINOL-COP, V128, P140; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	53	110	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17063	17068						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688722				2022-12-27	WOS:A1993LQ98800030
J	LI, W; HANDSCHUMACHER, RE				LI, W; HANDSCHUMACHER, RE			SPECIFIC INTERACTION OF THE CYCLOPHILIN-CYCLOSPORINE COMPLEX WITH THE B-SUBUNIT OF CALCINEURIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; IMMUNOSUPPRESSIVE AGENT; RECEPTOR; EXPRESSION; FK506	Calcineurin (CaN), a Ca2+/calmodulin-dependent serine/threonine phosphatase, has been shown to be inhibited by the complex of the immunosuppressant cyclosporin A (CsA) and its receptor, cyclophilin (CyP), but not by either alone. In the current study, the topological relationship between cyclophilin and the subunits of CaN has been explored using chemical crosslinking agents. In the presence of cyclosporin, I-125-CyP, shown to bind to CsA, is extensively cross-linked to the B subunit of CaN but not the catalytic A subunit. However, the A subunit is required for binding of the CyP.CsA complex, since cross-linking to recombinant B subunit alone does not occur. The kinetics of association indicate a saturable reaction with a K(d) of less than 70 nM. Cross-linking to the B subunit occurs with cross-linkers that span from 0 to 16 angstrom and employ different cross-linking chemistry, indicating direct contact between the B subunit and CyP. Similar cross-linking to the B subunit has been observed with the complex of I-125-labeled FK506 binding protein (FKBP) and FK506 but not with the FKBP-rapamycin complex. CyP.CsA cross-linking to CaN is Ca2+/calmodulin-dependent with intact CaN, but Ca2+/calmodulin-independent after digestion to remove the calmodulin binding and autoinhibitory domain.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University					NIGMS NIH HHS [GM40660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM040660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; COHEN DJ, 1984, ANN INTERN MED, V101, P667, DOI 10.7326/0003-4819-101-5-667; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FOOR F, 1992, NATURE, V360, P682; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KAHAN BD, 1991, TRANSPLANTATION, V52, P185, DOI 10.1097/00007890-199108000-00001; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MERKER M, 1983, TRANSPLANT P S1, V4, P2265; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOMSON AW, 1989, IMMUNOL TODAY, V10, P6, DOI 10.1016/0167-5699(89)90057-1	27	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14040	14044						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686148				2022-12-27	WOS:A1993LJ82500041
J	REZAEE, M; ISOKAWA, K; HALLIGAN, N; MARKWALD, RR; KRUG, EL				REZAEE, M; ISOKAWA, K; HALLIGAN, N; MARKWALD, RR; KRUG, EL			IDENTIFICATION OF AN EXTRACELLULAR 130-KDA PROTEIN INVOLVED IN EARLY CARDIAC MORPHOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUSHION TISSUE; ADHESION MOLECULES; HEART DEVELOPMENT; FLOOR PLATE; EXPRESSION; PATTERN; CELLS; GENE; CYTODIFFERENTIATION; DIFFERENTIATION	Previous studies indicate that the transformation of cardiac endothelium into mesenchyme is dependent upon a developmentally regulated signal expressed by its associated myocardium. This process can be mimicked in culture by substituting a non-cytolytic EDTA extract of embryonic heart tissue for the presence of myocardium. Polyclonal antibodies (ES1) generated against the EDTA-extractable proteins both localized to the cardiac extracellular matrix preceding the transformation of endothelium and blocked this process in culture. Based on these observations, we hypothesized that ES1 antigens participate in the formation of cardiac mesenchyme. The present study was undertaken to prepare cDNA and antibody probes for individual ES1 antigens to better characterize their involvement in this important morphogenetic event. An expression library was constructed in Uni-ZAP using poly(A+) RNA from embryonic cardiocyte cultures that had been shown previously to secrete proteins that engender the formation of cardiac mesenchyme. Screening of this expression library with ES1 antibodies resulted in several clones, one of which (''ES1-2.1a'') is described in this report. ES1-2.1a has a 2.6-kilobase pair insert, the sequence of which exhibits no apparent homology to those in data banks. A fragment (852 base pairs) from the 5' region of ES1-2.1a cDNA was subcloned into the expression vector pGEX-2T, and a 20-kDa fragment of the resulting protein used to prepare affinity-purified antibodies. Immunoblotting detected a 130-kDa protein (''ES/130'') in two preparations that elicit mesenchyme formation, i.e. EDTA extracts of embryonic hearts and conditioned medium of cardiocyte cultures. Functional studies showed that antibodies to ES/130 inhibited the epithelial-mesenchymal transformation of cardiac endothelium in culture. Immunohistochemistry of cardiocyte cultures localized ES/130 protein to the vacuolar system and secretory granules. By polymerase chain reaction analysis, the message for ES/130 was detected in the developing heart just prior to and during mesenchyme formation. These results are consistent with ES/130 being involved at a critical step in the initiation of the epithelial-mesenchymal transformation of cardiac endothelium.	MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,MILWAUKEE,WI 53226	Medical College of Wisconsin				Krug, Edward/0000-0002-4345-6580; Isokawa, Keitaro/0000-0002-7955-7252	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033756, R37HL033756, R01HL044928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44928, HL33756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BERNANKE DH, 1982, DEV BIOL, V91, P235, DOI 10.1016/0012-1606(82)90030-6; CROSSIN KL, 1991, DEV BIOL, V145, P277, DOI 10.1016/0012-1606(91)90126-N; Davis CL, 1924, ANAT REC, V27, P201; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FUNDERBURG FM, 1986, J CELL BIOL, V103, P2475, DOI 10.1083/jcb.103.6.2475; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; HALL R, 1984, NATURE, V311, P379, DOI 10.1038/311379a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; KRUG EL, 1987, DEV BIOL, V120, P348, DOI 10.1016/0012-1606(87)90237-5; KRUG EL, 1985, DEV BIOL, V112, P414, DOI 10.1016/0012-1606(85)90414-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, DECONTAMINATION DILU; MARKWALD RR, 1977, AM J ANAT, V148, P85, DOI 10.1002/aja.1001480108; MARKWALD RR, 1975, DEV BIOL, V42, P160, DOI 10.1016/0012-1606(75)90321-8; MARKWALD RR, 1990, ANN NY ACAD SCI, V588, P13, DOI 10.1111/j.1749-6632.1990.tb13193.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE PG, 1992, DEV DYNAM, V193, P24, DOI 10.1002/aja.1001930105; MJAATVEDT CH, 1987, DEV BIOL, V119, P59, DOI 10.1016/0012-1606(87)90206-5; MJAATVEDT CH, 1991, DEV BIOL, V145, P219, DOI 10.1016/0012-1606(91)90121-I; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLURSH M, 1984, CELL DIFFER DEV, V15, P17, DOI 10.1016/0045-6039(84)90025-3; STERN CD, 1990, DEVELOPMENT, V110, P1271; WEIDNER KM, 1990, J CELL BIOL, V111, P2094; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; [No title captured]	37	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14404	14411						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686155				2022-12-27	WOS:A1993LJ82500089
J	YEE, NS; LANGEN, H; BESMER, P				YEE, NS; LANGEN, H; BESMER, P			MECHANISM OF KIT-LIGAND, PHORBOL ESTER, AND CALCIUM-INDUCED DOWN-REGULATION OF C-KIT RECEPTORS IN MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; EPIDERMAL GROWTH-FACTOR; PERITONEAL-EXUDATE MACROPHAGES; STIMULATING FACTOR CSF-1; TYROSINE KINASE; SIGNAL TRANSDUCTION; W-LOCUS; INDEPENDENT MECHANISMS; TRANSMEMBRANE KINASE; INSULIN-RECEPTOR	The proto-oncogene c-kit is allelic with the white spotting locus (W) on mouse chromosome 5 and it encodes a transmembrane protein tyrosine kinase which belongs to the platelet-derived growth factor and macrophage-colony stimulating factor (CSF-1) receptor subfamily. In an effort to study the function of the c-kit receptor, specifically the physiological mechanism of controlling the signal induced by the ligand, the effect and mechanism of down-regulation of the c-kit receptor by the kit ligand (KL) was investigated in mast cells. Following preincubation with KL, the capacity of mast cells to bind kit antibody was reduced and binding of radiolabeled KL to mast cells decreased with similar kinetics, suggesting that KL stimulates the loss of c-kit receptor from the cell surface. After binding to the c-kit receptor, KL was rapidly internalized, and degradation of the receptor was accelerated. The c-kit receptor was transmodulated by the protein kinase C activator 12-O-tetradecanoylphorbol-13-acetate (TPA) and by the calcium ionophore ionomycin. TPA- and ionomycin-induced down-regulation of the c-kit receptor was accompanied by release of the extracellular domain of the receptor, presumably by proteolytic cleavage near the transmembrane domain. Release of the extracellular domain of the c-kit receptor occurred also in untreated cells but at a slow rate. In addition, ionomycin induced shedding of the intact c-kit receptor. In mast cells depleted of protein kinase C, the c-kit receptor remained sensitive to down-regulation induced by KL and ionomycin, but not by treatment with TPA. Therefore, the down-regulation of the c-kit receptor induced by KL, activated protein kinase C, and an increased level of intracellular calcium is mediated through independent mechanisms.	MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,1275 YORK AVE,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021; F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND	Memorial Sloan Kettering Cancer Center; Cornell University; Roche Holding					NATIONAL CANCER INSTITUTE [R37CA032926] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 32926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BRIZZI MF, 1991, J CELL PHYSIOL, V148, P24, DOI 10.1002/jcp.1041480104; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN BDM, 1985, J CELL PHYSIOL, V124, P305, DOI 10.1002/jcp.1041240221; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRUNBERGER G, 1982, AM J PHYSIOL, V243, pE319, DOI 10.1152/ajpendo.1982.243.4.E319; GUILBERT LJ, 1983, J CELL PHYSIOL, V115, P276, DOI 10.1002/jcp.1041150310; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KING AC, 1982, J BIOL CHEM, V257, P3053; KITAMURA Y, 1989, BIOESSAYS, V10, P193, DOI 10.1002/bies.950100604; LEE LS, 1979, P NATL ACAD SCI USA, V76, P5168, DOI 10.1073/pnas.76.10.5168; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LIU CM, 1978, J BIOL CHEM, V253, P5892; MAGUN BE, 1980, J BIOL CHEM, V255, P6373; MAJUMDER S, 1988, MOL CELL BIOL, V8, P4896, DOI 10.1128/MCB.8.11.4896; MORI S, 1992, J BIOL CHEM, V267, P6429; NAKAHATA T, 1986, NATURE, V324, P65, DOI 10.1038/324065a0; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PAWSON T, 1991, TRENDS GENET, V7, P343, DOI 10.1016/0168-9525(91)90252-L; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHIEH JH, 1991, J IMMUNOL, V146, P2648; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; Silvers W.K., 1979, COAT COLORS MICE, P206; STEIN J, 1991, ONCOGENE, V6, P601; TAKAGI M, 1992, J IMMUNOL, V148, P3446; THOMOPOULOS P, 1982, EUR J BIOCHEM, V29, P389; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; WHITE JR, 1985, P NATL ACAD SCI USA, V82, P8193, DOI 10.1073/pnas.82.23.8193; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YUNG YP, 1982, J IMMUNOL, V129, P1256; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	60	118	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14189	14201						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686152				2022-12-27	WOS:A1993LJ82500061
J	MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; NYKJAER, A; ANDREASEN, PA; RASMUSSEN, HH; SOTTRUPJENSEN, L; GLIEMANN, J				MOESTRUP, SK; HOLTET, TL; ETZERODT, M; THOGERSEN, HC; NYKJAER, A; ANDREASEN, PA; RASMUSSEN, HH; SOTTRUPJENSEN, L; GLIEMANN, J			ALPHA-2-MACROGLOBULIN-PROTEINASE COMPLEXES, PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1-PLASMINOGEN ACTIVATOR COMPLEXES, AND RECEPTOR-ASSOCIATED PROTEIN BIND TO A REGION OF THE ALPHA-2-MACROGLOBULIN RECEPTOR-CONTAINING A CLUSTER OF 8 COMPLEMENT-TYPE REPEATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; MONOCLONAL-ANTIBODIES; LIGAND RECOGNITION; HIGH-AFFINITY; DOMAIN; LRP; DNA	A region containing sites for ligand binding was localized in the 4525-amino acid residue alpha2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha2MR/LRP) by ligand- and immunoblotting of proteinase and CNBr digests of the purified human placental protein. I-125-Labeled rat alpha1-macroglobulin light chain, urokinase-plasminogen activator inhibitor type-1 complex, and alpha2MR-associated protein all bound to a 75-kDa CNBr-generated fragment (68 kDa after deglycosylation). In addition to the three ligands, the fragment bound a novel monoclonal antibody reacting in the region defined by amino acid residues 1165-1246 as determined by binding to recombinant fragments of alpha2MR/LRP. The positions of methionine residues in alpha2MR/LRP suggested that the ligand-binding CNBr fragment contained three disulfide-linked peptides comprising the residues 776-1399. This origin was confirmed by partial amino acid sequencing of the electroblotted fragment and polypeptides generated by reduction of the fragment. The identified region represents 13.6% of the molecular mass (nonglycosylated) of alpha2MR/LRP and contains one of three large clusters of complement-type repeats.	AARHUS UNIV, INST MOLEC BIOL, DK-8000 AARHUS, DENMARK; AARHUS UNIV, GENE EXPRESS LAB, DK-8000 AARHUS, DENMARK	Aarhus University; Aarhus University	MOESTRUP, SK (corresponding author), AARHUS UNIV, INST MED BIOCHEM, DK-8000 AARHUS, DENMARK.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736				BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; GLIEMANN J, 1986, BIOCHIM BIOPHYS ACTA, V885, P49, DOI 10.1016/0167-4889(86)90037-6; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1988, EMBO J, V7, P4419; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JENSEN PH, 1992, FEBS LETT, V305, P129, DOI 10.1016/0014-5793(92)80879-L; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P438; MARYNEN P, 1982, FEBS LETT, V137, P241, DOI 10.1016/0014-5793(82)80358-X; MOESTRUP SK, 1990, EXP CELL RES, V190, P195, DOI 10.1016/0014-4827(90)90185-D; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1988, NATURE, V332, P284, DOI 10.1038/332284a0; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SOTTRUPJENSEN L, 1980, FEBS LETT, V221, P55; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	35	117	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13691	13696						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685767				2022-12-27	WOS:A1993LH55300094
J	CASTELLANO, A; WEI, XY; BIRNBAUMER, L; PEREZREYES, E				CASTELLANO, A; WEI, XY; BIRNBAUMER, L; PEREZREYES, E			CLONING AND EXPRESSION OF A NEURONAL CALCIUM-CHANNEL BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONOTOXIN GVIA RECEPTOR; SKELETAL-MUSCLE; COMPLEMENTARY-DNA; DIHYDROPYRIDINE RECEPTOR; FUNCTIONAL EXPRESSION; BRAIN; PROTEINS; ALPHA-1-SUBUNIT; PHOSPHORYLATION	Although pharmacological and electrophysiological studies have demonstrated the existence of multiple types of voltage-dependent calcium channels in neuronal tissue, the subunit composition of these channels is not well known. Here, we report the cloning and expression of a new rat brain beta subunit (beta4). Northern blot analysis indicates that beta4 mRNA is expressed almost exclusively in neuronal tissues, with the highest levels being found in the cerebellum. Coexpression studies indicate that rat beta4 can interact with rabbit cardiac muscle alpha1, rabbit skeletal muscle alpha1, and calcium channels endogenous to Xenopus oocytes. Beta4 modulation of alpha1 activity is similar to the modulation induced by beta1, beta2, or beta3. The most striking effect of beta subunits is their ability to increase functional alpha1 activity, which can be measured as either increased dihydropyridine binding to membranes from transfected COS cells or increased calcium channel activity in Xenopus oocytes.	BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Castellano, Antonio/AAH-8829-2021; IBIS, VASCULAR/P-3934-2015; Castellano, Antonio/E-6285-2010	Castellano, Antonio/0000-0003-3955-5137; Castellano, Antonio/0000-0003-3955-5137	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL046702, P01HL037044, R55HL046702] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46702, HL-37044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHANG CF, 1991, J BIOL CHEM, V266, P16395; FRECH GC, 1989, GENE ANAL TECH, V6, P33, DOI 10.1016/0735-0651(89)90024-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HESS P, 1984, NATURE, V311, P538, DOI 10.1038/311538a0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; KLOCKNER U, 1992, PFLUG ARCH EUR J PHY, V420, P413, DOI 10.1007/BF00374479; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1992, FEBS LETT, V308, P7, DOI 10.1016/0014-5793(92)81038-N; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	37	206	222	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12359	12366						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685340				2022-12-27	WOS:A1993LG65800024
J	WEINER, KXB; WEINER, RS; MALEY, F; MALEY, GF				WEINER, KXB; WEINER, RS; MALEY, F; MALEY, GF			PRIMARY STRUCTURE OF HUMAN DEOXYCYTIDYLATE DEAMINASE AND OVEREXPRESSION OF ITS FUNCTIONAL PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEOSIDE TRIPHOSPHATE POOLS; T7 RNA-POLYMERASE; DCMP DEAMINASE; HAMSTER-CELLS; EXPRESSION; BACTERIOPHAGE-T4; SEQUENCE; GENE; PURIFICATION; DIAGNOSIS	The cDNA encoding human dCMP deaminase was isolated from a lambdaZAPII expression library using an antibody generated against highly purified HeLa cell dCMP deaminase. The cloned cDNA consists of 1856 base pairs and encodes a protein of 178 amino acids with a calculated molecular mass of 19,985 daltons. The sequence of several cyanogen bromide-cleaved peptides derived from HeLa cell dCMP deaminase are all contained within the deduced amino acid sequence. A zinc binding region is present in the enzyme, similar to that reported for cytidine deaminase (Yang, E. C., Carlow, D., Wolfenden, R., and Short, S. A. (1992) Biochemistry 31, 4168-4174). Northern blot analysis revealed a predominant messenger RNA species of 1.9 kilobases. Expression of the active protein to about 10% of Escherichia coli's total protein was achieved by subcloning the open reading frame into a high expression system using the polymerase chain reaction. Polyacrylamide gel electrophoresis revealed a prominent protein band which comigrated with affinity purified HeLa dCMP deaminase, while Western blot analysis yielded an immunoreactive band which comigrated with the single immunoreactive affinity column purified dCMP deaminase band. The enzyme which possesses a k(cat) of 1.02 x 10(3) s-1 was purified to homogeneity in over 60% yield. The overexpression of dCMP deaminase should permit more exacting studies on the regulation of this important allosteric enzyme which provides substrate for DNA synthesis.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, EMPIRE STATE PLAZA, POB 509, ALBANY, NY 12201 USA; SUNY Albany, SCH PUBL HLTH, DEPT BIOMED SCI, ALBANY, NY 12222 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BIRNBOIM HC, 1988, NUCLEIC ACIDS RES, V16, P1487, DOI 10.1093/nar/16.4.1487; CHIU CS, 1977, J BIOL CHEM, V252, P8603; DESAINTVINCENT BR, 1980, J BIOL CHEM, V255, P162; ELLIMS PH, 1981, J BIOL CHEM, V256, P6335; GELBARD AS, 1969, BIOCHIM BIOPHYS ACTA, V182, P564, DOI 10.1016/0005-2787(69)90209-3; GEORGIADES C, 1985, ACTA CARDIOL, V40, P247; GERACI G, 1967, BIOCHEMISTRY-US, V6, P183, DOI 10.1021/bi00853a030; JACKSON RC, 1978, J BIOL CHEM, V253, P7440; JONES DD, 1982, BRIT J OBSTET GYNAEC, V89, P314, DOI 10.1111/j.1471-0528.1982.tb04703.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALEY F, 1960, J BIOL CHEM, V235, P2968; MALEY F, 1961, CANCER RES, V21, P1421; MALEY F, 1967, METHOD ENZYMOL, V12, P170; MALEY F, 1972, CURR TOP CELL REGUL, V5, P177; MALEY GF, 1983, J BIOL CHEM, V258, P8290; MALEY GF, 1959, J BIOL CHEM, V234, P2975; MALEY GF, 1990, J BIOL CHEM, V265, P47; MALEY GF, 1993, BIOCHIM BIOPHYS ACTA, V1162, P161, DOI 10.1016/0167-4838(93)90143-F; MALEY GF, 1972, J BIOL CHEM, V247, P931; MALEY GF, 1970, ADV ENZYMES REGULATI, V8, P55; MCINTOSH EM, 1986, MOL CELL BIOL, V6, P1711, DOI 10.1128/MCB.6.5.1711; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MILLER RL, 1969, CLIN CHIM ACTA, V26, P405, DOI 10.1016/0009-8981(69)90067-9; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MOLLGAARD H, 1978, J BIOL CHEM, V253, P3536; MOORE JT, 1993, J BIOL CHEM, V268, P2288; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; REDMAN CWG, 1977, BRIT J OBSTET GYNAEC, V84, P904, DOI 10.1111/j.1471-0528.1977.tb12519.x; ROBERTS RG, 1978, ANN CLIN BIOCHEM, V15, P316, DOI 10.1177/000456327801500175; Rosen K., 1990, FOCUS, V12, P23; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; STEERS E, 1965, J BIOL CHEM, V240, P2478; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; WEINER KXB, 1990, MOL ENDOCRINOL, V4, P1249, DOI 10.1210/mend-4-8-1249; WEINER RS, 1992, ENDOCRINOLOGY, V131, P1026, DOI 10.1210/en.131.3.1026; WILLIAMS GF, 1975, BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5961.10; WILLIAMS GF, 1982, BRIT J OBSTET GYNAEC, V89, P309, DOI 10.1111/j.1471-0528.1982.tb04702.x; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; XU YZ, 1992, BIOCHEM PHARMACOL, V44, P1819; YANG C, 1992, BIOCHEMISTRY-US, V31, P4168, DOI 10.1021/bi00132a003; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	50	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12983	12989						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685356				2022-12-27	WOS:A1993LG65800109
J	SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL				SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL			RNA-DIRECTED RNA-POLYMERASE FROM TOMATO LEAVES .2. CATALYTIC INVITRO PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBER VIROID PSTV; FULL-LENGTH COPIES; SACCHAROMYCES-CEREVISIAE; LEAF TISSUE; DNA; TRANSCRIPTION; TEMPLATES; PURIFICATION; REPLICATION; SPECIFICITY	The catalytic properties of electrophoretically homogeneous RNA-directed RNA polymerase (RdRP, EC 2.7.7.48) from tomato leaf tissue were studied with the aid of oligonucleotides of defined sequence. It was found that RdRP catalyzes in vitro the transcription of short single-stranded RNA and DNA molecules into precisely complementary RNA copies up to the full length of these templates. The transcription of RNA- and DNA-oligonucleotide templates was equally effective. Differences in transcription efficiency were found to depend on nucleotide sequence rather than on the RNA or DNA nature of the single-stranded nucleic acid. Double-stranded nucleic acids such as poly(A) . poly(U) and a double-stranded DNA 14-mer were not transcribed. The RdRP-directed transcription could be primed because RNA and DNA dinucleotides and trinucleotides complementary to the 3'-terminal nucleotides of the template were extended by the enzyme. The unprimed transcription was shown to start preferentially at the 3'-terminal nucleotides of the template. RdRP is capable of adding a single noncomplementary nucleotide to the 3' terminus of about 50% of the runoff transcripts. AMP was preferred over GMP, whereas CMP and UMP were terminally added at very low frequency.	MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY	Max Planck Society								ASTIERMA.S, 1971, BIOCHIM BIOPHYS ACTA, V232, P484, DOI 10.1016/0005-2787(71)90602-2; ASTIERMANIFACIER S, 1978, CR ACAD SCI D NAT, V287, P1043; BAUSCH JN, 1983, J BIOL CHEM, V258, P1978; BIEBRICH.CK, 1973, P NATL ACAD SCI USA, V70, P934, DOI 10.1073/pnas.70.3.934; BLAKE RD, 1967, J MOL BIOL, V30, P291; BOEGE F, 1980, FEBS LETT, V121, P91, DOI 10.1016/0014-5793(80)81273-7; BOEGE F, 1982, BIOSCIENCE REP, V2, P185, DOI 10.1007/BF01116382; BROWNLEE GG, 1969, EUR J BIOCHEM, V11, P395, DOI 10.1111/j.1432-1033.1969.tb00786.x; COLLMER CW, 1985, P NATL ACAD SCI USA, V82, P3110, DOI 10.1073/pnas.82.10.3110; DIAMOND A, 1983, METHOD ENZYMOL, V100, P431; DIENER TO, 1972, NATURE-NEW BIOL, V235, P218, DOI 10.1038/newbio235218a0; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; DORSSERS L, 1983, VIROLOGY, V125, P155, DOI 10.1016/0042-6822(83)90071-5; DUDA CT, 1973, BIOCHIM BIOPHYS ACTA, V319, P62, DOI 10.1016/0005-2787(73)90041-5; DUDA CT, 1979, VIROLOGY, V92, P180, DOI 10.1016/0042-6822(79)90223-X; EVANS DMA, 1984, ANN BOT-LONDON, V54, P271, DOI 10.1093/oxfordjournals.aob.a086791; FRAENKELCONRAT H, 1986, CRC CR REV PLANT SCI, V4, P213, DOI 10.1080/07352688609382224; FRANK R, 1982, CHEM ENZYMATIC SYNTH, P225; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; HAAS B, 1988, NUCLEOS NUCLEOT, V7, P713, DOI 10.1080/07328318808056315; IKEGAMI M, 1979, J BIOL CHEM, V254, P149; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KELLY JL, 1986, J BIOL CHEM, V261, P340; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; KONARSKA MM, 1990, CELL, V63, P609, DOI 10.1016/0092-8674(90)90456-O; KUSMIEREK JT, 1982, BIOCHEMISTRY-US, V21, P5723, DOI 10.1021/bi00265a051; LAZCANO A, 1988, J MOL EVOL, V27, P365, DOI 10.1007/BF02101199; LOEB LA, 1969, J BIOL CHEM, V244, P1672; MARCOS JF, 1992, VIROLOGY, V186, P481, DOI 10.1016/0042-6822(92)90013-F; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; RACKWITZ HR, 1981, NATURE, V291, P297, DOI 10.1038/291297a0; RANDERATH E, 1983, METHODS DNA RNA SEQU, P169; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; Richards E. G, 1975, HDB BIOCH MOL BIOL, V1, P596; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROBERTSON HD, 1987, VIROIDS VIROID LIKE, P49; ROMAINE CP, 1978, VIROLOGY, V86, P241, DOI 10.1016/0042-6822(78)90024-7; SANGER F, 1965, J MOL BIOL, V14, P303, DOI 10.1016/S0022-2836(65)80253-4; SANGER HL, 1982, ENCY PLANT PHYSL B, V14, P368; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11851; SCHINDLER IM, 1992, PLANT SCI, V84, P221, DOI 10.1016/0168-9452(92)90138-C; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SCHNOLZER M, 1985, EMBO J, V4, P2181, DOI 10.1002/j.1460-2075.1985.tb03913.x; SELIGER H, 1980, NUCLEIC ACIDS RES S, V7, P191; SEMANCIK JS, 1984, P NATL ACAD SCI-BIOL, V81, P4429, DOI 10.1073/pnas.81.14.4429; SHARMEEN L, 1987, NUCLEIC ACIDS RES, V15, P6705, DOI 10.1093/nar/15.16.6705; SINGER B, 1983, P NATL ACAD SCI-BIOL, V80, P969, DOI 10.1073/pnas.80.4.969; SPIESMACHER E, 1985, BIOSCIENCE REP, V5, P251, DOI 10.1007/BF01119595; STECK TL, 1968, J BIOL CHEM, V243, P2769; TABLER M, 1985, EMBO J, V4, P2191, DOI 10.1002/j.1460-2075.1985.tb03914.x; TAKANAMI Y, 1982, BIOCHEMISTRY-US, V21, P3161, DOI 10.1021/bi00256a020; TAYLOR JM, 1991, CURR TOP MICROBIOL, V168, P141; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214	61	115	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11858	11867						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685023				2022-12-27	WOS:A1993LF28400061
J	JASPARD, E; WEI, L; ALHENCGELAS, F				JASPARD, E; WEI, L; ALHENCGELAS, F			DIFFERENCES IN THE PROPERTIES AND ENZYMATIC SPECIFICITIES OF THE 2 ACTIVE-SITES OF ANGIOTENSIN I-CONVERTING ENZYME (KININASE-II) - STUDIES WITH BRADYKININ AND OTHER NATURAL PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS DOMAINS; MOLECULAR-CLONING; ACTIVATION; INHIBITORS; HYDROLYSIS; ISOZYME; BINDING	Angiotensin I-converting enzyme (ACE, E.C.3.4.15.1) has been recently shown to contain two very similar domains, each of which bears a functional active site hydrolyzing Hip-His-Leu or angiotensin I (AI). The substrate specificity of the two active sites of ACE was compared using wild-type recombinant ACE and mutants, where one active site is suppressed by deletion or inactivated by mutations of 2 histidines coordinating an essential zinc atom. Both active sites converted bradykinin (BK) to BK1-7 and BK1-5 with similar kinetics and with K(m)app at least 30 times lower and k(cat)/K(m)app 10 times higher than for AI. The carboxyl-terminal active site, but not the amino-terminal site, was activated by chloride; however, chloride activation was minimal compared with AI. Both domains also hydrolyzed substance P and cleaved a carboxyl-terminal protected dipeptide and tripeptide. The carboxyl-terminal active site was more readily activated by chloride and hydrolyzed substance P faster. Luteinizing-hormone releasing hormone was hydrolyzed by both active sites, but hydrolysis by the amino-terminal active site was faster. It performed the endoproteolytic amino-terminal cleavage of this peptide at least 30 times faster than the carboxyl-terminal active site. Both active sites cleaved a carboxyl-terminal tripeptide from luteinizing hormone-releasing hormone. Thus, both active sites of ACE possess dipeptidyl carboxypeptidase and endopeptidase activities. However, only the carboxyl-terminal active site can undergo a chloride-induced alteration that greatly enhances the hydrolysis of Al or substance P, and the amino-terminal active site possesses an unusual amino-terminal endoproteolytic specificity for a natural peptide. This suggests physiologically important differences between the subsites of the two active centers, and different substrate specificity, despite the high degree of sequence homology.	INSERM,U367,17 RUE FER MOULIN,F-75005 PARIS,FRANCE; INSERM,U36,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			Alhenc-Gelas, Francois/F-9511-2017					Alberts B., 1983, MOL BIOL CELL, V4; ALHENCGELAS F, 1981, BIOCHIM BIOPHYS ACTA, V677, P477, DOI 10.1016/0304-4165(81)90262-2; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BRUNEVAL P, 1986, HISTOCHEMISTRY, V85, P73, DOI 10.1007/BF00508656; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; CHEN YNP, 1992, BIOCHEM BIOPH RES CO, V184, P306, DOI 10.1016/0006-291X(92)91193-T; DAUTRYVARSAT A, 1981, BIOCHEMISTRY-US, V20, P1396, DOI 10.1021/bi00508a056; Dixon M., 1979, ENZYMES, Vthird; DORER FE, 1974, CIRC RES, V34, P824, DOI 10.1161/01.RES.34.6.824; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; EHLERS MRW, 1989, P NATL ACAD SCI USA, V86, P7741, DOI 10.1073/pnas.86.20.7741; ISHIDA H, 1989, J PHARMACOL EXP THER, V251, P817; Kenny AJ, 1987, MAMMALIAN ECTOENZYME, P169; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; LATTION AL, 1989, FEBS LETT, V252, P99, DOI 10.1016/0014-5793(89)80897-X; Lehninger A. L., 1972, BIOCH MOL BASIS CELL; MOMBOULI JV, 1991, J CARDIOVASC PHARM, V18, P926, DOI 10.1097/00005344-199112000-00021; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P5315, DOI 10.1021/bi00292a010; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SKIDGEL RA, 1985, P NATL ACAD SCI USA, V82, P1025, DOI 10.1073/pnas.82.4.1025; SKIDGEL RA, 1987, NEUROPEPTIDES THEIR, P165; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEWART TA, 1981, PEPTIDES, V2, P145, DOI 10.1016/S0196-9781(81)80027-7; SUBISSI A, 1990, BRIT J PHARMACOL, V100, P502, DOI 10.1111/j.1476-5381.1990.tb15837.x; TAKADA Y, 1982, JPN CIRC J, V46, P503, DOI 10.1253/jcj.46.503; WEI L, 1992, J BIOL CHEM, V267, P13398; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WIEMER G, 1991, HYPERTENSION, V18, P558, DOI 10.1161/01.HYP.18.4.558; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6; YOSHIDA T, 1990, J NEUROCHEM, V55, P1861, DOI 10.1111/j.1471-4159.1990.tb05769.x	34	281	290	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9496	9503						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683654				2022-12-27	WOS:A1993LA68900054
J	LEE, H; HSU, S; WINAWER, S; FRIEDMAN, E				LEE, H; HSU, S; WINAWER, S; FRIEDMAN, E			SIGNAL TRANSDUCTION THROUGH EXTRACELLULAR SIGNAL-REGULATED KINASE-LIKE PP57 BLOCKED IN DIFFERENTIATED COLON-CARCINOMA CELLS HAVING LOW-LEVELS OF C-SRC KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PP60C-SRC PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; FACTOR RECEPTORS; ACTIVATION; MITOGEN; INSULIN; ERKS; AUTOPHOSPHORYLATION; ANTIBODIES	Basic fibroblast growth factor (FGF) induced a rapid increase in tyrosine phosphorylation of a 57-kDa cytoplasmic protein with functional myelin basic protein kinase activity and antigenic properties common to mitogen-activated kinases or extracellular signal-regulated kinases. Basic and acidic FGFs and the diacylglycerol diolein used the same signal transduction pathway to activate pp57. These FGFs, like diolein (Lee, H., Ghose-Dastidar, J., Winawer, S., and Friedman, E. (1993) J. Biol. Chem., 268, 5255-5263), increased the cellular concentration of long-chain diacylglycerols within the same short time period as they increased pp57 tyrosine phosphorylation. Both FGF and diolein increased phosphorylation of pp57 on the same V8 protease-generated fragments, suggesting a common pathway for the phosphorylation of pp57. FGF-induced signal transduction through pp57 mitogen-activated kinase led to cell growth in two undifferentiated colon carcinoma cell lines. In contrast, basic FGF neither increased tyrosine phosphorylation of pp57 nor increased cell growth in two colon goblet cell differentiated lines derived from the same parental line as the undifferentiated cells. Both goblet cell lines exhibited levels of protein-tyrosine kinase activity about one-fifth that of the undifferentiated lines. The decrease in tyrosine kinase activity was not due to down-regulation of FGF receptors or their tyrosine kinase activities. c-src kinase-specific activity was decreased 4-5-fold in both goblet cell lines, suggesting a role for c-src in pp57-mediated signal transduction.	MEM SLOAN KETTERING CANC CTR, GASTROINTESTINAL TUMOR BIOL LAB, POB 244, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R01 CA50645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BOWEN HJ, 1991, FOCUS, V12, P105; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FOSS FM, 1989, ONCOGENE RES, V5, P13; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARIAN B, 1989, CANCER RES, V49, P4231; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; RAY LB, 1988, J BIOL CHEM, V263, P12721; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SAFRAN A, 1990, ONCOGENE, V5, P635; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1992, ONCOGENE, V7, P801; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8181	8187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681838				2022-12-27	WOS:A1993KW97900086
J	LEVITSKY, DO; CLERGUE, M; LAMBERT, F; SOUPONITSKAYA, MV; LEJEMTEL, TH; LECARPENTIER, Y; LOMPRE, AM				LEVITSKY, DO; CLERGUE, M; LAMBERT, F; SOUPONITSKAYA, MV; LEJEMTEL, TH; LECARPENTIER, Y; LOMPRE, AM			SARCOPLASMIC-RETICULUM CALCIUM-TRANSPORT AND CA2+-ATPASE GENE-EXPRESSION IN THORACIC AND ABDOMINAL AORTAS OF NORMOTENSIVE AND SPONTANEOUSLY HYPERTENSIVE RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ENDOPLASMIC-RETICULUM; CA-2+ PUMP; CA-2+-ATPASE GENE; MOLECULAR-CLONING; PLASMA-MEMBRANE; MESSENGER-RNA; CELLS; SENSITIVITY; VESICLES	Increased intracellular Ca2+ concentration has been associated with the elevation of vascular tone in hypertensive animals. The increase in free cytosolic Ca2+ may partially result from a reduced activity of the sarcoplasmic reticulum (SR) calcium pump. Accordingly we investigated the Ca2+ transport function and the expression of the Ca2+-ATPase gene in thoracic and abdominal aortas of normotensive Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). Total SR Ca2+ pump activity was estimated by measuring the oxalate-stimulated Ca2+ transport rate on crude homogenates. Ca2+ transport was also measured on highly active microsomal fractions. Our data indicate that the Ca2+ uptake rate, expressed per mg of protein or per g of muscle, is greater in homogenates from aortas of SHR when compared with that of WKY rats. In microsomal fractions isolated from thoracic aortas of SHR compared with WKY rats, the activity and density of SR Ca2+ pump were only slightly increased. The SR Ca2+ transport rate and the amount of each SR Ca2+-ATPase mRNA isoform, i.e. SERCA 2a and SERCA 2b, normalized to 18 S ribosomal RNA, were greater in thoracic than in abdominal aorta in both strains. When compared with WKY rats, the level of each SERCA mRNA isoform is higher in the abdominal aorta of SHR but appears similar in the thoracic aorta. Thus, in contrast to previously published data that documented a depressed SR Ca2+ transport activity in the aorta of SHR, the present data indicate that the SR function is increased. These changes in SR activity are accompanied by quantitative changes in expression of the SR Ca2+-ATPase gene without alterations in the SR Ca2+-ATPase mRNA isoforms pattern.	ECOLE POLYTECH,ECOLE NATL SUPER TECH AVANCEES,CTR YVETTE,OPT APPLIQUEE LAB,INSERM,F-91128 PALAISEAU,FRANCE; CARDIOL RES CTR,MOSCOW 121552,RUSSIA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris; National Medical Research Center of Cardiology			LOMPRE, Anne-Marie/H-2872-2013					ASHIDA T, 1988, CIRC RES, V62, P854, DOI 10.1161/01.RES.62.4.854; BODIN P, 1987, CELL TISSUE RES, V247, P227, DOI 10.1007/BF00216565; CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHIESI M, 1984, BIOCHEM BIOPH RES CO, V124, P797, DOI 10.1016/0006-291X(84)91028-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS MD, 1992, CIRC RES, V70, P163, DOI 10.1161/01.RES.70.1.163; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DELABASTIE D, 1990, CIRC RES, V66, P557; DEMEIS L, 1981, SARCOPLASMIC RETICUL; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; EGGERMONT JA, 1988, CIRC RES, V62, P266, DOI 10.1161/01.RES.62.2.266; EGGERMONT JA, 1989, BIOCHEM J, V260, P757, DOI 10.1042/bj2600757; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; ENOUF J, 1988, J BIOL CHEM, V263, P13922; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GROVER AK, 1985, CELL CALCIUM, V6, P227, DOI 10.1016/0143-4160(85)90008-9; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; IKEMOTO N, 1974, J BIOL CHEM, V249, P649; KOCHER O, 1987, DIFFERENTIATION, V34, P201, DOI 10.1111/j.1432-0436.1987.tb00067.x; KOWARSKI D, 1985, J PHYSIOL-LONDON, V366, P153, DOI 10.1113/jphysiol.1985.sp015790; KWAN CY, 1985, CAN J PHYSIOL PHARM, V63, P366, DOI 10.1139/y85-066; LEJEMTEL TH, 1993, CIRC RES, V72, P341, DOI 10.1161/01.RES.72.2.341; LEVITSKY DO, 1981, J MOL CELL CARDIOL, V13, P785, DOI 10.1016/0022-2828(81)90236-4; LEVITSKY DO, 1986, AM J PHYSIOL, V250, pH360, DOI 10.1152/ajpheart.1986.250.3.H360; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; LOMPRE AM, 1989, FEBS LETT, V249, P35, DOI 10.1016/0014-5793(89)80010-9; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MOORE L, 1975, BIOCHIM BIOPHYS ACTA, V413, P432, DOI 10.1016/0005-2736(75)90126-1; ORIOWO MA, 1989, J PHARMACOL EXP THER, V251, P16; OSBORN M, 1981, DIFFERENTIATION, V20, P196, DOI 10.1111/j.1432-0436.1981.tb01176.x; PAPAGEORGIOU P, 1991, AM J PHYSIOL, V260, pH507, DOI 10.1152/ajpheart.1991.260.2.H507; POSTNOV YV, 1985, PHYSIOL REV, V65, P904, DOI 10.1152/physrev.1985.65.4.904; RAEYMAEKERS L, 1984, CELL CALCIUM, V5, P205, DOI 10.1016/0143-4160(84)90036-8; RINGBOM A, 1963, COMPLEXATION ANAL CH, P38; SOMLYO AP, 1985, CIRC RES, V57, P497, DOI 10.1161/01.RES.57.4.497; STAUBER WT, 1979, BLOOD VESSELS, V16, P17; SUGIYAMA T, 1986, BIOCHEM BIOPH RES CO, V141, P340, DOI 10.1016/S0006-291X(86)80374-6; TROSPER TL, 1984, CELL CALCIUM, V5, P211, DOI 10.1016/0143-4160(84)90037-X; WEBB RC, 1976, J MOL CELL CARDIOL, V8, P651, DOI 10.1016/0022-2828(76)90050-X; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	44	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8325	8331						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681842				2022-12-27	WOS:A1993KW97900106
J	ZIMMER, Y; GIVOL, D; YAYON, A				ZIMMER, Y; GIVOL, D; YAYON, A			MULTIPLE STRUCTURAL ELEMENTS DETERMINE LIGAND-BINDING OF FIBROBLAST GROWTH-FACTOR RECEPTORS - EVIDENCE THAT BOTH IG DOMAIN-2 AND DOMAIN-3 DEFINE RECEPTOR SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FGF RECEPTOR; BASIC-FGF; EXPRESSION; CLONING; FAMILY; MEMBER; GENES; FORMS; DNA; PROTEINS	The murine fibroblast growth factor receptor 2 (FGFR2) and keratinocyte growth factor receptor (KGFR) are two products of the same gene which display distinct binding specificities. We and others have shown that a major structural element underlying this functional divergence is a variable 50 amino acids long region constituting the C-terminal half of the third immunoglobulin (Ig)-like domain of the receptor. This region of the two receptors is encoded by two distinct exons which are alternatively used in cells of different tissues and origin. To further investigate the role of this confined variable region in determining ligand binding specificity we have generated a chimeric molecule between FGFR1 and KGFR where the variable segment of KGFR replaces the homologous region in FGFR1. Binding studies as well as chemical cross-linking of radiolabeled ligands revealed that the recombinant FGFR1/KGFR chimera has retained the binding affinity to acidic FGF and FGF4 (hst/kfgf) but lost the capacity to bind basic FGF (bFGF). This chimeric receptor bound keratinocyte growth factor (KGF), however, with significantly lower affinity as compared with KGFR. High affinity binding of KGF was acquired only when also domain 2 in this chimera was replaced by its homologous domain from FGFR2. These results demonstrate that ligand binding and specificity involves multiple receptor elements which are located at both Ig-like domain 2 and 3 of FGF receptors.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AVIVI A, 1991, ONCOGENE, V6, P1089; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	29	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7899	7903						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681832				2022-12-27	WOS:A1993KW97900049
J	SAEKI, T; UEDA, K; TANIGAWARA, Y; HORI, R; KOMANO, T				SAEKI, T; UEDA, K; TANIGAWARA, Y; HORI, R; KOMANO, T			HUMAN P-GLYCOPROTEIN TRANSPORTS CYCLOSPORINE-A AND FK506	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIDRUG-RESISTANT CELLS; MEMBRANE-VESICLES; PLASMA-MEMBRANE; K562 CELLS; BINDING; VINCRISTINE; VINBLASTINE; COLCHICINE; PROTEIN	Cyclosporin A, a cyclic undecapeptide, and FK506 are efficient immunosuppressive agents. They also attract attention as effective P-glycoprotein modulators that inhibit P-glycoprotein from binding to anticancer drugs and overcome multidrug resistance. Cyclosporin A itself interacts with a common binding site of P-glycoprotein to which Vinca alkaloids and verapamil bind. We were interested to determine whether cyclosporin A and FK506 are substrates for P-glycoprotein to transport, and we studied their transcellular transport. In LLC-PK1 cells, derived from porcine kidney proximal tubule and forming a highly polarized epithelium, cyclosporin A was transported in a saturable manner. LLC-GA5-COL300, a transformant cell line derived by transfecting LLC-PK1 with human MDR1 cDNA isolated from normal adrenal gland, expresses P-glycoprotein specifically on the apical surface and shows a typical multidrug-resistant phenotype. LLC-GA5-COL300 cells showed increased transport of cyclosporin A from the basal to the apical side. Kinetic analysis showed that this transport was a typical saturable transport with the calculated apparent Michaelis constant (K(m)app) and the maximum flux (V(max)) as 8.4 gm and 2.4 nmol/mg protein/h, respectively. LLC-GA5-COL300 also showed increased transport of FK506 from the basal to the apical side. These results indicate that P-glycoprotein transports the immunosuppressive agents cyclosporin A and FK506.	KYOTO UNIV,FAC AGR,DEPT AGR CHEM,BIOCHEM LAB,KYOTO 60601,JAPAN; KYOTO UNIV HOSP,FAC MED,DEPT PHARM,KYOTO 60601,JAPAN	Kyoto University; Kyoto University				Ueda, Kazumitsu/0000-0003-2980-6078				BLAIR JT, 1982, J PATHOL, V138, P163, DOI 10.1002/path.1711380206; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; GOLDBERG H, 1988, BIOCHEM BIOPH RES CO, V152, P552, DOI 10.1016/S0006-291X(88)80073-1; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; NAITO M, 1989, CANCER RES, V49, P1452; NAITO M, 1988, J BIOL CHEM, V263, P11887; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; NAITO M, 1991, J CELL PHARM, V2, P263; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RYFFEL B, 1985, TRANSPLANT P, V17, P1430; SAFA AR, 1989, BIOCHEM BIOPH RES CO, V162, P1402, DOI 10.1016/0006-291X(89)90830-9; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; TWENTYMAN PR, 1988, BRIT J CANCER, V57, P254, DOI 10.1038/bjc.1988.55; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; UEDA K, 1992, J BIOL CHEM, V267, P24248	25	614	638	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6077	6080						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681059				2022-12-27	WOS:A1993KT36800004
J	RATHANASWAMI, P; HACHICHA, M; SADICK, M; SCHALL, TJ; MCCOLL, SR				RATHANASWAMI, P; HACHICHA, M; SADICK, M; SCHALL, TJ; MCCOLL, SR			EXPRESSION OF THE CYTOKINE RANTES IN HUMAN RHEUMATOID SYNOVIAL FIBROBLASTS - DIFFERENTIAL REGULATION OF RANTES AND INTERLEUKIN-8 GENES BY INFLAMMATORY CYTOKINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; ACTIVATING FACTOR MCAF; MESSENGER-RNA; RECOMBINANT INTERLEUKIN-1; LYMPHOCYTES-T; CELLS; IL-4; STIMULATION; CLONING	A chronic inflammatory disease may be characterized by an accumulation of activated leukocytes at the site of inflammation. Since the chemokine RANTES may play an active role in recruiting leukocytes into inflammatory sites, we investigated the ability of cultured human synovial fibroblasts isolated from patients suffering from rheumatoid arthritis to produce this chemokine and compared its regulation to that of the closely related chemokine gene, interleukin-8 (IL-8). In unstimulated synovial fibroblasts, the expression of mRNA for both chemokines was undetectable, but was increased in both a time- and dose-dependent manner upon stimulation with the monokines tumor necrosis factor alpha (TNFalpha) and interleukin-1beta (IL-1beta). Preincubation of the cells with cycloheximide ''superinduced'' the level of IL-8 mRNA stimulated by TNFalpha and IL-1beta and RANTES mRNA stimulated by IL-1beta, but decreased the expression of RANTES mRNA in response to TNFalpha. In addition, differential regulation of these genes was noted when synovial fibroblasts were stimulated with a combination of cytokines. IL-4 down-regulated and IFNgamma enhanced the TNFalpha- and IL-1beta-induced increase in RANTES mRNA, whereas the induction of IL-8 mRNA by TNFalpha or IL-1beta was inhibited by IFNgamma and augmented by IL-4. Moreover, a combination of TNFalpha and IL-1beta synergistically induced IL-8 mRNA expression, whereas under the same conditions, the level of expression of RANTES mRNA was less than that induced by TNFalpha alone. These observations were also reflected at the level of chemokine secretion. These studies demonstrate that by expressing the chemokines RANTES and IL-8, synovial fibroblasts may participate in the ongoing inflammatory process in rheumatoid arthritis. In addition, the observation that these chemokine genes are differentially regulated, depending upon the presence of different cytokines, indicates that the type of cellular infiltrate and the progress of the inflammatory disease is likely to depend on the relative levels of stimulatory and inhibitory cytokines.	UNIV LAVAL,CHUL,CTR RECH INFLAMMAT IMMUNOL & RHUMATOL,2705 BLVD LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; GENENTECH INC,S SAN FRANCISCO,CA 94080	Laval University; Roche Holding; Genentech			Rathanaswami, Palaniswami/AAL-3979-2021; Rathanaswami, Palaniswami/AAL-7192-2021					AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; AREND WP, 1989, J IMMUNOL, V143, P118; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BECKER S, 1990, CELL IMMUNOL, V129, P351, DOI 10.1016/0008-8749(90)90211-9; CASE JP, 1990, J IMMUNOL, V145, P3755; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DONNELLY RP, 1991, J IMMUNOL, V146, P3431; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GALY AHM, 1991, J IMMUNOL, V147, P3823; HACHICHA M, 1993, IN PRESS ARTHRITIS R; HAMILTON JA, 1992, BLOOD, V79, P1413; HAMILTON JA, 1981, J IMMUNOL, V126, P851; HART PH, 1989, P NATL ACAD SCI USA, V86, P3803, DOI 10.1073/pnas.86.10.3803; KOCH AE, 1991, J IMMUNOL, V147, P2187; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LAFYATIS R, 1989, J CLIN INVEST, V83, P1267, DOI 10.1172/JCI114011; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEIZER T, 1987, ARTHRITIS RHEUM, V30, P562, DOI 10.1002/art.1780300511; LIEZER T, 1990, BLOOD, V76, P1989; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; OBARU K, 1986, J BIOCHEM-TOKYO, V99, P885, DOI 10.1093/oxfordjournals.jbchem.a135549; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RUGGIERO V, 1987, J IMMUNOL, V138, P661; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL T, 1991, Arthritis and Rheumatism, V34, pS117; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHMID J, 1987, J IMMUNOL, V139, P250; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SICA A, 1990, IMMUNOLOGY, V69, P548; STANDIFORD TJ, 1990, J IMMUNOL, V145, P1435; STASHENKO P, 1987, J IMMUNOL, V138, P1464; TAN PLJ, 1990, J RHEUMATOL, V17, P1608; VILLIGER PM, 1992, J IMMUNOL, V149, P722; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; ZACHARIAE COC, 1990, J EXP MED, V171, P2177, DOI 10.1084/jem.171.6.2177	43	305	309	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5834	5839						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680648				2022-12-27	WOS:A1993KR82200072
J	BURG, DL; HARRISON, ML; GEAHLEN, RL				BURG, DL; HARRISON, ML; GEAHLEN, RL			CELL CYCLE-SPECIFIC ACTIVATION OF THE PTK72 PROTEIN-TYROSINE KINASE IN LYMPHOCYTES-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIGEN RECEPTOR; PHOSPHORYLATION; STIMULATION; ANTIIMMUNOGLOBULIN; PROLIFERATION; ASSOCIATION; PROTEOLYSIS	The engagement of cell-surface antigen receptors on B lymphocytes by anti-IgM antibodies leads to the rapid tyrosine phosphorylation and activation of the protein-tyrosine kinase, PTK72. High concentrations of anti-IgM, which promote cell cycle entry and progression through G1, result in a biphasic change in the state of tyrosine phosphorylation of PTK72. An initial, rapid increase is seen within 5 min, which slowly declines to the level found in resting cells over a period of 9 h. A second increase is then observed 18-30 h following the initial stimulation. Low concentrations of anti-IgM, which promote cell cycle entry but not progression through G1, result only in the initial, rapid phosphorylation. The polyclonal mitogens lipopolysaccharide and dextran sulfate, which stimulate both cell cycle entry and progression to late G1, result only in the second, late phase of tyrosine phosphorylation. This second phase of elevated tyrosine phosphorylation is cell cycle-dependent, as demonstrated by its appearance in cells blocked at G1/S and absence in cells blocked at G2/M. The increase in the tyrosine phosphorylation of PTK72 is accompanied by an increase in its activity with no change in its concentration. These data suggest a possible second role for PTK72 in the commitment of activated B cells to proliferation.	PURDUE UNIV,DEPT MED CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007532] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline; NIDDK NIH HHS [DK07532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEFRANCO AL, 1985, J IMMUNOL, V135, P87; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; LANE PJL, 1990, J IMMUNOL, V144, P3684; MELCHERS F, 1985, P NATL ACAD SCI USA, V82, P7681, DOI 10.1073/pnas.82.22.7681; SEVERSON CD, 1987, IMMUNOL LETT, V15, P291, DOI 10.1016/0165-2478(87)90130-1; WETZEL GD, 1984, J IMMUNOL, V133, P2327; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	16	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2304	2306						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679095				2022-12-27	WOS:A1993KK81500010
J	BARTHA, K; BRISSON, C; ARCHIPOFF, G; DELASALLE, C; LANZA, F; CAZENAVE, JP; BERETZ, A				BARTHA, K; BRISSON, C; ARCHIPOFF, G; DELASALLE, C; LANZA, F; CAZENAVE, JP; BERETZ, A			THROMBIN REGULATES TISSUE FACTOR AND THROMBOMODULIN MESSENGER-RNA LEVELS AND ACTIVITIES IN HUMAN SAPHENOUS-VEIN ENDOTHELIAL-CELLS BY DISTINCT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN PROTEIN-C; PROCOAGULANT ACTIVITY; BLOOD-COAGULATION; CHROMOSOME LOCALIZATION; PLASMINOGEN-ACTIVATOR; PHORBOL ESTER; CDNA SEQUENCE; INTERLEUKIN-1; GENE	The effects of thrombin, D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone (PPACK)-inhibited thrombin, and thrombin receptor agonist peptide, SFLLRNPNDKYEPF (SFLL, a portion of the receptor unmasked after thrombin cleavage), on the expression of tissue factor (TF) and thrombomodulin by human saphenous vein endothelial cells (HSVECs) in culture were studied. Unstimulated cells contained very low amounts of TF mRNA as measured by the reverse transcriptase-PCR method. Thrombin treatment increased TF mRNA to 8.0 +/- 1.9 (n = 3) times the control level. The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA. Thrombin caused a 14.5 +/- 1.5-fold (n = 5) increase in TF activity on the surface of HSVECs and a 20.5 +/- 1.4-fold (mean +/- S.D., n = 2) increase in the extracellular matrix. The thrombin-induced effects on TF synthesis could be fully reproduced by the thrombin receptor agonist peptide, SFLL, whereas PPACK-inhibited thrombin did not influence TF expression. Thrombin increased thrombomodulin mRNA to 190 +/- 39% (n = 5) of control levels, whereas PPACK-inhibited thrombin or SFLL did not influence thrombomodulin mRNA levels. In contrast, surface-bound thrombomodulin cofactor activity and thrombomodulin antigen in the cell lysates did not change over 24 h of incubation with thrombin. However, thrombin caused a 2-fold increase in thrombomodulin antigen released into the conditioned medium, and immunoelectron microscopy of HSVECs also demonstrated the presence of thrombomodulin vesicles close to the luminal cell surface in thrombin-treated cultures. The Western blot pattern thrombomodulin in the conditioned medium of untreated and thrombin-treated cells was found to be similar, and soluble thrombomodulin occurred mainly as fragments of the cell-associated form. We conclude that the transcriptional control by thrombin causes an increase in both TF and thrombomodulin mRNA. The increase in TF mRNA levels is also paralleled by an increase in surface expression, is dependent on the proteolytic activity of thrombin, and is mediated by the same receptor as the recently cloned thrombin receptor in platelets. Up-regulation of thrombomodulin mRNA levels by thrombin is distinct from this pathway and is associated with unchanged expression on the cell surface.	CTR REG TRANSFUS SANGUINE,INSERM,UNITE 311,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Cazenave, Jean-Pierre/AAE-2935-2019; Beretz, Alain/ABA-3589-2020; Lanza, Francois/H-9252-2016	Beretz, Alain/0000-0002-1479-1697; Lanza, Francois/0000-0002-5802-4748				AMIRAL J, 1991, THROMB HAEMOSTASIS, V65, P947; ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BARTHA K, 1991, J BIOL CHEM, V266, P792; BERETZ A, 1989, BIOCHEM J, V259, P35, DOI 10.1042/bj2590035; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; CHINGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294; COLUCCI M, 1983, J CLIN INVEST, V71, P1893, DOI 10.1172/JCI110945; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DITTMAN WA, 1989, P NATL ACAD SCI USA, V86, P7179, DOI 10.1073/pnas.86.18.7179; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1982, J BIOL CHEM, V257, P859; FREYSSINET JM, 1989, BIOCHEM J, V261, P341, DOI 10.1042/bj2610341; FREYSSINET JM, 1988, BIOCHEM J, V256, P501, DOI 10.1042/bj2560501; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; KEY NS, 1990, P NATL ACAD SCI USA, V87, P7095, DOI 10.1073/pnas.87.18.7095; KLEINSOYER C, 1986, THROMB HAEMOSTASIS, V56, P232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOSATA M, 1983, BLOOD, V62, P549; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARUYAMA I, 1985, J BIOL CHEM, V260, P5432; MAYNARD JR, 1977, BLOOD, V50, P387; NAWROTH PP, 1985, THROMB RES, V40, P677, DOI 10.1016/0049-3848(85)90305-6; NEMERSON Y, 1988, BLOOD, V71, P1; NIEMETZ J, 1977, BLOOD, V49, P947; O'Brien D P, 1989, Baillieres Clin Haematol, V2, P801, DOI 10.1016/S0950-3536(89)80047-2; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; SAGO H, 1992, THROMB HAEMOSTASIS, V67, P331; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5748; STERN DM, 1985, J EXP MED, V162, P1223, DOI 10.1084/jem.162.4.1223; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; TIJBURG PNM, 1991, J BIOL CHEM, V266, P12067; TOUGARD C, 1986, AM J ANAT, V175, P161, DOI 10.1002/aja.1001750206; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1989, BLOOD, V73, P968; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025	48	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					421	429						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678000				2022-12-27	WOS:A1993KE60300065
J	BRENNAN, KJ; HARDEMAN, EC				BRENNAN, KJ; HARDEMAN, EC			QUANTITATIVE-ANALYSIS OF THE HUMAN ALPHA-SKELETAL ACTIN GENE IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED EXPRESSION; MUSCLE-SPECIFIC EXPRESSION; CARDIAC ACTIN; STRIATED-MUSCLE; DNA-SEQUENCES; MESSENGER-RNA; MOUSE; TRANSCRIPTION; DIFFERENTIATION; PROMOTER	Three aspects of the regulation of the human alpha-skeletal actin gene are examined in this study by quantitative analysis of transgenic tissues: level of expression, tissue specificity, and developmental regulation. Previous in vitro and in vivo studies analyzing the 5' end of the gene have indicated that regulation of tissue-specific expression is promoter based. Transgenic mice were produced carrying either a 9.5-kilobase pair (kb) human alpha-skeletal actin gene fragment or a deletion construct with 2.2-kb of 5' sequences of human alpha-skeletal skeletal actin linked to the chloramphenicol acetyl-transferase reporter gene. We found that the 9.5-kb transgene was capable of expression in adult skeletal muscle at a level equivalent to that of the endogenous gene in a non-transgenic mouse. The deletion construct was also capable of high-level expression. Both transgenes were expressed in a striated muscle-specific manner and were correctly regulated during development. We conclude that these three parameters of regulation of the human alpha-skeletal actin gene are mediated by sequences within the region -2000 to +239 of the promoter.	CHILDRENS MED RES INST,MUSCLE DEV UNIT,LOCKED BAG 23,WENTWORTHVILLE,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Hardeman, Edna C/F-8872-2012	Hardeman, Edna/0000-0003-1649-7712				AESADI G, 1991, NATURE, V352, P815; ALONSO S, 1990, J MOL BIOL, V211, P727, DOI 10.1016/0022-2836(90)90073-U; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; BUCKINGHAM ME, 1983, EUKARYOTIC GENES THE, P365; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLIE ESR, 1992, CELL GROWTH DIFFER, V3, P31; COX RD, 1992, DEV BIOL, V149, P228, DOI 10.1016/0012-1606(92)90279-P; COX RD, 1990, DIFFERENTIATION, V43, P183, DOI 10.1111/j.1432-0436.1990.tb00445.x; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; GARNER I, 1989, DEV BIOL, V134, P236, DOI 10.1016/0012-1606(89)90093-6; GRICHNIK JM, 1986, NUCLEIC ACIDS RES, V14, P1683, DOI 10.1093/nar/14.4.1683; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; HALLAUER PL, 1988, MOL CELL BIOL, V8, P5072, DOI 10.1128/MCB.8.12.5072; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; HOGAN B, 1986, MANIPULATING MOUSE E; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MELLOUL D, 1984, EMBO J, V3, P983, DOI 10.1002/j.1460-2075.1984.tb01917.x; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; MUSCAT GEO, 1991, MOL ENDOCRINOL, V5, P802, DOI 10.1210/mend-5-6-802; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; Sambrook J, 1989, MOL CLONING LABORATO; SEILERTUYNS A, 1984, P NATL ACAD SCI-BIOL, V81, P2980, DOI 10.1073/pnas.81.10.2980; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; WALSH K, 1988, MOL CELL BIOL, V8, P1800, DOI 10.1128/MCB.8.4.1800; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0	44	147	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					719	725						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678010				2022-12-27	WOS:A1993KE60300108
J	MINNING, DM; KLOEK, AP; YANG, J; MATHEWS, FS; GOLDBERG, DE				MINNING, DM; KLOEK, AP; YANG, J; MATHEWS, FS; GOLDBERG, DE			SUBUNIT INTERACTIONS IN ASCARIS HEMOGLOBIN OCTAMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUUM; SEQUENCE	The oxygen-avid, perienteric hemoglobin of Ascaris is a homooctamer. Each subunit contains two tandem globin domains that are highly homologous with the exception of a charged COOH-terminal extension, In solution, recombinant domain one (Hi) exists as a monomer, whereas recombinant domain two with the COOH-terminal tail (D2) is primarily an octamer, To examine the role of the COOH-terminal extension in Ascaris hemoglobin multimer formation, we attached the tail to the monomeric, heme-containing proteins, myoglobin and D1; neither construct was capable of multimer formation. Additionally, we removed the tail from both full-length Ascaris hemoglobin and D2. This substantially decreased, but did not eliminate, multimerization, We further characterized subunit interactions by disrupting full-length hemoglobin multimers with the chaotropic salt, NaSCN, which yielded intermediate oligomers, In solution, D2 demonstrated a greater propensity to dissociate than full-length hemoglobin, indicating that D1 contributes to octamer stability, D1 formed a weak dimer in its crystal; thus, we analyzed interactions along the subunit interface, Hydrogen bonds as well as hydrophobic and electrostatic forces appeared to contribute to dimer formation, Amino acid substitutions along this interface in D2 are predicted to enhance subunit interactions for that domain, Our studies reveal that the COOH-terminal tail is necessary, but not sufficient, for efficient octamer formation. Other regions, possibly within the E- and F-helices and AB loops of both domains, appear to be important for Ascaris hemoglobin octamer formation.	WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	12	5	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22248	22253		10.1074/jbc.270.38.22248	http://dx.doi.org/10.1074/jbc.270.38.22248			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673204	hybrid			2022-12-27	WOS:A1995RW31400030
J	SUGUMARAN, G; KATSMAN, M; DRAKE, RR				SUGUMARAN, G; KATSMAN, M; DRAKE, RR			PURIFICATION, PHOTOAFFINITY-LABELING, AND CHARACTERIZATION OF A SINGLE ENZYME FOR 6-SULFATION OF BOTH CHONDROITIN SULFATE AND KERATAN SULFATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN SULFOTRANSFERASE ACTIVITIES; CHICK-EMBRYO CHONDROCYTES; MOUSE MASTOCYTOMA-CELLS; ANIMAL SERA; 6-SULFOTRANSFERASE; BIOSYNTHESIS; CARTILAGE; 4-SULFATE; 4-SULFOTRANSFERASE; PROTEOCHONDROITIN	A soluble sulfotransferase that could 6-sulfate both chondroitin sulfate and corneal keratan sulfate was purified 27,500-fold using a sequence of affinity chromatographic steps with heparin-Sepharose, wheat germ agglutinin-agarose, and 3',5'-ADP-agarose. The essentially pure enzyme had a specific activity 40 times greater than the most purified chondroitin 6-sulfotransferase previously reported and exhibited a single sharp Coomassie Blue-stained and a heavy silver-stained protein band of 75 kDa on SDS-polyacrylamide gel electrophoresis, Chromatography of the purified enzyme on Sephacryl demonstrated a size of 150 kDa, which indicated that the native enzyme exists as a dimer, In addition to B-sulfation of nonsulfated GalNAc, the purified serum enzyme had the ability to sulfate GalNAc 4-sulfate residues to give GalNAc 4,6-disulfate residues, The purified enzyme exhibited a K-m of 40 mu M for adenosine 3'-phosphate 5'-phosphosulfate when either chondroitin sulfate or corneal keratan sulfate were used as the accepters. Use of both chondroitin sulfate and keratan sulfate in the same experiment demonstrated mutual competition, establishing that the sulfation of these substrates is by the same enzyme, Photoaffinity labeling of the purified enzyme with 2-azidoadenosine 3',5'-di[5'-P-32]phosphate occurred only with the 75-kDa protein, confirming that this is the chondroitin 6-sulfotransferase/keratan sulfotransferase.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; UNIV ARKANSAS MED SCI HOSP, DEPT BIOCHEM & MOLEC BIOL, LITTLE ROCK, AR 72205 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Arkansas System; University of Arkansas Medical Sciences	SUGUMARAN, G (corresponding author), EDITH NOURSE ROGERS MEM VET ADM HOSP, BLDG 70, 200 SPRINGS RD, BEDFORD, MA 01730 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041649] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41649] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRANDAN E, 1988, J BIOL CHEM, V263, P2417; DELUCA S, 1968, J BIOL CHEM, V243, P2725; FALTYNEK CR, 1978, J BIOL CHEM, V253, P7646; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1971, J BIOL CHEM, V246, P7357; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1982, BIOCHIM BIOPHYS ACTA, V717, P414, DOI 10.1016/0304-4165(82)90282-3; HABUCHI O, 1985, J BIOL CHEM, V260, P3102; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; INOUE H, 1986, J BIOL CHEM, V261, P4470; INOUE H, 1986, J BIOL CHEM, V261, P4460; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P239, DOI 10.1515/bchm2.1983.364.1.239; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; MALMSTRO.A, 1971, EUR J BIOCHEM, V18, P431, DOI 10.1111/j.1432-1033.1971.tb01260.x; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MOMBURG M, 1972, H-S Z PHYSIOL CHEM, V353, P1351, DOI 10.1515/bchm2.1972.353.2.1351; MOURAO PAS, 1983, MOL CELL BIOCHEM, V60, P49; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; OTTERNESS DM, 1991, MOL PHARMACOL, V39, P34; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; RUTER ER, 1984, J BIOL CHEM, V259, P1771; SAITO H, 1968, J BIOL CHEM, V243, P1536; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SILBERT JE, 1980, BIOCHEM J, V190, P307, DOI 10.1042/bj1900307; SUGAHARA K, 1989, J BIOCHEM-TOKYO, V106, P910, DOI 10.1093/oxfordjournals.jbchem.a122951; SUGAHARA K, 1987, ANAL BIOCHEM, V166, P404, DOI 10.1016/0003-2697(87)90591-4; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1986, J BIOL CHEM, V261, P2659; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; SUGUMARAN G, 1989, METHOD ENZYMOL, V179, P422; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; WLAD H, 1994, J BIOL CHEM, V269, P24538	36	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22483	22487		10.1074/jbc.270.38.22483	http://dx.doi.org/10.1074/jbc.270.38.22483			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673238	hybrid			2022-12-27	WOS:A1995RW31400067
J	SCHWARZMANN, G; HOFMANN, P; PUTZ, T; ALBRECHT, B				SCHWARZMANN, G; HOFMANN, P; PUTZ, T; ALBRECHT, B			DEMONSTRATION OF DIRECT GLYCOSYLATION OF NONDEGRADABLE GLUCOSYLCERAMIDE ANALOGS IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; INTRACELLULAR-TRANSPORT; ACTIVATOR PROTEIN; HUMAN-FIBROBLASTS; PURIFICATION; GLYCOSPHINGOLIPIDS; GLUCOCEREBROSIDASE; GANGLIOSIDES; BIOSYNTHESIS; DEGRADATION	After uptake by various cells (human skin fibroblasts, rat neuroblastoma B 104, human neuroblastoma SHSY5Y, murine cerebellar cells), a radioactive and a fluorescent analog of a nondegradable glucosylceramide with sulfur in the glycosidic link were glycosylated to a cell-specific pattern of glycolipid analogs, These results, for the first time, show that a glucosylceramide analog can be conveyed from the plasma membrane of cultured cells to those Golgi compartments that function in the early glycosylation steps of glycolipids, This observation is further confirmed by the fact that the cationic ionophore monensin, known to impede membrane flow from proximal to distal Golgi cisternae, inhibited the formation of complex ganglioside analogs but not those of lactosylceramide, sialyl lactosylceramide (G(M3)), and disialyl lactosylceramide (G(D3)).			SCHWARZMANN, G (corresponding author), UNIV BONN,INST ORGAN CHEM & BIOCHEM,GERHARD DOMAGK STR 1,D-53121 BONN,GERMANY.							AERTS JMFG, 1985, EUR J BIOCHEM, V150, P565, DOI 10.1111/j.1432-1033.1985.tb09058.x; ALBRECHT B, 1995, IN PRESS CARBOHYDR R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; DEAN KJ, 1979, J BIOL CHEM, V254, P9994; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; FENDERSON BA, 1985, J EXP MED, V160, P1591; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hinsberg O, 1908, BER DTSCH CHEM GES, V41, P2836, DOI 10.1002/cber.190804102232; KAARIAINEN L, 1980, J CELL BIOL, V87, P783, DOI 10.1083/jcb.87.3.783; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; MILLERPRODRAZA H, 1984, BIOCHIM BIOPHYS ACTA, V804, P44, DOI 10.1016/0167-4889(84)90097-1; OLAH GA, 1979, SYNTHESIS-STUTTGART, P61; REBHAN M, 1994, NEUROREPORT, V5, P941, DOI 10.1097/00001756-199404000-00022; SAITO M, 1985, J BIOL CHEM, V260, P2295; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; VANWEELY S, 1993, BIOCHIM BIOPHYS ACTA, V1181, P55, DOI 10.1016/0925-4439(93)90090-N; WEITZ G, 1983, H-S Z PHYSIOL CHEM, V364, P863, DOI 10.1515/bchm2.1983.364.2.863; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; ZSCHOCHE A, 1994, EUR J BIOCHEM, V222, P83, DOI 10.1111/j.1432-1033.1994.tb18844.x	28	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21271	21276		10.1074/jbc.270.36.21271	http://dx.doi.org/10.1074/jbc.270.36.21271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673162	hybrid			2022-12-27	WOS:A1995RU05400062
J	VANDERGOOT, FG; AUSIO, J; WONG, KR; PATTUS, F; BUCKLEY, JT				VANDERGOOT, FG; AUSIO, J; WONG, KR; PATTUS, F; BUCKLEY, JT			DIMERIZATION STABILIZES THE PORE-FORMING TOXIN AEROLYSIN IN SOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-HYDROPHILA; MEMBRANE-INSERTION; COLICIN-A; PROTEIN; CHANNEL; OLIGOMERIZATION; IDENTIFICATION; SEDIMENTATION; MUTAGENESIS; RECEPTOR	Aerolysin is a channel-forming protein secreted as a protoxin by Aeromonas hydrophila. Analytical centrifugation measurements showed that proaerolysin is a dimer in solution, and this was confirmed by chemical cross-linking with dimethyl suberimidate. Dissociation of proaerolysin with low concentrations of SDS resulted in the loss of tertiary structure, assessed by near ultraviolet circular dichroism. This was accompanied by an increase in the protein's ability to bind the hydrophobic dye 1-anilino-8-naphthalene sulfonate, as well as by increased sensitivity to proteolytic degradation. However, the monomer was not fully unfolded by the detergent, as the tryptophans remained in a hydrophobic environment, and the secondary structure measured by far ultraviolet circular dichroism did not seem to be affected. Aerolysin, the active form of the protein, was also shown to be a dimer, and its stability was found to be no different from the stability of the protoxin dimer. Substituting tryptophan 371 or tryptophan 373 with leucine greatly reduced the stability of dimeric proaerolysin. These substitutions are known to increase the protein's ability to oligomerize, supporting the conclusion that dimer dissociation is necessary for oligomerization to occur.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,BOX 3055,VICTORIA V8W 3P6,BC,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Victoria; European Molecular Biology Laboratory (EMBL)			van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X				AUSIO J, 1992, BIOPHYS J, V61, P1656, DOI 10.1016/S0006-3495(92)81969-0; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; BUCKLEY JT, 1992, FEBS LETT, V307, P30, DOI 10.1016/0014-5793(92)80896-O; CHAKRABORTY T, 1987, INFECT IMMUN, V55, P2274, DOI 10.1128/IAI.55.9.2274-2280.1987; Creighton TE, 1991, CURR OPIN STRUC BIOL, V1, P5, DOI 10.1016/0959-440X(91)90004-D; DIRR HW, 1991, BIOCHEM BIOPH RES CO, V180, P294, DOI 10.1016/S0006-291X(05)81291-4; EDELSTEIN SJ, 1967, J BIOL CHEM, V242, P306; EISENBERG H, 1990, EUR J BIOCHEM, V187, P7, DOI 10.1111/j.1432-1033.1990.tb15272.x; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HASCHEMEYER R, 1973, PROTEINS, P206; HOWARD SP, 1985, J BACTERIOL, V161, P1118, DOI 10.1128/JB.161.3.1118-1124.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; JANDA JM, 1988, REV INFECT DIS, V10, P980; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; KHARDORI N, 1988, ANNU REV MICROBIOL, V42, P395, DOI 10.1146/annurev.mi.42.100188.002143; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; Ptitsyn Oleg B., 1992, P243; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; TANFORD C, 1961, PHYSICAL CHEM MACROM, P327; TUCKER AD, 1990, J MOL BIOL, V212, P561, DOI 10.1016/0022-2836(90)90222-8; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WONG KR, 1991, J BIOL CHEM, V266, P14450; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	33	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18272	18279						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688743				2022-12-27	WOS:A1993LT74300092
J	SANDER, P; LANGERT, W; MUELLER, K				SANDER, P; LANGERT, W; MUELLER, K			MECHANISMS OF UPSTREAM ACTIVATION OF THE RRND PROMOTER P(1) OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; RATE-DEPENDENT REGULATION; PROTEIN; INITIATION; INVITRO; FIS; POLYMERASE; OPERONS; INVIVO; REGION	The rrn promoter regions of Escherichia coli contain a stretch of DNA, rich in A(n) and T(n) homopolymer sequences, which is located upstream of the tandem promoters P1 and P2. We have studied the effects of the upstream sequence of the rrnD operon on promoter function, using deletion variants for in vitro transcription. The presence of the upstream activating sequence (UAS) was found to increase P1 promoter strength without influencing P2. Two modes of P1 activation could be distinguished: a stimulation of P1 depending on the interaction of the factor of inversion stimulation (FIS) with the UAS (within the deletion boundaries of -50 and -112) and second, a factor-independent activation requiring the proximal part of the UAS (within the boundaries of -50 and -89). Both modes of activation were previously observed in the case of the rrnB operon and were ascribed to increased constants of RNA polymerase binding to P1 (Leirmo, S., and Gourse, R. L. (1991) J. Mol. Biol. 220, 555-568; Zacharias, M., Theissen, G., Bradaczek, C., and Wagner, R. (1991) Biochimie 73, 699-712). Our results show, however, that the mechanisms of upstream activation may vary with the reaction conditions. In a complex transcription system, originally designed for the use of cell extracts, FIS enhances first-order reactions that convert binary (open) complexes to transcribing complexes. Initiated complexes are stabilized by FIS. The factor-independent mode of P1 activation involves influences of the UAS on complex isomerizations as well as on binary complex formation. The results show that low molecular weight components of the complex transcription system change the function of the RNA polymerase at the rrn promoters (not at the reference promoter P(tac)), so that the conversion of open to transcribing P1-complexes becomes dependent on the UAS and FIS.	INST ALLGEMEINE ZOOL & GENET,SCHLOSSPL 5,W-4400 MUNSTER,GERMANY				Sander, Peter/D-2548-2009	Sander, Peter/0000-0003-1581-0682				Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CICHON C, 1990, THESIS WESTF WILHELM; CONDON C, 1992, EMBO J, V11, P4175, DOI 10.1002/j.1460-2075.1992.tb05511.x; ESCHERT H, 1992, THESIS WESTF WILHELM; GAAL T, 1989, J BACTERIOL, V171, P4852, DOI 10.1128/jb.171.9.4852-4861.1989; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HUBNER P, 1989, EMBO J, V8, P577, DOI 10.1002/j.1460-2075.1989.tb03412.x; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; JOSAITIS CA, 1990, BIOCHIM BIOPHYS ACTA, V1050, P312; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; LANGERT W, 1991, J BIOL CHEM, V266, P21608; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OZAKI M, 1992, NUCLEIC ACIDS RES, V20, P257, DOI 10.1093/nar/20.2.257; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; PRATT JM, 1984, TRANSCRIPTION TRANSL, P179; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; Sambrook J, 1989, MOL CLONING LABORATO; SANDER P, 1992, THESIS WESTF WILHELM; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SCHAFER R, 1973, EUR J BIOCHEM, V33, P207, DOI 10.1111/j.1432-1033.1973.tb02671.x; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; VERBEEK H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P302, DOI 10.1016/0167-4781(90)90185-5; VERBEEK H, 1992, NUCLEIC ACIDS RES, V20, P4077, DOI 10.1093/nar/20.15.4077; YOUNG RA, 1979, CELL, V17, P225, DOI 10.1016/0092-8674(79)90310-6; ZACHARIAS M, 1991, BIOCHIMIE, V73, P699, DOI 10.1016/0300-9084(91)90050-B	35	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					16907	16916						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688719				2022-12-27	WOS:A1993LQ98800010
J	THIERINGER, R; RAETZ, CRH				THIERINGER, R; RAETZ, CRH			PEROXISOME-DEFICIENT CHINESE-HAMSTER OVARY CELLS WITH POINT MUTATIONS IN PEROXISOME ASSEMBLY FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION ENZYMES; ZELLWEGER SYNDROME; TARGETING SIGNAL; MEMBRANE-PROTEIN; BINDING PROTEIN; BIOGENESIS; BIOSYNTHESIS; GLYOXYSOMES; GLYCOSOMES	Chinese hamster ovary (CHO) mutant cells deficient in peroxisome biogenesis regain peroxisomes after transfection with a cDNA coding for peroxisome assembly factor (PAF)-1 from rat liver. Reconstitution of the transfected mutant cells with wild-type cytoplasm was not required, demonstrating that expression of the PAF-1 gene alone was sufficient for the restoration of peroxisome biogenesis. Plasmalogen biosynthesis in the transfected mutants was also restored to approximately wild-type levels. The nucleotide sequence of the cDNA encoding the open reading frame for PAF-1 from CHO-K1 cells was determined. This allowed us to identify point mutations of PAF-1 in two peroxisomal mutant cell lines. The mutation in ZR-78 cells changed a cysteine to a tyrosine codon in a region located at the carboxyl terminus of the protein, which resembles the zinc finger motif of DNA-binding proteins. A point mutation in the PAF-1 gene of ZR-82 leads to premature termination.			THIERINGER, R (corresponding author), MERCK SHARP & DOHME LTD,POB 2000,RAHWAY,NJ 07065, USA.							ALLEN LAH, 1992, J BIOL CHEM, V267, P13191; ALLEN LAH, 1989, P NATL ACAD SCI USA, V86, P7012, DOI 10.1073/pnas.86.18.7012; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; BORST P, 1986, BIOCHIM BIOPHYS ACTA, V866, P179, DOI 10.1016/0167-4781(86)90044-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HEIKOOP JC, 1992, EUR J CELL BIOL, V57, P165; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MORAND OH, 1988, J BIOL CHEM, V263, P11597; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHRAM AW, 1986, P NATL ACAD SCI USA, V83, P6156, DOI 10.1073/pnas.83.16.6156; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; ZOELLER RA, 1986, P NATL ACAD SCI USA, V83, P5170, DOI 10.1073/pnas.83.14.5170; ZOELLER RA, 1989, J BIOL CHEM, V264, P21872; [No title captured]	34	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12631	12636						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685346				2022-12-27	WOS:A1993LG65800061
J	CHITNIS, VP; XU, Q; YU, L; GOLBECK, JH; NAKAMOTO, H; XIE, DL; CHITNIS, PR				CHITNIS, VP; XU, Q; YU, L; GOLBECK, JH; NAKAMOTO, H; XIE, DL; CHITNIS, PR			TARGETED INACTIVATION OF THE GENE PSAL ENCODING A SUBUNIT OF PHOTOSYSTEM-I OF THE CYANOBACTERIUM SYNECHOCYSTIS SP PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; SP PCC-6803; MOLECULAR-CLONING; CORE PROTEIN; IDENTIFICATION; PURIFICATION; CHLOROPLASTS; POLYPEPTIDE; MUTAGENESIS; FERREDOXIN	Photosystem I is a multisubunit pigment-protein complex that functions as a light-driven plastocyanin-ferredoxin oxidoreductase in thylakoid membranes of cyanobacteria and higher plants. A 16-kDa protein subunit of photosystem I complex was isolated from the cyanobacterium Synechocystis sp. PCC 6803. The sequence of its NH2-terminal residues was determined and a corresponding oligonucleotide probe was used to isolate the gene encoding this subunit. The gene, designated as psaL, codes for a protein of 16,605 Da. The deduced amino acid sequence is homologous to the subunit PsaL of barley photosystem I. There are two conserved hydrophobic regions in the subunit PsaL that may cross or interact with thylakoid membranes. The gene psaL exists as a single copy in the genome and is expressed as a monocistronic RNA. Stable mutant strains in which the gene psaL was interrupted by a gene conferring resistance to chloramphenicol, were generated by targeted mutagenesis. Growth and photosynthetic characteristics of a selected mutant strain under photoautotrophic conditions were similar to those of the wild type, suggesting that the function of PsaL is dispensable for photosynthesis in Synechocystis sp. PCC 6803. Western analysis and subunit composition of purified photosystem I revealed that the mutant strain contained other subunits of photosystem I in thylakoid membranes and in the assembled complex. When photosystem II activity was inhibited and glucose was supplied in the medium, mutant strains grew faster than the wild type. Under these conditions of growth, re-reduction of P700 in the mutant cells, but not in the wild type cells, showed a component with an uncharacteristically rapid half-time.	KANSAS STATE UNIV AGR & APPL SCI, DEPT BIOL, MANHATTAN, KS 66506 USA; UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA; ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Kansas State University; University of Nebraska System; University of Nebraska Lincoln; Roche Holding			Nakamoto, Hitoshi/H-5315-2012					ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; ANDERSON SL, 1991, PLANT MOL BIOL, V16, P487, DOI 10.1007/BF00023416; BENGIS C, 1975, J BIOL CHEM, V250, P2783; BENGIS C, 1977, J BIOL CHEM, V252, P4564; CHITNIS PR, 1991, J BIOL CHEM, V266, P20146; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1992, PLANT PHYSIOL, V99, P239, DOI 10.1104/pp.99.1.239; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P178; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HENRY RL, 1992, PLANT PHYSIOL BIOCH, V30, P357; KOIKE H, 1989, FEBS LETT, V253, P257, DOI 10.1016/0014-5793(89)80971-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAXWELL PC, 1976, BIOCHEMISTRY-US, V15, P3975, DOI 10.1021/bi00663a011; OKKELS JS, 1991, J BIOL CHEM, V266, P6767; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; REILLY P, 1988, J BIOL CHEM, V263, P17658; RHIEL E, 1988, LIGHT ENERGY TRANSDU, P320; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMART LB, 1991, PLANT MOL BIOL, V17, P959, DOI 10.1007/BF00037136; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; TAL M, 1985, J BIOL CHEM, V260, P9976; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WYNN RM, 1988, FEBS LETT, V229, P293, DOI 10.1016/0014-5793(88)81143-8; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; WYNN RM, 1989, BIOCHEMISTRY-US, V28, P5554, DOI 10.1021/bi00439a032; YU L, 1993, CURRENT RES PHOTOSYN; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1992, PLANT PHYSIOL, V99, P901, DOI 10.1104/pp.99.3.901; ZILBER AL, 1990, CURRENT RES PHOTOSYN, P575	39	76	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11678	11684						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685019				2022-12-27	WOS:A1993LF28400035
J	KWATRA, MM; SCHWINN, DA; SCHREURS, J; BLANK, JL; KIM, CM; BENOVIC, JL; KRAUSE, JE; CARON, MG; LEFKOWITZ, RJ				KWATRA, MM; SCHWINN, DA; SCHREURS, J; BLANK, JL; KIM, CM; BENOVIC, JL; KRAUSE, JE; CARON, MG; LEFKOWITZ, RJ			THE SUBSTANCE-P RECEPTOR, WHICH COUPLES TO GQ/11, IS A SUBSTRATE OF BETA-ADRENERGIC-RECEPTOR KINASE-1 AND KINASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MAMMALIAN BETA-2-ADRENERGIC RECEPTOR; ALPHA-SUBUNITS; BINDING-PROTEIN; PURIFICATION; PHOSPHORYLATION; IDENTIFICATION; ARRESTIN; AFFINITY; FAMILY; GTP	The agonist-occupied forms of several G-protein-coupled receptors that modulate the activity of adenylylcyclase via G(s) (e.g. beta2-adrenergic) or G(i) (e.g. alpha2-adrenergic and cardiac muscarinic) are phosphorylated by beta-adrenergic receptor kinases (betaARK 1 and betaARK 2). BetaARK-catalyzed phosphorylation of these receptors appears to correlate with their agonist-induced desensitization. The possibility that betaARK isozymes may also be involved in the desensitization of other G-protein-coupled receptors such as those mediating phosphoinositide (PI) hydrolysis was tested by determining the phosphorylation of the substance P receptor (SPR), which is coupled to PI hydrolysis in numerous tissues. Rat SPR was expressed in Sf9 cells, partially purified, and reconstituted in phospholipid vesicles. The reconstituted SPR bound the SPR agonist substance P, I-125-labeled with Bolton-Hunter reagent, with low affinity. However, addition of purified Gq/11 to the reconstituted SPR resulted in the conversion of all the receptors to a high affinity state, suggesting that SPR couples to Gq/11. Phosphorylation of the reconstituted SPR with purified betaARK 1 or 2 in the absence and presence of substance P (SP) was then studied. In the presence of 100 muM SP, both kinases promoted phosphorylation of the receptor to a stoichiometry of 9 +/- 2 mol of phosphate/mol of receptor. However, no phosphorylation of the receptor could be detected in the absence of agonist. Agonist-induced phosphorylation of the receptor was blocked by coincubation with the SPR antagonist spantide. These results show that. BetaARK isozymes may regulate the function both adenylylcyclase as well as PI-coupled receptors, and suggest a role for betaARK isozymes in SPR signal transduction.	DUKE UNIV,MED CTR,DEPT ANESTHESIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED RES INST,DURHAM,NC 27710; CHIRON CORP,EMERYVILLE,CA 94608; VANDERBILT UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Duke University; Duke University; Duke University; Novartis; Howard Hughes Medical Institute; Vanderbilt University; Jefferson University; Washington University (WUSTL)	KWATRA, MM (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3821,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021; Kwatra, Madan/ABD-2008-2020	Schwinn, Debra/0000-0002-9696-5231	NHLBI NIH HHS [4R37-HL 16037, HL 02490] Funding Source: Medline; NINDS NIH HHS [NS 29343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002490, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MACDONALD SG, 1989, J NEUROCHEM, V53, P264, DOI 10.1111/j.1471-4159.1989.tb07323.x; MORISHIMA Y, 1989, J NEUROCHEM, V53, P1428, DOI 10.1111/j.1471-4159.1989.tb08534.x; NAKATA Y, 1988, J NEUROCHEM, V50, P522, DOI 10.1111/j.1471-4159.1988.tb02942.x; PANG IH, 1990, J BIOL CHEM, V265, P18707; PUTNEY JW, 1991, ANN NY ACAD SCI, V632, P94, DOI 10.1111/j.1749-6632.1991.tb33097.x; REILANDER H, 1991, FEBS LETT, V282, P441, DOI 10.1016/0014-5793(91)80532-8; SEGAWA T, 1991, COMP BIOCH PHYSL C, V98, P146; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; VEENMAN CL, 1992, NEUR ABSTR, V18, P1165; WEBB N R, 1990, Technique (Philadelphia), V2, P173; YAKOTA Y, 1989, J BIOL CHEM, V264, P17649	30	192	192	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9161	9164						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683643				2022-12-27	WOS:A1993LA68900002
J	DAGA, A; MICOL, V; HESS, D; AEBERSOLD, R; ATTARDI, G				DAGA, A; MICOL, V; HESS, D; AEBERSOLD, R; ATTARDI, G			MOLECULAR CHARACTERIZATION OF THE TRANSCRIPTION TERMINATION FACTOR FROM HUMAN MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNALEU(UUR) GENE; SODIUM DODECYL-SULFATE; STROKE-LIKE EPISODES; RIBOSOMAL-RNA; INVITRO TRANSCRIPTION; GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; LACTIC-ACIDOSIS; MELAS SUBGROUP; POINT MUTATION	The transcription termination factor (mTERF), which plays a central role in the control of mitochondrial rRNA and mRNA synthesis in mammalian mitochondria, has been previously identified and purified by DNA affinity chromatography from a human mitochondrial lysate (Kruse, B., Narasimhan, N., and Attardi, G. (1989) Cell 58, 391-397). In the present work, this factor has been characterized as to its protein composition and the activities of the protein components. Three polypeptides, two of approximately 34-kDa molecular mass and one of approximately 31 kDa, were shown to be associated with the specific DNA binding and footprinting activity of the factor, with the 31-kDa component having a much lower affinity for the recognition sequence than the 34-kDa components. On the other hand, the transcription termination activity, as assayed in an in vitro system, was found to be associated exclusively with the two 34-kDa polypeptides. Mass spectroscopic analysis of tryptic peptides derived from highly purified polypeptides indicated that all three polypeptides share regions with common sequences. The evidence obtained suggests that differential phosphorylation is not responsible for the difference in electrophoretic mobility of the three polypeptides.			DAGA, A (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Micol, Vicente/K-6841-2014; daga, andrea/J-1865-2018	daga, andrea/0000-0001-8935-5489; Micol, Vicente/0000-0001-8089-0696	NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; CANTATORE P, 1980, NUCLEIC ACIDS RES, V8, P2605, DOI 10.1093/nar/8.12.2605; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CHRISTIANSON TW, 1988, MOL CELL BIOL, V8, P4502, DOI 10.1128/MCB.8.10.4502; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GAINES G, 1984, J MOL BIOL, V172, P451, DOI 10.1016/S0022-2836(84)80017-0; GAINES G, 1987, J BIOL CHEM, V262, P1907; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; MAHURAN D, 1983, ANAL BIOCHEM, V129, P513, DOI 10.1016/0003-2697(83)90585-7; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9; MONTOYA J, 1982, P NATL ACAD SCI USA, V79, P7179; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NARASIMHAN N, 1987, P NATL ACAD SCI USA, V84, P4078, DOI 10.1073/pnas.84.12.4078; SHUEY DJ, 1985, J BIOL CHEM, V260, P1952; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; YOZA BK, 1984, J BIOL CHEM, V259, P3909	27	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8123	8130						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681833				2022-12-27	WOS:A1993KW97900077
J	LAVAN, BE; LIENHARD, GE				LAVAN, BE; LIENHARD, GE			THE INSULIN-ELICITED 60-KDA PHOSPHOTYROSINE PROTEIN IN RAT ADIPOCYTES IS ASSOCIATED WITH PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIGNAL TRANSDUCTION; ENDOGENOUS SUBSTRATE; SEQUENCE-ANALYSIS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PURIFICATION; PI3-KINASE; TRANSPORT; LIPOLYSIS	Insulin stimulates the tyrosine phosphorylation of a 60-kDa protein (pp60) in rat adipocytes. After insulin treatment of these cells, pp60, as well as the 160-kDa insulin receptor substrate-1 (IRS-1), were found to be associated with the enzyme phosphatidylinositol 3-kinase (PtdIns-3-kinase) in separate complexes. By contrast, pp60 was not detected in insulin-treated mouse 3T3-L1 adipocytes, which contain abundant IRS-1.PtdIns-3-kinase complex. The pp60.PtdIns 3-kinase complex was located in both the soluble and membrane fractions of the rat adipocytes. Fusion proteins containing the isolated src homology 2 domains from the 85-kDa subunit of PtdIns-3-kinase bound to pp60 in lysates of insulin-treated rat adipocytes. This finding indicates that the most likely mode of association of pp60 with PtdIns-3-kinase is through binding of phosphotyrosine residues in pp60 to these domains. By immunoaffinity chromatography on a monoclonal antibody against phosphotyrosine, pp60 was purified in high percentage yield from insulin-stimulated rat adipocytes, but the low amount of the protein obtained (about 3 ng from the adipocytes of one rat) precluded sequence analysis.	DARTMOUTH COLL,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College					NIDDK NIH HHS [DK 42816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABLER A, 1992, J BIOL CHEM, V267, P3946; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER JA, 1989, PEPTIDES PROTEIN PHO, P85; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EZAKI O, 1989, J BIOL CHEM, V264, P16118; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIORGETTI S, 1992, EUR J BIOCHEM, V207, P599; GIORGINO F, 1992, ENDOCRINOLOGY, V130, P1433, DOI 10.1210/en.130.3.1433; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; KASAHARA T, 1990, BIOCHIM BIOPHYS ACTA, V1054, P89, DOI 10.1016/0167-4889(90)90209-V; KASUGA M, 1990, DIABETES CARE, V13, P317, DOI 10.2337/diacare.13.3.317; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1992, DIABETES S1, V41, pA167; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; MOONEY RA, 1992, ENDOCRINOLOGY, V130, P1533, DOI 10.1210/en.130.3.1533; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OKAMOTO M, 1991, DIABETES, V40, P66, DOI 10.2337/diabetes.40.1.66; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROTHENBERG PL, 1991, DIABETES S1, V40, pA242; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; WILDEN PA, 1992, J BIOL CHEM, V267, P13719	42	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5921	5928						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680652				2022-12-27	WOS:A1993KR82200085
J	WERNERFELMAYER, G; WERNER, ER; FUCHS, D; HAUSEN, A; REIBNEGGER, G; SCHMIDT, K; WEISS, G; WACHTER, H				WERNERFELMAYER, G; WERNER, ER; FUCHS, D; HAUSEN, A; REIBNEGGER, G; SCHMIDT, K; WEISS, G; WACHTER, H			PTERIDINE BIOSYNTHESIS IN HUMAN ENDOTHELIAL-CELLS - IMPACT ON NITRIC OXIDE-MEDIATED FORMATION OF CYCLIC-GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; RELAXING FACTOR; L-ARGININE; INTERFERON-GAMMA; MACROPHAGE OXIDATION; GTP-CYCLOHYDROLASE; NITROGEN-OXIDES; SYNTHASE; TETRAHYDROBIOPTERIN; PURIFICATION	Stimulation of nitric oxide (NO) synthase in endothelial cells by Ca2+ influx leads to increased intracellular levels of cGMP. NO synthase from various sources is known to use tetrahydrobiopterin, flavins, and NADPH as cofactors. We studied the effect of interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide on tetrahydrobiopterin biosynthetic activities in human umbilical vein endothelial cells (HUVEC). These stimuli led to an up to 40-fold increase of GTP cyclohydrolase I (EC 3.5.4.16) activity and to increased accumulation of neopterin and tetrahydrobiopterin in HUVEC. Further enzyme activities of tetrahydrobiopterin biosynthesis, i.e. 6-pyruvoyltetrahydropterin synthase and sepiapterin reductase (EC 1.1.1.153), remained unchanged. NO synthase activity in protein fractions from homogenates of cells treated with interferon-gamma plus tumor necrosis factor-alpha was not influenced as compared with untreated controls. However, interferon-gamma alone or in combination with tumor necrosis factor-alpha significantly increased intracellular cGMP formation in intact HUVEC by 50 and 80%, respectively. These stimuli increased intracellular tetrahydrobiopterin concentrations up to 14-fold. NO-triggered cGMP formation was similarity increased by incubation of otherwise untreated cells with sepiapterin, leading to elevated intracellular tetrahydrobiopterin levels. Thus, cytokines indirectly stimulate the activity of constitutive NO synthase in HUVEC by upregulating production of the cofactor tetrahydrobiopterin.	UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA; GRAZ UNIV, INST PHARMACOL & TOXICOL, A-8010 GRAZ, AUSTRIA	University of Innsbruck; University of Graz			Fuchs, Dietmar/AAL-8011-2021; Reibnegger, Gilbert/H-5742-2012	Fuchs, Dietmar/0000-0003-1627-9563; Reibnegger, Gilbert/0000-0001-7202-2426; Werner-Felmayer, Gabriele/0000-0002-2340-8063; Werner, Ernst R./0000-0003-1948-3391				ANDERT SE, 1992, CLIN EXP IMMUNOL, V88, P555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RR, 1989, CANCER RES, V49, P4941; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; DRAPIER JC, 1991, RES IMMUNOL, V142, P553, DOI 10.1016/0923-2494(91)90100-W; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FORSTERMANN U, 1986, CIRC RES, V58, P531, DOI 10.1161/01.RES.58.4.531; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOLLOWAY JH, 1960, ANAL CHEM, V32, P249, DOI 10.1021/ac60158a033; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KLATT P, 1992, FEBS LETT, V305, P160, DOI 10.1016/0014-5793(92)80886-L; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAMAS S, 1991, AM J PHYSIOL, V261, pC634, DOI 10.1152/ajpcell.1991.261.4.C634; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MITCHELL JA, 1991, BIOCHEM BIOPH RES CO, V176, P1417, DOI 10.1016/0006-291X(91)90444-C; MONCADA S, 1991, PHARMACOL REV, V43, P109; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; STROHMAIER W, 1987, CRIT CARE MED, V15, P757, DOI 10.1097/00003246-198708000-00009; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; VIVEROS OH, 1981, SCIENCE, V213, P349, DOI 10.1126/science.7017928; Wachter H, 1992, NEOPTERIN BIOCH METH, V10, P289; WERNER ER, 1987, CLIN CHEM, V33, P2028; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNER ER, 1989, BIOCHEM J, V262, P891; WERNERFELMAYER G, 1990, CANCER RES, V50, P2863; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; YIM JJ, 1976, J BIOL CHEM, V251, P5087; YUI Y, 1991, J BIOL CHEM, V266, P12544; YUI Y, 1991, J BIOL CHEM, V266, P3369; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026	50	250	252	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1842	1846						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678411				2022-12-27	WOS:A1993KH62000054
J	JULLIENFLORES, V; DORSEUIL, O; ROMERO, F; LETOURNEUR, F; SARAGOSTI, S; BERGER, R; TAVITIAN, A; GACON, G; CAMONIS, JH				JULLIENFLORES, V; DORSEUIL, O; ROMERO, F; LETOURNEUR, F; SARAGOSTI, S; BERGER, R; TAVITIAN, A; GACON, G; CAMONIS, JH			BRIDGING RAL GTPASE TO RHO-PATHWAYS - RLIP76, A RAL EFFECTOR WITH CDC42/RAC GTPASE-ACTIVATING PROTEIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCES; GENE	RalA and RalB are GTPases of unknown function and are activated by proteins, RalGDS, that interact with the active form of another GTPase, Pas. To elucidate Pal function, we have searched for proteins interacting with an activated-form of RalA using the two-hybrid method and a Jurkat cell library. We have identified a partial cDNA encoding a protein, RLIP1, which binds to activated RalA and this binding requires an intact effector domain of RalA. Biochemical data with purified RalA confirm the genetic results, This protein also bears a region of homology with GTPase-activating protein (GAP) domains that are involved in the regulation of GTPases of the Rho family and, indeed, RLIP1 displays a GAP activity acting upon Rad and CDC42, but not RhoA. This GAP region is not required for RLIP1 binding to Pal. The whole cDNA was cloned, and it encodes a 76-kDa polypeptide, RLIP76, which also binds RalA. The Rho pathway is involved in membrane and cytoskeleton modifications after mitogenic stimulation and acts in parallel to and synergistically with the Pas pathway, We propose that these pathways are linked through a cascade composed of Pas --> RalGDS --> Pal --> RLIP76 --> CDC42/Rac1/Rho, allowing modulation of the Rho pathway by the Pas pathway.	FAC MED LARIBOISIERE,INSERM,U248,F-75010 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U257,F-75014 PARIS,FRANCE; INST COCHIN GENET MOLEC,INSERM,U363,F-75014 PARIS,FRANCE; INST GENET MOLEC,CNRS,SD 401301,F-75010 PARIS,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Romero, Francisco/K-2101-2014	Romero, Francisco/0000-0002-9588-6881				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERIF D, 1990, P NATL ACAD SCI USA, V87, P6639, DOI 10.1073/pnas.87.17.6639; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FRECH M, 1990, J BIOL CHEM, V265, P6353; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASPAR ML, 1991, P NATL ACAD SCI USA, V88, P8606, DOI 10.1073/pnas.88.19.8606; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; Kaiser C., 1994, METHODS YEAST GENETI; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; XU XM, 1994, J BIOL CHEM, V269, P23569	34	277	286	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22473	22477		10.1074/jbc.270.38.22473	http://dx.doi.org/10.1074/jbc.270.38.22473			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673236	hybrid			2022-12-27	WOS:A1995RW31400065
J	FERBER, A; CHANG, CD; SELL, C; PTASZNIK, A; CRISTOFALO, VJ; HUBBARD, K; OZER, HL; ADAMO, M; ROBERTS, CT; LEROITH, D; DUMENIL, G; BASERGA, R				FERBER, A; CHANG, CD; SELL, C; PTASZNIK, A; CRISTOFALO, VJ; HUBBARD, K; OZER, HL; ADAMO, M; ROBERTS, CT; LEROITH, D; DUMENIL, G; BASERGA, R			FAILURE OF SENESCENT HUMAN FIBROBLASTS TO EXPRESS THE INSULIN-LIKE GROWTH FACTOR-I GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CULTURED HUMAN-FIBROBLASTS; SIMIAN VIRUS-40; SOMATOMEDIN PRODUCTION; CELLULAR SENESCENCE; DNA-SYNTHESIS; T-ANTIGEN; CELLS; IMMORTALIZATION; TRANSLOCATION	Senescent human diploid fibroblasts express several growth-regulated genes but fail to express others. In this paper we show, by a very sensitive technique (reverse transcriptase-polymerase chain reaction), that senescent cells fail to express insulin-like growth factor-1 (IGF-1) mRNA, which is expressed in moderate amounts by young cells. Human fibroblasts immortalized by transfection with a temperature-sensitive SV40 T antigen gene regain the ability to express IGF-1 mRNA, but only at the permissive temperature of 34-degrees-C. Under these conditions, the immortalized human fibroblasts grow even in 1% serum. At the restrictive temperature of 39-degrees-C, the temperature-sensitive T antigen is nonfunctional, IGF-1 RNA is not detectable, and the cells fail to grow even in 10% serum. The failure to express IGF-1 mRNA in postsenescent cells can be ascribed, at least in part, to a transcriptional mechanism. Despite the correlation among immortalization by SV40 T antigen, expression of IGF-1, and growth, it seems unlikely that the failure to express IGF-1 is the sole cause of cellular senescence; other requirements must be postulated.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,BLSB ROOM 624A,PHILADELPHIA,PA 19107; MED COLL PENN,CTR GERONTOL RES,PHILADELPHIA,PA 19129; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; NIDDKD,DIABET BRANCH,BETHESDA,MD 20892	Jefferson University; Drexel University; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Dumenil, Guillaume/N-3377-2019; Dumenil, Guillaume/F-7567-2015; Roberts, Charles/K-6953-2017	Dumenil, Guillaume/0000-0001-9174-9110; Dumenil, Guillaume/0000-0001-9174-9110; Roberts, Charles/0000-0003-1756-5772	NIA NIH HHS [AG 00378, AG 04821] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG004821] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMO M, 1993, IN PRESS ENDOCRINOLO; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BARRECA A, 1992, J CELL PHYSIOL, V151, P262, DOI 10.1002/jcp.1041510207; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; CLEMMONS DR, 1981, J CLIN INVEST, V67, P10, DOI 10.1172/JCI110001; CRISTOFALO VJ, 1989, J GERONTOL, V44, P55, DOI 10.1093/geronj/44.6.55; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; DAI ZH, 1992, J BIOL CHEM, V267, P19565; DEPPERT W, 1991, ONCOGENE, V6, P1931; FOYT HL, 1991, INSULIN LIKE GROWTH, P1; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; MOATSSTAATS BM, 1993, MOL ENDOCRINOL, V7, P171, DOI 10.1210/me.7.2.171; MOSES AC, 1991, INSULIN LIKE GROWTH, P245; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REISS K, 1991, CANCER RES, V51, P5997; REISS K, 1992, ONCOGENE, V7, P2243; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; WERNER H, 1991, INSULIN LIKE GROWTH, P17; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	35	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17883	17888						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688732				2022-12-27	WOS:A1993LT74300039
J	LI, RK; CUTLER, JE				LI, RK; CUTLER, JE			CHEMICAL DEFINITION OF AN EPITOPE ADHESIN MOLECULE ON CANDIDA-ALBICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1,2-LINKED OLIGOMANNOSYL RESIDUES; PHOSPHOMANNAN-PROTEIN COMPLEX; CELL-SURFACE HYDROPHOBICITY; BUCCAL EPITHELIAL-CELLS; SEROTYPE-A; NIH B-792; NIH-B-792 STRAIN; MOUSE-TISSUES; D-MANNAN; ADHERENCE	An antigen (Ag), as defined by reactivity with a monoclonal antibody (mAb 10G), was found on the cell wall surface and on the plasma membrane of Candida albicans yeast cells (Li, R. K., and Cutler, J. E. (1991) J. Gen. Microbiol. 137, 455-464). The 10G Ag from the cell surface location was solubilized by treatment with beta-mercaptoethanol and Zymolyase. Antigenic activity of the extract was lost following periodate oxidation, but was stable to proteolytic enzyme and heat treatments. Mannoproteins in the extract were fractionated by hexadecyltrimethylammonium bromide. A fraction containing the 10G Ag was degraded by mild acid hydrolysis and a tetrahexose eluted from a P-2 size exclusion column was found to be the epitope (10G epitope) part of the 10G Ag. By use of gas-liquid chromatography, mass spectroscopy, and H-1 proton NMR analysis, the 10G epitope was determined to be a linear beta-1,2-linked tetramannose. The 10G Ag, which was immunopurified from the Zymolyase extract, and the 10G epitope were involved in the attachment of C. albicans to mouse spleen marginal zone macrophages. Both the 10G Ag and the purified 10G epitope specifically inhibited C. albicans adherence in an ex vivo binding assay. Latex beads adsorbed with the 10G Ag or the 10G epitope adhered specifically to the splenic marginal zone macrophages. These data show that a beta-1,2-linked mannotetraose part of a C. albicans cell wall mannoprotein is an adhesin site that may play a role in pathogenesis of disseminated candidiasis.	MONTANA STATE UNIV, DEPT MICROBIOL, BOZEMAN, MT 59717 USA	Montana State University System; Montana State University Bozeman					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024912] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24912] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BRAWNER DL, 1987, MICROB PATHOGENESIS, V2, P249, DOI 10.1016/0882-4010(87)90123-9; BRAWNER DL, 1986, INFECT IMMUN, V51, P327, DOI 10.1128/IAI.51.1.327-336.1986; BRAWNER DL, 1986, INFECT IMMUN, V51, P337, DOI 10.1128/IAI.51.1.337-343.1986; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CARROW EW, 1985, INFECT IMMUN, V49, P172, DOI 10.1128/IAI.49.1.172-181.1985; Cassone A, 1989, Curr Top Med Mycol, V3, P248; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P629; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P637; CUTLER JE, 1990, INFECT IMMUN, V58, P1902, DOI 10.1128/IAI.58.6.1902-1908.1990; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DOWNS F, 1967, METHOD CARBOHYD CHEM, V7, P200; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EDWARDS JE, 1992, INFECT IMMUN, V60, P3087, DOI 10.1128/IAI.60.8.3087-3091.1992; Fleet G H, 1985, Curr Top Med Mycol, V1, P24; HAZEN BW, 1988, INFECT IMMUN, V56, P2521, DOI 10.1128/IAI.56.9.2521-2525.1988; HAZEN KC, 1990, INFECT IMMUN, V58, P3469, DOI 10.1128/IAI.58.11.3469-3476.1990; HAZEN KC, 1991, INFECT IMMUN, V59, P907, DOI 10.1128/IAI.59.3.907-912.1991; KANBE T, 1993, INFECT IMMUN, V61, P2578, DOI 10.1128/IAI.61.6.2578-2584.1993; KANBE T, 1972, INFECT IMMUN, V60, P1978; KOBAYASHI H, 1987, ARCH BIOCHEM BIOPHYS, V256, P381, DOI 10.1016/0003-9861(87)90459-0; KOBAYASHI H, 1990, ARCH BIOCHEM BIOPHYS, V278, P195, DOI 10.1016/0003-9861(90)90248-W; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; LI RK, 1991, J GEN MICROBIOL, V137, P455, DOI 10.1099/00221287-137-3-455; LLOYD KO, 1970, BIOCHEMISTRY-US, V9, P3446, DOI 10.1021/bi00819a025; MIYAKAWA Y, 1992, INFECT IMMUN, V60, P2493, DOI 10.1128/IAI.60.6.2493-2499.1992; MIYAKAWA Y, 1989, YEAST, V5, P225; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; PODZORSKI RP, 1989, ARCH SURG-CHICAGO, V124, P1290, DOI 10.1001/archsurg.1989.01410110044009; RIESSELMAN MH, 1991, J IMMUNOL METHODS, V145, P153, DOI 10.1016/0022-1759(91)90321-6; SANDIN RL, 1982, INFECT IMMUN, V35, P79, DOI 10.1128/IAI.35.1.79-85.1982; SANDIN RL, 1987, MYCOPATHOLOGIA, V98, P179, DOI 10.1007/BF00437653; SHEPHERD MG, 1987, CRC CR REV MICROBIOL, V15, P7, DOI 10.3109/10408418709104445; SHIBATA N, 1985, ARCH BIOCHEM BIOPHYS, V243, P338, DOI 10.1016/0003-9861(85)90511-9; SHIBATA N, 1992, INFECT IMMUN, V60, P4100, DOI 10.1128/IAI.60.10.4100-4110.1992; SHIBATA N, 1989, CARBOHYD RES, V187, P239, DOI 10.1016/0008-6215(89)80006-0; SHIBATA N, 1986, ARCH BIOCHEM BIOPHYS, V251, P697, DOI 10.1016/0003-9861(86)90379-6; TOJO M, 1988, CLIN CHEM, V34, P539; TOJO M, 1990, CARBOHYD RES, V199, P215, DOI 10.1016/0008-6215(90)84263-T; TOSH FD, 1992, INFECT IMMUN, V60, P4734, DOI 10.1128/IAI.60.11.4734-4739.1992; TRONCHIN G, 1988, INFECT IMMUN, V56, P1987, DOI 10.1128/IAI.56.8.1987-1993.1988; YORK WS, 1986, METHOD ENZYMOL, V118, P3	42	110	118	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18293	18299						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688744				2022-12-27	WOS:A1993LT74300095
J	YU, H; ERITJA, R; BLOOM, LB; GOODMAN, MF				YU, H; ERITJA, R; BLOOM, LB; GOODMAN, MF			IONIZATION OF BROMOURACIL AND FLUOROURACIL STIMULATES BASE MISPAIRING FREQUENCIES WITH GUANINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE INSERTION FIDELITY; PROTON NMR; MAGNETIC-RESONANCE; DYNAMIC PROPERTIES; DNA-SYNTHESIS; PAIR; OLIGONUCLEOTIDE; OLIGODEOXYNUCLEOTIDES; EQUILIBRIUM; MUTAGENESIS	To test whether ionized base pairs influence polymerase-catalyzed misinsertion rates, we measured the efficiency of forming 5-bromouracil (B), 5-fluorouracil (F), and thymine base pairs with guanine and adenine as a function of pH using avian myeloblastosis reverse transcriptase. When B, F, and T were present as dNTP substrates, misincorporation efficiencies opposite G, normalized to incorporation of C opposite G, increased by about 20-, 13-, and 7-fold, respectively, as reaction pH increased from 7.0 to 9.5. Incorporation efficiencies to form the correct base pairs, B.A and F.A, normalized to T.A, decreased by 4- and 8-fold, respectively; with increasing pH. The effects of pH on mis-incorporation efficiencies were about 10-fold greater when B, F, and T were present as template bases. The relative misincorporation efficiencies of G opposite template B, F, and T, normalized to incorporation of A opposite B, F, and T, increased by about 430-, 370-, and 70-fold, respectively, as pH was increased from 6.5 to 9.5, while correct incorporation of A opposite template B and F decreased about 10-fold over the same pH range. Plots depicting incorrect and correct incorporation efficiencies versus pH were fit to a pH titration equation giving the fraction of ionized base as a function of pH. We conclude that avian myeloblastosis reverse transcriptase forms B.G and F.G mispairs in an ionized Watson-Crick conformation in preference to a neutral wobble structure containing favored keto tautomers of B or F. Although participation of disfavored enol tautomers in enzyme-catalyzed base mispair formation cannot be ruled out, the results are inconsistent with the ''standard'' disfavored tautomer model of mutagenesis. Instead, the data support a model in which ionization of halouracil bases is primarily responsible for B- and F-induced mutagenesis.	CTR RES & DEV,DEPT MOLEC GENET,E-08034 BARCELONA,SPAIN		YU, H (corresponding author), UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089, USA.		Eritja, Ramon/B-5613-2008; Bloom, Linda B/F-3684-2014	Eritja, Ramon/0000-0001-5383-9334; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015034, R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15034, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOULARD Y, 1992, NUCLEIC ACIDS RES, V620, P1933; BRENNAN CA, 1985, NUCLEIC ACIDS RES, V13, P8665, DOI 10.1093/nar/13.24.8665; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; DRIGGERS PH, 1988, BIOCHEMISTRY-US, V27, P1729, DOI 10.1021/bi00405a052; DUNN DB, 1975, HDB BIOCH MOL BIOL, V1, P76; FAZAKERLEY GV, 1987, J BIOMOL STRUCT DYN, V5, P639, DOI 10.1080/07391102.1987.10506417; FERNANDEZFORNER D, 1990, NUCLEIC ACIDS RES, V18, P5729, DOI 10.1093/nar/18.19.5729; FREESE E, 1959, J MOL BIOL, V1, P87, DOI 10.1016/S0022-2836(59)80038-3; GOLDMAN D, 1983, NUCLEOS NUCLEOT, V2, P175, DOI 10.1080/07328318308081257; HANSCH C, 1973, J MED CHEM, V16, P1207, DOI 10.1021/jm00269a003; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KREMER AB, 1987, BIOCHEMISTRY-US, V26, P391, DOI 10.1021/bi00376a009; LAWLEY P. D., 1962, JOUR MOLECULAR BIOL, V4, P216, DOI 10.1016/S0022-2836(62)80053-9; MASSOULIE J, 1966, BIOCHIM BIOPHYS ACTA, V114, P16, DOI 10.1016/0005-2787(66)90249-8; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; PATEL DJ, 1984, FED PROC, V43, P2663; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SCHULHOF JC, 1987, NUCLEIC ACIDS RES, V15, P397, DOI 10.1093/nar/15.2.397; SOWERS LC, 1989, J MOL BIOL, V205, P437, DOI 10.1016/0022-2836(89)90353-7; SOWERS LC, 1986, BIOCHEMISTRY-US, V25, P3983, DOI 10.1021/bi00362a002; SOWERS LC, 1987, J BIOL CHEM, V262, P15436; SOWERS LC, 1988, J BIOL CHEM, V263, P14794; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; SOWERS LC, 1987, MUTAT RES, V177, P201, DOI 10.1016/0027-5107(87)90003-0; STRAZEWSKI P, 1990, ANGEW CHEM INT EDIT, V29, P36; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; VU H, 1990, TETRAHEDRON LETT, V31, P7269, DOI 10.1016/S0040-4039(00)88541-X; WANG C, 1991, J AM CHEM SOC, V113, P5486, DOI 10.1021/ja00014a068; WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0; WATSON JD, 1953, COLD SPRING HARB SYM, V18, P123, DOI 10.1101/SQB.1953.018.01.020	34	90	91	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15935	15943						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7688001				2022-12-27	WOS:A1993LN30500087
J	ALTHAUS, IW; GONZALES, AJ; CHOU, JJ; ROMERO, DL; DEIBEL, MR; CHOU, KC; KEZDY, FJ; RESNICK, L; BUSSO, ME; SO, AG; DOWNEY, KM; THOMAS, RC; ARISTOFF, PA; TARPLEY, WG; REUSSER, F				ALTHAUS, IW; GONZALES, AJ; CHOU, JJ; ROMERO, DL; DEIBEL, MR; CHOU, KC; KEZDY, FJ; RESNICK, L; BUSSO, ME; SO, AG; DOWNEY, KM; THOMAS, RC; ARISTOFF, PA; TARPLEY, WG; REUSSER, F			THE QUINOLINE U-78036 IS A POTENT INHIBITOR OF HIV-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SULFATED POLYSACCHARIDES; SELECTIVE-INHIBITION; PENTOSAN POLYSULFATE; ANTIVIRAL ACTIVITY; ENZYME-KINETICS; DNA-POLYMERASE; RNASE-H; TYPE-1; DERIVATIVES	The quinoline U-78036 represents a new class of non-nucleoside human immunodeficiency virus (HIV)-1 reverse transcriptase inhibitors. The agent possesses excellent antiviral activity at nontoxic doses in HIV-1-infected lymphocytes grown in tissue culture. Enzymatic kinetic studies of the HIV-1 reverse transcriptase (RT)-catalyzed RNA-directed DNA polymerase function were carried out in order to determine whether the inhibitor interacts with the template-primer or deoxyribonucleotide triphosphate (dNTP) binding sites of the polymerase. The data were analyzed using steady-state or Briggs-Haldane kinetics assuming that the template-primer binds to the enzyme first followed by the dNTP and that the polymerase functions processively. The calculated rate constants are in agreement with this model. The results show that the inhibitor acts as a mixed to noncompetitive inhibitor with respect to both the template-primer and the dNTP binding sites of the enzyme. Hence, U-78036 inhibits the RNA-directed DNA polymerase activity of RT by interacting with a site distinct from the template-primer and dNTP binding sites. Moreover, the potency of U-78036 is dependent on the base composition of the template-primer. The equilibrium constants for various enzyme-substrate-inhibitor complexes were at least seven times lower for the poly(rC) . (dG)10-catalyzed system than the one catalyzed by poly(rA).(dT)10. In addition, the inhibitor does not impair the DNA-dependent DNA polymerase activity and the RNase H function of HIV-1 RT nor does it inhibit the RNA-directed DNA polymerase activity of the HIV-2, avian myoblastoma virus, and murine leukemia virus RT enzymes.	UPJOHN CO,7295-25-2,KALAMAZOO,MI 49001; MT SINAI MED CTR,MIAMI BEACH,FL 33140; UNIV MIAMI,MIAMI,FL 33101	Pfizer; Mount Sinai Medical Center; University of Miami			Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Chou, Kuo-Chen/A-8340-2009	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; 				ALTHAUS IW, 1993, J BIOL CHEM, V268, P6119; ALTHAUS IW, 1992, EXPERIENTIA, V48, P1127, DOI 10.1007/BF01948005; ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679; BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BUSSO M, 1988, AIDS RES HUM RETROV, V4, P449, DOI 10.1089/aid.1988.4.449; BUSSO ME, 1990, ANTIMICROB AGENTS CH, V34, P1991, DOI 10.1128/AAC.34.10.1991; CHA S, 1968, J BIOL CHEM, V243, P820; CHOU KC, 1976, SCI SINICA, V19, P505; CHOU KC, 1989, J BIOL CHEM, V264, P12074; CHOU KC, 1990, BIOPHYS CHEM, V35, P1, DOI 10.1016/0301-4622(90)80056-D; CHOU KC, 1982, J AM CHEM SOC, V104, P1409, DOI 10.1021/ja00369a043; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; GERARD M, 1990, INTERSCI C ANTIMICRO, V176; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; POPP FD, 1961, J ORG CHEM, V26, P4930, DOI 10.1021/jo01070a036; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SHARMA SK, 1991, BIOTECHNOL APPL BIOC, V14, P69; SOSA MAG, 1991, BIOCHEM BIOPH RES CO, V174, P489, DOI 10.1016/0006-291X(91)91443-G; TAN CK, 1986, J BIOL CHEM, V261, P2310; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	36	175	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14875	14880						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686907				2022-12-27	WOS:A1993LL75900053
J	CIRINO, NM; KALAYJIAN, RC; JENTOFT, JE; LEGRICE, SFJ				CIRINO, NM; KALAYJIAN, RC; JENTOFT, JE; LEGRICE, SFJ			FLUOROMETRIC ANALYSIS OF RECOMBINANT P15 HIV-1 RIBONUCLEASE-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SITE-DIRECTED MUTAGENESIS; METAL CHELATE ADSORBENT; DNA-POLYMERASE-ACTIVITY; AMINO-ACID-RESIDUES; REVERSE-TRANSCRIPTASE; ESCHERICHIA-COLI; RNASE-H; HISTIDINE-RESIDUES; DOMAIN	We have exploited the sole tryptophan residue (Trp535) in the ribonuclease H (RNase H) domain of human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT) to study features of the isolated polypeptide (p15 RNase H) by fluorescence spectroscopy. Incubation of purified p15 RNase H with a synthetic RNA/DNA hybrid was accompanied by an alteration in Trp535 fluorescence intensity. This property was used to determine an apparent binding constant (K(app)) of 3.5 x 10(6) M-1 for p15 RNase H complexed with poly(rA)/oligo(dT)12-18 and an occluded site size of 4 nucleotides. A cooperativity coefficient (omega) of 910 was also determined which indicated that nearly three logs of the K(app) were due to cooperativity effects. Recombinant p15 RNase H preparations containing mutations at position 478 (Glu478 --> Gln 478) or 539 (His539 --> Phe539), which are highly conserved between bacterial and retroviral RNases H, were also analyzed. Under the same conditions, these mutants failed to bind the RNA/DNA hybrid, although they were structurally similar to the wild type polypeptide. Fluorescence spectroscopy thus appears to be an alternative and sensitive means of analyzing functional properties of the purified RNase H domain of HIV-1 RT under a variety of conditions.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DIV INFECT DIS,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046623] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07381] Funding Source: Medline; NIGMS NIH HHS [GM 46623] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; CERTA U, 1986, EMBO J, V5, P51; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; EVANS DB, 1991, J BIOL CHEM, V266, P20583; HAFKEMEYER P, 1991, NUCLEIC ACIDS RES, V19, P4059, DOI 10.1093/nar/19.15.4059; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOSTOMSKA Z, 1991, J BIOL CHEM, V266, P14697; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1991, EUR J BIOCHEM, V198, P437, DOI 10.1111/j.1432-1033.1991.tb16033.x; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P44; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LOYA S, 1990, ANTIMICROB AGENTS CH, V34, P2009, DOI 10.1128/AAC.34.10.2009; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MIZHRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; MOELLING K, 1971, NATURE, V234, P240; POWERS R, 1991, J MOL BIOL, V221, P1081, DOI 10.1016/0022-2836(91)80113-9; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHATZ O, 1990, ONCOGENESIS AIDS, P304; SCHWARZ G, 1983, J MOL BIOL, V163, P467, DOI 10.1016/0022-2836(83)90069-4; STAMMERS DK, 1991, FEBS LETT, V283, P298, DOI 10.1016/0014-5793(91)80613-8; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; WANG W, 1990, SCIENCE, V249, P1398	39	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14743	14749						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686904				2022-12-27	WOS:A1993LL75900034
J	BASU, M; HAKIMI, J; DHARM, E; KONDAS, JA; TSIEN, WH; PILSON, RS; LIN, P; GILFILLAN, A; HARING, P; BRASWELL, EH; NETTLETON, MY; KOCHAN, JP				BASU, M; HAKIMI, J; DHARM, E; KONDAS, JA; TSIEN, WH; PILSON, RS; LIN, P; GILFILLAN, A; HARING, P; BRASWELL, EH; NETTLETON, MY; KOCHAN, JP			PURIFICATION AND CHARACTERIZATION OF HUMAN RECOMBINANT IGE-FC FRAGMENTS THAT BIND TO THE HUMAN HIGH-AFFINITY IGE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-CHAIN FRAGMENT; HUMAN IMMUNOGLOBULIN-E; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; MURINE IGE; EXPRESSION; CELLS; PROTEIN; SITE	The Fc-region of immunoglobulin E (IgE) comprising C(epsilon)2, C(epsilon)3, and C(epsilon)4 domains is sufficient for binding to the alpha chain of the high affinity IgE-Fc receptor (FcepsilonRIalpha). In order to identify the smallest Fc fragment capable of binding to the FcepsilonRIalpha with high affinity, various regions of the IgE-Fc molecule were expressed in COS cells and investigated for their ability to bind FcepsilonRIalpha. The smallest fragment that showed FcepsilonRIalpha binding activity spans amino acids 329-547 and lacks the entire C(epsilon)2 domain. Two active fragments, viz. Fc(epsilon)(315-547) (containing Cys328 which is responsible for interchain S-S bonding) and Fc(epsilon)(329-547), have been overexpressed in CHO cells and purified to homogeneity. The purified proteins bind to the FcepsilonRIalpha with high affinity, similar to native IgE. SDS-polyacrylamide gel electrophoresis analyses indicate that Fc(epsilon)(315-547) is an S-S-linked dimer of apparent molecular mass of 68 kDa. Fc(epsilon)(329-547) appears on SDS-gel as three distinct bands at approximately 32 kDa, both under reducing and nonreducing conditions. However, size exclusion chromatography and analytical ultracentrifugation studies suggest that Fc(epsilon)(329-547) also remains associated as a dimer. The presence of N-linked glycosylation was detected in both proteins. The deglycosylated form of Fc(epsilon)(315-547) was isolated after Endo F/N-glycosidase F digestion and demonstrated to have binding activity comparable to that of the mock-digested protein. These results suggest that the presence of N-linked sugars is not necessary for FcepsilonRIalpha binding. Both proteins blocked the release of histamine from RBL cells expressing human FcepsilonRIalpha in a dose-dependent manner. The availability of these recombinant IgE-Fc proteins will be helpful in elucidating the key epitopes essential for the binding of IgE to its high affinity receptor.	HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT IMMUNOPHARMACOL, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT MOLEC GENET, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT BRONCHOPULM RES, NUTLEY, NJ 07110 USA; F HOFFMANN LA ROCHE & CO LTD, CH-4002 BASEL, SWITZERLAND; UNIV CONNECTICUT, STORRS, CT 06269 USA	Roche Holding; Roche Holding; Roche Holding; Roche Holding; University of Connecticut	BASU, M (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT PROT BIOCHEM, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA.							ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; BASU M, 1991, ARCH BIOCHEM BIOPHYS, V286, P638, DOI 10.1016/0003-9861(91)90093-X; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DORDAL MS, 1985, ENDOCRINOLOGY, V116, P2293, DOI 10.1210/endo-116-6-2293; DORRINGTON KJ, 1978, IMMUNOL REV, V41, P3, DOI 10.1111/j.1600-065X.1978.tb01458.x; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; GILFILLAN AM, 1992, J IMMUNOL, V149, P2445; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HANZJURGEN H, 1986, THERMODYNAMIC DATA B, P70; HAYES MP, 1988, BIOCHEM BIOPH RES CO, V150, P1096, DOI 10.1016/0006-291X(88)90742-5; HELM B, 1989, P NATL ACAD SCI USA, V86, P9465, DOI 10.1073/pnas.86.23.9465; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IKEYAMA S, 1987, MOL IMMUNOL, V24, P1039; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; JOHNSON ML, 1981, BIOPHYS J, V36, P578; KENTEN J, 1984, P NATL ACAD SCI-BIOL, V81, P2955, DOI 10.1073/pnas.81.10.2955; KUROKAWA T, 1983, NUCLEIC ACIDS RES, V11, P3077, DOI 10.1093/nar/11.10.3077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1984, P NATL ACAD SCI-BIOL, V81, P5369, DOI 10.1073/pnas.81.17.5369; MORRISVASIOS C, 1988, J VIROL, V62, P349, DOI 10.1128/JVI.62.1.349-353.1988; NISSIM A, 1991, EMBO J, V10, P101, DOI 10.1002/j.1460-2075.1991.tb07925.x; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; PAN YCE, 1986, METHODS PROTEIN MICR, P105; PEREZMONTFORT R, 1982, MOL IMMUNOL, V19, P1113, DOI 10.1016/0161-5890(82)90322-4; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; RISKE F, 1991, J BIOL CHEM, V266, P11245; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; SCHWARZBAUM S, 1989, EUR J IMMUNOL, V19, P1015, DOI 10.1002/eji.1830190610; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SKOV PS, 1985, ALLERGY, V40, P213; WEETALL M, 1990, J IMMUNOL, V145, P3849	39	78	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13118	13127						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685756				2022-12-27	WOS:A1993LH55300019
J	SAWADA, R; LOWE, JB; FUKUDA, M				SAWADA, R; LOWE, JB; FUKUDA, M			E-SELECTIN-DEPENDENT ADHESION EFFICIENCY OF COLONIC-CARCINOMA CELLS IS INCREASED BY GENETIC MANIPULATION OF THEIR CELL-SURFACE LYSOSOMAL MEMBRANE GLYCOPROTEIN-1 EXPRESSION LEVELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASN-LINKED OLIGOSACCHARIDES; SIALYL-LEX DETERMINANT; CARBOHYDRATE STRUCTURES; HUMAN-GRANULOCYTES; MOLECULE-1 ELAM-1; SUGAR CHAINS; TUMOR-CELLS; LEWIS-X; ANTIGEN; ANTIBODY	Lysosomal membrane glycoprotein (lamp)-1 and lamp-2 are the most abundant glycoproteins within the lysosomal membrane. A small amount of lamp-1 and lamp-2 molecules, however, can be present on the cell surface. We have shown previously that highly metastatic colonic carcinoma L4 cells express more lamp-1 and lamp-2 on the cell surface than low metastatic SP cells (Saitoh, O., Wang, W.-L., Lotan, R., and Fukuda, M. (1992) J. Biol. Chem. 267, 5700-5711). Since lamp-1 and lamp-2 are the major carriers for poly-N-acetyllactosamines that are able to display sialyl-Le(x) termini, we sought to determine if an increased amount of lamp-1 on the cell surface would lead to increased expression of cell surface sialyl-Le(x) determinants and to the increased adhesion of those cells to E-selectin. Expression of increased amounts of lamp-1 on the cell surface was achieved either by overexpression of lamp-1 or by expressing a mutant lamp-1 molecule preferentially at the plasma membrane, rather than in lysosomes. Cells that express variable amounts of cell surface lamp-1 were tested for their adhesion to activated endothelial cells or E-selectin expressing Chinese hamster ovary cells. The results clearly show that the extent of adhesion to E-selectin and cell surface sialyl-Le(x) determinants is proportional to the amount of cell surface lamp-1. Moreover, it was demonstrated that such adhesion can be inhibited by soluble lamp-1 generated from Chinese hamster ovary cells expressing sialyl-Le(x) structures. These results indicate that lamp-1 can efficiently present ligands for E-selectin and at the same time can be a useful reagent for inhibition of E-selectin (and possibly P-selectin)-mediated interaction.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037; UNIV MICHIGAN,HOWARD HUGHES,MED INST,ANN ARBOR,MI 48109	Sanford Burnham Prebys Medical Discovery Institute; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033189] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA48737] Funding Source: Medline; NIAID NIH HHS [P01 AI33189] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG EL, 1991, J BIOL CHEM, V266, P14869; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1985, J BIOL CHEM, V260, P1067; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; KAMEYAMA A, 1991, CARBOHYD RES, V209, pC1, DOI 10.1016/0008-6215(91)80171-I; KIM YS, 1988, CANCER RES, V48, P475; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAFERTE S, 1989, BIOCHEM J, V259, P569, DOI 10.1042/bj2590569; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE N, 1990, J BIOL CHEM, V265, P20476; LEY K, 1991, BLOOD, V77, P2553; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MORIKAWA K, 1988, CANCER RES, V48, P1943; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; Nicolson GL, 1989, CURR OPIN CELL BIOL, V1, P1009, DOI 10.1016/0955-0674(89)90073-2; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873	53	111	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12675	12681						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685349				2022-12-27	WOS:A1993LG65800067
J	BINDER, S; BRENNICKE, A				BINDER, S; BRENNICKE, A			TRANSCRIPTION INITIATION SITES IN MITOCHONDRIA OF OENOTHERA-BERTERIANA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECISE ASSIGNMENT; CYTOCHROME-OXIDASE; STRAND PROMOTER; CAPPED INVITRO; START SITES; DNA; GENE; IDENTIFICATION; SEQUENCE; GENOME	Toward the identification of promoter structures in dicot plant mitochondria, transcription initiation sites were localized by in vitro capping of mitochondrial RNAs from Oenothera berteriana. By this approach at least 15 initiation sites are detectable in the genome. Primary 5'-transcript termini were determined for coxII, atpA, and an 18 S rRNA precursor. Alignment of the sequences surrounding the transcript termini defines a conserved sequence block of 29 nucleotides between positions -20 and +9. A core of 9 nucleotides between positions -7 and +2 (5'-CRTAaGaGA-3') is conserved with soybean transcription initiation sites. All transcripts analyzed begin with the underlined GA-dinucleotide. Transcription initiation of these protein coding and ribosomal RNA genes at similar sequence elements suggests common binding specificities of the RNA polymerase or its cofactors for both types of genes. The putative promoter consensus motif for dicots is very different from monocot mitochondrial promoter sequences. Only the 5'-CRTA-3' tetranucleotide is conserved between both plant groups.			BINDER, S (corresponding author), INST GENBIOL FORSCH,IHNESTR 63,W-1000 BERLIN 33,GERMANY.							AUCHINCLOSS AH, 1989, BIOCHEM CELL BIOL, V67, P315, DOI 10.1139/o89-049; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BROWN GG, 1991, MOL GEN GENET, V228, P345, DOI 10.1007/BF00260626; CHANG DD, 1986, MOL CELL BIOL, V6, P3262, DOI 10.1128/MCB.6.9.3262; CHANG DD, 1984, CELL, V36, P635, DOI 10.1016/0092-8674(84)90343-X; CHANG DD, 1987, BIOCHIM BIOPHYS ACTA, V909, P85, DOI 10.1016/0167-4781(87)90029-7; CHANG DD, 1986, MOL CELL BIOL, V6, P3253, DOI 10.1128/MCB.6.9.3253; CHANG DD, 1986, MOL CELL BIOL, V6, P294, DOI 10.1128/MCB.6.1.294; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COVELLO PS, 1991, CURR GENET, V20, P245, DOI 10.1007/BF00326239; EDWARDS JC, 1982, CELL, V31, P337, DOI 10.1016/0092-8674(82)90127-1; GRAY MW, 1992, ANNU REV PLANT PHYS, V43, P145, DOI 10.1146/annurev.pp.43.060192.001045; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; HANICJOYCE PJ, 1991, MOL CELL BIOL, V11, P2035, DOI 10.1128/MCB.11.4.2035; HIESEL R, 1985, FEBS LETT, V193, P164, DOI 10.1016/0014-5793(85)80143-5; HIESEL R, 1983, EMBO J, V2, P2173, DOI 10.1002/j.1460-2075.1983.tb01719.x; HIXSON JE, 1985, P NATL ACAD SCI USA, V82, P2660, DOI 10.1073/pnas.82.9.2660; KENNELL JC, 1989, MOL CELL BIOL, V9, P3603, DOI 10.1128/MCB.9.9.3603; KENNELL JC, 1989, MOL GEN GENET, V216, P16, DOI 10.1007/BF00332225; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; MULLIGAN RM, 1988, MOL GEN GENET, V211, P373, DOI 10.1007/BF00425688; MULLIGAN RM, 1988, P NATL ACAD SCI USA, V85, P7998, DOI 10.1073/pnas.85.21.7998; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; RAPP WD, 1992, EMBO J, V11, P1065, DOI 10.1002/j.1460-2075.1992.tb05145.x; Sambrook J., 1989, MOL CLONING; SCHINKEL AH, 1989, TRENDS GENET, V5, P149, DOI 10.1016/0168-9525(89)90056-5; SCHUSTER W, 1986, MOL GEN GENET, V204, P29, DOI 10.1007/BF00330183; SCHUSTER W, 1989, CURR GENET, V15, P187, DOI 10.1007/BF00435505; SCHUSTER W, 1988, PLANT MOL BIOL PRACT, P79; SCHUSTER W, 1987, NATO ASI SER PLANT M, V140, P115; WARD BL, 1981, CELL, V25, P793, DOI 10.1016/0092-8674(81)90187-2; WISSINGER B, 1988, MOL GEN GENET, V212, P56, DOI 10.1007/BF00322444	34	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7849	7855						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681829				2022-12-27	WOS:A1993KW97900042
J	MISEVIC, GN; BURGER, MM				MISEVIC, GN; BURGER, MM			CARBOHYDRATE-CARBOHYDRATE INTERACTIONS OF A NOVEL ACIDIC GLYCAN CAN MEDIATE SPONGE CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIQUE PROTEOGLYCAN COMPLEX; AGGREGATION FACTOR; MICROCIONA-PROLIFERA; GEL-ELECTROPHORESIS; SELF-ASSOCIATION; HEPARAN-SULFATE; MELANOMA-CELLS; BINDING; RECOGNITION; AFFINITY	Cell recognition and adhesion were first demonstrated in marine sponges. These phenomena were later shown in Microciona prolifera sponge to be mediated by a Ca2+-dependent self-association of adhesion proteoglycans (APs) attached in a species-specific manner to cell-surface receptors. Using the same experimental system we now provide three lines of evidence that highly polyvalent Ca2+-dependent carbohydrate-carbohydrate interactions of a novel AP glycan represent the basis of AP-AP self-binding and thus of cell adhesion. 1) A specific monoclonal antibody which blocks cell aggregation and AP bead adhesion identified a highly repetitive novel carbohydrate epitope (2500 sites) in an acidic glycan of M(r) = 200 x 10(3) (g200) from AP. 2) Reconstitution of the Ca2+-dependent self-interaction activity of AP was achieved by cross-linking the purified protein-free g200 glycan into polymers of similar valency as the native AP. 3) Beads coated with the protein-free g200 glycan showed a Ca2+-dependent aggregation equivalent to that of AP beads. Carbohydrate and amino acid analyses of the g200 glycan purified by gel electrophoresis, high performance liquid chromatography gel filtration, and ion exchange chromatography yielded six components in the following proportions; 68 fucose, 32 glucuronic acid, 2 mannose, 18 galactose, 19 N-acetylglucosamine, and 1 asparagine residue. These unique chemical features together with immunological and enzymological analyses suggest that the g200 glycan is a large highly fucosylated, acidic, N-linked polysaccharide with a novel structure distinct from that of other known glycosaminoglycans.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Friedrich Miescher Institute for Biomedical Research; Marine Biological Laboratory - Woods Hole	MISEVIC, GN (corresponding author), UNIV HOSP BASEL, DEPT RES, HEBELSTR 20, CH-4031 BASEL, SWITZERLAND.		Misevic, Gradimir/D-8294-2016	Misevic, Gradimir/0000-0001-5047-2936				AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CAULDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051, DOI 10.1021/bi00740a017; CHAPLIN MF, 1982, ANAL BIOCHEM, V123, P336, DOI 10.1016/0003-2697(82)90455-9; DISCHE Z, 1947, J BIOL CHEM, V167, P189; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; Galtsoff PS, 1923, BIOL BULL-US, V45, P153, DOI 10.2307/1536625; HAMPSON IN, 1984, BIOCHEM J, V221, P697, DOI 10.1042/bj2210697; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HENRIKSON RL, 1984, ANAL BIOCHEM, V136, P65; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KOEHLER G, 1975, NATURE, V256, P495; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; Malinowski K, 1981, Methods Enzymol, V73, P418; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1990, J CELL BIOCHEM, V43, P307, DOI 10.1002/jcb.240430403; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MISEVIC GN, 1989, METHOD ENZYMOL, V179, P95; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; NYBROE O, 1989, J NEUROCHEM, V52, P1947, DOI 10.1111/j.1471-4159.1989.tb07283.x; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; SHIELDS R, 1960, ANAL CHEM, V32, P885, DOI 10.1021/ac60163a053; SPENCER B, 1960, BIOCHEM J, V75, P435, DOI 10.1042/bj0750435; STEWART DJ, 1974, ANAL BIOCHEM, V62, P349, DOI 10.1016/0003-2697(74)90167-5; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TURLEY EA, 1980, NATURE, V283, P268, DOI 10.1038/283268a0; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204	38	107	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4922	4929						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680344				2022-12-27	WOS:A1993KP88400056
J	CHOU, CF; OMARY, MB				CHOU, CF; OMARY, MB			MITOTIC ARREST-ASSOCIATED ENHANCEMENT OF O-LINKED GLYCOSYLATION AND PHOSPHORYLATION OF HUMAN KERATIN-8 AND KERATIN-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-FILAMENT PROTEINS; N-ACETYLGLUCOSAMINE RESIDUES; CYTOPLASMIC GLYCOPROTEINS; VIMENTIN FILAMENTS; MESSENGER-RNA; KINASE-C; CELLS; EXPRESSION; NUCLEAR; INVITRO	Arrest of the human colonic cell line HT29 at the G2/M phase of the cell cycle resulted in changes in keratin assembly that were coupled with a significant increase in the O-linked glycosylation and serine phosphorylation of keratin polypeptides 8 and 18 (K8/18). With mitotic arrest, enhanced keratin phosphorylation occurred preferentially on K8, whereas K18 showed a higher glycosylation level than K8. Removal of the arresting agent allowed cells to proceed through the cell cycle with a concomitant decrease in K8/18 glycosylation. In contrast, keratins isolated from S phase-enriched cells, obtained after synchronization with aphidicolin, did not show enhanced glycosylation. Tryptic peptide analysis of keratins in G2/M-arrested cells showed changes in the glycopeptide pattern of K8 and in the phosphopeptide patterns of K8 and K18. Labeling of K8/18 immunoprecipitates, isolated from G2/M-arrested cells, with [H-3]galactose followed by beta-elimination showed that K8/18 glycosylation consisted of single N-acetylglucosamine residues. Threonine was identified as the site of glycosylation after comparing acid hydrolysis products of beta-eliminated and non-beta-eliminated K8 and K18. Specific cleavage at tryptophan residues indicated that K18 glycosylation and phosphorylation were restricted to the head and proximal rod domains, whereas K8 did not show the same restriction. Our results show a unique association of the single O-linked N-acetylglucosamine type of modification of keratins with mitotic arrest in HT29 cells. There was no reciprocal relationship between K8/18 glycosylation and phosphorylation, and each keratin showed a preferential G2/M cell cycle-associated increase in either serine phosphorylation or threonine glycosylation.	VET ADM MED CTR, PALO ALTO, CA 94304 USA; STANFORD UNIV, MED CTR, SCH MED, CTR DIGEST DIS, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University				Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK 38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashihara T, 1979, Methods Enzymol, V58, P248; BARIBAULT H, 1989, J CELL BIOL, V109, P1665, DOI 10.1083/jcb.109.4.1665; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU CF, 1991, FEBS LETT, V282, P200, DOI 10.1016/0014-5793(91)80477-K; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; EVANS RM, 1988, EUR J CELL BIOL, V46, P152; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; GILMARTIN ME, 1984, J CELL BIOL, V98, P1144, DOI 10.1083/jcb.98.3.1144; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, CIBA F SYMP, V145, P102; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KING IA, 1989, J BIOL CHEM, V264, P14022; KLYMKOWSKY MW, 1989, CELL MOTIL CYTOSKEL, V14, P309, DOI 10.1002/cm.970140302; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; LAZARIDES E, 1982, ANNU REV BIOCHEM, V51, P219, DOI 10.1146/annurev.bi.51.070182.001251; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1975, J BIOL CHEM, V250, P4007; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; PEDRALINOY G, 1980, NUCLEIC ACIDS RES, V8, P377, DOI 10.1093/nar/8.2.377; QUARONI A, 1991, J BIOL CHEM, V266, P11923; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Savige W E, 1977, Methods Enzymol, V47, P459; SKALLI O, 1991, CELL MOTIL CYTOSKEL, V19, P67, DOI 10.1002/cm.970190202; STARR CM, 1990, J BIOL CHEM, V265, P6868; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; TANAKA K, 1965, J BIOL CHEM, V240, P1487; TOLLE HG, 1987, EUR J CELL BIOL, V43, P35; TORRES CR, 1984, J BIOL CHEM, V259, P3308; YAMAMOTO R, 1990, MOL ENDOCRINOL, V4, P370, DOI 10.1210/mend-4-3-370; YANO T, 1991, EUR J BIOCHEM, V197, P281, DOI 10.1111/j.1432-1033.1991.tb15909.x; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	48	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4465	4472						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680039				2022-12-27	WOS:A1993KN53300094
J	WANG, SK; WANG, XB; DENG, LP; RASSART, E; MILNE, RW; TALL, AR				WANG, SK; WANG, XB; DENG, LP; RASSART, E; MILNE, RW; TALL, AR			POINT MUTAGENESIS OF CARBOXYL-TERMINAL AMINO-ACIDS OF CHOLESTERYL ESTER TRANSFER PROTEIN - OPPOSITE FACES OF AN AMPHIPATHIC HELIX IMPORTANT FOR CHOLESTERYL ESTER TRANSFER OR FOR BINDING NEUTRALIZING ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; HUMAN-PLASMA	The cholesteryl ester transfer protein (CETP) mediates the transfer of neutral lipids between the plasma lipoproteins. A carboxyl-terminal sequence of CETP was recently shown to form the epitope of a neutralizing monoclonal antibody (TP2) and to be necessary for neutral lipid transfer activity. To determine the role of specific amino acids in the epitope and/or in lipid transfer activity, we made single amino acid substitution mutants between Pro446 and Ser476 by in vitro mutagenesis and expressed the mutants in mammalian cells. The binding of TP2 to CETP was abolished by mutations primarily of polar or charged amino acids that occurred periodically within the sequence between His466 and Leu475 and at amino acid Asp460; however, these mutants had well preserved cholesteryl ester (CE) transfer activity. By contrast, mutants of bulky hydrophobic amino acids in this region (particularly Leu475, Phe471, Leu468, Phe461, and Phe454) showed markedly decreased CE transfer specific activity, but essentially normal binding of TP2. The paradoxical effects on antibody binding and activity could be explained if amino acids determining monoclonal antibody binding and activity are disposed on opposite faces of an amphipathic helix between amino acids 465 and 476. This model was tested by substituting alanine residues for pairs of nonpolar amino acids which would be contiguous on a helix, resulting in low activity mutants equivalent to those produced by deletion of this region. We conclude that the hydrophobic face of a carboxyl-terminal helix of CETP is directly involved in the mechanism of CE transfer, and that TP2 inhibits activity by local sterical hindrance. The general hydrophobic character of this region, imparted by the bulky hydrophobic amino acids Leu and Phe, is important for normal CE transfer.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,630 W 168TH ST,NEW YORK,NY 10032; CLIN RES INST MONTREAL,MONTREAL H2W 1R7,QUEBEC,CANADA; UNIV QUEBEC,DEPT SCI BIOL,MONTREAL H3C 3P8,QUEBEC,CANADA	Columbia University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Quebec; University of Quebec Montreal			Tall, Alan/AAT-8528-2021		NCI NIH HHS [MRCPG-27] Funding Source: Medline; NHLBI NIH HHS [HL22682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOMSET JA, 1968, J LIPID RES, V9, P155; HESLER CB, 1988, J BIOL CHEM, V263, P5020; HESLER CB, 1987, J BIOL CHEM, V262, P2275; HODGES RS, 1988, J BIOL CHEM, V263, P11768; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORTON RE, 1982, J LIPID RES, V23, P1058; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHECHTER I, 1971, EUR J BIOCHEM, V18, P21; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SWENSON TL, 1988, J BIOL CHEM, V263, P5150; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WANG S, 1992, J BIOL CHEM, V267, P17487; WANG S, 1991, BIOCHEMISTRY-US, V30, P3484, DOI 10.1021/bi00228a019; WANG XB, 1989, DNA-J MOLEC CELL BIO, V8, P753, DOI 10.1089/dna.1989.8.753; YOUNG JA, 1992, P NATL ACAD SCI USA, V89, P4094	27	58	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1955	1959						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678413				2022-12-27	WOS:A1993KH62000070
J	BERTHIAUME, L; RESH, MD				BERTHIAUME, L; RESH, MD			BIOCHEMICAL-CHARACTERIZATION OF A PALMITOYL ACYLTRANSFERASE ACTIVITY THAT PALMITOYLATES MYRISTOYLATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERLAP EXTENSION; MYRISTYLATION; PURIFICATION; SYSTEM	Dynamic regulation of signal transduction by revers reversible palmitoylation-depalmitoylation cycles has been recently described, However, further understanding of fatty acylation reactions has been hampered by our lack of knowledge about the specific transferases and thio esterases involved. Here, we describe an assay for the palmitoyl acyltransferase (PAT) that palmitoylates ''myrGlyCys'' containing members of the Src family of protein tyrosine kinases (PTKs), Since N-myristoylation of Fyn PTK, a member of the Src family, has been shown to be a prerequisite for palmitoylation, a new single plasmid vector that allows overexpression of myristoylated Fyn substrate in Escherichia coli was developed, Purified myristoylated protein substrates were incubated with [I-125]iodopalmitoyl CoA, a palmitoyl CoA analog, in the presence of bovine brain lysates, Transfer of radiolabel to the Fyn substrate was detected by SDS-polyacrylamide gel electrophoresis and autoradiography. This assay was used to partially purify and characterize PAT activity from bovine brain. Here, we demonstrate that PAT is a membrane-bound enzyme, which palmitoylates myristoylated Fyn substrates containing a cysteine residue in position three. The PAT activity attached palmitate to Fyn proteins via a thioester Linkage and exhibited a fatty acyl CoA preference for long chain fatty acids, It is likely that palmitoylation of Fyn and other Src family members by PAT regulates PTK localization and signaling functions.	MEM SLOAN KETTERING CANC CTR,DEPT GENET & CELL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center				Resh, Marilyn/0000-0001-6118-9466; Berthiaume, Luc/0000-0003-0926-059X	NATIONAL CANCER INSTITUTE [R01CA052405] Funding Source: NIH RePORTER; NCI NIH HHS [CA52405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DASILVA AM, 1990, J CELL BIOL, V111, P401, DOI 10.1083/jcb.111.2.401; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; Fleischer S, 1974, Methods Enzymol, V31, P3; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILHINNEY RAJ, 1992, LIPID MODIFICATION P, P15; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; SCHWARZ H, 1992, BIOTECHNIQUES, V13, P205; SILVERMAN L, 1993, CELL GROWTH DIFFER, V4, P475; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	35	129	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22399	22405		10.1074/jbc.270.38.22399	http://dx.doi.org/10.1074/jbc.270.38.22399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673226	hybrid			2022-12-27	WOS:A1995RW31400053
J	WILLIAMS, AJ; KHACHIGIAN, LM; SHOWS, T; COLLINS, T				WILLIAMS, AJ; KHACHIGIAN, LM; SHOWS, T; COLLINS, T			ISOLATION AND CHARACTERIZATION OF A NOVEL ZINC-FINGER PROTEIN WITH TRANSCRIPTIONAL REPRESSOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC KIDNEY-DISEASE; WILMS-TUMOR GENE; ADENOVIRUS E1A PROTEIN; INSITU HYBRIDIZATION; TUBEROUS SCLEROSIS; HUMAN GENOME; ACTIVATION; DELETION; KRUPPEL; PROMOTER	To identify genes that can repress the expression of growth regulatory molecules, a human fetal cDNA library was screened with a degenerate oligonucleotide that corresponds to the conserved stretch of 6 amino acids connecting successive zinc-finger regions in the Wilms' tumor suppressor/Egr-1 family of DNA-binding proteins. One clone, designated zinc-finger protein 174 (ZNF174), corresponds to a putative transcription factor with three zinc fingers and a novel finger-associated domain, designated the SCAN box, The three Cys(2)-His(2)-type zinc fingers are positioned at the carboxyl terminus, while the 65-amino acid finger-associated SCAN box is located near the amino terminus, Chromosomal localization using somatic cell hybrid analysis and fluorescent in. situ hybridization mapped the gene for ZNF174 to human chromosome 16p13.3. The 2.5-kilobase transcript from this gene is expressed in a variety of human organs, but most strongly in adult testis and ovary. Fusion of the upstream regulatory region of ZNF174 to the DNA-binding domain of GAL4 revealed that the gene could confer a repression function on the heterologous DNA-binding domain. ZNF174 selectively repressed reporter activity driven by the platelet-derived growth factor-B chain and transforming growth factor-beta(1) promoters and bound to DNA in a specific manner. This member of the C2H2-type zinc-finger family is a novel transcriptional repressor.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; ROSWELL PK CANC INST,DEPT HUMAN GENET,BUFFALO,NY 14163	Harvard University; Harvard Medical School; Roswell Park Cancer Institute			Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323	NHLBI NIH HHS [HL35716, HL45462] Funding Source: Medline; PHS HHS [P01 36028] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035716, R37HL035716] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; [Anonymous], 1994, CELL, V77, P881; ATTAR RM, 1992, MOL CELL BIOL, V12, P2432, DOI 10.1128/MCB.12.5.2432; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BERGERHEIM U, 1989, CANCER RES, V49, P1390; CALABRO V, 1995, HUM GENET, V95, P18; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; CHOWDHURY K, 1992, MECH DEVELOP, V39, P129, DOI 10.1016/0925-4773(92)90040-Q; COWELL LG, 1994, TRENDS BIOCHEM SCI, V19, P38; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P647; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FRYER AE, 1987, LANCET, V1, P659; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HUFF V, 1991, AM J HUM GENET, V48, P997; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NOCE T, 1992, DEV BIOL, V153, P356, DOI 10.1016/0012-1606(92)90120-6; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PENGUE G, 1993, HUM MOL GENET, V2, P791, DOI 10.1093/hmg/2.6.791; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J, 1989, MOL CLONING LABORATO; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG ZY, 1993, J BIOL CHEM, V268, P9127; WERNER H, 1994, J BIOL CHEM, V269, P12577; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZHANG X, 1992, J MOL BIOL, V225, P1049, DOI 10.1016/0022-2836(92)90104-R; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	64	100	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22143	22152		10.1074/jbc.270.38.22143	http://dx.doi.org/10.1074/jbc.270.38.22143			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673192	hybrid			2022-12-27	WOS:A1995RW31400016
J	REARDON, DB; HUNG, MC				REARDON, DB; HUNG, MC			DOWNSTREAM SIGNAL-TRANSDUCTION DEFECTS THAT SUPPRESS TRANSFORMATION IN 2 REVERTANT CELL-LINES EXPRESSING ACTIVATED RAT NEU ONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE-ACTIVITY; MURINE LEUKEMIA-VIRUS; PHOSPHOLIPASE-C-GAMMA; HUMAN-BREAST CANCER; PDGF BETA-RECEPTOR; MOLECULAR-CLONING; POINT MUTATION; PROTO-ONCOGENE; NIH3T3 CELLS	The neu gene encodes the transmembrane tyrosine kinase growth factor receptor, p185. To study neu-induced cellular transformation, we developed revertant cells from the neu-transformed NIH 3T3 cell line, B 104-1-1, by treating the cells with the chemical mutagen ethyl methanesulfonate. The morphologically normal revertant cells were first selected by their ability either to attach to culture plates or to survive in the presence of the cytotoxic reagents colchicine or 5-fluoro-2-deoxyuridine. Two of the 21 candidate revertant cell lines isolated were further characterized and were found to lose their anchorage independence and ability to grow in 1% calf serum, indicating that they were nontransformed even though they still expressed p185 oncoprotein. The tyrosine residues of p185 in these two revertants were underphosphorylated, which may have contributed to their nontransformed status. In addition, these revertants also resisted transformation by neu and several additional oncogenes (H-ras, N-ras, v-mos, v-abl, and v-fos) as determined by focus forming assays. These results indicated that we had successfully developed, from neu-transformed cells, revertants exhibiting defective tyrosine phosphorylation of the neu oncoprotein. The results also suggested that neu and several other oncogenes may share common elements in their pathways for the induction of cellular transformation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL 79,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,GRAD SCH BIOMED SCI,HOUSTON,TX 77225	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	PHS HHS [58880] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BACUS SS, 1990, ARCH PATHOL LAB MED, V114, P164; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; GLASS DJ, 1990, ONCOGENE RES, V5, P175; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KUZUMAKI N, 1989, MOL CELL BIOL, V9, P2258, DOI 10.1128/MCB.9.5.2258; MATIN A, 1990, ONCOGENE, V5, P111; MCGUIRE WL, 1987, BREAST CANCER RES TR, V10, P5, DOI 10.1007/BF01806129; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PARKES HC, 1990, BRIT J CANCER, V61, P39, DOI 10.1038/bjc.1990.9; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROEBROEK AJM, 1986, VIRUS RES, V6, P15, DOI 10.1016/0168-1702(86)90053-5; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; TALBOT N, 1988, CYTOGENET CELL GENET, V48, P112, DOI 10.1159/000132602; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANDEWOUDE GF, 1979, P NATL ACAD SCI USA, V76, P4464; VARLEY JM, 1987, ONCOGENE, V1, P423; WEINER DB, 1989, ONCOGENE, V4, P1175; WISDOM R, 1990, MOL CELL BIOL, V10, P5626, DOI 10.1128/MCB.10.11.5626; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZHAO XY, 1992, MOL CELL BIOL, V12, P2739, DOI 10.1128/MCB.12.6.2739	56	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18136	18142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688739				2022-12-27	WOS:A1993LT74300073
J	OOI, GT; BROWN, DR; SUH, DS; TSENG, LYH; RECHLER, MM				OOI, GT; BROWN, DR; SUH, DS; TSENG, LYH; RECHLER, MM			CYCLOHEXIMIDE STABILIZES INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1 (IGFBP-1) MESSENGER-RNA AND INHIBITS IGFBP-1 TRANSCRIPTION IN H4-II-E RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; GENE-EXPRESSION; C-FOS; MULTIHORMONAL REGULATION; TRANSFERRIN RECEPTOR; REGENERATING LIVER; DOMINANT ROLE; BETA-TUBULIN; 3T3 CELLS	The insulin-like growth factor-binding proteins (IGFBPs) are a family of six proteins that modulate the biological activity of IGF-I and IGF-II and determine their bioavailability to tissues. One of the IGFBPs, IGFBP-1, is distinctive in the dynamic response of its levels in human plasma to metabolic changes. Parallel changes occur in IGFBP-1 mRNA and IGFBP-1 transcription in rat liver. Using the well differentiated H4-II-E rat hepatoma cell line as a model system, we demonstrated previously that IGFBP-1 transcription is positively regulated by dexamethasone and negatively regulated by insulin. We now examine the effect of the protein synthesis inhibitor, cycloheximide, on the hormonal regulation of IGFBP-1 gene expression. Preincubation of H4-II-E cells with 10.7 muM cycloheximide for 1.5 h did not prevent the induction of IGFBP-1 mRNA and IGFBP-1 transcription (determined in nuclear run-on assays) by dexamethasone. By contrast, cycloheximide treatment abolished the decrease in IGFBP-1 mRNA induced by insulin. Insulin rapidly decreased IGFBP-1 transcription in the absence of cycloheximide (>50% inhibition in 20 min) and caused a similar decrease in cells pretreated with cycloheximide. Cycloheximide alone also decreased IGFBP-1 transcription. Similar results were observed with a second protein synthesis inhibitor, anisomycin, which also prevented the insulin-induced decrease in IGFBP-1 mRNA without abolishing the insulin-induced inhibition of IGFBP-1 transcription. These results suggest that although insulin decreases IGFBP-1 gene transcription in the presence of protein synthesis inhibitors, IGFBP-1 mRNA levels are maintained because of stabilization of the mRNA. Stabilization was demonstrated directly in actinomycin D-treated cells, where the t1/2 of IGFBP-1 mRNA increased from approximately 2 to approximately 20 h in the presence of cycloheximide; insulin did not affect IGFBP-1 mRNA turnover. Thus, cycloheximide-sensitive labile proteins contribute to the maintenance of basal IGFBP-1 promoter activity and the rapid turnover of IGFBP-1 mRNA, which determine the dynamic regulation of IGFBP-1 gene expression.			OOI, GT (corresponding author), NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,GROWTH & DEV SECT,BLDG 10,RM 8D14,BETHESDA,MD 20892, USA.							ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGERVO M, 1992, BIOCHEM BIOPH RES CO, V189, P1177, DOI 10.1016/0006-291X(92)92328-U; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BAR RS, 1990, ENDOCRINOLOGY, V127, P1078, DOI 10.1210/endo-127-3-1078; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLUME JE, 1989, NUCLEIC ACIDS RES, V17, P9003, DOI 10.1093/nar/17.22.9003; BORTOFF KD, 1992, MOL CELL ENDOCRINOL, V84, P39, DOI 10.1016/0303-7207(92)90069-I; BRISMAR K, 1988, J ENDOCRINOL INVEST, V11, P599, DOI 10.1007/BF03350189; BROWN AL, 1986, J BIOL CHEM, V261, P3144; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DTW, 1988, J BIOL CHEM, V263, P13007; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COTTERILL AM, 1988, J CLIN ENDOCR METAB, V67, P882, DOI 10.1210/jcem-67-5-882; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; ERNEST MJ, 1982, BIOCHEMISTRY-US, V21, P6761, DOI 10.1021/bi00269a022; FARESE RV, 1984, J BIOL CHEM, V259, P7094; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GRANNER DK, 1987, KIDNEY INT, V32, pS82; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUA JL, 1992, MOL ENDOCRINOL, V6, P1418, DOI 10.1210/me.6.9.1418; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JOHNSON TM, 1993, J BIOL CHEM, V268, P464; JULKUNEN M, 1988, FEBS LETT, V236, P295, DOI 10.1016/0014-5793(88)80041-3; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KELLER SA, 1990, GENE DEV, V4, P1316, DOI 10.1101/gad.4.8.1316; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1992, ARCH BIOCHEM BIOPHYS, V298, P56, DOI 10.1016/0003-9861(92)90093-C; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; MESSINA JL, 1991, J BIOL CHEM, V266, P17995; MESSINA JL, 1992, BIOCHIM BIOPHYS ACTA, V1137, P225, DOI 10.1016/0167-4889(92)90205-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; MURPHY LJ, 1990, MOL ENDOCRINOL, V4, P329, DOI 10.1210/mend-4-2-329; NAKAMURA T, 1987, J BIOL CHEM, V262, P727; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NAWA K, 1986, J BIOL CHEM, V261, P6883; NELSON K, 1980, J BIOL CHEM, V255, P8509; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OOI GT, 1992, MOL ENDOCRINOL, V6, P2219, DOI 10.1210/me.6.12.2219; OOI GT, 1993, GROWTH REGULAT, V3, P12; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; RINGOLD GM, 1977, P NATL ACAD SCI USA, V74, P2879, DOI 10.1073/pnas.74.7.2879; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; UNTERMAN TG, 1990, ENDOCRINOLOGY, V127, P789, DOI 10.1210/endo-127-2-789; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; VAZQUEZ D, 1979, INHIBITORS PROTEIN S, P136; WIDMAIER EP, 1985, MOL CELL ENDOCRINOL, V43, P181, DOI 10.1016/0303-7207(85)90082-6; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANG YWH, 1990, MOL ENDOCRINOL, V4, P29, DOI 10.1210/mend-4-1-29; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	78	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16664	16672						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688368				2022-12-27	WOS:A1993LQ33600083
J	MARLETTA, MA				MARLETTA, MA			NITRIC-OXIDE SYNTHASE STRUCTURE AND MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							METHYL-L-ARGININE; MURINE MACROPHAGES; ENDOTHELIAL-CELLS; RELAXING FACTOR; CYTOCHROME-P-450; PURIFICATION; TETRAHYDROBIOPTERIN; COFACTOR; NITRATE; COMPLEXES		UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	MARLETTA, MA (corresponding author), UNIV MICHIGAN,COLL PHARM,INTERDEPT PROGRAM MEDICINAL CHEM,428 CHURCH ST,ANN ARBOR,MI 48109, USA.				NCI NIH HHS [CA 26731, CA 50414] Funding Source: Medline; NCRR NIH HHS [MO1RR00042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050414, P01CA026731] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BESSENBACHER C, 1989, INORG CHEM, V28, P4645, DOI 10.1021/ic00325a021; BOJE KM, 1990, J PHARMACOL EXP THER, V253, P20; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURSTYN JN, 1988, J AM CHEM SOC, V110, P1382, DOI 10.1021/ja00213a009; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COLE PA, 1991, J AM CHEM SOC, V113, P8130, DOI 10.1021/ja00021a044; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIKI K, 1992, J BIOCHEM-TOKYO, V111, P556, DOI 10.1093/oxfordjournals.jbchem.a123795; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KIESE M, 1966, PHARMACOL REV, V18, P1091; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA M A, 1990, Biofactors, V2, P219; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; MOAD G, 1979, J AM CHEM SOC, V101, P6068, DOI 10.1021/ja00514a033; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NASIR MS, 1992, J AM CHEM SOC, V114, P2264, DOI 10.1021/ja00032a054; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; OLKEN NM, 1992, J MED CHEM, V35, P1137, DOI 10.1021/jm00084a020; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PERKINSON J, 1991, INORG CHEM, V30, P719, DOI 10.1021/ic00004a023; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; PORTER TD, 1991, J BIOL CHEM, V266, P13469; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TAYLOR PJ, 1986, J CHEM SOC PERK T 2, P1765, DOI 10.1039/p29860001765; VANATTA RB, 1987, J AM CHEM SOC, V109, P1425, DOI 10.1021/ja00239a024; VAZ ADN, 1991, J AM CHEM SOC, V113, P5886, DOI 10.1021/ja00015a066; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	65	1171	1210	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12231	12234						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685338				2022-12-27	WOS:A1993LG65800001
J	OXVIG, C; SAND, O; KRISTENSEN, T; GLEICH, GJ; SOTTRUPJENSEN, L				OXVIG, C; SAND, O; KRISTENSEN, T; GLEICH, GJ; SOTTRUPJENSEN, L			CIRCULATING HUMAN PREGNANCY-ASSOCIATED PLASMA PROTEIN-A IS DISULFIDE-BRIDGED TO THE PROFORM OF EOSINOPHIL MAJOR BASIC-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; PAPP-A; FOLLICULAR-FLUID; HUMAN-PLACENTA; ALPHA-2-MACROGLOBULIN; PURIFICATION; LOCALIZATION; PRECURSOR; CLEAVAGE; CELLS	A previously unrecognized association between pregnancy-associated plasma protein-A (PAPP-A) and the proform of eosinophil major basic protein (proMBP) is demonstrated. PAPP-A isolated from pooled pregnancy serum is shown to be a disulfide-bridged complex with proMBP (PAPP-A/proMBP) in which the subunits of the constituents are present in a 1:1 molar ratio. The results are the outcome of analysis of tryptic and CNBr/tryptic peptides from PAPP-A/ProMBP, sequence analysis of intact and reduced and carboxymethylated PAPP-A/proMBP, and reaction with monoclonal antibodies directed against MBP and its proform. In addition, it is shown that commercial polyclonal anti-PAPP-A is polyspecific, also reacting with MBP.	AARHUS UNIV,DEPT MOLEC BIOL,BLDG 130,DK-8000 AARHUS,DENMARK; AARHUS UNIV,DEPT CHEM,DK-8000 AARHUS,DENMARK; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905	Aarhus University; Aarhus University; Mayo Clinic; Mayo Clinic				Oxvig, Claus/0000-0002-4715-9719	NIAID NIH HHS [AI 09728, AI 15231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015231, R37AI015231, R01AI009728, R37AI009728] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BISCHOF P, 1979, ARCH GYNECOL, V227, P315, DOI 10.1007/BF02109920; BISCHOF P, 1983, J CLIN ENDOCR METAB, V56, P359, DOI 10.1210/jcem-56-2-359; CRIMMINS DL, 1989, ANAL BIOCHEM, V176, P255, DOI 10.1016/0003-2697(89)90305-9; DAVEY MW, 1983, ANAL BIOCHEM, V131, P18, DOI 10.1016/0003-2697(83)90130-6; FOLKERSEN J, 1981, AM J OBSTET GYNECOL, V139, P910, DOI 10.1016/0002-9378(81)90957-1; FRIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; HAMANN KJ, 1991, AIRWAY EPITHELIUM PH, P255; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TM, 1976, SCIENCE, V193, P1249, DOI 10.1126/science.60782; LIN TM, 1974, AM J OBSTET GYNECOL, V118, P223, DOI 10.1016/0002-9378(74)90553-5; MADDOX DE, 1983, J EXP MED, V158, P1211, DOI 10.1084/jem.158.4.1211; MADDOX DE, 1984, J EXP MED, V160, P29, DOI 10.1084/jem.160.1.29; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MUNCH M, 1991, FEBS LETT, V295, P102, DOI 10.1016/0014-5793(91)81395-O; SINOSICH MJ, 1990, BIOCHEM INT, V20, P579; SINOSICH MJ, 1984, J CLIN ENDOCR METAB, V58, P500, DOI 10.1210/jcem-58-3-500; SJOBERG J, 1984, FERTIL STERIL, V41, P551; SJOBERG J, 1984, ARCH ANDROLOGY, V14, P253; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8293; SUTCLIFFE RG, 1980, BIOCHEM J, V191, P799, DOI 10.1042/bj1910799; TORNEHAVE D, 1984, PLACENTA, V5, P427, DOI 10.1016/S0143-4004(84)80023-5; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WASMOEN TL, 1988, J BIOL CHEM, V263, P12559; WASMOEN TL, 1989, J EXP MED, V170, P2051, DOI 10.1084/jem.170.6.2051; WASMOEN TL, 1991, AM J OBSTET GYNECOL, V165, P416, DOI 10.1016/0002-9378(91)90107-3; WASMOEN TL, 1987, P NATL ACAD SCI USA, V84, P3029, DOI 10.1073/pnas.84.9.3029; WESTERGAARD JG, 1983, ARCH GYNECOL, V233, P211, DOI 10.1007/BF02114602	33	156	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12243	12246						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685339				2022-12-27	WOS:A1993LG65800004
J	SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL				SCHIEBEL, W; HAAS, B; MARINKOVIC, S; KLANNER, A; SANGER, HL			RNA-DIRECTED RNA-POLYMERASE FROM TOMATO LEAVES .1. PURIFICATION AND PHYSICAL-PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBER VIROID PSTV; NUCLEOTIDE-SEQUENCE; REPLICATION COMPLEX; POLYACRYLAMIDE GELS; PROTEIN-SYNTHESIS; COWPEA; PLANTS; HOST; OLIGORIBONUCLEOTIDES; IDENTIFICATION	An RNA-directed RNA polymerase (RdRP, EC 2.7.7.48) from tomato leaf tissue was purified to electrophoretic homogeneity. A terminal transferase activity that was found to cofractionate with RdRP from DEAE-Sepharose and DNA-cellulose columns was removed by chromatography on a Mono Q column. The highly purified RdRP exhibits a specific activity of 500 nmol x mg-1 x 30 min-1, which corresponds to a 100,000-fold enrichment of the enzyme. In buffer containing 50% glycerol, its activity decreased by about 15%/month. RdRP activity coincided with the silver staining intensity of a single 128-kDa polypeptide when the fractions eluted from the Mono Q column were analyzed by electrophoresis in a SDS-polyacrylamide gel. Its molecular mass and its sedimentation coefficient of 6.6 S indicate that RdRP is a nearly globular molecule. The catalytic activity of RdRP is resistant to alpha-amanitin and actinomycin D. In tomato leaves systemically infected with potato spindle tuber viroid, the activity of RdRP was found to be increased about 3-fold compared with RdRP isolated from healthy leaf tissue.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society								ASTIERMA.S, 1971, BIOCHIM BIOPHYS ACTA, V232, P484, DOI 10.1016/0005-2787(71)90602-2; ASTIERMANIFACIER S, 1978, CR ACAD SCI D NAT, V287, P1043; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIEBRICHER CK, 1983, EVOL BIOL, V16, P1; BOEGE F, 1980, FEBS LETT, V121, P91, DOI 10.1016/0014-5793(80)81273-7; BOEGE F, 1982, BIOSCIENCE REP, V2, P379, DOI 10.1007/BF01119300; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDRESSE T, 1986, VIROLOGY, V152, P322, DOI 10.1016/0042-6822(86)90135-2; CONSIGLIO E, 1970, European Journal of Biochemistry, V17, P408, DOI 10.1111/j.1432-1033.1970.tb01180.x; DAVIES JW, 1974, VIROLOGY, V61, P281, DOI 10.1016/0042-6822(74)90262-1; DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4; DORSSERS L, 1984, P NATL ACAD SCI-BIOL, V81, P1951, DOI 10.1073/pnas.81.7.1951; DORSSERS L, 1983, VIROLOGY, V125, P155, DOI 10.1016/0042-6822(83)90071-5; DORSSERS L, 1982, VIROLOGY, V116, P236, DOI 10.1016/0042-6822(82)90416-0; DUDA CT, 1973, BIOCHIM BIOPHYS ACTA, V319, P62, DOI 10.1016/0005-2787(73)90041-5; DUDA CT, 1979, VIROLOGY, V92, P180, DOI 10.1016/0042-6822(79)90223-X; EDMONDS M, 1982, ENZYMES, V15, P217; FRAENKELCONRAT H, 1983, P NATL ACAD SCI-BIOL, V80, P422, DOI 10.1073/pnas.80.2.422; FRAENKELCONRAT H, 1986, CRC CR REV PLANT SCI, V4, P213, DOI 10.1080/07352688609382224; GOLDBACH R, 1985, MOL PLANT VIROLOGY, V2, P83; GROSS HJ, 1978, NATURE, V273, P203, DOI 10.1038/273203a0; HALL TC, 1974, VIROLOGY, V61, P486, DOI 10.1016/0042-6822(74)90284-0; HALL TC, 1982, ADV PLANT PATHOL, V1, P233; HAYES RJ, 1990, CELL, V63, P363, DOI 10.1016/0092-8674(90)90169-F; KHAN ZA, 1986, P NATL ACAD SCI USA, V83, P2383, DOI 10.1073/pnas.83.8.2383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUIS B G, 1972, Biochemical Journal, V128, P755; MANDAHAER CL, 1989, PLANT VIRUSES, V1, P125; MARSH LE, 1991, OXFORD SURV PLANT MO, V7, P297; MARTIN FH, 1971, J MOL BIOL, V57, P201, DOI 10.1016/0022-2836(71)90341-X; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MILDVAN AS, 1979, CRC CR REV BIOCH MOL, V6, P219, DOI 10.3109/10409237909102564; MIRAULT ME, 1971, EUR J BIOCHEM, V23, P372, DOI 10.1111/j.1432-1033.1971.tb01631.x; MOUCHES C, 1984, VIROLOGY, V134, P78, DOI 10.1016/0042-6822(84)90274-5; MUHLBACH HP, 1979, NATURE, V278, P185, DOI 10.1038/278185a0; NEER EJ, 1974, J BIOL CHEM, V249, P6527; OCHOA S, 1961, P NATL ACAD SCI USA, V47, P670, DOI 10.1073/pnas.47.5.670; QUADT R, 1989, MOL PLANT MICROBE IN, V2, P219, DOI 10.1094/MPMI-2-219; QUADT R, 1990, VIROLOGY, V178, P189, DOI 10.1016/0042-6822(90)90393-6; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RICHARDS O, 1990, CURR TOP MICROBIOL I, V161, P90; ROMAINE CP, 1978, VIROLOGY, V86, P241, DOI 10.1016/0042-6822(78)90024-7; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11858; SCHINDLER IM, 1992, PLANT SCI, V84, P221, DOI 10.1016/0168-9452(92)90138-C; SELIGER H, 1980, NUCLEIC ACIDS RES S, V7, P191; SEMANCIK JS, 1977, VIROLOGY, V80, P218, DOI 10.1016/0042-6822(77)90395-6; SMITH MH, 1970, HDB BIOCH, pC3; SOUTHERN EM, 1971, BIOCHEM J, V123, P613, DOI 10.1042/bj1230613; SPIESMACHER E, 1985, BIOSCIENCE REP, V5, P251, DOI 10.1007/BF01119595; TABLER M, 1984, EMBO J, V3, P3055, DOI 10.1002/j.1460-2075.1984.tb02257.x; TAKANAMI Y, 1982, BIOCHEMISTRY-US, V21, P3161, DOI 10.1021/bi00256a020; van Duin J., 1988, BACTERIOPHAGES, P117; VANDERMEER J, 1984, VIROLOGY, V132, P413, DOI 10.1016/0042-6822(84)90046-1; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; VOLLOCH V, 1987, J CELL BIOL, V105, P137, DOI 10.1083/jcb.105.1.137; VOLLOCH V, 1991, P NATL ACAD SCI USA, V88, P10671, DOI 10.1073/pnas.88.23.10671; WARD CD, 1988, J VIROL, V62, P558, DOI 10.1128/JVI.62.2.558-562.1988; WEISSBACH A, 1974, METHOD ENZYMOL, V34, P363; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZABEL P, 1976, J VIROL, V17, P679, DOI 10.1128/JVI.17.3.679-685.1976; ZABEL P, 1981, NUCLEIC ACIDS RES, V9, P2433, DOI 10.1093/nar/9.11.2433	61	78	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11851	11857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685022				2022-12-27	WOS:A1993LF28400060
J	FUJIMOTO, T; STROUD, E; WHATLEY, RE; PRESCOTT, SM; MUSZBEK, L; LAPOSATA, M; MCEVER, RP				FUJIMOTO, T; STROUD, E; WHATLEY, RE; PRESCOTT, SM; MUSZBEK, L; LAPOSATA, M; MCEVER, RP			P-SELECTIN IS ACYLATED WITH PALMITIC ACID AND STEARIC-ACID AT CYSTEINE-766 THROUGH A THIOESTER LINKAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; PLASMA-MEMBRANE; COVALENT MODIFICATION; MONOCLONAL-ANTIBODY; VIRAL GLYCOPROTEIN; ENDOTHELIAL-CELLS; CELLULAR PROTEINS; GMP-140; ACTIVATION	We report that the adhesion receptor P-selectin can be metabolically labeled with [H-3]palmitic acid in human platelets. Analysis of alkaline methanolysis products from labeled protein demonstrated that the radioactivity associated with P-selectin was covalently bound palmitic acid. [H-3]Palmitic acid was cleaved by hydroxylamine treatment at neutral pH and by reducing agents, indicating that acylation occurred through a thioester linkage. Both stearic acid and palmitic acid were detected by gas chromatography-mass spectrometry analysis of alkaline hydrolysates of purified P-selectin. Deletion or mutation of Cys766 eliminated [H-3] palmitic acid labeling of P-selectin in transfected COS-7 cells. We conclude that the cytoplasmic domain of P-selectin is acylated at Cys766 through a thioester bond. Fatty acid acylation may regulate intracellular trafficking or other functions of P-selectin.	UNIV OKLAHOMA HLTH SCI CTR,WK WARREN MED RES INST,DEPT MED,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; VET AFFAIRS MED CTR,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84112; UNIV UTAH,SCH MED,DEPT MED,NORA ECCLE HARRISON CARDIOVASC RES & TRAINING INST,SALT LAKE CITY,UT 84112; UNIV SCH MED DEBRECEN,DEPT CLIN CHEM,H-4012 DEBRECEN,HUNGARY; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114; UNIV OKLAHOMA HLTH SCI CTR,WK WARREN MED RES INST,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Debrecen; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NHLBI NIH HHS [HL 45510, HL 34363, HL 34127] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034363, R01HL034363, R01HL045510, R01HL034127] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BERGER M, 1984, J BIOL CHEM, V259, P7245; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLANOWSKI MA, 1984, J BIOL CHEM, V259, P4934; BONFANTI R, 1989, BLOOD, V73, P1109; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Capriotti A, 1986, J TISSUE CULTURE MET, V10, P219, DOI 10.1007/BF01404480; DEYKIN D, 1968, J CLIN INVEST, V47, P1590, DOI 10.1172/JCI105851; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GREEN SA, 1992, J CELL BIOL, V117, P47, DOI 10.1083/jcb.117.1.47; GRETCH DR, 1987, ANAL BIOCHEM, V163, P270, DOI 10.1016/0003-2697(87)90123-0; HATTORI R, 1989, J BIOL CHEM, V264, P7768; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MAGEE AI, 1990, J CELL SCI, V97, P581; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; MUSZBEK L, 1989, BLOOD, V74, P1339; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; MUSZBEK L, 1993, J BIOL CHEM, V268, P8251; NEWMAN JP, 1992, J CELL BIOL, V119, P239; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1985, J BIOL CHEM, V260, P3784; SANDERS WE, 1992, BLOOD, V80, P795; SCHMIDT M, 1988, J BIOL CHEM, V263, P18635; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SCULLION BF, 1987, J CELL BIOL, V105, P69, DOI 10.1083/jcb.105.1.69; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; WELLER A, 1992, J BIOL CHEM, V267, P15176	44	53	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11394	11400						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684381				2022-12-27	WOS:A1993LD46600098
J	GREEN, GR; LEE, HJ; POCCIA, DL				GREEN, GR; LEE, HJ; POCCIA, DL			PHOSPHORYLATION WEAKENS DNA-BINDING BY PEPTIDES CONTAINING MULTIPLE SPKK SEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN SPERM; HISTONE VARIANTS; LINKER DNA; CHROMATIN DECONDENSATION; CHROMOSOMAL-PROTEINS; CORE HISTONE; MOTIFS; KINASE; H-1; H2B	Sea urchin testis-specific H1 and H2B histones (Sp H1 and Sp H2B) are characterized by reversibly phosphorylated N-terminal regions consisting largely of multiple clustered ''SPKK'' tetrapeptides (serine-proline adjacent to two basic amino acids). This report presents data showing differences in DNA affinities between peptides containing dephosphorylated and phosphorylated N-terminal regions. Sp H1 and its phosphorylated derivative (pSp H1) were purified by hydroxylapatite chromatography. Peptides containing the N-terminal regions of Sp H1 and pSp H1 (NP and pNP, respectively) were produced by digestion with Staphylococcus aureus protease. NP and two forms of pNP differing in phosphate content were purified by DNA-cellulose chromatography. The DNA affinities of the peptides were compared using several criteria. NP was bound more tightly by DNA-cellulose than pNPs. NP precipitated DNA under a broad range of NaCl concentrations; pNPs did not. Both NP and pNPs protected DNA against thermal denaturation, but NP created a more stable DNA-peptide complex. Thirty to sixty times more pNP than NP was required to obtain equivalent inhibition of Hoechst 33258 binding to DNA. NP did not behave as a competitive inhibitor of DNA binding by Hoechst 33258 binding to DNA. We conclude that during spermatogenesis, dephosphorylation of the Sp H1 N-terminal region increases its basicity and thus its affinity for DNA.			GREEN, GR (corresponding author), AMHERST COLL,WEBSTER CTR BIOL SCI,DEPT BIOL,AMHERST,MA 01002, USA.							ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BERNARDI G, 1960, BIOCHIM BIOPHYS ACTA, V44, P96, DOI 10.1016/0006-3002(60)91527-4; BRANDT WF, 1988, EUR J BIOCHEM, V173, P547, DOI 10.1111/j.1432-1033.1988.tb14033.x; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CARRONDO MAAFDT, 1989, BIOCHEMISTRY-US, V28, P7849, DOI 10.1021/bi00445a047; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; GREEN GR, 1985, DEV BIOL, V108, P235, DOI 10.1016/0012-1606(85)90026-0; GREEN GR, 1989, DEV BIOL, V134, P413, DOI 10.1016/0012-1606(89)90113-9; GREEN GR, 1988, BIOCHEMISTRY-US, V27, P619, DOI 10.1021/bi00402a019; GREEN GR, 1990, PLANT PHYSIOL, V93, P1241, DOI 10.1104/pp.93.3.1241; GREEN GR, 1983, BIOCHIM BIOPHYS ACTA, V741, P251, DOI 10.1016/0167-4781(83)90066-0; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; HILL CS, 1990, EUR J BIOCHEM, V187, P145, DOI 10.1111/j.1432-1033.1990.tb15288.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAPLAN LJ, 1984, J BIOL CHEM, V259, P8777; LINDSEY GG, 1992, J BIOL CHEM, V267, P14622; LOONTIENS FG, 1990, BIOCHEMISTRY-US, V29, P9029, DOI 10.1021/bi00490a021; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; OZAKI H, 1971, DEV BIOL, V26, P209, DOI 10.1016/0012-1606(71)90123-0; PAOLETTI RA, 1969, BIOCHEMISTRY-US, V8, P1615, DOI 10.1021/bi00832a043; PJURA PE, 1987, J MOL BIOL, V197, P257, DOI 10.1016/0022-2836(87)90123-9; POCCIA D, 1990, EXP CELL RES, V188, P226, DOI 10.1016/0014-4827(90)90164-6; POCCIA D, 1981, DEV BIOL, V82, P287, DOI 10.1016/0012-1606(81)90452-8; POCCIA DL, 1987, DEV BIOL, V121, P445, DOI 10.1016/0012-1606(87)90181-3; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; POCCIA DL, 1986, METHOD CELL BIOL, V27, P153, DOI 10.1016/S0091-679X(08)60347-7; PORTER DC, 1988, J BIOL CHEM, V263, P2750; REEVES R, 1990, J BIOL CHEM, V265, P8573; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; STRICKLAND WN, 1977, EUR J BIOCHEM, V77, P277, DOI 10.1111/j.1432-1033.1977.tb11666.x; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TENG M, 1988, NUCLEIC ACIDS RES, V16, P2671, DOI 10.1093/nar/16.6.2671; VANHOLDE KE, 1989, CHROMATIN, P247; VODICKA M, 1990, J EXP ZOOL, V256, P179, DOI 10.1002/jez.1402560208; ZALENSKAYA IA, 1981, NUCLEIC ACIDS RES, V9, P473, DOI 10.1093/nar/9.3.473; [No title captured]	44	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11247	11255						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684375				2022-12-27	WOS:A1993LD46600078
J	KNOFLER, M; WALTNER, C; WINTERSBERGER, E; MULLNER, EW				KNOFLER, M; WALTNER, C; WINTERSBERGER, E; MULLNER, EW			TRANSLATIONAL REPRESSION OF ENDOGENOUS THYMIDINE KINASE MESSENGER-RNA IN DIFFERENTIATING AND ARRESTING MOUSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' UNTRANSLATED REGION; SERUM-STIMULATED CELLS; GENE PROMOTER; CYCLE REGULATION; MUSCLE-CELLS; HELA-CELLS; EXPRESSION; BINDING; PURIFICATION; FERRITIN	We observed that decline of thymidine kinase (TK) enzyme activity was severalfold faster than the decay of full length TK mRNA during growth arrest of 3T6 mouse fibroblasts or during differentiation of myoblasts (C2Cl12) or F9 embryonal carcinoma cells. In order to study the molecular mechanism of this disparate behavior, a polyclonal antiserum against mouse TK was raised in rabbit. High level expression of mouse TK polypeptide in Escherichia coli was achieved with a T7 RNA polymerase-directed expression system. Using the antiserum in immunoblotting, no indication for a pool of inactive enzyme was found during differentiation of F9 or growth arrest of 3T6 cells. Pulse labeling of these cells in vivo with [S-35]methionine showed a more than 6-fold decrease in the rate of TK-protein synthesis of in F9 cells after 3 days of treatment with retinoic acid as well as in 3T6 cells after 16 h under low serum. This was not due to increased turnover of the protein as measured in pulse chase experiments. In addition, full length TK mRNA stayed associated with polysomes under these conditions in F9 as well as 3T6 cells. Taken together the results suggest that endogenous TK mRNA becomes translationally repressed under a variety of conditions when mouse cells cease to grow.	UNIV VIENNA, VIENNA BIOCTR, INST MOLEC BIOL, DR BOHR GASSE 9, A-1030 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)								ARCOT SS, 1989, J BIOL CHEM, V264, P2343; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY DW, 1990, P NATL ACAD SCI USA, V87, P9310, DOI 10.1073/pnas.87.23.9310; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1982, EUR J BIOCHEM, V123, P539; Favaloro J, 1980, Methods Enzymol, V65, P718; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FRIDOVICHKEIL JL, 1991, CELL GROWTH DIFFER, V2, P67; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; ITO M, 1990, J BIOL CHEM, V265, P6954; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1991, ONCOGENE, V6, P1427; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; LEE LS, 1976, J BIOL CHEM, V251, P2600; LIANG HM, 1991, NUCLEIC ACIDS RES, V19, P2289, DOI 10.1093/nar/19.9.2289; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; LIN PF, 1985, MOL CELL BIOL, V5, P3149, DOI 10.1128/MCB.5.11.3149; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P6848, DOI 10.1073/pnas.86.18.6848; MARZLUFF WF, 1988, TRENDS BIOCHEM SCI, V13, P49, DOI 10.1016/0968-0004(88)90027-8; MULLNER E, 1983, BIOCHIM BIOPHYS ACTA, V740, P436, DOI 10.1016/0167-4781(83)90092-1; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; RINGERTZ NR, 1978, EXP CELL RES, V113, P233, DOI 10.1016/0014-4827(78)90363-4; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SEISER C, 1989, NUCLEIC ACIDS RES, V17, P185, DOI 10.1093/nar/17.1.185; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; WEICHSELBRAUN I, 1990, FEBS LETT, V275, P49, DOI 10.1016/0014-5793(90)81436-R; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; YONG KK, 1988, P NATL ACAD SCI USA, V85, P5894, DOI 10.1073/pnas.85.16.5894	51	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11409	11416						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684382				2022-12-27	WOS:A1993LD46600100
J	CHERNY, RC; HONAN, MA; THIAGARAJAN, P				CHERNY, RC; HONAN, MA; THIAGARAJAN, P			SITE-DIRECTED MUTAGENESIS OF THE ARGININE-GLYCINE-ASPARTIC ACID IN VITRONECTIN ABOLISHES CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SERUM SPREADING FACTOR; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; GLYCOPROTEIN-IIIA; HUMAN FIBRONECTIN; HUMAN-FIBRINOGEN; BINDING DOMAIN; S-PROTEIN; RECOGNITION	Vitronectin (VN), a major cell adhesion protein, is found in Plasma and in the extracellular matrix. At least three distinct cell surface receptors for vitronectin belonging to the integrin superfamily have been identified in normal and neoplastic cells. Many cell adhesion ligands, including vitronectin, contain an Arg-Gly-Asp (RGD) sequence mediating, in part, the ligand-receptor interaction. These ligands bind different integrins with varying specificity and affinity. The mechanism of receptor specificity remains controversial. To determine the role of the RGD sequence in receptor specificity, we amplified the cDNA for human vitronectin from a liver cDNA library and generated two separate mutants by utilizing site-directed mutagenesis resulting in aspartic acid (Asp47) to glutamic acid (Glu47) substitution and glycine (Gly46) to alanine (Ala46) substitution. The mammalian expression vector, pZEM229R, was used to transfect baby hamster kidney cells which secreted recombinant proteins into the supernatant. All recombinant proteins were isolated by heparin-agarose chromatography and tested for interaction with three known vitronectin receptors, namely, alpha(IIb)beta3 on thrombin-activated platelets, alpha(v)beta3 on human umbilical vein endothelial cells and alpha(v)beta5 on Panc-1 cells. Recombinant wild-type vitronectin behaved in a fashion similar to plasma-derived vitronectin. Both the RGE-VN and RAD-VN recombinant mutant proteins showed complete loss of cell adhesion activity, regardless of the receptor. These results confirm the essential and central role of the RGD sequence in vitronectin for cell adhesion. This expression system allows further structure/function analysis of vitronectin.	UNIV WASHINGTON,DEPT MED,DIV HEMATOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [K08CA001600] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040860, R01HL016919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01600] Funding Source: Medline; NHLBI NIH HHS [HL 16919, HL 40860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1983, P NATL ACAD SCI-BIOL, V80, P1362, DOI 10.1073/pnas.80.5.1362; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; FARRELL DH, 1986, BIOCHEM J, V27, P907; FITZGERALD LA, 1985, J BIOL CHEM, V260, P893; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HAYMAN EG, 1982, J CELL BIOL, V95, P20, DOI 10.1083/jcb.95.1.20; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; OBARA M, 1987, FEBS LETT, V213, P261, DOI 10.1016/0014-5793(87)81502-8; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PLOW EF, 1990, HEMOSTASIS THROMB, V9, P117; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, CELL, V52, P229; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; THIAGARAJAN P, 1985, J CLIN INVEST, V75, P896, DOI 10.1172/JCI111789; THIAGARAJAN P, 1988, THROMB HAEMOSTASIS, V60, P514; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	41	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9725	9729						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683657				2022-12-27	WOS:A1993LA68900084
J	LOYA, SS; HIZI, A				LOYA, SS; HIZI, A			THE INTERACTION OF ILLIMAQUINONE, A SELECTIVE INHIBITOR OF THE RNASE-H ACTIVITY, WITH THE REVERSE TRANSCRIPTASES OF HUMAN IMMUNODEFICIENCY AND MURINE LEUKEMIA RETROVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; RIBONUCLEASE-H; ESCHERICHIA-COLI; DNA-POLYMERASE; MUTATIONAL ANALYSIS; VIRUS TYPE-2; DOMAIN; EXPRESSION; ORGANIZATION; MUTAGENESIS	Illimaquinone, a natural marine product, was shown by us to inhibit preferentially the ribonuclease H (RNase H) activity of the reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1). We have also shown that illimaquinone inhibits the RNase H activity of HIV-2 RT in addition to that of HIV-1 RT, murine leukemia virus RT, and Escherichia coli RNase H. Chemical modifications of HIV-1 RT by sulfhydryl-specific reagents, such as N-ethylmaleimide (NEM) have been demonstrated to specifically inhibit the RNase H activity of the enzyme. Since our previous studies have suggested that cysteine 280 in HIV-1 RT interacts with the sulfhydryl reagents, we have examined the possibility that illimaquinone interacts with the RT molecules via amino acid residues located in the vicinity of cysteine 280 in both HIV-1 and HIV-2 RTs. In the combined effect studies of illimaquinone and NEM, the two structurally unrelated compounds were shown to be mutually exclusive, exhibiting an antagonistic interaction with both HIV-1 and murine leukemia virus-associated RNase H activities. This implicates cysteine 280, in both HIV-1 and HIV-2 RTs, to be in close proximity to the putative binding site of the enzyme to illimaquinone. The above conclusion is further supported by the fact that the RNase H activity of an enzymatically active mutant of HIV-1 RT, in which cysteine 280 was replaced by serine, was substantially more resistant to illimaquinone than the corresponding activity of the wild-type enzyme. The fact that NEM failed to inhibit E. coli RNase H as opposed to illimaquinone highlights a major difference between the retroviral and bacterial RNase H.	TEL AVIV UNIV,SACKLER SCH MED,DEPT CELL BIOL & HISTOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine					NIAID NIH HHS [AI31790] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031790] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CROUCH R J, 1990, New Biologist, V2, P771; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; FREEMANWITTING MJ, 1986, BIOCHEMISTRY-US, V25, P3050, DOI 10.1021/bi00358a047; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HIZI A, 1989, VIROLOGY, V170, P326, DOI 10.1016/0042-6822(89)90389-9; HIZI A, 1992, J BIOL CHEM, V267, P1293; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, GENE, V66, P319, DOI 10.1016/0378-1119(88)90369-1; HIZI A, 1991, J BIOL CHEM, V266, P6230; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148; HUGHES S H, 1991, Current Biology, V1, P323, DOI 10.1016/0960-9822(91)90100-B; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KRUG MS, 1991, BIOCHEMISTRY-US, V30, P10614, DOI 10.1021/bi00108a003; LEVIN JG, 1988, J VIROL, V62, P4376, DOI 10.1128/JVI.62.11.4376-4380.1988; LOWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; LOYA S, 1992, J BIOL CHEM, V267, P13879; LOYA S, 1990, ANTIMICROB AGENTS CH, V34, P2009, DOI 10.1128/AAC.34.10.2009; MILLER AD, 1984, J VIROL, V49, P214, DOI 10.1128/JVI.49.1.214-222.1984; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SHAHARABANY M, 1992, J BIOL CHEM, V267, P3674; SOKAL RR, 1981, BIOMETRY, P499; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; Webb JL, 1961, ENZYMES METABOL INH, V1, P66; Weiss R, 1985, RNA TUMOR VIRUSES; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	42	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9323	9328						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683648				2022-12-27	WOS:A1993LA68900029
J	SILENCE, K; COLLEN, D; LIJNEN, HR				SILENCE, K; COLLEN, D; LIJNEN, HR			INTERACTION BETWEEN STAPHYLOKINASE, PLASMIN(OGEN), AND ALPHA-2-ANTIPLASMIN - RECYCLING OF STAPHYLOKINASE AFTER NEUTRALIZATION OF THE PLASMIN-STAPHYLOKINASE COMPLEX BY ALPHA-2-ANTIPLASMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOLYTIC PROPERTIES; ACTIVATION; UROKINASE; CHAIN; STREPTOKINASE; PURIFICATION; MECHANISM; KINETICS; PROTEIN; SITE	Although the plasminogen activating equimolar complex of staphylokinase (STA) with human plasmin is very rapidly inhibited by alpha2-antiplasmin, STA is a potent fibrinolytic agent in a human plasma milieu which contains 1 muM alpha2-antiplasmin. In the present study, it was found that the complex of plasmin with recombinant STA (STAR), after neutralization with alpha2-antiplasmin, retained the full plasminogen activating potential of STAR when added to a plasminogen solution (93 +/- 5% residual activity). When added to human plasma containing a I-125-fibrin-labeled plasma clot, equi-effective concentrations (causing 50% lysis in 2 h) were 17 +/- 3.0, 13 +/- 1.0, and 20 +/- 1.0 nM for STAR, equimolar plasmin-STAR mixtures, and plasmin-STAR mixtures neutralized by alpha2-antiplasmin, respectively. Gel filtration of mixtures of plasmin(ogen) and STAR revealed elution as plasmin-STAR complex (M(r) almost-equal-to 100,000), whereas after addition of alpha2-antiplasmin, STAR eluted with an apparent M(r) of 20,000. When mixtures of plasmin and STAR were adsorbed to lysine-Sepharose, STAR adsorbed quantitatively (96 +/- 1%) to the gel, whereas it was nearly quantitatively recovered in the unbound fraction (92 +/- 4%) after addition of alpha2-antiplasmin to the mixture. Scatchard analysis of the binding of STAR to plasmin-Sepharose yielded a dissociation constant of 55 nM, whereas no specific binding of STAR to plasmin-alpha2-antiplasmin-Sepharose could be demonstrated. These findings indicate that, both in purified systems and in a human plasma milieu containing a I-125-fibrin-labeled plasma clot, neutralization of the plasmin-STAR complex by alpha2-antiplasmin results in dissociation of functionally active STAR from the complex and recycling of STAR to other plasminogen molecules. This dissociation-recycling process may explain the high fibrinolytic potency of STAR in a plasma milieu in the presence of high concentrations of alpha2-antiplasmin.	CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, CAMPUS GASTHUISBERG, O & N HERESTR 49, B-3000 LOUVAIN, BELGIUM	KU Leuven			Lijnen, Roger/AAA-4085-2020					BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1992, FIBRINOLYSIS, V6, P232, DOI 10.1016/0268-9499(92)90076-T; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ERICSON R, 1977, CHEM ABSTR, V86, P202; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; LEWIS JH, 1951, AM J PHYSIOL, V166, P594, DOI 10.1152/ajplegacy.1951.166.3.594; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, BIOCHIM BIOPHYS ACTA, V1118, P144, DOI 10.1016/0167-4838(92)90142-Z; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P468; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P214, DOI 10.1016/0268-9499(92)90074-R; MATSUO O, 1990, BLOOD, V76, P925; SAKAI M, 1989, BIOCHEM BIOPH RES CO, V162, P830, DOI 10.1016/0006-291X(89)92385-1; WIMAN B, 1977, EUR J BIOCHEM, V76, P129, DOI 10.1111/j.1432-1033.1977.tb11578.x; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P19	26	43	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9811	9816						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683664				2022-12-27	WOS:A1993LA68900095
J	BAUMANN, H; ZIEGLER, SF; MOSLEY, B; MORELLA, KK; PAJOVIC, S; GEARING, DP				BAUMANN, H; ZIEGLER, SF; MOSLEY, B; MORELLA, KK; PAJOVIC, S; GEARING, DP			RECONSTITUTION OF THE RESPONSE TO LEUKEMIA INHIBITORY FACTOR, ONCOSTATIN-M, AND CILIARY NEUROTROPHIC FACTOR IN HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-PROTEIN GENES; ACUTE PHASE RESPONSE; RAT ALPHA-1-ACID GLYCOPROTEIN; COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; FACTOR RECEPTOR; EXPRESSION; INTERLEUKIN-6; GP130; CLONING	Ciliary neurotrophic factor (CNTF) has been described as a neuro-active cytokine that shares functional similarities with the leukemia inhibitory factor (LIF). We demonstrate here that, like LIF, CNTF stimulates expression of acute phase plasma proteins in rat H-35 hepatoma cells. Transfection of the LIF receptor into Hep3B hepatoma cells reconstituted LIF and oncostatin M regulation of acute phase plasma protein genes. Co-expression of the LIF receptor and the CNTF receptor, but not expression of either subunit alone, generated CNTF responsiveness in Hep3B cells, suggesting cooperativity of these receptor subunits. Evidence is presented for direct interaction of the LIF receptor with the intracellular signal transduction machinery.	IMMUNEX CORP,SEATTLE,WA 98101	Immunex Corporation	BAUMANN, H (corresponding author), NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1992, CIBA F SYMP, V167, P100; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Fey G H, 1990, Prog Liver Dis, V9, P89; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL AK, 1992, TRENDS NEUROSCI, V15, P35, DOI 10.1016/0166-2236(92)90022-Z; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; SEHGAL PB, 1990, MOL BIOL MED, V7, P117; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242; ZIEGLER SF, 1993, IN PRESS MOL CELL BI	32	130	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8414	8417						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682551				2022-12-27	WOS:A1993KX81100009
J	NING, YM; SANCHEZ, ER				NING, YM; SANCHEZ, ER			POTENTIATION OF GLUCOCORTICOID RECEPTOR-MEDIATED GENE-EXPRESSION BY THE IMMUNOPHILIN LIGANDS FK506 AND RAPAMYCIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEAT-SHOCK PROTEIN; BINDING; ACTIVATION; COMPLEXES; FK-506; PHOSPHOPROTEIN; CYTOSOL; DOMAINS; CLONING; EXISTS	It has recently been discovered that the steroid receptor-associated heat shock protein, hsp56, belongs to the FK506 family of immunophilin proteins. The ability of hsp56 to bind the immunosuppressive macrolide FK506 has led to the speculation that the steroid receptor and immunophilin signal transduction pathways are functionally interrelated. We have tested this idea by assessing the effects of FK506 on glucocorticoid receptor (GR)-mediated expression of the murine mammary tumor virus-chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid. We report that combined treatment with FK506 and low concentrations of dexamethasone (10(-8) or 10(-7) M) results in a large enhancement of MMTV-CAT gene expression over that seen in response to dexamethasone (Dex) alone. FK506 potentiation of MMTV-CAT expression did not occur at 10(-6) M Dex or in the complete absence of hormone. We also show that potentiation of Dex-mediated MMTV-CAT expression occurs in response to rapamycin, that glucocorticoid-regulated enhancer sequences are sufficient for the FK506-mediated potentiation effect, and that this effect can be blocked by RU486 antagonist. Finally, we provide evidence that FK506 potentiation of GR-mediated gene expression is the result of increased translocation to the nucleus of the GR.	MED COLL OHIO,DEPT PHARMACOL,POB 10008,TOLEDO,OH 43699						NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043867, R29DK043867] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK043867, DK43867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DUMONT FJ, 1991, TRANSPLANT P, V23, P2870; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRETZ H, 1991, J AM CHEM SOC, V113, P1409, DOI 10.1021/ja00004a051; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTO T, 1991, TRANSPL P, V23, P2713; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAIN AB, 1991, TRANSPLANT P, V23, P3023; JIN YJ, 1991, P NATL ACAD SCI USA, V88, P6677, DOI 10.1073/pnas.88.15.6677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; ROSBOROUGH SL, 1991, TRANSPLANT P, V23, P2890; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIEKIERKA JJ, TRANSPLANT P, V23, P2720; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; YEM AW, 1992, J BIOL CHEM, V267, P2868	35	128	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6073	6076						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681058				2022-12-27	WOS:A1993KT36800003
J	YANAGAWA, H; YOSHIDA, K; TORIGOE, C; PARK, JS; SATO, K; SHIRAI, T; GO, M				YANAGAWA, H; YOSHIDA, K; TORIGOE, C; PARK, JS; SATO, K; SHIRAI, T; GO, M			PROTEIN ANATOMY - FUNCTIONAL ROLES OF BARNASE MODULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; HYDRATION-DEHYDRATION CYCLES; SACCHAROMYCES-CEREVISIAE; ALZHEIMER-DISEASE; STRUCTURAL UNITS; IDENTIFICATION; RIBONUCLEASES; SEQUENCE; FAMILY; KINASE	Globular proteins are composed of several modules that are contiguous polypeptide segments of compact conformation. Module boundaries are closely correlated with the intron positions of genes that encode proteins. The modules may thus have a one-to-one correspondence with exons in primordial genes. They may also be vestiges of polypeptide segments that initially appeared as primordial proteins in prebiological evolution. Clarification as to whether modules disconnected from one another have functional potentiality may validate these possibilities. Thus, in this study, each module of a protein was synthesized and assessed for functional potentiality. For this purpose, barnase, a bacterial ribonuclease, was decomposed into six modules (M1-M6), which were examined to determine whether they have an affinity for RNA and RNase activity. M2, M3, and M6, all of which form a shallow but wide cavity for RNA binding in native barnase, were found to bind to RNA and to possess RNase activity. However, M1 and M5, which support the other modules from the back side, and M4 did not bind to RNA and had no RNase activity. Protein modules with catalytic functions are described in this paper for the first time. That some modules of barnase possess catalytic activity indicates that protein modules may possibly have functioned as primitive catalysts in prebiological evolution.	NAGOYA UNIV,FAC SCI,DEPT BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	YANAGAWA, H (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BARBIER B, 1992, J AM CHEM SOC, V114, P3511, DOI 10.1021/ja00035a053; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BRESLOW R, 1989, P NATL ACAD SCI USA, V86, P1746, DOI 10.1073/pnas.86.6.1746; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DAY AG, 1992, BIOCHEMISTRY-US, V31, P6390, DOI 10.1021/bi00143a005; EGEBJERG J, 1989, J MOL BIOL, V206, P651, DOI 10.1016/0022-2836(89)90573-1; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FUJISAWASEHARA A, 1990, J BIOL CHEM, V265, P15219; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; Go M., 1985, Advances in Biophysics, V19, P91; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HARTLEY RW, 1972, NATURE-NEW BIOL, V235, P15, DOI 10.1038/newbio235015a0; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HOSHINO T, 1990, J BACTERIOL, V172, P5531, DOI 10.1128/jb.172.10.5531-5539.1990; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; ITO M, 1990, J MOL EVOL, V31, P187, DOI 10.1007/BF02109495; JENSEN EO, 1981, NATURE, V291, P677, DOI 10.1038/291677a0; MAUGUEN Y, 1982, NATURE, V297, P162, DOI 10.1038/297162a0; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NISHIMURA S, 1959, BIOCHEMISTRY-US, V46, P161; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSTERMAN HL, 1978, BIOCHEMISTRY-US, V17, P4124, DOI 10.1021/bi00613a003; PADDON CJ, 1986, GENE, V40, P231, DOI DOI 10.1016/0378-1119(85)90045-9; RICHARDS FM, 1971, ENZYMES, V4, P647; RUSHIZKY GW, 1963, BIOCHEMISTRY-US, V2, P787, DOI 10.1021/bi00904a028; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; YANAGAWA H, 1990, J MOL EVOL, V31, P180, DOI 10.1007/BF02109494	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5861	5865						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680649				2022-12-27	WOS:A1993KR82200076
J	PRYOR, WA; UPPU, RM				PRYOR, WA; UPPU, RM			A KINETIC-MODEL FOR THE COMPETITIVE REACTIONS OF OZONE WITH AMINO-ACID-RESIDUES IN PROTEINS IN REVERSE MICELLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; HYDROGEN-PEROXIDE; OXIDATIVE DAMAGE; IN-VITRO; OZONATION; EXPOSURE; PHOSPHATIDYLCHOLINE; PRODUCTS; TRYPTOPHAN; LYSOZYME	Lysozyme and 10 other proteins are solubilized in reverse micelles formed by 0.1 M sodium di-2-ethylhexylsulfosuccinate and 2.0-2.5 M water (pH 7.4) in isooctane solvent. Exposure of the protein-containing reverse micellar solutions to ozone causes oxidative damage to the proteins, as assessed by the oxidation of tryptophan residues. The oxidation product of the protein-bound tryptophan has a molar absorption coefficient of 3275 +/- 81 M-1 cm-1 (mean +/- S.D., n = 6) at 320 nm. The product is suggested to be a Criegee ozonide or a tautomer of the Criegee ozonide and not N-formylkynurenine. Ozonation of lysozyme in reverse micelles results in the formation of hydrogen peroxide in yields of only approximately 0.07 mol/mol of tryptophan residues oxidized. The recovery of hydrogen peroxide added as an internal standard to the lysozyme-containing reverse micellar solutions ranges from 84 to 88%, whether or not the samples are subjected to ozonation. This suggests that hydrogen peroxide is neither destroyed during the process of ozonation nor consumed by the protein to a significant extent in an adventitious reaction. A kinetic model for the overall reaction of ozone with the proteins is developed, taking into account the concentrations and the reactivities of individual amino acid residues toward ozone. The model predicts the fractional reaction of ozone with tryptophan residues in the proteins, despite differences in amino acid composition, molecular weight, and tertiary structures. The lack of influence of protein structure is confirmed further by the observation that the native lysozyme (with and without external S-carboxymethylcysteine) and S-carboxymethylated lysozyme give identical values of the fractional reaction of ozone with tryptophan residues. The kinetic equations for the competitive reactions of ozone with amino acid residues in proteins, with some minor modifications, are applicable to ozonations on complex mixtures of lipids, proteins, and antioxidants.			PRYOR, WA (corresponding author), LOUISIANA STATE UNIV, INST BIODYNAM, 711 CHOPPIN HALL, BATON ROUGE, LA 70803 USA.							BACHMANN PA, 1990, J AM CHEM SOC, V112, P8200, DOI 10.1021/ja00178a073; BADER H, 1981, WATER RES, V15, P449, DOI 10.1016/0043-1354(81)90054-3; BAILEY PS, 1958, CHEM REV, V58, P925, DOI 10.1021/cr50023a005; BAILEY PS, 1982, OZONATION ORGANIC CH, V2, P111; BANERJEE SK, 1992, ARCH BIOCHEM BIOPHYS, V295, P84, DOI 10.1016/0003-9861(92)90491-E; Blow D. M., 1971, ENZYMES, VIII, P185, DOI DOI 10.1016/S1874-6047(08)60397-2; CHAN PC, 1977, J BIOL CHEM, V252, P8537; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; CROSS CE, 1992, FEBS LETT, V298, P269, DOI 10.1016/0014-5793(92)80074-Q; CROSS CE, 1992, FREE RADICAL RES COM, V15, P347, DOI 10.3109/10715769209049150; CUETO R, 1992, BIOCHEM BIOPH RES CO, V188, P129, DOI 10.1016/0006-291X(92)92359-6; DAGLIESH CE, 1952, J CHEM SOC, V29, P137; DAYHOFF MO, 1973, ATLAS PROTEIN SEQUEN, V5; DAYHOFF MO, 1976, ATLAS PROTEIN SEQ S2, V5; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DAYHOFF MO, 1969, ATLAS PROTEIN SEQUEN, V4; DOOLEY MM, 1982, ARCH BIOCHEM BIOPHYS, V218, P459, DOI 10.1016/0003-9861(82)90368-X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREEMAN BA, 1979, ARCH BIOCHEM BIOPHYS, V197, P264, DOI 10.1016/0003-9861(79)90244-3; FREEMAN BA, 1979, ASSESSING TOXIC EFFE, P151; GIAMALVA DH, 1986, J AM CHEM SOC, V108, P6646, DOI 10.1021/ja00281a033; GIAMALVA DH, 1988, CHEM RES TOXICOL, V1, P144, DOI 10.1021/tx00003a002; GIESE AC, 1952, ARCH BIOCHEM BIOPHYS, V40, P71, DOI 10.1016/0003-9861(52)90075-1; GOLDSTEIN BD, 1975, ENVIRON RES, V9, P179, DOI 10.1016/0013-9351(75)90062-6; HOIGNE J, 1983, WATER RES, V17, P185, DOI 10.1016/0043-1354(83)90099-4; JOHNSON DA, 1980, AM REV RESPIR DIS, V121, P1031; KABANOV AV, 1989, ANAL BIOCHEM, V181, P145, DOI 10.1016/0003-2697(89)90408-9; KABANOV AV, 1991, FEBS LETT, V278, P143, DOI 10.1016/0014-5793(91)80103-A; KNIGHT KL, 1984, ARCH BIOCHEM BIOPHYS, V229, P259, DOI 10.1016/0003-9861(84)90152-8; KONINGS AWT, 1980, RADIAT RES, V81, P200, DOI 10.2307/3575396; KURODA M, 1975, J BIOCHEM-TOKYO, V78, P641, DOI 10.1093/oxfordjournals.jbchem.a130951; LAI CC, 1990, CHEM RES TOXICOL, V3, P517, DOI 10.1021/tx00018a005; LEH F, 1978, ENVIRON RES, V16, P179, DOI 10.1016/0013-9351(78)90154-8; LEH F, 1974, ACS SYM SER, V3, P22; LEVASHOV AV, 1982, J COLLOID INTERF SCI, V88, P444, DOI 10.1016/0021-9797(82)90273-9; MACGILLIVRAY RTA, 1982, P NATL ACAD SCI-BIOL, V79, P2504, DOI 10.1073/pnas.79.8.2504; MAKINO K, 1959, BIOCHIM BIOPHYS ACTA, V31, P301, DOI 10.1016/0006-3002(59)90001-0; MEINERS BA, 1977, ENVIRON RES, V14, P99, DOI 10.1016/0013-9351(77)90072-X; MUDD JB, 1969, ATMOS ENVIRON, V3, P669, DOI 10.1016/0004-6981(69)90024-9; NYMAN PO, 1964, BIOCHIM BIOPHYS ACTA, V85, P141, DOI 10.1016/0926-6569(64)90174-9; OOSTING RS, 1992, AM J PHYSIOL, V262, pL63, DOI 10.1152/ajplung.1992.262.1.L63; PAULS KP, 1980, NATURE, V283, P504, DOI 10.1038/283504a0; PREVIERO A, 1967, J MOL BIOL, V24, P261, DOI 10.1016/0022-2836(67)90331-2; PREVIERO A, 1964, GAZZ CHIM ITAL, V94, P630; PRYOR WA, 1992, CHEM RES TOXICOL, V5, P505, DOI 10.1021/tx00028a008; PRYOR WA, 1991, CHEM RES TOXICOL, V4, P341, DOI 10.1021/tx00021a014; PRYOR WA, 1991, CHEM-BIOL INTERACT, V79, P41, DOI 10.1016/0009-2797(91)90051-8; PRYOR WA, 1984, J AM CHEM SOC, V106, P7094, DOI 10.1021/ja00335a038; PRYOR WA, 1992, BIOCHEM BIOPH RES CO, V188, P618, DOI 10.1016/0006-291X(92)91101-U; PRYOR WA, 1985, J AM CHEM SOC, V107, P2793, DOI 10.1021/ja00295a036; PRYOR WA, 1983, J AM CHEM SOC, V105, P6858, DOI 10.1021/ja00361a019; RABINOWITZ JL, 1988, EXP LUNG RES, V14, P477, DOI 10.3109/01902148809087822; RAZUMOVSKII SD, 1971, IAN SSSR KH, V4, P686; SAKIYAMA F, 1978, CHEM LETT, P893, DOI 10.1246/cl.1978.893; SANTROCK J, 1992, CHEM RES TOXICOL, V5, P134, DOI 10.1021/tx00025a023; SQUADRITO GL, 1992, LIPIDS, V27, P955, DOI 10.1007/BF02535571; SRISANKAR EV, 1979, ARCH ENVIRON HEALTH, V34, P346, DOI 10.1080/00039896.1979.10667429; TEIGE B, 1974, CHEM PHYS LIPIDS, V12, P153, DOI 10.1016/0009-3084(74)90071-1; TODD GW, 1958, PHYSIOL PLANTARUM, V11, P457, DOI 10.1111/j.1399-3054.1958.tb08242.x; UPPU RM, 1992, BIOCHEM BIOPH RES CO, V187, P473, DOI 10.1016/S0006-291X(05)81518-9; VERWEIJ H, 1979, CHEMOSPHERE, V8, P443, DOI 10.1016/0045-6535(79)90004-3; Walsh K. A., 1970, METHODS ENZYMOL, V19, P41	62	63	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3120	3126						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679107				2022-12-27	WOS:A1993KM16100019
J	HORIE, M; BROXMEYER, HE				HORIE, M; BROXMEYER, HE			INVOLVEMENT OF IMMEDIATE-EARLY GENE-EXPRESSION IN THE SYNERGISTIC EFFECTS OF STEEL FACTOR IN COMBINATION WITH GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR OR INTERLEUKIN-3 ON PROLIFERATION OF A HUMAN FACTOR-DEPENDENT CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT PROTOONCOGENE; WILMS-TUMOR LOCUS; GROWTH-FACTOR; MOLECULAR-CLONING; FOS GENE; TRANSCRIPTIONAL ACTIVATION; 3RD MEMBER; 3T3 CELLS; GM-CSF; JUN-D	Steel factor (SLF) synergizes with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) to stimulate proliferation of human factor-dependent cell line, MO7e. To elucidate molecular mechanisms underlying this synergism, induction of immediate-early genes was studied. Treatment of MO7e cells with SLF, GM-CSF, and IL-3 induced/enhanced expression of c-fos, junB, egr-1, and c-myc genes. SLF treatment of MO7e cells led to higher expression of c-fos, junB, and egr-1 genes than did treatment with GM-CSF or IL-3. However, GM-CSF and IL-3 had more prolonged effects on enhancement of the c-myc gene than SLF. Using optimal dosages for cell proliferation, induction of c-fos and junB was greater than additive with SLF plus GM-CSF or IL-3, as compared with each factor alone. Using suboptimal amounts of SLF with optimal GM-CSF or IL-3, induction of c-fos,junB, egr-1, and c-myc genes was greater than additive. De novo protein synthesis was not required for greater induction of these immediate-early genes by the combination of SLF plus GM-CSF. Based on nuclear run-on and actinomycin D experiments, the data suggest that the synergistic effects of SLF plus GM-CSF on the induction of immediate-early genes may be mediated in part at the level of transcription and mRNA stabilization for c-fos, at the level of mRNA stabilization for junB, and at the level of transcription for egr-1.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,975 W WALNUT ST,IB501,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NCI NIH HHS [R37CA36464] Funding Source: Medline; NHLBI NIH HHS [R01HL49202, R01HL46549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049202, R01HL046549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, BLOOD, V77, P2142; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOU CC, 1987, P NATL ACAD SCI USA, V84, P2575, DOI 10.1073/pnas.84.9.2575; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAMILTON JA, 1989, J CELL PHYSIOL, V141, P618, DOI 10.1002/jcp.1041410321; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KANAKURA Y, 1991, J BIOL CHEM, V266, P490; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUJUBU DA, 1987, ONCOGENE, V1, P257; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIM RW, 1987, ONCOGENE, V1, P263; LITZJACKSON S, 1992, BLOOD, V79, P2404; LIU JW, 1991, J BIOL CHEM, V266, P5929; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ORLOFSKY A, 1987, EMBO J, V6, P2947, DOI 10.1002/j.1460-2075.1987.tb02599.x; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHABO Y, 1990, LEUKEMIA, V4, P797; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	52	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					968	973						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678261				2022-12-27	WOS:A1993KG07700034
J	ROBSON, P; WRIGHT, GM; SITARZ, E; MAITI, A; RAWAT, M; YOUSON, JH; KEELEY, FW				ROBSON, P; WRIGHT, GM; SITARZ, E; MAITI, A; RAWAT, M; YOUSON, JH; KEELEY, FW			CHARACTERIZATION OF LAMPRIN, AN UNUSUAL MATRIX PROTEIN FROM LAMPREY CARTILAGE - IMPLICATIONS FOR EVOLUTION, STRUCTURE, AND ASSEMBLY OF ELASTIN AND OTHER FIBRILLAR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILKMOTH CHORION PROTEINS; MESSENGER-RNA; PETROMYZON-MARINUS; COMPLEMENTARY-DNA; SEA LAMPREY; SPIDER SILK; SEQUENCE; TROPOELASTIN; CLONING; FIBER	Lamprin, an insoluble non-collagen, non-elastin protein, is the major connective tissue component of the fibrillar extracellular matrix of lamprey annular cartilage. Here we demonstrate that the soluble monomer of lamprin is a family of highly hydrophobic, self-aggregating proteins with molecular masses of 12 and 10 kDa. Two mRNAs for soluble lamprin were identified (0.9 and 2 kilobases), differing principally in the length of their 3'-untranslated tails. Variants of soluble lamprin appear to arise both as the products of multiple genes and by alternate splicing. Although not generally homologous to any other protein, soluble lamprins contain a tandemly repeated peptide sequence (GGLGY) which is present in both silkmoth chorion proteins and spider dragline silk. Strong homologies to this repeat sequence are also present in several mammalian and avian elastins. Monoclonal antibodies to VGVAPG, a repeated sequence in human elastin, also cross-react with lamprin. We suggest that these proteins share a structural motif which promotes self-aggregation and fibril formation in proteins through interdigitation of hydrophobic side chains in beta-sheet/beta-turn structures, a motif that has been preserved in recognizable form over several hundred million years of evolution.	HOSP SICK CHILDREN,RES INST,DIV CARDIOVASC RES,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; ATLANTIC VET COLL,DEPT ANAT & PHYSIOL,CHARLOTTETOWN C1A 4P3,PE,CANADA; UNIV TORONTO,SCARBOROUGH COLL,DEPT ZOOL,TORONTO M1C 1A4,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Prince Edward Island; University of Toronto; University Toronto Scarborough			Robson, Paul/A-3464-2009	Robson, Paul/0000-0002-0191-3958				ANDERSEN SO, 1964, BIOCHIM BIOPHYS ACTA, V93, P213, DOI 10.1016/0304-4165(64)90289-2; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1987, BIOCHEMISTRY-US, V26, P1497, DOI 10.1021/bi00380a001; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; DONG ZY, 1991, ARCH BIOCHEM BIOPHYS, V284, P53, DOI 10.1016/0003-9861(91)90262-H; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; ECK MJ, 1992, J BIOL CHEM, V267, P2119; GOLDSMITH MR, 1984, ANNU REV GENET, V18, P443, DOI 10.1146/annurev.ge.18.120184.002303; GOSLINE JM, 1986, ENDEAVOUR, V10, P37, DOI 10.1016/0160-9327(86)90049-9; GREEN NM, 1983, EMBO J, V2, P1357, DOI 10.1002/j.1460-2075.1983.tb01592.x; HAMODRAKAS SJ, 1983, INT J BIOL MACROMOL, V5, P149, DOI 10.1016/0141-8130(83)90029-6; HAMODRAKAS SJ, 1989, INT J BIOL MACROMOL, V11, P307, DOI 10.1016/0141-8130(89)90025-1; HAMODRAKAS SJ, 1985, J MOL BIOL, V186, P583, DOI 10.1016/0022-2836(85)90132-9; HAMODRAKAS SJ, 1982, BIOCHIM BIOPHYS ACTA, V700, P42, DOI 10.1016/0167-4838(82)90289-8; HAMODRAKAS SJ, 1988, PROTEIN ENG, V2, P201, DOI 10.1093/protein/2.3.201; INDIK Z, 1989, AM J MED GENET, V34, P81, DOI 10.1002/ajmg.1320340115; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; JONES CW, 1979, CELL, V18, P1317, DOI 10.1016/0092-8674(79)90242-3; KELLY J, 1988, J BIOL CHEM, V263, P980; KIMURA S, 1982, COMP BIOCHEM PHYS B, V73, P335, DOI 10.1016/0305-0491(82)90293-0; LECANIDOU R, 1983, P NATL ACAD SCI-BIOL, V80, P1955, DOI 10.1073/pnas.80.7.1955; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; MECHAM RP, 1991, CELL BIOL EXTRACELLU, P70; PIERCE RA, 1990, BIOCHEMISTRY-US, V29, P9677, DOI 10.1021/bi00493a024; PONTES M, 1987, BIOCHEMISTRY-US, V26, P1611, DOI 10.1021/bi00380a019; RAJU K, 1987, J BIOL CHEM, V262, P5755; SAGE H, 1982, J INVEST DERMATOL, V79, pS146, DOI 10.1111/1523-1747.ep12546048; SAGE H, 1983, COMP BIOCHEM PHYS B, V74, P373, DOI 10.1016/0305-0491(83)90197-9; TAMBURRO AM, 1990, BIOPOLYMERS, V29, P855, DOI 10.1002/bip.360290419; URRY DW, 1984, J PROTEIN CHEM, V3, P403, DOI 10.1007/BF01025061; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG YZ, 1989, BIOCHEMISTRY-US, V28, P9801, DOI 10.1021/bi00451a039; WRIGHT GM, 1983, EXPERIENTIA, V39, P495, DOI 10.1007/BF01965172; WRIGHT GM, 1983, AM J ANAT, V167, P59, DOI 10.1002/aja.1001670106; WRIGHT GM, 1984, CAN J ZOOL, V62, P2445, DOI 10.1139/z84-361; XU M, 1990, P NATL ACAD SCI USA, V87, P7120, DOI 10.1073/pnas.87.18.7120; [No title captured]	37	83	87	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1440	1447						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678258				2022-12-27	WOS:A1993KG07700101
J	JACKSON, DA; NATHANSON, NM				JACKSON, DA; NATHANSON, NM			SUBTYPE-SPECIFIC REGULATION OF MUSCARINIC RECEPTOR EXPRESSION AND FUNCTION BY HETEROLOGOUS RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; EMBRYONIC CHICK HEART; CYCLIC-AMP FORMATION; ACETYLCHOLINE-RECEPTOR; PHOSPHATIDYLINOSITOL TURNOVER; CELLS; AGONISTS; CLONING; GENE; ANTAGONISTS	Incubation of cultured embryonic chicken heart cells with the beta-adrenergic agonist isoproterenol resulted in a dose-dependent increase in the number of mAChR on the surface of intact cells. The isoproterenol-mediated increase in mAChR number was time dependent and reached a maximum by 48 h. Chick heart cells treated with isoproterenol exhibited a greater than 6-fold increase in the sensitivity for carbachol-mediated inhibition of adenylyl cyclase activity as compared to control. Stimulation of cultured heart cells for 24 h with isoproterenol resulted in a 25-35% increase in cm2 mRNA levels as compared to control cm2 mRNA levels. In contrast, the level of cm4 mRNA was not significantly affected by isoproterenol treatment. cm2 mRNA levels were maximally elevated by 15 h following isoproterenol stimulation and remained elevated for up to 72 h. Incubation of cells with isoproterenol in the presence of Rp-cAMP, an inhibitor of cAMP-dependent protein kinase, blocked the increase in the level of cm2 mRNA. Thus, prolonged activation of beta-adrenergic receptors results in an increase in mAChR number and muscarinic responsiveness in chick heart cells due to a cAMP-dependent protein kinase mediated increase in cm2 mRNA levels.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 30639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRAUN T, 1987, BIOCHEM BIOPH RES CO, V149, P125, DOI 10.1016/0006-291X(87)91613-5; BROWN JH, 1984, FED PROC, V43, P2613; BROWN JH, 1984, J BIOL CHEM, V259, P3777; FISHMAN WH, 1987, AM J CARDIOL, V59, pF26; GADBUT AP, 1994, J BIOL CHEM, V41, P25823; GALPER JB, 1982, J GEN PHYSIOL, V80, P231, DOI 10.1085/jgp.80.2.231; GALPER JB, 1980, J BIOL CHEM, V255, P9571; HABECKER BA, 1993, BIOCHEMISTRY-US, V32, P4986, DOI 10.1021/bi00070a003; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HIRASAWA K, 1985, ANNU REV PHARMACOL, V25, P147, DOI 10.1146/annurev.pharmtox.25.1.147; HUNTER DD, 1986, J NEUROSCI, V6, P3739; KUBO T, 1986, FEBS LETT, V209, P367, DOI 10.1016/0014-5793(86)81144-9; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; MARGUETANT R, 1992, J MOL CELL CARDIOL, V24, P535; MOTOMURA S, 1990, BRIT J CLIN PHARMACO, V30, pS112, DOI 10.1111/j.1365-2125.1990.tb05478.x; NATHANSON NM, 1978, P NATL ACAD SCI USA, V75, P1788, DOI 10.1073/pnas.75.4.1788; NATHANSON NM, 1983, J NEUROCHEM, V41, P1545, DOI 10.1111/j.1471-4159.1983.tb00862.x; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; ORELLANA SA, 1985, BIOCHEM PHARMACOL, V34, P1321, DOI 10.1016/0006-2952(85)90512-X; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PORT JD, 1992, J PHARMACOL EXP THER, V262, P217; PRICHARD BNC, 1983, J CARDIOVASC PHARM, V5, pS56, DOI 10.1097/00005344-198300051-00009; REITHMANN C, 1992, N-S ARCH PHARMACOL, V345, P530; RENAUD JF, 1980, DEV BIOL, V78, P184, DOI 10.1016/0012-1606(80)90328-0; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SUBERS EM, 1988, J MOL CELL CARDIOL, V20, P131, DOI 10.1016/S0022-2828(88)80026-9; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TIETJE KM, 1990, J BIOL CHEM, V265, P2828	35	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22374	22377		10.1074/jbc.270.38.22374	http://dx.doi.org/10.1074/jbc.270.38.22374			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673222	hybrid			2022-12-27	WOS:A1995RW31400049
J	WERA, S; FERNANDEZ, A; LAMB, NJC; TUROWSKI, P; HEMMINGSMIESZCZAK, M; MAYERJAEKEL, RE; HEMMINGS, BA				WERA, S; FERNANDEZ, A; LAMB, NJC; TUROWSKI, P; HEMMINGSMIESZCZAK, M; MAYERJAEKEL, RE; HEMMINGS, BA			DEREGULATION OF TRANSLATIONAL CONTROL OF THE 65-KDA REGULATORY SUBUNIT (PR65-ALPHA) OF PROTEIN PHOSPHATASE 2A LEADS TO MULTINUCLEATED CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; EUKARYOTIC RIBOSOMES; MAMMALIAN-CELLS; EXPRESSION; INITIATION; SEQUENCE	Efficient translation of the mRNA encoding the 65-kDa regulatory subunit (PR65 alpha) of protein phosphatase 2A (PP2A) is prevented by an out of frame upstream AUG and a stable stem-loop structure (Delta G = -55.9 kcal/mol) in the 5'-untranslated region (5'-UTR). Deletion of the 5'-UTR allows efficient translation of the PR65 alpha message in vitro and overexpression in COS-1 cells. Insertion of the 5'-UTR into the beta-galactosidase leader sequence dramatically inhibits translation of the beta-galactosidase message in vitro and in vivo, confirming that this sequence functions as a potent translation regulatory sequence. Cells transfected or microinjected with a PR65 alpha expression vector lacking the 5'-UTR, express high levels of PR65 alpha, accumulating in both nucleus and cytoplasm, PR65 alpha overexpressing rat embryo fibroblasts (REF-52 cells) become multinucleated. These data and previous results (Mayer-Jaekel, R. E., Ohkura, H., Gomes, R., Sunkel, C. E., Baumgartner, S., Hemmings, B. A., and Glover, D. M. (1993) Cell 72, 621-633) suggest that PP2A participates in the regulation of both mitosis and cytokinesis.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; INSERM, CNRS, CTR RECH BIOCHIM MACROMOLEC, DEPT CELL BIOL, F-34033 MONTPELLIER, FRANCE	Friedrich Miescher Institute for Biomedical Research; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KIEHART DP, 1982, J CELL BIOL, V94, P165, DOI 10.1083/jcb.94.1.165; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYER RE, 1991, ADV PROTEIN PHOSPHAT, V6, P265; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	44	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21374	21381		10.1074/jbc.270.36.21374	http://dx.doi.org/10.1074/jbc.270.36.21374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673173	hybrid			2022-12-27	WOS:A1995RU05400077
J	YAMAMOTO, K; SINOHARA, H				YAMAMOTO, K; SINOHARA, H			ISOLATION AND CHARACTERIZATION OF MOUSE COUNTERTRYPIN, A NEW TRYPSIN-INHIBITOR BELONGING TO THE MAMMALIAN FETUIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-HS GLYCOPROTEIN; AMINO-ACID-SEQUENCE; PROTEASE INHIBITOR; MOLECULAR-CLONING; HS-GLYCOPROTEIN; TYROSINE KINASE; BOVINE FETUIN; RAT PLASMA; CONTRAPSIN; MACROGLOBULIN	A novel trypsin inhibitor, tentatively named countertrypin, was isolated from mouse plasma in an apparently homogeneous state. Countertrypin is a 53-kDa glycoprotein having about 30% carbohydrate, and did not cross-react immunologically with either mouse alpha1-antiproteinase (also called alpha1-proteinase inhibitor or alpha1-antitrypsin) or contrapsin. Countertrypin had no inhibitory activity against chymotrypsin, pancreatic elastase, neutrophil elastase, thrombin, plasmin, plasma kallikrein, pancreatic kallikrein, clotting factor Xa, or papain. This inhibitory spectrum does not correspond to any of the known plasma proteinase inhibitors that have been well characterized in human or other mammals. NH2-terminal amino acid sequence analysis of the intact molecule and three peptides obtained by CNBr digestion revealed that a total of 93 amino acid residues could be aligned with stretches in human alpha2-HS glycoprotein, bovine fetuin, and rat pp63 (rat fetuin). Human alpha2-HS glycoprotein and bovine fetuin prepared without use of ethanol inhibited trypsin and pancreatic and neutrophil elastases. These results indicate that mouse countertrypin is a new member of the mammalian fetuin family, which possibly has the trypsin-inhibiting activity in common.			YAMAMOTO, K (corresponding author), KINKI UNIV, SCH MED, DEPT BIOCHEM, SAYAMA, OSAKA 589, JAPAN.							ABE K, 1989, J BIOCHEM-TOKYO, V106, P564; ARNAUD P, 1988, METHOD ENZYMOL, V163, P431; AUBERGER P, 1989, CELL, V58, P631, DOI 10.1016/0092-8674(89)90098-6; BAUMSTARK JS, 1977, BIOCHIM BIOPHYS ACTA, V482, P400, DOI 10.1016/0005-2744(77)90254-6; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVEAU M, 1990, FEBS LETT, V273, P79, DOI 10.1016/0014-5793(90)81055-S; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEUTSCH HF, 1954, J BIOL CHEM, V208, P669; DICKSON IR, 1975, NATURE, V256, P430, DOI 10.1038/256430a0; DZIEGIELEWSKA KM, 1990, J BIOL CHEM, V265, P4354; DZIEGIELEWSKA KM, 1987, CELL TISSUE RES, V248, P33, DOI 10.1007/BF01239959; Easson LH, 1936, PROC R SOC SER B-BIO, V121, P142, DOI 10.1098/rspb.1936.0055; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ESNARD F, 1985, FEBS LETT, V182, P125, DOI 10.1016/0014-5793(85)81168-6; FISHER DA, 1974, ENDOCRINOLOGY, V94, P49, DOI 10.1210/endo-94-1-49; FISHER HW, 1958, P NATL ACAD SCI USA, V44, P4, DOI 10.1073/pnas.44.1.4; GALEMBECK F, 1974, ARCH BIOCHEM BIOPHYS, V164, P326, DOI 10.1016/0003-9861(74)90038-1; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; GEJYO F, 1983, J BIOL CHEM, V258, P4966; HAASEMANN M, 1991, BIOCHEM J, V274, P899, DOI 10.1042/bj2740899; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KIDO H, 1988, J BIOL CHEM, V263, P18104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P4844; LOSKUTOFF DJ, 1978, J CELL PHYSIOL, V96, P361, DOI 10.1002/jcp.1040960312; MATSUSHIMA K, 1982, BIOCHIM BIOPHYS ACTA, V701, P200, DOI 10.1016/0167-4838(82)90114-5; OHKUBO K, 1991, BIOCHEM J, V276, P337, DOI 10.1042/bj2760337; OHKUBO K, 1991, J BIOCHEM-TOKYO, V109, P243; OHNISHI T, 1991, J BIOL CHEM, V266, P14636; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; ROHRLICH ST, 1981, J CELL PHYSIOL, V109, P1, DOI 10.1002/jcp.1041090102; SAITO A, 1985, J BIOL CHEM, V260, P775; SINOHARA H, 1984, BIOCHEM INT, V9, P315; SPIRO RG, 1960, J BIOL CHEM, V235, P2860; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; SUZUKI Y, 1990, J BIOCHEM, V108, P344, DOI 10.1093/oxfordjournals.jbchem.a123204; TAKAHARA H, 1982, J BIOL CHEM, V257, P2438; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; VANOSS CJ, 1974, IMMUNOL COMMUN, V3, P329, DOI 10.3109/08820137409061113; YACHNIN S, 1975, J EXP MED, V141, P242, DOI 10.1084/jem.141.1.242; YAMAMOTO K, 1986, SEIKAGAKU, V58, P711	47	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17750	17753						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688730				2022-12-27	WOS:A1993LT74300020
J	NEUFER, PD; CAREY, JO; DOHM, GL				NEUFER, PD; CAREY, JO; DOHM, GL			TRANSCRIPTIONAL REGULATION OF THE GENE FOR GLUCOSE-TRANSPORTER GLUT4 IN SKELETAL-MUSCLE - EFFECTS OF DIABETES AND FASTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; BINDING-PROTEIN; MESSENGER-RNA; INSULIN; EXPRESSION; RAT; CELLS; CAMP; HOMEOSTASIS	GLUT4 glucose transporter protein and mRNA levels in rat skeletal muscle are decreased with streptozotocin (STZ)-induced diabetes and increased by fasting, indicating that GLUT4 expression may be regulated at the pretranslational level. The purpose of the present study was to determine whether GLUT4 is subject to transcriptional regulation in skeletal muscle under the altered metabolic conditions of diabetes and fasting. Nuclei were isolated from red and white portions of the quadriceps and gastrocnemius/plantaris muscles of control, 7-day STZ-diabetic, and 3-day fasted rats. STZ-induced diabetes resulted in a 35% reduction in GLUT4 transcription in red skeletal muscle and thus accounted for a major portion of the corresponding 50% reduction in GLUT4 mRNA observed in red skeletal muscle. STZ-induced diabetes had no significant effect on GLUT4 transcription or mRNA in white skeletal muscle. Fasting, however, significantly increased both GLUT4 transcription (2.2-fold) and mRNA (2.9-fold) in white skeletal muscle with no change detected for either parameter in red skeletal muscle. The nearly 2-fold higher steady-state GLUT4 mRNA in red versus white skeletal muscle of control rats was not associated with any difference in basal transcription. These findings demonstrate that expression of the GLUT4 glucose transporter protein in skeletal muscle is subject to regulation in vivo at the level of transcription of the GLUT4 gene. In addition, GLUT4 transcription is regulated in a fiber type-specific manner in response to the metabolic challenges elicited by STZ-induced diabetes and fasting.			NEUFER, PD (corresponding author), E CAROLINA UNIV, SCH MED, DEPT BIOCHEM, GREENVILLE, NC 27858 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038416] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38416] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1992, J BIOL CHEM, V267, P5021; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; BARNARD RJ, 1990, ENDOCRINOLOGY, V126, P1921, DOI 10.1210/endo-126-4-1921; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BRADY LJ, 1981, AM J PHYSIOL, V240, pE184, DOI 10.1152/ajpendo.1981.240.2.E184; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DT, 1992, DIABETES, V41, pA144; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FRIEDMAN JE, 1991, AM J PHYSIOL, V261, pE782, DOI 10.1152/ajpendo.1991.261.6.E782; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HOUMARD JA, 1991, AM J PHYSIOL, V261, pE437, DOI 10.1152/ajpendo.1991.261.4.E437; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KAWASHIMA Y, 1992, TOXICOLOGY, V71, P151, DOI 10.1016/0300-483X(92)90062-J; KENT JD, 1991, AM J PHYSIOL, V260, pC409, DOI 10.1152/ajpcell.1991.260.3.C409; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KLIP A, 1992, J CELL BIOCHEM, V48, P51, DOI 10.1002/jcb.240480109; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE PC, 1990, BIOCHIM BIOPHYS ACTA, V1049, P244, DOI 10.1016/0167-4781(90)90093-H; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; NEUFER PD, 1992, CAN J PHYSIOL PHARM, V70, P1286, DOI 10.1139/y92-178; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; RAMAL T, 1989, ENDOCRINOLOGY, V125, P890; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; RICHARDSON JM, 1991, J BIOL CHEM, V266, P12690; RODNICK KJ, 1990, DIABETES, V39, P1425, DOI 10.2337/diabetes.39.11.1425; SASKI K, 1984, J BIOL CHEM, V259, P15242; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; STROUT HV, 1990, ENDOCRINOLOGY, V126, P2728, DOI 10.1210/endo-126-5-2728; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3	59	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					13824	13829						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686145				2022-12-27	WOS:A1993LJ82500012
J	BEHREND, EI; CHAMBERS, AF; WILSON, SM; DENHARDT, DT				BEHREND, EI; CHAMBERS, AF; WILSON, SM; DENHARDT, DT			COMPARATIVE-ANALYSIS OF 2 ALTERNATIVE 1ST EXONS REPORTED FOR THE MOUSE OSTEOPONTIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED PHOSPHOPROTEIN-I; TRANSFORMED MAMMALIAN-CELLS; MESSENGER-RNA; NEOPLASTIC TRANSFORMATION; BONE PHOSPHOPROTEIN; DEVELOPMENTAL EXPRESSION; NUCLEOTIDE-SEQUENCE; CHICKEN OSTEOPONTIN; MOLECULAR-CLONING; CDNA CLONING	Two conflicting conclusions regarding the structure of the mouse osteopontin (OPN) gene were tested for their validity. Miyazaki et al. (Miyazaki, Y., Setoguchi, M., Yoshida, S., Higuchi, Y., Akizuki, S., and Yamamoto, S. (1990) J. Biol. Chem. 265, 14432-14438) state that the OPN gene is composed of six exons and spans approximately 4.8 kilobases. Craig and Denhardt (Craig, A. M., and Denhardt, D. T. (1991) Gene (Amst.) 100, 163-171) independently reported an additional exon 5' to the region designated as ''exon 1'' by Miyazaki and colleagues. To investigate this discrepancy, we generated oligodeoxynucleotide probes to three regions of these reported sequences and used them to hybridize to Northern and Southern blots of RNA and DNA from mouse fibroblasts and macrophages. Two of these regions (probes ''A'' and ''B'') represent sequences that are disputed, while one of these regions (probe ''C'') is predicted to be in the mRNA of both sequences. Our results are consistent only with the OPN gene structure reported by Craig and Denhardt and show that a significant portion of the exon 1 reported by Miyazaki et al. is present in murine genomic DNA but is not found in cytoplasmic message. Our results also show that OPN RNA molecules from mouse fibroblasts and macrophages do not differ significantly in the regions tested.	LONDON REG CANC CTR,790 COMMISSIONERS RD E,LONDON N6A 4L6,ON,CANADA; UNIV WESTERN ONTARIO,DEPT ONCOL,LONDON N6A 4L6,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MICROBIOL & IMMUNOL,LONDON N6A 4L6,ON,CANADA; RUTGERS UNIV,DEPT BIOL SCI,PISCATAWAY,NJ 08855	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Rutgers State University New Brunswick			Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001295] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC01295] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; CHACKALAPARAMPIL I, 1985, J VIROL, V53, P841, DOI 10.1128/JVI.53.3.841-850.1985; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHAMBERS AF, 1993, CANCER RES, V53, P701; CHAMBERS AF, 1990, IN VIVO, V4, P215; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; CRAIG AM, 1989, THESIS U W ONTARIO L; FET V, 1989, GENOMICS, V5, P375, DOI 10.1016/0888-7543(89)90074-8; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GUO X, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P294; KERR JM, 1991, GENE, V108, P237, DOI 10.1016/0378-1119(91)90439-I; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; MARK MP, 1987, J HISTOCHEM CYTOCHEM, V35, P707, DOI 10.1177/35.7.3295029; MARK MP, 1988, CELL TISSUE RES, V251, P23, DOI 10.1007/BF00215443; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MIYAZAKI Y, 1989, NUCLEIC ACIDS RES, V17, P3298, DOI 10.1093/nar/17.8.3298; MIYAZAKI Y, 1990, J BIOL CHEM, V265, P14432; MOORE MA, 1991, BIOCHEMISTRY-US, V30, P2501, DOI 10.1021/bi00223a029; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PATARCA R, 1989, J EXP MED, V170, P145, DOI 10.1084/jem.170.1.145; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; RALPH P, 1977, CANCER RES, V37, P546; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1985, CANCER RES, V45, P5818; SENGER DR, 1988, CANCER RES, V48, P5770; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SHIRAGA H, 1992, P NATL ACAD SCI USA, V89, P426, DOI 10.1073/pnas.89.1.426; SMITH JH, 1987, J CELL BIOCHEM, V34, P13, DOI 10.1002/jcb.240340103; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; TUCK AB, 1991, J NATL CANCER I, V83, P4585; WRANA JL, 1989, NUCLEIC ACIDS RES, V17, P10119, DOI 10.1093/nar/17.23.10119; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZHANG Q, 1992, EUR J BIOCHEM, V207, P649, DOI 10.1111/j.1432-1033.1992.tb17092.x	43	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11172	11175						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684372				2022-12-27	WOS:A1993LD46600068
J	BLOBE, GC; KHAN, WA; HALPERN, AE; OBEID, LM; HANNUN, YA				BLOBE, GC; KHAN, WA; HALPERN, AE; OBEID, LM; HANNUN, YA			SELECTIVE REGULATION OF EXPRESSION OF PROTEIN-KINASE-C BETA-ISOENZYMES OCCURS VIA ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; GENE-EXPRESSION; HETEROGENEITY; ISOZYMES; NUCLEUS; POLY(A); STAGE; END	The mechanisms involved in regulating the selective expression of protein kinase C (PKC) isoenzymes are poorly understood. Two human B lymphoblastoid cell lines, IM-9 and BJA-B, exhibited differential expression of the two alternatively spliced products of the PKC beta gene, PKC betaI and betaII. The IM-9 cell line expressed 3-4-fold more PKC betaII protein than the BJA-B cell line, whereas the BJA-B cell line expressed 2-3-fold more PKC betaI protein. This differential expression was found to be regulated at the mRNA level. Comparison of PKC betaI and betaII messages in poly(A)+ mRNA and total cellular RNA revealed that selective polyadenylation was not involved. The messages for PKC betaI and betaII had comparable half-lives in both cell lines, ruling out differential message stability. In addition, similar ratios of PKC betaI and betaII messages in cytosolic and nuclear fractions suggested that differential mRNA transport was not involved. In the IM-9 cell line, the predominance of mature PKC betaII message as well as that of a larger message spliced to PKC betaII provided evidence that the differential expression of PKC betaII was regulated at the level of mRNA splicing. In the BJA-B cell line, equal amounts of mature PKC betaI and betaII message and the absence of the larger message suggested that the splicing of the PKC beta gene product can be regulated to produce altered ratios of PKC betaI and betaII. Implications of these studies on the differential expression of PKC isoenzymes and their roles in biology are discussed.	DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,BOX 3355,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; obeid, lina/0000-0002-0734-0847	NHLBI NIH HHS [HL-43707] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P91; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KUBA K, 1987, NUCLEIC ACIDS RES, V15, P7179; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; Sambrook J, 1989, MOL CLONING LABORATO; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; STORKUS WJ, 1986, J IMMUNOL, V136, P1542; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	25	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10627	10635						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683684				2022-12-27	WOS:A1993LB80000093
J	HUANG, JN; CHEN, F; PUETT, D				HUANG, JN; CHEN, F; PUETT, D			AMINO CARBOXYL-TERMINAL DELETION MUTANTS OF HUMAN CHORIOGONADOTROPIN-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SITE-DIRECTED MUTAGENESIS; LUTEINIZING-HORMONE; SUBUNIT; CELLS; EXPRESSION	Human choriogonadotropin (hCG) contains an a subunit common to other members of the glycoprotein hormone family, lutropin (LH), follitropin, and thyrotropin, and a hormone-specific beta subunit. hCGbeta contains a carboxyl-terminal extension of 25-30 amino acid residues not present in the other beta subunits; also, CGbeta and lutropin beta have an additional 6 or 7 amino-terminal residues that are not present in follitropin beta and thyrotropin beta. To delineate the contribution of these extensions in hCGbeta, site-directed mutagenesis was used to prepare several deletion fragments. Plasmids containing cDNAs for wild-type and mutant hCGbeta were transiently transfected into Chinese hamster ovary cells containing a stably integrated gene for bovine a. Medium from the transfected cells was used in two in vitro assays with a transformed murine Leydig cell line, MA-10. The deletion fragments, des(1-7), des(111-145), and des(1-7, 111-145), associated with alpha as well as hCGbeta wild-type; moreover, the potencies of the three mutant hormones were comparable to that of control. In contrast, des(1-7, 101-145)hCGbeta yielded very little heterodimer, although that which formed was partially active. These results define the shortest known core fragment of hCGbeta, amino acid residues 8-110, that retains significant functionality in vitro.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,REPROD SCI & ENDOCRINOL LABS,MIAMI,FL 33101	University of Miami					NIDDK NIH HHS [DK33973] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN F, 1991, BIOCHEMISTRY-US, V30, P10171, DOI 10.1021/bi00106a014; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN WY, 1991, J BIOL CHEM, V266, P6246; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KAETZEL DM, 1985, P NATL ACAD SCI USA, V82, P7280, DOI 10.1073/pnas.82.21.7280; KEUTMANN HT, 1991, 73RD ANN END SOC M, P281; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MISE T, 1981, J BIOL CHEM, V256, P6587; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; Segaloff D L, 1990, Recent Prog Horm Res, V46, P261; STRICKLAND TW, 1981, ENDOCRINOLOGY, V109, P1933, DOI 10.1210/endo-109-6-1933; Ward D.N., 1991, GONADOTROPINS REPROD, V4th, P25; XIA H, 1993, IN PRESS J MOL ENDOC	20	28	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9311	9315						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683647				2022-12-27	WOS:A1993LA68900027
J	BUSCONI, L; MICHEL, T				BUSCONI, L; MICHEL, T			ENDOTHELIAL NITRIC-OXIDE SYNTHASE - N-TERMINAL MYRISTOYLATION DETERMINES SUBCELLULAR-LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROTEIN ALPHA-SUBUNIT; KINASE-C; MEMBRANE; PURIFICATION; BINDING; PHOSPHORYLATION; FLAVOPROTEIN; ASSOCIATION; SUBSTRATE; CELLS	Nitric oxide synthases in diverse mammalian tissues catalyze the oxidation Of L-arginine to L-citrulline plus nitric oxide (NO). In the vascular endothelium, synthesis of NO yields a labile intercellular messenger molecule with potent biological activities, including vascular smooth muscle relaxation. We have recently documented that the endothelial cell NO synthase (EC-NOS) constitutes a genetically distinct tissue-specific enzyme isoform. In further contrast to the soluble NO synthases found in neural tissues and in macrophages , the endothelial enzyme is associated primarily with the particulate fraction. Analysis of molecular clones for the endothelial NO synthase reveals no obvious transmembrane-spanning region, but a consensus motif for N-terminal myristoylation was identified; such a consensus sequence is not evident in the primary sequence of the soluble macrophage and neural NO synthases. We performed oligonucleotide-directed mutagenesis of the myristoylation consensus sequence in the endothelial NO synthase cDNA, and studied the pattern of expression of the wild-type and mutant EC-NOS cDNAs in transient transfection experiments in COS-7 cells. The subcellular localization of heterologous endothelial NO synthase was determined using analyses of enzyme activity as well as immunoprecipitation of biosynthetically labeled NO synthase with a highly specific antipeptide antibody. Expression of the wild-type endothelial NO synthase cDNA in COS-7 cells results in targeting of both enzyme activity and NO synthase immunoreactivity primarily to the particulate fraction. By contrast, transient expression of the myristoylation- mutant cDNA in COS-7 cells yields NO synthase enzyme activity and immunoreactivity associated exclusively with the cytosol fraction. Following biosynthetic labeling with [H-3]myristate, the NO synthase can be specifically immunoprecipitated from the particulate fraction in endothelial and in COS-7 cells transfected with the wild-type cDNA, but not in cells transfected with the myristoylation- mutant EC-NOS cDNA. N-terminal myristoylation of the endothelial NO synthase may provide a potential point of regulation of the biological functions of endothelium-derived NO in situ.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School								ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BOJE KM, 1990, J PHARMACOL EXP THER, V253, P20; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P66; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	26	265	273	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8410	8413						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682550				2022-12-27	WOS:A1993KX81100008
J	RUFFJAMISON, S; MCGLADE, J; PAWSON, T; CHEN, K; COHEN, S				RUFFJAMISON, S; MCGLADE, J; PAWSON, T; CHEN, K; COHEN, S			EPIDERMAL GROWTH-FACTOR STIMULATES THE TYROSINE PHOSPHORYLATION OF SHC IN THE MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RECEPTORS; PROTEINS; KINASE	Previous studies have demonstrated that the administration of epidermal growth factor (EGF) to neonatal mice results in the tyrosine phosphorylation of multiple substrates in all organs examined (Donaldson, R. W., and Cohen, S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8477-8481). One of these substrates, a 55-kDa protein, was shown to associate with the receptor for EGF (EGFR). We now report the identification of this receptor-associated protein as SHC. Immunoprecipitation and Western blotting analyses have revealed that SHC associates only with the activated EGFR. In the absence of EGF stimulation, SHC exists in the liver as a cytoplasmic monomer. Intraperitoneal injection of EGF results, within minutes, in the translocation of 50-80% of SHC to the liver plasma membrane. The membrane-associated SHC was found to be tyrosine-phosphorylated; the subsequent release of SHC from the membrane correlated with a tyrosine dephosphorylation. We conclude that SHC is a physiological substrate that appears to participate in the in vivo signaling response to EGF.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, 607 LIGHT HALL, NASHVILLE, TN 37232 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA	Vanderbilt University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pawson, Tony J/E-4578-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000700] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-00700] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; COHEN S, 1982, P NATL ACAD SCI-BIOL, V79, P6237, DOI 10.1073/pnas.79.20.6237; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSAKISADCOCK M, 1992, NATURE, V360, P689; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	19	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7610	7612						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681824				2022-12-27	WOS:A1993KW97900003
J	ROBY, KF; DEB, S; GIBORI, G; SZPIRER, C; LEVAN, G; KWOK, SCM; SOARES, MJ				ROBY, KF; DEB, S; GIBORI, G; SZPIRER, C; LEVAN, G; KWOK, SCM; SOARES, MJ			DECIDUAL PROLACTIN-RELATED PROTEIN - IDENTIFICATION, MOLECULAR-CLONING, AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL LACTOGEN-II; COMPLEMENTARY DEOXYRIBONUCLEIC-ACID; DEVELOPING RAT PLACENTA; GROWTH-HORMONE; MESSENGER-RNA; ANTIPEPTIDE ANTIBODIES; LUTEOTROPHIC ACTION; TROPHOBLAST CELLS; DENOVO SYNTHESIS; GENE-EXPRESSION	In this report, we describe the isolation, molecular cloning, and characterization of a new member of the prolactin (PRL)-growth hormone (GH) family expressed in rat decidual tissue. A 29-kDa protein was isolated from medium conditioned by decidual explants. The protein possessed an affinity for concanavalin A and cross-reactivity with antibodies to two rat placental proteins, PRL-like protein-B (PLP-B) and PLP-C and with antibodies to human PRL. NH2-terminal sequencing of the isolated decidual protein indicated that it shared significant sequence identity with the NH2 terminus of PLP-C. The decidual protein was termed decidual prolactin-related protein (dPRP). A PLP-C cDNA was used to identify dPRP cDNAs from a rat decidual cDNA library. Nucleotide sequence analyses of the dPRP cDNAs predicted a mature protein of 239 amino acids, including a 28-amino acid signal sequence. The predicted dPRP amino acid sequence contains two putative N-linked glycosylation sites and 6 cysteine residues. The 6 cysteines are located in positions homologous to the cysteines of PLP-C and PRL. Additional sequence similarities with members of the PRL-GH family are evident. The dPRP gene was localized to rat chromosome 17, which also carries other members of the PRL gene family. Northern blot analysis showed that the dPRP cDNA clone specifically hybridized to a 1.0-kilobase mRNA. The relationship of dPRP with other members of the PRL-GH family and its putative role(s) in the, physiology of pregnancy are discussed.	UNIV KANSAS,MED CTR,DEPT PHYSIOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT BIOCHEM,KANSAS CITY,KS 66160; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612; UNIV LIBRE BRUXELLES,DEPT BIOL MOLEC,B-1640 RHODE ST GENESE,BELGIUM; GOTHENBURG UNIV,DEPT GENET,S-40033 GOTHENBURG,SWEDEN	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Universite Libre de Bruxelles; University of Gothenburg				Kwok, Simon/0000-0001-6003-5350	NICHD NIH HHS [HD-20676, HD-12356, HD-29036] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020676] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012356, R01HD029036] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAHL OP, 1977, GLYCOCONJUGATES, P385; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; BASURAY R, 1980, BIOL REPROD, V23, P507, DOI 10.1095/biolreprod23.3.507; BASURAY R, 1983, BIOL REPROD, V28, P551, DOI 10.1095/biolreprod28.3.551; BELL SC, 1983, OXFORD REV REPRODUCT, V5, P220; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL WJ, 1989, ENDOCRINOLOGY, V125, P1565, DOI 10.1210/endo-125-3-1565; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; CROZE F, 1990, ENDOCRINOLOGY, V127, P2665, DOI 10.1210/endo-127-6-2665; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEB S, 1991, ENDOCRINOLOGY, V128, P3066, DOI 10.1210/endo-128-6-3066; DEB S, 1989, J BIOL CHEM, V264, P14348; DEB S, 1990, MOL CELL ENDOCRINOL, V74, P163, DOI 10.1016/0303-7207(90)90118-R; DEB S, 1991, J BIOL CHEM, V266, P23027; DEB S, 1991, J BIOL CHEM, V266, P1605; DEB S, 1989, MOL CELL ENDOCRINOL, V63, P45, DOI 10.1016/0303-7207(89)90080-4; DEFEO VJ, 1963, ENDOCRINOLOGY, V72, P305, DOI 10.1210/endo-72-2-305; DEFEO VJ, 1966, ENDOCRINOLOGY, V79, P440, DOI 10.1210/endo-79-2-440; DEFEO VJ, 1967, CELLULAR BIOL UTERUS, P191; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DUCKWORTH ML, 1988, MOL ENDOCRINOL, V2, P912, DOI 10.1210/mend-2-10-912; DUCKWORTH ML, 1986, J BIOL CHEM, V261, P871; DUCKWORTH ML, 1986, J BIOL CHEM, V261, P879; DUCKWORTH ML, 1990, PLACENTA, V11, P143, DOI 10.1016/S0143-4004(05)80176-6; FARIA TN, 1990, DEV BIOL, V141, P279, DOI 10.1016/0012-1606(90)90384-U; GELLERSEN B, 1989, MOL CELL ENDOCRINOL, V64, P127, DOI 10.1016/0303-7207(89)90073-7; GIBORI G, 1981, ENDOCRINOLOGY, V108, P2060, DOI 10.1210/endo-108-6-2060; GIBORI G, 1985, ENDOCRINOLOGY, V116, P1784, DOI 10.1210/endo-116-5-1784; GIBORI G, 1984, ENDOCRINOLOGY, V115, P1157, DOI 10.1210/endo-115-3-1157; GIBORI G, 1974, ENDOCRINOLOGY, V95, P1113, DOI 10.1210/endo-95-4-1113; GIBORI G, 1987, REGULATION OVARIAN T, P379; GLASSER SR, 1991, TROPHOBLAST RES, V5, P229; GOLANDER A, 1978, SCIENCE, V202, P311, DOI 10.1126/science.694535; GOLANDER A, 1979, J ENDOCRINOL, V82, P263, DOI 10.1677/joe.0.0820263; GU Y, 1992, ENDOCRINOLOGY, V131, P1321, DOI 10.1210/en.131.3.1321; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; HERZ Z, 1986, ENDOCRINOLOGY, V118, P2203, DOI 10.1210/endo-118-6-2203; HWANG P, 1974, BIOCHEMISTRY-US, V13, P2354, DOI 10.1021/bi00708a018; ISLAM MQ, 1987, HEREDITAS, V107, P127, DOI 10.1111/j.1601-5223.1987.tb00277.x; JAYATILAK PG, 1989, ENDOCRINOLOGY, V125, P659, DOI 10.1210/endo-125-2-659; JAYATILAK PG, 1985, P NATL ACAD SCI USA, V82, P217, DOI 10.1073/pnas.82.1.217; JAYATILAK PG, 1986, J ENDOCRINOL, V110, P115, DOI 10.1677/joe.0.1100115; Levan G., 1990, Genetic maps: locus of complex genomes.; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; OGILVIE S, 1990, ENDOCRINOLOGY, V126, P2561, DOI 10.1210/endo-126-5-2561; OGILVIE S, 1990, ENDOCRINOLOGY, V126, P3271, DOI 10.1210/endo-126-6-3271; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RIDDICK DH, 1978, LIFE SCI, V23, P1913, DOI 10.1016/0024-3205(78)90557-X; ROBERTSON MC, 1990, ENDOCRINOLOGY, V127, P702, DOI 10.1210/endo-127-2-702; ROBERTSON MC, 1991, ENDOCRINOLOGY, V129, P2746, DOI 10.1210/endo-129-5-2746; ROTHCHILD I, 1975, ENDOCRINOLOGY, V97, P838, DOI 10.1210/endo-97-4-838; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SOARES MJ, 1988, J ENDOCRINOL, V116, P101, DOI 10.1677/joe.0.1160101; SOARES MJ, 1987, J REPROD FERTIL, V79, P335, DOI 10.1530/jrf.0.0790335; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; SOARES MJ, 1987, DEV BIOL, V124, P134, DOI 10.1016/0012-1606(87)90466-0; SOARES MJ, 1980, AUST J BIOL SCI, V33, P709, DOI 10.1071/BI9800709; SOUTHARD JN, 1991, MOL CELL ENDOCRINOL, V79, pC133, DOI 10.1016/0303-7207(91)90084-6; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZPIRER J, 1984, CYTOGENET CELL GENET, V38, P142, DOI 10.1159/000132047; [No title captured]	65	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3136	3142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679108				2022-12-27	WOS:A1993KM16100021
J	VOLKMANN, S; WOHRL, BM; TISDALE, M; MOELLING, K				VOLKMANN, S; WOHRL, BM; TISDALE, M; MOELLING, K			ENZYMATIC ANALYSIS OF 2 HIV-1 REVERSE-TRANSCRIPTASE MUTANTS WITH MUTATIONS IN CARBOXYL-TERMINAL AMINO-ACID-RESIDUES CONSERVED AMONG RETROVIRAL RIBONUCLEASES-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEPENDENT DNA-POLYMERASE; RNASE-H; ESCHERICHIA-COLI; DOMAIN-STRUCTURE; PRIMER; ENDONUCLEASE; MUTAGENESIS; EXONUCLEASE; MECHANISM	The reverse transcriptase (RT) of HIV-1 has been mutagenized within the carboxyl-terminal domain which harbors the RNase H. Two amino acids highly conserved among all 14 known RT sequences but not in the bacterial RNase H have been mutagenized resulting in the mutant proteins N494D and Q475E. They were expressed as recombinant proteins, purified, and analyzed for their in vitro properties in comparison to the p66 homodimeric wild-type and a previously described H539N mutant. The N494D mutant closely resembles the wild-type RNase H, exhibits art endonuclease activity and a processive RNase H activity, gives rise to small RNA hydrolysis products, and acts in concert with the RT. The Q475E mutant is more defective and resembles the H539N mutant, exhibits a retarded endonuclease activity and an impaired 3' --> 5' processive RNA cleavage activity, gives rise to predominantly larger RNA hydrolysis products, is less processive in the presence of competitor substrate, and is defective in its ability to hydrolyze the polypurine tract and homopolymeric hybrids. Short homopolymeric stretches cause a pausing of the RT of wild-type and mutants which results in a coordinated action of the RNase H. Pausing of the RT correlates with RNase H cleavages about 20 nucleotides behind the point of synthesis. The defects of the mutant enzymes can be interpreted on the basis of the known crystallography data.	MAX PLANCK INST MOLEC GENET, ABT SCHUSTER, IHNESTR 73, W-1000 BERLIN 33, GERMANY; WELLCOME RES LABS, DEPT MOLEC SCI, BECKENHAM BR3 3BS, KENT, ENGLAND	Max Planck Society; GlaxoSmithKline; Wellcome Research Laboratories								BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CROUCH R J, 1990, New Biologist, V2, P771; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DUDDING LR, 1990, BIOCHEM BIOPH RES CO, V167, P244, DOI 10.1016/0006-291X(90)91757-J; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1990, J BIOL CHEM, V265, P10565; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KRUG MS, 1991, BIOCHEMISTRY-US, V30, P10614, DOI 10.1021/bi00108a003; LAI MHT, 1978, J VIROL, V25, P652, DOI 10.1128/JVI.25.2.652-663.1978; LORI F, 1988, AIDS RES HUM RETROV, V4, P393, DOI 10.1089/aid.1988.4.393; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MANIATIS T, 1982, MOL CLONING LABORATO, V28, P9088; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; MOELLING K, 1992, MED MICROBIOL LETT, V1, P71; MOLLING K, 1971, NATURE-NEW BIOL, V234, P240, DOI 10.1038/newbio234240a0; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; OYAMA F, 1989, J BIOL CHEM, V264, P18808; PAINTER GR, 1990, J CELL BIOCHEM     S, V14, P109; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, GENE REGULATION AIDS, P293; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; TISDALE M, 1989, J ANTIMICROBIOL SA47, V23, pS4; VARMUS H, 1987, SCI AM, V257, P56, DOI 10.1038/scientificamerican0987-56; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WATSON KF, 1979, BIOCHEMISTRY-US, V18, P3210, DOI 10.1021/bi00582a004; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E; WOHRL BM, 1991, J MOL BIOL, V220, P801, DOI 10.1016/0022-2836(91)90119-Q; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	50	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2674	2683						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679100				2022-12-27	WOS:A1993KK81500063
J	PETRONILLI, V; COLA, C; BERNARDI, P				PETRONILLI, V; COLA, C; BERNARDI, P			MODULATION OF THE MITOCHONDRIAL CYCLOSPORINE A-SENSITIVE PERMEABILITY TRANSITION PORE .2. THE MINIMAL REQUIREMENTS FOR PORE INDUCTION UNDERSCORE A KEY ROLE FOR TRANSMEMBRANE ELECTRICAL POTENTIAL, MATRIX PH, AND MATRIX CA2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; HEART-MITOCHONDRIA; OXIDATIVE STRESS; N-ETHYLMALEIMIDE; CA-2+-DEPENDENT PORE; CALCIUM FLUXES; CA-2+ RELEASE; RUTHENIUM RED; INHIBITION	This paper reports an investigation on the minimal requirements for induction of the mitochondrial cyclosporin A-sensitive permeability transition pore (MTP). Energized rat liver mitochondria incubated in sucrose medium take up a Ca2+ pulse but do not show activation of the MTP upon addition of fully uncoupling concentrations of carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP). Yet, addition of ruthenium red immediately prior to FCCP or inclusion of acetate or low concentrations of phosphate in the incubation medium restore the ability of FCCP to trigger MTP opening. Since ruthenium red, phosphate, or acetate do not induce the MTP per se, they must act upon some additional factor(s) that counteract the increase of pore ''open'' probability induced by membrane depolarization (Bernardi, P. (1992) J. Biol. Chem. 267, 8834-8839). We show that two key factors determining the overall probability of pore opening are matrix pH and matrix [Ca2+] when the membrane is depolarized. Indeed, in the absence of ruthenium red, phosphate, or acetate the addition of FCCP is followed by fast Ca2+ efflux on the uniporter mirrored by intense matrix acidification following compensatory H+ influx via FCCP. Ruthenium red prevents both Ca2+ efflux and matrix acidification, acetate mainly prevents matrix acidification, and phosphate both slows down Ca2+ efflux and prevents matrix acidification. Taken together, our data indicate that membrane depolarization is both necessary and sufficient to trigger MTP opening when matrix acidification and rapid Ca2+ efflux are prevented. Thus, the wide variety of MTP ''inducing agents'' may largely reflect the wide variety of the possible combinatorial effects on the minimal requirements for MTP operation.	UNIV PADUA, SCH MED, DEPT BIOMED SCI, BIOPHYS & MEMBRANE BIOL LAB, I-35121 PADUA, ITALY	University of Padua	PETRONILLI, V (corresponding author), UNIV PADUA, SCH MED, CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Bernardi, Paolo/C-3656-2008; Petronilli, Valeria/C-3558-2015	Bernardi, Paolo/0000-0001-9187-3736; Petronilli, Valeria/0000-0003-4026-6404				AZZONE GF, 1976, BIOCHIM BIOPHYS ACTA, V459, P96; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1979, EUR J BIOCHEM, V102, P555, DOI 10.1111/j.1432-1033.1979.tb04272.x; BERNARDI P, 1984, BIOCHEMISTRY-US, V23, P1645, DOI 10.1021/bi00303a010; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1992, MECHANICS SWELLING C, P357; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, BIOCHEM J, V255, P357; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GARLID KD, 1986, J BIOL CHEM, V261, P1529; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HARRIS EJ, 1977, FEBS LETT, V79, P284, DOI 10.1016/0014-5793(77)80804-1; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; IGVABVOA U, 1991, BIOCHIM BIOPHYS ACTA, V1059, P339; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; LUFT JH, 1971, ANAT REC, V171, P347, DOI 10.1002/ar.1091710302; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; PFEIFFER DR, 1978, J BIOL CHEM, V253, P4165; POZZAN M, 1981, FEBS LETT, V127, P263; SCHLEGEL J, 1992, BIOCHEM J, V285, P65, DOI 10.1042/bj2850065; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004	33	217	221	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1011	1016						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678245				2022-12-27	WOS:A1993KG07700040
J	SCHUMACHER, R; SOOS, MA; SCHLESSINGER, J; BRANDENBURG, D; SIDDLE, K; ULLRICH, A				SCHUMACHER, R; SOOS, MA; SCHLESSINGER, J; BRANDENBURG, D; SIDDLE, K; ULLRICH, A			SIGNALING-COMPETENT RECEPTOR CHIMERAS ALLOW MAPPING OF MAJOR INSULIN-RECEPTOR BINDING DOMAIN DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE KINASE-ACTIVITY; AMINO-ACID-SEQUENCE; MONOCLONAL-ANTIBODIES; TERTIARY STRUCTURE; ALPHA-SUBUNIT; EGF-RECEPTOR; SITE; SPECIFICITY; DNA	Chimeric receptors were generated in which structurally defined subdomains of the insulin receptor (IR) and insulin growth factor-I receptor (IGF-1R) alpha-subunits were exchanged between their respective receptor backbone structures. Upon expression in human fibroblasts, nine IR/IGF-1R chimeras were transported to the cell surface, where they formed binding sites with differential properties. One IGF-1R/IR chimera (C3') exhibited to some extent high insulin specificity, demonstrating the presence of major insulin binding determinants within the amino acid 325-524 region of the IR alpha-subunit. Complementation of this region with subdomain 1 (amino acids 1-137) reconstituted full insulin binding potential within an IGF-1R framework. In addition, both the IGF-1R/IR C3' chimera and another chimera (C13') displayed high affinity binding properties for IGF-1, which suggests distinct locations for major insulin and IGF-1 binding determinants in their respective receptors, in agreement with our previous findings (Schumacher, R., Mosthaf, L., Schlessinger, J., Brandenburg, D., and Ullrich, A. (1991) J. Biol. Chem. 266, 19288-19295). The binding characteristics of all receptor chimeras correlated directly with the ability of the ligands to regulate their tyrosine kinase activity in intact cells. These results demonstrate direct coupling of ligand binding affinity and capacity for tyrosine kinase activation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; DEUTSCH WOLFORSCHUNGINST,W-5100 AACHEN,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; UNIV CAMBRIDGE,ADDENBROOKES HOSP,CAMBRIDGE CB2 2QR,ENGLAND	Max Planck Society; New York University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DINTZIS SM, 1990, EMBO J, V9, P77, DOI 10.1002/j.1460-2075.1990.tb08082.x; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; FABRY M, 1992, J BIOL CHEM, V267, P8950; FENDLY BM, 1990, CANCER RES, V50, P1550; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, pA660; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SOOS MA, 1992, J BIOL CHEM, V267, P12955; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; TORNQVIST HE, 1988, J BIOL CHEM, V263, P4593; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	44	109	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1087	1094						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678247				2022-12-27	WOS:A1993KG07700051
J	MASUMOTO, A; HEMLER, ME				MASUMOTO, A; HEMLER, ME			MULTIPLE ACTIVATION STATES OF VLA-4 - MECHANISTIC DIFFERENCES BETWEEN ADHESION TO CS1 FIBRONECTIN AND TO VASCULAR CELL-ADHESION MOLECULE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; INTEGRIN VLA-4; GPIIB-IIIA; T-CELLS; REGULATED EXPRESSION; LEUKOCYTE ADHESION; INDUCED PHOSPHORYLATION; LYMPHOCYTE ADHERENCE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS	We examined the effects of a stimulatory anti-beta1 mAb (TS2/16) and different divalent cations on VLA-4-mediated cell adhesion to vascular cell adhesion molecule-1 (VCAM-1), to the fibronectin-derived CS1 peptide, and to larger fibronectin fragments. Using optimal binding conditions (in the presence of mAb TS2/16 and 1.0 mm Mn2+), the levels of VLA-4-mediated adhesion to VCAM-1 and to CS1 peptide were virtually indistinguishable, and half-maximal inhibition of adhesion to both ligands was achieved using similar levels of an anti-alpha4 antibody. However, using suboptimal adhesion conditions, two critical differences between adhesion to CSI peptide (or larger fibronectin fragments) and VCAM-1 were consistently observed. First, stimulation by added mAb TS2/16 had a substantially greater effect on adhesion to CS1 than to VCAM-1 and second, Ca2+ was much less able to support adhesion to CS1 than to VCAM-1. These two differences between adhesion to CS1 peptide and to VCAM-1 were most obvious among cell lines which synthesized inactive or partly active VLA-4 but were not obvious for fully active VLA-4. Together, these results not only reveal crucial differences in the mechanisms of VLA-4 binding to its two ligands, but also lead to increased understanding of the variable activation states of VLA-4. The differential ability to utilize Ca2+ displayed by VLA-4 in different states of activation and the activation of inactive or partly active VLA-4 by the addition of Mn2+ both point to divalent cation sites playing an essential role in determining VLA-4 regulation and ligand specificity.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NIGMS NIH HHS [GM46526, GM38903] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903, R01GM046526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BUYON JP, 1990, J IMMUNOL, V144, P191; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHAN BMC, 1991, J IMMUNOL, V147, P398; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1991, P NATL ACAD SCI USA, V88, P8072, DOI 10.1073/pnas.88.18.8072; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GULINO D, 1992, J BIOL CHEM, V267, P1001; GULINO D, 1990, J BIOL CHEM, V265, P9575; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEMLER ME, 1983, J IMMUNOL, V131, P334; HEMLER ME, 1982, J IMMUNOL, V129, P2734; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P109; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAFFON A, 1991, J CLIN INVEST, V88, P546, DOI 10.1172/JCI115338; LARSON RS, 1990, CELL REGUL, V1, P359, DOI 10.1091/mbc.1.4.359; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PULLMAN WE, 1992, NATURE, V356, P529, DOI 10.1038/356529a0; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROLDAN E, 1992, J EXP MED, V175, P1739, DOI 10.1084/jem.175.6.1739; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; UTSUMI K, 1991, P NATL ACAD SCI USA, V88, P5685, DOI 10.1073/pnas.88.13.5685; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALSH GM, 1991, J IMMUNOL, V146, P3419; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WILKINS JA, 1991, EUR J IMMUNOL, V21, P517, DOI 10.1002/eji.1830210239; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; YAMAMOTO N, 1989, BLOOD, V73, P1552; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	79	254	259	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					228	234						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677996				2022-12-27	WOS:A1993KE60300036
J	VANDEPOLL, MLM; LENFERINK, AEG; VANVUGT, MJH; JACOBS, JJL; JANSSEN, JWH; JOLDERSMA, M; VANZOELEN, EJJ				VANDEPOLL, MLM; LENFERINK, AEG; VANVUGT, MJH; JACOBS, JJL; JANSSEN, JWH; JOLDERSMA, M; VANZOELEN, EJJ			A SINGLE AMINO-ACID EXCHANGE, ARG-45 TO ALA, GENERATES AN EPIDERMAL GROWTH-FACTOR (EGF) MUTANT WITH HIGH-AFFINITY FOR THE CHICKEN EGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING SITE; FACTOR-ALPHA; ESCHERICHIA-COLI; PROTEIN; PROTEOLYSIS; CELLS	The finding that human epidermal growth factor (hEGF) and human transforming growth factor (hTGF) alpha bind with similar affinity to the human EGF receptor but differ in their affinity for the chicken EGF receptor was used as a model system to study ligand-receptor interaction of EGF receptor agonists, We previously constructed domain-exchange mutants of hEGF and hTGF alpha and found that the region COOH-terminal of the sixth cysteine residue in hTGF alpha is important for high affinity binding to the chicken EGF receptor (Kramer, R. H., Lenferink, A. E. G., Lammerts van Eueren-Koornneef, I., van der Meer, A., van de Poll, M. L. M., and van Zoelen, E. J. J. (1994) J. Biol. Chem, 269, 8708-8711), To analyze this domain in more detail, we now constructed four additional chimeras in which either the region between the sixth cysteine residue and the highly conserved Leu-47 was exchanged or the region COOH-terminal of Leu-47, A mutant in which the latter region in hEGF was replaced by hTGF alpha (designated E6ET) showed intermediate binding affinity, whereas replacement of the former region in hEGF by hTGF alpha was sufficient to generate a mutant (designated E6TE) with a similar high affinity for the chicken EGF receptor as wild type hTGF alpha, Furthermore, a deletion mutant of hEGF lacking three COOH-terminal amino acids, EGF50, showed intermediate binding affinity for the chicken EGF receptor similar to E6ET, but upon additional deletions (EGF49 and EGF48), this initial gain in affinity was lost, A systematic analysis of the region between the sixth cysteine residue and Leu-47 showed that the low affinity of hEGF for the chicken EGF receptor is mainly due to the presence of Arg-45. Replacement of the positively charged Arg-45 by Ala, the corresponding amino acid in hTGF alpha, was sufficient to generate a mutant growth factor with high affinity for the chicken EGF receptor, This indicates that in hEGF Arg-45 may play an important role in receptor binding, A model is proposed in which positively charged amino acids close to or within the receptor recognition site of hEGF prohibit high affinity binding to the chicken EGF receptor due to electrostatic repulsion of positively charged amino acids in the putative ligand binding domain of the chicken EGF receptor.			VANDEPOLL, MLM (corresponding author), UNIV NIJMEGEN,DEPT CELL BIOL,TOERNOOIVELD 1,6525 ED NIJMEGEN,NETHERLANDS.		Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795				AVIVI A, 1991, ONCOGENE, V6, P673; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; CAMPION SR, 1992, J CELL BIOCHEM, V50, P35; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; FIELD JA, 1992, BIOCHEM J, V283, P91; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GALLAY J, 1993, EUR J BIOCHEM, V211, P213, DOI 10.1111/j.1432-1033.1993.tb19888.x; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P15283, DOI 10.1021/bi00255a009; KIENHUIS CBM, 1991, CLIN CHEM, V37, P1749; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAZAR E, 1988, MOL CELL BIOL, V8, P1247, DOI 10.1128/MCB.8.3.1247; MATSUNAMI RK, 1990, FEBS LETT, V264, P105, DOI 10.1016/0014-5793(90)80776-F; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RICHTER A, 1992, BIOCHEMISTRY-US, V31, P9546, DOI 10.1021/bi00155a006; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; SENDEROFF RI, 1994, PHARMACEUT RES, V11, P1712, DOI 10.1023/A:1018903014204; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; VANZOELEN EJJ, 1985, J CELL PHYSIOL, V123, P151, DOI 10.1002/jcp.1041230202; VIOLAND BN, 1991, INT J PEPT PROT RES, V37, P463; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; WU DG, 1989, J BIOL CHEM, V264, P17469	29	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22337	22343		10.1074/jbc.270.38.22337	http://dx.doi.org/10.1074/jbc.270.38.22337			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673217	Green Published, hybrid			2022-12-27	WOS:A1995RW31400044
J	AKOPIAN, AN; WOOD, JN				AKOPIAN, AN; WOOD, JN			PERIPHERAL NERVOUS SYSTEM-SPECIFIC GENES IDENTIFIED BY SUBTRACTIVE CDNA CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-ROOT GANGLIA; MUSCLE C-PROTEIN; MOLECULAR-CLONING; SPINAL-CORD; NEURONS; RAT; HYBRIDIZATION; PURIFICATION; MEMBRANE; COMPLEX	An improved method for constructing and screening subtractive cDNA libraries has been used to identify 46 mRNA transcripts that are expressed selectively in neonatal rat dorsal root ganglia (DRG) as judged by Northern blots and in situ hybridization. Sequence analysis demonstrates that both known (e.g. peripherin, calcitonin gene-related peptide, myelin PO) and novel identifiable transcripts (e.g. C-protein-like, synuclein-like, villin-like) are present in the library. Half of the transcripts (23) are undetectable in liver, kidney, heart, spleen, cerebellum, and cerebral cortex, Of the DRG-specific transcripts, 12 contain putative open reading frames that show no identity with known proteins. The construction of such a subtractive library thus provides us with both known and novel markers, and identifies new predicted DRG-specific proteins. In addition, the DRG-specific clones provide probes to define the regulatory elements that specify peripheral nervous-system-specific gene expression.			AKOPIAN, AN (corresponding author), UNIV LONDON UNIV COLL,DEPT ANAT & DEV BIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson David J., 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1082; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; FURST DO, 1992, J CELL SCI, V102, P769; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GHYSEN A, 1993, BIOESSAYS, V15, P293, DOI 10.1002/bies.950150502; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jan Yuh Nung, 1994, Current Opinion in Neurobiology, V4, P8, DOI 10.1016/0959-4388(94)90025-6; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOJIMA T, 1990, J BIOCHEM-TOKYO, V107, P470, DOI 10.1093/oxfordjournals.jbchem.a123069; KORNEEV S, 1994, PROG NEUROBIOL, V42, P339, DOI 10.1016/0301-0082(94)90074-4; KRISTAL SM, 1983, NEUROSCI LETT, V35, P41; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MAYEUX V, 1993, DEV BRAIN RES, V71, P201, DOI 10.1016/0165-3806(93)90172-7; NAKAJO S, 1993, EUR J BIOCHEM, V217, P57; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; ROISEN FJ, 1983, J MUSCLE RES CELL M, V4, P163, DOI 10.1007/BF00712028; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCOTT SA, 1993, SENSORY NEURONS; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; ZHANG JH, 1990, J COMP NEUROL, V302, P715, DOI 10.1002/cne.903020404	35	85	91	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21264	21270		10.1074/jbc.270.36.21264	http://dx.doi.org/10.1074/jbc.270.36.21264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673161	hybrid			2022-12-27	WOS:A1995RU05400061
J	NYKJAER, A; BENGTSSONOLIVECRONA, G; LOOKENE, A; MOESTRUP, SK; PETERSEN, CM; WEBER, W; BEISIEGEL, U; GLIEMANN, J				NYKJAER, A; BENGTSSONOLIVECRONA, G; LOOKENE, A; MOESTRUP, SK; PETERSEN, CM; WEBER, W; BEISIEGEL, U; GLIEMANN, J			THE ALPHA(2)-MACROGLOBULIN RECEPTOR LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN BINDS LIPOPROTEIN-LIPASE AND BETA-MIGRATING VERY-LOW-DENSITY LIPOPROTEIN ASSOCIATED WITH THE LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; LIGAND RECOGNITION; APOLIPOPROTEIN-E; CELL-SURFACE; LRP; CHYLOMICRONS; PURIFICATION; CONFORMATION; MECHANISM	Lipoprotein lipase (LPL) causes a marked increase in the cellular binding of beta-migrating very low density lipoprotein (beta-VLDL) to a large receptor compatible with the alpha2-macroglobulin receptor (alpha2MR)/low density lipoprotein receptor-related protein (LRP) (Beisiegel, U., Weber, W., and Bengtsson-Olivecrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346). Here we demonstrate that LPL binds to the alpha-chain of purified alpha2MR/LRP immobilized on microtiter plates. The binding, apparently to multiple sites, was blocked by heparin and inhibited by the alpha2MR-associated protein (alpha2MRAP) and by EDTA. Immobilized LPL bound alpha2MR/LRP in solution as well as beta-VLDL prepared from cholesterol-fed rabbits. Both binding reactions were dependent on an intact carboxyl-terminal folding domain of LPL, but were independent of its dimeric structure and intact catalytical function. Dimeric LPL could mediate binding of beta-VLDL to immobilized alpha2MR/LRP and to cells, e.g. monocytes. In contrast, LPL monomers were not able to mediate binding to immobilized alpha2MR/LRP, presumably because of cross-inhibition due to close relation between the binding regions for the lipoprotein and for the receptor in the carboxyl-terminal domain of the LPL monomer. Heparin, but not alpha2MRAP, inhibited cellular binding of I-125-LPL or I-125-beta-VLDL supplemented with LPL. However, alpha2MRAP inhibited degradation of the two ligands by about 90% and 40-50%, respectively. The results show that LPL is a ligand for alpha2MR/LRP and, because of its affinity for lipoprotein particles, dimeric LPL can mediate or strengthen binding of beta-VLDL to this receptor. It is proposed that LPL binds primarily to cell surface heparan sulfate in monocytes and is presented for endocytosis and degradation by alpha2MR/LRP. Moreover, beta-VLDL may be further supplemented with LPL at the cell surface and achieve affinity for alpha2MR/LRP.	UMEA UNIV, DEPT MED BIOCHEM & BIOPHYS, S-90187 UMEA, SWEDEN; UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, W-2000 HAMBURG 20, GERMANY	Umea University; University of Hamburg	NYKJAER, A (corresponding author), AARHUS UNIV, INST MED BIOCHEM, OLD WORMS ALLE, DK-8000 AARHUS, DENMARK.		Moestrup, Søren Kragh/AAD-1735-2019; Moestrup, Søren Kragh/A-1403-2014	Moestrup, Søren Kragh/0000-0003-3862-2107; Nykjaer, Anders/0000-0001-6422-6736				ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CELIS JE, 1992, ELECTROPHORESIS, V13, P893, DOI 10.1002/elps.11501301198; CHAJEKSHAUL T, 1982, BIOCHIM BIOPHYS ACTA, V712, P200, DOI 10.1016/0005-2760(82)90103-5; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1981, BIOCHIM BIOPHYS ACTA, V665, P454, DOI 10.1016/0005-2760(81)90258-7; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; FOJO SS, 1992, CURRENT OPINION LIPI, V3, P186; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; HADVARY P, 1991, J BIOL CHEM, V266, P2021; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; JENSEN PH, 1992, FEBS LETT, V305, P129, DOI 10.1016/0014-5793(92)80879-L; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1991, FEBS LETT, V288, P33, DOI 10.1016/0014-5793(91)80997-H; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	48	176	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15048	15055						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686910				2022-12-27	WOS:A1993LL75900075
J	YAJNIK, V; GODSON, GN				YAJNIK, V; GODSON, GN			SELECTIVE DECAY OF ESCHERICHIA-COLI DNAG MESSENGER-RNA IS INITIATED BY RNASE-E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INT GENE-EXPRESSION; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; SIGMA-SUBUNIT; POLYMERASE; STABILITY; AMS; PRIMASE; INVIVO; TRANSCRIPTION	The rpsU-dnaG-rpoD operon messenger RNA that encodes S21, primase, and sigma-70 is cleaved under normal physiological conditions. The dnaG coding portion of the mRNA is then rapidly degraded. An endonuclease activity has been isolated from wild type Escherichia coli cells that cleaves dnaG mRNA. This activity has been identified as RNase E, and the identity confirmed by the accumulation of the unprocessed operon polycistronic mRNA in RNase E mutants, rne-3071 and ams-1, when incubated at nonpermissive temperatures. Extracts prepared from RNase E mutant strains failed to cleave dnaG mRNA in vitro. The dnaG mRNA RNase E cleavage site (5'-AAGUGAUUUA-3') is only 50% homologous to the ribosomal RNA RNase E cleavage site. By using computer programs predicting secondary structure, the dnaG RNase E cleavage site appears to be in a single stranded RNA loop.	NYU MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA	New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038292] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38292] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1978, GENETICS, V90, P659; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BELASCO JG, 1985, CELL, V40, P171, DOI 10.1016/0092-8674(85)90320-4; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; DEUTSCHER M, 1990, METHOD ENZYMOL, V182, P291; DEUTSCHER MP, 1985, CELL, V40, P731, DOI 10.1016/0092-8674(85)90330-7; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; ENGBAEK F, 1976, MOL GEN GENET, V143, P291, DOI 10.1007/BF00269405; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GUARNEROS G, 1982, P NATL ACAD SCI-BIOL, V79, P238, DOI 10.1073/pnas.79.2.238; IWAKURA Y, 1974, MOL GEN GENET, V133, P1, DOI 10.1007/BF00268673; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; KJELDGAARD NO, 1974, RIBOSOMES, P368; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUPSKI JR, 1982, MOL GEN GENET, V185, P120, DOI 10.1007/BF00333800; LUPSKI JR, 1984, CELL, V30, P251; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NAKAMURA Y, 1984, MOL GEN GENET, V196, P179, DOI 10.1007/BF00334114; NILSSON G, 1988, EMBO J, V7, P2269, DOI 10.1002/j.1460-2075.1988.tb03067.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PANAYOTATOS N, 1985, NUCLEIC ACIDS RES, V13, P2227, DOI 10.1093/nar/13.7.2227; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; PRAGAI B, 1982, J MOL BIOL, V154, P465, DOI 10.1016/S0022-2836(82)80007-7; REGINIER P, 1991, J MOL BIOL, V217, P283; ROWEN L, 1978, J BIOL CHEM, V253, P758; Sambrook J, 1989, MOL CLONING LABORATO; SCHMEISSNER U, 1984, J MOL BIOL, V176, P39, DOI 10.1016/0022-2836(84)90381-4; SMILEY BL, 1982, P NATL ACAD SCI-BIOL, V79, P4550, DOI 10.1073/pnas.79.15.4550; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TAYLOR WE, 1984, CELL, V38, P371, DOI 10.1016/0092-8674(84)90492-6; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P4907, DOI 10.1073/pnas.79.16.4907; WONG HC, 1986, P NATL ACAD SCI USA, V83, P3233, DOI 10.1073/pnas.83.10.3233; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13253	13260						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685758				2022-12-27	WOS:A1993LH55300037
J	MA, JT; WU, JJ; TZENG, CM; PAN, RL				MA, JT; WU, JJ; TZENG, CM; PAN, RL			FUNCTIONAL SIZE ANALYSIS OF F-ATPASE FROM ESCHERICHIA-COLI BY RADIATION INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; OXIDATIVE-PHOSPHORYLATION; CATALYTIC SITES; BETA-SUBUNITS; H+-ATPASE; HYDROLYSIS; F1-ATPASE; PURIFICATION; MECHANISM	A radiation inactivation technique was employed to determine the functional size of adenosine triphosphatase from Escherichia coli (EF0EF1-ATPase). Functional units of the membrane-bound and the soluble ATPases were estimated to be 300 +/- 39 and 295 +/- 32 kDa, respectively. The presence of the free radical scavenger dithiothreitol was crucial in measuring the radiation inactivation size of ATPase. When gramicidin and carbonyl cyanide p-trifluoromethoxyphenylhydrazone were added, an increase in the functional mass of membrane-bound ATPase was observed. In contrast, valinomycin and KCl had hardly any effect on the functional size of ATPase. We also determined a functional unit of 355 +/- 33 kDa for proton translocation by a fluorescence quenching technique. A reconstitution study using irradiated coupling factor 1 (EF1)-depleted membrane revealed that the functional mass of the proton channel was 96 +/- 11 kDa. A similar functional size for ATP-P(i) exchange and ATP hydrolysis implies that both reactions might utilize identical machinery. Furthermore, functional units of soluble EF1 for unisite (nonsteady state) and multisite (steady state) ATP hydrolysis were calculated as 200 +/- 32 and 298 +/- 32 kDa, respectively. A working hypothesis was proposed from radiation inactivation analysis to elucidate the structure and mechanism of F1-ATPase.	NATL TSING HUA UNIV, COLL NUCL SCI, INST RADIAT BIOL, HSINCHU 30043, TAIWAN; NATL TSING HUA UNIV, COLL NUCL SCI, DEPT NUCL SCI, HSINCHU 30043, TAIWAN	National Tsing Hua University; National Tsing Hua University								AVRON M, 1960, BIOCHIM BIOPHYS ACTA, V40, P257, DOI 10.1016/0006-3002(60)91350-0; BEAUREGARD G, 1985, ANAL BIOCHEM, V150, P117, DOI 10.1016/0003-2697(85)90448-8; BERDEN JA, 1991, BIOCHIM BIOPHYS ACTA, V1057, P151, DOI 10.1016/S0005-2728(05)80099-4; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DAVENPORT JW, 1981, J BIOL CHEM, V256, P8947; DILLEY RA, 1987, ANNU REV PLANT PHYS, V38, P347; DOWNIE JA, 1979, ANNU REV BIOCHEM, V48, P103, DOI 10.1146/annurev.bi.48.070179.000535; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; FRIEDL P, 1979, EUR J BIOCHEM, V100, P175, DOI 10.1111/j.1432-1033.1979.tb02046.x; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HART EJ, 1967, RAD DOSIMETRY, V2, P167; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; LUNARDI J, 1979, BIOCHEMISTRY-US, V18, P5310, DOI 10.1021/bi00591a008; MATSUNOYAGI A, 1984, BIOCHEMISTRY-US, V23, P3508, DOI 10.1021/bi00310a019; MAY YW, 1988, J BIOL CHEM, V263, P8838; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PAN RS, 1987, PLANT PHYSIOL, V85, P158, DOI 10.1104/pp.85.1.158; ROTTENBERG H, 1990, BIOCHIM BIOPHYS ACTA, V1018, P1, DOI 10.1016/0005-2728(90)90103-B; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WANG JH, 1984, BIOCHEMISTRY-US, V23, P6350, DOI 10.1021/bi00321a010; WANG JH, 1985, J BIOL CHEM, V260, P1374; WESTERHOFF HV, 1984, FEBS LETT, V165, P1, DOI 10.1016/0014-5793(84)80002-2; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	36	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10802	10807						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684367				2022-12-27	WOS:A1993LD46600017
J	SCARPETTA, MA; UHLER, MD				SCARPETTA, MA; UHLER, MD			EVIDENCE FOR 2 ADDITIONAL ISOFORMS OF THE ENDOGENOUS PROTEIN-KINASE INHIBITOR OF CAMP-DEPENDENT PROTEIN-KINASE IN MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; PHOSPHORYLATION; PURIFICATION; CLONING; TESTIS; MUSCLE	Oligonucleotides derived from the previously published rat testicular protein kinase inhibitor (PKI) sequence (Van Patten, S. M., Ng, D. C., Th'ng, J. P. H., Angelos, K. L., Smith, A. J., and Walsh, D. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5383-5387) were used to isolate a DNA fragment coding for a mouse homologue of the rat testicular PKI. This DNA fragment was then used to screen a mouse brain cDNA library, and two cDNA clones related to the testicular PKI (PKIbeta) were isolated. Sequencing and comparison showed that the two cDNAs differ only in the presence of a 105-base pair insert, which results in an aminoterminal extension of the predicted PKIbeta2 protein by 20 residues relative to the PKIbeta1 protein. By using the appropriate primers, PCR was used to amplify specific regions of both of these clones from mouse brain cDNA. When both clones were expressed in vitro, the mRNA for PKIbeta2 produced a protein product that was larger and much more effectively translated, suggesting a functional role for the inserted sequence. Both isoforms were transiently expressed in COS-1 cells to evaluate their ability to inhibit the catalytic subunit of PKA in vivo. Extracts from cells expressing the PKIbeta2 isoform showed greater inhibition of catalytic subunit kinase activity than extracts expressing the PKIbeta1 isoform. Northern blot analysis of poly(A)+ RNA from various mouse tissues showed the presence of transcripts of 1.8 kilobases related to these cDNAs. Analysis of brain RNA from several species indicated that expression of these PKI mRNAs is evolutionarily conserved. Together with previous studies, these results indicate the presence of at least three PKI proteins in mouse. The skeletal muscle isoform has been designated PKIalpha, while the testicular isoform is PKIbeta. We propose to designate the two testicular isoforms described here PKIbeta1 and PKIbeta2.	UNIV MICHIGAN,MENTAL HLTH RES INST,205 ZINA PITCHER PL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038788, R29GM038788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015794] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38788] Funding Source: Medline; NIMH NIH HHS [MH15794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS WB, 1982, P NATL ACAD SCI-BIOL, V79, P3877, DOI 10.1073/pnas.79.12.3877; ASHBY CD, 1973, J BIOL CHEM, V248, P1255; ASHBY CD, 1972, J BIOL CHEM, V247, P6637; BEALE EG, 1977, ENDOCRINOLOGY, V101, P1621, DOI 10.1210/endo-101-5-1621; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V118, P5294; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DONNELLY TE, 1973, J BIOL CHEM, V248, P190; FERRAZ C, 1979, BIOCHIMIE, V61, P645, DOI 10.1016/S0300-9084(79)80162-5; GROVE JR, 1989, J BIOL CHEM, V264, P19506; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREBS EG, 1986, ENZYMES, P3; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; POSNER JB, 1965, J BIOL CHEM, V240, P982; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SKALA JP, 1974, BIOCHEM J, V138, P195, DOI 10.1042/bj1380195; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WHITEHOUSE S, 1980, ARCH BIOCHEM BIOPHYS, V203, P734, DOI 10.1016/0003-9861(80)90233-7	27	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10927	10931						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684369				2022-12-27	WOS:A1993LD46600035
J	ENGLERT, C; PFEIFER, F				ENGLERT, C; PFEIFER, F			ANALYSIS OF GAS VESICLE GENE-EXPRESSION IN HALOFERAX-MEDITERRANEI REVEALS THAT GVPA AND GVPC ARE BOTH GAS VESICLE STRUCTURAL PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOBACTERIUM-HALOBIUM; CYANOBACTERIA	Gas vesicle synthesis in Haloferax mediterranei involves several gene products encoded by a 9.4-kilobase pair DNA region (mc-vac region) that contains 13 genes in addition to gvpA encoding the major structural gas vesicle protein. The expression of part of this region, encompassing the genes gvpA, gvpC, gvpN, and gvpO was investigated. These genes are transcribed from a common promoter located upstream of gvpA. Transcripts of 0.34 (gvpA only), 1.8 (gvpA/C), 2.4 (gvpA/C/N) and 3 kilobases (gvpA/C/N/O) were observed, with the gvpA transcript being the predominant mRNA species. The majority of the mRNA formed terminates 64 base pairs downstream of gvpA at the cytosine of the sequence 5' TTTTTC 3'. The synthesis of the GvpA and GvpC proteins was investigated by Western analyses. An antiserum raised against isolated gas vesicles of Hf. mediterranei detects, in addition to gas vesicle fragments, the GvpA protein of the M(r) of approximately 8,000 in lysates derived from different halobacteria or from Escherichia coli expressing gvpA. In samples containing isolated gas vesicles, mainly partially disaggregated gas vesicle fragments hybridize, but a minor amount of monomeric GvpA is also seen. For the detection of the GvpC protein, two versions of the gvpC gene (full length and gvpDELTAC lacking the 3' part encoding the acidic C terminus) were expressed in E. coli, and the resulting proteins were purified. The two antisera raised against these GvpC versions indicate the expression of gvpC in different halobacteria. By Western analysis, GvpC is also detectable in samples containing isolated gas vesicles demonstrating that GvpC is a second, but minor, gas vesicle structural protein.	MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society				Pfeifer, Felicitas/0000-0003-1631-1543; Englert, Christoph/0000-0002-5931-3189				DAMERVAL T, 1987, GENE, V54, P83, DOI 10.1016/0378-1119(87)90350-7; DAMERVAL T, 1989, J BACTERIOL, V171, P1445, DOI 10.1128/jb.171.3.1445-1452.1989; ENGLERT C, 1992, J MOL BIOL, V227, P586, DOI 10.1016/0022-2836(92)90914-6; ENGLERT C, 1990, MOL GEN GENET, V222, P225, DOI 10.1007/BF00633822; ENGLERT C, 1992, MOL MICROBIOL, V6, P3543, DOI 10.1111/j.1365-2958.1992.tb01789.x; GRIFFITHS AE, 1992, J GEN MICROBIOL, V138, P1243, DOI 10.1099/00221287-138-6-1243; HALLADAY JT, 1992, GENE, V119, P131, DOI 10.1016/0378-1119(92)90078-4; HAYES PK, 1988, MOL MICROBIOL, V2, P545, DOI 10.1111/j.1365-2958.1988.tb00062.x; HAYES PK, 1992, ARCH MICROBIOL, V157, P229, DOI 10.1007/BF00245155; HORNE M, 1991, MOL MICROBIOL, V5, P1159, DOI 10.1111/j.1365-2958.1991.tb01889.x; HORNE M, 1989, MOL GEN GENET, V218, P437, DOI 10.1007/BF00332407; HORNE M, 1988, MOL GEN GENET, V213, P459, DOI 10.1007/BF00339616; JONES JG, 1991, GENE, V102, P117, DOI 10.1016/0378-1119(91)90549-Q; PFEIFER F, 1988, J BACTERIOL, V170, P3718, DOI 10.1128/jb.170.8.3718-3724.1988; PFEIFER F, 1992, J BIOENERG BIOMEMBR, V24, P577, DOI 10.1007/BF00762350; REITER WD, 1988, NUCLEIC ACIDS RES, V16, P2454; RODRIGUEZVALERA F, 1983, SYST APPL MICROBIOL, V4, P369, DOI 10.1016/S0723-2020(83)80021-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON RD, 1981, J GEN MICROBIOL, V125, P103; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; SUREK B, 1988, J BACTERIOL, V70, P1746; WALSBY AE, 1989, BIOCHEM J, V264, P313, DOI 10.1042/bj2640313; ZACCAI G, 1989, J MOL BIOL, V208, P491, DOI 10.1016/0022-2836(89)90512-3	24	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9329	9336						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683649				2022-12-27	WOS:A1993LA68900030
J	TOUNG, YPS; HSIEH, TS; TU, CPD				TOUNG, YPS; HSIEH, TS; TU, CPD			THE GLUTATHIONE-S-TRANSFERASE D-GENES - A DIVERGENTLY ORGANIZED, INTRONLESS GENE FAMILY IN DROSOPHILA-MELANOGASTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SUBUNIT CDNA; HUMAN-LIVER; SECONDARY-STRUCTURE; SUPERGENE FAMILY; MULTIGENE FAMILY; ESCHERICHIA-COLI; HEAT-SHOCK; EXPRESSION; SEQUENCE	We have characterized a cluster of glutathione S-transferase genes located at 87B on the Drosophila polytene chromosome near the heat shock genes, hsp70. These genes, designated gst Ds in the glutathione S-transferase gene superfamily, are closely linked within a approximately 60-kilobase DNA segment. The gene family has a minimum of eight intronless genes organized in divergent orientations. Two of the genes are probably GST pseudogenes in that their open reading frames are shorter than functional GSTs, and no RNAs from them have been detected thus far. The amino acid sequence identity among the functional genes ranges from 53 to 75% in pairwise comparisons. The intergenic regions are much more AT rich (63-73%) than the coding regions (41-52%), consistent with being promoter/regulatory sequences in Drosophila melanogaster. The mRNA size for each gene suggests that these genes are probably expressed individually from separate promoters. This is the first documentation of definitive physical linkage of a functional glutathione S-transferase multigene family. The genes are divergently organized, and a gradation of sequence similarity exists among the encoded GST isozymes. The patterns of sequence similarity in pairwise comparisons of the family members suggest that gene conversion may have played a role in the evolution of this GST multigene family. We propose that the Drosophila gst D genes provide a unique system for studying GST gene regulation, in vivo physiological functions, and evolution of substrate specificities with a global perspective. The gst D genes in other organisms should be intronless and can be isolated directly from genomic DNAs for functional analyses at the gene and protein levels.	PENN STATE UNIV,DEPT MOLEC & CELL BIOL,401 PAUL M ALTHOUSE LAB,UNIV PK,PA 16802; DUKE UNIV,SCH MED,DEPT BIOCHEM,DURHAM,NC 27709	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Duke University			Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NCRR NIH HHS [2 SO7 RR07082] Funding Source: Medline; NIGMS NIH HHS [GM29006] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATIST G, 1986, J BIOL CHEM, V261, P5544; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENNAN RG, 1989, TRENDS BIOCHEM SCI, V14, P286, DOI 10.1016/0968-0004(89)90066-2; CHANG CK, 1981, INSECT BIOCHEM, V11, P179, DOI 10.1016/0020-1790(81)90094-9; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CLARK AG, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P369; DEJONG JL, 1988, NUCLEIC ACIDS RES, V16, P8541, DOI 10.1093/nar/16.17.8541; DEJONG JL, 1988, J BIOL CHEM, V263, P8430; DEJONG JL, 1991, BIOCHEM BIOPH RES CO, V180, P15, DOI 10.1016/S0006-291X(05)81248-3; DONOFRIO M, 1991, J BIOL CHEM, V266, P11980; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FOURNIER D, 1992, J BIOL CHEM, V267, P1840; FREAR DS, 1970, PHYTOCHEMISTRY, V9, P2123, DOI 10.1016/S0031-9422(00)85377-7; GRANT DF, 1989, PESTIC BIOCHEM PHYS, V33, P132, DOI 10.1016/0048-3575(89)90004-7; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; HAYES JD, 1990, GLUTATHIONE S TRANSF; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KANO T, 1987, CANCER RES, V47, P5626; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; KONIGSBERG W, 1983, P NATL ACAD SCI-BIOL, V80, P687, DOI 10.1073/pnas.80.3.687; KOTZE AC, 1987, PESTIC BIOCHEM PHYS, V29, P77, DOI 10.1016/0048-3575(87)90086-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI HCJ, 1986, J BIOL CHEM, V261, P3793; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; LAROCHE SD, 1990, J BACTERIOL, V172, P164, DOI 10.1128/JB.172.1.164-171.1990; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIU SX, 1992, J BIOL CHEM, V267, P4296; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MOZER TJ, 1983, BIOCHEMISTRY-US, V22, P1068, DOI 10.1021/bi00274a011; OTTEA JA, 1984, PESTIC BIOCHEM PHYS, V22, P203, DOI 10.1016/0048-3575(84)90091-9; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIMABUKURO RH, 1971, PLANT PHYSIOL, V47, P10, DOI 10.1104/pp.47.1.10; SHPAER EG, 1985, NUCLEIC ACIDS RES, V13, P275, DOI 10.1093/nar/13.1.275; SITZLER S, 1991, GENE, V100, P155, DOI 10.1016/0378-1119(91)90361-E; STENBERG G, 1991, BIOCHEM J, V274, P549, DOI 10.1042/bj2740549; STENERSEN J, 1987, COMP BIOCHEM PHYS C, V86, P73, DOI 10.1016/0742-8413(87)90147-2; TATE LG, 1978, COMP BIOCHEM PHYS C, V61, P165, DOI 10.1016/0306-4492(78)90128-4; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TOUNG YPS, 1991, BIOCHEM BIOPH RES CO, V178, P1205, DOI 10.1016/0006-291X(91)91021-4; TOUNG YPS, 1992, BIOCHEM BIOPH RES CO, V182, P355, DOI 10.1016/S0006-291X(05)80152-4; TOUNG YPS, 1990, P NATL ACAD SCI USA, V87, P31, DOI 10.1073/pnas.87.1.31; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; TU CPD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P357; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; TU CPD, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P379; TU CPD, 1986, J BIOL CHEM, V261, P9540; TU CPD, 1983, J BIOL CHEM, V258, P4659; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; WANG AL, 1985, CANCER TREAT REP, V69, P677; WANG JY, 1991, MOL GEN GENET, V227, P260, DOI 10.1007/BF00259679; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X	66	93	105	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9737	9746						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683659				2022-12-27	WOS:A1993LA68900086
J	ZHAN, X; HU, XG; FRIESEL, R; MACIAG, T				ZHAN, X; HU, XG; FRIESEL, R; MACIAG, T			LONG-TERM GROWTH-FACTOR EXPOSURE AND DIFFERENTIAL TYROSINE PHOSPHORYLATION ARE REQUIRED FOR DNA-SYNTHESIS IN BALB/C 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR FAMILY; FIBROBLAST GROWTH; HEPARIN-BINDING; FACTOR-I; ENDOTHELIAL-CELLS; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; TRANSFORMED-CELLS; KINASE-ACTIVITY; DOWN-REGULATION	The importance of growth factor-mediated immediate-early cellular events to the cell cycle has influenced the development and identity of oncogenes and tumor suppressor genes as well as the concept that growth factors commit mammalian cells to enter a biochemical program that ultimately yields DNA synthesis. However, the mid and late events involved in the regulation of growth factor-induced signal transduction remain largely unknown. In this report we demonstrate that BALB/c 3T3 cells require continuous exposure to fibroblast growth factor (FGF)-1 for a minimum of 12 h to achieve near maximal DNA synthesis. This correlates with the continuous internalization of radiolabeled FGF-1 into the cytosol and nucleus of BALB/c 3T3 cells and the maintenance of a low level of FGF receptors on the cell surface during the entire G1 phase of the cell cycle. Further analysis demonstrates the maintenance of a continuous series of differential FGF-1-induced tyrosine phosphorylation events including the phosphorylation of phospholipase C-gamma as well as novel FGF receptor polypeptide substrates, p60, p85, p90, and p130 throughout the G1 phase of the BALB/c 3T3 cell cycle. The tyrosine phosphorylation events are biphasic during the 12-h period after the administration of FGF-1, and the second phase is characterized by hyper-tyrosine phosphorylation of p60, p85, and p130. Interestingly, NIH 3T3 cells which overexpress the FGF receptor-1 polypeptide demonstrate exaggerated tyrosine phosphorylation of p60 and p85 but not p90 and exhibit growth factor-independent cell proliferation. These results suggest that the initiation of DNA synthesis in BALB/c 3T3 cells by FGF-1 is regulated by a complex biochemical program that involves the continuous tyrosine phosphorylation of known and novel polypeptides throughout the G0 to G1 transition period of the cell cycle.	AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [HL32348, HL44336] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, P50HL044336] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5; CAMPISI J, 1982, P NATL ACAD SCI-BIOL, V79, P436, DOI 10.1073/pnas.79.2.436; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIESEL R, 1988, BIOCHEM BIOPH RES CO, V151, P957, DOI 10.1016/S0006-291X(88)80459-5; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GAY CG, 1990, J BIOL CHEM, V265, P3284; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARICS I, 1989, ONCOGENE, V4, P335; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; QUARTO N, 1989, ONCOGENE RES, V5, P101; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAPP UR, 1991, ONCOGENE, V6, P495; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RYBAK SM, 1988, J CELL PHYSIOL, V136, P312, DOI 10.1002/jcp.1041360214; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STARK KL, 1991, DEVELOPMENT, V113, P641; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAKAHASHI JA, 1991, FEBS LETT, V288, P65, DOI 10.1016/0014-5793(91)81004-R; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	79	117	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9611	9620						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683656				2022-12-27	WOS:A1993LA68900070
J	LEEBLUNDBERG, LMF; SONG, XH				LEEBLUNDBERG, LMF; SONG, XH			IDENTIFICATION OF P125, A COMPONENT OF A GROUP OF 120-KDA PROTEINS THAT ARE PHOSPHORYLATED ON TYROSINE RESIDUES IN RESPONSE TO BRADYKININ AND BOMBESIN STIMULATION, IN ANTI-RAS-GTPASE-ACTIVATING PROTEIN IMMUNOPRECIPITATES OF SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GUANINE-NUCLEOTIDES; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL TURNOVER; SIGNAL TRANSDUCTION; ARACHIDONIC-ACID; RECEPTOR NUMBER; KINASE-C; GAP; ONCOGENE	Bradykinin (BK) and bombesin (BN) stimulate an increase in the tyrosine phosphorylation of a 120-kDa group of proteins (pps120) in Swiss 3T3 cells (Leeb-Lundberg, L. M. F., and Song X.-H. (1991) J. Biol. Chem. 266, 7746-7749). Here, we show that a component of pps120, p125, was specifically immunoprecipitated with antibodies against the p21ras GTPase-activating protein (GAP). The major portion of GAP in nonstimulated cells (96%) was located in the cytosol, and this distribution was not affected by exposure of cells to 1 muM BK for 1 min. A significant amount of GAP in nonstimulated cells was recovered in anti-phosphotyrosine (anti-Tyr(P)) immunoprecipitates, and the cellular distribution of this GAP essentially paralleled that of total GAP. Recovery of GAP in anti-Tyr(P) immunoprecipitates of nonstimulated cells appeared to be caused at least in part by the presence of GAP complexed to a 190-kDa tyrosine-phosphorylated protein (p190). Exposure of cells to 1 muM BK for 1 min resulted in an increase in the recovery of a portion of the cellular GAP in anti-Tyr(P) immunoprecipitates. This increase was paralleled by the appearance of a tyrosine-phosphorylated protein species of 125 kDa (p125) in anti-GAP immunoprecipitates. Tyrosine-phosphorylated p125 was present also in anti-GAP immunoprecipitates after exposure of cells to 1 muM BN. High performance gel exclusion liquid chromatography of the anti-GAP-immunoprecipitated proteins on a Protein-Pak 300SW column revealed that p125 is not GAP. Anti-GAP immunoprecipitation of p125 was prevented by prior denaturation of cell lysates in sodium dodecyl sulfate suggesting that p125 is physically associated with GAP. Chromatography of cell lysates revealed that the pps120 group of tyrosine phosphoproteins includes a 125- and a 120-kDa protein. The anti-GAP-immunoprecipitable p125 migrated identically to the 125-kDa phosphoprotein component of pps120. These observations show that the pps120 group of tyrosine phosphoproteins is composed of at least two physically distinct protein components, p125 and p120. p125 is associated in some manner with a portion of the cellular GAP after exposure of cells to BK and BN.			LEEBLUNDBERG, LMF (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FITZGERALD TJ, 1986, J BIOL CHEM, V261, P6871; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; IKEDA M, 1984, LIFE SCI, V34, P529, DOI 10.1016/0024-3205(84)90485-5; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MATHIS SA, 1991, BIOCHEM J, V276, P141, DOI 10.1042/bj2760141; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLSEN R, 1988, J BIOL CHEM, V263, P18030; PANDIELLA A, 1989, J BIOL CHEM, V264, P3122; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; ROBERTS RA, 1989, J CELL SCI, V94, P527; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	45	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8151	8157						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681835				2022-12-27	WOS:A1993KW97900081
J	WILLIAMS, KP; SHOELSON, SE				WILLIAMS, KP; SHOELSON, SE			A PHOTOAFFINITY SCAN MAPS REGIONS OF THE P85 SH2 DOMAIN INVOLVED IN PHOSPHOPROTEIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHOTYROSINE; PROTEINS	Src homology 2 (SH2) domains are modular phosphotyrosine binding pockets found within a wide variety of cytoplasmic signaling molecules. Here we develop a new approach to analyzing protein-protein interfaces termed photoaffinity scanning, and apply the method to map regions of the phosphatidylinositol 3-kinase p85 SH2 domain that participate in phosphoprotein binding. Each residue except phosphotyrosine (pY) within a tightly binding, IRS-1-derived phosphopeptide (GNGDpYMPMSPKS) was substituted with the photoactive amino acid, benzoylphenylalanine (Bpa). Whereas most substitutions had little effect on binding affinity, Bpa substitution of either Met (+1 and +3 with respect to pY) reduced affinity 50-100-fold to confirm their importance in the pYMXM recognition motif. In three cases photolysis of SH2 domain/Bpa phosphopeptide complexes led to cross-linking of >50% of the SH2 domain; cross-link positions were identified by microsequence, amino acid composition, and electrospray mass spectrometric analyses. Bpa-1 cross-links within alpha-helix I, whereas Bpa+1 and Bpa+4 cross-link the SH2 domain within the flexible loop C-terminal to alpha-helix II. Moreover, cross-linking at any position prevents SH2 domain cleavage at a trypsin-sensitive site within the flexible loop between beta-strands 1 and 2. Therefore, at least three distinct SH2 regions in addition to the beta-sheet participate in phosphoprotein binding; the loop cross-linked by phosphopeptide residues C-terminal to pY appears to confer specificity to the phosphoprotein/SH2 domain interaction.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02215	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, IN PRESS MOL CELL BI; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAUER JC, 1986, J BIOL CHEM, V261, P695; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PICCIONE E, 1993, IN PRESS BIOCHEMISTR; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	22	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5361	5364						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680644				2022-12-27	WOS:A1993KR82200006
J	POSAS, F; CLOTET, J; MUNS, MT; COROMINAS, J; CASAMAYOR, A; ARINO, J				POSAS, F; CLOTET, J; MUNS, MT; COROMINAS, J; CASAMAYOR, A; ARINO, J			THE GENE PPG ENCODES A NOVEL YEAST PROTEIN PHOSPHATASE INVOLVED IN GLYCOGEN ACCUMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SYNTHASE; TYPE-1; PHOSPHORYLASE; PURIFICATION; KINASES; TRANSFORMATION; METABOLISM; DISTINCT	Degenerate oligonucleotides were used to selectively amplify yeast genomic sequences related to Ser/Thr protein phosphatases. Among the sequences obtained, clone ST4-2 was found to code for a novel sequence related to previously known phosphatases. A size-selected yeast genomic library was constructed and screened using clone ST4-2 as probe, and one positive clone, named PPG, was isolated. DNA sequencing of a 1.8-kilobase pair fragment of this clone revealed an open reading frame of 1104 base pairs which codes for a 368-amino acid protein. On the basis of its amino acid sequence, the product of gene PPG would be an acidic protein, structurally more related to type 2A than to type 1 or 2B phosphatases, and is characterized by an extension of about 50 amino acids at the carboxyl terminus. The gene, which is located in chromosome XIV, is expressed as a 1.3-kilobase mRNA and is not essential for growth. Haploid mutants carrying a disrupted copy of the gene were able to grow in glucose as well as in other carbon sources, but they accumulated less glycogen than the wild type strain. However, the state of activation of glycogen synthase was essentially identical in wild type and mutant cells. The finding that, in early exponential phase, mutant cells contain higher levels of glycogen phosphorylase a, in addition to a lower amount of total glycogen synthase activity observed in medium-late exponential phase, could account for the difference found in glycogen accumulation.	UNIV AUTONOMA BARCELONA,FAC VET,DEPT BIOQUIM & BIOL MOLEC,E-08193 BARCELONA,SPAIN	Autonomous University of Barcelona			Posas, Francesc/K-1364-2013; Casamayor, Antonio/A-3190-2012; Arino, Joaquin/D-3756-2011	Posas, Francesc/0000-0002-4164-7076; Casamayor, Antonio/0000-0003-2788-7329; Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FENG ZH, 1991, J BIOL CHEM, V266, P23796; FERNANDEZBANARES I, 1991, FEBS LETT, V290, P38, DOI 10.1016/0014-5793(91)81220-3; FOSSET M, 1971, BIOCHEMISTRY-US, V10, P4105, DOI 10.1021/bi00798a015; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; HOEKSTRA MF, 1991, TRENDS GENET, V7, P293, DOI 10.1016/0168-9525(91)90178-S; HOEKSTRA MF, 1991, TRENDS GENET, V7, P256, DOI 10.1016/0168-9525(91)90161-I; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; MISHRA C, 1983, FEMS MICROBIOL LETT, V18, P25; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PENG ZY, 1991, J BIOL CHEM, V266, P10925; PENG ZY, 1990, J BIOL CHEM, V265, P13871; POSAS F, 1992, J BIOL CHEM, V267, P11734; POSAS F, 1991, FEBS LETT, V279, P341, DOI 10.1016/0014-5793(91)80183-4; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; WINGENDERDRISSEN R, 1983, BIOCHIM BIOPHYS ACTA, V743, P343, DOI 10.1016/0167-4838(83)90392-8	38	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1349	1354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678255				2022-12-27	WOS:A1993KG07700088
J	HATTORI, K; HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K				HATTORI, K; HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K			PURIFICATION AND CHARACTERIZATION OF PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE-II FROM BOVINE LIVER CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; FACTOR 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; HUMAN ERYTHROCYTES; ENDOTHELIAL-CELLS; DIFFERENTIATION; PAF; PHOSPHATIDYLCHOLINE; HYDROLYSIS; THROMBIN	Platelet-activating factor (PAF) acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is distributed widely in plasma and tissues. In a previous study, we demonstrated that the PAF acetylhydrolase activity present in the soluble fraction of bovine brain cortex could be separated chromatographically into three peaks (tentatively designated isoforms Ia, Ib, and II) (Hattori, M., Arai, H., and Inoue, a (1993) J. Biol. Chem, 268, 18748-18753). In this study, these three isoforms were also detected in kidney and Liver cytosols, although their relative activity ratios in these tissues differed. In particular, isoform II was responsible for the majority of the bovine liver PAF acetylhydrolase activity. We purified isoform II from bovine Liver cytosol to near homogeneity and demonstrated that it is a single 40-kDa polypeptide. This enzyme was inactivated by diisopropyl fluorophosphate and 5,5'-dithiobis(2-nitrobenzoic acid), suggesting that both serine and cysteine residues are required for the enzyme activity, and [H-3]diisopropyl fluorophosphate labeled only the 80-kDa polypeptide, confirming the enzyme's identity. Isoform II showed a comparatively broader substrate specificity than isoform Ib. Isoform II hydrolyzed propionyl and butyroyl moieties at the sn-2 position approximately half as effectively as it did PAF, whereas isoform Ib hardly hydrolyzed these substrates. Taken together with previous data, the current findings indicate that tissue cytosol contains at least two types of PAF acetylhydrolase with respect to polypeptide composition, substrate specificity, and tissue distribution and suggest that these two enzymes may share distinct physiological functions in tissues.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT HLTH CHEM, BUNKYO KU, TOKYO 113, JAPAN; SUNTORY INST BIOMED RES, OSAKA 618, JAPAN	University of Tokyo; Suntory Holdings Ltd			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				AARSMAN AJ, 1991, EUR J BIOCHEM, V200, P187, DOI 10.1111/j.1432-1033.1991.tb21066.x; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; ELSTAD MR, 1989, J BIOL CHEM, V264, P8467; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; GUOTA CM, 1977, P NATL ACAD SCI USA, V74, P4315; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NIJSSEN JG, 1986, BIOCHIM BIOPHYS ACTA, V876, P611, DOI 10.1016/0005-2760(86)90050-0; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; SNYDER F, 1987, PLATELET ACTIVATING; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; STAFFORINI DM, 1991, METHOD ENZYMOL, V197, P411; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	31	93	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22308	22313		10.1074/jbc.270.38.22308	http://dx.doi.org/10.1074/jbc.270.38.22308			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673213	hybrid			2022-12-27	WOS:A1995RW31400040
J	INOUE, A; TORIGOE, T; SOGAHATA, K; KAMIGUCHI, K; TAKAHASHI, S; SAWADA, Y; SAIJO, M; TAYA, Y; ISHII, S; SATO, N; KIKUCHI, K				INOUE, A; TORIGOE, T; SOGAHATA, K; KAMIGUCHI, K; TAKAHASHI, S; SAWADA, Y; SAIJO, M; TAYA, Y; ISHII, S; SATO, N; KIKUCHI, K			70-KDA HEAT-SHOCK COGNATE PROTEIN INTERACTS DIRECTLY WITH THE N-TERMINAL REGION OF THE RETINOBLASTOMA GENE-PRODUCT PRB - IDENTIFICATION OF A NOVEL REGION OF PRB-MEDIATING PROTEIN-INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; E2F TRANSCRIPTION FACTOR; LARGE T-ANTIGEN; ESCHERICHIA-COLI; RB PROTEIN; CELL-CYCLE; BINDING; P53; TRANSFORMATION; MUTATIONS	Retinoblastoma protein (pRb) functions as a tumor suppressor, and certain proteins are known to bind to pRb in the C-terminal region. Although the N-terminal region of pRb may also mediate interaction with some proteins, no such protein has been identified yet. We demonstrated previously the in vivo protein association between pRb and 73-kDa heat shock cognate protein (hsc73) in certain human tumor cell lines. In this report we analyzed the interaction between these two proteins in vitro, Our data showed that hsc73 interacts with the novel N-terminal region of pRb; that is, pRb binds directly to hsc73 and dissociates from hsc73 in an ATP-dependent manner. By using deletion mutants of cDNA encoding pRb, the hsc73 binding site of pRb was determined to be located in the region (residues 301-372) outside the so-called A pocket (residues 373-579) of this tumor suppressor protein. This finding was compatible with the fact that the adenovirus E1A oncoprotein, which is known to bind to the E2F binding pocket region of pRb, could not compete with hsc73 for the binding, Furthermore, phosphorylation of pRb by cyclin-dependent kinase inhibited the binding of pRb to hsc73. These data suggest that hsc73 may act exclusively as the molecular chaperone for nonphosphorylated pRb. As a result, hsc73 may function as a molecular stabilizer of nonphosphorylated pRb.	SAPPORO MED UNIV,SCH MED,DEPT PATHOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; SAPPORO MED UNIV,SCH MED,DEPT BIOL MOLEC,SAPPORO,HOKKAIDO 060,JAPAN; SAPPORO MED UNIV,SCH MED,DEPT ORTHOPED,SAPPORO,HOKKAIDO 060,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,TOKYO 104,JAPAN	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; National Cancer Center - Japan								BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHO JM, 1991, CANCER RES, V51, P4250; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARA I, 1991, MICROBIOL IMMUNOL, V35, P995, DOI 10.1111/j.1348-0421.1991.tb01621.x; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHMAN TA, 1991, CANCER RES, V51, P4090; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; NEVINS JR, 1992, SCIENCE, V258, P424; NIHEI T, 1993, CANCER RES, V53, P1702; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHITE E, 1988, J VIROL, V62, P4153, DOI 10.1128/JVI.62.11.4153-4166.1988; YATSUNAMI J, 1993, CANCER RES, V53, P239; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803	41	40	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22571	22576		10.1074/jbc.270.38.22571	http://dx.doi.org/10.1074/jbc.270.38.22571			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673249	hybrid			2022-12-27	WOS:A1995RW31400079
J	BENNER, GE; DENNIS, PB; MASARACCHIA, RA				BENNER, GE; DENNIS, PB; MASARACCHIA, RA			ACTIVATION OF AN S6/H4 KINASE (PAK-65) FROM HUMAN PLACENTA BY INTRAMOLECULAR AND INTERMOLECULAR AUTOPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PURIFICATION; CLEAVAGE	The S6/H4 kinase purified from human placenta catalyzes phosphorylation of the S6 ribosomal protein, histone H4, and myelin basic protein. In vitro activation of the p60 S6/H4 kinase requires removal of an autoinhibitory domain by mild trypsin digestion and autophosphorylation of the catalytic domain (p40 S6/H4 kinase). The two autophosphorylation/autoactivation sites contain the sequences SSMVGTPY (site 1) and SVIDPVPAPVGD-SHVDGAAK (site 2). These sequences identify S6/H4 kinase as the rac-activated PAK65 (Martin, G. A., Bollag, G., McCormick, F. and Abo, A. (1995) EMBO J. 14, 1971-1978). Site 1 phosphorylation is most rapid, but activation does not occur until site 2 is autophosphorylated. The site 1 phosphorylation occurs by an intramolecular mechanism whereas site 2 autophosphorylation occurs by an intermolecular mechanism. A model is proposed in which phosphorylation of sites 1 and 2 occurs sequentially. The model proposes that trypsin treatment of the inactive holoenzyme removes an inhibitory rac-binding domain which blocks MgATP access to the catalytic site. The pseudosubstrate domain at site 1 is autophosphorylated and subsequent bimolecular autophosphorylation at site 2 fully opens the catalytic site. Phosphorylation by a regulatory protein kinase may occur at site 2 in vivo.	UNIV N TEXAS, DEPT BIOL SCI, DIV MOLEC BIOL & BIOCHEM, DENTON, TX 76203 USA	University of North Texas System; University of North Texas Denton					PHS HHS [32350] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANDON SD, 1991, J BIOL CHEM, V266, P380; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DELAHOUSSAYE BA, 1983, J BIOL CHEM, V258, P4272; DENNIS PB, 1993, J BIOL CHEM, V268, P19833; ECKOLS TK, 1983, EUR J BIOCHEM, V134, P249, DOI 10.1111/j.1432-1033.1983.tb07558.x; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GUO H, 1993, J BIOL CHEM, V268, P11193; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; JUHL H, 1983, METHOD ENZYMOL, V99, P37; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG SD, 1987, J BIOL CHEM, V262, P9421; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	25	61	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21121	21128		10.1074/jbc.270.36.21121	http://dx.doi.org/10.1074/jbc.270.36.21121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673144	hybrid, Green Published			2022-12-27	WOS:A1995RU05400042
J	BERTELOOT, A; STDENIS, JF; VANDEWERVE, G				BERTELOOT, A; STDENIS, JF; VANDEWERVE, G			EVIDENCE FOR A MEMBRANE EXCHANGEABLE GLUCOSE POOL IN THE FUNCTIONING OF RAT-LIVER GLUCOSE-6-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; MICROSOMAL GLUCOSE-6-PHOSPHATASE; TRANSPORT PROTEIN; SYSTEM; IDENTIFICATION; PYROPHOSPHATE; PHOSPHATE; GENE	We have investigated the kinetics of tracer uptake into rat liver microsomes in relation to [C-14]glucose 6-phosphate (Glu-6-P) hydrolysis by glucose 6-phosphatase (Glu-6-Pase). 1) The steady-state levels of intravesicular tracer accumulated during the rapid (AMP(1)) and slow (AMP(2)) phases of uptake both demonstrate Michaelis-Menten kinetics relative to outside Glu-6-P concentrations with K-m values similar to those observed for the initial burst (V-i) and steady-state (V-ss) rates of Glu-6-P hydrolysis. 2) The AMP(1)/AMP(2) ratio is constant (mean value = 0.105 +/- 0.018) over the whole range of outside Glu-6-P concentrations and is equal to the AMP(1max)/AMP(2max) ratio (0.109 +/- 0.032), 3) Linear relationships are observed between the initial rates of glucose transport during the slow uptake phase (V-a2) and [AMP(1)], and between [V-ss] and [AMP(2)]. 4) The value of V-ss max exceeds by more than 10-fold that of V-a2 max. 5) It is concluded that the substrate transport model is incompatible with those results and that AMP, represents a membrane exchangeable glucose pool. 6) We propose a new version of the conformational model in which the catalytic site lies deep within a hydrophilic pocket of an intrinsic membrane protein and communicates with the extra- and intravesicular spaces through channels with different glucose permeabilities.	UNIV MONTREAL,DEPT NUTR,ENDOCRINOL METAB LAB,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,GRP RECH TRANSPORT MEMBRANAIRE,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT PHYSIOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal								ARION WJ, 1980, J BIOL CHEM, V255, P396; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; BURCHELL A, 1994, BIOCHEM SOC T, V22, P658, DOI 10.1042/bst0220658; LEI KJ, 1995, J CLIN INVEST, V95, P234, DOI 10.1172/JCI117645; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; NORDLIE RC, 1982, METHOD ENZYMOL, V87, P319; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; SCHULZE HU, 1986, J BIOL CHEM, V261, P6571; SCHULZE HU, 1980, EUR J BIOCHEM, V106, P505, DOI 10.1111/j.1432-1033.1980.tb04597.x; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; STDENIS JF, 1995, J BIOL CHEM, V270, P21092, DOI 10.1074/jbc.270.36.21092; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STDENIS JF, 1995, BIOCHEM J, V310, P221, DOI 10.1042/bj3100221; VIDAL H, 1992, FEBS LETT, V302, P197, DOI 10.1016/0014-5793(92)80439-N; WADDELL ID, 1988, FEBS LETT, V229, P179, DOI 10.1016/0014-5793(88)80822-6; WADDELL ID, 1991, BIOCHEM J, V275, P363, DOI 10.1042/bj2750363; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WOHLHUETER RM, 1980, INT REV CYTOL, V64, P171, DOI 10.1016/S0074-7696(08)60238-7	20	26	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21098	21102		10.1074/jbc.270.36.21098	http://dx.doi.org/10.1074/jbc.270.36.21098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673140	hybrid			2022-12-27	WOS:A1995RU05400038
J	SCHWERK, C; KLOTZBUCHER, M; SACHS, M; ULBER, V; KLEINHITPASS, L				SCHWERK, C; KLOTZBUCHER, M; SACHS, M; ULBER, V; KLEINHITPASS, L			IDENTIFICATION OF A TRANSACTIVATION FUNCTION IN THE PROGESTERONE-RECEPTOR THAT INTERACTS WITH THE TAF(II)110 SUBUNIT OF THE TFIID COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR; MOLECULAR-CLONING; RNA-POLYMERASE; ESTROGEN; COACTIVATORS; SUPERFAMILY; EXPRESSION	Transcriptional activation of target genes by the human progesterone receptor is thought to involve direct or indirect protein-protein interactions between the progesterone receptor and general transcription factors. A key role in transcription plays the general transcription factor TFIID, a multiprotein complex consisting of the TATA-binding protein and several tightly associated factors (TAFs). TAFs have been shown to be required for activated transcription and are, thus, potential targets of activator proteins. Using in vitro interaction assays, we could identify specific interactions between the progesterone receptor and the TATA-binding protein-associated factor dTAF(II)110. The dTAF(II)110 domain responsible for the interaction is distinct from that reported to suffice for binding to Sp1. Somewhat surprisingly, deletion analysis indicated that the previously identified activation functions 1 and 2 of the progesterone receptor are not required for this interaction but pointed to an important role of the DNA binding domain. In cotransfection experiments and an in vitro transcription assay, the DNA binding domain of the progesterone receptor displayed significant activation potential. These findings, taken together, suggest that an interaction between the progesterone receptor and TAF(II)110 may represent an important step in the mechanism of activation.	UNIV ESSEN GESAMTHSCH KLINIKUM,INST ZELLBIOL TUMORFORSCH,D-45122 ESSEN,GERMANY	University of Duisburg Essen			Schwerk, Christian/GNP-5375-2022					BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DOBBELING U, 1988, EMBO J, V7, P2495, DOI 10.1002/j.1460-2075.1988.tb03096.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MCEWAN IJ, 1994, J BIOL CHEM, V269, P25629; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; NARDULLI AM, 1991, J BIOL CHEM, V266, P24070; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PFITZNER E, 1993, MOL ENDOCRINOL, V7, P1061, DOI 10.1210/me.7.8.1061; Sambrook J, 1989, MOL CLONING LABORATO; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VASSEN L, 1994, CELL CULTURE PHARM R, V11, P267; VONSTRANDMANN EP, 1995, DEVELOPMENT, V121, P1217; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKIMORI K, 1993, GENE DEV, V7, P2587; ZAPP D, 1993, MOL CELL BIOL, V13, P6416, DOI 10.1128/MCB.13.10.6416; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	53	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21331	21338		10.1074/jbc.270.36.21331	http://dx.doi.org/10.1074/jbc.270.36.21331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673170	hybrid			2022-12-27	WOS:A1995RU05400071
J	VILLAMORUZZI, E; LAPI, S; PRAT, M; GAUDINO, G; COMOGLIO, PM				VILLAMORUZZI, E; LAPI, S; PRAT, M; GAUDINO, G; COMOGLIO, PM			A PROTEIN-TYROSINE-PHOSPHATASE ACTIVITY ASSOCIATED WITH THE HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MET PROTEIN; HUMAN-PLACENTA; PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR; KINASE; PROTOONCOGENE; AUTOPHOSPHORYLATION; DEPHOSPHORYLATION; PURIFICATION; PHOSPHORYLATION	The receptor for the growth and motility factor, hepatocyte growth factor/scatter factor (HGF/SF), is a transmembrane tyrosine kinase encoded by the MET oncogene. Previous work has shown that receptor phosphorylation on tyrosine is critical for both kinase activation and association with intracellular signal transducers. In this paper, we report that a protein tyrosine phosphatase activity (PTP) coprecipitates with the HGF/SF receptor. The associated PTP activity correlates with the kinase activation of the receptor, increasing up to 5-fold over the basal level after HGF/SF stimulation. The increase is reversible and time- and dose-dependent. A comparable level of activity is associated with constitutively tyrosine-phosphorylated receptors immunoprecipitated from cells where the MET oncogene is amplified and overexpressed. In these cells, a parallel decrease in PTP activity is observed after inhibition of receptor tyrosine phosphorylation following protein kinase C activation. The associated PTP activity is effective in dephosphorylating the HGF/SF receptor. These data show that a protein tyrosine phosphatase is functionally coupled to the HGF/SF receptor.	UNIV TURIN, SCH MED, DEPT BIOMED SCI & ONCOL, I-10124 TURIN, ITALY	University of Turin	VILLAMORUZZI, E (corresponding author), UNIV PISA, DEPT EXPTL BIOMED, I-56100 PISA, ITALY.			Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PERALDI P, 1992, BIOCHEM J, V285, P71, DOI 10.1042/bj2850071; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; VILLAMORUZZI E, 1991, FEBS LETT, V293, P67, DOI 10.1016/0014-5793(91)81154-Z; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; WANG JYJ, 1985, J BIOL CHEM, V260, P64; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	33	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18176	18180						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688741				2022-12-27	WOS:A1993LT74300078
J	CHANG, JD; XU, YP; RAYCHOWDHURY, MK; WARE, JA				CHANG, JD; XU, YP; RAYCHOWDHURY, MK; WARE, JA			MOLECULAR-CLONING AND EXPRESSION OF A CDNA-ENCODING A NOVEL ISOENZYME OF PROTEIN-KINASE-C (NPKC) - A NEW MEMBER OF THE NPKC FAMILY EXPRESSED IN SKELETAL-MUSCLE, MEGAKARYOBLASTIC CELLS, AND PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; CELLULAR-REGULATION; CATALYTIC DOMAINS; ACTIVATION; BINDING; PHOSPHATIDYLSERINE; DIACYLGLYCEROL; GLYCOPROTEINS; CONTAINS; MULTIPLE	At least seven bacteriophage lambda clones encoding structurally related but unique polypeptides with PKC activity have been isolated from mammalian brain, epidermis, and lung cDNA libraries. The possibility that additional isoenzymes are expressed in human blood platelets or megakaryoblastoid human erythroleukemia cells was examined by polymerase chain reaction amplification of reverse transcribed RNA employing oligonucleotide primers corresponding to conserved peptide sequences. cDNAs encoding a novel PKC-related sequence, designated PKC-theta, and four (alpha, beta, delta, and eta) previously identified isoenzymes were isolated from reverse transcribed total RNA of human erythroleukemia cells and platelets. PKC-theta lacks a conserved region (C2) that is present in the calcium-dependent isoenzymes and therefore belongs to the group of novel, or nPKC, isoenzymes. Significantly increased [H-3] phorbol 12,13-dibutyrate binding and cytoskeleton-associated calcium-independent PKC activity were found in COS cells expressing the transfected cDNA. Northern transfer analysis of mRNA from various human tissues revealed high level expression of PKC-theta in skeletal muscle, lung, and brain, and minimal expression in cardiac muscle, placenta, and liver. These findings extend the PKC family and suggest a novel approach to the study of diversity within this pathway of intracellular signal transduction.	BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,HARVARD THORNDIKE LAB,330 BROOKLINE AVE,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL02271, HL38820] Funding Source: Medline; NIDA NIH HHS [DA06363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL002271, R01HL038820, R29HL038820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R18DA006363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKITA Y, 1990, J BIOL CHEM, V265, P354; AUSUBEL FM, 1988, CURRENT PROTOCOLS S, V13; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BELL RM, 1991, J BIOL CHEM, V266, P4661; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; GRABAREK J, 1992, J BIOL CHEM, V267, P1011; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GRUBER JR, 1992, J BIOL CHEM, V267, P13356; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HASHIMOTO K, 1990, FEBS LETT, V263, P31, DOI 10.1016/0014-5793(90)80698-I; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KROLL MH, 1989, BLOOD, V74, P1181; LEE MH, 1986, J BIOL CHEM, V261, P4867; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; RINK TJ, 1983, NATURE, V305, P317, DOI 10.1038/305317a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TANAKA Y, 1992, J BIOCHEM-TOKYO, V111, P265, DOI 10.1093/oxfordjournals.jbchem.a123747; WARE JA, 1989, AM J PHYSIOL, V256, pC35, DOI 10.1152/ajpcell.1989.256.1.C35; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0	44	121	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14208	14214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686153				2022-12-27	WOS:A1993LJ82500063
J	HERNANDEZ, VJ; BREMER, H				HERNANDEZ, VJ; BREMER, H			CHARACTERIZATION OF RNA AND DNA-SYNTHESIS IN ESCHERICHIA-COLI STRAINS DEVOID OF PPGPP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-RATE CONTROL; RIBOSOMAL-RNA; GUANOSINE TETRAPHOSPHATE; B-R; DEOXYRIBONUCLEIC-ACID; STRINGENT CONTROL; RIBONUCLEIC-ACID; CHROMOSOME-REPLICATION; FEEDBACK-REGULATION; POLYMERASE ACTIVITY	The synthesis rates of DNA, rRNA, bulk mRNA, protein, and RNA polymerase beta- and beta'-subunits were determined as functions of growth rate in a wild-type Escherichia coli strain, which produces guanosine tetraphosphate (ppGpp), and in a DELTArelA DELTAspoT mutant which does not produce ppGpp. The rate of stable RNA synthesis per amount of protein depends on three factors: RNA polymerase concentration, RNA polymerase activity, and the distribution of active RNA polymerase between stable and mRNA genes, measured as the stable RNA synthesis rate/total RNA synthesis rate, r(s)/r(t). In the wild-type strain, all three factors increase with growth rate. In the ppGpp-deficient strains, only RNA polymerase synthesis and activity, but not r(s)/r(t), increased with growth rate. Thus, adjustments of r(s)/r(t) require ppGpp. In the absence of ppGpp, the synthesis of rRNA and bulk mRNA both varied in direct proportion to the concentration of active RNA polymerase, in contrast to the wild-type strain, in which only rRNA synthesis increased with growth rate, while mRNA synthesis remained constant. Thus, a control specific for rRNA is absent in strains lacking ppGpp. In rich media, the ppGpp-deficient strain synthesized up to 4-fold more mRNA than wild-type bacteria, which was associated with a similarly increased RNA polymerase activity. We propose that RNA polymerase is rendered inactive in wild-type bacteria due to ppGpp-dependent transcriptional pausing during the synthesis of mRNA. Finally, the control of replication initiation was altered in ppGpp-less bacteria, apparently reflecting indirect changes in the cell physiology, rather than a direct effect of ppGpp on replication initiation.	UNIV TEXAS,MOLEC PROGRAMS,RICHARDSON,TX 75083; UNIV TEXAS,CELL BIOL PROGRAM,RICHARDSON,TX 75083	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas								BARACCHINI E, 1988, MOL GEN GENET, V213, P379, DOI 10.1007/BF00339606; BARACCHINI E, 1991, J BIOL CHEM, V266, P11753; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARACCHINI E, 1987, ANAL BIOCHEM, V167, P245, DOI 10.1016/0003-2697(87)90160-6; BIRD RE, 1972, J MOL BIOL, V70, P549, DOI 10.1016/0022-2836(72)90559-1; BREMER H, 1982, J GEN MICROBIOL, V128, P2865; BREMER H, 1977, J BACTERIOL, V130, P692, DOI 10.1128/JB.130.2.692-697.1977; BREMER H, 1968, J MOL BIOL, V38, P163, DOI 10.1016/0022-2836(68)90404-X; BREMER H, 1975, J THEOR BIOL, V53, P115, DOI 10.1016/0022-5193(75)90106-X; BREMER H, 1979, J THEOR BIOL, V74, P69; BREMER H, 1987, CELLULAR MOL BIOL, P1527; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1987, CELLULAR MOL BIOL, P1410; CHIARAMELLO AE, 1989, J BACTERIOL, V171, P4272, DOI 10.1128/JB.171.8.4272-4280.1989; CHIARAMELLO AE, 1990, J BACTERIOL, V172, P2013, DOI 10.1128/jb.172.4.2013-2019.1990; CHURCHWARD G, 1982, J BACTERIOL, V150, P572, DOI 10.1128/JB.150.2.572-581.1982; CHURCHWARD G, 1977, J BACTERIOL, V130, P1206, DOI 10.1128/JB.130.3.1206-1213.1977; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; DENNIS PD, 1972, J BIOL CHEM, V247, P2842; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; DOWNING W, 1991, J BIOL CHEM, V266, P1304; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GALLANT J, 1977, CELL, V11, P181, DOI 10.1016/0092-8674(77)90329-4; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GENTRY DR, 1989, J BACTERIOL, V171, P1271, DOI 10.1128/jb.171.3.1271-1277.1989; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HASELTINE WA, 1973, P NATL ACAD SCI USA, V70, P1564, DOI 10.1073/pnas.70.5.1564; HELMSTETTER CE, 1967, J MOL BIOL, V24, P417, DOI 10.1016/0022-2836(67)90228-8; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JINKSROBERTSON S, 1987, CELLULAR MOL BIOL, P1358; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2878; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LINDAHL L, 1986, ANNU REV GENET, V20, P297; LITTLE R, 1983, J BACTERIOL, V155, P1426, DOI 10.1128/JB.155.3.1426-1428.1983; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maaloe O, 1969, DEVELOP BIOL       S, V3, P33; Miller J. H, 1972, EXPT MOL GENETICS; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; PRITCHARD RH, 1970, NATURE, V226, P126, DOI 10.1038/226126a0; ROKEACH LA, 1986, CELL, V46, P763, DOI 10.1016/0092-8674(86)90352-1; RYALS J, 1982, J BACTERIOL, V151, P1425, DOI 10.1128/JB.151.3.1425-1432.1982; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; SCHLEIF R, 1967, J MOL BIOL, V27, P41, DOI 10.1016/0022-2836(67)90350-6; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHAY JW, 1990, J BIOL CHEM, V265, P14802; SHEN V, 1977, J BACTERIOL, V130, P1109, DOI 10.1128/JB.130.3.1109-1116.1977; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; XIAO H, 1991, J BIOL CHEM, V266, P5980; ZYSKIND J, 1990, CELL, V69, P5; [No title captured]	72	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10851	10862						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684368				2022-12-27	WOS:A1993LD46600024
J	ZINOVIEVA, RD; TOMAREV, SI; PIATIGORSKY, J				ZINOVIEVA, RD; TOMAREV, SI; PIATIGORSKY, J			ALDEHYDE DEHYDROGENASE-DERIVED OMEGA-CRYSTALLINS OF SQUID AND OCTOPUS - SPECIALIZATION FOR LENS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CORNEAL PROTEIN; RAT; RECRUITMENT; CDNA; SEQUENCE; SITE; EVOLUTION; ENZYMES; EYE	OMEGA-crystallin of the octopus lens is related to aldehyde dehydrogenases (ALDH) of vertebrates (Tomarev, S. I., Zinovieva, R. D., and Piatigorsky, J. (1991) J. Biol. Chem. 266, 24226-24231) and ALDH1/eta-crystallin of elephant shrews (Wistow, G., and Kim, H. (1991) J. Mol. Evol. 32, 262-269). Only very low amounts of OMEGA-crystallin are present in the squid lens. Here, we have cloned OMEGA-crystallin cDNAs of the octopus (Octopus dofleini) and squid (Ommastrephes sloani pacificus) lenses. The deduced amino acid sequences of OMEGA-crystallin from these species are 78% identical to each other, 56-58% identical to cytoplasmic ALDH1 and mitochondrial ALDH2 of vertebrates (which are 66-68% identical to each other), and 40% identical to Escherichia coli and spinach ALDHs. These data are consistent with the idea that the ALDH1/ALDH2 gene duplication in vertebrates occurred after divergence of cephalopods from the line giving rise to vertebrates, but before the separation of squid and octopus. Southern blot hybridization indicated that OMEGA-crystallin is encoded by few genes (possibly just one) in octopus and squid. Northern blot hybridization revealed two bands (2.7 and 9.0 kilobases) of OMEGA-crystallin RNA in the octopus lens and one band (4.2 kilobases) in the squid lens; OMEGA-crystallin RNAs were undetectable in numerous non-lens tissues of octopus and squid, suggesting lens-specific expression of this gene(s). Finally, extracts of the octopus lens had no detectable ALDH activity using different substrates, consistent with OMEGA-crystallin having no enzymatic activity. Taken together, our results suggest that OMEGA-crystallin evolved by duplication of an ancestral gene encoding ALDH and subsequently specialized for refraction in the transparent lens while losing ALDH activity and expression in other tissues.	NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ABRIOLA DP, 1987, BIOCHEMISTRY-US, V26, P5679, DOI 10.1021/bi00392a015; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BOYD LA, 1991, GENE, V103, P45, DOI 10.1016/0378-1119(91)90389-S; CHIOU SH, 1988, FEBS LETT, V241, P261, DOI 10.1016/0014-5793(88)81073-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK DA, 1988, COGNITIVE THER RES, V12, P1, DOI 10.1007/BF01172777; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FORMAN HJ, 1986, ANNU REV PHYSIOL, V48, P669; HEAD MW, 1991, EXP CELL RES, V193, P370, DOI 10.1016/0014-4827(91)90109-8; HEINECKE JW, 1992, J BIOL CHEM, V267, P7959; HEMPEL J, 1982, BIOCHEMISTRY-US, V21, P6834, DOI 10.1021/bi00269a032; HERRING PJ, 1981, J MAR BIOL ASSOC UK, V61, P901, DOI 10.1017/S0025315400023043; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; Klebanoff SJ, 1991, PEROXIDASES CHEM BIO, V1, P1; LINDROTH RL, 1991, INSECT PLANT INTERAC, V3, P1; MEINERTZHAGEN A, 1990, SQUID EXPT ANIMAL, P399; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MONTGOMERY MK, 1992, J BIOL CHEM, V267, P20999; PACKARD A, 1972, BIOL REV, V47, P241, DOI 10.1111/j.1469-185X.1972.tb00975.x; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PIETRUSZKO R, 1989, BIOCH PHYSL SUBSTANC, V1, P89; PIETRUSZKO R, 1991, ENZYMOLOGY MOL BIOL, V3, P19; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spector A., 1991, OXIDATIVE STRESS OXI, P529; THOMAS G, 1990, New Biologist, V2, P903; TOMAREV SI, 1993, J BIOL CHEM, V268, P4534; TOMAREV SI, 1992, J BIOL CHEM, V267, P8604; TOMAREV SI, 1988, NATURE, V336, P86, DOI 10.1038/336086a0; TOMAREV SI, 1991, J BIOL CHEM, V266, P24226; VONBAHRLINDSTROM H, 1985, BIOCHEMISTRY-US, V24, P5847, DOI 10.1021/bi00342a023; WEINER H, 1991, ENZYMOLOGY MOL BIOL, V3, P13; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403	46	52	55	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11449	11455						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684383				2022-12-27	WOS:A1993LD46600105
J	ABBOTTS, J; BEBENEK, K; KUNKEL, TA; WILSON, SH				ABBOTTS, J; BEBENEK, K; KUNKEL, TA; WILSON, SH			MECHANISM OF HIV-1 REVERSE-TRANSCRIPTASE - TERMINATION OF PROCESSIVE SYNTHESIS ON A NATURAL DNA-TEMPLATE IS INFLUENCED BY THE SEQUENCE OF THE TEMPLATE-PRIMER STEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I LARGE FRAGMENT; POLYMERASE-I; OLIGONUCLEOTIDES; ALPHA; IDENTIFICATION; SPECIFICITY; REPLICATION; BINDING; SITE	During processive DNA synthesis in vitro, the human immunoefficiency virus, type 1 (HIV-1) reverse transcriptase encounters template nucleotide positions at which continued synthesis is difficult. At these positions, the enzyme has a relatively high probability of dissociating from the template, and product molecules of corresponding length accumulate as the incubation proceeds. These positions, which are known as termination sites, could be associated with template secondary structures in some cases, but many termination sites appear to be template sequence-related rather than secondary structure-related. Mechanisms producing these blocks in processive DNA synthesis are not well understood. In this study, to examine further the effects of template sequence on termination, we engineered selected single-base changes in the M13mp2 template, and we found that such changes can influence termination. Several general trends emerged from the study. First, strong termination sites rarely correspond to dATP as the ''incoming'' substrate opposite template T. Second, the sequence of the template-primer stem is more important for termination than the sequence of the single-stranded template ahead of the primer. Thus, we note the phenomenon of action at a distance: changing sequence at one nucleotide position in the template-primer stem alters termination at other positions, a few nucleotides distant at the primer 3' end. A and C as template bases in the template-primer stem have opposite effects. A is the strongest terminator residue, and C is the weakest terminator residue, followed by G. Since termination sites are produced by reverse transcriptase dissociation from the template-primer, the results suggest that the HIV-1 reverse transcriptase has properties reminiscent of a sequence-specific double-stranded DNA-binding protein in that its binding mechanism can distinguish both base residues and positions in the double-stranded DNA template-primer stem.	NIEHS, MOLEC GENET LAB E3-01, POB 12233, RES TRIANGLE PK, NC 27709 USA; NIH, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA			Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1991, J BIOL CHEM, V266, P3937; ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; ABBOTTS J, 1991, GWUMC DEPT, P1; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DETERA SD, 1982, J BIOL CHEM, V257, P9770; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; FISHER PA, 1981, BIOCHEMISTRY-US, V20, P4570, DOI 10.1021/bi00519a009; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JOYCE CM, 1986, UCLA S MOL ELL BIOL, V39, P197; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; Maxam A M, 1980, Methods Enzymol, V65, P499; MENDENHALL W, 1981, MATH STATISTICS APPL, P287; NEVINSKY GA, 1990, BIOCHEMISTRY-US, V29, P1200, DOI 10.1021/bi00457a016; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WEAVER DT, 1982, J BIOL CHEM, V257, P2075	25	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10312	10323						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683674				2022-12-27	WOS:A1993LB80000053
J	SIMON, PL; KUMAR, V; LILLQUIST, JS; BHATNAGAR, P; EINSTEIN, R; LEE, J; PORTER, T; GREEN, D; SATHE, G; YOUNG, PR				SIMON, PL; KUMAR, V; LILLQUIST, JS; BHATNAGAR, P; EINSTEIN, R; LEE, J; PORTER, T; GREEN, D; SATHE, G; YOUNG, PR			MAPPING OF NEUTRALIZING EPITOPES AND THE RECEPTOR-BINDING SITE OF HUMAN INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-BETA; BIOLOGICAL-ACTIVITY; H-1-NMR SPECTRA; HUMAN IL-1-BETA; IL-1 RECEPTOR; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC SELECTION; MONOCLONAL-ANTIBODY; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE	Antibodies to synthetic peptides of human interleukin 1beta (IL-1beta) and to recombinant human IL-1beta were used to identify epitopes of IL-1beta associated with the neutralization of its biological activity. Analysis of antisera raised to 17 synthetic peptides derived from the mature IL-1beta sequence showed that five regions (residues 6-15, 49-80, 58-80,92-101, and 120-133) were both immunoprecipitating and neutralizing. Using a hexamer epitope mapping method, comparison of the regions recognized by four neutralizing rabbit antisera with those recognized by a rabbit antiserum raised to denatured IL-1beta suggested two further neutralizing epitopes, residues 39-48 and 83-95. Finally, a neutralizing monoclonal antibody was shown to bind to the peptides 6-11 and 87-95 by peptide binding and mutagenesis. All of these regions appear predominantly on one face of IL-1beta. The effect of mutations in residues 4-11 and 88-97, which lie within this face, on receptor binding and biological activity was determined. Most of the mutations tested affected both receptor binding and activity, whereas mutations in another face of IL-1beta (residues 74-80) had no effect. Purification of two of the mutants with reduced bioactivity and receptor binding and analysis by two-dimensional NMR indicated no gross changes in tertiary structure. A third mutant had reduced bioactivity in two different bioassays but no change in receptor binding. Although two-dimensional NMR revealed no gross changes in conformation, small changes did occur at a site distal from that mutated. The data are consistent with other epitope mapping and receptor binding mutagenesis data and suggest that the neutralizing antibodies and receptor recognize different but overlapping regions of IL-1beta.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC GENET,POB 1539,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PHYS & STRUCT CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PEPTIDE CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								AURON PE, 1992, BIOCHEMISTRY-US, V31, P6632, DOI 10.1021/bi00144a002; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CHANG JY, 1992, BIOCHEMISTRY-US, V31, P2874, DOI 10.1021/bi00126a005; CHOLLET A, 1990, J IMMUNOL METHODS, V127, P179, DOI 10.1016/0022-1759(90)90067-6; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; DAUMY GO, 1991, FEBS LETT, V278, P98, DOI 10.1016/0014-5793(91)80093-I; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1989, J IMMUNOL, V142, P4314; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GAFFNEY EW, 1987, BIOTECHNIQUES, V5, P652; Gait M. J, 1984, OLIGONUCLEOTIDE SYNT; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GOFF SA, 1987, DNA-J MOLEC CELL BIO, V6, P381, DOI 10.1089/dna.1987.6.381; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRONENBORN AM, 1988, FEBS LETT, V231, P135, DOI 10.1016/0014-5793(88)80717-8; GRONENBORN AM, 1986, EUR J BIOCHEM, V161, P37, DOI 10.1111/j.1432-1033.1986.tb10121.x; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HAZUDA DJ, 1991, J BIOL CHEM, V266, P7081; HERZBECK H, 1989, SCAND J IMMUNOL, V30, P549, DOI 10.1111/j.1365-3083.1989.tb02462.x; HORLICK RA, 1992, PROTEIN ENG, V5, P427, DOI 10.1093/protein/5.5.427; HORUK R, 1987, J BIOL CHEM, V262, P16275; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KAMOGASHIRA T, 1988, J BIOCHEM-TOKYO, V104, P837, DOI 10.1093/oxfordjournals.jbchem.a122559; KAMOGASHIRA T, 1988, BIOCHEM BIOPH RES CO, V150, P1106, DOI 10.1016/0006-291X(88)90743-7; KAWASHIMA H, 1992, PROTEIN ENG, V5, P171, DOI 10.1093/protein/5.2.171; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LILLQUIST JS, 1988, J IMMUNOL, V141, P1975; LIVI GP, 1991, J BIOL CHEM, V266, P15348; LIVI GP, 1990, GENE, V88, P297, DOI 10.1016/0378-1119(90)90048-V; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MACDONALD HR, 1986, FEBS LETT, V209, P295, DOI 10.1016/0014-5793(86)81130-9; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MASSONE A, 1988, J IMMUNOL, V140, P3812; MASUI Y, 1989, THERAPEUTIC PEPTIDES, P167; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MEYERS CA, 1987, J BIOL CHEM, V262, P11176; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAITO Y, 1990, BIOCHEM BIOPH RES CO, V167, P103, DOI 10.1016/0006-291X(90)91736-C; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SIMON PL, 1985, J IMMUNOL METHODS, V84, P85, DOI 10.1016/0022-1759(85)90417-X; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STOCKMAN BJ, 1992, BIOCHEMISTRY-US, V31, P5237, DOI 10.1021/bi00138a001; TAM JP, 1987, PEPTIDES, V9, P185; VANOOSTRUM J, 1991, J STRUCT BIOL, V107, P189; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WINGFIELD P, 1989, EUR J BIOCHEM, V179, P565, DOI 10.1111/j.1432-1033.1989.tb14584.x; WINGFIELD P, 1987, FEBS LETT, V215, P160, DOI 10.1016/0014-5793(87)80133-3; WOLFSON AJ, 1991, PROTEIN ENG, V4, P313, DOI 10.1093/protein/4.3.313; YAMAYOSHI M, 1990, LYMPHOKINE RES, V9, P405; YANOFSKY SD, 1990, J BIOL CHEM, V265, P13000; YEM AW, 1989, J BIOL CHEM, V264, P17691; YOUNG P R, 1992, Current Opinion in Biotechnology, V3, P408, DOI 10.1016/0958-1669(92)90170-N; YOUNG PR, 1989, PROTEIN ENG, V2, P545, DOI 10.1093/protein/2.7.545	72	28	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9771	9779						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683661				2022-12-27	WOS:A1993LA68900090
J	YANG, BH; ZANG, LY; TURLEY, EA				YANG, BH; ZANG, LY; TURLEY, EA			IDENTIFICATION OF 2 HYALURONAN-BINDING DOMAINS IN THE HYALURONAN RECEPTOR RHAMM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINK PROTEIN; HOMING RECEPTOR; CELL-ADHESION; PROTEOGLYCANS; ACID; GLYCOSAMINOGLYCANS; SEQUENCE	We have identified two discrete hyaluronan- (HA) binding domains in the HA receptor RHAMM (Receptor for HA-Mediated Motility) that mediates the locomotion of H-ras transformed fibroblasts. A complete RHAMM cDNA (1.43 kilobases (kb)) was expressed as a fusion protein with pGEX-2T in Escherichia coli HB101 and was shown to bind specifically to both biotin-labeled HA in a transblot assay and to HA-Sepharose. The complete cDNA was truncated with restriction endonucleases from the 3' end resulting in 1.30-, 1.02-, 0.71-, and 0.41-kb cDNAs which were then expressed in HB101. Only the fusion peptide expressed from the complete cDNA and the 1.30-kb cDNA bound to HA indicating that the region located between 1.02-1.30 kb of RHAMM cDNA was critical for recognition of this glycosaminoglycan. Deletion of 114 bases in this region virtually eliminated HA binding activity thus defining the major glycosaminoglycan binding region to amino acids 400-434 located near the carboxyl terminus of RHAMM. Two domains containing clusters of basic amino acids were identified within this region. Synthetic peptides mimicking these two domains both inhibited HA binding to the complete 1.43-kb expressed glutathione s-transferase-RHAMM fusion protein, and also directly bound to HA-Sepharose. Random peptides and peptides mimicking other regions in RHAMM did not inhibit HA-RHAMM interactions and bound weakly to HA-Sepharose. Oligonucleotides encoding either of these two peptides were linked to the NH2-terminal 0.71 kb of RHAMM which encoded a peptide that did not contain HA binding activity. Fusion proteins containing either of these recombinant peptides acquired HA binding activity as assessed with a transblot assay. Thus, we have identified two domains within RHAMM that are responsible for its HA binding activity.	UNIV MANITOBA, MANITOBA INST CELL BIOL, 100 OLIVIA ST, WINNIPEG R3E 0V9, MANITOBA, CANADA; UNIV MANITOBA, DEPT PEDIAT & CHILD HLTH, WINNIPEG R3E 0V9, MANITOBA, CANADA	University of Manitoba; University of Manitoba					NCI NIH HHS [CA 51540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bayer E A, 1980, Methods Biochem Anal, V26, P1; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOEGE K, 1986, P NATL ACAD SCI USA, V83, P3761, DOI 10.1073/pnas.83.11.3761; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EHRLICH HJ, 1992, J BIOL CHEM, V267, P8857; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; IOZZO RV, 1985, LAB INVEST, V53, P373; ISACSSON U, 1974, ANAL CHIM ACTA, V68, P339, DOI 10.1016/S0003-2670(01)82590-3; KISS I, 1987, P NATL ACAD SCI USA, V84, P6399, DOI 10.1073/pnas.84.18.6399; KOST C, 1992, J BIOL CHEM, V267, P12098; KVIST TN, 1970, J EXP ZOOL, V175, P221, DOI 10.1002/jez.1401750209; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; MARKWALD RR, 1978, DEV BIOL, V62, P292, DOI 10.1016/0012-1606(78)90218-X; MCCARTHY MT, 1989, J CELL PHYSIOL, V141, P191, DOI 10.1002/jcp.1041410127; MCCLAY DR, 1987, ANNU REV CELL BIOL, V3, P319, DOI 10.1146/annurev.cellbio.3.1.319; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1992, J BIOL CHEM, V267, P8789; Roswell D. F., 1978, METHOD ENZYMOL, V57, P409, DOI [10.1016/0076-6879(78)57038-9, DOI 10.1016/0076-6879(78)57038-9]; Sambrook J, 1989, MOL CLONING LABORATO; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOOLE BP, 1982, CONNECT TISSUE RES, V10, P93, DOI 10.3109/03008208209034409; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1984, CANCER METAST REV, V3, P325, DOI 10.1007/BF00051458; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1987, BIOCHEMISTRY-US, V26, P2997, DOI 10.1021/bi00385a007	34	134	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8617	8623						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682552				2022-12-27	WOS:A1993KX81100038
J	KANALAS, JJ; MAKKER, SP				KANALAS, JJ; MAKKER, SP			ANALYSIS OF A 45-KDA PROTEIN THAT BINDS TO THE HEYMANN NEPHRITIS AUTOANTIGEN GP330	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; ANTIGEN GP330; CDNA CLONING; GLYCOPROTEIN; PLASMINOGEN; AFFINITY; LIGAND; CELLS	Previously, we have shown that gp330, the putative autoantigen of Heymann nephritis which is located on the glomerular and tubular epithelial cells, is a receptor for plasminogen. During our analysis of the function of gp330, we also observed by means of Western analysis the binding of gp330 to a 45-kDa protein. This 45-kDa protein was obtained from extracts of rat kidney and purified to apparent homogeneity. Enzyme-linked immunosorbent assay analysis indicate that gp330 can bind to the 45-kDa protein. In fact, both the 45-kDa protein and plasminogen can bind to gp330 simultaneously, indicating that gp330 has two separate sites for each respective protein. No inhibition of binding of either ligand to gp330 is observed when both ligands were simultaneously incubated with immobilized gp330. A rabbit polyclonal antibody raised against this 45-kDa protein was used to screen a rat kidney lambdagt11 expression library. Sequence analysis of the isolated clones revealed that this protein is similar to the human alpha2-macroglobulin receptor-related protein and murine heparin-binding protein-44. It is also identical to a previously reported, supposedly pathogenic, domain of gp330. However, our results show that the cDNAs encode for a 45-kDa protein, which is not a part of gp330 but a separate protein which binds to gp330.			KANALAS, JJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PEDIAT,SAN ANTONIO,TX 78284, USA.				NIADDK NIH HHS [R01-AM 33941] Funding Source: Medline; NIDDK NIH HHS [R29-DK 40189] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM033941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040189] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALOUSI MA, 1967, FED PROC, V26, P743; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EDGINGTON TS, 1967, SCIENCE, V155, P1432, DOI 10.1126/science.155.3768.1432; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HERZ J, 1991, J BIOL CHEM, V266, P21232; HEYMANN W, 1959, P SOC EXP BIOL MED, V100, P660; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KANALAS JJ, 1988, J IMMUNOL, V141, P4152; KANALAS JJ, 1990, J AM SOC NEPHROL, V1, P792; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; MAKKER SP, 1990, KIDNEY INT, V37, P64, DOI 10.1038/ki.1990.9; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364	18	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8188	8192						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681839				2022-12-27	WOS:A1993KW97900087
J	SELVA, E; RADEN, DL; DAVIS, RJ				SELVA, E; RADEN, DL; DAVIS, RJ			MITOGEN-ACTIVATED PROTEIN-KINASE STIMULATION BY A TYROSINE KINASE-NEGATIVE EPIDERMAL GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; EGF RECEPTOR; CELLS; PHOSPHORYLATION; SITE	Mutation of the epidermal growth factor receptor (EGF-R) within the ATP binding subdomain results in a receptor that lacks tyrosine kinase activity and is defective in signal transduction. However, this kinase-negative EGF-R is able to activate MAP kinase (Campos-Gonzalez, R., and Glenny, J. R. (1992) J. Biol. Chem. 267, 14535-14538). This observation suggests that signal initiation by the EGF-R can occur by a mechanism that is independent of the receptor tyrosine kinase activity. Here, we report that the kinase-negative EGF-R is phosphorylated on tyrosine in EGF-treated cells. The mechanism of tyrosine phosphorylation can be accounted for by the action of EGF to stimulate a protein kinase activity that is associated with the kinase-negative EGF-R. This protein kinase activity is not intrinsic to the receptor and can be separated from the EGF-R by incubation with 0.5 M NaCl. MAP kinase activation by the kinase-negative EGF-R may therefore occur by a mechanism that requires a receptor-associated tyrosine kinase. Thus, it is unnecessary to propose a novel kinase-independent mechanism of signal initiation to account for MAP kinase activation by the kinase-negative EGF-R.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NCI NIH HHS [CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; LEISTER KJ, 1989, P NATL ACAD SCI USA, V86, P783, DOI 10.1073/pnas.86.3.783; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; NORTHWOOD IC, 1990, P NATL ACAD SCI USA, V87, P6107, DOI 10.1073/pnas.87.16.6107; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	20	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2250	2254						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678418				2022-12-27	WOS:A1993KH62000112
J	CARDOZO, C; ELEUTERI, AM; ORLOWSKI, M				CARDOZO, C; ELEUTERI, AM; ORLOWSKI, M			DIFFERENCES IN CATALYTIC ACTIVITIES AND SUBUNIT PATTERN OF MULTICATALYTIC PROTEINASE COMPLEXES (PROTEASOMES) ISOLATED FROM BOVINE PITUITARY, LUNG, AND LIVER - CHANGES IN LMP7 AND THE COMPONENT NECESSARY FOR EXPRESSION OF THE CHYMOTRYPSIN-LIKE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; SENSITIVE NEUTRAL ENDOPEPTIDASE; CLASS-II REGION; CDNA CLONING; LINKED LMP; HUMAN MHC; UBIQUITIN; GENE; SPECIFICITY; PROTEOLYSIS	Polyacrylamide gel electrophoresis and high performance liquid chromatography of multicatalytic proteinase complexes (MPC) isolated from bovine pituitary, lung and liver showed marked differences in the pattern of subunits, The concentrations of LMP7 in the lung and liver were 10 and 5 times, respectively, greater than those in the pituitary, whereas the chymotrypsin-like activity and the amount of a subunit (BO2), necessary for its expression, were markedly decreased in the lung and moderately decreased in the liver, Lower trypsinlike, small neutral amino acid preferring, and peptidyl-glutamyl-peptide hydrolyzing activities were also found in the lung and liver. The activity of the branched chain amino acid preferring component (BrAAP), predominantly latent in the pituitary, was highly activated in the lung and liver, as evidenced by a greatly decreased IT, and a 20-fold increase of the specificity constant V-max/K-m, indicating facilitated substrate access to its active site and increased affinity toward substrates with branched chain amino acids in the P-1 position, It is suggested that overexpression of LMP7 in the lung is related to increased exposure of the airways to foreign antigens, The possible association between amounts of LMP7 and the activation of the BrAAP component needs further examination.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029; UNIV CAMERINO,I-62032 CAMERINO,ITALY	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Camerino			Cardozo, Christopher/R-6021-2019	Cardozo, Christopher/0000-0003-4013-2537; Eleuteri, Anna Maria/0000-0003-0461-1346	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025377] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8 HL02835] Funding Source: Medline; NIDDK NIH HHS [DK 25377] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKI M, 1992, FEBS LETT, V301, P65, DOI 10.1016/0014-5793(92)80211-X; AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; AMSTERDAM A, 1993, P NATL ACAD SCI USA, V90, P99, DOI 10.1073/pnas.90.1.99; ARRIBAS J, 1990, J BIOL CHEM, V265, P13696; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BURNETTE WN, 1991, ANAL BIOCHEM, V112, P195; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CARDOZO C, 1994, BIOCHEMISTRY-US, V33, P6483, DOI 10.1021/bi00187a014; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; Falk K, 1993, Semin Immunol, V5, P81, DOI 10.1006/smim.1993.1012; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GLYNNE R, 1993, EUR J IMMUNOL, V23, P860, DOI 10.1002/eji.1830230414; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4601; HOUGH R, 1987, J BIOL CHEM, V262, P8303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; ORLOWSKI M, 1991, BIOCHEMISTRY-US, V30, P5999, DOI 10.1021/bi00238a025; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SATO S, 1990, BIOCHIM BIOPHYS ACTA, V1041, P269, DOI 10.1016/0167-4838(90)90283-L; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SHIVANANDAPPA T, 1991, CURR EYE RES, V10, P871, DOI 10.3109/02713689109013883; TAMURA T, 1990, FEBS LETT, V264, P91, DOI 10.1016/0014-5793(90)80773-C; TANAKA K, 1994, J LEUKOCYTE BIOL, V56, P571, DOI 10.1002/jlb.56.5.571; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; WAGNER BJ, 1991, CURR EYE RES, V10, P485, DOI 10.3109/02713689109001756; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YU B, 1993, J BIOL CHEM, V268, P2029	56	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22645	22651		10.1074/jbc.270.38.22645	http://dx.doi.org/10.1074/jbc.270.38.22645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673255	hybrid			2022-12-27	WOS:A1995RW31400089
J	DASGUPTA, M; BLUMENTHAL, DK				DASGUPTA, M; BLUMENTHAL, DK			CHARACTERIZATION OF THE REGULATORY DOMAIN OF THE GAMMA-SUBUNIT OF PHOSPHORYLASE-KINASE - THE 2 NONCONTIGUOUS CALMODULIN-BINDING SUBDOMAINS ARE ALSO AUTOINHIBITORY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SEPHAROSE AFFINITY-CHROMATOGRAPHY; GLYCOGEN-PHOSPHORYLASE; CATALYTIC SUBUNIT; PROTEIN-KINASES; PURIFICATION; SPECIFICITY; ACTIVATION; COMPLEXES; ALPHA	Phosphorylase kinase is a multimeric protein kinase (alpha(4) beta(4) gamma(4) delta(4)) whose enzymatic activity is conferred by its gamma-subunit. A library of 18 overlapping synthetic peptides spanning residues 277-386 of the gamma-subunit has been prepared to use in identifying important regulatory structures in the protein. In the present study, the library was screened to identify regions that might function as autoinhibitory domains, Peptides from two distinct regions were found to inhibit the Ca2+-activated holoenzyme. The same regions were previously found to bind calmodulin (i.e. the delta-subunit; Dasgupta, M. Honeycutt, T., and Blumenthal, D. K. (1989) J. Biol. Chem. 264, 17156-17163). The most potent substrate antagonist peptides were PhK13 (residues 302-326; K-i = 300 nM) and PhK5 (residues 342-366; K-i = 20 mu M). Both peptides inhibited the holoenzyme competitively with respect to phosphorylase b and noncompetitively with respect to Mg . ATP. When the pattern of inhibition with both peptides present was analyzed, inhibition was observed to be synergistic and modestly cooperative indicating that the two peptides can simultaneously occupy the protein substrate-binding site(s), These data are consistent with a model in which the regions of the gamma-subunit represented by PhK5 and PhK13 work in concert as regulatory subdomains that transduce Ca2+-induced conformational changes in the delta-subunit to the catalytic gamma-subunit through a pseudosubstrate autoinhibitory mechanism.	UNIV UTAH, DEPT PHARMACOL & TOXICOL, SALT LAKE CITY, UT 84112 USA; UNIV TEXAS, CTR HLTH, DEPT BIOCHEM, TYLER, TX 75710 USA	Utah System of Higher Education; University of Utah; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)				Blumenthal, Donald/0000-0002-8614-1167; /0000-0002-7260-3746	NIGMS NIH HHS [GM39290] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039290] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN KFJ, 1982, J BIOL CHEM, V257, P5948; COHEN P, 1973, EUR J BIOCHEM, V34, P1, DOI 10.1111/j.1432-1033.1973.tb02721.x; Corbin J D, 1974, Methods Enzymol, V38, P287; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P10274, DOI 10.1021/bi00106a027; GEUSS U, 1985, EUR J BIOCHEM, V153, P327, DOI 10.1111/j.1432-1033.1985.tb09305.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAVES DJ, 1983, METHOD ENZYMOL, V99, P268; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; HUANG CYF, 1993, MOL CELL BIOCHEM, V128, P7, DOI 10.1007/BF01076753; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KASTENSCHMIDT LL, 1968, BIOCHEMISTRY-US, V7, P3590, DOI 10.1021/bi00850a037; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KENNELLY PJ, 1987, J BIOL CHEM, V262, P11958; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; NEWSHOLME P, 1992, J BIOL CHEM, V267, P810; PICKETTGIES CR, 1985, ENZYMES, P395; REIMANN EM, 1984, BIOCHEMISTRY-US, V23, P4185, DOI 10.1021/bi00313a027; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANCHEZ VE, 1993, J BIOL CHEM, V268, P17889; SEGEL IH, 1974, ENZYME KINETICS; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TABATABAI LB, 1978, J BIOL CHEM, V253, P2196; TAKIO K, 1985, BIOCHEMISTRY-US, V24, P6028, DOI 10.1021/bi00343a002; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; YAZAWA M, 1978, J BIOCHEM-TOKYO, V84, P1259, DOI 10.1093/oxfordjournals.jbchem.a132244	32	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22283	22289		10.1074/jbc.270.38.22283	http://dx.doi.org/10.1074/jbc.270.38.22283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673209	hybrid			2022-12-27	WOS:A1995RW31400036
J	LLOYD, QP; KUHN, MA; GAY, CV				LLOYD, QP; KUHN, MA; GAY, CV			CHARACTERIZATION OF CALCIUM TRANSLOCATION ACROSS THE PLASMA-MEMBRANE OF PRIMARY OSTEOBLASTS USING A LIPOPHILIC CALCIUM-SENSITIVE FLUORESCENT DYE, CALCIUM-GREEN-C-18	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; INTRACELLULAR CALCIUM; CYTOSOLIC CALCIUM; ATPASE ACTIVITY; CA++-ATPASE; CELLS; INHIBITION; CALMODULIN; TRANSPORT; VESICLES	The synthesis of Calcium Green C-18, a lipophilic fluorescent calcium-sensitive dye, and its use as a monitor of Ca2+ efflux from cells is described, This indicator consists of a Calcium Green-1 molecule conjugated to a lipophilic 18-carbon alkyl chain which will intercalate into cell membranes, The K-d of the indicator for Ca2+ in aqueous solution (pH 7.2, 22 degrees C, ionic strength 0.1 M) is 0.23 +/- 0.04 mu M and in the presence of liposomes is 0.062 +/- 0.007 mu M. Due to its high negativity, the calcium chelating fluorophore faces the cell exterior, when loaded under a defined set of conditions. The dye was found largely on the surface of the cells when loaded at a concentration of 5 mu M for 10 min at 37 degrees C, Five minutes after introduction of EGTA, 83-95% fluorescence disappeared, indicating that most of the fluorophore was on the cell surface, Photobleaching was minimal (3-13%), th confocal laser scanning microscope was used to detect and quantify fluorescence. Internalized dye was apparent in cells loaded for longer times (30-60 min) and in membrane-impaired cells, as shown by uptake of propidium iodide, Under defined confocal laser scanning microscope settings, a transient fluorescence at the periphery of similar to 30% of the cells was observed following 10(-8) M parathyroid hormone treatment, indicating the presence of outwardly directed calcium transport across the plasma membrane, Calcium efflux usually lasted 7-10 min, peaking at around 2-3 min, Changes in cell shape were also observed, Calcium efflux was shown to be sensitive to (a) 10 mu M quercetin and 10 mu M vanadate, partially specific inhibitors of plasma membrane Ca2+ ATPase, to (b) 0.1 mM trifluoperazine, an agent which renders calmodulin ineffective, and to (c) 10 mM neomycin sulfate, which blocks release of Ca2+ from intracellular stores, Thapsigargin (5 mu M), an inhibitor of Ca2+-ATPase of the endoplasmic reticulum, prolonged fluorescence, These observations indicate that cell surface fluorescence was due to the capture of Ca2+ by Calcium Green C-18 after Ca2+ had been translocated across osteoblast plasma membranes, Involvement of the plasma membrane Ca2+-ATPase, known to be present in osteoblasts in substantial amounts, is implicated.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT POULTRY SCI, UNIVERSITY PK, PA 16802 USA; MOLEC PROBES INC, EUGENE, OR 97402 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIDCR NIH HHS [DE09459] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009459] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKISAKA T, 1988, J BONE MINER RES, V3, P19; ALI NN, 1990, J BONE MINER RES, V5, P115; BIDWELL JP, 1991, ENDOCRINOLOGY, V129, P2993, DOI 10.1210/endo-129-6-2993; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BOND GH, 1980, BIOCHIM BIOPHYS ACTA, V600, P781, DOI 10.1016/0005-2736(80)90480-0; CARAFOLI E, 1990, PROG CLIN BIOL RES, V332, P181; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARIDE AJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P363, DOI 10.1016/0005-2736(83)90136-0; CIVITELLI R, 1989, ENDOCRINOLOGY, V125, P1204, DOI 10.1210/endo-125-3-1204; EBERHARD M, 1991, BIOCHEM BIOPH RES CO, V180, P209, DOI 10.1016/S0006-291X(05)81278-1; EGAN JJ, 1991, J CELL BIOCHEM, V45, P101, DOI 10.1002/jcb.240450117; ETTER EF, 1994, J BIOL CHEM, V269, P10141; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; GARRAHAN PJ, 1990, INTRACELLULAR CALCIU, P271; GAY CV, 1995, COMP BIOCHEM PHYS A, V111, P257, DOI 10.1016/0300-9629(95)00004-Q; GAY CV, 1994, IN VITRO CELL DEV-AN, V30A, P379, DOI 10.1007/BF02634358; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; HAUGLAND R, 1993, FLUORESCENT LUMINESC, P34; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P113; KRAUSFRIEDMANN N, 1982, EUR J BIOCHEM, V129, P7, DOI 10.1111/j.1432-1033.1982.tb07014.x; KRIEGER NS, 1992, J BONE MINER RES, V7, P1105; KUMAR R, 1993, J BONE MINER RES, V8, P505; KURIKI Y, 1976, BIOCHEMISTRY-US, V15, P4951, DOI 10.1021/bi00668a001; LOWIK CWGM, 1985, CELL CALCIUM, V6, P311, DOI 10.1016/0143-4160(85)90002-8; LUTHRA MG, 1982, BIOCHIM BIOPHYS ACTA, V692, P271, DOI 10.1016/0005-2736(82)90531-4; LYTTON J, 1991, J BIOL CHEM, V266, P17067; NIGGLI V, 1981, J BIOL CHEM, V256, P395; OCHS DL, 1983, J BIOL CHEM, V258, P116; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; Philipson K D, 1993, Int Rev Cytol, V137C, P199; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; RIBEIRO CP, 1992, AM J PHYSIOL, V262, pF209, DOI 10.1152/ajprenal.1992.262.2.F209; SASAKI T, 1987, CELL TISSUE RES, V248, P103, DOI 10.1007/BF01239969; SHORT CL, 1994, J BONE MINER RES, V9, P1159; TAKUMA T, 1985, BIOCHEM J, V227, P239, DOI 10.1042/bj2270239; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VANLEEUWEN JPTM, 1988, BONE MINER, V4, P177; WUTHRICH A, 1980, CELL CALCIUM, V1, P21, DOI 10.1016/0143-4160(80)90010-X; YAMAGUCHI DT, 1991, CELL CALCIUM, V12, P609, DOI 10.1016/0143-4160(91)90058-M	40	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22445	22451		10.1074/jbc.270.38.22445	http://dx.doi.org/10.1074/jbc.270.38.22445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673232	hybrid			2022-12-27	WOS:A1995RW31400061
J	HACKETT, RH; WANG, YD; LARNER, AC				HACKETT, RH; WANG, YD; LARNER, AC			MAPPING OF THE CYTOPLASMIC DOMAIN OF THE HUMAN GROWTH-HORMONE RECEPTOR REQUIRED FOR THE ACTIVATION OF JAK2 AND STAT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; DNA-BINDING FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; CYTOKINE RECEPTORS; INVITRO ACTIVATION; PHOSPHORYLATION; PHOSPHATASE; PROMOTER	Incubation of cells with growth hormone (GH) stimulates both tyrosine phosphorylation of the Jak2 tyrosine kinase and, in some cells, the transcription factor Stat1 alpha (1-4). When the promyeloid cell line FDC-P1 is transfected with the human growth hormone receptor, these cells can grow in the presence of GH and in the absence of interleukin-3. Growth hormone treatment of cells expressing the human growth hormone receptor did not activate Stat1 alpha. However, a complex is present in extracts prepared from growth hormone treated cells that binds to the gamma response region, an enhancer present in the promoter of the high affinity Fc gamma R1 receptor to which cytokine-activated Stat complexes bind. When truncations of the cytoplasmic domain of the receptor are expressed in FDC-P1 cells only the membrane-proximal 80 amino acids (containing box 1 and box 2) are required for activation of both a GH-stimulated binding activity (GHSF) and tyrosine phosphorylation of Jak2. Activation of GHSF can be inhibited in a cell-free system by the addition of a glutathione S-transferase fusion protein containing these SO amino acids. Replacement of the one tyrosine in this region of the receptor with a phenylalanine does not alter the activation of either GHSF or Jak2, suggesting that tyrosine phosphorylation of the receptor is not required for GH activation of GHSF. Moreover, a cell line expressing a receptor with only the 54 membrane-proximal amino acids of the intracellular domain (including box 1) shows constitutively tyrosine phosphorylated Jak2 as well as GHSF binding. With this truncated receptor, there is little if any additional GH-induced tyrosine phosphorylation of Jak2 or induced binding to the gamma response region. These results define the importance of the membrane-proximal 80 amino acids of the GH receptor (with the conserved box 1 and box 2 domains) with regard to GH activation of both Jak2 and Stat(s). They also suggest that within these domains there may be positive and negative elements that regulate Jak2 function.	CTR BIOL EVALUAT & RES, DIV CYTOKINE BIOL, BETHESDA, MD 20892 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA	US Food & Drug Administration (FDA); Roche Holding; Genentech								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1993, J BIOL CHEM, V268, P6593; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOUJON L, 1994, P NATL ACAD SCI USA, V91, P957, DOI 10.1073/pnas.91.3.957; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HE TC, 1994, J BIOL CHEM, V269, P18291; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1993, BLOOD, V82, P1960; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	42	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21326	21330		10.1074/jbc.270.36.21326	http://dx.doi.org/10.1074/jbc.270.36.21326			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673169	hybrid			2022-12-27	WOS:A1995RU05400070
J	KENYON, K; MODI, WS; CONTENTE, S; FRIEDMAN, RM				KENYON, K; MODI, WS; CONTENTE, S; FRIEDMAN, RM			A NOVEL HUMAN CDNA WITH A PREDICTED PROTEIN SIMILAR TO LYSYL OXIDASE MAPS TO CHROMOSOME-15Q24-Q25	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; MARFAN-SYNDROME; MESSENGER-RNA; GENE; LOCALIZATION; ASSIGNMENT; CLONING; INSITU	A novel human cDNA with a predicted protein homologous to the carboxyl end of lysyl oxidase, an extracellular enzyme involved in the maturation of collagen and elastin, has been isolated. The homology to lysyl oxidase begins exactly at the position of the exon 1/exon 2 boundary in the mouse gene (Contente, S., Csiszar, K., Kenyon, K., and Friedman, R. M. (1993) Genomics 16, 395-400). This lysyl oxidase-like gene, which appears to be no larger than 22.1 kilobases, codes for a single poly-adenylated RNA species of 2.48 kilobases and has been mapped to chromosome 15q24-q25.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KENYON, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814, USA.			Contente, Sara/0000-0002-8099-2817	NCI NIH HHS [R01 CA37351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CONTENTE S, 1993, GENOMICS, V16, P395, DOI 10.1006/geno.1993.1202; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; HAMALAINEN ER, 1991, GENOMICS, V11, P508, DOI 10.1016/0888-7543(91)90057-L; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LANDEGENT JE, 1987, HUM GENET, V77, P366, DOI 10.1007/BF00291428; LAWRENCE JB, 1988, CELL, V52, P51; LAYFIELD R, 1992, EUR J BIOCHEM, V204, P591, DOI 10.1111/j.1432-1033.1992.tb16672.x; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MAGENIS RE, 1991, GENOMICS, V11, P346, DOI 10.1016/0888-7543(91)90142-2; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; SAKAI LY, 1990, ELASTIN CHEM BIOL AS, P215; Sambrook J, 1989, MOL CLONING LABORATO; SCHWEIZER D, 1981, HUM GENET, V57, P1; SHARMA RC, 1993, BIOTECHNIQUES, V14, P176; SVINARICH DM, 1992, J BIOL CHEM, V267, P14382; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHOU J, 1992, PLANT MOL BIOL, V20, P5, DOI 10.1007/BF00029144	25	83	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18435	18437						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689553				2022-12-27	WOS:A1993LV65900010
J	GUIHARD, G; BENEDETTI, H; BESNARD, M; LETELLIER, L				GUIHARD, G; BENEDETTI, H; BESNARD, M; LETELLIER, L			PHOSPHATE EFFLUX THROUGH THE CHANNELS FORMED BY COLICINS AND PHAGE T5 IN ESCHERICHIA-COLI-CELLS IS RESPONSIBLE FOR THE FALL IN CYTOPLASMIC ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVIVO PROPERTIES; CONTACT SITES; ION CHANNELS; MEMBRANE; TRANSLOCATION; INFECTION; PROTEIN; TRANSPORT; DNA; PERMEABILITY	Previous studies have shown that channel formation in the cytoplasmic membrane of Escherichia coli by colicin A and phage T5 leads to an efflux of cytoplasmic potassium and to a membrane depolarization. Here we show that upon opening of these channels, the intracellular ATP concentration is decreased to 10% of its original value in <5 min. ATP is not found in the external medium, but is hydrolyzed in the cytoplasm into ADP and AMP. The rate of ATP hydrolysis depends on the number of channels and on their activity. ATP hydrolysis takes place if the F1F0-ATPase is absent or inhibited. Depolarization of the inner membrane is not the main cause of ATP hydrolysis. Opening of the phage and colicin channels also leads to an efflux of inorganic phosphate. Conditions that prevent the efflux of phosphate (i.e. depolarization of the cells and high external phosphate concentration) prevent ATP hydrolysis. We propose that ATP is hydrolyzed as a consequence of a shift in the ATP equilibrium due to the efflux of phosphate through the channels. The consequences for the cells of this ATP depletion are discussed.	UNIV PARIS 11, BIOMEMBRANES LAB, CNRS, URA 1116, BAT 433, F-91405 ORSAY, FRANCE; CTR BIOCHIM & BIOL MOLEC, INGN & DYNAM SYST MEMBRANAIRES LAB, UPR 27, F-7113402 MARSEILLE 9, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								ALTENDORF K, 1975, FEBS LETT, V59, P268, DOI 10.1016/0014-5793(75)80390-5; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BEPPU T, 1972, J BACTERIOL, V110, P485, DOI 10.1128/JB.110.2.485-493.1972; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; CAVARD D, 1981, FEMS MICROBIOL LETT, V12, P311; CAVARD D, 1979, EUR J BIOCHEM, V96, P519, DOI 10.1111/j.1432-1033.1979.tb13065.x; CHAPMAN AG, 1971, J BACTERIOL, V108, P1072, DOI 10.1128/JB.108.3.1072-1086.1971; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CONDIT RC, 1975, J MOL BIOL, V98, P45, DOI 10.1016/S0022-2836(75)80100-8; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FEINGOLD D S, 1970, Journal of Membrane Biology, V3, P372, DOI 10.1007/BF01868024; FEUCHT A, 1990, J BIOL CHEM, V265, P18561; FIELDS KL, 1969, J BACTERIOL, V97, P64, DOI 10.1128/JB.97.1.64-77.1969; FIELDS KL, 1969, J BACTERIOL, V97, P57, DOI 10.1128/JB.97.1.57-63.1969; GELI V, 1986, MOL GEN GENET, V202, P455, DOI 10.1007/BF00333276; GUIHARD G, 1992, J BIOL CHEM, V267, P3173; HIRATA H, 1969, J BIOCHEM-TOKYO, V65, P843, DOI 10.1093/oxfordjournals.jbchem.a129088; HOUSSIN C, 1991, BIOCHIM BIOPHYS ACTA, V1056, P76, DOI 10.1016/S0005-2728(05)80075-1; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024; KEWELOH HW, 1984, J BACTERIOL, V160, P354, DOI 10.1128/JB.160.1.354-359.1984; KOPECKY AL, 1975, P NATL ACAD SCI USA, V72, P4631, DOI 10.1073/pnas.72.11.4631; LABEDAN B, 1981, P NATL ACAD SCI-BIOL, V78, P215, DOI 10.1073/pnas.78.1.215; LANNI YT, 1958, VIROLOGY, V5, P481, DOI 10.1016/0042-6822(58)90041-2; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LETELLIER L, 1992, BIOCHIM BIOPHYS ACTA, V1101, P218; LETELLIER L, 1993, ALKALI CATION TRANSP, P359; LETELLIER L, 1992, BACTERIOCINS MICROCI, P119; LURIA SE, 1964, ANN I PASTEUR PARIS, VS, P67; NEU HC, 1965, J BIOL CHEM, V240, P3685; PATTUS F, 1990, EXPERIENTIA, V46, P180; PLATE CA, 1974, J BIOL CHEM, V249, P6138; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SINGH AP, 1974, J BACTERIOL, V119, P129, DOI 10.1128/JB.119.1.129-137.1974; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; WAGNER EF, 1980, J BIOL CHEM, V255, P540; WAGNER EF, 1980, J BIOL CHEM, V255, P534; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WILSON DB, 1982, J BACTERIOL, V152, P1091; ZILBERSTEIN D, 1979, BIOCHEMISTRY-US, V18, P669, DOI 10.1021/bi00571a018	44	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17775	17780						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688731				2022-12-27	WOS:A1993LT74300024
J	ELMOATASSIM, C; DUBYAK, GR				ELMOATASSIM, C; DUBYAK, GR			DISSOCIATION OF THE PORE-FORMING AND PHOSPHOLIPASE-D ACTIVITIES STIMULATED VIA P(2Z) PURINERGIC RECEPTORS IN BAC1.2F5 MACROPHAGES - PRODUCT INHIBITION OF PHOSPHOLIPASE-D ENZYME-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PAROTID ACINAR-CELLS; EXTRACELLULAR ATP; PHOSPHATIDIC-ACID; PLASMA-MEMBRANE; GROWTH-FACTOR; D ACTIVATION; PHOSPHATIDYLCHOLINE BREAKDOWN; TYROSINE PHOSPHORYLATION; HUMAN NEUTROPHILS	We have previously reported that the occupancy of P2z purinergic receptors in BAC1.2F5 macrophages stimulates both the formation of nonselective membrane pores/channels and a novel phospholipase D (PLD) activity. In the present study, the relationship between these two P2z receptor-mediated responses was investigated. In [H-3]oleic acid-labeled macrophages, isoosmotic replacement of extracellular Na+ with choline completely abolished 3'-O-(4-benzoyl) benzoyl-ATP (BzATP)-stimulated [H-3]phosphatidylethanol ([H-3]PEt) accumulation. This inhibitory effect of choline was mimicked when Na+ was replaced with other amine-containing cations (N-methylglucamine, ethanolamine, Tris+), but not with inorganic cations (K+, Li+). In contrast, substitution of Na+ with choline (or other cationic amines) did not prevent BzATP-induced Ca2+ influx and membrane depolarization. Thus, choline, which enters the cells through the BzATP-induced pores, can act to inhibit P2z receptor-stimulated PLD activity but not pore formation. The two responses also exhibit differential sensitivities to the pH of the incubation medium, to depletion of intracellular ATP, and to chronic phorbol ester treatment. These observations indicate that P2z receptor-mediated pore formation can be functionally uncoupled from the activation of PLD. However, both pore formation and PLD activity are similarly inhibited when the cells are: 1) partially desensitized by previous treatment with P2z agonists and 2) preincubated with 2',3'-dialdehyde-ATP or 4',4'-diisothiocyanostilbene-2,2'-disulfonate. This suggests that these two distinct responses are mediated by the same, or similar, P2z receptors.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University				Dubyak, George/0000-0001-9720-4226	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036387] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36387] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; ANTHES JC, 1991, ARCH BIOCHEM BIOPHYS, V287, P53, DOI 10.1016/0003-9861(91)90387-X; BALSINDE J, 1990, FEBS LETT, V259, P237, DOI 10.1016/0014-5793(90)80017-D; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; COCKCROFT S, 1980, BIOCHEM J, V188, P789, DOI 10.1042/bj1880789; COLMAN RF, 1990, ENZYMES, V19, P283; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DALY PF, 1987, J BIOL CHEM, V262, P14875; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; ELMOATASSIM C, 1987, EUR J PHARMACOL, V18, P111; EXTON JH, 1990, J BIOL CHEM, V265, P1; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRIEDBERG I, 1985, J MEMBRANE BIOL, V83, P251, DOI 10.1007/BF01868699; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GAY JC, 1991, BIOCHIM BIOPHYS ACTA, V1095, P236, DOI 10.1016/0167-4889(91)90105-7; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; GOMPERTS BD, 1985, TRENDS BIOCHEM SCI, V10, P414, DOI 10.1016/0968-0004(85)90020-9; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HUANG CF, 1992, J BIOL CHEM, V267, P16859; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1989, J BIOL CHEM, V264, P1483; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LIN PY, 1991, J IMMUNOL, V146, P1609; LIN PY, 1992, BIOCHEM J, V287, P325, DOI 10.1042/bj2870325; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MCKENZIE FR, 1992, J BIOL CHEM, V267, P22759; MCMILLIAN MK, 1988, BIOCHEM J, V255, P291; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NUTTLE LC, 1993, IN PRESS MOL PHARM; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PERRY DK, 1992, J IMMUNOL, V149, P2749; PIZZO P, 1991, BIOCHEM J, V274, P139, DOI 10.1042/bj2740139; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; ROZENGURT E, 1979, J BIOL CHEM, V254, P708; SOLTOFF SP, 1992, AM J PHYSIOL, V262, pC934, DOI 10.1152/ajpcell.1992.262.4.C934; STEINBERG TH, 1989, METHOD CELL BIOL, V31, P45; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; THOMAS SA, 1991, BRIT J PHARMACOL, V103, P1963, DOI 10.1111/j.1476-5381.1991.tb12360.x; THOMPSON NT, 1991, TRENDS PHARMACOL SCI, V12, P404, DOI 10.1016/0165-6147(91)90617-2; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WEISMAN GA, 1989, METHOD ENZYMOL, V171, P857; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WRIGHT TM, 1992, BIOCHEM J, V285, P395, DOI 10.1042/bj2850395	63	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15571	15578						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687997				2022-12-27	WOS:A1993LN30500040
J	KOUNNAS, MZ; CHAPPELL, DA; STRICKLAND, DK; ARGRAVES, WS				KOUNNAS, MZ; CHAPPELL, DA; STRICKLAND, DK; ARGRAVES, WS			GLYCOPROTEIN-330, A MEMBER OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR FAMILY, BINDS LIPOPROTEIN-LIPASE IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEYMANN NEPHRITIS ANTIGEN; ALPHA-2-MACROGLOBULIN RECEPTOR; MESSENGER-RNA; LDL-RECEPTOR; MEMBRANE GLYCOPROTEIN; HIGH-AFFINITY; RAT-TISSUES; PROTEIN; IDENTIFICATION; LIGAND	Glycoprotein 330 (gp330), a cell-surface protein that is localized in clathrin-coated pits, is structurally related to both the low density lipoprotein receptor (LDLR) and the LDLR-related protein/alpha2-macroglobulin receptor (LRP). We recently demonstrated that gp330 and LRP may be functionally related as well; both bind the 39-kDa polypeptide referred to as receptor-associated protein (Kounnas, M. Z., Argraves, W. S., and Strickland, D. K. (1992) J. Biol. Chem. 267, 21162-21166). In this report, we tested several other LRP ligands for their ability to interact with human and rat gp330 in vitro. Gp330 did not exhibit detectable binding to the LRP ligands, alpha2-macroglobulin protease complex or Pseudomonas aeruginosa exotoxin A. However, we found that gp330 (purified from human or rat) bound the lipolytic enzyme lipoprotein lipase (LPL) with high affinity (K(d) = 6.1 and 2.7 nM, respectively). The binding was saturable, divalent cation dependent, and inhibited by heparin or receptor-associated protein. Because LRP has also been shown to bind LPL, the present findings further extend the functional similarities between gp330 and LRP. By analogy to the postulated role of the LRP-LPL interaction in facilitating hepatic clearance of LPL-associated lipoproteins from the blood (Beisiegel, U., Weber, W., and Bengtsson-Olivercrona, G. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346; Chappell, D. A., Fry, G. L., Waknitz, M. A., Iverius, P. H., Williams, S. E., and Strickland, D. K. (1992) J. Biol. Chem. 267, 25764-25767), we speculate that the gp330-LPL interaction described herein may contribute to the uptake of LPL-associated lipoproteins in tissues expressing gp330. Consistent with this possibility, we found that LPL promoted in vitro binding of I-125-lipoproteins to gp330.	AMER RED CROSS, DEPT BIOCHEM, ROCKVILLE, MD 20855 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA	American Red Cross; University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912, R01GM042581] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45598] Funding Source: Medline; NIGMS NIH HHS [GM42912, GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERHARD EE, 1986, BIOCHIM BIOPHYS ACTA, V875, P6, DOI 10.1016/0005-2760(86)90004-4; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUCCARON MH, 1987, ANN INST PASTEUR IMM, V138, P707, DOI 10.1016/S0769-2625(87)80026-0; CHAJEK T, 1977, ATHEROSCLEROSIS, V26, P549, DOI 10.1016/0021-9150(77)90122-8; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CORITSIDIS G, 1991, KIDNEY INT, V39, P858, DOI 10.1038/ki.1991.108; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DAUGHERTY A, 1985, J BIOL CHEM, V260, P4564; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DOBBS LG, 1982, BIOCHIM BIOPHYS ACTA, V713, P118, DOI 10.1016/0005-2760(82)90174-6; DOXSEY S, 1983, J CELL BIOL, V97, pA178; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GAL S, 1982, BIOCHIM BIOPHYS ACTA, V713, P222, DOI 10.1016/0005-2760(82)90239-9; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOLLENBERG CH, 1962, J LIPID RES, V3, P445; Iverius P H, 1986, Methods Enzymol, V129, P691; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LEE LB, 1962, AM J PHYSIOL, V203, P27, DOI 10.1152/ajplegacy.1962.203.1.27; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LISTON TE, 1987, BIOCHIM BIOPHYS ACTA, V921, P449, DOI 10.1016/0005-2760(87)90071-3; MAHONEY EM, 1982, P NATL ACAD SCI-BIOL, V79, P1639, DOI 10.1073/pnas.79.5.1639; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OKABE T, 1984, BIOCHEM BIOPH RES CO, V125, P273, DOI 10.1016/S0006-291X(84)80364-2; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TEDDER TF, 1991, AM J RESP CELL MOL, V5, P305, DOI 10.1165/ajrcmb/5.4.305; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WRIGHT JR, 1987, AM REV RESPIR DIS, V136, P426, DOI 10.1164/ajrccm/136.2.426; YACOUB LK, 1990, J LIPID RES, V31, P1845; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	57	125	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14176	14181						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686151				2022-12-27	WOS:A1993LJ82500059
J	CHEN, SRW; ZHANG, L; MACLENNAN, DH				CHEN, SRW; ZHANG, L; MACLENNAN, DH			ANTIBODIES AS PROBES FOR CA2+ ACTIVATION SITES IN THE CA2+ RELEASE CHANNEL (RYANODINE RECEPTOR) OF RABBIT SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDUCED RELEASE; CA-2+ RELEASE; ADENINE-NUCLEOTIDES; PROTEINS; PURIFICATION; CAFFEINE; BINDING; EXPRESSION; MEMBRANE; SYSTEM	In earlier studies (Chen, S. R. W., Zhang, L., and MacLennan, D. H. (1992) J. Biol. Chem. 267,23318-23326), an amino acid sequence, designated 13c2, lying between amino acid residues 4478 and 4512 in the skeletal muscle ryanodine receptor was shown, through the use of a polyclonal antibody, to be involved in Ca2+ induced Ca2+ release. In the present study, an immobilized synthetic peptide, PEPEPEPEPE, corresponding to part of the predicted high affinity Ca2+ binding site between residues 4489 and 4499, was used to purify specific antibodies from an anti-13C2 rabbit antiserum. The effect of this affinity-purified, anti-peptide (anti-13c2p1) antibody on Ca2+ release channel function was then characterized using single channel recordings across planar lipid bilayers. The anti-peptide antibody inhibited Ca2+ or caffeine-activated channel activities without closing the channel but did not diminish ATP-activated channel activity. The addition of ATP reversed the inhibition of the Ca2+- or caffeine-activated channel by the antibody, and the antibody-bound, ATP-activated channel was further modulated by Mg2+, ryanodine, and ruthenium red. The major epitopes in the anti-13c2 antibody, previously shown to activate the Ca2+ release channel by increasing the Ca2+ sensitivity of the channel, did not lie in the PE repeat. These results suggest that the PE repeat sequence forms a site involved in the Ca2+ activation pathway.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, 112 COLL ST, TORONTO M5G 1L6, ONTARIO, CANADA	University of Toronto								ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; INUI M, 1987, J BIOL CHEM, V262, P1740; KIRINO Y, 1983, J BIOCHEM-TOKYO, V94, P1111, DOI 10.1093/oxfordjournals.jbchem.a134454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1987, BIOCHEM BIOPH RES CO, V143, P704, DOI 10.1016/0006-291X(87)91411-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; NAGASAKI K, 1983, J BIOCHEM-TOKYO, V94, P1101, DOI 10.1093/oxfordjournals.jbchem.a134453; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALDIVIA HH, 1991, AM J PHYSIOL, V261, pC237, DOI 10.1152/ajpcell.1991.261.2.C237; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	35	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13414	13421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685761				2022-12-27	WOS:A1993LH55300058
J	DECHECCHI, MC; TAMANINI, A; BERTON, G; CABRINI, G				DECHECCHI, MC; TAMANINI, A; BERTON, G; CABRINI, G			PROTEIN-KINASE-C ACTIVATES CHLORIDE CONDUCTANCE IN C127 CELLS STABLY EXPRESSING THE CYSTIC-FIBROSIS GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-DOMAIN; CHANNELS; CFTR; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; TRANSPORT; EPITHELIA	The regulatory domain (R domain) of the cystic fibrosis transmembrane conductance regulator (CFTR) is phosphorylated by protein kinase A and protein kinase C (PKC) in vivo (Picciotto, M. R., Cohn, J. A., Bertuzzi, G., Greengard, P., and Nairn, A. C. (1992) J. Biol. Chem. 267, 12742-12752), but so far the functional effect of the PKC-dependent phosphorylation has not been clarified. We investigated the effect of PKC on the CFTR-mediated Cl- transport by treating with phorbol 12-myristate 13-acetate (PMA), the cell line C127i stably expressing CFTR wild type (C127 CFTRw/t), or CFTR bearing the most common mutation deltaF508 (C127 CFTRdF508). We show that PMA activates Cl- efflux in C127 CFTRw/t, but not in C127 CFTRdF508 and C127i. The PMA-dependent activation of CFTR is not mediated by increase of intracellular [cAMP] and is not the result of a primary activation of a K+ conductive pathway. These results strongly suggest that PKC activates directly CFTR-mediated Cl- transport.	OSPED CIVILE,CTR CYST FIBROSIS,PIAZZALE STEFANI 1,I-37126 VERONA,ITALY; UNIV VERONA,INST GEN PATHOL,I-37100 VERONA,ITALY	University of Verona			Dechecchi, Maria Cristina/K-5139-2016; Cabrini, Giulio/K-4761-2016	Dechecchi, Maria Cristina/0000-0002-5005-6585; Cabrini, Giulio/0000-0003-2720-0742; Tamanini, Anna/0000-0002-7427-0981				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BAJENATH RB, 1992, J MEMBRANE BIOL, V127, P81; BEAR CE, 1992, AM J PHYSIOL, V262, pC251, DOI 10.1152/ajpcell.1992.262.1.C251; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DECHECCHI MC, 1992, FEBS LETT, V311, P25, DOI 10.1016/0014-5793(92)81358-S; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KAHINTORN U, 1992, AM J PHYSIOL, V262, pC15; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LIN PY, 1987, J BIOL CHEM, V262, P15345; LINDEMAN RP, 1992, AM J PHYSIOL, V263, pC140, DOI 10.1152/ajpcell.1992.263.1.C140; LIYANAGE M, 1992, BIOCHEM J, V283, P781, DOI 10.1042/bj2830781; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAMANINI A, 1991, ENZYME, V45, P97, DOI 10.1159/000468874; VAANDRAGER AB, 1992, AM J PHYSIOL, V262, pG249, DOI 10.1152/ajpgi.1992.262.2.G249; VANDENBERGHE N, 1992, BIOCHEM J, V285, P673, DOI 10.1042/bj2850673; VERKMAN AS, 1992, AM J PHYSIOL, V262, pC23, DOI 10.1152/ajpcell.1992.262.1.C23; WARHURST G, 1991, AM J PHYSIOL, V261, pG220, DOI 10.1152/ajpgi.1991.261.2.G220; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	35	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11321	11325						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684379				2022-12-27	WOS:A1993LD46600088
J	FUKUOKA, SI; ZHANG, DE; TANIGUCHI, Y; SCHEELE, GA				FUKUOKA, SI; ZHANG, DE; TANIGUCHI, Y; SCHEELE, GA			STRUCTURE OF THE CANINE PANCREATIC COLIPASE GENE INCLUDES 2 PROTEIN-BINDING SITES IN THE PROMOTER REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; EXOCRINE PANCREAS; SECRETORY PROTEINS; CDNA SEQUENCE; MESSENGER-RNA; DIABETIC RATS; DNA; ENHANCER; PORCINE; TRANSCRIPTION	Characterization of a lambda phage genomic clone, CL5A, which encodes the canine pancreatic colipase gene, revealed the primary structure of 987 nucleotides (nt) of 5'-flanking sequence, 2066 nt defining the primary transcriptional unit, which is organized into three exon sequences, and 130 nt of 3'-flanking sequence. Exon 1 encodes the amino-terminal signal peptide, the propeptide (Val1-Pro-Asp-Pro-Arg), and the hydrophobic lipid-binding region (Gly6-Ile-Ile-Ile) at the amino terminus of the mature coenzyme. Exon 2 encodes carboxylate residues (Glu12 and Glu15) likely to be involved in binding of pancreatic lipase to colipase at the aqueous-lipid interface. Exon 3 encodes the hydrophobic sequence (Leu54-Tyr-Gly-Tyr-Tyr) that is essential for binding the central tightly structured disulfide-bonded region of the coenzyme to lipid. Southern blot analysis was consistent with the presence of a single-copy colipase gene and a potential colipase gene homologue. Among 16 tissues examined by Northern blot analysis, colipase expression was detected only in pancreas. Proteins contained in nuclear extracts prepared from dog pancreas conferred two regions of DNase I protection coincident for both coding and noncoding strands (positions -62 to -44 (CL-I site) and -128 to -106 (CL-II site) in the coding strand). Competition gel mobility shift experiments indicated that protein-DNA interactions that occur at colipase sites I and II are sequence- and protein-specific and unrelated to the PAN-binding sequence described in the 5'-enhancer region of the rat chymotrypsin B gene (Nelson, C., Shen, L.P., Meister, A., Fodor, E., and Rutter, W. J. (1990) Genes & Dev. 4, 1035-1043). Nuclear extracts from pancreas and brain, but not liver, contain similar CL-I and CL-II-binding proteins. CL-I and CL-II represent protein-binding elements that may participate as additional promoter regions in regulated expression of the colipase gene. CL-I contains a central homopolymeric d(G) sequence. CL-II shows a GC-rich region on the noncoding strand (5' GGGGGCGTGT 3') that is similar (8/9 match) to the Sp1-binding sequence.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,THORNDIKE LAB,CELL & MOLEC BIOL LAB,DA-554,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BOSTON,MA 02115; BETH ISRAEL HOSP,BOSTON,MA 02215; KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Kyoto University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018532] Funding Source: NIH RePORTER; NIDDK NIH HHS [DDK-18532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BONICEL J, 1981, BIOCHIM BIOPHYS ACTA, V669, P39, DOI 10.1016/0005-2795(81)90221-X; BORGSTROM B, 1979, FEBS LETT, V108, P407, DOI 10.1016/0014-5793(79)80574-8; BORGSTROM B, 1984, LIPASES, P152; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DAVIS RC, 1991, GENOMICS, V10, P262, DOI 10.1016/0888-7543(91)90509-D; DESNUELLE P, 1986, MOL CELLULAR BASIS D, P289; DUAN RD, 1989, PANCREAS, V4, P329, DOI 10.1097/00006676-198906000-00009; DUAN RD, 1990, PANCREAS, V5, P136, DOI 10.1097/00006676-199003000-00003; DUAN RD, 1992, AM J PHYSIOL, V262, pG779, DOI 10.1152/ajpgi.1992.262.5.G779; DUAN RD, 1992, PANCREAS, V7, P465, DOI 10.1097/00006676-199207000-00008; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERLANSON C, 1977, BIOCHIM BIOPHYS ACTA, V489, P150, DOI 10.1016/0005-2760(77)90241-7; ERLANSON C, 1974, BIOCHIM BIOPHYS ACTA, V359, P198, DOI 10.1016/0005-2795(74)90143-3; ERLANSONALBERTSSON C, 1981, BIOCHIM BIOPHYS ACTA, V665, P250, DOI 10.1016/0005-2760(81)90009-6; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FUKUOKA S, 1990, NUCLEIC ACIDS RES, V18, P5549, DOI 10.1093/nar/18.18.5549; GASKIN KJ, 1982, J CLIN INVEST, V69, P427, DOI 10.1172/JCI110466; GHISHAN FK, 1984, GASTROENTEROLOGY, V86, P1580; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILDEBRAND H, 1982, GUT, V23, P243, DOI 10.1136/gut.23.3.243; HOWARD G, 1989, NUCLEIC ACIDS RES, V17, P8185, DOI 10.1093/nar/17.20.8185; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KERFELEC B, 1990, EUR J BIOCHEM, V190, P299, DOI 10.1111/j.1432-1033.1990.tb15576.x; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KRUSE F, 1988, MOL CELL BIOL, V8, P893, DOI 10.1128/MCB.8.2.893; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOWE ME, 1990, BIOCHEMISTRY-US, V29, P823, DOI 10.1021/bi00455a032; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYLIE MF, 1973, BIOCHEM BIOPH RES CO, V52, P291, DOI 10.1016/0006-291X(73)90986-8; MCINTYRE JC, 1987, BIOCHEM J, V245, P821, DOI 10.1042/bj2450821; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MORGAN RGH, 1969, BIOCHIM BIOPHYS ACTA, V175, P65, DOI 10.1016/0005-2795(69)90146-9; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PTASHNE MS, 1991, CANCER, V67, P2422, DOI 10.1002/1097-0142(19910515)67:10<2422::AID-CNCR2820671003>3.0.CO;2-3; RATHELOT J, 1981, BIOCHIM BIOPHYS ACTA, V671, P155, DOI 10.1016/0005-2795(81)90129-X; RENAUD W, 1991, PANCREAS, V6, P157, DOI 10.1097/00006676-199103000-00005; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; SARI H, 1978, FEBS LETT, V95, P229, DOI 10.1016/0014-5793(78)81000-X; SCHEELE G, 1980, J CELL BIOL, V87, P611, DOI 10.1083/jcb.87.3.611; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SWIFT GH, 1984, J BIOL CHEM, V259, P4271; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WEINRICH SL, 1991, MOL CELL BIOL, V11, P4985, DOI 10.1128/MCB.11.10.4985; WICKER C, 1990, BIOCHEM BIOPH RES CO, V167, P130, DOI 10.1016/0006-291X(90)91740-J; WIELOCH T, 1978, FEBS LETT, V85, P271, DOI 10.1016/0014-5793(78)80471-2; WIELOCH T, 1981, FEBS LETT, V128, P217, DOI 10.1016/0014-5793(81)80084-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	59	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11312	11320						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684378				2022-12-27	WOS:A1993LD46600087
J	VANDENMAAGDENBERG, AMJM; HOFKER, MH; KRIMPENFORT, PJA; DEBRUIJN, I; VANVLIJMEN, B; VANDERBOOM, H; HAVEKES, LM; FRANTS, RR				VANDENMAAGDENBERG, AMJM; HOFKER, MH; KRIMPENFORT, PJA; DEBRUIJN, I; VANVLIJMEN, B; VANDERBOOM, H; HAVEKES, LM; FRANTS, RR			TRANSGENIC MICE CARRYING THE APOLIPOPROTEIN-E3-LEIDEN GENE EXHIBIT HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL DYSBETALIPOPROTEINEMIA; PLASMA; CHOLESTEROL; OVEREXPRESSION; EXPRESSION; E3-LEIDEN; PROTEIN; VARIANT; LOCUS; MOUSE	Apolipoprotein (apo) E3-Leiden, described in a large Dutch family, is associated with a dominantly inherited form of familial dysbetalipoproteinemia. To study the effect of the APOE*3-Leiden mutation in vivo, transgenic mice were generated using a genomic 27-kilobase DNA construct isolated from the APOE*3-Leiden proband. This construct carried the APOE gene, the APOC1 gene, and all known regulatory elements including an element that mediates liver expression. Three strains were generated that showed human APOE and APOC1 expression. All strains had significantly elevated levels of total plasma cholesterol and triglycerides on a regular diet. When mice of one strain were fed a semisynthetic cholesterol-rich diet, total plasma cholesterol and triglyceride levels increased dramatically. This increase was observed mainly in the very low density lipoprotein (VLDL)- and low density lipoprotein (LDL)-sized fractions. In cholesterol-fed mice, the apoE3-Leiden protein became equally distributed between the VLDL/LDL and HDL-sized fractions, while in mice kept on a regular diet, apoE3-Leiden protein was mainly associated with HDL-sized fractions. The presence of hyperlipoproteinemia in the APOE*3-Leiden-expressing transgenic mice supports our finding that the apoE3-Leiden variant behaves like a dominant trait in the expression of familial dysbetalipoproteinemia. ApoE3-Leiden transgenic mice may serve as a model to elucidate additional factors involved in the metabolism of apoE containing remnant lipoproteins in general and the etiology of familial dysbetalipoproteinemia in particular.	TNO,IVVO,GAUBIUS LAB,2300 RA LEIDEN,NETHERLANDS; GENE PHARMING EUROPE BV,LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research	VANDENMAAGDENBERG, AMJM (corresponding author), LEIDEN UNIV,MGC,DEPT HUMAN GENET,2300 RA LEIDEN,NETHERLANDS.		van den Maagdenberg, Arn M.J.M./AAE-9052-2019					AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BURY J, 1986, CLIN CHEM, V32, P265; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; HAVEKES L, 1986, HUM GENET, V73, P157, DOI 10.1007/BF00291607; HOFKER MH, 1986, HUM GENET, V74, P270, DOI 10.1007/BF00282547; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; HOGAN B, 1986, MANIPULATING MOUSE E; HORIUCHI K, 1989, J BIOCHEM-TOKYO, V106, P98, DOI 10.1093/oxfordjournals.jbchem.a122828; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; KNOTT TJ, 1984, NUCLEIC ACIDS RES, V12, P3909, DOI 10.1093/nar/12.9.3909; KRUMLAUF R, 1991, METHODS MOL BIOL GEN, P307; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; NISHINA PM, 1990, J LIPID RES, V31, P859; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SMIT M, 1990, J LIPID RES, V31, P45; SMITH JD, 1990, J BIOL CHEM, V265, P14709; UTERMANN G, 1985, DIABETES OBESITY HYP, V3, P1; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; WALSH A, 1989, J BIOL CHEM, V264, P6488; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495	30	193	197	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10540	10545						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683682				2022-12-27	WOS:A1993LB80000081
J	ZHOU, GC; CHARBONNEAU, H; COLMAN, RF; ZALKIN, H				ZHOU, GC; CHARBONNEAU, H; COLMAN, RF; ZALKIN, H			IDENTIFICATION OF SITES FOR FEEDBACK-REGULATION OF GLUTAMINE 5-PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE BY NUCLEOTIDES AND RELATIONSHIP TO RESIDUES IMPORTANT FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-PURF; AMINO-ACID-SEQUENCE; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; BINDING DOMAIN; 5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE; SYNTHETASE; PROTEINS; CLONING; ENZYME; KINASE	Glutamine phosphoribosylpyrophosphate amido-transferase, the key regulatory enzyme for de novo purine nucleotide synthesis, is subject to feedback regulation by adenine and guanine nucleotides. Affinity labeling with 5'-p-fluorosulfonylbenzoyladenosine (FSBA) and 8-azidoadenosine 5'-monophosphate (N3-AMP) was used to identify purine nucleotide sites for feedback control of the Escherichia coli amidotransferase. FSBA inactivated the amidotransferase with saturation kinetics. Specificity for inactivation was shown by the covalent attachment of 2.0-2.4 eq of [H-3] sulfobenzoyladenosine (SBA) per subunit and protection by GMP and AMP against inactivation and incorporation of [H-3]SBA. Six chymotryptic peptides modified with [H-3]SBA were isolated and identified by differential labeling followed by high performance liquid chromatography and radioactivity. Mass spectrometry and Edman degradation analysis were used to identify 5 residues that were covalently modified by [H-3]SBA: Tyr74, Tyr258, Lys326, Tyr329, and Tyr465. Tyr258 was also modified by N3-AMP. Mutant enzymes K326Q and Y329A had activity similar to that of the wild type enzyme. However, both mutants exhibited decreased sensitivity to inhibition by GMP and decreased binding of GMP but were inhibited by AMP. Mutant enzymes Y74A and Y258F were normally feedback-inhibited but were defective in glutamine amide transfer and synthase functions, respectively. Therefore Tyr74 and Tyr258 are important for activity and modification by FSBA and N3-AMP accounts for enzyme inactivation. These results localize residues important for catalysis in close proximity to a site for nucleotide binding. Two additional mutant enzymes, G331I and N351A, were constructed which were refractory to inhibition by GMP with little change in inhibition by AMP. A replacement of Tyr465 indicates that this residue is not essential for catalysis or feedback inhibition. Overall, these results are interpreted in terms of a two-nucleotide site model with Lys326, Tyr329, Gly331, and Asn351 defining a site required for inhibition by GMP. A second nucleotide site not affinity labeled by analogs is very close to or overlaps with the catalytic site.	PURDUE UNIV, DEPT BIOCHEM, 1153 BIOCHEM BLDG, W LAFAYETTE, IN 47907 USA; UNIV DELAWARE, DEPT CHEM & BIOCHEM, NEWARK, DE 19716 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Delaware					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK 20542] Funding Source: Medline; NIGMS NIH HHS [GM24685] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; KIM H, 1991, BIOCONJUGATE CHEM, V2, P142, DOI 10.1021/bc00009a002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MEI B, 1989, J BIOL CHEM, V264, P16613; MEI BG, 1990, J BACTERIOL, V172, P3512, DOI 10.1128/jb.172.6.3512-3514.1990; MELOCHE HP, 1967, BIOCHEMISTRY-US, V6, P2273, DOI 10.1021/bi00860a002; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MEYER E, 1979, J BIOL CHEM, V254, P5397; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; SWITZER RL, 1989, ALLOSTERIC ENZYMES, P129; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1982, J BIOL CHEM, V257, P3532; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WYATT JL, 1977, BIOCHEMISTRY-US, V16, P1333, DOI 10.1021/bi00626a015; ZALKIN H, 1992, PROG NUCLEIC ACID RE, V42, P259, DOI 10.1016/S0079-6603(08)60578-4	27	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10471	10481						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683680				2022-12-27	WOS:A1993LB80000072
J	ROTONDA, J; BURBAUM, JJ; CHAN, HK; MARCY, AI; BECKER, JW				ROTONDA, J; BURBAUM, JJ; CHAN, HK; MARCY, AI; BECKER, JW			IMPROVED CALCINEURIN INHIBITION BY YEAST FKBP12-DRUG COMPLEXES - CRYSTALLOGRAPHIC AND FUNCTIONAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYCLOSPORINE-A; CYCLOPHILIN; ACTIVATION; FKBP-FK506; REFINEMENT; FK506	The protein phosphatase calcineurin is the putative target for the immunosuppressive drug FK-506. The enzyme is inhibited by the complex of the drug with its intracellular receptor, the 12-kDa FK-506-binding protein (FKBP12), and the strength of inhibition usually correlates strongly with immunosuppressive potency. We find, however, that the complex of yeast FKBP12 with L-685,818, a well characterized antagonist of FK-506 immunosuppression, is a potent inhibitor of calcineurin. The corresponding human complex does not inhibit the enzyme, and both human and yeast complexes with FK-506 do inhibit. To understand the structural basis of these findings, we have determined the three-dimensional structure of the complex of yeast FKBP12 with FK-506 by x-ray crystallography, and have found that the structure of the yeast complex is strikingly similar to its human homolog. These observations indicate that specific sequence elements in the yeast protein provide stronger binding interactions with a heterologous calcineurin than do the corresponding elements in the human protein, and suggest structural modifications that may improve the potency of this class of immunosuppressants.	MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,POB 2000 R80M-203,RAHWAY,NJ 07065; RUTGERS STATE UNIV,DEPT CHEM,OLSON LABS,NEWARK,NJ 07102	Merck & Company; Rutgers State University Newark; Rutgers State University New Brunswick								ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; LEPRE CA, 1992, FEBS LETT, V302, P89, DOI 10.1016/0014-5793(92)80292-O; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3986; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; POLITINO M, 1990, J BIOL CHEM, V265, P7619; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SUSSMAN JL, 1985, METHOD ENZYMOL, V115, P271; TOCCI MJ, 1989, J IMMUNOL, V143, P718; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753	21	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7607	7609						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681823				2022-12-27	WOS:A1993KW97900002
J	HENDRIX, P; TUROWSKI, P; MAYERJAEKEL, RE; GORIS, J; HOFSTEENGE, J; MERLEVEDE, W; HEMMINGS, BA				HENDRIX, P; TUROWSKI, P; MAYERJAEKEL, RE; GORIS, J; HOFSTEENGE, J; MERLEVEDE, W; HEMMINGS, BA			ANALYSIS OF SUBUNIT ISOFORMS IN PROTEIN PHOSPHATASE-2A HOLOENZYMES FROM RABBIT AND XENOPUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-T-ANTIGEN; CATALYTIC SUBUNIT; OKADAIC ACID; TYPE-2A PHOSPHATASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SKELETAL-MUSCLE; DNA-REPLICATION; KINASE ACTIVITY; LAEVIS OOCYTES	A dimeric and two trimeric forms of protein phosphatase 2A (PP2A) were purified from rabbit and Xenopus tissues and analyzed using antisera specific for the catalytic and regulatory subunits. The dimeric holoenzyme consists of a complex between a 36-kDa catalytic subunit associated with a approximately 65-kDa regulatory subunit. The two trimeric holoenzymes consist of the catalytic subunit complexed with 65- and 55-kDa subunits, or 65- and 72-kDa subunits. Antisera were raised against synthetic peptides specific for the alpha- and beta-isoforms of the 65-kDa (PR65alpha/beta) and 55-kDa (PR55alpha/beta) subunits identified by molecular cloning. Anti-peptide antisera to the 36-kDa catalytic subunit of PP2A were prepared against two selected regions: one specific for the alpha-isoform and one to a peptide common to both the alpha- and beta-isoforms. Immunochemical analysis of all three mammalian holoenzymes showed that the catalytic, 55- and 65-kDa subunits are both predominantly of the alpha-isoform, which is consistent with the peptide sequence data. The 65-kDa subunit of PP2A holoenzymes isolated from Xenopus skeletal muscle reacted with both anti-alpha and anti-beta PR65-specific antisera whereas the PP2A holoenzymes isolated from Xenopus oocytes reacted preferentially with the beta-specific antisera, indicating developmental changes in the expression of the 65-kDa subunit isoform. Taken together, these results show that the ''core'' subunits of the PP2A holoenzymes consist of the catalytic complexed with the 65-kDa subunit and that the association of the third subunit does not appear to be influenced by the isoform of these two core subunits.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND; CATHOLIC UNIV LEUVEN, FAC GENEESKUNDE, AFDELING BIOCHEM, B-3000 LOUVAIN, BELGIUM	Friedrich Miescher Institute for Biomedical Research; KU Leuven								AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; AGOSTINIS P, 1987, BIOCHEM J, V248, P785, DOI 10.1042/bj2480785; AGOSTINIS P, 1990, EUR J BIOCHEM, V189, P235, DOI 10.1111/j.1432-1033.1990.tb15482.x; AGOSTINIS P, 1987, J BIOL CHEM, V262, P1061; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1986, ENZYMES, V17, P311; BASSIRI RM, 1979, METHOD HORM RADIOIMM, P46; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHEN SC, 1989, J BIOL CHEM, V264, P7267; CHERNOFF J, 1983, J BIOL CHEM, V258, P7852; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GORIS J, 1988, BIOCHEM J, V256, P1029, DOI 10.1042/bj2561029; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HEMMINGS BA, 1988, NUCLEIC ACIDS RES, V16, P11366, DOI 10.1093/nar/16.23.11366; HERMANN J, 1988, EUR J BIOCHEM, V173, P17, DOI 10.1111/j.1432-1033.1988.tb13961.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JESSUS C, 1989, EUR J BIOCHEM, V180, P15, DOI 10.1111/j.1432-1033.1989.tb14609.x; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYER RE, 1991, ADV PROTEIN PHOSPHAT, V6, P265; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; MAYERJAEKEL RE, 1993, IN PRESS CELL; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1669; SHENOLIKAR S, 1991, ADV 2ND MESSENGER PH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDE, 1988, FEBS LETT, V242, P106, DOI 10.1016/0014-5793(88)80995-5; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; STONE SR, 1988, NUCLEIC ACIDS RES, V16, P11365, DOI 10.1093/nar/16.23.11365; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; USUI H, 1988, J BIOL CHEM, V263, P3752; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WAELKENS E, 1987, BIOCHEM INT, V15, P385; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WAELKENS E, 1987, ADV ENZYME REGUL, V2, P467; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	56	79	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1993	268	10					7330	7337						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KV141	7681822				2022-12-27	WOS:A1993KV14100073
J	FRATINI, A; POWELL, BC; ROGERS, GE				FRATINI, A; POWELL, BC; ROGERS, GE			SEQUENCE, EXPRESSION, AND EVOLUTIONARY CONSERVATION OF A GENE ENCODING A GLYCINE TYROSINE-RICH KERATIN-ASSOCIATED PROTEIN OF HAIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; WOOL KERATIN; CDNA CLONES; SHEEP WOOL; DNA; ELEMENTS; ENHANCER; FAMILY; CELL; HYBRIDIZATION	In hair differentiation several families of keratin proteins with distinctive amino acid compositions are produced. To study the role and regulation of one of these families, the glycine/tyrosine-rich keratin-associated proteins encoded by the KAP6 gene family, a partial wool follicle cDNA clone encoding a sheep KAP6 protein was sequenced and the corresponding gene isolated from a sheep cosmid library. The KAP6.1 gene encodes a basic protein of 82 amino acids (M(r) = 8,296) with a combined glycine and tyrosine content of approximately 60 mol %. There are several KAP6 genes in the sheep genome, all located within a 1,050-kilobase SfiI fragment. Northern blot analysis demonstrated that at least one member of the KAP6 family is expressed in the wool follicle. A rabbit KAP6 gene was isolated and its sequence and expression patterns were compared with the sheep gene. The sheep and rabbit genes have a nucleotide sequence identity of 89%, suggesting that they are equivalent genes and indicating strong selection pressure during evolution. Both genes contain several conserved sequence motifs of 7-9 nucleotides in their 5'-flanking regions that may be involved in the regulation of their expression. Localization of KAP6 mRNAs in sheep wool and rabbit hair follicles by in situ hybridization suggests that the genes are expressed in the cells of the hair shaft cortex in varying expression patterns. KAP6 expression starts relatively late in hair follicle differentiation, and the proportion of hair cortical cells that express it may change from follicle to follicle.			FRATINI, A (corresponding author), UNIV ADELAIDE, DEPT BIOCHEM, GPO BOX 498, ADELAIDE, SA 5001, AUSTRALIA.							BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; CAMERON GN, 1988, NUCLEIC ACIDS RES, V16, P1865, DOI 10.1093/nar/16.5.1865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P244; DOPHEIDE TA, 1973, EUR J BIOCHEM, V34, P120, DOI 10.1111/j.1432-1033.1973.tb02737.x; DOWLING LM, 1990, 8TH P INT WOOL TEXT, V1, P205; DUNCAN CH, 1987, NUCLEIC ACIDS RES, V15, P1340, DOI 10.1093/nar/15.3.1340; ELIOPOULOS E, 1982, INT J BIOL MACROMOL, V4, P263, DOI 10.1016/0141-8130(82)90053-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER C, 1991, DEVELOPMENT, V111, P253; Fraser R.D.B., 1972, KERATINS THEIR COMPO; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; GALLI G, 1981, NATURE, V294, P626, DOI 10.1038/294626a0; Gillespie J.M., 1991, PHYSL BIOCH MOL BIOL, P625; GILLESPIE JM, 1974, COMP BIOCHEM PHYSIOL, V47, P339, DOI 10.1016/0305-0491(74)90063-7; GILLESPIE JM, 1971, AUST J BIOL SCI, V24, P1189, DOI 10.1071/BI9711189; GILLESPIE JM, 1972, COMP BIOCHEM PHYSIOL, V41, P723, DOI 10.1016/0305-0491(72)90085-5; Gillespie JM, 1990, CELLULAR MOL BIOL IN, P95; GILLESPIE JM, 1976, 5TH P INT WOOL TEXT, V1, P265; GOODMAN M, 1982, MACROMOLECULAR SEQUE, P114; GREGG K, 1984, EMBO J, V3, P175, DOI 10.1002/j.1460-2075.1984.tb01779.x; GUPTA RC, 1979, NUCLEIC ACIDS RES, V7, P959, DOI 10.1093/nar/7.4.959; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HOHL D, 1991, J BIOL CHEM, V266, P6626; INGLIS AS, 1988, PROTEIN STRUCTURE FU, P767; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUCZEK E, 1985, EUR J BIOCHEM, V146, P89, DOI 10.1111/j.1432-1033.1985.tb08623.x; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; LAWRENCE CB, 1985, NUCLEIC ACIDS RES, V13, P4239, DOI 10.1093/nar/13.12.4239; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; MARSHALL RC, 1980, 6TH P INT WOOL TEXT, V2, P147; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Overhauser J., 1987, FOCUS, V9, P8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWELL B, 1992, DEVELOPMENT, V114, P417; Powell B.C., 1990, CELLULAR MOL BIOL IN, P267; POWELL BC, 1991, ANN NY ACAD SCI, V642, P1; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; POWELL BC, 1986, P NATL ACAD SCI USA, V83, P5048, DOI 10.1073/pnas.83.14.5048; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; QUAX W, 1985, CELL, V43, P327, DOI 10.1016/0092-8674(85)90038-8; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Rogers G. E., 1989, BIOL WOOL HAIR, P69; ROGERS GE, 1959, ANN NY ACAD SCI, V83, P378; ROGERS GE, 1991, ANN NY ACAD SCI, V642, P64; SAKAMOTO K, 1985, J MOL EVOL, V22, P134, DOI 10.1007/BF02101691; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; Swift JA, 1977, CHEM NATURAL PROTEIN, P81; WATANABE Y, 1982, NUCLEIC ACIDS RES, V10, P1459, DOI 10.1093/nar/10.5.1459; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHITELEY KJ, 1977, J TEXT I, V68, P384, DOI 10.1080/00405007708631416; WILSON BW, 1988, GENE, V73, P21, DOI 10.1016/0378-1119(88)90309-5; WINTER G, 1980, NUCLEIC ACIDS RES, V8, P1965, DOI 10.1093/nar/8.9.1965	69	63	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4511	4518						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680040				2022-12-27	WOS:A1993KN53300101
J	YOSHIMURA, K; CHU, CS; CRYSTAL, RG				YOSHIMURA, K; CHU, CS; CRYSTAL, RG			ALTERNATIVE SPLICING OF INTRON-23 OF THE HUMAN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESULTING IN A NOVEL EXON AND TRANSCRIPT CODING FOR A SHORTENED INTRACYTOPLASMIC-C TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; EPITHELIAL-CELLS; DNA; EXPRESSION; IDENTIFICATION; CFTR; SEQUENCES; FRAGMENTS; MUTATIONS; INVITRO	The cystic fibrosis transmembrane conductance regulator (CFTR) gene, the gene responsible for the lethal hereditary disorder cystic fibrosis, codes for a membrane protein functioning as a cAMP-regulated Cl- channel. Evaluation of human CFTR mRNA transcripts from epithelial and nonepithelial cells demonstrated a CFTR cDNA containing a 260-base pair (bp) insertion between the known CFTR exons 23 and 24, introducing a premature stop codon that would result in a CFTR protein shortened by 61 amino acids at the carboxyl terminus compared to that expected from the normal reported human CFTR coding sequences. Sequence analysis of intron 23 of the CFTR gene demonstrated that the 260-bp insertion (named exon 24a), a part of the reported intron 23 and located consecutive to exon 24, is likely generated by an alternative splice acceptor site. The exon 24a+ CFTR mRNA transcripts represented 3-16% of the total CFTR transcripts in epithelial and nonepithelial cells. These observations suggest an unexpected plasticity of expression of the CFTR gene, where alternative splicing of precursor CFTR mRNA transcripts permits the use of an alternative exon derived from a genomic segment previously believed to function as an intron.			YOSHIMURA, K (corresponding author), NHLBI, PULM BRANCH, BETHESDA, MD 20892 USA.							ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KINNIBURGH AJ, 1979, CELL, V17, P915, DOI 10.1016/0092-8674(79)90331-3; KOBAYASHI K, 1990, AM J HUM GENET, V47, P611; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAWLAK A, 1990, J BIOL CHEM, V265, P3256; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	41	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					686	690						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678008				2022-12-27	WOS:A1993KE60300103
J	MCALISTERHENN, L; STEFFAN, JS; MINARD, KI; ANDERSON, SL				MCALISTERHENN, L; STEFFAN, JS; MINARD, KI; ANDERSON, SL			EXPRESSION AND FUNCTION OF A MISLOCALIZED FORM OF PEROXISOMAL MALATE-DEHYDROGENASE (MDH3) IN YEAST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; ISOCITRATE DEHYDROGENASE; CITRATE SYNTHASE; MITOCHONDRIAL; GENE; INACTIVATION; DISRUPTION; GLUCOSE; DNA	The malate dehydrogenase isozyme MDH3 of Saccharomyces cerevisiae was found to be localized to peroxisomes by cellular fractionation and density gradient centrifugation. However, unlike other yeast peroxisomal enzymes that function in the glyoxylate pathway, MDH3 was found to be refractory to catabolite inactivation, i.e. to rapid inactivation and degradation following glucose addition. To examine the structural requirements for organellar localization, the Ser-Lys-Leu carboxyl-terminal tripeptide, a common motif for localization of peroxisomal proteins, was removed by mutagenesis of the MDH3 gene. This resulted in cytosolic localization of MDH3 in yeast transformants. To examine structural requirements for catabolite inactivation, a 12-residue amino-terminal extension from the yeast cytosolic MDH2 isozyme was added to the amino termini of the peroxisomal and mislocalized ''cytosolic'' forms of MDH3. This extension was previously shown to be essential for catabolite inactivation of MDH2 but failed to confer this property to MDH3. The mislocalized cytosolic forms of MDH3 were found to be catalytically active and competent for metabolic functions normally provided by MDH2.	UNIV CALIF IRVINE,SCH MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine	MCALISTERHENN, L (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284, USA.				NIGMS NIH HHS [GM33218] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033218] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRKTOFT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P6166, DOI 10.1073/pnas.79.20.6166; BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTRENNE H, 1955, BIOCHIM BIOPHYS ACTA, V16, P410, DOI 10.1016/0006-3002(55)90246-8; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; GANCEDO C, 1976, ARCH MICROBIOL, V109, P221, DOI 10.1007/BF00446632; GIETL C, 1994, P NATL ACAD SCI USA, V91, P3151, DOI 10.1073/pnas.91.8.3151; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; LOPEZBOADO YS, 1987, ARCH MICROBIOL, V147, P231, DOI 10.1007/BF00463480; Maniatis T., 1982, MOL CLONING; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MCCAMMON MT, 1990, J BACTERIOL, V172, P5816, DOI 10.1128/jb.172.10.5816-5827.1990; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MINARD KI, 1992, J BIOL CHEM, V267, P17458; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RODERICK SL, 1986, J BIOL CHEM, V261, P9461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH KK, 1992, MOL CELL BIOL, V12, P5593, DOI 10.1128/MCB.12.12.5593; Singh N., 1993, Molecular Biology of the Cell, V4, p106A; Srere P. A., 1972, ENERGY METABOLISM RE, P79; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; THOMPSON LM, 1988, BIOCHEMISTRY-US, V27, P8393, DOI 10.1021/bi00422a015; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	34	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21220	21225		10.1074/jbc.270.36.21220	http://dx.doi.org/10.1074/jbc.270.36.21220			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673155	hybrid			2022-12-27	WOS:A1995RU05400055
J	KNIBBS, RN; OSBORNE, SE; GLICK, GD; GOLDSTEIN, IJ				KNIBBS, RN; OSBORNE, SE; GLICK, GD; GOLDSTEIN, IJ			BINDING DETERMINANTS OF THE SIALIC ACID-SPECIFIC LECTIN FROM THE SLUG LIMAX-FLAVUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPIC DEMONSTRATION; N-ACETYLNEURAMINIC ACID; MAACKIA-AMURENSIS; INFLUENZA-VIRUS; LINKED OLIGOSACCHARIDES; STRUCTURAL VARIATIONS; SAMBUCUS-NIGRA; RESIDUES; RECOGNITION; LOCALIZATION	The specific structural features of 24 N-acetylneuraminic acid derivatives required for the high affinity interaction of sialoglycoconjugates with the sialic acid-specific lectin from the slug Limax flavus were studied by hapten inhibition of precipitation. These results provide insight regarding the structure of the binding pocket for N-acetylneuraminic acid that exists in L. flavus agglutinin (LFA). The alpha-anomer of sialic acid is a very important factor in binding to the slug lectin. The carboxylic acid group makes only a moderate contribution to binding, since modifications of the carboxylic group decrease binding approximately 5-fold. Modification or removal of the hydroxyl group on carbon 4 does not affect binding. However, when the C4 epimer was tested, there was a dramatic decrease in binding, suggesting that whereas the equatorial hydroxyl at C4 does not contribute to binding, the introduction of an axial hydroxyl group at C4 sterically hinders the binding interaction. The substituent on the 5-amino group occupies an important role in binding of Neu5Ac to LFA as well. When the acetyl is modified by the addition of a hydroxyl group to yield the N-glycolyl derivative, we observed a 20-fold decrease, while the removal of the methyl to form the N-formyl derivative resulted in a 50-fold decrease. The 5-amino derivative was the poorest inhibitor of all compounds examined, indicating a critical role for the N-acetyl group in high affinity binding to LFA. The glyceryl tail also appears to be critical for binding inasmuch as acetylation of the C9 hydroxyl group or periodate cleavage of carbons 8 and 9 resulted in a 20- to 50-fold decrease in binding. The equilibrium constant (K(a)) for binding of Neu5Ac to LFA is 3.8 x 10(4) M-1, with a single binding site (n = 0.85) per monomer.	UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	KNIBBS, RN (corresponding author), UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA020424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20424] Funding Source: Medline; NIGMS NIH HHS [GM 29470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1977, P NATL ACAD SCI USA, V74, P1521, DOI 10.1073/pnas.74.4.1521; BRANDSTETTER HH, 1983, LIEBIGS ANN CHEM, P2055; BROSSMER R, 1992, J BIOL CHEM, V267, P8752; CHAVIN SI, 1984, J BIOL CHEM, V259, P3387; Cram D.J., 1986, ANGEW CHEM, V98, P1041, DOI DOI 10.1021/ja102148f; CZARNIECKI MF, 1977, J AM CHEM SOC, V99, P8273, DOI 10.1021/ja00467a025; FORSTNER M, 1989, CARBOHYD RES, V193, P294, DOI 10.1016/0008-6215(89)85130-4; GLICK GD, 1991, J BIOL CHEM, V266, P23660; GOLDSTEIN IJ, 1986, LECTINS PROPERTIES F, P209; GROSS HJ, 1990, ANAL BIOCHEM, V186, P127, DOI 10.1016/0003-2697(90)90585-W; GROSS HJ, 1988, BIOCHEMISTRY-US, V27, P4279, DOI 10.1021/bi00412a012; HAGEDORN HW, 1986, HELV CHIM ACTA, V69, P2127, DOI 10.1002/hlca.19860690837; HARTMANN M, 1989, MONATSH CHEM, V120, P899, DOI 10.1007/BF00811129; HARTMANN M, 1990, LIEBIGS ANN CHEM, P83; HAVERKAMP J, 1975, H-S Z PHYSIOL CHEM, V356, P1575, DOI 10.1515/bchm2.1975.356.2.1575; HEDMAN K, 1986, J HISTOCHEM CYTOCHEM, V34, P1069, DOI 10.1177/34.8.3734417; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDAL C, 1990, EXPERIENTIA, V46, P433, DOI 10.1007/BF01954221; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MILLER RL, 1982, J INVERTEBR PATHOL, V39, P210, DOI 10.1016/0022-2011(82)90012-X; MORELL AG, 1971, J BIOL CHEM, V246, P1461; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3213; OGURA H, 1986, CARBOHYD RES, V158, P37, DOI 10.1016/0008-6215(86)84004-6; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; ROBERTS DD, 1989, J BIOL CHEM, V264, P9289; ROGERS GN, 1985, J BIOL CHEM, V260, P7362; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; SATA T, 1989, J HISTOCHEM CYTOCHEM, V37, P1577, DOI 10.1177/37.11.2478613; SATA T, 1991, AM J PATHOL, V139, P1435; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; Schauer R, 1978, Methods Enzymol, V50, P64; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHAUER R, 1984, PURE APPL CHEM, V56, P907, DOI 10.1351/pac198456070907; SCHULTE BA, 1984, HISTOCHEM J, V16, P1125, DOI 10.1007/BF01002899; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SMILEY ML, 1985, J VIROL, V55, P857, DOI 10.1128/JVI.55.3.857-861.1985; TACHIBANA M, 1990, EUR ARCH OTO-RHINO-L, V247, P240; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; WAGNER M, 1990, LECTINS BIOL BIOCH C, V7, P83; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; YAMASHITA K, 1988, J BIOL CHEM, V263, P17482; YU RK, 1969, J BIOL CHEM, V244, P1306; ZENG FY, 1992, Z NATURFORSCH C, V47, P641	51	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18524	18531						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689555				2022-12-27	WOS:A1993LV65900026
J	KIM, NS; UMEZAWA, Y; OHMURA, S; KATO, S				KIM, NS; UMEZAWA, Y; OHMURA, S; KATO, S			HUMAN GLYOXALASE-I - CDNA CLONING, EXPRESSION, AND SEQUENCE SIMILARITY TO GLYOXALASE-I FROM PSEUDOMONAS-PUTIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY CHROMATOGRAPHY; HUMAN-ERYTHROCYTES; PURIFICATION; ENZYMES; YEAST	Glyoxalase I (EC 4.4.1.5) catalyzes the transformation of methylglyoxal and glutathione to S-lactoylglutathione. We have isolated human cDNA clones encoding glyoxalase I from a phorbol myristate acetate-treated U937 cDNA library. This cDNA encodes a protein of 184 amino acids with a calculated M(r) of 20,719. The amino acid composition calculated from the deduced amino acid sequence agreed with that reported for glyoxalase I purified from human erythrocytes. The Escherichia coli cells carrying the expression vector of this cDNA acquired methylglyoxal resistance and the cell lysate showed the high activity of glyoxalase I. The amino acid sequence of human glyoxalase I exhibited 57% identity with Pseudomonas putida glyoxalase I at the C-terminal two-thirds, suggesting that the two enzymes may have originated from a common ancestor.	SAGAMI CHEM RES CTR,4-4-1 NISHI OHNUMA,SAGAMIHARA,KANAGAWA 229,JAPAN; KANAGAWA ACAD SCI & TECHNOL,KAWASAKI,KANAGAWA 213,JAPAN	Kanagawa Academy Science & Technology								ARONSSON AC, 1977, BIOCHEM J, V165, P503, DOI 10.1042/bj1650503; ARONSSON AC, 1979, ANAL BIOCHEM, V92, P390, DOI 10.1016/0003-2697(79)90676-6; BROWN RS, 1983, MET IONS BIOL SYST, V15, P55; CASTRO VM, 1990, CARCINOGENESIS, V11, P1569, DOI 10.1093/carcin/11.9.1569; GILLESPIE E, 1981, BIOCHEM BIOPH RES CO, V98, P463, DOI 10.1016/0006-291X(81)90862-7; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KOBATAKE E, 1990, J BIOTECHNOL, V16, P87, DOI 10.1016/0168-1656(90)90067-L; KOMPF J, 1975, HUMANGENETIK, V27, P141; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARSEN K, 1985, COMP BIOCHEM PHYS B, V82, P625, DOI 10.1016/0305-0491(85)90499-7; Maniatis T., 1982, MOL CLONING; MANNERVIK B, 1982, METHOD ENZYMOL, V90, P535; MARMSTAL E, 1979, BIOCHEM J, V183, P23, DOI 10.1042/bj1830023; MARMSTAL E, 1978, FEBS LETT, V85, P275, DOI 10.1016/0014-5793(78)80472-4; ORAY B, 1982, METHOD ENZYMOL, V90, P542; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; RACKER E, 1951, J BIOL CHEM, V190, P685; RHEE H, 1986, BIOCHEM BIOPH RES CO, V141, P993, DOI 10.1016/S0006-291X(86)80142-5; RHEE HI, 1988, AGR BIOL CHEM TOKYO, V52, P2243	19	43	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11217	11221						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684374				2022-12-27	WOS:A1993LD46600074
J	ISHII, K; HEIN, L; KOBILKA, B; COUGHLIN, SR				ISHII, K; HEIN, L; KOBILKA, B; COUGHLIN, SR			KINETICS OF THROMBIN RECEPTOR CLEAVAGE ON INTACT-CELLS - RELATION TO SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELETS; FIBROBLASTS; ACTIVATION; PROTEINS	Thrombin, a protease generated at sites of vascular injury, signals cellular responses vital for hemostasis and thrombosis. How thrombin, an enzyme rather than a classical ligand, effects graded and concentration-dependent responses in its target cells has been a long-standing question. Thrombin activates its receptor by cleaving off an activation peptide to unmask a tethered peptide ligand. We utilized a thrombin receptor with an epitope-tagged activation peptide to directly demonstrate thrombin receptor cleavage and to examine the kinetics of receptor activation on intact cells. The rate of thrombin receptor cleavage was proportional to thrombin concentration over the physiologic range, but low thrombin concentrations ultimately cleaved and activated all receptors. Cumulative phosphoinositide hydrolysis in response to thrombin correlated precisely with cumulative receptor cleavage. These data strongly suggest that each cleaved and activated thrombin receptor produces a ''quantum'' of phosphatidylinositol hydrolysis, then shuts off. Surprisingly, this shut off occurred despite the continued presence of cleaved and ''activated'' receptors on the cell surface and at a time when the cells were refractory to thrombin but sensitive to agonist peptide, suggesting that a novel shut off mechanism may have evolved to deal with the tethered ligand. Unlike the case with classical ligands, cells thus cannot detect differences in thrombin concentrations as differences in fractional occupancy but rather must sense different rates of receptor activation. Because each cleaved thrombin receptor generates a quantum of second messenger, the magnitude of the cell's response to thrombin must be determined by the balance between rates of receptor activation and second messenger clearance.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, BOX 0524, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907, HL43821] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BRASS LF, 1992, J BIOL CHEM, V267, P6044; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DETWILER TC, 1973, BIOCHEMISTRY-US, V12, P282, DOI 10.1021/bi00726a017; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNG DT, 1992, J BIOL CHEM, V267, P20831; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LIU LW, 1991, J BIOL CHEM, V266, P16977; MARTIN BM, 1975, BIOCHEMISTRY-US, V14, P1308, DOI 10.1021/bi00677a032; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PARIS S, 1988, J BIOL CHEM, V263, P11250; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; REIMERS HJ, 1973, BRIT J HAEMATOL, V25, P675, DOI 10.1111/j.1365-2141.1973.tb01780.x; RITTENHOUSESIMMONS S, 1979, J CLIN INVEST, V63, P580, DOI 10.1172/JCI109339; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SHUMAN MA, 1979, J CLIN INVEST, V63, P1211, DOI 10.1172/JCI109416; SIMON K, 1987, J CELL BIOL, V104, P1165, DOI 10.1083/jcb.104.5.1165; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	31	205	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9780	9786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683662				2022-12-27	WOS:A1993LA68900091
J	GOROSPE, M; KUMAR, S; BAGLIONI, C				GOROSPE, M; KUMAR, S; BAGLIONI, C			TUMOR-NECROSIS-FACTOR INCREASES STABILITY OF INTERLEUKIN-1 MESSENGER-RNA BY ACTIVATING PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; POSTTRANSCRIPTIONAL REGULATION; CELLS; FIBROBLASTS; EXPRESSION; INTERFERON; LYMPHOKINE; INDUCTION; LEVEL	The mRNAs coding for interleukin-1alpha (IL-1alpha) and IL-1beta are constitutively transcribed but do not accumulate in human diploid fibroblasts and in fibrosarcoma cells. Treatment of these cells with tumor necrosis factor (TNF) induces accumulation of IL-1 mRNA by an unknown mechanism. This induction of IL-1 mRNA was investigated in HT-1080 cells. The induction was quite fast, with maximum levels of IL-1alpha and beta mRNA reached 4 h after addition of TNF. Nuclear run-off experiment showed that TNF did not increase the rate of transcription of IL-1 mRNA. This mRNA was apparently unstable in untreated cells, but it accumulated in cycloheximide-treated cells. Phorbol esters induced IL-1 mRNA, suggesting that activation of protein kinase C was responsible for the accumulation of this mRNA. This hypothesis was confirmed by experiments with the PKC inhibitors staurosporine and calphostin C, which prevented the induction of IL-1 mRNA by TNF and accelerated the decay of this mRNA in cells pretreated with TNF. Both IL-1alpha and IL-1beta were detected in TNF-treated cells by Western blot analysis and enzyme-linked immunosorbent assay. These results indicate that the TNF-mediated induction of IL-1 can be entirely accounted for by stabilization of this mRNA.			GOROSPE, M (corresponding author), SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA.				NCI NIH HHS [CA-29895] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; ELIAS JA, 1989, P NATL ACAD SCI USA, V86, P6171, DOI 10.1073/pnas.86.16.6171; GESSANI S, 1988, J BIOL CHEM, V263, P7454; GESSANI S, 1991, J VIROL, V65, P989, DOI 10.1128/JVI.65.2.989-991.1991; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUY GR, 1991, J BIOL CHEM, V266, P14343; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LEPEZUNIGA JL, 1984, CLIN IMMUNOL IMMUNOP, V31, P222, DOI 10.1016/0090-1229(84)90242-3; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703	27	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6214	6220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681061				2022-12-27	WOS:A1993KT36800024
J	BLECHMAN, JM; LEV, S; BRIZZI, MF; LEITNER, O; PEGORARO, L; GIVOL, D; YARDEN, Y				BLECHMAN, JM; LEV, S; BRIZZI, MF; LEITNER, O; PEGORARO, L; GIVOL, D; YARDEN, Y			SOLUBLE C-KIT PROTEINS AND ANTIRECEPTOR MONOCLONAL-ANTIBODIES CONFINE THE BINDING-SITE OF THE STEM-CELL FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; TYROSINE KINASE RECEPTOR; INSULIN-RECEPTOR; PROTO-ONCOGENE; W-LOCUS; SIGNAL TRANSDUCTION; LIGAND; MOUSE; IDENTIFICATION	The binding of the stem cell factor (SCF) to the c-kit-encoded receptor tyrosine kinase stimulates a variety of biochemical responses that culminate in cellular proliferation, migration, or survival. The extracellular domain of p145kit consists of five immunoglobulin-like domains. To confine the ligand binding site to this portion of the receptor we generated a panel of murine monoclonal antibodies (mAbs) to the Kit protein and identified two mAbs that efficiently displaced receptor-bound SCF and also inhibited proliferation of SCF-dependent human megakaryocytes. To map the epitopes of these mAbs we constructed and expressed soluble portions of the extracellular domain of Kit, which included either the two amino-terminal Ig-like domains (denoted Kit 1-2), three Ig-like domains (Kit 1-2-3), or the entire extracellular portion (Kit-X). All three recombinant proteins were recognized by the ligand inhibitory mAbs, suggesting that the SCF binding site resides in the amino-terminal half of the ecto-domain. Consistent with this conclusion, all of the soluble proteins inhibited SCF binding to Kit-expressing cells, and they also underwent specific covalent cross-linking to the radiolabeled ligand. However, whereas Kit 1-2-3 and Kit-X displayed comparable ligand affinities, deletion of the third Ig-like domain, in Kit 1-2, involved significant reduction in SCF binding. Hence, the binding site of SCF probably includes Ig-like domains 1 and 2, but structural determinants distal to this portion may also participate in ligand recognition.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; UNIV TURIN, DIPARTMENTO SCI BIOMED & ONCOL UMANA, I-10126 TURIN, ITALY	Weizmann Institute of Science; University of Turin			Lev, Sima/AAP-7880-2020; YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016	Lev, Sima/0000-0002-2108-3330; 	NCI NIH HHS [CA 51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BENNETT DOROTHEA, 1956, J MORPH, V98, P199, DOI 10.1002/jmor.1050980202; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DUAN DSR, 1991, J BIOL CHEM, V266, P413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KJELDSEN T, 1991, P NATL ACAD SCI USA, V88, P4404, DOI 10.1073/pnas.88.10.4404; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LEV S, 1992, J BIOL CHEM, V267, P10866; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MINTZ B, 1957, J EXP ZOOL, V134, P207, DOI 10.1002/jez.1401340202; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Silvers W.K., 1979, COAT COLORS MICE, P206; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; YIP CC, 1991, BIOCHEMISTRY-US, V30, P695, DOI 10.1021/bi00217a016; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	51	59	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4399	4406						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680037				2022-12-27	WOS:A1993KN53300085
J	DOWBENKO, D; ANDALIBI, A; YOUNG, PE; LUSIS, AJ; LASKY, LA				DOWBENKO, D; ANDALIBI, A; YOUNG, PE; LUSIS, AJ; LASKY, LA			STRUCTURE AND CHROMOSOMAL LOCALIZATION OF THE MURINE GENE ENCODING GLYCAM-1 - A MUCIN-LIKE ENDOTHELIAL LIGAND FOR L-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; STEM-CELL ANTIGEN; HUMAN LEUKOSIALIN; LECTIN DOMAIN; MOUSE; IDENTIFICATION; EXPRESSION; PROTEINS; SEQUENCE; CD43	We recently described the molecular cloning of a murine cDNA encoding an endothelial cell surface ligand for the leukocyte adhesion molecule, L Selectin (Lasky, L. A., Singer, M., Dowbenko, D., Ima, Y., Henzel, W., Grimley, C., Gennie, C., Gillett, N., Watson, S., and Rosen, S. D (1992) Cell 69, 927-938). This glycoprotein ligand was found to resemble mucins in that it contained a large percentage of serine and threonine residues that were apparently O-glycosylated. At least one of the O-linked carbohydrates found on this endothelial ligand interacts with the lectin domain of L Selectin. These data suggest that this endothelial ligand is an adhesion molecule that accomplishes cell binding by presenting carbohydrate(s) to the lectin domain of L Selectin, and the name GLYCAM 1 (GLY-cosylation-dependent Cell Adhesion Molecule 1) has been proposed. In this paper we describe the genomic structure and chromosomal localization of this unique Selectin ligand. The gene has been found to be encoded on four separate exons, and it thus differs from the cell surface mucin leukosialin, whose coding region is contained on one exon, but is similar to glycophorin and CD34, other cell surface mucins whose genes are divided into multiple coding exons. While there is some correlation between exon division and protein domain structure, these relationships are not as clear as they are in other genes. The gene encoding GLYCAM 1 was found to map to murine chromosome 15.	GENENTECH INC,DEPT IMMUNOL,460 PT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; UNIV CALIF LOS ANGELES,DEPT MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Roche Holding; Genentech; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NHLBI NIH HHS [HL30568] Funding Source: Medline; PHS HHS [H42488] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; HUPPI K, 1988, IMMUNOGENETICS, V27, P215, DOI 10.1007/BF00346589; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; KUDO S, 1991, J BIOL CHEM, V266, P8483; KUDO S, 1989, P NATL ACAD SCI USA, V86, P4619, DOI 10.1073/pnas.86.12.4619; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1992, IN PRESS INFLAMMATIO; MOLGAARD HV, 1989, LEUKEMIA, V3, P773; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; Rosen SD, 1989, CURR OPIN CELL BIOL, V1, P913, DOI 10.1016/0955-0674(89)90058-6; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; VANCONG N, 1991, HUM GENET, V86, P77; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	24	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4525	4529						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680041				2022-12-27	WOS:A1993KN53300103
J	VAUGHAN, KT; WEBER, FE; EINHEBER, S; FISCHMAN, DA				VAUGHAN, KT; WEBER, FE; EINHEBER, S; FISCHMAN, DA			MOLECULAR-CLONING OF CHICKEN MYOSIN-BINDING PROTEIN (MYBP)-H (86-KDA PROTEIN) REVEALS EXTENSIVE HOMOLOGY WITH MYBP-C (C-PROTEIN) WITH CONSERVED IMMUNOGLOBULIN-C2 AND FIBRONECTIN TYPE-III MOTIFS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; THICK FILAMENT PROTEIN; CELL-ADHESION MOLECULE; 86 KD PROTEIN; X-PROTEIN; PECTORALIS-MUSCLE; LIGHT-CHAINS; H-PROTEIN; SEQUENCE; PURIFICATION	The complete nucleotide sequence of a cDNA clone encoding the chicken skeletal muscle myosin-binding protein H (MyBP-H), formerly termed 86-kDa protein, has been established and the predicted amino acid sequence compared with other proteins entered into the GenBank(TM) data base. The full-length cDNA of 2066 base pairs contains a single open reading frame of 1611 base pairs encoding a muscle-specific protein of 58,487 Da. The predicted molecular weight differs significantly from the relative mobility of 86-kDa protein in reducing sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE). The full-length protein expressed in Escherichia coli also exhibits an anomalously slow mobility in SDS-PAGE; this gel retardation is a property of the N-terminal 24 kDa of the protein which contain two extended motifs of alternating alanine and proline residues, resembling the N terminus of skeletal muscle myosin light chain 1 (Nabeshima, Y. I., Fujii-Kuriyama, Y., Muramatsu, M., and Ogata, K. (1984) Nature 308, 333-338). The C-terminal 40 kDa share 49.6% sequence identity and 17% conservative substitutions with chicken skeletal muscle MyBP-C (C-protein) (Einheber, S., and Fischman, D. A. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2157-2161). The protein contains four internal repeats of approximately 100 amino acids each, two of which bear significant resemblance to the C2 set of the immunoglobulin superfamily, and the other two are related to the type III fibronectin repeat. The arrangement of these repeats, -III-C2-III-C2-, is identical to that seen in the C-terminal 40-kDa section of MyBP-C. This repeat structure is implicated in myosin binding for the MyBP family. Finally, genomic Southern blots indicate that a single gene encodes fast skeletal muscle MyBP-H.	CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021	Cornell University			Weber, Franz E./I-7831-2019	Weber, Franz E./0000-0003-1670-2296	NIAMS NIH HHS [AR32147] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032147] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYMESOUTHGATE A, 1991, P NATL ACAD SCI USA, V88, P7973, DOI 10.1073/pnas.88.18.7973; BAHLER M, 1985, J MOL BIOL, V186, P381, DOI 10.1016/0022-2836(85)90112-3; BAHLER M, 1985, J MOL BIOL, V186, P393, DOI 10.1016/0022-2836(85)90113-5; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; BENNETT P, 1985, J MOL BIOL, V184, P297, DOI 10.1016/0022-2836(85)90381-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; EINHEBER S, 1990, P NATL ACAD SCI USA, V87, P2157, DOI 10.1073/pnas.87.6.2157; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHMAN DA, 1991, FRONTIERS MUSCLE RES, P211; GMACHL M, 1990, FEBS LETT, V260, P145, DOI 10.1016/0014-5793(90)80088-Z; HEMPERLY JJ, 1986, P NATL ACAD SCI USA, V83, P3037, DOI 10.1073/pnas.83.9.3037; HOFMANN PA, 1991, J PHYSIOL-LONDON, V439, P701, DOI 10.1113/jphysiol.1991.sp018689; HOFMANN PA, 1991, J GEN PHYSIOL, V97, P1141, DOI 10.1085/jgp.97.6.1141; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Hynes RO, 1990, FIBRONECTINS; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NAVE R, 1990, J CELL SCI, V95, P535; NAVE R, 1991, J CELL SCI, V98, P491; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PRICE M, 1991, J CELL BIOCHEM, V15, P63; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; REINACH FC, 1983, J CELL BIOL, V96, P297, DOI 10.1083/jcb.96.1.297; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTHEISS T, 1990, J CELL BIOL, V110, P1159, DOI 10.1083/jcb.110.4.1159; Squire J, 1981, STRUCTURAL BASIS MUS; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; STARR R, 1983, J MOL BIOL, V170, P675, DOI 10.1016/S0022-2836(83)80127-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKANOOHMURO H, 1989, J MUSCLE RES CELL M, V10, P369, DOI 10.1007/BF01758433; TALIAN JC, 1983, J CELL BIOL, V97, P1277, DOI 10.1083/jcb.97.4.1277; WAGNER PD, 1982, METHOD ENZYMOL, V85, P72; WEBER F E, 1991, Journal of Cell Biology, V115, p29A; WILLIAMS AF, 1989, COLD SPRING HARB SYM, V54, P637; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAMOTO K, 1983, J BIOL CHEM, V258, P8395	50	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3670	3676						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679114				2022-12-27	WOS:A1993KM16100097
J	AZUMA, H; HAYASHI, T; DENT, JA; RUGGERI, ZM; WARE, J				AZUMA, H; HAYASHI, T; DENT, JA; RUGGERI, ZM; WARE, J			DISULFIDE BOND REQUIREMENTS FOR ASSEMBLY OF THE PLATELET GLYCOPROTEIN-IB-BINDING DOMAIN OF VONWILLEBRAND-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIII-RELATED ANTIGEN; RNA-POLYMERASE; EXPRESSION; SECRETION; SITE; IDENTIFICATION; FRAGMENT; CELLS	von Willebrand factor (vWF) is a multimeric glycoprotein of plasma and the subendothelial matrix that interacts with specific platelet receptors to establish platelet adhesion at a site of vascular injury. The vWF domain containing the platelet receptor glycoprotein Ib-binding site can be expressed in heterologous cells as a recombinant homodimeric fragment that mediates platelet-platelet interaction, analogous to multimeric vWF. The recombinant domain, r116, contains 7 Cys residues within its 290-residue monomeric subunit paired in an unidentified intra- and intermolecular disulfide bond arrangement. In this report we define the disulfide bond-dependent framework of r116 that provides the domain with its essential structural features that support dimer formation and the generation of a disulfide bond-dependent epitope. The results demonstrate that a triplet of Cys residues at positions 459, 462, and 464 are essential for efficient dimer formation. An intramolecular Cys509/Cys695 disulfide loop is required for generating a functional dimeric molecule, and monomeric molecules containing a Cys509/Cys695 intramolecular disulfide bond are unable to support ristocetin-mediated platelet aggregation. The disulfide arrangement in r116 is similar, if not identical, to the proposed arrangement within the corresponding region of plasma vWF, and these studies document the inherent Cys-dependent maturation of an isolated vWF domain.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, SBR 8, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050545] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050545, R01 HL050545-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BAUMGARTNER HR, 1978, THROMB HAEMOSTASIS, V39, P782; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KOUTTS J, 1978, J CLIN INVEST, V62, P1255, DOI 10.1172/JCI109246; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LOESBERG C, 1983, BIOCHIM BIOPHYS ACTA, V763, P160, DOI 10.1016/0167-4889(83)90039-3; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; Marston F. A. O., 1987, DNA CLONING, P59; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MOHRI H, 1988, J BIOL CHEM, V263, P17901; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUGGERI ZM, 1981, BLOOD, V57, P1140; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; Sambrook J, 1989, MOL CLONING LABORATO; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SPORN LA, 1987, BLOOD, V69, P1531; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STEL HV, 1985, BLOOD, V65, P85; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946; WEISS HJ, 1986, BLOOD, V67, P322	27	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2821	2827						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679102				2022-12-27	WOS:A1993KK81500083
J	KAJITA, Y; NAKAYAMA, J; AIZAWA, M; ISHIKAWA, F				KAJITA, Y; NAKAYAMA, J; AIZAWA, M; ISHIKAWA, F			THE UUAG-SPECIFIC RNA-BINDING PROTEIN, HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN-D0 - COMMON MODULAR STRUCTURE AND BINDING-PROPERTIES OF THE 2XRBD-GLY-FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP-C-PROTEINS; CDNA CLONING; DROSOPHILA-MELANOGASTER; DNA; DOMAIN; GENE; ORGANIZATION; COMPLEXES; HOMOLOGY	Human cDNA clones encoding the UUAG-binding heterogeneous nuclear ribonucleoprotein (hnRNP) DO protein have been isolated and expressed. The protein has two RNA-binding domains (RBDs) in the middle part of the protein and an RGG box, a region rich in glycine and arginine residues, in the C-terminal part (''2xRBD-Gly'' structure), The hnRNP Al, A2/B1, and DO proteins, all possess common features of the 2xRBD-Gly structure and binding specificity toward RNA. Together, they form a subfamily of RED class RNA binding proteins (the 2xRBD-Gly family), One of the structural characteristics shared by these proteins is the presence of several isoforms presumably resulting from alternative splicing. Filter binding assays, using the recombinant hnRNP DO proteins that have one of the two REDs, indicated that one RED specifically binds to the UUAG sequence. However, two isoforms with or without a 19-amino acid insertion at the N-terminal RED showed different preference toward mutant RNA substrates. The 19-amino acid insertion is located in the N-terminal end of the first RED. This result establishes the participation of the N terminus of RED in determining the sequence specificity of binding, A similar insertion was also reported with the hnRNP A2/B1 proteins, Thus, it might be possible that this type of insertion with the 2xRBD-Gly type RNA binding proteins plays a role in ''fine tuning'' the specificity of RNA binding. RED is supposed to bind with RNA in general and sequence specific manners. These two discernible binding modes are proposed to be performed by different regions of the RED. A structural model of these two binding sites is presented.	TOKYO INST TECHNOL,DEPT BIOENGN,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology	KAJITA, Y (corresponding author), TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,4259 NAGATSUTA,YOKOHAMA,KANAGAWA 226,JAPAN.		Ishikawa, Fuyuki/AAU-4056-2021; Yanagida, Yasuko/F-6727-2014; Nakayama, Jun-ichi/C-6003-2011	Ishikawa, Fuyuki/0000-0002-5580-2305; Yanagida, Yasuko/0000-0002-7882-3651; Nakayama, Jun-ichi/0000-0002-5597-8239				BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EHRENMAN K, 1994, GENE, V149, P315, DOI 10.1016/0378-1119(94)90168-6; GARRETT DS, 1994, BIOCHEMISTRY-US, V33, P2852, DOI 10.1021/bi00176a015; GOOD PJ, 1993, NUCLEIC ACIDS RES, V21, P999, DOI 10.1093/nar/21.4.999; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KHAN FA, 1991, FEBS LETT, V290, P159, DOI 10.1016/0014-5793(91)81249-8; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; LAHIRI DK, 1986, NUCLEIC ACIDS RES, V14, P4077, DOI 10.1093/nar/14.10.4077; MATUNIS EL, 1992, J CELL BIOL, V116, P257, DOI 10.1083/jcb.116.2.257; MATUNIS MJ, 1992, J CELL BIOL, V116, P245, DOI 10.1083/jcb.116.2.245; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MAYEDA A, 1994, EMBO J, V13, P5483, DOI 10.1002/j.1460-2075.1994.tb06883.x; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; SHARP ZD, 1990, BIOCHIM BIOPHYS ACTA, V1048, P306, DOI 10.1016/0167-4781(90)90073-B; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SMIDT MP, 1994, BBA-GENE STRUCT EXPR, V1219, P115, DOI 10.1016/0167-4781(94)90253-4; SRIVASTAVA M, 1990, J BIOL CHEM, V265, P14922; TAY N, 1992, J VIROL, V66, P6841, DOI 10.1128/JVI.66.12.6841-6848.1992; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	41	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22167	22175		10.1074/jbc.270.38.22167	http://dx.doi.org/10.1074/jbc.270.38.22167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673195	hybrid			2022-12-27	WOS:A1995RW31400019
J	SUN, WJ; BARCHI, RL; COHEN, SA				SUN, WJ; BARCHI, RL; COHEN, SA			PROBING SODIUM-CHANNEL CYTOPLASMIC DOMAIN-STRUCTURE - EVIDENCE FOR THE INTERACTION OF THE RSKM1 AMINO AND CARBOXYL TERMINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; MONOCLONAL-ANTIBODIES; FUNCTIONAL RECONSTITUTION; TERTIARY STRUCTURE; LOCALIZATION; INFERENCES; SARCOLEMMA; SEQUENCE; SUBTYPES	Epitopes for monoclonal antibodies directed against the purified adult rat skeletal muscle sodium channel (rSkM1) were localized using channel proteolysis and fusion proteins, The interactions between these and other monoclonal antibodies with site-specific polyclonal antibodies were used to investigate the spatial relationships among rSkM1 cytoplasmic segments. Competition between antibodies for binding was performed using a solution-phase assay in which solubilized channel protein retains many of the biophysical characteristics of the rSkM1 protein in vivo. Our results support a model in which: 1) the amino terminus assumes a rigid structure having a fixed orientation with respect to other intracellular segments; 2) the interdomain 2-3 region is centrally located on the cytoplasmic surface of the channel, extends farther into the cytoplasm, and has an intermediate degree of flexibility; 3) the beginning of the amino terminus and end of the carboxyl terminus specifically interact with each other; and 4) domains 1 and 4 are adjacent. The sequences responsible for the interaction of the amino and carboxyl termini were identified by demonstrating the specific binding of a synthetic peptide encompassing the first 30 residues of the rSkM1 amino terminus to a fusion protein containing the rSkM1 carboxyl terminus.	PHILADELPHIA VET ADM MED CTR,DEPT MED,CARDIOL SECT 111C,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,INST NEUROL SCI,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania								BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BARCHI RL, 1980, P NATL ACAD SCI-BIOL, V77, P1306, DOI 10.1073/pnas.77.3.1306; BARCHI RL, 1984, J CELL BIOCHEM, V26, P135, DOI 10.1002/jcb.240260302; CASADEI JM, 1987, J NEUROCHEM, V48, P773, DOI 10.1111/j.1471-4159.1987.tb05584.x; CASADEI JM, 1984, P NATL ACAD SCI-BIOL, V81, P6227, DOI 10.1073/pnas.81.19.6227; COHEN SA, 1992, J MEMBRANE BIOL, V128, P219; GORDON RD, 1988, J NEUROSCI, V8, P3742; GORDON RD, 1987, P NATL ACAD SCI USA, V84, P308, DOI 10.1073/pnas.84.1.308; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAIMOVICH B, 1987, J NEUROSCI, V7, P2957; KRANER S, 1989, J BIOL CHEM, V264, P13273; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; SCHOTLAND DL, 1991, MUSCLE NERVE, V14, P142, DOI 10.1002/mus.880140209; SUN WJ, 1995, ANAL BIOCHEM, V226, P188, DOI 10.1006/abio.1995.1210; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; WEIGELE JB, 1982, P NATL ACAD SCI-BIOL, V79, P3651, DOI 10.1073/pnas.79.11.3651; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P215; ZWERLING SJ, 1991, J BIOL CHEM, V266, P4574	21	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22271	22276		10.1074/jbc.270.38.22271	http://dx.doi.org/10.1074/jbc.270.38.22271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673207	hybrid			2022-12-27	WOS:A1995RW31400034
J	KITAMURA, K; MAITI, A; NG, DHW; JOHNSON, P; MAIZEL, AL; TAKEDA, A				KITAMURA, K; MAITI, A; NG, DHW; JOHNSON, P; MAIZEL, AL; TAKEDA, A			CHARACTERIZATION OF THE INTERACTION BETWEEN CD45 AND CD45-AP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; HUMAN LYMPHOCYTES-T; TYROSINE PROTEIN-KINASE; PHOSPHOTYROSINE PHOSPHATASE; MONOCLONAL-ANTIBODIES; MEMBRANE-PROTEINS; MESSENGER-RNA; PHOSPHORYLATION; SURFACE; CDNA	CD45, a leukocyte-specific transmembrane protein tyrosine phosphatase, is required for critical signal transduction pathways in immune responses. To elucidate the molecular interactions of CD45 with other proteins involved in CD45-mediated signal transduction path ways, we have recently cloned a 30 kDa phosphorylated protein, CD45-AP, which specifically associates with CD45. Binding analysis employing several deleted or chimeric forms of CD45-AP and CD45 demonstrated that the potential transmembrane segment of CD45-AP bound to the transmembrane portion of CD45. CD45-AP was found in particulate fractions of lymphocytes along with CD45, indicating that it is likely to be a transmembrane protein. In addition, CD45-AP was resistant to proteolysis by tosylphenylalanyl chloromethyl ketone-treated trypsin applied to intact cells. This is consistent with the most likely membrane orientation of CD45-AP predicted from the amino acid sequence, that is, only a short amino-terminal segment of CD45-AP is extracellular. We propose that CD45-AP interacts with CD45 at the plasma membrane and that the bulk of CD45-AP located in the cytoplasm act as an adapter which directs the interaction between CD45 and other molecules involved in CD45-mediated signal transduction pathways.	BROWN UNIV,ROGER WILLIAMS MED CTR,DEPT PATHOL,PROVIDENCE,RI 02908; UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA	Brown University; Roger Williams Medical Center; University of British Columbia			Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653	NCI NIH HHS [CA 45148] Funding Source: Medline; NIGMS NIH HHS [GM 48188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA045148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL GM, 1993, J IMMUNOL, V151, P3646; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BROWN VK, 1994, J BIOL CHEM, V269, P17238; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; CIKES M, 1973, J NATL CANCER I, V50, P347, DOI 10.1093/jnci/50.2.347; DIANZANI U, 1992, EUR J IMMUNOL, V22, P365, DOI 10.1002/eji.1830220212; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGH S, 1987, BIOCHEM J, V243, P277, DOI 10.1042/bj2430277; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESLEY J, 1984, CELL IMMUNOL, V83, P14, DOI 10.1016/0008-8749(84)90220-X; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P2155; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PERSCHL A, 1995, J CELL SCI, V108, P1033; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; RANKIN BM, 1993, J IMMUNOL, V150, P605; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STUDIER FW, 1990, METHOD ENZYMOL, V185, P6; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085	44	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21151	21157		10.1074/jbc.270.36.21151	http://dx.doi.org/10.1074/jbc.270.36.21151			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673147	hybrid			2022-12-27	WOS:A1995RU05400046
J	SCHISCHMANOFF, PO; WINARDI, R; DISCHER, DE; PARRA, MK; BICKNESE, SE; WITKOWSKA, HE; CONBOY, JG; MOHANDAS, N				SCHISCHMANOFF, PO; WINARDI, R; DISCHER, DE; PARRA, MK; BICKNESE, SE; WITKOWSKA, HE; CONBOY, JG; MOHANDAS, N			DEFINING OF THE MINIMAL DOMAIN OF PROTEIN-4.1 INVOLVED IN SPECTRIN-ACTIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; GLUTATHIONE-S-TRANSFERASE; BETA-SPECTRIN; MEMBRANE SKELETON; ESCHERICHIA-COLI; PEPTIDE-FRAGMENTS; COMPLEX; PHOSPHORYLATION; ASSOCIATIONS; ISOFORMS	The spectrin-actin-binding domain of protein 4.1 is encoded by a 21-amino acid alternative exon and a 59-amino acid constitutive exon, To characterize the minimal domain active for interactions with spectrin and actin, we functionally characterized recombinant 4.1 peptides containing the 21-amino acid cassette plus varying portions of the 59-amino acid cassette (designated 21.10 to 21.59). Peptide 21.43 was shown fully functional in binary interactions with spectrin (by cosedimentation and coimmunoprecipitation experiments) and in ternary complex formation with spectrin and actin (by an in vitro gelation assay), Further truncation produced peptides incapable of binary interactions but fully competent for ternary complex formation (peptides 21.36 and 21.31), shorter peptides with reduced ternary complex activity and altered kinetics (21.26 and 0.59), and inactive peptides (21.20 and 21.10), Binding studies and circular dichroism experiments suggested that residues 37-43 of the constitutive domain were directly involved in spectrin binding. These data indicate that 4.1-spectrin binary interaction requires the 21-amino acid alternative cassette plus the 43 N-terminal residues of the constitutive domain, Moreover, the existence of two possible ternary complex assembly pathways is suggested: one initiated by 4.1-spectrin interactions, and a second by 4.1-actin interactions, The latter may require a putative actin binding motif within the 26 N-terminal residues of the constitutive domain.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; UNIV CALIF BERKELEY & SAN FRANCISCO,JOINT GRAD GRP BIOENGN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California San Francisco; University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland				discher, dennis/0000-0001-6163-2229	NCRR NIH HHS [RR 06506-01] Funding Source: Medline; NIDDK NIH HHS [DK 26263, DK 32094] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R37DK026263, R01DK026263] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER PS, 1990, EUR J BIOCHEM, V193, P827, DOI 10.1111/j.1432-1033.1990.tb19406.x; BRENNER SL, 1980, J BIOL CHEM, V255, P1670; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHASIS JA, 1989, BLOOD, V74, P1112, DOI 10.1182/blood.V74.3.1112.1112; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; COHEN CM, 1980, CELL, V21, P875, DOI 10.1016/0092-8674(80)90451-1; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P4488, DOI 10.1021/bi00314a039; COLEMAN TR, 1987, J CELL BIOL, V104, P519, DOI 10.1083/jcb.104.3.519; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DISCHER D, 1993, J BIOL CHEM, V268, P7186; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; ELZINGER M, 1983, P NATL ACAD SCI USA, V70, P2687; FOWLER V, 1980, J CELL BIOL, V85, P361, DOI 10.1083/jcb.85.2.361; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HORNE WC, 1993, BLOOD, V82, P2558; HUANG JP, 1993, J BIOL CHEM, V268, P3758; KAM Z, 1977, BIOCHEMISTRY-US, V16, P5568, DOI 10.1021/bi00644a028; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING E, 1988, J BIOL CHEM, V263, P2209; LIU SC, 1992, SEMIN HEMATOL, V29, P231; LORENZO F, 1994, J CLIN INVEST, V94, P1651, DOI 10.1172/JCI117508; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MAYS KT, 1992, BLOOD S1, V80, pA273; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; OHANIAN V, 1984, BIOCHEMISTRY-US, V23, P4416, DOI 10.1021/bi00314a027; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PFUHL M, 1994, EMBO J, V13, P1782, DOI 10.1002/j.1460-2075.1994.tb06446.x; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; REID ME, 1990, BLOOD, V75, P2229; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; TANG TK, 1990, J CELL BIOL, V110, P617, DOI 10.1083/jcb.110.3.617; TYLER JM, 1980, J BIOL CHEM, V255, P7034; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WOLFE LC, 1982, NEW ENGL J MED, V307, P1367, DOI 10.1056/NEJM198211253072203; WU CSC, 1983, BIOCHIM BIOPHYS ACTA, V746, P72, DOI 10.1016/0167-4838(83)90012-2	52	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21243	21250		10.1074/jbc.270.36.21243	http://dx.doi.org/10.1074/jbc.270.36.21243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673158	hybrid			2022-12-27	WOS:A1995RU05400058
J	BARTFELD, NS; PASQUALE, EB; GELTOSKY, JE; LANGUINO, LR				BARTFELD, NS; PASQUALE, EB; GELTOSKY, JE; LANGUINO, LR			THE ALPHA-V-BETA-3 INTEGRIN ASSOCIATES WITH A 190-KDA PROTEIN THAT IS PHOSPHORYLATED ON TYROSINE IN RESPONSE TO PLATELET-DERIVED GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; FIBRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; CELL-ADHESION; EMBRYO FIBROBLASTS; LAMININ RECEPTOR; KINASE-ACTIVITY; BETA-SUBUNIT; STEM-CELLS; PHOSPHOTYROSINE	Integrins are cell surface heterodimers that mediate cell adhesion to the extracellular matrix. We show that in mouse 3T3 fibroblasts the alpha(v)beta3 integrin (vitronectin receptor) coprecipitates with a tyrosine-phosphorylated 190-kDa protein, as detected by antibodies to phosphotyrosine. Three different antibodies to the vitronectin receptor, all of which precipitate the alpha/beta complex, coprecipitated a 190-kDa protein. The three antibodies were raised against the purified placental vitronectin receptor, the platelet alpha(IIb)beta3 integrin, and the cytoplasmic domain of the alpha(v) subunit. The association was specific for the vitronectin receptor, since an antibody to the alpha5beta1 integrin (fibronectin receptor) did not coprecipitate any tyrosine-phosphorylated protein. The phosphorylation of the 190-kDa protein was observed only following cell activation by platelet-derived growth factor, which is known to stimulate tyrosine kinase activity and to modulate cell adhesion. Antibodies raised against the platelet-derived growth factor alpha and beta receptors (M(r) = 170,000 and 190,000, respectively) did not recognize the 190-kDa, integrin-associated phosphorylated protein. Occupancy of the vitronectin receptor by one of its ligands, vitronectin, resulted in an increased amount of tyrosine phosphorylation of the 190-kDa protein. Our data suggest that the association of tyrosine-phosphorylated proteins with integrins may play an important role in growth factor-mediated modulation of cell adhesion.	RW JOHNSON PHARMACEUT RES INST, 3535 GEN ATOM CT, SUITE 100, SAN DIEGO, CA 92121 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute				Languino, Lucia/0000-0001-9011-7031				BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; COSSETTE LJ, 1992, MOL BIOL CELL, V3, pA147; DAHL SC, 1989, J CELL BIOL, V108, P183, DOI 10.1083/jcb.108.1.183; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; FALCIONI R, 1989, MOL CARCINOGEN, V2, P361, DOI 10.1002/mc.2940020611; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PLOW EF, 1986, BIOCH PLATELETS, P226; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; [No title captured]	49	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17270	17276						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688723				2022-12-27	WOS:A1993LQ98800060
J	KLATT, P; SCHMIDT, K; URAY, G; MAYER, B				KLATT, P; SCHMIDT, K; URAY, G; MAYER, B			MULTIPLE CATALYTIC FUNCTIONS OF BRAIN NITRIC-OXIDE SYNTHASE - BIOCHEMICAL-CHARACTERIZATION, COFACTOR-REQUIREMENT, AND THE ROLE OF N(G.W)-HYDROXY-L-ARGININE AS AN INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; HYDROXY-L-ARGININE; RELAXING FACTOR; MACROPHAGE OXIDATION; PORCINE CEREBELLUM; GUANYLYL CYCLASE; PURIFICATION; TETRAHYDROBIOPTERIN; BIOSYNTHESIS; NITRATE	Brain NO (nitric oxide) synthase contains FAD, FMN, heme, and tetrahydrobiopterin as prosthetic groups and represents a multi-functional oxidoreductase catalyzing oxidation of L-arginine to NO and L-citrulline, formation of H2O2, and reduction of cytochrome c. We show that substrate analogues and inhibitors interacting with the heme block both the reductive activation of oxygen and the oxidation of L-arginine without affecting cytochrome c reduction. We further demonstrate that N(omega)-hydroxy-L-arginine is an intermediate in enzymatic NO synthesis. The ratio of L-citrulline to free N(omega)-hydroxy-L-arginine was greater-than-or-equal-to 50 under various assay conditions, but could markedly be reduced down to 4 by redox active inhibitors. Brain NO synthase is shown to utilize both L-arginine and N(omega)-hydroxy-L-arginine for the formation of stoichiometric amounts of NO and L-citrulline. Tetrahydrobiopterin equally enhanced reaction rates from either substrate (approximately 5-fold), but its rate accelerating effects were only observed at NADPH concentrations greater-than-or-equal-to 3 muM. In the absence of L-arginine or tetrahydrobiopterin, brain NO synthase catalyzes the generation of H2O2. We now show that, in contrast to L-arginine, N(omega)-hydroxy-L-arginine fully blocked H2O2 formation in the absence of exogenous tetrahydrobiopterin, indicating that N(omega)-hydroxy-L-arginine is a direct inhibitor of enzymatic oxygen activation. Based on these data, a hypothetical mechanism of enzymatic NO formation is discussed.	GRAZ UNIV,INST PHARMACOL & TOXIKOL,UNIV PL 2,A-8010 GRAZ,AUSTRIA; GRAZ UNIV,INST ORGAN CHEM,A-8010 GRAZ,AUSTRIA	University of Graz; University of Graz			Mayer, Bernd/B-9391-2008	Mayer, Bernd/0000-0002-2921-3494				ATKINS WM, 1988, BIOCHEMISTRY-US, V27, P1610, DOI 10.1021/bi00405a033; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; DEMONTELLANO PRO, 1989, TRENDS PHARMACOL SCI, V10, P654; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; EVANS T, 1992, P NATL ACAD SCI USA, V89, P5361, DOI 10.1073/pnas.89.12.5361; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KAUFMAN S, 1987, ENZYMES, P217; KLATT P, 1992, FEBS LETT, V305, P160, DOI 10.1016/0014-5793(92)80886-L; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LAMBERT LE, 1991, LIFE SCI, V48, P69, DOI 10.1016/0024-3205(91)90426-C; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1991, J CARDIOVASC PHARM, V17, pS46, DOI 10.1097/00005344-199117003-00009; MAYER B, 1992, J NEUROCHEM, V59, P2024; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULSCH A, 1990, N-S ARCH PHARMACOL, V341, P143; MURPHY ME, 1991, J BIOL CHEM, V266, P19378; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POU S, 1992, J BIOL CHEM, V267, P24173; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V154, P213, DOI 10.1016/0014-2999(88)90101-X; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SUNDQVIST T, 1991, J CELL PHYSIOL, V148, P152, DOI 10.1002/jcp.1041480118; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; WALLACE GC, 1991, J MED CHEM, V34, P1746, DOI 10.1021/jm00109a032; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YUI Y, 1991, J BIOL CHEM, V266, P12544; ZEMBOWICZ A, 1991, P NATL ACAD SCI USA, V88, P11172, DOI 10.1073/pnas.88.24.11172	56	259	268	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14781	14787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686905				2022-12-27	WOS:A1993LL75900040
J	VITALE, N; MUKAI, H; ROUOT, B; THIERSE, D; AUNIS, D; BADER, MF				VITALE, N; MUKAI, H; ROUOT, B; THIERSE, D; AUNIS, D; BADER, MF			EXOCYTOSIS IN CHROMAFFIN CELLS - POSSIBLE INVOLVEMENT OF THE HETEROTRIMERIC GTP-BINDING PROTEIN-G(O)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDES; WASP VENOM; MAST-CELLS; KINASE-C; CATECHOLAMINE RELEASE; ACTIN-FILAMENTS; SECRETORY-CELLS; PEPTIDE TOXIN; ALPHA-SUBUNIT; MASTOPARAN	The use of non-hydrolyzable analogues of GTP in permeabilized secretory cells suggests that guanine nucleotide-binding regulatory proteins (G proteins) may be involved in regulated exocytosis. Because GTP analogues are known to modulate both monomeric low molecular mass G proteins and heterotrimeric G proteins, we have examined the effect of mastoparan, an activator of heterotrimeric G proteins, on secretion from intact and permeabilized chromaffin cells. In intact cells, mastoparan inhibited catecholamine secretion evoked by nicotine but had no effect on release induced by other secretagogues. In permeabilized cells, mastoparan inhibited calcium-dependent secretion providing that the pores created in the plasma membrane allow the penetration of the peptide into the cytoplasm. These results indicate that mastoparan blocks the exocytotic machinery through an intracellular target protein that may not be located just beneath the plasma membrane. Accordingly, mastoparan was able to stimulate G proteins associated with purified chromaffin granule membranes, in a range of concentration and Mg2+ requirement that was similar to its inhibitory effect on secretion. Mas 17, a mastoparan analogue inactive on purified G proteins, neither modified catecholamine secretion nor stimulated chromaffin granule G proteins. The substance P-related peptide, GPAnt-2, known to antagonize the effects of mastoparan on G(o), blocked both the inhibitory effect of mastoparan on secretion and the mastoparan-stimulated GTPase activity in chromaffin granule membranes. Moreover, specific antibodies raised against the carboxyl terminus of G(oalpha) reversed in a dose-dependent manner the inhibition by mastoparan on catecholamine release and the stimulation by mastoparan of chromaffin granule-associated G proteins. These results suggest that the secretory machinery in chromaffin cells can be blocked by activating a G(o) protein. Consistent with this finding, two other known activators of heterotrimeric G proteins, aluminum fluoride and benzalkonium chloride, inhibited calcium-evoked catecholamine secretion in streptolysin O-permeabilized chromaffin cells. We conclude that an inhibitory G(o) protein, possibly located on the membrane of secretory granules, is involved in the final stages of exocytosis in chromaffin cells.	INSERM,U338,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE; UNIV MONTPELLIER 2,INSERM,U65,F-34095 MONTPELLIER 05,FRANCE; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Dominique, Aunis/W-1419-2019; Bader, Marie-France/O-2098-2016; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; ATHAYDE CM, 1990, BIOCHEM SOC T, V18, P452, DOI 10.1042/bst0180452; AUNIS D, 1988, J EXP BIOL, V139, P253; BADER MF, 1986, J BIOL CHEM, V261, P5777; BADER MF, 1986, J CELL BIOL, V102, P636, DOI 10.1083/jcb.102.2.636; BADER MF, 1989, J BIOL CHEM, V264, P16426; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARNETTE MS, 1983, BIOCHEM PHARMACOL, V32, P2929, DOI 10.1016/0006-2952(83)90398-2; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BOKSA P, 1984, J NEUROCHEM, V42, P618, DOI 10.1111/j.1471-4159.1984.tb02727.x; BON S, 1990, EUR J BIOCHEM, V190, P221, DOI 10.1111/j.1432-1033.1990.tb15567.x; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BRUNING A, 1992, J BIOL CHEM, V267, P5052; BUEB JL, 1990, MOL PHARMACOL, V38, P816; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HIRAI Y, 1979, CHEM PHARM BULL, V27, P1942; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KNIGHT DE, 1985, FEBS LETT, V189, P345, DOI 10.1016/0014-5793(85)81053-X; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; LUINI A, 1990, J NEUROCHEM, V54, P30, DOI 10.1111/j.1471-4159.1990.tb13279.x; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MUKAI H, 1987, AM J PHYSIOL, V252, pE765, DOI 10.1152/ajpendo.1987.252.6.E765; MUKAI H, 1992, J BIOL CHEM, V267, P16237; NEYLON CB, 1992, J BIOL CHEM, V267, P7295; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; OETTING M, 1986, FEBS LETT, V208, P99, DOI 10.1016/0014-5793(86)81540-X; OHARAIMAIZUMI M, 1992, J NEUROCHEM, V58, P2275, DOI 10.1111/j.1471-4159.1992.tb10974.x; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROUOT B, 1989, BIOCHEM J, V260, P307, DOI 10.1042/bj2600307; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Sillen L.G., 1971, STABILITY CONSTANTS; SIMON JP, 1989, BIOCHEM J, V260, P915, DOI 10.1042/bj2600915; SONTAG JM, 1992, EUR J NEUROSCI, V4, P98, DOI 10.1111/j.1460-9568.1992.tb00112.x; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; SONTAG JM, 1991, BIOCHEM J, V274, P339, DOI 10.1042/bj2740339; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TOHKIN M, 1990, FEBS LETT, V260, P179, DOI 10.1016/0014-5793(90)80098-4; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WILSON SP, 1989, FEBS LETT, V247, P239, DOI 10.1016/0014-5793(89)81343-2; WU YN, 1992, J BIOL CHEM, V267, P8396; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4	63	128	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14715	14723						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686903				2022-12-27	WOS:A1993LL75900031
J	BRISTOW, J; GITELMAN, SE; TEE, MK; STAELS, B; MILLER, WL				BRISTOW, J; GITELMAN, SE; TEE, MK; STAELS, B; MILLER, WL			ABUNDANT ADRENAL-SPECIFIC TRANSCRIPTION OF THE HUMAN P450C21A PSEUDOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE GENES; MOLECULAR CHARACTERIZATION; POINT MUTATIONS; HYPERPLASIA; DEFICIENCY; FAMILY; HAPLOTYPES; CONVERSION; EVOLUTION; REARRANGEMENTS	Human adrenal steroid 21-hydroxylase (P450c21) is encoded by the CYP21A1 (21B) gene located in the class III region of the HLA locus. A tandemly duplicated gene designated CYP21A1P (21A), which lies 30 kilobases upstream, contains several point mutations and an 8-base pair deletion so that it cannot encode P450c21 protein; as a result, it is generally considered to be a pseudogene. We previously showed that two additional genes, XA and XB, lie on the opposite strand of DNA overlapping the 3'-ends of the 21A and 21B genes. We have now identified a third pair of duplicated overlapping genes in this locus, termed YA and YB, whose transcriptional orientation is the same as 21A and 21B and opposite to XA and XB. YA transcripts use the 21A promoter, have 5'-ends that are similar to 21B mRNA, and have approximately 10-20% of the abundance of 21B transcripts, but have unique 3'-ends. The YA gene encodes a 7.5-kilobase RNA that overlaps XA completely and a 3.0-kilobase RNA that excludes most of XA. The YB gene appears to be similar in size and organization to YA. The YA and YB genes extend beyond the limit of the duplication in this locus; hence, their cDNAs are distinguishable by differences in their 3'-sequences. YA and YB transcripts are expressed only in the fetal and adult adrenal glands, but their cDNAs do not contain a long open reading frame. Although the function of these genes is not yet clear, the complex genetic organization of three overlapping genes (21/X/Y) appears to be unique among higher eukaryotes. As YA transcription is initiated by the 21A 5'-flanking DNA and includes 21A sequences, the designation of 21A as a ''pseudogene'' merits reconsideration.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BRISTOW, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA.		Miller, Walter L/J-3696-2012; Staels, Bart/N-9497-2016	Staels, Bart/0000-0002-3784-1503	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922, R01DK042154] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42154, T32-DK07171, DK-37922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; DONOHOUE PA, 1986, J CLIN ENDOCR METAB, V62, P995, DOI 10.1210/jcem-62-5-995; GILES CM, 1987, HUM GENET, V77, P359, DOI 10.1007/BF00291427; GITELMAN SE, 1990, PEDIATR RES, V27, pA76; GITELMAN SE, 1992, MOL CELL BIOL, V12, P2124, DOI 10.1128/MCB.12.5.2124; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HIGASHI Y, 1988, AM J HUM GENET, V42, P17; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HILDEBRANDT M, 1992, CELL, V69, P197, DOI 10.1016/0092-8674(92)90130-5; HOOD L, 1975, ANNU REV GENET, V9, P305, DOI 10.1146/annurev.ge.09.120175.001513; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIEBHABER SA, 1981, NATURE, V290, P26, DOI 10.1038/290026a0; MATTESON KJ, 1987, P NATL ACAD SCI USA, V84, P5858, DOI 10.1073/pnas.84.16.5858; McLean RH, 1988, GENOMICS, V2, P76, DOI 10.1016/0888-7543(88)90111-5; MELLON SH, 1989, J CLIN INVEST, V84, P1497, DOI 10.1172/JCI114325; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; Morel Y, 1991, Adv Hum Genet, V20, P1; MOREL Y, 1989, J CLIN INVEST, V83, P527, DOI 10.1172/JCI113914; MOREL Y, 1989, J CLIN ENDOCR METAB, V68, P592, DOI 10.1210/jcem-68-3-592; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; PALSDOTTIR A, 1987, HUM GENET, V76, P220; PANG S, 1988, PEDIATRICS, V81, P866; RODRIGUES NR, 1987, EMBO J, V6, P1653, DOI 10.1002/j.1460-2075.1987.tb02414.x; SOLISH SB, 1989, J CLIN ENDOCR METAB, V69, P1148, DOI 10.1210/jcem-69-6-1148; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; XUN X, 1990, P NATL ACAD SCI USA, V87, P2097, DOI 10.1073/pnas.87.6.2097; YU CY, 1987, IMMUNOGENETICS, V25, P383	36	76	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12919	12924						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685353				2022-12-27	WOS:A1993LG65800099
J	FRIEDMAN, JE; YUN, JS; PATEL, YM; MCGRANE, MM; HANSON, RW				FRIEDMAN, JE; YUN, JS; PATEL, YM; MCGRANE, MM; HANSON, RW			GLUCOCORTICOIDS REGULATE THE INDUCTION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP) GENE-TRANSCRIPTION DURING DIABETES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; MESSENGER-RNA; CYCLIC-AMP; RAT-LIVER; MULTIHORMONAL REGULATION; PROMOTER ELEMENTS; TRANSGENIC MICE; GLUCOSE OUTPUT; INSULIN; CAMP	The hormonal regulation of transcription of the phosphoenolpyruvate carboxykinase (GTP) (4.1.1.32) (PEPCK) gene during diabetes was studied using transgenic mice containing a chimeric gene consisting of segments of the PEPCK promoter (-2000/+73, -460/+73, -355/+73) linked to bovine growth hormone (bGH) reporter gene. The effect of diabetes and insulin on transgenic mice containing a mutation in cAMP regulatory sequences at -90/-82 and -250/-234 was also studied. In addition, we analyzed the transcriptional response of the PEPCK gene to adrenalectomy, the administration of glucocorticoids, and alterations in dietary protein and carbohydrate. Our results indicate that deletion of the insulin regulatory sequence of the PEPCK promoter did not affect dietary control of PEPCK gene expression. However, glucocorticoids and the glucocorticoid regulatory unit appear to be essential for induction of PEPCK gene transcription by diabetes. By contrast, mutation of cAMP regulatory elements of the PEPCK promoter did not limit induction of PEPCK transcription by diabetes, nor did it affect negative regulation of transcription by insulin. These results provide evidence for the interaction of insulin and glucocorticoid regulatory elements in the control of PEPCK gene transcription and suggest an important role of glucocorticoids as a gluconeogenic activator during diabetes.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,ATHENS,OH 45701	Case Western Reserve University; University System of Ohio; Ohio University	FRIEDMAN, JE (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,PEW CTR MOLEC NUTR,CLEVELAND,OH 44106, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021859, F32DK008477, R37DK021859] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-F3208477, DK-21859, DK-2441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1987, DIABETES, V36, P274, DOI 10.2337/diabetes.36.3.274; BEALE EG, 1986, DIABETES, V35, P546, DOI 10.2337/diabetes.35.5.546; CHANG AY, 1970, DIABETOLOGIA, V6, P274, DOI 10.1007/BF01212238; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSOLI A, 1990, ANN MED, V22, P191, DOI 10.3109/07853899009147268; DEFRONZO R, 1982, DIABETOLOGIA, V23, P3113; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; EXTON JH, 1979, GLUCOCORTICOID HORMO, P517; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMANN N, 1967, BIOCHEM BIOPH RES CO, V29, P113, DOI 10.1016/0006-291X(67)90550-5; GIEBELHAUS DH, 1985, DEV BIOL, V107, P407, DOI 10.1016/0012-1606(85)90322-7; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GUNN JM, 1975, BIOCHEM J, V150, P195, DOI 10.1042/bj1500195; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HELMS SR, 1990, NUCLEIC ACIDS RES, V18, P255, DOI 10.1093/nar/18.2.255; HOD Y, 1988, J BIOL CHEM, V263, P7747; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; KUMARASIRI MH, 1985, J BIOL CHEM, V260, P4529; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU JS, 1991, J BIOL CHEM, V266, P19095; Long CNH, 1936, J EXP MED, V63, P465, DOI 10.1084/jem.63.4.465; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; NELSON K, 1980, J BIOL CHEM, V255, P8509; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PERET J, 1981, J NUTR, V111, P1173, DOI 10.1093/jn/111.7.1173; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASAKI K, 1988, P NATL ACAD SCI USA, V85, P2954, DOI 10.1073/pnas.85.9.2954; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHAFRIR E, 1988, FRONTIERS DIABETES R, P304; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; UNGER RH, 1970, J CLIN INVEST, V49, P837, DOI 10.1172/JCI106297; VENEZIALE CM, 1983, J BIOL CHEM, V257, P14257	45	111	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12952	12957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685354				2022-12-27	WOS:A1993LG65800104
J	KNUDSON, CM; STANG, KK; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP				KNUDSON, CM; STANG, KK; MOOMAW, CR; SLAUGHTER, CA; CAMPBELL, KP			PRIMARY STRUCTURE AND TOPOLOGICAL ANALYSIS OF A SKELETAL MUSCLE-SPECIFIC JUNCTIONAL SARCOPLASMIC-RETICULUM GLYCOPROTEIN (TRIADIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; H-3 RYANODINE RECEPTOR; CA-2+ RELEASE CHANNEL; AMINO-ACID SEQUENCE; DIHYDROPYRIDINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; MESSENGER-RNAS; FOOT PROTEIN; IDENTIFICATION; CALSEQUESTRIN	The primary amino acid sequence for a highly abundant junctional sarcoplasmic reticulum glycoprotein (triadin) has been deduced from the cDNA sequence. Based on both biochemical analysis and the predicted amino acid sequence we suggest that this protein is an intrinsic membrane glycoprotein containing a single transmembrane domain that separates the protein into cytoplasmic and luminal domains. The cytoplasmic domain is proposed to contain the amino-terminal 47 amino acids. The remainder of the protein including the carboxyl terminus is proposed to be found within the lumen of the sarcoplasmic reticulum and contains an extremely high concentration of basic residues. Protease analysis of intact triads was consistent with the topological predictions. Western and Northern blots suggest that the protein is specifically expressed in skeletal muscle and not cardiac muscle or brain. The abundance and localization of this protein suggest that it plays an important regulatory or structural role in excitation-contraction coupling in skeletal muscle.	UNIV IOWA, COLL MED, HHMI, DEPT PHYSIOL & BIOPHYS, 400A EMRB, IOWA CITY, IA 52242 USA; HOWARD HUGHES MED INST, BIOPOLYMER FACIL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute				Campbell, Kevin/0000-0003-2066-5889; Knudson, Charles Michael/0000-0003-3964-5466	NHLBI NIH HHS [HL39265, HL14388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039265] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CAMPBELL KP, 1984, J BIOL CHEM, V259, P5384; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CHADWICK CC, 1988, J BIOL CHEM, V263, P10872; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FILL M, 1989, ANN NY ACAD SCI, V560, P155, DOI 10.1111/j.1749-6632.1989.tb24092.x; FLIEGEL L, 1989, FEBS LETT, V242, P297, DOI 10.1016/0014-5793(89)80488-0; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1989, J BIOL CHEM, V264, P10795; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MITCHELL RD, 1983, J BIOL CHEM, V258, P9867; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP AH, 1987, J BIOL CHEM, V262, P12309; SPIECKER W, 1979, NATURE, V280, P158, DOI 10.1038/280158a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG AS, 1983, METHOD ENZYMOL, V93, P12; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737; ZAIDI NF, 1989, J BIOL CHEM, V264	39	128	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12646	12654						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685347				2022-12-27	WOS:A1993LG65800063
J	YAMAZAKI, T; TOBE, K; HOH, E; MAEMURA, K; KAIDA, T; KOMURO, I; TAMEMOTO, H; KADOWAKI, T; NAGAI, R; YAZAKI, Y				YAMAZAKI, T; TOBE, K; HOH, E; MAEMURA, K; KAIDA, T; KOMURO, I; TAMEMOTO, H; KADOWAKI, T; NAGAI, R; YAZAKI, Y			MECHANICAL LOADING ACTIVATES MITOGEN-ACTIVATED PROTEIN-KINASE AND S6 PEPTIDE KINASE IN CULTURED RAT CARDIAC MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LEFT-VENTRICULAR HYPERTROPHY; SERINE THREONINE KINASES; CELL-CYCLE CONTROL; MAP KINASE; PROGNOSTIC IMPLICATIONS; PHOSPHORYLATION SITES; HYPERTENSIVE PATIENTS; FIBROBLASTIC CELLS; PRESSURE OVERLOAD	The molecular mechanisms by which overloaded cardiac myocytes increase the cell size (hypertrophy) remain unknown. We have previously shown that mechanical loading increased the protein synthesis and the expression of proto-oncogene c-fos mRNA (Komuro, I., Kaida, T., Shibazaki, Y., Kurabayashi, M., Katoh, Y. Hoh, E., Takaku, F., and Yazaki, Y. (1990) J. Biol. Chem. 265, 3595-3598; Komuro, I., Katoh, Y., Kaida, T., Shibazaki, Y., Kurabayashi, M., Hoh, E., Takaku, F., and Yazaki, Y. (1991) J. Biol. Chem. 266, 1265-1268). It has been known that both mitogen-activated protein (MAP) kinase and S6 kinase can be activated by many kinds of growth factors. To clarify whether MAP kinase(s) and S6 kinase(s) are associated with the intracellular signaling of cardiac hypertrophy induced by mechanical loading, we cultured neonatal rat cardiac myocytes in deformable dishes and imposed an in vitro mechanical loading by stretching the adherent myocytes. In this study, we demonstrated that 1) myocyte stretching maximally activated a kinase activity toward myelin basic protein (MBP) at 10 min after stretching, and the kinase activity returned to the control level at 30 min after stretching; 2) kinase assays in MBP-containing gel, after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, revealed that stretch-induced MBP kinase activity mainly migrated at 42 kDa in the immunoprecipitated fraction of anti-MAP kinase antibody, suggesting that the stretching mainly increased the 42-kDa MAP kinase activity in cardiac myocytes; 3) phosphorylation of MAP kinase was induced after stretching cardiac myocytes; 4) when protein kinase C was depleted by preincubating myocytes with 100 nm 12-O-tetradecanoyl-phorbol-13-acetate for 24 h or 2 nm staurosporin for 30 min, stretch-induced MBP kinase activity was decreased by approximately 60-70% as compared with the kinase activity in myocytes without protein kinase C depletion; 5) although the receptor tyrosine kinases were depleted by preincubating myocytes with 50 muM tyrphostin or 20 muM genistein for 30 min, there was no change in the stretch-induced MBP kinase activity; 6) stretch-induced MBP kinase activity was partially dependent on transsarcolemmal influx of Ca2+; 7) myocyte stretching also increased S6 peptide (RRLSSLRA) kinase activity in the anti-S6 kinase II antibody immunoprecipitates. From these results, we conclude that myocyte stretching increases the activities of MAP kinase and S6 peptide kinase, which may play an important role in the induction of the specific genes and the increase in the protein synthesis.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; AHN NG, 1990, J BIOL CHEM, V265, P11495; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anderson K, 1990, AM HEART J, V121, P293; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CODY RJ, 1978, CLIN SCI MOL MED, V55, P453, DOI 10.1042/cs0550453; DEVEREUX RB, 1987, MED CLIN N AM, V71, P813, DOI 10.1016/S0025-7125(16)30810-0; FAGARD R, 1980, AM J CARDIOL, V46, P295, DOI 10.1016/0002-9149(80)90074-0; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRADI AM, 1989, AM J CARDIOL, V63, P1093; GREGORY JS, 1989, J BIOL CHEM, V266, P22003; GUENNEC JYL, 1991, Q J EXP PHYSL, V76, P975; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1987, J CLIN INVEST, V79, P971; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KASAKO H, 1992, EMBO J, V11, P2903; KOMURO I, 1988, CIRC RES, V62, P1075, DOI 10.1161/01.RES.62.6.1075; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KURABAYASHI M, 1990, J BIOL CHEM, V265, P19271; LAVIE CJ, 1991, DRUGS, V42, P945, DOI 10.2165/00003495-199142060-00004; LEENEN FHH, 1987, AM J MED, V82, P969, DOI 10.1016/0002-9343(87)90160-4; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LYALL RM, 1989, J BIOL CHEM, V264, P14503; NAGAI R, 1988, AM J PHYSIOL, V255, pH325, DOI 10.1152/ajpheart.1988.255.2.H325; NAKASHIMA Y, 1984, AM J CARDIOL, V53, P1044, DOI 10.1016/0002-9149(84)90634-9; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIGURDSON W, 1992, AM J PHYSIOL, V262, pH1110, DOI 10.1152/ajpheart.1992.262.4.H1110; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; TANAKA H, 1991, JPN CIRC J, V55, P1233, DOI 10.1253/jcj.55.1233; TOBE K, 1992, J BIOL CHEM, V267, P21089; TOBE K, 1991, J BIOL CHEM, V266, P24793; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VOGT PK, 1988, ONCOGENE, V3, P3; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YAMAMOTOHONDA R, 1990, J BIOL CHEM, V265, P14777; ZAK R, 1974, CIRC RES, V35, P17	65	257	260	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12069	12076						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685031				2022-12-27	WOS:A1993LF28400091
J	YOSHINO, H; WAKITA, M; IZUMI, Y				YOSHINO, H; WAKITA, M; IZUMI, Y			CALCIUM-DEPENDENT CHANGES IN STRUCTURE OF CALMODULIN WITH SUBSTANCE-P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; LIGHT-CHAIN KINASE; TROPONIN-C; CONFORMATIONAL CHANGE; SKELETAL-MUSCLE; BINDING DOMAIN; CENTRAL HELIX; MELITTIN; MASTOPARAN; PEPTIDES	Solution x-ray scattering using synchrotron radiation as an x-ray source has been used to study the solution structure of calmodulin complexed with substance P, a undecapeptide neurotransmitter. The x-ray data indicate that the complex has a compact globular structure, the formation of which is dependent upon, the binding of Ca2+ to calmodulin. In the Ca2+-saturated condition, the radius of gyration of complexed calmodulin was 4.2 angstrom smaller than that of uncomplexed calmodulin. The Ca2+-dependent change in radius of gyration of calmodulin with substance P is complete by the third and fourth Ca2+ binding. The behavior of the Guinier plot at small-to-moderate angles for uncomplexed calmodulin corresponds to a dumbbell shape. The Guinier plot for complexed calmodulin, however, corresponds to a non-dumbbell shape. The susceptibility of calmodulin to proteolytic attack with trypsin was used to examine the nature of the calmodulin complexed with substance P. In the presence of equimolar substance P, the first and second Ca2+ binding to calmodulin was enough to form a trypsin-resistant complex. These biochemical and x-ray data suggest that the binding of substance P to calmodulin is completed when the C-terminal half of calmodulin is occupied by Ca2+, while a significant structural change of calmodulin in the complex is still induced by successive Ca2+ occupancy on the N-terminal half of this molecule.	HOKKAIDO UNIV,FAC SCI,DEPT POLYMER SCI,SAPPORO,HOKKAIDO 060,JAPAN; YAMAGATA UNIV,FAC ENGN,MACROMOLEC RES LAB,YONEZAWA,YAMAGATA 992,JAPAN	Hokkaido University; Yamagata University	YOSHINO, H (corresponding author), SAPPORO MED COLL,DEPT CHEM,S-1,W-17,SAPPORO,HOKKAIDO 060,JAPAN.							BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; CADAY CG, 1986, BIOCHEM BIOPH RES CO, V135, P419, DOI 10.1016/0006-291X(86)90011-2; CHASSAING G, 1986, EUR J BIOCHEM, V154, P77, DOI 10.1111/j.1432-1033.1986.tb09361.x; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COX JA, 1985, J BIOL CHEM, V260, P2527; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; FUJISAWA T, 1987, J APPL CRYSTALLOGR, V20, P349, DOI 10.1107/S0021889887086497; GIEDROC DP, 1983, BIOCHEMISTRY-US, V22, P5584, DOI 10.1021/bi00293a020; Guinier A., 1955, SMALL ANGLE SCATTERI; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; INAGAKI F, 1989, BIOCHEMISTRY-US, V28, P5985, DOI 10.1021/bi00440a040; IZUMI Y, 1992, BIOCHEMISTRY-US, V31, P12266, DOI 10.1021/bi00163a041; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MALENCIK DA, 1983, BIOCHEMISTRY-US, V22, P1995, DOI 10.1021/bi00277a040; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P3480, DOI 10.1021/bi00257a035; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MINOWA O, 1988, J BIOCHEM-TOKYO, V103, P531, DOI 10.1093/oxfordjournals.jbchem.a122303; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; RAO U, 1992, PROTEINS, V14, P127, DOI 10.1002/prot.340140202; SASAKI T, 1992, J BIOL CHEM, V267, P21518; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SEATON BA, 1985, BIOCHEMISTRY-US, V24, P6740, DOI 10.1021/bi00345a002; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; TREWHELLA J, 1992, CELL CALCIUM, V13, P377, DOI 10.1016/0143-4160(92)90051-S; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; WALSH M, 1977, J BIOL CHEM, V252, P7440; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869; YOSHINO H, 1989, J BIOL CHEM, V264, P19706	45	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12123	12128						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685032				2022-12-27	WOS:A1993LF28400098
J	KJELDSEN, L; JOHNSEN, AH; SENGELOV, H; BORREGAARD, N				KJELDSEN, L; JOHNSEN, AH; SENGELOV, H; BORREGAARD, N			ISOLATION AND PRIMARY STRUCTURE OF NGAL, A NOVEL PROTEIN ASSOCIATED WITH HUMAN NEUTROPHIL GELATINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR; IV COLLAGENASE; LIPOCALIN; MEMBER; FAMILY; PURIFICATION; EXPRESSION; CLEAVAGE	A 25-kDa protein was found to be associated with purified human neutrophil gelatinase. Polyclonal antibodies raised against gelatinase not only recognized gelatinase but also this 25-kDa protein. Specific antibodies against the 25-kDa protein were obtained by affinity purification of the gelatinase antibodies. Immunoblotting and immunoprecipitation studies demonstrated the 135-kDa form of gelatinase to be a complex of 92-kDa gelatinase and the 25-kDa protein, and the 220-kDa form was demonstrated to be a homodimer of the 92-kDa protein, thus explaining the 220-, 135-, and 92-kDa forms characteristic of neutrophil gelatinase. The 25-kDa protein was purified to apparent homogeneity from exocytosed material from phorbol myristate acetate-stimulated neutrophils. The primary structure of the 25-kDa protein was determined as a 178-residue protein. It was susceptible to treatment with N-glycanase, and one N-glycosylation site was identified. The sequence did not match any known human protein, but showed a high degree of similarity with the deduced sequences of rat alpha2-microglobulin-related protein and the mouse protein 24p3. It is thus a new member of the lipocalin family. The function of the 25-kDa protein, named neutrophil gelatinase-associated lipocalin (NGAL), remains to be determined.	UNIV COPENHAGEN HOSP, RIGSHOSP, DEPT CLIN BIOCHEM, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	KJELDSEN, L (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP,DEPT HEMATOL L,GRANULOCYTE RES LAB, AFSNIT 4041, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.		Kjeldsen, Lars/AAF-2096-2019	Sengelov, Henrik/0000-0002-5991-2958				AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSBY TF, 1980, VOX SANG, V39, P93, DOI 10.1111/j.1423-0410.1980.tb01843.x; CHAN YL, 1988, NUCLEIC ACIDS RES, V16, P11368, DOI 10.1093/nar/16.23.11368; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DEWALD B, 1982, J CLIN INVEST, V70, P518, DOI 10.1172/JCI110643; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; DRAYNA D, 1986, J BIOL CHEM, V261, P6535; EMONARD H, 1990, CELL MOL BIOL, V36, P131; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; KJELDSEN L, 1992, BIOCHEM J, V287, P603, DOI 10.1042/bj2870603; KJELDSEN L, 1992, EUR J HAEMATOL, V49, P180; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERCER E, 1985, BIOCHEM J, V231, P505, DOI 10.1042/bj2310505; MOLL UM, 1990, CANCER RES, V50, P6162; MURPHY G, 1980, BIOCHEM J, V192, P517, DOI 10.1042/bj1920517; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; OPDENAKKER G, 1991, FEBS LETT, V284, P73, DOI 10.1016/0014-5793(91)80765-U; PEITSCH MC, 1991, TRENDS BIOCHEM SCI, V16, P363, DOI 10.1016/0968-0004(91)90149-P; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; REYNOLDS JJ, 1986, ANN BIOL CLIN-PARIS, V44, P188; SCHUSTER R, 1988, J CHROMATOGR-BIOMED, V431, P271, DOI 10.1016/S0378-4347(00)83096-0; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRICKLIN GP, 1983, J BIOL CHEM, V258, P2252; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	36	966	1075	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10425	10432						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683678				2022-12-27	WOS:A1993LB80000066
J	CARPENTER, CL; AUGER, KR; CHANUDHURI, M; YOAKIM, M; SCHAFFHAUSEN, B; SHOELSON, S; CANTLEY, LC				CARPENTER, CL; AUGER, KR; CHANUDHURI, M; YOAKIM, M; SCHAFFHAUSEN, B; SHOELSON, S; CANTLEY, LC			PHOSPHOINOSITIDE 3-KINASE IS ACTIVATED BY PHOSPHOPEPTIDES THAT BIND TO THE SH2 DOMAINS OF THE 85-KDA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; RECEPTOR TYROSINE KINASES; FACTOR-I RECEPTOR; SIGNAL TRANSDUCTION; PDGF RECEPTOR; PHOSPHORYLATION; POLYOMAVIRUS; TRANSFORMATION; PROTEIN	Tyrosine-phosphorylated peptides based on the regions of polyoma virus middle t antigen and the platelet-derived growth factor receptor that bind phosphoinositide 3-kinase are shown to activate this enzyme 2-3-fold in vitro. The concentrations of the peptides required to activate the enzyme are at least 10-1000-fold higher than the dissociation constants of these peptides for the individual SH2 domains of the 85-kDa subunit (K(D) < 100 nM). Doubly phosphorylated peptides are more effective than singly phosphorylated peptides. The results suggest that a fraction of the cellular phosphoinositide 3-kinase has SH2 domains with relatively low affinity for phosphopeptides and that binding of phosphopeptides to these enzymes causes activation. Thus, SH2 domains may be involved not only in recruiting the enzyme but also in regulating activity.	BETH ISRAEL HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Tufts University; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA 34722, R01 CA034722] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM 36624, GM 41890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA034722, R01CA034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890, R01GM036624] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KORNBLUTH S, 1990, J VIROL, V64, P1584, DOI 10.1128/JVI.64.4.1584-1589.1990; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN BS, 1985, VIROLOGY, V143, P671, DOI 10.1016/0042-6822(85)90410-6; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; ULUG ET, 1990, J VIROL, V64, P3895, DOI 10.1128/JVI.64.8.3895-3904.1990; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	331	343	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9478	9483						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683653				2022-12-27	WOS:A1993LA68900051
J	NATARAJAN, K; DATTA, A				NATARAJAN, K; DATTA, A			MOLECULAR-CLONING AND ANALYSIS OF THE NAG1 CDNA CODING FOR GLUCOSAMINE-6-PHOSPHATE DEAMINASE FROM CANDIDA-ALBICANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; GERM-TUBE FORMATION; SINGLE-STEP METHOD; N-ACETYLGLUCOSAMINE; ESCHERICHIA-COLI; CATABOLIC PATHWAY; RNA ISOLATION; D-GLUCOSAMINE; PLASMID DNA; YEAST	Candida albicans and other pathogenic Candida species can use N-acetylglucosamine as a sole carbon source for growth. GlcNAc induces the enzymes of GlcNAc catabolic pathway; besides, under certain conditions, GlcNAc also induces a change from the yeast to germ tube morphology. Glucosamine-6-phosphate deaminase (EC 5.3.1.10) is the terminal enzyme of the GlcNAc catabolic pathway. We have purified the deaminase from C. albicans and studied its characteristics. The size of the deaminase estimated from SDS-polyacrylamide gel electrophoresis is 28 kDa. N-Acetylglucosamine 6-phosphate, an allosteric activator of the Escherichia coli deaminase, has no effect on the activity of the C. albicans enzyme. The deaminase is induced over 100-fold by GlcNAc and its level is about 0.3-0.5% of the proteins in crude extract. Three cDNA clones were obtained from a lambdagt11 expression library by immunoscreening with deaminase antiserum. C. albicans genomic DNA blot hybridization revealed that the NAG1 gene, encoding the glucosamine-6-phosphate deaminase, is present in a single copy. Hybrid-selected translation and immunoprecipitation experiments revealed that the purified deaminase and the protein encoded by the clones were similar in size and in their antigenicity. DNA sequencing revealed that the largest cDNA clone contained the complete open reading frame, which can code for a 27.5-kDa protein. The NH2-terminal sequence (35 residues) determined from the purified deaminase was identical to the sequence of the deduced protein. The Nag1 protein has about 47% identity with the sequence of the E. coli glucosamine-6-phosphate deaminase. Furthermore, RNA blot hybridization showed that GlcNAc induces the expression of NAG1 gene.	JAWAHARLAL NEHRU UNIV, SCH LIFE SCI, NEW DELHI 110067, INDIA	Jawaharlal Nehru University, New Delhi								ALTAMIRANO MM, 1992, BIOCHEMISTRY-US, V31, P1153, DOI 10.1021/bi00119a026; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISWAS M, 1979, BIOCHIM BIOPHYS ACTA, V585, P535, DOI 10.1016/0304-4165(79)90186-7; BONNER WM, 1987, METHOD ENZYMOL, V152, P55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALCAGNO M, 1984, BIOCHIM BIOPHYS ACTA, V787, P165, DOI 10.1016/0167-4838(84)90076-1; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chrambach A, 1985, PRACTICE QUANTITATIV, P177; CORNER BE, 1986, J GEN MICROBIOL, V132, P15; DAS M, 1982, BIOCHEM INT, V5, P735; DATTA A, 1989, ADV MICROB PHYSIOL, V30, P53; DAVIS JS, 1967, ANAL BIOCHEM, V19, P72, DOI 10.1016/0003-2697(67)90135-2; DAVIS LG, 1986, BASIC METHODS MOL BI, P222; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GANESAN K, 1991, INFECT IMMUN, V59, P2972, DOI 10.1128/IAI.59.9.2972-2977.1991; GARVEY JS, 1977, METHOD IMMUNOL, P1; GOPAL P, 1982, J GEN MICROBIOL, V128, P2319; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HOHEISEL J, 1986, NUCLEIC ACIDS RES, V14, P3605, DOI 10.1093/nar/14.8.3605; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IWAMOTO R, 1991, J BIOCHEM-TOKYO, V109, P66; JAGUS R, 1987, METHOD ENZYMOL, V152, P567; KELLY R, 1987, MOL CELL BIOL, V7, P199, DOI 10.1128/MCB.7.1.199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVVY GA, 1959, BIOCHEM J, V73, P127, DOI 10.1042/bj0730127; LOSBERGER C, 1989, NUCLEIC ACIDS RES, V17, P9488, DOI 10.1093/nar/17.22.9488; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORAN LS, 1990, GENE, V93, P163, DOI 10.1016/0378-1119(90)90153-I; NAKADA HI, 1966, METHOD ENZYMOL, V9, P575; NOLTMANN EA, 1972, ENZYMES, V6, P271; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERI KG, 1990, BIOCHEM CELL BIOL, V68, P123, DOI 10.1139/o90-017; PLUMBRIDGE JA, 1990, J BACTERIOL, V172, P2728, DOI 10.1128/jb.172.5.2728-2735.1990; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROGERS MJ, 1988, GENE, V62, P197; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPHERD MG, 1983, FEMS MICROBIOL LETT, V17, P167; SHEPHERD MG, 1980, EXP MYCOL, V4, P147, DOI 10.1016/0147-5975(80)90018-3; SIMONETTI N, 1974, NATURE, V250, P344, DOI 10.1038/250344a0; SINGH B, 1979, BIOCHIM BIOPHYS ACTA, V557, P248, DOI 10.1016/0005-2736(79)90107-X; SINGH B, 1979, BIOCHEM J, V178, P427, DOI 10.1042/bj1780427; SINGH B, 1979, BIOCHIM BIOPHYS ACTA, V583, P28, DOI 10.1016/0304-4165(79)90306-4; SINGH BR, 1978, BIOCHEM BIOPH RES CO, V84, P58, DOI 10.1016/0006-291X(78)90262-0; VOGLER AP, 1989, MOL GEN GENET, V219, P97, DOI 10.1007/BF00261163; White R J, 1975, Methods Enzymol, V41, P497; WHITE RJ, 1968, BIOCHEM J, V106, P847, DOI 10.1042/bj1060847; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	57	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9206	9214						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683645				2022-12-27	WOS:A1993LA68900013
J	FOROUGH, R; ZHAN, X; MACPHEE, M; FRIEDMAN, S; ENGLEKA, KA; SAYERS, T; WILTROUT, RH; MACIAG, T				FOROUGH, R; ZHAN, X; MACPHEE, M; FRIEDMAN, S; ENGLEKA, KA; SAYERS, T; WILTROUT, RH; MACIAG, T			DIFFERENTIAL TRANSFORMING ABILITIES OF NON-SECRETED AND SECRETED FORMS OF HUMAN FIBROBLAST GROWTH FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL GROWTH; ENDOTHELIAL-CELLS; GENE; STIMULATION; EXPRESSION; SEQUENCE; SIGNAL; PHOSPHORYLATION; TUMORIGENESIS	Fibroblast growth factor (FGF)-1(1-154), the precursor for acidic FGF-1(21-154), is a potent angiogenic polypeptide, the structure of which lacks a signal peptide sequence for secretion. To investigate the biological significance of this structural feature, we have attempted forced secretion of FGF-1 through fusion of the entire FGF-1 coding frame with the signal peptide (sp) from the hst/KS3 gene, a secretory member of the heparin-binding growth factor family. We also studied the transforming ability of the signal-less forms of FGF-1 comprising FGF1-154 and FGF-1(21-154). The presence of a soluble and biologically active form of FGF-1 was readily detected in the conditioned medium of NIH 3T3 cells transfected with sp-hst/KS3:FGF-1(1-154) as demonstrated by Western blot analysis and DNA synthesis assays, whereas sp-hst/KS3:FGF-1(21-154) was not detectable in conditioned medium even though the protein was detected in cellular extracts. The secreted form of sp-hst/KS3:FGF-1(1-154) stimulated the proliferation of human umbilical vein endothelial cells in vitro and was able to induce receptor-mediated tyrosine phosphorylation. Furthermore, the forced secretion of biologically active FGF-1 resulted in NIH 3T3 cell transformation as demonstrated by altered morphology in vitro, the formation of discrete colonies in soft agarose, growth under serum-free conditions, and ability to rapidly form highly vascular tumors in vivo. Interestingly, sp-hst/KS3:FGF-1(21-154) also mediated the transition to a transformed phenotype despite the inability to detect extracellular FGF-1 in the media conditioned by these NIH 3T3 cell transfectants. Although the transfection of FGF-1(21-154) yielded similar NIH 3T3 cell morphologic changes, these transfectants did not grow under serum-free conditions or yield colonies in soft agarose, and formed tumors in vivo with delayed kinetics. Furthermore, the FGF-1(1-154) NIH 3T3 cell transfectants did not exhibit morphologic changes, and this may be due to the inability of mRNA to express protein. These data suggest that although non-sp forms of FGF-1 may alter the monolayer phenotype of NIH 3T3 cells in vitro, the ability of FGF-1 to transform NIH 3T3 cells requires the function of a sp-directed secretory pathway and suggests that this pathway increases tumorigenicity in vivo.	AMER RED CROSS, JEROME H HOLLAND LAB BIOMED SCI, DEPT MOLEC BIOL, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA; NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, EXPTL THERAPEUT SECT, FREDERICK, MD 21702 USA; PRI DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA				Sayers, Thomas J/G-4859-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, R01HL032348] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline; NHLBI NIH HHS [HL32348, HL44336] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1985, J BIOL CHEM, V260, P1389; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DAVIET I, 1990, FEBS LETT, V259, P315, DOI 10.1016/0014-5793(90)80035-H; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GAY CG, 1990, J BIOL CHEM, V265, P3284; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KOZAK M, 1986, IN TRANSLATIONAL CON; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARICS I, 1989, ONCOGENE, V4, P335; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MOSCAT J, 1988, P NATL ACAD SCI USA, V85, P659, DOI 10.1073/pnas.85.3.659; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THOMPSON JA, 1989, P NATL ACAD SCI USA, V86, P7928, DOI 10.1073/pnas.86.20.7928; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	41	104	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2960	2968						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679105				2022-12-27	WOS:A1993KK81500103
J	STEINERT, PM; PARRY, DAD				STEINERT, PM; PARRY, DAD			THE CONSERVED H1 DOMAIN OF THE TYPE-II KERATIN-1 CHAIN PLAYS AN ESSENTIAL ROLE IN THE ALIGNMENT OF NEAREST NEIGHBOR MOLECULES IN MOUSE AND HUMAN KERATIN-1/KERATIN-10 INTERMEDIATE FILAMENTS AT THE 2-MOLECULE TO 4-MOLECULE LEVEL OF STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION ELECTRON-MICROSCOPY; BOVINE EPIDERMAL KERATIN; COILED-COIL MOLECULES; AMINO-ACID SEQUENCES; ALPHA-KERATIN; INVITRO; CELLS; VIMENTIN; PROTEIN; EXPRESSION	A number of fundamental questions pertaining to the registration and packing of the constituent coiled-coil molecules in keratin intermediate filaments, and to the regions of the sequences that are responsible for these levels of organization, remain to be elucidated. In this study, small assembly-competent oligomers of mouse and human keratin 1/keratin 10 keratin filaments were cross-linked by the formation of disulfide bonds catalyzed by the copper-phenanthroline reaction. By isolation and characterization of cross-linked peptides, it has been possible to establish two major modes of molecule alignment: an antiparallel arrangement of half-staggered molecules with their 2B segments overlapping and an antiparallel arrangement of molecules in close axial registration. These data confirm earlier models based on theoretical considerations (Crewther, W. G., Dowling, L. M., Steinert, P. M., and Parry, D. A. D. (1983) Int. J. Biol. Macromol. 5, 267-274). Interestingly, these models place the conserved H1 and H2 end domain segments, which flank the ends of the rod domains of the type II keratin 1 chain, in alignment with either the ends of the rod domains and/or with the L2 segment near the center of the rod domains, of the nearest neighbor molecules. Competition experiments with synthetic peptides suggest that the conserved H1 (and possibly H2) subdomain sequences unique to type II keratin chains play pivotal roles in the registration of neighboring molecules in keratin filaments. The data thus afford a molecular explanation for why keratin filaments require a type II chain for assembly in vivo and in vitro.	MASSEY UNIV,DEPT PHYS & BIOPHYS,PALMERSTON NORTH,NEW ZEALAND	Massey University	STEINERT, PM (corresponding author), NIAMSD,SKIN BIOL BRANCH,BLDG 6,RM 425,BETHESDA,MD 20892, USA.							AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; BAIRD PA, 1976, J BIOL CHEM, V251, P9653; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; CREWTHER WG, 1983, INT J BIOL MACROMOL, V5, P267, DOI 10.1016/0141-8130(83)90040-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGEL A, 1985, J ULTRA MOL STRUCT R, V90, P323, DOI 10.1016/S0022-5320(85)80010-1; Fraser R.D.B., 1990, CELLULAR MOL BIOL IN, P205; FRASER RDB, 1985, INT J BIOL MACROMOL, V7, P258, DOI 10.1016/0141-8130(85)90024-8; FRASER RDB, 1983, BIOSCIENCE REP, V3, P517, DOI 10.1007/BF01120695; FRASER RDB, 1986, P NATL ACAD SCI USA, V83, P1179, DOI 10.1073/pnas.83.5.1179; FRASER RDB, 1988, INT J BIOL MACROMOL, V10, P106, DOI 10.1016/0141-8130(88)90017-7; GEISLER N, 1985, J MOL BIOL, V182, P173, DOI 10.1016/0022-2836(85)90035-X; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; HATZFELD M, 1990, J CELL SCI, V97, P317; HATZFELD M, 1992, J CELL BIOL, V116, P157, DOI 10.1083/jcb.116.1.157; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HOHL D, 1991, J BIOL CHEM, V266, P6626; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; MACK JW, 1988, BIOCHEMISTRY-US, V27, P5418, DOI 10.1021/bi00415a006; MACK JW, 1991, J INVEST DERMATOL, V96, pA615; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; POTSCHKA M, 1990, EUR J CEL LBIOL, V190, P505; QUINLAN RA, 1982, P NATL ACAD SCI-BIOL, V79, P3452, DOI 10.1073/pnas.79.11.3452; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; QUINLAN RA, 1985, ANN NY ACAD SCI, V455; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; SOELLNER P, 1985, P NATL ACAD SCI USA, V82, P7929, DOI 10.1073/pnas.82.23.7929; SPARROW LG, 1989, BIOL WOOL HAIR, P145; STEINERT P, 1978, SCIENCE, V200, P1491, DOI 10.1126/science.566466; STEINERT P, 1982, METHOD CELL BIOL, V24, P399; STEINERT PM, 1975, BIOCHEM J, V149, P39, DOI 10.1042/bj1490039; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; STEINERT PM, 1976, J MOL BIOL, V108, P547, DOI 10.1016/S0022-2836(76)80136-2; STEINERT PM, 1985, ANNU REV CELL BIOL, V1, P41; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, J BIOL CHEM, V263, P13333; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STEINERT PM, 1984, P NATL ACAD SCI-BIOL, V81, P5709, DOI 10.1073/pnas.81.18.5709; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEINERT PM, 1993, IN PRESS J MOL BIOL; STEVEN AC, 1985, ANN NY ACAD SCI, V455, P371, DOI 10.1111/j.1749-6632.1985.tb50423.x; STEVEN AC, 1982, P NATL ACAD SCI-BIOL, V79, P3101, DOI 10.1073/pnas.79.10.3101; STEVEN AC, 1983, J BIOL CHEM, V258, P8323; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; SUN TT, 1984, CANCER CELL TRANSFOR, P167; WHITMANAYNARDI M, 1984, J CELL BIOL, V98, P1407; ZHOU XM, 1988, J BIOL CHEM, V263, P15584	61	99	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2878	2887						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679103				2022-12-27	WOS:A1993KK81500091
J	LORSBACH, RB; MURPHY, WJ; LOWENSTEIN, CJ; SNYDER, SH; RUSSELL, SW				LORSBACH, RB; MURPHY, WJ; LOWENSTEIN, CJ; SNYDER, SH; RUSSELL, SW			EXPRESSION OF THE NITRIC-OXIDE SYNTHASE GENE IN MOUSE MACROPHAGES ACTIVATED FOR TUMOR-CELL KILLING - MOLECULAR-BASIS FOR THE SYNERGY BETWEEN INTERFERON-GAMMA AND LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-MAJOR AMASTIGOTES; NECROSIS FACTOR CACHECTIN; L-ARGININE; MURINE MACROPHAGES; IFN-GAMMA; PERITONEAL-MACROPHAGES; EFFECTOR MECHANISM; FACTOR-ALPHA; INDUCTION; NITRATE	Macrophages can become activated to kill both tumor cells and a variety of microbes. Results here show that synthesis of nitric oxide (NO), a mediator of many macrophage cytotoxic functions, was greatly increased when cells of the mouse macrophage cell line RAW 264.7 were costimulated with bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma), compared to LPS alone. This increase paralleled increases in cytotoxicity. Northern analysis showed that increased production of NO was preceded by markedly enhanced expression of mRNA for the inducible form of macrophage NO synthase (mac-NOS), which catalyzes the synthesis of NO. Cycloheximide inhibited the induction of mac-NOS mRNA by IFN-gamma and LPS, indicating that expression of this mRNA required de novo protein synthesis. Elevated expression of mac-NOS mRNA was not due to an increase in its stability. Rather, the combination of IFN-gamma and LPS induced a much higher rate of transcription of the mac-NOS gene than did stimulation with LPS alone. These results provide one explanation of why priming and triggering stimuli, such as IFN-gamma and LPS, respectively, synergistically activate macrophages and may be applicable to explaining how IFN-gamma augments NO-dependent microbicidal activity in macrophages as well.	UNIV KANSAS,MED CTR,CTR CANC,WILKINSON LAB,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT PATHOL & ONCOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT MICROBIOL MICROBIAL GENET & IMMUNOL,KANSAS CITY,KS 66160; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Johns Hopkins University; Johns Hopkins University				Lowenstein, Charles/0000-0003-0485-7514	NCI NIH HHS [R01 CA31199, P01 CA54474] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA054474, R01CA031199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS LB, 1991, J IMMUNOL, V147, P1642; ADAMS LB, 1990, J IMMUNOL, V144, P2725; ALLEN RW, 1987, J BIOL CHEM, V262, P649; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; COWLEY BD, 1989, J BIOL CHEM, V264, P8389; DESCOTEAUX A, 1990, J IMMUNOL, V145, P846; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN SJ, 1990, J IMMUNOL, V145, P4290; GREEN SJ, 1990, J IMMUNOL, V144, P278; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIBBS JB, 1977, SCIENCE, V197, P279, DOI 10.1126/science.327547; KELLER R, 1990, CANCER RES, V50, P1421; LEVIN J, 1970, J LAB CLIN MED, V75, P903; LIEW FY, 1990, J IMMUNOL, V145, P4306; LORSBACH RB, 1992, INFECT IMMUN, V60, P2133, DOI 10.1128/IAI.60.5.2133-2135.1992; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACKAY RJ, 1986, J IMMUNOL, V137, P1392; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MELLOUK S, 1991, J IMMUNOL, V146, P3971; MORRISON DC, 1975, J BIOL CHEM, V250, P2911; MURRAY HW, 1985, J IMMUNOL, V134, P1619; PACE JL, 1981, J IMMUNOL, V126, P1863; PACE JL, 1983, P NATL ACAD SCI-BIOL, V80, P3782, DOI 10.1073/pnas.80.12.3782; PACE JL, 1985, J IMMUNOL, V134, P977; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RUCO LP, 1978, J IMMUNOL, V121, P2035; RUSSELL SW, 1977, J EXP MED, V146, P1511, DOI 10.1084/jem.146.6.1511; RUSSELL SW, 1980, J RETICULOENDOTH SOC, V27, P607; Sambrook J, 1989, MOL CLONING LABORATO; STEEG PS, 1982, J EXP MED, V156, P1780, DOI 10.1084/jem.156.6.1780; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TANNENBAUM CS, 1988, J IMMUNOL, V140, P3640; UCLA C, 1990, J CLIN INVEST, V85, P185, DOI 10.1172/JCI114411; WYNN TA, 1991, J IMMUNOL, V147, P4384; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	47	627	643	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1908	1913						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678412				2022-12-27	WOS:A1993KH62000063
J	TSURUOKA, T; TSUJI, T; NOJIRI, H; HOLMES, EH; HAKOMORI, S				TSURUOKA, T; TSUJI, T; NOJIRI, H; HOLMES, EH; HAKOMORI, S			SELECTION OF A MUTANT-CELL LINE BASED ON DIFFERENTIAL EXPRESSION OF GLYCOSPHINGOLIPID, UTILIZING ANTI-LACTOSYLCERAMIDE ANTIBODY AND COMPLEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINIDE 3-ALPHA-L-FUCOSYLTRANSFERASE; RESISTANT MELANOMA CLONE; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; RAT-LIVER; GANGLIOSIDE; GLYCOPROTEINS; INDUCTION; VARIANTS; GM3	A mouse mammary carcinoma mutant cell line showing a characteristic alteration of glycosphingolipid (GSL) composition, but with unchanged protein glycosylation pattern, was isolated. Parent cell line FM3A/F28-7 is characterized by the predominance of lactosylceramide (LacCer) and virtual absence of more complex GSLs. Mutant cell line FUA169 was isolated after treatment of F28-7 cells with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine and incubation with anti-LacCer monoclonal antibody T5A7 and complement. FUA169 cells were characterized by a dramatic reduction in LacCer and by the presence of a major ganglioside identified as G(M3). They also showed high activity of CMP-sialic acid:LacCer 2,3-sialosyltransferase, whereas F28-7 cells had no detectable activity of this enzyme. In contrast to the difference in GSL pattern, F28-7 and FUA169 showed identical protein glycosylation patterns, as evidenced by ''Western blotting'' with various lectins and surface labeling with galactose oxidase/(NaBH4)-H-3 and periodate/(NaBH4)-H-3. Thus, FUA169 is identified as a glycosylation mutant with regard to G(M3) expression and will be useful for studies of the functional role of G(M3). Growth of FUA169 cells, relative to F28-7 cells, showed greater temperature sensitivity and greater inhibitability based on restriction of growth factors, particularly insulin.	BIOMEMBRANE INST,201 ELLIOT AVE W,SEATTLE,WA 98119; FRED HUTCHINSON CANC RES CTR,DEPT BIOCHEM ONCOL MEMBRANE RES,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98119; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98119	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL CANCER INSTITUTE [R35CA042505, R01CA020026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023100] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505, CA20026] Funding Source: Medline; NIGMS NIH HHS [GM23100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYUSAWA D, 1980, SOMAT CELL GENET, V6, P261, DOI 10.1007/BF01538800; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; DEN H, 1971, J BIOL CHEM, V246, P2721; FINNE J, 1980, CANCER RES, V40, P2580; FUKUDA MN, 1979, J BIOL CHEM, V254, P5458; GOTTLIEB C, 1976, J BIOL CHEM, V251, P7761; GOTTLIEB C, 1974, P NATL ACAD SCI USA, V71, P1078, DOI 10.1073/pnas.71.4.1078; HAKOMORI S, 1984, MONOCLONAL ANTIBODIE, P67; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HOLMES EH, 1983, J BIOL CHEM, V258, P3706; HYMAN R, 1974, JNCI-J NATL CANCER I, V52, P963, DOI 10.1093/jnci/52.3.963; KANNAGI R, 1982, J BIOL CHEM, V257, P4438; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; MEAGER A, 1975, NATURE, V257, P137, DOI 10.1038/257137a0; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; PRIEELS JP, 1983, EUR J BIOCHEM, V130, P347, DOI 10.1111/j.1432-1033.1983.tb07159.x; SCHENGRUND CL, 1973, J BIOL CHEM, V248, P4424; SENN HJ, 1981, EUR J BIOCHEM, V120, P59, DOI 10.1111/j.1432-1033.1981.tb05670.x; SWEELEY CC, 1985, ANNU REV BIOCHEM, V54, P765, DOI 10.1146/annurev.biochem.54.1.765; SYMINGTON FW, 1984, J BIOL CHEM, V259, P6008; TAO TW, 1977, NATURE, V270, P437, DOI 10.1038/270437a0; WATANABE K, 1981, J LIPID RES, V22, P1020; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; WRIGHT JA, 1973, J CELL BIOL, V56, P666, DOI 10.1083/jcb.56.3.666; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	32	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2211	2216						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678417				2022-12-27	WOS:A1993KH62000106
J	CARROLL, SS; OLSEN, DB; BENNETT, CD; GOTLIB, L; GRAHAM, DJ; CONDRA, JH; STERN, AM; SHAFER, JA; KUO, LC				CARROLL, SS; OLSEN, DB; BENNETT, CD; GOTLIB, L; GRAHAM, DJ; CONDRA, JH; STERN, AM; SHAFER, JA; KUO, LC			INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY PYRIDINONE DERIVATIVES - POTENCY, BINDING CHARACTERISTICS, AND EFFECT OF TEMPLATE SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS; REPLICATION; DIPYRIDODIAZEPINONE; BI-RG-587; KINETICS; SITE	The inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by pyridinone compounds has been investigated using as templates synthetic RNA with sequences based on the HIV-1 genome sequence. In reactions catalyzed by the enzyme that incorporated more than one nucleotide per primer, inhibition by a representative pyridinone inhibitor, 3-[2-(1,3-benzoxazol-2-yl)ethyl]-5-ethyl-6-methyl-pyridin-2(1H)one (L-696,229), was noncompetitive against deoxynucleotide triphosphate. For reactions that incorporated one deoxynucleotide per primer, IC50 values ranged from 20 to 200 nM, depending on the position of incorporation of the incoming deoxynucleotide base on the template. Inhibition of synthesis on a set of four templates differing only at the template base complementary to the incoming nucleotide had similar IC50 values. These results demonstrate that inhibitory potency is dependent on the primary structure of the template and that inhibitory potency is largely independent of the identity of the incoming nucleotide base. The inhibition of HIV-1 reverse transcription by L-696,229 also displayed slow-binding characteristics. The slow-binding aspect was exploited to gauge the interaction between inhibitor and enzyme. By titrating the reduction in the extent of the burst of synthesis observed in a reaction incorporating dideoxythymidine monophosphate into poly(rA)-oligo(dT)18, the apparent equilibrium constant for dissociation of the reverse transcriptase-L-696,229 complex was estimated to be 400 nM.	MERCK RES LABS,DEPT VIRUS & CELL BIOL,W POINT,PA 19486	Merck & Company	CARROLL, SS (corresponding author), MERCK RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.			Stern, Andrew/0000-0002-8437-2957; olsen, david/0000-0001-5521-0206				ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; AZZOLINA B, 1990, FASEB J, V4, pA2253; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; COHEN KA, 1991, J BIOL CHEM, V266, P14670; CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; FRANK KB, 1991, J BIOL CHEM, V266, P14232; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOPP EB, 1991, NUCLEIC ACIDS RES, V19, P3035, DOI 10.1093/nar/19.11.3035; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; MA QF, 1992, BIOCHEMISTRY-US, V31, P1375, DOI 10.1021/bi00120a013; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OLSEN DB, 1991, BIOCHEMISTRY-US, V30, P9735, DOI 10.1021/bi00104a024; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RESTLE T, 1990, J BIOL CHEM, V265, P8986; ROBERT D, 1990, FEBS LETT, V277, P239, DOI 10.1016/0014-5793(90)80855-D; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SAARI WS, 1991, J MED CHEM, V34, P2925; SARDANA VV, 1992, J BIOL CHEM, V267, P17526; WHITE EL, 1991, ANTIVIR RES, V16, P257, DOI 10.1016/0166-3542(91)90005-C; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	26	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					276	281						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677997				2022-12-27	WOS:A1993KE60300043
J	HOCKERMAN, GH; JOHNSON, BD; SCHEUER, T; CATTERALL, WA				HOCKERMAN, GH; JOHNSON, BD; SCHEUER, T; CATTERALL, WA			MOLECULAR DETERMINANTS OF HIGH-AFFINITY PHENYLALKYLAMINE BLOCK OF L-TYPE CALCIUM CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; RECEPTOR; EXPRESSION; CLONING; D600; SITE	The high affinity phenylalkylamine (-)D888 blocks ion currents through L-type Ca2+ channels containing the alpha(1C) subunit with an apparent K-d of 50 nM, but N-type Ca2+ channels in the pheochromocytoma cell line PC12 are blocked with a 100-fold higher K-d value of 5 mu M. L-type Ca2+ channels containing alpha(1C) subunits with the site-directed mutations Y1463A, A1467S, or I1470A in the putative transmembrane segment S6 in domain IV (IVS6) were 6-12 times less sensitive to block. by (-)D888 than control alpha(1C). Ca2+ channels containing paired combinations of these mutations were even less sensitive to block by (-)D888 than the single mutants, and channels containing all three mutations were > 100 times less sensitive to (-)D888 block, similar to N-type Ca2+ channels, In addition, the Y1463A mutant and all combination mutants including the Y1463A mutation had altered ion selectivity, suggesting that Tyr-1463 faces the pore and is involved in ion permeation. Since these three critical amino acid residues are aligned on the same face of the putative IVS6 alpha-helix, we propose that they contribute to a receptor site in the pore that confers a high affinity block of L-type channels by (-)D888.			HOCKERMAN, GH (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NHLBI NIH HHS [P01 HL44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; EHARA T, 1978, J PHARMACOL EXP THER, V207, P49; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; ERDMANN R, 1989, J PHYSIOL-LONDON, V413, P521, DOI 10.1113/jphysiol.1989.sp017667; Fleckenstein A, 1980, Eur Heart J, V1, P15; GOLL A, 1984, FEBS LETT, V176, P371, DOI 10.1016/0014-5793(84)81199-0; GRANTHAM CJ, 1984, BRIT J PHARMACOL, V111, P483; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HESCHELER J, 1982, PFLUG ARCH EUR J PHY, V393, P287, DOI 10.1007/BF00581411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MARGOLSKEE RF, 1994, BIOTECHNIQUES, V15, P906; MCDONALD TF, 1984, J PHYSIOL-LONDON, V352, P217, DOI 10.1113/jphysiol.1984.sp015288; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; SHIEH CC, 1994, BIOPHYS J, V67, P2316, DOI 10.1016/S0006-3495(94)80718-0; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; STRIESSNIG J, 1987, FEBS LETT, V212, P247, DOI 10.1016/0014-5793(87)81354-6; TAGLIALATELA M, 1994, J BIOL CHEM, V269, P13867; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0	25	113	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22119	22122		10.1074/jbc.270.38.22119	http://dx.doi.org/10.1074/jbc.270.38.22119			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673189	hybrid			2022-12-27	WOS:A1995RW31400012
J	HOPKINS, C; GRILLEY, M; MILLER, C; SHON, KJ; CRUZ, LJ; GRAY, WR; DYKERT, J; RIVIER, J; YOSHIKAMI, D; OLIVERA, BM				HOPKINS, C; GRILLEY, M; MILLER, C; SHON, KJ; CRUZ, LJ; GRAY, WR; DYKERT, J; RIVIER, J; YOSHIKAMI, D; OLIVERA, BM			A NEW FAMILY OF CONUS PEPTIDES TARGETED TO THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEOGRAPHUS VENOM; ALPHA-CONOTOXIN; OMEGA-CONOTOXIN; PURIFICATION; SPECTROSCOPY; CHANNELS	In this work, a new family of Conus peptides, the alpha A-conotoxins, which target the nicotinic acetylcholine receptor, is defined, The first members of this family have been characterized from the eastern Pacific species, Conus purpurascens (the purple cone); three peptides that cause paralysis in fish were purified and characterized from milked venom, The sequence and disulfide bonding pattern of one of these, alpha A-conotoxin PIVA, is as follows: [GRAPHICS] where O represents trans 4-hydroxyproline. The two other peptides purified from C. purpurascens venom are the under-hydroxylated derivatives, [Pro(13)]alpha A-conotoxin PIVA and [Pro(7,13)]alpha A-conotoxin PNA. The peptides have been chemically synthesized in a biologically active form, Both electrophysiological experiments and competition binding with alpha-bungarotoxin demonstrate that alpha A-PIVA acts as an antagonist of the nicotinic acetylcholine receptor at the postsynaptic membrane.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; UNIV PHILIPPINES,INST MARINE SCI,QUEZON 1101,PHILIPPINES	Utah System of Higher Education; University of Utah; Salk Institute; University of the Philippines System; University of the Philippines Diliman				Hopkins, Chris/0000-0002-6981-6329	NIGMS NIH HHS [P01 GM 28677] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028677] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRUZ LJ, 1983, NRCP SALIGANG SALIKS, V2, P118; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; GRAY WR, 1981, J BIOL CHEM, V256, P4734; KOBAYASHI Y, 1989, BIOCHEMISTRY-US, V28, P4853, DOI 10.1021/bi00437a050; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; MYERS RA, 1989, J NEUROSCI, V15, P678; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; PARDI A, 1989, BIOCHEMISTRY-US, V28, P5494, DOI 10.1021/bi00439a026; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; RIVIER J, 1987, J BIOL CHEM, V262, P1194; RIVIER J, 1984, J CHROMATOGR, V288, P303, DOI 10.1016/S0021-9673(01)93709-4; YOSHIKAMI D, 1989, ANN NY ACAD SCI, V560, P230, DOI 10.1111/j.1749-6632.1989.tb24100.x; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	17	123	129	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22361	22367		10.1074/jbc.270.38.22361	http://dx.doi.org/10.1074/jbc.270.38.22361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673220	hybrid			2022-12-27	WOS:A1995RW31400047
J	KUROKI, J; HOSOYA, T; ITAKURA, M; HIROSE, S; TAMECHIKA, I; YOSHIMOTO, T; GHONEIM, MA; NARA, K; KATO, A; SUZUKI, Y; FURUKAWA, M; TACHIBANA, S				KUROKI, J; HOSOYA, T; ITAKURA, M; HIROSE, S; TAMECHIKA, I; YOSHIMOTO, T; GHONEIM, MA; NARA, K; KATO, A; SUZUKI, Y; FURUKAWA, M; TACHIBANA, S			CLONING, CHARACTERIZATION, AND TISSUE DISTRIBUTION OF PORCINE SPAI, A PROTEIN WITH A TRANSGLUTAMINASE SUBSTRATE DOMAIN AND THE WAP MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; 4-DISULFIDE CORE; POTENT INHIBITOR; CROSS-LINKING; K+-ATPASE; CDNA; GENE; PEPTIDE; VASOPRESSIN	The primary and gene structures and tissue distribution of porcine SPAI-2, a protein that belongs to the WAP protein superfamily and has a sodium-potassium ATPase inhibitory activity, were determined by molecular cloning and Northern analysis. A full-length cDNA clone was isolated from a porcine duodenum cDNA Library. The cDNA insert encoded a polypeptide of 187 amino acids, which is composed of three domains: a hydrophobic presequence of 21 amino acids, a prosegment of 105 amino acids ending with Asp(126), and the mature SPAI-2 sequence of 61 amino acids beginning with pro(127). The prosegment contained 16 repeats of a hexapeptide that is highly homologous to the repetitive sequence found in the transglutaminase domain of the human elafin, an elastase-specific inhibitor that also belongs to the WAP superfamily, The repetitive sequence was demonstrated to be a good substrate of transglutaminase using a recombinant preparation produced in Escherichia coli. A porcine genomic Library was then screened for the SPAI gene. Characterization and sequencing of positive clones indicated that the gene is similar to the elafin gene, having 3 exons encoding the 5'-untranslated region and signal sequence, proSPAI, and 3'-untranslated region, respectively. Northern blot analysis revealed intestine-specific expression of SPAI mRNA; the message was especially abundant in the small intestine, ProSPAI was also found in the circulation. The similarity of proSPAI to elafin in the domain structure, the acid-labile nature of the cleavage site (Asp(126)-pro(127)), and the fact that the major form of SPAI in the plasma is proSPAI strongly suggest that proSPAI is not the precursor but rather it is the native form of SPAI. Like elafin, therefore, SPAI appears to be a new type of biologically active substance with a transglutaminase substrate domain that acts as an anchoring sequence.	TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Tokyo Institute of Technology; Eisai Co Ltd			Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443; ghoneim, magdy/0000-0003-0185-3024				ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BEG OU, 1986, EUR J BIOCHEM, V159, P195, DOI 10.1111/j.1432-1033.1986.tb09852.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUTO MA, 1992, INFECT IMMUN, V60, P5042, DOI 10.1128/IAI.60.12.5042-5047.1992; DANDEKAR AM, 1982, P NATL ACAD SCI-BIOL, V79, P3987, DOI 10.1073/pnas.79.13.3987; DRENTH J, 1980, J BIOL CHEM, V255, P2652; DRENTH J, 1981, J BIOL CHEM, V256, P2601; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAZAL A, 1989, FEBS LETT, V257, P260, DOI 10.1016/0014-5793(89)81548-0; FIETZ MJ, 1990, J CELL BIOL, V110, P427, DOI 10.1083/jcb.110.2.427; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; HENNINGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P3733, DOI 10.1093/nar/10.12.3733; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ISHIZUKA N, 1991, BIOCHIM BIOPHYS ACTA, V1069, P259, DOI 10.1016/0005-2736(91)90133-S; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KATO I, 1979, FED PROC, V38, P832; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	36	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22428	22433		10.1074/jbc.270.38.22428	http://dx.doi.org/10.1074/jbc.270.38.22428			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673229	hybrid			2022-12-27	WOS:A1995RW31400058
J	PALMER, RH; DEKKER, LV; WOSCHOLSKI, R; LEGOOD, JA; GIGG, R; PARKER, PJ				PALMER, RH; DEKKER, LV; WOSCHOLSKI, R; LEGOOD, JA; GIGG, R; PARKER, PJ			ACTIVATION OF PRK1 BY PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE AND PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE - A COMPARISON WITH PROTEIN-KINASE-C ISOTYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; ZETA	As potential targets for polyphosphoinositides, activation of protein kinase C (PKC) isotypes (beta(1), epsilon, zeta, eta) and a member of the PKC-related kinase (PRK) family, PRK1, has been compared in vitro. PRK1 is shown to be activated by both phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P-2) as well as phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P-3) either as pure sonicated lipids or in detergent mixed micelles. When presented as sonicated lipids, PtdIns-4,5-P-2 and PtdIns-3,4,5-P-3 were equipotent in activating PRK1, and, furthermore, sonicated phosphatidylinositol (PtdIns) and phosphatidylserine (PtdSer) were equally effective. In detergent mixed micelles, PtdIns-4,B-P-2 and PtdIns-3,4,5-P-3 also showed a similar potency, but PtdIns and PtdSer were 10-fold less effective in this assay. Similarly, PKC-beta(1), -epsilon, and -eta were all activated by PtdIns-4,5-P-2 and PtdIns-3,4,5-P-3 in detergent mixed micelles. The activation constants for PtdIns-4,5-P, and PtdIns-3,4,5-P, were essentially the same for all the kinases tested, implying no specificity in this in vitro analysis. Consistent with this conclusion, the effects of PtdIns-4,5-P-2 and PtdIns-3,4,5-P-3 were found to be inhibited at 10 mM Mg2+ and mimicked by high concentrations of inositol hexaphosphate and inositol hexasulfate. The similar responses of these two classes of lipid-activated protein kinase to these phosphoinositides are discussed in light of their potential roles as second messengers.	IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Cancer Research UK; MRC National Institute for Medical Research			Dekker, Lodewijk/J-6934-2013; Parker, Peter j/D-5192-2013	Dekker, Lodewijk/0000-0001-5247-3297; parker, peter/0000-0002-6218-2933; Le Good, Jessie/0000-0002-6332-9239				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; DESAI T, 1995, SYNTHESIS LIPID CHEM; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EPAND RM, 1990, TRENDS PHARMACOL SCI, V11, P317, DOI 10.1016/0165-6147(90)90234-Y; HANNUN YA, 1985, J BIOL CHEM, V260, P39; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1995, BIOCHEM J, V309, P315, DOI 10.1042/bj3090315; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; STABEL S, 1991, METHOD ENZYMOL, P670; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TOKER A, 1994, J BIOL CHEM, V269, P32358; WAYS DK, 1992, J BIOL CHEM, V267, P4799	17	121	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22412	22416		10.1074/jbc.270.38.22412	http://dx.doi.org/10.1074/jbc.270.38.22412			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673228	hybrid			2022-12-27	WOS:A1995RW31400055
J	CHOI, ME; BALLERMANN, BJ				CHOI, ME; BALLERMANN, BJ			INHIBITION OF CAPILLARY MORPHOGENESIS AND ASSOCIATED APOPTOSIS BY DOMINANT-NEGATIVE MUTANT TRANSFORMING GROWTH-FACTOR-BETA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DEVELOPMENTAL EXPRESSION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; FORMATION INVITRO; II RECEPTOR; ANGIOGENESIS; PROLIFERATION; FACTOR-BETA-1; ACTIVATION	Transforming growth factor-beta 1 (TGF-beta 1) induces angiogenesis in vivo and capillary morphogenesis in vitro. Two receptor serine/threonine kinases (types I and II) have been identified as signal transducing TGF-beta receptors. We explored the possibility of inhibiting TGF-beta-mediated events in glomerular capillary endothelial cells using a TGF-beta type II receptor (TPR-II) transdominant negative mutant. A mutant TGF-beta type II receptor (T beta R-IIM), lacking the cytoplasmic serine/threonine kinase domain, was produced by polymerase chain reaction using rat T beta R-II cDNA as template. Since T beta R-II and TGF-beta type I receptor (T beta R-I) heterodimerize for signal transduction, the mutant receptor competes for binding to wild-type T beta R-I, hence acting in a dominant negative fashion. Glomerular capillary endothelial cells were stably transfected with T beta R-IIM, and four independent clones were expanded. That the T beta R-IIM mRNA was expressed was shown by reverse transcriptase-polymerase chain reaction. RNase protection assay, and Northern analysis. Presence of cell surface T beta R-IIM protein was shown by affinity cross-linking with I-125-TGF-beta 1. In wild-type endothelial cells, TGF-beta 1 (2 ng/ml) significantly inhibited [H-3]thymidine incorporation to 63 +/- 10% of control (n = 4). In transfected endothelial cells carrying T beta R-IIM, TGF-beta 1 stimulated [H-3]thymidine incorporation to 131 +/- 9% of control (n = 4, p < 0.005). Also, in wild-type endothelial cells, endogenous and exogenous TGF-beta 1 induced apoptosis and associated capillary formation. Both apoptosis and capillary formation were uniformly and entirely absent in transfected endothelial. cells carrying T beta R-IIM. This represents the first demonstration that capillary morphogenesis in vitro is associated with apoptosis, and that interference with T beta R-II signaling inhibits this process in glomerular capillary endothelial cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University	CHOI, ME (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DIV NEPHROL,BALTIMORE,MD 21205, USA.		Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381	NIDDK NIH HHS [5-K12-DK0129809] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1993, DEVELOPMENT, V117, P183; BALLERMANN BJ, 1989, AM J PHYSIOL, V256, pC182, DOI 10.1152/ajpcell.1989.256.1.C182; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOI ME, 1993, KIDNEY INT, V44, P948, DOI 10.1038/ki.1993.336; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FOLKMAN J, 1987, SCIENCE, V235, P42; FRATERSCHRODER M, 1986, BIOCHEM BIOPH RES CO, V137, P295, DOI 10.1016/0006-291X(86)91209-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731; ZENTELLA A, 1992, P NATL ACAD SCI USA, V89, P5176, DOI 10.1073/pnas.89.11.5176	41	121	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21144	21150		10.1074/jbc.270.36.21144	http://dx.doi.org/10.1074/jbc.270.36.21144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673146	hybrid			2022-12-27	WOS:A1995RU05400045
J	HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM				HULETT, MD; WITORT, E; BRINKWORTH, RI; MCKENZIE, IFC; HOGARTH, PM			MULTIPLE REGIONS OF HUMAN FC-GAMMA-RII (CD32) CONTRIBUTE TO THE BINDING OF IGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER CELLS; EPSILON-RI; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; ALPHA-SUBUNIT; RECEPTOR; EXPRESSION; IDENTIFICATION; POLYMORPHISM; ANTIGEN	The low affinity receptor for IgG, Fc gamma RII (CD32), has a wide distribution on hematopoietic cells where it is responsible for a diverse range of cellular responses crucial for immune regulation and resistance to infection. Fc gamma RII is a member of the immunoglobulin superfamily, containing an extracellular region of two Ig-like domains. The IgG binding site of human Fc gamma RII has been localized to an 8-amino acid segment of the second extracellular domain, Asn(154)-Ser(161). In this study, evidence is presented to suggest that domain 1 and two additional regions of domain 2 also contribute to the binding of IgG by Fc gamma RII. Chimeric receptors generated by exchanging the extracellular domains and segments of domain 2 between Fc gamma RII and the structurally related Fc epsilon RI alpha chain were used to demonstrate that substitution of domain 1 in its entirety or the domain 2 regions encompassing residues Ser(109)-Val(116) and Ser(130)-Thr(135) resulted in a loss of the ability of these receptors to bind hIgG1 in dimeric form. Site-directed mutagenesis performed on individual residues within and flanking the Ser(109)-Val(116) and Ser(130)-Thr(135) domain 2 segments indicated that substitution of Lys(113), Pro(114), Leu(115), Val(116), Phe(129) and His(131) profoundly decreased the binding of hIgG1, whereas substitution of Asp(133) and Pro(134) increased binding. These findings suggest that not only is domain 1 contributing to the affinity of IgG binding by Fc gamma RII but, importantly, that the domain 2 regions Ser(109)-Val(116) and Phe(129)-Thr(135) also play key roles in the binding of hIgG1. The location of these binding regions on a molecular model of the entire extracellular region of Fc gamma RII indicates that they comprise loops that are juxtaposed in domain 2 at the interface with domain 1, with the putative crucial binding residues forming a hydrophobic pocket surrounded by a wall of predominantly aromatic and basic residues.	AUSTIN HOSP,AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV QUEENSLAND,CTR DRUG DESIGN & DEV,BRISBANE,QLD 4072,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Queensland			Hulett, Mark D/C-4160-2012	Hogarth, Mark/0000-0002-0360-7890; Hulett, Mark/0000-0003-2072-5968				ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FARBER DL, 1993, J IMMUNOL, V1504, P4364; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; HARLOW E, 1988, ANTIBODIES LABORATOR, P328; HIBBS ML, 1988, P NATL ACAD SCI USA, V85, P2240, DOI 10.1073/pnas.85.7.2240; HIBBS ML, 1985, IMMUNOGENETICS, V22, P335, DOI 10.1007/BF00430917; HIBBS ML, 1994, J IMMUNOL, V152, P4466; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; HORTON RM, 1988, GENE AMST, V77, P61; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IERINO FL, 1993, J IMMUNOL, V150, P1794; LAH M, 1990, IMMUNOGENETICS, V31, P202, DOI 10.1007/BF00211557; LOPEZ AF, 1983, IMMUNOLOGY, V48, P503; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; PARISH CR, 1974, PROC R SOC SER B-BIO, V187, P47, DOI 10.1098/rspb.1974.0060; PIETERSZ GA, CANCER RES, V48, P4469; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; RIGLEY KP, 1989, EUR J IMMUNOL, V19, P481, DOI 10.1002/eji.1830190311; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROBINSON MW, 1993, J IBOL CHEM, V268, P12736; Sambrook J, 1989, MOL CLONING LABORATO; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; STUART SG, 1987, J EXP MED, V166, P1668, DOI 10.1084/jem.166.6.1668; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; TATE BJ, 1992, IMMUNOL CELL BIOL, V70, P79, DOI 10.1038/icb.1992.12; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WARMERDAM PAM, 1991, J IMMUNOL, V147, P1338; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	43	57	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21188	21194		10.1074/jbc.270.36.21188	http://dx.doi.org/10.1074/jbc.270.36.21188			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673151	hybrid			2022-12-27	WOS:A1995RU05400051
J	SASAKI, H; NAGURA, K; ISHINO, M; TOBIOKA, H; KOTANI, K; SASAKI, T				SASAKI, H; NAGURA, K; ISHINO, M; TOBIOKA, H; KOTANI, K; SASAKI, T			CLONING AND CHARACTERIZATION OF CELL-ADHESION KINASE-BETA, A NOVEL PROTEIN-TYROSINE KINASE OF THE FOCAL ADHESION KINASE SUBFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; PP125(FAK); EXPRESSION; IDENTIFICATION; ACTIVATION; RECEPTORS; TRANSFORMATION; CONSTRUCTION; LYMPHOCYTE; EFFICIENT	A second protein-tyrosine kinase (PTK) of the focal adhesion kinase (FAK) subfamily, cell adhesion kinase beta (CAK beta), was identified by cDNA cloning. The rat CAK beta is a 115.7-kDa PTK that contains N- and C-terminal domains of 418 and 330 amino acid residues besides the central kinase domain, The rat CAK beta has a homology with mouse FAK over their entire lengths except for the extreme N-terminal 88 residues and shares 45% overall sequence identity (60% identical in the catalytic domain), which indicates that CAK beta is a protein structurally related to but different from FAK. The CAK beta gene is less evenly expressed in a variety of rat organs than the FAK gene, Anti-CAK beta antibody immunoprecipitated a 113-kDa protein from rat brain, 3Y1 fibroblasts, and COS-7 cells transfected with CAK beta cDNA, The tyrosine-phosphorylated state of CAK beta was not reduced on trypsinization, nor enhanced in response to plating 3Y1 cells onto fibronectin, CAK beta localized to sites of cell-to-cell contact in COS-7 transfected with CAK beta cDNA, in which FAK was found at the bottom of the cells. Thus, CAK beta is a PTK possibly participating in the signal transduction regulated by cell-to-cell contacts.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, DEPT PATHOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University; Sapporo Medical University								AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUTKIND JS, 1992, BIOCHEM BIOPH RES CO, V188, P155; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MURAKAMI T, 1993, BIOIMAGES, V1, P1; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; RANKIN S, 1994, J BIOL CHEM, V269, P704; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA H, 1988, J CELL PHYSIOL, V136, P421, DOI 10.1002/jcp.1041360305; TANIGUCHI T, 1994, ONCOGENE, V9, P861; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; YAGIHASHI A, 1988, CANCER RES, V48, P2798; YAMASHITA Y, 1991, FEBS LETT, V288, P46, DOI 10.1016/0014-5793(91)81000-X; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHANG C, 1994, J BIOL CHEM, V269, P25247; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	349	363	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21206	21219		10.1074/jbc.270.36.21206	http://dx.doi.org/10.1074/jbc.270.36.21206			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673154	hybrid			2022-12-27	WOS:A1995RU05400054
J	FERNANDEZ, JA; HEEB, MJ; GRIFFIN, JH				FERNANDEZ, JA; HEEB, MJ; GRIFFIN, JH			IDENTIFICATION OF RESIDUES 413-433 OF PLASMA PROTEIN-S AS ESSENTIAL FOR BINDING TO C4B-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VIII; COFACTOR ACTIVITY; DEFICIENCY; INACTIVATION; THROMBOSIS; SEQUENCE; ARTERIAL; REGIONS; BOVINE; CELLS	Reversible association of protein S with C4b-binding protein (C4BP) in plasma down-regulates protein S activity, since free protein S but not the protein S.C4BP complex is an anticoagulant cofactor for activated protein C. To identify regions on the surface of protein S that mediate complex formation with C4BP, a number of nonoverlapping synthetic pentadecapeptides comprising protein S sequences were prepared and tested for their ability to inhibit complex formation. The most potent pentadecapeptide, residues 420-434 (PSP-420) (SGIKEIIQEKQNKHC), gave half-maximal effect at 20 muM. A peptide with the reverse sequence, 434-420, did not inhibit. A peptide containing the sequence of protein S residues 408-434 inhibited complex formation by >95% with 50% inhibition at 5 muM peptide. Biotinylated C4BP bound specifically to plates coated with PSP-420 but not with the 434-420 peptide; and biotinylated PSP-420 bound to plates coated with C4BP. Rabbit antibodies were raised against several keyhole limpet hemocyanin-conjugated peptides, and each was tested for ability to inhibit complex formation. Anti-PSP-420 antibody potently inhibited complex formation with half-maximal effect at 25 nM IgG. A monoclonal antibody (LJ-56) made against PSP-420 showed high affinity for protein S and inhibited complex formation; this monoclonal antibody specifically recognized free protein S but not the protein S.C4BP complex. These results imply that the PSP-420 sequence is surface-exposed, capable of binding to C4BP, and essential for protein S binding to C4BP.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, BCR-5, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-21544] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROEKMANS AW, 1985, THROMB HAEMOSTASIS, V53, P273; BROWN JP, 1980, J BIOL CHEM, V255, P4980; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; CHANG GTG, 1992, THROMB HAEMOSTASIS, V67, P526; CHANG GTG, 1991, BLOOD, V78, P277; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1986, P NATL ACAD SCI USA, V83, P4199, DOI 10.1073/pnas.83.12.4199; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FERNANDEZ JA, 1992, CIRCULATION, V86, P814; FERNANDEZ JA, 1991, THROMB HAEMOSTASIS, V65, P711; GARDINER JE, 1984, CIRCULATION, V70, P205; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; GREENGARD JS, 1992, BLOOD, V80, P266; GRIFFIN JH, 1992, BLOOD, V79, P3203; GRIFFIN JH, 1993, IN PRESS THROMB HAEM; HEEB MJ, 1993, J BIOL CHEM, V268, P2872; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KIRSCHENBAUM DM, 1973, ANAL BIOCHEM, V56, P237, DOI 10.1016/0003-2697(73)90186-3; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LAURELL CB, 1965, ANAL BIOCHEM, V10, P358, DOI 10.1016/0003-2697(65)90278-2; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANNUCCI PM, 1986, THROMB HAEMOSTASIS, V55, P440; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MILLER M, 1992, CIRCULATION, V86, P674; NELSON RM, 1991, BIOCHEMISTRY-US, V30, P2384, DOI 10.1021/bi00223a013; NELSON RM, 1992, J BIOL CHEM, V267, P8140; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCHWARZ HP, 1986, THROMB HAEMOSTASIS, V56, P382; SCHWARZ HP, 1989, BLOOD, V74, P213; SIE P, 1989, THROMB HAEMOSTASIS, V62, P1040; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1989, J BIOL CHEM, V264, P17645; WEINSTEIN RE, 1990, J CLIN INVEST, V86, P1928, DOI 10.1172/JCI114926	38	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1993	268	22					16788	16794						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ336	7688369				2022-12-27	WOS:A1993LQ33600099
J	RAINES, MA; KOLESNICK, RN; GOLDE, DW				RAINES, MA; KOLESNICK, RN; GOLDE, DW			SPHINGOMYELINASE AND CERAMIDE ACTIVATE MITOGEN-ACTIVATED PROTEIN-KINASE IN MYELOID HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; EPIDERMAL GROWTH-FACTOR; MICROTUBULE-ASSOCIATED PROTEIN-2; TYROSINE PHOSPHORYLATION; FACTOR-ALPHA; MAP KINASE; DIFFERENTIATION; IDENTIFICATION; INTERFERON; INSULIN	Mechanisms involved in tumor necrosis factor (TNF)-alpha signal transduction are incompletely understood. In some circumstances, TNF may use a signal transduction pathway involving hydrolysis of sphingomyelin to ceramide and stimulation of a ceramide-activated protein kinase. In HL-60 cells, TNF rapidly activates this pathway and induces monocytic differentiation. Here, we demonstrate that treatment of HL-60 cells with TNF selectively increases tyrosine phosphorylation of p42 mitogen-activated protein kinase (p42mapk) and stimulates its enzymatic activity. Induction of p42mapk phosphorylation was time- and dose-dependent and closely paralleled activation of sphingomyelin hydrolysis. Direct engagement of the sphingomyelin signal transduction pathway by addition of bacterial sphingomyelinase led to MAP kinase activation. The time course of p42mapk phosphorylation in the sphingomyelinase-treated cells was similar to that of TNF, with maximal response occurring at 5 min. A maximal concentration of sphingomyelinase (0.01 unit/ml) was more potent than TNF at inducing MAP kinase enzymatic activity (2.6-fold) and phosphorylation of MAP kinase and tyrosine. The cell-permeable ceramide analogs, C2- and C6-ceramide, which mimic effects of TNF, also induced p42mapk phosphorylation within seconds. These studies indicate that the sphingomyelin pathway can regulate MAP kinase activity and suggest that MAP kinase activation by this mechanism may be involved in TNF-induced signal transduction.	MEM SLOAN KETTERING CANC CTR,MOLEC PHARMACOL & THERAPEUT PROGRAM,1275 YORK AVE,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NCI NIH HHS [R37 CA30388, P30 CA08748] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R37CA030388] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HALL FL, 1991, J BIOL CHEM, V266, P17430; HATTORI S, 1992, J BIOL CHEM, V267, P20346; KIM MY, 1991, J BIOL CHEM, V266, P484; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OKUDA K, 1992, BLOOD, V79, P2880; RAINES MA, 1992, BLOOD, V79, P3350; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHANENKING C, 1991, NEURON, V6, P915, DOI 10.1016/0896-6273(91)90232-O; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SETH A, 1992, J BIOL CHEM, V267, P24796; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOLDKORN T, 1991, J BIOL CHEM, V266, P16092; TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632	38	276	281	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14572	14575						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686898				2022-12-27	WOS:A1993LL75900006
J	USHIYAMA, S; LAUE, TM; MOORE, KL; ERICKSON, HP; MCEVER, RP				USHIYAMA, S; LAUE, TM; MOORE, KL; ERICKSON, HP; MCEVER, RP			STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF MONOMERIC SOLUBLE P-SELECTIN AND COMPARISON WITH MEMBRANE P-SELECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-VA; ELECTRON-MICROSCOPY; ADHESION RECEPTORS; MOLECULAR-WEIGHT; CELL-ADHESION; GMP-140 BINDS; PROTEINS; NEUTROPHILS; PLATELETS; SURFACE	P-selectin is an adhesion receptor for leukocytes on thrombin-activated platelets and endothelial cells. It contains a NH2-terminal carbohydrate-recognition domain, an epidermal growth factor motif, nine consensus repeats, a transmembrane domain, and a cytoplasmic tail. We expressed two soluble forms of P-selectin, one truncated after the ninth repeat (tPS) and the other lacking the transmembrane domain due to alternative RNA splicing (asPS). When visualized by electron microscopy, each was a monomeric rod-like structure with a globular domain at one end, whereas membrane P-selectin (mPS) from platelets formed rosettes with the globular domains facing outward. Sedimentation velocity and equilibrium studies confirmed that tPS and asPS were asymmetric monomers, whereas mPS was oligomeric. HL-60 cells adhered to immobilized tPS and asPS, although less efficiently than to mPS. I-125-Labeled tPS and asPS bound to approximately 25,000 sites/neutrophil and approximately 36,000 sites/HL-60 cell with an apparent K(d) of 70 nM. Treatment of HL-60 cells with O-sialoglycoprotease eliminated the binding sites for asPS. We conclude that 1) P-selectin is a rigid, asymmetric protein; 2) monomeric soluble P-selectin binds to high affinity ligands with sialylated O-linked oligosaccharides on leukocytes; and 3) oligomerization of mPS enhances its avidity for leukocytes.	UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,WK WARREN MED RES INST,825 NE 13TH ST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA HLTH SCI CTR,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University System Of New Hampshire; University of New Hampshire; Duke University					NCI NIH HHS [CA 47056] Funding Source: Medline; NHLBI NIH HHS [HL 34363, HL 45510] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047056, R37CA047056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R01HL045510, R37HL034363] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ARNAOUT MA, 1984, J CLIN INVEST, V74, P1291, DOI 10.1172/JCI111539; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DUNLOP LC, 1992, J EXP MED, V175, P1147, DOI 10.1084/jem.175.4.1147; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P108; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FUJIMOTO T, 1993, J BIOL CHEM, V268, P11394; GENG JG, 1991, J BIOL CHEM, V266, P22313; GENG JG, 1992, J BIOL CHEM, V267, P19846; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HAMBURGER SA, 1990, BLOOD, V75, P550; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KATAYAMA M, 1992, J IMMUNOL METHODS, V153, P41, DOI 10.1016/0022-1759(92)90303-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P63; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LAUE TM, 1992, SHORT COLUMN EQUILIB; LAVER WG, 1969, VIROLOGY, V38, P105, DOI 10.1016/0042-6822(69)90132-9; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEY K, 1991, BLOOD, V77, P2553; LOEB JA, 1987, J BIOL CHEM, V262, P3022; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1993, STRUCTURE, FUNCTION, AND REGULATION OF MOLECULES INVOLVED IN LEUKOCYTE ADHESION, P135; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEWMAN PJ, 1992, NOUV REV FR HEMATOL, V34, P9; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; OLSEN PH, 1992, BIOCHEMISTRY-US, V31, P746, DOI 10.1021/bi00118a016; PATEL KD, 1992, J BIOL CHEM, V267, P15168; RECNY MA, 1990, J BIOL CHEM, V265, P8542; REYNOLDS JA, 1985, METHOD ENZYMOL, V117, P41; RICE KG, 1990, J BIOL CHEM, V265, P18429; SANDERS WE, 1992, BLOOD, V80, P795; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEININGER CN, 1992, BIOCHEM BIOPH RES CO, V188, P760, DOI 10.1016/0006-291X(92)91121-6; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALLS JD, 1990, BIOTECHNIQUES, V8, P138; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WELLER A, 1992, J BIOL CHEM, V267, P15176; WINNARD PT, 1989, ARCH BIOCHEM BIOPHYS, V269, P339, DOI 10.1016/0003-9861(89)90115-X; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	66	268	284	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15229	15237						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686912				2022-12-27	WOS:A1993LL75900099
J	ZIEGLER, I; HULTNER, L; EGGER, D; KEMPKES, B; MAILHAMMER, R; GILLIS, S; RODL, W				ZIEGLER, I; HULTNER, L; EGGER, D; KEMPKES, B; MAILHAMMER, R; GILLIS, S; RODL, W			IN A CONCERTED ACTION KIT-LIGAND AND INTERLEUKIN-3 CONTROL THE SYNTHESIS OF SEROTONIN IN MURINE BONE MARROW-DERIVED MAST-CELLS - UP-REGULATION OF GTP CYCLOHYDROLASE-I AND TRYPTOPHAN 5-MONOOXYGENASE ACTIVITY BY THE KIT-LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ENHANCING ACTIVITY; C-KIT; STEEL LOCUS; T-CELL; MOUSE; TETRAHYDROBIOPTERIN; PROLIFERATION; HYDROXYLASE; FORMS; 5-HYDROXYTRYPTAMINE	Mouse bone marrow-derived mast cells (BMMC) store and release serotonin whose synthesis is initiated by tryptophan 5-monooxygenase. (6R)-H4biopterin serves as the natural cofactor for this reaction. GTP cyclohydrolase I catalyzes the first and rate-limiting step of its synthesis. In this study we demonstrate that among a panel of growth-promoting cytokines including kit ligand (KL), interleukin 3 (IL-3), IL-4, IL-9, and nerve growth factor, KL selectively enhances the synthesis of H4biopterin through up-regulation of GTP cyclohydrolase I activity to 6.2-fold levels. The activities of the subsequent enzymes 6-pyruvoyl-H4pterin synthase and sepiapterin reductase remain unaffected. The activity of tryptophan 5-monooxygenase was selectively enhanced 4.5-fold by the combination of IL-3 with KL. All other factors could not substitute for KL. The constitutive high activity of aromatic L-amino acid decarboxylase is not different in cells cultured in IL-3 and/or KL. In consequence, the concerted action of IL-3 and KL on the GTP cyclohydrolase I and the tryptophan 5-monooxygenase reaction enhances the production of serotonin to about 20-fold levels. Additionally, KL specifically causes the release of about half of total serotonin produced. Hence, our data demonstrate a novel role of these cytokines for the function of mouse BMMC and provide a coherent view of the regulation of serotonin synthesis in this cell type.	GSF MUNICH,INST EXPTL HAMATOL,W-8000 MUNICH 70,GERMANY; IMMUNEX CORP,SEATTLE,WA 98101	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Immunex Corporation	ZIEGLER, I (corresponding author), GSF MUNICH,INST KLIN MOLEK BIOL & TUMORGENET,MARCHIONINISTR 25,W-8000 MUNICH 70,GERMANY.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BURG AW, 1968, J BIOL CHEM, V243, P2349; COLUMBO M, 1992, J IMMUNOL, V149, P599; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DAVIS MD, 1992, P NATL ACAD SCI USA, V89, P10109, DOI 10.1073/pnas.89.21.10109; DAVIS MD, 1991, P NATL ACAD SCI USA, V88, P385, DOI 10.1073/pnas.88.2.385; DUTCH DS, 1991, J NUTR BIOCH, V2, P411; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1991, FASEB J, V5, pA1092; GERSHON MD, 1981, ANNU REV NEUROSCI, V4, P227, DOI 10.1146/annurev.ne.04.030181.001303; GUTLICH M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P133, DOI 10.1016/0167-4781(92)90112-D; HASEGAWA H, 1987, BIOCHEM J, V248, P501, DOI 10.1042/bj2480501; HOLGATE ST, 1988, ALLERGY PRINCIPLES P, V1, P135; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; HULTNER L, 1989, IMMUNOLOGY, V67, P408; IHLE JN, 1983, J IMMUNOL, V131, P282; ISOBE T, 1991, J MOL BIOL, V217, P125, DOI 10.1016/0022-2836(91)90616-E; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAUFMAN S, 1962, OXYGENASES, P285; KERLER F, 1989, BIOCHIM BIOPHYS ACTA, V990, P15, DOI 10.1016/S0304-4165(89)80005-4; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; Kitamura Y., 1989, MAST CELL BASOPHIL D, P15; KUHN DM, 1980, ARCH BIOCHEM BIOPHYS, V199, P355, DOI 10.1016/0003-9861(80)90291-X; KUHN DM, 1980, J BIOL CHEM, V255, P4137; KUHN DM, 1985, FOLATES PTERINS, V2, P354; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MILSTIEN S, 1986, P169; MOELLER J, 1990, J IMMUNOL, V144, P4231; MORRISON DC, 1974, J IMMUNOL, V112, P573; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; NAKAJIMA K, 1992, BIOCHEM BIOPH RES CO, V183, P1076, DOI 10.1016/S0006-291X(05)80300-6; NAKATA H, 1982, EUR J BIOCHEM, V124, P595; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; REISBACH G, 1993, EXP HEMATOL, V21, P74; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; STOLL J, 1990, GENOMICS, V7, P88, DOI 10.1016/0888-7543(90)90522-V; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TOGARI A, 1992, BIOCHEM BIOPH RES CO, V187, P359, DOI 10.1016/S0006-291X(05)81501-3; TRAIFFORT E, 1991, J CHROMATOGR-BIOMED, V571, P231, DOI 10.1016/0378-4347(91)80449-M; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; WEITZMAN G, 1985, INT ARCH ALLER A IMM, V77, P189, DOI 10.1159/000233782; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; WINGREN U, 1983, INT ARCH ALLER A IMM, V70, P193, DOI 10.1159/000233322; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1985, J CELL BIOCHEM, V28, P197, DOI 10.1002/jcb.240280303; ZIEGLER I, 1992, FEBS LETT, V307, P147, DOI 10.1016/0014-5793(92)80755-6; ZIEGLER I, 1990, MED RES REV, V10, P95, DOI 10.1002/med.2610100104; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; ZUO DM, 1991, J CHROMATOGR-BIOMED, V567, P381, DOI 10.1016/0378-4347(91)80144-2	54	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12544	12551						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685343				2022-12-27	WOS:A1993LG65800049
J	PIDGEON, C; MARKOVICH, RJ; LIU, MD; HOLZER, TJ; NOVAK, RM; KEYER, KA				PIDGEON, C; MARKOVICH, RJ; LIU, MD; HOLZER, TJ; NOVAK, RM; KEYER, KA			ANTIVIRAL PHOSPHOLIPIDS - ANTI-HIV DRUGS CONJUGATED TO THE GLYCEROBACKBONE OF PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLTRANSFERASE; HUMAN IMMUNODEFICIENCY VIRUS-1; GAG POLYPROTEIN PRECURSOR; MYRISTIC ACID; CELLULAR PROTEINS; MEMBRANE; PURIFICATION; ACYLATION; ACTIVATION; GLYCERIDES	Heteroatom fatty acid analogs of myristic acid containing oxygen or sulfur substituted for the alkyl methylene groups inhibit replication of the human immunodeficiency virus (HIV) in infected cells by acting as alternative substrates during the viral protein myristoylation event. In this class of compounds, 12-methoxydodecanoic acid is the most potent compound but is approximately 10(3)-fold less active than azidothymidine. The antiviral activity of 12-methoxydodecanoic acid can be enhanced >40-fold by preparing L-alpha-phosphatidylethanolamine containing 12-methoxydodecanoic acid in both alkyl chains. In addition, the diacylated L-alpha-phosphatidylcholine analog containing 12-methoxydodecanoic acid in both alkyl chains (i) has a 15-fold better antiviral selectivity, (ii) is 7-fold more potent, and (iii) is 10-100-fold more synergistic with azidothymidine than 12-methoxydodecanoic acid. Because of potent synergism, the antiviral selectivity of the diacylated L-alpha-phosphatidylcholine analog is >10(4) when coadministered with azidothymidine. Phospholipid conjugates are chiral at the C-2 carbon of the glycerol backbone and most interesting is the observation that both the D- and L-isomers of phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, and phosphatidylserine have approximately equal antiviral activity. Phospholipase A2 stereospecifically hydrolyzes only the L isomer of phospholipids and similar activity for both the D- and L- phospholipid isomers suggests that phospholipase A2 is not the rate-limiting enzyme for release of the drugs in vivo.	ABBOTT LABS,DIV DIAGNOST,N CHICAGO,IL 60064; UNIV ILLINOIS,DEPT MED,CHICAGO,IL 60612	Abbott Laboratories; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	PIDGEON, C (corresponding author), PURDUE UNIV,SCH PHARM,DEPT MEDICINAL CHEM & PHARMACOGNOSY,W LAFAYETTE,IN 47907, USA.							ADAMS SP, 1989, Patent No. 327523; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ARYA SK, 1986, P NATL ACAD SCI USA, V83, P2209, DOI 10.1073/pnas.83.7.2209; BATHURST IC, 1989, J VIROL, V63, P3176, DOI 10.1128/JVI.63.7.3176-3179.1989; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; GARZONABURBEH A, 1983, J MED CHEM, V26, P1200, DOI 10.1021/jm00362a021; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HALENDA SP, 1989, BIOCHEMISTRY-US, V28, P7356, DOI 10.1021/bi00444a031; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HOSTETLER KY, 1990, J BIOL CHEM, V265, P6112; HOSTETLER KY, 1991, Patent No. 2447; MANTELLI S, 1985, CHEM PHYS LIPIDS, V37, P329, DOI 10.1016/0009-3084(85)90087-8; MARKOVICH RJ, 1991, ANAL CHEM, V63, P1851, DOI 10.1021/ac00017a034; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OUSLEY AH, 1992, J BIOL CHEM, V267, P10362; PAIGE LA, 1990, BIOCHEMISTRY-US, V29, P10566, DOI 10.1021/bi00498a021; PARIS GY, 1980, J MED CHEM, V23, P9, DOI 10.1021/jm00175a003; PARIS GY, 1980, J MED CHEM, V23, P79, DOI 10.1021/jm00175a015; PIDGEON C, 1991, ANAL BIOCHEM, V194, P163, DOI 10.1016/0003-2697(91)90164-O; PIDGEON C, 1990, Patent No. 4931498; PRICHARD MM, 1900, ANTIVRAL RES, V14, P181; SCHMIDT MFG, 1984, EMBO J, V3, P2295, DOI 10.1002/j.1460-2075.1984.tb02129.x; THOMPSON GA, 1984, PHYSL MEMBRANE FLUID, V1; THURNHOFER H, 1991, BIOCHIM BIOPHYS ACTA, V1064, P275, DOI 10.1016/0005-2736(91)90312-V; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988	31	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7773	7778						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681828				2022-12-27	WOS:A1993KW97900032
J	PADH, H; HA, JH; LAVASA, M; STECK, TL				PADH, H; HA, JH; LAVASA, M; STECK, TL			A POST-LYSOSOMAL COMPARTMENT IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; PINOCYTOSED FLUID; KINETIC EVIDENCE; TEMPORAL CHANGES; ENDOCYTOSIS; CELLS; VACUOLES; PROBE; MACROPHAGES; FIBROBLASTS	Fluorescein isothiocyanate (FITC)-dextran and pyranine were fed to the social amoeba, Dictyostelium discoideum. These membrane-impermeable, pH-sensitive fluorophores initially entered a congruent-to neutral endocytic compartment. They encountered maximal acidity (pH congruent-to 5) about 15 min after ingestion, in what appeared to be digestive vacuoles (lysosomes). The environment of the probes returned to near neutrality by 30 min. At that time, the probes accumulated in a decreasing number of vacuoles of increasing size; ultimately, there were only a small number of vacuoles per cell with diameters of up to 3 mum. The late vacuoles sedimented more rapidly than did proton pumps, acid hydrolases, and recently ingested cargo. Unlike the vacuoles harvested immediately after the cells were fed FITC-dextran, the late vacuoles were not acidified by MgATP in vitro. Egestion of ingested FITC-dextran commenced after a lag of congruent-to 45 min. A similar lag was observed for the resurfacing of two endocytosed bilayer-intercalated fluorophores. These results suggest that, in Dictyostelium, undigested endocytic cargo accumulates in and is returned to the cell surface through a distinctive compartment of large and nearly neutral post-lysosomal vacuoles. It will be important to determine the degree to which internalized plasma membrane components follow this post-lysosomal pathway.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA	University of Chicago				Padh, Harish/0000-0003-2305-6229				ADAMS CJ, 1982, J CELL BIOL, V93, P632, DOI 10.1083/jcb.93.3.632; ALEY SB, 1984, J EXP MED, V160, P724, DOI 10.1084/jem.160.3.724; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BOWERS B, 1983, J CELL BIOL, V97, P317, DOI 10.1083/jcb.97.2.317; BRENOT F, 1992, BIOCHIMIE, V74, P883, DOI 10.1016/0300-9084(92)90072-M; BRONNER C, 1986, BIOCHEMISTRY-US, V25, P2149, DOI 10.1021/bi00356a045; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; BUSH JM, 1989, J BIOL CHEM, V264, P7630; Cardelli J.A., 1988, P363; CASCIOLAROSEN LAF, 1991, J BIOL CHEM, V266, P4341; Chapman-Andresen C., 1973, P319; DAEMS WT, 1969, LYSOSOM BIOL PATHOL, P64; DAUKAS G, 1983, J CELL BIOL, V96, P1642, DOI 10.1083/jcb.96.6.1642; DECHASTELLIER C, 1983, EUR J CELL BIOL, V30, P233; Fok A.K., 1990, International Review of Cytology, V123, P61, DOI 10.1016/S0074-7696(08)60671-3; FOK AK, 1985, J PROTOZOOL, V32, P6, DOI 10.1111/j.1550-7408.1985.tb03004.x; GEISOW MJ, 1981, J CELL BIOL, V89, P645, DOI 10.1083/jcb.89.3.645; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Holtzman E, 1989, LYSOSOMES; IDRISS JM, 1991, J BIOL CHEM, V266, P9438; ILLINGER D, 1990, BIOCHIM BIOPHYS ACTA, V1030, P73, DOI 10.1016/0005-2736(90)90240-O; JENSEN MS, 1973, J CELL BIOL, V56, P379, DOI 10.1083/jcb.56.2.379; JONAS AJ, 1990, J BIOL CHEM, V265, P17545; KITCHING JA, 1956, PROTOPLASMATOLOGIA, P1; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; LAGUNOFF DAVID, 1964, COMPT REND TRAV LAB CARLSBERG, V34, P433; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; NILSSON JR, 1979, BIOCH PHYSL PROTOZOA, V2, P502; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OHKUMA S, 1987, LYSOSOMES THEIR ROLE, P115; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1991, J BIOL CHEM, V266, P12123; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; ROEDERER M, 1989, EUR J CELL BIOL, V48, P37; RYTER A, 1976, J ULTRA MOL STRUCT R, V57, P309, DOI 10.1016/S0022-5320(76)80119-0; RYTER A, 1977, J CELL BIOL, V75, P200, DOI 10.1083/jcb.75.1.200; SIPE DM, 1991, J BIOL CHEM, V266, P3469; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; Stockem W, 1977, MAMMALIAN CELL MEMBR, V5, P151; STRAUBINGER RM, 1990, BIOCHEMISTRY-US, V29, P4929, DOI 10.1021/bi00472a025; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; Vickerman K, 1976, BIOL KINETOPLASTIDA, P35; WEBSTER P, 1989, EUR J CELL BIOL, V49, P295	50	79	79	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6742	6747						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681066				2022-12-27	WOS:A1993KT36800095
J	INOUE, G; KUZUYA, H; HAYASHI, T; OKAMOTO, M; YOSHIMASA, Y; KOSAKI, A; KONO, S; OKAMOTO, M; MAEDA, I; KUBOTA, M; IMURA, H				INOUE, G; KUZUYA, H; HAYASHI, T; OKAMOTO, M; YOSHIMASA, Y; KOSAKI, A; KONO, S; OKAMOTO, M; MAEDA, I; KUBOTA, M; IMURA, H			EFFECTS OF ML-9 ON INSULIN STIMULATION OF GLUCOSE-TRANSPORT IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; HEXOSE-TRANSPORT; PHORBOL ESTER; S6 KINASE; CATECHOLAMINE SECRETION; PLASMA-MEMBRANE; SWISS 3T3-CELLS; PROTEIN-KINASES; GROWTH-FACTORS; MAP KINASE	Treatment of 3T3-L1 adipocytes with insulin resulted in activation of 2-deoxyglucose transport activity and translocation of glucose transporters (GLUT4 and GLUT1) from the cytoplasmic space to the plasma membrane. ML-9 (a myosin light chain kinase inhibitor) inhibited insulin stimulation of 2-deoxyglucose transport activity by 80% at 100 muM (IC50 = 27 muM) without affecting 2-deoxyglucose transport activity in the basal state. The inhibition was independent of extracellular Ca2+ concentration and almost fully reversible at 40 muM ML-9. ML-9 did not inhibit insulin-stimulated tyrosine phosphorylation of 95-kDa protein in the wheat germ agglutinin-purified preparation and of 95- and 160-kDa proteins in intact cells. However, ML-9 inhibited insulin-induced translocation of both GLUT4 and GLUT1 in a dose-dependent manner. The dose-response curves were similar to those observed for the inhibition of insulin stimulation of 2-deoxyglucose transport activity. Neither insulin nor ML-9 affected the phosphorylation state of both heavy and light chains of myosin. Therefore, it seems likely that ML-9 inhibits the insulin-induced translocation of glucose transporters at a step beyond the insulin receptor kinase activity by a mechanism different from that affecting phosphorylation of the myosin light chain. Phosphorylating activity of microtubule-associated protein 2 and myelin basic protein was stimulated by insulin, and this stimulation was not affected by ML-9. ML-9, however, inhibited the phosphorylating activity in vitro and insulin stimulation of the phosphorylating activity of ribosomal protein S6 in intact cells in a dose-dependent manner similar to that observed for the inhibition of insulin stimulation of glucose transport. These results suggest that mitogen-activated protein kinase may be one of the constituents in intracellular insulin signaling to the glucose transport system.			INOUE, G (corresponding author), KYOTO UNIV,SCH MED,DIV INTERNAL MED 2,54 KAWAHARACHO,SAKYO KU,KYOTO 606,JAPAN.			hayashi, Tatsuya/0000-0001-7600-4735				AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BAINES AJ, 1987, NATURE, V326, P646, DOI 10.1038/326646a0; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BURGOYNE RD, 1990, ANNU REV PHYSIOL, V52, P647; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIBBS EM, 1991, BIOCHEM J, V275, P145, DOI 10.1042/bj2750145; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KASUGA M, 1985, METHOD ENZYMOL, V109, P609; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOSAKI A, 1991, MOL CELL ENDOCRINOL, V75, P189, DOI 10.1016/0303-7207(91)90160-T; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RM, 1992, J BIOL CHEM, V267, P1088; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MAJERCIK MH, 1988, BIOCHEM J, V252, P815, DOI 10.1042/bj2520815; MEIER KE, 1991, J BIOL CHEM, V266, P1914; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAGATSU T, 1987, BIOCHEM BIOPH RES CO, V143, P1045, DOI 10.1016/0006-291X(87)90357-3; NAKANISHI A, 1989, BIOCHEM PHARMACOL, V38, P2615, DOI 10.1016/0006-2952(89)90546-7; OKAMOTO M, 1992, J NUTR BIOCHEM, V3, P241, DOI 10.1016/0955-2863(92)90046-L; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; SAITOH M, 1986, BIOCHEM BIOPH RES CO, V140, P280, DOI 10.1016/0006-291X(86)91087-9; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Sherton C C, 1974, Methods Enzymol, V30, P506; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369	44	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5272	5278						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680348				2022-12-27	WOS:A1993KP88400101
J	KARP, SJ; MASU, M; EKI, T; OZAWA, K; NAKANISHI, S				KARP, SJ; MASU, M; EKI, T; OZAWA, K; NAKANISHI, S			MOLECULAR-CLONING AND CHROMOSOMAL LOCALIZATION OF THE KEY SUBUNIT OF THE HUMAN N-METHYL-D-ASPARTATE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID RECEPTORS; CA2+ PERMEABILITY; XENOPUS OOCYTES; CHANNELS; ANTAGONISTS; EXPRESSION; SEQUENCE; GENES	A complementary DNA encoding the key subunit of the human N-methyl-D-aspartate (NMDA) receptor (NMDAR1) has been cloned using a probe derived from the rat NMDAR1 cDNA. The cDNA encodes a 938-amino acid protein, which shows 99% amino acid homology with the rat counterpart. Of the 7 of 938 amino acids which are different, three occur in the region of the signal peptide and the others in the extracellular amino-terminal domain preceding the 4 putative transmembrane segments. Expression in Xenopus oocytes demonstrated that the single protein encoded by the cloned cDNA possesses the electrophysiological and pharmacological properties characteristic of the NMDA receptor, including Ca2+ permeability, voltage-dependent Mg2+ block, and inhibition by selective antagonists such as Zn2+ and channel blockers. The high evolutionary conservation in the structure and properties of NMDAR1 argues strongly for the importance of this receptor in functions of glutamate neurotransmission. RNA blot analysis showed abundant expression of mRNA whose size is about 4.5 and 4.8 kilonucleotides. The human gene encoding the NMDAR1 subunit has been mapped to chromosome 9q34.3 by the analyses of blot hybridization of a DNA panel of human/hamster somatic cell hybrids and fluorescence in situ hybridization of human chromosomes.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENE BANK,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	KARP, SJ (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.							BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DAVISSON MT, 1991, CYTOGENET CELL GENET, V58, P1152, DOI 10.1159/000133726; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISHII T, 1993, IN PRESS J BIOL CHEM, V268; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LEONARD JP, 1990, NEURON, V4, P53, DOI 10.1016/0896-6273(90)90443-J; LODGE D, 1990, TRENDS PHARMACOL SCI, V11, P81, DOI 10.1016/0165-6147(90)90323-Z; MACDONALD JF, 1990, TRENDS PHARMACOL SCI, V11, P167, DOI 10.1016/0165-6147(90)90070-O; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; POVEY S, 1991, CYTOGENET CELL GENET, V58, P403, DOI 10.1159/000133169; PUCKETT C, 1991, P NATL ACAD SCI USA, V88, P7557, DOI 10.1073/pnas.88.17.7557; SAKURADA K, 1993, IN PRESS J BIOL CHEM, V268; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOFIELD PR, 1989, FEBS LETT, V244, P361, DOI 10.1016/0014-5793(89)80563-0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A	33	102	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3728	3733						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679115				2022-12-27	WOS:A1993KM16100106
J	JOHNSON, GR; KANNAN, B; SHOYAB, M; STROMBERG, K				JOHNSON, GR; KANNAN, B; SHOYAB, M; STROMBERG, K			AMPHIREGULIN INDUCES TYROSINE PHOSPHORYLATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR AND P185(ERBB2) - EVIDENCE THAT AMPHIREGULIN ACTS EXCLUSIVELY THROUGH THE EPIDERMAL GROWTH-FACTOR RECEPTOR AT THE SURFACE OF HUMAN EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-RECEPTOR; HUMAN-BREAST; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; NEU ONCOGENE; A431 CELLS; PROTEIN; GENE; LINE	The COOH-terminal half of the amphiregulin (AR) molecule has sequence homology to epidermal growth factor (EGF). The ability of AR to elicit in vivo phosphorylation of the EGF receptor (EGFR) and p185erbB2 was studied in four human epithelial cell lines which expressed either or both of the receptor tyrosine kinases. AR induced the phosphorylation of the EGFR and p185erbB2, and phosphoamino acid analysis revealed enhanced phosphorylation of tyrosine residues in both receptor proteins. A monoclonal antibody (mAb) which binds to the extracellular domain of the EGFR blocked the phosphorylation of the EGFR and p185erbB2 as well as AR-induced mitogenesis indicating that the EGFR mediated these responses. In MDA-MB-453 cells which lack EGFRs, AR did not induce phosphorylation of p185erbB2, did not affect proliferation, and had no detectable effect on the phosphorylation of cellular proteins isolated using an anti-phosphotyrosine mAb. Qualitatively, in vivo phosphorylations induced by AR and EGF were found to be indistinguishable as demonstrated by analysis of cellular P-32-labeled proteins isolated with the anti-phosphotyrosine mAb. Moreover, in the presence of the anti-EGFR mAb, AR had no effect on the proliferation of cells. These results provide strong evidence that the EGFR is the sole cell surface mediator of the action of AR in human epithelial cells.	BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA	Bristol-Myers Squibb	JOHNSON, GR (corresponding author), US FDA, DIV CYTOKINE BIOL,CELL BIOL LAB,HFM-511,BLDG 29A, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CIARDIELLO F, 1991, P NATL ACAD SCI USA, V88, P7792, DOI 10.1073/pnas.88.17.7792; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; COCHET C, 1984, J BIOL CHEM, V259, P2553; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; HANCOCK MC, 1991, CANCER RES, V51, P4575; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; SAEKI T, 1992, CANCER RES, V52, P3467; SATO JD, 1987, METHOD ENZYMOL, V146, P63; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SOULE HD, 1990, CANCER RES, V50, P6075; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STROMBERG K, 1992, CANCER RES, V52, P341; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	60	136	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2924	2931						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679104				2022-12-27	WOS:A1993KK81500098
J	LOPEZCABRERA, M; NUEDA, A; VARA, A; GARCIAAGUILAR, J; TUGORES, A; CORBI, AL				LOPEZCABRERA, M; NUEDA, A; VARA, A; GARCIAAGUILAR, J; TUGORES, A; CORBI, AL			CHARACTERIZATION OF THE P150,95 LEUKOCYTE INTEGRIN ALPHA-SUBUNIT (CD11C) GENE PROMOTER - IDENTIFICATION OF CIS-ACTING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-CELL LEUKEMIA; REGULATED EXPRESSION; MONOCLONAL-ANTIBODIES; GLYCOPROTEIN FAMILY; MAMMALIAN-CELLS; ADHESION; TRANSCRIPTION; MAC-1; RECEPTOR; LFA-1	The leukocyte integrin p150,95 (CD11c/CD18) is involved in a number of cell-cell and cell-extracellular matrix interactions and mediates signal transduction into the cytoplasm. p150,95 is expressed on cells of the myeloid lineage as well as on certain activated T and B lymphocytes, and its expression is regulated during cell activation and differentiation. Since CD18 is expressed on all leukocyte lineages, the restricted expression of p150,95 must be controlled at the level of CD11c gene transcription. To understand the mechanisms that direct the constitutive and regulated leukocyte expression of p150,95 we have structurally characterized the CD11c promoter region and initiated its functional dissection. The CD11c promoter lacks TATA- and CCAAT-boxes, directs the synthesis of transcripts with heterogeneous 5'-ends, and contains an initiator-like sequence at the major transcription initiation site. Several putative binding sequences for ubiquitous (Sp1, AP-1, AP-2, and NF-kB) and leukocyte-specific (PU.1) transcription factors have been identified in the proximal region of the CD11c promoter which may participate in the regulation of the expression of p150,95. Transient expression of CD11c-based reporter gene constructs indicates that the CD11c promoter dictates the tissue-specific expression of p150,95 and that sequences contained within 160 base pairs 5' from the major transcriptional start site are involved in the tissue-specific and regulated expression of p150,95. DNase I protection analysis on the promoter region spanning from -160 to +40 revealed four regions of DNA-protein interactions (FPI-FPIV), two of which (FPIII and FPIV) correlate with the cell type-specific and regulated expression of the CD11c gene.	HOSP PRINCESA DIEGO LEON 62, UNIDAD BIOL MOLEC, PLANTA 9, E-28006 MADRID, SPAIN; HOSP PRINCESA, SERV INMUNOL, E-28006 MADRID, SPAIN	Hospital de La Princesa			Corbí, Angel L./ABC-8146-2020; Tugores, Antonio/AAE-7939-2021; Cabrera, Manuel López/AAA-5463-2019; Corbi, Angel/B-7194-2011	Corbí, Angel L./0000-0003-1980-5733; Corbi, Angel/0000-0003-1980-5733; Lopez Cabrera, Manuel/0000-0002-0976-9719; Nueda, Arsenio/0000-0001-8373-500X; Tugores, Antonio/0000-0002-1849-9239				AGURA ED, 1992, BLOOD, V79, P602; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; CORBI AL, 1990, J BIOL CHEM, V265, P2782; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUITS AJ, 1991, SCAND J IMMUNOL, V33, P151, DOI 10.1111/j.1365-3083.1991.tb03745.x; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANSON CA, 1990, BLOOD, V76, P2360; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1987, J IMMUNOL, V138, P3130; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUDO S, 1991, J BIOL CHEM, V266, P8483; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEBEAU MM, 1985, NATURE, V313, P709, DOI 10.1038/313709a0; LO SK, 1989, J EXP MED, V169, P1779, DOI 10.1084/jem.169.5.1779; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; MILLER LJ, 1986, J IMMUNOL, V137, P2891; PAHL HL, 1992, BLOOD, V79, P865; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSMARIN AG, 1992, BLOOD, V79, P2598; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTING R, 1985, BLOOD, V65, P974; SHELLEY CS, 1991, P NATL ACAD SCI USA, V88, P10525, DOI 10.1073/pnas.88.23.10525; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STACKER SA, 1991, J IMMUNOL, V146, P648; UZAN G, 1991, J BIOL CHEM, V266, P8932	41	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1187	1193						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678251				2022-12-27	WOS:A1993KG07700064
J	UCHINO, T; SAKURAI, Y; NISHIGAI, M; TAKAHASHI, T; ARAKAWA, H; IKAI, A; TAKAHASHI, K				UCHINO, T; SAKURAI, Y; NISHIGAI, M; TAKAHASHI, T; ARAKAWA, H; IKAI, A; TAKAHASHI, K			ISOLATION AND CHARACTERIZATION OF A NOVEL SERINE PROTEINASE COMPLEXED WITH ALPHA-2-MACROGLOBULIN FROM PORCINE GASTRIC-MUCOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATHEPSIN-E; HUMAN-PLASMA; B-CHAIN; INHIBITORS; PURIFICATION; LOCALIZATION; SPECIFICITY; PEPSINOGEN; PROTEASE; CLEAVAGE	Porcine stomach mucosa was found to contain a 740-kDa protein having endopeptidase activity toward peptide 4-methylcoumaryl-7-amide substrates and low molecular mass peptides. This protein was purified to an apparent homogeneity by a series of chromatographic steps on DEAE-cellulose, Sepharose CL-4B, hydroxylapatite, and fast protein liquid chromatography Mono Q columns. The protein was shown to be a complex of the plasma proteinase inhibitor alpha2-macroglobulin and a 25-kDa endopeptidase. The enzyme activity was completely inhibited by diisopropyl fluorophosphate, p-amidinophenylmethanesulfonyl fluoride, leupeptin, antipain, bovine pancreatic trypsin inhibitor, soybean trypsin inhibitor, and ovomucoid, indicating that the entrapped enzyme is a serine proteinase. The proteinase could be released from alpha2-macroglobulin by mild acid treatment and the released enzyme showed activity toward protein substrates. Substrate specificity studies using synthetic and peptide substrates indicated that the enzyme preferentially hydrolyzes Arg-X bonds and, to a much lesser extent, Lys-X bonds, and is apparently distinct from thrombin, kallikrein, plasmin, and other trypsin-like proteinases so far reported including tryptase. Thus, the present enzyme is thought to be a novel type of serine proteinase. The proteinase associated with alpha2-macroglobulin was also found in porcine intestinal mucosa, but not in plasma.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO INST TECHNOL,BIODYNAM LAB,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology								ATHAUDA SBP, 1991, BIOCHEM BIOPH RES CO, V175, P152, DOI 10.1016/S0006-291X(05)81213-6; ATHAUDA SBP, 1990, BIOCHEM BIOPH RES CO, V168, P878, DOI 10.1016/0006-291X(90)92403-M; ATHAUDA SBP, 1991, FEBS LETT, V292, P53, DOI 10.1016/0014-5793(91)80832-N; AZUMA T, 1989, J BIOL CHEM, V264, P16748; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BARRETT AJ, 1980, BIOCHEM J, V187, P909, DOI 10.1042/bj1870909; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DEBRUIN PAF, 1987, CANCER RES, V47, P4654; FIEDLER F, 1981, METHOD ENZYMOL, V80, P493; Fruton J. S., 1971, ENZYMES, V3, P119; Fujita T, 1988, PARANEURON, P165, DOI [10.1007/978-4-431-68066-6_16, DOI 10.1007/978-4-431-68066-6_16]; HAYANO T, 1988, J BIOL CHEM, V263, P1382; KAGEYAMA T, 1980, J BIOCHEM, V87, P725, DOI 10.1093/oxfordjournals.jbchem.a132801; KAGEYAMA T, 1983, J BIOCHEM, V93, P743, DOI 10.1093/jb/93.3.743; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurell C., 1975, PLASMA PROTEINS, P229; Lundblad R L, 1976, Methods Enzymol, V45, P156; MATSUZAKI O, 1988, BIOMED RES-TOKYO, V9, P515; MCCONNELL DJ, 1972, J CLIN INVEST, V51, P1611, DOI 10.1172/JCI106962; NISHIGAI M, 1985, BIOCHIM BIOPHYS ACTA, V831, P236, DOI 10.1016/0167-4838(85)90040-8; OSADA T, 1988, J BIOCHEM-TOKYO, V103, P212, DOI 10.1093/oxfordjournals.jbchem.a122250; SAMLOFF IM, 1987, GASTROENTEROLOGY, V93, P77, DOI 10.1016/0016-5085(87)90317-9; SAMLOFF IM, 1969, GASTROENTEROLOGY, V57, P659; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TJ, 1984, J BIOL CHEM, V259, P1046; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; SOGAWA K, 1978, J BIOCHEM, V84, P763, DOI 10.1093/oxfordjournals.jbchem.a132187; Starkey P. M., 1977, PROTEINASES MAMMALIA, P663; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUJI A, 1989, J BIOL CHEM, V264, P16093; TSUJI A, 1991, BIOCHIM BIOPHYS ACTA, V1078, P85, DOI 10.1016/0167-4838(91)90096-I; VOGT W, 1976, N-S ARCH PHARMACOL, V294, P75, DOI 10.1007/BF00692787; WOOLLEY DE, 1976, BIOCHEM J, V153, P119, DOI 10.1042/bj1530119	39	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					527	533						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678002				2022-12-27	WOS:A1993KE60300080
J	FUKUDA, K; MORIOKA, H; IMAJOU, S; IKEDA, S; OHTSUKA, E; TSURIMOTO, T				FUKUDA, K; MORIOKA, H; IMAJOU, S; IKEDA, S; OHTSUKA, E; TSURIMOTO, T			STRUCTURE-FUNCTION RELATIONSHIP OF THE EUKARYOTIC DNA-REPLICATION FACTOR, PROLIFERATING CELL NUCLEAR ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING STRAND SYNTHESIS; DELTA AUXILIARY PROTEIN; POLYMERASE-DELTA; FACTOR-C; ACCESSORY PROTEINS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; EXCISION REPAIR; INVITRO; PCNA	Proliferating cell nuclear antigen (PCNA) is essential for eukaryotic DNA replication and functions as a processivity factor of DNA polymerase delta (pol delta), Due to the functional and structural similarity with the beta-subunit of Escherichia coli DNA polymerase III, it has been proposed that PCNA would act as a molecular clamp during DNA synthesis, By site-directed mutagenesis and biochemical analyses, we have studied the functional domains of human PCNA required for stimulation of replication factor C (RF-C) ATPase and DNA synthesis by pol delta, Short deletions from either the N or C termini caused drastic changes in extraction and chromatographic behaviors, suggesting that both of these terminal regions are crucial to fold the tertiary structure of PCNA, The short C-terminal stretch from Lys(254) to Glu(256) is necessary for stimulation of RF-C ATPase activity, but not for stimulation of DNA synthesis by pol delta, Nine basic amino acids that are essential for activating DNA synthesis by pol delta are positioned at the internal alpha-helices of PCNA, This result is in good agreement with the observation that PCNA has a ring structure similar to the beta-subunit and clamps a template DNA through this positively charged internal surface, Several other charged amino acids are also required to stimulate either RF-C ATPase or pol delta DNA synthesis, Some of them are positioned at loops which are exposed on one of the side surface of PCNA adjacent to the C-terminal loop. In addition, the beta-sheets composing the intermolecular interface of the trimeric PCNA are important for interaction with pol delta, Therefore, the outer surface of PCNA has multiple functional surfaces which are responsible for the interaction with multiple factors, Furthermore, the two side surfaces seem to be functionally distinguishable, and this may determine the orientation of tracking PCNA along the DNA.	NARA INST SCI & TECHNOL,INST MOLEC & CELLULAR BIOL,NARA 63001,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Nara Institute of Science & Technology; Hokkaido University				Tsurimoto, Toshiki/0000-0001-7597-2216				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Higuchi R., 1989, PCR TECHNOLOGY, P61; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V166, P1376; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SUZUKA I, 1991, EUR J BIOCHEM, V195, P571, DOI 10.1111/j.1432-1033.1991.tb15739.x; TAN CK, 1986, J BIOL CHEM, V261, P2310; TINKER RL, 1994, CELL, V77, P225, DOI 10.1016/0092-8674(94)90315-8; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1990, NAURE, V346, P1; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; XIONG Y, 1993, CELL, V71, P505; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YODER BL, 1991, J BIOL CHEM, V266, P22689; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG H, 1993, MOL BIOL CELL, V4, P879	33	149	154	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22527	22534		10.1074/jbc.270.38.22527	http://dx.doi.org/10.1074/jbc.270.38.22527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673244	hybrid			2022-12-27	WOS:A1995RW31400073
J	WILLIAMSON, RA; YEA, CM; ROBSON, PA; CURNOCK, AP; GADHER, S; HAMBLETON, AB; WOODWARD, K; BRUNEAU, JM; HAMBLETON, P; MOSS, D; THOMSON, TA; SPINELLAJAEGLE, S; MORAND, P; COURTIN, O; SAUTES, C; WESTWOOD, R; HERCEND, T; KUO, EA; RUUTH, E				WILLIAMSON, RA; YEA, CM; ROBSON, PA; CURNOCK, AP; GADHER, S; HAMBLETON, AB; WOODWARD, K; BRUNEAU, JM; HAMBLETON, P; MOSS, D; THOMSON, TA; SPINELLAJAEGLE, S; MORAND, P; COURTIN, O; SAUTES, C; WESTWOOD, R; HERCEND, T; KUO, EA; RUUTH, E			DIHYDROOROTATE DEHYDROGENASE IS A HIGH-AFFINITY BINDING-PROTEIN FOR A77-1726 AND MEDIATOR OF A RANGE OF BIOLOGICAL EFFECTS OF THE IMMUNOMODULATORY COMPOUND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE NUCLEOTIDE BIOSYNTHESIS; HWA-486; PURIFICATION; LEFLUNOMIDE; INHIBITION; DETERGENT; RECEPTOR	A protein with high affinity (K-d 12 nM) for the immunomodulatory compound A77 1726 has been isolated from mouse spleen and identified as the mitochondrial enzyme dihydroorotate dehydrogenase (EC 1.3.3.1), The purified protein had a pi 9.6-9.8 and a subunit M(r) of 43,000, Peptides derived from the mouse protein displayed high microsequence similarity to human and rat dihydroorotate dehydrogenase with, respectively, 35 and 39 out of 43 identified amino acids identical. Dihydroorotate dehydrogenase catalyzes the fourth step in de novo pyrimidine biosynthesis. The in vitro antiproliferative effects of A77 1726 are mediated by enzyme inhibition and can be overcome by addition of exogenous uridine, The rank order of potency of A77 1726 and its analogues in binding or enzyme inhibition was similar to that for inhibition of the mouse delayed type hypersensitivity response. It is proposed that inhibition of dihydroorotate dehydrogenase is an in vivo mechanism of action of the A77 1726 class of compounds. This was confirmed using uridine to counteract inhibition of the murine acute graft versus host response.	ROUSSEL UCLAF, DEPT TOXICOL, F-93235 PARIS, FRANCE; INST CURIE, INSERM, U255, F-75231 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	WILLIAMSON, RA (corresponding author), HOECHST ROUSSEL PHARMACEUT PROPRIETARY LTD, IMMUNOL DOMAIN, SWINDON SN3 5BZ, WILTS, ENGLAND.		Morand, Philippe/C-1213-2016	Morand, Philippe/0000-0003-0306-8759; sautes-fridman, catherine/0000-0003-1735-8722				BARTLETT RR, 1985, INT J IMMUNOPHARMACO, V7, P7, DOI 10.1016/0192-0561(85)90003-7; BARTLETT RR, 1989, THERAPEUTIC APPROACHES TO INFLAMMATORY DISEASES, P215; BARTLETT RR, 1991, AGENTS ACTIONS, V32, P10, DOI 10.1007/BF01983301; CHEN SF, 1986, CANCER RES, V46, P5014; CHERWINSKI HM, 1995, J PHARMACOL EXP THER, V272, P460; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; DOMLJAN Z, 1994, ARTHRITIS RHEUM S, V36, pS56; HINES V, 1986, J BIOL CHEM, V261, P1386; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KEANA JFW, 1978, MEMBRANE BIOCHEM, V1, P323, DOI 10.3109/09687687809063854; KEPPLER D, 1982, METABOLIC COMPARTMEN, P147; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKASCHUS G, 1992, BIOCHEM PHARMACOL, V43, P1025, DOI 10.1016/0006-2952(92)90609-M; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MATTAR T, 1993, FEBS LETT, V334, P161, DOI 10.1016/0014-5793(93)81704-4; MCCHESNEY LP, 1994, TRANSPLANTATION, V57, P1717, DOI 10.1097/00007890-199457120-00005; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MINET M, 1992, GENE, V121, P393, DOI 10.1016/0378-1119(92)90150-N; POPOVIC S, 1986, AGENTS ACTIONS, V19, P313, DOI 10.1007/BF01971235; ROUDEBUSH RE, 1992, AGENTS ACTIONS, V35, P260, DOI 10.1007/BF01997509; TARAYRE JP, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1125; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILLIAMSON RA, 1990, J NEUROCHEM, V55, P1357, DOI 10.1111/j.1471-4159.1990.tb03147.x	24	184	194	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22467	22472		10.1074/jbc.270.38.22467	http://dx.doi.org/10.1074/jbc.270.38.22467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673235	hybrid			2022-12-27	WOS:A1995RW31400064
J	LORENZ, MW; KELLNER, R; HOFFMANN, KH				LORENZ, MW; KELLNER, R; HOFFMANN, KH			A FAMILY OF NEUROPEPTIDES THAT INHIBIT JUVENILE-HORMONE BIOSYNTHESIS IN THE CRICKET, GRYLLUS-BIMACULATUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCKROACH DIPLOPTERA-PUNCTATA; CORPORA ALLATA; ALLATOSTATIN; IDENTIFICATION; SEQUENCE	Four nonapeptides that inhibit juvenile hormone synthesis have been isolated by four high performance liquid chromatographic steps from extracts of the brain of the field cricket, Gryllus bimaculatus. The primary structures of these peptides were assigned by Edman degradation and mass spectrometry as Gly-Trp-Gln-Asp-Leu-Asn-Gly-Gly-Trp-NH2 (Grb-AST B1), Gly-Trp-Arg-Asp-Leu-Asn-Gly-Gly-Trp-NH2 (Grb-AST B2), Ala-Trp-Arg-Asp-Leu-Ser-Gly-Gly-Trp-NH2 (Grb-AST B3), and Ala-Trp-Glu-Arg-Phe-His-Gly-Ser-Trp-NH2 (Grb-AST B4). Each of the peptides shows high sequence similarity to the locustamyoinhibiting peptide (Lom-MIP), but is structurally different from all the allatostatins so far identified. The synthetic allatostatins Grb-AST B1-4 are potent inhibitors (50% inhibition at 10(-8) to 7 x 10(-8) M) of juvenile hormone III biosynthesis by corpora allata from 3 day-old virgin females of G. bimaculatus using an in vitro bioassay. At 10(-7) M, Grb-AST B1 also strongly inhibits juvenile hormone III biosynthesis by corpora allata from 2-day-old adult males and 1-day-old (males and females) and 4-day-old (females) last instar larvae of G. bimaculatus. The inhibitory effect of Grb-AST B1 was also evident on corpora allata from a related species, Acheta domesticus, Inhibition of juvenile hormone synthesis by Grb-AST B1-4 is reversible.	UNIV BAYREUTH,LEHRSTUHL TIEROKOL 1,D-95440 BAYREUTH,GERMANY; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY	University of Bayreuth; Johannes Gutenberg University of Mainz			Lorenz, Matthias/C-4106-2011	Hoffmann, Klaus H./0000-0002-7942-9779				Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BELLES X, 1994, REGUL PEPTIDES, V53, P237, DOI 10.1016/0167-0115(94)90172-4; DONLY BC, 1993, P NATL ACAD SCI USA, V90, P8807, DOI 10.1073/pnas.90.19.8807; DUVE H, 1993, P NATL ACAD SCI USA, V90, P2456, DOI 10.1073/pnas.90.6.2456; DUVE H, 1994, J BIOL CHEM, V269, P21059; DUVE H, 1994, CELL TISSUE RES, V276, P367, DOI 10.1007/BF00306122; FEYEREISEN R, 1981, ANAL BIOCHEM, V111, P372, DOI 10.1016/0003-2697(81)90575-3; GADE G, 1987, PHYSIOL ENTOMOL, V12, P309, DOI 10.1111/j.1365-3032.1987.tb00755.x; GERSTENLAUER B, 1995, EUR J ENTOMOL, V92, P81; HAYES TK, 1994, PEPTIDES, V15, P1165, DOI 10.1016/0196-9781(94)90138-4; KRAMER SJ, 1991, P NATL ACAD SCI USA, V88, P9458, DOI 10.1073/pnas.88.21.9458; LORENZ MW, 1995, REGUL PEPTIDES, V57, P227, DOI 10.1016/0167-0115(95)00036-B; NEUHAUSER T, 1994, J COMP PHYSIOL B, V164, P23, DOI 10.1007/BF00714567; PRATT GE, 1989, BIOCHEM BIOPH RES CO, V163, P1243, DOI 10.1016/0006-291X(89)91111-X; PRATT GE, 1991, P NATL ACAD SCI USA, V88, P2412, DOI 10.1073/pnas.88.6.2412; PRATT GE, 1990, MOL CELL ENDOCRINOL, V70, P185, DOI 10.1016/0303-7207(90)90158-5; PRATT GE, 1974, LIFE SCI, V14, P575, DOI 10.1016/0024-3205(74)90372-5; RAINA AK, 1988, INSECT BIOCHEM, V18, P785, DOI 10.1016/0020-1790(88)90101-1; REICHWALD K, 1994, P NATL ACAD SCI USA, V91, P11894, DOI 10.1073/pnas.91.25.11894; SCHOOFS L, 1991, REGUL PEPTIDES, V36, P111, DOI 10.1016/0167-0115(91)90199-Q; SMART D, 1994, J COMP NEUROL, V347, P426, DOI 10.1002/cne.903470308; SMIT AB, 1992, J NEUROSCI, V12, P1709; STAY B, 1994, ADV INSECT PHYSIOL, V25, P267; TOBVE SS, 1974, BIOCHEM J, V14, P4107; WEAVER RJ, 1994, COMP BIOCHEM PHYS C, V107, P119, DOI 10.1016/1367-8280(94)90018-3; WEAVER RJ, 1991, J INSECT PHYSIOL, V37, P111, DOI 10.1016/0022-1910(91)90096-I; WOODHEAD AP, 1994, INSECT BIOCHEM MOLEC, V24, P257, DOI 10.1016/0965-1748(94)90005-1; WOODHEAD AP, 1992, ARCH INSECT BIOCHEM, V20, P253, DOI 10.1002/arch.940200403; WOODHEAD AP, 1989, P NATL ACAD SCI USA, V80, P5997	29	163	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21103	21108		10.1074/jbc.270.36.21103	http://dx.doi.org/10.1074/jbc.270.36.21103			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673141	hybrid			2022-12-27	WOS:A1995RU05400039
J	PATTON, WF; ERDJUMENTBROMAGE, H; MARKS, AR; TEMPST, P; TAUBMAN, MB				PATTON, WF; ERDJUMENTBROMAGE, H; MARKS, AR; TEMPST, P; TAUBMAN, MB			COMPONENTS OF THE PROTEIN-SYNTHESIS AND FOLDING MACHINERY ARE INDUCED IN VASCULAR SMOOTH-MUSCLE CELLS BY HYPERTROPHIC AND HYPERPLASTIC AGENTS - IDENTIFICATION BY COMPARATIVE PROTEIN PHENOTYPING AND MICROSEQUENCING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN ELONGATION FACTOR-1-BETA; MYOSIN HEAVY-CHAINS; ANGIOTENSIN-II; DISULFIDE-ISOMERASE; MESSENGER-RNA; GROWTH-FACTOR; POLYACRYLAMIDE GELS; MOLECULAR CHAPERONE; EXPRESSION	Vascular smooth muscle cells (VSMC) are the principal cellular component of the blood vessel wall. Atherosclerosis, hypertension, and angiogenesis are associated with abnormal VSMC growth. Angiotensin II is hypertrophic for cultured adult rat aortic VSMC, whereas platelet-derived growth factor and serum are hyperplastic. To identify changes in specific proteins associated with either hyperplastic or hypertrophic growth, high resolution two dimensional gel electrophoresis was performed on extracts from quiescent rat aortic VSMC and from VSMC exposed for 24 h to growth factors (10% fetal calf serum, platelet-derived growth factor, or angiotensin II). 12 proteins were up-regulated and 5 down-regulated by treatment with growth factors. Eight of the up-regulated and one of the down-regulated proteins were identified by internal protein microsequencing from electroblotted two-dimensional gels or by co-electrophoresis of purified proteins in two-dimensional gels. Four of the proteins up-regulated by growth factors were identified as mediators of protein folding. These were heat shock proteins, HSP-60 and HSP-70, protein disulfide isomerase, and protein disulfide isomerase isozyme Q-2. Additional proteins were identified as elongation factor EF-1 beta, a component of the protein synthesis apparatus, and calreticulin, another putative molecular chaperone. Vimentin and actin were also upregulated, whereas an isoform of myosin heavy chain was down-regulated. Hyperplastic and hypertrophic growth were accompanied by similar changes in protein expression, suggesting that both types of growth require up-regulation of the protein synthesis and folding machinery.	CUNY MT SINAI SCH MED, INST CARDIOVASC, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029814] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline; NHLBI NIH HHS [R01 HL43302] Funding Source: Medline; NINDS NIH HHS [R01 NS29814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BIRUKOV KG, 1993, EXP CELL RES, V204, P46, DOI 10.1006/excr.1993.1007; BLAKE MJ, 1993, ENDOCRINOLOGY, V132, P1063, DOI 10.1210/en.132.3.1063; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CAVUSOGLU E, 1994, CIRCULATION, V90, P140; CELIS JE, 1993, ELECTROPHORESIS, V14, pU1091, DOI 10.1002/elps.11501401178; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; DAVIES P, 1994, J CELL PHYSIOL, V159, P399, DOI 10.1002/jcp.1041590303; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FENG P, 1993, J BIOL CHEM, V268, P9387; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GADEAU AP, 1991, J CELL PHYSIOL, V146, P356, DOI 10.1002/jcp.1041460304; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; HAMET P, 1990, J HYPERTENS, V8, pS47; HASHIMOTO T, 1991, J HYPERTENS, V9, pS170; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLYCROSS BJ, 1993, J VASC RES, V30, P80, DOI 10.1159/000158979; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LIAU G, 1990, J CELL PHYSIOL, V142, P236, DOI 10.1002/jcp.1041420204; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; MARMUR JD, 1992, CIRCULATION, V86, P53; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OWENS GK, 1989, AM J PHYSIOL, V257, pH1755, DOI 10.1152/ajpheart.1989.257.6.H1755; PATTON WF, 1992, BIOTECHNIQUES, V12, P580; PATTON WF, 1990, BIOTECHNIQUES, V8, P518; PATTON WF, 1991, ANAL BIOCHEM, V197, P25, DOI 10.1016/0003-2697(91)90350-3; PATTON WF, 1993, ELECTROPHORESIS, V14, P650, DOI 10.1002/elps.11501401101; PERALTA D, 1990, NUCLEIC ACIDS RES, V18, P7162, DOI 10.1093/nar/18.23.7162; PUIG A, 1994, J BIOL CHEM, V269, P7764; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHMAN A, 1994, J BIOL CHEM, V269, P6399; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANDERS J, 1991, NUCLEIC ACIDS RES, V19, P4551, DOI 10.1093/nar/19.16.4551; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; UDELSMAN R, 1994, SURGERY, V116, P177; VONDERKAMMER H, 1991, BIOCHEM BIOPH RES CO, V177, P312, DOI 10.1016/0006-291X(91)91984-K; WAX SD, 1994, J BIOL CHEM, V269, P13041; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; XIONG YM, 1991, IN VITRO CELL DEV B, V27, P355	69	49	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21404	21410		10.1074/jbc.270.36.21404	http://dx.doi.org/10.1074/jbc.270.36.21404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673176	hybrid			2022-12-27	WOS:A1995RU05400081
J	TAKADA, Y; PUZON, W				TAKADA, Y; PUZON, W			IDENTIFICATION OF A REGULATORY REGION OF INTEGRIN-BETA-1 SUBUNIT USING ACTIVATING AND INHIBITING ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GP-IIB-IIIA; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; BETA-1 SUBUNIT; T-CELLS; 3-DIMENSIONAL STRUCTURE; SIGNAL TRANSDUCTION; LIGAND-BINDING; LYMPHOCYTES-T; CROSS-LINKING	Members of the beta1 integrin subfamily recognize multiple ligands such as fibronectin, laminin, and collagen and mediate cell-cell and cell-extracellular matrix interactions. Beta1 subunit may play a central role in regulating beta1 integrin avidity. Here we have identified a small region of beta1 subunit (residues 207-218) that is critical for the binding of both activating (8A2, A1A5, and TS2/16) and inhibiting (4B4, 4B5, 13, AIIB2, and P4C10) monoclonal antibodies against human beta1 using interspecies chimeric beta1 and site-directed mutagenesis. Chicken beta1 that has human sequence within residues 207-218 (CH mutant) is recognized by all the human specific antibodies listed above. The region 207-218 is located between the two putative ligand binding sites (residues 120-182 and 220-231), and the amino acid sequence of the region involves a predicted bend structure. The other anti-beta1 antibodies that do not affect cell attachment to ligands (K20, 102DF5, LM442, and LM534) recognized the carboxyl-terminal regions of extracellular domain of beta1 (residues 426-587 for K20 and 588-708 for 102DF5, LM442, and LM534, respectively). Our data suggest a potential mechanism for the avidity regulation of beta1 integrin through conformational changes of beta1 subunit.			TAKADA, Y (corresponding author), SCRIPPS RES INST, COMM VASC BIOL, CVB-2, LA JOLLA, CA 92037 USA.			takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; AMIOT M, 1986, SCAND J IMMUNOL, V23, P109, DOI 10.1111/j.1365-3083.1986.tb01948.x; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BRACIALE TJ, 1986, J IMMUNOL, V137, P995; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHARO IF, 1991, J BIOL CHEM, V266, P1415; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; PHILLIPS DR, 1988, BLOOD, V71, P831; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SMITH JW, 1988, J BIOL CHEM, V263, P18726; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YAMADA A, 1991, J IMMUNOL, V146, P53; YAMADA A, 1991, EUR J IMMUNOL, V21, P319, DOI 10.1002/eji.1830210212; YAMADA KM, 1990, CANCER RES, V50, P4485; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628	53	207	212	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17597	17601						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688727				2022-12-27	WOS:A1993LQ98800102
J	DIAMOND, RH; DU, K; LEE, VM; MOHN, KL; HABER, BA; TEWARI, DS; TAUB, R				DIAMOND, RH; DU, K; LEE, VM; MOHN, KL; HABER, BA; TEWARI, DS; TAUB, R			NOVEL DELAYED-EARLY AND HIGHLY INSULIN-INDUCED GROWTH-RESPONSE GENES - IDENTIFICATION OF HRS, A POTENTIAL REGULATOR OF ALTERNATIVE PREMESSENGER RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE EXPRESSION; STIMULATED H-35 CELLS; IMMEDIATE-EARLY GENES; CULTURED MOUSE CELLS; REGENERATING LIVER; 3T3 CELLS; MOLECULAR-CLONING; PHOSPHOENOLPYRUVATE CARBOXYKINASE; LYMPHOCYTE MITOGENS; BINDING PROTEINS	We have identified 41 novel and many previously known growth response genes induced in regenerating liver and insulin-treated Reuber H35 cells, a rat hepatoma cell line that grows in response to physiologic concentrations of insulin and retains some properties of regenerating liver. Although many genes are expressed similarly in the two systems, there are important differences in the kinetics of induction of some genes. These differences allowed us to identify and characterize novel genes that are highly insulin-induced and expressed as delayed-early genes in regenerating liver. Sequence analysis of CL-6, the most abundant insulin-induced gene, resulted in the identification of a highly hydrophobic hepatic protein. Sequence analysis of HRS, a highly insulin-induced delayed-early gene, demonstrated that it is a member of the family of regulators of alternative pre-mRNA splicing. Different forms of HRS mRNA are temporally regulated during the growth response, suggesting that HRS could autoregulate processing of its pre-mRNA. Given the dramatic increase in RNA production during late G1, proteins induced by mitogens like insulin that control RNA processing are likely to have important roles in cell cycle regulation.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DEPT MED,DIV GASTROENTEROL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NIDDK NIH HHS [K11 DK02096, K11 DK01905] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002096, K11DK001905] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARRA R, 1977, J EXP ZOOL, V201, P93, DOI 10.1002/jez.1402010111; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUCHER NLR, 1975, P NATL ACAD SCI USA, V72, P1157, DOI 10.1073/pnas.72.3.1157; BUCHER NLR, 1978, CELL REPRODUCTION HO, P661; BUCHER NLR, 1976, METABOLISM, V25, P14231; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CHAMPLIN DT, 1991, GENE DEV, V5, P1611, DOI 10.1101/gad.5.9.1611; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; FAUSTO N, 1989, LAB INVEST, V60, P4; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Higgins GM, 1931, ARCH PATHOL, V12, P186; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JEFFERSON LS, 1980, DIABETES, V29, P487, DOI 10.2337/diab.29.6.487; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOONTZ JW, 1984, MOL CELL BIOCHEM, V58, P139, DOI 10.1007/BF00240613; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LIM RW, 1987, ONCOGENE, V1, P263; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LLOYD CE, 1987, J CELL PHYSL, V21, pC205; LU XP, 1992, J BIOL CHEM, V267, P2841; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PEAVY DE, 1985, ENDOCRIN METAB CLIN, V248, pE656; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAUB R, 1987, J BIOL CHEM, V262, P10893; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041; ZUMSTEIN P, 1987, J BIOL CHEM, V262, P11252	51	103	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					15185	15192						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686911				2022-12-27	WOS:A1993LL75900093
J	SCOTT, PG; DODD, CM; PRINGLE, GA				SCOTT, PG; DODD, CM; PRINGLE, GA			MAPPING THE LOCATIONS OF THE EPITOPES OF 5 MONOCLONAL-ANTIBODIES TO THE CORE PROTEIN OF DERMATAN SULFATE PROTEOGLYCAN-II (DECORIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN PROTEODERMATAN SULFATE; SMALL INTERSTITIAL PROTEOGLYCANS; BOVINE TEMPOROMANDIBULAR-JOINT; N-LINKED OLIGOSACCHARIDES; AMINO-ACID-SEQUENCES; CONNECTIVE TISSUES; ARTICULAR DISK; COLLAGEN; PREDICTION; MATRIX	Antibodies to dermatan sulfate proteoglycan II (decorin) have been used to study various aspects of the structure, function, and occurrence of this proteoglycan. The epitopes of five monoclonal antibodies (7B1, 5D1, 3B3, 6D6, and 1XA) were localized to specific cyanogen bromide fragments of the protein core separated by gel filtration. One large (159 residue) cyanogen bromide peptide was further digested with endoproteinase Lys-C and the peptides separated by reversed phase high performance liquid chromatography. In this way sequences of a suitable length (21-52 residues) for epitope mapping by synthesis of overlapping hexa- and octapeptides were identified. For each of the five monoclonal antibodies a short linear sequence with antigenic activity, from 4 to 8 amino acids long, depending on the particular antibody, was identified. The locations of the epitopes were correlated with various properties of the protein core predicted from the known amino acid sequence. It was observed that, at most, only one was localized in a region predicted to involve a beta-turn. Although four epitopes were in regions predicted to be moderately hydrophilic, accessible, and flexible, one was located in a hydrophobic sequence predicted to be highly inflexible and inaccessible. The implications of this observation in relation to the function of this proteoglycan are discussed.	UNIV WESTERN ONTARIO,DEPT PATHOL,LONDON N6A 5C1,ONTARIO,CANADA	Western University (University of Western Ontario)	SCOTT, PG (corresponding author), UNIV ALBERTA,DEPT ORAL BIOL,EDMONTON T6G 2N8,ALBERTA,CANADA.							BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DAMLE SP, 1982, J BIOL CHEM, V257, P5523; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRANZEN A, 1984, BIOCHEM J, V224, P59, DOI 10.1042/bj2240059; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAININ J, 1979, NATURE, V277, P491; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KRYSTEK SR, 1985, ENDOCRINOLOGY, V117, P1110, DOI 10.1210/endo-117-3-1110; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENNON DP, 1991, MATRIX, V11, P412, DOI 10.1016/S0934-8832(11)80196-4; MECHANIC G, 1979, SKELETAL RES EXPT AP, P227; NAKANO T, 1989, ARCH ORAL BIOL, V34, P749, DOI 10.1016/0003-9969(89)90082-4; NAKANO T, 1988, BIOMED RES-TOKYO, V9, P269, DOI 10.2220/biomedres.9.269; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PEARSON CH, 1986, ARCH ORAL BIOL, V31, P541, DOI 10.1016/0003-9969(86)90148-2; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PRINGLE GA, 1985, COLLAGEN REL RES, V5, P23; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SCOTT JE, 1981, BIOCHEM J, V195, P573, DOI 10.1042/bj1950573; SCOTT JE, 1985, BIOCHEM SOC T, V13, P933, DOI 10.1042/bst0130933; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT PG, 1989, BIOCHEM SOC T, V17, P1031, DOI 10.1042/bst0171031; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; SCOTT PG, 1989, MATRIX, V9, P284, DOI 10.1016/S0934-8832(89)80004-6; SOBUE M, 1988, J HISTOCHEM CYTOCHEM, V36, P479, DOI 10.1177/36.5.3356894; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WINTERBOTTOM N, 1987, THESIS U ALBERTA; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	45	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11558	11564						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685016				2022-12-27	WOS:A1993LF28400019
J	CSERMELY, P; SCHNAIDER, T; CHEATHAM, B; OLSON, MOJ; KAHN, CR				CSERMELY, P; SCHNAIDER, T; CHEATHAM, B; OLSON, MOJ; KAHN, CR			INSULIN INDUCES THE PHOSPHORYLATION OF NUCLEOLIN - A POSSIBLE MECHANISM OF INSULIN-INDUCED RNA EFFLUX FROM NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; MESSENGER-RNA; RAT-LIVER; NUCLEOSIDE TRIPHOSPHATASE; 3T3-L1 ADIPOCYTES; RIBOSOMAL-RNA; CELLS; TRANSPORT	Insulin induces the serine phosphorylation of the nucleolar protein nucleolin at subnanomolar concentrations in differentiated 3T3-442A cells. The stimulation is biphasic with phosphorylation reaching a maximum at 10 pM insulin and then declining to only 40% of basal levels at insulin concentrations of 1 muM. These changes are rapid, reaching half-maximal after 4 min and maximal after 15 min of incubation. The cell-permeable casein kinase II inhibitor 5,6-dichlorobenzimidazole-riboside prevents the insulin-stimulated phosphorylation of nucleolin suggesting that casein kinase II may mediate this effect of the hormone. Insulin-like growth factor 1 mimics the action of insulin on dephosphorylation of nucleolin at nanomolar concentrations suggesting that the latter effect may be mediated by insulin-like growth factor 1 receptors. Insulin treatment of 3T3-442A cells also results in a stimulation of RNA efflux from isolated, intact cell nuclei. The dose dependence of insulin-induced nucleolin phosphorylation and insulin-stimulated RNA efflux from intact cell nuclei are almost identical. Insulin induces an increase in the RNA efflux at subnanomolar concentrations in 3T3-442A adipocytes, while high (micromolar) concentrations of insulin inhibited the efflux of RNA. These data indicate that insulin regulates the phosphorylation/dephosphorylation of nucleolin, possibly via stimulation of casein kinase II, and this may play a role in regulation of the RNA efflux from nuclei.	JOSLIN DIABET CTR,DIV RES,ONE JOSLIN PL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MISSISSIPPI,MED CTR,JACKSON,MS 39216	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Mississippi; University of Mississippi Medical Center			Kahn, Ronald/AAY-2435-2021; Csermely, Peter/J-2067-2017	Kahn, Ronald/0000-0002-7583-9228; Csermely, Peter/0000-0001-9234-0659	FOGARTY INTERNATIONAL CENTER [F05TW004319] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK033201] Funding Source: NIH RePORTER; FIC NIH HHS [1F05 TW04319-01 B1-5] Funding Source: Medline; NIDDK NIH HHS [DK 36836, DK 33201] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUTTER PS, 1979, BIOCHEM J, V182, P811, DOI 10.1042/bj1820811; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON H, 1983, FEBS LETT, V155, P218, DOI 10.1016/0014-5793(82)80606-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHEN CM, 1991, J BIOL CHEM, V266, P7754; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CZECH MP, 1988, J BIOL CHEM, V263, P11017; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FRIEDMAN DL, 1988, J BIOL CHEM, V263, P1103; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KLARLUND JK, 1991, J BIOL CHEM, V266, P4052; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; MADOFF DH, 1988, BIOCHEM J, V252, P7, DOI 10.1042/bj2520007; MARMACK MD, 1979, BIOCHEMISTRY-US, V18, P3381; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OLSON MOJ, 1983, BIOCHEMISTRY-US, V22, P3345, DOI 10.1021/bi00283a007; OLSON MOJ, 1974, J BIOL CHEM, V249, P2823; OLSON MOJ, 1981, EXP CELL RES, V135, P259, DOI 10.1016/0014-4827(81)90161-0; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PURRELLO F, 1983, P NATL ACAD SCI-BIOL, V80, P1189, DOI 10.1073/pnas.80.5.1189; PURRELLO F, 1982, SCIENCE, V216, P1005, DOI 10.1126/science.6281885; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SCHINDLER M, 1987, J CELL BIOL, V104, P849, DOI 10.1083/jcb.104.4.849; SCHNEIDER HR, 1989, EUR J BIOCHEM, V180, P449, DOI 10.1111/j.1432-1033.1989.tb14667.x; SCHNEIDER HR, 1989, BIOCHIM BIOPHYS ACTA, V1014, P98, DOI 10.1016/0167-4889(89)90246-2; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; SCHRODER HC, 1990, BIOCHEMISTRY-US, V29, P2368, DOI 10.1021/bi00461a022; SCHUMM DE, 1981, ARCH BIOCHEM BIOPHYS, V210, P275, DOI 10.1016/0003-9861(81)90190-9; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUZUKI N, 1991, BIOCHIM BIOPHYS ACTA, V1092, P367, DOI 10.1016/S0167-4889(97)90014-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804	51	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9747	9752						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683660				2022-12-27	WOS:A1993LA68900087
J	CASTELLANO, A; WEI, XY; BIRNBAUMER, L; PEREZREYES, E				CASTELLANO, A; WEI, XY; BIRNBAUMER, L; PEREZREYES, E			CLONING AND EXPRESSION OF A 3RD CALCIUM-CHANNEL BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONOTOXIN GVIA RECEPTOR; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; DIHYDROPYRIDINE RECEPTOR; GAMMA-SUBUNIT; ALPHA-1-SUBUNIT; SEQUENCE; PROTEINS; CDNA	The skeletal muscle dihydropyridine receptor/Ca2+ channel consists of five distinct subunits (alpha1, alpha2delta, beta1, and gamma). Homologous alpha1, alpha2delta, and beta2 subunits are expressed in heart and brain. The present study reports the cloning and expression of a third beta subunit, beta3, which is expressed predominantly in brain. Its open reading frame encodes a protein with 484 amino acids with a predicted molecular mass of 54,571 Da. Coexpression of beta3 with a cardiac alpha1 in Xenopus oocytes induces similar changes in Ca2+ channel activity as beta1 and beta2, that is, it increases peak currents, modulates the voltage dependence of activation, and accelerates activation. In addition, beta3 accelerates the rate of inactivation at positive test potentials.	BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Castellano, Antonio/E-6285-2010; Castellano, Antonio/AAH-8829-2021; IBIS, VASCULAR/P-3934-2015	Castellano, Antonio/0000-0003-3955-5137; Castellano, Antonio/0000-0003-3955-5137; 	NHLBI NIH HHS [HL-46702, HL-37044] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044, R29HL046702, R55HL046702] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; CHANG CF, 1991, J BIOL CHEM, V266, P16395; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FRECH GC, 1989, GENE ANAL TECH, V6, P33, DOI 10.1016/0735-0651(89)90024-1; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ITAGAKI K, 1992, FEBS LETT, V297, P221, DOI 10.1016/0014-5793(92)80542-O; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	39	200	202	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3450	3455						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679112				2022-12-27	WOS:A1993KM16100067
J	EDBERG, JC; LIN, CT; LAU, D; UNKELESS, JC; KIMBERLY, RP				EDBERG, JC; LIN, CT; LAU, D; UNKELESS, JC; KIMBERLY, RP			THE CA2+ DEPENDENCE OF HUMAN FC-GAMMA RECEPTOR-INITIATED PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MEDIATED PHAGOCYTOSIS; HUMAN-NEUTROPHILS; IGE RECEPTOR; EPSILON-RI; MOUSE MACROPHAGES; HUMAN-MONOCYTES; MAST-CELLS; ACTIVATION; DISTINCT	Differing roles for [Ca2+](i) transients in Fc gamma R-mediated phagocytosis have been suggested based on the observations that antibody-opsonized erythrocyte phagocytosis by human neutrophils shows a [Ca2+](i) dependence, while that by murine macrophages appears [Ca2+](i)-independent. To explore whether this difference might reflect different receptor isoforms or different cell types, we studied the [Ca2+](i) dependence of receptor-initiated phagocytosis by human Fc gamma RIIa and a panel of Fc gamma RIIa cytoplasmic domain mutants expressed in murine P388D1 cells and by human Fc gamma R endogenously expressed on human neutrophils and monocytes, Wild-type and point mutants of huFc gamma RIIa stably transfected into murine P388D1 cells have different capacities to initiate a [Ca2+](i) transient, which are closely correlated with quantitative phagocytosis (r = 0.94, p < 0.0001), Phagocytosis both by huFc gamma RIIa in P388D1 cells and by huFc gamma RIIa endogenously expressed on neutrophils and blood monocytes shows [Ca2+](i) dependence, Phagocytosis of antibody opsonized erythrocytes by neutrophils demonstrated greater susceptibility to [Ca2+](i) quenching compared with Fc gamma RIIa-specific internalization with E-IV.3, suggesting that the phagocytosis activating property of Fc gamma RIIIb in neutrophils also engages a [Ca2+](i)-dependent element. In contrast, phagocytosis by human Fc gamma RIa, endogenously expressed on blood monocytes, is [Ca2+](i)-independent, Despite the importance of a consensus tyrosine activation motif for both receptors, Fc gamma RIa and Fc gamma IIa engage at least some distinct signaling elements to initiate phagocytosis, The recognition that both of the phagocytic receptors on murine macrophages and human Fc gamma RIa associate with the Fc epsilon RI gamma-chain, which contains a tyrosine activation motif distinct from that in the Fc gamma RIIa cytoplasmic domain, suggests that [Ca2+](i)-independent phagocytosis is a property associated with the utilization of gamma-chains by Fc gamma R.	CORNELL UNIV,HOSP SPECIAL SURG,COLL MED,MED CTR,GRAD PROGRAM IMMUNOL,NEW YORK,NY 10021; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029	Cornell University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai				Kimberly, Robert/0000-0002-5330-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024322, R37AI024322, P01AI024671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR033062] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24322, AI-24671] Funding Source: Medline; NIAMS NIH HHS [AR-33062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ALBER G, 1992, J IMMUNOL, V149, P2428; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DELLABIANCA V, 1990, J IMMUNOL, V144, P1411; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DURDEN DL, 1994, BLOOD, V84, P2102; EDBERG JC, 1989, J IMMUNOL, V143, P1642; EDBERG JC, 1994, J IMMUNOL, V152, P5826; EDBERG JC, 1992, J IMMUNOL METHODS, V148, P179, DOI 10.1016/0022-1759(92)90171-O; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GOSSELIN EJ, 1990, J IMMUNOL, V144, P1817; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HISHIKAWA T, 1991, J CELL BIOL, V115, P59, DOI 10.1083/jcb.115.1.59; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; HUNTER S, 1994, P NATL ACAD SCI USA, V91, P10232, DOI 10.1073/pnas.91.21.10232; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEINER PA, 1993, J BIOL CHEM, V268, P24442; KIMBERLY RP, 1995, ARTHRITIS RHEUM, V38, P306, DOI 10.1002/art.1780380303; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; MACINTYRE EA, 1988, J IMMUNOL, V141, P4333; MCNEIL PL, 1986, J CELL BIOL, V102, P1586, DOI 10.1083/jcb.102.5.1586; MILLER J, 1985, J IMMUNOL, V134, P4212; MITCHELL MA, 1994, BLOOD, V84, P1753; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Paolini R, 1994, Immunomethods, V4, P35, DOI 10.1006/immu.1994.1005; PARREN PWHI, 1992, J CLIN INVEST, V90, P1537, DOI 10.1172/JCI116022; PORGES AJ, 1994, J IMMUNOL, V153, P1271; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; ROSALES C, 1992, J BIOL CHEM, V267, P1443; ROSALES C, 1994, P NATL ACAD SCI USA, V91, P3534, DOI 10.1073/pnas.91.9.3534; ROSALES C, 1981, J IMMUNOL, V146, P3937; SALMON JE, 1990, J CLIN INVEST, V85, P1287, DOI 10.1172/JCI114566; SALMON JE, 1992, J CLIN INVEST, V89, P1274, DOI 10.1172/JCI115712; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TAX WJM, 1984, J IMMUNOL, V133, P1185; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZHOU MJ, 1993, J IMMUNOL, V150, P3030	61	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22301	22307		10.1074/jbc.270.38.22301	http://dx.doi.org/10.1074/jbc.270.38.22301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673212	hybrid			2022-12-27	WOS:A1995RW31400039
J	ROHLFS, RJ; HUANG, LX; HILLE, R				ROHLFS, RJ; HUANG, LX; HILLE, R			PROTOTROPIC CONTROL OF INTRAMOLECULAR ELECTRON-TRANSFER IN TRIMETHYLAMINE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND COENZYME; IRON-SULFUR CLUSTER; DIMETHYLAMINE DEHYDROGENASE; METHYLOTROPHIC BACTERIA; PROSTHETIC GROUPS; FLAVOPROTEIN; FLAVIN	The pH dependence of static optical/EPR spectra of trimethylamine dehydrogenase reduced to the level of two equivalents (TMADH(2eq)) has been examined and indicates the existence of three different states for this iron-sulfur flavoprotein, At pH 6, TMADH(2eq) exists principally in a form possessing flavin mononucleotide hydroquinone, with its iron-sulfur center oxidized, At pH 8, the enzyme principally contains flavin mononucleotide semiquinone and reduced iron-sulfur, but despite the proximity of the two centers to one another, their magnetic moments do not interact, At pH 10, TMADH(2eq) exhibits the EPR spectrum that is diagnostic of a previously characterized spin-interacting state in which the magnetic moments of the flavin semiquinone and reduced iron-sulfur center are strongly ferromagnetically coupled, The kinetics of the interconversion of these three states have been investigated using a pH jump technique in both H2O and D2O. The observed kinetics are consistent with a reaction mechanism involving sequential protonation/deprotonation and intramolecular electron transfer events, All reactions studied show a normal solvent kinetic isotope effect, Proton inventory analysis indicates that at least one proton is involved in the reaction between pH 6 and 8, which principally controls intramolecular electron transfer, whereas at least two protons are involved between pH 8 and 10, which principally control formation of the spin-interacting state, The results of these and previous studies indicate that for TMADH(2eq) between pH 10 and 6, at least three protonation/deprotonation events are associated with intramolecular electron transfer and formation of the spin-interacting state, with estimated pK(alpha) values of 6.0, 8.0, and similar to 9.5, These pK(alpha) values are attributed to the flavin hydroquinone, flavin semiquinone, and an undesignated basic group on the protein, respectively.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University								BELLAMY HD, 1988, J BIOL CHEM, V284, P11887; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DUDLEY KH, 1965, HELV CHIM ACTA, V47, P1354; EHRENBERG A, 1967, EUR J BIOCHEM, V2, P286, DOI 10.1111/j.1432-1033.1967.tb00137.x; Gross P, 1936, T FARADAY SOC, V32, P0879, DOI 10.1039/tf9363200879; GUTFREUND, 1977, ENZYMES PHYSICAL PRI, P173; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HILLE R, 1986, J BIOL CHEM, V261, P1241; HILLE R, 1991, BIOCHEMISTRY-US, V30, P8521; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; Klinman J P, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P415; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MATHEWS FS, 1987, FLAVINS FLAVOPROTEIN, P663; Orr WJC, 1937, J CHEM SOC, P330, DOI 10.1039/jr9370000330; PALMER G, 1969, J BIOL CHEM, V244, P2614; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; Schowen R. L, 1978, TRANSIT STATES BIOCH, P225; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P233, DOI 10.1042/bj2070233; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STEVENSON RC, 1986, BIOCHIM BIOPHYS ACTA, V869, P81, DOI 10.1016/0167-4838(86)90313-4; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	30	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22196	22207		10.1074/jbc.270.38.22196	http://dx.doi.org/10.1074/jbc.270.38.22196			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673198	hybrid			2022-12-27	WOS:A1995RW31400023
J	TOMIC, S; GREISER, U; LAMMERS, R; KHARITONENKOV, A; IMYANITOV, E; ULLRICH, A; BOHMER, FD				TOMIC, S; GREISER, U; LAMMERS, R; KHARITONENKOV, A; IMYANITOV, E; ULLRICH, A; BOHMER, FD			ASSOCIATION OF SH2 DOMAIN PROTEIN-TYROSINE PHOSPHATASES WITH THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN TUMOR-CELLS - PHOSPHATIDIC-ACID ACTIVATES RECEPTOR DEPHOSPHORYLATION BY PTP1C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SIGNAL TRANSDUCTION; EXPRESSION; PHOSPHORYLATION; PURIFICATION; KINASES; INSULIN; MITOSIS; BETA; TRANSFORMATION	The SH2 domain protein tyrosine phosphatases (PTPases) PTP1C and PTP1D were found associated with epidermal growth factor (EGF) receptor which was purified from A431 cell. membranes by several steps of chromatography, Both PTPases also associated with the EGF receptor upon exposure of immunoprecipitated receptor to lysates of MCF7 mammary carcinoma cells, The associated PTPases had little activity toward the bound receptor when it was autophosphorylated in vitro, Receptor dephosphorylation could, however, be initiated by treatment of the receptor PTPase complex with phosphatidic acid (PA). When autophosphorylated EGF receptor was exposed to lysates of PTP1C or PTP1D overexpressing 293 cells, the association of PTP1C but not of PTP1D was enhanced in the presence of PA, In intact A431 cells, an association of PTP1C and PTP1D with the EGF receptor was detectable by coimmunoprecipitation experiments, PA treatment reduced the phosphorylation state of ligand activated EGF receptors in A431 cells and in 293 cells overexpressing EGF receptors together with PTP1C but not in 293 cells overexpressing EGF receptors alone or together with PTP1D. We conclude that PTP1C but not PTP1D participates in dephosphorylation of activated EGF receptors, A possible role of PA for physiological modulation of EGF receptor signaling is discussed.	UNIV JENA,FAC MED,GROWTH FACTOR SIGNAL TRANSDUCT RES UNIT,MAX PLANCK SOC,D-07747 JENA,GERMANY; MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Friedrich Schiller University of Jena; Max Planck Society; Max Planck Society			Imyanitov, Evgeny/ABG-8619-2021					AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BRAUTIGAN DL, 1981, J BIOL CHEM, V256, P6519; BROWNSHIMER S, 1992, CANCER RES, V52, P478; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAURE R, 1992, J BIOL CHEM, V267, P11215; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; KASZKIN M, 1992, CANCER RES, V52, P5627; KASZKIN M, 1991, CANCER RES, V51, P4328; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; POT DA, 1991, J BIOL CHEM, V266, P19688; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	46	133	136	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21277	21284		10.1074/jbc.270.36.21277	http://dx.doi.org/10.1074/jbc.270.36.21277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673163	hybrid			2022-12-27	WOS:A1995RU05400063
J	KIM, JS; RAINES, RT				KIM, JS; RAINES, RT			BOVINE SEMINAL RIBONUCLEASE PRODUCED FROM A SYNTHETIC GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; TRANSLATION INITIATION; QUATERNARY STRUCTURE; SECONDARY STRUCTURE; EXPRESSION; DEGRADATION; SEQUENCE	Bovine seminal ribonuclease (BS-RNase), a homolog of bovine pancreatic ribonuclease (RNase A), is isolated as a dimer in which the subunits are cross-linked by two disulfide bonds. In addition to this anomalous quaternary structure, the enzyme has extraordinary biological properties, such as antispermatogenic, antitumor, and immunosuppressive activities. The molecular bases for these properties are well-suited for exploration with the techniques of recombinant DNA. Accordingly, a gene encoding BS-RNase was designed based on criteria expected to maximize the translational efficiency of its mRNA in Escherichia coli. This gene was constructed from 12 synthetic oligonucleotides and expressed with the phage T7 system. The protein thus produced was insoluble and accumulated under optimal conditions to 15% of total cellular protein or 200 mg/liter of culture. Ribonuclease activity was generated by air oxidation of the reduced and denatured protein. Three forms of active BS-RNase were isolated by gel filtration chromatography: the well-characterized dimer and monomer and a previously uncharacterized form that migrated as a trimer. The ribonuclease activities of all three forms were equivalent to or higher than that of dimeric BS-RNase isolated from bull seminal plasma.	UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison			Raines, Ronald T./A-5009-2013; KIM, Jin-Soo/M-6918-2013	Raines, Ronald T./0000-0001-7164-1719; KIM, Jin-Soo/0000-0003-4847-1306	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44783] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; Ausubel FM, 1988, MOL REPROD DEV; BEINTEMA JJ, 1987, LIFE CHEM REPORTS, V4, P333; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; CANNISTRARO VJ, 1991, J BACTERIOL, V173, P4653, DOI 10.1128/jb.173.15.4653-4659.1991; CAPASSO S, 1983, BIOPOLYMERS, V22, P327, DOI 10.1002/bip.360220142; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DOSTAL J, 1973, J REPROD FERTIL, V33, P263, DOI 10.1530/jrf.0.0330263; GHEYSEN D, 1982, GENE, V17, P55, DOI 10.1016/0378-1119(82)90100-7; GOLD L, 1990, METHOD ENZYMOL, V185, P11; GUILLEMETTE JG, 1991, PROTEIN ENG, V4, P585, DOI 10.1093/protein/4.5.585; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HERMES JD, 1987, P RA WELCH F, V31, P207; HORN T, 1986, TETRAHEDRON LETT, V27, P4705, DOI 10.1016/S0040-4039(00)85043-1; ISERENTANT D, 1980, GENE, V9, P1, DOI 10.1016/0378-1119(80)90163-8; KIM JS, 1993, PROTEIN SCI, V2, P348; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LACCETTI P, 1992, CANCER RES, V52, P4582; LI XM, 1991, PROTEIN ENG, V4, P995, DOI 10.1093/protein/4.8.995; MAZZARELLA L, 1987, GAZZ CHIM ITAL, V117, P91; NAMBIAR KP, 1987, EUR J BIOCHEM, V163, P67, DOI 10.1111/j.1432-1033.1987.tb10737.x; PARENTE A, 1985, EUR J BIOCHEM, V149, P381, DOI 10.1111/j.1432-1033.1985.tb08936.x; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; PICCOLI R, 1990, 2ND P INT M STRUCT M, P131; PREUSS KD, 1990, NUCLEIC ACIDS RES, V18, P1057, DOI 10.1093/nar/18.4.1057; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SMITH GK, 1978, BIOCHEMISTRY-US, V17, P2633, DOI 10.1021/bi00606a027; SORRENTINO S, 1980, BIOCHIM BIOPHYS ACTA, V609, P40, DOI 10.1016/0005-2787(80)90199-9; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI H, 1987, BIOL CHEM H-S, V368, P1305, DOI 10.1515/bchm3.1987.368.2.1305; TAMBURRINI M, 1989, J PROTEIN CHEM, V8, P719, DOI 10.1007/BF01024897; TAMBURRINI M, 1986, ITAL J BIOCHEM, V35, P22; TAMBURRINI M, 1990, EUR J BIOCHEM, V190, P145, DOI 10.1111/j.1432-1033.1990.tb15557.x; WHITAKER JR, 1963, ANAL CHEM, V35, P1950, DOI 10.1021/ac60205a048; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	42	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17392	17396						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688724				2022-12-27	WOS:A1993LQ98800075
J	BERTRAN, J; WERNER, A; CHILLARON, J; NUNES, V; BIBER, J; TESTAR, X; ZORZANO, A; ESTIVILL, X; MURER, H; PALACIN, M				BERTRAN, J; WERNER, A; CHILLARON, J; NUNES, V; BIBER, J; TESTAR, X; ZORZANO, A; ESTIVILL, X; MURER, H; PALACIN, M			EXPRESSION CLONING OF A HUMAN RENAL CDNA THAT INDUCES HIGH-AFFINITY TRANSPORT OF L-CYSTINE SHARED WITH DIBASIC AMINO-ACIDS IN XENOPUS-OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER VESICLES; ECOTROPIC RETROVIRUS RECEPTOR; MONOCLONAL-ANTIBODY 4F2; MEMBRANE-VESICLES; PROTEIN; FIBROBLASTS; PATHWAYS; TUBULES; CULTURE; SYSTEM	A renal cDNA clone (rBAT) that induces system b(o,+)-like amino acid transport activity in Xenopus oocytes has recently been isolated (Bertran, J., Werner, A., Moore, M. L., Stange, G., Markovich, D., Biber, J., Testar, X., Zorzano, A., Palacin, and Murer, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5601-5605). Here we show the isolation of a cDNA clone by screening a human kidney cortex cDNA library for expression of sodium-independent transport of L-[H-3]arginine in Xenopus oocytes. The cRNA of this clone induces in oocytes, in addition to the uptake Of L-arginine, that of L-[S-35]cystine and L-[H-3]leucine. Expressed uptake of these amino acids is mutually cis-inhibitable by the other 2 amino acids. Expressed uptake of L-cystine is saturable and shows an apparent K(m) in the micromolar range. All these characteristics resemble induction of system b(o,+) related to rBAT in the oocytes. Human rBAT mRNA (approximately 2.5 kilobases) is found in kidney, small intestine (i.e., jejunum), pancreas, and liver. Human kidney poly(A)+ RNA (mRNA) induces sodium-independent uptake Of L-cystine, L-arginine, and L-leucine in Xenopus oocytes. Hybrid depletion with an antisense oligonucleotide of the isolated clone greatly prevents (80-97%) human kidney mRNA-dependent induction of the uptake of these amino acids (i.e. L-cystine, L-arginine, and L-leucine). The isolated-clone (2304 base pairs in length) contains a poly(A) tail and encodes a predicted 78.8-kDa protein which is 85 and 80% identical to the rabbit and rat rBAT, respectively. This predicted protein corresponds to a membrane glycoprotein, and contains six potential N-glycosylation sites which might be functional in the oocyte: [S-35] methionine labeling of oocytes shows a specific band of 94 kDa in crude membranes of these human cRNA-injected oocytes; treatment of these oocytes with tunicamycin shifts the cRNA-specific translation product to approximately 72 kDa. We conclude that we have isolated a functional cDNA corresponding to human rBAT. The isolation of this human cDNA would lead to the study of the possible involvement of rBAT in human hyperaminoacidurias.	UNIV BARCELONA,DEPT BIOQUIM & FISIOL,AVDA DIAGONAL 645,E-08028 BARCELONA,SPAIN; UNIV ZURICH,INST PHYSIOL,CH-8057 ZURICH,SWITZERLAND; INST RECERCA ONCOL,DEPT GENET MOLEC,E-08907 BARCELONA,SPAIN	University of Barcelona; University of Zurich			Zorzano, Antonio/R-5479-2018; Chillaron, Josep/ABF-7663-2021; Palacín, Manuel/G-9786-2015; Estivill, Xavier/A-3125-2013; Wilson, Matthew H/K-3193-2013; Nunes, Virginia/AAD-1014-2019	Chillaron, Josep/0000-0003-3068-7598; Estivill, Xavier/0000-0002-0723-2256; Nunes, Virginia/0000-0002-5747-9310; Bertran, Joan/0000-0002-4276-336X; Palacin, Manuel/0000-0002-8670-293X				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BANNAI S, 1980, J BIOL CHEM, V255, P2372; Bergeron M, 1985, KIDNEY PHYSL PATHOPH, P1725; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COICADAN L, 1980, PEDIATR RES, V14, P109, DOI 10.1203/00006450-198002000-00008; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; GROTH U, 1972, J CLIN INVEST, V51, P2130, DOI 10.1172/JCI107020; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P9608; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEMLER ME, 1982, J IMMUNOL, V129, P623; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KWON HM, 1992, J BIOL CHEM, V267, P6297; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSCHER B, 1985, J IMMUNOL, V153, P3951; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MCNAMARA PD, 1991, J BIOL CHEM, V266, P986; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MIRCHEFF AK, 1982, J MEMBRANE BIOL, V64, P113, DOI 10.1007/BF01870773; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; ROSENBERG LE, 1967, J CLIN INVEST, V46, P30, DOI 10.1172/JCI105508; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; TAKADA A, 1984, J BIOL CHEM, V259, P2441; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; THIER SO, 1965, J CLIN INVEST, V44, P442, DOI 10.1172/JCI105157; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VOLKL H, 1982, PFLUG ARCH EUR J PHY, V395, P196, DOI 10.1007/BF00584809; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WERNER A, 1991, P NATL ACAD SCI USA, V88, P9608, DOI 10.1073/pnas.88.21.9608; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982	51	130	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14842	14849						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686906				2022-12-27	WOS:A1993LL75900049
J	PALLA, E; BENSI, G; SOLITO, E; BUONAMASSA, DT; FASSINA, G; RAUGEI, G; SPANO, F; GALEOTTI, C; MORA, M; DOMENIGHINI, M; ROSSINI, M; GALLO, E; CARINCI, V; BUGNOLI, M; BERTINI, F; PARENTE, L; MELLI, M				PALLA, E; BENSI, G; SOLITO, E; BUONAMASSA, DT; FASSINA, G; RAUGEI, G; SPANO, F; GALEOTTI, C; MORA, M; DOMENIGHINI, M; ROSSINI, M; GALLO, E; CARINCI, V; BUGNOLI, M; BERTINI, F; PARENTE, L; MELLI, M			LOOP SUBSTITUTION AS A TOOL TO IDENTIFY ACTIVE-SITES OF INTERLEUKIN-1-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; IL-1 RECEPTOR; B-CELLS; BINDING; PROTEIN; EXPRESSION; IL-1-BETA; FRAGMENT; PURIFICATION; PEPTIDE	By computer analysis of the amino acid sequence of human interleukin-1beta (IL-1beta) and of the human type I IL-1 receptor (IL-1RI), we have identified two hydropathically complementary peptides (Fassina, G., Roller, P. P., Olson, A. D., Thorgeirsson, S. S., and Omichinski, J. G. (1989) J. Biol. Chem. 264, 11252-11257) capable of binding to each other. The sequence of the IL-1beta peptide corresponds to that of residues 88-99 (loop 7 of the crystal structure of mature IL-1beta) of mature IL-1beta, one of the exposed and highly charged regions of the molecule. The substitution of this loop with an amino acid sequence of the same length but different hydropathic profile generates a mutant with drastically reduced binding activity to IL-1RI. In contrast, the binding affinity to the type II IL-1R (IL-1RII) is the same as that of wild type IL-1beta. The results show that 1) loop 7 is part of the binding site of IL-1beta to IL-1RI, but not to IL-1RII. 2) The structure of the mutant protein is not grossly altered except locally at the position of the substituted loop. 3) The substitution of amino acids by site-directed mutagenesis of the loop 7 region generates mutants with binding affinity constants slightly lower than that of wild type IL-1beta and not comparable to that of the loop substitution analogue. 4. All mutants analyzed, including the loop substitutions, are biologically active, confirming the structural integrity of the proteins. We propose a binding site in which the cooperation of several low energy bonds extended over a wide area results in a high affinity complex between IL-1 and the type I receptor.	IMMUNOBIOL RES INST SIENA, DEPT MOLEC BIOL, VIA FIORENTINA 1, I-53100 SIENA, ITALY; IMMUNOBIOL RES INST SIENA, DEPT PHARMACOL, I-53100 SIENA, ITALY; TECHNOGEN, I-20131 MILAN, ITALY				Fassina, Giorgio/I-7127-2012; SPANO, FURIO/O-2294-2015; Parente, Luca/G-8997-2012	Fassina, Giorgio/0000-0003-1845-2657; Solito, Egle/0000-0001-5279-0049; Spano, Furio/0000-0002-7324-0895; raugei, giovanni/0000-0003-1294-786X				ANTONI G, 1986, J IMMUNOL, V137, P3201; BALDARI C, 1987, EMBO J, V6, P229, DOI 10.1002/j.1460-2075.1987.tb04743.x; BERTOGLIO JH, 1988, J IMMUNOL, V141, P1191; BIGIO M, 1989, J IMMUNOL METHODS, V123, P1, DOI 10.1016/0022-1759(89)90023-9; BLALOCK JE, 1990, TRENDS BIOTECHNOL, V8, P140, DOI 10.1016/0167-7799(90)90159-U; BORASCHI D, 1989, Biotherapy (Dordrecht), V1, P377, DOI 10.1007/BF02171014; BORASCHI D, 1988, J EXP MED, V168, P675, DOI 10.1084/jem.168.2.675; BORASCHI D, 1987, Annales de l'Institut Pasteur Immunology, V138, P492; CASAGLI MC, 1989, PREP BIOCHEM, V19, P23, DOI 10.1080/10826068908544894; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P4668, DOI 10.1021/bi00471a023; FASSINA G, 1992, INT J PEPT PROT RES, V39, P540; FASSINA G, 1989, J BIOL CHEM, V264, P11252; FASSINA G, 1992, INT J PEPT PROT RES, V39, P549; FASSINA G, 1991, Patent No. 411503; GRONENBORN AM, 1986, EUR J BIOCHEM, V161, P37, DOI 10.1111/j.1432-1033.1986.tb10121.x; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HORLICK RA, 1992, PROTEIN ENG, V5, P427, DOI 10.1093/protein/5.5.427; HORUK R, 1987, J BIOL CHEM, V262, P16275; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAYE J, 1984, J IMMUNOL, V133, P1339; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LOWENTHAL JW, 1986, J EXP MED, V164, P1060, DOI 10.1084/jem.164.4.1060; Maniatis T., 1982, MOL CLONING; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; Rothstein R., 1985, DNA CLONING, VII, P45; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SOLITO E, 1989, BRIT J PHARMACOL, V96, P656, DOI 10.1111/j.1476-5381.1989.tb11865.x; STOPPACCIARO A, 1991, J IMMUNOL, V147, P1561; TATE S, 1992, BIOCHEMISTRY-US, V31, P2435, DOI 10.1021/bi00123a032; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WIEBEL F, 1969, J CELL PHYSIOL, V74, P191, DOI 10.1002/jcp.1040740211; WOLFSON AJ, 1991, PROTEIN ENG, V4, P313, DOI 10.1093/protein/4.3.313	41	21	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13486	13492						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685764				2022-12-27	WOS:A1993LH55300067
J	HA, HJ; HAJEK, P; BEDWELL, DM; BURROWS, PD				HA, HJ; HAJEK, P; BEDWELL, DM; BURROWS, PD			A MITOCHONDRIAL PORIN CDNA PREDICTS THE EXISTENCE OF MULTIPLE HUMAN PORINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MUTANT LACKING; OUTER-MEMBRANE; FORMING PROTEIN; MESSENGER-RNA; IMPORT; IDENTIFICATION; ACCUMULATION; TRANSLATION; EXPRESSION; PARTICLES	Pores formed in the outer membrane of mitochondria by mitochondrial porin make it permeable to water-soluble metabolites smaller than approximately 5 kDa. We have isolated a full-length cDNA encoding a human porin. This probe detects a single approximately 1.5-kilobase mRNA species on Northern blots, but multiple hybridizing bands on genomic Southern blots. The open reading frame predicts a 38.1-kDa protein with a pl of 6.59 that is homologous but not identical to a previously reported protein sequence of a 31-kDa porin isolated from human lymphocytes (porin 31HL). The most striking difference between the two porins is that the sequence predicted by the cDNA is longer than the 31HL porin by 27 amino acids at the amino terminus and 38 amino acids at the carboxyl terminus. The porin cDNA directs the in vitro translation of two protein species of approximately 32 and approximately 36 kDa, which appear to result from alternate usage of AUG initiation codons. The 32-kDa protein is the predominant species imported into both rat and yeast mitochondria in vitro. Taken together, these results suggest that multiple porin proteins can be expressed in humans. Additionally, a porin consensus protein sequence has been identified that is conserved in eukaryotic organisms as diverse as yeast and man.	UNIV ALABAMA,CTR COMPREHENS CANC,DEPT BIOCHEM,364 TUMOR INST,BIRMINGHAM,AL 35294; UNIV ALABAMA,CTR COMPREHENS CANC,DIV DEV & CLIN IMMUNOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Bedwell, David/0000-0002-6605-818X	NIAID NIH HHS [AI 30879, AI 26394] Funding Source: Medline; NIAMS NIH HHS [P60AR 20614-15] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI026394, P01AI030879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABEL D, 1991, BIOL CHEM H-S, V372, P1027, DOI 10.1515/bchm3.1991.372.2.1027; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; BLACHLY-DYSON E, 1991, Biophysical Journal, V59, p216A; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE BE, 1985, J GEN VIROL, V145, P227; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIHANICH M, 1990, EXPERIENTIA, V46, P131, DOI 10.1007/BF02027307; DIHANICH M, 1987, EMBO J, V6, P723, DOI 10.1002/j.1460-2075.1987.tb04813.x; DIHANICH M, 1989, MOL CELL BIOL, V9, P1100, DOI 10.1128/MCB.9.3.1100; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; ERNST H, 1985, P NATL ACAD SCI USA, V82, P48, DOI 10.1073/pnas.82.1.48; GLASER SM, 1990, MOL CELL BIOL, V10, P1873, DOI 10.1128/MCB.10.5.1873; HA HJ, 1992, J IMMUNOL, V148, P1526; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KONIG U, 1991, BIOL CHEM H-S, V372, P565, DOI 10.1515/bchm3.1991.372.2.565; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LUDWIG O, 1988, EUR BIOPHYS J BIOPHY, V15, P269, DOI 10.1007/BF00256477; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; MURAKAMI H, 1989, J CELL BIOL, V107, P2052; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; PERSING DH, 1985, P NATL ACAD SCI USA, V82, P3440, DOI 10.1073/pnas.82.10.3440; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; PFALLER R, 1988, J CELL BIOL, V107, P4283; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771	41	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12143	12149						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685033				2022-12-27	WOS:A1993LF28400101
J	MOLHUIZEN, HOF; ALKEMADE, HAC; ZEEUWEN, PLJM; DEJONGH, GJ; WIERINGA, B; SCHALKWIJK, J				MOLHUIZEN, HOF; ALKEMADE, HAC; ZEEUWEN, PLJM; DEJONGH, GJ; WIERINGA, B; SCHALKWIJK, J			SKALP/ELAFIN - AN ELASTASE INHIBITOR FROM CULTURED HUMAN KERATINOCYTES - PURIFICATION, CDNA SEQUENCE, AND EVIDENCE FOR TRANSGLUTAMINASE CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PIG SEMINAL-VESICLE; POLYMORPHONUCLEAR LEUKOCYTES; PROTEINASE-INHIBITOR; ARTICULAR-CARTILAGE; 4-DISULFIDE CORE; HUMAN-SKIN; DEGRADATION; CLEAVAGE; INACTIVATION	SKALP/Elafin is a proteinase inhibitor found in psoriatic epidermis as a short polypeptide of 6 kDa. Here we present evidence that this protein is synthesized as a larger precursor molecule with distinct biological features. Purification and NH2-terminal sequencing of SKALP/elafin from cultured human keratinocytes and the cloning of its cDNA revealed the existence of a mature protein, which upon cleavage of a hydrophobic signal sequence of 22 amino acids has a calculated molecular mass of 9.9 kDa (95 amino acids). In addition to the known proteinase inhibitor domain, the mature protein contains a domain with 4 repeats which are homologous to putative transglutaminase substrate motifs. We were able to demonstrate on Western blots that immunoreactive SKALP is present in high molecular weight proteins extracted from psoriatic skin. This suggests that SKALP is covalently attached to epidermal proteins. In addition it was found that both the complete SKALP molecule and a synthetic peptide of the NH2-terminal portion of SKALP could be used as a transglutaminase substrate. We therefore speculate that SKALP/elafin, secreted by epidermal keratinocytes in inflamed skin, exists both as a free 6-kDa form and as an immobilized 9.9-kDa form covalently attached to the cornified envelopes by transglutaminase cross-linking.	ACAD HOSP NIJMEGEN,DEPT DERMATOL,POB 9101,6500 HB NIJMEGEN,NETHERLANDS; CATHOLIC UNIV NIJMEGEN,FAC MED,DEPT CELL BIOL & HISTOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Schalkwijk, Joost/R-7509-2019; Schalkwijk, Joost/N-1774-2013; Zeeuwen, Patrick/N-1779-2013; Wieringa, Berend/A-5346-2011	Schalkwijk, Joost/0000-0002-1308-1319; Zeeuwen, Patrick/0000-0002-6878-2438; Wieringa, Berend/0000-0001-9192-8020				ALKEMADE H, 1992, J INVEST DERMATOL, V99, P3, DOI 10.1111/1523-1747.ep12611375; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BERBERS GAM, 1984, P NATL ACAD SCI-BIOL, V81, P7017, DOI 10.1073/pnas.81.22.7017; BRIGGAMAN RA, 1984, J EXP MED, V160, P1027, DOI 10.1084/jem.160.4.1027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DRENTH J, 1980, J BIOL CHEM, V255, P2652; GROENEN PJTA, 1992, EUR J BIOCHEM, V205, P671, DOI 10.1111/j.1432-1033.1992.tb16827.x; HAGSTROM JE, 1989, MOL ENDOCRINOL, V3, P1797, DOI 10.1210/mend-3-11-1797; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; JANOFF A, 1968, J EXP MED, V128, P1137, DOI 10.1084/jem.128.5.1137; JANOFF A, 1976, J CLIN INVEST, V57, P615, DOI 10.1172/JCI108317; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MAINARDI CL, 1980, J BIOL CHEM, V255, P5435; MAINARDI CL, 1980, J BIOL CHEM, V255, P2006; MOORE JT, 1987, P NATL ACAD SCI USA, V84, P6712, DOI 10.1073/pnas.84.19.6712; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; SCHALKWIJK J, 1990, BRIT J DERMATOL, V122, P631, DOI 10.1111/j.1365-2133.1990.tb07285.x; SCHALKWIJK J, 1987, BRIT J EXP PATHOL, V68, P81; SCHALKWIJK J, 1993, IN PRESS J INVEST DE; SCHRIJVER G, 1989, J EXP MED, V169, P1435, DOI 10.1084/jem.169.4.1435; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; TAKAMORI K, 1988, INT J DERMATOL, V27, P533, DOI 10.1111/j.1365-4362.1988.tb02399.x; THOMPSON RC, 1986, P NATL ACAD SCI USA, V83, P6692, DOI 10.1073/pnas.83.18.6692; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANERP PEJ, 1988, CYTOMETRY, V9, P627, DOI 10.1002/cyto.990090618; VANHOOIJDONK CAEM, 1991, ACTA DERM-VENEREOL, V71, P173; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; WIEDOW O, 1992, 18TH P WORLD C DERM	39	159	165	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12028	12032						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685029				2022-12-27	WOS:A1993LF28400085
J	WALDBESER, LS; TOLMASKY, ME; ACTIS, LA; CROSA, JH				WALDBESER, LS; TOLMASKY, ME; ACTIS, LA; CROSA, JH			MECHANISMS FOR NEGATIVE REGULATION BY IRON OF THE FATA OUTER-MEMBRANE PROTEIN GENE-EXPRESSION IN VIBRIO-ANGUILLARUM 775	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHINE-DALGARNO REGION; ESCHERICHIA-COLI; MESSENGER-RNA; PLASMID PJM1; UPTAKE SYSTEM; MOLECULAR CHARACTERIZATION; TRANSPORT-SYSTEM; LAC MESSENGER; CLONING; DECAY	Synthesis of the 86-kDa FatA outer membrane protein is repressed under iron-rich conditions. Complementation of transposition mutants derived from clones containing the pJM1 iron uptake region revealed the existence of an antisense RNA, RNAalpha. This RNA is only expressed under iron-rich conditions and acts as a negative regulator of FatA synthesis, with slight but discernible decrease in the steady-state level of fatA mRNA determined by RNase protection and by Northern blot analysis. Primer extension experiments revealed that the level of several possible fatA transcripts was reduced in the presence of RNAalpha. In addition, we found that fatA mRNA expression is slightly reduced in the presence of Escherichia coli Fur. We have identified and cloned a chromosomally encoded fur-like gene in Vibrio anguillarum.	OREGON HLTH SCI UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL L220, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA	Oregon Health & Science University			Tolmasky, Marcelo/AAC-5316-2020	Tolmasky, Marcelo/0000-0002-6298-7811	NIAID NIH HHS [AI19010] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACTIS LA, 1988, J BIOL CHEM, V263, P2853; ACTIS LA, 1985, J BACTERIOL, V161, P736, DOI 10.1128/JB.161.2.736-742.1985; ACTIS LA, 1986, J BACTERIOL, V167, P57, DOI 10.1128/jb.167.1.57-65.1986; ALTUVIA S, 1987, P NATL ACAD SCI USA, V84, P6511, DOI 10.1073/pnas.84.18.6511; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAGG A, 1985, J BACTERIOL, V161, P450, DOI 10.1128/JB.161.1.450-453.1985; BARCLAY R, 1985, MED LAB SCI, V42, P166; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CALDERWOOD SB, 1988, J BACTERIOL, V170, P1015, DOI 10.1128/jb.170.2.1015-1017.1988; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHO KO, 1988, J MOL BIOL, V204, P51, DOI 10.1016/0022-2836(88)90598-0; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; CROSA JH, 1980, NATURE, V284, P566, DOI 10.1038/284566a0; CROSA JH, 1981, INFECT IMMUN, V31, P223, DOI 10.1128/IAI.31.1.223-227.1981; CROSA JH, 1984, ANNU REV MICROBIOL, V38, P69, DOI 10.1146/annurev.mi.38.100184.000441; CROSA JH, 1989, MICROBIOL REV, V53, P517, DOI 10.1128/MMBR.53.4.517-530.1989; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; ERNST JF, 1978, J BACTERIOL, V135, P928, DOI 10.1128/JB.135.3.928-934.1978; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GHOSH PK, 1978, J MOL BIOL, V126, P813, DOI 10.1016/0022-2836(78)90022-0; GOLDBERG MB, 1990, J BACTERIOL, V172, P6863, DOI 10.1128/jb.172.12.6863-6870.1990; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; HANTKE K, 1984, MOL GEN GENET, V197, P337, DOI 10.1007/BF00330982; HIGGINS CF, 1988, GENE, V72, P3, DOI 10.1016/0378-1119(88)90122-9; JALAL MAF, 1989, J AM CHEM SOC, V111, P292, DOI 10.1021/ja00183a044; KOSTER WL, 1991, J BIOL CHEM, V266, P23829; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIM LW, 1979, J MOL BIOL, V135, P369, DOI 10.1016/0022-2836(79)90442-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURAKAWA GJ, 1991, J BACTERIOL, V173, P28, DOI 10.1128/jb.173.1.28-36.1991; NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PAYNE SM, 1978, J CLIN INVEST, V61, P1428, DOI 10.1172/JCI109062; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; QUEEN C, 1981, CELL, V25, P241, DOI 10.1016/0092-8674(81)90249-X; SALINAS PC, 1989, P NATL ACAD SCI USA, V86, P3529, DOI 10.1073/pnas.86.10.3529; SALINAS PC, 1993, IN PRESS GENE AMST; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1989, GENE, V78, P59, DOI 10.1016/0378-1119(89)90314-4; STAGGS TM, 1991, J BACTERIOL, V173, P417, DOI 10.1128/jb.173.2.417-425.1991; TAI SPS, 1988, INFECT IMMUN, V56, P2430, DOI 10.1128/IAI.56.9.2430-2436.1988; TAYLOR RK, 1985, J BACTERIOL, V162, P1054, DOI 10.1128/JB.162.3.1054-1060.1985; TOLMASKY ME, 1991, BIOL MET, V4, P33, DOI 10.1007/BF01135554; TOLMASKY ME, 1992, GENE, V110, P41, DOI 10.1016/0378-1119(92)90442-R; TOLMASKY ME, 1984, J BACTERIOL, V160, P860, DOI 10.1128/JB.160.3.860-866.1984; TOLMASKY ME, 1988, J BACTERIOL, V170, P1913, DOI 10.1128/jb.170.4.1913-1919.1988; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WALTER MA, 1983, J BACTERIOL, V156, P880, DOI 10.1128/JB.156.2.880-887.1983; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; WOLOJ M, 1986, ANTIMICROB AGENTS CH, V29, P315, DOI 10.1128/AAC.29.2.315	54	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10433	10439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683679				2022-12-27	WOS:A1993LB80000067
J	ENGHILD, JJ; SALVESEN, G; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; HEFTA, SA				ENGHILD, JJ; SALVESEN, G; THOGERSEN, IB; VALNICKOVA, Z; PIZZO, SV; HEFTA, SA			PRESENCE OF THE PROTEIN-GLYCOSAMINOGLYCAN-PROTEIN COVALENT CROSS-LINK IN THE INTER-ALPHA-INHIBITOR-RELATED PROTEINASE-INHIBITOR HEAVY CHAIN-2 BIKUNIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; TRYPSIN-INHIBITOR; HUMAN-PLASMA; QUANTITIES; COMPLEX	HC2/bikunin is a human plasma proteinase inhibitor composed of two polypeptide chains that resist dissociation under reducing conditions in SDS-polyacrylamide gel electrophoresis. This observation suggests that a nondisulfide cross-link is responsible for the association of these two polypeptide chains. In this study, we have utilized a variety of techniques to investigate the structural basis for this observation. We show that the cross-link between the two protein chains is sensitive to chondroitin sulfate-degrading enzymes and to 50 mM NaOH, properties shared by the protein-glycosaminoglycan-protein cross-link found in the related pre-alpha-inhibitor (Enghild, J. J., Salvesen, G., Hefta, S., Thogersen, I. B., Rutherfurd, S., and Pizzo, S. V. (1991) J. Biol. Chem. 266, 747-751). Biochemical and mass spectrometric analysis of the peptides containing the cross-link indicate that it is mediated by a chondroitin-4-sulfate chain that originates from a typical O-glycosidic link to Ser10 of bikunin. The COOH-terminal Asp648 residue of heavy chain 2 is esterified via the alpha-carbon to C-6 of an internal N-acetylgalactosamine of the chondroitin-4-sulfate chain. This suggests that the protein-glycosaminoglycan-protein cross-link that assembles the chains of pre-alpha-inhibitor is identical to that which assembles HC2/bikunin, and is probably a characteristic of the bikunin proteins.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope	ENGHILD, JJ (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,POB 3712,DURHAM,NC 27710, USA.			Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R01HL049542, R37HL024066] Funding Source: NIH RePORTER; NCI NIH HHS [CA33572] Funding Source: Medline; NHLBI NIH HHS [HL-24066, HL-49542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDUYCK M, 1986, EUR J BIOCHEM, V158, P417, DOI 10.1111/j.1432-1033.1986.tb09769.x; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DIARRAMEHRPOUR M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P114, DOI 10.1016/0167-4781(92)90065-8; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; GEBHARD W, 1988, FEBS LETT, V229, P63, DOI 10.1016/0014-5793(88)80798-1; GEBHARD W, 1990, BIOL CHEM H-S, V371, P13; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; KAUMEYER JK, 1989, NUCLEIC ACIDS RES, V14, P7839; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEANS GE, 1971, CHEM MODIFICATION PR, P139; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; SALIER JP, 1983, BIOCHIM BIOPHYS ACTA, V742, P206; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P240; SHULMAN R, 1955, J BIOL CHEM, V213, P655; SUNDQVIST B, 1984, BIOMED MASS SPECTROM, V11, P242, DOI 10.1002/bms.1200110509	22	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8711	8716						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682553				2022-12-27	WOS:A1993KX81100052
J	CAPUANO, V; THOMAS, JC; DEMARSAC, NT; HOUMARD, J				CAPUANO, V; THOMAS, JC; DEMARSAC, NT; HOUMARD, J			AN INVIVO APPROACH TO DEFINE THE ROLE OF THE LCM, THE KEY POLYPEPTIDE OF CYANOBACTERIAL PHYCOBILISOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING ANTENNA; ANACYSTIS-NIDULANS R2; MOLECULAR CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; ENERGY-TRANSFER; FOREIGN DNA; WILD-TYPE; GENE; CLONING; CORE	In cyanobacteria, phycobilisomes are regularly arrayed on the surface of the photosynthetic membranes, and their role is to funnel light energy to the underlying photosystem II reaction center. A model has recently been proposed that ascribes to the so-called L(CM), a central role in the building up of the phycobilisome, in addition to its role of terminal energy acceptor (Capuano, V., Braux, A.-S., Tandeau de Marsac, N., and Houmard, J. (1991) J. Biol. Chem. 266, 7239-7247). The phycobilisomes of Calothrix sp. PCC 7601 are typically of the type found in most cyanobacteria. Those of Synechococcus PCC 7942 (or PCC 6301) differ in having central cores made up of two instead of three cylinders. We have integrated the Calothrix PCC 7601 apcE gene that encodes the L(CM) into the chromosome of a Synechococcus PCC 7942 strain. We have observed that the heterologous gene is expressed and that the corresponding product carries a bilin-type chromophore and can be detected in the phycobilisome fraction of the Synechococcus strain. Moreover, it is shown that, in agreement with our model, this L(CM) can direct the formation of phycobilisomes that have three-cylinder cores.	INST PASTEUR, UNITE PHYSIOL MICROBIENNE,CNRS,URA 1129, 28 RUE DR ROUX, F-75724 PARIS 15, FRANCE; ECOLE NORMALE SUPER, BIOMEMBRANES LAB, CNRS, URA 311, F-75230 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)				Capuano, Veronique/0000-0001-8738-0947				ANDERSON LK, 1986, J MOL BIOL, V191, P441, DOI 10.1016/0022-2836(86)90139-7; Bryant D. A., 1991, CELL CULTURE SOMATIC, P257; BRYANT DA, 1979, ARCH MICROBIOL, V123, P113, DOI 10.1007/BF00446810; CAPUANO V, 1991, J BIOL CHEM, V266, P7239; DAMERVAL T, 1991, PLANT CELL, V3, P191; DEMARSAC NT, 1982, GENE, V20, P111, DOI 10.1016/0378-1119(82)90092-0; DEMARSAC NT, 1985, NUCLEIC ACIDS RES, V13, P7223, DOI 10.1093/nar/13.20.7223; DEMARSAC NT, 1988, PHOTOSYNTH RES, V18, P99, DOI 10.1007/BF00042981; ELMORJANI K, 1986, ARCH MICROBIOL, V146, P186, DOI 10.1007/BF00402349; GANTT E, 1979, PLANT PHYSIOL, V63, P615, DOI 10.1104/pp.63.4.615; GINGRICH JC, 1983, J CELL BIOCHEM, V22, P1, DOI 10.1002/jcb.240220102; GLAUSER M, 1992, EUR J BIOCHEM, V205, P907, DOI 10.1111/j.1432-1033.1992.tb16857.x; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1983, ANNU REV BIOCHEM, V52, P125, DOI 10.1146/annurev.bi.52.070183.001013; GLAZER AN, 1979, P NATL ACAD SCI USA, V76, P6162, DOI 10.1073/pnas.76.12.6162; GLAZER AN, 1983, ANN INST PASTEUR MIC, VB134, P159, DOI 10.1016/S0769-2609(83)80103-3; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; GOLDEN SS, 1989, J BACTERIOL, V171, P24, DOI 10.1128/jb.171.1.24-29.1989; HANKER JS, 1977, HISTOCHEM J, V9, P789, DOI 10.1007/BF01003075; HOUMARD J, 1990, P NATL ACAD SCI USA, V87, P2152, DOI 10.1073/pnas.87.6.2152; HOUMARD J, 1986, MOL GEN GENET, V205, P404, DOI 10.1007/BF00338074; KOLOWSKY KS, 1984, GENE, V27, P289, DOI 10.1016/0378-1119(84)90073-8; KUHLEMEIER CJ, 1983, PLASMID, V10, P156, DOI 10.1016/0147-619X(83)90068-9; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; MIMURO M, 1986, BIOCHIM BIOPHYS ACTA, V852, P126, DOI 10.1016/0005-2728(86)90065-4; RAPS S, 1990, PLANT PHYSIOL, V92, P358, DOI 10.1104/pp.92.2.358; REDLINGER T, 1982, P NATL ACAD SCI-BIOL, V79, P5542, DOI 10.1073/pnas.79.18.5542; STANIER RY, 1977, ANNU REV MICROBIOL, V31, P225, DOI 10.1146/annurev.mi.31.100177.001301; TANDEAUDEMARSAC N, 1977, P NATL ACAD SCI USA, V74, P1635; VANDENHONDEL CAMJJ, 1980, P NATL ACAD SCI-BIOL, V77, P1570; VANDENHONDEL CAMJJ, 1980, A VAN LEEUW J MICROB, V46, P228, DOI 10.1007/BF00444081; VANDERPLAS J, 1990, GENE, V95, P39, DOI 10.1016/0378-1119(90)90411-J; VANDERPLAS J, 1988, PHOTOSYNTH RES, V18, P179, DOI 10.1007/BF00042984; WILLIAMS JGK, 1983, GENE, V24, P37, DOI 10.1016/0378-1119(83)90129-4; YAMANAKA G, 1982, J BIOL CHEM, V257, P4077; YAMANAKA G, 1980, J BIOL CHEM, V255, P1004	38	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					8277	8283						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681841				2022-12-27	WOS:A1993KW97900100
J	VANDERVOORN, L; TOL, O; HENGEVELD, TM; PLOEGH, HL				VANDERVOORN, L; TOL, O; HENGEVELD, TM; PLOEGH, HL			STRUCTURAL AND FUNCTIONAL-STUDIES ON THE G(0)-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; BOVINE BRAIN MEMBRANES; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; ADENYLATE-CYCLASE; MOLECULAR-CLONING; SEQUENCE DETERMINATION; BETA-SUBUNITS; GO-ALPHA	Monoclonal antibodies were raised against purified bovine and human brain G-proteins. The epitopes recognized by three monoclonal antibodies (MONO, 3C2, and 3E7) were mapped by expressing defined parts of the bovine G(o)alpha-cDNA in bacteria, followed by immunoblotting. All three antibodies recognize the recombinant bovine alpha(o)-protein, but at distinct sites. The epitopes of MONO and 3C2 were mapped between alpha(o) amino acids 80 and 145, and both antibodies recognize alpha(o) exclusively. Heterotrimeric G(o)-proteins as well as guanosine 5'-3-O-(thio)triphosphate-liganded free alpha(o)-subunits are readily immunoprecipitated by these monoclonal antibodies. Binding of MONO or 3C2 does not affect ADP-ribosylation of the alpha(o)-subunit by pertussis toxin. Apparently, the antibodies do not bind to or induce large conformational changes in regions of the alpha(o)-subunit that are involved in association with betagamma-subunits or ADP-ribosylation. 3E7 behaves as an anti common alpha-subunit antibody when used in immunoblots. However, under nondenaturing conditions, 3E7 recognizes alpha(o) exclusively. After binding of 3E7, the pertussis toxin-dependent ADP-ribosylation of alpha(o) is effectively blocked, while the ADP-ribosylation of the various alpha(i)-subunits is not affected. The epitope of 3E7 was mapped between alpha(o) amino acids 13-88, a region which has been implicated in the interaction between alpha- and betagamma-subunits. Possibly, the inhibitory effect of 3E7 on ADP-ribosylation of G(o) is secondary to the loss of betagamma-subunits that is observed upon binding of 3E7.			VANDERVOORN, L (corresponding author), NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; ASANO T, 1988, J NEUROCHEM, V50, P1164, DOI 10.1111/j.1471-4159.1988.tb10588.x; BERTRAND P, 1990, J BIOL CHEM, V265, P18576; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CERIONE RA, 1988, J BIOL CHEM, V263, P345; CORREZE C, 1987, J BIOL CHEM, V262, P15182; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1989, J BIOL CHEM, V264, P11475; HAMM HE, 1987, J BIOL CHEM, V262, P10831; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KIM SH, 1988, COLD SPRING HARB SYM, V53, P273, DOI 10.1101/SQB.1988.053.01.034; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVU S, 1988, BIOCHEM BIOPH RES CO, V150, P811, DOI 10.1016/0006-291X(88)90463-9; LINGHAM RB, 1986, BIOCHEM J, V236, P267, DOI 10.1042/bj2360267; Maniatis T., 1982, MOL CLONING; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILLIGAN G, 1988, BIOCHEM J, V255, P1; Milligan G., 1990, G PROTEINS MEDIATORS, P31; NAVON SE, 1988, J BIOL CHEM, V263, P489; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; PARHAM P, 1979, J IMMUNOL, V123, P342; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TOUTANT M, 1987, FEBS LETT, V215, P339, DOI 10.1016/0014-5793(87)80174-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVOORN L, 1992, FEBS LETT, V308, P75, DOI 10.1016/0014-5793(92)81054-P; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252	59	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5131	5138						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680347				2022-12-27	WOS:A1993KP88400083
J	UCHIDA, S; SASAKI, S; FURUKAWA, T; HIRAOKA, M; IMAI, T; HIRATA, Y; MARUMO, F				UCHIDA, S; SASAKI, S; FURUKAWA, T; HIRAOKA, M; IMAI, T; HIRATA, Y; MARUMO, F			MOLECULAR-CLONING OF A CHLORIDE CHANNEL THAT IS REGULATED BY DEHYDRATION AND EXPRESSED PREDOMINANTLY IN KIDNEY MEDULLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THIN ASCENDING LIMB; FUNCTIONAL EXPRESSION; TRANSPORT INHIBITORS; RECEPTOR SHOWS; CL TRANSPORT; HENLES LOOP; PERMEABILITY; SODIUM	Complementary DNA encoding a rat kidney chloride channel (ClC-K1) was isolated by a polymerase chain reaction (PCR) cloning strategy. We designed degenerate primers, based on the regions where previously cloned chloride channels (ClC-0, -1, and -2) possess significant amino acid identity, and performed reverse transcription PCR with whole kidney mRNA. The 686-amino acid protein encoded by ClC-K1 is about 40% identical to the previously cloned chloride channels and has a similar hydropathy profile. Expression of ClC-K1 in Xenopus oocytes induced Cl- currents that activate instantaneously upon hyperpolarization and depolarization, and displayed a slightly outwardly rectifying current-voltage relationship. The message for ClC-K1 was 2.4 kilobases and was found predominantly in kidney, especially in the inner medulla. Reverse transcription PCR technique using microdissected nephron segments revealed that the main site of expression in kidney was the thin ascending limb of Henle's loop, which has the highest Cl- permeability among the nephron segments and is thought to be involved in a counter-current system for urine concentration in the inner medulla. The abundance of ClC-K1 mRNA in kidney increased about 4-fold as rats became dehydrated by deprivation of water for 5 days. The site of expression and the regulation by dehydration suggest that ClC-K1 function may be important in urinary concentrating mechanisms.	TOKYO MED & DENT UNIV,INST MED RES,DEPT CARDIOVASC DIS,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)	UCHIDA, S (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN.							GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; IMAI M, 1974, J CLIN INVEST, V53, P393, DOI 10.1172/JCI107572; IMAI M, 1987, KIDNEY INT, V31, P565, DOI 10.1038/ki.1987.37; IMAI M, 1976, J CLIN INVEST, V58, P1054, DOI 10.1172/JCI108556; ISOZAKI T, 1991, KIDNEY INT, V40, pS113; ISOZAKI T, 1989, AM J PHYSIOL, V257, pF92, DOI 10.1152/ajprenal.1989.257.1.F92; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KONDO Y, 1987, AM J PHYSIOL, V253, pF1206; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KWON HM, 1992, J BIOL CHEM, V267, P6297; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOYIYAMA T, 1990, AM J PHYSIOL, V258, pF1470; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; REEVES WB, 1992, ANNU REV PHYSIOL, V54, P29, DOI 10.1146/annurev.physiol.54.1.29; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1991, J BIOL CHEM, V266, P9605; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; UCHIDA S, 1991, Journal of the American Society of Nephrology, V2, P769; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YOSHITOMI K, 1988, J CLIN INVEST, V82, P866, DOI 10.1172/JCI113691	25	228	232	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3821	3824						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680033				2022-12-27	WOS:A1993KN53300007
J	HILL, KJ; STEVENS, TH				HILL, KJ; STEVENS, TH			VMA22P IS A NOVEL ENDOPLASMIC RETICULUM-ASSOCIATED PROTEIN REQUIRED FOR ASSEMBLY OF THE YEAST VACUOLAR H+-ATPASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE ENCODES; SECRETORY PATHWAY; MEMBRANE GLYCOPROTEIN; PEP4 GENE; SUBUNIT; TRANSPORT; MUTANTS; BIOSYNTHESIS; ENZYME	The Saccharomyces cerevisiae vacuolar H+-ATPase (V-ATPase) is a multi-subunit complex that can be structurally and functionally divided into peripheral (V-1) and integral membrane (V-0) sectors. The vma22-1 mutation was isolated in a screen for mutants defective in V-ATPase function. vma22 Delta cells contain no V-ATPase activity due to a failure to assemble the enzyme complex; V-1 subunits accumulate in the cytosol, and the V-0 100-kDa subunit is rapidly degraded. Turnover of the 100-kDa integral membrane protein was found to occur in the endoplasmic reticulum (ER) of vma22 Delta cells. The product of the VMA22 gene, Vma22p, is a 21-kDa hydrophilic protein that is not a subunit of the V-ATPase but rather is associated with ER membranes. The association of Vma22p with ER membranes was perturbed by mutations in VMA12, a gene that encodes an ER membrane protein (Vma12p) that is also required for V-ATPase assembly. These results indicate that Vma22p, along with Vma21p and Vma12p, form a set of ER proteins required for V-ATPase assembly.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA	University of Oregon				Stevens, Tom/0000-0001-6427-6848	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FOURY F, 1990, J BIOL CHEM, V265, P18554; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; OHYA Y, 1991, J BIOL CHEM, V266, P13971; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	52	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22329	22336		10.1074/jbc.270.38.22329	http://dx.doi.org/10.1074/jbc.270.38.22329			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673216	hybrid			2022-12-27	WOS:A1995RW31400043
J	MARTINEY, JA; CERAMI, A; SLATER, AFG				MARTINEY, JA; CERAMI, A; SLATER, AFG			VERAPAMIL REVERSAL OF CHLOROQUINE RESISTANCE IN THE MALARIA PARASITE PLASMODIUM-FALCIPARUM IS SPECIFIC FOR RESISTANT PARASITES AND INDEPENDENT OF THE WEAK BASE EFFECT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING DIFFERENT LEVELS; P-GLYCOPROTEIN; HEMOGLOBIN DEGRADATION; EFFLUX; MECHANISM; CULTURE; ACCUMULATION; SENSITIVITY; QUINOLINE; PIGMENT	Verapamil increases the net uptake and cytotoxicity of structurally diverse hydrophobic molecules in many multidrug-resistant mammalian cell lines, This compound has also been reported to reverse chloroquine resistance in the human malaria parasite Plasmodium falciparum (Martin, S. K., Oduola, A. M. J., and Milhous, W. K. (1987) Science 235, 899-901), Although the mechanism of this reversal is unknown, it apparently involves an increase in the amount of chloroquine present in erythrocytes infected with the resistant parasites, Chloroquine is a diprotic weak base that accumulates in acidic organelles as a function of the pH gradient present between the organelle and the external medium, By changing the external medium pH, this property of chloroquine was used to alter the cytotoxicity phenotype of genetically chloroquine-sensitive and -resistant trophozoites, Verapamil was also found to be toxic for malaria trophozoites, although this toxicity was independent of external pH and consistently about 3-4-fold higher against resistant strains, When verapamil was tested for its effects on chloroquine cytotoxicity under conditions of phenotypic reversal, it was still found to exert only a measurable effect on the genetically resistant trophozoites, In short time incubations, verapamil was found to increase net chloroquine accumulation in erythrocytes infected with both chloroquine-sensitive and -resistant organisms, but only to affect the chloroquine susceptibility of the latter, Analysis of our data demonstrates that verapamil works independently of the overall pH gradient concentrating chloroquine into a trophozoite's lysosome, Instead, we propose that it inhibits the activity of a membrane ion channel indirectly responsible for determining chloroquine transit within the parasite's cytoplasm.	KAROLINSKA INST, DIV TOXICOL, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	MARTINEY, JA (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030660] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-30660-S1, R01-AI-30660-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAY PG, 1994, MOL BIOCHEM PARASIT, V63, P87, DOI 10.1016/0166-6851(94)90011-6; BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; BRAY PG, 1993, FEMS MICROBIOL LETT, V113, P1, DOI 10.1111/j.1574-6968.1993.tb06479.x; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; FOOTE SJ, 1994, ACTA TROP, V56, P157, DOI 10.1016/0001-706X(94)90061-2; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; GLUZMAN IY, 1987, ANTIMICROB AGENTS CH, V31, P32, DOI 10.1128/AAC.31.1.32; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; JACOBS GH, 1988, AM J TROP MED HYG, V39, P15, DOI 10.4269/ajtmh.1988.39.15; JENSEN JB, 1977, J PARASITOL, V63, P883, DOI 10.2307/3279900; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LUZ JG, 1994, BIOCHEMISTRY-US, V33, P7239, DOI 10.1021/bi00189a028; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; ROEPE PD, 1994, TRENDS PHARMACOL SCI, V15, P445, DOI 10.1016/0165-6147(94)90056-6; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; THEVENOD F, 1994, J BIOL CHEM, V269, P24410; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VALVERDE MA, 1995, FASEB J, V9, P509, DOI 10.1096/fasebj.9.7.7737459; WEI LY, 1994, BIOCHEMISTRY-US, V33, P7229, DOI 10.1021/bi00189a027; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	35	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22393	22398		10.1074/jbc.270.38.22393	http://dx.doi.org/10.1074/jbc.270.38.22393			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673225	hybrid			2022-12-27	WOS:A1995RW31400052
J	SKERKA, C; DECKER, EL; ZIPFEL, PF				SKERKA, C; DECKER, EL; ZIPFEL, PF			A REGULATORY ELEMENT IN THE HUMAN INTERLEUKIN-2 GENE PROMOTER IS A BINDING-SITE FOR THE ZINC-FINGER PROTEINS SP1 AND EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; TRANSCRIPTION FACTOR; CYCLOSPORINE-A; CULTURED-CELLS; GROWTH-FACTORS; NUCLEAR FACTOR; ACTIVATION; ENCODES; EXPRESSION; SEQUENCE	Activation of the interleukin 2 (IL-2) gene after antigen recognition is a critical event for T cell proliferation and effector function. Prior studies have identified several transcription factors that contribute to the activity of the IL-2 promoter in stimulated T lymphocytes. Here we describe a novel regulatory element within the IL-2 promoter located immediately upstream of the nuclear factor of activated T cell (NFAT) domain. This region (termed the zinc finger protein binding region (ZIP)) serves as binding site for two differently regulated zinc finger proteins: the constitutively expressed transcription factor Spl and the inducible early growth response protein EGR-1. In unstimulated cells which do not secrete IL-2, only Spl binds to this region, while in stimulated IL-2 secreting cells the inducible EGR-1 protein recognizes this element. In Jurkat T cells, the ZIP site serves as an activator for IL-2 gene expression, and a combination of ZIP and NFAT binding sites is required for maximal IL-2 promoter activity. These results suggest a critical role of the ZIP site for IL-2 promoter activity.	BERNHARD NOCHT INST TROP MED,DEPT BIOL MOLEC,D-20359 HAMBURG,GERMANY	Bernhard Nocht Institut fur Tropenmedizin								ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHEN D, 1993, MOL CELL BIOL, V13, P228, DOI 10.1128/MCB.13.1.228; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MAGES HW, 1993, INT IMMUNOL, V5, P63, DOI 10.1093/intimm/5.1.63; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SERFLING E, 1995, IN PRESS BIOCH BIOPH; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YU CY, 1991, J BIOL CHEM, V266, P8907; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	44	123	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22500	22506		10.1074/jbc.270.38.22500	http://dx.doi.org/10.1074/jbc.270.38.22500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673240	hybrid			2022-12-27	WOS:A1995RW31400069
J	CULOUSCOU, JM; PLOWMAN, GD; CARLTON, GW; GREEN, JM; SHOYAB, M				CULOUSCOU, JM; PLOWMAN, GD; CARLTON, GW; GREEN, JM; SHOYAB, M			CHARACTERIZATION OF A BREAST-CANCER CELL-DIFFERENTIATION FACTOR THAT SPECIFICALLY ACTIVATES THE HER4/P180(ERBB4) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROWTH-FACTOR-RECEPTOR; EGF RECEPTOR; MONOCLONAL-ANTIBODIES; C-ERBB-2 ONCOGENE; PROTO-ONCOGENE; LIGAND; IDENTIFICATION; AMPLIFICATION; GLYCOPROTEIN; GENE	We recently reported the molecular cloning of HER4/p180erbB4, a new member of the epidermal growth factor receptor family, as well as its activation by a partially purified ligand (Plowman, G. D., Culouscou, J.-M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., and Shoyab, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1746-1750). In this report we describe the purification to homogeneity of a 45-kDa protein (p45) that induces the differentiation of MDA-MB-453 human breast cancer cells and stimulates the tyrosine phosphorylation of p180erbB4, the HER4-encoded protein. Hydrophobic interaction, ion-exchange, heparin, and size exclusion chromatographies were used to purify this p180erbB4 activator to homogeneity. N-terminal amino acid sequencing suggests that p45 is related to heregulin, a recently reported ligand for p185erBB2. Binding and cross-linking experiments demonstrated that p45 specifically binds to cells expressing recombinant p180erbB4 and not cells expressing recombinant p185erbB2.			CULOUSCOU, JM (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		PLOWMAN, Greg D/E-2012-2011	Plowman, Gregory D/0000-0002-6465-309X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1992, CANCER RES, V52, P2580; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCANN A, 1990, CANCER, V65, P88, DOI 10.1002/1097-0142(19900101)65:1<88::AID-CNCR2820650119>3.0.CO;2-Z; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOKOTA J, 1986, LANCET, V1, P765; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHAU HE, 1990, MOL CARCINOG, V3, P354; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	34	66	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1993	268	25					18407	18410						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LV659	7689552				2022-12-27	WOS:A1993LV65900003
J	SCHWARTZ, CFW				SCHWARTZ, CFW			INSULIN REGULATION OF PROTEIN-PHOSPHORYLATION IN H4 HEPATOMA-CELLS - EXAMINATION OF RAPID EFFECTS USING 2-DIMENSIONAL ELECTROPHORESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SERINE THREONINE KINASES; TWO-DIMENSIONAL GEL; TYROSINE PHOSPHORYLATION; 3T3-L1 CELLS; STIMULATES PHOSPHORYLATION; MESSENGER-RNA; INTACT-CELLS; SRC GENE; INVITRO	Activation of the insulin receptor tyrosine kinase is thought to initiate a chain of phosphorylation changes which regulate various metabolic and growth processes. Insulin has been shown to regulate some kinases by affecting their phosphorylation states; however, direct connections between activation of the receptor tyrosine kinase and subsequent altered phosphorylations of these kinases have yet to be established. To define the constituents of these regulated phosphorylation cascade systems, the time course of insulin-induced phosphorylation changes has been examined. P-32-Labeled H4IIE hepatoma cells were treated with insulin for 5-300 s, and then cell extracts were subjected to two-dimensional gel electrophoresis. Computer analysis of autoradiograms was employed to quantify insulin-induced phosphorylation changes. Phosphotyrosine was assessed by KOH digestion, by anti-phosphotyrosine immunoprecipitation, and by phenylarsine oxide treatment. Insulin induced a hierarchy of phosphorylation changes over the 300-s time course, with most increases being detectable within 10 s. Of these, only four did not undergo enhanced tyrosine phosphorylation. Eight proteins were found to undergo transient phosphorylation changes. Phenylarsine oxide elicited the appearance of novel low molecular weight phosphoproteins. These results support the concept of insulin-directed phosphorylation cascades, but indicate the magnitude of potential targets of the insulin receptor has been underestimated.	UNIV VIRGINIA,HLTH SCI CTR,DEPT SURG,CHARLOTTESVILLE,VA 22908	University of Virginia								AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; AVRUCH J, 1978, J BIOL CHEM, V253, P4754; AVRUCH J, 1985, MOL BASIS INSULIN AC, P263; AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1990, J BIOL CHEM, V265, P2713; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P2487; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; COBB MH, 1986, J BIOL CHEM, V261, P2994; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HIRANO H, 1989, J PROTEIN CHEM, V8, P115, DOI 10.1007/BF01025083; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HOFMANN C, 1980, DIABETES, V29, P865, DOI 10.2337/diabetes.29.11.865; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON G, 1977, J IMMUNOL METHODS, V15, P20; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LAWRENCE JC, 1983, J BIOL CHEM, V288, P10710; LECAM A, 1982, J BIOL CHEM, V257, P8376; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEMENOFF RA, 1986, ARCH BIOCHEM BIOPHYS, V245, P196, DOI 10.1016/0003-9861(86)90205-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHWARTZ CFW, 1989, ADV PROTEIN PHOSPHAT, V5, P645; SEGER R, 1992, J BIOL CHEM, V267, P14373; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TABARINI D, 1985, P NATL ACAD SCI USA, V82, P4369, DOI 10.1073/pnas.82.13.4369; TOTH B, 1988, J BIOL CHEM, V263, P14061; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	53	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14450	14460						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686156				2022-12-27	WOS:A1993LJ82500095
J	CLAY, CM; KERI, RA; FINICLE, AB; HECKERT, LL; HAMERNIK, DL; MARSCHKE, KM; WILSON, EM; FRENCH, FS; NILSON, JH				CLAY, CM; KERI, RA; FINICLE, AB; HECKERT, LL; HAMERNIK, DL; MARSCHKE, KM; WILSON, EM; FRENCH, FS; NILSON, JH			TRANSCRIPTIONAL REPRESSION OF THE GLYCOPROTEIN HORMONE ALPHA-SUBUNIT GENE BY ANDROGEN MAY INVOLVE DIRECT BINDING OF ANDROGEN RECEPTOR TO THE PROXIMAL PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; MESSENGER-RNA LEVELS; MAMMARY-TUMOR VIRUS; LUTEINIZING-HORMONE; NEGATIVE REGULATION; RESPONSE ELEMENT; MAMMALIAN-CELLS; PITUITARY; RAT; EXPRESSION	Testicular androgens suppress the synthesis and secretion of the pituitary gonadotropins, in particular, luteinizing hormone. This suppressive effect includes transcription of both the common alpha subunit gene and the unique beta subunit genes. Herein, we demonstrate that 1500 base pairs (bp) of proximal 5'-flanking region derived from the human alpha subunit gene and a shorter 315-bp segment of the bovine alpha subunit gene confer negative regulation by androgen to the gene encoding bacterial chloramphenicol acetyltransferase in transgenic mice. Cotransfection assays with human androgen receptor indicated that the 1500-bp promoter region of the human alpha subunit gene also confers androgen regulation (transcriptional suppression) to reporter genes in both pituitary and placental cell lines. This raises the possibility of a role for DNA binding in suppression of alpha subunit transcription by activated androgen receptor. Consistent with this possibility, we have used a gel-mobility shift assay to detect several high affinity binding sites for androgen receptor located in the proximal promoter of the human alpha subunit gene. The strongest androgen receptor binding site is located at approximately -101 in the proximal 5'-flanking region. This steroid receptor binding site overlaps another binding site that defines one of several contiguous cis-acting regulatory elements required for basal transcriptional activity. Thus, binding of activated androgen receptor to this region may block the binding of a requisite transacting factor and lead to an attenuation in transcription. We conclude that this interaction, which occurs directly at the level of the pituitary, represents one of several physiological avenues through which androgens regulate gonadotropin gene expression.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; UNIV N CAROLINA, SCH MED, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA	Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028559, F32DK008612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007382] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28559, DK08612] Funding Source: Medline; NIGMS NIH HHS [GM 07382] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLQUIST JAO, 1990, J MOL ENDOCRINOL, V5, P1, DOI 10.1677/jme.0.0050001; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BONSALL RW, 1985, J STEROID BIOCHEM, V23, P389, DOI 10.1016/0022-4731(85)90184-0; BRINKLEY HJ, 1981, BIOL REPROD, V24, P22, DOI 10.1095/biolreprod24.1.22; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHATTERJEE VKK, 1991, MOL ENDOCRINOL, V5, P100, DOI 10.1210/mend-5-1-100; CHUBB C, 1983, AM J PHYSIOL, V244, pE575, DOI 10.1152/ajpendo.1983.244.6.E575; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DESJARDINS C, 1981, BIOL REPROD, V24, P1, DOI 10.1095/biolreprod24.1.1; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; FINKELSTEIN JS, 1991, J CLIN ENDOCR METAB, V73, P609, DOI 10.1210/jcem-73-3-609; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMERNIK DL, 1992, MOL ENDOCRINOL, V6, P1745, DOI 10.1210/me.6.10.1745; HOJVAT S, 1982, NEUROENDOCRINOLOGY, V34, P327, DOI 10.1159/000123322; HOSTETTER G, 1987, NEUROENDOCRINOLOGY, V46, P185, DOI 10.1159/000124818; KENDALL SK, 1991, MOL ENDOCRINOL, V5, P2025, DOI 10.1210/mend-5-12-2025; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KERI RA, 1991, MOL ENDOCRINOL, V5, P725, DOI 10.1210/mend-5-5-725; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; NAESS O, 1975, ENDOCRINOLOGY, V96, P1; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PAUL SJ, 1990, MOL ENDOCRINOL, V4, P1943, DOI 10.1210/mend-4-12-1943; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; SCHANBACHER BD, 1984, J STEROID BIOCHEM, V20, P1227, DOI 10.1016/0022-4731(84)90149-3; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; TAN JA, 1992, J BIOL CHEM, V267, P4456; THIEULANT ML, 1979, J STEROID BIOCHEM, V10, P677, DOI 10.1016/0022-4731(79)90521-1; TILBROOK AJ, 1991, ENDOCRINOLOGY, V129, P3080, DOI 10.1210/endo-129-6-3080; WIERMAN ME, 1990, BIOL REPROD, V42, P563, DOI 10.1095/biolreprod42.3.563; WIERMAN ME, 1988, MOL ENDOCRINOL, V2, P492, DOI 10.1210/mend-2-6-492; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	38	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13556	13564						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685765				2022-12-27	WOS:A1993LH55300077
J	GROBMYER, SR; KUO, A; ORISHIMO, M; OKADA, SS; CINES, DB; BARNATHAN, ES				GROBMYER, SR; KUO, A; ORISHIMO, M; OKADA, SS; CINES, DB; BARNATHAN, ES			DETERMINANTS OF BINDING AND INTERNALIZATION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY HUMAN VASCULAR SMOOTH-MUSCLE AND ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; EXTRACELLULAR-MATRIX; INHIBITOR PAI-1; UROKINASE; MEMBRANE; GROWTH; IDENTIFICATION; LOCALIZATION; COLLAGENASE; MIGRATION	Vascular injury induced by angioplasty is often followed by smooth muscle cell (SMC) proliferation, migration, and accumulation of extracellular matrix. Since plasminogen activators and their receptors may be important both in cell migration and the clearance of plasminogen activators, we studied the binding, internalization, and degradation of radiolabeled tissue-type plasminogen activator (t-PA) by explant cultures of human vascular SMC. Binding of t-PA to SMC at 4-degrees-C was rapid, specific, saturable, and inhibitable by antibodies to plasminogen activator inhibitor type 1 (PAI-1). At 37-degrees-C, labeled t-PA was internalized and degraded by SMC but not by human umbilical vein endothelial cells. Internalization and degradation was mediated by the low density lipoprotein receptor related protein/alpha2-macroglobulin receptor (LRP) in that these processes were inhibited by an anti-LRP antibody, recombinant LRP-associated protein, urokinase-type plasminogen activator-PAI-1 complexes, and lactoferrin. The portion of t-PA most important for internalization after complexing with PAI-1 is likely to be in the finger and/or epidermal growth factor domains or in the carbohydrate at amino acid 117, in that the internalization of preformed t-PA.PAI-1 complexes or complexes formed on the cell surface was inhibited by an excess of active site-blocked wild type t-PA, but not by an active site blocked t-PA variant missing these domains. These studies are consistent with a model in which t-PA binds initially to SMC-associated PAI-1 with subsequent t-PA.PAI-1 internalization via LRP. SMC may play an important role in clearing t-PA.PAI-1 complexes from within the vessel wall.	UNIV PENN, SCH MED,DEPT MED,DIV CARDIOVASC, 503 JOHNSON PAVIL 6060,36TH & HAMILTON WALK, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [R01HL47839, F32HL08621-01, P01HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL047839, F32HL008621] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AU YPT, 1992, J BIOL CHEM, V267, P3438; BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEEBE DP, 1987, THROMB RES, V46, P241, DOI 10.1016/0049-3848(87)90286-6; BEEBE DP, 1989, BLOOD, V74, P2034; BOOYSE FM, 1981, BLOOD, V58, P788; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; DUVE CD, 1974, BIOCHEM PHARMACOL, V23, P2495; FUKAO H, 1992, BIOCHEM BIOPH RES CO, V187, P956, DOI 10.1016/0006-291X(92)91290-7; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1992, CIRCULATION, V86, P148; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; INYANG AL, 1990, BIOCHEM BIOPH RES CO, V171, P1326, DOI 10.1016/0006-291X(90)90831-7; KAMPS JAAM, 1992, EUR J BIOCHEM, V206, P973, DOI 10.1111/j.1432-1033.1992.tb17008.x; KNUDSEN BS, 1986, J BIOL CHEM, V261, P765; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LAUG WE, 1985, THROMB HAEMOSTASIS, V54, P498; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LIOTTA LA, 1981, CANCER RES, V41, P4629; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SAKATA Y, 1988, J BIOL CHEM, V263, P1960; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SKRIVER L, 1984, J CELL BIOL, V99, P753, DOI 10.1083/jcb.99.2.753; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; SPERTI G, 1992, CIRC RES, V71, P385, DOI 10.1161/01.RES.71.2.385; SPRENGERS ED, 1987, BLOOD, V69, P381; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; YEN FT, 1992, CIRCULATION, V86, P611	48	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13291	13300						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685759				2022-12-27	WOS:A1993LH55300043
J	GALLI, J; WIESLANDER, L				GALLI, J; WIESLANDER, L			A REPETITIVE SECRETORY PROTEIN GENE OF A NOVEL TYPE IN CHIRONOMUS-TENTANS IS SPECIFICALLY EXPRESSED IN THE SALIVARY-GLANDS AND EXHIBITS EXTENSIVE LENGTH POLYMORPHISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BALBIANI RING GENES; INVOLUCRIN GENE; SEQUENCE; DNA; EVOLUTION; POLYPEPTIDE; DROSOPHILA; HOMINOIDS; CONTAIN; REPEATS	The secretion from the salivary glands in the dipteran Chironomus tentans has previously been shown to contain secretory proteins encoded by a set of related genes belonging to the Balbiani ring multigene family. Here we describe the characterization of a gene for an additional secretory protein of a novel type. This sp240/420 gene is built from virtually identical 477-base pair repeats organized in tandem. The gene exhibits extensive length polymorphism since allelic length variants with from 12 to 22 repeats were recorded. Antibodies have been raised against the gene product, and it is shown also that the protein varies in size between 240 and 420 kDa. The protein is rich in serine and threonine residues (30%) and has N-linked carbohydrate chains, presumably on each repeat. Despite careful preparation of the gland lumen proteins, the sp240/420 protein was found to form protein ladders of regularly degraded protein, suggesting that this degradation occurs naturally in the salivary glands. Although all previously characterized salivary gland secretory protein genes in C. tentans belong to the same multigene family, the sp240/420 gene appears to represent a novel, unrelated type of repetitive gene. The chromosomal location of the gene was mapped and was found to reside in region 17 on chromosome I.	KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Wieslander, Lars/B-4670-2016	Wieslander, Lars/0000-0003-3271-6946				Armour JAL, 1992, CURR OPIN GENET DEV, V2, P850, DOI 10.1016/S0959-437X(05)80106-6; BEERMANN W, 1973, CHROMOSOMA, V41, P297, DOI 10.1007/BF00344024; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Case S.T., 1992, Results and Problems in Cell Differentiation, V19, P187; COSTA R, 1991, J MOL EVOL, V32, P238, DOI 10.1007/BF02342746; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM SS, 1989, J BIOL CHEM, V264, P9444; DJIAN P, 1989, P NATL ACAD SCI USA, V86, P8447, DOI 10.1073/pnas.86.21.8447; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DOVER GA, 1986, TRENDS GENET, V2, P159, DOI 10.1016/0168-9525(86)90211-8; DREESEN TD, 1988, J CELL BIOL, V106, P21, DOI 10.1083/jcb.106.1.21; DREESEN TD, 1985, J BIOL CHEM, V260, P1824; DWORKINRASTL E, 1984, CELL, V39, P321, DOI 10.1016/0092-8674(84)90010-2; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDSTROM JE, 1982, DEV BIOL, V91, P131, DOI 10.1016/0012-1606(82)90016-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GALLI J, 1990, J MOL EVOL, V31, P40, DOI 10.1007/BF02101791; GALLI J, 1993, IN PRESS J MOL BIOL; Grond C., 1987, Results and Problems in Cell Differentiation, V14, P69; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; Grossbach U., 1977, Results Probl Cell Differ, V8, P147; HOOG C, 1988, J MOL BIOL, V200, P655, DOI 10.1016/0022-2836(88)90478-0; ICHIMURA S, 1992, J MOL EVOL, V35, P123, DOI 10.1007/BF00183223; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; KAO WY, 1985, J CELL BIOL, V101, P1044, DOI 10.1083/jcb.101.3.1044; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LOPEZ JA, 1992, J BIOL CHEM, V267, P10055; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEYER B, 1983, DEV BIOL, V98, P265, DOI 10.1016/0012-1606(83)90357-3; PAULSSON G, 1992, J MOL BIOL, V225, P349, DOI 10.1016/0022-2836(92)90926-B; PAULSSON G, 1990, J MOL BIOL, V211, P331, DOI 10.1016/0022-2836(90)90355-P; PAULSSON G, 1992, J MOL EVOL, V35, P205; POOLE CB, 1992, P NATL ACAD SCI USA, V89, P5986, DOI 10.1073/pnas.89.13.5986; PUSTELL J, 1984, J MOL EVOL, V20, P281, DOI 10.1007/BF02104734; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; Sambrook J, 1989, MOL CLONING LABORATO; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SORIMACHI H, 1990, J MOL BIOL, V211, P35, DOI 10.1016/0022-2836(90)90009-B; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TEUMER J, 1989, P NATL ACAD SCI USA, V86, P1283, DOI 10.1073/pnas.86.4.1283; WELLMAN SE, 1989, J BIOL CHEM, V264, P10878; WIESLANDER L, 1984, J MOL EVOL, V20, P304, DOI 10.1007/BF02104736; WIESLANDER L, 1992, P NATL ACAD SCI USA, V89, P4578, DOI 10.1073/pnas.89.10.4578; WYSS C, 1982, EXP CELL RES, V319, P297	50	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11888	11893						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685024				2022-12-27	WOS:A1993LF28400065
J	LEE, SC; KIM, IG; MAREKOV, LN; OKEEFE, EJ; PARRY, DAD; STEINERT, PM				LEE, SC; KIM, IG; MAREKOV, LN; OKEEFE, EJ; PARRY, DAD; STEINERT, PM			THE STRUCTURE OF HUMAN TRICHOHYALIN - POTENTIAL MULTIPLE ROLES AS A FUNCTIONAL EF-HAND-LIKE CALCIUM-BINDING PROTEIN, A CORNIFIED CELL-ENVELOPE PRECURSOR, AND AN INTERMEDIATE FILAMENT-ASSOCIATED (CROSS-LINKING) PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN LORICRIN GENE; HAIR FOLLICLE; EPIDERMAL-KERATINOCYTES; EXPRESSION; MOUSE; CITRULLINE; FILAGGRIN; PEPTIDES; REGION	Trichohyalin is an intermediate filament-associated protein that associates in regular arrays with keratin intermediate filaments (KIF) of the inner root sheath cells of the hair follicle and the granular layer of the epidermis and is a known substrate of transglutaminases. We have determined the full-length sequence of human trichohyalin by use of RNA-mediated anchored polymerase chain reaction methods and from a genomic clone and analyzed its potential secondary structure. We show here that trichohyalin may have at least three important functions in these cells. The protein of 248 kDa is unusual in that it contains one of the highest contents of charged residues of any protein. Of several defined domains, domains 2-4, 6, and 8 are almost entirely alpha-helical, configured as a series of peptide repeats of varying regularity, and are thought to form a single-stranded alpha-helical rod stabilized by ionic interactions between successive turns of the alpha-helix. Domain 6 is the most regular and may bind KIF directly by ionic interactions. Domains 5 and 7 are less well organized and may introduce folds in the molecule. Thus, human trichohyalin is predicted to be an elongated flexible rod at least 215 nm long and to function as a KIF-associated protein by cross-linking the filaments in loose networks. In addition, trichohyalin is similar to, but several times longer than, involucrin, a known cell envelope constituent, so that together, involucrin and trichohyalin may serve as scaffold proteins in the organization of the cell envelope of these cells or even anchor the cell envelope to the KIF network. Finally, trichohyalin possesses a pair of functional calcium-binding domains of the EF-hand type at its amino terminus that may be involved in its calcium-dependent postsynthetic processing during terminal differentiation.	NIAMSD, SKIN BIOL BRANCH, BLDG 6, ROOM 425, BETHESDA, MD 20892 USA; UNIV N CAROLINA, DEPT DERMATOL, CHAPEL HILL, NC 27514 USA; MASSEY UNIV, DEPT PHYS & BIOPHYS, PALMERSTON NORTH, NEW ZEALAND	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of North Carolina; University of North Carolina Chapel Hill; Massey University								BADEN HP, 1987, J INVEST DERMATOL, V89, P454, DOI 10.1111/1523-1747.ep12460759; BECKER T, 1992, FEBS LETT, V207, P541; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P223, DOI 10.1083/jcb.3.2.223; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORIN JR, 1990, GENOMICS, V8, P420, DOI 10.1016/0888-7543(90)90027-R; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FIETZ MJ, 1990, J CELL BIOL, V110, P427, DOI 10.1083/jcb.110.2.427; Fraser R.D.B., 1972, KERATINS THEIR COMPO; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJISAKI M, 1981, J BIOCHEM, V89, P257, DOI 10.1093/oxfordjournals.jbchem.a133189; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HAMILTON EH, 1992, J INVEST DERMATOL, V98, P881, DOI 10.1111/1523-1747.ep12459412; HARDAS BD, 1992, J INVEST DERMATOL, V98, P569; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; HEID HW, 1988, DIFFERENTIATION, V37, P137, DOI 10.1111/j.1432-0436.1988.tb00805.x; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; KARTASOVA T, 1987, NUCLEIC ACIDS RES, V15, P5945, DOI 10.1093/nar/15.15.5945; KAWASAKI H, 1985, ANAL BIOCHEM, V148, P297, DOI 10.1016/0003-2697(85)90232-5; KLIGMAN D, 1991, NOVEL CA2PLUS BINDIN, P65; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBILUS J, 1980, BIOCHIM BIOPHYS ACTA, V615, P246, DOI 10.1016/0005-2744(80)90027-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE EB, 1985, ANN NY ACAD SCI, V455, P241, DOI 10.1111/j.1749-6632.1985.tb50415.x; LYNCH MH, 1986, J CELL BIOL, V103, P2593, DOI 10.1083/jcb.103.6.2593; MARKOVA N, 1993, MOL CELL BIOL, V13, P167; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MICHEL S, 1987, J INVEST DERMATOL, V88, P301, DOI 10.1111/1523-1747.ep12466177; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OKEEFE E, 1993, IN PRESS J INVEST DE, V101; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; ROGERS GE, 1958, EXP CELL RES, V14, P378, DOI 10.1016/0014-4827(58)90195-2; ROGERS GE, 1983, NORMAL ABNORMAL EPID, P171; ROGERS GE, 1964, EPIDERMIS, P179; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sambrook J, 1989, MOL CLONING LABORATO; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; STEINERT PM, 1969, BIOCHIM BIOPHYS ACTA, V175, P1, DOI 10.1016/0005-2795(69)90138-X; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1983, NATURE, V302, P794, DOI 10.1038/302794a0; STEINERT PM, 1992, J INVEST DERMATOL, V98, P559; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOD L, 1991, J INVEST DERMATOL, V96, P383, DOI 10.1111/1523-1747.ep12466230; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YONEDA K, 1991, J INVEST DERMATOL, V96, P541; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238; ZHOU XM, 1988, J BIOL CHEM, V263, P15584; [No title captured]	63	145	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12164	12176						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685034				2022-12-27	WOS:A1993LF28400104
J	PRASAD, L; SHARMA, S; VANDONSELAAR, M; QUAIL, JW; LEE, JS; WAYGOOD, EB; WILSON, KS; DAUTER, Z; DELBAERE, LTJ				PRASAD, L; SHARMA, S; VANDONSELAAR, M; QUAIL, JW; LEE, JS; WAYGOOD, EB; WILSON, KS; DAUTER, Z; DELBAERE, LTJ			EVALUATION OF MUTAGENESIS FOR EPITOPE MAPPING - STRUCTURE OF AN ANTIBODY-PROTEIN ANTIGEN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HISTIDINE-CONTAINING PROTEIN; SUGAR PHOSPHOTRANSFERASE SYSTEM; MONOCLONAL FAB FRAGMENT; ESCHERICHIA-COLI; CRYSTALLOGRAPHIC REFINEMENT; PHOSPHOENOLPYRUVATE; RESOLUTION; BINDING; SITES	The location and description of epitopes on proteins describe the basis of immunological specificity. The 2.8-angstrom structure of the phosphocarrier protein, HPr from Escherichia coli, complexed to the Fab fragment of the monoclonal antibody, Jel42, has been determined. This allows the first comparison of epitope predictions from extensive site-directed mutagenesis experiments, coupled with biological activity studies (Sharma, S., Georges, F., Klevit, R. E., Delbaere, L. T. J., Lee, J. S., and Waygood, E. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4877-4881), with those from x-ray analysis. There are 14 amino acid residues of E. coli HPr that interact with the Jel42 antigen-binding site. Nine of these were correctly assigned by the mutagenesis studies. Of the 5 remaining residues, Met-1 could not be altered; two others appear to have critical roles in determining protein conformation; the other 2 residues have a minimal effect on antibody binding since they are located on the periphery of the epitope with one face of their side chains in van der Waals contact with the antibody and the other face in contact with solvent. Four residues were incorrectly assigned to the epitope. These residues were located adjacent to epitope residues that were likely perturbed by these mutations. This study demonstrates that mutations which caused greater than 10-fold changes in antibody binding affinity were correctly assigned to the epitope by the mutagenesis experiments. Guidelines are also presented in order to minimize incorrect assignments.	UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT CHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; EUROPEAN MOLEC BIOL LAB,HAMBURG OUTSTN,W-2000 HAMBURG,GERMANY	University of Saskatchewan; University of Saskatchewan; European Molecular Biology Laboratory (EMBL)				Wilson, Keith/0000-0002-3581-2194				BACON D, 1991, PRERAS3D RASTER3D GR; BENTLEY GA, 1989, COLD SH Q B, V54, P239; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DELBAERE LTJ, 1989, J BIOL CHEM, V264, P18645; DELUCAS LJ, 1992, ADV SPACE RES-SERIES, V12, P393, DOI 10.1016/0273-1177(92)90310-T; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; JEFFREY P, 1989, THESIS U OXFORD; JIA Z, 1992, THESIS U SASKATCHEWA; JIA ZC, 1993, NATURE, V361, P94, DOI 10.1038/361094a0; KABAT EA, 1991, NIH913242 PUBL, P664; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1990, PROTEINS, V7, P112, DOI 10.1002/prot.340070203; PRASAD L, 1988, J BIOL CHEM, V263, P2571; ROSSMANN MG, 1972, MOL REPLACEMENT METH, P1; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; STEEVES T, 1991, BIOCHEM CELL BIOL, V69, P297, DOI 10.1139/o91-045; TULIP WR, 1992, J MOL BIOL, V227, P122, DOI 10.1016/0022-2836(92)90687-F; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; WAYGOOD EB, 1987, J BACTERIOL, V169, P2810, DOI 10.1128/jb.169.6.2810-2818.1987; 1979, SERC UK4 DAR LAB COL	28	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					10705	10708						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684366				2022-12-27	WOS:A1993LD46600002
J	BEBENEK, K; ABBOTTS, J; WILSON, SH; KUNKEL, TA				BEBENEK, K; ABBOTTS, J; WILSON, SH; KUNKEL, TA			ERROR-PRONE POLYMERIZATION BY HIV-1 REVERSE-TRANSCRIPTASE - CONTRIBUTION OF TEMPLATE-PRIMER MISALIGNMENT, MISCODING, AND TERMINATION PROBABILITY TO MUTATIONAL HOT-SPOTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; EUKARYOTIC DNA-POLYMERASES; BASE SUBSTITUTION; TRANSIENT MISALIGNMENT; FIDELITY; MUTAGENESIS; SPECIFICITY; REPLICATION; FRAMESHIFT; MECHANISM	We have observed previously that DNA template-directed polymerization by the type 1 human immunodeficiency virus reverse transcriptase is error-prone for single-nucleotide substitution, addition and deletion errors at homopolymeric sequences. We have also noted strong termination of processive synthesis at these positions (Bebenek, K., Abbotts, J., Roberts, J. D., Wilson, S. H., and Kunkel, T. A. (1989) J. Biol. Chem. 264, 16948-16956). Here we have tested three models to explain errors at these hot spots: template-primer misalignment for deletion errors, and dislocation and direct miscoding for substitution errors. The approach involves introducing single-nucleotide changes within or flanking the homopolymeric hot spots and examining the effects that these changes have on human immunodeficiency virus type 1 (HIV-1) reverse transcriptase error rate, error specificity, and termination probability. The results obtained suggest that single-nucleotide deletion errors in homopolymeric runs result from template-primer misalignment and that both direct miscoding and template-primer dislocation contribute to the base substitution hot spots. The data also suggest that base substitution errors at one position can be templated by the preceding nucleotide or either of the next two nucleotides. Frameshift error rates at homopolymeric sites were affected by changes in the sequences flanking the runs, including single-nucleotide differences in the single-stranded template strand and in the double-stranded primer region as many as six nucleotides distant from the hot spot. Both increases and decreases in frameshift fidelity were observed, and most of these correlated with concomitant increases or decreases in the probability that HIV-1 reverse transcriptase terminated processive synthesis within the run. These data provide further support for a relationship between the frameshift fidelity and the processivity of DNA-dependent DNA synthesis by HIV-1 reverse transcriptase.	NIEHS, MOLEC GENET LAB E3-01, POB 12233, RES TRIANGLE PK, NC 27709 USA; NIH, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA			Kunkel, Thomas A./D-5088-2019; Wilson, Samuel H/E-6644-2019	Kunkel, Thomas A./0000-0002-9900-1788; Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ABBOTTS J, 1988, J BIOL CHEM, V263, P15094; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; FOWLER RG, 1974, MOL GEN GENET, V133, P179, DOI 10.1007/BF00267667; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; YU H, 1992, J BIOL CHEM, V267, P10888	21	149	152	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10324	10334						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683675				2022-12-27	WOS:A1993LB80000054
J	SOKER, S; SVAHN, CM; NEUFELD, G				SOKER, S; SVAHN, CM; NEUFELD, G			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS INACTIVATED BY BINDING TO ALPHA-2-MACROGLOBULIN AND THE BINDING IS INHIBITED BY HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; COVALENT BINDING; FACTOR-BETA; MITOGEN; CELLS; RECEPTOR; PROTEINS; SERUM; GENE; MACROGLOBULIN	Vascular endothelial growth factor (VEGF) is a mitogen for cultured endothelial cells, and a potent angiogenic factor in vivo. Incubation of I-125-VEGF with human or bovine serum led to the formation of I-125-VEGF containing complexes that had a molecular mass greater than 300 kDa. These complexes were specifically immunoprecipitated with anti-human alpha2-macroglobulin (alpha2M) antibodies. Similar high molecular weight complexes were formed when I-125-VEGF was incubated with commercially available alpha2M. The I-125-VEGF.alpha2M complexes were resistant to boiling in the presence of SDS. The formation of I-125-VEGF.alpha2M complexes was inhibited by iodoacetic acid, indicating that free sulfhydryl groups are required for complex assembly. Tryptic digestion of alpha2M did not affect its VEGF binding ability. Tryptic digestion of I-125-VEGF.alpha2M complexes on the other hand, resulted in the degradation of bound I-125-VEGF, indicating that alpha2M does not protect bound I-125-VEGF from proteolytic digestion. The binding of I-125-VEGF to alpha2M was partially inhibited by an excess of basic fibroblast growth factor. Other growth factors which bind to alpha2M, such as platelet-derived growth factor and insulin, did not inhibit the binding of I-125-VEGF. The binding of VEGF to alpha2M inhibited its receptor binding ability, indicating that alpha2M may function as a VEGF removal and inactivation factor. Heparin and heparan sulfate, but not other glycosaminoglycans such as chondroitin sulfate, efficiently inhibited the binding of I-125-VEGF to alpha2M. It is possible that heparin-like molecules released from extracellular matrixes could prevent the inactivation of VEGF by alpha2M resulting in the potentiation of processes such as tumor angiogenesis.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL TECH,IL-32000 HAIFA,ISRAEL; KABI PHARM THERAPEUT,DIV RES & DEV,S-11287 STOCKHOLM,SWEDEN	Technion Israel Institute of Technology			Neufeld, Gera/F-1524-2019					BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Ferrara N, 1991, Growth Factors, V5, P141, DOI 10.3109/08977199109000278; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HARDOUIN S, 1987, EUR J BIOCHEM, V170, P121, DOI 10.1111/j.1432-1033.1987.tb13676.x; Harpel P C, 1976, Methods Enzymol, V45, P639; HOFFMANN R, 1973, EXP CELL RES, V80, P275, DOI 10.1016/0014-4827(73)90297-8; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SALVESEN GS, 1980, BIOCHEM J, V187, P695, DOI 10.1042/bj1870695; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361	40	103	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7685	7691						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681826				2022-12-27	WOS:A1993KW97900018
J	HUI, Y; CZAPLA, TH				HUI, Y; CZAPLA, TH			ISOLATION AND CHARACTERIZATION OF CDNA CLONES ENCODING JACALIN ISOLECTINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; RICINUS-COMMUNIS AGGLUTININ; ARTOCARPUS-INTEGRIFOLIA; CARBOXYPEPTIDASE-Y; ENDOPLASMIC-RETICULUM; MACLURA-POMIFERA; BARLEY LECTIN; PLANT-LECTINS; PRO-REGION; PEP4 GENE	Four jacalin cDNA clones (pSKcJA1, pSKcJA3, pSKcJA15, and pSKcJA17) have been obtained from an Artocarpus integrifolia (jackfruit) seed cDNA library. These clones share over 94% sequence homology, and their deduced polypeptide sequences confirm the existence of multiple jacalin isolectins in jackfruit seeds. The deduced amino acid sequences show that jacalin appears to be initially synthesized as a prepropeptide with the following structure: N-signal (21 residues) --> propeptide (39 residues) --> beta-peptide (20 residues) --> linker region (4 residues) --> alpha-peptide (133 residues). These observations are supported by Western blot analysis of jackfruit seed extract and by immunoprecipitation of in vitro translated products of both pSKcJA3 transcript and jackfruit seed poly(A)+ RNA. Sequence analysis of the 39-residue propeptide reveals that it has the potential to facilitate proper folding of jacalin protein. The unusual primary structure of jacalin prepropeptide suggests a quite interesting processing of this lectin precursor into mature alpha- and beta-subunits.			HUI, Y (corresponding author), PIONEER HI BRED INT INC,DIV PLANT BREEDING,DEPT BIOTECHNOL,7250 NW 62ND AVE,JOHNSTON,IA 50131, USA.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; AUCOUTURIER P, 1987, MOL IMMUNOL, V24, P503, DOI 10.1016/0161-5890(87)90025-3; BANERJEE R, 1991, J MOL BIOL, V221, P773, DOI 10.1016/0022-2836(91)80174-S; BEDNAREK SY, 1990, PLANT CELL, V2, P1145, DOI 10.1105/tpc.2.12.1145; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BUNNMORENO MM, 1981, J IMMUNOL, V127, P427; BUTTERWORTH AG, 1983, EUR J BIOCHEM, V137, P57, DOI 10.1111/j.1432-1033.1983.tb07795.x; CARRINGTON DM, 1985, NATURE, V313, P64, DOI 10.1038/313064a0; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CZAPLA TH, 1990, J ECON ENTOMOL, V83, P2480, DOI 10.1093/jee/83.6.2480; ETZLER ME, 1985, ANNU REV PLANT PHYS, V36, P209, DOI 10.1146/annurev.pp.36.060185.001233; ETZLER ME, 1985, CHEM BIOL LECTINS; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Firestone G.L., 1990, METHOD ENZYMOL, V182, P688, DOI 10.1016/0076-6879(90)82054-6; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAGIWARA K, 1988, MOL IMMUNOL, V25, P69, DOI 10.1016/0161-5890(88)90092-2; HANKINS CN, 1980, PLANT PHYSIOL, V65, P618, DOI 10.1104/pp.65.4.618; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HATTORI T, 1985, PLANT MOL BIOL, V5, P313, DOI 10.1007/BF00020629; HEMPERLY JJ, 1982, J BIOL CHEM, V257, P7903; HIGGINS TJV, 1983, J BIOL CHEM, V258, P9544; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KNOX RB, 1976, P NATL ACAD SCI USA, V73, P2788, DOI 10.1073/pnas.73.8.2788; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; LIU YC, 1990, BIOTECHNIQUES, V9, P558; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; NAMJUNTRA P, 1985, BIOCHEM BIOPH RES CO, V128, P833, DOI 10.1016/0006-291X(85)90122-6; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SILEN JL, 1988, GENE, V69, P237, DOI 10.1016/0378-1119(88)90434-9; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDAMME E, 1991, THESIS KATHOLIEKE U, P87; VASANTHA N, 1984, J BACTERIOL, V159, P811, DOI 10.1128/JB.159.3.811-819.1984; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VIJAYAKUMAR T, 1986, BIOL PLANTARUM, V28, P370, DOI 10.1007/BF02902249; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKINS TA, 1989, PLANT CELL, V1, P541, DOI 10.1105/tpc.1.5.541; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YOUNG NM, 1991, FEBS LETT, V282, P382, DOI 10.1016/0014-5793(91)80518-8; YOUNG NM, 1989, ARCH BIOCHEM BIOPHYS, V270, P596, DOI 10.1016/0003-9861(89)90542-0; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	54	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5905	5910						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680651				2022-12-27	WOS:A1993KR82200083
J	SAIKAWA, Y; KNIGHT, CB; SAIKAWA, T; PAGE, ST; CHABNER, BA; ELWOOD, PC				SAIKAWA, Y; KNIGHT, CB; SAIKAWA, T; PAGE, ST; CHABNER, BA; ELWOOD, PC			DECREASED EXPRESSION OF THE HUMAN FOLATE RECEPTOR MEDIATES TRANSPORT-DEFECTIVE METHOTREXATE RESISTANCE IN KB CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BINDING-PROTEIN; L1210 CELLS; DIHYDROFOLATE-REDUCTASE; MEMBRANE-TRANSPORT; LEUKEMIA-CELLS; FLUORESCEINATED METHOTREXATE; SYNTHETASE-ACTIVITY; HEPATOMA-CELLS; AFFINITY	The human membrane-associated folate binding protein, or folate receptor (hFR), is a necessary component of folate and methotrexate (MTX) transport in some cell lines. To investigate the role of hFR in acquired MTX resistance in human cells, we characterized nine MTX-resistant clones selected from human nasopharyngeal epidermoid carcinoma (KB) cells (cells which transport folates/anti-folates via the hFR) cultured in media containing low folate concentrations. Compared with wild type KB cells, the level of resistance of the clones ranges from 2- to 80-fold higher and the resistant phenotypes of the clones are characterized as follows. 1) DHFR levels are increased (3-13-fold) in four of nine clones; 2) MTX polyglutamation is not detectably different; 3) the extents of MTX efflux are similar; 4) initial rates of MTX efflux are similar except for two clones which exhibit slightly faster efflux rates (approximately 2-fold); and 5) the V(max) for specific MTX and 5-methyltetrahydrofolate transport are decreased (2-18-fold) in all mutants. The K(t) values for MTX transport of each mutant are similar to the K(t) of KB cells. These results indicate that all nine MTX-resistant clones exhibit defective MTX transport and that four clones also have increased DHFR levels. Based on folic acid binding assays, the hFR is reduced by 1.8-24-fold in these clones relative to KB cell hFR expression. Western, Northern, and Southern analyses are consistent with decreased hFR expression in these clones rather than mutations, resulting in alterations in the size or ligand binding affinities of the hFR. The decrement in hFR expression correlates closely with the degree of reduction in MTX transport V(max) for each clone. Since folate and MTX influx proceed via hFR in KB cells and in these mutants, the correlation (R2 = 0.90) between hFR expression and the MTX transport V(max) of each clone indicates that hFR expression is an important determinant of acquired MTX resistance in this human tumor cell line. These studies demonstrate that defective transport (manifested by decreased V(max)) resulting from decreased expression of the hFR is frequent in KB cells cultured under these conditions and suggest that modulation of hFR may be relevant to MTX cytotoxicity or resistance in tissues or cells expressing functionally significant levels of hFR.	NCI, MED BRANCH,BLDG 10,RM 12N226,9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALLEGRA CJ, 1990, CANCER CHEMOTHERAPY, P110; ALT FW, 1978, J BIOL CHEM, V253, P1357; ANTONY AC, 1985, J BIOL CHEM, V260, P4911; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ASSARAF YG, 1987, P NATL ACAD SCI USA, V84, P7154, DOI 10.1073/pnas.84.20.7154; AYUSAWA D, 1981, CANCER RES, V41, P1497; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CALABRESI P, 1985, PHARMACOL BASIS THER, P1240; CHABNER BA, 1982, PHARM PRINCIPLES CAN, P229; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN KH, 1984, J BIOL CHEM, V259, P793; CURT GA, 1985, J CLIN INVEST, V76, P1323, DOI 10.1172/JCI112106; DAVIS LG, 1986, BASIC METHODS MOL BI, P44; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DOLNICK BJ, 1985, J BIOL CHEM, V260, P3006; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; FAN JG, 1991, J BIOL CHEM, V266, P14862; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FLINTOFF WF, 1980, BIOCHEMISTRY-US, V19, P4321, DOI 10.1021/bi00559a027; FREI E, 1984, P NATL ACAD SCI-BIOL, V81, P2873, DOI 10.1073/pnas.81.9.2873; FRY DW, 1983, CANCER RES, V43, P1087; GALIVAN J, 1979, CANCER RES, V39, P735; GALIVAN J, 1981, CANCER RES, V41, P1757; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1986, CANCER RES, V46, P1639; HENDERSON GB, 1986, CANCER RES, V46, P1633; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON JF, 1984, ANTITUMOR DRUG RESIS, P23; HOFFMEISTER RT, 1983, AM J MED, V75, P69, DOI 10.1016/0002-9343(83)90477-1; JACKSON RC, 1977, EUR J CANCER, V13, P567, DOI 10.1016/0014-2964(77)90118-9; JANSEN G, 1989, CANCER RES, V49, P1959; JANSEN G, 1989, CANCER RES, V49, P2455; JANSEN G, 1990, J BIOL CHEM, V265, P18272; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KNIGHT CB, 1989, ADV ENZYME REGUL, V29, P3, DOI 10.1016/0065-2571(89)90090-3; KOIZUMI S, 1988, JPN J CANCER RES, V79, P1230, DOI 10.1111/j.1349-7006.1988.tb01549.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHERLY LH, 1991, CANCER RES, V51, P3420; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; MCCORMICK JI, 1981, ARCH BIOCHEM BIOPHYS, V212, P311, DOI 10.1016/0003-9861(81)90371-4; MYERS CE, 1975, P NATL ACAD SCI USA, V72, P3683, DOI 10.1073/pnas.72.9.3683; NORRIS MD, 1991, CANCER, V68, P981, DOI 10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; PRICE EM, 1987, BIOCHEMISTRY-US, V26, P4757, DOI 10.1021/bi00389a024; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHILSKY RL, 1981, BIOCHEM PHARMACOL, V30, P1537, DOI 10.1016/0006-2952(81)90378-6; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SHERWOOD SW, 1990, CANCER RES, V50, P4946; SIROTNAK FM, 1985, CANCER RES, V45, P3992; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; WEITMAN SD, 1992, CANCER RES, V52, P3396; WHITE JC, 1981, J BIOL CHEM, V256, P5722; YANG CH, 1988, J BIOL CHEM, V263, P9703	65	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5293	5301						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680349				2022-12-27	WOS:A1993KP88400104
J	FRETTO, LJ; SNAPE, AJ; TOMLINSON, JE; SEROOGY, JJ; WOLF, DL; LAROCHELLE, WJ; GIESE, NA				FRETTO, LJ; SNAPE, AJ; TOMLINSON, JE; SEROOGY, JJ; WOLF, DL; LAROCHELLE, WJ; GIESE, NA			MECHANISM OF PLATELET-DERIVED GROWTH-FACTOR (PDGF)-AA, (PDGF)-AB, AND (PDGF)-BB BINDING TO ALPHA-PDGF AND BETA-PDGF RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; KINASE ACTIVATION; LIGAND-BINDING; CDNA CLONING; B-PROTEIN; A-CHAIN; EXPRESSION; LOCALIZATION; DIMERIZATION; HETERODIMERS	The biological effects of platelet-derived growth factor (PDGF) are mediated by cell surface alpha and beta PDGF receptors, which, as a result of ligand binding, undergo dimerization in a manner consistent with PDGF being bivalent. In order to directly demonstrate PDGF bivalency and to define the binding of PDGF AB to isolated beta receptor, we developed solid-phase binding assays using purified recombinant extracellular domain of human PDGF receptors. PDGF AA, AB, and BB were prepared from the monomeric chains expressed in Escherichia coli, and each was purified to homogeneity; PDGF AB contained <0.5% of either homodimer. The interactions of these isoforms with immobilized PDGF receptors were examined by several approaches. Scatchard analysis revealed high affinity binding (K(d) = 0.5-1.0 nM) of radiolabeled PDGF AA and AB to alpha receptor and of PDGF BB to both receptor subtypes. Contrary to previous reports, PDGF AB also bound beta receptor with high affinity (K(d) = 0.9 nM). When a B-chain-specific monoclonal antibody that recognizes the putative binding domain of PDGF BB was used for ligand detection, we found that PDGF AB binding to beta receptor occurred exclusively through the B-chain subunit, whereas binding to alpha receptor occurred through either subunit. In addition, site-directed mutagenesis was used to specifically inactivate the B chain of PDGF AB, which eliminated binding to the beta receptor without affecting alpha receptor binding. These results establish that PDGF is bivalent and that monovalent ligand retains high affinity receptor binding.	COR THERAPEUT INC,256 E GRAND AVE,S SAN FRANCISCO,CA 94080; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUAN DSR, 1991, J BIOL CHEM, V266, P413; ESCOBEDO JA, 1988, SCIENCE, V240, P1532, DOI 10.1126/science.2836953; GESUALDO L, 1991, LAB INVEST, V65, P160; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	46	67	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3625	3631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679113				2022-12-27	WOS:A1993KM16100091
J	HAGLER, J; SHUMAN, S				HAGLER, J; SHUMAN, S			NASCENT RNA CLEAVAGE BY PURIFIED TERNARY COMPLEXES OF VACCINIA RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; ESCHERICHIA-COLI; CHAIN ELONGATION; INITIATION; PROMOTER; PURIFICATION; VIRIONS; ENZYME; VIEW; DNA	Ternary complexes of vaccinia virus RNA polymerase containing 3'-OMeGMP-arrested transcripts were purified by native gel electrophoresis. These complexes resumed elongation in situ when gel slices were incubated with magnesium and NTPs. Elongation occurred in the absence of pyrophosphate, suggesting that the blocking 3'-OMeGMP residue was removed via a novel pathway. We show that purified elongation complexes contain an intrinsic nuclease activity that shortens nascent RNA from the 3'-end. RNA cleavage was absolutely dependent on a divalent cation and was stimulated by CTP. The initial 5' cleavage product remained associated with the ternary complex and could be elongated in the presence of NTPs. Multiple stepwise cleavages generated progressively shorter chains. Purified ternary complexes containing 3'-OH-terminated RNAs also displayed nuclease activity. Involvement of the vaccinia RNA polymerase subunit rpo30 in the transcript-shortening reaction is suggested based on sequence similarity of rpo30 to mammalian protein SII (TFIIS), an extrinsic transcription factor required for nascent RNA cleavage by RNA polymerase II (Reines, D. (1991) J. Biol. Chem. 267, 3795-3800).			HAGLER, J (corresponding author), SLOAN KETTERING INST CANC RES,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BATEMAN E, 1988, MOL CELL BIOL, V8, P1940, DOI 10.1128/MCB.8.5.1940; BLANK A, 1986, BIOCHEMISTRY-US, V25, P5920, DOI 10.1021/bi00368a013; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10099, DOI 10.1073/pnas.89.21.10099; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; HAGLER J, 1992, J BIOL CHEM, V267, P7644; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LIBBY RT, 1989, EMBO J, V8, P3153, DOI 10.1002/j.1460-2075.1989.tb08469.x; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LUO Y, 1991, J BIOL CHEM, V266, P13303; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MOSS B, 1991, J BIOL CHEM, V266, P1355; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1991, J BIOL CHEM, V266, P10510; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983	32	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2166	2173						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678416				2022-12-27	WOS:A1993KH62000100
J	SANDER, M; CARTER, M; HUANG, SM				SANDER, M; CARTER, M; HUANG, SM			EXPRESSION OF DROSOPHILA RRP1 PROTEIN IN ESCHERICHIA-COLI - ENZYMATIC AND PHYSICAL CHARACTERIZATION OF THE INTACT PROTEIN AND A CARBOXYL-TERMINALLY DELETED EXONUCLEASE-DEFICIENT MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; REPAIR ENZYMES; RECA PROTEIN; APURINIC ENDONUCLEASE; BRANCH MIGRATION; SEQUENCE; GENE; PURIFICATION	Drosophila Rrp1 protein purified from embryos has four tightly associated enzymatic activities: DNA strand transfer, single-strand DNA renaturation, 3'-exonuclease, and apurinic endonuclease. Copurifying with these activities is a single polypeptide that has an apparent M(r) of 105,000 when estimated by SDS-polyacrylamide gel electrophoresis. To determine if this polypeptide is sufficient for these activities, it has been overexpressed in Escherichia coli. In crude extracts of E. coli cells, an ATP-independent Mg2+-dependent strand transfer activity is observed upon activation of the promoter that drives expression of Rrp1. Rrp1 protein purified from induced E. coli cells has electrophoretic, chromatographic, and enzymatic properties similar to those of Drosophila Rrp1 protein. The carboxyl-terminal region of Rrp1 (amino acids 428-679) is homologous to E. coli exonuclease III. Rrp1 deleted for this region cannot carry out DNA strand transfer, but can renature complementary single-strand DNA. The strand transfer activity of this truncated protein can be restored if DNA 3'-exonuclease is provided in trans by pretreating the double-strand DNA substrate with E. coli exonuclease III. This demonstrates a likely role of the exonuclease in the in vitro DNA strand transfer reaction carried out by Rrp1 protein. Such a role is also suggested by an analysis of the polarity of the strand transfer reaction.			SANDER, M (corresponding author), NIEHS,GENET LAB,POB 12233,RES TRIANGLE PK,NC 27709, USA.							BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTREIX M, 1991, J MOL BIOL, V219, P645, DOI 10.1016/0022-2836(91)90661-O; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; EGGLESTON AK, 1991, BIOCHIMIE, V73, P163, DOI 10.1016/0300-9084(91)90199-B; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HEYER WD, 1988, J BIOL CHEM, V263, P15189; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KONFORTI BB, 1991, J BIOL CHEM, V266, P10112; KONFORTI BB, 1990, J BIOL CHEM, V265, P6916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MCCARTHY JG, 1988, P NATL ACAD SCI USA, V85, P5854, DOI 10.1073/pnas.85.16.5854; MOORE SP, 1990, J BIOL CHEM, V265, P11108; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SEKI S, 1991, J BIOL CHEM, V266, P20797; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH GR, 1987, ANNU REV GENET, V21, P179, DOI 10.1146/annurev.genet.21.1.179; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					2075	2082						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678415				2022-12-27	WOS:A1993KH62000087
J	FUKAMI, Y; SATO, K; IKEDA, K; KAMISANGO, K; KOIZUMI, K; MATSUNO, T				FUKAMI, Y; SATO, K; IKEDA, K; KAMISANGO, K; KOIZUMI, K; MATSUNO, T			EVIDENCE FOR AUTOINHIBITORY REGULATION OF THE C-SRC GENE-PRODUCT - A POSSIBLE INTERACTION BETWEEN THE SRC HOMOLOGY-2 DOMAIN AND AUTOPHOSPHORYLATION SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; DEPENDENT PROTEIN-KINASE; PHOSPHOTYROSINE-CONTAINING PROTEINS; EXPRESS HIGH-LEVELS; CYTOPLASMIC SIGNALING PROTEINS; GROWTH-FACTOR RECEPTOR; CRK ONCOGENE PRODUCT; TYROSINE KINASE; SCHIZOSACCHAROMYCES-POMBE; AFFINITY-CHROMATOGRAPHY	In the previous study (Sato, K., Miki, S., Tachibana, H., Hayashi, F., Akiyama, T., and Fukami, Y. (1990) Biochem. Biophys. Res. Commun. 171, 1152-1159), we found a synthetic peptide, termed peptide A, that inhibited the kinase activity of p60v-src. The peptide A sequence corresponds to residues 137 to 157 of p60v-src which are included in the amino-terminal portion of the src homology 2 domain. In this study, we attempted to specify the inhibitory sequence in this domain and to identify its target site. The most potent peptide A derivative was one that corresponds to residues 140 through 157. The target site of peptide A was assumed to reside in the autophosphorylation site of p60v-src, since synthetic peptides containing the sequence Phe424-Pro-Ile-Lys-Trp428 which is present downstream of the autophosphorylated Tyr416 partially counteracted the inhibitory effect of peptide A. An antibody was prepared against one of such target peptides, termed pepY. Cross-linking experiments showed that I-125-labeled peptide A could bind to p60v-src blotted on a membrane, and the binding was blocked by the anti-pepY antibody but not by other anti-p60v-src antibodies. Conversely, immunoblotting of p60v-src with anti-pepY antibody was blocked by the cross-linking of peptide A to p60v-src. To our surprise, anti-pepY antibody did not affect the p60v-src activity. Furthermore, p60c-src was activated 2- to 6-fold by this antibody. These results suggest that the pepY region in the catalytic domain of p60v-src or of p60c-src is not essential for the catalytic activity but rather is involved in the negative regulation of the kinase activity of p60c-src.	CHUGAI PHARMACEUT CO LTD, EXPLORATORY RES LABS, KOMAKADO, GOTEMBA 412, JAPAN	Chugai Pharmaceutical Co., Ltd.; Roche Holding	FUKAMI, Y (corresponding author), KOBE UNIV, BIOSIGNAL RES CTR, MOLEC BIOL LAB, KOBE 657, JAPAN.							AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASNELLIE JE, 1984, P NATL ACAD SCI USA, V81, P6679; CHENG HC, 1986, J BIOL CHEM, V261, P989; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; FUKAMI Y, 1985, P NATL ACAD SCI USA, V82, P321, DOI 10.1073/pnas.82.2.321; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GOULD KL, 1989, GENE, V342, P39; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUNTER T, 1986, ENZYMES, V17, P192; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; IZUMI T, 1988, J BIOL CHEM, V263, P10386; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KISHIMOTO A, 1991, METHOD ENZYMOL, V200, P447; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SATO K, 1990, BIOCHEM BIOPH RES CO, V171, P1152, DOI 10.1016/0006-291X(90)90805-W; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; ZHANG B, 1991, J BIOL CHEM, V266, P990	65	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1132	1140						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678249				2022-12-27	WOS:A1993KG07700057
J	CARLOS, S; JUTGLAR, L; BORRELL, I; HUNT, DF; AUSIO, J				CARLOS, S; JUTGLAR, L; BORRELL, I; HUNT, DF; AUSIO, J			SEQUENCE AND CHARACTERIZATION OF A SPERM-SPECIFIC HISTONE H1-LIKE PROTEIN OF MYTILUS-CALIFORNIANUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SECONDARY STRUCTURE; NUCLEOSOMAL ORGANIZATION; NUCLEAR PROTEINS; INFRARED-SPECTRA; CHROMATIN; H-1; H1; MICROHETEROGENEITY; GALLOPROVINCIALIS	The major protein fraction of the protamine-like PL-II* (phi2B) from the sperm of Mytilus californianus has been sequenced and characterized. Immunological and sequence analyses unequivocally show that this protein is indeed a member of the histone H1 family. Along with proteins of the histone H1 class, the protein also shows cross-reactivity and sequence identity, in its NH2-terminal region, with the major protamine-like protein component of Mytilus sperm: PL-III (phi1), of smaller molecular mass. Indeed it is the unusual repetitive sequence motif of the NH2-terminal domain of PL-II* that bestows to this protein its protamine-like nature. Fourier-transform infrared spectroscopy spectroscopy indicates that the protein contains considerable secondary structure: 18% alpha-helix, 21% beta-sheet, 39% turns and bends, 22% random coil. At the higher levels of structure, PL-II* exhibits ionic strength-dependent folding which is indistinguishable from that of histone H5, as monitored by fluorescence anisotropy.	UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA V8W 3P6, BC, CANADA; CSIC, ESCOLA TECN SUPER ENGN IND, UNIDAD QUIM MACROMOLEC, E-08028 BARCELONA, SPAIN; CTR ENSENANZA TECN SUPER INST QUIM SARRIA, CTR ASOCIADO CSIC, DEPT QUIM ORGAN, E-08017 BARCELONA, SPAIN; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	University of Victoria; Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Ramon Llull; Institut Quimic de Sarria; University of Virginia			Hunt, Donald F/I-6936-2012; Borrell, Jose I./M-1646-2013	Hunt, Donald F/0000-0003-2815-6368; Borrell, Jose I./0000-0001-9409-2919				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ANDO T, 1969, INT J PROT RES, V1, P221; AUSIO J, 1987, BIOCHEMISTRY-US, V26, P975, DOI 10.1021/bi00378a001; AUSIO J, 1988, J BIOL CHEM, V263, P10141; AUSIO J, 1989, EUR J BIOCHEM, V182, P569, DOI 10.1111/j.1432-1033.1989.tb14865.x; AUSIO J, 1988, CELL DIFFER DEV, V23, P175, DOI 10.1016/0045-6039(88)90070-X; AUSIO J, 1982, J BIOL CHEM, V257, P2802; AUSIO J, 1982, BIOCHEMISTRY-US, V21, P5910, DOI 10.1021/bi00266a028; AUSIO J, 1982, EXP CELL RES, V141, P39, DOI 10.1016/0014-4827(82)90065-9; AUSIO J, 1986, COMP BIOCHEM PHYS B, V85, P439, DOI 10.1016/0305-0491(86)90025-8; AUSIO J, 1987, EUR J BIOCHEM, V165, P363, DOI 10.1111/j.1432-1033.1987.tb11449.x; AVRAMOVA Z, 1984, EXP CELL RES, V152, P231, DOI 10.1016/0014-4827(84)90248-9; BLOCH DP, 1969, GENETICS, V61, P93; BRADBURY EM, 1975, EUR J BIOCHEM, V52, P605, DOI 10.1111/j.1432-1033.1975.tb04032.x; BRIAND G, 1980, FEBS LETT, V112, P147, DOI 10.1016/0014-5793(80)80167-0; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CARLOS S, 1993, J BIOL CHEM, V268, P195; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Cohn E. J., 1943, PROTEINS AMINO ACIDS; COLE RD, 1984, ANAL BIOCHEM, V136, P24, DOI 10.1016/0003-2697(84)90303-8; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DOWNING MR, 1976, ANAL BIOCHEM, V74, P298, DOI 10.1016/0003-2697(76)90211-6; GARCIA-RAMIREZ M, 1990, Protein Expression and Purification, V1, P40, DOI 10.1016/1046-5928(90)90043-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIANCOTTI V, 1983, EUR J BIOCHEM, V136, P509, DOI 10.1111/j.1432-1033.1983.tb07770.x; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HILL CS, 1989, EMBO J, V8, P2591, DOI 10.1002/j.1460-2075.1989.tb08398.x; HOLLOWAY PW, 1989, BIOCHEMISTRY-US, V28, P931, DOI 10.1021/bi00429a002; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; HURLEY CK, 1977, ANAL BIOCHEM, V80, P624, DOI 10.1016/0003-2697(77)90687-X; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; JUTGLAR L, 1991, J BIOL CHEM, V266, P8184; KMIECIK D, 1985, EUR J BIOCHEM, V150, P359, DOI 10.1111/j.1432-1033.1985.tb09028.x; Koening J. K., 1980, ANAL APPLICATIONS FT, P241; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI ZC, 1988, MOL CELL BIOL, V8, P1842, DOI 10.1128/MCB.8.4.1842; MANTSCH HH, 1986, SPECTROSCOPY BIOL SY, P1; MAYES ELV, 1982, HMG CHROMOSOMAL PROT, P223; MOGENSEN C, 1991, FEBS LETT, V282, P273, DOI 10.1016/0014-5793(91)80493-M; MULLER S, 1989, METHOD ENZYMOL, V170, P251; NAKANO M, 1976, INT J PEPT PROT RES, V8, P565; OKAMOTO Y, 1987, J BIOCHEM-TOKYO, V101, P1017, DOI 10.1093/oxfordjournals.jbchem.a121943; OLIVARES C, 1991, MOL CELL BIOCHEM, V101, P93; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PEPE I, 1990, BIOCHIM BIOPHYS ACTA, V1041, P14, DOI 10.1016/0167-4838(90)90116-W; PHELAN JJ, 1974, J BIOL CHEM, V249, P1099; RISLEY MS, 1990, CHROMOSOMES EUKARYOT, V2, P61; SANDERS MM, 1978, J CELL BIOL, V79, P97, DOI 10.1083/jcb.79.1.97; SHAY CE, 1988, COMP BIOCHEM PHYS B, V91, P69, DOI 10.1016/0305-0491(88)90115-0; SMERDON MJ, 1976, BIOCHEMISTRY-US, V15, P4233, DOI 10.1021/bi00664a016; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; STRICKLAND WN, 1982, BIOCHIM BIOPHYS ACTA, V700, P127, DOI 10.1016/0167-4838(82)90300-4; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; SUBIRANA JA, 1990, BIOPOLYMERS, V29, P1351, DOI 10.1002/bip.360291003; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Susi H., 1972, METHODS ENZYMOL, V26, P445; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; USCHEWA A, 1985, CELL BIOL INT REP, V9, P253, DOI 10.1016/0309-1651(85)90042-6; van Holde KE., 1989, SPRINGER SERIES MOL; VANDERWE.DR, 1974, BIOCHIM BIOPHYS ACTA, V359, P341, DOI 10.1016/0005-2795(74)90233-5; YAGUCHI M, 1979, BIOCHEM BIOPH RES CO, V90, P1400, DOI 10.1016/0006-291X(79)91191-4; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZALENSKAYA IA, 1985, FEBS LETT, V188, P243; ZALENSKY AO, 1982, STUD BIOPHYS, V87, P137	66	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					185	194						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677995				2022-12-27	WOS:A1993KE60300029
J	DICERA, E; GUINTO, ER; VINDIGNI, A; DANG, QD; AYALA, YM; WUYI, M; TULINSKY, A				DICERA, E; GUINTO, ER; VINDIGNI, A; DANG, QD; AYALA, YM; WUYI, M; TULINSKY, A			THE NA+ BINDING-SITE OF THROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN ALPHA-THROMBIN; PRO-ARG CHLOROMETHYLKETONE; CRYSTAL-STRUCTURE; ACTIVATED ENZYME; TRP INSERTION; PROTEIN-C; SPECIFICITY; COMPLEXES; CATIONS	Thrombin is an allosteric serine protease existing in two forms, slow and fast, targeted toward anticoagulant and procoagulant activities, The slow --> fast transition is induced by Na+ binding to a site contained within a cylindrical cavity formed by three antiparallel beta-strands of the B-chain (Met(180)-Tyr(184a), Lys(224)-Tyr(228), and Val(213)-Gly(219)) diagonally crossed by the Glu(188) Glu(192) strand, The site is shaped further by the loop connecting the last two beta-strands and is located more than 15 Angstrom away from the catalytic triad. The cavity traverses through thrombin from the active site to the opposite surface and contains Asp(189) of the primary specificity site near its midpoint, The bound Na+ is coordinated octahedrally by the carbonyl oxygen atoms of Tyr(184a), Arg(221a), and Lys(224), and by three highly conserved water molecules in the D-Phe-Pro-Arg chloromethylketone thrombin. The sequence in the Na+ binding loop is highly conserved in thrombin from II different species and is homologous to that found in other serine proteases involved in blood coagulation, Mutation of two Asp residues flanking Arg(221a) (D221A/D222K) almost abolishes the allosteric properties of thrombin and shows that the Na+ binding loop is also involved in direct recognition of protein C and antithrombin.	MICHIGAN STATE UNIV,DEPT CHEM,E LANSING,MI 48824	Michigan State University	DICERA, E (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,BOX 8231,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043229, R01HL049413, R29HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL43229] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BECK WS, 1991, HEMATOLOGY; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; DANG QD, 1994, J PROTEIN CHEM, V13, P367, DOI 10.1007/BF01901692; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; EVANS HJ, 1966, ANN REV PLANT PHYSIO, V17, P47, DOI 10.1146/annurev.pp.17.060166.000403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LEBIODA L, 1992, J APPL CRYSTALLOGR, V25, P323, DOI 10.1107/S0021889891011342; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; MANN KG, 1990, BLOOD, V76, P1; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; NI F, 1992, BIOCHEMISTRY-US, V31, P11551, DOI 10.1021/bi00161a037; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; ORTHNER CL, 1978, ARCH BIOCHEM BIOPHYS, V185, P400, DOI 10.1016/0003-9861(78)90182-0; ORTHNER CL, 1980, ARCH BIOCHEM BIOPHYS, V202, P63, DOI 10.1016/0003-9861(80)90406-3; RATNOFF OD, 1991, DISORDERS HEMOSTASIS; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SKRZYPCZAKJANKUN E, 1989, J MOL BIOL, V206, P755, DOI 10.1016/0022-2836(89)90582-2; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STEINER SA, 1980, BIOCHEM BIOPH RES CO, V94, P340, DOI 10.1016/S0006-291X(80)80226-9; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	32	223	231	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22089	22092		10.1074/jbc.270.38.22089	http://dx.doi.org/10.1074/jbc.270.38.22089			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673182	hybrid			2022-12-27	WOS:A1995RW31400004
J	GREENFEDER, SA; VARNELL, T; POWERS, G; LOMBARDGILLOOLY, K; SHUSTER, D; MCINTYRE, KW; RYAN, DE; LEVIN, W; MADISON, V; JU, G				GREENFEDER, SA; VARNELL, T; POWERS, G; LOMBARDGILLOOLY, K; SHUSTER, D; MCINTYRE, KW; RYAN, DE; LEVIN, W; MADISON, V; JU, G			INSERTION OF A STRUCTURAL DOMAIN OF INTERLEUKIN (IL)-1-BETA CONFERS AGONIST ACTIVITY TO THE IL-1 RECEPTOR ANTAGONIST - IMPLICATIONS FOR IL-1 BIOACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; BIOLOGICAL-ACTIVITY; HUMAN IL-1-BETA; BINDING-SITE; II RECEPTOR; EXPRESSION; PROTEIN; RESOLUTION; INHIBITOR; CLONING	We showed previously that replacement of Lys-145 in the IL-1 receptor antagonist (IL-1ra) with Asp resulted in an analog (IL-1ra K145D) with partial agonist activity. To identify additional amino acids that affect IL-1 bioactivity, we created second site mutations in IL-1ra K145D, Substitutions of single amino acids surrounding position 145 were made; none of these substitutions increased the bioactivity of IL-1ra K145D. However, the insertion of the beta-bulge (QGEESN) of IL-1 beta at the corresponding region of IL-1ra K145D resulted in a 3-4-fold augmentation of bioactivity. An additional increase in agonist activity was observed when the beta-bulge was coexpressed with a second substitution (Kis-54 --> Pro) in IL-1ra K145D, We also show that the bioactivity of both IL-1ra K145D and the triple mutant IL-1ra K145D/H54P/QGEESN is dependent on interaction with the newly cloned IL-1 receptor accessory protein.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT CHEM PHYS,NUTLEY,NJ 07110	Roche Holding; Roche Holding								ANTONI G, 1986, J IMMUNOL, V137, P3201; AREND WP, 1994, J IMMUNOL, V153, P4766; AREND WP, 1985, J IMMUNOL, V134, P3868; AURON PE, 1992, BIOCHEMISTRY-US, V31, P6632, DOI 10.1021/bi00144a002; BECKERS W, 1993, J IMMUNOL, V151, P1757; BORASCHI D, 1988, J EXP MED, V168, P675, DOI 10.1084/jem.168.2.675; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHIZZONITE R, 1991, J IMMUNOL, V147, P1548; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DINARELLO CA, 1991, BLOOD, V77, P1627; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; FRASCA D, 1988, J IMMUNOL, V141, P2651; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOPKINS SJ, 1989, J IMMUNOL METHODS, V120, P271, DOI 10.1016/0022-1759(89)90252-4; HUANG JJ, 1987, FEBS LETT, V223, P294, DOI 10.1016/0014-5793(87)80307-1; JU G, 1991, P NATL ACAD SCI USA, V88, P2658, DOI 10.1073/pnas.88.7.2658; KAWASHIMA H, 1992, PROTEIN ENG, V5, P171, DOI 10.1093/protein/5.2.171; LABRIOLATOMPKIN.E, 1993, PROTEIN ENG, V8, P535; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZZEI GJ, 1990, EUR J IMMUNOL, V20, P683, DOI 10.1002/eji.1830200332; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; SIMON PL, 1993, J BIOL CHEM, V268, P9771; SIMONCSITS A, 1994, CYTOKINE, V6, P206, DOI 10.1016/1043-4666(94)90043-4; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; STOCKMAN BJ, 1994, FEBS LETT, V349, P79, DOI 10.1016/0014-5793(94)00643-1; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; VIGERS GPK, 1994, J BIOL CHEM, V269, P12874; WOLFSON AJ, 1993, BIOCHEMISTRY-US, V32, P5327, DOI 10.1021/bi00071a007	44	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22460	22466		10.1074/jbc.270.38.22460	http://dx.doi.org/10.1074/jbc.270.38.22460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673234	hybrid			2022-12-27	WOS:A1995RW31400063
J	IKEDA, Y; FUJII, J; ANDERSON, ME; TANIGUCHI, N; MEISTER, A				IKEDA, Y; FUJII, J; ANDERSON, ME; TANIGUCHI, N; MEISTER, A			INVOLVEMENT OF SER-451 AND SER-452 IN THE CATALYSIS OF HUMAN GAMMA-GLUTAMYL-TRANSPEPTIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERASE TRANSPEPTIDASE; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS STRAIN; MOLECULAR-CLONING; ESCHERICHIA-COLI; SITE; KIDNEY; IDENTIFICATION; MECHANISM; AFFINITY	The serine residue required for catalysis of gamma-glutamyl transpeptidase was identified by site-specific mutagenesis of the conserved serine residues on the basis of sequence alignment of the light subunit of human, rat, pig and two bacterial enzymes, Recombinant human gamma-glutamyl transpeptidases with replacements of these serine residues by Ala were expressed using a baculovirus-insect cell system, Substitutions of Ala at Ser-385, -413 or -425 yielded almost fully active enzymes, However, substitutions of Ala at Ser-451 or -452 yielded enzymes that were only about 1% as active as the wild-type enzyme, Further, their double mutant is only 0.002% as active as the wild type, Kinetic analysis of transpeptidation using glycylglycine as acceptor indicates that the V-max values of Ser-451 and -452 mutants are substantially decreased (to about 3% of the wild type); however, their K-m values for L-gamma-glutamyl-p-nitroanilide as donor were only increased about 5 fold compared to that of the wild type, The double mutation of Ser-451 and -452 further decreased the V-max value to only about 0.005% of the wild type, while this mutation produced only a minor effect (2-fold increase) on the K-m value for the donor, The kinetic values for the hydrolysis reaction of L-gamma-glutamyl-p-nitroanilide in the mutants followed similar trends to those for transpeptidation, The rates of inactivation of Ser-451, -452 and their double mutant enzymes by acivicin, a potent inhibitor, were less than 1% that of the wild-type enzyme, The Ri value of the double mutant for L-serine as a competitive inhibitor of the gamma-glutamyl group is only 9 fold increased over that of the wild type, whereas the K-i for the serine-borate complex, which acts as an inhibitory transition-state analog, was more than 1,000 times higher than for the wild-type enzyme, These results suggest that both Ser-451 and -452 are located at the position able to interact with the gamma-glutamyl group and participate in catalysis, probably as nucleophiles or through stabilization of the transition state.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021	Osaka University; Cornell University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Fujii, Junichi/0000-0003-2267-7357	NIAID NIH HHS [AI31804] Funding Source: Medline; NIDDK NIH HHS [2 R37 DK12034] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012034] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON RD, 1985, METHOD ENZYMOL, V113, P419; BAROUKI R, 1984, J BIOL CHEM, V259, P7970; CAPRARO MA, 1983, FEBS LETT, V157, P139, DOI 10.1016/0014-5793(83)81132-6; CARTER P, 1988, NATURE, V332, P654; COLOMA J, 1986, NUCLEIC ACIDS RES, V14, P1393, DOI 10.1093/nar/14.3.1393; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GRIFFITH OW, 1980, P NATL ACAD SCI-BIOL, V77, P3384, DOI 10.1073/pnas.77.6.3384; HEISTERKAMP N, 1991, P NATL ACAD SCI USA, V88, P6303, DOI 10.1073/pnas.88.14.6303; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; IKEDA Y, 1993, J BIOL CHEM, V268, P3980; IKEDA Y, 1995, P NATL ACAD SCI USA, V92, P126, DOI 10.1073/pnas.92.1.126; IKEDA Y, 1995, J BIOL CHEM, V270, P12471, DOI 10.1074/jbc.270.21.12471; INOUE M, 1977, EUR J BIOCHEM, V73, P335, DOI 10.1111/j.1432-1033.1977.tb11323.x; INOUE M, 1978, BIOCHEM BIOPH RES CO, V82, P1183, DOI 10.1016/0006-291X(78)90311-X; ISHIYE M, 1993, BIOTECHNOL PROGR, V9, P323, DOI 10.1021/bp00021a012; ISHIYE M, 1992, BIOCHIM BIOPHYS ACTA, V1132, P233, DOI 10.1016/0167-4781(92)90155-S; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; Meister A, 1981, Methods Enzymol, V77, P237; Meister A, 1976, ENZYMES BIOL MEMBR, Vv3, P315; Meister A, 1989, GLUTATHIONE CHEM BIO, P367; NASH B, 1984, J BIOL CHEM, V259, P678; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PAPANDRIKOPOULOU A, 1989, EUR J BIOCHEM, V183, P693, DOI 10.1111/j.1432-1033.1989.tb21100.x; PIWNICAWORMS H, 1987, CURRENT PROTOCOLS MO; RAJPERTDEMEYTS E, 1988, P NATL ACAD SCI USA, V85, P8840, DOI 10.1073/pnas.85.23.8840; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SAKAMURO D, 1988, GENE, V73, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH TK, 1995, P NATL ACAD SCI USA, V92, P2360, DOI 10.1073/pnas.92.6.2360; SMITH TK, 1995, J BIOL CHEM, V270, P12476, DOI 10.1074/jbc.270.21.12476; STOLE E, 1990, P NATL ACAD SCI USA, V87, P1706, DOI 10.1073/pnas.87.5.1706; STOLE E, 1991, J BIOL CHEM, V266, P17850; STOOPS JK, 1990, J BIOL CHEM, V265, P16971; SUZUKI H, 1989, J BACTERIOL, V171, P5169, DOI 10.1128/jb.171.9.5169-5172.1989; TATE SS, 1978, P NATL ACAD SCI USA, V75, P4806, DOI 10.1073/pnas.75.10.4806; TATE SS, 1977, P NATL ACAD SCI USA, V74, P931, DOI 10.1073/pnas.74.3.931; TATE SS, 1985, METHOD ENZYMOL, V113, P400; THOMPSON GA, 1976, BIOCHEM BIOPH RES CO, V71, P32, DOI 10.1016/0006-291X(76)90245-X	42	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22223	22228		10.1074/jbc.270.38.22223	http://dx.doi.org/10.1074/jbc.270.38.22223			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673200	hybrid			2022-12-27	WOS:A1995RW31400026
J	JOE, YA; WOLFF, EC; PARK, MH				JOE, YA; WOLFF, EC; PARK, MH			CLONING AND EXPRESSION OF HUMAN DEOXYHYPUSINE SYNTHASE CDNA - STRUCTURE-FUNCTION STUDIES WITH THE RECOMBINANT ENZYME AND MUTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; HYPUSINE; IDENTIFICATION; SPERMIDINE; PURIFICATION; FIBROBLAST; PRECURSOR	Deoxyhypusine synthase catalyzes the first step in the post-translational formation of hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine). cDNA clones encoding deoxyhypusine synthase were isolated from a human HeLa cell library. Full-length cDNA clones encoding a 369-amino acid protein (calculated molecular mass of 40,970 Da) and a shorter cDNA clone that would potentially encode a protein with an internal deletion of 56 amino acids (Asp(262)-Ser(317)) were isolated. The deduced amino acid sequence of the human enzyme shows a high degree of identity to that of yeast deoxyhypusine synthase and to the known sequences of tryptic peptides from the rat and Neurospora crassa enzymes. The recombinant enzyme formed upon expression in Escherichia coli effectively catalyzed deoxyhypusine synthesis. Variant human recombinant proteins with (i) a truncation of 48 or 97 NH2-terminal amino acids, (ii) a truncation of 39 COOH-terminal amino acids, or (iii) an internal deletion (Asp(262)-Ser(317)) were inactive. A chimeric protein consisting of the complete human sequence and 16 amino acids of the yeast sequence (Gln(197)-Asn(212), not present in the human enzyme) inserted between Glu(193) and Gln(194) exhibited moderate activity.	NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BARTIG D, 1990, SYST APPL MICROBIOL, V13, P112, DOI 10.1016/S0723-2020(11)80156-6; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CARDINALI M, 1995, INT J CANCER, V61, P98, DOI 10.1002/ijc.2910610117; CHANG SE, 1992, INT J CANCER, V52, P896, DOI 10.1002/ijc.2910520612; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HUH TL, 1990, J BIOL CHEM, V265, P13320; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; KANG HA, 1994, J BIOL CHEM, V269, P3934; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; MAGDOLEN V, 1994, MOL GEN GENET, V224, P646; MCCAFFREY TA, 1995, J CLIN INVEST, V95, P446, DOI 10.1172/JCI117684; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Parkinson EK, 1991, HUMAN CANCER PRIMARY, P187; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Sambrook J, 1989, MOL CLONING LABORATO; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; 1986, EUR J BIOCHEM, V186, P1	32	77	85	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22386	22392		10.1074/jbc.270.38.22386	http://dx.doi.org/10.1074/jbc.270.38.22386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673224	hybrid			2022-12-27	WOS:A1995RW31400051
J	KENNEDY, BP; PAYETTE, P; MUDGETT, J; VADAS, P; PRUZANSKI, W; KWAN, M; TANG, C; RANCOURT, DE; CROMLISH, WA				KENNEDY, BP; PAYETTE, P; MUDGETT, J; VADAS, P; PRUZANSKI, W; KWAN, M; TANG, C; RANCOURT, DE; CROMLISH, WA			A NATURAL DISRUPTION OF THE SECRETORY GROUP-II PHOSPHOLIPASE-A(2) GENE IN INBRED MOUSE STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SEMINAL PLASMA; ENHANCING FACTOR; INDUCED ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; SMALL-INTESTINES; SYNOVIAL-FLUID; EXPRESSION; INHIBITOR; MICE; CARRAGEENAN	The synovial fluid or group II secretory phospholipase A(2) (sPLA(2)) has been implicated as an important agent involved in a number of inflammatory processes. In an attempt to determine the role of sPLA(2) in inflammation, we set out to generate sPL(2)-deficient mice. During this investigation, we observed that in a number of inbred mouse strains, the sPLA(2) gene was already disrupted by a frameshift mutation in exon 3. This mutation, a T insertion at position 166 from the ATG of the cDNA, terminates out of frame in exon 4, resulting in the disruption of the calcium binding domain in exon 3 and loss of both activity domains coded by exons 4 and 5. The mouse strains C57BL/6, 129/Sv, and B10.RIII were found to be homozygous for the defective sPLA(2) gene, whereas outbred CD-1:SW mice had variable genotype at this locus. BALB/c, C3H/HE, DBA/1, DBA/2, NZB/B1N, and MRL lpr/lpr mice had a normal sPLA(2) genotype. The sPLA(2) mRNA was expressed at very high levels in the BALB/c mouse small intestine, whereas in the small intestine of the sPLA(2) mutant mouse strains, sPLA(2) mRNA was undetectable. In addition, PLA(2) activity in acid extracts of the small intestine were approximately 40 times higher in BALB/c than in the mutant mice. Transcription of the mutant sPLA(2) gene resulted in multiple transcripts due to exon skipping. None of the resulting mutant mRNAs encoded an active product. The identification of this mutation should not only help define the physiological role of sPLA(2) but also has important implications in mouse inflammatory models developed by targeted mutagenesis.	MERCK RES LABS,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065; UNIV TORONTO,WELLESLEY HOSP,INFLAMMAT RES GRP,TORONTO,ON M4Y 1J3,CANADA; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Merck & Company; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	KENNEDY, BP (corresponding author), MERCK FROSST CANADA INC,MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POB 1005,POINTE CLAIRE,PQ H9R 4P8,CANADA.							BEATON HG, 1994, J MED CHEM, V37, P557, DOI 10.1021/jm00031a001; BOIE Y, 1993, J BIOL CHEM, V268, P5530; BOMALASKI JS, 1993, ARTHRITIS RHEUM-US, V36, P190, DOI 10.1002/art.1780360208; BRACKERTZ D, 1977, ARTHRITIS RHEUM, V20, P841, DOI 10.1002/art.1780200314; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BREITENSTEIN W, 1994, EUR J MED CHEM, V29, P649, DOI 10.1016/0223-5234(94)90026-4; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; DENG CX, 1992, MOL CELL BIOL, V12, P3365, DOI 10.1128/MCB.12.8.3365; DESAI SJ, 1991, HISTOCHEMISTRY, V96, P371, DOI 10.1007/BF00271359; Festing M. F. W., 1993, Mouse Genome, V91, P393; FUKAO T, 1994, J CLIN INVEST, V93, P1035, DOI 10.1172/JCI117052; GLANT TT, 1987, ARTHRITIS RHEUM-US, V30, P201, DOI 10.1002/art.1780300211; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HOGAN B, 1994, MANIPULATING MOUSE E, P3; HUANG CH, 1993, J BIOL CHEM, V268, P25902; JOYNER A, 1994, GENE TARGETING PRACT, P33; KAZAZIAN HH, 1988, BLOOD, V72, P1107; KOMADA M, 1990, BIOCHEM BIOPH RES CO, V168, P1059, DOI 10.1016/0006-291X(90)91137-H; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUSUNOKI C, 1990, BIOCHIM BIOPHYS ACTA, V1087, P95, DOI 10.1016/0167-4781(90)90127-N; LEMAHIEU RA, 1993, J MED CHEM, V36, P3029, DOI 10.1021/jm00072a025; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Maniatis T, 1989, DECONTAMINATION DILU; MIYAKE A, 1993, BRIT J PHARMACOL, V110, P447, DOI 10.1111/j.1476-5381.1993.tb13831.x; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; MULHERKAR R, 1986, J CELL PHYSL, V117, P183; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NEVALAINEN TJ, 1993, ANDROLOGIA, V25, P355; NORDLING C, 1992, ARTHRITIS RHEUM, V35, P717, DOI 10.1002/art.1780350619; OGATA M, 1992, INFECT IMMUN, V60, P2432, DOI 10.1128/IAI.60.6.2432-2437.1992; ORKIN SH, 1984, ANNU REV GENET, V18, P131; PRUZANSKI W, 1994, J RHEUMATOL, V21, P1951; PRUZANSKI W, 1988, J RHEUMATOL, V115, P1351; PRUZANSKI W, 1995, MEDIATORS INFLAMMATI, V4; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; STEFANSKI E, 1986, J BIOCHEM-TOKYO, V100, P1297, DOI 10.1093/oxfordjournals.jbchem.a121836; TAKAYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P1505, DOI 10.1016/0006-291X(91)91064-J; TANAKA K, 1993, INFLAMMATION, V17, P107, DOI 10.1007/BF00916098; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TRAMPOSCH KM, 1992, BIOCHEM BIOPH RES CO, V189, P272, DOI 10.1016/0006-291X(92)91554-4; VADAS P, 1992, LIFE SCI, V50, P807, DOI 10.1016/0024-3205(92)90186-S; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VADAS P, 1993, CRIT CARE MED, V21, P1087, DOI 10.1097/00003246-199307000-00027; VANSCHAIK RHN, 1993, BIOCHIM BIOPHYS ACTA, V1169, P1, DOI 10.1016/0005-2760(93)90075-K; WOOLEY PH, 1985, J IMMUNOL, V135, P2443	49	308	312	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22378	22385		10.1074/jbc.270.38.22378	http://dx.doi.org/10.1074/jbc.270.38.22378			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673223	hybrid			2022-12-27	WOS:A1995RW31400050
J	LANDER, HM; OGISTE, JS; TENG, KK; NOVOGRODSKY, A				LANDER, HM; OGISTE, JS; TENG, KK; NOVOGRODSKY, A			P21(RAS) AS A COMMON SIGNALING TARGET OF REACTIVE FREE-RADICALS AND CELLULAR REDOX STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; STIMULATION; CELLS; LYMPHOCYTES; INHIBITION; HEMIN; DNA	Reactive free radicals have been implicated in mediating signal transduction by a variety of stimuli. We have investigated the role of p21(ras) in mediating free radical signaling. Our studies revealed that signaling by oxidative agents which modulate cellular redox status, such as H2O2, hemin, Hg2+, and nitric oxide was prevented in cells in which p21(ras) activity was blocked either through expression of a dominant negative mutant or by treating with a farnesyltransferase inhibitor, as assessed by NF-kappa B binding activity. Furthermore, the NP-kappa B response to these oxidative stress stimuli was found to be enhanced when cells from the human T cell line, Jurkat, were pretreated with L-buthionine-(S,R)-sulfoximine, an inhibitor of glutathione synthesis. We directly assayed p21(ras) and mitogen-activated protein kinase activities in jurkat cells and found both of these signaling molecules to be activated in cells treated with the redox modulating agents. Blocking glutathione synthesis made cells 10- to 100-fold more sensitive to these agents. Finally, using recombinant p21(ras) in vitro, we found that redox modulators directly promoted guanine nucleotide exchange on p21(ras). This study suggests that direct activation of p21(ras) may be a central mechanism by which a variety of redox stress stimuli transmit their signal to the nucleus.	CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; FELSENSTEIN MED RES CTR,IL-49100 PETAH TIQWA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Cornell University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	LANDER, HM (corresponding author), CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021, USA.			Teng, Kenneth/0000-0002-9392-2172	NIAID NIH HHS [AI37637] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037637] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BOS JL, 1989, CANCER RES, V49, P4682; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; LANDER HM, 1993, BIOCHEM J, V291, P281, DOI 10.1042/bj2910281; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; MUEHLEMATTER D, 1988, CARCINOGENESIS, V9, P239, DOI 10.1093/carcin/9.2.239; REARDON CL, 1987, IMMUNOBIOLOGY, V175, P455, DOI 10.1016/S0171-2985(87)80073-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; STENZEL KH, 1981, J IMMUNOL, V127, P2469; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; WARNER GL, 1986, CELL IMMUNOL, V101, P425, DOI 10.1016/0008-8749(86)90155-3; YAN SD, 1994, J BIOL CHEM, V269, P9889	24	353	357	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21195	21198		10.1074/jbc.270.36.21195	http://dx.doi.org/10.1074/jbc.270.36.21195			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673152	hybrid			2022-12-27	WOS:A1995RU05400052
J	TRAVIS, SM; CARSON, MR; RIES, DR; WELSH, MJ				TRAVIS, SM; CARSON, MR; RIES, DR; WELSH, MJ			INTERACTION OF NUCLEOTIDES WITH MEMBRANE-ASSOCIATED CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CFTR CHLORIDE CHANNEL; SYNTHETIC PEPTIDE; BINDING-SITES; TRANSPORT; CELLS; GENE; ATP; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION	Cystic fibrosis transmembrane conductance regulator (CFTR) is a Cl- channel that is regulated by cytosolic nucleotides and by cAMP-dependent phosphorylation. In excised membrane patches, CFTR Cl- channel activity requires hydrolyzable nucleotides and Mg2+, and is inhibited by ADP. We examined the interactions between CFTR and nucleotides using 8-azidoadenosine 5'-triphosphate (8-N3ATP), a photoactivatable ATP analog. Because CFTR functions as a membrane ion channel, we studied CFTR in membranes of Sf9 insect cells. We found that [alpha-P-32]8-N3ATP specifically photolabeled CFTR, with half-maximal labeling at 10 muM 8-N3ATP in the presence of Mg2+ and 100 muM in the absence of Mg2+. The 8-N3ATP also substituted for ATP in activating CFTR Cl- channels, indicating that it interacts with the active site(s). Both ATP and GTP prevented photolabeling with half-maximal inhibition at 1 mM. ADP and adenyl-5'-yl imidodiphosphate (AMP-PNP) prevented photolabeling but at much higher concentrations, whereas AMP did not inhibit photolabeling at concentrations of up to 100 mM. Phosphorylation of CFTR was not a prerequisite for nucleotide binding. These results demonstrate that CFTR interacts directly with nucleotides at concentrations that regulate CFTR Cl- channel activity.	UNIV IOWA, COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED, 500 EMRB, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa				Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BELL CL, 1993, AM J PHYSIOL, V264, pC925, DOI 10.1152/ajpcell.1993.264.4.C925; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; HALEY BE, 1991, METHOD ENZYMOL, V200, P477; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660	25	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15336	15339						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687995				2022-12-27	WOS:A1993LN30500004
J	OBLATTMONTAL, M; BUHLER, LK; IWAMOTO, T; TOMICH, JM; MONTAL, M				OBLATTMONTAL, M; BUHLER, LK; IWAMOTO, T; TOMICH, JM; MONTAL, M			SYNTHETIC PEPTIDES AND 4-HELIX BUNDLE PROTEINS AS MODEL SYSTEMS FOR THE PORE-FORMING STRUCTURE OF CHANNEL PROTEINS .1. TRANSMEMBRANE SEGMENT M2 OF THE NICOTINIC CHOLINERGIC RECEPTOR-CHANNEL IS A KEY PORE-LINING STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; TORPEDO-CALIFORNICA; XENOPUS OOCYTES; IONIC CHANNELS; AMINO-ACIDS; PERMEABILITY; SUBUNITS; BILAYERS; CATIONS; HELICES	Monomeric peptides and four-helix bundle proteins with amino acid sequences of the predicted transmembrane segment M2 of nicotinic acetylcholine receptors (AChR) were designed, synthesized, and used as probes to elucidate the pore-forming structure of the authentic AChR channel. Peptides M2delta and M2alpha4 with sequences of M2 from muscle-like Torpedo californica AChR delta subunit and from rat neuronal AChR alpha4 subunit form cation-selective channels in lipid bilayers with predominant single-channel conductances in 0.5 M KCl of 20 pS and 27 pS, respectively. Corresponding analogs with presumed pore-lining residues serine 8 or phenylalanine 16 specifically substituted by alanine retain the ability to self-assemble into conductive oligomers and form channels with primary conductances of 16 pS and 22 pS for M2delta analogs and of 14 pS and 26 pS for M2alpha4 analogs. In contrast, peptides with randomized sequences and the same amino acid composition as M2delta do not form channels. Four-helix bundle proteins T4M2delta and T4M2alpha4 exhibit conductances in 0.5 M KCl of 20 pS and 26 pS. Analogs of T4M2delta with selective replacement of serine 8 for alanine exhibit lower conductances, whereas substitution of phenylalanine 16 for alanine increases the single-channel conductance. T4M2delta channels are blocked by open channel blockers such as the quaternary derivative of lidocaine QX-222 and by chlorpromazine. Channel open probability is reduced, and open time is abbreviated. Conduction properties of T4M2delta and analogs are in accord with several properties of authentic AChRs. These comprehensive studies provide insights into the components of the pore-forming structure of nicotinic AChRs.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV SO CALIF, SCH MED, DEPT BIOCHEM, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, CHILDRENS HOSP, LOS ANGELES, CA 90027 USA	University of California System; University of California San Diego; University of Southern California; University of Southern California; Children's Hospital Los Angeles; University of Southern California				TOMICH, JOHN M./0000-0001-7848-8307	NIGMS NIH HHS [GM-42340, GM43617] Funding Source: Medline; NIMH NIH HHS [MH-44638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042340, R29GM043617, R01GM043617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; BALLIVET M, 1988, NEURON, V1, P847, DOI 10.1016/0896-6273(88)90132-8; BECHINGER B, 1991, Journal of Biomolecular NMR, V1, P167, DOI 10.1007/BF01877228; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; EISENMAN G, 1990, PROG CELL R, V1, P195; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GROVE A, 1992, METHOD ENZYMOL, V207, P510; GROVE A, 1991, SER SYMP AD, V4, P89; GROVE A, 1991, P NATL ACAD SCI USA, V88, P6418, DOI 10.1073/pnas.88.15.6418; Hille B., 1992, IONIC CHANNELS EXCIT; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; IMOTO K, 1991, FEBS LETT, V289, P193, DOI 10.1016/0014-5793(91)81068-J; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; KARLIN A, 1991, HARVEY LECT, V85, P71; LABARCA P, 1984, J NEUROSCI, V4, P502; LABARCA P, 1984, J GEN PHYSIOL, V83, P473, DOI 10.1085/jgp.83.4.473; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MERRIFIELD RB, 1965, SCIENCE, V150, P178, DOI 10.1126/science.150.3693.178; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; MONTAL M, 1986, ION CHANNEL RECONSTI, P157; NUMA S, 1989, HARVEY LECT, V83, P121; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OIKI S, 1990, PROTEINS, V8, P226, DOI 10.1002/prot.340080305; PAPKE RL, 1989, NEURON, V3, P589, DOI 10.1016/0896-6273(89)90269-9; REDDY GL, 1993, J BIOL CHEM, V268, P14608; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SAKMANN B, 1992, SCIENCE, V256, P503, DOI 10.1126/science.1373907; SAKMANN B, 1985, NATURE, V318, P538, DOI 10.1038/318538a0; STRICHARTZ GR, 1987, HDB EXPT PHARM, V81, P1; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; [No title captured]	41	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14601	14607						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686900				2022-12-27	WOS:A1993LL75900014
J	NASKI, MC; LAWRENCE, DA; MOSHER, DF; PODOR, TJ; GINSBURG, D				NASKI, MC; LAWRENCE, DA; MOSHER, DF; PODOR, TJ; GINSBURG, D			KINETICS OF INACTIVATION OF ALPHA-THROMBIN BY PLASMINOGEN-ACTIVATOR INHIBITOR-1 - COMPARISON OF THE EFFECTS OF NATIVE AND UREA-TREATED FORMS OF VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; ANTITHROMBIN-III; S-PROTEIN; TRANSIENT KINETICS; ENDOTHELIAL-CELLS; BINDING-PROTEIN; HUMAN-PLASMA; HEPARIN; PURIFICATION; PAI-1	Kinetic studies are presented which show that native human vitronectin, but not urea-treated vitronectin, accelerates the inactivation of human alpha-thrombin by human plasminogen activator inhibitor-1 (PAI-1). We demonstrate that although urea-treated vitronectin binds PAI-1 with an affinity greater than that of native vitronectin, it does not accelerate the rate of inactivation of alpha-thrombin by PAI-1. We present evidence to suggest that the inability of urea-treated vitronectin to accelerate the reaction between alpha-thrombin and PAI-1 results at least in part from the inability of urea-treated vitronectin to bind to alpha-thrombin. The accelerated reaction between PAI-1 and alpha-thrombin can be accounted for by the formation of a tight complex between native vitronectin and PAI-1 that reacts in a saturable manner (K(d) = 75 nM) with alpha-thrombin. The second-order rate constant (k(I)/K(d)) for the reaction of the native vitronectin-PAI-1 complex with alpha-thrombin (1.64 x 10(5) M--1 s-1) is 270-fold greater than the second-order rate constant for the reaction in the absence of vitronectin (610 M-1 s-1). The increase in the second-order rate constant is largely due to an increase in the affinity of alpha-thrombin for the native vitronectin-PAI-1 complex, as reflected by a greater than 25-fold reduction in the dissociation constant (K(d)) observed for the vitronectin-PAI-1 complex relative to that of uncomplexed PAI-1.	HOWARD HUGHES MED INST,4520 MSRB I,1150 W MED CTR DR,ANN ARBOR,MI 48109; MCMASTER UNIV,HAMILTON CIV HOSP,RES CTR,DEPT PATHOL,HAMILTON L8S 4L8,ONTARIO,CANADA; UNIV MICHIGAN,SCH MED,DEPT MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	Howard Hughes Medical Institute; McMaster University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029586, R01HL039137] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-PO1-HL29586, 1-RO1-HL39137] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EDELBERG JM, 1991, J BIOL CHEM, V266, P7488; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GREENGARD JS, 1991, THROMB HAEMOSTASIS, V65, P1277; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KEIJER J, 1991, BLOOD, V78, P1254; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LEWIS SD, 1984, THROMB RES, V35, P111, DOI 10.1016/0049-3848(84)90206-8; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NASKI MC, 1990, J BIOL CHEM, V265, P1401; NASKI MC, 1992, J BIOL CHEM, V265, P1344; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1982, J BIOL CHEM, V257, P1491; OWENSBY DA, 1991, J BIOL CHEM, V266, P4334; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PODOR TJ, 1992, ANN NY ACAD SCI, V667, P46, DOI 10.1111/j.1749-6632.1992.tb51595.x; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHLEEF RR, 1988, HAEMOSTASIS, V18, P328; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SPRENGERS ED, 1987, BLOOD, V69, P381; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2; WUN TC, 1989, J BIOL CHEM, V264, P7862; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHOU JM, 1989, BIOCHEMISTRY-US, V28, P1070, DOI 10.1021/bi00429a022	41	92	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12367	12372						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685341				2022-12-27	WOS:A1993LG65800025
J	BEDOWS, E; HUTH, JR; SUGANUMA, N; BARTELS, CF; BOIME, I; RUDDON, RW				BEDOWS, E; HUTH, JR; SUGANUMA, N; BARTELS, CF; BOIME, I; RUDDON, RW			DISULFIDE BOND MUTATIONS AFFECT THE FOLDING OF THE HUMAN CHORIONIC GONADOTROPIN-BETA SUBUNIT IN TRANSFECTED CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; FORM; SALT; DNA	Previous kinetic studies have characterized the intracellular folding pathway of the human chorionic gonadotropin (hCG)-beta subunit in which each of the folding intermediates can be biochemically identified based on the formation of disulfide (S-S) bonds: pbeta1-early --> pbeta1-late --> pbeta2-free --> pbeta2-combined --> native hCG-alphabeta. Based on these data, we postulated that hCG-beta folding coincides with the formation of specific S-S bonds. We have now tested this hypothesis employing Chinese hamster ovary cells transfected with mutated hCG-beta genes in which the Cys residues required for the formation of the final four (of six total) S-S bonds were replaced by Ala. When the Cys residues required for the third hCG-beta S-S linkage to form (bond 9-90) were substituted, folding did not proceed beyond the earliest detectable folding intermediate (pbeta1-early). In the absence of the subsequently formed S-S bond (bond 23-72), pbeta1-early was converted into a second folding intermediate (pbeta1-late), but conversion to the next intermediate (pbeta2-free) was inhibited. When either of the final two S-S bonds (the carboxyl-terminal 93-100 or 26-110 bonds) were removed, conversion of pbeta1-late to pbeta2-free was detected, but conversion of pbeta2-free to the last folding intermediate (pbeta2-combined) was not observed. These data support the hypothesis that individual S-S bonds are involved in discrete steps in the hCG-beta folding pathway.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Michigan System; University of Michigan; Washington University (WUSTL); Washington University (WUSTL); University of Nebraska System; University of Nebraska Medical Center					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023398] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [F05TW004124] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA032949] Funding Source: NIH RePORTER; FIC NIH HHS [1F05TW04124] Funding Source: Medline; NCI NIH HHS [CA32949] Funding Source: Medline; NICHD NIH HHS [HD23398] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BREMS DN, 1989, PROTEINS, V5, P93, DOI 10.1002/prot.340050110; CHEN F, 1991, J BIOL CHEM, V266, P6904; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; MCGUIRE MC, 1989, P NATL ACAD SCI USA, V86, P953, DOI 10.1073/pnas.86.3.953; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MULLENBACH R, 1989, TRENDS GENET, V5, P391; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OMURA F, 1992, EUR J BIOCHEM, V205, P551, DOI 10.1111/j.1432-1033.1992.tb16812.x; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RUDDON RW, 1987, J BIOL CHEM, V262, P12533; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; TANIYAMA Y, 1992, J BIOL CHEM, V267, P4619; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	26	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11655	11662						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685018				2022-12-27	WOS:A1993LF28400032
J	WOLFF, DJ; DATTO, GA; SAMATOVICZ, RA				WOLFF, DJ; DATTO, GA; SAMATOVICZ, RA			THE DUAL-MODE OF INHIBITION OF CALMODULIN-DEPENDENT NITRIC-OXIDE SYNTHASE BY ANTIFUNGAL IMIDAZOLE AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; BOVINE BRAIN; BINDING; KETOCONAZOLE; REDUCTASE; SEQUENCE; AGONIST; PROTEIN; DOMAINS	The antifungal imidazoles miconazole, ketoconazole, and clotrimazole inhibit citrulline formation by nitric-oxide synthase. These agents both increase the concentration of calmodulin required to activate the enzyme half-maximally and reduce the maximal velocity of citrulline formation. This inhibition was not reversed by increased concentrations of either the arginine substrate or (6R)-5,6,7,8-tetrahydro-L-biopterin. Miconazole, ketoconazole, and clotrimazole also inhibited the cytochrome-c reductase activity of nitric-oxide synthase competitively versus calmodulin concentration, with apparent K(i) (IC50) values of 8, 20, and 0.8 muM, respectively. Miconazole, ketoconazole, and clotrimazole inhibited the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase competitively versus calmodulin concentration, with apparent K(i) values of 6, 18, and 25 muM, respectively. These observations are consistent with the proposal that the antifungal imidazoles inhibit citrulline formation by interaction with the nitric-oxide synthase at two sites. Interaction at site 1 reduces the responsiveness of the enzyme to activation by calmodulin, whereas interaction at site 2 (involving putative binding of the imidazole to the heme iron) reduces the maximal velocity of citrulline formation. The interactions of calmodulin antagonists at site 1 occur at substantially lower concentrations of drug than those at site 2 and are the principal determinant of enzyme inhibition.			WOLFF, DJ (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011252] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-11252] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; AMBRE JJ, 1991, AM MED ASS DRUG EVAL, P1479; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P1; Beavo J A, 1974, Methods Enzymol, V38, P299; BENSON JM, 1988, CLIN PHARMACY, V7, P424; BODEY GP, 1988, MED CLIN N AM, V72, P637, DOI 10.1016/S0025-7125(16)30763-5; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BROOKER G, 1968, BIOCHEMISTRY-US, V7, P4177, DOI 10.1021/bi00852a006; BROSTROM CO, 1974, ARCH BIOCHEM BIOPHYS, V165, P715, DOI 10.1016/0003-9861(74)90300-2; BROWN MW, 1985, CLIN PHARMACOL THER, V37, P290, DOI 10.1038/clpt.1985.42; DAMANHOURI Z, 1988, J ANTIMICROB CHEMOTH, V21, P187, DOI 10.1093/jac/21.2.187; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; EDELMAN AM, 1985, J BIOL CHEM, V260, P1275; HUANG YC, 1986, ANTIMICROB AGENTS CH, V30, P206, DOI 10.1128/AAC.30.2.206; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MASON JI, 1985, BIOCHEM PHARMACOL, V34, P1087, DOI 10.1016/0006-2952(85)90613-6; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NEWTON DL, 1984, FEBS LETT, V165, P269, DOI 10.1016/0014-5793(84)80183-0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OSHIRO Y, 1970, ARCH BIOCHEM BIOPHYS, V138, P392, DOI 10.1016/0003-9861(70)90361-9; PUTKEY JA, 1986, J BIOL CHEM, V261, P9896; ROLAN PE, 1983, BRIT MED J, V287, P1760, DOI 10.1136/bmj.287.6407.1760; Segel I.H., 1975, ENZYME KINETICS; SHEETS JJ, 1986, BIOCHEM PHARMACOL, V35, P487, DOI 10.1016/0006-2952(86)90224-8; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; VANDENBOSSCHE H, 1978, CHEM-BIOL INTERACT, V21, P59, DOI 10.1016/0009-2797(78)90068-6; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WOLFF DJ, 1981, J BIOL CHEM, V256, P1846; WOLFF DJ, 1985, J BIOL CHEM, V260, P4195; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; WOLFF DJ, 1992, BIOCHEM J, V285, P201, DOI 10.1042/bj2850201; YOSHIDA Y, 1987, BIOCHEM PHARMACOL, V36, P229, DOI 10.1016/0006-2952(87)90694-0	35	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9430	9436						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683652				2022-12-27	WOS:A1993LA68900045
J	ALTHAUS, IW; CHOU, JJ; GONZALES, AJ; DEIBEL, MR; CHOU, KC; KEZDY, FJ; ROMERO, DL; ARISTOFF, PA; TARPLEY, WG; REUSSER, F				ALTHAUS, IW; CHOU, JJ; GONZALES, AJ; DEIBEL, MR; CHOU, KC; KEZDY, FJ; ROMERO, DL; ARISTOFF, PA; TARPLEY, WG; REUSSER, F			STEADY-STATE KINETIC-STUDIES WITH THE NONNUCLEOSIDE HIV-1 REVERSE-TRANSCRIPTASE INHIBITOR U-87201E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SULFATED POLYSACCHARIDES; SELECTIVE-INHIBITION; PENTOSAN POLYSULFATE; ANTIVIRAL ACTIVITY; ENZYME-KINETICS; RNASE-H; TYPE-1; DERIVATIVES; POTENT	The multifunctional HIV-1 RT (human immunodeficiency virus type 1-reverse transcriptase) enzyme possesses three main functions including the RNA- and DNA-directed DNA polymerases and the RNase H. The bisheteroarylpiperazine U-87201E inhibits the two polymerase functions but not the RNase H. Enzymatic kinetic studies of the HIV-1 RT-cataLyzed RNA- and DNA-directed DNA polymerase activities were carried out in order to determine if the inhibitor interferes with either the template:primer or the deoxyribonucleotide triphosphate (dNTP)-binding sites of the enzyme. The data were analyzed using steady-state kinetics, considering that the polymerase reaction is ordered in that the template:primer is added first, followed by the dNTP and that the enzyme funCtions processively. The data were consistent with the model. The steady-state rate constants for the forward and backward reactions were of similar magnitude for both the RNA- and DNA-catalyzed DNA polymerases and suggest that both functions share the same substrate-binding sites. The dissociation constants for the enzyme-inhibitor and enzyme-substrate-inhibitor compleXes were somewhat higher for the DNA-directed DNA polymerase function as compared to the RNA directed one. This indicates that U-87201E is a more potent inhibitor for the RNA-directed DNA polymerase than the DNA-directed DNA polymerase. The pattern of inhibition exerted by U-87201E was noncompetitive with respect to both the nucleic acid and nucleotide-binding sites of the RT enzyme for both the RNA- and DNA-directed DNA polymerases. Hence, U-87201E inhibits these functions by interacting with a Site distinct from the template: primer and dNTP-binding sites. HIV-2 RT was insensitive to U-87201E, demonstrating the unique sensitivity of HIV-1 RT to this inhibitor.	UPJOHN CO,KALAMAZOO,MI 49001; UNIV MICHIGAN,DEPT PHYS,ANN ARBOR,MI 48109	Pfizer; University of Michigan System; University of Michigan			Chou, James J/N-9840-2013; Chou, James/AAD-6230-2022; Chou, Kuo-Chen/A-8340-2009	Chou, James J/0000-0002-4442-0344; Chou, James/0000-0002-4442-0344; 				ALTHAUS IW, 1992, EXPERIENTIA, V48, P1127, DOI 10.1007/BF01948005; ANAND R, 1990, AIDS RES HUM RETROV, V6, P679, DOI 10.1089/aid.1990.6.679; BABA M, 1990, J ACQ IMMUN DEF SYND, V3, P493; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356; BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3; BABA M, 1988, ANTIMICROB AGENTS CH, V32, P1742, DOI 10.1128/AAC.32.11.1742; BUSSO M, 1988, AIDS RES HUM RETROV, V4, P449, DOI 10.1089/aid.1988.4.449; CHA S, 1968, J BIOL CHEM, V243, P820; CHATTOPADHYAY D, 1992, PROTEIN EXPRES PURIF, V3, P151, DOI 10.1016/S1046-5928(05)80032-4; CHOU KC, 1976, SCI SINICA, V19, P505; CHOU KC, 1989, J BIOL CHEM, V264, P12074; CHOU KC, 1990, BIOPHYS CHEM, V35, P1, DOI 10.1016/0301-4622(90)80056-D; CHOU KC, 1982, J AM CHEM SOC, V104, P1409, DOI 10.1021/ja00369a043; Coffin JM, 1990, VIROLOGY, V2, P1437; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECLERCQ E, 1987, ANTIVIR RES, V7, P1, DOI 10.1016/0166-3542(87)90034-9; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; GERARD M, 1990, ANTIVIRAL THERAPY HU, P176; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HUBER HE, 1989, J BIOL CHEM, V264, P4669; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MOELLING K, 1989, J VIROL, V63, P5489, DOI 10.1128/JVI.63.12.5489-5491.1989; MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3; SOSA MAG, 1991, BIOCHEM BIOPH RES CO, V174, P489, DOI 10.1016/0006-291X(91)91443-G; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	34	174	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6119	6124						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681060				2022-12-27	WOS:A1993KT36800010
J	RON, D; REICH, R; CHEDID, M; LENGEL, C; COHEN, OE; CHAN, AML; NEUFELD, G; MIKI, T; TRONICK, SR				RON, D; REICH, R; CHEDID, M; LENGEL, C; COHEN, OE; CHAN, AML; NEUFELD, G; MIKI, T; TRONICK, SR			FIBROBLAST GROWTH-FACTOR RECEPTOR-4 IS A HIGH-AFFINITY RECEPTOR FOR BOTH ACIDIC AND BASIC FIBROBLAST GROWTH-FACTOR BUT NOT FOR KERATINOCYTE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC AMPLIFICATION; MESSENGER-RNA; CELL-GROWTH; DNA; IDENTIFICATION; TRANSFORMATION; FAMILY; EXPRESSION; INDUCTION; MEMBER	A cDNA predicted to encode a transmembrane tyrosine kinase receptor with sequence features characteristic of known fibroblast growth factor (FGF) receptors was isolated from an expression library constructed from the human mammary epithelial cell line B5/589. This cDNA, designated cl44, encodes a product of 803 amino acid residues and was readily distinguishable from known FGF receptors. During the course of our studies, Partanen et al. (Partanen, J., Makela, T. P., Eerola, E., Korhonen, J., Hirvonen, H., Claesson, W. L., and Alitalo, K. (1991) EMBO J. 10, 1347-1354) isolated a new FGF receptor, designated FGFR4, from the human leukemia cell line, K562. Its amino acid sequence is identical to that of cl44 with the exception of 1 residue. The 5'-untranslated sequences of the two cDNAs diverged far upstream of the initiation codon. A myoblast line, L6E9, which lacks FGF receptors, was utilized to express high levels of FGFR4. We found, in contrast to Partenen et al., who reported only binding of acidic FGF, that FGFR4 bound both acidic and basic FGF with dissociation constants of 10-15 and 120 pM, respectively. No detectable binding of keratinocyte growth factor was observed. In studies aimed to determine whether FGF receptors contribute to the development of human tumors, we screened RNAs prepared from cell lines derived from a variety of solid tumors. High levels of the cl44 transcript were detected in 8 of 14 and 6 of 9 human mammary and kidney carcinomas, respectively, but only infrequently in other types of tumors. In contrast, FGFR1 was found to be frequently expressed in kidney, but not in breast tumor cells, suggesting a possible role for FGFR4 in human mammary cancer.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	RON, D (corresponding author), TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL.		Neufeld, Gera/F-1524-2019; Chan, Andrew Man-Lok/J-9497-2013	Chan, Andrew Man-Lok/0000-0001-9923-5464				ARMSTRONG E, 1992, CANCER RES, V52, P2004; AVIVI A, 1991, ONCOGENE, V6, P1089; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRUMELY G, 1992, ONCOGENE, V6, P2255; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EISEMANN A, 1991, ONCOGENE, V6, P1195; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAN M, 1991, METHOD ENZYMOL, V198, P158; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T, 1989, MOL CLONING; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1990, RECOMBINANT SYSTEMS IN PROTEIN EXPRESSION, P125; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUNSON PJ, 1980, BIOCHEMISTRY-US, V25, P3487; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RON D, 1993, J BIOL CHEM, V268, P2984; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; TORU M, 1991, SCIENCE, V252, P72; TORU M, 1992, P NATL ACAD SCI USA, V89, P246; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360; YUEN S, 1991, METHOD ENZYMOL, V198, P91; ZHAN Z, 1988, MOL CELL BIOL, V8, P4387	56	93	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5388	5394						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680645				2022-12-27	WOS:A1993KR82200011
J	WONG, P; PINEAULT, J; LAKINS, J; TAILLEFER, D; LEGER, J; WANG, CY; TENNISWOOD, M				WONG, P; PINEAULT, J; LAKINS, J; TAILLEFER, D; LEGER, J; WANG, CY; TENNISWOOD, M			GENOMIC ORGANIZATION AND EXPRESSION OF THE RAT TRPM-2 (CLUSTERIN) GENE, A GENE IMPLICATED IN APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PROSTATIC DUCTAL SYSTEM; SULFATED GLYCOPROTEIN-2; VENTRAL PROSTATE; MOLECULAR-CLONING; MESSENGER-RNA; FUNCTIONAL-CHARACTERIZATION; TRANSCRIPTION FACTOR; ANDROGEN WITHDRAWAL; REGIONAL VARIATION	We describe the genomic structure of the rat TRPM-2 gene. This gene is induced de novo during the regression of the prostate and other hormone-dependent tissues after hormone ablation and plays an important role in apoptosis, or active cell death. TRPM-2 is a single copy gene, organized into nine exons, ranging in size from 47 base pairs (exon I) to 412 base pairs (exon IV), spanning a region of 13,750 base pairs. Comparison with sequences registered in the data bases shows that it has extensive homology to SGP-2, a gene that is expressed constitutively in the testis, although the sequences diverge dramatically in the 5'-untranslated region of the mRNA (coded for by exon I in TRPM-2), raising the possibility of alternative exon I usage in SGP-2. Primer extension, S1 nuclease protection, and extensive polymerase chain reaction analysis suggest that the TRPM-2 transcript from the prostate and the SGP-2 transcript from the testis are in fact identical and only contain the exon I sequence identified in the TRPM-2 genomic clone. Analysis of the promoter region of the TRPM-2 gene demonstrates that the putative control region contains several potential regulatory elements that may regulate the complex tissue-specific control of a gene which must be constitutively expressed in some tissues but repressed in others until induced during active cell death.	UNIV OTTAWA, DEPT BIOCHEM, 451 SMYTH RD, OTTAWA K1H 8M5, ONTARIO, CANADA	University of Ottawa				Tenniswood, Martin/0000-0001-7896-4019				ALLDAY MJ, 1987, NUCLEIC ACIDS RES, V15, P10592, DOI 10.1093/nar/15.24.10592; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURSCH W, 1991, CARCINOGENESIS, V12, P855, DOI 10.1093/carcin/12.5.855; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHENG CY, 1988, BIOCHEM BIOPH RES CO, V155, P398; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; CYR DG, 1992, ENDOCRINOLOGY, V130, P2160, DOI 10.1210/en.130.4.2160; DAY JR, 1990, MOL ENDOCRINOL, V4, P1995, DOI 10.1210/mend-4-12-1995; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; GRIMA J, 1990, ENDOCRINOLOGY, V126, P2989, DOI 10.1210/endo-126-6-2989; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JOH K, 1986, J MOL BIOL, V190, P401, DOI 10.1016/0022-2836(86)90011-2; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYPRIANOU N, 1989, BIOCHEM BIOPH RES CO, V165, P73, DOI 10.1016/0006-291X(89)91035-8; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; KYPRIANOU N, 1990, CANCER RES, V50, P3748; KYPRIANOU N, 1991, CANCER RES, V51, P162; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; LAPING NJ, 1991, BRAIN RES, P291; LEE C, 1987, J UROLOGY, V138, P903, DOI 10.1016/S0022-5347(17)43413-6; LEE C, 1990, BIOL REPROD, V43, P1079, DOI 10.1095/biolreprod43.6.1079; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEGER JG, 1988, PROSTATE, V13, P131, DOI 10.1002/pros.2990130205; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MCNEILL TH, 1991, EXP NEUROL, V111, P140, DOI 10.1016/0014-4886(91)90062-H; MICHEL D, 1989, ONCOGENE RES, V4, P127; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PRINS GS, 1992, ENDOCRINOLOGY, V130, P3066, DOI 10.1210/en.130.5.3066; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PURRELLO M, 1991, GENOMICS, V10, P151, DOI 10.1016/0888-7543(91)90495-Z; RENNIE PS, 1988, CANCER RES, V48, P6309; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; ROULEAU M, 1990, MOL ENDOCRINOL, V4, P2003, DOI 10.1210/mend-4-12-2003; SAMBOROK J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SENSIBAR JA, 1991, ENDOCRINOLOGY, V128, P2091, DOI 10.1210/endo-128-4-2091; SLAWIN K, 1990, BIOCHEM BIOPH RES CO, V172, P160, DOI 10.1016/S0006-291X(05)80187-1; SMITH FF, 1992, MOL REPROD DEV, V33, P363, DOI 10.1002/mrd.1080330402; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TRUSS M, 1992, J STEROID BIOCHEM, V41, P241, DOI 10.1016/0960-0760(92)90350-R; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; WONG P, 1989, GENE, V85, P59, DOI 10.1016/0378-1119(89)90464-2; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; ZAKERI Z, 1992, MOL REPROD DEV, V33, P373, DOI 10.1002/mrd.1080330403	73	193	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					5021	5031						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680346				2022-12-27	WOS:A1993KP88400069
J	KATO, H; FARIA, TN; STANNARD, B; ROBERTS, CT; LEROITH, D				KATO, H; FARIA, TN; STANNARD, B; ROBERTS, CT; LEROITH, D			ROLE OF TYROSINE KINASE-ACTIVITY IN SIGNAL TRANSDUCTION BY THE INSULIN-LIKE GROWTH FACTOR-I (IGF-I) RECEPTOR - CHARACTERIZATION OF KINASE-DEFICIENT IGF-I RECEPTORS AND THE ACTION OF AN IGF-I-MIMETIC ANTIBODY (ALPHA-IR-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; ORNITHINE DECARBOXYLASE; MESSENGER-RNA; CELLS; PHOSPHORYLATION; OVEREXPRESSION; REPLACEMENT; BINDING; AUTOPHOSPHORYLATION; EXPRESSION	The insulin-like growth factor-I (IGF-I) receptor is a member of a large family of transmembrane signal transducing molecules. The defining characteristic of this class of receptors is the intrinsic tyrosine kinase activity of the cytoplasmic domain. While it has been demonstrated that this tyrosine kinase activity is necessary for the action of a number of transmembrane tyrosine kinase receptors, no evidence of this type has been adduced to date with respect to the signaling requirement of the IGF-I receptor. We have now shown that stably transfected NIH-3T3 cell lines overexpressing human IGF-I receptors display increased responses to IGF-I and an IGF-I-mimetic antibody, alphaIR-3, in terms of short, intermediate, and long term actions initiated by activation of the IGF-I receptor. These include receptor autophosphorylation, activation of phosphatidylinositol-3-kinase and 2-deoxyglucose uptake, induction of ornithine decarboxylase gene expression, and stimulation of thymidine incorporation. In short term responses, the kinetics seen with alphaIR-3 were slower than those seen with IGF-I. These effects were severely decreased in clones expressing human IGF-I receptors in which the lysine residue in the ATP-binding site of the tyrosine kinase domain had been mutated to alanine or arginine. This was true for both IGF-I and alphaIR-3. These results indicate that, for all parameters tested, the tyrosine kinase activity of the IGF-I receptor is necessary for activation of the IGF-I-stimulated signal transduction cascade. Additionally, the effects of alphaIR-3 also require tyrosine kinase activity.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				ADAMO M, 1991, BIOFACTORS, V3, P151; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CHEN SC, 1991, CANCER RES, V51, P1898; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DURONIO V, 1988, RECEPTOR BIOCH MET B, V12, P3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GHERZI R, 1987, J BIOL CHEM, V262, P16900; GOTTSCHALK WK, 1991, J BIOL CHEM, V266, P8814; HARI J, 1987, J BIOL CHEM, V262, P15341; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HOVIS JG, 1986, J BIOL CHEM, V261, P380; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LOWE WL, 1987, P NATL ACAD SCI USA, V84, P8946, DOI 10.1073/pnas.84.24.8946; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MORGAN DO, 1987, P NATL ACAD SCI USA, V84, P41, DOI 10.1073/pnas.84.1.41; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; OEMAR BS, 1991, J BIOL CHEM, V266, P24241; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; RAFAELOFF R, 1991, BIOCHEM BIOPH RES CO, V179, P912, DOI 10.1016/0006-291X(91)91905-R; ROTH RA, 1988, COLD SPRING HARB SYM, V53, P3537; ROTH RA, 1991, MODERN CONCEPTS INSU, P505; SIMPSON IA, 1984, SCIENCE, V223, P1301, DOI 10.1126/science.6367041; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STEELEPERKINS G, 1990, BIOCHEM BIOPH RES CO, V171, P1244, DOI 10.1016/0006-291X(90)90819-9; STEELEPERKINS G, 1990, J BIOL CHEM, V265, P9458; SUNG CK, 1989, J BIOL CHEM, V264, P18951; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Ulrich A., 1985, NATURE, V313, P756; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358; XIONG LM, 1992, P NATL ACAD SCI USA, V89, P5356, DOI 10.1073/pnas.89.12.5356; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1984, J BIOL CHEM, V259, P4396	43	247	255	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2655	2661						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679099				2022-12-27	WOS:A1993KK81500060
J	WEBERSCHURHOLZ, S; WISCHMEYER, E; LAURIEN, M; JOCKUSCH, H; SCHURHOLZ, T; LANDRY, DW; ALAWQATI, Q				WEBERSCHURHOLZ, S; WISCHMEYER, E; LAURIEN, M; JOCKUSCH, H; SCHURHOLZ, T; LANDRY, DW; ALAWQATI, Q			INDANYLOXYACETIC ACID-SENSITIVE CHLORIDE CHANNELS FROM OUTER MEMBRANES OF SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER GOLGI MEMBRANES; VOLTAGE DEPENDENCE; ANION CHANNEL; PURIFICATION; CONDUCTANCE; MANNOSIDASE	In mature mammalian muscle, the chloride conductance of the membrane is an important factor in the regulation of excitability. Up to now, no ligand was available for the biochemical characterization of muscle chloride channels. In order to localize and characterize these channels, we have used indanyloxyacetic acid (IAA)-94, a ligand previously used for epithelial Cl- channels (Landry, D. W., Reitman, M., Cragoe, E. J., Jr., and Al-Awqati, Q. (1987) J. Gen. Physiol. 90, 779-798; Landry, D. W., Akabas, M. H., Redhead, C., Edelman, A., Cragoe, E. J., Jr., and Al-Awqati, Q. (1989) Science 244, 1469-1472). IAA induced myotonic responses when microinjected into mature mouse muscle fibers, indicating a blockade of Cl- channels from the cytoplasmic side. Membrane vesicles were prepared from rabbit skeletal muscle and separated by sucrose gradient centrifugation. Fractions obtained (in the order of increasing density) were sarcolemma (SL), T-tubules (TT), sarcoplasmatic reticulum (SR), and triads and mitochondria (TR/M). The fraction enriched for SL was characterized by high specific binding capacity for [H-3]saxitoxin (Na+ channel), whereas TT-rich fractions bound [H-3]PN 200-110 (dihydropyridine receptor) with high specific activity. Upon patch-clamping of lipid supplemented vesicles, IAA-sensitive Cl- channels were found in the SL fraction but not in the SR. Highest specific activities in electrical diffusion potential sensitive Cl-36 transport and [H-3]IAA-94 binding were found in the SL. SL vesicles were solubilized with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and subjected to IAA-Sepharose affinity chromatography. Specifically bound protein was eluted with 100 muM IAA-94 and either analyzed by SDS-gel electrophoresis or reconstituted into phospholipid vesicles. The eluate contained four polypeptides (specifically bound, m(app) 110-120 and 60 kDa; unspecifically bound m(app) 67 and 50 kDa) and was highly enriched for IAA-sensitive chloride channels as shown by patch-clamping after reconstitution. The IAA-sensitive 100/280-picosiemens chloride channels of the sarcolemma are likely to be responsible for its major chloride conductance and thereby for the stabilization of resting potential.	UNIV BIELEFELD,DEV BIOL UNIT,W-4800 BIELEFELD 1,GERMANY; UNIV BIELEFELD,DEPT PHYSIOCHEM,W-4800 BIELEFELD 1,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	University of Bielefeld; University of Bielefeld; Columbia University			Al-Awqati, Qais/B-2465-2009	Al-Awqati, Qais/0000-0001-7141-1040				BLATZ AL, 1985, BIOPHYS J, V47, P119, DOI 10.1016/S0006-3495(85)83884-4; BLATZ AL, 1986, J PHYSIOL-LONDON, V378, P141, DOI 10.1113/jphysiol.1986.sp016212; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BROWN GB, 1986, J NEUROSCI, V6, P2064; BURTON F, 1988, MUSCLE NERVE, V11, P1029, DOI 10.1002/mus.880111004; CORREA AM, 1988, BIOPHYS J, V54, P569, DOI 10.1016/S0006-3495(88)82991-6; DULHUNTY A, 1982, J MEMBRANE BIOL, V67, P81, DOI 10.1007/BF01868650; Fleischer S., 1967, METHOD ENZYMOL, V10, P406; HALS GD, 1990, BIOPHYS J, V57, P1037, DOI 10.1016/S0006-3495(90)82622-9; HORGAN DJ, 1988, ARCH BIOCHEM BIOPHYS, V260, P1, DOI 10.1016/0003-9861(88)90417-1; IMAGAWA T, 1987, J BIOL CHEM, V262, P16336; JOCKUSCH H, 1993, IN PRESS J CELL MOTI; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; LANDRY DW, 1987, J GEN PHYSIOL, V90, P779, DOI 10.1085/jgp.90.6.779; MEHRKE G, 1988, MUSCLE NERVE, V11, P440, DOI 10.1002/mus.880110505; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; RAN S, 1992, J BIOL CHEM, V267, P3618; REDHEAD CR, 1992, P NATL ACAD SCI USA, V89, P3716, DOI 10.1073/pnas.89.9.3716; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; WOLL KH, 1987, PFLUG ARCH EUR J PHY, V410, P641, DOI 10.1007/BF00581325	24	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					547	551						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678003				2022-12-27	WOS:A1993KE60300083
J	BAJORATH, J; HARRIS, L; NOVOTNY, J				BAJORATH, J; HARRIS, L; NOVOTNY, J			CONFORMATIONAL SIMILARITY AND SYSTEMATIC DISPLACEMENT OF COMPLEMENTARITY-DETERMINING REGION LOOPS IN HIGH-RESOLUTION ANTIBODY X-RAY STRUCTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HYPERVARIABLE REGIONS	Comparison of seven high resolution x-ray structures shows that the conformations of canonical complementarity determining region (CDR) loops, which are shared by these antibodies, are very similar, However, large spatial displacements (up to 2.7 Angstrom) of the essentially identical CDR loops become evident when the antibody beta-sheet frameworks, to which the loops are attached, are least-squares superposed, The loop displacements follow, and amplify, small positional differences in framework/loop splice points, Intradomain structural variability and, to a lesser extent, domain-domain orientation appear to cause the observed loop divergences, The results suggest that the selection of framework regions for loop grafting procedures is more critical than previously thought.			BAJORATH, J (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		Bajorath, Jürgen/F-7493-2014					ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; HARRIS L, 1995, PROTEIN SCI, V4, P306; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; Kabat EA, 1991, SEQUENCES PROTEINS I; LESK AM, 1991, ANTIBODY ENG PRACTIC, P1; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4	15	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22081	22084		10.1074/jbc.270.38.22081	http://dx.doi.org/10.1074/jbc.270.38.22081			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673180	hybrid			2022-12-27	WOS:A1995RW31400002
J	COLE, PA; GRACE, MR; PHILLIPS, RS; BURN, P; WALSH, CT				COLE, PA; GRACE, MR; PHILLIPS, RS; BURN, P; WALSH, CT			THE ROLE OF THE CATALYTIC BASE IN THE PROTEIN-TYROSINE KINASE-CSK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MECHANISM; SUBUNIT; INHIBITOR; BINDING	A potential distinguishing feature between protein tyrosine kinases and homologous serine/threonine kinases is the function of the catalytic base in these enzymes. In this study, we show that a peptide containing the unnatural amino acid trifluorotyrosine shows remarkably similar efficiency as a substrate of the tyrosine kinase Csk (C-terminal Src kinase) compared with the corresponding tyrosine-containing peptide despite a 4-unit change in the phenolic pK(alpha). These results argue against the importance of early tyrosine deprotonation by a catalytic base in Csk. To further explore the role of the proposed catalytic base, the Csk mutant protein D314E was produced. This mutant displayed a significant reduction in k(cat) (approximately 10(4)) but relatively little effect on substrate K-m values compared with wild-type Csk. Examination of the thio effect (k(cat)-ATP/k(cat)-adenosine 5'-O-(thiotriphosphate)) for D314E Csk led to the suggestion that a role of aspartate 314 may be to enhance the reactivity of the gamma-phosphate of ATP toward electrophilic attack. These results may have significant impact on protein tyrosine kinase inhibitor design.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; UNIV GEORGIA, DEPT CHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA; HOFFMANN LA ROCHE INC, NUTLEY, NJ 07110 USA	Harvard University; Harvard Medical School; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Roche Holding				Phillips, Robert/0000-0001-8710-562X	NIGMS NIH HHS [GM42588] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1993, J BIOL CHEM, V268, P7747; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BRUNATI AM, 1992, FEBS LETT, V313, P291, DOI 10.1016/0014-5793(92)81212-5; CHANDLER AJ, 1994, J CHEM SOC PERK T 2, P327, DOI 10.1039/p29940000327; CHEN HY, 1993, BIOCHEMISTRY-US, V32, P11591, DOI 10.1021/bi00094a016; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FILLER R, 1969, J ORG CHEM, V34, P534, DOI 10.1021/jo01255a011; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEATH DF, 1956, J CHEM SOC, P3796, DOI 10.1039/jr9560003796; HEBEL D, 1992, BIOORG MED CHEM LETT, V2, P41, DOI 10.1016/S0960-894X(00)80651-4; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1994, J AM CHEM SOC, V116, P11631, DOI 10.1021/ja00105a001; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kemp BE, 1990, PEPTIDES PROTEIN PHO; KHAN SA, 1970, J CHEM SOC B, P1172, DOI 10.1039/j29700001172; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MADHUSUDAN, 1994, PROTEIN SCI, V3, P176; MANTEL M, 1970, P NATL ACAD SCI USA, V65, P660, DOI 10.1073/pnas.65.3.660; MILDVAN AS, 1987, ADV ENZYMOL RAMB, V59, P241; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUAN CJ, 1990, J BIOL CHEM, V265, P16205; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	29	56	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22105	22108		10.1074/jbc.270.38.22105	http://dx.doi.org/10.1074/jbc.270.38.22105			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673185	hybrid			2022-12-27	WOS:A1995RW31400008
J	JAMES, F; NOLTE, KD; HANSON, AD				JAMES, F; NOLTE, KD; HANSON, AD			PURIFICATION AND PROPERTIES OF S-ADENOSYL-L-METHIONINE-L-METHIONINE S-METHYLTRANSFERASE FROM WOLLASTONIA-BIFLORA LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEMNA-PAUCICOSTATA; EUGLENA-GRACILIS; 3-O-METHYLTRANSFERASE; ENZYMES; ACID	The plant enzyme S-adenosylmethionine:methionine S-methyltransferase (EC 2.1.1.12, MMT) catalyzes the synthesis of S-methylmethionine. MMT was purified 620-fold to apparent homogeneity from leaves of Wollastonia biflora, The four-step purification included fractionation with polyethylene glycol, affinity chromatography on adenosine-agarose, anion exchange chromatography, and gel filtration, Protein yield was about 180 mu g/kg of leaves, Estimates of molecular mass from sodium dodecyl sulfate-polyacrylamide gel electrophoresis and native gel filtration chromatography were, respectively, 115 and 450 kDa, suggesting a tetramer of 115-kDa subunits, The 115-kDa subunit was photoaffinity labeled by S-adenosyl[H-3]methionine. Antibodies raised against W. biflora MMT recognized a 115-kDa polypeptide in partially purified MMT preparations from leaves of lettuce, cabbage, clover, and maize. The pH optimum of W. biflora MMT was 7.2, Kinetic analysis of substrate interaction and product inhibition patterns indicated an Ordered Pi Bi mechanism, with S-adenosylmethionine the first reactant to bind and S-adenosylhomocysteine the last product to be released, The enzyme catalyzed methylation of selenomethionine and ethionine, but not of S-methylcysteine, homocysteine, cysteine, or peptidylmethionine. Tests with other substrate analogs indicated that a free carboxyl group was required for enzyme activity, and that a free amino group was not.	UNIV FLORIDA,PLANT MOLEC & CELLULAR BIOL PROGRAM,GAINESVILLE,FL 32611	State University System of Florida; University of Florida								Bezzubov A. A., 1992, Prikladnaya Biokhimiya i Mikrobiologiya, V28, P423; Blunden G., 1986, Progress phycol. Res., V4, P39; Borchardt RT, 1980, ENZYMATIC BASIS DETO, V2, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTONI GL, 1979, TRANSMETHYLATION, P155; CHIRPICH T, 1968, THESIS U CALIFORNIA; Cleland W. W, 1970, ENZYMES, V2, P1; DACEY JWH, 1987, NATURE, V330, P643, DOI 10.1038/330643a0; DATKO AH, 1984, PLANT PHYSIOL, V75, P474, DOI 10.1104/pp.75.2.474; DODD WA, 1968, PHYTOCHEMISTRY, V7, P2143, DOI 10.1016/S0031-9422(00)85670-8; DROTAR A, 1985, PLANT CELL PHYSIOL, V26, P847; EDWARDS R, 1991, ARCH BIOCHEM BIOPHYS, V287, P372, DOI 10.1016/0003-9861(91)90492-2; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FAROOQUI JZ, 1985, J BIOL CHEM, V260, P537; FUJIOKA M, 1992, INT J BIOCHEM, V24, P1917, DOI 10.1016/0020-711X(92)90287-B; Gamboa Lewis B. A., 1976, Environmental Biogeochemistry. Volume 1. Carbon, Nitrogen, Phosphorus, Sulfur and Selenium Cycles. Proceedings, 2nd International Symposium on Environmental Biogeochemistry, Hamilton, Ontario, Canada, April 8-12th, 1975, P389; Giovanelli J., 1980, BIOCH PLANTS, VVolume 5, P453, DOI [DOI 10.1016/B978-0-12-675405-6.50018-8, 10.1016/b978-0-12-675405-6.50018-8]; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; HANSON AD, 1995, ENV PLANT B, P189; HANSON AD, 1976, PLANT PHYSIOL, V57, P528, DOI 10.1104/pp.57.4.528; HANSON AD, 1994, PLANT PHYSIOL, V105, P103, DOI 10.1104/pp.105.1.103; HURST JH, 1984, BIOCHEM BIOPH RES CO, V122, P499, DOI 10.1016/S0006-291X(84)80061-3; KAGEYAMA T, 1990, EUR J BIOCHEM, V193, P203, DOI 10.1111/j.1432-1033.1990.tb19324.x; KHOURI HE, 1988, ARCH BIOCHEM BIOPHYS, V265, P1, DOI 10.1016/0003-9861(88)90364-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARHER F, 1977, PHYTOCHEMISTRY, V16, P2019, DOI 10.1016/0031-9422(77)80117-9; LEE HS, 1978, ARCH BIOCHEM BIOPHYS, V185, P239, DOI 10.1016/0003-9861(78)90164-9; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; LILLO C, 1980, BIOCHEM PHYSIOL PFL, V175, P104, DOI 10.1016/S0015-3796(80)80047-3; MACNICOL PK, 1987, PLANT PHYSIOL, V83, P354, DOI 10.1104/pp.83.2.354; Maw GA, 1981, CHEM SULPHONIUM GR 2, P703; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; PAQUET L, 1994, AUST J PLANT PHYSIOL, V21, P37, DOI 10.1071/PP9940037; PREISIG CL, 1989, PLANT PHYSIOL, V91, P559, DOI 10.1104/pp.91.2.559; SCHLENK F, 1965, FORT CHEM ORG NAT, V23, P61; Segel I.H., 1975, ENZYME KINETICS; Somero G. N., 1992, Water and life: comparative analysis of water relationships at the organismic, cellular and molecular level. Tenth international conference on comparative physiology, Grans-sur-Serre, Switzerland, 15-17 Sep 1990., P3; TAKEMURA M, 1992, J BIOL CHEM, V267, P15687; Takhtajan A, 1969, FLOWERING PLANTS ORI; TOENNIES G, 1945, J AM CHEM SOC, V67, P849, DOI 10.1021/ja01221a046; WALTON NJ, 1994, PLANTA, V193, P9, DOI 10.1007/BF00191600; WEISIGER RA, 1979, ARCH BIOCHEM BIOPHYS, V196, P631, DOI 10.1016/0003-9861(79)90317-5; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; [No title captured]	44	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22344	22350		10.1074/jbc.270.38.22344	http://dx.doi.org/10.1074/jbc.270.38.22344			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673218	hybrid			2022-12-27	WOS:A1995RW31400045
J	KOERTE, A; CHONG, T; LI, XO; WAHANE, K; CAI, MJ				KOERTE, A; CHONG, T; LI, XO; WAHANE, K; CAI, MJ			SUPPRESSION OF THE YEAST MUTATION RFT1-1 BY HUMAN P53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE; PROTEIN; DNA; GROWTH; GENES; ASSOCIATION; IRRADIATION; RESISTANCE	Mutations in the gene encoding p53 have been found to be the most common genetic alterations in human cancer. p53 is thought to exert its function of tumor suppression through inhibition of cell proliferation or induction of apoptosis in response to DNA damage. Although there have been no proteins homologous to p53 identified in lower eucaryotic organisms, it is known that overexpression of mild-type human p53 can inhibit cell growth of Schizosaccharomyces pombe and Saccharomyces cerevisiae (Bischoff et al., 1992; Nigro et al., 1992), suggesting that certain aspects of p53 function may manifest or exist in yeast. In an attempt to identify the p53-like proteins in the yeast S. cerevisiae, we isolated a mutant that requires wild-type p53 for its viability. The mutant, rft1-1, is defective in cell cycle progression and arrests before mitosis when p53 protein is depleted. Genetic and biochemical studies show that p53 suppresses the rft1-1 mutation by forming a protein-protein complex with the Rft1 protein.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1986, CANCER CELL, V4, P387; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEDE W, 1994, GENETICS, V138, P271; SIKORSKI RS, 1989, GENETICS, V122, P19; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	46	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22556	22564		10.1074/jbc.270.38.22556	http://dx.doi.org/10.1074/jbc.270.38.22556			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673248	hybrid			2022-12-27	WOS:A1995RW31400077
J	MORIYAMA, Y; YAMAMOTO, A				MORIYAMA, Y; YAMAMOTO, A			VESICULAR L-GLUTAMATE TRANSPORTER IN MICROVESICLES FROM BOVINE PINEAL GLANDS - DRIVING-FORCE, MECHANISM OF CHLORIDE ANION ACTIVATION, AND SUBSTRATE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN SYNAPTIC VESICLES; CHROMAFFIN GRANULE MEMBRANES; PROTON PUMP; BINDING-SITE; AMINO-ACIDS; H+-ATPASE; RAT-BRAIN; SYSTEM; RECONSTITUTION; PURIFICATION	Pinealocytes, endocrine cells that synthesize and secrete melatonin, possess a large number of synaptic-like microvesicles (MVs) containing the L-glutamate transporter (Moriyama, Y., and Yamamoto, A. (1995) FEBS Left., 367, 233-236). In this study, the L-glutamate transporter in MVs isolated from bovine pineal glands was characterized as to its driving force, requirement of anions, and substrate specificity. Upon the addition of ATP, the MVs accumulated L-glutamate. The uptake was significantly dependent on the extravesicular Cl- concentration, being negligible in the absence of Cl- and maximum at 25 mM and decreasing gradually at 20-100 mM. The membrane potential (inside positive) was maximum at 0-10 mM Cl- and then decreased gradually depending on the Cl- concentration, whereas a pH gradient was practically absent without Cl- and increased gradually up to 100 mw Cl-. Ammonium acetate or nigericin plus K+, a dissipator of a pH gradient, had little effect on or was slightly stimulatory toward the uptake, whereas valinomycin plus K+ inhibited both formation of the membrane potential and the glutamate uptake to similar extents. The ATP- and Cl--dependent glutamate uptake was inhibited by fluoride, iodide, or thiocyanate, without vacuolar HC-ATPase being affected. An anion channel blocker, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, similarly inhibited the glutamate uptake in a Cl- protectable manner. Furthermore, ATP- and glutamate-dependent acidification of MVs was observed when 4 mM Cl- was present. Among more than 50 kinds of glutamate analogues tested, only a few compounds, including 1-aminocyclohexane-trans-1,3-dicarboxylic acid, caused similar acidification. A good correlation was observed between the acidification and the inhibition of glutamate uptake by glutamate analogues. These results indicated that 1) the major driving force of the glutamate uptake is the membrane potential, 2) Cl- regulates the glutamate uptake, probably via anion-binding site(s) on the transporter, and 3) the transporter shows strict substrate specificity. Hence, the overall properties of the vesicular glutamate transporter in the MVs well matched those of the synaptic vesicle glutamate transporter. We concluded that the vesicular glutamate transporter, being similar if not identical to the neuronal counterpart, operates in endocrine cells.	KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	MORIYAMA, Y (corresponding author), HIROSHIMA UNIV,FAC SCI,GRAD DEPT GENE SCI,BIOL MARINE LAB,HIROSHIMA 722,JAPAN.							ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; CIDON S, 1989, J BIOL CHEM, V264, P8281; DEVIES SH, 1993, CELL S, V72, P139; DUNLOP J, 1991, NEUROREPORT, V2, P377, DOI 10.1097/00001756-199107000-00005; EDABI M, 1986, ADV PINEAL RES, P99; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOVITRAPONG P, 1988, NEUROCHEM INT, V13, P223, DOI 10.1016/0197-0186(88)90058-7; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KARASEK M, 1992, MICROSC RES TECHNIQ, V21, P136, DOI 10.1002/jemt.1070210206; KUS L, 1994, J NEUROCHEM, V62, P2241; KUS L, 1993, J PINEAL RES, V14, P39, DOI 10.1111/j.1600-079X.1993.tb00483.x; MALVIN PV, 1993, MAMMALIAN NEUROENDOC, P141; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MORIYAMA Y, 1995, J BIOL CHEM, V270, P11424, DOI 10.1074/jbc.270.19.11424; MORIYAMA Y, 1995, FEBS LETT, V367, P233, DOI 10.1016/0014-5793(95)00559-R; MORIYAMA Y, 1990, J BIOCHEM, V108, P689, DOI 10.1093/oxfordjournals.jbchem.a123264; MORIYAMA Y, 1992, J EXP BIOL, V172, P171; MORIYAMA Y, 1982, J BIOCHEM-TOKYO, V92, P1333, DOI 10.1093/oxfordjournals.jbchem.a134053; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OKSCHE A, 1986, PINEAL RETINAL RELAT, P1; REDECKER P, 1993, J NEUROSCI RES, V34, P79, DOI 10.1002/jnr.490340109; REITER RJ, 1981, AM J ANAT, V162, P287, DOI 10.1002/aja.1001620402; ROSETH S, 1995, NEUROSCI LETT, V183, P62, DOI 10.1016/0304-3940(94)11115-Y; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; TABB JS, 1992, J BIOL CHEM, V267, P15412; TABB JS, 1991, J NEUROSCI, V11, P1822; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; TOLL L, 1980, J BIOL CHEM, V255, P1787; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Ueda T, 1986, EXCITATORY AMINO ACI, P173; VANDYKE RW, 1988, J BIOL CHEM, V263, P2603; VANWYK E, 1994, MED SCI RES, V22, P635; WINTER HC, 1993, NEUROCHEM RES, V18, P79, DOI 10.1007/BF00966925; XIE XS, 1989, J BIOL CHEM, V264, P18870	46	83	84	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22314	22320		10.1074/jbc.270.38.22314	http://dx.doi.org/10.1074/jbc.270.38.22314			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673214	hybrid			2022-12-27	WOS:A1995RW31400041
J	RANEY, KD; BENKOVIC, SJ				RANEY, KD; BENKOVIC, SJ			BACTERIOPHAGE-T4 DDA HELICASE TRANSLOCATES IN A UNIDIRECTIONAL FASHION ON SINGLE-STRANDED-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI REP; GENE-41 PROTEIN; PURIFICATION; REPLICATION; BINDING; OVEREXPRESSION; SEQUENCE	The T4 bacteriophage Dda helicase is believed to be involved in early events in T4 DNA replication and has been shown to stimulate genetic recombination processes in vitro. Dda unwinds double-stranded DNA with 5' to 3' polarity but its ability to translocate on DNA has not been established. The DNA stimulated ATPase activity of Dda helicase has been used to probe translocation on single-strand DNA (ssDNA). Dda exhibits higher ATPase activity in the presence of poly(dT) than oligo(dT)(16), indicating that Dda translocates on ssDNA. Oligonucleotides containing biotin/streptavidin blocks on the 5' or 3' end were used to probe directionality of translocation. The K-act (K-m for DNA) for Dda ATPase activity was reduced in the presence of a streptavidin block. on the 3' end, whereas a streptavidin block on the 5' end had only a small effect on the steady-state ATPase parameters. These results suggest that Dda translocates unidirectionally in a 5' to 3' manner and upon encountering the block remains bound 60 the oligonucleotide rather than sliding off the 3' end. The direction of translocation on ssDNA is consistent with the direction in which Dda unwinds duplex DNA and is not dependent on duplex structure.	PENN STATE UNIV,DEPT CHEM,DAVEY LAB 152,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIEHS NIH HHS [ES05576] Funding Source: Medline; NIGMS NIH HHS [GM13306] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005576] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARRY J, 1994, J BIOL CHEM, V269, P33063; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; CHAMBERLIN MJ, 1965, FED PROC, V24, P1446; CHAO KL, 1990, J BIOL CHEM, V265, P1067; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GAUSS P, 1994, J BACTERIOL, V176, P1667, DOI 10.1128/jb.176.6.1667-1672.1994; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; HACKER KJ, 1992, J BIOL CHEM, V267, P20674; JONGENEEL CV, 1984, J BIOL CHEM, V259, P2925; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KRELL H, 1979, EUR J BIOCHEM, V93, P387, DOI 10.1111/j.1432-1033.1979.tb12835.x; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MAINE IP, 1994, BIOCHEM BIOPH RES CO, V198, P1070, DOI 10.1006/bbrc.1994.1152; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; NOTARNICOLA SM, 1994, J CELL BIOCHEM, V18, P153; PANUSKA JR, 1980, J BIOL CHEM, V225, P5208; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSO PO, 1966, BIOCHEMISTRY-US, V5, P4153, DOI 10.1021/bi00876a052; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	32	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22236	22242		10.1074/jbc.270.38.22236	http://dx.doi.org/10.1074/jbc.270.38.22236			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673202	hybrid			2022-12-27	WOS:A1995RW31400028
J	WANG, G; GLAZER, PM				WANG, G; GLAZER, PM			ALTERED REPAIR OF TARGETED PSORALEN PHOTOADDUCTS IN THE CONTEXT OF AN OLIGONUCLEOTIDE-MEDIATED TRIPLE-HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; FORMING-OLIGONUCLEOTIDES; ESCHERICHIA-COLI; GENE-EXPRESSION; SHUTTLE VECTOR; CROSS-LINKS; DNA; INHIBITION; BINDING; MUTAGENESIS	Oligonucleotides can bind as third strands of DNA in a sequence-specific manner to form triple helices, Psoralen-conjugated, tripler-forming oligonucleotides (TFOs) have been used for the site-specific modification of DNA to inhibit transcription and to target mutations to selected genes. Such strategies, however, must take into account the ability of the cell to repair the triplex-directed lesion, We report experiments showing that the pattern of mutations produced by tripler-targeted psoralen adducts in an SV40 shuttle vector in monkey COS cells can be influenced by the associated third strand, Mutations induced by psoralen adducts in the context of a TFO of length 10 were the same as those generated by isolated adducts but were found to be different from those generated in the presence of a TFO of length 30 at the same target site, In complementary experiments, HeLa whole cell extracts were used to directly assess repair of the TFO-directed psoralen adducts in vitro, Excision of the damaged DNA was inhibited in the context of the 30-mer TFO, but not the 10-mer, These results suggest that an extended triple helix of length 30, which exceeds the typical size of the nucleotide excision repair patch in mammalian cells, can alter repair of an associated psoralen adduct, We present a model correlating these results and proposing that the incision steps in nucleotide excision repair in mammalian cells can be blocked by the presence of a third strand of sufficient length and binding affinity, thereby changing the pattern of mutations, These results may have implications for the use of tripler-forming oligonucleotides for genetic manipulation, and they may lead to the use of such oligonucleotides as tools to probe DNA repair pathways.	YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06520	Yale University			Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560	NATIONAL CANCER INSTITUTE [R01CA064186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005775, R01ES005775] Funding Source: NIH RePORTER; NCI NIH HHS [CA64186] Funding Source: Medline; NIEHS NIH HHS [ES05775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BROITMAN SL, 1987, P NATL ACAD SCI USA, V84, P5120, DOI 10.1073/pnas.84.15.5120; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DEGOLS G, 1994, J BIOL CHEM, V269, P16933; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; GASPARRO FP, 1994, NUCLEIC ACIDS RES, V22, P2845, DOI 10.1093/nar/22.14.2845; GLAZER PM, 1986, P NATL ACAD SCI USA, V83, P1041, DOI 10.1073/pnas.83.4.1041; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HAVRE PA, 1993, P NATL ACAD SCI USA, V90, P7879, DOI 10.1073/pnas.90.16.7879; HAVRE PA, 1993, J VIROL, V67, P7324, DOI 10.1128/JVI.67.12.7324-7331.1993; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES BK, 1990, J BIOL CHEM, V265, P3489; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; PARRIS CN, 1992, GENE, V117, P1, DOI 10.1016/0378-1119(92)90482-5; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; REARDON JT, 1991, NUCLEIC ACIDS RES, V19, P4623, DOI 10.1093/nar/19.17.4623; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SANDOR Z, 1994, NUCLEIC ACIDS RES, V22, P2051, DOI 10.1093/nar/22.11.2051; SLADEK FM, 1989, P NATL ACAD SCI USA, V86, P3982, DOI 10.1073/pnas.86.11.3982; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; THOMAS DC, 1988, P NATL ACAD SCI USA, V85, P3723, DOI 10.1073/pnas.85.11.3723; WANG G, 1995, MOL CELL BIOL, V15, P1759; WOOD RD, 1985, J MOL BIOL, V184, P577, DOI 10.1016/0022-2836(85)90304-3; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	35	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22595	22601		10.1074/jbc.270.38.22595	http://dx.doi.org/10.1074/jbc.270.38.22595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673252	hybrid			2022-12-27	WOS:A1995RW31400082
J	YBARRA, J; HOROWITZ, PM				YBARRA, J; HOROWITZ, PM			REFOLDING AND REASSEMBLY OF ACTIVE CHAPERONIN GROEL AFTER DENATURATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE LIVER RHODANESE; CPN60	Conditions are reported that, for the first time, permit the folding and assembly of active chaperonin, GroEL, following denaturation in 8 at urea. The folding could be achieved by dilution or dialysis, and the best yields required the simultaneous presence of ammonium sulfate and the Mg2+ complexes of ATP or ADP, Ammonium sulfate was the key to this particular protocol, since there was a small recovery of oligomer in its presence, but no detectable recovery was induced by ATP or ADP without ammonium sulfate, The refolded/reassembled GroEL could arrest the spontaneous folding of rhodanese, and it could participate in the chaperonin-assisted refolding of rhodanese as effectively as GroEL that had never been unfolded, The results demonstrate that the primary sequence of GroEL contains the information required far its folding, assembly, and function, Thus, in contrast to previous studies, although chaperonins may facilitate GroEL folding, they are not necessary for the acquisition of the functional oligomeric state of this chaperone, This ability to fold denatured GroEL in vitro will facilitate studies of the influences that determine the interesting folding pattern adopted by the native protein.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLUBINOFF P, 1989, NATURE, V337, P44; HAYERHARTL MK, 1993, FEBS LETT, V320, P83, DOI 10.1016/0014-5793(93)81663-K; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LISSIN NM, 1993, FEBS LETT, V324, P41, DOI 10.1016/0014-5793(93)81528-8; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MENDOZA JA, 1995, BBA-PROTEIN STRUCT M, V1247, P209, DOI 10.1016/0167-4838(94)00231-5; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; PRICE NC, 1993, BIOCHIM BIOPHYS ACTA, V1161, P52, DOI 10.1016/0167-4838(93)90195-W; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, FEBS LETT, V334, P129; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363	19	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22113	22115		10.1074/jbc.270.38.22113	http://dx.doi.org/10.1074/jbc.270.38.22113			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673187	hybrid			2022-12-27	WOS:A1995RW31400010
J	LAMBERT, B; JESTIN, JL; BREHIN, P; OLEYKOWSKI, C; YEUNG, AT; MAILLIET, P; PRETOT, C; LEPECQ, JB; JACQUEMINSABLON, A; CHOTTARD, JC				LAMBERT, B; JESTIN, JL; BREHIN, P; OLEYKOWSKI, C; YEUNG, AT; MAILLIET, P; PRETOT, C; LEPECQ, JB; JACQUEMINSABLON, A; CHOTTARD, JC			BINDING OF THE ESCHERICHIA-COLI UVRAB PROTEINS TO THE DNA MONOADDUCTS AND DIADDUCTS OF CIS-[N-2-AMINO-N-2-METHYLAMINO-2,2,1-BICYCLOHEPTANE]DICHLOROPLATINUM(II) AND CISPLATIN - ANALYSIS OF THE FACTORS CONTROLLING RECOGNITION AND PROOF OF MONOADDUCT-MEDIATED UVRB-DNA CROSS-LINKING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CISPLATIN; DAMAGED DNA; PLATINUM COMPLEXES; (A)BC EXCINUCLEASE; EXCISION NUCLEASE; ANTITUMOR AGENTS; ABC EXCINUCLEASE; REPAIR SYNTHESIS; ADDUCTS; INVITRO	The interactions of the Escherichia coli endonuclease UvrAB proteins with the DNA mono- and diadducts of both the cis-racemic exo-[N-2-amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II (complex (1) under bar) and cisplatin (cis-diamminedichloroplatinum(II) (cis-DDP)), have been studied, Complex (1) under bar reacts faster with DNA than cis-DDP and gives monoadducts with a longer lifetime (8 h 20 min chelation t(1/2) compared with 2 h 40 min for cis-DDP), Using pSP65 plasmid [H-3]DNA, the filter binding assay was associated with the analysis of the nucleoprotein complexes to characterize the UvrAB recognition of the platinum adducts and to demonstrate the occurrence of platinum-mediated DNA-protein cross-linking, First, it is shown that the UvrAB proteins recognize the complex (1) under bar mono- and diadducts with a higher affinity than those of cis-DDP. Fifteen times more cis-DDP adducts per plasmid are required than complex (1) under bar adducts, to lead to similar UvrAB binding, However, the UvrAB proteins recognize monoadducts and diadducts of each complex with a similar affinity, Second, it is shown that UvrB is the protein involved in the nucleoprotein complexes formed from mono- and diadducts of complex (1) under bar and cis-DDP, This protein is also partly cross-linked to DNA with a similar efficiency by monoadducts derived from complex (1) under bar and cis-DDP, However, as UvrB has a greater affinity for the DNA adducts of complex (1) under bar than for those of cis-DDP, more UvrB-platinum-DNA cross-links are formed with complex 1 than with cis-DDP, This study, using a bacterial repair system as a model, points to a possible strategy for making new cytotoxic platinum complexes for mammalian cells.	UNIV PARIS 05,CNRS,URA 400,F-75270 PARIS 06,FRANCE; FOX CHASE CANC CTR,PHILADELPHIA,PA 19111; RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,INST BIOTECHNOL,F-94407 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Fox Chase Cancer Center; Sanofi-Aventis	LAMBERT, B (corresponding author), INST GUSTAVE ROUSSY,CNRS,URA 147,INSERM,U140,39 RUE CAMILLE DESMOULINS,F-94800 VILLEJUIF,FRANCE.		LAMBERT, Bernard/K-6207-2015		NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALAZARD R, 1982, MUTAT RES, V93, P327, DOI 10.1016/0027-5107(82)90148-8; ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BANCROFT DP, 1990, J AM CHEM SOC, V112, P6860, DOI 10.1021/ja00175a020; BAUER W, 1978, BIOCHEMISTRY-US, V17, P1060, DOI 10.1021/bi00599a019; BECK DJ, 1985, NUCLEIC ACIDS RES, V13, P7395, DOI 10.1093/nar/13.20.7395; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BERNGES F, 1991, NUCLEIC ACIDS RES, V19, P1483, DOI 10.1093/nar/19.7.1483; BRABEC V, 1994, BIOCHEMISTRY-US, V33, P1316, DOI 10.1021/bi00172a005; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; CHAO CCK, 1991, MOL CELL BIOL, V11, P2075, DOI 10.1128/MCB.11.4.2075; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; CHU G, 1994, J BIOL CHEM, V269, P787; DJURAN MI, 1991, INORG CHEM, V30, P2648, DOI 10.1021/ic00012a016; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EASTMAN A, 1987, CHEM-BIOL INTERACT, V61, P241, DOI 10.1016/0009-2797(87)90004-4; FARRELL N, 1992, CANCER RES, V52, P5065; FILIPSKI J, 1979, SCIENCE, V204, P181, DOI 10.1126/science.571145; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; HOLLIS LS, 1989, J MED CHEM, V32, P128, DOI 10.1021/jm00121a024; HOLLIS LS, 1991, CANCER RES, V51, P1866; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; HUSAIN I, 1985, J BACTERIOL, V163, P817, DOI 10.1128/JB.163.3.817-823.1985; JOHNSON NP, 1980, CHEM-BIOL INTERACT, V30, P151, DOI 10.1016/0009-2797(80)90122-2; JONES JC, 1991, J BIOL CHEM, V266, P7101; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KOZELKA J, 1986, INORG CHEM, V25, P1075, DOI 10.1021/ic00228a002; LAMBERT B, 1989, P NATL ACAD SCI USA, V86, P6557, DOI 10.1073/pnas.86.17.6557; LIN JJ, 1992, J BIOL CHEM, V267, P17693; MAILLIET P, 1994, ANTI-CANCER DRUG DES, V10, P51; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PAGE JD, 1990, BIOCHEMISTRY-US, V29, P1016, DOI 10.1021/bi00456a026; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SEGALBENDIRDJIA.E, 1991, PLATINUM OTHER METAL, P37; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1991, J BIOL CHEM, V266, P7609; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; VOIGT JM, 1989, J BIOL CHEM, V264, P5172; WALTER RB, 1988, J MOL BIOL, V203, P939, DOI 10.1016/0022-2836(88)90119-2; WOODBURY CP, 1983, BIOCHEMISTRY-US, V22, P4730, DOI 10.1021/bi00289a018; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	49	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21251	21257		10.1074/jbc.270.36.21251	http://dx.doi.org/10.1074/jbc.270.36.21251			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673159	hybrid			2022-12-27	WOS:A1995RU05400059
J	AMARATUNGA, A; MORIN, PJ; KOSIK, KS; FINE, RE				AMARATUNGA, A; MORIN, PJ; KOSIK, KS; FINE, RE			INHIBITION OF KINESIN SYNTHESIS AND RAPID ANTEROGRADE AXONAL-TRANSPORT IN-VIVO BY AN ANTISENSE OLIGONUCLEOTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; MONOCLONAL-ANTIBODIES; HEAVY-CHAIN; PROTEINS; IDENTIFICATION; MICROTUBULES; MOTILITY; CELLS; EXPRESSION; INVITRO	Synthetic antisense oligonucleotides have been used to inhibit specific protein synthesis in vivo. Antisense oligonucleotides directed to kinesin heavy chain were injected into the vitreous of anesthetized rabbits in order to assess the effects on transport in the retinal ganglion cells whose axons form the optic nerve. The antisense oligonucleotide specifically inhibited retinal kinesin synthesis by 82 +/- 7% (n = 4). The rapid axonal transport of the membrane proteins into the optic nerve was concomitantly inhibited by 70 +/- 10% (n = 4). These results provide direct evidence for the specific role of kinesin in rapid anterograde transport in vivo and indicate the utility of antisense oligonucleotides to explore neuronal dynamics in a specific neuronal cell type in a living animal.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,CTR NEUROL DIS,BOSTON,MA 02115; EDITH NOURSE ROGERS MEM VET ADM HOSP,BEDFORD,MA 01730	Boston University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL EYE INSTITUTE [R01EY008535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029031] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY 08535] Funding Source: Medline; NINDS NIH HHS [R01NS 29031] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZAWA H, 1992, J CELL BIOL, V119, P1069; BAITINGER C, 1987, J NEUROSCI, V7, P3723; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; GIOLLI RA, 1969, J COMP NEUROL, V136, P99, DOI 10.1002/cne.901360107; GUILLERY RW, 1986, TRENDS NEUROSCI, V9, P364, DOI 10.1016/0166-2236(86)90115-3; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JAMES DE, 1987, J BIOL CHEM, V262, P11817; KUZNETSOV SA, 1989, J BIOL CHEM, V264, P589; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; MORIN PJ, 1991, J NEUROCHEM, V56, P415, DOI 10.1111/j.1471-4159.1991.tb08167.x; MORIN PJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P275, DOI 10.1016/0005-2736(93)90366-8; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PENNINGROTH SM, 1987, FEBS LETT, V222, P204, DOI 10.1016/0014-5793(87)80220-X; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WAGNER JA, 1979, BRAIN RES, V168, P97, DOI 10.1016/0006-8993(79)90130-6; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	25	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1993	268	23					17427	17430						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LQ988	7688725				2022-12-27	WOS:A1993LQ98800080
J	KOH, J; SFERRA, TJ; COLLINS, FS				KOH, J; SFERRA, TJ; COLLINS, FS			CHARACTERIZATION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROMOTER REGION - CHROMATIN CONTEXT AND TISSUE-SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TRANSCRIPTS; LOCUS ACTIVATION REGION; HYPERSENSITIVE SITES; MAMMALIAN-CELLS; DNASE-I; INITIATOR CODON; DOWN-REGULATION; GENE; EXPRESSION; SEQUENCE	Expression of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) is tightly regulated. Using a panel of cell lines expressing different levels of CFTR mRNA, we investigated the mechanisms mediating control of CFTR transcription. In highly expressing cells, multiple sites of transcription initiation can be identified between positions -95 and +50 of the CFTR gene, and an alternatively initiated splice variant transcript is also present. Non-epithelial cell lines expressing very low levels of CFTR utilize a start site at -32. Promoter sequence elements from -83 to +111 are at least partially responsible for dictating CFTR transcriptional tissue-specificity, while multiple elements located farther 5' augment promoter strength. Analysis of the chromatin structure and methylation status of the CFTR promoter region reveals cell line differences which correlate with expression levels, suggesting that the physical context of the CFTR gene in vivo may contribute significantly to appropriate regulation of CFTR transcription. Taken together, these findings indicate that cellular control of CFTR gene expression is likely to be a complex function of several overlapping regulatory pathways.	UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PEDIAT & COMMUN DIS, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NICHD NIH HHS [HD-22297] Funding Source: Medline; NIDDK NIH HHS [DK 42718, DK 39690] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042718, R01DK039690] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGON J, 1992, MOL CELL BIOL, V12, P1872, DOI 10.1128/MCB.12.4.1872; BARGON J, 1992, J BIOL CHEM, V267, P16056; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BOORSTEIN WR, 1989, METHOD ENZYMOL, V180, P347; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; BREUER W, 1992, J BIOL CHEM, V267, P10465; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU JL, 1991, J BIOL CHEM, V266, P24471; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HARRIS A, 1991, DEVELOPMENT, V113, P305; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTROSERAFIZADEH C, 1992, J BIOL CHEM, V267, P19299; MORANDI C, 1982, J MOL BIOL, V156, P583, DOI 10.1016/0022-2836(82)90268-6; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; NIENHUIS AW, 1987, MOL BASIS BLOOD DISE, P28; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PINTO M, 1983, BIOL CELL, V47, P323; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; STRONG TV, 1990, PEDIATR PULMON S, V5, P195; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; Tsui L C, 1991, Adv Hum Genet, V20, P153; Tsui LC, 1991, ADV HUM GENET, V20, P311; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; WU C, 1979, CELL, V16, P797, DOI 10.1016/0092-8674(79)90095-3; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	53	85	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15912	15921						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7688000				2022-12-27	WOS:A1993LN30500084
J	OH, YM; MULLER, HL; LAMSON, G; ROSENFELD, RG				OH, YM; MULLER, HL; LAMSON, G; ROSENFELD, RG			INSULIN-LIKE GROWTH-FACTOR (IGF)-INDEPENDENT ACTION OF IGF-BINDING PROTEIN-3 IN HS578T HUMAN BREAST-CANCER CELLS - CELL-SURFACE BINDING AND GROWTH-INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN FIBROBLASTS; CHRONIC-RENAL-FAILURE; FACTOR-I; MOLECULAR-CLONING; CARRIER PROTEINS; HUMAN-SERUM; FACTOR-BETA; RECEPTOR; IDENTIFICATION; EXPRESSION	Estrogen receptor-negative Hs578T human breast cancer cells secrete insulin-like growth factor binding protein (IGFBP)-3 and IGFBP-4 as major binding protein (BP) species. Our previous immunohistochemical studies (Oh, Y., Muller, H. L., Pham, H., Lamson, G., and Rosenfeld, R. G. (1992) Endocrinology 131, 3123-3125) have demonstrated the existence of cell surface-associated IGFBP-3 and release of cell surface-associated IGFBP-3 into conditioned media by addition of IGF peptide in Hs578T cells. In this study, we have demonstrated that IGFBP-3 binding on the cell surface is specific and receptor-mediated, by showing: 1) a dose-dependent increase of IGFBP-3 binding by addition of divalent cations (CaCl2 and MnCl2); 2) dose-dependent competition of I-125-IGFBP-3E. coli by unlabeled IGFBP-3E.coli (>80% competition at 100 nM), but not by IGFBP-1 or fibronectin. In addition, exogenous IGFBP-3 treatment resulted in a significant inhibitory effect on monolayer growth of Hs578T cells. This inhibitory effect of IGFBP-3 was shown to be specific and IGF-independent by demonstrating: 1) dose-dependent inhibition on cell growth (60% inhibition at 20 nM) and inhibition on DNA synthesis (10 nM; p < 0.05, 20 nM; p < 0.005) by exogenous IGFBP-3E.coli, but not by IGFBP- 1; 2) absence of stimulatory effects on monolayer cell growth by either native IGFs or IGF analogs which have significantly decreased affinity for IGFBPs, but retain full affinity for type 1 and 2 IGF receptors; 3) significant diminution of the IGFBP-3 inhibitory effects on monolayer growth by coincubation with native IGFs, but not by coincubation with IGF analogs with decreased affinity for IGFBP-3. In conclusion, exogenous IGFBP-3 shows specific binding on the cell surface and can inhibit Hs578T cell monolayer growth by itself, suggesting the existence of specific membrane-associated proteins or receptors for IGFBP-3. Furthermore, IGF-I and -II can attenuate inhibitory effect of IGFBP-3 by forming IGF.IGFBP-3 complexes, thereby preventing cell surface binding of IGFBP-3.			OH, YM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV PEDIAT ENDOCRINOL,ROOM S306,STANFORD,CA 94305, USA.		müller, Hermann l/AAC-1637-2020	Muller, Hermann L./0000-0003-4929-9966	NCI NIH HHS [CA58110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACHRACH LK, 1989, ENDOCRINOLOGY, V125, P2831, DOI 10.1210/endo-125-6-2831; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BINOUX M, 1988, J CLIN ENDOCR METAB, V67, P509, DOI 10.1210/jcem-67-3-509; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CARA JF, 1990, J BIOL CHEM, V265, P17820; CEDA GP, 1992, ENDOCRINOLOGY, V130, P1483, DOI 10.1210/en.130.3.1483; CEDA GP, 1991, ENDOCRINOLOGY, V128, P249; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, ENDOCRINOLOGY, V126, P3139, DOI 10.1210/endo-126-6-3139; CONOVER CA, 1986, BIOCHEM BIOPH RES CO, V139, P501, DOI 10.1016/S0006-291X(86)80019-5; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DELBE J, 1990, J CELL PHYSIOL, V142, P359, DOI 10.1002/jcp.1041420219; DELBE J, 1991, BIOCHEM BIOPH RES CO, V179, P495, DOI 10.1016/0006-291X(91)91398-V; DELEON DD, 1989, MOL ENDOCRINOL, V3, P567, DOI 10.1210/mend-3-3-567; DELEON DD, 1990, J CLIN ENDOCR METAB, V71, P530, DOI 10.1210/jcem-71-2-530; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DEVROEDE MA, 1986, J CLIN INVEST, V77, P602, DOI 10.1172/JCI112343; EDWARDS JG, 1988, J CELL SCI, V89, P507; ELENIUS K, 1990, J BIOL CHEM, V265, P17837; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; FURLANETTO RW, 1984, CANCER RES, V44, P2122; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3041; HOSSENLOPP P, 1986, FEBS LETT, V208, P439, DOI 10.1016/0014-5793(86)81065-1; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMSON G, 1989, J CLIN ENDOCR METAB, V69, P852, DOI 10.1210/jcem-69-4-852; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; LIU L, 1992, J CELL PHYSIOL, V153, P15, DOI 10.1002/jcp.1041530104; LOTAN R, 1979, CANCER RES, V39, P1014; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; MARTIN JL, 1988, ENDOCRINOLOGY, V123, P1907, DOI 10.1210/endo-123-4-1907; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MINNITI CP, 1992, J BIOL CHEM, V267, P9000; MONDSCHEIN JS, 1990, ENDOCRINOLOGY, V127, P2298, DOI 10.1210/endo-127-5-2298; MORIWAKE T, 1992, ENDOCRINOLOGY, V130, P1071, DOI 10.1210/en.130.2.1071; NEELY EK, 1992, ENDOCRINOLOGY, V130, P985, DOI 10.1210/en.130.2.985; NISHIMOTO I, 1987, BIOCHEM BIOPH RES CO, V142, P275, DOI 10.1016/0006-291X(87)90481-5; OH Y, 1991, BIOCHEM J, V278, P249, DOI 10.1042/bj2780249; OH Y, 1992, ENDOCRINOLOGY, V131, P3123, DOI 10.1210/en.131.6.3123; OH Y, 1993, GROWTH REGULAT, V3, P84; POWELL DR, 1986, J CLIN ENDOCR METAB, V63, P1186; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSENFELD RG, 1986, BIOCHEM BIOPH RES CO, V138, P304, DOI 10.1016/0006-291X(86)90280-9; ROSENFELD RG, 1989, J CLIN ENDOCR METAB, V68, P638, DOI 10.1210/jcem-68-3-638; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; RUTANEN EM, 1988, J CLIN ENDOCR METAB, V66, P173, DOI 10.1210/jcem-66-1-173; SCHMID C, 1989, FEBS LETT, V244, P328, DOI 10.1016/0014-5793(89)80556-3; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SMITH EP, 1990, ENDOCRINOLOGY, V127, P2744, DOI 10.1210/endo-127-6-2744; SMITH EP, 1992, ENDOCRINOLOGY, V131, P2733, DOI 10.1210/en.131.6.2733; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; WOOD WI, 1988, MOL ENDOCRINOL, V2, P1176, DOI 10.1210/mend-2-12-1176; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	76	470	479	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14964	14971						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686909				2022-12-27	WOS:A1993LL75900065
J	GAIDA, FJ; PIEPER, D; RODER, UW; SHIVELY, JE; WAGENER, C; NEUMAIER, M				GAIDA, FJ; PIEPER, D; RODER, UW; SHIVELY, JE; WAGENER, C; NEUMAIER, M			MOLECULAR CHARACTERIZATION OF A CLONED IDIOTYPIC CASCADE CONTAINING A NETWORK ANTIGENIC DETERMINANT SPECIFIC FOR THE HUMAN CARCINOEMBRYONIC ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION ACTIVITY; ESCHERICHIA-COLI; ANTIBODY; SEQUENCE; DOMAINS; NCA; CLONING; SURFACE; SITES; GENES	The monoclonal anti-idiotypic antibody (maId) 6G6.C4, directed against the carcinoembryonic antigen (CEA)-specific T84.66 immunoglobulin, was recently shown to act as a surrogate antigen for CEA in experimental animals. In this report, we have extended our studies. 1) The kinetics of complex formation in this CEA-specific idiotypic cascade were investigated using Biosensor technology. 2) Bacterial expression studies show that the mimicked epitope can be delimited to the A3 domain of CEA. 3) We cloned and characterized the genes coding for maId 6G6.C4. 4) Comparison of this epitope-bearing domain with the hypervariable region sequences of 6G6.C4 yields substantial amino acid similarity. Sequence homology between maId 6G6.C4 and anti-CEA antibodies binding to the T84.66 epitope led us to investigate the interaction of maId 6G6.C4 and CEA. Surprisingly, 6G6.C4 specifically binds to CEA but not CEA-related antigens in Western blots. 6G6.C4 and T84.66 recognize different epitopes on CEA. Our results suggest that the T84.66 epitope functionally mimicked by maId 6G6.C4 may be involved in the homophilic binding between CEA molecules, and that heterophilic interactions in the CEA-family are mediated by different binding sites. A model for the intermolecular adhesion of CEA is presented.	UNIV HAMBURG,KRANKENHAUS EPPENDORF,MED CLIN,DEPT CLIN CHEM,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; PHARMACIA BIOSYST,W-7800 FREIBURG,GERMANY; CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010	University of Hamburg; City of Hope; Beckman Research Institute of City of Hope								ATTANASIO R, 1993, MOL IMMUNOL, V30, P9, DOI 10.1016/0161-5890(93)90421-7; BATES PA, 1992, FEBS LETT, V301, P207, DOI 10.1016/0014-5793(92)81249-L; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; CABILLY S, 1984, P NATL ACAD SCI-BIOL, V81, P3273, DOI 10.1073/pnas.81.11.3273; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; EATON S, 1987, P NATL ACAD SCI USA, V84, P7637; GAIDA FJ, 1992, INT J CANCER, V51, P459, DOI 10.1002/ijc.2910510320; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GIANNETTI BM, 1986, FRESEN Z ANAL CHEM, V324, P253, DOI 10.1007/BF00487899; HAMMARSTROM S, 1989, CANCER RES, V49, P4852; HASS GM, 1991, CANCER RES, V51, P1876; HASTINGS A, 1992, CANCER RES, V52, P1681; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; IKEDA S, 1992, MOL IMMUNOL, V29, P229; KUROKI M, 1992, IMMUNOL INVEST, V21, P241, DOI 10.3109/08820139209072262; MARSTON FAO, 1984, BIO-TECHNOL, V2, P800, DOI 10.1038/nbt0984-800; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; NAP M, 1992, CANCER RES, V52, P2329; NEUMAIER M, 1988, J BIOL CHEM, V263, P3202; NEUMAIER M, 1990, CANCER RES, V50, P2128; OIKAWA S, 1987, BIOCHEM BIOPH RES CO, V142, P511, DOI 10.1016/0006-291X(87)90304-4; OIKAWA S, 1989, BIOCHEM BIOPH RES CO, V164, P39, DOI 10.1016/0006-291X(89)91679-3; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; RAYCHAUDHURI S, 1990, J IMMUNOL, V145, P760; Sambrook J, 1989, MOL CLONING LABORATO; SIKORSKA HM, 1988, J BIOL RESP MODIF, V7, P327; TAUB R, 1992, J BIOL CHEM, V267, P5977; TSUJISAKI M, 1993, J IMMUNOL, V150, P508; WAGENER C, 1983, J IMMUNOL, V130, P2302; WAGENER C, 1990, METHOD ENZYMOL, V184, P507; WETTENDORFF M, 1989, P NATL ACAD SCI USA, V86, P3787, DOI 10.1073/pnas.86.10.3787; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	36	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14138	14145						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686150				2022-12-27	WOS:A1993LJ82500054
J	LEE, VH; SCHWOEBEL, E; PRASAD, S; CHEUNG, P; TIMMONS, TM; COOK, R; DUNBAR, BS				LEE, VH; SCHWOEBEL, E; PRASAD, S; CHEUNG, P; TIMMONS, TM; COOK, R; DUNBAR, BS			IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF THE 75-KDA RABBIT ZONA-PELLUCIDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SPERM RECEPTOR; ANTIGEN PPZA; PORCINE; ZP3; HETEROIMMUNIZATION; ALLOIMMUNIZATION; PROTEOGLYCAN; EXPRESSION; ANTIBODIES; FERTILITY	A cDNA (rc75) encoding a 75-kDa rabbit zona pellucida (ZP) glycoprotein (R75) has been cloned and sequenced. The predicted amino acid sequence consists of 676 amino acids including seven potential N-glycosylation sites. The cDNA hybridizes to a 2.4-kilobase mRNA in ovary that is not detectable in other rabbit tissues. The R75 mRNA was also found to be expressed during the early stages of rabbit ovarian development (2-6 weeks of age) when the ovary contains primordial, primary, and early secondary follicles. The deduced amino acid sequence of rc75 has 77% similarity to the mouse ZP2 protein but no similarity to mouse ZP3. R75 also contains regions with 35-55% similarity to a previously cloned rabbit 55-kDa ZP protein. Monte Carlo simulation comparison confirmed that R75 has a significant probability of homology with mouse ZP2 and the rabbit 55-kDa ZP protein. Antibodies were developed against a fragment of R75 (rc75a cDNA) expressed in the pEX expression vector. These antibodies were used to confirm that the expressed protein contained epitopes found in the native rabbit ZP glycoprotein. These data suggest that some, but not all, ZP proteins may be conserved among different species and that within a species ZP proteins may share similar regions.	BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	DUNBAR, BS (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.							ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; BARKER WC, 1972, ATLAS PROTEIN SEQUEN, P101; BENSON S A, 1984, Biotechniques, V2, P126; BYARS NE, 1991, VACCINE, V9, P309, DOI 10.1016/0264-410X(91)90056-C; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dunbar B.S., 1983, P139; Dunbar B. S., 1991, A comparative overview of mammalian fertilization., P97; DUNBAR BS, 1981, BIOL REPROD, V24, P1111; DUNBAR BS, 1984, MODERN CELL BIOL, P71; DUNBAR BS, 1987, 2 DIMENSIONA ELECTRO; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KINLOCH RA, 1990, DEV BIOL, V142, P414, DOI 10.1016/0012-1606(90)90363-N; KINLOCH RA, 1988, P NATL ACAD SCI USA, V85, P6409, DOI 10.1073/pnas.85.17.6409; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CB, 1988, COMPUT APPL BIOSCI, V4, P25; LEE VH, 1993, DEV BIOL, V155, P371, DOI 10.1006/dbio.1993.1036; LIANG LF, 1990, MOL CELL BIOL, V10, P1507, DOI 10.1128/MCB.10.4.1507; LUNSFORD RD, 1990, GENOMICS, V6, P184, DOI 10.1016/0888-7543(90)90465-7; Maniatis T., 1982, MOL CLONING; MARESH GA, 1987, J EXP ZOOL, V244, P299, DOI 10.1002/jez.1402440214; MILLAR SE, 1989, SCIENCE, V246, P935, DOI 10.1126/science.2479101; MOOS M, 1988, J BIOL CHEM, V263, P6005; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RINGUETTE MJ, 1988, DEV BIOL, V127, P287, DOI 10.1016/0012-1606(88)90315-6; SACCO AG, 1981, BIOL REPROD, V25, P997, DOI 10.1095/biolreprod25.5.997; SACCO AG, 1983, FERTIL STERIL, V39, P350; SALZMANN GS, 1983, EMBO J, V2, P1451, DOI 10.1002/j.1460-2075.1983.tb01607.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHWOEBEL E, 1991, J BIOL CHEM, V266, P7214; SCHWOEBEL ED, 1992, BIOL REPROD, V47, P857, DOI 10.1095/biolreprod47.5.857; SKINNER SM, 1984, ENDOCRINOLOGY, V115, P2418, DOI 10.1210/endo-115-6-2418; SKINNER SM, 1987, J REPROD IMMUNOL, V12, P81, DOI 10.1016/0165-0378(87)90037-4; SKINNER SM, 1990, IMMUNOL ALLERGY CLIN, V10, P185; SKINNER SM, 1986, IMMUNOLOGICAL APPROA, P251; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; TIMMONS TM, 1987, BIOL REPROD, V36, P1275, DOI 10.1095/biolreprod36.5.1275; TIMMONS TM, 1990, CONRAD W S, P277; TIMMONS TM, 1988, PERSPECTIVES IMMUNOR, P242; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; WASHENIK K, 1989, MAMMALIAN EGG COAT S, P49; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WASSARMAN PM, 1984, MOL BIOL DEV, P213; WILKINS B, 1992, IN PRESS J REPROD S; WOOD DM, 1981, J EXP ZOOL, V217, P423, DOI 10.1002/jez.1402170314; WOOD DM, 1981, BIOL REPROD, V25, P439, DOI 10.1095/biolreprod25.2.439; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YUREWICZ EC, 1987, J BIOL CHEM, V262, P564; YURWICZ EC, 1991, MOL REPROD DEV, V30, P126	54	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12412	12417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685342				2022-12-27	WOS:A1993LG65800031
J	WANG, Z; ORLOWSKI, J; SHULL, GE				WANG, Z; ORLOWSKI, J; SHULL, GE			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A NOVEL GASTROINTESTINAL ISOFORM OF THE RAT NA/H EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NA+/H+ ANTIPORTER; CELLS	A cDNA encoding a new isoform of the rat Na/H exchanger (NHE) family has been identified by cross-hybridization with an NHE-1 cDNA probe. The 3.9-kilobase stomach cDNA encodes a protein of 813 amino acids with an M(r) of 91,296. The amino acid sequence of the protein, termed NHE-2, is 42% identical to NHE-1, 36% identical to NHE-3, and 57% identical to NHE-4. Na/H exchanger-deficient Chinese hamster ovary cells that were transfected with an expression construct containing the complete coding sequence of this cDNA exhibit amiloride-sensitive, H+-dependent Na-22+ influx, demonstrating that the protein it encodes is a functional Na/H exchanger. Northern hybridization analyses show that the corresponding mRNA is expressed predominantly in small intestine, colon, and stomach, with much lower levels present in skeletal muscle, kidney, brain, testis, uterus, heart, and lung. This suggests that NHE-2 plays an important role in gastrointestinal physiology and functions in many other organ systems as well.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	University System of Ohio; University of Cincinnati; McGill University				Orlowski, John/0000-0001-7371-175X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039626] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39626] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; KOZAK M, 1991, J BIOL CHEM, V266, P19867; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; RAJENDRAN VM, 1990, J BIOL CHEM, V265, P8408; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Sambrook J, 1989, MOL CLONING LABORATO; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; TSE C M, 1991, Gastroenterology, V100, pA258; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340	13	236	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11925	11928						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685026				2022-12-27	WOS:A1993LF28400070
J	HAYAKAWA, M; ISHIDA, N; TAKEUCHI, K; SHIBAMOTO, S; HORI, T; OKU, N; ITO, F; TSUJIMOTO, M				HAYAKAWA, M; ISHIDA, N; TAKEUCHI, K; SHIBAMOTO, S; HORI, T; OKU, N; ITO, F; TSUJIMOTO, M			ARACHIDONIC ACID-SELECTIVE CYTOSOLIC PHOSPHOLIPASE-A(2) IS CRUCIAL IN THE CYTOTOXIC ACTION OF TUMOR-NECROSIS-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; CELL-LINE; EXTRACELLULAR PHOSPHOLIPASE-A2; SYNOVIAL-FLUID; CYTO-TOXICITY; RAT PLATELETS; PURIFICATION; EXPRESSION; INVITRO; INVOLVEMENT	The role of phospholipase A2 (PLA2) in the cytotoxic action of tumor necrosis factor (TNF) was examined. Recently, we described the characterization of TNF-resistant sublines isolated from TNF-sensitive cell line L929 (Hayakawa, M., Oku, N., Takagi, T., Hori, T., Shibamoto, S., Yamanaka, Y., Takeuchi, K., Tsujimoto, M., and Ito, F. (1991) Cell Struct. Funct. 16, 333-340). The most remarkable features of these TNF-resistant sublines were the defects in TNF-stimulated arachidonate metabolism. In this study, we characterized the PLA2 activities of these sublines and found a significant decrease in the activity in one of the TNF-resistant sublines, C12 cells. The enzymological features, such as Ca2+ requirement and substrate specificity, suggested that the high molecular weight arachidonoyl-selective cytosolic PLA2 (cPLA2) was involved in the TNF action. Northern hybridization analysis demonstrated the reduced expression of high molecular weight cPLA2 in C12 cells. Furthermore, expression of a cloned cPLA2 cDNA in C12 cells increased the sensitivity of cells to the TNF cytotoxicity. These results indicate the crucial role of the high molecular weight cPLA2 in the TNF-induced cytolysis.	SUNTORY INST BIOMED RES, MISHIMA, OSAKA 618, JAPAN; UNIV SHIZUOKA, SCH PHARMACEUT SCI, DEPT RADIOBIOCHEM, OYA, SHIZUOKA 422, JAPAN	Suntory Holdings Ltd; University of Shizuoka	HAYAKAWA, M (corresponding author), SETSUNAN UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, HIRAKATA, OSAKA 57301, JAPAN.			Ito, Fumiaki/0000-0002-4129-4899				BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAYAKAWA M, 1988, J BIOCHEM-TOKYO, V104, P767, DOI 10.1093/oxfordjournals.jbchem.a122547; HAYAKAWA M, 1991, CELL STRUCT FUNCT, V16, P333, DOI 10.1247/csf.16.333; HORI T, 1989, J CELL PHYSIOL, V141, P275, DOI 10.1002/jcp.1041410207; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; ISHIDA N, 1992, J CLIN INVEST, V89, P1431, DOI 10.1172/JCI115732; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LE JM, 1987, LAB INVEST, V56, P234; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; MALIK STA, 1992, TUMOR NECROSIS FACTO, P239; MARAGANORE JM, 1986, J BIOL CHEM, V261, P4797; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; MUTCH DG, 1992, CANCER RES, V52, P866; NAKANO T, 1990, J BIOL CHEM, V265, P12745; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; REID T, 1991, J BIOL CHEM, V266, P16580; REID TR, 1989, J BIOL CHEM, V264, P4583; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	38	257	261	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11290	11295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684376				2022-12-27	WOS:A1993LD46600084
J	MIYAZAWA, K; SHIMOMURA, T; KITAMURA, A; KONDO, J; MORIMOTO, Y; KITAMURA, N				MIYAZAWA, K; SHIMOMURA, T; KITAMURA, A; KONDO, J; MORIMOTO, Y; KITAMURA, N			MOLECULAR-CLONING AND SEQUENCE-ANALYSIS OF THE CDNA FOR A HUMAN SERINE PROTEASE RESPONSIBLE FOR ACTIVATION OF HEPATOCYTE GROWTH-FACTOR - STRUCTURAL SIMILARITY OF THE PROTEASE PRECURSOR TO BLOOD-COAGULATION FACTOR-XII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BETA-FACTOR-XIIA; HAGEMAN-FACTOR; EPITHELIAL-CELLS; HEPATOPOIETIN-A; SCATTER FACTOR; HEAVY-CHAIN; PURIFICATION; IDENTIFICATION; RNA	Hepatocyte growth factor (HGF) is a potent mitogen for parenchymal liver cells, epithelial cells, and endothelial cells and may play an important role in liver regeneration following hepatic injury. HGF is homologous to plasminogen and is first synthesized and secreted as an inactive single-chain precursor and then activated to a heterodimeric form by endoproteolytic processing. Recently, a novel serine protease responsible for this processing (HGF activator) has been purified from fetal bovine serum (Shimomura, T., Ochiai, M., Kondo, J., and Morimoto, Y. (1992) Cytotechnology 8, 219-229). In this study, we purified HGF activator from human serum and determined its partial amino acid sequence. Based on the amino acid sequence, we have molecularly cloned the cDNA for human HGF activator. The nucleotide sequence of the cDNA revealed that HGF activator is derived from the COOH-terminal half region of a precursor protein of 655 amino acids and that the precursor consists of multiple putative domains homologous to those observed in blood coagulation factor XII. These domains may be involved in the conversion of the precursor to the active form of HGF activator.	KANSAI MED UNIV,INST LIVER RES,MORIGUCHI,OSAKA 570,JAPAN; MITSUBISHI KASEI CORP,RES CTR,MIDORI KU,YOKOHAMA 227,JAPAN	Kansai Medical University			MIYAZAWA, KEIJI/I-9713-2014					COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COOL DE, 1985, J BIOL CHEM, V260, P3666; DUNN JT, 1982, J BIOL CHEM, V257, P1779; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; FUJIKAWA K, 1981, METHOD ENZYMOL, V80, P198; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HEIMARK RL, 1980, NATURE, V286, P456, DOI 10.1038/286456a0; HERNANDEZ J, 1992, J CELL PHYSIOL, V150, P116, DOI 10.1002/jcp.1041500116; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Marshall R D, 1974, Biochem Soc Symp, P17; MCMULLEN BA, 1985, J BIOL CHEM, V260, P5328; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; QUE BG, 1986, BIOCHEMISTRY-US, V25, P1525, DOI 10.1021/bi00355a009; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; TRIPODI M, 1986, NUCLEIC ACIDS RES, V14, P3146, DOI 10.1093/nar/14.7.3146; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VONHEIJNE G, 1982, J MOL BIOL, V159, P537, DOI 10.1016/0022-2836(82)90300-X; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YOSHIYAMA Y, 1991, BIOCHEM BIOPH RES CO, V175, P660, DOI 10.1016/0006-291X(91)91616-K; ZARNEGAR R, 1989, CANCER RES, V49, P3314	38	355	372	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10024	10028						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683665				2022-12-27	WOS:A1993LB80000016
J	BACH, LA; HSIEH, S; SAKANO, K; FUJIWARA, H; PERDUE, JF; RECHLER, MM				BACH, LA; HSIEH, S; SAKANO, K; FUJIWARA, H; PERDUE, JF; RECHLER, MM			BINDING OF MUTANTS OF HUMAN INSULIN-LIKE GROWTH FACTOR-II TO INSULIN-LIKE GROWTH-FACTOR BINDING PROTEINS-1-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; IGF-II; FACTOR (IGF)-I; CELL-LINE; RECEPTOR; FIBROBLASTS; EXPRESSION; SECRETION; RESIDUES	A family of six specific insulin-like growth factor binding proteins (IGFBPs) modulates the biological actions of the insulin-like growth factors, IGF-I and IGF-II. In the present study, we determined the binding affinity of purified human IGFBPs 1-6 for recombinant human IGF-II mutants whose binding to IGF-I, IGF-II/mannose 6-phosphate, and insulin receptors was previously reported (Sakano, K., Enjoh, T., Numata, F., Fujiwara, H., Marumoto, Y., Higashihashi, N., Sato, Y., Perdue, J. F., and Fujita-Yamaguchi, Y. (1991) J. Biol. Chem. 266, 20626-20635). Of the regions studied, the most important determinants of IGF-II binding to the IGFBPs were A-domain residues 4850 and B-domain residue 26. Substitution of residues 48-50 with the analogous residues from human insulin (Thr-Ser-Ile) reduced binding to IGFBP-1, -5, and -6 more than 50-fold and to IGFBP-4 by 15-50-fold; binding to IGFBP-2 and -3 was reduced 6-12-fold. The same substitution markedly reduced binding to the IGF-II/mannose 6-phosphate receptor but not to IGF-I or insulin receptors. Although substitution of residues 54 and 55 with the analogous residues from IGF-I (Arg-Arg) abolished binding to the IGF-II/mannose 6-phosphate receptor, binding to IGFBPs was not substantially affected. Substitution of Phe26 with Ser or Leu, which decreased binding to the IGF-I and insulin receptors, reduced binding to IGFBP-1 and -6 up to 80-fold, but had lesser effects on the other IGFBPs. [Leu27]IGF-II and [Leu43]IGF-II, which had a more markedly reduced affinity for the IGF-I and insulin receptors than did [Ser26]IGF-II, were bound by the IGFBPs with relatively unchanged affinity compared with IGF-II. Thus, the determinants of IGF-II binding to IGFBPs partially overlap those for the IGF-II/mannose 6-phosphate receptor and overlap those for the IGF-I receptor to a lesser extent. IGFBP-I and IGFBP-6 are most sensitive to changes in IGF-II structure, although IGFBP-I binds IGF-I and IGF-II with equal affinity, whereas IGFBP-6 has a marked preferential binding affinity for IGF-II. IGF-II mutants with selective impairment in recognition by specific IGFBPs or receptors will provide a useful tool for dissecting the role of the different IGF binding macromolecules in the mediation of IGF-II actions.	DAIICHI PHARMACEUT CO LTD,MOLEC BIOL RES LAB,EDOGAWA KU,TOKYO 134,JAPAN; AMER RED CROSS,JEROME H HOLLAND LAB,MOLEC BIOL LAB,ROCKVILLE,MD 20855	Daiichi Sankyo Company Limited; American Red Cross	BACH, LA (corresponding author), NIDDKD,MOLEC & CELLULAR ENDOCRINOL BRANCH,GROWTH & DEV SECT,BLDG 10,RM 8D14,BETHESDA,MD 20892, USA.			Bach, Leon/0000-0002-9062-1518	NCI NIH HHS [CA 47150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACH LA, 1992, BIOCHEM BIOPH RES CO, V186, P301, DOI 10.1016/S0006-291X(05)80807-1; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1990, J BIOL CHEM, V265, P15648; BEUKERS MW, 1991, ENDOCRINOLOGY, V128, P1201, DOI 10.1210/endo-128-2-1201; BLUNDELL TL, 1983, FED PROC, V42, P2592; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEUNG PT, 1991, ENDOCRINOLOGY, V129, P1006, DOI 10.1210/endo-129-2-1006; CLEMMONS DR, 1990, J BIOL CHEM, V265, P12210; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FORBES B, 1990, J ENDOCRINOL, V126, P497, DOI 10.1677/joe.0.1260497; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; LUTHI C, 1992, EUR J BIOCHEM, V205, P483, DOI 10.1111/j.1432-1033.1992.tb16804.x; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MOSS JA, 1991, J BIOL CHEM, V266, P909; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; RECHLER MM, 1991, INSULIN LIKE GROWTH, P87; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; ROMANUS JA, 1987, ENDOCRINOLOGY, V121, P1041, DOI 10.1210/endo-121-3-1041; ROTH BV, 1991, BIOCHEM BIOPH RES CO, V181, P907, DOI 10.1016/0006-291X(91)91277-J; RUTANEN EM, 1988, BIOCHEM BIOPH RES CO, V152, P208, DOI 10.1016/S0006-291X(88)80701-0; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SATO A, 1992, J BIOCHEM-TOKYO, V111, P529, DOI 10.1093/oxfordjournals.jbchem.a123791; SOMMER A, 1991, MODERN CONCEPTS INSU, P715	38	129	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9246	9254						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683646				2022-12-27	WOS:A1993LA68900018
J	DE, BP; BURDSALL, AL; BANERJEE, AK				DE, BP; BURDSALL, AL; BANERJEE, AK			ROLE OF CELLULAR ACTIN IN HUMAN PARAINFLUENZA VIRUS TYPE-3 GENOME TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARA-INFLUENZA VIRUS-3; NEWCASTLE-DISEASE VIRUS; VESICULAR STOMATITIS-VIRUS; MESSENGER-RNA SYNTHESIS; SENDAI VIRUS; P-PROTEIN; SEQUENCE-ANALYSIS; MEASLES-VIRUS; MUMPS-VIRUS; INFECTED-CELLS	The transcribing ribonucleoprotein (RNP) complex of human parainfluenza virus type 3 (HPIV-3) requires cellular actin for transcription of viral genome in vitro (De, B. P., Lesoon, A., and Banerjee, A. K. (1991) J. Virol. 65, 3268-3275). In this communication, we have studied the interactions between different molecular forms of actin and the RNP of HPIV-3 to understand the role of actin in mRNA synthesis. We demonstrate that both polymeric and monomeric forms of actin (obtained by DNase I treatment) bind strongly to the RNP at 100 mm KCl concentration (polymerizing buffer). The binding was virtually abolished at zero KCl concentration (depolymerizing buffer). Isolation of the RNP-actin complex and subsequent use in a transcription reaction showed that the bound actin alone was sufficient for mRNA synthesis in vitro. Interestingly, the DNase I-arrested monomeric form of actin failed to activate mRNA synthesis, indicating a requirement of polymerization of the bound actin during HPIV-3 transcription. Electron microscopic analyses revealed that a drastic structural modification of the RNP occurred because of the polymerization of actin from a loosely coiled and irregular structure to a condensed and flexible structure. Activation of transcription was observed also with poly-L-glutamic acid, a highly acidic polypeptide. However, unlike cellular actin, poly-L glutamic acid was able to activate only 10% of the input RNP. These results suggest that cellular actin activates HPIV-3 transcription by polymerizing specifically on the RNP complex. This event results in an alteration of the RNP structure that enhances its suitability for efficient transcription. The acidic domain of actin may play an important role in this process.			DE, BP (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.				NIAID NIH HHS [AI 32027] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SC, 1988, J VIROL, V62, P834, DOI 10.1128/JVI.62.3.834-838.1988; BOHN W, 1986, VIROLOGY, V149, P91, DOI 10.1016/0042-6822(86)90090-5; CATTANEO R, 1989, CELL, V56, P759, DOI 10.1016/0092-8674(89)90679-X; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARLTON CA, 1991, J VIROL, V65, P1219, DOI 10.1128/JVI.65.3.1219-1227.1991; CHINCHAR VG, 1981, VIROLOGY, V115, P192, DOI 10.1016/0042-6822(81)90101-X; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CURRAN J, 1992, VIROLOGY, V189, P647, DOI 10.1016/0042-6822(92)90588-G; DE BP, 1990, J VIROL, V64, P1135, DOI 10.1128/JVI.64.3.1135-1142.1990; DE BP, 1991, J VIROL, V65, P3268, DOI 10.1128/JVI.65.6.3268-3275.1991; DESHPANDE KL, 1985, VIROLOGY, V140, P125, DOI 10.1016/0042-6822(85)90451-9; EATON BT, 1987, VIROLOGY, V157, P107, DOI 10.1016/0042-6822(87)90319-9; EGLY JM, 1984, EMBO J, V3, P2363, DOI 10.1002/j.1460-2075.1984.tb02141.x; EINBERGER H, 1990, J VIROL, V64, P4274, DOI 10.1128/JVI.64.9.4274-4280.1990; ELLIOTT GD, 1990, J GEN VIROL, V71, P1555, DOI 10.1099/0022-1317-71-7-1555; FRANKEL S, 1990, J BIOL CHEM, V265, P17980; GALINSKI MS, 1986, VIROLOGY, V155, P46, DOI 10.1016/0042-6822(86)90167-4; GALINSKI MS, 1992, VIROLOGY, V186, P543, DOI 10.1016/0042-6822(92)90020-P; GALINSKI MS, 1990, PARAMYXOVIRUSES, P41; GIUFFRE RM, 1982, J VIROL, V42, P963, DOI 10.1128/JVI.42.3.963-968.1982; GORDON DJ, 1977, J BIOL CHEM, V252, P8300; GRIGERA PR, 1988, VIROLOGY, V165, P584, DOI 10.1016/0042-6822(88)90602-2; HAMAGUCHI M, 1985, VIROLOGY, V147, P295, DOI 10.1016/0042-6822(85)90132-1; HAMAGUCHI M, 1983, VIROLOGY, V128, P105, DOI 10.1016/0042-6822(83)90322-7; HARTWIG JH, 1981, J MOL BIOL, V145, P563, DOI 10.1016/0022-2836(81)90545-3; HEGGENESS MH, 1980, P NATL ACAD SCI-BIOL, V77, P2631, DOI 10.1073/pnas.77.5.2631; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; JAMBOU RC, 1985, J VIROL, V56, P298, DOI 10.1128/JVI.56.1.298-302.1985; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KONDO K, 1990, VIROLOGY, V178, P321, DOI 10.1016/0042-6822(90)90413-L; KORN ED, 1978, P NATL ACAD SCI USA, V75, P588, DOI 10.1073/pnas.75.2.588; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RA, 1976, VIROLOGY, V69, P116, DOI 10.1016/0042-6822(76)90199-9; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LUFTIG RB, 1982, J THEOR BIOL, V99, P173, DOI 10.1016/0022-5193(82)90397-6; LUK D, 1986, VIROLOGY, V153, P318, DOI 10.1016/0042-6822(86)90036-X; MACLEANFLETCHER S, 1980, CELL, V20, P329, DOI 10.1016/0092-8674(80)90619-4; MARUYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V626, P494; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MOYER SA, 1986, P NATL ACAD SCI USA, V83, P5405, DOI 10.1073/pnas.83.15.5405; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; OHGIMOTO S, 1990, VIROLOGY, V177, P116, DOI 10.1016/0042-6822(90)90465-4; ORVELL C, 1978, J GEN VIROL, V41, P527, DOI 10.1099/0022-1317-41-3-527; PATERSON RG, 1990, J VIROL, V64, P4137, DOI 10.1128/JVI.64.9.4137-4145.1990; PELUSO RW, 1977, J VIROL, V23, P177, DOI 10.1128/JVI.23.1.177-187.1977; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; SANCHEZ A, 1985, VIROLOGY, V143, P45, DOI 10.1016/0042-6822(85)90095-9; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SOUTHERN JA, 1990, VIROLOGY, V177, P388, DOI 10.1016/0042-6822(90)90497-F; SPRIGGS MK, 1986, J GEN VIROL, V67, P2705, DOI 10.1099/0022-1317-67-12-2705; STALLCUP KC, 1983, VIROLOGY, V124, P59, DOI 10.1016/0042-6822(83)90290-8; STOREY DG, 1984, J VIROL, V52, P761, DOI 10.1128/JVI.52.3.761-766.1984; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P1942, DOI 10.1021/bi00304a009; TAKEUCHI K, 1990, VIROLOGY, V178, P247, DOI 10.1016/0042-6822(90)90400-L; THOMAS SM, 1988, CELL, V54, P891, DOI 10.1016/S0092-8674(88)91285-8; TYRRELL DLJ, 1978, J GEN VIROL, V39, P219, DOI 10.1099/0022-1317-39-2-219; VIDAL S, 1990, J VIROL, V64, P239, DOI 10.1128/JVI.64.1.239-246.1990; VOLKMAN LE, 1987, VIROLOGY, V156, P32, DOI 10.1016/0042-6822(87)90433-8; Wang E., 1976, CELL MOTILITY, P589; WECHSLER SL, 1985, VIRUS RES, V3, P339, DOI 10.1016/0168-1702(85)90434-4	61	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5703	5710						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680647				2022-12-27	WOS:A1993KR82200052
J	KISTNER, U; WENZEL, BM; VEH, RW; CASESLANGHOFF, C; GARNER, AM; APPELTAUER, U; VOSS, B; GUNDELFINGER, ED; GARNER, CC				KISTNER, U; WENZEL, BM; VEH, RW; CASESLANGHOFF, C; GARNER, AM; APPELTAUER, U; VOSS, B; GUNDELFINGER, ED; GARNER, CC			SAP90, A RAT PRESYNAPTIC PROTEIN RELATED TO THE PRODUCT OF THE DROSOPHILA TUMOR SUPPRESSOR GENE DLG-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANYLATE KINASE; SYNAPTIC VESICLES; NERVOUS-SYSTEM; BINDING; PURIFICATION; COMPONENT; JUNCTIONS; MEMBRANE; ONCOGENE; ELEMENTS	A novel synapse-associated protein, SAP90, accumulates around the axon hillock of Purkinje cells in rat cerebellum. By immuno-electron microscopy, SAP90 has been localized to the presynaptic termini of basket cells forming inhibitory, gamma-aminobutyric acid (GABA)ergic synapses onto Purkinje cell axon hillocks. The amino acid sequence for SAP90 has been deduced from the nucleotide sequence of a series of overlapping cDNA clones. SAP90 is related to the gene product encoded by the Drosophila tumor suppressor gene dlg-A. SAP90 and the dlg-A product share an overall sequence identity of 54%. Three distinct domains can be identified: (i) a potential cytoskeletal region consisting of three repeats of 90 amino acids in length, (ii) a domain with similarity to SH3, a putative regulatory motif found in the src family of non-receptor protein tyrosine kinases and several proteins associated with the cortical cytoskeleton, and (iii) a carboxyl-terminal domain homologous to yeast guanylate kinase. These features suggest a possible role for SAP90 in a guanine nucleotide-mediated signal transduction pathway at a subset of GABAergic synapses in the rat cerebellum.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY; RUHR UNIV BOCHUM,INST ANAT,W-4630 BOCHUM 1,GERMANY	University of Hamburg; Ruhr University Bochum				Garner, Craig/0000-0003-1970-5417				BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DASILVA PP, 1982, CELL, V28, P441, DOI 10.1016/0092-8674(82)90198-2; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FAZELI MS, 1992, TRENDS NEUROSCI, V15, P115, DOI 10.1016/0166-2236(92)90350-H; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; GARNER CC, 1988, GENE, V71, P483, DOI 10.1016/0378-1119(88)90065-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT, P1; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HAYES NVL, 1991, J NEUROCHEM, V57, P397, DOI 10.1111/j.1471-4159.1991.tb03766.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANDIS DMD, 1988, INTRINSIC DETERMINAN, V37, P201; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LYNCH G, 1988, INTRINSIC DETERMINAN, V37, P217; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; Noirot-Timothee C., 1980, International Review of Cytology, V63, P97, DOI 10.1016/S0074-7696(08)61758-1; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PAWSON T, 1988, ONCOGENE, V3, P491; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; SOMOGYI P, 1985, J HISTOCHEM CYTOCHEM, V33, P240, DOI 10.1177/33.3.2579123; SOUSA R, 1992, J NEUROSCI, V12, P2130; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SU B, 1991, J NEUROSCI RES, V29, P461, DOI 10.1002/jnr.490290406; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WESTEL WC, 1992, J CELL BIOL, V117, P121; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WU K, 1986, MOL BRAIN RES, V1, P167, DOI 10.1016/0169-328X(86)90008-2	36	374	382	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1993	268	7					4580	4583						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KP884	7680343				2022-12-27	WOS:A1993KP88400004
J	KAMIMURA, S; GALLIENI, M; ZHONG, M; BERON, T; SLATOPOLSKY, E; DUSSO, A				KAMIMURA, S; GALLIENI, M; ZHONG, M; BERON, T; SLATOPOLSKY, E; DUSSO, A			MICROTUBULES MEDIATE CELLULAR 25-HYDROXYVITAMIN-D-3 TRAFFICKING AND THE GENOMIC RESPONSE TO 1,25-DIHYDROXYVITAMIN-D-3 IN NORMAL HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRA-RENAL PRODUCTION; VITAMIN-D METABOLISM; INTRACELLULAR-LOCALIZATION; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTORS; MACROPHAGES; CALCITRIOL; BINDING; TRANSLOCATION; LYMPHOCYTES	The genomic actions of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) are mediated by the intracellular vitamin D receptor (VDR). Although immunocytochemistry has shown that disruption of microtubular assembly prevents nuclear access of the sterol-VDR complex, the role of microtubules in the response to 1,25(OH)(2)D-3 has not been studied in viable cells. Our studies examined this interaction in normal human monocytes. Monocytes convert 25(OR)D-3 to 1,25(OH)(2)D-3 and to 24-hydroxylated metabolites more polar than 1,25(OH)(2)D-3. Microtubule disruption totally abolished the ability of exogenous 1,25(OH)(2)D-3 to suppress its own synthesis and to induce 24-hydroxylase mRNA and activity, without affecting either total 1,25(OH)(2)D-3 uptake or maximal 1,25(OH)(2)D(-)3VDR binding. Thus, intact microtubules are essential for 1,25(OH)(2)D-3-dependent modulation of gene transcription. Interestingly, microtubule disruption also decreased monocyte 1,25(OH)(2)D-3 synthesis, not by decreasing the V-max of monocyte mitochondrial 1 alpha-hydroxylase but through an increase in the K-m for 25(OH)D-3. We examined 25(OH)D-3 transport. Microtubule disruption did not affect total cellular 25(OH)D-3 uptake but reduced its intracellular trafficking to the mitochondria. Thus, microtubules participate in intracellular 25(OH)D-3 transport, and their integrity determines normal 1,25(OH)(2)D-3 synthesis.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV RENAL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Dusso, Adriana S/E-8617-2011; Gallieni, Maurizio/H-2895-2019	Gallieni, Maurizio/0000-0002-2011-2160	NIDDK NIH HHS [DK-09976, DK-07126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976, T32DK007126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JS, 1985, J EXP MED, V161, P755, DOI 10.1084/jem.161.4.755; ADAMS JS, 1994, ENDOCRINOLOGY, V134, P2567, DOI 10.1210/en.134.6.2567; AKNER G, 1990, EUR J CELL BIOL, V53, P390; AMIZUKA N, 1992, ARCH HISTOL CYTOL, V55, P77, DOI 10.1679/aohc.55.77; ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BARSHAVIT Z, 1981, CALCIFIED TISSUE INT, V33, P673, DOI 10.1007/BF02409507; BARSONY J, 1990, J CELL BIOL, V111, P2385, DOI 10.1083/jcb.111.6.2385; BARSONY J, 1992, J BIOL CHEM, V267, P24457; BARSONY J, VITAMIN D THERAPEUTI, P345; BHALLA AK, 1986, CELL IMMUNOL, V98, P311, DOI 10.1016/0008-8749(86)90291-1; COHEN MS, 1986, J IMMUNOL, V136, P1049; DIBARTOLOMEIS MJ, 1984, J BIOL CHEM, V259, P159; DUSSO A, 1988, KIDNEY INT, V34, P368, DOI 10.1038/ki.1988.190; DUSSO A, 1989, KIDNEY INT, V35, P860, DOI 10.1038/ki.1989.64; DUSSO A, 1992, J BONE MINER RES, V7, pS151; DUSSO AS, 1991, J CLIN ENDOCR METAB, V72, P157, DOI 10.1210/jcem-72-1-157; ESCOLAR G, 1993, AM J PATHOL, V143, P823; GALLIENI M, 1995, AM J PHYSIOL, V37, pF746; GIBBONS IR, 1988, J BIOL CHEM, V263, P15837; GREEN DE, 1955, J BIOL CHEM, V217, P551; HALLORAN BP, 1984, J CLIN ENDOCR METAB, V59, P1063, DOI 10.1210/jcem-59-6-1063; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HEWISON M, 1993, CLIN ENDOCRINOL, V39, P663, DOI 10.1111/j.1365-2265.1993.tb02424.x; KEENAN MJ, 1991, INT J BIOCHEM, V23, P1225, DOI 10.1016/0020-711X(91)90220-H; KOREN R, 1986, FEBS LETT, V205, P113, DOI 10.1016/0014-5793(86)80876-6; LAMBERT PW, 1982, J CLIN INVEST, V69, P722, DOI 10.1172/JCI110501; LEPECQ JB, 1966, ANAL BIOCHEM, V17, P100, DOI 10.1016/0003-2697(66)90012-1; PAPAMICHAIL M, 1980, EXP CELL RES, V125, P490, DOI 10.1016/0014-4827(80)90144-5; PIKE JW, 1982, P NATL ACAD SCI-BIOL, V79, P7719, DOI 10.1073/pnas.79.24.7719; PIKE JW, 1982, J BIOL CHEM, V257, P6766; PRATT WB, 1993, J BIOL CHEM, V268, P21455; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SCHACHTE.H, 1970, J BIOL CHEM, V245, P1090; SHANY S, 1993, J BONE MINER RES, V8, P269; SPAZARY D, 1994, J STEROID BIOCHEM, V51, P143; SPINDLER BJ, 1975, J BIOL CHEM, V250, P4113; STETSON DL, 1983, AM J PHYSIOL, V245, pC113, DOI 10.1152/ajpcell.1983.245.1.C113; TAFT JL, 1986, BIOCHEM BIOPH RES CO, V134, P218, DOI 10.1016/0006-291X(86)90550-4; WALTERS MR, 1985, ENDOCR REV, V6, P512, DOI 10.1210/edrv-6-4-512; WALTERS SN, 1986, ARCH BIOCHEM BIOPHYS, V246, P366, DOI 10.1016/0003-9861(86)90481-9; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	41	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22160	22166		10.1074/jbc.270.38.22160	http://dx.doi.org/10.1074/jbc.270.38.22160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673194	hybrid			2022-12-27	WOS:A1995RW31400018
J	KING, C; EISENBERG, E; GREENE, L				KING, C; EISENBERG, E; GREENE, L			POLYMERIZATION OF 70-KDA HEAT-SHOCK PROTEIN BY YEAST DNAJ IN ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; COATED VESICLES; TRANSLOCATION; HSP70; HOMOLOG; TEMPERATURES; POLYPEPTIDES	DnaK, the Escherichia coli hsp(70) protein, interacts with DnaJ, a protein cofactor that appears to be involved in presenting protein substrates to DnaK. The yeast DnaJ homolog, YDJ1, has also been shown to interact with yeast hsp70, although the function of this interaction is unknown. In the present study, we investigated the interaction of YDJ1 with both yeast and bovine brain hsp70. We found that, in the presence of ATP, where hsp70 is normally monomeric, YDJ1 induced almost all of the yeast and bovine brain hsp70 to form large polymers, which are readily sedimentable. These polymers were much larger than the dimers and trimers of hsp70, which normally form in the presence of ADP. YDJ1 appeared to be acting catalytically since very little YDJ1 copolymerized with the hsp70, and maximum polymerization occurred at low ratios of YDJ1 to hsp70. The polymerization required ATP and was completely reversed when ATP was replaced by ADP. These data suggest that, in the presence of ATP, YDJ1 may present one hsp70 to another just as under other conditions DnaJ is able to present protein substrates to DnaK.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BAROUCH W, 1993, MOL BIOL CELL, V4, P95; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V120, P1355; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO B, 1993, MOL BIOL CELL, V4, P96; GAO BC, 1991, J BIOL CHEM, V266, P19565; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAKEY EK, 1987, P NATL ACAD SCI USA, V84, P1659, DOI 10.1073/pnas.84.6.1659; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; PRASAD K, 1994, J BIOL CHEM, V269, P6931; PRASAD K, 1994, MOL BIOL CELL, V5, P329; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	43	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22535	22540		10.1074/jbc.270.38.22535	http://dx.doi.org/10.1074/jbc.270.38.22535			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673245	hybrid			2022-12-27	WOS:A1995RW31400074
J	THOMAS, WG; BAKER, KM; MOTEL, TJ; THEKKUMKARA, TJ				THOMAS, WG; BAKER, KM; MOTEL, TJ; THEKKUMKARA, TJ			ANGIOTENSIN-II RECEPTOR ENDOCYTOSIS INVOLVES 2 DISTINCT REGIONS EF THE CYTOPLASMIC TAIL - A ROLE FOR RESIDUES ON THE HYDROPHOBIC FACE OF A PUTATIVE AMPHIPATHIC HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MEDIATED ENDOCYTOSIS; POTENTIAL MECHANISM; CARBOXYL-TERMINUS; INTERNALIZATION; PROTEIN; BINDING; SEQUESTRATION; CLATHRIN	Following agonist stimulation, many receptors are rapidly internalized from the plasma membrane via a mechanism which presumably involves recognition motifs within the cytoplasmic domains of the receptor. We have previously demonstrated (Thomas, W. G., Thekkumkara, T. J., Motel, T. J., and Baker, K. M. (1995) J. Biol Chem. 270, 207-213) that truncation of the angiotensin II (AT(1A)) receptor, to remove 45 amino acids from the cytoplasmic tail, markedly reduced agonist stimulated receptor endocytosis. In the present study, we have stably and transiently expressed wild type and carboxyl terminus mutated AT(1A) receptors in Chinese hamster ovary cells to identify regions and specific amino acids important for this process. Wild type AT(1A) receptors rapidly internalized (t(1/2) = 2.5 min; Y-max = 76.4%) after AII stimulation. Using AT(1A) receptor mutants, truncated and deleted at the carboxyl terminus, two distinct regions important for internalization were identified: one membrane proximal site between residues 315-329 and another distal to Lys(333), within the terminal 26 amino acids. Point mutations (Y302A, Y312A, L316F, Y319A, and K325A) were performed to identify residues contributing to the membrane proximal site. Mutation of Y302A, Y312A, and K325A had little effect on the rate (t(1/2) = 4.3, 2.8, and 2.8 min) and maximal amount (Y-max = 81.7, 67.8, and 73.5%) of AII induced internalization. In contrast, L316F and Y319A mutations displayed an approximately 2.5-fold reduction in rate (t(1/2) = 6.1 and 6.2 min) and L316F a decreased maximal level (Y-max 38.1 and 71.4%, respectively) compared to wild type. Interestingly, Leu(316) and Tyr(319) are closely aligned within the hydrophobic aspect of a putative amphipathic helix, possibly representing an internalization motif for the AT(1A) receptor. We conclude that the AT(1A) receptor does not use the NPXXY (NPLFY(302)) motif, first described for the beta(2)-adrenergic receptor, to mediate agonist stimulated endocytosis. Rather, two distinct regions of the carboxyl terminus are utilized: one involving hydrophobic and aromatic residues on a putative alpha-helix and another serine/threonine-rich domain.	WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA				Thomas, Walter/I-2208-2015	Thomas, Walter/0000-0003-0685-2952; Thekkumkara, Thomas/0000-0001-8865-1446	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044883] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44883] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOOZ GW, 1992, ENDOCRINOLOGY, V130, P3641, DOI 10.1210/en.130.6.3641; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATT KJ, 1993, RENIN ANGIOTENSIN SY, V1; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; CROZAT A, 1986, ENDOCRINOLOGY, V118, P2312, DOI 10.1210/endo-118-6-2312; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GRIENDLING KK, 1987, J BIOL CHEM, V262, P14555; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; HUNYADY L, 1994, KIDNEY INT, V46, P1496, DOI 10.1038/ki.1994.428; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROBERTSON JI, 1993, RENIN ANGIOTENSIN SY, V1; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSUGA H, 1994, J BIOL CHEM, V269, P32522; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; VAUX D, 1992, Trends in Cell Biology, V2, P189, DOI 10.1016/0962-8924(92)90232-C; WILDE A, 1994, J BIOL CHEM, V269, P7131; YU SS, 1993, J BIOL CHEM, V268, P337	55	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22153	22159		10.1074/jbc.270.38.22153	http://dx.doi.org/10.1074/jbc.270.38.22153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673193	hybrid			2022-12-27	WOS:A1995RW31400017
J	ITOH, N; JOBO, K; TSUJIMOTO, K; OHTA, M; KAWASAKI, T				ITOH, N; JOBO, K; TSUJIMOTO, K; OHTA, M; KAWASAKI, T			2 TRUNCATED FORMS OF RAT INSULIN RECEPTOR-RELATED RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTORS; SECRETED FORM; EXPRESSION; BINDING; CLONING; TISSUE; PROTEINS; LIGAND; FAMILY	The insulin receptor-related receptor (IRR) (1271 amino acids) is expected to have unique functions as a novel member of the insulin receptor family. In this paper, we report two alternatively spliced variants of rat IRR mRNA, which are predicted to encode two truncated forms of IRR, sIRR-1 (410 amino acids) and sIRR-2 (469 amino acids). The amino acid sequence of sIRR-1 is identical to the N-terminal 410-amino acid sequence of IRR. sIRR-2 has an additional 59-amino acid insertion in the C-terminal region. Both truncated forms retain the N-terminal and cysteine-rich domains but lack the transmembrane and intracellular tyrosine kinase domains, indicating that the truncated forms are the secreted forms. The translation products of the truncated form mRNAs were detected in the stomach and kidney by Western analysis. However, the physiological significance of the secreted forms remains to be elucidated.	UTANO NATL HOSP,CLIN RES CTR,KYOTO 616,JAPAN		ITOH, N (corresponding author), KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,KYOTO 60601,JAPAN.							CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS LG, 1986, METHOD MOL BIOL, P47; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GOLDSTEIN BJ, 1987, MOL ENDOCRINOL, V1, P759, DOI 10.1210/mend-1-11-759; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KURACHI H, 1992, BIOCHEM BIOPH RES CO, V187, P934, DOI 10.1016/0006-291X(92)91287-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PEZZINO V, 1992, J CLIN ENDOCR METAB, V74, P1116, DOI 10.1210/jc.74.5.1116; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SHIER P, 1992, MOL ENDOCRINOL, V6, P723, DOI 10.1210/me.6.5.723; SHIER P, 1989, J BIOL CHEM, V264, P14605; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5408; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG B, 1992, J BIOL CHEM, V267, P18320	22	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17983	17986						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688734				2022-12-27	WOS:A1993LT74300053
J	ISBERG, RR; YANG, YX; VOORHIS, DL				ISBERG, RR; YANG, YX; VOORHIS, DL			RESIDUES ADDED TO THE CARBOXYL-TERMINUS OF THE YERSINIA-PSEUDOTUBERCULOSIS INVASIN PROTEIN INTERFERE WITH RECOGNITION BY INTEGRIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MAMMALIAN-CELLS; ALKALINE-PHOSPHATASE; POLYACRYLAMIDE GELS; BINDING DOMAIN; IDENTIFICATION; ADHESION; PATHOGENICITY; SEQUENCE; FUSIONS; FAMILY	Escherichia coli strains encoding the Yersinia pseudotuberculosis invasin protein are efficiently internalized by mammalian cells. Bacterial uptake into cultured cell lines became defective, however, if invasin was altered by fusion of its carboxyl terminus to E. coli alkaline phosphatase or by the addition of two hydrophobic amino acids to its carboxyl-terminal end. Probing with anti-invasin monoclonal antibodies revealed that the amino-terminal end of invasin was properly localized on the bacterial cell surface in strains encoding invasin with 2 additional amino acids, whereas the carboxyl terminus was not accessible to the monoclonal antibody. Therefore, the 2 additional amino acids interfered with the folding or orientation of the carboxyl terminus in the outer membrane. Alkylation experiments in the absence of reduction indicated that this defect was not caused by a gross inability to form a critical disulfide bond. Revertants were selected from a strain encoding this mutant protein by enriching for organisms able to enter cultured mammalian cells. The vast majority of revertants that were isolated following this enrichment contained a stop codon at the usual position found in the wild type inv gene. The most efficient of the remaining revertants resulted in the introduction of a glycine residue at the site of the wild type stop codon, presumably restoring proper conformation of the carboxyl-terminal region.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University	ISBERG, RR (corresponding author), TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02111 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI23538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER PB, 1975, INFECT IMMUN, V11, P164, DOI 10.1128/IAI.11.1.164-170.1975; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FALKOW S, 1987, REV INFECT DIS, V9, pS450; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GUAN C, 1988, GENE, V67, P21; HAYMAN EG, 1982, J CELL BIOL, V95, P20, DOI 10.1083/jcb.95.1.20; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISBERG RR, 1988, P NATL ACAD SCI USA, V85, P6682, DOI 10.1073/pnas.85.18.6682; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; ROSS L, 1992, J BIOL CHEM, V267, P8537; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1991, CELL, V88, P2815; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TAKEUCHI A, 1965, AM J PATHOL, V47, P1011; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOORHIS DL, 1991, MOL MICROBIOL, V5, P317, DOI 10.1111/j.1365-2958.1991.tb02112.x	41	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15840	15846						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687999				2022-12-27	WOS:A1993LN30500075
J	KAKU, H; MORI, Y; GOLDSTEIN, IJ; SHIBUYA, N				KAKU, H; MORI, Y; GOLDSTEIN, IJ; SHIBUYA, N			MONOMERIC, MONOVALENT DERIVATIVE OF MAACKIA-AMURENSIS LEUKOAGGLUTININ - PREPARATION AND APPLICATION TO THE STUDY OF CELL-SURFACE GLYCOCONJUGATES BY FLOW-CYTOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING-SPECIFICITY; TERMINAL SIALIC-ACID; L BARK LECTIN; CONCANAVALIN-A; MONO-VALENT; LINKED OLIGOSACCHARIDES; EXPRESSION; ALPHA-2,3; RESIDUES; SEQUENCE	A stable subunit of Maackia amurensis leukoagglutinin (MMAL) was prepared by the selective reduction of disulfide bridges between the subunits followed by alkylation with 4-vinylpyridine. MMAL failed to precipitate fetuin, whereas it retained its ability to bind to the same glycoprotein coated on a plastic plate, indicating the monovalency of this derivative. This binding to immobilized fetuin was inhibited by a haptenic sugar, Neu5Acalpha2-3lactose, with the same inhibitory potency as against the native M. amurensis leukoagglutinin. Microscopic observation as well as flow cytometric analyses showed that Chinese hamster ovary cells were clearly stained with fluorescein isothiocyanate-labeled MMAL without any detectable agglutination. This staining was inhibited by the addition of fetuin or by the sugar chains of fetuin. Differences in the types of sialylated glycoconjugates on the cell surface of several cell lines were detected by the combined use of fluorescein isothiocyanate-labeled MMAL and the monomeric derivative of elderberry bark lectin (specific for the Neu5Acalpha2-6Gal/GalNAc sequence) by flow cytometry. These results demonstrate the usefulness of these monovalent derivatives of sialylated oligosaccharide-specific lectins as probes for the analysis of cell surface glycoconjugates containing sialic acid by the technique of flow cytometry.	NATL INST ANIM HLTH, DEPT BIOL PROD, TSUKUBA 305, JAPAN; UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; University of Michigan System; University of Michigan	KAKU, H (corresponding author), NATL INST AGROBIOL RESOURCES, DEPT CELL BIOL, TSUKUBA 305, JAPAN.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEPPU M, 1979, J BIOCHEM-TOKYO, V85, P1275; CHAVIN SI, 1984, J BIOL CHEM, V259, P3387; FRASER AR, 1976, P NATL ACAD SCI USA, V73, P790, DOI 10.1073/pnas.73.3.790; ISHII S, 1984, J PROTEIN CHEM, V3, P63, DOI 10.1007/BF01024837; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; KAKU H, 1992, FEBS LETT, V306, P176, DOI 10.1016/0014-5793(92)80994-R; KAO FT, 1969, P NATL ACAD SCI USA, V64, P1284, DOI 10.1073/pnas.64.4.1284; KAWAGUCHI T, 1974, J BIOL CHEM, V249, P2786; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KUROKAWA T, 1976, J BIOL CHEM, V251, P5686; LEE EU, 1989, J BIOL CHEM, V264, P13848; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCOY JP, 1986, CYTOMETRY, V7, P142, DOI 10.1002/cyto.990070204; ROLLINGHOFF M, 1973, P SOC EXP BIOL MED, V144, P813; SATA T, 1989, J HISTOCHEM CYTOCHEM, V37, P1577, DOI 10.1177/37.11.2478613; SATA T, 1991, AM J PATHOL, V139, P1435; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SHIBUYA N, 1987, ARCH BIOCHEM BIOPHYS, V254, P1, DOI 10.1016/0003-9861(87)90074-9; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SUYA H, 1982, J BIOCHEM-TOKYO, V92, P1251, DOI 10.1093/oxfordjournals.jbchem.a134043; TANAKA I, 1981, J BIOCHEM-TOKYO, V89, P1643, DOI 10.1093/oxfordjournals.jbchem.a133360; TARR J, 1986, METHODS PROTEIN MICR, P155; WANG JL, 1978, J BIOL CHEM, V253, P3000; WANG WC, 1988, J BIOL CHEM, V263, P4576	26	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13237	13241						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685757				2022-12-27	WOS:A1993LH55300034
J	LEE, CG; ZAMORE, PD; GREEN, MR; HURWITZ, J				LEE, CG; ZAMORE, PD; GREEN, MR; HURWITZ, J			RNA ANNEALING ACTIVITY IS INTRINSICALLY ASSOCIATED WITH U2AF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; SPLICING FACTOR; BIOCHEMICAL-CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; BINDING PROTEINS; NUCLEAR EXTRACTS; AUXILIARY FACTOR; HELA-CELLS; GENE	U2AF is a protein that is essential for the formation of the prespliceosome complex during pre-mRNA splicing. It contains two subunits, 65 and 35 kDa, although only the 65-kDa subunit has been shown to be essential for its splicing activity. Here, we show that the 65-kDa subunit mediates the annealing of complementary single-stranded RNAs or single-stranded DNAs. This activity was shown to reverse the action of RNA helicase A, an enzyme that catalyzes the displacement of duplex RNAs. The NH2-terminal region of the 65-kDa subunit of U2AF, containing arginine-serine (RS) dipeptides and basic amino acid sequences, was shown to be essential for the annealing of complementary sequences, RNA binding, and the inhibition of RNA helicase A activity. Thus, through the combined action of U2AF and RNA helicases, duplex RNA regions can be reversibly formed and displaced. Such reactions appear to be critical for pre-mRNA splicing, translation, and transcription.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	LEE, CG (corresponding author), MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LEE CG, 1992, J BIOL CHEM, V267, P4398; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MERIC C, 1986, J VIROL, V60, P450; MOORE SP, 1990, J BIOL CHEM, V265, P11108; MUNROE SH, 1988, EMBO J, V7, P2523, DOI 10.1002/j.1460-2075.1988.tb03100.x; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; REYNOLDS P, 1985, EMBO J, V4, P3549, DOI 10.1002/j.1460-2075.1985.tb04115.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SUNG P, 1992, NATURE, V355, P743, DOI 10.1038/355743a0; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	31	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13472	13478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685763				2022-12-27	WOS:A1993LH55300065
J	WOHRL, BM; EHRESMANN, B; KEITH, G; LEGRICE, SFJ				WOHRL, BM; EHRESMANN, B; KEITH, G; LEGRICE, SFJ			NUCLEASE FOOTPRINTING OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE TRANSFER RNA(LYS-3) COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; PHENYLALANINE TRANSFER-RNA; METAL CHELATE ADSORBENT; AVIAN-SARCOMA VIRUS; PRIMER TRANSFER-RNA; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENOMIC RNA; INITIATION; SYNTHETASE	Nuclease footprinting has been used to probe features of binary complexes of type 1 human immunodeficiency virus reverse transcriptase (HIV-1 RT) with both natural and synthetic preparations of its cognate replication primer, tRNA(Lys-3). In addition to heterodimeric RT (p66/p51), ribonucleoprotein complexes containing either the p66 or p51 subunit were analyzed. Footprinting experiments employed both structure- and sequence-specific nucleases. Our results indicate a similar mode of interaction for the three RT preparations tested, suggesting contact with each loop of the tRNA primer (D, anticodon, and TPSIC), as well as minor perturbation of the anticodon stem. Although there is little evidence for extensive disruption of the 3'-acceptor stem, RNase A footprinting data with natural and synthetic tRNA suggests that potential base pairing between the TPSIC and D loops is disrupted in the presence of RT.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; INST BIOL MOLEC & CELLULAIRE, CNRS, UPR 9002, F-67084 STRASBOURG, FRANCE	Case Western Reserve University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg					NIAID NIH HHS [AI 31147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; BURTON AS, 1982, EUR J BIOCHEM, V121, P587; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; GERWIN BI, 1977, J VIROL, V24, P478, DOI 10.1128/JVI.24.2.478-488.1977; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HARADA F, 1975, J BIOL CHEM, V250, P3487; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOWARD KJ, 1991, J BIOL CHEM, V266, P23003; KHAN R, 1992, J BIOL CHEM, V267, P6689; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LEVIN JG, 1979, J VIROL, V29, P328, DOI 10.1128/JVI.29.1.328-335.1979; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MULLER B, 1989, J BIOL CHEM, V264, P13975; MULLER WEG, 1991, BIOCHEMISTRY-US, V30, P2027, DOI 10.1021/bi00222a004; PARK SJ, 1988, J BIOL CHEM, V263, P16527; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PETERS G, 1979, J VIROL, V31, P398, DOI 10.1128/JVI.31.2.398-407.1979; PETERS GG, 1980, J VIROL, V36, P692, DOI 10.1128/JVI.36.3.692-700.1980; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SAMPSON JR, 1989, SCIENCE, V243, P1363; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; TAYLOR JM, 1975, J VIROL, V16, P553, DOI 10.1128/JVI.16.3.553-558.1975; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VASSILENKO SK, 1975, BIOKHIMIYA, V40, P796; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WEISS S, 1992, GENE, V111, P183, DOI 10.1016/0378-1119(92)90686-J; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0	44	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13617	13624						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	7685766				2022-12-27	WOS:A1993LH55300085
J	ABE, K; KUSAKABE, Y; TANEMURA, K; EMORI, Y; ARAI, S				ABE, K; KUSAKABE, Y; TANEMURA, K; EMORI, Y; ARAI, S			PRIMARY STRUCTURE AND CELL-TYPE-SPECIFIC EXPRESSION OF A GUSTATORY G-PROTEIN-COUPLED RECEPTOR-RELATED TO OLFACTORY RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; TASTE CELLS; BOVINE RHODOPSIN; LIGAND-BINDING; CYSTEINE RESIDUE-110; BITTER SUBSTANCES; K+ CHANNELS; TRANSDUCTION; MEMBRANE; GENE	We have reported on the partial structures of a multigene family encoding GTP-binding protein (G protein)-coupled, seven-transmembrane receptors expressed in the tongue (Abe, K., Kusakabe, Y., Tanemura, K., Emori, Y., and Arai, S. (1993) FEBS Lett. 316, 253-256). Here we describe a full-length cDNA clone encoding a tongue cell-type specific receptor. The encoded protein consists of 312 amino acid residues. In overall structure, the protein is similar to known G protein-coupled, seven-transmembrane receptors such as an olfactory receptor (56% identity) but is significantly different in part, particularly in NH2-terminal extracellular and COOH-terminal cytoplasmic domain structures. Northern analysis showed that the mRNA for this protein is expressed only in the epithelium of the tongue, not in other organs. In situ hybridization experiments clearly indicated that the mRNA is expressed exclusively on the tongue apical surface, not on the reverse side of the tongue nor in its muscle layer. Expression was also detected in the taste buds and surrounding cellular tissues of the fungiform and circumvallate papillae. It is suggested that this gustatory receptor structurally related to olfactory receptors may be a candidate for a taste receptor.	UNIV TOKYO, FAC AGR, DEPT VET ANAT, BUNKYO KU, TOKYO 113, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo; University of Tokyo	ABE, K (corresponding author), UNIV TOKYO, FAC AGR, DEPT AGR CHEM, BUNKYO KU, TOKYO 113, JAPAN.							ABE K, 1993, FEBS LETT, V316, P253, DOI 10.1016/0014-5793(93)81302-G; APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; ARVIDSON K, 1980, SCIENCE, V209, P807, DOI 10.1126/science.7403846; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DEHAN R, 1971, EXPERIENTIA, V27, P823, DOI 10.1007/BF02136888; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; Getchell TV, 1991, SMELL TASTE HLTH DIS; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1988, CHEM SENSES, V13, P115, DOI 10.1093/chemse/13.1.115; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUMAZAWA T, 1990, J GEN PHYSIOL, V95, P1007, DOI 10.1085/jgp.95.5.1007; KUMAZAWA T, 1988, BIOCHEMISTRY-US, V27, P1239, DOI 10.1021/bi00404a025; KUMAZAWA T, 1985, BRAIN RES, V333, P27, DOI 10.1016/0006-8993(85)90120-9; Maniatis T., 1982, MOL CLONING; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MIYAMOTO T, 1988, J PHYSIOL-LONDON, V405, P699, DOI 10.1113/jphysiol.1988.sp017356; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; OZEKI M, 1972, COMP BIOCHEM PHYSIOL, V41, P391, DOI 10.1016/0300-9629(72)90070-9; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; ROPER S, 1983, SCIENCE, V220, P1311, DOI 10.1126/science.6857254; SCHIFFMAN SS, 1983, P NATL ACAD SCI-BIOL, V80, P6136, DOI 10.1073/pnas.80.19.6136; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; YOKOUCHI Y, 1991, DEVELOPMENT, V113, P431	45	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					12033	12039						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685030				2022-12-27	WOS:A1993LF28400086
J	SHEN, QC; CHU, FF; NEWBURGER, PE				SHEN, QC; CHU, FF; NEWBURGER, PE			SEQUENCES IN THE 3'-UNTRANSLATED REGION OF THE HUMAN CELLULAR GLUTATHIONE-PEROXIDASE GENE ARE NECESSARY AND SUFFICIENT FOR SELENOCYSTEINE INCORPORATION AT THE UGA CODON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CHROMOSOMAL LOCALIZATION; ESCHERICHIA-COLI; ACTIVE-SITE; EXPRESSION; SELENIUM; CDNA; CELLS; IDENTIFICATION; DEIODINASE	Glutathione peroxidase (EC 1.11.1.9) is one of a unique group of prokaryotic and eukaryotic enzymes that contain the unusual amino acid selenocysteine. The genes for these selenoproteins encode for the atypical amino acid at a TGA codon (UGA in the mRNA transcripts), which normally functions as a termination signal. The present studies analyzed the functional importance of sequences in the coding and 3'-untranslated regions of transcripts of the primary human cellular glutathione peroxidase gene (GPX1) to the insertion of selenocysteine at this UGA codon. Deletions in potential stem-loop or hairpin structures in the coding region did not substantially diminish incorporation of selenocysteine into glutathione peroxidase transiently expressed by the pCMV4 vector in COS-1 cells. However, selenocysteine insertion was completely abolished by deletion of four-nucleotide sequences in the 3'-untranslated region from within a conserved ''selenocysteine insertion sequence'' motif also found in the 3'-untranslated region of mammalian genes for other selenoproteins. Moreover, in constructs fusing the glutathione peroxidase 3'-untranslated region to the coding region of rab5b (an unrelated protein normally without any selenium moiety), the glutathione peroxidase 3'-untranslated region was sufficient to direct the translation of an opal (UGA) mutation as selenocysteine. Thus, our data directly demonstrate the importance of the selenocysteine insertion motif in the glutathione peroxidase gene and specifically show that sequence elements in the 3'-untranslated region are both necessary and sufficient for translational insertion of selenocysteine at a UGA codon in eukaryotic mRNA.	UNIV MASSACHUSETTS,SCH MED,DEPT PEDIAT,S5-859,WORCESTER,MA 01655; CITY HOPE NATL MED CTR,DEPT MED ONCOL & THERAPEUT RES,DUARTE,CA 91010	University of Massachusetts System; University of Massachusetts Worcester; City of Hope				Newburger, Peter/0000-0002-8615-673X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041625] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASHI M, 1991, BLOOD, V78, P2005; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; BRAWERMAN G, 1981, CRC CR REV BIOCH MOL, V10, P1, DOI 10.3109/10409238109114634; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHADA S, 1990, GENOMICS, V6, P268, DOI 10.1016/0888-7543(90)90566-D; CHADA S, 1989, BLOOD, V74, P2535; CHADA S, 1988, OXYRADICALS MOL BIOL, P273; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; CHU FF, 1990, NUCLEIC ACIDS RES, V18, P1531, DOI 10.1093/nar/18.6.1531; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESWORTHY RS, 1991, ARCH BIOCHEM BIOPHYS, V286, P330, DOI 10.1016/0003-9861(91)90048-N; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; HATFIELD D, 1985, TRENDS BIOCHEM SCI, V10, P201, DOI 10.1016/0968-0004(85)90192-6; HAWKES WC, 1982, BIOCHIM BIOPHYS ACTA, V699, P183, DOI 10.1016/0167-4781(82)90106-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KURATA H, 1992, FEBS LETT, V312, P10, DOI 10.1016/0014-5793(92)81400-G; LEE BJ, 1989, J BIOL CHEM, V264, P9724; MANIATIS T, 1990, MOL CLONING; MULLENBACH GT, 1987, NUCLEIC ACIDS RES, V15, P5484, DOI 10.1093/nar/15.13.5484; READ R, 1990, J BIOL CHEM, V265, P17899; ROCHER C, 1991, GENE, V98, P193, DOI 10.1016/0378-1119(91)90173-9; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; TAKAHASHI K, 1986, BLOOD, V68, P640; WILSON DB, 1992, J CLIN INVEST, V89, P996, DOI 10.1172/JCI115683; ZINONI F, 1990, P NATL ACAD SCI USA, V87, P4660, DOI 10.1073/pnas.87.12.4660; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	29	109	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11463	11469						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684384				2022-12-27	WOS:A1993LD46600107
J	JIANG, WP; SADLER, PM; JENKINS, NA; GILBERT, DJ; COPELAND, NG; BOND, JS				JIANG, WP; SADLER, PM; JENKINS, NA; GILBERT, DJ; COPELAND, NG; BOND, JS			TISSUE-SPECIFIC EXPRESSION AND CHROMOSOMAL LOCALIZATION OF THE ALPHA-SUBUNIT OF MOUSE MEPRIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOHISTOCHEMICAL LOCALIZATION; KIDNEY; GENE; METALLOENDOPEPTIDASES; EXTRACTION; MEMBRANE; MEP-1; MICE; RAT; DNA	Meprins, membrane-bound oligomeric metalloendopeptidases, contain alpha and/or beta subunits. Their activities have been found in the mouse and rat kidney. The cloned cDNA for the mouse alpha subunit of meprin A (EC 3.4.24.18) was used here to survey mRNA expression in kidney of different mouse strains and in various tissues of mice and rats. A single message of 3.6 kilobases was found in kidney of random bred (ICR) and inbred mice (C57BL/6, DBA/2) that contain high meprin A activity and in Sprague-Dawley rat kidney. The alpha subunit message was undetectable in the kidney of C3H/He and CBA mice, inbred strains that do not express meprin A activity. Therefore, meprin A activity in the kidney of mouse strains correlates with the amount of alpha subunit mRNA present. The 3.6-kilobase mRNA meprin alpha subunit message was also detected in the small intestine of the rat but not in mice. No message was detected in brain, heart, skeletal muscle, liver, lung, or spleen of mice or rats. Polymerase chain reaction amplification or Southern blot analysis of genomic DNA revealed that the gene for the alpha subunit is present in all mouse strains as well as in human, monkey, rat, mouse, dog, cow, rabbit, and chicken, but it was not detected in yeast. There is one gene copy present in the mouse genome. The gene was localized to mouse chromosome 17 centromeric to the major histocompatibility complex (H-2) by the interspecific backcrossing method. The localization of this allele to Mep-1, the gene previously found to regulate the expression of meprin A activity in mice, supports the proposal that Mep-1 is the structural gene for the alpha subunit.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LABS INC,MAMALIAN GENET LAB,FREDERICK,MD 21702	Virginia Polytechnic Institute & State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019691, R37DK019691, R56DK019691] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES K, 1989, BIOCHEM J, V264, P335, DOI 10.1042/bj2640335; BEYNON RJ, 1983, SCIENCE, V219, P1351, DOI 10.1126/science.6338590; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BEYNON RJ, 1985, INTRACELLULAR PROTEI, P185; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOND JS, 1988, MAMMALIAN BRUSH BORD, P139; BOND JS, 1984, P NATL ACAD SCI USA, V81, P5541; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; CRAIG SS, 1991, J HISTOCHEM CYTOCHEM, V39, P123, DOI 10.1177/39.1.1701182; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; Green EL, 1981, GENETICS PROBABILITY, P77; GUNNING P, 1987, MOL CELL BIOL, V7, P4100, DOI 10.1128/MCB.7.11.4100; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KENNY AJ, 1987, BIOCHEM J, V245, P525; LEPAGE T, 1992, DEVELOPMENT, V114, P147; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; RECKELHOFF JF, 1988, IMMUNOGENETICS, V27, P298, DOI 10.1007/BF00376127; RECKELHOFF JF, 1985, IMMUNOGENETICS, V22, P617, DOI 10.1007/BF00430310; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; Sambrook J, 1989, MOL CLONING LABORATO; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SIRACUSA LD, 1991, GENETICS, V127, P169; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	32	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10380	10385						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683677				2022-12-27	WOS:A1993LB80000061
J	LEE, KM; TOSCAS, K; VILLEREAL, ML				LEE, KM; TOSCAS, K; VILLEREAL, ML			INHIBITION OF BRADYKININ-INDUCED AND THAPSIGARGIN-INDUCED CA(2+) ENTRY BY TYROSINE KINASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HUMAN-FIBROBLASTS; SIGNAL TRANSDUCTION; CALCIUM ENTRY; DNA-SYNTHESIS; SELECTIVE INHIBITOR; PROTEIN-KINASE; ACINAR-CELLS; RECEPTOR; ACTIVATION; PHOSPHORYLATION	We examined the involvement of tyrosine kinase activity in the bradykinin (BK)-mediated signal transduction process. Immunoblots with anti-phosphotyrosine antibodies following BK stimulation of human fibroblasts showed tyrosine phosphorylation of specific proteins that could be inhibited by the tyrosine kinase inhibitors genistein and tyrphostin. Image analysis data from individual cells stimulated by BK in the presence of genistein and tyrphostin showed that these inhibitors block the plateau phase but not the rapid transient phase of the BK-induced calcium response. That the loss of the plateau phase was due to blockage of calcium entry rather than stimulation of calcium pump activity was confirmed by examining the influx of Ba2+ following BK stimulation. The Ca2+ imaging results were confirmed by Ca-45(2+) uptake measurements and extended to another tyrosine kinase inhibitor (methyl 2,5-dihydroxycinnamate), which was found to interfere with the fura-2 signal and therefore could not be used in imaging experiments. The fact that three structurally distinct inhibitors of tyrosine kinase activity inhibited BK-stimulated calcium influx, while an inactive analogue of genistein (daidzein) did not, strongly suggests the involvement of tyrosine kinases in the regulation of a BK-induced calcium entry pathway. To our knowledge, this is the first report of tyrosine kinase involvement in the regulation of calcium entry following activation of a receptor that lacks endogenous tyrosine kinase activity and is known to be coupled to phosphatidylinositol turnover. We found that calcium entry in HSWP (human foreskin fibroblast) cells can also be stimulated by emptying the intracellular calcium stores with thapsigargin. Genistein also inhibits the plateau phase of the thapsigargin-induced calcium response while leaving the transient phase intact. This suggests that the Ca2+ influx pathway induced by depletion of intracellular calcium stores with thapsigargin also may be regulated via a tyrosine kinase pathway.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAUMGARTEN LB, 1992, J BIOL CHEM, V267, P10524; BYRON KL, 1989, J BIOL CHEM, V264, P18234; BYRON KL, 1992, J BIOL CHEM, V267, P108; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1; FAHEY JV, 1977, AGENTS ACTIONS, V7, P255, DOI 10.1007/BF01969984; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONG SL, 1981, J BIOL CHEM, V256, P5215; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; JAMIESON GA, 1987, ARCH BIOCHEM BIOPHYS, V252, P478, DOI 10.1016/0003-9861(87)90054-3; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MULDOON LL, 1985, AM J PHYSIOL, V249, pC140, DOI 10.1152/ajpcell.1985.249.1.C140; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PEPPELENBOSCH MP, 1991, J BIOL CHEM, V266, P19938; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROBERTS RA, 1989, J CELL SCI, V94, P527; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SNIDER RM, 1984, J NEUROCHEM, V43, P1749, DOI 10.1111/j.1471-4159.1984.tb06104.x; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	33	218	220	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9945	9948						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683685				2022-12-27	WOS:A1993LB80000003
J	LIN, HH; LI, WY; ANN, DK				LIN, HH; LI, WY; ANN, DK			THE HELIX-LOOP-HELIX PROTEINS (SALIVARY-SPECIFIC CAMP RESPONSE ELEMENT-BINDING PROTEINS) CAN MODULATE CAMP-INDUCIBLE RP4 GENE-EXPRESSION IN SALIVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEIN; DNA-BINDING; TRANSCRIPTION FACTORS; CATALYTIC SUBUNIT; CYCLIC-AMP; ENHANCER; SEQUENCE; KINASE; RAT; ISOPROTERENOL	Salivary-specific and cAMP-inducible expression of the rat proline-rich protein gene RP4 is dependent on a 28-base pair sequence of a salivary-specific cAMP response element (SCRE) (Lin, H. H., and Ann, D. K. (1992) Gene Expression 2, 365-377). To unravel its trans-acting factor(s), we used double-stranded oligoprobes corresponding to the SCRE to screen a randomly primed lambdagt11 cDNA expression library made from RNA of rat salivary cells. In this report, we describe the cDNA cloning of these helix-loop-helix SCRE-binding proteins (SCBPs) and demonstrate that there are at least three isoforms in salivary cells, namely SCBPalpha, SCBPbeta, and SCBPgamma. RNA polymerase chain reaction and sequence analyses further confirmed the existence of these three different SCBP isoforms, which code for putative proteins of 707, 706, and 682 amino acids, respectively. Expression of the cloned SCBP cDNAs in salivary cells stimulates the expression of a cotransfected reporter construct containing multicopies of the SCRE cloned upstream of the thymidine kinase promoter and the chloramphenicol acetyltransferase structural gene. This stimulation is much more pronounced in transfections in which SCBPalpha and SCBPbeta are cotransfected than when they are transfected individually. Furthermore, when low concentrations of SCBPalpha and SCBPbeta are cotransfected with the SCRE reporter gene, coexpression of the catalytic subunit of protein kinase A is required to efficiently activate the expression of the reporter gene. These results strongly suggest that the observed stimulation of the SCRE is achieved through the coordinated expression of the SCBPalpha, SCBPbeta, and protein kinase A activities, perhaps via a direct association of the two SCBPs and their phosphorylation by protein kinase A. We conclude that the isolated SCBPalpha and SCBPbeta cDNAs encode transcription activators that participate in the control of the inducible RP4 gene expression in salivary cells.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,3-249 MILLARD HALL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K04DE000292, R29DE009175] Funding Source: NIH RePORTER; NIDCR NIH HHS [K04-DE00292, R29-DE09175] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J CELL SCI, V100, P641; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GONALEZ GA, 1989, NATURE, V337, P748; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HE XJ, 1989, J CELL PHYSIOL, V138, P527, DOI 10.1002/jcp.1041380312; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; Lin H. Helen, 1992, Gene Expression, V2, P365; LIN HH, 1991, GENE, V104, P219, DOI 10.1016/0378-1119(91)90253-8; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NURMBERGER M, 1991, EMBO J, V10, P2957; PARK CW, 1992, J BIOL CHEM, V267, P15642; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555	39	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10214	10220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683670				2022-12-27	WOS:A1993LB80000041
J	WU, J; AMANDORON, E; LI, XG; WAINBERG, MA; PARNIAK, MA				WU, J; AMANDORON, E; LI, XG; WAINBERG, MA; PARNIAK, MA			MONOCLONAL ANTIBODY-MEDIATED INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE POLYMERASE-ACTIVITY - INTERACTION WITH A POSSIBLE DEOXYNUCLEOSIDE TRIPHOSPHATE BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIDOVUDINE AZT; TYPE-1; PROTEINS; ENZYME; IDENTIFICATION; CHROMATOGRAPHY; SENSITIVITY; PREDICTION; SUBSTRATE; MECHANISM	A series of monoclonal antibodies against p51/p66 human immunodeficiency virus-1 (HIV-1) reverse transcriptase (RT) were prepared by immunizing mice with the native enzyme immobilized on nitrocellulose. One of these antibodies, designated 1E8, was found to inhibit both RNA-dependent and DNA-dependent polymerase activities of RT but had no effect on the RNase H activity of the enzyme. This inhibition was noncompetitive with respect to primer/template and competitive with respect to deoxynucleoside triphosphate (dNTP). The extent of 1E8 inhibition of RT polymerase activity decreased with increasing concentrations of dNTP in the incubation but was not affected by changes in primer/template concentration. 1E8 bound equally well in solution to both free RT and to the RT-primer/template complex. However, binding to the latter was significantly reduced by the addition of increasing concentrations of dNTP. The ability of dNTP to inhibit the interaction of 1E8 with the RT-primer/template complex was dependent on the identity of the homopolymeric primer/template used; only that dNTP complementary to the template was effective in this respect. 1E8 bound to the p51/p66 reverse transcriptase heterodimer in solution and reacted with both p51 and p66 subunits of reverse transcriptase on Western blots. The antibody is therefore presumed to recognize a linear surface epitope on the enzyme. 1E8 was found to specifically recognize a peptide with the sequence KKDSTKWRK. This sequence corresponds to residues 65-73 of HIV-1 reverse transcriptase, a region identified as highly antigenic by several computer algorithms. Two mutations within this sequence have been identified with resistance to 3'-azido,3'-deoxythymidine. We conclude that residues 65-73 of HIV-1 reverse transcriptase may be at or near the polymerase active site of the enzyme, and may form part of the deoxynucleoside triphosphate binding domain of the enzyme.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,3755 COTE STE CATHERINE RD,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,MCGILL AIDS CTR,MONTREAL H3T 1E2,QUEBEC,CANADA	Lady Davis Institute; McGill University; McGill University								BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BASU A, 1989, J BIOL CHEM, V264, P8746; BRUCK C, 1986, METHOD ENZYMOL, V121, P587; CHENG YC, 1987, J BIOL CHEM, V262, P2187; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; COTTON RGH, 1985, MED RES REV, V5, P77, DOI 10.1002/med.2610050104; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; FERNS RB, 1991, AIDS RES HUM RETROV, V7, P307, DOI 10.1089/aid.1991.7.307; FERRIS AL, 1990, VIROLOGY, V175, P456, DOI 10.1016/0042-6822(90)90430-Y; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HIZI A, 1991, J BIOL CHEM, V266, P6230; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LI XG, 1993, J MED VIROL, V39, P251, DOI 10.1002/jmv.1890390314; LINDBORG B, 1992, ANTIVIR CHEM CHEMOTH, V3, P223, DOI 10.1177/095632029200300405; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MITCHELL LLW, 1992, BIOCHEMISTRY-US, V31, P7707, DOI 10.1021/bi00148a035; NARASIMHAN LS, 1992, PROTEIN ENG, V5, P139, DOI 10.1093/protein/5.2.139; ORVELL C, 1991, J GEN VIROL, V72, P1913, DOI 10.1099/0022-1317-72-8-1913; PAINTER GR, 1991, J BIOL CHEM, V266, P19362; PARKER JMR, 1986, BIOCHEMISTRY-US, V25, P5425, DOI 10.1021/bi00367a013; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RESTLE T, 1992, J BIOL CHEM, V267, P14654; SZILVAY AM, 1992, J ACQ IMMUN DEF SYND, V5, P647; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	37	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					9980	9985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683687				2022-12-27	WOS:A1993LB80000010
J	REARDON, JE				REARDON, JE			HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE - A KINETIC-ANALYSIS OF RNA-DEPENDENT AND DNA-DEPENDENT DNA POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I KLENOW; ENZYME FUNCTION; MECHANISM; RETROVIRUS; EXONUCLEASE; INITIATION; FIDELITY; GENOME	A minimal kinetic mechanism for HIV reverse transcriptase (RT)-catalyzed RNA-dependent and DNA-dependent DNA polymerization was determined by pre-steady-state kinetic methods to be: [GRAPHICS] where E, TP, dNTP, and PP(i) are RT, template-primer, 2'-deoxynucleoside 5'-triphosphate, and inorganic pyrophosphate, respectively. Defined sequence template-primers that encode for incorporation of dTTP were prepared by annealing either a 44-mer RNA template or a 44-mer DNA template (of the same sequence) to a 21-mer DNA primer (r44:d21-mer and d44:d21-mer, respectively). The values of the above kinetic constants were determined for dTMP and 3'-azido-3'-deoxythymidine 5'-monophosphate (AZTMP) incorporation into both template primers. The k(cat) and K(m) values calculated from these kinetic constants were similar to the values directly determined from steady-state experiments. Further, the net rate constants for processive incorporation of three successive nucleotides into the r44:d21-mer were similar indicating that a rate-determining step did not follow catalysis. A 20-fold difference in the rate constants (k(p)) for incorporation of dTMP into the r44:d21-mer versus the d44:d21-mer was largely responsible for the difference in the calculated processivity numbers of 340 and 5, respectively. Finally, the rate constant for pyrophosphorolysis of the 3'-AZTMP-terminated r44:d21-mer (k(pyro)) was similar to the rate constant for dissociation of the chain-terminated template primer from the enzyme (k(off)) indicating that millimolar concentrations of intracellular inorganic pyrophosphate would be required for pyrophosphorolysis of AZTMP-terminated retroviral genomes.			REARDON, JE (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							ALBERY WJ, 1976, BIOCHEMISTRY-US, V15, P5631, DOI 10.1021/bi00670a032; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W; BENKOVIC SJ, 1971, ENZYMES, V8, P20; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; Cleland W W, 1979, Methods Enzymol, V63, P103; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; FREEMAN GA, 1992, J MED CHEM, V35, P3192, DOI 10.1021/jm00095a014; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HASSETT A, 1982, BIOCHEMISTRY-US, V21, P6335, DOI 10.1021/bi00268a002; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOPKINS S, 1989, BIOCHEM BIOPH RES CO, V163, P106, DOI 10.1016/0006-291X(89)92105-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; REY MA, 1984, BIOCHEM BIOPH RES CO, V121, P126, DOI 10.1016/0006-291X(84)90696-X; SMITH JK, 1984, J VIROL, V49, P200, DOI 10.1128/JVI.49.1.200-204.1984; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; VANDRAANEN NA, 1992, J BIOL CHEM, V267, P25019; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	32	103	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1993	268	12					8743	8751						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KX811	7682554				2022-12-27	WOS:A1993KX81100056
J	GUSOVSKY, F; LUEDERS, JE; KOHN, EC; FELDER, CC				GUSOVSKY, F; LUEDERS, JE; KOHN, EC; FELDER, CC			MUSCARINIC RECEPTOR-MEDIATED TYROSINE PHOSPHORYLATION OF PHOSPHOLIPASE C-GAMMA - AN ALTERNATIVE MECHANISM FOR CHOLINERGIC-INDUCED PHOSPHOINOSITIDE BREAKDOWN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; CALCIUM ENTRY; G-PROTEINS; VASOPRESSIN; ACTIVATION; HYDROLYSIS; ENDOTHELIN; INHIBITOR; BOMBESIN; INFLUX	In Chinese hamster ovary cells transfected with m5 muscarinic receptors, carbachol stimulates both calcium influx and calcium release from intracellular stores. The marine toxin maitotoxin (MTX) elicits a similar response on calcium influx. Carbachol- and MTX-induced calcium influx can be inhibited by the proposed blockers of receptor-operated calcium channels (ROCC), CAI and SK&F 96365. Both carbachol and MTX induce a significant increase in total protein tyrosine phosphorylation, which is dependent on extracellular calcium and can be inhibited by CAI and SK&F 96365. Phospholipase C-gamma was identified as one of the substrates subject to calcium-dependent tyrosine phosphorylation following carbachol or MTX stimulation. Carbachol-induced [H-3]inositol trisphosphate formation was partially inhibited by an inhibitor of tyrosine kinases, by removal of extracellular calcium, and by the inhibitor of receptor-operated calcium channels CAI suggesting that phosphorylation of phospholipase C-gamma plays a role in the muscarinic activation of phosphoinositide breakdown. Such an effect of carbachol is reminiscent of effects observed with peptide growth factors and represents a novel alternative signaling pathway for a muscarinic G protein-coupled receptor.	NIMH,CELL BIOL LAB,BLDG 36,RM 3A-15,BETHESDA,MD 20892; NIDDK,BIOORGAN CHEM LAB,BETHESDA,MD; NCI,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Felder, Christian/0000-0003-1134-8881				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRAUTIGAN DL, 1981, J BIOL CHEM, V256, P6519; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FORCE T, 1991, J BIOL CHEM, V266, P6650; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSOVSKY F, 1990, BIOCHEM PHARMACOL, V39, P1633, DOI 10.1016/0006-2952(90)90105-T; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HUPE DJ, 1989, Patent No. 4847257; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SOERGEL DG, 1992, MOL PHARMACOL, V41, P487; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	29	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7768	7772						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681827				2022-12-27	WOS:A1993KW97900031
J	CHEN, WI; LIM, HH; LIM, L				CHEN, WI; LIM, HH; LIM, L			A NEW MEMBER OF THE RAS SUPERFAMILY, THE RAC1 HOMOLOG FROM CAENORHABDITIS-ELEGANS - CLONING AND SEQUENCE-ANALYSIS OF CDNA, PATTERN OF DEVELOPMENTAL EXPRESSION, AND BIOCHEMICAL-CHARACTERIZATION OF THE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MOLECULAR-CLONING; RHO GENE; IDENTIFICATION; PRODUCT; FAMILY; INHIBITION; ENCODES; LET-60; G25K	A new member of the ras superfamily, designated CErac1 has been identified. The CErac1 cDNA clone was isolated from a Caenorhabditis elegans mixed stage library and encodes a protein of 191 amino acids with 82 and 79% identity to human rac1 and rac2 proteins, respectively. The CErac1 cDNA maps to a position on C. elegans chromosome IV in close proximity to cha-1, a choline acetyltransferase gene. The CErac1 cDNA hybridizes to two mRNAs (1.7 and 0.9 kilobases). Their expression is developmentally regulated, that of the more abundant 1.7 kilobases being highest at the embryonic stage and decreasing dramatically during development with 10% of the embryonic level in adult nematodes. The glutathione-S-transferase/CErac1 fusion protein expressed in Escherichia coli binds GTP and exhibits intrinsic GTPase activity. The GTPase activity of the CErac1 protein is stimulated by human n-chimaerin, a GTPase-activating protein for p21 rac1. These data suggest a role of CErac1 in C. elegans early development. The conserved biochemical properties indicate that further characterization of CErac1 by genetic analysis will be helpful in elucidating not only its role in the signal transduction, but also the biological function of its mammalian homologues.	INST NEUROL,LONDON WC1N 1PJ,ENGLAND	University of London; University College London	CHEN, WI (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.			Lim, Hong Hwa/0000-0002-0951-7220; , Yang/0000-0002-6620-8897				ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; DIAZGUERRA M, 1989, BIOCHEM BIOPH RES CO, V162, P802, DOI 10.1016/0006-291X(89)92381-4; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILES JG, 1983, J MOL BIOL, V164, P355, DOI 10.1016/0022-2836(83)90056-6; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LEV Z, 1985, MOL CELL BIOL, V105, P443; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PAWSON T, 1985, MOL CELL BIOL, V5, P33, DOI 10.1128/MCB.5.1.33; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL D, 1986, MOL CELL BIOL, V6, P2241; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; Wood WB, 1988, NEMATODE CAENORHABDI; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	32	34	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					320	324						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677998				2022-12-27	WOS:A1993KE60300049
J	CHEN, YH; RIBY, J; SRIVASTAVA, P; BARTHOLOMEW, J; DENISON, M; BJELDANES, L				CHEN, YH; RIBY, J; SRIVASTAVA, P; BARTHOLOMEW, J; DENISON, M; BJELDANES, L			REGULATION OF CYP1A1 BY INDOLO[3,2-B]CARBAZOLE IN MURINE HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH-RECEPTOR; RAT-LIVER; BINDING-SITES; HALF-LIFE; WILD-TYPE; INDUCTION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPRESSION; GENE; INDOLE-3-CARBINOL	To determine the basis for unexpected differences in CYP1A1 inducing potencies and efficacies for the diet-derived indole derivative, indolo[3,2-b]carbazole (ICZ) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), we conducted a systematic analysis of events involved in the induced expression of CYP1A1 in murine hepatoma-derived cell lines (Hepa-1), In contrast to the effects of TCDD, induction kinetics and CYP1A1 mRNA half-life were dependent on ICZ concentration, and the response from low doses of inducer was transient due to rapid clearance of ICZ, TCDD and ICZ produced the same maximum response (i.e. equal efficacies) from a TCDD-responsive CAT reporter construct in Hepa-1 cells, When measured by the immediate responses associated with CYP1A1 expression, including cellular uptake of inducer, receptor transformation and binding to DRE (gel mobility shift assay), initiation of transcription (nuclear run-on assay), and short-term accumulation of mRNA (Northern blot assay), ICZ also exhibited an efficacy equal to that of TCDD and a potency that corresponds to its receptor affinity, ICZ is a potent and selective noncompetitive inhibitor of ethoxyresorufin O-deethylase activity (K-i = 1.5 nM). Taken together these results indicate that ICZ is a bifunctional modulator of CYP1A1 expression with intrinsic efficacy equal to that of TCDD.	UNIV CALIF BERKELEY, DEPT NUTR SCI, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; LAWRENCE LIVERMORE NATL LAB, DEPT ENVIRONM TOXICOL, DAVIS, CA 95616 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory					NATIONAL CANCER INSTITUTE [R55CA049250] Funding Source: NIH RePORTER; NCI NIH HHS [CA49250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASTROFF B, 1989, TOXICOLOGY, V59, P285, DOI 10.1016/0300-483X(89)90198-4; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; CAI YN, 1993, CHEM RES TOXICOL, V6, P872, DOI 10.1021/tx00036a018; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038; CHRISTOU M, 1990, CARCINOGENESIS, V11, P1691, DOI 10.1093/carcin/11.10.1691; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DARGY R, 1989, PHARMACOL TOXICOL, V64, P33, DOI 10.1111/j.1600-0773.1989.tb00596.x; DAUJAT M, 1991, EUR J BIOCHEM, V200, P501, DOI 10.1111/j.1432-1033.1991.tb16211.x; DEKRUIF CA, 1991, CHEM-BIOL INTERACT, V80, P303, DOI 10.1016/0009-2797(91)90090-T; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DURRIN LK, 1989, MOL CELL BIOL, V9, P5733, DOI 10.1128/MCB.9.12.5733; GATTI RA, 1984, BIOTECHNIQUES    MAY, P148; GILLNER M, 1985, MOL PHARMACOL, V28, P357; GILLNER M, 1993, MOL PHARMACOL, V44, P336; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; ISRAEL DI, 1983, J BIOL CHEM, V258, P390; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KLEMAN MI, 1994, J BIOL CHEM, V269, P5137; KWON CS, 1994, J AGR FOOD CHEM, V42, P2536, DOI 10.1021/jf00047a030; LANDERS JP, 1991, BIOCHEM J, V276, P273, DOI 10.1042/bj2760273; LESCA P, 1979, CHEM-BIOL INTERACT, V24, P189, DOI 10.1016/0009-2797(79)90007-3; LESCA P, 1978, BIOCHEM PHARMACOL, V27, P1203, DOI 10.1016/0006-2952(78)90453-7; LIU H, 1994, JNCI-J NATL CANCER I, V86, P1758, DOI 10.1093/jnci/86.23.1758; LUBET RA, 1985, ARCH BIOCHEM BIOPHYS, V238, P43, DOI 10.1016/0003-9861(85)90138-9; MCDANELL R, 1988, FOOD CHEM TOXICOL, V26, P59, DOI 10.1016/0278-6915(88)90042-7; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MURRAY M, 1990, PHARMACOL REV, V42, P85; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PESONEN M, 1991, XENOBIOTICA, V21, P461, DOI 10.3109/00498259109039486; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; ROBINSON B, 1963, J CHEM SOC, P3097, DOI 10.1039/jr9630003097; SABLE AD, 1989, CARCINOGENESIS, V10, P629; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIESS MH, 1990, FOOD ADDIT CONTAM, V7, pS178, DOI 10.1080/02652039009373876; SILVER G, 1988, J BIOL CHEM, V263, P11802; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; TAKAHASHI N, 1995, FOOD CHEM TOXICOL, V33, P111, DOI 10.1016/0278-6915(94)00117-7; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITLOCK JP, 1989, MOL BIOL MED, V6, P169; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; XU LC, 1990, BIOCHEM PHARMACOL, V40, P1399; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	49	83	84	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22548	22555		10.1074/jbc.270.38.22548	http://dx.doi.org/10.1074/jbc.270.38.22548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673247	hybrid			2022-12-27	WOS:A1995RW31400076
J	KODURI, RS; TIEN, M				KODURI, RS; TIEN, M			OXIDATION OF GUAIACOL BY LIGNIN PEROXIDASE - ROLE OF VERATRYL ALCOHOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; DEGRADING BASIDIOMYCETE; MANGANESE PEROXIDASE; HYDROGEN-PEROXIDE; COMPOUND-III; DECOMPOSITION; MECHANISM; ENZYME; BIODEGRADATION; BURDS	We have investigated the Lignin peroxidase-catalyzed oxidation of guaiacol and the role of veratryl alcohol in this reaction by steady-state and pre-steady-state methods. Pre-steady-state kinetic analyses demonstrated that guaiacol is a good substrate for both compounds I and II, the two- and one-electron oxidized enzyme intermediates, respectively, of Lignin peroxidase. The rate constant for the reaction with compound I is 1.2 x 10(6) M(-1) s(-1). The reaction of guaiacol with compound II exhibits a K-d of 64 mu M and a first-order rate constant of 17 s(-1). Oxridation of guaiacol leads to tetraguaiacol formation. This reaction exhibits classical Michaelis-Menten kinetics with a K-m of 160 mu M and a k(cat) of 7.7 s(-1). Veratryl alcohol, a secondary metabolite of ligninolytic fungi, is capable of mediating the oxidation of guaiacol. This was shown by steady-state inhibition studies. Guaiacol completely inhibited the oxidation of veratryl alcohol, whereas veratryl alcohol had no corresponding inhibitory effect on guaiacol oxidation, In fact, at low guaiacol concentrations, veratryl alcohol stimulated the rate of guaiacol oxidation. These results collectively demonstrate that veratryl alcohol can serve as a mediator for phenolic substrates in the lignin peroxidase reaction.	PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR BIOMOLEC STRUCT & FUNCT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIEHS NIH HHS [1-P42ES04922-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004922] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARR DP, 1994, ARCH BIOCHEM BIOPHYS, V312, P511, DOI 10.1006/abbi.1994.1339; BARR DP, 1994, ARCH BIOCHEM BIOPHYS, V311, P378, DOI 10.1006/abbi.1994.1251; CAI DY, 1992, J BIOL CHEM, V267, P11149; CANCEL AM, 1993, APPL ENVIRON MICROB, V59, P2909, DOI 10.1128/AEM.59.9.2909-2913.1993; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; Cleland W W, 1979, Methods Enzymol, V63, P103; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; HAEMMERLI SD, 1987, FEBS LETT, V220, P149, DOI 10.1016/0014-5793(87)80893-1; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1990, J BIOTECHNOL, V13, P169, DOI 10.1016/0168-1656(90)90102-H; KHINDARIA A, 1995, BIOCHEMISTRY-US, V34, P6020, DOI 10.1021/bi00018a003; KIRK TK, 1986, BIOCHEM J, V236, P279, DOI 10.1042/bj2360279; KIRK TK, 1986, ENZYME MICROB TECH, V8, P27, DOI 10.1016/0141-0229(86)90006-2; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; KUAN IC, 1993, J BIOL CHEM, V268, P20064; LUNDQUIST K, 1978, PHYTOCHEMISTRY, V17, P1676, DOI 10.1016/S0031-9422(00)94674-0; Maehly AC, 1954, METHOD BIOCHEM ANAL, P358; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; PASZCZYNSKI A, 1986, ARCH BIOCHEM BIOPHYS, V244, P750, DOI 10.1016/0003-9861(86)90644-2; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; SANTIMONE M, 1974, CR ACAD SCI D NAT, V279, P951; Segel, 1975, ENZYME KINETICS BEHA, P274; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TONON F, 1988, APPL ENVIRON MICROB, V54, P466, DOI 10.1128/AEM.54.2.466-472.1988; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X	31	99	98	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22254	22258		10.1074/jbc.270.38.22254	http://dx.doi.org/10.1074/jbc.270.38.22254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673205	hybrid			2022-12-27	WOS:A1995RW31400031
J	PENA, MMO; BULLERJAHN, GS				PENA, MMO; BULLERJAHN, GS			THE DPSA PROTEIN OF SYNECHOCOCCUS SP STRAIN-PCC7942 IS A DNA-BINDING HEMOPROTEIN - LINKAGE OF THE DPS AND BACTERIOFERRITIN PROTEIN FAMILIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI	The Dps family of proteins are a diverse group of bacterial stress-inducible polypeptides that bind DNA and likely confer resistance to peroxide damage during periods of oxidative stress and long term nutrient limitation. Some members of the Dps protein family have been shown to form large (similar to 150-kDa), hexameric complexes that bind chromosomal DNA with little sequence specificity. In this paper we report the nucleotide sequence of the dpsA gene from Synechococcus sp. PCC7942 encoding a cyanobacterial Dps homolog. The deduced amino acid sequence of the Synechococcus sp. DpsA protein revealed that a carboxyl-terminal domain of the protein was >60% homologous to the COOH-terminal half of bacterioferritin, Other known Dps family members lack such high similarity 60 the bacterioferritins. Purification and spectroscopic analysis of the Synechococcus sp. DpsA protein complex revealed that the complex contains heme and has a weak catalase activity in vitro. Activity staining of nondenaturing polyacrylamide gels showed that the protein complex comigrated with both the heme and the catalase activity, and O-2 evolution measurements yielded a maximal specific activity of 1.7 mu mol of H2O2 consumed/mu g of protein(-1) min(-1). We speculate that the protein may have a peroxide-consuming mechanism located on the chromosomal DNA, and we also suggest that this activity may be a necessary feature to handle the endogenous oxidative stresses associated with oxygenic photosynthesis. Last, the evolutionary link between the Dps protein family and the bacterioferritins is discussed.	BOWLING GREEN STATE UNIV,CTR PHOTOCHEM SCI,DEPT BIOL SCI,BOWLING GREEN,OH 43403	University System of Ohio; Bowling Green State University			Bullerjahn, George S/F-4428-2010	Bullerjahn, George/0000-0001-5319-7896				ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; ANDREWS SC, 1991, FEBS LETT, V293, P164, DOI 10.1016/0014-5793(91)81177-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN L, 1993, J BACTERIOL, V175, P5428, DOI 10.1128/JB.175.17.5428-5437.1993; FALK JE, 1964, PORPHYRINS METALLOPO, P181; FERNANDEZ J, 1988, NUCLEIC ACIDS RES, V16, P7583; GROSSMAN MJ, 1992, P NATL ACAD SCI USA, V89, P2419, DOI 10.1073/pnas.89.6.2419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAULHERE JP, 1992, BIOCHEM J, V281, P785, DOI 10.1042/bj2810785; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOMOVSKAYA OL, 1994, J BACTERIOL, V176, P3928, DOI 10.1128/JB.176.13.3928-3935.1994; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; NOORDHOEK GT, 1989, MICROB PATHOGENESIS, V6, P29, DOI 10.1016/0882-4010(89)90005-3; PENA MMO, 1995, ARCH MICROBIOL, V163, P337, DOI 10.1007/BF00404206; PESSOLANI MCV, 1994, J EXP MED, V180, P319, DOI 10.1084/jem.180.1.319; PFEIFER O, 1992, J GEN MICROBIOL, V138, P1123, DOI 10.1099/00221287-138-6-1123; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOODBURY W, 1971, ANAL BIOCHEM, V44, P301, DOI 10.1016/0003-2697(71)90375-7	22	104	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22478	22482		10.1074/jbc.270.38.22478	http://dx.doi.org/10.1074/jbc.270.38.22478			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673237	hybrid			2022-12-27	WOS:A1995RW31400066
J	VANTHOF, R; DEKRUIJFF, B				VANTHOF, R; DEKRUIJFF, B			CHARACTERIZATION OF THE IMPORT PROCESS OF A TRANSIT PEPTIDE INTO CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; PROTEIN IMPORT; SMALL SUBUNIT; FERREDOXIN PRECURSOR; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; SECONDARY STRUCTURE; INVITRO SYNTHESIS; TRANSPORT; BINDING; TRANSLOCATION	In order to get insight into the functioning of transit sequences in chloroplast protein transport, the import of the full-length transit peptide of ferredoxin (trfd) was investigated. trfd rapidly associated with chloroplasts under import conditions and becomes protected against externally added proteases. Import of radiolabeled trfd is inhibited equally efficiently by nonlabeled trfd as well as by the intact precursor of ferredoxin. This strongly suggests that trfd enters the general import pathway of proteins into chloroplasts. trfd import was stimulated by ATP, which is the first demonstration that ATP is involved in membrane translocation of a targeting signal. Imported trfd was membrane-associated but was also partially degraded by internal proteases, most likely present in the stroma, indicating that the membrane-associated fraction of trfd is en route to its functional localization. The degradation products are exported out of the organelle. In contrast to the import of the precursor of ferredoxin, the import of trfd was independent of protease-sensitive components on the chloroplast surface, indicating that the initial binding of precursor proteins may be facilitated by transit sequence-lipid interactions.	UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,INST BIOMEMBRANES,DEPT BIOCHEM MEMBRANES,3584 CH UTRECHT,NETHERLANDS	Utrecht University								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULYCHEV A, 1994, FEBS LETT, V356, P204, DOI 10.1016/0014-5793(94)01259-8; CHUPIN V, 1994, FEBS LETT, V350, P104, DOI 10.1016/0014-5793(94)00734-9; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CORNWELL KL, 1987, PLANT PHYSIOL, V85, P780, DOI 10.1104/pp.85.3.780; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DOBBERSTEIN B, 1977, P NATL ACAD SCI USA, V74, P1082, DOI 10.1073/pnas.74.3.1082; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; FLUGGE UI, 1990, J BIOENERG BIOMEMBR, V22, P769; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GASSER SM, 1982, ARCH BIOCHEM BIOPHYS, V277, P368; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HORNIAK L, 1993, FEBS LETT, V334, P241, DOI 10.1016/0014-5793(93)81720-K; HUISMAN JG, 1978, BIOCHEM BIOPH RES CO, V82, P1121, DOI 10.1016/0006-291X(78)90303-0; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; PFISTERER J, 1982, EUR J BIOCHEM, V126, P143, DOI 10.1111/j.1432-1033.1982.tb06758.x; PILON M, 1992, FEBS LETT, V302, P65, DOI 10.1016/0014-5793(92)80286-P; PILON M, 1990, J BIOL CHEM, V265, P3358; PILON M, 1992, J BIOL CHEM, V267, P2548; PILON M, 1992, J BIOL CHEM, V267, P19907; PILON M, 1995, J BIOL CHEM, V270, P3882, DOI 10.1074/jbc.270.8.3882; REIS B, 1978, MOL GEN GENET, V209, P116; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SMEEKENS J, 1989, MOL GEN GENET, V261, P178; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; SMITH SM, 1979, NATURE, V278, P662, DOI 10.1038/278662a0; THEG SM, 1989, J BIOL CHEM, V264, P6730; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANTHOF R, 1995, FEBS LETT, V361, P35, DOI 10.1016/0014-5793(95)00135-V; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1991, FEBS LETT, V278, P3335; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WU CB, 1993, J BIOL CHEM, V268, P19384	52	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22368	22373		10.1074/jbc.270.38.22368	http://dx.doi.org/10.1074/jbc.270.38.22368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673221	hybrid			2022-12-27	WOS:A1995RW31400048
J	THOMMES, P; FARR, CL; MARTON, RF; KAGUNI, LS; COTTERILL, S				THOMMES, P; FARR, CL; MARTON, RF; KAGUNI, LS; COTTERILL, S			MITOCHONDRIAL SINGLE-STRANDED DNA-BINDING PROTEIN FROM DROSOPHILA EMBRYOS - PHYSICAL AND BIOCHEMICAL-CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; REPLICATION; POLYMERASE; SSB; PURIFICATION; COMPLEXES; CLONING	Using a stringent purification procedure on single-stranded DNA cellulose, we have isolated the mitochondrial single-stranded DNA-binding protein from Drosophila melanogaster embryos. Its identity is demonstrated by amino-terminal sequencing of the homogeneous protein and by its localization to a mitochondrial protein fraction. The mitochondrial protein is immunologically and biochemically distinct from the previously characterized nuclear replication protein A from Drosophila (Mitsis, P. G., Kowalczykowski, S. C., and Lehman, I. R. (1993) Biochemistry 32, 5257-5266; Marton, R. F., Thommes, P., and Cotterill, S. (1994) FEES Lett. 342, 139-144). It consists of a single polypeptide of 18 kDa, which is responsible for the DNA binding activity. Sedimentation analysis suggests that D. melanogaster mitochondrial single stranded DNA-binding protein exists as a homo-oligomer, possibly a tetramer, in solution. The protein binds to DNA in its single-stranded form with a strong preference over double-stranded DNA or RNG and binds to polypyrimidines preferentially over polypurines. Drosophila mitochondrial single-stranded DNA-binding protein exhibits a greater affinity for long oligonucleotides as compared to short ones, yet does not show high cooperativity. Its binding site size, determined by competition studies and by fluorescence quenching, is approximately 17 nucleotides under low salt conditions, and increases in the presence of greater than 150 mM NaCl. The homogeneous protein stimulates the activity of mitochondrial DNA polymerase from D. melanogaster embryos, increasing dramatically the rate of initiation of DNA synthesis on a singly primed DNA template.	MARIE CURIE RES INST,OXTED,SURREY RH8 0TL,ENGLAND; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bradford MM, 1976, ANAL BIOCHEM, V142, P79; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; COX MM, 1982, J BIOL CHEM, V257, P8523; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; GENUARIO R, 1993, CELL MOL BIOL RES, V39, P625; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; KAGUNI J, 1979, J MOL BIOL, V135, P863, DOI 10.1016/0022-2836(79)90516-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MARTON RF, 1994, FEBS LETT, V342, P139, DOI 10.1016/0014-5793(94)80488-5; MEYER RR, 1990, MICROBIOL REV, V54, pP53; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; Sambrook J, 1989, MOL CLONING LABORATO; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; THOMMES P, 1993, FEBS LETT, V319, P95, DOI 10.1016/0014-5793(93)80044-U; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860	28	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21137	21143		10.1074/jbc.270.36.21137	http://dx.doi.org/10.1074/jbc.270.36.21137			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673145	hybrid			2022-12-27	WOS:A1995RU05400044
J	JOSHIBARVE, SS; RANGNEKAR, VV; SELLS, SF; RANGNEKAR, VM				JOSHIBARVE, SS; RANGNEKAR, VV; SELLS, SF; RANGNEKAR, VM			INTERLEUKIN-1-INDUCIBLE EXPRESSION OF GRO-BETA VIA NF-KAPPA-B ACTIVATION IS DEPENDENT UPON TYROSINE KINASE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN IMMUNODEFICIENCY VIRUS; T-CELLS; GENE-EXPRESSION; HUMAN-FIBROBLASTS; TRANSCRIPTION FACTOR; PROTEIN-KINASE; IL-1 RECEPTORS; FACTOR BINDING; INDUCTION	Interleukin-1 (IL-1) induces programmed growth arrest in human melanoma cells, A375-C6. IL-1 action in these cells is associated with induction of a cell type-specific immediate-early (IE) gene expression program characterized by strong, rapid, and sustained induction of gro-alpha and gro-beta, but transient induction of c-jun, IRG-9, and NAK-1, and lack of induction of c-myc. With the exception of gro-alpha and gro-beta, these IE genes are also associated with growth-stimulatory responses in the melanoma cells, suggesting that the gro-genes may play key roles in the growth arrest action of the cytokine. To elucidate the early intracellular signals associated with IL-1 action, we are studying the second messenger signals and transcription factors required for induction of gro-genes. Here, we present evidence that IL-1-inducible gro-gene expression is dependent on tyrosine kinase signaling. Using gel retardation and transient expression assays, we show that IL-1 causes protein tyrosine phosphorylation-dependent activation of NF-kappaB enhancer binding protein, which then induces transcription of the gro-genes via an NF-kappaB site located 76 base pairs upstream from the cap site. IL-1-activated protein tyrosine phosphorylation is also required for gro-gene induction in human cervical carcinoma cells, HeLa; human fibroblast cells, WI-38; and mouse fibroblast cells, L929. Thus, in diverse cell types, IL-1 induces gro-genes via tyrosine kinase-dependent signals.	UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky					NCI NIH HHS [PTHB1 R29CA52839] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; ANISOWICZ A, 1991, J IMMUNOL, V147, P520; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BIRD TA, 1990, J BIOL CHEM, V265, P235; BOMSZTYK K, 1989, P NATL ACAD SCI USA, V86, P8034, DOI 10.1073/pnas.86.20.8034; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANFORTH DN, 1991, CANCER RES, V51, P1488; DINARELLO CA, 1991, BLOOD, V77, P1627; DONATI D, 1990, J IMMUNOL, V145, P4115; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; ENDO Y, 1988, J IMMUNOL, V141, P2342; ENSOLI B, 1989, EMBO J, V8, P3019, DOI 10.1002/j.1460-2075.1989.tb08452.x; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; FRYLING C, 1989, CANCER RES, V49, P3333; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HORUK R, 1987, J BIOL CHEM, V262, P16275; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KILIAN PL, 1991, CANCER RES, V51, P1823; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIZEL SB, 1982, IMMUNOL REV, V63, P51, DOI 10.1111/j.1600-065X.1982.tb00411.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUNOZ E, 1991, J IMMUNOL, V146, P136; MUNOZ E, 1992, EUR J IMMUNOL, V22, P1391, DOI 10.1002/eji.1830220610; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAMURA S, 1986, JPN J CANCER RES, V77, P767; ONOZAKI K, 1985, J IMMUNOL, V135, P314; ONOZAKI K, 1988, J IMMUNOL, V140, P112; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAGER R, 1991, ADV EXPT BIOL MED CH; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V12, P3454; TWEARDY DJ, 1990, J IMMUNOL, V144, P2233; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; USAI N, 1991, CANCER RES, V51, P769; VILCEK J, 1987, J BIOL CHEM, V262, P11908; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; WEN DZ, 1989, EMBO J, V8, P1761, DOI 10.1002/j.1460-2075.1989.tb03569.x; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	81	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18018	18029						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688736				2022-12-27	WOS:A1993LT74300058
J	SARGEANT, P; FARNDALE, RW; SAGE, SO				SARGEANT, P; FARNDALE, RW; SAGE, SO			ADP-EVOKED AND THAPSIGARGIN-EVOKED CA2+ ENTRY AND PROTEIN-TYROSINE PHOSPHORYLATION ARE INHIBITED BY THE TYROSINE KINASE INHIBITORS GENISTEIN AND METHYL-2,5-DIHYDROXYCINNAMATE IN FURA-2-LOADED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PLASMA-MEMBRANE; CALCIUM ENTRY; CA-2+ ENTRY; SIGNAL TRANSDUCTION; INOSITOL PHOSPHATES; ADENYLATE-CYCLASE; RABBIT PLATELETS; TUMOR PROMOTER; PHORBOL ESTERS	We have investigated the mechanism of Ca2+ entry in fura-2-loaded human platelets using the inhibitors of tyrosine kinases, genistein, and methyl-2,5-dihydroxycinnamate. Genistein (100 muM; 30 min) or methyl-2,5-dihydroxycinnamate (1 mug/ml; 30 min) reduced ADP-evoked protein-tyrosine phosphorylation at specific bands as assessed by gel electrophoresis and Western blotting with a specific antiphosphotyrosine antibody. Both compounds also reduced ADP-evoked [Ca2+]i rises in the presence, but not the absence, of external Ca2+, suggesting a relatively selective inhibition of Ca2+ entry over internal release. The inactive analogue of genistein, daidzein, was without effect on protein-tyrosine phosphorylation or ADP-evoked Ca2+ elevation in the presence or absence of external Ca2+. Methyl-2,5-dihydroxycinnamate (1 mug/ml; 5 min) significantly reduced the Ca2+ influx evoked by depletion of the intracellular Ca2+ stores using the inhibitor of the endomembranous Ca2+-ATPase, thapsigargin. These results with tyrosine kinase inhibitors are unlikely to be the result of the inhibition of other protein kinases since kinases A, C, and G all inhibit agonist-evoked rises in [Ca2+]i in platelets. These data support a role for tyrosine kinases in the control of Ca2+ entry in human platelets.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge	SARGEANT, P (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.			Sage, Stewart/0000-0001-8578-3558				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BACHELOT C, 1992, BIOCHEM J, V284, P923, DOI 10.1042/bj2840923; CROUCH MF, 1989, J BIOL CHEM, V264, P584; DHAR A, 1990, MOL PHARMACOL, V37, P519; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; ISSHIKI K, 1987, J ANTIBIOT, V40, P1209, DOI 10.7164/antibiotics.40.1209; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KASSIS S, 1985, J BIOL CHEM, V260, P8911; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MACINTYRE DE, 1982, THROMB HAEMOSTASIS, V47, P22; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1101; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; ODA A, 1992, AM J PHYSIOL, V262, pC701, DOI 10.1152/ajpcell.1992.262.3.C701; OGAWARA H, 1986, J ANTIBIOT, V39, P606, DOI 10.7164/antibiotics.39.606; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; PRESEK P, 1988, BIOCHIM BIOPHYS ACTA, V969, P271, DOI 10.1016/0167-4889(88)90062-6; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RENDU F, 1989, BLOOD, V73, P1545; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAGE SO, 1992, BIOCHEM J, V285, P341, DOI 10.1042/bj2850341; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SARGEANT P, 1993, FEBS LETT, V315, P242, DOI 10.1016/0014-5793(93)81172-V; SARGEANT P, 1992, CELL CALCIUM, V13, P553, DOI 10.1016/0143-4160(92)90035-Q; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859	47	204	205	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18151	18156						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688740				2022-12-27	WOS:A1993LT74300075
J	STOUFFER, GA; LAMARRE, J; GONIAS, SL; OWENS, GK				STOUFFER, GA; LAMARRE, J; GONIAS, SL; OWENS, GK			ACTIVATED ALPHA-2-MACROGLOBULIN AND TRANSFORMING GROWTH-FACTOR-BETA-1 INDUCE A SYNERGISTIC SMOOTH-MUSCLE CELL PROLIFERATIVE RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; FACTOR-BETA; EXPRESSION CLONING; BINDING PROTEINS; DENSITY; INHIBITION; CLEARANCE; COMPLEX; HYPERTROPHY; METHYLAMINE	The role that soluble binding proteins might play in regulating transforming growth factor-beta1 (TGF-beta1)-induced growth of smooth muscle cells (SMC) is unknown. Alpha2-macroglobulin (alpha2M) is the major plasma binding protein for TGF-beta. Reaction of alpha2M with methylamine (alpha2M-MA) forms ''activated'' alpha2M which binds TGF-beta and specific cell surface receptors. The objectives of these studies were to determine whether native alpha2M or alpha2M-MA influences growth responses of cultured rat aortic SMC to TGF-beta1. Results demonstrated that native alpha2M was not mitogenic. Treatment with alpha2M-MA or TGF-beta1 stimulated a 3- or 3.5-fold increase in [H-3]thymidine incorporation, respectively. Cotreatment with TGF-beta1 and alpha2M-MA resulted in a 70-fold increase in [H-3]thymidine incorporation. SMC bound alpha2M-MA in a specific and saturable manner and expressed alpha2M receptor/low density lipoprotein receptor-related protein (LRP). A modified form of alpha2M-MA (alpha2M-MA-cis-dichlorodiammine platinum), which bound TGF-beta1 but did not bind alpha2M receptors, failed to enhance TGF-beta1-induced growth. In summary, results demonstrated that alpha2M-MA enhanced TGF-beta1-induced growth responses and that this effect was dependent on alpha2M-MA binding to alpha2M receptor/LRP.	UNIV VIRGINIA,SCH MED,DEPT MOLEC PHYSIOL & CELLULAR BIOPHYS,BOX 449,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PATHOL & BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia			Stouffer, George/AAK-4763-2021		NCI NIH HHS [R01-CA-53462] Funding Source: Medline; NHLBI NIH HHS [P01-HL-19242, R01-HL-38854] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038854, P01HL019242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BONNER JC, 1990, J CELL PHYSIOL, V145, P1, DOI 10.1002/jcp.1041450102; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GONIAS SL, 1992, EXP HEMATOL, V20, P302; GOODMAN LV, 1989, J BIOL CHEM, V264, P5241; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JANAT MF, 1992, J CELL PHYSIOL, V150, P232, DOI 10.1002/jcp.1041500203; KERAMIDAS M, 1992, MOL CELL ENDOCRINOL, V84, P243, DOI 10.1016/0303-7207(92)90035-5; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAMARRE J, 1991, LAB INVEST, V65, P3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIBBY P, 1985, J CELL PHYSIOL, V125, P357, DOI 10.1002/jcp.1041250302; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MERWIN JR, 1991, AM J PATHOL, V138, P37; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MORISAKI N, 1991, ATHEROSCLEROSIS, V88, P227, DOI 10.1016/0021-9150(91)90085-H; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P301, DOI 10.1016/S0006-291X(88)80047-0; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STOUFFER GA, 1993, AM J PHYSIOL, V264, pC390, DOI 10.1152/ajpcell.1993.264.2.C390; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9	40	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					18340	18344						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688745				2022-12-27	WOS:A1993LT74300102
J	OURY, TD; PIANTADOSI, CA; CRAPO, JD				OURY, TD; PIANTADOSI, CA; CRAPO, JD			COLD-INDUCED BRAIN EDEMA IN MICE - INVOLVEMENT OF EXTRACELLULAR-SUPEROXIDE DISMUTASE AND NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; AQUEOUS-SOLUTION; NERVOUS-SYSTEM; FREE-RADICALS; ENDOTHELIUM; INJURY; ACID; PEROXYNITRITE; FERRIOXAMINE; INFARCTION	The role of extracellular superoxide in the pathogenesis of vasogenic edema was studied using transgenic mice expressing a 5-fold increase in extracellular superoxide dismutase (EC-SOD) activity in their brains. Increased EC-SOD expression offered significant protection against edema development after cold-induced injury (44% less edema than nontransgenic littermates, p < 0.05). Since iron may contribute to vasogenic edema by catalyzing the production of hydroxyl radical from superoxide and hydrogen peroxide, the effects of the chelator deferoxamine were studied. Deferoxamine reduced edema formation after cold-induced injury (43% less edema than controls, p < 0.05); however, treatment with iron-saturated deferoxamine also reduced edema development in mice (32-48% less edema, p < 0.05). This suggested that the protection offered by deferoxamine was independent of its ability to chelate iron. An iron-independent mechanism by which superoxide can contribute to vasogenic edema is via reaction with nitric oxide to produce the potentially toxic peroxynitrite anion, which is also scavenged by deferoxamine. Mice treated with an inhibitor of nitric oxide synthase were protected against cold-induced edema (37% less edema, p < 0.05). EC-SOD transgenic mice received no additional protection by inhibition of nitric oxide synthesis, supporting this novel alternative mechanism of edema formation.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	OURY, TD (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044571, P01HL031992] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44571, P01 HL31992] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1991, BIOCHEM J, V279, P263, DOI 10.1042/bj2790263; ADACHI T, 1989, J BIOL CHEM, V264, P8537; BARAT F, 1970, J CHEM SOC A, P1982, DOI 10.1039/j19700001982; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BLOUGH NV, 1985, INORG CHEM, V24, P3502, DOI 10.1021/ic00216a003; BULT H, 1988, BRIT J PHARMACOL, V95, P1308, DOI 10.1111/j.1476-5381.1988.tb11769.x; Chan P H, 1990, Adv Neurol, V52, P177; CHAN PH, 1984, FED PROC, V43, P210; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; ERLANSSON M, 1990, FREE RADICAL BIO MED, V9, P59, DOI 10.1016/0891-5849(90)90050-S; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1989, FREE RADICAL RES COM, V5, P315, DOI 10.3109/10715768909073413; HEIJMAN MGJ, 1985, RADIAT PHYS CHEM, V26, P83, DOI 10.1016/0146-5724(85)90037-8; HENDRICKSON DJ, 1990, GENOMICS, V8, P736, DOI 10.1016/0888-7543(90)90264-U; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HOE S, 1982, CHEM-BIOL INTERACT, V41, P75, DOI 10.1016/0009-2797(82)90018-7; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; Ikeda Y, 1990, Adv Neurol, V52, P203; INOUE M, 1990, FEBS LETT, V269, P89, DOI 10.1016/0014-5793(90)81126-9; KARLSSON K, 1988, BIOCHEM J, V255, P223; KEITH WG, 1969, J CHEM SOC A, P90, DOI 10.1039/j19690000090; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MONZYK B, 1982, J AM CHEM SOC, V104, P4921, DOI 10.1021/ja00382a031; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; NUCCI GD, 1988, P NATL ACAD SCI USA, V85, P2334; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; OURY TD, 1992, UNDERSEA BIOMED RE S, V19, P158; PATT A, 1990, J PEDIATR SURG, V25, P224, DOI 10.1016/0022-3468(90)90407-Z; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH815, DOI 10.1152/ajpheart.1986.250.5.H815; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; Sambrook J, 1989, MOL CLONING LABORATO; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; TIBELL L, 1987, P NATL ACAD SCI USA, V84, P6634, DOI 10.1073/pnas.84.19.6634; WILLMORE LJ, 1982, BRAIN RES, V246, P113, DOI 10.1016/0006-8993(82)90147-0; YAMAMOTO S, 1992, J CEREBR BLOOD F MET, V12, P717, DOI 10.1038/jcbfm.1992.102	45	127	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1993	268	21					15394	15398						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LN305	7687996				2022-12-27	WOS:A1993LN30500015
J	HOMA, FL; HOLLANDER, T; LEHMAN, DJ; THOMSEN, DR; ELHAMMER, AP				HOMA, FL; HOLLANDER, T; LEHMAN, DJ; THOMSEN, DR; ELHAMMER, AP			ISOLATION AND EXPRESSION OF A CDNA CLONE ENCODING A BOVINE UDP-GALNAC-POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; CELL-LINE SF9; O-GLYCOSYLATION; HUMAN FIBRONECTIN; MESSENGER-RNA; PROTEIN; SEQUENCE; OLIGOSACCHARIDES; PURIFICATION; TRANSFERASE	NH2-terminal amino acid sequence obtained from a UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase (GalNAc-transferase) isolated from bovine colostrum was used for the construction of synthetic oligonucleotide primers. Subsequent polymerase chain reaction and library screenings of a bovine intestine cDNA library produced seven positive clones. The largest clone had a 2294-base pair insert that contained an open reading frame coding for a protein composed of 559 amino acids with a predicted polypeptide molecular mass of 64,173 Da. The cloned molecule has no significant sequence homology to previously reported cloned glycosyltransferases, but appears to have a similar domain structure. It is a type II membrane protein with a 23-amino acid putative transmembrane region starting 8 amino acids from the NH2 terminus. The transmembrane segment of the molecule is immediately followed by a sequence rich in proline residues. The molecule contains three consensus sequences for N-linked glycosylation and five predicted sites for O-glycosylation. Northern blot analysis of poly(A+) mRNA isolated from Madin-Darby bovine kidney cells, bovine mammary tissue, and eight human tissues demonstrated the expression of two transcripts differing in size by approximately 1 kilobase. The cloned DNA was expressed in insect cells using a baculovirus vector. This resulted in an almost 100=fold increase in GalNAc-transferase activity in lysates prepared from cells infected with virus containing the GalNAc-transferase gene compared to cells infected with virus containing DNA coding for an unrelated molecule or uninfected cells. Immunoprecipitation from lysates prepared from infected cells labeled in vivo with [S-35] methionine showed a large increase in the recovery of an approximately 67-kDa protein.	UPJOHN CO,BIOCHEM RES UNIT,7240-209-622,301 HENRIETTA ST,KALAMAZOO,MI 49001; UPJOHN CO,BIOCHEM RES UNIT,KALAMAZOO,MI 49001	Pfizer; Pfizer								BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BUSHWAY AA, 1979, BIOCHIM BIOPHYS ACTA, V572, P146, DOI 10.1016/0005-2760(79)90209-1; CHEN WY, 1991, J BIOL CHEM, V266, P6246; DAVIS CG, 1986, J BIOL CHEM, V261, P2828; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; HAGOPIAN A, 1971, J BIOL CHEM, V246, P2519; HILL HD, 1977, J BIOL CHEM, V252, P3799; HOMA FL, 1986, MOL CELL BIOL, V6, P3652, DOI 10.1128/MCB.6.11.3652; HSIEH P, 1984, J BIOL CHEM, V259, P2375; HUGHES RC, 1988, CARBOHYD RES, V178, P259, DOI 10.1016/0008-6215(88)80117-4; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; MATSUURA H, 1989, J BIOL CHEM, V264, P10472; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; PARODI AJ, 1984, MOL CELL BIOCHEM, V58, P157, DOI 10.1007/BF00240615; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRIEELS JP, 1975, EUR J BIOCHEM, V60, P525, DOI 10.1111/j.1432-1033.1975.tb21031.x; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SUMMERS MD, 1986, MANUAL METHODS BACUL; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; THOMSEN DR, 1990, J CELL BIOCHEM, V43, P67, DOI 10.1002/jcb.240430107; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG Y, 1992, J BIOL CHEM, V267, P12706; WATHEN MW, 1991, BIOCHEMISTRY-US, V30, P2863, DOI 10.1021/bi00225a019; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P2512; YOUNG JD, 1979, BIOCHEMISTRY-US, V18, P4444, DOI 10.1021/bi00587a026	48	151	159	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12609	12616						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	7685345				2022-12-27	WOS:A1993LG65800058
J	PANETTI, TS; MCKEOWNLONGO, PJ				PANETTI, TS; MCKEOWNLONGO, PJ			THE ALPHA(V)BETA(5) INTEGRIN RECEPTOR REGULATES RECEPTOR-MEDIATED ENDOCYTOSIS OF VITRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMINOGEN-ACTIVATOR INHIBITOR-1; THROMBIN-ANTITHROMBIN-III; EXTRACELLULAR-MATRIX; CELL-SURFACE; HUMAN-PLASMA; VONWILLEBRAND-FACTOR; ENDOTHELIAL-CELLS; ADHESION RECEPTOR; S-PROTEIN; FIBRONECTIN	Vitronectin is an adhesive glycoprotein that binds to the extracellular matrix and interacts with integrin receptors on the surface of adherent cells. Previous studies have demonstrated that the conformationally altered, heparin binding form of vitronectin is removed from the matrix by receptor-mediated endocytosis and degraded through a lysosomal pathway (Panetti, T. S., and McKeown-Longo, P. J. (1993) J. Biol. Chem. 268, 11988-11993). The present studies were undertaken to determine the role of cell surface integrins in the endocytosis and degradation of vitronectin. RGDS peptides, used to disrupt the binding of vitronectin to cell surface integrins, inhibited degradation of vitronectin but had no effect on the binding of vitronectin to the cell layer. Localization of vitronectin in the cell layer by indirect immunofluorescence indicated that the RGDS peptides inhibited degradation by preventing the internalization of vitronectin by the cells. To determine which vitronectin receptor was involved in mediating the endocytosis, vitronectin degradation was measured in the presence of monoclonal antibodies. Antibodies against the alpha(v)beta5 but not the alpha(v)beta3 integrin inhibited degradation of vitronectin by 80%. This study demonstrates a new role for integrins in regulating internalization and degradation of molecules from the extracellular matrix.	ALBANY MED COLL,DEPT PHYSIOL & CELL BIOL,NEIL HELLMAN MED RES BLDG,ALBANY,NY 12208	Albany Medical College					NATIONAL CANCER INSTITUTE [R01CA037785, R01CA058626, R56CA058626] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37785, CA-58626] Funding Source: Medline; NHLBI NIH HHS [HL-01794] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLYSTONE SD, 1991, BLOOD, V78, P2900; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; HANDAGAMA P, 1993, J CLIN INVEST, V91, P193, DOI 10.1172/JCI116170; HARRISON P, 1989, J CLIN INVEST, V84, P1320, DOI 10.1172/JCI114300; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; ILL CR, 1985, J BIOL CHEM, V260, P5610; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; KRUITHOF EKO, 1984, BLOOD, V64, P907; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MIMURO J, 1989, J BIOL CHEM, V264, P936; MIMURO J, 1989, J BIOL CHEM, V264, P5058; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PODACK ER, 1978, J IMMUNOL, V120, P1841; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; ROVELLI G, 1990, EUR J BIOCHEM, V192, P797, DOI 10.1111/j.1432-1033.1990.tb19293.x; SMITH JW, 1990, J BIOL CHEM, V265, P11008; TOMASINI BR, 1988, BLOOD, V72, P903; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7671; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WOODS A, 1992, ADV EXP MED BIOL, V313, P87; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	38	98	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11492	11495						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685013				2022-12-27	WOS:A1993LF28400006
J	DARLING, DS; CARTER, RL; YEN, PM; WELBORN, JM; CHIN, WW; UMEDA, PK				DARLING, DS; CARTER, RL; YEN, PM; WELBORN, JM; CHIN, WW; UMEDA, PK			DIFFERENT DIMERIZATION ACTIVITIES OF ALPHA AND BETA THYROID-HORMONE RECEPTOR ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE PROMOTER ACTIVITY; RESPONSE ELEMENT; DNA-BINDING; T3 RECEPTOR; CDNA CLONE; IDENTIFICATION; PROTEIN; TRANSCRIPTION; EXPRESSION; 3,5,3'-TRIIODOTHYRONINE	Thyroid hormone receptors (TR) are ligand-dependent transcription factors that are encoded as multiple isoforms on two genes. To date, no functional differences have been shown between the TR isoforms; however, the maintenance of alpha and beta genes during vertebrate evolution argues that functional differences do exist. We have localized a TR-binding site in the rabbit beta-myosin heavy chain gene. This site and TR-binding sites in the chicken lysozyme and rat alpha-glycoprotein hormone genes were used to compare the DNA-binding activities of TRalpha and TRbeta and the influence of auxiliary proteins (TRAP). TRalpha formed alpha/alpha homodimers poorly, whereas TRbeta formed beta/beta homodimers preferentially. This difference was not due to either a lower amount of TRalpha synthesized in the reticulocyte lysate or to an inability of the expressed TRalpha to form dimers, since both TRalpha and TRbeta readily formed heterodimers with TRAP on these TR-binding sites. Additionally, a TRalpha fragment containing the dimerization domains (TRalphaC291) blocks TRbeta/TRAP complexes but not TRalpha/TRAP complexes. This indicates that TRbeta/TRalpha dimers form more readily than TRalpha/TRalpha dimers. We conclude that on the binding sites examined, TRbeta has a greater tendency to form homodimers than TRalpha, whereas both isoforms form heterodimers similarly. The different homodimerization potentials of TRalpha and TRbeta may underlie functional differences that affect thyroid hormone responses.	UNIV ALABAMA, DEPT MED, DIV CARDIOVASC DIS, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, DIV CARDIOVASC DIS, BIRMINGHAM, AL 35294 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GENET, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			Darling, Douglas S/D-4573-2009; Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114; Darling, Douglas/0000-0002-9039-1169	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044332] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44094] Funding Source: Medline; NIDDK NIH HHS [DK 44332] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Maxam A M, 1980, Methods Enzymol, V65, P499; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; MURRAY MB, 1988, J BIOL CHEM, V263, P12270; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SHOWERS MO, 1991, DNA CELL BIOL, V10, P211, DOI 10.1089/dna.1991.10.211; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; UMEDA PK, 1987, AM J CARDIOL, V59, pA49, DOI 10.1016/0002-9149(87)90176-7; UMEDA PK, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P61; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Usala S J, 1991, Thyroid, V1, P361, DOI 10.1089/thy.1991.1.361; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZANG XK, 1992, NATURE, V355, P441	54	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10221	10227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683671				2022-12-27	WOS:A1993LB80000042
J	DIAZ, A; MUNOZ, E; JOHNSTON, R; KORN, JH; JIMENEZ, SA				DIAZ, A; MUNOZ, E; JOHNSTON, R; KORN, JH; JIMENEZ, SA			REGULATION OF HUMAN LUNG FIBROBLAST-ALPHA-1(I) PROCOLLAGEN GENE-EXPRESSION BY TUMOR-NECROSIS-FACTOR-ALPHA, INTERLEUKIN-1-BETA, AND PROSTAGLANDIN-E(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; MESSENGER-RNA LEVELS; GROWTH-FACTOR-BETA; COLLAGEN-SYNTHESIS; INTERFERON-GAMMA; RECOMBINANT INTERLEUKIN-1; INHIBITS COLLAGEN; DEOXYRIBONUCLEIC-ACID; SYNOVIAL-CELLS; III COLLAGENS	We investigated the participation of prostaglandin (PG) E2 in the regulation of the alpha1(I) procollagen gene expression by tumor necrosis factor alpha (TNFalpha), and interleukin-1beta (IL-1beta) in normal adult human lung fibroblasts. TNFalpha (100 units/ml) and IL-1beta (100 units/ml) stimulated the production of PGE2 and caused a dose-dependent inhibition of up to 54 and 66%, respectively, of the production of type I procollagen. Preincubation of cultures with indomethacin partially reversed the inhibition of procollagen production induced by the cytokines. Cytokine-stimulated endogenous fibroblast PG accounted for 35 and 68% of the inhibition induced by TNFalpha and IL-1beta, respectively. Steady-state mRNA levels for alpha1(I) procollagen paralleled the changes in collagen production. The transcription rate of the alpha1(I) procollagen gene was reduced by 58% by TNFalpha and by 43% by IL-1beta. Cytokine-stimulated endogenous PG production accounted for half of these effects. These results indicate that TNFalpha and IL-1beta inhibit the expression of the alpha1(I) procollagen gene in human lung fibroblasts at the transcriptional level by a PGE2-independent effect as well as through the effect of endogenous fibroblast PGE2 released under the stimulus of the cytokines.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL,ROOM 509 BLUEMLE LIFE SCI BLDG,PHILADELPHIA,PA 19107; UNIV CONNECTICUT,SCH MED,VET ADM MED CTR,DIV RHEUMAT DIS,NEWINGTON,CT 06111	Jefferson University; University of Connecticut; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System				Jimenez, Sergio/0000-0001-5213-1203	NHLBI NIH HHS [HL 41214] Funding Source: Medline; NIAMS NIH HHS [AR 32343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS SL, 1989, AM J RESP CELL MOL, V1, P161, DOI 10.1165/ajrcmb/1.3.161; ARENZANASEISDEDOS F, 1988, P NATL ACAD SCI USA, V85, P6087, DOI 10.1073/pnas.85.16.6087; BACHWICH PR, 1986, BIOCHEM BIOPH RES CO, V136, P94, DOI 10.1016/0006-291X(86)90881-8; BARILE FA, 1988, ARCH BIOCHEM BIOPHYS, V265, P441, DOI 10.1016/0003-9861(88)90147-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BHATNAGAR R, 1986, BIOCHEM INT, V13, P709; BISSONNETTE E, 1989, INFLAMMATION, V13, P329, DOI 10.1007/BF00914399; BREUL SD, 1980, J BIOL CHEM, V255, P5250; CANALIS E, 1986, ENDOCRINOLOGY, V118, P74, DOI 10.1210/endo-118-1-74; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; CHANDRASEKHAR S, 1990, EXP CELL RES, V191, P105, DOI 10.1016/0014-4827(90)90042-9; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; DIAZ A, 1989, J BIOL CHEM, V264, P11554; DIAZ A, 1992, J BIOL CHEM, V267, P10816; DUBOIS CM, 1989, AM REV RESPIR DIS, V139, P1257, DOI 10.1164/ajrccm/139.5.1257; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; ELIAS JA, 1990, ANN NY ACAD SCI, V580, P233, DOI 10.1111/j.1749-6632.1990.tb17932.x; ELIAS JA, 1988, J CLIN INVEST, V81, P325, DOI 10.1172/JCI113324; ELIAS JA, 1987, J IMMUNOL, V138, P3812; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; GOLDSTEIN RH, 1986, J BIOL CHEM, V261, P8734; HAMPSON F, 1989, AM J PHYSIOL, V256, pC336, DOI 10.1152/ajpcell.1989.256.2.C336; HARRISON JR, 1990, MOL ENDOCRINOL, V4, P184, DOI 10.1210/mend-4-2-184; KAHALEH MB, 1988, CLIN IMMUNOL IMMUNOP, V49, P261, DOI 10.1016/0090-1229(88)90116-X; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; KORN JH, 1985, ARTHRITIS RHEUM, V28, P315, DOI 10.1002/art.1780280312; KORN JH, 1983, J CLIN INVEST, V71, P1240, DOI 10.1172/JCI110873; LAURENT GJ, 1986, THORAX, V41, P418, DOI 10.1136/thx.41.6.418; LE JM, 1987, LAB INVEST, V56, P234; LEFEBVRE V, 1990, BIOCHIM BIOPHYS ACTA, V1052, P366, DOI 10.1016/0167-4889(90)90145-4; MARTINET Y, 1988, AM REV RESPIR DIS, V138, P659, DOI 10.1164/ajrccm/138.3.659; MARUSIC A, 1991, ENDOCRINOLOGY, V129, P2699, DOI 10.1210/endo-129-5-2699; MAUVIEL A, 1988, FEBS LETT, V236, P47, DOI 10.1016/0014-5793(88)80283-7; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1988, BIOCHEM J, V252, P247, DOI 10.1042/bj2520247; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; RAISZ LG, 1974, PROSTAGLANDINS, V8, P377, DOI 10.1016/0090-6980(74)90113-0; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHARFFETTER K, 1989, EXP CELL RES, V181, P409, DOI 10.1016/0014-4827(89)90098-0; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; TYLER JA, 1988, COLLAGEN REL RES, V8, P393; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7	53	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10364	10371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683676				2022-12-27	WOS:A1993LB80000059
J	END, P; GOUT, I; FRY, MJ; PANAYOTOU, G; DHAND, R; YONEZAWA, K; KASUGA, M; WATERFIELD, MD				END, P; GOUT, I; FRY, MJ; PANAYOTOU, G; DHAND, R; YONEZAWA, K; KASUGA, M; WATERFIELD, MD			A BIOSENSOR APPROACH TO PROBE THE STRUCTURE AND FUNCTION OF THE P85-ALPHA-SUBUNIT OF THE PHOSPHATIDYLINOSITOL 3-KINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; PDGF RECEPTOR; SIGNAL TRANSDUCTION; BOVINE BRAIN; SH2 DOMAINS; RAT-LIVER; MIDDLE-T; PROTEINS; PHOSPHORYLATION	Phosphatidylinositol 3-kinase, which generates putative novel second messenger phospholipids, is a heterodimer composed of regulatory adaptor 85-kDa and catalytic 110-kDa subunits. The p85alpha subunit contains a NH2-terminal src homology (SH) 3 domain, a region with homology to the product of the breakpoint cluster region (bcr) gene, and a COOH-terminal portion of the molecule which contains two SH2 domains, separated by a spacer region. In this study a panel of monoclonal antibodies (mAb) was raised against recombinant bovine p85alpha to probe its multidomain structure in relation to function. These mAbs were characterized using a BIAcore biosensor instrument. Epitopes for nine mAbs were mapped in relation to the domain structure of p85alpha using recombinant protein fragments expressed in bacteria. These mAbs were then used to map the sites on p85alpha which are involved in growth factor receptor binding. Two interesting classes of functional mAbs were identified. First, mAb U14, whose epitope lies within the NH2-terminal SH2 domain of p85alpha, blocked the interaction of p85alpha with activated protein-tyrosine kinase receptors. Second, real-time binding experiments using phospholipid-containing vesicles showed that p85alpha by itself could specifically bind certain phospholipids. Two mAbs (U9 and U15) with epitopes located in the inter-SH2 spacer region blocked the binding of lipids to this site. The relevance of these observations to understanding the relationship of structure to function of p85 and the phosphatidylinositol 3-kinase are discussed.	LUDWIG INST CANC RES,91 RIDING HOUSE ST,LONDON W1P 8BT,ENGLAND; KOBE UNIV,SCH MED,CHUO KU,KOBE 650,JAPAN; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Ludwig Institute for Cancer Research; Kobe University; University of London; University College London				Fry, Michael/0000-0001-8518-1370				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARDELLI A, 1992, ONCOGENE, V7, P1973; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRY M J, 1992, Current Biology, V2, P78, DOI 10.1016/0960-9822(92)90207-Q; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HALL A, 1992, CELL, V69, P398; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; JONSSON U, 1992, ADV BIOSENSORS, V2; KAVANAUGH WM, 1992, MOL CELL BIOL, V12, P3415, DOI 10.1128/MCB.12.8.3415; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOFAS S, 1990, J CHEM SOC CHEM COMM, V21, P1526; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PELES E, 1992, J BIOL CHEM, V267, P12266; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHANG J, 1992, J BIOL CHEM, V267, P4686	58	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10066	10075						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683666				2022-12-27	WOS:A1993LB80000022
J	GETHER, U; JOHANSEN, TE; SCHWARTZ, TW				GETHER, U; JOHANSEN, TE; SCHWARTZ, TW			CHIMERIC NK1 (SUBSTANCE-P)NK3 (NEUROKININ-B) RECEPTORS - IDENTIFICATION OF DOMAINS DETERMINING THE BINDING-SPECIFICITY OF TACHYKININ AGONISTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SUBSTANCE-P RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; EXTRACELLULAR DOMAIN; SELECTIVE AGONISTS; LIGAND-BINDING; K RECEPTOR; EXPRESSION; CDNA; INHIBITORS	The NK1 (substance P) and NK3 (neurokinin B) receptors are G protein-coupled receptors sharing approximately 70% identity within the membrane-spanning domains. However, they each have a distinct pharmacological profile in respect of peptide binding. To identify epitopes that determine their selectivity for natural and synthetic tachykinin peptides, we constructed a series of chimeric NK1/NK3 receptors in which carboxyl-terminal segments of increasing length in the NK1 receptor were exchanged with the corresponding segments from the NK3 receptor. The general, structural integrity of the chimeric constructs was confirmed by the amphibian tachykinin peptide, eledoisin, which was recognized equally well by both of the wild-type receptors and bound with a similar or even higher affinity to all the chimeric receptors. Competition binding studies showed that the affinity of the two natural ligands, substance P and neurokinin B, changed gradually through the series of chimeric receptors indicating that several binding epitopes throughout the receptor structure are involved in the selective recognition of these peptides. However, whereas the single, largest change in binding affinity for substance P occurred when segments in the amino-terminal end of the receptor were exchanged, this occurred for neurokinin B in the carboxyl-terminal end of the receptor. The affinity of the NK1-selective ligand, [Sar9,Met(O2)11]SP, changed even more gradually through the series of chimeric receptors than that of substance P. In contrast, the NK3-selective hexapeptide, senktide, was recognized only when transmembrane segment III and IV from the NK3 receptor were incorporated into the chimeric constructs. These data suggest that several receptor domains contribute to the binding specificity of tachykinin agonists but in varying degrees for each peptide. It is concluded that the tachykinin peptides, in partially different ways, interact with multiple epitopes scattered throughout the receptor structure, but conceivably these epitopes are closely located in space around a hypothetical receptor center.			GETHER, U (corresponding author), UNIV COPENHAGEN, RIGSHOSP 6321, DEPT CLIN BIOCHEM, MOLEC ENDOCRINOL LAB, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807				BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CASCIERI MA, 1992, MOL PHARMACOL, V41, P1096; CASCIERI MA, 1985, J BIOL CHEM, V260, P1501; CHANG MM, 1970, J BIOL CHEM, V245, P4784; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOPHYS J, V62, P59, DOI 10.1016/S0006-3495(92)81778-2; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; INGI T, 1991, J PHARMACOL EXP THER, V259, P968; IVERSEN LL, 1990, ALFRED BENZON SYMP S, V29, P363; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; PERNOW B, 1983, PHARMACOL REV, V35, P85; REGOLI D, 1988, TRENDS PHARMACOL SCI, V9, P290, DOI 10.1016/0165-6147(88)90013-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WATLING KJ, 1992, TRENDS PHARMACOL SCI, V13, P266, DOI 10.1016/0165-6147(92)90082-H; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WORMSER U, 1986, EMBO J, V5, P2805, DOI 10.1002/j.1460-2075.1986.tb04571.x; XIE YB, 1990, J BIOL CHEM, V265, P21411; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	36	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1993	268	11					7893	7898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KW979	7681831				2022-12-27	WOS:A1993KW97900048
J	RAMASWAMY, H; SWAMY, CVB; DAS, MR				RAMASWAMY, H; SWAMY, CVB; DAS, MR			PURIFICATION AND CHARACTERIZATION OF A HIGH-MOLECULAR-WEIGHT RIBONUCLEASE FROM HUMAN-MILK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; AMINO-ACID SEQUENCE; HUMAN-URINE; PANCREATIC RIBONUCLEASE; POLYACRYLAMIDE GELS; NUCLEOTIDE-SEQUENCE; HUMAN LACTOFERRIN; ALLOSTERIC MODEL; CO-OPERATIVITY; HUMAN-SERUM	We have purified a high molecular weight ribonuclease (hmRNase) from human milk by a two-step column chromatographic procedure and characterized the enzyme. The molecular mass of hmRNase is 80 kDa as determined from SDS-polyacrylamide gel electrophoresis. The pH optimum of the enzyme is in the range of 7.5-8.0, similar to other secretory RNases. hmRNase is pyrimidine-specific and cleaves the phosphodiester bond 3' to a pyrimidine residue. It selectively degrades the pyrimidine strand in poly(rA):poly(rU) and poly(dA):poly(rU) double stranded substrates. The extent of degradation for naturally occurring RNAs vary in the order tRNA < rRNA < mRNA at low enzyme concentrations. hmRNase shows allosteric behavior with positive cooperativity in its reaction on polynucleotide substrates. The activity of the enzyme is enhanced in the presence of monoribonucleotides. Antiserum obtained against purified hmRNase did not cross-react with low molecular weight RNase which is also present in milk. In addition, an immunologically cross-reacting species could not be detected in the serum, suggesting the origin of hmRNase in the mammary gland but not blood.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)								AKAGI K, 1976, BIOCHIM BIOPHYS ACTA, V442, P368, DOI 10.1016/0005-2787(76)90311-7; BEINTEMA JJ, 1988, BIOCHEMISTRY-US, V27, P4530, DOI 10.1021/bi00412a046; BIENTEMA JJ, 1984, ANAL BIOCHEM, V136, P48; BIENTEMA JJ, 1988, BIOCHEM J, V255, P501; BINGHAM EW, 1964, ARCH BIOCHEM BIOPHYS, V106, P235, DOI 10.1016/0003-9861(64)90182-1; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BLANK A, 1981, BIOCHEMISTRY-US, V20, P2261, DOI 10.1021/bi00511a030; CORBISHLEY TP, 1982, CLIN CHIM ACTA, V124, P225, DOI 10.1016/0009-8981(82)90390-4; COULSON EJ, 1964, ARCH BIOCHEM BIOPHYS, V107, P336, DOI 10.1016/0003-9861(64)90340-6; DALALY BK, 1980, BIOCHIM BIOPHYS ACTA, V615, P381, DOI 10.1016/0005-2744(80)90505-7; DAS MR, 1979, CANCER RES, V39, P5106; DAS MR, 1976, NATURE, V262, P802, DOI 10.1038/262802a0; DIDONATO A, 1987, BIOCHEM J, V241, P435, DOI 10.1042/bj2410435; FURMANSKI P, 1989, J EXP MED, V170, P415, DOI 10.1084/jem.170.2.415; GLAZER AN, 1975, LABORATORY TECHNIQUE, V4, P23; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; JENNESS R, 1970, MILK PROTEINS CHEMIS, V1, P17; JUSSAWALLA DJ, 1970, BRIT J CANCER, V24, P56, DOI 10.1038/bjc.1970.8; KALNITSKY G, 1959, J BIOL CHEM, V234, P1512; KALYANARAMAN S, 1983, MOL BIOL REP, V9, P179, DOI 10.1007/BF00775365; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU DK, 1982, COMP BIOCHEM PHYS B, V71, P535, DOI 10.1016/0305-0491(82)90424-2; LIU DK, 1983, INT J BIOCHEM, V15, P1273, DOI 10.1016/0020-711X(83)90218-5; LIU DK, 1979, BIOCHEM J, V178, P241, DOI 10.1042/bj1780241; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAVROTHALASSITIS GJ, 1984, EUR J BIOCHEM, V142, P481, DOI 10.1111/j.1432-1033.1984.tb08311.x; MCCORMICK JJ, 1974, NATURE, V251, P737, DOI 10.1038/251737a0; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; MIDGLEY JEM, 1965, BIOCHIM BIOPHYS ACTA, V95, P232, DOI 10.1016/0005-2787(65)90488-0; MIZUTA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P144, DOI 10.1016/0003-9861(90)90424-W; MORITA T, 1986, J BIOCHEM-TOKYO, V99, P17, DOI 10.1093/oxfordjournals.jbchem.a135456; NANDI S, 1973, ADV CANCER RES, V17, P353; NEUWELT EA, 1976, J BIOL CHEM, V251, P5752; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OUCHTERLONY O, 1962, PROG ALLERGY, V6, P30, DOI 10.1159/000313795; PAYMASTER JC, 1970, INT J CANCER, V5, P426, DOI 10.1002/ijc.2910050318; PICCOLI R, 1984, J BIOL CHEM, V259, P693; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; POWELL MJ, 1990, NUCLEIC ACIDS RES, V18, P4013, DOI 10.1093/nar/18.13.4013; RABIN EZ, 1982, BIOCHIM BIOPHYS ACTA, V701, P132, DOI 10.1016/0167-4838(82)90321-1; REY MW, 1990, NUCLEIC ACIDS RES, V18, P5288, DOI 10.1093/nar/18.17.5288; RICHARDS FM, 1971, ENZYMES, V4, P647; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1989, J EXP MED, V170, P163, DOI 10.1084/jem.170.1.163; SAHA BK, 1982, NUCLEIC ACIDS RES, V10, P645, DOI 10.1093/nar/10.2.645; SCHEIT KH, 1979, NATURE, V279, P728, DOI 10.1038/279728a0; SCHMUKLER M, 1975, J BIOL CHEM, V250, P2206; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; Sierakowska H, 1977, Prog Nucleic Acid Res Mol Biol, V20, P59; SKUP D, 1981, BIOL INTERFERON SYST, P81; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SORRENTINO S, 1988, J BIOL CHEM, V263, P16125; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; SUGIYAMA RH, 1981, BIOCHEMISTRY-US, V20, P2268, DOI 10.1021/bi00511a031; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER EJ, 1976, BIOCHEM J, V153, P329, DOI 10.1042/bj1530329; WALKER EJ, 1975, BIOCHEM J, V147, P425, DOI 10.1042/bj1470425; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; YASUDA T, 1990, ARCH BIOCHEM BIOPHYS, V279, P130, DOI 10.1016/0003-9861(90)90472-B	61	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					4181	4187						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680036				2022-12-27	WOS:A1993KN53300057
J	JONES, JI; BUSBY, WH; WRIGHT, G; SMITH, CE; KIMACK, NM; CLEMMONS, DR				JONES, JI; BUSBY, WH; WRIGHT, G; SMITH, CE; KIMACK, NM; CLEMMONS, DR			IDENTIFICATION OF THE SITES OF PHOSPHORYLATION IN INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-1 - REGULATION OF ITS AFFINITY BY PHOSPHORYLATION OF SERINE-101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; AMNIOTIC-FLUID; PURIFICATION; INVITRO; PLASMA; FORMS; CELLS; DNA	Serine phosphorylation of insulin-like growth factor binding protein-1 (IGFBP-1) has been shown to alter its affinity for the insulin-like growth factors (IGF-I and IGF-II) and to modify its capacity to modulate cellular responses to the IGFs. Because of this, we determined the sites of serine phosphorylation. Purification of P-32-labeled IGFBP-1 was followed by digestion with trypsin and endoproteinase Glu-C and radiosequencing of labeled peptides. Three serines were found to be phosphorylated, with Ser101, Ser119, and Ser169 containing 70%, 5%, and 25% of the incorporated P-32, respectively. A mutated IGFBP-1, substituting alanine for serine at positions 98 and 101, was expressed in CHO cells. On nondenaturing gels, the wild type protein migrated as five isoforms (one non-phosphorylated and four phosphorylated). However, in the mutated protein, the most rapidly migrating band (a phosphorylated form) was not present. The cells containing the mutated cDNA incorporated 60% less P-32 into immunoprecipitable IGFBP-1. The mutated protein had a 3-fold reduction in affinity for IGF-I compared to the wild type protein. We conclude that Ser101 represents the major site of phosphorylation containing 63% of the total P-32 incorporated and that phosphorylation of Ser101 is important for maintenance of high affinity binding for this growth factor.	UNIV N CAROLINA, SCH MED, DEPT MED, CB 7170 MACNIDER, CHAPEL HILL, NC 27599 USA; MONSANTO CORP RES, CHESTERFIELD, MO 63198 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Monsanto					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER; NIA NIH HHS [AG02331] Funding Source: Medline; NIDDK NIH HHS [DK02024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAXTER RC, 1991, MODERN CONCEPTS INSU, P371; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BREWER MT, 1988, BIOCHEM BIOPH RES CO, V152, P1289, DOI 10.1016/S0006-291X(88)80425-X; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; BUSBY WH, 1989, ENDOCRINOLOGY, V125, P773, DOI 10.1210/endo-125-2-773; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FROST RA, 1991, J BIOL CHEM, V266, P18082; Higuchi R., 1989, PCR TECHNOLOGY, P61; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; JYUNG RW, 1992, IN PRESS ENDOCRINOLO; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; MARTIN JL, 1990, J BIOL CHEM, V265, P4124; MCCUSKER RH, 1992, AUG ANN M AM SOC AN; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMASAKI S, 1990, J BIOL CHEM, V265, P2198; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; SVOBODA ME, 1980, BIOCHEMISTRY-US, V19, P790, DOI 10.1021/bi00545a027	23	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1125	1131						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678248				2022-12-27	WOS:A1993KG07700056
J	BINDER, S; HATZACK, F; BRENNICKE, A				BINDER, S; HATZACK, F; BRENNICKE, A			A NOVEL PEA MITOCHONDRIAL IN-VITRO TRANSCRIPTION SYSTEM RECOGNIZES HOMOLOGOUS AND HETEROLOGOUS MESSENGER-RNA AND TRANSFER-RNA PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION SITES; INVITRO TRANSCRIPTION; ATP SYNTHASE; PLANT-MITOCHONDRIA; CYTOCHROME-OXIDASE; MESSENGER-RNA; ALPHA-SUBUNIT; GENE; IDENTIFICATION; DNA	To elucidate the mechanism involved in the transcription initiation process in mitochondria of dicotyledonous plants, an in vitro transcription system was established for pea (Pisum sativum L.). The partially purified mitochondrial protein extract initiates transcription on homologous pea templates as well as on heterologous mitochondrial DNA from other dicot plant species. lit vitro transcription begins within the nonanucleotide 5'-((-7))CRTAAGAGA((+2))-3' (transcription start site is underlined) conserved at most of the identified transcription initiation sites in dicot plant mitochondria. The in vitro initiation at promoters of protein as well as of tRNA coding genes indicates a common mode of transcription initiation for different types of RNA. The competent recognition of different heterologous templates supports a general functional role of the conserved nonanucleotide within mitochondrial promoters of dicotyledonous plants. Initial studies of the promoter structure by deletion analysis in the 5' region of the pea atp9 promoter show that in addition to the conserved nonanucleotide, which is essential for transcription initiation in vitro, sequences up to 25 nucleotides upstream of the transcription start site are necessary for an efficient initiation event.	UNIV ULM,INST ALLGEMEINE BOT,D-89069 ULM,GERMANY	Ulm University	BINDER, S (corresponding author), INST GENBIOL FORSCH,IHNESTR 63,D-14195 BERLIN,GERMANY.							BINDER S, 1993, J BIOL CHEM, V268, P7849; BINDER S, 1994, CURR GENET, V26, P519, DOI 10.1007/BF00309943; BINDER S, 1993, NUCLEIC ACIDS RES, V21, P5012, DOI 10.1093/nar/21.22.5012; BOGENHAGEN DF, 1986, MOL CELL BIOL, V6, P2543, DOI 10.1128/MCB.6.7.2543; BROWN GG, 1991, MOL GEN GENET, V228, P345, DOI 10.1007/BF00260626; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; COVELLO PS, 1991, CURR GENET, V20, P245, DOI 10.1007/BF00326239; EDWARDS JC, 1982, CELL, V31, P337, DOI 10.1016/0092-8674(82)90127-1; GRAY MW, 1982, ANN REV PLANT PHYSL, V43, P145; HANICJOYCE PJ, 1991, MOL CELL BIOL, V11, P2035, DOI 10.1128/MCB.11.4.2035; KENNELL JC, 1989, MOL CELL BIOL, V9, P3603, DOI 10.1128/MCB.9.9.3603; LEVINGS CS, 1989, CELL, V56, P171, DOI 10.1016/0092-8674(89)90890-8; MOON E, 1985, NUCLEIC ACIDS RES, V13, P3195, DOI 10.1093/nar/13.9.3195; MORIKAMI A, 1987, J BIOCHEM-TOKYO, V101, P967, DOI 10.1093/oxfordjournals.jbchem.a121966; MORIKAMI A, 1993, BIOSCI BIOTECH BIOCH, V57, P1530, DOI 10.1271/bbb.57.1530; MULLIGAN RM, 1988, MOL GEN GENET, V211, P373, DOI 10.1007/BF00425688; MULLIGAN RM, 1991, MOL CELL BIOL, V11, P533, DOI 10.1128/MCB.11.1.533; MULLIGAN RM, 1988, P NATL ACAD SCI USA, V85, P7998, DOI 10.1073/pnas.85.21.7998; NEWTON KJ, 1988, ANNU REV PLANT PHYS, V39, P503, DOI 10.1146/annurev.arplant.39.1.503; RAPP WD, 1993, MOL CELL BIOL, V13, P7232, DOI 10.1128/MCB.13.12.7232; RAPP WD, 1992, EMBO J, V11, P1065, DOI 10.1002/j.1460-2075.1992.tb05145.x; ROTHENBERG M, 1987, MOL GEN GENET, V209, P21, DOI 10.1007/BF00329831; Sambrook J, 1989, MOL CLONING LABORATO; SCHMITT ME, 1993, CURR OPIN GENET DEV, V3, P769, DOI 10.1016/S0959-437X(05)80097-8; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; WALBERG MW, 1983, J BIOL CHEM, V258, P1268; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; YOUNG EG, 1986, NUCLEIC ACIDS RES, V14, P7995, DOI 10.1093/nar/14.20.7995	28	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22182	22189		10.1074/jbc.270.38.22182	http://dx.doi.org/10.1074/jbc.270.38.22182			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673196	hybrid			2022-12-27	WOS:A1995RW31400021
J	GEHRING, MR; CONDON, B; MARGOSIAK, SA; KAN, CC				GEHRING, MR; CONDON, B; MARGOSIAK, SA; KAN, CC			CHARACTERIZATION OF THE PHE-81 AND VAL-82 HUMAN FIBROBLAST COLLAGENASE CATALYTIC DOMAIN PURIFIED FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTITIAL COLLAGENASE; PROCOLLAGENASE; ACTIVATION; STROMELYSIN; EXPRESSION; METALLOPROTEINASES; IDENTIFICATION; PURIFICATION; INHIBITORS; POLYMERASE	Soluble recombinant human fibroblast collagenase catalytic domain was highly expressed and purified from Escherichia coli, The expression construct utilized the T7 gene 10 promoter for transcription of a two-cistron messenger RNA which encoded the ubiquitin-collagenase catalytic domain fusion protein as the second cistron. The ubiquitin domain was attached to the collagenase catalytic domain with the linker sequences Gly-Gly-Thr-Gly-Asp-Val-Ala-Gln (wild type) or Gly-Gly-Thr-Gly-Asp-Val-Gly-His (mutant) which served as cleavage sites for in vitro activation. The last four residues of the linker were included based on the crystal structure of human prostromelysin-l catalytic domain. Soluble fusion proteins purified from E. coli retained the proteolytic activity of the collagenase catalytic domain, The collagenase catalytic domain was released by either autoproteolytic or stromelysin-1-catalyzed cleavage, purified to homogeneity, and separately possess Phe-81, Val-82, or Leu-83 as the amino-terminal residue. Very similar K-cat/K-m values were determined for the Phe-81 and Val-82 forms using continuous fluorogenic and chromogenic peptide cleavage assays.	AGOURON PHARMACEUT INC, SAN DIEGO, CA 92121 USA	Pfizer								BLASER J, 1991, EUR J BIOCHEM, V202, P1223, DOI 10.1111/j.1432-1033.1991.tb16494.x; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; DAVIES B, 1993, CANCER RES, V53, P2087; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HORWITZ AL, 1977, P NATL ACAD SCI USA, V74, P897, DOI 10.1073/pnas.74.3.897; KAN CC, 1992, J PROTEIN CHEM, V11, P467, DOI 10.1007/BF01025023; KNAUPER V, 1993, BIOCHEM J, V295, P581; KNAUPER V, 1993, BIOCHEM J, V291, P847; KNAUPER V, 1990, EUR J BIOCHEM, V189, P295, DOI 10.1111/j.1432-1033.1990.tb15489.x; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEE SC, 1992, J BIOL CHEM, V267, P2849; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MALLYA SK, 1990, BIOCHEMISTRY-US, V29, P10628, DOI 10.1021/bi00499a008; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1992, J BIOL CHEM, V267, P9612; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TEMPLETON NS, 1990, CANCER RES, V50, P5431; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WILLENBROCK F, 1995, FEBS LETT, V358, P189, DOI 10.1016/0014-5793(94)01421-V; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008	33	11	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22507	22513		10.1074/jbc.270.38.22507	http://dx.doi.org/10.1074/jbc.270.38.22507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673241	hybrid			2022-12-27	WOS:A1995RW31400070
J	FUKUDA, H; OHTSUBO, E				FUKUDA, H; OHTSUBO, E			LARGE-SCALE PURIFICATION AND CHARACTERIZATION OF TRAI ENDONUCLEASE ENCODED BY SEX FACTOR PLASMID R100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE-I; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; BINDING; ORIT; IDENTIFICATION; DIMERIZATION; CATALYZES; PROTEINS	The TraI protein encoded by plasmid R100 was purified in a large scale by monitoring the strand and site-specific nicking activity at the origin of transfer, oriT, The N-terminal amino acid sequence of the purified protein was identical to that deduced from the DNA sequence of an open reading frame encoding TraI. The TraI protein is a DNA helicase which is highly processive and unwinds DNA in the 5' to 3' direction. The Stokes radius and the sedimentation coefficient for the TraI protein in 200 mM NaCl indicate that the protein is a rod-shaped monomer, whose native molecular weight is 186,000. Chemical cross-linking analysis revealed that there exist more dimers of TraI under the low salt conditions, under which both nicking and unwinding reactions catalyzed by TraI are the most efficient, indicating that the TraI protein is functionally active in a dimer form. TraI hardly introduced a nick into the linearized plasmid DNA and only slightly into the relaxed closed circular DNA, indicating that TraI requires superhelical structure of substrate DNA for the nicking reaction. Deletion analysis in the oriT region revealed that a particular region of 54 base pairs containing oriT is required for the nicking reaction.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P431, DOI 10.1111/j.1432-1033.1976.tb10358.x; ABDELMONEM M, 1977, J MOL BIOL, V110, P867; BENZ I, 1990, EUR J BIOCHEM, V189, P267, DOI 10.1111/j.1432-1033.1990.tb15486.x; BRADSHAW HD, 1990, J BACTERIOL, V172, P4127, DOI 10.1128/jb.172.7.4127-4131.1990; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; INAMOTO S, 1991, J BIOL CHEM, V266, P10086; INAMOTO S, 1990, J GEN APPL MICROBIOL, V36, P287, DOI 10.2323/jgam.36.287; INAMOTO S, 1990, J BIOL CHEM, V265, P6461; INAMOTO S, 1988, J BACTERIOL, V170, P2749, DOI 10.1128/jb.170.6.2749-2757.1988; INAMOTO S, 1994, J BIOCHEM-TOKYO, V116, P834; KUHM B, 1978, J BIOL CHEM, V254, P11343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LOHMAN TM, 1902, MOL MICROBIOL, V6, P5; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MATSON SW, 1991, J BIOL CHEM, V266, P16232; OHKI M, 1968, COLD SPRING HARB SYM, V33, P651, DOI 10.1101/SQB.1968.033.01.074; OHTSUBO E, 1978, MOL GEN GENET, V159, P131, DOI 10.1007/BF00270886; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUPP WD, 1968, COLD SPRING HARB SYM, V33, P647, DOI 10.1101/SQB.1968.033.01.073; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WONG I, 1992, J BIOL CHEM, V267, P7596; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIOKA Y, 1987, J BACTERIOL, V169, P619, DOI 10.1128/jb.169.2.619-623.1987; YOSHIOKA Y, 1990, J MOL BIOL, V214, P39, DOI 10.1016/0022-2836(90)90145-C	30	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21319	21325		10.1074/jbc.270.36.21319	http://dx.doi.org/10.1074/jbc.270.36.21319			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673168	hybrid			2022-12-27	WOS:A1995RU05400069
J	ISAS, JM; YANNONE, SM; BURGESS, BK				ISAS, JM; YANNONE, SM; BURGESS, BK			AZOTOBACTER-VINELANDII NADPH-FERREDOXIN REDUCTASE CLONING, SEQUENCING, AND OVEREXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; ESCHERICHIA-COLI; ENCODING FLAVODOXIN; CLUSTER; ACTIVATION; MUTAGENESIS; NITROGENASE; RESOLUTION; PROTEIN	Azotobacter vinelandii ferredoxin I (AvFdI) controls the expression of another protein that was originally designated Protein X. Recently we reported that Protein X is a NADPH-specific flavoprotein that binds specifically to FdI (Isas, J. M., and Burgess, B. K. (1994) J. Biol. Chem, 269, 19404-19409), The gene encoding this protein has now been cloned and sequenced, Protein X is 33% identical and has an overall 53% similarity with the fpr gene product from Escherichia coli that encodes NADPH:ferredoxin reductase, On the basis of this similarity and the similarity of the physical properties of the two proteins, we now designate Protein X as A. vinelandii NADPH:ferredoxin reductase and its gene as the fpr gene, The protein has been overexpressed in its native background in A. vinelandii by using the broad host range multicopy plasmid, pKT230. In addition to being regulated by FdI, the fpr gene product is overexpressed when A. vinelandii is grown under N-2-fixing conditions even though the fpr gene is not preceded by a nif specific promoter, By analogy to what is known about fpr expression in E. coli, we propose that FdI may exert its regulatory effect on fpr by interacting with the SoxRS regulon.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine			Yannone, Steven/G-1927-2011		NIGMS NIH HHS [R01-GM45209] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045209] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENNETT LT, 1988, J BIOL CHEM, V263, P1364; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BIENERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P331; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; DILLER TC, 1994, J MOL BIOL, V241, P620, DOI 10.1006/jmbi.1994.1535; EMPTAGE MH, 1980, J BIOL CHEM, V255, P1793; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KLUGKIST J, 1986, EUR J BIOCHEM, V155, P41, DOI 10.1111/j.1432-1033.1986.tb09456.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MERRICK MJ, 1993, CURR PLANT SCI BIOT, V17, P43; MERRITT EA, 1993, ACTA CRYSTALLOGR D, V49, P272, DOI 10.1107/S0907444992007248; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MORIMYO M, 1988, J BACTERIOL, V170, P2136, DOI 10.1128/jb.170.5.2136-2142.1988; MOSHIRI F, 1991, J BIOL CHEM, V266, P23169; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1993, J BIOL CHEM, V268, P25920; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1021; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; VAZQUEZ A, 1994, PROTEIN EXPRES PURIF, V5, P96, DOI 10.1006/prep.1994.1014; VETTER J, 1971, HOPPESEYLERS Z PHYSL, V352, P443	36	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21258	21263		10.1074/jbc.270.36.21258	http://dx.doi.org/10.1074/jbc.270.36.21258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673160	hybrid			2022-12-27	WOS:A1995RU05400060
J	WITHERS, DJ; BLOOM, SR; ROZENGURT, E				WITHERS, DJ; BLOOM, SR; ROZENGURT, E			DISSOCIATION OF CAMP-STIMULATED MITOGENESIS FROM ACTIVATION OF THE MITOGEN-ACTIVATED PROTEIN-KINASE CASCADE IN SWISS 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTOR; CYCLIC-AMP; SIGNAL-TRANSDUCTION; DEPENDENT ACTIVATION; GS-ALPHA; C-FOS; PHOSPHORYLATION; PATHWAY; RAF	Elevation of intracellular cAMP by forskolin, 8-bromoadenosine 3':5'-cyclic monophosphate, and prostaglandin E(1), in synergy with insulin, stimulated DNA synthesis in quiescent Swiss 3T3 cells to the same level achieved by platelet-derived growth factor (PDGF) or bombesin. Both forskolin and 8-bromoadenosine 3':5'-cyclic monophosphate stimulated a significant increase in cell number which, in the presence of insulin, reached the same level achieved with PDGF. Treatment with either PDGF or bombesin caused a marked and persistent stimulation of p42(MAPK) and p44(MAPK). In striking contrast, no activation was seen with mitogenic combinations of cAMP as shown by three different assays. Swiss 3T3 cells stably transfected with a constitutively activated Gs alpha subunit were 100-fold more sensitive to the mitogenic effects of forskolin but in this distinct cellular model forskolin did not activate p42(MAPK). Swiss 3T3 cells stably transfected with interfering mutants of MEK-1 showed a 60% decrease in PDGF-stimulated p42 MAPK activation, but there was no inhibition of the mitogenic effect of forskolin in these cells. Furthermore, the upstream kinases MEK-1/MEK-2 and p74(raf-1) were not activated by mitogenic combinations of cAMP while PDGF caused marked stimulation of their activity. Treatment of 3T3 cells with forskolin attenuated PDGF-stimulated p74(raf-1) and p42(MAPK) activation but enhanced the mitogenic effects of this agent. Mitogenic combinations of cAMP strongly stimulated the phosphorylation and activation of p70(s6k) an effect that was inhibited by rapamycin. This agent markedly inhibited cAMP-stimulated DNA synthesis suggesting a critical role for p70(s6k) in cAMP mitogenic signaling. These results demonstrate that cAMP-induced mitogenesis can be dissociated from activation of the mitogen-activated protein kinase cascade and that this is not an obligatory point of convergence in mitogenic signaling in Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; HAMMERSMITH HOSP,DEPT MED,DIV ENDOCRINOL,LONDON W12 0NN,ENGLAND	Cancer Research UK; Imperial College London			Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FERRARI S, 1990, P NATL ACAD SCI USA, V89, P7282; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG N, 1994, J BIOL CHEM, V269, P548; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MEHMET H, 1988, ONCOGENE RES, V3, P281; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; POSADA J, 1992, MOL BIOL CELL, V3, P383; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; ROZENGURT E, 1983, J CELL PHYSL, V16, P379; SAKURAI T, 1994, J BIOL CHEM, V269, P14118; SETH A, 1991, J BIOL CHEM, V266, P23521; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUNIER B, 1995, J BIOL CHEM, V270, P3693; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K	54	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					21411	21419		10.1074/jbc.270.36.21411	http://dx.doi.org/10.1074/jbc.270.36.21411			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673177	hybrid			2022-12-27	WOS:A1995RU05400082
J	HERWALD, H; JAHNENDECHENT, W; ALLA, SA; HOCK, J; BOUMA, BN; MULLERESTERL, W				HERWALD, H; JAHNENDECHENT, W; ALLA, SA; HOCK, J; BOUMA, BN; MULLERESTERL, W			MAPPING OF THE HIGH-MOLECULAR-WEIGHT KININOGEN BINDING-SITE OF PREKALLIKREIN - EVIDENCE FOR A DISCONTINUOUS EPITOPE FORMED BY DISTINCT SEGMENTS OF THE PREKALLIKREIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA PREKALLIKREIN; BLOOD-COAGULATION FACTOR; 4 TANDEM REPEATS; HUMAN FACTOR-XI; LIGHT CHAIN; ANTIIDIOTYPIC ANTIBODIES; DISULFIDE BONDS; APPLE DOMAINS; PROTEINS; LOCALIZATION	Prekallikrein, a glycoprotein involved in contact phase activation, circulates in plasma in the form of a binary complex with high molecular weight kininogen (H-kininogen). The binding to H-kininogen is mediated by the prekallikrein heavy chain consisting of four repetitive domains, A1-A4. To define more precisely the region(s) involved in kininogen binding, we have employed an affinity cross-linking strategy with a synthetic peptide of 31 residues which mimics the prekallikrein binding site of H-kininogen. Cross-linking of the radiolabeled peptide to (pre)kallikrein revealed a binding segment in the NH2-terminal portion of the prekallikrein heavy chain; another binding segment was located in the COOH-terminal part of the heavy chain. The latter binding segment is harbored by a previously identified fragment of the kallikrein heavy chain involved in H-kininogen binding (Page, J. D., and Colman, R. W. (1991) J. Biol. Chem. 266, 8143-8148). Chemical cleavage of the heavy chain cross-linked with the radiolabeled peptide mapped the NH2-terminal binding segment to 60 residues (positions 53-112) of A1. Synthesis of a peptide (positions 56-86) and development of specific antibodies to this peptide narrowed down the kininogen binding segment to 31 residues of the center portion of A1. This NH2-terminal segment is equivalent to a kininogen binding site previously identified in factor XI (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1992) J. Biol. Chem. 267, 4247-4252). We conclude that prekallikrein exposes at least two segments on its heavy chain portion which form a continuous surface thereby facilitating the intimate binding of the zymogen to its nonenzymatic cofactor, H-kininogen.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, DUESBERGWEG 6, W-6500 MAINZ 1, GERMANY; BEHRINGWERKE AG, W-3550 MARBURG, GERMANY; ACAD HOSP UTRECHT, DEPT HEMATOL, 3584 CX UTRECHT, NETHERLANDS	Johannes Gutenberg University of Mainz; Utrecht University; Utrecht University Medical Center			Jahnen-Dechent, Willi/A-7608-2011; Herwald, Heiko/AAN-3708-2021	Jahnen-Dechent, Willi/0000-0003-1315-4407; Herwald, Heiko/0000-0002-8111-2842				ATASSI MZ, 1984, EUR J BIOCHEM, V145, P1, DOI 10.1111/j.1432-1033.1984.tb08516.x; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BARDEHLE G, 1991, PARASITOLOGY, V103, P387, DOI 10.1017/S0031182000059904; BEAUBIEN G, 1991, BIOCHEMISTRY-US, V30, P1628, DOI 10.1021/bi00220a027; BOCK PE, 1985, J BIOL CHEM, V260, P2434; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HEIMARK RL, 1980, NATURE, V286, P456, DOI 10.1038/286456a0; HOCK J, 1990, J BIOL CHEM, V265, P12005; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KAPLAN AP, 1987, BLOOD, V70, P1; KELLERMANN J, 1989, J BIOL CHEM, V264, P14121; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE R, 1977, J BIOL CHEM, V252, P6097; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; MULLERESTERL W, 1988, METHOD ENZYMOL, V163, P240; PAGE JD, 1991, J BIOL CHEM, V266, P8143; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; SCARSDALE JN, 1990, J PROTEIN CHEM, V9, P647, DOI 10.1007/BF01025019; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1982, J BIOL CHEM, V257, P4300; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VOGEL R, 1990, J BIOL CHEM, V265, P12494; YOU JL, 1991, J PROTEIN CHEM, V10, P301, DOI 10.1007/BF01025629	38	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1993	268	19					14527	14535						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LJ825	7686159				2022-12-27	WOS:A1993LJ82500105
J	ZHANG, GH; ICHIMURA, T; MAIER, JAM; MACIAG, T; STEVENS, JL				ZHANG, GH; ICHIMURA, T; MAIER, JAM; MACIAG, T; STEVENS, JL			A ROLE FOR FIBROBLAST GROWTH-FACTOR TYPE-1 IN NEPHROGENIC REPAIR - AUTOCRINE EXPRESSION IN RAT-KIDNEY PROXIMAL TUBULE EPITHELIAL-CELLS INVITRO AND IN THE REGENERATING EPITHELIUM FOLLOWING NEPHROTOXIC DAMAGE BY S-(1,1,2,2-TETRAFLUOROETHYL)-L-CYSTEINE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE CONJUGATE TOXICITY; FACTOR-I; ENDOTHELIAL-CELLS; FACTOR-BETA; DEFINED MEDIUM; MESSENGER-RNA; FACTOR FAMILY; MOUSE KIDNEY; FACTOR-ALPHA; BINDING	The regenerating proximal tubule epithelium in the rat has striking similarity with rat kidney proximal tubule epithelial cells (RPTE) in primary culture (Wallin, A., Zhang, G., Jones, T. W., Jaken, S., and Stevens, J. L. (1992) Lab. Invest. 66, 474-484). We used this in vitro model to investigate mechanisms which may regulate aspects of nephrogenic repair in vivo, and in particular the role of fibroblast (heparin-binding) growth factor type-1 (FGF-1) expression. FGF-1 was present predominantly as a 14.3-kDa polypeptide in rat kidney. Biological activity and mRNA for FGF-1 increased dramatically in primary RPTE in culture along with an increase in a 18.3-kDa FGF-1. Cycloheximide blocked FGF-1 expression in primary culture indicating that the increase represents newly synthesized factor rather than release from the extracellular matrix. The maximal increase in expression occurs after the peak of RPTE proliferation. Activity was not present in the medium but intracellular FGF-1 was released from RPTE by scrape wounding. Immunohistochemical analysis showed that FGF-1 expression increased in regenerating proximal tubule epithelial cells 5 days after nephrotoxic damage. Collectively, the data suggest that autocrine expression of FGF-1 by regenerating proximal tubule epithelial cells plays a role in the regulation of nephrogenic repair.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; AMER RED CROSS,DEPT MOLEC BIOL,HOLLAND LAB,ROCKVILLE,MD 20855	American Red Cross			Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221	NHLBI NIH HHS [HL32348] Funding Source: Medline; NIDDK NIH HHS [DK38925] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSSON G, 1988, ACTA PHYSIOL SCAND, V132, P453, DOI 10.1111/j.1748-1716.1988.tb08352.x; ANDERSSON GL, 1988, ACTA ENDOCRINOL-COP, V119, P555, DOI 10.1530/acta.0.1190555; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BACALLAO R, 1989, AM J PHYSIOL, V257, pF913, DOI 10.1152/ajprenal.1989.257.6.F913; BORTZ JD, 1988, J CELL BIOL, V107, P811, DOI 10.1083/jcb.107.2.811; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG SD, 1982, J CELL BIOL, V95, P118, DOI 10.1083/jcb.95.1.118; COIMBRA TM, 1990, AM J PHYSIOL, V259, pF438, DOI 10.1152/ajprenal.1990.259.3.F438; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FU YM, 1991, J CELL BIOL, V114, P1261, DOI 10.1083/jcb.114.6.1261; GAJDUSEK CM, 1989, J CELL PHYSIOL, V139, P570, DOI 10.1002/jcp.1041390317; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GRONE HJ, 1987, AM J PATHOL, V129, P1; GROUXMUSCATELLI B, 1990, DEV BIOL, V142, P380, DOI 10.1016/0012-1606(90)90358-P; HAMMERMAN MR, 1992, AM J PHYSIOL, V262, pF523, DOI 10.1152/ajprenal.1992.262.4.F523; HAMMERMAN MR, 1989, AM J PHYSIOL, V257, pF503, DOI 10.1152/ajprenal.1989.257.4.F503; HATZINGER PB, 1989, IN VITRO CELL DEV B, V25, P205; HATZINGER PB, 1988, BIOCHEM BIOPH RES CO, V157, P1316, DOI 10.1016/S0006-291X(88)81018-0; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, J BIOL CHEM, V266, P18415; HUMES HD, 1989, J CLIN INVEST, V84, P1757, DOI 10.1172/JCI114359; HUMES HD, 1991, LAB INVEST, V64, P538; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAN M, 1985, IN VITRO CELL DEV B, V21, P181; KANDA S, 1989, CELL BIOL INT REP, V13, P687; Maciag T, 1990, Important Adv Oncol, P85; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; Mendley S., 1988, ANNU REV PHYSIOL, V51, P33; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NAGAIKE M, 1991, J BIOL CHEM, V266, P22781; NONCLERCQ D, 1991, NEPHRON, V57, P210, DOI 10.1159/000186253; NORMAN J, 1990, CLIN SCI, V78, P445, DOI 10.1042/cs0780445; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; SALIDO EC, 1989, AM J PHYSIOL, V256, pF632, DOI 10.1152/ajprenal.1989.256.4.F632; SALIDO EC, 1986, J HISTOCHEM CYTOCHEM, V34, P1155, DOI 10.1177/34.9.2426343; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SEGAL R, 1989, KIDNEY INT, V36, pS2; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; STEVENS J, 1986, J BIOL CHEM, V261, P3325; SULLIVAN DE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P17, DOI 10.1016/0167-4781(91)90031-G; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOBACK FG, 1992, KIDNEY INT, V41, P226, DOI 10.1038/ki.1992.32; TOUBEAU G, 1991, KIDNEY INT, V40, P691, DOI 10.1038/ki.1991.262; WALKER C, 1991, CANCER RES, V51, P2973; WALLIN A, 1992, LAB INVEST, V66, P474; ZHANG GH, 1991, J CELL PHYSIOL, V148, P295, DOI 10.1002/jcp.1041480216	59	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1993	268	16					11542	11547						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LF284	7685015				2022-12-27	WOS:A1993LF28400016
J	SUWANICHKUL, A; DEPAOLIS, LA; LEE, PDK; POWELL, DR				SUWANICHKUL, A; DEPAOLIS, LA; LEE, PDK; POWELL, DR			IDENTIFICATION OF A PROMOTER ELEMENT WHICH PARTICIPATES IN CAMP-STIMULATED EXPRESSION OF HUMAN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; MULTIPLE SEQUENCE ELEMENTS; SITE-SPECIFIC MUTAGENESIS; HUMAN AMNIOTIC-FLUID; ATF CDNA CLONES; C-FOS PROMOTER; CYCLIC-AMP; GENE-TRANSCRIPTION; HEPATOMA-CELLS; IGF-I	In hepatocytes, insulin-like growth factor-binding protein-1 (IGFBP-1) levels are increased by glucocorticoids and by agents that raise intracellular cAMP levels such as glucagon, theophylline, forskolin, and cAMP analogues. In contrast, insulin lowers IGFBP-1 levels, an effect dominant over the glucocorticoid and cAMP effects. Previous studies showed that dibutyryl cAMP (Bt2cAMP) and theophylline increase IGFBP-1 promoter activity in HEP G2 human hepatoma cells and that insulin abolishes this increase. In studies reported here, HEP G2 cells were used to further evaluate the role of cAMP in stimulating IGFBP-1 expression. Initial studies found that either 0.5 or 5.0 mM Bt2cAMP alone, or the combination of 0.5 mM Bt2cAMP and 2 mM theophylline, increased IGFBP-1 protein levels, mRNA levels, and promoter activity, but that the addition of theophylline to Bt2cAMP was required to give a approximately 5-fold increase in promoter activity. Deletion mutations of the IGFBP-1 promoter were used to show that much of the effect of Bt2cAMP and theophylline was conferred by the region between 269 and 246 base pairs (bp) 5' of the IGFBP-1 mRNA cap site. DNase I protection assays showed that HEP G2 nuclear extract footprinted the region from 273 to 249 bp 5' of the cap site; this region, designated P2, has a central CGTCA motif common to cAMP-responsive elements (CREs). Mutating the CGTCA motif in the 1205-bp IGFBP-1 promoter construct to TAGCA led to a 51% decrease in the ability of Bt2cAMP and theophylline to stimulate IGFBP-1 promoter activity above control levels. In addition, cotransfection of the catalytic subunit of cAMP-dependent protein kinase A (PKA) with the native 1205-bp IGFBP-1 promoter construct stimulated IGFBP-1 promoter activity 3.9-fold, but the TAGCA mutation decreased by 73% the ability of PKA to stimulate IGFBP-1 promoter activity above control levels. Mutating the CGTCA motif to TAGCA also blocked the ability of both crude HEP G2 nuclear extract and recombinant CRE-binding protein to bind to the P2 element. These data suggest that the P2 element is a CRE that confers at least part of the stimulatory effect of cAMP on the human IGFBP-1 promoter.	BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine				Lee, Phillip/0000-0002-6856-4262	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK-38773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P432, DOI 10.1210/jcem-65-3-432; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRINKMAN A, 1988, EMBO J, V7, P2417, DOI 10.1002/j.1460-2075.1988.tb03087.x; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CONOVER CA, 1992, J CLIN ENDOCR METAB, V74, P1355, DOI 10.1210/jc.74.6.1355; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, DIABETES, V39, P1251, DOI 10.2337/diabetes.39.10.1251; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P908, DOI 10.1210/jcem-59-5-908; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FINK JS, 1991, J BIOL CHEM, V266, P3882; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JULKUNEN M, 1988, FEBS LETT, V236, P295, DOI 10.1016/0014-5793(88)80041-3; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KLEMM DJ, 1990, MOL CELL BIOL, V10, P480, DOI 10.1128/MCB.10.2.480; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE PDK, 1993, IN PRESS METABOLISM; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; LIU JS, 1991, J BIOL CHEM, V266, P19095; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Maxam A M, 1980, Methods Enzymol, V65, P499; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; Montminy M R, 1990, Recent Prog Horm Res, V46, P219; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEERS B, 1991, J BIOL CHEM, V266, P18127; POWELL DR, 1989, INT CONGR SER, V881, P3; POWELL DR, 1991, J BIOL CHEM, V266, P18868; POWELL DR, 1993, IN PRESS DNA CELL BI; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; WYNSHAWBORIS A, 1984, J BIOL CHEM, V259, P2161	64	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1993	268	13					9730	9736						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LA689	7683658				2022-12-27	WOS:A1993LA68900085
J	CHANG, DY; MARAIA, RJ				CHANG, DY; MARAIA, RJ			A CELLULAR PROTEIN BINDS B1 AND ALU SMALL CYTOPLASMIC RNAS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ALPHA-FETOPROTEIN GENE; SRP-RNA; REPETITIVE SEQUENCES; SECONDARY STRUCTURE; 7S RNA; DOMAIN; DNA; TRANSLOCATION; COMPLEMENTARY	B1 and Alu are sequence-homologous interspersed elements of unknown function that have expanded in the genomes of mice and humans, respectively. A minority of B1 and Alu sequences are expressed as small cytoplasmic RNAs. These RNAs have conserved a secondary structure motif also present in signal recognition particle (SRP) RNA despite substantial sequence divergence, whereas random B1 and Alu sequences have not. This RNA structure has also been conserved by the source sequences that gave rise to successive transpositions during B1 and Alu evolution. In the present work small cytoplasmic B1 and Alu RNAs synthesized in vitro were found to bind a cellular protein by mobility shift and UV cross-linking analyses. The mouse and human proteins demonstrate the same specificity to a panel of competitor RNAs. Results using mutated B1 RNA indicate that a single strand loop in the conserved Alu motif is essential for binding. Previous work by Strub et al. (Stub, K., Moss, J. B., and Walter, P. (1991) Mol. Cell. Biol. 11, 3949-3959) demonstrated that the Alu-specific protein SRP 9/14 does not footprint to this region of SRP RNA. This observation coupled with the failure of anti-SRP/9 antibodies to identify SRP 9/14 in the B1 RNA-protein complex as well as the apparent mass and other characteristics of the protein described here suggest that it is a novel B1-Alu RNA-binding protein. Conservation of primary and secondary structure by B1 and Alu small cytoplasmic RNAs as well as features of their specific expression and ability to interact with the conserved binding protein indicate that these RNAs are more homologous than previously appreciated.	NICHHD, MOLEC GROWTH REGULAT LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ANDREWS PG, 1987, J BIOL CHEM, V262, P2908; BATZER MA, 1990, NUCLEIC ACIDS RES, V18, P6793, DOI 10.1093/nar/18.23.6793; GEORGIEV GP, 1982, COLD SPRING HARB SYM, V47, P1109, DOI 10.1101/SQB.1983.047.01.125; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GIORDANO T, 1990, NUCLEIC ACIDS RES, V18, P4627, DOI 10.1093/nar/18.15.4627; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; HOWARD B H, 1990, New Biologist, V2, P759; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; LABUDA D, 1991, J MOL EVOL, V32, P405, DOI 10.1007/BF02101280; LABUDA D, 1989, NUCLEIC ACIDS RES, V17, P2477, DOI 10.1093/nar/17.7.2477; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MATERA AG, 1990, NUCLEIC ACIDS RES, V18, P6019, DOI 10.1093/nar/18.20.6019; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; ROUAULT TA, 1989, P NATL ACAD SCI USA, V86, P5768, DOI 10.1073/pnas.86.15.5768; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; SINNETT D, 1991, J BIOL CHEM, V266, P8675; STRUB K, 1990, MOL CELL BIOL, V10, P777, DOI 10.1128/MCB.10.2.777; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEINER AM, 1980, CELL, V22, P209, DOI 10.1016/0092-8674(80)90169-5; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	33	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6423	6428						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681065				2022-12-27	WOS:A1993KT36800052
J	PULLEN, KA; RATTRAY, AJ; CHAMPOUX, JJ				PULLEN, KA; RATTRAY, AJ; CHAMPOUX, JJ			THE SEQUENCE FEATURES IMPORTANT FOR PLUS STRAND PRIMING BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; AVIAN-MYELOBLASTOSIS VIRUS; RNASE-H ACTIVITY; SITE-SPECIFIC MUTAGENESIS; RIBONUCLEASE-H; DNA-SYNTHESIS; NUCLEOTIDE-SEQUENCE; INTEGRATION SITE; POLYMERASE; INITIATION	A specific cleavage by the reverse transcriptase-associated RNase H activity generates the RNA primer for plus strand DNA synthesis during reverse transcription. Previously, we used site-directed mutagenesis to define the sequence features of the polypurine tract (PPT) required for correct plus strand priming by the Moloney murine leukemia virus (M-MuLV) reverse transcriptase (Rattray, A. J., and Champoux, J. J. (1989) J. Mol. Biol. 208, 445-456). Although the sequences of human immunodeficiency virus type 1 (HIV-1) and M-MuLV diverge completely outside a 20-base region encompassing the PPT, within this region there are only three differences between the two viruses. Here we show that the HIV-1 reverse transcriptase will utilize the M-MuLV PPT as an origin for plus strand initiation in vitro. This finding enabled us to use the set of PPT mutants previously generated in M-MuLV, in conjunction with a small set of newly derived mutations within the HIV-1 PPT, to study plus strand priming by the HIV-I reverse transcriptase. Despite the similarity between the two PPT regions, the sequence features important for positioning RNase H for the cleavage reaction that generates the plus strand primer are different for the two viruses. For M-MuLV, the -7A residue is a critical specificity determinant in the priming reaction, whereas for HIV-1, the -2G and -4G residues play key roles in determining the specificity of priming.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle			Rattray, Alison/A-4847-2008		NCI NIH HHS [CA51605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051605, R37CA051605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BALTIMORE D, 1972, J BIOL CHEM, V247, P7282; BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BLUM HE, 1985, VIROLOGY, V142, P270, DOI 10.1016/0042-6822(85)90335-6; CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FURFINE ES, 1991, BIOCHEMISTRY-US, V30, P7041, DOI 10.1021/bi00243a001; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUNGNES O, 1991, ARCH VIROL, V116, P133, DOI 10.1007/BF01319237; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; MITRA SW, 1982, J BIOL CHEM, V257, P5983; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PANGANIBAN AT, 1983, NATURE, V306, P155, DOI 10.1038/306155a0; PULLEN KA, 1992, J VIROL, V66, P367, DOI 10.1128/JVI.66.1.367-373.1992; PULLEN KA, 1990, J VIROL, V64, P6274, DOI 10.1128/JVI.64.12.6274-6277.1990; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; STARNES MC, 1989, J BIOL CHEM, V264, P7073; TOBALYTAPIERO J, 1991, J GEN VIROL, V72, P605, DOI 10.1099/0022-1317-72-3-605; VARMUS H, 1989, MOBILE DNA, P53; VARMUS H, 1982, RNA TUMOR VIRUSES, V1, P369; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VARMUS HE, 1985, RNA TUMOR VIRUSES, V2, P75; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	37	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1993	268	9					6221	6227						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KT368	7681062				2022-12-27	WOS:A1993KT36800025
J	MEDHORA, MM; TEITELBAUM, S; CHAPPEL, J; ALVAREZ, J; MIMURA, H; ROSS, FP; HRUSKA, K				MEDHORA, MM; TEITELBAUM, S; CHAPPEL, J; ALVAREZ, J; MIMURA, H; ROSS, FP; HRUSKA, K			1-ALPHA,25-DIHYDROXYVITAMIN-D3 UP-REGULATES EXPRESSION OF THE OSTEOCLAST INTEGRIN ALPHA-V-BETA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION RECEPTORS; GROWTH FACTOR-BETA; BONE-MARROW-CELLS; VITRONECTIN RECEPTOR; MACROPHAGE DIFFERENTIATION; FIBRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; GENE PROMOTER; 1,25-DIHYDROXYVITAMIN-D3; GLYCOPROTEIN	Osteoclast precursors selectively attach to bone and differentiate into multinucleated cells that function to remodel and resorb it. We have shown previously that attachment of osteoclasts to bone and subsequent resorption are mediated by the integrin alpha(v)beta3. 1Alpha,25-dihydroxyvitamin D3 (1,25-(OH)2D3) enhances osteoclast precursor differentiation in vivo by mechanisms that are still not clearly understood but entail enhanced attachment of cells to bone. This observation raises the possibility that at least one component of vitamin D-induced osteoclast precursor differentiation involves modulation of integrin expression. To test if the steroid modulates the osteoclast integrin alpha(v)beta3 (the vitronectin receptor), we examined the effects of 1,25-(OH)2D3 on transcription of the alpha(v) gene as well as surface expression and function Of alpha(v)beta3, in chicken osteoclast precursors. Treatment of the cells with 1,25-(OH)2D3 led to a progressive dose-dependent increase in steady state alpha(v) mRNA levels with enhanced expression evident within 24 h. The effect was receptor-mediated as indicated by the effects of other vitamin D analogs. The increase in alpha(v) mRNA levels did not reflect decreased message degradation but, as demonstrated by nuclear run-on experiments, was due to accelerated rates of transcription. Most importantly, induction of alpha(v) mRNA by 1,25-(OH)2D3 was mirrored by higher levels of expression of alpha(v)beta3 on the cell surface, as well enhanced attachment to its substrate, vitronectin.	WASHINGTON UNIV, JEWISH HOSP ST LOUIS, DIV RENAL, 216 S KINGSHIGHWAY, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, JEWISH HOSP ST LOUIS, DEPT PATHOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)				Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR32087, AR39561] Funding Source: Medline; NIDDK NIH HHS [DK09976] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, R01AR039561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BILLECOCQ A, 1990, P NATL ACAD SCI USA, V87, P6470, DOI 10.1073/pnas.87.16.6470; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HEIDENREICH R, 1990, BIOCHEMISTRY-US, V29, P1232, DOI 10.1021/bi00457a020; HEINO J, 1989, J BIOL CHEM, V264, P380; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, P177; HORTON MA, 1989, J BONE MINER RES, V4, P803; HORTON MA, 1991, EXP CELL RES, V195, P368, DOI 10.1016/0014-4827(91)90386-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KNUDSEN KA, 1985, EXP CELL RES, V157, P218, DOI 10.1016/0014-4827(85)90164-8; KOEFFLER HP, 1984, CANCER RES, V44, P5624; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MATSUYAMA T, 1989, J EXP MED, V170, P1133, DOI 10.1084/jem.170.4.1133; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; MERKE J, 1986, J CLIN INVEST, V77, P312, DOI 10.1172/JCI112292; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; ROODMAN GD, 1985, P NATL ACAD SCI USA, V82, P8213, DOI 10.1073/pnas.82.23.8213; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SOKAL RR, 1981, BIOMETRY, P432; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TINKLER SMB, 1981, J ANAT, V133, P91; UCKER DS, 1984, J BIOL CHEM, V259, P7416	40	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1456	1461						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678259				2022-12-27	WOS:A1993KG07700103
J	RUP, DM; VEENSTRA, RD; WANG, HZ; BRINK, PR; BEYER, EC				RUP, DM; VEENSTRA, RD; WANG, HZ; BRINK, PR; BEYER, EC			CHICK CONNEXIN-56, A NOVEL LENS GAP JUNCTION PROTEIN - MOLECULAR-CLONING AND FUNCTIONAL EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; CHANNELS; CELLS; DNA; CULTURES; HEART; LIVER; PAIRS; GENE	We used primers corresponding to the amino-terminal sequence shared by rat connexin-46 and ovine MP70 and a consensus sequence of the second extracellular loop conserved in all connexins to amplify and subsequently clone from chick genomic DNA a new member of the connexin family of gap junction proteins, chick connexin-56. The derived chick connexin-56 polypeptide contains 510 amino acids with a predicted molecular mass of 55,857 daltons. Although identical in the first 70 amino acids to rat connexin-46, chick connexin-56 diverges significantly in length and composition in predicted cytoplasmic regions, which have previously been inferred to determine functional and regulatory specificity. We were able to detect hybridization of connexin-56 probes only to RNA derived from lens. Connexin-56 was functionally expressed by the stable transfection of communication-deficient Neuro2A cells. The connexin-56-transfected cells demonstrated intercellular coupling by transfer of microinjected 6-carboxyfluorescein. Double whole-cell patch clamp recordings demonstrated electrical coupling. The induced intercellular conductances were insensitive to uncoupling by heptanol, octanol, or acidification. This behavior of chick connexin-56 may explain previous observations of the unusual physiology of lens fiber gap junctions.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; SUNY HLTH SCI CTR,DEPT PHARMACOL,SYRACUSE,NY 13210; SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Beyer, Eric/V-1317-2019	Beyer, Eric/0000-0001-8044-1356	NATIONAL EYE INSTITUTE [U10EY006381, R01EY008368, R29EY008368, U01EY006381] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045466, R01HL042220] Funding Source: NIH RePORTER; NEI NIH HHS [EY08368, EY06381] Funding Source: Medline; NHLBI NIH HHS [R01 HL042220, HL45466] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1990, J BIOL CHEM, V265, P14439; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BUKAUSKAS F, 1992, J PHYSIOL-LONDON, V448, P321, DOI 10.1113/jphysiol.1992.sp019044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GOODENOUGH DA, 1979, INVEST OPHTH VIS SCI, V18, P1104; GUSTAFSON S, 1987, ANAL BIOCHEM, V165, P294, DOI 10.1016/0003-2697(87)90272-7; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; KISTLER J, 1985, J CELL BIOL, V101, P28, DOI 10.1083/jcb.101.1.28; KISTLER J, 1988, NATURE, V331, P721, DOI 10.1038/331721a0; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MATHIAS RT, 1985, AM J PHYSIOL, V249, pC181, DOI 10.1152/ajpcell.1985.249.3.C181; MENKO AS, 1987, DEV BIOL, V123, P307, DOI 10.1016/0012-1606(87)90389-7; MENKO AS, 1984, DEV BIOL, V103, P129, DOI 10.1016/0012-1606(84)90014-9; MILLER T, 1988, BIOSCIENCE REP, V8, P455, DOI 10.1007/BF01121644; MILLER TM, 1986, J CELL BIOL, V102, P194, DOI 10.1083/jcb.102.1.194; MORENO AP, 1991, BIOPHYS J, V60, P1254, DOI 10.1016/S0006-3495(91)82159-2; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUETZE SM, 1982, J CELL BIOL, V92, P694, DOI 10.1083/jcb.92.3.694; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; VEENSTRA RD, 1992, CIRC RES, V71, P1277, DOI 10.1161/01.RES.71.5.1277; VEENSTRA RD, 1990, AM J PHYSIOL, V258, pC662, DOI 10.1152/ajpcell.1990.258.4.C662; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711	33	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					706	712						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678009				2022-12-27	WOS:A1993KE60300106
J	SONNENBURG, WK; SEGER, D; BEAVO, JA				SONNENBURG, WK; SEGER, D; BEAVO, JA			MOLECULAR-CLONING OF A CDNA-ENCODING THE 61-KDA CALMODULIN-STIMULATED CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE - TISSUE-SPECIFIC EXPRESSION OF STRUCTURALLY RELATED ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHODIESTERASE; SMOOTH-MUSCLE; BOVINE BRAIN; RAT-BRAIN; INHIBITORS; ACTIVATION; SEQUENCE; ISOZYMES; RECEPTOR; CALCIUM	We have isolated a 2287-bp cDNA encoding the 61-kDa calmodulin-stimulated cyclic nucleotide phosphodiesterase (CaM PDE) from a bovine brain library. A large open reading frame within the cDNA encodes a 530-residue polypeptide which is identical to the sequence of the purified protein previously determined by direct amino acid sequencing. Moreover, COS cells transfected with the cDNA express a cAMP and cGMP hydrolytic activity that is stimulated by calcium and calmodulin, confirming that the cDNA represents a mRNA species encoding a CaM PDE isozyme. RNase protection analyses indicate that either 61-kDa CaM PDE mRNA or structurally related transcripts encoding different CaM PDE isoforms are expressed in a tissue-specific manner. Total RNA isolated from brain (cerebral cortex, basal ganglia, hippocampus, cerebellum, and medulla/spinal cord), heart, aorta, liver, kidney outer medulla, kidney papilla, trachea, and lung completely protected a 410-base antisense riboprobe corresponding to sequence encoding a portion of the catalytic domain. Little or no protection was detected using adrenal cortex, adrenal medulla, liver, kidney cortex, spleen, or T-lymphocyte total RNA. Only brain RNA completely protected a 240-base antisense riboprobe corresponding to the 61-kDa CaM PDE amino terminus encompassing a putative calmodulin-binding domain. However, heart, aorta, liver, kidney, trachea, and lung RNA protected 150 bases of this riboprobe suggesting that these tissues express an isoform structurally related to the 61-kDa CaM PDE. Northern analysis of mRNA isolated from brain, heart, aorta, liver, kidney, lung, and trachea revealed that the cDNA hybridizes with a 3.8- and a 4.4-kb (kilobase) mRNA species. Interestingly, Northern blots of bovine cerebral cortex and heart mRNA probed under stringent conditions with antisense transcripts corresponding to either the 5'- or 3'-untranslated sequence of the 61-kDa CaM PDE cDNA hybridized with only the 4.4-kb mRNA from both tissues. Since different, yet structurally similar CaM PDE isoforms are expressed in brain and in heart, this result, in addition to the RNase protection data, is consistent with the idea that the mRNAs encoding these two CaM PDE isoforms are products of an alternately spliced gene.	UNIV WASHINGTON,DEPT PHARMACOL,SJ-30,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK21023] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1983, NEUROSCIENCE, V10, P707, DOI 10.1016/0306-4522(83)90212-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BODE DC, 1991, CIRC RES, V68, P1070, DOI 10.1161/01.RES.68.4.1070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1990, CYCLIC NUCLEOTIDE PH, V2, P267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAGIWARA M, 1984, BIOCHEM PHARMACOL, V33, P453, DOI 10.1016/0006-2952(84)90240-5; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; HURWITZ RL, 1990, J BIOL CHEM, V265, P8901; KINCAID RL, 1987, P NATL ACAD SCI USA, V84, P1118, DOI 10.1073/pnas.84.4.1118; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAMER RH, 1988, J NEUROSCI, V8, P1804; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LORENZ KL, 1983, MOL PHARMACOL, V23, P424; LUDVIG N, 1991, NEUROSCIENCE, V44, P491, DOI 10.1016/0306-4522(91)90072-V; LUGNIER C, 1986, BIOCHEM PHARMACOL, V35, P1743, DOI 10.1016/0006-2952(86)90333-3; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MIOT F, 1983, FEBS LETT, V151, P273, DOI 10.1016/0014-5793(83)80085-4; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ROSSI P, 1988, J BIOL CHEM, V263, P15521; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; SHARMA RK, 1984, J BIOL CHEM, V259, P9248; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH WL, 1989, ADV EXP MED BIOL, V259, P131; SONNENBURG WK, 1991, J BIOL CHEM, V266, P17655; SUMNERS C, 1991, AM J PHYSIOL, V260, pC79, DOI 10.1152/ajpcell.1991.260.1.C79; TANNER LI, 1986, MOL PHARMACOL, V29, P455; TORPHY TJ, 1991, MOL PHARMACOL, V39, P376; WANG JH, 1990, MOL PHARM CELL REGUL, V2, P19; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9	45	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					645	652						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678006				2022-12-27	WOS:A1993KE60300097
J	NOHNO, T; ISHIKAWA, T; SAITO, T; HOSOKAWA, K; NOJI, S; WOLSING, DH; ROSENBAUM, JS				NOHNO, T; ISHIKAWA, T; SAITO, T; HOSOKAWA, K; NOJI, S; WOLSING, DH; ROSENBAUM, JS			IDENTIFICATION OF A HUMAN TYPE-II RECEPTOR FOR BONE MORPHOGENETIC PROTEIN-4 THAT FORMS DIFFERENTIAL HETEROMERIC COMPLEXES WITH BONE MORPHOGENETIC PROTEIN TYPE-I RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SERINE THREONINE KINASE; TGF-BETA; EXPRESSION CLONING; ACTIVIN RECEPTOR; FAMILY; PUNT	Bone morphogenetic proteins (BMPs) comprise the largest subfamily of TGF-beta-related Ligands and are known to bind to type I and type II receptor serine/threonine kinases. Although several mammalian BMP type I receptors have been identified, the mammalian BMP type II receptors have remained elusive. We have isolated a cDNA encoding a novel transmembrane serine/threonine kinase from human skin fibroblasts which we demonstrate here to be a type II receptor that binds BMP-4. This receptor (BRK-3) is distantly related to other known type II receptors and is distinguished from them by an extremely long carboxyl-terminal sequence following the intracellular kinase domain. The BRK-3 gene is widely expressed in a variety of adult tissues. When expressed alone in COS cells, BRK-3 specifically binds BMP-4, but cross-linking of BMP-4 to BRK-3 is undetectable in the absence of either the BRK-1 or BRK-2 BMP type I receptors. Cotransfection of BRK-2 with BRK-3 greatly enhanced affinity labeling of BMP-4 to the type I receptor, in contrast to the affinity labeling pattern observed with the BRK-1 + BRK-3 heteromeric complex. Furthermore, a subpopulation of super-high affinity binding sites is formed in COS cells upon cotransfection only of BRK-2 + BRK-3, suggesting that the different heteromeric BMP receptor complexes have different signaling potential.	PROCTER & GAMBLE CO, MIAMI VALLEY LABS,DIV CORP RES, CINCINNATI, OH 45253 USA; UNIV TOKUSHIMA, FAC ENGN,DEPT BIOL SCI & TECHNOL, TOKUSHIMA 770, JAPAN; Kawasaki Med Sch, DEPT PHARMACOL, KURASHIKI, OKAYAMA 70101, JAPAN; Kawasaki Med Sch, DEPT BIOCHEM, KURASHIKI, OKAYAMA 70101, JAPAN	Procter & Gamble; Tokushima University; Kawasaki Medical School; Kawasaki Medical School			Nohno, Tsutomu/B-6923-2008; Noji, Sumihare/E-3047-2010	Nohno, Tsutomu/0000-0002-0351-5603; 				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1992, CIBA F SYMP, V165, P219; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MOUSTAKAS A, 1995, J BIOL CHEM, V270, P765, DOI 10.1074/jbc.270.2.765; PANARETTO BA, 1993, REPROD FERT DEVELOP, V5, P345, DOI 10.1071/RD9930345; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Sambrook J, 1989, MOL CLONING LABORATO; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; Sumitomo S, 1993, DNA Seq, V3, P297, DOI 10.3109/10425179309020827; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAKUMI T, 1995, EXP CELL RES, V216, P208, DOI 10.1006/excr.1995.1026; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	40	200	215	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22522	22526		10.1074/jbc.270.38.22522	http://dx.doi.org/10.1074/jbc.270.38.22522			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673243	hybrid			2022-12-27	WOS:A1995RW31400072
J	SHIMAMOTO, T; TANIMURA, T; YONEDA, Y; KOBAYAKAWA, Y; SUGASAWA, K; HANAOKA, F; OKA, M; OKADA, Y; TANAKA, K; KOHNO, K				SHIMAMOTO, T; TANIMURA, T; YONEDA, Y; KOBAYAKAWA, Y; SUGASAWA, K; HANAOKA, F; OKA, M; OKADA, Y; TANAKA, K; KOHNO, K			EXPRESSION AND FUNCTIONAL ANALYSES OF THE DXPA GENE, THE DROSOPHILA HOMOLOG OF THE HUMAN EXCISION-REPAIR GENE XPA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 CHROMOSOMES; A COMPLEMENTING PROTEIN; HUMAN CELL-EXTRACTS; PIGMENTOSUM GROUP-G; XERODERMA-PIGMENTOSUM; DNA-REPAIR; DAMAGED DNA; MOLECULAR CHARACTERIZATION; YEAST HOMOLOG; CDNA CLONING	Xeroderma pigmentosum (XP) is a human hereditary disease characterized by a defect in DNA repair after exposure to ultraviolet Light. Among the seven groups of XP, group A (XP-A) patients show the most severe deficiency in excision repair and a wide variety of cutaneous and neurological disorders. We have cloned homologs of the human XPA gene from chicken, Xenopus, and Drosophila, and sequence analysis revealed that these genes are highly conserved throughout evolution. Here, we report characterization of the Drosophila homolog of the human XPA gene (Dxpa). The Dxpa gene product shows DNA repair activities in an in vitro repair system, and Dxpa cDNA has been shown to complement a mutant allele of human XP-A cells by transfection. Polytene chromosome in situ hybridization mapped Dxpa to 3F6-8 on the X chromosome, where no mutant defective in excision repair was reported. Northern blot analysis showed that the gene is continuously expressed in all stages of fly development. Interestingly, the Dxpa protein is strongly expressed in the central nervous system and muscles as revealed by immunohistochemical analysis using anti-Dxpa antibodies, consistent with the results obtained in transgenic flies expressing a Dxpa-beta-galactosidase fusion gene driven by the Dxpa promoter.	NARA INST SCI & TECHNOL,RES & EDUC CTR GENET INFORMAT,NARA 63001,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 810,JAPAN; INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN; SENRI LIFE SCI CTR,TOYONAKA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT & CELL BIOL,SUITA,OSAKA 565,JAPAN	Nara Institute of Science & Technology; Osaka University; Kyushu University; RIKEN; Osaka University								ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; BAKER BS, 1972, GENETICS, V71, P255; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BOYD JB, 1976, GENETICS, V84, P527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KOKEN MHM, 1992, NUCLEIC ACIDS RES, V20, P5541, DOI 10.1093/nar/20.21.5541; LEGERSKI R, 1992, NATURE, V359, P70, DOI 10.1038/359070a0; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MASUTANI C, 1993, J BIOL CHEM, V268, P9105; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; MOUNKES LC, 1992, CELL, V71, P925, DOI 10.1016/0092-8674(92)90389-T; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V181, P1231, DOI 10.1016/0006-291X(91)92070-Z; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YAMAMOTO AH, 1990, MUTAT RES, V229, P17, DOI 10.1016/0027-5107(90)90004-N; ZUCKER CS, 1985, CELL, V40, P851	41	18	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22452	22459		10.1074/jbc.270.38.22452	http://dx.doi.org/10.1074/jbc.270.38.22452			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673233	hybrid			2022-12-27	WOS:A1995RW31400062
J	ABUMRAD, NA; ELMAGHRABI, MR; AMRI, EZ; LOPEZ, E; GRIMALDI, PA				ABUMRAD, NA; ELMAGHRABI, MR; AMRI, EZ; LOPEZ, E; GRIMALDI, PA			CLONING OF A RAT ADIPOCYTE MEMBRANE-PROTEIN IMPLICATED IN BINDING OR TRANSPORT OF LONG-CHAIN FATTY-ACIDS THAT IS INDUCED DURING PREADIPOCYTE DIFFERENTIATION - HOMOLOGY WITH HUMAN CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AP2 GENE-EXPRESSION; GLYCOPROTEIN-IV; SEQUENCE; CDNA; PERMEATION; ANTIBODY; LINE	A cDNA for an adipocyte membrane protein, implicated in the transport of long-chain fatty acids, was isolated by screening with a synthetic oligonucleotide derived from the amino terminal sequence of the protein. The 88-kDa adipocyte membrane protein was previously identified by covalent labeling with N-sulfosuccinimidyl esters of long-chain fatty acids which irreversibly inhibited fatty acid transport by 75% (Harmon, C. M., and Abumrad, N. A. (1993) J. Membr. Biol. 124, 261-268). The cDNA (FAT, 2432 base pairs (bp)) contained 70 bp of 5'-untranslated sequence, an open reading frame encoding a 472-amino acid protein with a predicted molecular mass of 52466, and 940 bp of 3'-untranslated sequence with two polyadenylation signal sequences but with no polyadenylation tail. The deduced protein sequence predicted two transmembrane segments and 10 potential N-linked glycosylation sites. Extensive glycosylation most likely explains why the molecular mass of the isolated protein (88 kDa) is different from that deduced from the cDNA sequence (53 kDa). The sequence of FAT is 85% homologous with that of glycoprotein IV (CD36) identified in human platelets and in lactating mammary epithelium. Consistent with this, a polyclonal antibody against CD36 reacted with adipocyte plasma membranes and detected a single band at 88 kDa. Northern blot analysis of RNA obtained from rat adipose tissue and probed with the cDNA identified two major transcripts of 4.8 and 2.9 kilobases which were abundant in heart, intestine, fat, muscle, and testis. The mRNAs were not detectable in cultured adipose cell lines (Ob1771, 3T3F442A) at the fibroblastic stage but were strongly induced during the differentiation process and by treatment of preadipocytes with dexamethasone, conditions that were also associated with an increase in oleate transport. In contrast, the fibroblastic cell lines 3T3-C2 and L929, which do not differentiate, did not express the mRNAs at all stages of culture. The data suggest that FAT and CD36 belong to a family of proteins that bind/transport long-chain fatty acids or function as regulators of these processes.	UNIV NICE,SOPHIA ANTIPOLIS,CNRS,UMR 134,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	ABUMRAD, NA (corresponding author), SUNY,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794, USA.			amri, Ez-Zoubir/0000-0001-8426-5396	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1991, P NATL ACAD SCI USA, V88, P6008, DOI 10.1073/pnas.88.14.6008; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; AIKEN ML, 1990, BLOOD, V76, P2501; AMRI EZ, 1991, J LIPID RES, V32, P1449; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CALDER PC, 1990, BIOCHEM J, V269, P807, DOI 10.1042/bj2690807; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FITZ JG, 1991, AM J PHYSIOL, V261, pG83, DOI 10.1152/ajpgi.1991.261.1.G83; GOLDSTEIN SAN, 1991, BIOPHYS J, V59; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREENWALT DE, 1985, J CELL BIOL, V100, P397, DOI 10.1083/jcb.100.2.397; GREENWALT DE, 1992, BLOOD, V80, P1105; GRIMALDI PA, 1992, P NATL ACAD SCI USA, V89, P10930, DOI 10.1073/pnas.89.22.10930; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HARMON CM, 1993, J MEMBRANE BIOL, V124, P261; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; MECHTERSHEIMER G, 1991, VIRCHOWS ARCH A, V419, P7, DOI 10.1007/BF01600148; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TRIMBLE ME, 1990, MOL CELL BIOCHEM, V98, P201; TRIMBLE ME, 1989, AM J PHYSIOL, V257, pF539, DOI 10.1152/ajprenal.1989.257.4.F539; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; ZHAO Y, 1992, J CUTAN PATHOL, V18, P323	35	823	857	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1993	268	24					17665	17668						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LT743	7688729				2022-12-27	WOS:A1993LT74300005
J	LIDOFSKY, SD; XIE, MH; SOSTMAN, A; SCHARSCHMIDT, BF; FITZ, JG				LIDOFSKY, SD; XIE, MH; SOSTMAN, A; SCHARSCHMIDT, BF; FITZ, JG			VASOPRESSIN INCREASES CYTOSOLIC SODIUM CONCENTRATION IN HEPATOCYTES AND ACTIVATES CALCIUM INFLUX THROUGH CATION-SELECTIVE CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; GROWTH-FACTOR; ANGIOTENSIN-II; ACINAR-CELLS; ION CHANNELS; LIVER-CELLS; FREE NA+; TRANSPORT; CA-2+; PROLIFERATION	A variety of hormonal agonists activate transmembrane Na+ and Ca2+ flux in hepatocytes, but the responsible mechanisms are poorly understood. We employed microfluorimetric and patch clamp recording techniques in hepatocytes to determine the effect of the hormone vasopressin on cytosolic Na+ concentration ([Na+]i) and to identify the transmembrane Na+ transport pathways activated by this agonist. Under basal conditions, [Na+]i, measured using the Na+-sensitive fluorophore sodium-binding benzofuran isophthalate, averaged 12.1 +/- 1.6 mM. Exposure to vasopressin rapidly increased [Na+]i by 8.3 +/- 0.9 mM. This increase was attributable to activation of Na+ influx. It occurred in the absence of solutes co-transported with Na+ and was not associated with activation of Na+/H+ antiport. In cell-attached membrane patches, vasopressin activated ion channels that carried inward positive current at the resting membrane potential. Further characterization in excised membrane patches revealed two classes of ion channels, with conductances of 16.0 +/- 2.8 and 30.9 +/- 3.1 picosiemens, respectively. Single channel currents reversed near 0 mV, and ion substitution studies demonstrated that each channel type was permeable to Na+, Ca2+, and K+ but not Cl-. These observations in hepatocytes indicate that vasopressin increases [Na+]i and activates cation-selective channels, which likely accounts for vasopressin-activated Na+ and Ca2+ influx.	UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; DUKE UNIV,DEPT MED,DURHAM,NC 27710	University of California System; University of California San Francisco; Duke University	LIDOFSKY, SD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,GI UNIT,HSW 1120,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001987, R01DK043278, R01DK026270] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-01987, DK-26270, DK-43278] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1992, HEPATOLOGY, V15, P134, DOI 10.1002/hep.1840150123; BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BERTHON B, 1985, BRIT J PHARMACOL, V86, P151, DOI 10.1111/j.1476-5381.1985.tb09445.x; BISSELL DM, 1987, J CLIN INVEST, V79, P801, DOI 10.1172/JCI112887; BORIN M, 1991, J BIOL CHEM, V266, P13153; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; FEHLMANN M, 1981, J BIOL CHEM, V256, P7449; FITZ JG, 1991, J MEMBRANE BIOL, V122, P1, DOI 10.1007/BF01872734; FITZ JG, 1991, AM J PHYSIOL, V261, pG803, DOI 10.1152/ajpgi.1991.261.5.G803; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN CA, 1991, J BIOL CHEM, V266, P18573; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARVEY RD, 1991, P NATL ACAD SCI USA, V88, P6946, DOI 10.1073/pnas.88.16.6946; HWANG SB, 1986, J BIOL CHEM, V261, P532; JOHNSON RM, 1987, J BIOL CHEM, V262, P17285; JOSEPH SK, 1985, J BIOL CHEM, V260, P2508; KANEKO A, 1992, HEPATOLOGY, V15, P1173, DOI 10.1002/hep.1840150632; KILBERG MS, 1982, J MEMBRANE BIOL, V69, P1, DOI 10.1007/BF01871236; Koch K S, 1980, Ann N Y Acad Sci, V349, P111, DOI 10.1111/j.1749-6632.1980.tb29520.x; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; KOCH KS, 1984, CELL BIOL INT REP, V8, P309, DOI 10.1016/0309-1651(84)90157-7; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LIDOFSKY SD, 1990, AM J PHYSIOL, V259, pG56, DOI 10.1152/ajpgi.1990.259.1.G56; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; MARUYAMA Y, 1982, NATURE, V300, P61, DOI 10.1038/300061a0; MAUGER JP, 1984, BIOCHEM J, V221, P121, DOI 10.1042/bj2210121; MOTULSKY HJ, 1983, J BIOL CHEM, V258, P3913; NEGULESCU PA, 1990, CELL REGUL, V1, P259, DOI 10.1091/mbc.1.3.259; NILIUS B, 1990, PFLUG ARCH EUR J PHY, V416, P609, DOI 10.1007/BF00382697; OKADA K, 1991, AM J PHYSIOL, V261, pF1007; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; SCHARSCHMIDT BF, 1981, P NATL ACAD SCI-BIOL, V78, P986, DOI 10.1073/pnas.78.2.986; THORN P, 1992, J GEN PHYSIOL, V100, P11, DOI 10.1085/jgp.100.1.11; VANDYKE RW, 1983, J BIOL CHEM, V258, P2912; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071	38	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1993	268	20					14632	14636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LL759	7686902				2022-12-27	WOS:A1993LL75900019
J	BECKER, JW; ROTONDA, J; MCKEEVER, BM; CHAN, HK; MARCY, AI; WIEDERRECHT, G; HERMES, JD; SPRINGER, JP				BECKER, JW; ROTONDA, J; MCKEEVER, BM; CHAN, HK; MARCY, AI; WIEDERRECHT, G; HERMES, JD; SPRINGER, JP			FK-506-BINDING PROTEIN - 3-DIMENSIONAL STRUCTURE OF THE COMPLEX WITH THE ANTAGONIST L-685,818	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; CYTOSOLIC-BINDING-PROTEIN; CYCLOSPORINE-A; MACROMOLECULAR CRYSTALLOGRAPHY; IMMUNOSUPPRESSANT FK506; ATOMIC-STRUCTURE; MESSENGER-RNA; T-CELLS; CYCLOPHILIN; IMMUNOPHILIN	L-685,818 differs only slightly in structure from the immunosuppressive drug FK-506, and both compounds bind with comparable affinity to the 12-kDa FK-506-binding protein (FKBP12), the major intracellular receptor for the drug. Despite these similarities, L-685,818 is a potent antagonist of both the immunosuppressive and toxic effects of the drug. Here, we present a structural analysis of this problem. Although FK-506 and L-685,818 differ greatly in pharmacology, we have found that the three-dimensional structures of their complexes with FKBP12 are essentially identical. Approximately half of each ligand is in contact with the receptor protein, and half is exposed to solvent; the exposed region includes the two sites where the compounds differ. These results indicate that the profound differences in the pharmacology of these two compounds are not caused by any difference in their interaction with FKBP12. Rather, these effects arise because relatively minor changes in the exposed part of a bound ligand have a strong effect on how FKBP12-ligand complexes interact with calcineurin, their putative intracellular target. In addition, FK-506 complexes with FKBP12 proteins from several species all inhibit mammalian calcineurin. Analysis of the three-dimensional structure of the complex with respect to residues conserved among these proteins suggests a small number of surface residues near the bound ligands that may play a critical role in interactions between the protein-drug complex and calcineurin.	MERCK SHARP & DOHME LTD,DEPT IMMUNOL RES,RAHWAY,NJ 07065	Merck & Company	BECKER, JW (corresponding author), MERCK SHARP & DOHME LTD,DEPT BIOPHYS CHEM,POB 2000 R80M-203,RAHWAY,NJ 07065, USA.							ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUREY W, 1990, 1990 AM CRYST ASS M; GRANELLIPIPERNO A, 1988, J EXP MED, V168, P1649, DOI 10.1084/jem.168.5.1649; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HEROLD KC, 1986, J IMMUNOL, V136, P1315; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KARUSO P, 1990, J AM CHEM SOC, V112, P9434, DOI 10.1021/ja00181a078; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUMANO K, 1991, TRANSPL P, V23, P512; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEPRE CA, 1992, FEBS LETT, V302, P89, DOI 10.1016/0014-5793(92)80292-O; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; NELSON PA, 1991, GENE, V109, P255, DOI 10.1016/0378-1119(91)90617-K; OHARA K, 1990, TRANSPLANT P, V22, P83; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; ROTONDA J, 1993, J BIOL CHEM, V268, P7607; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIEKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; SIEKIERKA JJ, 1989, J IMMUNOL, V143, P1580; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STEIGEMANN W, 1974, THESIS TU MUNCHEN; TAGA T, 1987, ACTA CRYSTALLOGR C, V43, P751, DOI 10.1107/S0108270187094253; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; WIEDERRECHT G, 1991, P NATL ACAD SCI USA, V88, P1029, DOI 10.1073/pnas.88.3.1029	51	60	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1993	268	15					11335	11339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LD466	7684380				2022-12-27	WOS:A1993LD46600090
J	JI, ZS; BRECHT, WJ; MIRANDA, RD; HUSSAIN, MM; INNERARITY, TL; MAHLEY, RW				JI, ZS; BRECHT, WJ; MIRANDA, RD; HUSSAIN, MM; INNERARITY, TL; MAHLEY, RW			ROLE OF HEPARAN-SULFATE PROTEOGLYCANS IN THE BINDING AND UPTAKE OF APOLIPOPROTEIN-E-ENRICHED REMNANT LIPOPROTEINS BY CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; FIBROBLAST GROWTH-FACTOR; CHYLOMICRON REMNANTS; ALPHA-2-MACROGLOBULIN RECEPTOR; LDL RECEPTOR; LIVER; ENDOCYTOSIS; LIPASE; PURIFICATION	Addition of apolipoprotein (apo) E to rabbit beta-very low density lipoproteins (beta-VLDL) has been shown to result in a marked enhancement of their binding and uptake by various cell types. Apolipoprotein E binds to lipoprotein receptors and proteoglycans. To distinguish between apoE binding to these sites, cells were treated with heparinase. Heparinase treatment of receptor-negative familial hypercholesterolemic (FH) fibroblasts and human hepatoma cells (HepG2) released 30-40% of newly synthesized cell surface S-35-labeled proteoglycans and decreased the binding of beta-VLDL+apoE to FH and normal fibroblasts and HepG2 cells by more than 80%. Furthermore, heparinase treatment significantly decreased the uptake of fluorescently labeled beta-VLDL+apoE by HepG2 cells and decreased cholesteryl ester synthesis in FH fibroblasts by 75%. Likewise, canine chylomicron remnants enriched in apoE demonstrated enhanced binding that was 80% inhibited by heparinase treatment of HepG2 cells. Heparinase treatment did not affect beta-VLDL (without added apoE) or low density lipoprotein (LDL) binding to these cells or the binding activity of beta-VLDL+apoE to the LDL receptor-related protein (LRP) or to the LDL receptor on ligand blots. Chinese hamster ovary (CHO) mutant cells lacking the synthesis of either heparan sulfate (pgsD-677) or all proteoglycans (pgsA-745) did not display any enhanced binding of the beta-VLDL+apoE. By comparison, wild-type CHO cells demonstrated enhanced binding of beta-VLDL+apoE that could be abolished by treatment with heparinase. These mutant cells and wild-type CHO cells possessed a similar amount of LRP, as determined by ligand blot analyses and by alpha2-macroglobulin binding, and possessed a similar amount of LDL receptor activity, as determined by LDL binding. Therefore, we would interpret these data as showing that heparan sulfate proteoglycan may be involved in the initial binding of the apoE-enriched remnants with the subsequent involvement of the LRP in the uptake of these lipoproteins. It remains to be determined whether the heparan sulfate proteoglycan can function by itself in both the binding and internalization of the apoE-enriched remnants or whether the proteoglycan is part of a complex with LRP that mediates a two-step process, i.e. binding and subsequent internalization by the receptor.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, POB 419100, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, J CLIN INVEST, V72, P743, DOI 10.1172/JCI111044; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CHAJEKSHAUL T, 1982, BIOCHIM BIOPHYS ACTA, V712, P200, DOI 10.1016/0005-2760(82)90103-5; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HUETTINGER M, 1992, J BIOL CHEM, V267, P18551; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KHAN MY, 1991, ANAL BIOCHEM, V196, P373; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OKA K, 1989, ANN NY ACAD SCI, V556, P173; RALL SC, 1986, METHOD ENZYMOL, V128, P273; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; STOW JL, 1985, J CELL BIOL, V100, P975, DOI 10.1083/jcb.100.3.975; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; WERNETTEHAMMOND ME, 1989, ARTERIOSCLEROSIS, V9, P501, DOI 10.1161/01.ATV.9.4.501; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMASHIRO DJ, 1989, J CELL PHYSIOL, V139, P377, DOI 10.1002/jcp.1041390221; YANG VC, 1985, J BIOL CHEM, V260, P1849; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	42	277	284	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1993	268	14					10160	10167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LB800	7683668				2022-12-27	WOS:A1993LB80000035
J	TORIBARA, NW; ROBERTON, AM; HO, SB; KUO, WL; GUM, E; HICKS, JW; GUM, JR; BYRD, JC; SIDDIKI, B; KIM, YS				TORIBARA, NW; ROBERTON, AM; HO, SB; KUO, WL; GUM, E; HICKS, JW; GUM, JR; BYRD, JC; SIDDIKI, B; KIM, YS			HUMAN GASTRIC MUCIN - IDENTIFICATION OF A UNIQUE SPECIES BY EXPRESSION CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE LOCUS PUM; MOLECULAR-CLONING; EPITHELIAL MUCINS; CDNA SEQUENCES; CARCINOMA; ANTIGEN; DNA; POLYMORPHISM; CONTAINS; RAT	Gastric mucin is a large glycoprotein which is thought to play a major role in the protection of the gastrointestinal tract from acid, proteases, pathogenic microorganisms, and mechanical trauma. In this paper we describe the isolation by expression cloning and characterization of cDNAs which code for human gastric mucin. The cDNA sequence is characterized by a tandem repeat region whose individual repeat unit is 507 base pairs (169 amino acids) long. The translated sequence is rich in threonine, serine, and proline (31, 18, and 15%, respectively) and contains a relatively large amount of histidine (7.1%) and alanine (5.6%). RNA blot analysis shows a polydisperse pattern which is characteristic of mucins. Expression of this gene is highest in the stomach and gall bladder, with weaker expression in the terminal ileum and right colon. This expression pattern is different from other human mucins and indicates that this gene codes for a unique mucin. Fluorescence in situ hybridization techniques have localized this gene to chromosome 11p15.4-11p15.5. This is the third mucin to be localized to the 11p15 region and suggests a clustering of secretory mucin genes. We propose that this gene for human gastric mucin be called MUC6.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV AUCKLAND,DEPT BIOCHEM,AUCKLAND,NEW ZEALAND; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455; DEPT VET AFFAIRS MED CTR,MINNEAPOLIS,MN	University of California System; University of California San Francisco; University of Auckland; University of Minnesota System; University of Minnesota Twin Cities	TORIBARA, NW (corresponding author), DEPT VET AFFAIRS MED CTR,GASTROINTESTINAL RES LAB 151M2,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.							AUBERT JP, 1991, AM J RESP CELL MOL, V5, P178, DOI 10.1165/ajrcmb/5.2.178; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BYRD JC, 1989, BIOCHEM J, V261, P617, DOI 10.1042/bj2610617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER J, 1991, BIOCHEM J, V277, P423, DOI 10.1042/bj2770423; DEKKER J, 1989, J BIOL CHEM, V264, P10431; FOUAD FM, 1980, H-S Z PHYSIOL CHEM, V361, P703, DOI 10.1515/bchm2.1980.361.1.703; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GERARD C, 1990, J CLIN INVEST, V86, P1921, DOI 10.1172/JCI114925; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HASE T, 1992, BIOMED RES-TOKYO, V13, P149, DOI 10.2220/biomedres.13.149; HO SB, 1993, CANCER RES, V53, P641; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHI ZR, 1988, J HISTOCHEM CYTOCHEM, V36, P317, DOI 10.1177/36.3.3278057; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SLOMIANY BL, 1992, J CLIN GASTROENTEROL, V14, pS114, DOI 10.1097/00004836-199206001-00020; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SWALLOW DM, 1987, ANN HUM GENET, V51, P289, DOI 10.1111/j.1469-1809.1987.tb01063.x; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1989, CANCER RES, V49, P3321; TRASK BJ, 1991, AM J HUM GENET, V48, P1; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANCONG N, 1990, HUM GENET, V86, P167; WESLEY A, 1985, J BIOL CHEM, V260, P7955; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YOUNAN F, 1982, GASTROENTEROLOGY, V82, P827	37	359	366	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1993	268	8					5879	5885						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KR822	7680650				2022-12-27	WOS:A1993KR82200079
J	HALLENBECK, PL; PHYILLAIER, M; NIKODEM, VM				HALLENBECK, PL; PHYILLAIER, M; NIKODEM, VM			DIVERGENT EFFECTS OF 9-CIS-RETINOIC ACID RECEPTOR ON POSITIVE AND NEGATIVE THYROID-HORMONE RECEPTOR-DEPENDENT GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OSTEOCALCIN GENE; RESPONSIVE ELEMENT; RETINOIC ACID; BINDING; PROMOTER	The thyroid hormone (TH)-inducible expression of some genes has recently been shown to be enhanced by 9-cis-retinoic acid (9-cis-RA) receptor (RXR). This effect appears to be at least partially elicited by the ability of RXR to heterodimerize with TH receptor (THR) and enhance its binding to the cis-acting thyroid hormone responsive elements (TREs) found within those genes. However, whether RXRbeta enhances TH/THR-mediated transactivation of all TRE-containing genes, and if RXR has any effect on TH-dependent negative regulation are not known. In the present study, we show that the TH/THR-inducible expression of the myelin basic protein (MBP) gene is not enhanced by RXRbeta, despite high affinity binding of the RXRbeta.THRalpha heterodimer to the MBP-TRE. We also demonstrate that RXRbeta reverses the TH/THR-dependent down-regulation mediated by the negative TRE found within the promoter of the mouse thyroid stimulating hormone gene (TSH). The ligand for RXRbeta (9-cis-RA), either alone or in combination with TH, did not enhance the transcription mediated by either the MBP-TRE, TSH-TRE, or the malic enzyme (ME)-TRE. However, the ME-TRE is known to confer RXRbeta-dependent enhancement of TH-induced gene expression. Thus, the capacity of RXRbeta to modulate TH-dependent transcriptional regulation depends upon the nature of the TRE.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DATTA S, 1992, MOL ENDOCRINOL, V6, P815, DOI 10.1210/me.6.5.815; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEUSTER G, 1991, MOL CELL BIOL, V11, P1638; FARSETTI A, 1991, J BIOL CHEM, V266, P23226; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MAARKS MS, 1992, EMBO J, V11, P1419; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; OZONO K, 1990, J BIOL CHEM, V265, P21881; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	28	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1993	268	6					3825	3828						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KN533	7680034				2022-12-27	WOS:A1993KN53300008
J	FLOTTE, TR; AFIONE, SA; SOLOW, R; DRUMM, ML; MARKAKIS, D; GUGGINO, WB; ZEITLIN, PL; CARTER, BJ				FLOTTE, TR; AFIONE, SA; SOLOW, R; DRUMM, ML; MARKAKIS, D; GUGGINO, WB; ZEITLIN, PL; CARTER, BJ			EXPRESSION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FROM A NOVEL ADENOASSOCIATED VIRUS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR; CHLORIDE CHANNELS; ADENOASSOCIATED VIRUS; EPITHELIAL-CELLS; GENE; DNA; REPLICATION; INTEGRATION; CLONING	Adeno-associated virus type 2 (AAV) vectors have been used for gene expression in respiratory epithelial cells and may be useful in gene therapy for diseases like cystic fibrosis (CF) which affect the airways. The AAV p5 promoter together with the AAV inverted terminal repeat (ITR) forms a 263-base pair cassette which mediated efficient expression in a CF bronchial epithelial cell line. We report here that the ITR itself can mediate gene expression. In stable transfection assays, AAV-CF vectors expressing the full-length cystic fibrosis transmembrane conductance regulator (CFTR) cDNA from either the p5 promoter or the ITR restored cAMP regulation of the chloride efflux characteristic of CFTR function. An AAV-ITR-CF vector deleted for the amino terminus of CFTR was also functional. This vector was packaged into AAV particles and used to transduce cells without selection. Transduced cells also exhibited cAMP-regulated Cl- efflux. The complemented cell lines showed increased levels of CFTR protein immunofluorescence, and the presence of intact AAV-CF vector sequence was confirmed by Southern blot analysis of rescued vector sequences. These studies provide.novel insights into AAV gene expression, and this newly described promoter allows for the production of AAV vectors expressing CFTR in those differentiated cells affected in CF.	TARGETED GENET CORP, SEATTLE, WA 98101 USA; JOHNS HOPKINS MED INST, DEPT PHYSIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS MED INST, EUDOWOOD DIV PEDIAT RESP SCI, BALTIMORE, MD 21205 USA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	FLOTTE, TR (corresponding author), NIDDKD, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA.			Zeitlin, Pamela/0000-0002-2719-1834				ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ARISPE N, 1992, P NATL ACAD SCI USA, V89, P1539, DOI 10.1073/pnas.89.5.1539; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTER BJ, 1979, VIROLOGY, V92, P449, DOI 10.1016/0042-6822(79)90149-1; CARTER BJ, 1983, VIROLOGY, V126, P505, DOI 10.1016/S0042-6822(83)80008-7; CARTER BJ, 1990, HDB PARVOVIRUSES, V2, P247; CARTER BJ, 1992, IN PRESS CURR OPIN B, V3; CHANG LS, 1989, J VIROL, V63, P3479, DOI 10.1128/JVI.63.8.3479-3488.1989; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FLOTTE TR, 1992, AM J RESP CELL MOL, V7, P349, DOI 10.1165/ajrcmb/7.3.349; HERMONAT PL, 1984, P NATL ACAD SCI-BIOL, V81, P6466, DOI 10.1073/pnas.81.20.6466; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KOTIN RM, 1989, VIROLOGY, V170, P460, DOI 10.1016/0042-6822(89)90437-6; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LAUGHLIN CA, 1988, GENE, V23, P65; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LUO L, 1989, PFLUGERS ARCH, V415, P198; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; PITLUK ZW, 1991, J VIROL, V65, P6661, DOI 10.1128/JVI.65.12.6661-6670.1991; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Sambrook J, 1989, MOL CLONING LABORATO; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SAMULSKI RJ, 1989, J VIROL, V63, P3822, DOI 10.1128/JVI.63.9.3822-3828.1989; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TRATSCHIN JD, 1984, MOL CELL BIOL, V4, P2072, DOI 10.1128/MCB.4.10.2072; TRATSCHIN JD, 1984, J VIROL, V51, P611, DOI 10.1128/JVI.51.3.611-619.1984; WALSH CE, 1992, P NATL ACAD SCI USA, V89, P7257, DOI 10.1073/pnas.89.15.7257; WALZ C, 1992, J VIROL, V66, P2990, DOI 10.1128/JVI.66.5.2990-3002.1992; WONDISFORD FE, 1988, MOL ENDOCRINOL, V2, P32, DOI 10.1210/mend-2-1-32; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	48	295	352	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1993	268	5					3781	3790						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KM161	7679117				2022-12-27	WOS:A1993KM16100114
J	AUKHIL, I; JOSHI, P; YAN, YZ; ERICKSON, HP				AUKHIL, I; JOSHI, P; YAN, YZ; ERICKSON, HP			CELL-BINDING AND HEPARIN-BINDING DOMAINS OF THE HEXABRACHION ARM IDENTIFIED BY TENASCIN EXPRESSION PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EXTRACELLULAR-MATRIX; ADHESIVE FUNCTION; DECREASING SULFATION; ELECTRON-MICROSCOPY; SUBSTRATE ADHESION; FIBROBLAST GROWTH; HUMAN FIBRONECTIN; CULTURED-CELLS; RECEPTOR	We have produced a set of bacterial expression proteins corresponding to 10 segments of tenascin and two of fibronectin and tested them for heparin binding and cell adhesion. We used polymerase chain reaction cloning to terminate the segments precisely at domain boundaries. Heparin binding activity was mapped to two different tenascin segments: one comprising the fourth and fifth fibronectin type III domains, and to TNfbg, the fibrinogen-like terminal knob. TNfbg, but none of the other tenascin segments, also supported adhesion of primary rat embryo skin fibroblasts. The fibroblasts did not spread on TNfbg but remained rounded. Cell binding to TNfbg occurred in the presence or absence of divalent cations and was not inhibited by RGD peptides, suggesting that integrins are not involved. Fibroblast binding to TNfbg was strongly inhibited by soluble heparin, by treating the cells with heparitinase, or by culture conditions that cause undersulfation of proteoglycans. These observations suggest that cell attachment to TNfbg is mediated by cell surface proteoglycans. We have also made full-length cDNA constructs for the largest and smallest splice variants of human tenascin, as well as one truncated after the 14th epidermal growth factor-like domain, in the pNUT mammalian cell expression vector. Stably transfected baby hamster kidney cell lines secreted large quantities of tenascin, and this was assembled into normal hexabrachions, the arm length corresponding to the construct.	DUKE UNIV, SCH MED, DEPT CELL BIOL, DURHAM, NC 27710 USA; UNIV N CAROLINA, SCH DENT, DEPT PERIODONT, CHAPEL HILL, NC 27514 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA-47056] Funding Source: Medline; NIDCR NIH HHS [DE-07801] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA047056, R01CA047056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE007801] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOTA S, 1991, J BIOL CHEM, V266, P15938; ARNHEIM N, 1992, ANNU REV BIOCHEM, V61, P131, DOI 10.1146/annurev.bi.61.070192.001023; AUKHIL I, 1990, MATRIX, V10, P98, DOI 10.1016/S0934-8832(11)80176-9; BORSI L, 1986, ANAL BIOCHEM, V155, P335, DOI 10.1016/0003-2697(86)90443-4; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BRETSCHER MS, 1985, EMBO J, V4, P1941, DOI 10.1002/j.1460-2075.1985.tb03874.x; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1991, EUR J BIOCHEM, V199, P379, DOI 10.1111/j.1432-1033.1991.tb16134.x; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; DELATORRE JG, 1981, Q REV BIOPHYS, V14, P81, DOI 10.1017/S0033583500002080; DRAKE SL, 1992, J CELL BIOL, V117, P1331, DOI 10.1083/jcb.117.6.1331; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERICKSON HP, 1984, NATURE, V311, P267, DOI 10.1038/311267a0; ERICKSON HP, 1987, J CELL BIOL, V105, P1387, DOI 10.1083/jcb.105.3.1387; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FAISSNER A, 1990, J NEUROCHEM, V54, P1004, DOI 10.1111/j.1471-4159.1990.tb02350.x; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FRIEDLANDER DR, 1988, J CELL BIOL, V107, P2329, DOI 10.1083/jcb.107.6.2329; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULCHER JR, 1990, GENOMICS, V6, P616, DOI 10.1016/0888-7543(90)90495-G; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; HOFFMAN S, 1987, P NATL ACAD SCI USA, V84, P2523, DOI 10.1073/pnas.84.8.2523; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHANSSON S, 1984, J CELL BIOL, V98, P810, DOI 10.1083/jcb.98.3.810; KIMIZUKA F, 1991, J BIOCHEM-TOKYO, V110, P284, DOI 10.1093/oxfordjournals.jbchem.a123572; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LIGHTNER VA, 1989, J CELL BIOL, V108, P2483, DOI 10.1083/jcb.108.6.2483; LIGHTNER VA, 1990, J CELL SCI, V95, P263; Linker A., 1972, METHODS ENZYMOL, P902; LORIES V, 1992, J BIOL CHEM, V267, P1116; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; MARTON LS, 1989, J BIOL CHEM, V264, P13145; MOSESSON MW, 1970, J BIOL CHEM, V245, P5728; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURRAY BA, 1992, J CELL BIOL, V117, P1311, DOI 10.1083/jcb.117.6.1311; NIES DE, 1991, J BIOL CHEM, V266, P2818; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROHRBACH MS, 1973, ANAL BIOCHEM, V52, P127, DOI 10.1016/0003-2697(73)90338-2; SAGINATI M, 1992, EUR J BIOCHEM, V205, P545, DOI 10.1111/j.1432-1033.1992.tb16811.x; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAN SS, 1987, P NATL ACAD SCI USA, V84, P7977, DOI 10.1073/pnas.84.22.7977; TAYLOR HC, 1989, J CELL BIOCHEM, V41, P71, DOI 10.1002/jcb.240410204; VAUGHAN L, 1987, EMBO J, V6, P349, DOI 10.1002/j.1460-2075.1987.tb04761.x; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	60	216	223	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1993	268	4					2542	2553						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KK815	7679097				2022-12-27	WOS:A1993KK81500045
J	DESCAMPS, O; BILHEIMER, D; HERZ, J				DESCAMPS, O; BILHEIMER, D; HERZ, J			INSULIN STIMULATES RECEPTOR-MEDIATED UPTAKE OF APOE-ENRICHED LIPOPROTEINS AND ACTIVATED ALPHA-2-MACROGLOBULIN IN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; TRANSFERRIN RECEPTORS; CELL-SURFACE; 3T3-L1 ADIPOCYTES; APOLIPOPROTEIN-E; PLASMA-MEMBRANE; HEPATIC-UPTAKE; PROTEIN; RAT; BINDING	The low density lipoprotein receptor-related protein (LRP) is a cell surface receptor that binds and internalizes several macromolecules including apolipoprotein E-enriched remnant lipoproteins and protease/antiprotease complexes such as activated alpha2-macroglobulin. Its function has been studied primarily in cultured fibroblasts and in liver. In the current studies, we provide evidence that LRP is present on the surface of primary adipocytes isolated from rat epididymal fat pads. The activity of the receptor increases 2-3-fold within minutes after the adipocytes are exposed to physiological concentrations of insulin as indicated by an increase in the uptake of I-125-labeled activated alpha2-macroglobulin. There is a corresponding increase in the uptake of [H-3]cholesteryl esters from radiolabeled apoE-enriched beta-very low density lipoprotein. The latter uptake was inhibited by an antibody against LRP and by a fusion protein containing the 39-kDa protein, also called receptor-associated protein, a known inhibitor of LRP function. In vivo, rats that had been fed ad libitum accumulated approximately 24-fold more chylomicron cholesteryl esters in their epididymal fat pads than did fasted control animals. We suggest that insulin stimulation of LRP, in a synergistic action with lipoprotein lipase, increases the endocytic uptake of cholesteryl esters and triglycerides from remnant lipoproteins in postprandial adipocytes.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	DESCAMPS, O (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV LIPID METAB,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angel A., 1983, ADIPOCYTE OBESITY CE, P179; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BERGMAN EN, 1971, J CLIN INVEST, V50, P1831, DOI 10.1172/JCI106674; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1; CORVERA S, 1989, J BIOL CHEM, V264, P10133; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLIEMANN J, 1983, BIOCHIM BIOPHYS ACTA, V756, P230, DOI 10.1016/0304-4165(83)90096-X; GOODMAN DS, 1962, J CLIN INVEST, V41, P1886, DOI 10.1172/JCI104645; GOODMAN DS, 1965, J LIPID RES, V6, P390; HAVEL RJ, 1961, J LIPID RES, V2, P389; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUWAJIMA M, 1988, METABOLISM, V37, P597, DOI 10.1016/0026-0495(88)90178-3; LOSSOW WJ, 1962, J LIPID RES, V3, P207; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MJOS OD, 1975, J CLIN INVEST, V56, P603, DOI 10.1172/JCI108130; MOODY AJ, 1974, HORM METAB RES, V6, P12, DOI 10.1055/s-0028-1093895; NESTEL PJ, 1962, J CLIN INVEST, V41, P1915, DOI 10.1172/JCI104648; NESTEL PJ, 1963, J CLIN INVEST, V42, P1313, DOI 10.1172/JCI104815; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; QUARFORDT SH, 1967, J LIPID RES, V8, P264; SHELBURNE F, 1980, J CLIN INVEST, V65, P652, DOI 10.1172/JCI109710; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANNER LI, 1987, J BIOL CHEM, V262, P8975; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WINDLER E, 1980, J BIOL CHEM, V255, P5475; WINDLER E, 1985, J LIPID RES, V26, P556	42	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					974	981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678262				2022-12-27	WOS:A1993KG07700035
J	BIKLE, DD; MUNSON, S; MORRISON, N; EISMAN, J				BIKLE, DD; MUNSON, S; MORRISON, N; EISMAN, J			ZIPPER PROTEIN, A NEWLY DESCRIBED TROPOMYOSIN-LIKE PROTEIN OF THE INTESTINAL BRUSH-BORDER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; LEUCINE ZIPPER; MESSENGER-RNA; CDNA CLONES; SEQUENCE; EXPRESSION; ACTIN; GENE; MECHANOENZYME; MICROVILLI	We have cloned and sequenced from a chick intestinal library the cDNA for a new tropomyosin-like protein with an extensive leucine zipper motif. The cDNA recognized a 2.5-kilobase transcript with highest levels in the intestine. The open reading frame encoded a protein with 239 residues (28 kDa), the deduced sequence of which forms 27 heptad repeats, 21 of which begin with leucine and the other 6 with conservative substitutions (methionine, valine, threonine). This sequence predicts a coiled coil dimer similar to that of tropomyosin with which it has 34% homology. We have named this newly described protein zipper protein. The protein was expressed in bacteria. Antibodies were made to peptides representing different regions of the deduced sequence and tested for their ability to recognize the recombinant zipper protein on immunoblots. Such antibodies were used to immunolocalize zipper protein to the intestinal brush border. A radioimmunoassay was then established using recombinant zipper protein as standard and tracer and one of the affinity-purified antisera as primary antibody. Extracts from intestine, kidney, and liver displaced tracer zipper protein in parallel with that of the standard curve, and zipper protein levels were readily measured in those tissues to be 2.5 +/- 0.4, 0.34 +/- 0.03, and 0.15 +/- 0.03 mug/mg of protein, respectively. Brain contained no detectable zipper protein. We conclude that zipper protein is a tropomyosin-like protein found predominantly in the intestinal brush border; its location and structural similarity to tropomyosin suggest a possible role in regulating the interaction of brush border myosin 1 with the actin core of the microvillus.	GARVAN INST MED RES,SYDNEY,AUSTRALIA; VET ADM MED CTR,SAN FRANCISCO,CA 94121	Garvan Institute of Medical Research; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BIKLE, DD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121, USA.		Morrison, Nigel A/F-4082-2012; Eisman, John A/C-2886-2014	Morrison, Nigel A/0000-0003-4774-3808; 				Ausubel FM, 1988, MOL REPROD DEV; Battey, 1986, BASIC METHODS MOL BI; BIKLE DD, 1991, GASTROENTEROLOGY, V100, P395, DOI 10.1016/0016-5085(91)90208-3; BRADAC JA, 1989, MOL CELL BIOL, V9, P185, DOI 10.1128/MCB.9.1.185; BURGESS DR, 1987, J CELL BIOL, V104, P29, DOI 10.1083/jcb.104.1.29; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GLENNEY JR, 1982, EXP CELL RES, V138, P199, DOI 10.1016/0014-4827(82)90106-9; HOSHIMARU M, 1987, J BIOL CHEM, V262, P14625; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; Huynh T.V., 1984, DNA CLONING PRACTICA; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KAUFMAN J, 1989, IMMUNOGENETICS, V30, P440, DOI 10.1007/BF02421176; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LINDQUESTER GJ, 1989, NUCLEIC ACIDS RES, V17, P2099, DOI 10.1093/nar/17.5.2099; MATSUDAIRA PT, 1982, J CELL BIOL, V92, P657, DOI 10.1083/jcb.92.3.657; MOOSEKER MS, 1989, J CELL BIOL, V109, P1153, DOI 10.1083/jcb.109.3.1153; MOOSEKER MS, 1989, J CELL BIOL, V108, P2395, DOI 10.1083/jcb.108.6.2395; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	24	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					620	626						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7678004				2022-12-27	WOS:A1993KE60300093
J	UNEYAMA, H; UNEYAMA, C; AKAIKE, N				UNEYAMA, H; UNEYAMA, C; AKAIKE, N			INTRACELLULAR MECHANISMS OF CYTOPLASMIC CA2+ OSCILLATION IN RAT MEGAKARYOCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; FREE CALCIUM-CONCENTRATION; INOSITOL TRISPHOSPHATE; CA-2+ OSCILLATIONS; FURA-2-LOADED HEPATOCYTES; PLATELET-AGGREGATION; POSITIVE FEEDBACK; SMOOTH-MUSCLE; ACINAR-CELLS; CYCLIC-AMP	Extracellular application of ATP and ADP evoked the oscillatory K+ currents (I(KCa)) resulting from the periodic rise in cytoplasmic Ca2+ concentration ([Ca2+]i) of megakaryocyte isolated from rat bone marrow (Uneyama, H., Uneyama, C., and Akaike, N. (1992) Jpn. J. Pharmacol. 58, 231). The intracellular mechanism of ATP-induced cytoplasmic Ca2+ oscillation was investigated by the use of nystatin-perforated patch-clamp technique. Caffeine and ryanodine, which release Ca2+ from the Ca2+-induced Ca2+ release pool (CICR), and procaine, a blocker of Ca2+ release from CICR, had no effect on the I(KCa) oscillation in megakaryocyte. Thapsigargin and A23187 activated I(KCa) irreversibly by mobilizing Ca2+, but under Ca2+-free conditions they activated I(KCa) transiently. Intracellular application of inositol 1,4,5-triphosphate (IP3) also induced I(KCa) oscillation. Phorbol myristate acetate (PMA), a strong activator of protein kinase C (PKC), inhibited the oscillation completely. The inhibitory action of PMA was reversed by an inhibitor of PKC, staurosporin. The oscillation of ATP-induced I(KCa) was disrupted by staurosporin or calmodulin (CaM) antagonists such as W-7 and trifluoperazine, resulting in a transient and successive plateau-like I(KCa). These results suggest that Ca2+ oscillation in megakaryocyte is caused by the interaction of both the Ca2+ release from IP3-sensitive Ca2+ pool and the Ca2+ uptake stimulated by PKC and Ca2+/CaM complex. Furthermore, forskolin, an activator of adenylate cyclase, and isobutylmethylxanthin, an inhibitor of phosphodiesterase, inhibited the frequency, latency, and current amplitude of the oscillation in a concentration-dependent manner. These reagents inhibited IP3-induced oscillation as well as an ATP-induced oscillation. Thus, the ATP-induced [Ca2+]i oscillation of rat megakaryocyte is also modulated by cAMP.	TOHOKU UNIV,SCH MED,DEPT NEUROPHYSIOL,SENDAI,MIYAGI 980,JAPAN	Tohoku University								BALL RL, 1990, J BIOL CHEM, V265, P12836; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOUCHARD RA, 1989, BRIT J PHARMACOL, V97, P1279, DOI 10.1111/j.1476-5381.1989.tb12590.x; CARAFOLI E, 1988, J CARDIOVASC PHARM, V12, pS77; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; EBIHARA S, 1992, BRIT J PHARMACOL, V106, P823, DOI 10.1111/j.1476-5381.1992.tb14419.x; EDES I, 1987, Membrane Biochemistry, V7, P175, DOI 10.3109/09687688709039993; ENYEDI A, 1986, J BIOL CHEM, V261, P9558; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HAMATANI Y, 1991, AM J PHYSIOL, V261, pE325, DOI 10.1152/ajpendo.1991.261.3.E325; HAROOTUNIAN AT, 1988, COLD SPRING HARB SYM, V53, P935, DOI 10.1101/SQB.1988.053.01.108; HAROOTUNIAN AT, 1991, CELL CALCIUM, V12, P153, DOI 10.1016/0143-4160(91)90017-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IKEDA M, 1992, J PHYSIOL-LONDON, V447, P711, DOI 10.1113/jphysiol.1992.sp019025; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAWA K, 1990, J PHYSIOL-LONDON, V431, P207, DOI 10.1113/jphysiol.1990.sp018327; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KOBAYASHI S, 1989, J BIOL CHEM, V264, P17997; KRISHNAMURTHI S, 1988, BIOCHEM J, V250, P209, DOI 10.1042/bj2500209; KROLL MH, 1988, BIOCHIM BIOPHYS ACTA, V970, P61, DOI 10.1016/0167-4889(88)90222-4; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LEVEN RM, 1982, J CELL BIOL, V92, P313, DOI 10.1083/jcb.92.2.313; LEVINE RF, 1976, J CELL BIOL, V69, P159, DOI 10.1083/jcb.69.1.159; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MURASE K, 1989, NEUROSCI LETT, V103, P56, DOI 10.1016/0304-3940(89)90485-0; NAKAGAWA T, 1990, NEUROSCI RES, V8, P114, DOI 10.1016/0168-0102(90)90063-K; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PALADE P, 1989, MOL PHARMACOL, V36, P673; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; PIKE GK, 1989, J MUSCLE RES CELL M, V10, P337, DOI 10.1007/BF01758430; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SAGE SO, 1989, J BIOL CHEM, V264, P6; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; SCHICK BP, 1981, BIOCHIM BIOPHYS ACTA, V663, P239, DOI 10.1016/0005-2760(81)90210-1; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; SOSLAU G, 1989, BLOOD, V74, P984; TANAKA M, 1990, BIOCHEM PHARMACOL, V40, P991; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; UNEYAMA H, 1992, NEUROREPORT, V3, P633, DOI 10.1097/00001756-199207000-00023; UNEYAMA H, 1992, JPN J PHARMACOL, V58, P231; USHIYAMA S, 1988, PROSTAGLANDINS, V36, P477, DOI 10.1016/0090-6980(88)90044-5; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WALTER U, 1988, European Heart Journal, V9, P1; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8	55	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1993	268	1					168	174						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KE603	7677993				2022-12-27	WOS:A1993KE60300026
